cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
GBM	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-17.09	2.41e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-17.09	2.41e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-17.09	2.41e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-17.09	2.41e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-17.09	2.43e-33	3.1e-27	-1.03	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-17.07	2.67e-33	3.1e-27	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-16.88	6.51e-33	5.38e-27	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-16.88	6.51e-33	5.38e-27	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-16.88	6.51e-33	5.38e-27	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-16.88	6.51e-33	5.38e-27	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-16.88	6.51e-33	5.38e-27	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-16.88	6.51e-33	5.38e-27	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	16.88	6.51e-33	5.38e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	16.88	6.51e-33	5.38e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	16.88	6.51e-33	5.38e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	16.88	6.51e-33	5.38e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	16.88	6.51e-33	5.38e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	16.88	6.51e-33	5.38e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	16.88	6.51e-33	5.38e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	16.81	9.09e-33	7.16e-27	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-16.81	9.15e-33	7.16e-27	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	16.78	1.05e-32	7.81e-27	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-16.78	1.05e-32	7.81e-27	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-16.58	2.84e-32	1.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-16.58	2.9e-32	1.71e-26	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-16.58	2.9e-32	1.71e-26	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-16.58	2.9e-32	1.71e-26	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-16.57	2.95e-32	1.72e-26	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-16.57	3.07e-32	1.73e-26	-1	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-16.56	3.22e-32	1.75e-26	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-16.56	3.22e-32	1.75e-26	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	16.53	3.59e-32	1.93e-26	1	0.84	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-16.48	4.64e-32	2.41e-26	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-16.47	4.83e-32	2.41e-26	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-16.47	4.83e-32	2.41e-26	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-16.47	4.83e-32	2.41e-26	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	16.47	4.98e-32	2.46e-26	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-16.33	9.76e-32	3.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-16.33	9.76e-32	3.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-16.33	9.76e-32	3.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-16.33	9.76e-32	3.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-16.33	9.76e-32	3.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-16.33	9.76e-32	3.71e-26	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	16.33	9.76e-32	3.71e-26	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	16.3	1.14e-31	4.1e-26	0.99	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-16.25	1.45e-31	4.12e-26	-1.02	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	16.25	1.45e-31	4.12e-26	1.02	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	16.17	2.12e-31	5.96e-26	0.99	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-16.17	2.18e-31	6.09e-26	-1.01	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	16.15	2.35e-31	6.37e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	16.15	2.35e-31	6.37e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	16.15	2.35e-31	6.37e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	16.15	2.35e-31	6.37e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-16.15	2.39e-31	6.43e-26	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	16.09	3.13e-31	8.37e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-16.04	4.04e-31	8.73e-26	-1.01	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-16.04	4.04e-31	8.73e-26	-1.01	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-16.04	4.04e-31	8.73e-26	-1.01	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-16.04	4.04e-31	8.73e-26	-1.01	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-16.04	4.04e-31	8.73e-26	-1.01	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-16.04	4.04e-31	8.73e-26	-1.01	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	16.04	4.04e-31	8.73e-26	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	15.94	6.77e-31	1.44e-25	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-15.93	6.95e-31	1.47e-25	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-15.77	1.6e-30	3.31e-25	-1	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	15.71	2.19e-30	4.48e-25	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	15.66	2.78e-30	5.66e-25	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-15.53	5.28e-30	9.75e-25	-0.97	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	15.51	5.78e-30	1.06e-24	1	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-15.49	6.34e-30	1.16e-24	-1	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	15.44	8.43e-30	1.53e-24	1	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	15.38	1.12e-29	2.02e-24	1.02	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	15.19	3e-29	4.25e-24	1.2	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
GBM	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	15.18	3.08e-29	4.31e-24	0.93	0.82	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
GBM	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	15.17	3.18e-29	4.42e-24	1.21	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
GBM	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	15.17	3.18e-29	4.42e-24	1.21	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	15.13	4.08e-29	5.64e-24	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	15.12	4.23e-29	5.79e-24	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	15.12	4.23e-29	5.79e-24	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-15.09	4.93e-29	6.71e-24	-0.97	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	15.01	7.4e-29	9.79e-24	0.92	0.81	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	15.01	7.4e-29	9.79e-24	0.92	0.81	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	15.01	7.4e-29	9.79e-24	0.92	0.81	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	15.01	7.52e-29	9.89e-24	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-15	7.65e-29	1e-23	-1	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	15	7.81e-29	1.02e-23	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
GBM	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	14.96	9.5e-29	1.23e-23	1.21	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	14.91	1.25e-28	1.59e-23	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	14.79	2.31e-28	2.89e-23	0.83	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	14.79	2.31e-28	2.89e-23	0.83	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	14.69	3.74e-28	4.67e-23	0.83	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
GBM	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	14.65	4.57e-28	5.64e-23	0.97	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	14.59	6.19e-28	7.38e-23	0.97	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-14.55	7.57e-28	8.99e-23	-0.97	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-14.54	7.98e-28	9.16e-23	-0.97	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-14.54	7.98e-28	9.16e-23	-0.97	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-14.54	7.98e-28	9.16e-23	-0.97	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-14.54	7.98e-28	9.16e-23	-0.97	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-14.54	7.98e-28	9.16e-23	-0.97	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	14.53	8.39e-28	9.55e-23	1.21	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
GBM	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-14.53	8.54e-28	9.64e-23	-0.91	-0.8	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-14.53	8.54e-28	9.64e-23	-0.91	-0.8	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	14.53	8.54e-28	9.64e-23	0.91	0.8	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	14.44	1.35e-27	1.5e-22	0.91	0.8	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-14.4	1.65e-27	1.77e-22	-0.96	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-14.4	1.65e-27	1.77e-22	-0.96	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-14.4	1.65e-27	1.77e-22	-0.96	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	14.4	1.65e-27	1.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	14.4	1.69e-27	1.81e-22	1.23	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-14.38	1.84e-27	1.94e-22	-0.96	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-14.38	1.84e-27	1.94e-22	-0.96	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
GBM	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-14.35	2.16e-27	2.26e-22	-0.94	-0.8	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
GBM	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	14.33	2.36e-27	2.46e-22	1.17	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
GBM	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	14.33	2.36e-27	2.46e-22	1.17	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
GBM	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	14.3	2.85e-27	2.96e-22	0.95	0.8	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-14.29	2.91e-27	3.01e-22	-0.96	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
GBM	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	14.28	3.1e-27	3.14e-22	0.9	0.8	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
GBM	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	14.27	3.36e-27	3.37e-22	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
GBM	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	14.26	3.49e-27	3.48e-22	1.19	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-14.25	3.72e-27	3.69e-22	-0.95	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-14.25	3.72e-27	3.69e-22	-0.95	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-14.25	3.72e-27	3.69e-22	-0.95	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	14.24	3.81e-27	3.77e-22	1.2	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	14.24	3.85e-27	3.79e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	14.23	3.97e-27	3.91e-22	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
GBM	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-14.23	3.99e-27	3.91e-22	-0.92	-0.8	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	14.22	4.2e-27	4.09e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	14.22	4.2e-27	4.09e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	14.22	4.2e-27	4.09e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	14.21	4.4e-27	4.26e-22	0.91	0.8	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	14.21	4.4e-27	4.26e-22	0.91	0.8	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-14.2	4.77e-27	4.61e-22	-0.82	-0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
GBM	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	14.19	4.96e-27	4.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	14.19	4.96e-27	4.77e-22	0.96	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	14.17	5.55e-27	5.26e-22	1.2	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
GBM	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	14.17	5.55e-27	5.26e-22	0.89	0.8	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
GBM	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	14.17	5.55e-27	5.26e-22	0.89	0.8	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
GBM	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	14.17	5.55e-27	5.26e-22	0.89	0.8	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	14.17	5.55e-27	5.26e-22	0.89	0.8	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
GBM	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	14.17	5.59e-27	5.28e-22	1.21	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
GBM	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-14.14	6.44e-27	6.06e-22	-1.02	-0.8	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-14.13	6.7e-27	6.28e-22	-0.93	-0.8	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-14.13	6.7e-27	6.28e-22	-0.93	-0.8	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
GBM	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	14.12	6.99e-27	6.52e-22	1.21	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	14.12	7.11e-27	6.56e-22	0.95	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	14.12	7.11e-27	6.56e-22	0.95	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	14.12	7.11e-27	6.56e-22	0.95	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	14.12	7.11e-27	6.56e-22	0.95	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	14.12	7.11e-27	6.56e-22	0.95	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	14.11	7.45e-27	6.86e-22	0.84	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
GBM	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	14.09	8.28e-27	7.48e-22	0.97	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	14.08	8.74e-27	7.86e-22	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
GBM	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	14.07	9.15e-27	8.21e-22	0.9	0.8	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
GBM	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-14.03	1.12e-26	1e-21	-0.96	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-14.01	1.25e-26	1.1e-21	-0.94	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	14.01	1.28e-26	1.12e-21	0.94	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	13.98	1.48e-26	1.28e-21	1.18	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
GBM	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	13.98	1.49e-26	1.29e-21	0.9	0.79	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
GBM	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-13.97	1.55e-26	1.34e-21	-0.91	-0.79	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
GBM	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	13.97	1.58e-26	1.37e-21	0.92	0.79	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
GBM	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	13.93	1.9e-26	1.62e-21	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	13.93	1.9e-26	1.62e-21	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	13.92	1.98e-26	1.69e-21	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	13.89	2.34e-26	1.96e-21	0.93	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-13.88	2.43e-26	2.02e-21	-0.91	-0.79	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-13.88	2.43e-26	2.02e-21	-0.91	-0.79	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	13.87	2.6e-26	2.16e-21	0.95	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	13.85	2.99e-26	2.46e-21	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
GBM	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	13.85	2.99e-26	2.46e-21	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-13.81	3.63e-26	2.97e-21	-0.95	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
GBM	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-13.77	4.34e-26	3.53e-21	-1.03	-0.79	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
GBM	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	13.75	4.95e-26	4.02e-21	0.95	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	13.73	5.32e-26	4.31e-21	0.94	0.79	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
GBM	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-13.71	6.06e-26	4.9e-21	-1.23	-0.79	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
GBM	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	13.71	6.18e-26	4.99e-21	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
GBM	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	13.69	6.8e-26	5.42e-21	0.92	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	13.69	6.8e-26	5.42e-21	0.92	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	13.69	6.8e-26	5.42e-21	0.92	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	13.68	6.93e-26	5.52e-21	0.94	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	13.66	7.86e-26	6.2e-21	0.89	0.79	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	13.64	8.55e-26	6.71e-21	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	13.64	8.55e-26	6.71e-21	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
GBM	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-13.63	9.38e-26	7.33e-21	-1.22	-0.79	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-13.61	1.04e-25	8.03e-21	-1.22	-0.79	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
GBM	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-13.61	1.04e-25	8.03e-21	-1.22	-0.79	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	13.57	1.28e-25	9.79e-21	1.15	0.78	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	13.56	1.32e-25	1.01e-20	0.81	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
GBM	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	13.55	1.38e-25	1.04e-20	0.88	0.78	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	13.55	1.38e-25	1.04e-20	0.88	0.78	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
GBM	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	13.53	1.58e-25	1.19e-20	1	0.78	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
GBM	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	13.53	1.58e-25	1.19e-20	1	0.78	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
GBM	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	13.52	1.6e-25	1.2e-20	0.99	0.78	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	13.52	1.6e-25	1.2e-20	0.99	0.78	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	13.52	1.6e-25	1.2e-20	0.99	0.78	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	13.52	1.6e-25	1.2e-20	0.99	0.78	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
GBM	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	13.52	1.61e-25	1.2e-20	1	0.78	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	13.52	1.63e-25	1.21e-20	1	0.78	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	13.52	1.63e-25	1.21e-20	1	0.78	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	13.51	1.74e-25	1.28e-20	1	0.78	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-13.51	1.77e-25	1.31e-20	-1.21	-0.78	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
GBM	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	13.5	1.84e-25	1.36e-20	1.16	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
GBM	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-13.47	2.08e-25	1.5e-20	-1.13	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
GBM	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	13.47	2.15e-25	1.54e-20	1	0.78	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	13.47	2.15e-25	1.54e-20	1	0.78	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-13.46	2.28e-25	1.62e-20	-0.9	-0.78	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
GBM	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-13.45	2.4e-25	1.7e-20	-1.11	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
GBM	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	13.44	2.46e-25	1.74e-20	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	13.43	2.66e-25	1.87e-20	0.81	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	13.43	2.66e-25	1.87e-20	0.81	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	13.43	2.66e-25	1.87e-20	0.81	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	13.43	2.66e-25	1.87e-20	0.81	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
GBM	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	13.42	2.83e-25	1.98e-20	0.94	0.78	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
GBM	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	13.36	3.8e-25	2.64e-20	1	0.78	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
GBM	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	13.35	3.91e-25	2.71e-20	1.18	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
GBM	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-13.35	3.99e-25	2.75e-20	-1.21	-0.78	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
GBM	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	13.32	4.69e-25	3.22e-20	0.91	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
GBM	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-13.32	4.74e-25	3.25e-20	-0.94	-0.78	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	13.32	4.74e-25	3.25e-20	0.94	0.78	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
GBM	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	13.3	5.24e-25	3.57e-20	0.92	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
GBM	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-13.29	5.48e-25	3.72e-20	-0.92	-0.78	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	13.29	5.54e-25	3.75e-20	0.95	0.78	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	13.29	5.54e-25	3.75e-20	0.95	0.78	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
GBM	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-13.26	6.49e-25	4.36e-20	-1.01	-0.78	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-13.26	6.49e-25	4.36e-20	-1.01	-0.78	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-13.26	6.49e-25	4.36e-20	-1.01	-0.78	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
GBM	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-13.24	7.1e-25	4.74e-20	-0.92	-0.78	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
GBM	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	13.24	7.16e-25	4.74e-20	1.01	0.78	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	13.24	7.16e-25	4.74e-20	1.01	0.78	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	13.24	7.16e-25	4.74e-20	1.01	0.78	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	13.24	7.16e-25	4.74e-20	1.01	0.78	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
GBM	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	13.24	7.16e-25	4.74e-20	1.01	0.78	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-13.23	7.55e-25	4.99e-20	-1.17	-0.78	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
GBM	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-13.23	7.66e-25	5.02e-20	-1	-0.78	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
GBM	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
GBM	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-13.23	7.73e-25	5.02e-20	-0.98	-0.78	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	13.22	7.75e-25	5.02e-20	0.99	0.78	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
GBM	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	13.22	7.77e-25	5.02e-20	1.16	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
GBM	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-13.22	7.99e-25	5.11e-20	-1	-0.78	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-13.22	7.99e-25	5.11e-20	-1	-0.78	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
GBM	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-13.22	7.99e-25	5.11e-20	-1	-0.78	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-13.22	7.99e-25	5.11e-20	-1	-0.78	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
GBM	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-13.22	7.99e-25	5.11e-20	-1	-0.78	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-13.22	8.01e-25	5.11e-20	-0.98	-0.78	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-13.22	8.01e-25	5.11e-20	-0.98	-0.78	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
GBM	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	13.22	8.15e-25	5.17e-20	1	0.78	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	13.22	8.15e-25	5.17e-20	1	0.78	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	13.22	8.15e-25	5.17e-20	1	0.78	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
GBM	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	13.2	8.76e-25	5.54e-20	1	0.78	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	13.2	8.8e-25	5.54e-20	0.8	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	13.2	8.8e-25	5.54e-20	0.8	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	13.2	8.8e-25	5.54e-20	0.8	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
GBM	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	13.17	1.02e-24	6.39e-20	0.87	0.78	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	13.17	1.03e-24	6.44e-20	1	0.78	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
GBM	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	13.17	1.04e-24	6.5e-20	0.89	0.78	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
GBM	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	13.17	1.04e-24	6.5e-20	0.89	0.78	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
GBM	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	13.16	1.06e-24	6.63e-20	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
GBM	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	13.16	1.09e-24	6.79e-20	0.99	0.78	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
GBM	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	13.14	1.2e-24	7.46e-20	1.16	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
GBM	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	13.13	1.28e-24	7.93e-20	0.96	0.77	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
GBM	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	13.13	1.3e-24	8.05e-20	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	13.13	1.3e-24	8.05e-20	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	13.13	1.3e-24	8.05e-20	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
GBM	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-13.12	1.33e-24	8.17e-20	-1.12	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
GBM	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	13.12	1.38e-24	8.49e-20	1.14	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
GBM	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	13.1	1.48e-24	9.05e-20	1	0.77	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
GBM	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-13.1	1.51e-24	9.24e-20	-1.2	-0.77	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
GBM	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	13.08	1.66e-24	1.01e-19	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
GBM	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-13.08	1.67e-24	1.01e-19	-1.12	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
GBM	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-13.08	1.67e-24	1.02e-19	-1	-0.77	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
GBM	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	13.08	1.68e-24	1.02e-19	1.16	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
GBM	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	13.08	1.68e-24	1.02e-19	1.16	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
GBM	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	13.07	1.78e-24	1.08e-19	1.14	0.77	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
GBM	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-13.06	1.88e-24	1.13e-19	-0.98	-0.77	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
GBM	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-13.06	1.88e-24	1.13e-19	-0.98	-0.77	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-13.06	1.88e-24	1.13e-19	-0.98	-0.77	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-13.06	1.88e-24	1.13e-19	-0.98	-0.77	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
GBM	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-13.06	1.9e-24	1.14e-19	-1.1	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
GBM	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-13.05	1.97e-24	1.18e-19	-1.1	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
GBM	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	13.04	2.09e-24	1.24e-19	1.15	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
GBM	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	13.04	2.09e-24	1.24e-19	1.15	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
GBM	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-13.03	2.18e-24	1.29e-19	-0.97	-0.77	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-13.03	2.18e-24	1.29e-19	-0.97	-0.77	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
GBM	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-13.01	2.39e-24	1.41e-19	-0.98	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	13	2.58e-24	1.53e-19	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
GBM	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-12.96	3.13e-24	1.83e-19	-1.1	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
GBM	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-12.96	3.18e-24	1.85e-19	-1.01	-0.77	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-12.96	3.18e-24	1.85e-19	-1.01	-0.77	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
GBM	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-12.95	3.29e-24	1.91e-19	-0.98	-0.77	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
GBM	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-12.94	3.41e-24	1.97e-19	-0.87	-0.77	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	12.94	3.45e-24	1.99e-19	0.9	0.77	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	12.94	3.45e-24	1.99e-19	0.9	0.77	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
GBM	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-12.93	3.77e-24	2.17e-19	-0.94	-0.77	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
GBM	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-12.91	4.1e-24	2.35e-19	-0.99	-0.77	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
GBM	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	12.9	4.22e-24	2.41e-19	1.11	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
GBM	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-12.9	4.22e-24	2.41e-19	-0.95	-0.77	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
GBM	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	12.9	4.22e-24	2.41e-19	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
GBM	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-12.9	4.23e-24	2.41e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
GBM	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	12.89	4.52e-24	2.56e-19	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	12.89	4.52e-24	2.56e-19	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	12.89	4.52e-24	2.56e-19	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	12.89	4.52e-24	2.56e-19	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
GBM	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-12.89	4.57e-24	2.59e-19	-1.01	-0.77	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
GBM	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	12.89	4.63e-24	2.62e-19	1	0.77	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
GBM	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	12.88	4.78e-24	2.69e-19	0.96	0.77	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	12.88	4.78e-24	2.69e-19	0.96	0.77	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
GBM	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	12.87	5e-24	2.82e-19	0.9	0.77	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
GBM	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	12.87	5.14e-24	2.88e-19	0.87	0.77	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
GBM	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	12.86	5.28e-24	2.96e-19	0.98	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
GBM	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-12.83	6.4e-24	3.58e-19	-0.91	-0.77	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
GBM	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-12.82	6.48e-24	3.62e-19	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	12.81	7.02e-24	3.92e-19	1.14	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-12.81	7.06e-24	3.93e-19	-0.79	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
GBM	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-12.8	7.22e-24	4.01e-19	-1.02	-0.77	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
GBM	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-12.8	7.22e-24	4.01e-19	-1.02	-0.77	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
GBM	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-12.8	7.24e-24	4.02e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-12.79	7.95e-24	4.4e-19	-1.08	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-12.77	8.51e-24	4.65e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
GBM	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-12.77	8.51e-24	4.65e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
GBM	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-12.77	8.51e-24	4.65e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
GBM	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-12.77	8.51e-24	4.65e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
GBM	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-12.77	8.51e-24	4.65e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
GBM	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-12.77	8.51e-24	4.65e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
GBM	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-12.77	8.51e-24	4.65e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
GBM	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	12.77	8.59e-24	4.68e-19	0.87	0.77	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	12.77	8.59e-24	4.68e-19	0.87	0.77	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	12.77	8.59e-24	4.68e-19	0.87	0.77	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
GBM	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	12.77	8.76e-24	4.72e-19	0.9	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
GBM	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	12.76	8.87e-24	4.72e-19	1.09	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
GBM	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-12.76	8.88e-24	4.72e-19	-0.96	-0.77	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-12.76	8.88e-24	4.72e-19	-0.96	-0.77	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-12.76	8.88e-24	4.72e-19	-0.96	-0.77	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-12.76	8.88e-24	4.72e-19	-0.96	-0.77	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
GBM	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-12.76	8.88e-24	4.72e-19	-0.96	-0.77	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
GBM	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-12.76	9.05e-24	4.76e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-12.76	9.05e-24	4.76e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-12.76	9.05e-24	4.76e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-12.76	9.05e-24	4.76e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
GBM	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-12.76	9.05e-24	4.76e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-12.76	9.05e-24	4.76e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-12.76	9.05e-24	4.76e-19	-1.11	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
GBM	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-12.76	9.22e-24	4.82e-19	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
GBM	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	12.76	9.23e-24	4.82e-19	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	12.76	9.23e-24	4.82e-19	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	12.76	9.23e-24	4.82e-19	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	12.76	9.23e-24	4.82e-19	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	12.76	9.23e-24	4.82e-19	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
GBM	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	12.76	9.29e-24	4.84e-19	0.98	0.77	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-12.74	1.01e-23	5.26e-19	-0.96	-0.77	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
GBM	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-12.74	1.01e-23	5.26e-19	-1.14	-0.77	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
GBM	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	12.73	1.08e-23	5.6e-19	1	0.76	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
GBM	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	12.71	1.18e-23	6.1e-19	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
GBM	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	12.71	1.18e-23	6.1e-19	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	12.71	1.18e-23	6.1e-19	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	12.7	1.27e-23	6.54e-19	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	12.69	1.3e-23	6.69e-19	0.97	0.76	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
GBM	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-12.68	1.35e-23	6.94e-19	-1.2	-0.76	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
GBM	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	12.68	1.37e-23	7.01e-19	0.98	0.76	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	12.63	1.78e-23	9.09e-19	0.82	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
GBM	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-12.63	1.86e-23	9.46e-19	-0.97	-0.76	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
GBM	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-12.62	1.91e-23	9.67e-19	-1.19	-0.76	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
GBM	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	12.62	1.94e-23	9.83e-19	0.99	0.76	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
GBM	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-12.62	1.96e-23	9.92e-19	-0.98	-0.76	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
GBM	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-12.6	2.07e-23	1.05e-18	-0.98	-0.76	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
GBM	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	12.59	2.19e-23	1.1e-18	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
GBM	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-12.59	2.26e-23	1.14e-18	-0.95	-0.76	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
GBM	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	12.59	2.27e-23	1.14e-18	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	12.59	2.27e-23	1.14e-18	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	12.59	2.27e-23	1.14e-18	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
GBM	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	12.56	2.69e-23	1.34e-18	0.99	0.76	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
GBM	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	12.55	2.76e-23	1.35e-18	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
GBM	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-12.55	2.77e-23	1.35e-18	-1.02	-0.76	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
GBM	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	12.55	2.78e-23	1.35e-18	0.94	0.76	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
GBM	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	12.55	2.78e-23	1.35e-18	0.94	0.76	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
GBM	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	12.55	2.78e-23	1.35e-18	0.94	0.76	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
GBM	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	12.55	2.78e-23	1.35e-18	0.94	0.76	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
GBM	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-12.55	2.78e-23	1.35e-18	-0.97	-0.76	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
GBM	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-12.55	2.78e-23	1.35e-18	-0.97	-0.76	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
GBM	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	12.54	2.91e-23	1.41e-18	0.94	0.76	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
GBM	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	12.54	2.91e-23	1.41e-18	0.94	0.76	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	12.53	3.08e-23	1.47e-18	0.98	0.76	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	12.53	3.08e-23	1.47e-18	0.98	0.76	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	12.53	3.08e-23	1.47e-18	0.98	0.76	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	12.53	3.08e-23	1.47e-18	0.98	0.76	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	12.53	3.08e-23	1.47e-18	0.98	0.76	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	12.53	3.08e-23	1.47e-18	0.98	0.76	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	12.53	3.13e-23	1.49e-18	0.98	0.76	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
GBM	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-12.52	3.2e-23	1.52e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-12.52	3.2e-23	1.52e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-12.52	3.2e-23	1.52e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
GBM	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	12.52	3.25e-23	1.53e-18	0.98	0.76	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
GBM	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	12.52	3.25e-23	1.53e-18	0.98	0.76	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	12.52	3.32e-23	1.57e-18	0.98	0.76	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	12.52	3.32e-23	1.57e-18	0.98	0.76	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	12.52	3.33e-23	1.57e-18	0.96	0.76	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	12.52	3.33e-23	1.57e-18	0.96	0.76	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
GBM	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	12.51	3.36e-23	1.58e-18	0.94	0.76	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
GBM	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-12.5	3.55e-23	1.64e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-12.5	3.55e-23	1.64e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
GBM	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	12.5	3.67e-23	1.69e-18	0.98	0.76	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	12.49	3.77e-23	1.72e-18	0.96	0.76	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
GBM	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	12.49	3.79e-23	1.73e-18	0.95	0.76	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
GBM	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	12.49	3.79e-23	1.73e-18	0.95	0.76	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
GBM	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	12.49	3.79e-23	1.73e-18	0.95	0.76	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
GBM	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-12.49	3.83e-23	1.74e-18	-1.12	-0.76	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
GBM	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	12.48	3.99e-23	1.8e-18	0.96	0.76	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
GBM	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-12.48	4.02e-23	1.81e-18	-1.06	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
GBM	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-12.47	4.21e-23	1.85e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
GBM	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	12.46	4.4e-23	1.92e-18	0.87	0.76	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
GBM	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	12.45	4.65e-23	2.02e-18	0.82	0.76	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	12.45	4.81e-23	2.09e-18	0.87	0.76	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
GBM	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	12.42	5.43e-23	2.35e-18	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-12.42	5.52e-23	2.39e-18	-0.78	-0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
GBM	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-12.42	5.63e-23	2.42e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	12.42	5.64e-23	2.42e-18	0.81	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	12.42	5.64e-23	2.42e-18	0.81	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	12.42	5.64e-23	2.42e-18	0.81	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	12.42	5.64e-23	2.42e-18	0.81	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	12.42	5.64e-23	2.42e-18	0.81	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
GBM	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	12.41	5.87e-23	2.52e-18	0.95	0.76	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	12.41	5.87e-23	2.52e-18	0.95	0.76	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
GBM	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	12.4	6.05e-23	2.59e-18	0.95	0.76	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
GBM	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	12.38	6.8e-23	2.89e-18	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
GBM	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-12.37	7.16e-23	3.04e-18	-0.87	-0.76	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	12.37	7.16e-23	3.04e-18	0.87	0.76	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	12.37	7.16e-23	3.04e-18	0.87	0.76	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
GBM	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-12.37	7.17e-23	3.04e-18	-0.9	-0.76	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
GBM	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	12.36	7.69e-23	3.25e-18	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
GBM	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-12.36	7.8e-23	3.29e-18	-1.16	-0.76	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
GBM	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-12.35	7.86e-23	3.31e-18	-0.89	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
GBM	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	12.35	7.96e-23	3.35e-18	0.98	0.76	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
GBM	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	12.34	8.52e-23	3.58e-18	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
GBM	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-12.34	8.53e-23	3.58e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
GBM	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	12.34	8.63e-23	3.62e-18	0.82	0.75	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
GBM	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-12.33	8.83e-23	3.7e-18	-0.96	-0.75	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
GBM	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	12.33	9e-23	3.76e-18	0.98	0.75	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	12.33	9.14e-23	3.81e-18	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	12.33	9.14e-23	3.81e-18	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	12.33	9.14e-23	3.81e-18	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	12.33	9.14e-23	3.81e-18	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	12.29	1.1e-22	4.51e-18	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	12.29	1.1e-22	4.51e-18	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	12.29	1.1e-22	4.51e-18	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	12.29	1.1e-22	4.51e-18	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
GBM	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-12.29	1.11e-22	4.51e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
GBM	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-12.26	1.32e-22	5.33e-18	-1.11	-0.75	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	12.26	1.32e-22	5.33e-18	1.11	0.75	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	12.26	1.32e-22	5.33e-18	1.11	0.75	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
GBM	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	12.25	1.35e-22	5.48e-18	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
GBM	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	12.24	1.42e-22	5.75e-18	0.96	0.75	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
GBM	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	12.22	1.58e-22	6.35e-18	0.93	0.75	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
GBM	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-12.21	1.7e-22	6.83e-18	-1.15	-0.75	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
GBM	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-12.21	1.73e-22	6.94e-18	-0.89	-0.75	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	12.2	1.76e-22	7.05e-18	0.91	0.75	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
GBM	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-12.2	1.8e-22	7.22e-18	-0.95	-0.75	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
GBM	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-12.19	1.91e-22	7.66e-18	-0.88	-0.75	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-12.19	1.91e-22	7.66e-18	-0.88	-0.75	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
GBM	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	12.18	2e-22	7.99e-18	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	12.18	2.03e-22	8.08e-18	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
GBM	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	12.17	2.14e-22	8.51e-18	0.86	0.75	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	12.16	2.24e-22	8.9e-18	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
GBM	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	12.15	2.36e-22	9.34e-18	0.86	0.75	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	12.15	2.36e-22	9.34e-18	0.86	0.75	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	12.15	2.39e-22	9.47e-18	0.86	0.75	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
GBM	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	12.13	2.64e-22	1.04e-17	0.94	0.75	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	12.13	2.64e-22	1.04e-17	0.94	0.75	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
GBM	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	12.13	2.64e-22	1.04e-17	0.94	0.75	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
GBM	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-12.12	2.7e-22	1.06e-17	-0.9	-0.75	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
GBM	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	12.11	2.93e-22	1.15e-17	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	12.07	3.58e-22	1.4e-17	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	12.07	3.65e-22	1.42e-17	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	12.07	3.65e-22	1.42e-17	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
GBM	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	12.07	3.65e-22	1.42e-17	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	12.07	3.65e-22	1.42e-17	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
GBM	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-12.05	4.09e-22	1.59e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
GBM	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	12.05	4.09e-22	1.59e-17	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
GBM	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-12.04	4.16e-22	1.62e-17	-0.95	-0.75	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
GBM	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	12.04	4.32e-22	1.68e-17	0.94	0.75	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
GBM	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-12.02	4.61e-22	1.78e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-12.02	4.61e-22	1.78e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-12.02	4.61e-22	1.78e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
GBM	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-12.01	4.85e-22	1.87e-17	-0.86	-0.75	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
GBM	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-12	5.25e-22	2.01e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-12	5.25e-22	2.01e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-12	5.25e-22	2.01e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-12	5.3e-22	2.03e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-12	5.36e-22	2.05e-17	-0.92	-0.75	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-11.97	6.12e-22	2.33e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
GBM	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	11.97	6.23e-22	2.37e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	11.97	6.23e-22	2.37e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
GBM	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	11.96	6.6e-22	2.5e-17	0.91	0.74	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
GBM	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	11.95	6.78e-22	2.57e-17	0.9	0.74	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
GBM	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	11.95	6.87e-22	2.6e-17	0.85	0.74	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
GBM	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-11.91	8.43e-22	3e-17	-0.92	-0.74	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-11.89	9.39e-22	3.32e-17	-0.89	-0.74	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-11.89	9.39e-22	3.32e-17	-0.89	-0.74	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
GBM	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	11.89	9.59e-22	3.35e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
GBM	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-11.88	9.95e-22	3.35e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
GBM	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	11.88	1e-21	3.37e-17	0.93	0.74	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
GBM	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	11.87	1.03e-21	3.46e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
GBM	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-11.87	1.05e-21	3.52e-17	-0.88	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
GBM	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	11.87	1.06e-21	3.56e-17	0.95	0.74	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
GBM	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-11.86	1.12e-21	3.71e-17	-0.89	-0.74	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-11.86	1.12e-21	3.71e-17	-0.89	-0.74	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-11.85	1.19e-21	3.94e-17	-0.91	-0.74	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
GBM	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	11.83	1.33e-21	4.39e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
GBM	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	11.83	1.33e-21	4.39e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
GBM	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	11.83	1.33e-21	4.39e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	11.83	1.33e-21	4.4e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	11.83	1.33e-21	4.4e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
GBM	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	11.81	1.42e-21	4.67e-17	0.83	0.74	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-11.81	1.42e-21	4.67e-17	-0.83	-0.74	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-11.81	1.42e-21	4.67e-17	-0.83	-0.74	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
GBM	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	11.81	1.43e-21	4.69e-17	0.9	0.74	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
GBM	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	11.81	1.47e-21	4.82e-17	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-11.8	1.58e-21	5.14e-17	-0.8	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
GBM	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-11.79	1.62e-21	5.28e-17	-0.97	-0.74	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
GBM	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-11.79	1.62e-21	5.28e-17	-0.97	-0.74	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
GBM	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	11.78	1.69e-21	5.5e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	11.78	1.69e-21	5.5e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	11.78	1.69e-21	5.5e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
GBM	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-11.76	1.86e-21	6.04e-17	-1.12	-0.74	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
GBM	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-11.73	2.26e-21	7.22e-17	-0.9	-0.74	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-11.73	2.26e-21	7.22e-17	-0.9	-0.74	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-11.73	2.26e-21	7.22e-17	-0.9	-0.74	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
GBM	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	11.72	2.37e-21	7.56e-17	0.89	0.74	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
GBM	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	11.72	2.37e-21	7.56e-17	0.89	0.74	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	11.72	2.42e-21	7.7e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	11.72	2.42e-21	7.7e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	11.72	2.42e-21	7.7e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	11.72	2.42e-21	7.7e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	11.72	2.42e-21	7.7e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	11.72	2.42e-21	7.7e-17	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
GBM	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-11.71	2.56e-21	8.12e-17	-0.88	-0.74	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
GBM	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-11.7	2.61e-21	8.3e-17	-0.88	-0.74	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	11.7	2.68e-21	8.5e-17	0.76	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
GBM	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	11.7	2.69e-21	8.5e-17	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
GBM	cis	rs6452524	0.618	rs10462394	ENSG00000248112.1	RP11-78C3.1	11.69	2.78e-21	8.79e-17	0.84	0.74	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:82919376~82921119:-
GBM	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	11.69	2.81e-21	8.87e-17	0.83	0.74	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
GBM	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-11.67	3.07e-21	9.65e-17	-0.88	-0.74	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-11.66	3.31e-21	1.03e-16	-0.92	-0.74	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
GBM	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	11.66	3.35e-21	1.04e-16	0.82	0.74	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	11.65	3.46e-21	1.07e-16	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
GBM	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	11.64	3.69e-21	1.14e-16	0.84	0.74	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
GBM	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	11.64	3.7e-21	1.14e-16	0.93	0.74	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
GBM	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	11.62	4.15e-21	1.28e-16	0.87	0.73	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
GBM	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	11.62	4.15e-21	1.28e-16	0.87	0.73	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
GBM	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	11.62	4.15e-21	1.28e-16	0.87	0.73	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
GBM	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	11.61	4.3e-21	1.33e-16	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
GBM	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	11.61	4.38e-21	1.35e-16	0.88	0.73	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	11.59	4.67e-21	1.44e-16	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
GBM	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	11.58	4.92e-21	1.51e-16	0.86	0.73	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
GBM	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-11.57	5.18e-21	1.58e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-11.57	5.18e-21	1.58e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-11.57	5.18e-21	1.58e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-11.57	5.18e-21	1.58e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-11.57	5.18e-21	1.58e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-11.57	5.18e-21	1.58e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-11.57	5.18e-21	1.58e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
GBM	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-11.55	6.03e-21	1.83e-16	-0.98	-0.73	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
GBM	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	11.54	6.29e-21	1.91e-16	0.83	0.73	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	11.53	6.46e-21	1.96e-16	0.77	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	11.53	6.6e-21	2e-16	0.77	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
GBM	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	11.51	7.29e-21	2.19e-16	0.84	0.73	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	11.51	7.35e-21	2.21e-16	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
GBM	cis	rs6452524	0.618	rs6867727	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs7723639	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs2306336	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.589	rs6882386	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs6860752	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs3899556	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.56	rs6895174	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs6452503	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs6452504	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs6452506	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs1993948	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs2075685	ENSG00000248112.1	RP11-78C3.1	11.49	8.26e-21	2.46e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	11.49	8.28e-21	2.46e-16	0.84	0.73	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.648	rs27364	ENSG00000248112.1	RP11-78C3.1	11.48	8.44e-21	2.5e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs255561	ENSG00000248112.1	RP11-78C3.1	11.48	8.44e-21	2.5e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs1871203	ENSG00000248112.1	RP11-78C3.1	11.48	8.44e-21	2.5e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs7722924	ENSG00000248112.1	RP11-78C3.1	11.48	8.44e-21	2.5e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs10051445	ENSG00000248112.1	RP11-78C3.1	11.48	8.44e-21	2.5e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:82919376~82921119:-
GBM	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-11.48	8.72e-21	2.58e-16	-0.89	-0.73	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
GBM	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-11.47	9.17e-21	2.7e-16	-0.9	-0.73	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-11.47	9.17e-21	2.7e-16	-0.9	-0.73	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-11.47	9.17e-21	2.7e-16	-0.9	-0.73	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
GBM	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	11.44	1.05e-20	3.07e-16	0.81	0.73	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
GBM	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	11.43	1.1e-20	3.22e-16	0.86	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
GBM	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	11.41	1.26e-20	3.66e-16	0.83	0.73	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
GBM	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	11.39	1.36e-20	3.94e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	11.39	1.38e-20	3.96e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	11.39	1.38e-20	3.96e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	11.39	1.38e-20	3.96e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	11.39	1.38e-20	3.96e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	11.39	1.38e-20	3.96e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
GBM	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-11.39	1.38e-20	3.97e-16	-0.89	-0.73	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
GBM	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-11.38	1.5e-20	4.29e-16	-1.21	-0.73	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-11.38	1.5e-20	4.29e-16	-1.21	-0.73	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-11.38	1.5e-20	4.29e-16	-1.21	-0.73	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
GBM	cis	rs6452524	0.618	rs6452502	ENSG00000248112.1	RP11-78C3.1	11.36	1.63e-20	4.64e-16	0.83	0.73	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:82919376~82921119:-
GBM	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-11.35	1.76e-20	5.01e-16	-1.06	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
GBM	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	11.34	1.84e-20	5.22e-16	0.84	0.73	Depression;	chr6:28303421	chr6:28176188~28176674:+
GBM	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	11.34	1.84e-20	5.22e-16	0.84	0.73	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
GBM	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	11.34	1.84e-20	5.22e-16	0.84	0.73	Depression;	chr6:28327262	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	11.34	1.86e-20	5.27e-16	0.93	0.73	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
GBM	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-11.33	1.95e-20	5.53e-16	-0.84	-0.73	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
GBM	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	11.32	2.01e-20	5.67e-16	0.84	0.73	Depression;	chr6:28317705	chr6:28176188~28176674:+
GBM	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	11.32	2.01e-20	5.67e-16	0.84	0.73	Depression;	chr6:28323463	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	11.31	2.1e-20	5.91e-16	0.83	0.73	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
GBM	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	11.31	2.2e-20	6.18e-16	0.83	0.73	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
GBM	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-11.28	2.5e-20	6.85e-16	-0.91	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
GBM	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-11.27	2.73e-20	7.44e-16	-0.88	-0.72	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-11.26	2.76e-20	7.52e-16	-0.75	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
GBM	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-11.26	2.79e-20	7.56e-16	-0.89	-0.72	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-11.26	2.79e-20	7.56e-16	-0.89	-0.72	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-11.26	2.79e-20	7.56e-16	-0.89	-0.72	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-11.26	2.79e-20	7.56e-16	-0.89	-0.72	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-11.26	2.79e-20	7.56e-16	-0.89	-0.72	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
GBM	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	11.26	2.89e-20	7.84e-16	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-11.25	2.9e-20	7.86e-16	-0.9	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	11.25	2.92e-20	7.89e-16	0.9	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
GBM	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	11.25	2.92e-20	7.9e-16	0.83	0.72	Depression;	chr6:28240757	chr6:28176188~28176674:+
GBM	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	11.24	3.09e-20	8.35e-16	0.84	0.72	Depression;	chr6:28301886	chr6:28176188~28176674:+
GBM	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-11.24	3.21e-20	8.67e-16	-0.88	-0.72	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	11.23	3.27e-20	8.82e-16	0.78	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
GBM	cis	rs6452524	0.618	rs4266384	ENSG00000248112.1	RP11-78C3.1	11.22	3.44e-20	9.26e-16	0.82	0.72	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.618	rs1478487	ENSG00000248112.1	RP11-78C3.1	11.22	3.44e-20	9.26e-16	0.82	0.72	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:82919376~82921119:-
GBM	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-11.22	3.45e-20	9.28e-16	-0.91	-0.72	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
GBM	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-11.22	3.53e-20	9.46e-16	-1.21	-0.72	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-11.22	3.53e-20	9.46e-16	-1.21	-0.72	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-11.22	3.53e-20	9.46e-16	-1.21	-0.72	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-11.22	3.53e-20	9.46e-16	-1.21	-0.72	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-11.22	3.53e-20	9.46e-16	-1.21	-0.72	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
GBM	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-11.21	3.61e-20	9.64e-16	-0.85	-0.72	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	11.2	3.99e-20	1.06e-15	0.77	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
GBM	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-11.18	4.4e-20	1.11e-15	-0.87	-0.72	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
GBM	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-11.17	4.59e-20	1.15e-15	-0.9	-0.72	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
GBM	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	11.14	5.47e-20	1.37e-15	0.84	0.72	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
GBM	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-11.1	6.85e-20	1.68e-15	-0.87	-0.72	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
GBM	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-11.09	7.09e-20	1.74e-15	-1.18	-0.72	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
GBM	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	11.08	7.35e-20	1.8e-15	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	11.08	7.35e-20	1.8e-15	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	11.08	7.35e-20	1.8e-15	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
GBM	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	11.08	7.35e-20	1.8e-15	0.91	0.72	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	11.08	7.35e-20	1.8e-15	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
GBM	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-11.08	7.48e-20	1.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	11.07	7.76e-20	1.88e-15	0.89	0.72	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
GBM	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	11.07	7.98e-20	1.93e-15	0.82	0.72	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	11.05	8.83e-20	2.11e-15	0.74	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	11.05	8.83e-20	2.11e-15	0.74	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
GBM	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	11.04	9.44e-20	2.26e-15	0.83	0.72	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
GBM	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	11.01	1.07e-19	2.54e-15	0.92	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
GBM	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-11.01	1.1e-19	2.62e-15	-1.18	-0.72	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-11	1.17e-19	2.77e-15	-1.22	-0.72	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
GBM	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	11	1.18e-19	2.78e-15	1	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
GBM	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	11	1.18e-19	2.78e-15	1	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
GBM	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-10.99	1.19e-19	2.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-10.99	1.19e-19	2.81e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
GBM	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	10.98	1.29e-19	3.03e-15	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-10.98	1.29e-19	3.04e-15	-0.74	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
GBM	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-10.97	1.32e-19	3.11e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-10.97	1.32e-19	3.11e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-10.97	1.32e-19	3.11e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-10.97	1.32e-19	3.11e-15	-0.89	-0.72	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
GBM	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	10.96	1.41e-19	3.29e-15	1.04	0.71	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
GBM	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	10.96	1.43e-19	3.34e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
GBM	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-10.96	1.45e-19	3.37e-15	-1	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
GBM	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-10.96	1.45e-19	3.37e-15	-1	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
GBM	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	10.95	1.51e-19	3.52e-15	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
GBM	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	10.95	1.53e-19	3.55e-15	0.92	0.71	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
GBM	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	10.94	1.56e-19	3.62e-15	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	10.94	1.56e-19	3.62e-15	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
GBM	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	10.94	1.59e-19	3.69e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	10.94	1.59e-19	3.69e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	10.94	1.59e-19	3.69e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	10.94	1.59e-19	3.69e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
GBM	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-10.92	1.73e-19	3.96e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-10.92	1.73e-19	3.96e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-10.92	1.73e-19	3.96e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
GBM	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	10.92	1.81e-19	4.15e-15	0.81	0.71	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	10.92	1.81e-19	4.15e-15	0.81	0.71	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
GBM	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-10.91	1.84e-19	4.21e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-10.91	1.84e-19	4.21e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-10.91	1.84e-19	4.21e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-10.91	1.84e-19	4.21e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
GBM	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	10.91	1.89e-19	4.3e-15	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
GBM	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-10.9	1.96e-19	4.45e-15	-1.21	-0.71	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
GBM	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	10.89	2.13e-19	4.82e-15	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
GBM	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	10.89	2.13e-19	4.82e-15	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
GBM	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	10.89	2.13e-19	4.82e-15	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
GBM	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	10.88	2.17e-19	4.89e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	10.88	2.17e-19	4.89e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	10.88	2.17e-19	4.89e-15	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
GBM	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	10.88	2.19e-19	4.94e-15	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
GBM	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	10.88	2.21e-19	4.98e-15	0.85	0.71	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
GBM	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-10.87	2.34e-19	5.26e-15	-0.87	-0.71	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
GBM	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	10.87	2.34e-19	5.26e-15	0.8	0.71	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	10.87	2.34e-19	5.26e-15	0.8	0.71	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
GBM	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	10.86	2.38e-19	5.34e-15	0.86	0.71	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
GBM	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-10.86	2.39e-19	5.34e-15	-0.83	-0.71	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-10.86	2.42e-19	5.41e-15	-0.83	-0.71	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
GBM	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	10.86	2.45e-19	5.49e-15	0.84	0.71	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
GBM	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-10.86	2.48e-19	5.55e-15	-0.86	-0.71	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	10.84	2.7e-19	6.01e-15	0.74	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-10.84	2.73e-19	6.06e-15	-0.93	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-10.84	2.73e-19	6.06e-15	-0.93	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
GBM	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	10.83	2.84e-19	6.29e-15	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
GBM	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	10.83	2.84e-19	6.29e-15	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	10.83	2.84e-19	6.29e-15	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	10.83	2.84e-19	6.29e-15	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	10.83	2.84e-19	6.29e-15	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
GBM	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-10.83	2.86e-19	6.33e-15	-0.86	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	10.82	3.02e-19	6.66e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	10.82	3.02e-19	6.66e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	10.82	3.02e-19	6.66e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	10.82	3.02e-19	6.66e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
GBM	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-10.82	3.09e-19	6.8e-15	-1.19	-0.71	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-10.82	3.09e-19	6.8e-15	-1.19	-0.71	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	10.82	3.09e-19	6.8e-15	0.76	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
GBM	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-10.81	3.26e-19	7.16e-15	-0.87	-0.71	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-10.81	3.26e-19	7.16e-15	-0.87	-0.71	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-10.81	3.26e-19	7.16e-15	-0.87	-0.71	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
GBM	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	10.81	3.28e-19	7.17e-15	0.84	0.71	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	10.8	3.35e-19	7.31e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	10.8	3.35e-19	7.31e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	10.8	3.35e-19	7.31e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
GBM	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-10.8	3.38e-19	7.37e-15	-0.87	-0.71	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-10.8	3.42e-19	7.47e-15	-0.89	-0.71	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-10.78	3.74e-19	8.13e-15	-0.88	-0.71	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
GBM	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	10.78	3.78e-19	8.21e-15	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
GBM	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	10.77	3.88e-19	8.42e-15	0.84	0.71	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-10.77	3.92e-19	8.51e-15	-0.83	-0.71	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
GBM	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-10.76	4.14e-19	8.9e-15	-0.86	-0.71	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-10.76	4.14e-19	8.9e-15	-0.86	-0.71	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-10.76	4.14e-19	8.9e-15	-0.86	-0.71	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-10.76	4.14e-19	8.9e-15	-0.86	-0.71	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	10.75	4.54e-19	9.51e-15	0.73	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
GBM	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	10.72	5.12e-19	1.07e-14	0.83	0.71	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
GBM	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	10.72	5.12e-19	1.07e-14	0.83	0.71	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
GBM	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	10.72	5.18e-19	1.08e-14	0.92	0.71	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
GBM	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-10.71	5.47e-19	1.14e-14	-0.85	-0.71	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-10.71	5.5e-19	1.14e-14	-0.92	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
GBM	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-10.69	6.05e-19	1.25e-14	-0.84	-0.71	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-10.69	6.08e-19	1.26e-14	-0.82	-0.71	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	10.68	6.42e-19	1.32e-14	0.75	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
GBM	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-10.68	6.59e-19	1.36e-14	-0.89	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
GBM	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-10.67	6.78e-19	1.39e-14	-0.86	-0.71	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-10.67	6.78e-19	1.39e-14	-0.86	-0.71	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-10.67	6.78e-19	1.39e-14	-0.86	-0.71	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
GBM	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-10.67	6.99e-19	1.44e-14	-1.06	-0.71	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	10.66	7.38e-19	1.51e-14	0.73	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-10.65	7.74e-19	1.58e-14	-0.72	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
GBM	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-10.64	7.97e-19	1.63e-14	-0.85	-0.7	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
GBM	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-10.62	8.83e-19	1.8e-14	-0.88	-0.7	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
GBM	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	10.62	8.88e-19	1.81e-14	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	10.62	9e-19	1.84e-14	0.75	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
GBM	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-10.6	9.72e-19	1.97e-14	-0.84	-0.7	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
GBM	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-10.6	9.72e-19	1.97e-14	-0.84	-0.7	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-10.6	9.72e-19	1.97e-14	-0.84	-0.7	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
GBM	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	10.6	9.81e-19	1.99e-14	0.84	0.7	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
GBM	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-10.59	1.05e-18	2.12e-14	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
GBM	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	10.59	1.06e-18	2.14e-14	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
GBM	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-10.58	1.11e-18	2.24e-14	-0.83	-0.7	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-10.58	1.12e-18	2.26e-14	-0.84	-0.7	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-10.57	1.16e-18	2.32e-14	-0.72	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
GBM	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	10.57	1.18e-18	2.36e-14	0.82	0.7	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	10.55	1.27e-18	2.54e-14	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
GBM	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	10.55	1.28e-18	2.55e-14	1.09	0.7	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
GBM	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-10.55	1.33e-18	2.65e-14	-0.85	-0.7	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-10.54	1.38e-18	2.75e-14	-0.8	-0.7	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-10.54	1.38e-18	2.75e-14	-0.8	-0.7	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-10.54	1.38e-18	2.75e-14	-0.8	-0.7	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
GBM	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	10.54	1.38e-18	2.75e-14	1.08	0.7	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
GBM	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	10.54	1.41e-18	2.81e-14	0.84	0.7	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
GBM	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	10.52	1.53e-18	3.03e-14	0.84	0.7	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-10.52	1.56e-18	3.08e-14	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
GBM	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	10.52	1.57e-18	3.1e-14	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
GBM	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	10.5	1.67e-18	3.29e-14	0.8	0.7	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
GBM	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	10.5	1.67e-18	3.29e-14	0.8	0.7	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
GBM	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-10.5	1.69e-18	3.34e-14	-0.82	-0.7	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-10.5	1.69e-18	3.34e-14	-0.82	-0.7	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
GBM	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-10.5	1.74e-18	3.43e-14	-0.84	-0.7	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-10.5	1.75e-18	3.43e-14	-0.95	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
GBM	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-10.49	1.77e-18	3.48e-14	-0.88	-0.7	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-10.46	2.1e-18	4.11e-14	-0.78	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	10.46	2.11e-18	4.13e-14	0.78	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
GBM	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-10.46	2.12e-18	4.15e-14	-0.84	-0.7	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	10.46	2.17e-18	4.25e-14	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
GBM	cis	rs6452524	0.618	rs6452501	ENSG00000248112.1	RP11-78C3.1	10.45	2.31e-18	4.51e-14	0.8	0.7	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:82919376~82921119:-
GBM	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	10.44	2.4e-18	4.68e-14	0.9	0.7	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
GBM	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-10.44	2.41e-18	4.7e-14	-1	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
GBM	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-10.44	2.42e-18	4.71e-14	-0.83	-0.7	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
GBM	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	10.42	2.65e-18	5.14e-14	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
GBM	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-10.42	2.69e-18	5.22e-14	-0.85	-0.7	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
GBM	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-10.42	2.71e-18	5.26e-14	-0.85	-0.7	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
GBM	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-10.41	2.76e-18	5.35e-14	-0.96	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
GBM	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-10.41	2.76e-18	5.35e-14	-0.96	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
GBM	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-10.4	2.9e-18	5.61e-14	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
GBM	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-10.4	2.92e-18	5.64e-14	-0.89	-0.7	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
GBM	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-10.39	3.07e-18	5.92e-14	-0.84	-0.7	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
GBM	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	10.39	3.16e-18	6.1e-14	1.08	0.7	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-10.38	3.28e-18	6.32e-14	-0.73	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
GBM	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-10.37	3.4e-18	6.53e-14	-0.85	-0.7	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
GBM	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-10.37	3.49e-18	6.71e-14	-0.89	-0.7	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
GBM	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	10.37	3.54e-18	6.79e-14	0.9	0.7	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
GBM	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-10.36	3.57e-18	6.86e-14	-0.85	-0.69	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
GBM	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	10.36	3.58e-18	6.86e-14	0.9	0.69	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
GBM	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	10.35	3.81e-18	7.3e-14	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
GBM	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	10.35	3.81e-18	7.3e-14	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
GBM	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	10.35	3.81e-18	7.3e-14	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	10.35	3.88e-18	7.42e-14	0.75	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
GBM	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-10.34	3.98e-18	7.59e-14	-1.2	-0.69	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
GBM	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-10.33	4.28e-18	8.13e-14	-0.9	-0.69	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
GBM	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-10.33	4.28e-18	8.13e-14	-0.9	-0.69	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
GBM	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-10.33	4.38e-18	8.3e-14	-0.81	-0.69	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-10.33	4.38e-18	8.3e-14	-0.81	-0.69	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
GBM	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	10.32	4.5e-18	8.52e-14	0.9	0.69	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	10.32	4.5e-18	8.52e-14	0.9	0.69	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
GBM	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-10.31	4.75e-18	8.98e-14	-0.87	-0.69	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-10.31	4.75e-18	8.98e-14	-0.87	-0.69	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
GBM	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	10.31	4.82e-18	9.11e-14	0.9	0.69	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
GBM	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-10.3	5.06e-18	9.54e-14	-0.84	-0.69	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
GBM	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-10.3	5.08e-18	9.57e-14	-0.84	-0.69	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-10.3	5.08e-18	9.57e-14	-0.84	-0.69	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-10.3	5.08e-18	9.57e-14	-0.84	-0.69	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
GBM	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-10.3	5.14e-18	9.67e-14	-0.89	-0.69	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	10.3	5.14e-18	9.67e-14	0.89	0.69	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
GBM	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	10.29	5.2e-18	9.77e-14	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	10.29	5.2e-18	9.77e-14	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
GBM	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	10.29	5.2e-18	9.77e-14	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
GBM	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	10.29	5.29e-18	9.92e-14	0.8	0.69	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
GBM	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	10.26	6.18e-18	1.15e-13	1.07	0.69	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
GBM	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-10.26	6.42e-18	1.2e-13	-0.92	-0.69	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
GBM	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	10.25	6.68e-18	1.24e-13	1.07	0.69	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	10.25	6.68e-18	1.24e-13	1.07	0.69	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	10.25	6.68e-18	1.24e-13	1.07	0.69	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	10.25	6.68e-18	1.24e-13	1.07	0.69	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
GBM	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	10.24	6.86e-18	1.28e-13	0.89	0.69	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
GBM	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	10.24	6.98e-18	1.3e-13	0.82	0.69	Depression;	chr6:28314871	chr6:28176188~28176674:+
GBM	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	10.22	7.62e-18	1.41e-13	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
GBM	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-10.22	7.62e-18	1.42e-13	-0.87	-0.69	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
GBM	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	10.22	7.9e-18	1.46e-13	0.83	0.69	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
GBM	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	10.21	8.36e-18	1.55e-13	0.82	0.69	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
GBM	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-10.2	8.45e-18	1.56e-13	-0.97	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
GBM	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-10.2	8.45e-18	1.56e-13	-0.97	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
GBM	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-10.2	8.62e-18	1.59e-13	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
GBM	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	10.2	8.86e-18	1.64e-13	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	10.2	8.86e-18	1.64e-13	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	10.2	8.86e-18	1.64e-13	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
GBM	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	10.2	8.86e-18	1.64e-13	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-10.19	9.1e-18	1.68e-13	-0.9	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
GBM	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-10.19	9.16e-18	1.69e-13	-1.14	-0.69	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
GBM	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	10.19	9.35e-18	1.72e-13	1.05	0.69	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	10.18	9.52e-18	1.75e-13	0.72	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
GBM	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-10.18	9.58e-18	1.76e-13	-0.84	-0.69	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
GBM	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	10.18	9.72e-18	1.79e-13	1.07	0.69	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
GBM	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-10.18	9.86e-18	1.81e-13	-0.89	-0.69	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-10.18	9.86e-18	1.81e-13	-0.89	-0.69	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-10.17	1.01e-17	1.86e-13	-0.93	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-10.17	1.01e-17	1.86e-13	-0.93	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-10.17	1.01e-17	1.86e-13	-0.93	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-10.17	1.01e-17	1.86e-13	-0.93	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-10.17	1.01e-17	1.86e-13	-0.93	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
GBM	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	10.15	1.11e-17	2.03e-13	0.8	0.69	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
GBM	cis	rs6452524	0.901	rs10079680	ENSG00000248112.1	RP11-78C3.1	10.15	1.12e-17	2.05e-13	0.8	0.69	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:82919376~82921119:-
GBM	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-10.15	1.13e-17	2.07e-13	-0.84	-0.69	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	10.13	1.25e-17	2.27e-13	0.81	0.69	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-10.13	1.25e-17	2.27e-13	-0.81	-0.69	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
GBM	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-10.13	1.25e-17	2.27e-13	-0.78	-0.69	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
GBM	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-10.13	1.28e-17	2.33e-13	-0.83	-0.69	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
GBM	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	10.13	1.3e-17	2.36e-13	0.8	0.69	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	10.13	1.3e-17	2.36e-13	0.8	0.69	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	10.13	1.3e-17	2.36e-13	0.8	0.69	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	10.13	1.3e-17	2.36e-13	0.8	0.69	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
GBM	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	10.12	1.33e-17	2.41e-13	0.86	0.69	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
GBM	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-10.12	1.33e-17	2.41e-13	-0.86	-0.69	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-10.11	1.44e-17	2.61e-13	-0.8	-0.69	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
GBM	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	10.1	1.48e-17	2.68e-13	0.83	0.69	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
GBM	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-10.09	1.55e-17	2.81e-13	-0.85	-0.69	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
GBM	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	10.09	1.56e-17	2.83e-13	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
GBM	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-10.09	1.57e-17	2.83e-13	-0.86	-0.69	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-10.07	1.74e-17	3.14e-13	-0.87	-0.68	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
GBM	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	10.07	1.78e-17	3.2e-13	0.78	0.68	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
GBM	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	10.06	1.86e-17	3.33e-13	0.87	0.68	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
GBM	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-10.06	1.89e-17	3.38e-13	-0.86	-0.68	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
GBM	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-10.05	1.91e-17	3.41e-13	-0.95	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
GBM	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-10.05	1.91e-17	3.41e-13	-0.95	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
GBM	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-10.05	1.95e-17	3.48e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-10.05	1.97e-17	3.51e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-10.05	1.97e-17	3.51e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-10.04	2.06e-17	3.67e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-10.04	2.06e-17	3.67e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-10.04	2.06e-17	3.67e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-10.04	2.06e-17	3.67e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-10.04	2.06e-17	3.67e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-10.04	2.06e-17	3.67e-13	-0.88	-0.68	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
GBM	cis	rs6452524	0.935	rs11750799	ENSG00000248112.1	RP11-78C3.1	10.04	2.07e-17	3.67e-13	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs10942321	ENSG00000248112.1	RP11-78C3.1	10.04	2.07e-17	3.67e-13	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs6868416	ENSG00000248112.1	RP11-78C3.1	10.04	2.07e-17	3.67e-13	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1478485	ENSG00000248112.1	RP11-78C3.1	10.04	2.07e-17	3.67e-13	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:82919376~82921119:-
GBM	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	10.03	2.13e-17	3.78e-13	0.93	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	10.03	2.17e-17	3.85e-13	0.73	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
GBM	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-10.03	2.18e-17	3.85e-13	-0.83	-0.68	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
GBM	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-10.02	2.24e-17	3.95e-13	-0.92	-0.68	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
GBM	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	10.02	2.28e-17	4.03e-13	0.94	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
GBM	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	10.02	2.28e-17	4.03e-13	0.94	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
GBM	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-10.01	2.37e-17	4.16e-13	-0.95	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
GBM	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	10	2.53e-17	4.44e-13	0.84	0.68	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	10	2.53e-17	4.44e-13	0.84	0.68	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
GBM	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	10	2.59e-17	4.55e-13	0.8	0.68	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
GBM	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-9.99	2.72e-17	4.77e-13	-0.93	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-9.98	2.9e-17	5.08e-13	-0.9	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
GBM	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	9.97	2.96e-17	5.17e-13	0.82	0.68	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
GBM	cis	rs6452524	0.935	rs7718472	ENSG00000248112.1	RP11-78C3.1	9.94	3.45e-17	6.02e-13	0.78	0.68	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:82919376~82921119:-
GBM	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-9.94	3.46e-17	6.04e-13	-0.84	-0.68	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
GBM	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	9.94	3.53e-17	6.15e-13	0.82	0.68	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
GBM	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-9.94	3.55e-17	6.18e-13	-0.82	-0.68	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000224205.1	AP000351.4	-9.91	4.15e-17	7.23e-13	-0.79	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000224205.1	AP000351.4	9.91	4.17e-17	7.25e-13	0.79	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23987320~23991421:-
GBM	cis	rs6452524	0.967	rs4616871	ENSG00000248112.1	RP11-78C3.1	9.9	4.4e-17	7.63e-13	0.81	0.68	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs11949474	ENSG00000248112.1	RP11-78C3.1	9.9	4.4e-17	7.63e-13	0.81	0.68	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:82919376~82921119:-
GBM	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	9.9	4.45e-17	7.73e-13	0.86	0.68	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
GBM	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-9.9	4.49e-17	7.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
GBM	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-9.89	4.57e-17	7.89e-13	-0.86	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
GBM	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	9.88	4.83e-17	8.32e-13	0.83	0.68	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
GBM	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-9.88	4.96e-17	8.55e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-9.88	4.96e-17	8.55e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
GBM	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-9.87	5.04e-17	8.67e-13	-0.83	-0.68	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
GBM	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	9.87	5.21e-17	8.95e-13	0.83	0.68	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
GBM	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	9.85	5.61e-17	9.63e-13	0.81	0.68	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
GBM	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	9.85	5.65e-17	9.68e-13	0.92	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
GBM	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	9.85	5.65e-17	9.68e-13	0.92	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
GBM	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	9.85	5.68e-17	9.74e-13	0.87	0.68	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
GBM	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-9.85	5.7e-17	9.76e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-9.85	5.82e-17	9.96e-13	-0.89	-0.68	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
GBM	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	9.84	6.01e-17	1.03e-12	0.87	0.68	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
GBM	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	9.84	6.06e-17	1.04e-12	0.71	0.68	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
GBM	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	9.84	6.18e-17	1.05e-12	0.82	0.68	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	9.84	6.18e-17	1.05e-12	0.82	0.68	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.935	rs6880566	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.905	rs6884981	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.905	rs6896548	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs6896953	ENSG00000248112.1	RP11-78C3.1	-9.84	6.2e-17	1.05e-12	-0.8	-0.68	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.901	rs1600362	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1580311	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1580310	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1011979	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.901	rs17284211	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1382374	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs10071617	ENSG00000248112.1	RP11-78C3.1	9.84	6.2e-17	1.05e-12	0.8	0.68	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:82919376~82921119:-
GBM	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-9.83	6.4e-17	1.09e-12	-0.8	-0.68	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
GBM	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-9.83	6.4e-17	1.09e-12	-0.8	-0.68	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
GBM	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-9.83	6.42e-17	1.09e-12	-0.83	-0.68	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
GBM	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-9.82	6.59e-17	1.12e-12	-0.79	-0.68	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
GBM	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	9.82	6.6e-17	1.12e-12	0.81	0.68	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	9.82	6.6e-17	1.12e-12	0.81	0.68	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	9.82	6.6e-17	1.12e-12	0.81	0.68	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.967	rs11741420	ENSG00000248112.1	RP11-78C3.1	9.82	6.72e-17	1.13e-12	0.79	0.68	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs4401555	ENSG00000248112.1	RP11-78C3.1	9.82	6.72e-17	1.13e-12	0.79	0.68	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs62374400	ENSG00000248112.1	RP11-78C3.1	9.82	6.72e-17	1.13e-12	0.79	0.68	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs10040363	ENSG00000248112.1	RP11-78C3.1	9.82	6.72e-17	1.13e-12	0.79	0.68	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs10051542	ENSG00000248112.1	RP11-78C3.1	9.82	6.72e-17	1.13e-12	0.79	0.68	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs10051557	ENSG00000248112.1	RP11-78C3.1	9.82	6.72e-17	1.13e-12	0.79	0.68	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:82919376~82921119:-
GBM	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	9.82	6.78e-17	1.14e-12	1.1	0.68	Shingles;	chr7:38346957	chr7:38343894~38350022:-
GBM	cis	rs6452524	0.935	rs9293330	ENSG00000248112.1	RP11-78C3.1	9.81	7.07e-17	1.19e-12	0.81	0.68	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:82919376~82921119:-
GBM	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-9.81	7.11e-17	1.2e-12	-0.92	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
GBM	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	9.81	7.29e-17	1.22e-12	0.81	0.67	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	9.81	7.29e-17	1.22e-12	0.81	0.67	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
GBM	cis	rs6452524	1	rs6452531	ENSG00000248112.1	RP11-78C3.1	9.8	7.38e-17	1.24e-12	0.83	0.67	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:82919376~82921119:-
GBM	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	9.8	7.44e-17	1.25e-12	0.84	0.67	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
GBM	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-9.8	7.65e-17	1.28e-12	-0.8	-0.67	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
GBM	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	9.8	7.7e-17	1.29e-12	1.13	0.67	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
GBM	cis	rs9637599	0.967	rs7661312	ENSG00000246375.2	RP11-10L7.1	9.79	8.05e-17	1.35e-12	0.72	0.67	Metabolite levels (small molecules and protein measures);	chr4:88279855	chr4:88284942~88331421:+
GBM	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-9.79	8.1e-17	1.35e-12	-0.89	-0.67	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
GBM	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	9.79	8.1e-17	1.35e-12	0.77	0.67	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
GBM	cis	rs6452524	0.934	rs2940543	ENSG00000248112.1	RP11-78C3.1	9.79	8.11e-17	1.35e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2974450	ENSG00000248112.1	RP11-78C3.1	9.79	8.11e-17	1.35e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2974449	ENSG00000248112.1	RP11-78C3.1	9.79	8.11e-17	1.35e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2662241	ENSG00000248112.1	RP11-78C3.1	9.79	8.11e-17	1.35e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs2940544	ENSG00000248112.1	RP11-78C3.1	9.79	8.11e-17	1.35e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2731865	ENSG00000248112.1	RP11-78C3.1	9.79	8.11e-17	1.35e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs4541638	ENSG00000248112.1	RP11-78C3.1	9.77	8.81e-17	1.46e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs28360104	ENSG00000248112.1	RP11-78C3.1	9.77	8.81e-17	1.46e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:82919376~82921119:-
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-9.77	8.96e-17	1.49e-12	-0.88	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-9.77	8.96e-17	1.49e-12	-0.88	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-9.77	8.96e-17	1.49e-12	-0.88	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
GBM	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	9.76	9.11e-17	1.51e-12	0.84	0.67	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
GBM	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	9.76	9.19e-17	1.52e-12	1.13	0.67	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
GBM	cis	rs6452524	0.711	rs1478486	ENSG00000248112.1	RP11-78C3.1	9.76	9.22e-17	1.53e-12	0.87	0.67	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:82919376~82921119:-
GBM	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	9.76	9.26e-17	1.53e-12	0.79	0.67	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	9.76	9.26e-17	1.53e-12	0.79	0.67	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	9.76	9.26e-17	1.53e-12	0.79	0.67	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	9.76	9.26e-17	1.53e-12	0.79	0.67	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	9.76	9.33e-17	1.54e-12	0.85	0.67	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
GBM	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-9.76	9.39e-17	1.55e-12	-0.76	-0.67	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
GBM	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	9.76	9.53e-17	1.57e-12	0.78	0.67	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	9.76	9.56e-17	1.57e-12	0.71	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
GBM	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-9.75	9.74e-17	1.6e-12	-1.15	-0.67	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	9.74	1.05e-16	1.72e-12	0.7	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
GBM	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	9.73	1.07e-16	1.74e-12	0.82	0.67	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
GBM	cis	rs6452524	1	rs1382364	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs1382363	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs9293334	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs11741897	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs2126990	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10076000	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs13436667	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7726564	ENSG00000248112.1	RP11-78C3.1	9.72	1.17e-16	1.91e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:82919376~82921119:-
GBM	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-9.72	1.19e-16	1.92e-12	-0.75	-0.67	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
GBM	cis	rs6452524	1	rs1382368	ENSG00000248112.1	RP11-78C3.1	9.71	1.2e-16	1.94e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs1382366	ENSG00000248112.1	RP11-78C3.1	9.71	1.2e-16	1.94e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs13358361	ENSG00000248112.1	RP11-78C3.1	9.71	1.2e-16	1.94e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6452528	ENSG00000248112.1	RP11-78C3.1	9.71	1.2e-16	1.94e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6864479	ENSG00000248112.1	RP11-78C3.1	9.71	1.2e-16	1.94e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:82919376~82921119:-
GBM	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	9.7	1.28e-16	2.06e-12	0.78	0.67	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
GBM	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-9.7	1.29e-16	2.07e-12	-0.8	-0.67	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-9.7	1.29e-16	2.07e-12	-0.8	-0.67	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
GBM	cis	rs6452524	0.967	rs2974443	ENSG00000248112.1	RP11-78C3.1	9.7	1.29e-16	2.08e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2974441	ENSG00000248112.1	RP11-78C3.1	9.7	1.29e-16	2.08e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:82919376~82921119:-
GBM	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	9.7	1.31e-16	2.09e-12	1.01	0.67	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
GBM	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	9.7	1.31e-16	2.09e-12	1.01	0.67	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
GBM	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-9.7	1.31e-16	2.09e-12	-0.89	-0.67	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-9.7	1.31e-16	2.09e-12	-0.89	-0.67	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-9.7	1.31e-16	2.09e-12	-0.89	-0.67	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
GBM	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	9.7	1.31e-16	2.09e-12	0.8	0.67	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	9.7	1.31e-16	2.09e-12	0.8	0.67	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	9.7	1.31e-16	2.09e-12	0.8	0.67	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.967	rs4290995	ENSG00000248112.1	RP11-78C3.1	9.7	1.31e-16	2.09e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs965674	ENSG00000248112.1	RP11-78C3.1	9.7	1.31e-16	2.09e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2662242	ENSG00000248112.1	RP11-78C3.1	9.7	1.31e-16	2.09e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2731844	ENSG00000248112.1	RP11-78C3.1	9.7	1.31e-16	2.09e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.901	rs2940540	ENSG00000248112.1	RP11-78C3.1	9.7	1.31e-16	2.09e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.905	rs7736289	ENSG00000248112.1	RP11-78C3.1	9.69	1.35e-16	2.16e-12	0.79	0.67	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:82919376~82921119:-
GBM	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	9.69	1.36e-16	2.18e-12	0.85	0.67	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
GBM	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-9.69	1.38e-16	2.2e-12	-0.86	-0.67	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
GBM	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	9.69	1.39e-16	2.22e-12	1.02	0.67	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
GBM	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	9.69	1.39e-16	2.22e-12	1.02	0.67	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
GBM	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-9.69	1.39e-16	2.22e-12	-0.89	-0.67	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-9.69	1.39e-16	2.22e-12	-0.89	-0.67	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
GBM	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	9.68	1.42e-16	2.26e-12	1.09	0.67	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	9.68	1.43e-16	2.27e-12	0.69	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-9.68	1.45e-16	2.31e-12	-0.87	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-9.68	1.45e-16	2.31e-12	-0.87	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-9.68	1.45e-16	2.31e-12	-0.87	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-9.68	1.45e-16	2.31e-12	-0.87	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
GBM	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-9.67	1.51e-16	2.39e-12	-0.93	-0.67	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
GBM	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-9.67	1.52e-16	2.42e-12	-0.78	-0.67	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
GBM	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-9.67	1.55e-16	2.46e-12	-0.79	-0.67	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
GBM	cis	rs6452524	0.967	rs2974445	ENSG00000248112.1	RP11-78C3.1	-9.67	1.55e-16	2.46e-12	-0.79	-0.67	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2974444	ENSG00000248112.1	RP11-78C3.1	9.67	1.55e-16	2.46e-12	0.79	0.67	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2940542	ENSG00000248112.1	RP11-78C3.1	9.67	1.55e-16	2.46e-12	0.79	0.67	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs2731861	ENSG00000248112.1	RP11-78C3.1	9.67	1.55e-16	2.46e-12	0.79	0.67	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.934	rs10473870	ENSG00000248112.1	RP11-78C3.1	9.66	1.57e-16	2.49e-12	0.78	0.67	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:82919376~82921119:-
GBM	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	9.66	1.58e-16	2.49e-12	0.85	0.67	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	9.66	1.6e-16	2.52e-12	0.72	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	9.66	1.6e-16	2.52e-12	0.72	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	9.66	1.6e-16	2.52e-12	0.72	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	9.66	1.6e-16	2.52e-12	0.72	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	9.66	1.6e-16	2.52e-12	0.72	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	9.66	1.63e-16	2.57e-12	0.77	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	9.66	1.63e-16	2.57e-12	0.77	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
GBM	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	9.64	1.82e-16	2.85e-12	0.85	0.67	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-9.63	1.84e-16	2.89e-12	-0.72	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
GBM	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-9.63	1.88e-16	2.95e-12	-0.76	-0.67	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-9.63	1.88e-16	2.95e-12	-0.76	-0.67	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-9.63	1.92e-16	3.02e-12	-0.78	-0.67	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
GBM	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	9.62	1.95e-16	3.05e-12	0.79	0.67	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
GBM	cis	rs6452524	1	rs10474094	ENSG00000248112.1	RP11-78C3.1	9.62	1.95e-16	3.06e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1382376	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs12109517	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs12109514	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs6897075	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs10065973	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs12153441	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs12152891	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs6452507	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs6452508	ENSG00000248112.1	RP11-78C3.1	9.62	1.96e-16	3.06e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:82919376~82921119:-
GBM	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	9.62	1.99e-16	3.1e-12	0.8	0.67	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
GBM	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-9.62	2.03e-16	3.16e-12	-0.8	-0.67	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
GBM	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	9.61	2.11e-16	3.28e-12	1.11	0.67	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
GBM	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	9.61	2.11e-16	3.28e-12	1.11	0.67	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
GBM	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-9.61	2.12e-16	3.29e-12	-0.8	-0.67	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
GBM	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-9.61	2.14e-16	3.3e-12	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
GBM	cis	rs6452524	1	rs62374373	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10043018	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs10037501	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.904	rs6452525	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7716931	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7721416	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6882220	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6452526	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6452527	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10055844	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10077862	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs9293332	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10474093	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs10473868	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6868817	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs10042018	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs10036418	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10055948	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10037872	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs62374374	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs1382372	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs1382371	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs1382369	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs2386240	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs9986131	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs4591730	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs1031902	ENSG00000248112.1	RP11-78C3.1	9.61	2.15e-16	3.3e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10042854	ENSG00000248112.1	RP11-78C3.1	-9.61	2.15e-16	3.3e-12	-0.81	-0.67	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:82919376~82921119:-
GBM	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	9.6	2.16e-16	3.31e-12	1.09	0.67	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
GBM	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-9.6	2.17e-16	3.32e-12	-0.77	-0.67	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
GBM	cis	rs6452524	1	rs2126988	ENSG00000248112.1	RP11-78C3.1	9.6	2.2e-16	3.37e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs17284288	ENSG00000248112.1	RP11-78C3.1	9.6	2.2e-16	3.37e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs11740478	ENSG00000248112.1	RP11-78C3.1	9.6	2.2e-16	3.37e-12	0.81	0.67	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:82919376~82921119:-
GBM	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-9.6	2.21e-16	3.37e-12	-0.77	-0.67	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
GBM	cis	rs6452524	0.935	rs10076059	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs7736783	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs11951257	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs767771	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.905	rs1478482	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs10045744	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1542539	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1543847	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs1564211	ENSG00000248112.1	RP11-78C3.1	9.6	2.24e-16	3.39e-12	0.8	0.67	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:82919376~82921119:-
GBM	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	9.59	2.37e-16	3.6e-12	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
GBM	cis	rs6452524	1	rs6452524	ENSG00000248112.1	RP11-78C3.1	-9.58	2.42e-16	3.66e-12	-0.81	-0.67	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:82919376~82921119:-
GBM	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	9.58	2.48e-16	3.74e-12	0.87	0.67	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
GBM	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	9.57	2.53e-16	3.81e-12	1.01	0.67	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
GBM	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	9.57	2.53e-16	3.81e-12	1.01	0.67	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
GBM	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	9.57	2.53e-16	3.81e-12	1.01	0.67	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
GBM	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-9.57	2.64e-16	3.97e-12	-0.79	-0.67	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
GBM	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	9.56	2.71e-16	4.07e-12	0.79	0.67	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
GBM	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	9.56	2.72e-16	4.09e-12	0.87	0.67	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
GBM	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	9.56	2.74e-16	4.11e-12	1.01	0.67	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
GBM	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	9.56	2.74e-16	4.11e-12	1.01	0.67	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
GBM	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	9.56	2.77e-16	4.14e-12	0.8	0.67	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
GBM	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-9.56	2.77e-16	4.14e-12	-0.77	-0.67	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-9.56	2.77e-16	4.14e-12	-0.88	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
GBM	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	9.56	2.78e-16	4.15e-12	0.82	0.67	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	9.55	2.84e-16	4.24e-12	0.87	0.67	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
GBM	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	9.55	2.85e-16	4.24e-12	0.75	0.67	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	9.55	2.85e-16	4.24e-12	0.75	0.67	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	9.55	2.85e-16	4.24e-12	0.75	0.67	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	9.55	2.85e-16	4.24e-12	0.75	0.67	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	9.55	2.85e-16	4.24e-12	0.75	0.67	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
GBM	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-9.55	2.87e-16	4.27e-12	-0.79	-0.67	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
GBM	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	9.55	2.92e-16	4.35e-12	1	0.66	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
GBM	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-9.54	2.98e-16	4.43e-12	-0.77	-0.66	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
GBM	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	9.54	3.01e-16	4.45e-12	0.77	0.66	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-9.54	3.01e-16	4.45e-12	-0.77	-0.66	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
GBM	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	9.54	3.01e-16	4.45e-12	0.8	0.66	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.901	rs1580309	ENSG00000248112.1	RP11-78C3.1	9.54	3.02e-16	4.47e-12	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:82919376~82921119:-
GBM	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	9.54	3.05e-16	4.49e-12	0.75	0.66	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	9.54	3.05e-16	4.49e-12	0.75	0.66	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	9.54	3.05e-16	4.49e-12	0.75	0.66	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	9.54	3.05e-16	4.49e-12	0.75	0.66	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	9.54	3.05e-16	4.49e-12	0.75	0.66	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
GBM	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-9.54	3.11e-16	4.57e-12	-0.86	-0.66	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
GBM	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	9.54	3.12e-16	4.59e-12	0.78	0.66	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
GBM	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-9.53	3.14e-16	4.62e-12	-0.91	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
GBM	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	9.53	3.17e-16	4.67e-12	0.87	0.66	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	9.53	3.3e-16	4.83e-12	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
GBM	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-9.51	3.51e-16	5.1e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
GBM	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-9.51	3.51e-16	5.1e-12	-0.76	-0.66	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
GBM	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	9.51	3.54e-16	5.13e-12	0.78	0.66	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	9.51	3.54e-16	5.13e-12	0.78	0.66	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	9.51	3.54e-16	5.13e-12	0.78	0.66	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-9.51	3.54e-16	5.13e-12	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-9.51	3.54e-16	5.13e-12	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-9.51	3.54e-16	5.13e-12	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	9.51	3.56e-16	5.15e-12	0.84	0.66	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
GBM	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-9.51	3.61e-16	5.22e-12	-0.89	-0.66	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
GBM	cis	rs6452524	0.836	rs1478484	ENSG00000248112.1	RP11-78C3.1	9.5	3.7e-16	5.34e-12	0.78	0.66	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs7714710	ENSG00000248112.1	RP11-78C3.1	9.5	3.7e-16	5.34e-12	0.78	0.66	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1017794	ENSG00000248112.1	RP11-78C3.1	9.5	3.7e-16	5.34e-12	0.78	0.66	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:82919376~82921119:-
GBM	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-9.5	3.7e-16	5.35e-12	-0.91	-0.66	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
GBM	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-9.5	3.71e-16	5.35e-12	-0.77	-0.66	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-9.5	3.71e-16	5.35e-12	-0.77	-0.66	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-9.5	3.71e-16	5.35e-12	-0.77	-0.66	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-9.5	3.71e-16	5.35e-12	-0.77	-0.66	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
GBM	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	9.5	3.74e-16	5.39e-12	1.02	0.66	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
GBM	cis	rs6452524	1	rs6887846	ENSG00000248112.1	RP11-78C3.1	-9.5	3.83e-16	5.51e-12	-0.79	-0.66	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:82919376~82921119:-
GBM	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-9.49	3.93e-16	5.65e-12	-0.76	-0.66	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-9.49	3.95e-16	5.67e-12	-0.78	-0.66	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-9.48	4.11e-16	5.88e-12	-0.78	-0.66	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-9.48	4.11e-16	5.88e-12	-0.78	-0.66	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-9.48	4.11e-16	5.88e-12	-0.78	-0.66	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-9.48	4.11e-16	5.88e-12	-0.78	-0.66	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-9.48	4.11e-16	5.88e-12	-0.78	-0.66	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-9.48	4.11e-16	5.88e-12	-0.78	-0.66	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-9.48	4.11e-16	5.88e-12	-0.78	-0.66	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
GBM	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-9.48	4.32e-16	6.18e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-9.47	4.4e-16	6.28e-12	-0.76	-0.66	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
GBM	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-9.47	4.47e-16	6.36e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
GBM	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-9.47	4.47e-16	6.36e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-9.47	4.47e-16	6.36e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-9.47	4.47e-16	6.36e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-9.47	4.47e-16	6.36e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-9.47	4.47e-16	6.36e-12	-0.77	-0.66	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
GBM	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	9.47	4.49e-16	6.38e-12	0.77	0.66	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	9.46	4.61e-16	6.54e-12	0.86	0.66	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	9.46	4.61e-16	6.54e-12	0.86	0.66	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
GBM	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-9.46	4.72e-16	6.67e-12	-0.83	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
GBM	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-9.46	4.73e-16	6.68e-12	-0.87	-0.66	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
GBM	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-9.46	4.76e-16	6.72e-12	-0.79	-0.66	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
GBM	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	9.45	4.87e-16	6.86e-12	0.86	0.66	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
GBM	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-9.45	4.89e-16	6.88e-12	-0.76	-0.66	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-9.45	4.89e-16	6.88e-12	-0.76	-0.66	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-9.45	4.89e-16	6.88e-12	-0.76	-0.66	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-9.45	4.89e-16	6.88e-12	-0.76	-0.66	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-9.45	4.89e-16	6.88e-12	-0.76	-0.66	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-9.45	4.89e-16	6.88e-12	-0.76	-0.66	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
GBM	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-9.44	5.14e-16	7.21e-12	-0.78	-0.66	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
GBM	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-9.44	5.14e-16	7.21e-12	-0.78	-0.66	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-9.44	5.14e-16	7.21e-12	-0.78	-0.66	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
GBM	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-9.44	5.23e-16	7.34e-12	-0.76	-0.66	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
GBM	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	9.44	5.27e-16	7.4e-12	0.83	0.66	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
GBM	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	9.44	5.33e-16	7.47e-12	0.86	0.66	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
GBM	cis	rs6452524	0.935	rs7736296	ENSG00000248112.1	RP11-78C3.1	-9.44	5.35e-16	7.49e-12	-0.78	-0.66	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:82919376~82921119:-
GBM	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-9.44	5.35e-16	7.49e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-9.44	5.35e-16	7.49e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-9.44	5.35e-16	7.49e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
GBM	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	9.43	5.6e-16	7.83e-12	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
GBM	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-9.43	5.62e-16	7.83e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
GBM	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-9.43	5.64e-16	7.85e-12	-0.76	-0.66	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
GBM	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-9.43	5.64e-16	7.85e-12	-0.76	-0.66	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-9.43	5.64e-16	7.85e-12	-0.76	-0.66	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-9.43	5.64e-16	7.85e-12	-0.76	-0.66	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-9.43	5.64e-16	7.85e-12	-0.76	-0.66	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-9.43	5.64e-16	7.85e-12	-0.76	-0.66	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
GBM	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-9.42	5.71e-16	7.93e-12	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
GBM	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	9.42	5.95e-16	8.26e-12	0.79	0.66	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
GBM	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	9.41	5.99e-16	8.31e-12	0.77	0.66	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-9.41	6.13e-16	8.49e-12	-0.87	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
GBM	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-9.41	6.16e-16	8.54e-12	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-9.4	6.42e-16	8.88e-12	-0.77	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
GBM	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-9.4	6.44e-16	8.9e-12	-0.76	-0.66	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	9.4	6.47e-16	8.94e-12	0.77	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
GBM	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-9.4	6.47e-16	8.94e-12	-0.76	-0.66	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-9.4	6.47e-16	8.94e-12	-0.76	-0.66	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	9.4	6.5e-16	8.98e-12	0.7	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
GBM	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	9.4	6.53e-16	9.01e-12	0.81	0.66	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-9.4	6.56e-16	9.04e-12	-0.76	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
GBM	cis	rs6452524	0.686	rs6452518	ENSG00000248112.1	RP11-78C3.1	9.4	6.59e-16	9.08e-12	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6452519	ENSG00000248112.1	RP11-78C3.1	9.4	6.59e-16	9.08e-12	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10069402	ENSG00000248112.1	RP11-78C3.1	9.4	6.59e-16	9.08e-12	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:82919376~82921119:-
GBM	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	9.39	6.7e-16	9.22e-12	1.06	0.66	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
GBM	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-9.38	7.3e-16	9.95e-12	-0.78	-0.66	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
GBM	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	9.38	7.32e-16	9.97e-12	0.91	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
GBM	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	9.37	7.47e-16	1.02e-11	0.77	0.66	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
GBM	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	9.37	7.56e-16	1.03e-11	0.84	0.66	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
GBM	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-9.37	7.56e-16	1.03e-11	-0.88	-0.66	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
GBM	cis	rs6452524	1	rs10076271	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10076274	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10061521	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7733151	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7733330	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7733354	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs4634330	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs2386238	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs2386239	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.934	rs7700253	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs10067439	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7710900	ENSG00000248112.1	RP11-78C3.1	9.37	7.68e-16	1.04e-11	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:82919376~82921119:-
GBM	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-9.37	7.68e-16	1.04e-11	-0.8	-0.66	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	9.37	7.72e-16	1.04e-11	0.84	0.66	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
GBM	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
GBM	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	9.36	7.87e-16	1.06e-11	0.87	0.66	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
GBM	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-9.36	8.17e-16	1.1e-11	-0.77	-0.66	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-9.36	8.21e-16	1.1e-11	-0.76	-0.66	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-9.36	8.21e-16	1.1e-11	-0.76	-0.66	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
GBM	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	9.35	8.4e-16	1.13e-11	0.87	0.66	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
GBM	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	9.35	8.51e-16	1.14e-11	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
GBM	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	9.35	8.63e-16	1.16e-11	0.8	0.66	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	9.35	8.63e-16	1.16e-11	0.8	0.66	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	9.35	8.63e-16	1.16e-11	0.8	0.66	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	9.35	8.63e-16	1.16e-11	0.8	0.66	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	9.35	8.63e-16	1.16e-11	0.8	0.66	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	9.35	8.63e-16	1.16e-11	0.8	0.66	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
GBM	cis	rs9637599	1	rs9637599	ENSG00000246375.2	RP11-10L7.1	9.35	8.71e-16	1.17e-11	0.69	0.66	Metabolite levels (small molecules and protein measures);	chr4:88285078	chr4:88284942~88331421:+
GBM	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-9.34	8.73e-16	1.17e-11	-0.88	-0.66	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
GBM	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	9.34	9.05e-16	1.21e-11	0.78	0.66	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
GBM	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	9.33	9.23e-16	1.23e-11	0.85	0.66	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-9.33	9.53e-16	1.27e-11	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
GBM	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-9.33	9.62e-16	1.28e-11	-0.81	-0.66	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-9.33	9.62e-16	1.28e-11	-0.81	-0.66	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
GBM	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-9.33	9.65e-16	1.29e-11	-0.86	-0.66	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
GBM	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	9.33	9.68e-16	1.29e-11	0.82	0.66	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
GBM	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	9.32	9.72e-16	1.3e-11	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
GBM	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	9.31	1.06e-15	1.4e-11	0.99	0.66	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
GBM	cis	rs916888	0.602	rs199508	ENSG00000262539.1	RP11-259G18.3	-9.3	1.14e-15	1.51e-11	-0.89	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:46259551~46260606:-
GBM	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
GBM	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-9.29	1.14e-15	1.51e-11	-0.74	-0.65	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
GBM	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	9.29	1.15e-15	1.52e-11	0.84	0.65	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
GBM	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	9.28	1.21e-15	1.6e-11	0.78	0.65	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
GBM	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	9.28	1.22e-15	1.6e-11	0.76	0.65	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
GBM	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-9.28	1.22e-15	1.6e-11	-0.87	-0.65	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
GBM	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-9.28	1.24e-15	1.64e-11	-0.75	-0.65	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
GBM	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	9.28	1.26e-15	1.66e-11	0.75	0.65	Breast cancer;	chr11:750849	chr11:779617~780755:+
GBM	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	9.28	1.26e-15	1.66e-11	0.85	0.65	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
GBM	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	9.27	1.28e-15	1.69e-11	0.88	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
GBM	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	9.27	1.28e-15	1.69e-11	0.88	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
GBM	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-9.27	1.29e-15	1.7e-11	-0.76	-0.65	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-9.27	1.29e-15	1.7e-11	-0.76	-0.65	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-9.27	1.29e-15	1.7e-11	-0.76	-0.65	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
GBM	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-9.27	1.31e-15	1.72e-11	-0.76	-0.65	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-9.27	1.31e-15	1.72e-11	-0.76	-0.65	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-9.27	1.31e-15	1.72e-11	-0.76	-0.65	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
GBM	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	9.27	1.32e-15	1.73e-11	0.85	0.65	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	9.27	1.32e-15	1.73e-11	0.85	0.65	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	9.27	1.32e-15	1.73e-11	0.85	0.65	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
GBM	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-9.26	1.34e-15	1.76e-11	-0.78	-0.65	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
GBM	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	9.26	1.34e-15	1.76e-11	0.82	0.65	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
GBM	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-9.26	1.35e-15	1.77e-11	-0.75	-0.65	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-9.26	1.37e-15	1.79e-11	-0.75	-0.65	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	9.26	1.38e-15	1.79e-11	0.68	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
GBM	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	9.26	1.38e-15	1.79e-11	0.86	0.65	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
GBM	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-9.26	1.4e-15	1.81e-11	-0.79	-0.65	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
GBM	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-9.26	1.4e-15	1.81e-11	-0.79	-0.65	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
GBM	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	9.25	1.46e-15	1.87e-11	0.82	0.65	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
GBM	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	9.24	1.51e-15	1.93e-11	1.07	0.65	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
GBM	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-9.23	1.6e-15	2.05e-11	-0.77	-0.65	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-9.23	1.6e-15	2.05e-11	-0.77	-0.65	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
GBM	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	9.23	1.61e-15	2.05e-11	0.9	0.65	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
GBM	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	9.23	1.63e-15	2.07e-11	0.88	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
GBM	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	9.23	1.64e-15	2.09e-11	0.82	0.65	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
GBM	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	9.23	1.64e-15	2.09e-11	0.99	0.65	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
GBM	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	9.23	1.64e-15	2.09e-11	0.82	0.65	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
GBM	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	9.22	1.69e-15	2.14e-11	0.75	0.65	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
GBM	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-9.22	1.69e-15	2.14e-11	-0.75	-0.65	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
GBM	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	9.22	1.7e-15	2.15e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
GBM	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	9.22	1.71e-15	2.16e-11	0.78	0.65	Depression;	chr6:28363475	chr6:28176188~28176674:+
GBM	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-9.22	1.71e-15	2.16e-11	-0.81	-0.65	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	9.22	1.75e-15	2.21e-11	0.68	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
GBM	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-9.21	1.75e-15	2.21e-11	-0.75	-0.65	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-9.21	1.75e-15	2.21e-11	-0.75	-0.65	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-9.21	1.75e-15	2.21e-11	-0.75	-0.65	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
GBM	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
GBM	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
GBM	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
GBM	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
GBM	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
GBM	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
GBM	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	9.21	1.83e-15	2.28e-11	0.85	0.65	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
GBM	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	9.2	1.86e-15	2.32e-11	0.84	0.65	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
GBM	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	9.2	1.87e-15	2.33e-11	0.79	0.65	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
GBM	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	9.2	1.9e-15	2.36e-11	0.83	0.65	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	9.2	1.9e-15	2.36e-11	0.83	0.65	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	9.2	1.9e-15	2.36e-11	0.83	0.65	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	9.2	1.9e-15	2.36e-11	0.83	0.65	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	9.2	1.9e-15	2.36e-11	0.83	0.65	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	9.2	1.93e-15	2.39e-11	0.85	0.65	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
GBM	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	9.18	2.16e-15	2.66e-11	0.93	0.65	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
GBM	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-9.18	2.17e-15	2.67e-11	-0.86	-0.65	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
GBM	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	9.17	2.25e-15	2.77e-11	0.76	0.65	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
GBM	cis	rs6452524	0.901	rs2662238	ENSG00000248112.1	RP11-78C3.1	9.17	2.28e-15	2.8e-11	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:82919376~82921119:-
GBM	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-9.16	2.33e-15	2.86e-11	-0.77	-0.65	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-9.16	2.33e-15	2.86e-11	-0.77	-0.65	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-9.16	2.33e-15	2.86e-11	-0.77	-0.65	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
GBM	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-9.16	2.36e-15	2.9e-11	-0.75	-0.65	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
GBM	cis	rs916888	0.602	rs199508	ENSG00000214401.4	KANSL1-AS1	-9.16	2.4e-15	2.94e-11	-0.87	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:46193576~46196723:+
GBM	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-9.16	2.4e-15	2.95e-11	-0.76	-0.65	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-9.15	2.43e-15	2.98e-11	-0.67	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
GBM	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	9.15	2.46e-15	3e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
GBM	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	9.15	2.48e-15	3.03e-11	0.87	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
GBM	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-9.15	2.52e-15	3.07e-11	-0.77	-0.65	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
GBM	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	9.14	2.55e-15	3.11e-11	0.83	0.65	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
GBM	cis	rs6452524	0.967	rs2974448	ENSG00000248112.1	RP11-78C3.1	9.14	2.6e-15	3.18e-11	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:82919376~82921119:-
GBM	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	9.14	2.61e-15	3.18e-11	0.81	0.65	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	9.14	2.61e-15	3.18e-11	0.81	0.65	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	9.14	2.61e-15	3.18e-11	0.81	0.65	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
GBM	cis	rs6452524	1	rs6452520	ENSG00000248112.1	RP11-78C3.1	9.14	2.62e-15	3.19e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6452521	ENSG00000248112.1	RP11-78C3.1	9.14	2.62e-15	3.19e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs6452522	ENSG00000248112.1	RP11-78C3.1	9.14	2.62e-15	3.19e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:82919376~82921119:-
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	9.14	2.63e-15	3.2e-11	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
GBM	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	9.14	2.66e-15	3.23e-11	0.84	0.65	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
GBM	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	9.14	2.66e-15	3.23e-11	0.8	0.65	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	9.14	2.66e-15	3.23e-11	0.8	0.65	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	9.14	2.66e-15	3.23e-11	0.8	0.65	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-9.13	2.81e-15	3.4e-11	-0.8	-0.65	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
GBM	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	9.12	2.85e-15	3.43e-11	0.82	0.65	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	9.12	2.85e-15	3.43e-11	0.82	0.65	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	9.12	2.85e-15	3.43e-11	0.82	0.65	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
GBM	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-9.12	2.85e-15	3.43e-11	-0.76	-0.65	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-9.12	2.85e-15	3.43e-11	-0.76	-0.65	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-9.12	2.85e-15	3.43e-11	-0.76	-0.65	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-9.12	2.85e-15	3.43e-11	-0.76	-0.65	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-9.12	2.85e-15	3.43e-11	-0.76	-0.65	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-9.12	2.85e-15	3.43e-11	-0.76	-0.65	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-9.12	2.85e-15	3.43e-11	-0.76	-0.65	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-9.12	2.86e-15	3.44e-11	-0.76	-0.65	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-9.12	2.86e-15	3.44e-11	-0.76	-0.65	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
GBM	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	9.12	2.87e-15	3.45e-11	0.75	0.65	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	9.12	2.87e-15	3.45e-11	0.75	0.65	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
GBM	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	9.12	2.88e-15	3.46e-11	0.81	0.65	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
GBM	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-9.12	2.89e-15	3.47e-11	-0.76	-0.65	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
GBM	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	9.12	2.92e-15	3.5e-11	0.83	0.65	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	9.12	2.92e-15	3.5e-11	0.83	0.65	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
GBM	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	9.12	2.98e-15	3.57e-11	0.89	0.65	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
GBM	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	9.11	3.01e-15	3.61e-11	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
GBM	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	9.11	3.02e-15	3.62e-11	0.85	0.65	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	9.11	3.06e-15	3.66e-11	0.74	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
GBM	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	9.11	3.1e-15	3.71e-11	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	9.11	3.1e-15	3.71e-11	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	9.11	3.1e-15	3.71e-11	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	9.11	3.1e-15	3.71e-11	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
GBM	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-9.11	3.11e-15	3.72e-11	-0.78	-0.65	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
GBM	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	9.11	3.12e-15	3.72e-11	0.83	0.65	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
GBM	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	9.11	3.15e-15	3.73e-11	0.78	0.65	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
GBM	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-9.1	3.17e-15	3.76e-11	-0.78	-0.65	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
GBM	cis	rs6452524	0.905	rs10040244	ENSG00000248112.1	RP11-78C3.1	9.09	3.45e-15	4.07e-11	0.78	0.65	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs10474081	ENSG00000248112.1	RP11-78C3.1	9.09	3.45e-15	4.07e-11	0.78	0.65	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:82919376~82921119:-
GBM	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	9.08	3.62e-15	4.26e-11	0.79	0.65	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
GBM	cis	rs6452524	0.934	rs12153179	ENSG00000248112.1	RP11-78C3.1	9.08	3.67e-15	4.3e-11	0.78	0.65	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:82919376~82921119:-
GBM	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	9.07	3.71e-15	4.36e-11	0.8	0.65	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	9.07	3.71e-15	4.36e-11	0.8	0.65	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	9.07	3.71e-15	4.36e-11	0.8	0.65	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
GBM	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	9.07	3.72e-15	4.37e-11	0.82	0.65	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
GBM	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-9.07	3.75e-15	4.4e-11	-0.82	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
GBM	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	9.06	3.95e-15	4.62e-11	0.74	0.65	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	9.06	4.05e-15	4.73e-11	0.88	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-9.05	4.13e-15	4.83e-11	-0.87	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
GBM	cis	rs6452524	0.967	rs7717964	ENSG00000248112.1	RP11-78C3.1	9.05	4.2e-15	4.88e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.934	rs1120477	ENSG00000248112.1	RP11-78C3.1	9.05	4.2e-15	4.88e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.934	rs1120478	ENSG00000248112.1	RP11-78C3.1	9.05	4.2e-15	4.88e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.934	rs6452512	ENSG00000248112.1	RP11-78C3.1	9.05	4.2e-15	4.88e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs6452514	ENSG00000248112.1	RP11-78C3.1	9.05	4.2e-15	4.88e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs6884543	ENSG00000248112.1	RP11-78C3.1	9.05	4.2e-15	4.88e-11	0.79	0.65	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:82919376~82921119:-
GBM	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	9.05	4.21e-15	4.9e-11	0.86	0.64	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
GBM	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	9.05	4.24e-15	4.93e-11	0.79	0.64	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	9.05	4.24e-15	4.93e-11	0.79	0.64	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
GBM	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	9.05	4.3e-15	4.93e-11	0.8	0.64	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
GBM	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
GBM	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	9.05	4.35e-15	4.93e-11	0.8	0.64	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
GBM	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-9.04	4.43e-15	5.02e-11	-0.76	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
GBM	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-9.03	4.62e-15	5.23e-11	-0.74	-0.64	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
GBM	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	9.03	4.63e-15	5.23e-11	0.8	0.64	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	9.03	4.71e-15	5.32e-11	0.81	0.64	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
GBM	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	9.03	4.75e-15	5.36e-11	0.88	0.64	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
GBM	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	9.03	4.75e-15	5.36e-11	0.88	0.64	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
GBM	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	9.03	4.75e-15	5.36e-11	0.88	0.64	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
GBM	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	9.03	4.81e-15	5.42e-11	0.78	0.64	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
GBM	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	9.02	4.86e-15	5.45e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
GBM	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	9.02	4.96e-15	5.57e-11	0.73	0.64	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
GBM	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	9.02	5.08e-15	5.7e-11	0.76	0.64	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
GBM	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	9.01	5.15e-15	5.78e-11	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
GBM	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-9.01	5.23e-15	5.86e-11	-0.74	-0.64	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
GBM	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	9.01	5.24e-15	5.87e-11	0.8	0.64	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	9.01	5.26e-15	5.88e-11	0.66	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
GBM	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-9.01	5.34e-15	5.98e-11	-0.77	-0.64	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	9	5.41e-15	6.05e-11	0.8	0.64	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.836	rs10041617	ENSG00000248112.1	RP11-78C3.1	9	5.52e-15	6.17e-11	0.78	0.64	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:82919376~82921119:-
GBM	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	9	5.62e-15	6.27e-11	0.81	0.64	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
GBM	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-8.99	5.75e-15	6.4e-11	-0.75	-0.64	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
GBM	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	8.99	5.78e-15	6.43e-11	0.83	0.64	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	8.99	5.78e-15	6.43e-11	0.83	0.64	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
GBM	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	8.99	5.79e-15	6.45e-11	0.76	0.64	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
GBM	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-8.99	5.85e-15	6.5e-11	-0.96	-0.64	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
GBM	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-8.99	5.87e-15	6.52e-11	-0.74	-0.64	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-8.99	5.87e-15	6.52e-11	-0.74	-0.64	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-8.99	5.87e-15	6.52e-11	-0.74	-0.64	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
GBM	cis	rs6597981	0.543	rs3901233	ENSG00000279672.1	CMB9-55F22.1	8.99	5.98e-15	6.63e-11	0.74	0.64	Breast cancer;	chr11:749452	chr11:779617~780755:+
GBM	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	8.98	6.01e-15	6.66e-11	1.09	0.64	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
GBM	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-8.98	6.09e-15	6.74e-11	-0.8	-0.64	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-8.98	6.14e-15	6.8e-11	-0.75	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
GBM	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-8.98	6.24e-15	6.9e-11	-0.8	-0.64	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
GBM	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-8.98	6.31e-15	6.97e-11	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
GBM	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	8.98	6.31e-15	6.98e-11	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	8.97	6.4e-15	7.07e-11	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
GBM	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-8.97	6.44e-15	7.11e-11	-0.81	-0.64	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
GBM	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	8.97	6.49e-15	7.16e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	8.97	6.49e-15	7.16e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
GBM	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	8.97	6.61e-15	7.29e-11	0.96	0.64	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
GBM	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	8.97	6.66e-15	7.32e-11	0.84	0.64	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	8.97	6.66e-15	7.32e-11	0.84	0.64	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
GBM	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	8.97	6.66e-15	7.32e-11	0.84	0.64	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
GBM	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	8.97	6.66e-15	7.32e-11	0.84	0.64	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
GBM	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	8.97	6.66e-15	7.32e-11	0.84	0.64	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	8.97	6.66e-15	7.32e-11	0.81	0.64	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	8.97	6.66e-15	7.32e-11	0.81	0.64	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
GBM	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
GBM	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Depression;	chr6:28399886	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	8.96	6.73e-15	7.38e-11	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
GBM	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-8.96	6.88e-15	7.52e-11	-0.82	-0.64	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	8.96	6.91e-15	7.54e-11	0.68	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
GBM	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-8.95	7.1e-15	7.72e-11	-0.75	-0.64	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	8.94	7.42e-15	8e-11	0.76	0.64	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
GBM	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	8.94	7.51e-15	8.09e-11	0.79	0.64	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	8.94	7.53e-15	8.11e-11	0.83	0.64	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	8.94	7.73e-15	8.32e-11	0.8	0.64	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	8.93	7.93e-15	8.53e-11	0.69	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
GBM	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-8.93	8.07e-15	8.67e-11	-0.64	-0.64	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
GBM	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	8.93	8.11e-15	8.7e-11	0.74	0.64	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
GBM	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	8.92	8.45e-15	9.05e-11	0.8	0.64	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	8.92	8.45e-15	9.05e-11	0.8	0.64	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
GBM	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.92	8.46e-15	9.06e-11	0.76	0.64	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
GBM	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	8.92	8.48e-15	9.07e-11	0.79	0.64	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	8.92	8.48e-15	9.07e-11	0.79	0.64	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	8.92	8.48e-15	9.07e-11	0.79	0.64	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
GBM	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	8.92	8.62e-15	9.22e-11	0.75	0.64	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
GBM	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	8.91	8.99e-15	9.57e-11	0.83	0.64	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	8.9	9.48e-15	1.01e-10	0.84	0.64	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	8.9	9.55e-15	1.01e-10	0.94	0.64	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	8.9	9.55e-15	1.01e-10	0.94	0.64	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	8.9	9.59e-15	1.02e-10	0.94	0.64	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
GBM	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-8.9	9.61e-15	1.02e-10	-0.77	-0.64	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-8.9	9.61e-15	1.02e-10	-0.77	-0.64	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	8.9	9.67e-15	1.03e-10	0.83	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-8.89	9.94e-15	1.05e-10	-0.77	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
GBM	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	8.88	1.04e-14	1.1e-10	0.76	0.64	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	8.88	1.04e-14	1.1e-10	0.76	0.64	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	8.88	1.04e-14	1.1e-10	0.76	0.64	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	8.88	1.04e-14	1.1e-10	0.76	0.64	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	8.88	1.04e-14	1.1e-10	0.76	0.64	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
GBM	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	8.88	1.04e-14	1.1e-10	0.7	0.64	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
GBM	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-8.88	1.05e-14	1.1e-10	-0.86	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	8.87	1.09e-14	1.14e-10	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
GBM	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	8.87	1.11e-14	1.16e-10	0.77	0.64	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	8.86	1.16e-14	1.21e-10	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
GBM	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-8.86	1.18e-14	1.23e-10	-0.74	-0.64	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
GBM	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	8.86	1.18e-14	1.23e-10	0.79	0.64	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	8.86	1.18e-14	1.23e-10	0.79	0.64	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	8.86	1.18e-14	1.23e-10	0.79	0.64	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	8.86	1.18e-14	1.23e-10	0.79	0.64	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	8.86	1.18e-14	1.23e-10	0.79	0.64	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	8.86	1.18e-14	1.23e-10	0.79	0.64	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
GBM	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-8.86	1.19e-14	1.24e-10	-0.74	-0.64	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
GBM	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-8.85	1.21e-14	1.25e-10	-0.75	-0.64	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
GBM	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	8.85	1.21e-14	1.25e-10	0.8	0.64	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	8.85	1.21e-14	1.25e-10	0.8	0.64	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	8.85	1.21e-14	1.25e-10	0.8	0.64	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	8.85	1.21e-14	1.25e-10	0.8	0.64	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	8.85	1.21e-14	1.25e-10	0.8	0.64	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	8.85	1.21e-14	1.25e-10	0.8	0.64	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	8.85	1.22e-14	1.26e-10	0.68	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
GBM	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-8.85	1.24e-14	1.28e-10	-0.72	-0.64	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
GBM	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	8.85	1.25e-14	1.3e-10	0.77	0.64	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
GBM	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	8.85	1.26e-14	1.3e-10	0.73	0.64	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
GBM	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	8.84	1.27e-14	1.32e-10	0.87	0.64	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
GBM	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	8.84	1.28e-14	1.32e-10	0.73	0.64	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.71	rs7708124	ENSG00000248112.1	RP11-78C3.1	8.84	1.28e-14	1.32e-10	0.79	0.64	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs11958314	ENSG00000248112.1	RP11-78C3.1	8.84	1.28e-14	1.32e-10	0.79	0.64	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.686	rs6452517	ENSG00000248112.1	RP11-78C3.1	8.84	1.28e-14	1.32e-10	0.79	0.64	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:82919376~82921119:-
GBM	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-8.84	1.29e-14	1.33e-10	-0.77	-0.64	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
GBM	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	8.84	1.3e-14	1.34e-10	0.76	0.64	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
GBM	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-8.83	1.36e-14	1.4e-10	-0.72	-0.64	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	8.83	1.37e-14	1.41e-10	0.74	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
GBM	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	8.83	1.38e-14	1.42e-10	0.75	0.64	Myopia;	chr6:28302807	chr6:28176188~28176674:+
GBM	cis	rs6452524	0.967	rs12186460	ENSG00000248112.1	RP11-78C3.1	8.83	1.4e-14	1.43e-10	0.78	0.64	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:82919376~82921119:-
GBM	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-8.83	1.41e-14	1.44e-10	-0.75	-0.64	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	8.82	1.41e-14	1.44e-10	0.74	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
GBM	cis	rs6452524	0.935	rs3901654	ENSG00000248112.1	RP11-78C3.1	8.82	1.43e-14	1.46e-10	0.78	0.64	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs1478480	ENSG00000248112.1	RP11-78C3.1	8.82	1.43e-14	1.46e-10	0.78	0.64	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:82919376~82921119:-
GBM	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	8.82	1.45e-14	1.47e-10	0.79	0.64	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
GBM	cis	rs6452524	0.967	rs2662243	ENSG00000248112.1	RP11-78C3.1	8.82	1.45e-14	1.48e-10	0.75	0.64	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:82919376~82921119:-
GBM	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	8.82	1.48e-14	1.51e-10	0.8	0.64	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	8.82	1.48e-14	1.51e-10	0.8	0.64	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
GBM	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	8.81	1.52e-14	1.55e-10	0.75	0.63	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
GBM	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	8.81	1.52e-14	1.55e-10	0.8	0.63	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
GBM	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	8.81	1.54e-14	1.56e-10	0.84	0.63	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
GBM	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	8.8	1.57e-14	1.6e-10	0.79	0.63	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	8.8	1.61e-14	1.63e-10	0.79	0.63	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
GBM	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-8.8	1.61e-14	1.63e-10	-0.82	-0.63	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
GBM	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	8.8	1.63e-14	1.65e-10	0.75	0.63	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
GBM	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	8.79	1.65e-14	1.67e-10	0.83	0.63	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
GBM	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	8.79	1.65e-14	1.67e-10	0.79	0.63	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
GBM	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	8.79	1.67e-14	1.68e-10	0.85	0.63	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
GBM	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-8.79	1.68e-14	1.7e-10	-0.83	-0.63	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	8.79	1.68e-14	1.7e-10	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
GBM	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	8.79	1.69e-14	1.71e-10	0.79	0.63	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
GBM	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	8.78	1.77e-14	1.77e-10	0.71	0.63	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
GBM	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	8.78	1.81e-14	1.8e-10	0.77	0.63	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
GBM	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	8.77	1.84e-14	1.83e-10	0.73	0.63	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
GBM	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-8.77	1.89e-14	1.87e-10	-0.88	-0.63	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	8.76	1.96e-14	1.94e-10	0.67	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
GBM	cis	rs6452524	0.935	rs7718284	ENSG00000248112.1	RP11-78C3.1	-8.76	2e-14	1.98e-10	-0.77	-0.63	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:82919376~82921119:-
GBM	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-8.76	2e-14	1.98e-10	-0.85	-0.63	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
GBM	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	8.76	2.02e-14	2e-10	0.78	0.63	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
GBM	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	8.75	2.06e-14	2.04e-10	0.94	0.63	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
GBM	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-8.75	2.08e-14	2.05e-10	-0.73	-0.63	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.74	2.16e-14	2.12e-10	0.75	0.63	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
GBM	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.74	2.16e-14	2.12e-10	0.75	0.63	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
GBM	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-8.74	2.16e-14	2.12e-10	-0.8	-0.63	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-8.74	2.16e-14	2.12e-10	-0.8	-0.63	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
GBM	cis	rs6452524	0.967	rs1031901	ENSG00000248112.1	RP11-78C3.1	8.74	2.26e-14	2.22e-10	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-8.74	2.26e-14	2.22e-10	-0.74	-0.63	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
GBM	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	8.74	2.27e-14	2.22e-10	0.79	0.63	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	8.74	2.27e-14	2.22e-10	0.79	0.63	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	8.74	2.27e-14	2.22e-10	0.79	0.63	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	8.74	2.27e-14	2.22e-10	0.79	0.63	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	8.74	2.27e-14	2.22e-10	0.79	0.63	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	8.74	2.27e-14	2.22e-10	0.79	0.63	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
GBM	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-8.73	2.27e-14	2.23e-10	-0.78	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
GBM	cis	rs6452524	0.935	rs7703318	ENSG00000248112.1	RP11-78C3.1	8.73	2.35e-14	2.3e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:82919376~82921119:-
GBM	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	8.72	2.4e-14	2.35e-10	0.81	0.63	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
GBM	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	8.72	2.52e-14	2.45e-10	0.77	0.63	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
GBM	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-8.71	2.53e-14	2.46e-10	-0.8	-0.63	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
GBM	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	8.71	2.57e-14	2.49e-10	0.85	0.63	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
GBM	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	8.69	2.84e-14	2.74e-10	1.18	0.63	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
GBM	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	8.68	3.03e-14	2.92e-10	0.85	0.63	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
GBM	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	8.68	3.03e-14	2.92e-10	0.85	0.63	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	8.68	3.03e-14	2.92e-10	0.85	0.63	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
GBM	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	8.68	3.03e-14	2.92e-10	0.85	0.63	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
GBM	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	8.68	3.06e-14	2.95e-10	0.86	0.63	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	8.68	3.07e-14	2.95e-10	0.77	0.63	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	8.68	3.07e-14	2.95e-10	0.77	0.63	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	8.68	3.07e-14	2.95e-10	0.77	0.63	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	8.68	3.07e-14	2.95e-10	0.77	0.63	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	8.68	3.07e-14	2.95e-10	0.77	0.63	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
GBM	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-8.68	3.09e-14	2.97e-10	-0.75	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
GBM	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	8.68	3.12e-14	3e-10	0.78	0.63	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
GBM	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	8.67	3.14e-14	3.01e-10	1.12	0.63	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	8.67	3.14e-14	3.01e-10	1.12	0.63	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
GBM	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	8.67	3.2e-14	3.07e-10	0.75	0.63	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
GBM	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	8.67	3.2e-14	3.07e-10	0.75	0.63	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
GBM	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	8.66	3.35e-14	3.22e-10	0.77	0.63	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
GBM	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	8.66	3.38e-14	3.25e-10	0.71	0.63	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	8.66	3.39e-14	3.25e-10	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
GBM	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	8.66	3.41e-14	3.27e-10	0.79	0.63	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
GBM	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-8.64	3.75e-14	3.59e-10	-0.71	-0.63	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-8.64	3.75e-14	3.59e-10	-0.71	-0.63	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
GBM	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	8.64	3.82e-14	3.64e-10	0.86	0.63	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
GBM	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	8.64	3.82e-14	3.64e-10	0.86	0.63	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
GBM	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	8.64	3.82e-14	3.64e-10	0.86	0.63	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
GBM	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	8.64	3.82e-14	3.64e-10	0.86	0.63	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	8.64	3.82e-14	3.64e-10	0.86	0.63	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
GBM	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	8.64	3.82e-14	3.64e-10	0.86	0.63	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
GBM	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-8.64	3.85e-14	3.66e-10	-0.86	-0.63	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
GBM	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-8.63	3.88e-14	3.69e-10	-0.82	-0.63	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
GBM	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-8.63	3.95e-14	3.72e-10	-0.76	-0.63	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	8.63	3.95e-14	3.72e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
GBM	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	8.63	4.03e-14	3.79e-10	0.76	0.63	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	8.63	4.03e-14	3.79e-10	0.76	0.63	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	8.63	4.03e-14	3.79e-10	0.76	0.63	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	8.63	4.05e-14	3.8e-10	0.77	0.63	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
GBM	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	8.62	4.12e-14	3.87e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	8.62	4.16e-14	3.9e-10	0.67	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
GBM	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	8.62	4.22e-14	3.96e-10	0.79	0.63	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	8.62	4.24e-14	3.97e-10	0.76	0.63	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	8.62	4.24e-14	3.97e-10	0.76	0.63	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	8.62	4.24e-14	3.97e-10	0.76	0.63	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	8.62	4.24e-14	3.97e-10	0.76	0.63	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	8.62	4.24e-14	3.97e-10	0.76	0.63	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	8.62	4.24e-14	3.97e-10	0.76	0.63	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
GBM	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	8.62	4.25e-14	3.98e-10	0.81	0.63	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
GBM	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	8.61	4.3e-14	4.02e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	8.61	4.3e-14	4.02e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	8.61	4.3e-14	4.02e-10	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
GBM	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	8.61	4.32e-14	4.04e-10	1.13	0.63	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
GBM	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-8.61	4.42e-14	4.12e-10	-0.84	-0.63	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
GBM	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-8.61	4.42e-14	4.12e-10	-0.75	-0.63	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
GBM	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-8.61	4.43e-14	4.12e-10	-0.71	-0.63	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
GBM	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
GBM	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
GBM	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
GBM	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	8.61	4.44e-14	4.12e-10	0.78	0.63	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
GBM	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	8.61	4.47e-14	4.14e-10	0.78	0.63	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	8.61	4.47e-14	4.14e-10	0.78	0.63	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	8.61	4.47e-14	4.14e-10	0.78	0.63	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	8.61	4.47e-14	4.14e-10	0.78	0.63	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	8.61	4.47e-14	4.14e-10	0.78	0.63	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	8.61	4.47e-14	4.14e-10	0.78	0.63	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
GBM	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	8.61	4.47e-14	4.14e-10	0.84	0.63	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	8.61	4.47e-14	4.14e-10	0.84	0.63	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	8.61	4.47e-14	4.14e-10	0.84	0.63	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	8.61	4.47e-14	4.14e-10	0.84	0.63	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	8.61	4.47e-14	4.14e-10	0.84	0.63	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
GBM	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-8.6	4.67e-14	4.32e-10	-0.77	-0.63	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
GBM	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	8.6	4.69e-14	4.33e-10	0.79	0.63	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	8.6	4.69e-14	4.33e-10	0.79	0.63	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
GBM	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-8.6	4.74e-14	4.37e-10	-0.78	-0.63	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
GBM	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	8.6	4.75e-14	4.39e-10	0.73	0.63	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
GBM	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	8.59	4.78e-14	4.4e-10	0.82	0.63	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-8.59	4.78e-14	4.4e-10	-0.82	-0.63	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
GBM	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-8.59	4.88e-14	4.47e-10	-0.81	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
GBM	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	8.59	4.92e-14	4.51e-10	0.78	0.63	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
GBM	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	8.59	4.95e-14	4.54e-10	0.83	0.63	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	8.59	4.95e-14	4.54e-10	0.83	0.63	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	8.59	4.95e-14	4.54e-10	0.83	0.63	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	8.59	4.95e-14	4.54e-10	0.83	0.63	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	8.59	4.95e-14	4.54e-10	0.83	0.63	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	8.59	4.95e-14	4.54e-10	0.83	0.63	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
GBM	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	8.59	5.01e-14	4.58e-10	0.76	0.63	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	8.59	5.01e-14	4.58e-10	0.76	0.63	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	8.58	5.09e-14	4.65e-10	0.77	0.62	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
GBM	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	8.58	5.09e-14	4.66e-10	0.75	0.62	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
GBM	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	8.58	5.11e-14	4.67e-10	0.84	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
GBM	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	8.58	5.17e-14	4.72e-10	0.75	0.62	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
GBM	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
GBM	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
GBM	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
GBM	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
GBM	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
GBM	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
GBM	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
GBM	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	8.58	5.2e-14	4.73e-10	0.77	0.62	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
GBM	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-8.58	5.26e-14	4.78e-10	-0.75	-0.62	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
GBM	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	8.57	5.32e-14	4.84e-10	0.77	0.62	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
GBM	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	8.57	5.45e-14	4.95e-10	0.92	0.62	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
GBM	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	8.57	5.45e-14	4.95e-10	0.78	0.62	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-8.57	5.6e-14	5.08e-10	-0.66	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
GBM	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-8.56	5.61e-14	5.08e-10	-0.72	-0.62	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-8.56	5.61e-14	5.08e-10	-0.72	-0.62	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-8.56	5.61e-14	5.08e-10	-0.72	-0.62	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-8.56	5.61e-14	5.08e-10	-0.72	-0.62	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-8.56	5.61e-14	5.08e-10	-0.72	-0.62	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
GBM	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	8.56	5.68e-14	5.14e-10	0.76	0.62	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	8.56	5.81e-14	5.25e-10	0.88	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
GBM	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	8.56	5.83e-14	5.27e-10	0.83	0.62	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
GBM	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-8.56	5.86e-14	5.29e-10	-0.71	-0.62	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-8.56	5.86e-14	5.29e-10	-0.71	-0.62	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-8.56	5.86e-14	5.29e-10	-0.71	-0.62	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-8.56	5.88e-14	5.31e-10	-0.88	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
GBM	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	8.56	5.89e-14	5.31e-10	0.8	0.62	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
GBM	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-8.55	5.96e-14	5.37e-10	-0.76	-0.62	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
GBM	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	8.55	6.02e-14	5.42e-10	0.85	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	8.55	6.02e-14	5.42e-10	0.72	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
GBM	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	8.55	6.11e-14	5.51e-10	0.83	0.62	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	8.55	6.11e-14	5.51e-10	0.83	0.62	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
GBM	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	8.55	6.13e-14	5.52e-10	0.85	0.62	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	8.55	6.13e-14	5.52e-10	0.85	0.62	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	8.55	6.21e-14	5.59e-10	0.85	0.62	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	8.55	6.21e-14	5.59e-10	0.85	0.62	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
GBM	cis	rs6452524	1	rs7738033	ENSG00000248112.1	RP11-78C3.1	8.54	6.33e-14	5.69e-10	0.78	0.62	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6860239	ENSG00000248112.1	RP11-78C3.1	8.54	6.33e-14	5.69e-10	0.78	0.62	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:82919376~82921119:-
GBM	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	8.54	6.5e-14	5.84e-10	0.78	0.62	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
GBM	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-8.53	6.58e-14	5.91e-10	-0.74	-0.62	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
GBM	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-8.53	6.63e-14	5.95e-10	-0.81	-0.62	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
GBM	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-8.53	6.74e-14	6.04e-10	-1.01	-0.62	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
GBM	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	8.53	6.8e-14	6.1e-10	0.74	0.62	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
GBM	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	8.53	6.82e-14	6.11e-10	0.76	0.62	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
GBM	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-8.53	6.86e-14	6.14e-10	-0.92	-0.62	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
GBM	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	8.52	6.95e-14	6.21e-10	0.82	0.62	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	8.52	6.95e-14	6.21e-10	0.82	0.62	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	8.52	6.95e-14	6.21e-10	0.82	0.62	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	8.52	6.95e-14	6.21e-10	0.82	0.62	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	8.52	6.95e-14	6.21e-10	0.82	0.62	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	8.52	6.95e-14	6.21e-10	0.82	0.62	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
GBM	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	8.52	7.2e-14	6.43e-10	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	8.52	7.2e-14	6.43e-10	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	8.52	7.2e-14	6.43e-10	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	8.52	7.26e-14	6.48e-10	0.66	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
GBM	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	8.51	7.38e-14	6.55e-10	1.12	0.62	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
GBM	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	8.51	7.59e-14	6.74e-10	0.77	0.62	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
GBM	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	8.51	7.64e-14	6.78e-10	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
GBM	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	8.51	7.64e-14	6.78e-10	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
GBM	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	8.51	7.66e-14	6.79e-10	0.77	0.62	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	8.51	7.66e-14	6.79e-10	0.77	0.62	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
GBM	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-8.5	7.74e-14	6.86e-10	-0.84	-0.62	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-8.5	7.74e-14	6.86e-10	-0.84	-0.62	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
GBM	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	8.5	7.85e-14	6.96e-10	0.82	0.62	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
GBM	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	8.5	8.02e-14	7.09e-10	0.84	0.62	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	8.49	8.14e-14	7.19e-10	0.82	0.62	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	8.49	8.21e-14	7.25e-10	0.67	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
GBM	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	8.49	8.28e-14	7.31e-10	0.77	0.62	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
GBM	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	8.49	8.32e-14	7.34e-10	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
GBM	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	8.49	8.44e-14	7.45e-10	0.78	0.62	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
GBM	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	8.49	8.45e-14	7.45e-10	1.1	0.62	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
GBM	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	8.48	8.63e-14	7.6e-10	0.81	0.62	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	8.48	8.68e-14	7.64e-10	0.74	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
GBM	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-8.48	8.82e-14	7.75e-10	-0.83	-0.62	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
GBM	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	8.48	8.91e-14	7.83e-10	1.12	0.62	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
GBM	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	8.48	8.96e-14	7.86e-10	0.81	0.62	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
GBM	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-8.48	9e-14	7.89e-10	-0.74	-0.62	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
GBM	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	8.47	9.1e-14	7.97e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
GBM	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	8.47	9.11e-14	7.97e-10	0.72	0.62	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
GBM	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	8.47	9.14e-14	8e-10	0.82	0.62	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
GBM	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	8.47	9.28e-14	8.11e-10	0.77	0.62	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
GBM	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	8.47	9.31e-14	8.12e-10	0.79	0.62	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
GBM	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	8.47	9.31e-14	8.12e-10	0.77	0.62	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	8.47	9.31e-14	8.12e-10	0.77	0.62	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	8.47	9.31e-14	8.12e-10	0.77	0.62	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	8.47	9.31e-14	8.12e-10	0.77	0.62	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	8.47	9.31e-14	8.12e-10	0.77	0.62	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	8.47	9.31e-14	8.12e-10	0.77	0.62	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
GBM	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	8.47	9.35e-14	8.15e-10	0.74	0.62	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
GBM	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-8.47	9.38e-14	8.15e-10	-0.81	-0.62	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
GBM	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	8.47	9.4e-14	8.15e-10	0.76	0.62	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
GBM	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	8.47	9.4e-14	8.15e-10	0.8	0.62	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	8.47	9.4e-14	8.15e-10	0.8	0.62	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	8.47	9.4e-14	8.15e-10	0.8	0.62	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	8.47	9.41e-14	8.15e-10	0.82	0.62	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
GBM	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
GBM	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
GBM	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
GBM	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	8.46	9.56e-14	8.24e-10	0.85	0.62	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
GBM	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	8.46	9.69e-14	8.34e-10	0.81	0.62	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
GBM	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-8.46	9.86e-14	8.48e-10	-0.71	-0.62	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
GBM	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	8.46	9.94e-14	8.52e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	8.46	9.94e-14	8.52e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	8.46	9.94e-14	8.52e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	8.46	9.94e-14	8.52e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	8.46	9.94e-14	8.52e-10	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
GBM	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	8.45	1.01e-13	8.62e-10	1.04	0.62	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
GBM	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	8.45	1.01e-13	8.68e-10	0.77	0.62	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	8.45	1.01e-13	8.68e-10	0.77	0.62	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	8.45	1.01e-13	8.68e-10	0.77	0.62	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
GBM	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	8.45	1.04e-13	8.86e-10	0.83	0.62	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	8.45	1.04e-13	8.86e-10	0.83	0.62	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	8.45	1.04e-13	8.86e-10	0.83	0.62	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	8.45	1.04e-13	8.86e-10	0.83	0.62	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-8.45	1.05e-13	8.96e-10	-0.86	-0.62	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
GBM	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-8.45	1.05e-13	8.96e-10	-0.69	-0.62	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
GBM	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	8.44	1.07e-13	9.08e-10	0.75	0.62	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	8.44	1.07e-13	9.08e-10	0.75	0.62	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	8.44	1.07e-13	9.08e-10	0.75	0.62	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	8.44	1.07e-13	9.08e-10	0.75	0.62	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	8.44	1.09e-13	9.29e-10	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	8.44	1.09e-13	9.29e-10	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	8.44	1.09e-13	9.29e-10	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
GBM	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	8.44	1.09e-13	9.3e-10	0.82	0.62	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	8.44	1.09e-13	9.3e-10	0.82	0.62	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
GBM	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	8.44	1.1e-13	9.32e-10	0.92	0.62	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	8.44	1.1e-13	9.33e-10	0.66	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
GBM	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	8.44	1.11e-13	9.4e-10	0.92	0.62	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
GBM	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-8.43	1.11e-13	9.45e-10	-0.71	-0.62	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
GBM	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	8.43	1.12e-13	9.51e-10	0.8	0.62	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
GBM	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
GBM	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-8.43	1.13e-13	9.53e-10	-0.84	-0.62	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	8.43	1.15e-13	9.73e-10	0.75	0.62	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	8.43	1.15e-13	9.73e-10	0.75	0.62	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
GBM	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-8.43	1.15e-13	9.75e-10	-0.83	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
GBM	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	8.43	1.16e-13	9.82e-10	0.73	0.62	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	8.43	1.16e-13	9.82e-10	0.73	0.62	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	8.43	1.16e-13	9.82e-10	0.73	0.62	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	8.43	1.16e-13	9.82e-10	0.73	0.62	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	8.43	1.16e-13	9.82e-10	0.73	0.62	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	8.43	1.16e-13	9.82e-10	0.73	0.62	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	8.42	1.19e-13	1e-09	0.72	0.62	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	8.42	1.19e-13	1e-09	0.72	0.62	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
GBM	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	8.42	1.23e-13	1.04e-09	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
GBM	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
GBM	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	8.41	1.25e-13	1.05e-09	0.83	0.62	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
GBM	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.72	0.62	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.72	0.62	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.72	0.62	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.72	0.62	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	8.41	1.25e-13	1.05e-09	0.72	0.62	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
GBM	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	8.41	1.26e-13	1.06e-09	0.75	0.62	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
GBM	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	8.41	1.26e-13	1.06e-09	0.82	0.62	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
GBM	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-8.41	1.27e-13	1.06e-09	-0.85	-0.62	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-8.41	1.27e-13	1.06e-09	-0.85	-0.62	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-8.41	1.27e-13	1.06e-09	-0.85	-0.62	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-8.41	1.27e-13	1.06e-09	-0.85	-0.62	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-8.41	1.27e-13	1.06e-09	-0.85	-0.62	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-8.41	1.27e-13	1.06e-09	-0.85	-0.62	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
GBM	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-8.41	1.27e-13	1.06e-09	-0.85	-0.62	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
GBM	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	8.41	1.27e-13	1.06e-09	1.06	0.62	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
GBM	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	8.41	1.28e-13	1.06e-09	0.77	0.62	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
GBM	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-8.41	1.28e-13	1.06e-09	-0.75	-0.62	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
GBM	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
GBM	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
GBM	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-8.4	1.32e-13	1.09e-09	-0.84	-0.62	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
GBM	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	8.4	1.33e-13	1.1e-09	0.76	0.62	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
GBM	cis	rs6452524	0.935	rs2731846	ENSG00000248112.1	RP11-78C3.1	8.4	1.34e-13	1.11e-09	0.74	0.62	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:82919376~82921119:-
GBM	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	8.4	1.35e-13	1.11e-09	0.8	0.62	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
GBM	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	8.4	1.36e-13	1.12e-09	0.76	0.62	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
GBM	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	8.4	1.36e-13	1.12e-09	0.76	0.62	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
GBM	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-8.4	1.37e-13	1.13e-09	-0.76	-0.62	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
GBM	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	8.4	1.37e-13	1.13e-09	0.83	0.62	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
GBM	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-8.4	1.37e-13	1.13e-09	-0.59	-0.62	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
GBM	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-8.39	1.38e-13	1.13e-09	-0.84	-0.62	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
GBM	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-8.39	1.38e-13	1.13e-09	-0.84	-0.62	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-8.39	1.38e-13	1.13e-09	-0.84	-0.62	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
GBM	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	8.39	1.38e-13	1.14e-09	1.11	0.62	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
GBM	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-8.39	1.39e-13	1.15e-09	-0.85	-0.62	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	8.39	1.42e-13	1.17e-09	0.75	0.62	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
GBM	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	8.39	1.42e-13	1.17e-09	0.82	0.62	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
GBM	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-8.39	1.44e-13	1.18e-09	-0.81	-0.62	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
GBM	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	8.39	1.45e-13	1.19e-09	1.06	0.62	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
GBM	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-8.38	1.46e-13	1.2e-09	-0.75	-0.62	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
GBM	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	8.38	1.47e-13	1.21e-09	0.79	0.62	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
GBM	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	8.38	1.47e-13	1.21e-09	0.79	0.62	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
GBM	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-8.38	1.51e-13	1.23e-09	-0.7	-0.62	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
GBM	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-8.38	1.51e-13	1.23e-09	-0.7	-0.62	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
GBM	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-8.37	1.54e-13	1.26e-09	-0.82	-0.62	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-8.37	1.54e-13	1.26e-09	-0.82	-0.62	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
GBM	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-8.37	1.56e-13	1.27e-09	-0.82	-0.62	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-8.37	1.56e-13	1.27e-09	-0.82	-0.62	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-8.37	1.56e-13	1.27e-09	-0.82	-0.62	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
GBM	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	8.37	1.56e-13	1.27e-09	1.09	0.62	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	8.37	1.56e-13	1.27e-09	1.09	0.62	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	8.37	1.56e-13	1.27e-09	1.09	0.62	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	8.37	1.56e-13	1.27e-09	1.09	0.62	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	8.37	1.56e-13	1.27e-09	1.09	0.62	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
GBM	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-8.37	1.6e-13	1.3e-09	-0.83	-0.62	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-8.37	1.61e-13	1.31e-09	-1.14	-0.62	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-8.37	1.61e-13	1.31e-09	-1.14	-0.62	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
GBM	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-8.36	1.63e-13	1.32e-09	-0.7	-0.61	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
GBM	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-8.36	1.64e-13	1.33e-09	-0.73	-0.61	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	8.36	1.64e-13	1.33e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
GBM	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	8.36	1.66e-13	1.34e-09	0.75	0.61	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	8.36	1.66e-13	1.34e-09	0.75	0.61	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	8.36	1.66e-13	1.34e-09	0.75	0.61	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
GBM	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-8.36	1.66e-13	1.34e-09	-0.66	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
GBM	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	8.36	1.7e-13	1.37e-09	0.75	0.61	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	8.36	1.7e-13	1.37e-09	0.75	0.61	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	8.36	1.7e-13	1.37e-09	0.75	0.61	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	8.36	1.7e-13	1.37e-09	0.75	0.61	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	8.36	1.7e-13	1.37e-09	0.75	0.61	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
GBM	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	8.35	1.7e-13	1.37e-09	0.73	0.61	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
GBM	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-8.35	1.76e-13	1.42e-09	-0.84	-0.61	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-8.35	1.76e-13	1.42e-09	-0.84	-0.61	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
GBM	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-8.35	1.77e-13	1.42e-09	-0.73	-0.61	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
GBM	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	8.34	1.79e-13	1.44e-09	0.84	0.61	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
GBM	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	8.34	1.79e-13	1.44e-09	0.84	0.61	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
GBM	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	8.34	1.79e-13	1.44e-09	0.84	0.61	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	8.34	1.79e-13	1.44e-09	0.84	0.61	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	8.34	1.79e-13	1.44e-09	0.84	0.61	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	8.34	1.79e-13	1.44e-09	0.84	0.61	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	8.34	1.79e-13	1.44e-09	0.76	0.61	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	8.34	1.79e-13	1.44e-09	0.76	0.61	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
GBM	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	8.34	1.8e-13	1.44e-09	0.83	0.61	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	8.34	1.8e-13	1.44e-09	0.83	0.61	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
GBM	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	8.34	1.8e-13	1.44e-09	0.83	0.61	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	8.34	1.8e-13	1.44e-09	0.83	0.61	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	8.34	1.8e-13	1.44e-09	0.75	0.61	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
GBM	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	8.34	1.81e-13	1.45e-09	1.08	0.61	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	8.34	1.81e-13	1.45e-09	1.08	0.61	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
GBM	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	8.34	1.81e-13	1.45e-09	1.08	0.61	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	8.34	1.81e-13	1.45e-09	1.08	0.61	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
GBM	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	8.34	1.82e-13	1.46e-09	1.06	0.61	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
GBM	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	8.34	1.86e-13	1.49e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	8.34	1.86e-13	1.49e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	8.34	1.86e-13	1.49e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
GBM	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	8.33	1.89e-13	1.51e-09	0.74	0.61	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	8.33	1.9e-13	1.52e-09	0.76	0.61	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
GBM	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	8.33	1.93e-13	1.53e-09	0.69	0.61	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
GBM	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	8.33	1.94e-13	1.54e-09	0.75	0.61	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
GBM	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	8.33	1.94e-13	1.55e-09	0.77	0.61	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
GBM	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-8.33	1.98e-13	1.58e-09	-0.82	-0.61	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	8.33	1.98e-13	1.58e-09	0.82	0.61	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	8.33	1.98e-13	1.58e-09	0.82	0.61	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	8.33	1.98e-13	1.58e-09	0.82	0.61	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	8.33	1.98e-13	1.58e-09	0.82	0.61	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	8.33	1.98e-13	1.58e-09	0.82	0.61	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
GBM	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	8.33	1.99e-13	1.58e-09	1.08	0.61	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
GBM	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	8.32	2.01e-13	1.59e-09	0.8	0.61	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	8.32	2.01e-13	1.59e-09	0.8	0.61	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	8.32	2.01e-13	1.59e-09	0.8	0.61	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	8.32	2.01e-13	1.59e-09	0.8	0.61	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
GBM	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	8.32	2.03e-13	1.61e-09	0.72	0.61	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
GBM	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	8.32	2.04e-13	1.62e-09	0.82	0.61	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
GBM	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	8.32	2.09e-13	1.65e-09	0.83	0.61	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	8.32	2.09e-13	1.65e-09	0.83	0.61	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	8.32	2.09e-13	1.65e-09	0.83	0.61	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	8.32	2.09e-13	1.65e-09	0.83	0.61	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	8.31	2.1e-13	1.66e-09	0.81	0.61	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	8.31	2.11e-13	1.67e-09	0.76	0.61	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-8.31	2.13e-13	1.68e-09	-0.73	-0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
GBM	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	8.31	2.17e-13	1.71e-09	0.83	0.61	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
GBM	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	8.31	2.17e-13	1.71e-09	0.83	0.61	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	8.31	2.17e-13	1.71e-09	0.83	0.61	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	8.31	2.17e-13	1.71e-09	0.83	0.61	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	8.31	2.17e-13	1.71e-09	0.83	0.61	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	8.31	2.19e-13	1.73e-09	0.75	0.61	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
GBM	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	8.3	2.22e-13	1.75e-09	0.74	0.61	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
GBM	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	8.3	2.23e-13	1.75e-09	0.74	0.61	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	8.3	2.23e-13	1.75e-09	0.74	0.61	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
GBM	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	8.3	2.24e-13	1.76e-09	0.73	0.61	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
GBM	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	8.3	2.25e-13	1.77e-09	1.09	0.61	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
GBM	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	8.3	2.26e-13	1.78e-09	0.81	0.61	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
GBM	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-8.3	2.27e-13	1.79e-09	-0.82	-0.61	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
GBM	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	8.3	2.28e-13	1.79e-09	0.83	0.61	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	8.3	2.28e-13	1.79e-09	0.83	0.61	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	8.3	2.3e-13	1.8e-09	0.75	0.61	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
GBM	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	8.29	2.41e-13	1.88e-09	0.81	0.61	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
GBM	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
GBM	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
GBM	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-8.28	2.48e-13	1.93e-09	-0.81	-0.61	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
GBM	cis	rs6452524	0.901	rs12514607	ENSG00000248112.1	RP11-78C3.1	-8.28	2.48e-13	1.93e-09	-0.73	-0.61	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:82919376~82921119:-
GBM	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	8.28	2.52e-13	1.97e-09	0.88	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
GBM	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	8.28	2.52e-13	1.97e-09	0.71	0.61	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
GBM	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	8.28	2.53e-13	1.97e-09	0.7	0.61	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	8.28	2.54e-13	1.97e-09	0.75	0.61	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
GBM	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-8.27	2.62e-13	2.03e-09	-0.81	-0.61	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-8.27	2.62e-13	2.03e-09	-0.81	-0.61	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-8.27	2.62e-13	2.03e-09	-0.81	-0.61	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
GBM	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-8.27	2.62e-13	2.03e-09	-0.81	-0.61	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-8.27	2.62e-13	2.03e-09	-0.81	-0.61	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
GBM	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	8.27	2.67e-13	2.07e-09	0.81	0.61	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
GBM	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-8.27	2.7e-13	2.09e-09	-0.73	-0.61	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
GBM	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	8.26	2.77e-13	2.14e-09	0.7	0.61	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
GBM	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-8.26	2.81e-13	2.17e-09	-0.7	-0.61	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
GBM	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	8.26	2.82e-13	2.18e-09	0.8	0.61	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
GBM	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	8.26	2.82e-13	2.18e-09	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
GBM	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	8.26	2.85e-13	2.19e-09	0.82	0.61	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-8.26	2.87e-13	2.21e-09	-0.78	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
GBM	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	8.25	2.88e-13	2.21e-09	0.79	0.61	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	8.25	2.89e-13	2.22e-09	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
GBM	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-8.25	2.98e-13	2.29e-09	-0.72	-0.61	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-8.24	3.07e-13	2.33e-09	-0.71	-0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
GBM	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-8.24	3.14e-13	2.39e-09	-1.14	-0.61	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
GBM	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	8.23	3.21e-13	2.43e-09	0.78	0.61	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	8.23	3.26e-13	2.46e-09	0.75	0.61	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.901	rs1842020	ENSG00000248112.1	RP11-78C3.1	8.23	3.26e-13	2.47e-09	0.75	0.61	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.934	rs1120476	ENSG00000248112.1	RP11-78C3.1	8.23	3.26e-13	2.47e-09	0.75	0.61	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:82919376~82921119:-
GBM	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	8.23	3.26e-13	2.47e-09	1.01	0.61	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
GBM	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	8.23	3.27e-13	2.47e-09	0.74	0.61	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
GBM	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	8.23	3.28e-13	2.48e-09	0.82	0.61	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-8.23	3.28e-13	2.48e-09	-1.16	-0.61	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
GBM	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	8.23	3.36e-13	2.53e-09	0.76	0.61	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	8.23	3.36e-13	2.53e-09	0.76	0.61	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	8.23	3.36e-13	2.53e-09	0.76	0.61	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
GBM	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	8.23	3.37e-13	2.54e-09	1.02	0.61	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
GBM	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	8.22	3.42e-13	2.57e-09	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
GBM	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-8.22	3.44e-13	2.59e-09	-0.77	-0.61	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
GBM	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	8.22	3.46e-13	2.6e-09	0.81	0.61	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	8.22	3.46e-13	2.6e-09	0.81	0.61	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	8.22	3.51e-13	2.63e-09	0.77	0.61	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	8.22	3.51e-13	2.63e-09	0.76	0.61	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	8.22	3.51e-13	2.63e-09	0.76	0.61	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	8.22	3.51e-13	2.63e-09	0.76	0.61	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	8.21	3.6e-13	2.7e-09	0.71	0.61	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
GBM	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-8.21	3.62e-13	2.71e-09	-0.83	-0.61	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-8.21	3.62e-13	2.71e-09	-0.83	-0.61	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
GBM	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-8.21	3.62e-13	2.71e-09	-0.83	-0.61	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-8.21	3.69e-13	2.76e-09	-0.81	-0.61	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-8.21	3.69e-13	2.76e-09	-0.81	-0.61	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	8.2	3.76e-13	2.81e-09	0.75	0.61	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-8.2	3.85e-13	2.86e-09	-0.72	-0.61	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	8.2	3.85e-13	2.86e-09	0.72	0.61	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	8.2	3.85e-13	2.86e-09	0.72	0.61	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	8.2	3.85e-13	2.86e-09	0.72	0.61	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
GBM	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
GBM	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
GBM	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	8.2	3.86e-13	2.86e-09	1.07	0.61	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
GBM	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	8.2	3.86e-13	2.86e-09	0.69	0.61	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
GBM	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	8.19	3.99e-13	2.94e-09	0.75	0.61	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	8.19	3.99e-13	2.94e-09	0.75	0.61	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	8.19	3.99e-13	2.94e-09	0.75	0.61	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	8.19	3.99e-13	2.94e-09	0.75	0.61	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	8.19	4.05e-13	2.99e-09	0.66	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-8.19	4.06e-13	2.99e-09	-0.69	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
GBM	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	8.19	4.12e-13	3.02e-09	0.68	0.61	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	8.19	4.12e-13	3.02e-09	0.68	0.61	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
GBM	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	8.19	4.13e-13	3.03e-09	0.73	0.61	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
GBM	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	8.19	4.13e-13	3.03e-09	0.73	0.61	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	8.19	4.13e-13	3.03e-09	0.73	0.61	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	8.19	4.13e-13	3.03e-09	0.73	0.61	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
GBM	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-8.18	4.2e-13	3.07e-09	-0.81	-0.61	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
GBM	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	8.18	4.24e-13	3.11e-09	0.73	0.61	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
GBM	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-8.18	4.35e-13	3.18e-09	-0.75	-0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
GBM	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	8.17	4.38e-13	3.2e-09	0.82	0.61	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	8.17	4.38e-13	3.2e-09	0.82	0.61	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
GBM	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-8.17	4.43e-13	3.23e-09	-0.79	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-8.17	4.43e-13	3.23e-09	-0.79	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
GBM	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	8.17	4.44e-13	3.23e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-8.17	4.55e-13	3.31e-09	-0.66	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
GBM	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-8.17	4.6e-13	3.33e-09	-1.04	-0.61	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-8.17	4.6e-13	3.33e-09	-1.04	-0.61	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
GBM	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	8.17	4.6e-13	3.33e-09	1.04	0.61	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
GBM	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-8.17	4.6e-13	3.33e-09	-0.98	-0.61	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
GBM	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	8.16	4.78e-13	3.45e-09	0.81	0.61	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
GBM	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	8.15	4.93e-13	3.55e-09	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
GBM	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-8.15	4.97e-13	3.58e-09	-0.83	-0.61	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
GBM	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-8.15	4.97e-13	3.58e-09	-0.83	-0.61	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-8.15	4.97e-13	3.58e-09	-0.81	-0.61	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
GBM	cis	rs1799949	0.757	rs9915489	ENSG00000198496.9	NBR2	-8.15	5.02e-13	3.61e-09	-0.72	-0.61	Menopause (age at onset);	chr17:43021209	chr17:43125610~43153671:+
GBM	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	8.15	5.08e-13	3.65e-09	1.08	0.6	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	8.15	5.08e-13	3.65e-09	1.08	0.6	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	8.15	5.08e-13	3.65e-09	1.08	0.6	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
GBM	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	8.15	5.08e-13	3.65e-09	1.08	0.6	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
GBM	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	8.14	5.12e-13	3.68e-09	0.74	0.6	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	8.14	5.26e-13	3.77e-09	0.71	0.6	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	8.14	5.26e-13	3.77e-09	0.71	0.6	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	8.14	5.26e-13	3.77e-09	0.71	0.6	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	8.14	5.26e-13	3.77e-09	0.71	0.6	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	8.14	5.26e-13	3.77e-09	0.71	0.6	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	8.14	5.26e-13	3.77e-09	0.71	0.6	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
GBM	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	8.14	5.29e-13	3.78e-09	0.75	0.6	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	8.14	5.29e-13	3.78e-09	0.75	0.6	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
GBM	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-8.14	5.29e-13	3.79e-09	-0.83	-0.6	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
GBM	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	8.14	5.31e-13	3.8e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
GBM	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	8.14	5.32e-13	3.8e-09	1.07	0.6	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	8.14	5.32e-13	3.8e-09	1.07	0.6	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
GBM	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-8.14	5.33e-13	3.81e-09	-0.83	-0.6	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-8.14	5.33e-13	3.81e-09	-0.83	-0.6	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
GBM	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	8.13	5.44e-13	3.88e-09	1.02	0.6	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
GBM	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	8.13	5.51e-13	3.93e-09	0.82	0.6	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
GBM	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-8.13	5.52e-13	3.94e-09	-0.83	-0.6	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	8.13	5.53e-13	3.94e-09	0.74	0.6	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	8.13	5.63e-13	4.01e-09	0.72	0.6	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	8.13	5.63e-13	4.01e-09	0.72	0.6	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
GBM	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	8.13	5.68e-13	4.04e-09	1.05	0.6	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
GBM	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	8.12	5.74e-13	4.09e-09	0.72	0.6	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
GBM	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-8.12	5.9e-13	4.19e-09	-0.71	-0.6	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-8.12	5.9e-13	4.19e-09	-0.71	-0.6	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
GBM	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
GBM	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
GBM	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
GBM	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
GBM	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
GBM	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
GBM	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-8.11	6.01e-13	4.24e-09	-0.81	-0.6	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
GBM	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	8.11	6.1e-13	4.29e-09	0.76	0.6	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
GBM	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	8.11	6.11e-13	4.3e-09	0.71	0.6	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
GBM	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	8.11	6.15e-13	4.33e-09	0.74	0.6	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
GBM	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-8.1	6.45e-13	4.53e-09	-0.84	-0.6	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
GBM	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	8.1	6.49e-13	4.55e-09	0.72	0.6	Depression;	chr6:28273214	chr6:28176188~28176674:+
GBM	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	8.1	6.49e-13	4.55e-09	0.72	0.6	Depression;	chr6:28273215	chr6:28176188~28176674:+
GBM	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	8.1	6.63e-13	4.64e-09	1.11	0.6	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	8.09	6.74e-13	4.7e-09	0.99	0.6	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
GBM	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	8.09	6.81e-13	4.73e-09	0.78	0.6	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
GBM	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	8.09	6.81e-13	4.73e-09	0.78	0.6	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
GBM	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-8.09	6.88e-13	4.77e-09	-0.69	-0.6	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
GBM	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	8.09	6.89e-13	4.77e-09	0.72	0.6	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	8.09	6.89e-13	4.77e-09	0.72	0.6	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	8.09	6.89e-13	4.77e-09	0.72	0.6	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-8.09	6.89e-13	4.77e-09	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-8.09	6.89e-13	4.77e-09	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-8.09	6.89e-13	4.77e-09	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-8.09	6.89e-13	4.77e-09	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-8.09	6.89e-13	4.77e-09	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
GBM	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	8.08	7.11e-13	4.92e-09	1.04	0.6	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
GBM	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-8.08	7.22e-13	4.99e-09	-0.73	-0.6	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
GBM	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	8.08	7.38e-13	5.09e-09	1	0.6	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	8.08	7.38e-13	5.09e-09	1	0.6	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
GBM	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	8.07	7.43e-13	5.13e-09	0.79	0.6	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
GBM	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	8.07	7.53e-13	5.19e-09	0.79	0.6	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
GBM	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	8.07	7.53e-13	5.19e-09	0.8	0.6	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	8.07	7.53e-13	5.19e-09	0.8	0.6	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
GBM	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	8.07	7.61e-13	5.24e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	8.07	7.61e-13	5.24e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	8.07	7.61e-13	5.24e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
GBM	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-8.07	7.72e-13	5.31e-09	-0.82	-0.6	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-8.06	7.98e-13	5.49e-09	-0.82	-0.6	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-8.06	7.98e-13	5.49e-09	-0.82	-0.6	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-8.06	8.01e-13	5.51e-09	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-8.06	8.04e-13	5.52e-09	-0.73	-0.6	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
GBM	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	8.06	8.13e-13	5.58e-09	0.68	0.6	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
GBM	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-8.05	8.21e-13	5.62e-09	-0.8	-0.6	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
GBM	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	8.04	8.64e-13	5.9e-09	1.07	0.6	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
GBM	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	8.04	8.68e-13	5.92e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	8.04	8.68e-13	5.92e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	8.04	8.78e-13	5.98e-09	0.71	0.6	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
GBM	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	8.04	9.03e-13	6.12e-09	0.68	0.6	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
GBM	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-8.03	9.34e-13	6.33e-09	-0.72	-0.6	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
GBM	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	8.03	9.37e-13	6.35e-09	0.79	0.6	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
GBM	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	8.03	9.39e-13	6.36e-09	0.75	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
GBM	cis	rs6452524	1	rs6882179	ENSG00000248112.1	RP11-78C3.1	8.03	9.42e-13	6.38e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs7732092	ENSG00000248112.1	RP11-78C3.1	8.03	9.42e-13	6.38e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs4590162	ENSG00000248112.1	RP11-78C3.1	8.03	9.42e-13	6.38e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:82919376~82921119:-
GBM	cis	rs853679	0.517	rs2281588	ENSG00000199851.2	U3	8.03	9.44e-13	6.39e-09	0.99	0.6	Depression;	chr6:28104824	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs1947862	ENSG00000199851.2	U3	8.03	9.44e-13	6.39e-09	0.99	0.6	Depression;	chr6:28137418	chr6:28015568~28015777:+
GBM	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	8.03	9.44e-13	6.39e-09	0.82	0.6	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
GBM	cis	rs4713118	0.5	rs9461434	ENSG00000199851.2	U3	8.03	9.45e-13	6.39e-09	1.06	0.6	Parkinson's disease;	chr6:28134687	chr6:28015568~28015777:+
GBM	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	8.03	9.58e-13	6.48e-09	0.8	0.6	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
GBM	cis	rs6452524	1	rs7716962	ENSG00000248112.1	RP11-78C3.1	8.02	9.79e-13	6.61e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs6863300	ENSG00000248112.1	RP11-78C3.1	8.02	9.79e-13	6.61e-09	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:82919376~82921119:-
GBM	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	8.02	9.83e-13	6.64e-09	0.8	0.6	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
GBM	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	8.02	9.83e-13	6.64e-09	0.8	0.6	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	8.02	9.83e-13	6.64e-09	0.8	0.6	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	8.02	9.83e-13	6.64e-09	0.8	0.6	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
GBM	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	8.02	9.87e-13	6.66e-09	0.8	0.6	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	8.02	9.87e-13	6.66e-09	0.8	0.6	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
GBM	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-8.02	9.89e-13	6.67e-09	-0.65	-0.6	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
GBM	cis	rs950027	0.62	rs2467862	ENSG00000259433.2	CTD-2651B20.4	-8.02	1.01e-12	6.78e-09	-0.62	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45330209~45332634:-
GBM	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	8.01	1.03e-12	6.92e-09	0.78	0.6	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	8.01	1.03e-12	6.92e-09	0.78	0.6	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
GBM	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	8.01	1.03e-12	6.92e-09	0.72	0.6	Depression;	chr6:28402301	chr6:28176188~28176674:+
GBM	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	8.01	1.04e-12	6.97e-09	0.7	0.6	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
GBM	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-8.01	1.05e-12	7.02e-09	-0.73	-0.6	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
GBM	cis	rs950027	0.62	rs1145093	ENSG00000259433.2	CTD-2651B20.4	-8.01	1.05e-12	7.07e-09	-0.62	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	8.01	1.06e-12	7.12e-09	0.63	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
GBM	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	8	1.07e-12	7.16e-09	1.11	0.6	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	8	1.07e-12	7.16e-09	1.11	0.6	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
GBM	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	8	1.09e-12	7.27e-09	0.98	0.6	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
GBM	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	8	1.11e-12	7.39e-09	0.73	0.6	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
GBM	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	7.99	1.12e-12	7.5e-09	0.74	0.6	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
GBM	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-7.99	1.12e-12	7.51e-09	-0.67	-0.6	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
GBM	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	7.99	1.13e-12	7.54e-09	0.58	0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
GBM	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	7.99	1.13e-12	7.56e-09	0.75	0.6	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	7.99	1.13e-12	7.56e-09	0.75	0.6	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	7.99	1.13e-12	7.56e-09	0.75	0.6	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	7.99	1.13e-12	7.56e-09	0.75	0.6	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
GBM	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-7.99	1.14e-12	7.63e-09	-1.05	-0.6	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
GBM	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	7.99	1.15e-12	7.66e-09	0.67	0.6	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-7.99	1.18e-12	7.83e-09	-0.73	-0.6	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
GBM	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
GBM	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
GBM	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
GBM	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
GBM	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-7.99	1.18e-12	7.84e-09	-0.81	-0.6	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-7.98	1.21e-12	8.01e-09	-0.8	-0.6	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
GBM	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	7.98	1.24e-12	8.22e-09	0.79	0.6	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-7.97	1.29e-12	8.5e-09	-1.11	-0.6	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
GBM	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-7.97	1.29e-12	8.5e-09	-0.66	-0.6	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
GBM	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	7.97	1.3e-12	8.5e-09	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
GBM	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	7.97	1.3e-12	8.5e-09	0.98	0.6	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
GBM	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-7.97	1.3e-12	8.55e-09	-0.83	-0.6	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
GBM	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-7.97	1.31e-12	8.56e-09	-0.85	-0.6	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
GBM	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	7.96	1.32e-12	8.66e-09	1.13	0.6	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	7.96	1.32e-12	8.66e-09	1.13	0.6	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	7.96	1.32e-12	8.66e-09	1.13	0.6	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
GBM	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-7.96	1.32e-12	8.66e-09	-0.73	-0.6	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
GBM	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-7.96	1.35e-12	8.84e-09	-0.68	-0.6	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
GBM	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	7.96	1.38e-12	9.01e-09	0.8	0.6	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	7.96	1.38e-12	9.01e-09	0.8	0.6	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	7.96	1.38e-12	9.01e-09	0.8	0.6	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	7.96	1.38e-12	9.01e-09	0.8	0.6	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
GBM	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	7.95	1.39e-12	9.04e-09	1.02	0.6	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
GBM	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-7.95	1.39e-12	9.08e-09	-0.81	-0.6	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
GBM	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	7.95	1.4e-12	9.11e-09	1.05	0.6	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	7.95	1.4e-12	9.11e-09	1.05	0.6	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	7.95	1.4e-12	9.11e-09	1.05	0.6	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
GBM	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	7.95	1.4e-12	9.13e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	7.95	1.4e-12	9.13e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	7.95	1.4e-12	9.13e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	7.95	1.4e-12	9.13e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	7.95	1.4e-12	9.13e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	7.95	1.4e-12	9.13e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
GBM	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-7.95	1.42e-12	9.21e-09	-0.79	-0.6	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
GBM	cis	rs6452524	0.967	rs62374399	ENSG00000248112.1	RP11-78C3.1	7.95	1.42e-12	9.23e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.967	rs62374401	ENSG00000248112.1	RP11-78C3.1	7.95	1.42e-12	9.23e-09	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:82919376~82921119:-
GBM	cis	rs950027	0.62	rs1145076	ENSG00000259433.2	CTD-2651B20.4	-7.95	1.45e-12	9.43e-09	-0.61	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45330209~45332634:-
GBM	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-7.95	1.45e-12	9.43e-09	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
GBM	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-7.94	1.46e-12	9.45e-09	-0.83	-0.6	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
GBM	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	7.94	1.46e-12	9.46e-09	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
GBM	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	7.94	1.48e-12	9.58e-09	1.04	0.6	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	7.94	1.48e-12	9.61e-09	1.03	0.6	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	7.94	1.49e-12	9.65e-09	1.02	0.6	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
GBM	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	7.94	1.49e-12	9.67e-09	0.67	0.6	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000224205.1	AP000351.4	7.93	1.57e-12	1.01e-08	0.66	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23987320~23991421:-
GBM	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-7.93	1.59e-12	1.03e-08	-0.99	-0.59	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000235689.1	AP000351.13	7.92	1.62e-12	1.04e-08	0.65	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:24006305~24008258:-
GBM	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	7.92	1.64e-12	1.05e-08	0.79	0.59	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
GBM	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-7.92	1.67e-12	1.08e-08	-0.66	-0.59	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
GBM	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-7.92	1.68e-12	1.08e-08	-1.09	-0.59	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-7.92	1.68e-12	1.08e-08	-1.09	-0.59	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-7.92	1.68e-12	1.08e-08	-1.09	-0.59	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
GBM	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-7.92	1.68e-12	1.08e-08	-1.09	-0.59	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-7.92	1.68e-12	1.08e-08	-1.09	-0.59	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-7.92	1.69e-12	1.09e-08	-0.68	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
GBM	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	7.91	1.71e-12	1.1e-08	0.74	0.59	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
GBM	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-7.91	1.72e-12	1.1e-08	-0.68	-0.59	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
GBM	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-7.91	1.72e-12	1.1e-08	-0.81	-0.59	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	7.91	1.73e-12	1.11e-08	0.8	0.59	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
GBM	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	7.91	1.74e-12	1.11e-08	0.77	0.59	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
GBM	cis	rs950027	0.62	rs2453533	ENSG00000259433.2	CTD-2651B20.4	-7.91	1.76e-12	1.13e-08	-0.61	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45330209~45332634:-
GBM	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	7.91	1.77e-12	1.13e-08	0.72	0.59	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
GBM	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-7.91	1.77e-12	1.13e-08	-0.83	-0.59	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-7.91	1.77e-12	1.13e-08	-0.83	-0.59	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-7.91	1.77e-12	1.13e-08	-0.83	-0.59	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-7.91	1.77e-12	1.13e-08	-0.83	-0.59	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-7.91	1.77e-12	1.13e-08	-0.83	-0.59	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
GBM	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	7.91	1.78e-12	1.13e-08	0.75	0.59	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
GBM	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	7.9	1.8e-12	1.15e-08	0.7	0.59	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	7.9	1.8e-12	1.15e-08	0.7	0.59	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
GBM	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.9	1.83e-12	1.16e-08	0.76	0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
GBM	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
GBM	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-7.9	1.83e-12	1.16e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
GBM	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	7.9	1.86e-12	1.18e-08	0.66	0.59	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	7.9	1.86e-12	1.18e-08	0.66	0.59	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	7.9	1.86e-12	1.18e-08	0.66	0.59	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	7.9	1.86e-12	1.18e-08	0.66	0.59	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	7.9	1.86e-12	1.18e-08	0.66	0.59	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	7.9	1.86e-12	1.18e-08	0.66	0.59	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
GBM	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	7.9	1.86e-12	1.18e-08	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	7.9	1.86e-12	1.18e-08	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	7.9	1.86e-12	1.18e-08	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
GBM	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	7.9	1.86e-12	1.18e-08	0.79	0.59	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	7.9	1.86e-12	1.18e-08	0.79	0.59	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	7.9	1.86e-12	1.18e-08	0.79	0.59	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	7.9	1.86e-12	1.18e-08	0.79	0.59	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
GBM	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-7.9	1.87e-12	1.18e-08	-0.81	-0.59	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	7.9	1.87e-12	1.18e-08	0.68	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	7.9	1.87e-12	1.18e-08	0.68	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	7.9	1.87e-12	1.18e-08	0.68	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	7.9	1.87e-12	1.18e-08	0.68	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
GBM	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	7.89	1.92e-12	1.21e-08	0.7	0.59	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
GBM	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	7.89	1.93e-12	1.22e-08	1.05	0.59	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	7.89	1.93e-12	1.22e-08	1.05	0.59	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	7.89	1.94e-12	1.22e-08	1.02	0.59	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
GBM	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	7.89	1.94e-12	1.22e-08	0.67	0.59	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	7.89	1.94e-12	1.22e-08	0.67	0.59	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	7.89	1.94e-12	1.22e-08	0.67	0.59	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	7.89	1.94e-12	1.22e-08	0.67	0.59	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	7.89	1.94e-12	1.22e-08	0.67	0.59	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
GBM	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-7.89	1.97e-12	1.23e-08	-0.77	-0.59	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
GBM	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-7.89	1.97e-12	1.23e-08	-0.77	-0.59	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
GBM	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-7.89	1.97e-12	1.23e-08	-0.77	-0.59	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
GBM	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-7.89	1.97e-12	1.23e-08	-0.77	-0.59	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
GBM	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-7.89	1.97e-12	1.23e-08	-0.77	-0.59	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
GBM	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	7.89	1.98e-12	1.23e-08	0.71	0.59	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	7.89	1.98e-12	1.23e-08	0.71	0.59	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	7.89	1.98e-12	1.23e-08	0.71	0.59	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-7.89	1.98e-12	1.23e-08	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
GBM	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	7.89	1.98e-12	1.23e-08	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
GBM	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	7.89	1.98e-12	1.24e-08	0.72	0.59	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	7.88	1.99e-12	1.24e-08	0.74	0.59	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
GBM	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	7.88	2.01e-12	1.25e-08	0.78	0.59	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	7.88	2.01e-12	1.25e-08	0.78	0.59	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	7.88	2.01e-12	1.25e-08	0.78	0.59	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
GBM	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	7.88	2.01e-12	1.25e-08	0.78	0.59	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	7.88	2.01e-12	1.25e-08	0.78	0.59	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
GBM	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	7.88	2.04e-12	1.27e-08	0.67	0.59	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	7.88	2.04e-12	1.27e-08	0.67	0.59	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
GBM	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	7.88	2.04e-12	1.27e-08	0.73	0.59	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
GBM	cis	rs950027	0.62	rs35861938	ENSG00000259433.2	CTD-2651B20.4	-7.88	2.06e-12	1.28e-08	-0.61	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45330209~45332634:-
GBM	cis	rs950027	0.596	rs2467865	ENSG00000259433.2	CTD-2651B20.4	-7.88	2.06e-12	1.28e-08	-0.61	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45330209~45332634:-
GBM	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	7.88	2.06e-12	1.28e-08	0.68	0.59	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
GBM	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	7.88	2.08e-12	1.29e-08	0.97	0.59	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
GBM	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.88	2.09e-12	1.3e-08	-0.76	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
GBM	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	7.87	2.12e-12	1.31e-08	0.79	0.59	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
GBM	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	7.87	2.12e-12	1.31e-08	0.79	0.59	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	7.87	2.12e-12	1.31e-08	0.79	0.59	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	7.87	2.12e-12	1.31e-08	0.79	0.59	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	7.87	2.12e-12	1.31e-08	0.79	0.59	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	7.87	2.15e-12	1.33e-08	0.71	0.59	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
GBM	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-7.87	2.15e-12	1.33e-08	-0.68	-0.59	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
GBM	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	7.87	2.2e-12	1.36e-08	0.68	0.59	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
GBM	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	7.87	2.2e-12	1.36e-08	0.79	0.59	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	7.87	2.2e-12	1.36e-08	0.79	0.59	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	7.86	2.21e-12	1.37e-08	0.74	0.59	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	7.86	2.21e-12	1.37e-08	0.74	0.59	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	7.86	2.24e-12	1.39e-08	0.74	0.59	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000235689.1	AP000351.13	-7.86	2.27e-12	1.4e-08	-0.64	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:24006305~24008258:-
GBM	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	7.86	2.27e-12	1.4e-08	0.78	0.59	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
GBM	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-7.85	2.33e-12	1.43e-08	-0.81	-0.59	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
GBM	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-7.85	2.34e-12	1.43e-08	-0.74	-0.59	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-7.85	2.35e-12	1.44e-08	-1.14	-0.59	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
GBM	cis	rs950027	0.62	rs2461700	ENSG00000259433.2	CTD-2651B20.4	-7.85	2.39e-12	1.46e-08	-0.61	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45330209~45332634:-
GBM	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	7.85	2.39e-12	1.46e-08	0.73	0.59	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
GBM	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	7.85	2.41e-12	1.47e-08	0.72	0.59	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	7.85	2.41e-12	1.47e-08	0.72	0.59	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	7.85	2.41e-12	1.47e-08	0.72	0.59	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
GBM	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	7.85	2.42e-12	1.48e-08	0.77	0.59	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
GBM	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-7.84	2.47e-12	1.51e-08	-0.82	-0.59	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	7.84	2.51e-12	1.53e-08	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
GBM	cis	rs9322193	0.923	rs2184370	ENSG00000231760.4	RP11-350J20.5	7.84	2.53e-12	1.54e-08	0.74	0.59	Lung cancer;	chr6:149843242	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	7.84	2.56e-12	1.56e-08	0.77	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
GBM	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	7.84	2.57e-12	1.57e-08	0.73	0.59	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
GBM	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-7.83	2.59e-12	1.58e-08	-0.81	-0.59	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
GBM	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	7.83	2.62e-12	1.59e-08	1.11	0.59	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	7.83	2.62e-12	1.6e-08	0.71	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
GBM	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	7.83	2.67e-12	1.63e-08	1.04	0.59	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
GBM	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	7.83	2.7e-12	1.64e-08	0.66	0.59	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
GBM	cis	rs950027	0.62	rs1153862	ENSG00000259433.2	CTD-2651B20.4	-7.83	2.7e-12	1.64e-08	-0.61	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45330209~45332634:-
GBM	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	7.83	2.71e-12	1.65e-08	1.01	0.59	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	7.83	2.71e-12	1.65e-08	1.01	0.59	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
GBM	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-7.82	2.72e-12	1.65e-08	-0.71	-0.59	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-7.82	2.72e-12	1.65e-08	-0.71	-0.59	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
GBM	cis	rs6452524	0.967	rs62372752	ENSG00000248112.1	RP11-78C3.1	7.82	2.75e-12	1.67e-08	0.73	0.59	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:82919376~82921119:-
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	7.82	2.8e-12	1.7e-08	0.68	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	7.82	2.8e-12	1.7e-08	0.68	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	7.82	2.8e-12	1.7e-08	0.68	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
GBM	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
GBM	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
GBM	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-7.82	2.83e-12	1.71e-08	-0.8	-0.59	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
GBM	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	7.81	2.87e-12	1.73e-08	0.72	0.59	Depression;	chr6:28428413	chr6:28176188~28176674:+
GBM	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	7.81	2.87e-12	1.73e-08	0.72	0.59	Depression;	chr6:28430971	chr6:28176188~28176674:+
GBM	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	7.81	2.87e-12	1.73e-08	0.72	0.59	Depression;	chr6:28431469	chr6:28176188~28176674:+
GBM	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	7.81	2.87e-12	1.73e-08	0.72	0.59	Depression;	chr6:28432562	chr6:28176188~28176674:+
GBM	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	7.81	2.87e-12	1.73e-08	0.8	0.59	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
GBM	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	7.81	2.89e-12	1.74e-08	0.79	0.59	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	7.81	2.89e-12	1.74e-08	0.79	0.59	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	7.81	2.94e-12	1.77e-08	0.65	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-7.81	2.95e-12	1.78e-08	-0.65	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
GBM	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	7.81	3.01e-12	1.81e-08	0.67	0.59	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
GBM	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	7.8	3.04e-12	1.83e-08	0.73	0.59	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	7.8	3.04e-12	1.83e-08	0.73	0.59	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
GBM	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-7.8	3.05e-12	1.83e-08	-0.68	-0.59	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
GBM	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	7.8	3.06e-12	1.83e-08	1.01	0.59	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
GBM	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-7.8	3.06e-12	1.84e-08	-0.66	-0.59	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
GBM	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-7.8	3.06e-12	1.84e-08	-0.66	-0.59	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
GBM	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	7.8	3.07e-12	1.84e-08	0.73	0.59	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
GBM	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	7.8	3.15e-12	1.89e-08	0.97	0.59	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
GBM	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-7.79	3.18e-12	1.9e-08	-0.66	-0.59	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
GBM	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	7.79	3.29e-12	1.97e-08	0.68	0.59	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
GBM	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	7.79	3.3e-12	1.98e-08	0.77	0.59	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	7.79	3.3e-12	1.98e-08	0.77	0.59	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	7.79	3.3e-12	1.98e-08	0.72	0.59	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
GBM	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-7.79	3.33e-12	1.99e-08	-0.66	-0.59	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-7.79	3.33e-12	1.99e-08	-0.69	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
GBM	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-7.78	3.35e-12	2e-08	-0.97	-0.59	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
GBM	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	7.78	3.36e-12	2.01e-08	0.69	0.59	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
GBM	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	7.78	3.44e-12	2.05e-08	0.73	0.59	Depression;	chr6:28407125	chr6:28176188~28176674:+
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000235689.1	AP000351.13	7.78	3.46e-12	2.06e-08	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:24006305~24008258:-
GBM	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-7.78	3.47e-12	2.07e-08	-0.76	-0.59	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	7.78	3.49e-12	2.08e-08	0.72	0.59	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
GBM	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-7.77	3.52e-12	2.1e-08	-0.65	-0.59	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
GBM	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-7.77	3.53e-12	2.1e-08	-0.7	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
GBM	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	7.77	3.55e-12	2.11e-08	0.78	0.59	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-7.77	3.57e-12	2.13e-08	-0.8	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000235689.1	AP000351.13	7.77	3.58e-12	2.13e-08	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000235689.1	AP000351.13	7.77	3.58e-12	2.13e-08	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:24006305~24008258:-
GBM	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-7.77	3.61e-12	2.15e-08	-0.76	-0.59	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	7.77	3.68e-12	2.19e-08	1.08	0.59	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	7.77	3.68e-12	2.19e-08	1.08	0.59	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
GBM	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-7.77	3.69e-12	2.2e-08	-0.76	-0.59	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
GBM	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	7.77	3.71e-12	2.2e-08	0.96	0.59	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	7.77	3.71e-12	2.2e-08	0.96	0.59	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
GBM	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	7.76	3.73e-12	2.21e-08	1	0.59	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
GBM	cis	rs950027	0.62	rs1346267	ENSG00000259433.2	CTD-2651B20.4	-7.76	3.73e-12	2.21e-08	-0.6	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45330209~45332634:-
GBM	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	7.76	3.75e-12	2.22e-08	0.72	0.59	Depression;	chr6:28379133	chr6:28176188~28176674:+
GBM	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	7.76	3.75e-12	2.22e-08	0.72	0.59	Depression;	chr6:28379168	chr6:28176188~28176674:+
GBM	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	7.76	3.75e-12	2.22e-08	0.72	0.59	Depression;	chr6:28386473	chr6:28176188~28176674:+
GBM	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	7.76	3.75e-12	2.22e-08	0.72	0.59	Depression;	chr6:28391932	chr6:28176188~28176674:+
GBM	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	7.76	3.75e-12	2.22e-08	0.72	0.59	Depression;	chr6:28399846	chr6:28176188~28176674:+
GBM	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-7.76	3.76e-12	2.23e-08	-0.83	-0.59	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000224205.1	AP000351.4	7.76	3.76e-12	2.23e-08	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23987320~23991421:-
GBM	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	7.76	3.76e-12	2.23e-08	0.68	0.59	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
GBM	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-7.76	3.78e-12	2.24e-08	-0.68	-0.59	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
GBM	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	7.75	3.98e-12	2.35e-08	0.8	0.59	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
GBM	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-7.75	4.09e-12	2.41e-08	-0.8	-0.59	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-7.74	4.13e-12	2.44e-08	-1.06	-0.59	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	7.74	4.13e-12	2.44e-08	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
GBM	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.74	4.17e-12	2.46e-08	-0.75	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
GBM	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	7.74	4.18e-12	2.46e-08	0.96	0.59	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
GBM	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	7.74	4.21e-12	2.48e-08	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
GBM	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	7.74	4.22e-12	2.48e-08	0.65	0.59	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	7.74	4.22e-12	2.48e-08	0.65	0.59	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	7.74	4.22e-12	2.48e-08	0.65	0.59	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
GBM	cis	rs950027	0.62	rs2486274	ENSG00000259433.2	CTD-2651B20.4	-7.74	4.24e-12	2.49e-08	-0.61	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45330209~45332634:-
GBM	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	7.74	4.29e-12	2.52e-08	0.66	0.59	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	7.74	4.29e-12	2.52e-08	0.66	0.59	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
GBM	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	7.74	4.3e-12	2.52e-08	0.73	0.59	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
GBM	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	7.74	4.32e-12	2.53e-08	0.69	0.59	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	7.74	4.32e-12	2.53e-08	0.69	0.59	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
GBM	cis	rs6452524	0.934	rs12153440	ENSG00000248112.1	RP11-78C3.1	7.74	4.33e-12	2.53e-08	0.73	0.58	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:82919376~82921119:-
GBM	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	7.73	4.39e-12	2.57e-08	0.72	0.58	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
GBM	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	7.73	4.43e-12	2.59e-08	0.66	0.58	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
GBM	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	7.73	4.45e-12	2.6e-08	0.74	0.58	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
GBM	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	7.73	4.47e-12	2.62e-08	0.88	0.58	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
GBM	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	7.73	4.48e-12	2.62e-08	0.95	0.58	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
GBM	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-7.73	4.48e-12	2.62e-08	-0.83	-0.58	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
GBM	cis	rs6452524	0.934	rs6452510	ENSG00000248112.1	RP11-78C3.1	7.73	4.49e-12	2.62e-08	0.73	0.58	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:82919376~82921119:-
GBM	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	7.73	4.52e-12	2.64e-08	0.75	0.58	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
GBM	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	7.73	4.55e-12	2.66e-08	0.73	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
GBM	cis	rs6452524	0.967	rs7718278	ENSG00000248112.1	RP11-78C3.1	7.72	4.66e-12	2.72e-08	0.73	0.58	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:82919376~82921119:-
GBM	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-7.72	4.68e-12	2.73e-08	-0.8	-0.58	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
GBM	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	7.72	4.72e-12	2.75e-08	0.72	0.58	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
GBM	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-7.72	4.79e-12	2.79e-08	-0.63	-0.58	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000224205.1	AP000351.4	7.71	4.84e-12	2.81e-08	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000224205.1	AP000351.4	7.71	4.84e-12	2.81e-08	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23987320~23991421:-
GBM	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	7.71	4.85e-12	2.82e-08	0.78	0.58	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
GBM	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	7.71	4.97e-12	2.87e-08	0.72	0.58	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
GBM	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-7.71	5.03e-12	2.91e-08	-0.59	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-7.71	5.03e-12	2.91e-08	-0.59	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-7.71	5.03e-12	2.91e-08	-0.59	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
GBM	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	7.71	5.05e-12	2.92e-08	0.66	0.58	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
GBM	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	7.7	5.13e-12	2.96e-08	0.77	0.58	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
GBM	cis	rs950027	0.62	rs1719246	ENSG00000259433.2	CTD-2651B20.4	-7.7	5.13e-12	2.96e-08	-0.61	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45330209~45332634:-
GBM	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-7.7	5.18e-12	2.99e-08	-0.81	-0.58	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
GBM	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	7.7	5.19e-12	2.99e-08	0.78	0.58	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	7.7	5.19e-12	2.99e-08	0.78	0.58	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
GBM	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	7.7	5.19e-12	2.99e-08	0.78	0.58	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
GBM	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	7.7	5.19e-12	2.99e-08	0.78	0.58	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
GBM	cis	rs950027	0.62	rs1145089	ENSG00000259433.2	CTD-2651B20.4	-7.7	5.23e-12	3.01e-08	-0.61	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45330209~45332634:-
GBM	cis	rs950027	0.62	rs1049518	ENSG00000259433.2	CTD-2651B20.4	-7.7	5.23e-12	3.01e-08	-0.61	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45330209~45332634:-
GBM	cis	rs950027	0.584	rs1145086	ENSG00000259433.2	CTD-2651B20.4	-7.7	5.23e-12	3.01e-08	-0.61	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45330209~45332634:-
GBM	cis	rs950027	0.62	rs1153857	ENSG00000259433.2	CTD-2651B20.4	-7.7	5.27e-12	3.03e-08	-0.61	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45330209~45332634:-
GBM	cis	rs950027	0.62	rs1153855	ENSG00000259433.2	CTD-2651B20.4	-7.7	5.27e-12	3.03e-08	-0.61	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45330209~45332634:-
GBM	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	7.7	5.28e-12	3.03e-08	0.71	0.58	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	7.7	5.28e-12	3.03e-08	0.71	0.58	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-7.69	5.42e-12	3.11e-08	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-7.69	5.42e-12	3.11e-08	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-7.69	5.42e-12	3.11e-08	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
GBM	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-7.69	5.48e-12	3.14e-08	-0.71	-0.58	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
GBM	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-7.69	5.5e-12	3.15e-08	-0.76	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
GBM	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	7.69	5.57e-12	3.19e-08	0.97	0.58	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	7.68	5.61e-12	3.21e-08	1.09	0.58	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
GBM	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	7.68	5.67e-12	3.25e-08	0.71	0.58	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
GBM	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	7.68	5.68e-12	3.25e-08	0.7	0.58	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
GBM	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	7.68	5.68e-12	3.25e-08	0.7	0.58	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
GBM	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	7.68	5.74e-12	3.28e-08	0.97	0.58	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
GBM	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-7.68	5.76e-12	3.29e-08	-0.71	-0.58	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-7.68	5.76e-12	3.29e-08	-0.71	-0.58	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	7.68	5.76e-12	3.29e-08	0.71	0.58	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
GBM	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	7.68	5.78e-12	3.3e-08	0.96	0.58	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
GBM	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	7.68	5.78e-12	3.3e-08	0.77	0.58	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
GBM	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-7.68	5.79e-12	3.3e-08	-1.11	-0.58	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-7.67	5.97e-12	3.4e-08	-0.76	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000235689.1	AP000351.13	7.67	6.09e-12	3.46e-08	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:24006305~24008258:-
GBM	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-7.67	6.19e-12	3.52e-08	-1.07	-0.58	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
GBM	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-7.66	6.25e-12	3.55e-08	-0.77	-0.58	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
GBM	cis	rs6452524	0.967	rs6452509	ENSG00000248112.1	RP11-78C3.1	7.66	6.29e-12	3.57e-08	0.72	0.58	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:82919376~82921119:-
GBM	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	7.66	6.39e-12	3.62e-08	0.71	0.58	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000235689.1	AP000351.13	7.66	6.44e-12	3.65e-08	0.64	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:24006305~24008258:-
GBM	cis	rs950027	0.62	rs1145080	ENSG00000259433.2	CTD-2651B20.4	-7.66	6.46e-12	3.66e-08	-0.6	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	7.66	6.5e-12	3.68e-08	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	7.66	6.5e-12	3.68e-08	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	7.66	6.5e-12	3.68e-08	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	7.66	6.5e-12	3.68e-08	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	7.66	6.5e-12	3.68e-08	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
GBM	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	7.65	6.57e-12	3.72e-08	0.68	0.58	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
GBM	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	7.64	6.95e-12	3.93e-08	1.02	0.58	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	7.64	6.95e-12	3.93e-08	1.02	0.58	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
GBM	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	7.64	7.01e-12	3.96e-08	0.7	0.58	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	7.64	7.06e-12	3.99e-08	0.72	0.58	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
GBM	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	7.64	7.09e-12	4e-08	0.72	0.58	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
GBM	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-7.64	7.11e-12	4.01e-08	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
GBM	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-7.64	7.17e-12	4.04e-08	-0.68	-0.58	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
GBM	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-7.64	7.2e-12	4.04e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
GBM	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	7.64	7.25e-12	4.07e-08	0.68	0.58	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
GBM	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	7.63	7.28e-12	4.08e-08	0.74	0.58	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
GBM	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-7.63	7.3e-12	4.1e-08	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-7.63	7.3e-12	4.1e-08	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
GBM	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	7.62	7.66e-12	4.29e-08	0.66	0.58	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
GBM	cis	rs9326248	0.608	rs1076485	ENSG00000254851.1	RP11-109L13.1	7.62	7.67e-12	4.29e-08	1.06	0.58	Blood protein levels;	chr11:116901725	chr11:117135528~117138582:+
GBM	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	7.62	7.9e-12	4.42e-08	0.75	0.58	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	7.62	7.9e-12	4.42e-08	0.75	0.58	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	7.62	8.03e-12	4.48e-08	0.73	0.58	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	7.61	8.18e-12	4.56e-08	0.65	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
GBM	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	7.61	8.31e-12	4.63e-08	0.76	0.58	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
GBM	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	7.61	8.35e-12	4.65e-08	0.76	0.58	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
GBM	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-7.61	8.42e-12	4.69e-08	-0.98	-0.58	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
GBM	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	7.6	8.46e-12	4.72e-08	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
GBM	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-7.6	8.49e-12	4.73e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-7.6	8.49e-12	4.73e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-7.6	8.49e-12	4.73e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
GBM	cis	rs950027	0.62	rs1145084	ENSG00000259433.2	CTD-2651B20.4	-7.6	8.83e-12	4.91e-08	-0.61	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45330209~45332634:-
GBM	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-7.6	8.86e-12	4.92e-08	-0.75	-0.58	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
GBM	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-7.59	8.91e-12	4.95e-08	-0.66	-0.58	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-7.59	8.91e-12	4.95e-08	-0.66	-0.58	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	7.59	8.91e-12	4.95e-08	0.65	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
GBM	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	7.59	9.01e-12	5e-08	0.74	0.58	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
GBM	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-7.59	9.22e-12	5.11e-08	-0.81	-0.58	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
GBM	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	7.58	9.39e-12	5.19e-08	1.09	0.58	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000235689.1	AP000351.13	7.58	9.39e-12	5.19e-08	0.65	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:24006305~24008258:-
GBM	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	7.58	9.44e-12	5.22e-08	0.79	0.58	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	7.58	9.44e-12	5.22e-08	0.79	0.58	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
GBM	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	7.58	9.44e-12	5.22e-08	0.79	0.58	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
GBM	cis	rs6452524	1	rs10068099	ENSG00000248112.1	RP11-78C3.1	7.58	9.64e-12	5.32e-08	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:82919376~82921119:-
GBM	cis	rs6452524	1	rs67683443	ENSG00000248112.1	RP11-78C3.1	7.58	9.64e-12	5.32e-08	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:82919376~82921119:-
GBM	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-7.58	9.64e-12	5.32e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-7.58	9.64e-12	5.32e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-7.58	9.64e-12	5.32e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-7.58	9.64e-12	5.32e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-7.58	9.64e-12	5.32e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-7.58	9.64e-12	5.32e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-7.58	9.64e-12	5.32e-08	-0.82	-0.58	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
GBM	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	7.58	9.65e-12	5.32e-08	0.71	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
GBM	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-7.58	9.75e-12	5.38e-08	-0.59	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-7.58	9.75e-12	5.38e-08	-0.59	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
GBM	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-7.58	9.87e-12	5.44e-08	-0.66	-0.58	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
GBM	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	7.57	9.88e-12	5.45e-08	0.73	0.58	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
GBM	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	7.57	1e-11	5.52e-08	0.72	0.58	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs7349753	ENSG00000248112.1	RP11-78C3.1	7.57	1.01e-11	5.56e-08	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:82919376~82921119:-
GBM	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-7.57	1.02e-11	5.62e-08	-1.01	-0.58	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-7.57	1.02e-11	5.64e-08	-0.66	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
GBM	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-7.57	1.03e-11	5.68e-08	-0.72	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
GBM	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-7.57	1.04e-11	5.7e-08	-0.7	-0.58	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
GBM	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	7.56	1.04e-11	5.73e-08	0.71	0.58	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
GBM	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-7.56	1.05e-11	5.8e-08	-0.71	-0.58	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	7.55	1.1e-11	6.02e-08	0.73	0.58	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
GBM	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-7.55	1.11e-11	6.06e-08	-0.65	-0.58	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
GBM	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-7.55	1.11e-11	6.08e-08	-0.81	-0.58	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
GBM	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	7.55	1.12e-11	6.1e-08	0.77	0.58	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
GBM	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	7.55	1.12e-11	6.11e-08	0.72	0.58	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.508	rs256795	ENSG00000248112.1	RP11-78C3.1	-7.55	1.12e-11	6.14e-08	-0.71	-0.58	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:82919376~82921119:-
GBM	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	7.55	1.13e-11	6.18e-08	0.55	0.58	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
GBM	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	7.55	1.14e-11	6.22e-08	0.65	0.58	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	7.55	1.14e-11	6.22e-08	0.65	0.58	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
GBM	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-7.55	1.15e-11	6.26e-08	-0.73	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7.55	1.15e-11	6.26e-08	-0.73	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
GBM	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-7.54	1.17e-11	6.37e-08	-0.66	-0.58	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
GBM	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	7.54	1.18e-11	6.4e-08	0.7	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	7.54	1.18e-11	6.4e-08	0.7	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
GBM	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	7.54	1.19e-11	6.44e-08	0.74	0.58	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
GBM	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	7.54	1.19e-11	6.47e-08	0.76	0.58	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
GBM	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	7.54	1.21e-11	6.53e-08	1.01	0.57	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
GBM	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	7.53	1.21e-11	6.58e-08	0.91	0.57	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
GBM	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-7.53	1.22e-11	6.6e-08	-0.69	-0.57	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
GBM	cis	rs9326248	0.569	rs473172	ENSG00000254851.1	RP11-109L13.1	-7.53	1.22e-11	6.62e-08	-1.09	-0.57	Blood protein levels;	chr11:116937254	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	7.53	1.23e-11	6.64e-08	0.62	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000235689.1	AP000351.13	7.53	1.23e-11	6.64e-08	0.62	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000235689.1	AP000351.13	7.53	1.23e-11	6.64e-08	0.62	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000235689.1	AP000351.13	7.53	1.23e-11	6.64e-08	0.62	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:24006305~24008258:-
GBM	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-7.53	1.23e-11	6.67e-08	-0.67	-0.57	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
GBM	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-7.53	1.24e-11	6.71e-08	-0.82	-0.57	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
GBM	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-7.53	1.25e-11	6.76e-08	-0.85	-0.57	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
GBM	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-7.53	1.25e-11	6.76e-08	-0.79	-0.57	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	7.52	1.29e-11	6.95e-08	0.67	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	7.52	1.31e-11	7.03e-08	0.62	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
GBM	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	7.52	1.32e-11	7.09e-08	0.7	0.57	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	7.52	1.32e-11	7.09e-08	0.7	0.57	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
GBM	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	7.52	1.34e-11	7.19e-08	0.69	0.57	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000224205.1	AP000351.4	-7.52	1.34e-11	7.2e-08	-0.62	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23987320~23991421:-
GBM	cis	rs950027	0.596	rs2467853	ENSG00000259433.2	CTD-2651B20.4	-7.51	1.35e-11	7.23e-08	-0.6	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45330209~45332634:-
GBM	cis	rs950027	0.595	rs2486288	ENSG00000259433.2	CTD-2651B20.4	-7.51	1.35e-11	7.23e-08	-0.6	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.539	rs2433601	ENSG00000259433.2	CTD-2651B20.4	-7.51	1.35e-11	7.23e-08	-0.6	-0.57	Glomerular filtration rate;	chr15:45424227	chr15:45330209~45332634:-
GBM	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-7.51	1.36e-11	7.29e-08	-0.68	-0.57	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
GBM	cis	rs950027	0.62	rs1153860	ENSG00000259433.2	CTD-2651B20.4	7.51	1.37e-11	7.34e-08	0.6	0.57	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45330209~45332634:-
GBM	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-7.51	1.39e-11	7.48e-08	-0.71	-0.57	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	7.5	1.42e-11	7.6e-08	0.74	0.57	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
GBM	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	7.5	1.42e-11	7.62e-08	0.66	0.57	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
GBM	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	7.5	1.43e-11	7.67e-08	0.79	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
GBM	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
GBM	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-7.5	1.43e-11	7.68e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
GBM	cis	rs950027	0.62	rs1426932	ENSG00000259433.2	CTD-2651B20.4	-7.5	1.46e-11	7.79e-08	-0.6	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45330209~45332634:-
GBM	cis	rs950027	0.62	rs1145077	ENSG00000259433.2	CTD-2651B20.4	7.5	1.47e-11	7.84e-08	0.61	0.57	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45330209~45332634:-
GBM	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	7.5	1.47e-11	7.87e-08	0.74	0.57	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
GBM	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	7.5	1.47e-11	7.87e-08	0.74	0.57	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
GBM	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-7.48	1.59e-11	8.48e-08	-0.81	-0.57	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
GBM	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-7.48	1.63e-11	8.68e-08	-0.81	-0.57	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
GBM	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-7.48	1.64e-11	8.72e-08	-0.72	-0.57	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
GBM	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	7.47	1.65e-11	8.77e-08	0.65	0.57	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
GBM	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	7.47	1.65e-11	8.8e-08	0.75	0.57	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
GBM	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	7.47	1.65e-11	8.8e-08	0.75	0.57	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
GBM	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	7.47	1.65e-11	8.8e-08	0.75	0.57	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
GBM	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-7.47	1.67e-11	8.88e-08	-0.95	-0.57	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
GBM	cis	rs4713118	0.662	rs9380046	ENSG00000199851.2	U3	7.47	1.72e-11	9.12e-08	0.91	0.57	Parkinson's disease;	chr6:28062721	chr6:28015568~28015777:+
GBM	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-7.47	1.72e-11	9.15e-08	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
GBM	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-7.46	1.74e-11	9.25e-08	-0.69	-0.57	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
GBM	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	7.46	1.75e-11	9.26e-08	0.71	0.57	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
GBM	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	7.46	1.75e-11	9.26e-08	0.78	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
GBM	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	7.46	1.75e-11	9.26e-08	0.78	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
GBM	cis	rs4713118	0.662	rs9393881	ENSG00000199851.2	U3	7.46	1.76e-11	9.34e-08	0.9	0.57	Parkinson's disease;	chr6:28055973	chr6:28015568~28015777:+
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-7.46	1.79e-11	9.47e-08	-0.77	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
GBM	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	7.46	1.8e-11	9.47e-08	0.67	0.57	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	7.46	1.8e-11	9.47e-08	0.67	0.57	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
GBM	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
GBM	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
GBM	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
GBM	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
GBM	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
GBM	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
GBM	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
GBM	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
GBM	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
GBM	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
GBM	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
GBM	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	7.45	1.83e-11	9.57e-08	0.74	0.57	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
GBM	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-7.45	1.83e-11	9.57e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
GBM	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-7.45	1.83e-11	9.57e-08	-0.67	-0.57	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
GBM	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	7.45	1.84e-11	9.63e-08	0.95	0.57	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
GBM	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	7.45	1.84e-11	9.64e-08	0.95	0.57	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	7.45	1.84e-11	9.64e-08	0.95	0.57	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	7.45	1.84e-11	9.64e-08	0.95	0.57	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000224205.1	AP000351.4	7.45	1.84e-11	9.64e-08	0.62	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23987320~23991421:-
GBM	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-7.45	1.85e-11	9.66e-08	-0.73	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
GBM	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	7.45	1.88e-11	9.8e-08	0.8	0.57	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
GBM	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-7.45	1.89e-11	9.84e-08	-0.72	-0.57	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
GBM	cis	rs7301826	0.627	rs10744480	ENSG00000256299.1	RP11-989F5.3	-7.45	1.9e-11	9.89e-08	-0.68	-0.57	Plasma plasminogen activator levels;	chr12:130792602	chr12:130810821~130812622:-
GBM	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	7.45	1.9e-11	9.91e-08	0.71	0.57	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
GBM	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	7.45	1.91e-11	9.94e-08	0.68	0.57	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
GBM	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-7.45	1.91e-11	9.96e-08	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-7.45	1.91e-11	9.96e-08	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-7.45	1.91e-11	9.96e-08	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-7.45	1.91e-11	9.96e-08	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-7.45	1.91e-11	9.96e-08	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-7.45	1.91e-11	9.96e-08	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
GBM	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-7.44	1.93e-11	1e-07	-0.62	-0.57	Breast cancer;	chr11:743813	chr11:779617~780755:+
GBM	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	7.44	1.93e-11	1e-07	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
GBM	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	7.44	1.94e-11	1.01e-07	0.77	0.57	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
GBM	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-7.44	1.97e-11	1.02e-07	-0.7	-0.57	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-7.44	1.97e-11	1.02e-07	-0.7	-0.57	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
GBM	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-7.44	1.99e-11	1.03e-07	-0.8	-0.57	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-7.44	2.02e-11	1.04e-07	-0.77	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
GBM	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	7.43	2.05e-11	1.06e-07	0.71	0.57	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
GBM	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-7.43	2.06e-11	1.06e-07	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-7.43	2.06e-11	1.06e-07	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-7.43	2.06e-11	1.06e-07	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-7.43	2.06e-11	1.06e-07	-0.66	-0.57	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
GBM	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-7.43	2.08e-11	1.07e-07	-0.67	-0.57	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
GBM	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-7.43	2.08e-11	1.07e-07	-0.67	-0.57	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
GBM	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-7.43	2.1e-11	1.08e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-7.43	2.1e-11	1.08e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-7.43	2.1e-11	1.08e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
GBM	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-7.42	2.16e-11	1.11e-07	-0.72	-0.57	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
GBM	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	7.42	2.19e-11	1.12e-07	1.02	0.57	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
GBM	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-7.42	2.19e-11	1.13e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-7.42	2.19e-11	1.13e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-7.42	2.19e-11	1.13e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-7.42	2.19e-11	1.13e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-7.42	2.19e-11	1.13e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	7.42	2.19e-11	1.13e-07	0.72	0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
GBM	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	7.42	2.22e-11	1.14e-07	0.78	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
GBM	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	7.42	2.22e-11	1.14e-07	0.76	0.57	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000235689.1	AP000351.13	-7.41	2.24e-11	1.15e-07	-0.62	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:24006305~24008258:-
GBM	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	7.41	2.28e-11	1.17e-07	0.69	0.57	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
GBM	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	7.41	2.29e-11	1.17e-07	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	7.41	2.29e-11	1.17e-07	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	7.41	2.29e-11	1.17e-07	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-7.41	2.3e-11	1.18e-07	-0.71	-0.57	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-7.41	2.3e-11	1.18e-07	-0.71	-0.57	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
GBM	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	7.41	2.3e-11	1.18e-07	0.75	0.57	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
GBM	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	7.41	2.3e-11	1.18e-07	0.75	0.57	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-7.41	2.31e-11	1.18e-07	-0.71	-0.57	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
GBM	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-7.41	2.32e-11	1.19e-07	-0.75	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
GBM	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-7.41	2.34e-11	1.19e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
GBM	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-7.4	2.37e-11	1.21e-07	-0.82	-0.57	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
GBM	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-7.4	2.39e-11	1.22e-07	-0.57	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000224205.1	AP000351.4	7.4	2.41e-11	1.23e-07	0.64	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000224205.1	AP000351.4	7.4	2.42e-11	1.23e-07	0.63	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23987320~23991421:-
GBM	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-7.39	2.5e-11	1.27e-07	-0.74	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
GBM	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	7.39	2.5e-11	1.27e-07	0.78	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
GBM	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	7.39	2.53e-11	1.29e-07	0.74	0.57	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
GBM	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	7.39	2.54e-11	1.29e-07	0.71	0.57	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
GBM	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-7.38	2.61e-11	1.32e-07	-0.67	-0.57	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-7.38	2.61e-11	1.32e-07	-0.67	-0.57	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
GBM	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	7.38	2.61e-11	1.32e-07	0.69	0.57	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
GBM	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-7.38	2.67e-11	1.35e-07	-0.78	-0.57	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-7.38	2.69e-11	1.36e-07	-0.75	-0.57	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-7.38	2.69e-11	1.36e-07	-0.75	-0.57	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
GBM	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-7.38	2.71e-11	1.37e-07	-0.64	-0.57	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
GBM	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	7.38	2.73e-11	1.38e-07	1.08	0.57	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
GBM	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	7.38	2.74e-11	1.38e-07	0.72	0.57	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
GBM	cis	rs4713118	0.662	rs149946	ENSG00000199851.2	U3	-7.37	2.76e-11	1.39e-07	-0.9	-0.57	Parkinson's disease;	chr6:28002253	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs156744	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:27999496	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs149947	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28004655	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.629	rs203890	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28054470	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9357060	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28056708	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9468271	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28056792	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9380045	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28057501	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.616	rs9348789	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28057708	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9468274	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28058299	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9468275	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28058358	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9468276	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28059910	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9468277	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28060612	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs9468278	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28060704	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs13218430	ENSG00000199851.2	U3	7.37	2.76e-11	1.39e-07	0.9	0.57	Parkinson's disease;	chr6:28062059	chr6:28015568~28015777:+
GBM	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-7.37	2.76e-11	1.39e-07	-0.75	-0.57	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
GBM	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	7.37	2.77e-11	1.39e-07	0.66	0.57	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
GBM	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	7.37	2.77e-11	1.39e-07	0.66	0.57	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	7.37	2.77e-11	1.39e-07	0.66	0.57	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
GBM	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	7.37	2.77e-11	1.39e-07	0.66	0.57	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
GBM	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	7.37	2.81e-11	1.41e-07	0.75	0.57	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
GBM	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	7.37	2.81e-11	1.41e-07	0.75	0.57	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
GBM	cis	rs11650106	0.529	rs35391268	ENSG00000266992.1	DHX40P1	-7.37	2.84e-11	1.42e-07	-0.75	-0.57	Lipoprotein-associated phospholipase A2 activity and mass;	chr17:59692637	chr17:59976009~60002384:-
GBM	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	7.37	2.84e-11	1.43e-07	0.58	0.57	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	7.37	2.84e-11	1.43e-07	0.58	0.57	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
GBM	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	7.37	2.85e-11	1.43e-07	0.74	0.57	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
GBM	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-7.37	2.87e-11	1.44e-07	-0.7	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
GBM	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-7.37	2.89e-11	1.44e-07	-0.81	-0.57	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	7.36	2.9e-11	1.45e-07	0.64	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
GBM	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	7.36	2.92e-11	1.46e-07	0.69	0.57	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
GBM	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-7.36	2.93e-11	1.46e-07	-0.8	-0.57	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
GBM	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-7.36	2.94e-11	1.47e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	7.36	2.94e-11	1.47e-07	0.72	0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
GBM	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	7.36	2.95e-11	1.47e-07	0.94	0.57	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	7.36	2.95e-11	1.47e-07	0.94	0.57	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	7.36	2.95e-11	1.47e-07	0.94	0.57	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
GBM	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-7.36	3.04e-11	1.51e-07	-0.72	-0.57	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
GBM	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	7.35	3.05e-11	1.52e-07	0.75	0.57	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
GBM	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	7.35	3.08e-11	1.53e-07	0.74	0.57	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-7.35	3.08e-11	1.53e-07	-0.74	-0.57	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
GBM	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-7.35	3.12e-11	1.55e-07	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-7.35	3.19e-11	1.59e-07	-0.72	-0.57	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
GBM	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	7.34	3.35e-11	1.66e-07	0.67	0.56	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
GBM	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-7.34	3.35e-11	1.66e-07	-0.78	-0.56	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
GBM	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	7.34	3.36e-11	1.67e-07	1.08	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
GBM	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-7.33	3.38e-11	1.68e-07	-0.74	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
GBM	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.33	3.45e-11	1.71e-07	-0.72	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
GBM	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	7.33	3.47e-11	1.72e-07	0.77	0.56	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
GBM	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-7.33	3.48e-11	1.72e-07	-0.57	-0.56	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
GBM	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-7.33	3.48e-11	1.72e-07	-0.68	-0.56	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
GBM	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-7.33	3.5e-11	1.73e-07	-0.69	-0.56	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
GBM	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	7.33	3.52e-11	1.74e-07	0.58	0.56	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
GBM	cis	rs7115242	0.699	rs12285074	ENSG00000254851.1	RP11-109L13.1	7.33	3.54e-11	1.75e-07	1.14	0.56	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891312	chr11:117135528~117138582:+
GBM	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	7.32	3.55e-11	1.76e-07	0.72	0.56	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
GBM	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	7.32	3.58e-11	1.77e-07	0.72	0.56	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
GBM	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-7.32	3.61e-11	1.78e-07	-0.66	-0.56	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
GBM	cis	rs4713118	0.629	rs203889	ENSG00000199851.2	U3	7.32	3.61e-11	1.78e-07	0.87	0.56	Parkinson's disease;	chr6:28053997	chr6:28015568~28015777:+
GBM	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	7.32	3.62e-11	1.78e-07	1.09	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
GBM	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	7.32	3.64e-11	1.79e-07	0.7	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
GBM	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-7.32	3.67e-11	1.81e-07	-0.76	-0.56	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
GBM	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	7.32	3.69e-11	1.82e-07	0.96	0.56	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
GBM	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	7.31	3.84e-11	1.89e-07	0.7	0.56	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	7.31	3.84e-11	1.89e-07	0.7	0.56	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
GBM	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	7.31	3.88e-11	1.91e-07	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
GBM	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	7.31	3.89e-11	1.91e-07	0.65	0.56	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	7.31	3.89e-11	1.91e-07	0.65	0.56	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
GBM	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	7.31	3.89e-11	1.91e-07	0.65	0.56	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
GBM	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	7.31	3.89e-11	1.91e-07	0.65	0.56	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000235689.1	AP000351.13	7.31	3.91e-11	1.92e-07	0.63	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:24006305~24008258:-
GBM	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-7.3	3.95e-11	1.94e-07	-0.86	-0.56	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
GBM	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	7.3	3.98e-11	1.96e-07	1.03	0.56	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
GBM	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-7.3	4.05e-11	1.99e-07	-0.93	-0.56	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-7.3	4.06e-11	1.99e-07	-0.74	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
GBM	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	7.29	4.2e-11	2.05e-07	1.1	0.56	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
GBM	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	7.29	4.2e-11	2.05e-07	0.65	0.56	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
GBM	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	7.29	4.2e-11	2.05e-07	0.65	0.56	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	7.29	4.2e-11	2.05e-07	0.65	0.56	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
GBM	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	7.29	4.24e-11	2.07e-07	0.62	0.56	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	7.29	4.24e-11	2.07e-07	0.62	0.56	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
GBM	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	7.29	4.33e-11	2.11e-07	0.68	0.56	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	7.29	4.33e-11	2.11e-07	0.68	0.56	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	7.29	4.33e-11	2.11e-07	0.68	0.56	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
GBM	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-7.28	4.35e-11	2.12e-07	-0.56	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-7.28	4.41e-11	2.15e-07	-0.56	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
GBM	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-7.28	4.42e-11	2.16e-07	-0.64	-0.56	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
GBM	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-7.28	4.48e-11	2.18e-07	-0.7	-0.56	Depression;	chr6:28422360	chr6:28176188~28176674:+
GBM	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-7.28	4.5e-11	2.19e-07	-0.69	-0.56	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	7.28	4.51e-11	2.19e-07	0.63	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
GBM	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	7.28	4.51e-11	2.19e-07	0.8	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
GBM	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-7.27	4.78e-11	2.32e-07	-0.65	-0.56	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
GBM	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	7.27	4.78e-11	2.32e-07	0.73	0.56	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
GBM	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	7.27	4.8e-11	2.33e-07	0.73	0.56	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
GBM	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-7.26	4.82e-11	2.34e-07	-0.92	-0.56	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
GBM	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-7.26	4.82e-11	2.34e-07	-0.92	-0.56	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
GBM	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-7.26	4.83e-11	2.34e-07	-0.97	-0.56	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
GBM	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-7.26	4.86e-11	2.36e-07	-1.04	-0.56	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-7.26	4.89e-11	2.37e-07	-0.75	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-7.26	4.92e-11	2.38e-07	-0.63	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
GBM	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-7.25	5.06e-11	2.45e-07	-1.09	-0.56	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-7.25	5.06e-11	2.45e-07	-1.09	-0.56	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
GBM	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-7.25	5.06e-11	2.45e-07	-1.09	-0.56	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-7.25	5.06e-11	2.45e-07	-1.09	-0.56	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-7.25	5.06e-11	2.45e-07	-1.09	-0.56	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
GBM	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-7.25	5.07e-11	2.45e-07	-0.71	-0.56	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
GBM	cis	rs8135665	0.6	rs6519096	ENSG00000233739.1	RP5-1039K5.13	7.25	5.09e-11	2.46e-07	0.69	0.56	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38055382	chr22:38057180~38073940:-
GBM	cis	rs8135665	0.6	rs6519097	ENSG00000233739.1	RP5-1039K5.13	7.25	5.09e-11	2.46e-07	0.69	0.56	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38055458	chr22:38057180~38073940:-
GBM	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-7.25	5.1e-11	2.47e-07	-0.48	-0.56	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
GBM	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-7.25	5.11e-11	2.47e-07	-0.68	-0.56	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
GBM	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	7.25	5.12e-11	2.47e-07	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
GBM	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-7.25	5.13e-11	2.48e-07	-0.62	-0.56	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
GBM	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-7.25	5.14e-11	2.48e-07	-0.65	-0.56	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
GBM	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-7.25	5.16e-11	2.49e-07	-0.92	-0.56	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
GBM	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-7.25	5.17e-11	2.49e-07	-0.69	-0.56	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
GBM	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-7.25	5.25e-11	2.53e-07	-0.71	-0.56	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-7.25	5.25e-11	2.53e-07	-0.71	-0.56	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-7.25	5.25e-11	2.53e-07	-0.71	-0.56	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
GBM	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	7.25	5.26e-11	2.53e-07	0.68	0.56	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
GBM	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	7.25	5.29e-11	2.55e-07	0.73	0.56	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
GBM	cis	rs8135665	0.6	rs8139025	ENSG00000233739.1	RP5-1039K5.13	7.25	5.31e-11	2.55e-07	0.68	0.56	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38054874	chr22:38057180~38073940:-
GBM	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	7.24	5.36e-11	2.58e-07	0.69	0.56	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
GBM	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-7.24	5.43e-11	2.61e-07	-0.71	-0.56	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
GBM	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	7.24	5.45e-11	2.61e-07	1	0.56	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
GBM	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-7.24	5.45e-11	2.62e-07	-0.92	-0.56	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
GBM	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	7.24	5.48e-11	2.63e-07	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
GBM	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	7.24	5.52e-11	2.65e-07	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	7.24	5.52e-11	2.65e-07	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
GBM	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	7.24	5.53e-11	2.65e-07	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
GBM	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-7.23	5.6e-11	2.68e-07	-1.11	-0.56	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
GBM	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	7.23	5.61e-11	2.69e-07	0.7	0.56	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	7.23	5.64e-11	2.7e-07	0.7	0.56	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000235689.1	AP000351.13	7.23	5.73e-11	2.74e-07	0.61	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000235689.1	AP000351.13	7.23	5.73e-11	2.74e-07	0.61	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000235689.1	AP000351.13	7.23	5.73e-11	2.74e-07	0.61	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:24006305~24008258:-
GBM	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-7.23	5.83e-11	2.79e-07	-0.67	-0.56	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
GBM	cis	rs8135665	0.625	rs8142185	ENSG00000233739.1	RP5-1039K5.13	7.22	5.93e-11	2.83e-07	0.67	0.56	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38055073	chr22:38057180~38073940:-
GBM	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	7.22	5.96e-11	2.85e-07	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
GBM	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-7.22	6.05e-11	2.89e-07	-0.69	-0.56	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
GBM	cis	rs6452524	1	rs10080123	ENSG00000248112.1	RP11-78C3.1	-7.21	6.22e-11	2.97e-07	-0.67	-0.56	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:82919376~82921119:-
GBM	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	7.21	6.37e-11	3.04e-07	0.97	0.56	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
GBM	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	7.21	6.37e-11	3.04e-07	0.97	0.56	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
GBM	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	7.21	6.37e-11	3.04e-07	0.97	0.56	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
GBM	cis	rs4713118	0.662	rs149901	ENSG00000199851.2	U3	7.21	6.46e-11	3.08e-07	0.87	0.56	Parkinson's disease;	chr6:27997725	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs464312	ENSG00000199851.2	U3	7.21	6.46e-11	3.08e-07	0.87	0.56	Parkinson's disease;	chr6:27999813	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs469228	ENSG00000199851.2	U3	7.21	6.46e-11	3.08e-07	0.87	0.56	Parkinson's disease;	chr6:28002926	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.54	rs469227	ENSG00000199851.2	U3	7.21	6.46e-11	3.08e-07	0.87	0.56	Parkinson's disease;	chr6:28002927	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs149948	ENSG00000199851.2	U3	7.21	6.46e-11	3.08e-07	0.87	0.56	Parkinson's disease;	chr6:28007039	chr6:28015568~28015777:+
GBM	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	7.21	6.47e-11	3.08e-07	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
GBM	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	7.21	6.47e-11	3.08e-07	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
GBM	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	7.21	6.47e-11	3.08e-07	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
GBM	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	7.21	6.47e-11	3.08e-07	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
GBM	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-7.21	6.49e-11	3.09e-07	-0.61	-0.56	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
GBM	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	7.21	6.5e-11	3.09e-07	0.68	0.56	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
GBM	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-7.2	6.52e-11	3.1e-07	-0.67	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
GBM	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-7.2	6.53e-11	3.11e-07	-0.69	-0.56	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
GBM	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	7.2	6.58e-11	3.13e-07	0.91	0.56	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
GBM	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-7.2	6.64e-11	3.15e-07	-0.64	-0.56	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
GBM	cis	rs7615952	0.611	rs12488771	ENSG00000171084.14	FAM86JP	7.2	6.64e-11	3.16e-07	1.23	0.56	Blood pressure (smoking interaction);	chr3:125981683	chr3:125916620~125930024:+
GBM	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	7.2	6.75e-11	3.2e-07	0.67	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-7.2	6.76e-11	3.21e-07	-0.72	-0.56	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
GBM	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	7.2	6.8e-11	3.23e-07	0.63	0.56	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
GBM	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	7.2	6.83e-11	3.24e-07	0.76	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
GBM	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	7.2	6.83e-11	3.24e-07	0.76	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
GBM	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	7.2	6.83e-11	3.24e-07	0.64	0.56	Height;	chr11:118786602	chr11:118688039~118690600:-
GBM	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	7.19	6.87e-11	3.25e-07	0.74	0.56	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
GBM	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	7.19	6.89e-11	3.26e-07	0.68	0.56	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
GBM	cis	rs853679	0.55	rs1150692	ENSG00000199851.2	U3	7.19	6.92e-11	3.27e-07	0.9	0.56	Depression;	chr6:28206179	chr6:28015568~28015777:+
GBM	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-7.19	6.99e-11	3.3e-07	-0.69	-0.56	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	7.19	6.99e-11	3.3e-07	0.71	0.56	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-7.19	6.99e-11	3.3e-07	-0.71	-0.56	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
GBM	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	7.19	7e-11	3.3e-07	0.92	0.56	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
GBM	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-7.19	7.01e-11	3.31e-07	-0.92	-0.56	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
GBM	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-7.19	7.01e-11	3.31e-07	-0.92	-0.56	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
GBM	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-7.19	7.01e-11	3.31e-07	-0.92	-0.56	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
GBM	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-7.19	7.01e-11	3.31e-07	-0.92	-0.56	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
GBM	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-7.19	7.01e-11	3.31e-07	-0.92	-0.56	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
GBM	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-7.19	7.07e-11	3.33e-07	-0.61	-0.56	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
GBM	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-7.19	7.07e-11	3.33e-07	-0.61	-0.56	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
GBM	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	7.19	7.07e-11	3.33e-07	0.72	0.56	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs11632419	ENSG00000259433.2	CTD-2651B20.4	7.19	7.1e-11	3.35e-07	0.6	0.56	Glomerular filtration rate;	chr15:45265258	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs2271438	ENSG00000259433.2	CTD-2651B20.4	7.19	7.1e-11	3.35e-07	0.6	0.56	Glomerular filtration rate;	chr15:45265270	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11854365	ENSG00000259433.2	CTD-2651B20.4	7.19	7.1e-11	3.35e-07	0.6	0.56	Glomerular filtration rate;	chr15:45265885	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-7.19	7.13e-11	3.36e-07	-0.75	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
GBM	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	7.19	7.14e-11	3.36e-07	0.99	0.56	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	7.19	7.14e-11	3.36e-07	0.99	0.56	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
GBM	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-7.19	7.19e-11	3.39e-07	-0.47	-0.56	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
GBM	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-7.18	7.22e-11	3.39e-07	-0.67	-0.56	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
GBM	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-7.18	7.22e-11	3.39e-07	-0.67	-0.56	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
GBM	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	7.18	7.23e-11	3.4e-07	0.72	0.56	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
GBM	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	7.18	7.3e-11	3.43e-07	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
GBM	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	7.18	7.32e-11	3.44e-07	0.7	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-7.18	7.32e-11	3.44e-07	-0.71	-0.56	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-7.18	7.32e-11	3.44e-07	-0.71	-0.56	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
GBM	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	7.18	7.34e-11	3.44e-07	0.71	0.56	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
GBM	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-7.18	7.35e-11	3.45e-07	-0.77	-0.56	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
GBM	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	7.18	7.45e-11	3.48e-07	1.02	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	7.18	7.45e-11	3.48e-07	1.02	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	7.18	7.45e-11	3.48e-07	1.02	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	7.18	7.45e-11	3.48e-07	1.02	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	7.18	7.45e-11	3.48e-07	1.02	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	7.18	7.45e-11	3.48e-07	1.02	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
GBM	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-7.18	7.51e-11	3.51e-07	-0.61	-0.56	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
GBM	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	7.18	7.51e-11	3.51e-07	0.71	0.56	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
GBM	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-7.18	7.54e-11	3.52e-07	-1.01	-0.56	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	7.18	7.54e-11	3.52e-07	1.01	0.56	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	7.18	7.54e-11	3.52e-07	1.01	0.56	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	7.18	7.54e-11	3.52e-07	1.01	0.56	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
GBM	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	7.18	7.55e-11	3.53e-07	0.64	0.56	Height;	chr11:118761813	chr11:118688039~118690600:-
GBM	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	7.17	7.58e-11	3.54e-07	0.96	0.56	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
GBM	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-7.17	7.63e-11	3.56e-07	-0.71	-0.56	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
GBM	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	7.17	7.66e-11	3.57e-07	0.69	0.56	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
GBM	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	7.17	7.68e-11	3.58e-07	0.76	0.56	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
GBM	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	7.17	7.87e-11	3.66e-07	0.79	0.56	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
GBM	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-7.16	8.02e-11	3.73e-07	-0.66	-0.56	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
GBM	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	7.16	8.03e-11	3.74e-07	0.69	0.56	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
GBM	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-7.16	8.03e-11	3.74e-07	-0.69	-0.56	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-7.16	8.03e-11	3.74e-07	-0.69	-0.56	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
GBM	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	7.16	8.08e-11	3.75e-07	1.02	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
GBM	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-7.16	8.1e-11	3.76e-07	-0.66	-0.56	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
GBM	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-7.16	8.23e-11	3.82e-07	-0.62	-0.56	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
GBM	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-7.16	8.26e-11	3.83e-07	-0.64	-0.56	Breast cancer;	chr11:825777	chr11:779617~780755:+
GBM	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-7.16	8.28e-11	3.84e-07	-1.06	-0.56	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-7.16	8.28e-11	3.84e-07	-1.06	-0.56	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
GBM	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	7.16	8.29e-11	3.85e-07	0.96	0.56	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
GBM	cis	rs8135665	0.6	rs8142379	ENSG00000233739.1	RP5-1039K5.13	7.16	8.31e-11	3.85e-07	0.67	0.56	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38054964	chr22:38057180~38073940:-
GBM	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-7.16	8.32e-11	3.86e-07	-0.63	-0.56	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	7.15	8.4e-11	3.89e-07	0.84	0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
GBM	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-7.15	8.4e-11	3.89e-07	-0.61	-0.55	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
GBM	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-7.15	8.42e-11	3.9e-07	-0.96	-0.55	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
GBM	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-7.15	8.49e-11	3.93e-07	-0.81	-0.55	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
GBM	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	7.15	8.49e-11	3.93e-07	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
GBM	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	7.15	8.49e-11	3.93e-07	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
GBM	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-7.15	8.64e-11	3.99e-07	-0.63	-0.55	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
GBM	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	7.15	8.73e-11	4.03e-07	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
GBM	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	7.15	8.81e-11	4.06e-07	0.52	0.55	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
GBM	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	7.14	8.81e-11	4.06e-07	0.68	0.55	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
GBM	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-7.14	8.85e-11	4.08e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
GBM	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-7.14	8.85e-11	4.08e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-7.14	8.85e-11	4.08e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-7.14	8.85e-11	4.08e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-7.14	8.85e-11	4.08e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
GBM	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-7.14	8.85e-11	4.08e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
GBM	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	7.14	8.93e-11	4.11e-07	0.92	0.55	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
GBM	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-7.14	9.06e-11	4.16e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
GBM	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-7.14	9.06e-11	4.16e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
GBM	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-7.14	9.06e-11	4.16e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
GBM	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-7.14	9.06e-11	4.16e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
GBM	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-7.14	9.06e-11	4.16e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
GBM	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-7.14	9.06e-11	4.16e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
GBM	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-7.14	9.06e-11	4.16e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
GBM	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-7.14	9.07e-11	4.17e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-7.14	9.07e-11	4.17e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
GBM	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-7.14	9.08e-11	4.17e-07	-0.99	-0.55	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
GBM	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-7.14	9.08e-11	4.17e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-7.14	9.08e-11	4.17e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-7.14	9.08e-11	4.17e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-7.14	9.08e-11	4.17e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
GBM	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-7.14	9.17e-11	4.21e-07	-0.67	-0.55	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
GBM	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	7.14	9.18e-11	4.21e-07	0.63	0.55	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
GBM	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	7.14	9.2e-11	4.22e-07	0.81	0.55	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
GBM	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	7.13	9.31e-11	4.27e-07	0.71	0.55	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	7.13	9.31e-11	4.27e-07	0.71	0.55	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	7.13	9.31e-11	4.27e-07	0.71	0.55	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	7.13	9.31e-11	4.27e-07	0.71	0.55	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000235689.1	AP000351.13	7.13	9.34e-11	4.28e-07	0.61	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:24006305~24008258:-
GBM	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-7.13	9.39e-11	4.29e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
GBM	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	7.13	9.4e-11	4.29e-07	0.65	0.55	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
GBM	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-7.13	9.43e-11	4.29e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
GBM	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-7.13	9.43e-11	4.29e-07	-0.47	-0.55	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
GBM	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-7.13	9.47e-11	4.29e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
GBM	cis	rs853679	0.517	rs9380047	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28070115	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs7755442	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28071237	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713135	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28071808	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs55747925	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28076559	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs56310871	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28076704	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs34716816	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28078391	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380049	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28080757	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380050	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28080760	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393885	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28082231	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393886	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28082261	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.515	rs9368549	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28082269	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs56364346	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28082984	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9357061	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28083994	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368550	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28084025	chr6:28015568~28015777:+
GBM	cis	rs853679	0.542	rs2295594	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28085319	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs2273564	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28089816	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs1853097	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28090857	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393888	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28091439	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs3734573	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28091659	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9357063	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28092227	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs3823180	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28093966	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368551	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28094014	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393890	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28096077	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9366715	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28096855	chr6:28015568~28015777:+
GBM	cis	rs853679	0.598	rs9380054	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28099759	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.547	rs2116981	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28100173	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368552	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28100648	chr6:28015568~28015777:+
GBM	cis	rs853679	0.542	rs34131763	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28107222	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs35193936	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28108492	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs36078605	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28110254	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393891	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28111382	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9468286	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28111650	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.516	rs7739216	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28112168	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs35512245	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28112175	chr6:28015568~28015777:+
GBM	cis	rs853679	0.542	rs9393892	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28113616	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380055	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28113851	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368553	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28114487	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368554	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28114933	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713137	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28115743	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9348793	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28116411	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.586	rs6905516	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28118700	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.586	rs6905522	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28118701	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.586	rs9468290	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28119896	chr6:28015568~28015777:+
GBM	cis	rs853679	0.542	rs6934769	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28123153	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs17711801	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28124529	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.527	rs9461433	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28127394	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9468292	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28127577	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs1947863	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28131566	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713141	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28133900	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380056	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28136698	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380057	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28136856	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs6941992	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28138363	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.516	rs4713142	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28138569	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713143	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28138981	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713144	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28139012	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713145	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28139049	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs3757187	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28139876	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs3757185	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28139998	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs1904840	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28140454	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368555	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28141189	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393893	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28141484	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713146	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28143758	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393894	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28144784	chr6:28015568~28015777:+
GBM	cis	rs853679	0.513	rs9468296	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28145952	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4711164	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28147378	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4711165	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28147406	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713148	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28148143	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9348794	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28149979	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9468297	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28151096	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9295758	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28152885	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs17774663	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28153120	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9468298	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28154567	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9295759	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28156691	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9348796	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28158424	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs11552219	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28159056	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393895	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28159843	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393896	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28159925	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393897	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28159932	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9357065	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28161802	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9357066	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28162053	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368556	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28163375	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368557	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28163759	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380059	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28164580	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380060	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28164825	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs35227624	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28164948	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380061	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28165025	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9368558	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28165528	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.587	rs9393899	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28165750	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713150	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28168434	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.527	rs4713151	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Parkinson's disease;	chr6:28168578	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393901	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28169019	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs3173443	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28169249	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs4713152	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28169676	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9348797	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28169755	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380062	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28169791	chr6:28015568~28015777:+
GBM	cis	rs853679	0.542	rs9380063	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28170075	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs12332979	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28173770	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs67878650	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28174809	chr6:28015568~28015777:+
GBM	cis	rs853679	0.569	rs9348798	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28175233	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380065	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28176973	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9295761	ENSG00000199851.2	U3	7.13	9.49e-11	4.29e-07	0.89	0.55	Depression;	chr6:28180209	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs16893666	ENSG00000199851.2	U3	-7.13	9.49e-11	4.29e-07	-0.89	-0.55	Depression;	chr6:28086929	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs868987	ENSG00000199851.2	U3	-7.13	9.49e-11	4.29e-07	-0.89	-0.55	Depression;	chr6:28142370	chr6:28015568~28015777:+
GBM	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-7.13	9.49e-11	4.29e-07	-0.8	-0.55	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
GBM	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-7.13	9.64e-11	4.33e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-7.13	9.64e-11	4.33e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-7.13	9.64e-11	4.33e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
GBM	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	7.12	9.75e-11	4.38e-07	0.69	0.55	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
GBM	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-7.12	9.81e-11	4.41e-07	-0.69	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
GBM	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	7.12	9.84e-11	4.42e-07	0.57	0.55	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
GBM	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	7.12	9.91e-11	4.45e-07	0.83	0.55	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
GBM	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-7.12	9.92e-11	4.45e-07	-0.64	-0.55	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
GBM	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	7.12	9.92e-11	4.45e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	7.12	9.92e-11	4.45e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
GBM	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-7.12	1.01e-10	4.54e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
GBM	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	7.12	1.01e-10	4.55e-07	0.81	0.55	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
GBM	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-7.12	1.02e-10	4.55e-07	-0.7	-0.55	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
GBM	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	7.11	1.03e-10	4.6e-07	0.66	0.55	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
GBM	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	7.11	1.03e-10	4.61e-07	0.62	0.55	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
GBM	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-7.11	1.03e-10	4.61e-07	-0.71	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
GBM	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-7.11	1.03e-10	4.62e-07	-1.07	-0.55	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
GBM	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	7.11	1.04e-10	4.66e-07	0.69	0.55	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
GBM	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-7.11	1.04e-10	4.66e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
GBM	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-7.11	1.04e-10	4.67e-07	-1.01	-0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
GBM	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-7.11	1.06e-10	4.72e-07	-1.09	-0.55	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
GBM	cis	rs853679	0.517	rs12174753	ENSG00000199851.2	U3	7.11	1.07e-10	4.77e-07	0.89	0.55	Depression;	chr6:28074687	chr6:28015568~28015777:+
GBM	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	7.11	1.08e-10	4.8e-07	0.73	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
GBM	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	7.1	1.08e-10	4.82e-07	0.69	0.55	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
GBM	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-7.1	1.08e-10	4.82e-07	-0.73	-0.55	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
GBM	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-7.1	1.08e-10	4.83e-07	-0.71	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-7.1	1.08e-10	4.83e-07	-0.71	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
GBM	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-7.1	1.09e-10	4.85e-07	-0.63	-0.55	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
GBM	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-7.1	1.09e-10	4.88e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
GBM	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	7.1	1.1e-10	4.91e-07	0.63	0.55	Height;	chr11:118742526	chr11:118688039~118690600:-
GBM	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	7.1	1.1e-10	4.91e-07	0.63	0.55	Height;	chr11:118746590	chr11:118688039~118690600:-
GBM	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	7.1	1.11e-10	4.94e-07	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
GBM	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-7.1	1.11e-10	4.95e-07	-0.62	-0.55	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-7.1	1.11e-10	4.95e-07	-0.62	-0.55	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
GBM	cis	rs853679	0.506	rs1150693	ENSG00000199851.2	U3	7.1	1.12e-10	4.98e-07	0.89	0.55	Depression;	chr6:28206812	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.587	rs61471148	ENSG00000199851.2	U3	7.1	1.12e-10	4.99e-07	0.89	0.55	Parkinson's disease;	chr6:28069254	chr6:28015568~28015777:+
GBM	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-7.1	1.12e-10	4.99e-07	-0.65	-0.55	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
GBM	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-7.1	1.12e-10	4.99e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-7.1	1.12e-10	4.99e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
GBM	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-7.1	1.13e-10	5.02e-07	-0.67	-0.55	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
GBM	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-7.09	1.13e-10	5.04e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
GBM	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	7.09	1.16e-10	5.14e-07	0.68	0.55	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
GBM	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-7.09	1.17e-10	5.17e-07	-0.89	-0.55	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
GBM	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-7.09	1.17e-10	5.18e-07	-0.75	-0.55	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
GBM	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-7.09	1.17e-10	5.18e-07	-0.65	-0.55	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-7.09	1.17e-10	5.18e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
GBM	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	7.09	1.17e-10	5.2e-07	0.65	0.55	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
GBM	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	7.09	1.19e-10	5.25e-07	0.63	0.55	Height;	chr11:118773873	chr11:118688039~118690600:-
GBM	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-7.09	1.19e-10	5.27e-07	-0.67	-0.55	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
GBM	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-7.08	1.2e-10	5.31e-07	-0.7	-0.55	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
GBM	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	7.08	1.2e-10	5.32e-07	0.62	0.55	Height;	chr11:118737823	chr11:118688039~118690600:-
GBM	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	7.08	1.2e-10	5.32e-07	0.62	0.55	Height;	chr11:118737916	chr11:118688039~118690600:-
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000235689.1	AP000351.13	7.08	1.21e-10	5.34e-07	0.61	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:24006305~24008258:-
GBM	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	7.08	1.21e-10	5.34e-07	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
GBM	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-7.08	1.22e-10	5.37e-07	-0.75	-0.55	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
GBM	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	7.08	1.22e-10	5.39e-07	0.75	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
GBM	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-7.08	1.22e-10	5.4e-07	-0.75	-0.55	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
GBM	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
GBM	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
GBM	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
GBM	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-7.08	1.24e-10	5.47e-07	-1.06	-0.55	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
GBM	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	7.08	1.24e-10	5.47e-07	0.7	0.55	Depression;	chr6:28364057	chr6:28176188~28176674:+
GBM	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	7.08	1.25e-10	5.49e-07	0.64	0.55	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
GBM	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-7.08	1.25e-10	5.49e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
GBM	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-7.08	1.25e-10	5.51e-07	-1.05	-0.55	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
GBM	cis	rs853679	0.55	rs9295762	ENSG00000199851.2	U3	-7.07	1.26e-10	5.53e-07	-0.84	-0.55	Depression;	chr6:28187640	chr6:28015568~28015777:+
GBM	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-7.07	1.26e-10	5.53e-07	-0.72	-0.55	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
GBM	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-7.07	1.26e-10	5.53e-07	-0.66	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
GBM	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-7.07	1.28e-10	5.61e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
GBM	cis	rs853679	0.517	rs9380052	ENSG00000199851.2	U3	7.07	1.28e-10	5.63e-07	0.91	0.55	Depression;	chr6:28096845	chr6:28015568~28015777:+
GBM	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	7.07	1.29e-10	5.67e-07	0.97	0.55	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
GBM	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	7.07	1.3e-10	5.7e-07	0.67	0.55	Height;	chr11:118703185	chr11:118688039~118690600:-
GBM	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	7.07	1.3e-10	5.7e-07	0.67	0.55	Height;	chr11:118703207	chr11:118688039~118690600:-
GBM	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	7.07	1.3e-10	5.7e-07	0.67	0.55	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
GBM	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-7.07	1.3e-10	5.7e-07	-0.67	-0.55	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
GBM	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-7.07	1.3e-10	5.7e-07	-0.64	-0.55	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
GBM	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	7.07	1.3e-10	5.71e-07	0.63	0.55	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
GBM	cis	rs7829975	0.627	rs876954	ENSG00000253893.2	FAM85B	-7.07	1.3e-10	5.72e-07	-0.69	-0.55	Mood instability;	chr8:8453413	chr8:8167819~8226614:-
GBM	cis	rs4713118	0.662	rs149969	ENSG00000199851.2	U3	7.07	1.3e-10	5.72e-07	0.89	0.55	Parkinson's disease;	chr6:28009959	chr6:28015568~28015777:+
GBM	cis	rs853679	0.628	rs9368560	ENSG00000199851.2	U3	7.07	1.31e-10	5.74e-07	0.84	0.55	Depression;	chr6:28192182	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1225598	ENSG00000199851.2	U3	7.07	1.31e-10	5.74e-07	0.84	0.55	Depression;	chr6:28193021	chr6:28015568~28015777:+
GBM	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	7.07	1.31e-10	5.75e-07	0.65	0.55	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	7.07	1.31e-10	5.75e-07	0.65	0.55	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
GBM	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-7.07	1.32e-10	5.77e-07	-0.63	-0.55	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
GBM	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	7.06	1.32e-10	5.78e-07	1	0.55	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	7.06	1.32e-10	5.78e-07	1	0.55	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
GBM	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-7.06	1.32e-10	5.78e-07	-0.66	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000235689.1	AP000351.13	-7.06	1.33e-10	5.81e-07	-0.59	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:24006305~24008258:-
GBM	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	7.06	1.33e-10	5.81e-07	0.68	0.55	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-7.06	1.33e-10	5.81e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-7.06	1.33e-10	5.81e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-7.06	1.33e-10	5.81e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-7.06	1.33e-10	5.81e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-7.06	1.33e-10	5.81e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
GBM	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-7.06	1.34e-10	5.88e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
GBM	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	7.06	1.35e-10	5.89e-07	0.72	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
GBM	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-7.06	1.35e-10	5.89e-07	-0.68	-0.55	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
GBM	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	7.06	1.35e-10	5.91e-07	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
GBM	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-7.06	1.36e-10	5.94e-07	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
GBM	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-7.06	1.36e-10	5.95e-07	-0.72	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
GBM	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-7.06	1.36e-10	5.95e-07	-0.66	-0.55	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
GBM	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-7.06	1.36e-10	5.96e-07	-1.02	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-7.06	1.36e-10	5.96e-07	-1.02	-0.55	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
GBM	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-7.06	1.37e-10	5.98e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-7.06	1.38e-10	6e-07	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
GBM	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-7.05	1.39e-10	6.09e-07	-0.66	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
GBM	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	7.05	1.4e-10	6.09e-07	0.65	0.55	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-7.05	1.4e-10	6.09e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
GBM	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-7.05	1.41e-10	6.16e-07	-1.04	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
GBM	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-7.05	1.42e-10	6.19e-07	-0.63	-0.55	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
GBM	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-7.05	1.42e-10	6.2e-07	-0.63	-0.55	Height;	chr11:118758322	chr11:118688039~118690600:-
GBM	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	7.05	1.43e-10	6.22e-07	0.67	0.55	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
GBM	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-7.05	1.43e-10	6.24e-07	-0.71	-0.55	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
GBM	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-7.05	1.44e-10	6.25e-07	-0.65	-0.55	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
GBM	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-7.05	1.44e-10	6.28e-07	-0.65	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
GBM	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-7.05	1.44e-10	6.28e-07	-0.65	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
GBM	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-7.04	1.46e-10	6.35e-07	-0.91	-0.55	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
GBM	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.46e-10	6.35e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
GBM	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-7.04	1.46e-10	6.35e-07	-0.53	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-7.04	1.46e-10	6.35e-07	-0.53	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
GBM	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	7.04	1.47e-10	6.37e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
GBM	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	7.04	1.47e-10	6.38e-07	0.97	0.55	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
GBM	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-7.04	1.47e-10	6.39e-07	-0.71	-0.55	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
GBM	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-7.04	1.47e-10	6.39e-07	-0.71	-0.55	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
GBM	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	7.04	1.48e-10	6.43e-07	0.63	0.55	Height;	chr11:118791319	chr11:118688039~118690600:-
GBM	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.48e-10	6.43e-07	-0.57	-0.55	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
GBM	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	7.04	1.51e-10	6.54e-07	0.73	0.55	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
GBM	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-7.04	1.51e-10	6.55e-07	-0.69	-0.55	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
GBM	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	7.04	1.52e-10	6.57e-07	0.99	0.55	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	7.04	1.52e-10	6.57e-07	0.99	0.55	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
GBM	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-7.04	1.52e-10	6.57e-07	-0.58	-0.55	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
GBM	cis	rs4713118	0.662	rs175954	ENSG00000199851.2	U3	7.04	1.52e-10	6.58e-07	0.87	0.55	Parkinson's disease;	chr6:28043807	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs149900	ENSG00000199851.2	U3	7.04	1.52e-10	6.58e-07	0.87	0.55	Parkinson's disease;	chr6:28046819	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs149961	ENSG00000199851.2	U3	7.04	1.52e-10	6.58e-07	0.87	0.55	Parkinson's disease;	chr6:28047791	chr6:28015568~28015777:+
GBM	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-7.04	1.53e-10	6.6e-07	-0.64	-0.55	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-7.04	1.53e-10	6.6e-07	-0.64	-0.55	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
GBM	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-7.04	1.53e-10	6.6e-07	-0.64	-0.55	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
GBM	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-7.04	1.53e-10	6.61e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-7.04	1.53e-10	6.61e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-7.04	1.53e-10	6.61e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-7.04	1.53e-10	6.61e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-7.04	1.53e-10	6.61e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
GBM	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-7.03	1.54e-10	6.63e-07	-0.68	-0.55	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	7.03	1.55e-10	6.67e-07	0.62	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
GBM	cis	rs2486288	0.656	rs7162022	ENSG00000259433.2	CTD-2651B20.4	7.03	1.55e-10	6.67e-07	0.6	0.55	Glomerular filtration rate;	chr15:45273055	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000224205.1	AP000351.4	7.03	1.55e-10	6.68e-07	0.61	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23987320~23991421:-
GBM	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	7.03	1.56e-10	6.71e-07	0.68	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
GBM	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	7.03	1.56e-10	6.71e-07	0.68	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
GBM	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	7.03	1.56e-10	6.72e-07	0.75	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
GBM	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	7.03	1.56e-10	6.74e-07	0.68	0.55	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
GBM	cis	rs2486288	0.656	rs9921035	ENSG00000259433.2	CTD-2651B20.4	7.03	1.57e-10	6.74e-07	0.61	0.55	Glomerular filtration rate;	chr15:45254462	chr15:45330209~45332634:-
GBM	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-7.03	1.57e-10	6.75e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
GBM	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-7.03	1.57e-10	6.78e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
GBM	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-7.03	1.57e-10	6.78e-07	-0.65	-0.55	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
GBM	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	7.03	1.58e-10	6.81e-07	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	7.03	1.58e-10	6.81e-07	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
GBM	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	7.03	1.58e-10	6.81e-07	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
GBM	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-7.03	1.59e-10	6.85e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
GBM	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-7.03	1.6e-10	6.87e-07	-0.68	-0.55	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
GBM	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-7.03	1.6e-10	6.87e-07	-0.53	-0.55	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
GBM	cis	rs858239	0.704	rs466240	ENSG00000230658.1	KLHL7-AS1	-7.02	1.63e-10	6.99e-07	-0.69	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23101228~23105703:-
GBM	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	7.02	1.64e-10	7.03e-07	0.65	0.55	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	7.02	1.64e-10	7.03e-07	0.65	0.55	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	7.02	1.64e-10	7.03e-07	0.65	0.55	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	7.02	1.64e-10	7.03e-07	0.65	0.55	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	7.02	1.64e-10	7.03e-07	0.65	0.55	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	7.02	1.64e-10	7.03e-07	0.65	0.55	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	7.02	1.64e-10	7.03e-07	0.65	0.55	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
GBM	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-7.02	1.65e-10	7.07e-07	-0.63	-0.55	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-7.02	1.65e-10	7.07e-07	-0.63	-0.55	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
GBM	cis	rs2486288	0.656	rs2413768	ENSG00000259433.2	CTD-2651B20.4	7.02	1.65e-10	7.07e-07	0.6	0.55	Glomerular filtration rate;	chr15:45269786	chr15:45330209~45332634:-
GBM	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	7.02	1.65e-10	7.07e-07	0.63	0.55	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
GBM	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	7.02	1.66e-10	7.08e-07	0.64	0.55	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
GBM	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	7.02	1.66e-10	7.08e-07	0.57	0.55	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-7.02	1.66e-10	7.08e-07	-0.57	-0.55	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-7.02	1.66e-10	7.08e-07	-0.57	-0.55	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-7.02	1.66e-10	7.08e-07	-0.57	-0.55	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-7.02	1.66e-10	7.08e-07	-0.57	-0.55	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-7.02	1.66e-10	7.08e-07	-0.57	-0.55	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
GBM	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	7.01	1.69e-10	7.21e-07	0.73	0.55	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
GBM	cis	rs2486288	0.656	rs11637838	ENSG00000259433.2	CTD-2651B20.4	7.01	1.7e-10	7.22e-07	0.61	0.55	Glomerular filtration rate;	chr15:45258459	chr15:45330209~45332634:-
GBM	cis	rs4682868	0.611	rs734969	ENSG00000273328.4	RP11-141M3.6	-7.01	1.7e-10	7.23e-07	-0.65	-0.55	Monocyte percentage of white cells;	chr3:42876414	chr3:42809414~42908105:+
GBM	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-7.01	1.71e-10	7.26e-07	-0.63	-0.55	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-7.01	1.71e-10	7.26e-07	-0.63	-0.55	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
GBM	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	7.01	1.71e-10	7.27e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	7.01	1.71e-10	7.27e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	7.01	1.71e-10	7.27e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	7.01	1.71e-10	7.27e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	7.01	1.71e-10	7.27e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
GBM	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-7.01	1.72e-10	7.3e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-7.01	1.72e-10	7.3e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
GBM	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	7.01	1.74e-10	7.35e-07	0.75	0.55	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
GBM	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	7.01	1.75e-10	7.41e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	7.01	1.75e-10	7.41e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	7.01	1.75e-10	7.41e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	7.01	1.75e-10	7.41e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	7.01	1.75e-10	7.41e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	7.01	1.75e-10	7.41e-07	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
GBM	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	7.01	1.76e-10	7.44e-07	0.65	0.55	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
GBM	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-7.01	1.77e-10	7.47e-07	-0.64	-0.55	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
GBM	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	7.01	1.78e-10	7.49e-07	0.68	0.55	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
GBM	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-7.01	1.78e-10	7.49e-07	-0.64	-0.55	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
GBM	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-7	1.79e-10	7.55e-07	-0.59	-0.55	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
GBM	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-7	1.83e-10	7.71e-07	-1.04	-0.55	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-7	1.83e-10	7.71e-07	-1.04	-0.55	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
GBM	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	7	1.83e-10	7.72e-07	0.65	0.55	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	7	1.83e-10	7.72e-07	0.65	0.55	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
GBM	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-7	1.86e-10	7.83e-07	-0.77	-0.55	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
GBM	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-6.99	1.89e-10	7.92e-07	-0.58	-0.55	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
GBM	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	6.99	1.89e-10	7.94e-07	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
GBM	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-6.99	1.89e-10	7.94e-07	-0.83	-0.55	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-6.99	1.89e-10	7.94e-07	-0.83	-0.55	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-6.99	1.89e-10	7.94e-07	-0.83	-0.55	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-6.99	1.89e-10	7.94e-07	-0.83	-0.55	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
GBM	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	6.99	1.93e-10	8.1e-07	1.01	0.55	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
GBM	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	6.99	1.94e-10	8.13e-07	0.92	0.55	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
GBM	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-6.99	1.95e-10	8.14e-07	-0.71	-0.55	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-6.99	1.95e-10	8.14e-07	-0.71	-0.55	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-6.99	1.95e-10	8.14e-07	-0.71	-0.55	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-6.99	1.95e-10	8.14e-07	-0.71	-0.55	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-6.99	1.95e-10	8.14e-07	-0.71	-0.55	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-6.99	1.95e-10	8.17e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-6.99	1.96e-10	8.18e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
GBM	cis	rs853679	0.55	rs6901017	ENSG00000199851.2	U3	6.99	1.96e-10	8.19e-07	0.83	0.55	Depression;	chr6:28184805	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1150689	ENSG00000199851.2	U3	6.99	1.96e-10	8.19e-07	0.83	0.55	Depression;	chr6:28197321	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1225599	ENSG00000199851.2	U3	6.99	1.96e-10	8.19e-07	0.83	0.55	Depression;	chr6:28197412	chr6:28015568~28015777:+
GBM	cis	rs853679	0.574	rs1233705	ENSG00000199851.2	U3	6.99	1.96e-10	8.19e-07	0.83	0.55	Depression;	chr6:28198669	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1233699	ENSG00000199851.2	U3	6.99	1.96e-10	8.19e-07	0.83	0.55	Depression;	chr6:28201380	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1233707	ENSG00000199851.2	U3	6.99	1.96e-10	8.19e-07	0.83	0.55	Depression;	chr6:28205175	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1233704	ENSG00000199851.2	U3	-6.99	1.96e-10	8.19e-07	-0.83	-0.55	Depression;	chr6:28199145	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1233701	ENSG00000199851.2	U3	-6.99	1.96e-10	8.19e-07	-0.83	-0.55	Depression;	chr6:28200948	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs1237875	ENSG00000199851.2	U3	-6.99	1.96e-10	8.19e-07	-0.83	-0.55	Depression;	chr6:28205232	chr6:28015568~28015777:+
GBM	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	6.99	1.96e-10	8.19e-07	0.62	0.55	Height;	chr11:118749988	chr11:118688039~118690600:-
GBM	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	6.99	1.96e-10	8.19e-07	0.62	0.55	Height;	chr11:118760944	chr11:118688039~118690600:-
GBM	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	6.99	1.96e-10	8.19e-07	0.62	0.55	Height;	chr11:118764443	chr11:118688039~118690600:-
GBM	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	6.98	1.97e-10	8.22e-07	0.72	0.55	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
GBM	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-6.98	1.99e-10	8.29e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-6.98	1.99e-10	8.29e-07	-0.65	-0.55	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
GBM	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-6.98	1.99e-10	8.29e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-6.98	1.99e-10	8.29e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-6.98	1.99e-10	8.29e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-6.98	1.99e-10	8.29e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
GBM	cis	rs2487048	1	rs2487046	ENSG00000226334.1	RP11-217B7.2	-6.98	2e-10	8.31e-07	-0.72	-0.55	Intraocular pressure;	chr9:104929948	chr9:104927553~104928892:+
GBM	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	6.98	2e-10	8.32e-07	0.64	0.55	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	6.98	2e-10	8.32e-07	0.64	0.55	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	6.98	2e-10	8.32e-07	0.64	0.55	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
GBM	cis	rs4713118	0.629	rs149899	ENSG00000199851.2	U3	6.98	2.01e-10	8.38e-07	0.84	0.55	Parkinson's disease;	chr6:28052201	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.629	rs172165	ENSG00000199851.2	U3	6.98	2.01e-10	8.38e-07	0.84	0.55	Parkinson's disease;	chr6:28053036	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.597	rs172166	ENSG00000199851.2	U3	6.98	2.01e-10	8.38e-07	0.84	0.55	Parkinson's disease;	chr6:28053042	chr6:28015568~28015777:+
GBM	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-6.98	2.02e-10	8.39e-07	-0.62	-0.55	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-6.98	2.02e-10	8.39e-07	-0.62	-0.55	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
GBM	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	6.98	2.04e-10	8.49e-07	0.58	0.55	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
GBM	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-6.98	2.05e-10	8.51e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-6.98	2.05e-10	8.51e-07	-0.7	-0.55	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
GBM	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	6.98	2.06e-10	8.54e-07	0.65	0.55	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
GBM	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-6.98	2.07e-10	8.56e-07	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
GBM	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	6.97	2.07e-10	8.57e-07	0.61	0.55	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
GBM	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	6.97	2.08e-10	8.63e-07	0.84	0.55	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
GBM	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-6.97	2.09e-10	8.63e-07	-0.65	-0.55	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
GBM	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	6.97	2.09e-10	8.66e-07	0.64	0.55	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
GBM	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-6.97	2.1e-10	8.67e-07	-1.1	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
GBM	cis	rs4713118	0.621	rs9368548	ENSG00000199851.2	U3	6.97	2.1e-10	8.69e-07	0.88	0.55	Parkinson's disease;	chr6:28066959	chr6:28015568~28015777:+
GBM	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-6.97	2.11e-10	8.71e-07	-0.68	-0.55	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
GBM	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	6.97	2.11e-10	8.74e-07	0.66	0.55	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
GBM	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	6.97	2.11e-10	8.74e-07	0.98	0.54	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	6.97	2.11e-10	8.74e-07	0.98	0.54	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
GBM	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	6.97	2.12e-10	8.75e-07	0.76	0.54	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
GBM	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-6.97	2.12e-10	8.76e-07	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-6.97	2.12e-10	8.76e-07	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
GBM	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-6.97	2.12e-10	8.77e-07	-0.63	-0.54	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
GBM	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	6.97	2.13e-10	8.8e-07	0.64	0.54	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
GBM	cis	rs853679	0.517	rs1340004	ENSG00000199851.2	U3	6.97	2.17e-10	8.95e-07	0.86	0.54	Depression;	chr6:28135913	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs17711344	ENSG00000199851.2	U3	-6.97	2.17e-10	8.95e-07	-0.86	-0.54	Depression;	chr6:28109824	chr6:28015568~28015777:+
GBM	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-6.96	2.25e-10	9.27e-07	-1	-0.54	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
GBM	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	6.96	2.26e-10	9.3e-07	0.65	0.54	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	6.96	2.26e-10	9.3e-07	0.65	0.54	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
GBM	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	6.96	2.26e-10	9.32e-07	0.72	0.54	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
GBM	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-6.96	2.27e-10	9.34e-07	-0.65	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
GBM	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-6.96	2.28e-10	9.38e-07	-1.07	-0.54	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
GBM	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	6.96	2.28e-10	9.38e-07	0.64	0.54	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
GBM	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-6.96	2.28e-10	9.39e-07	-0.72	-0.54	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
GBM	cis	rs507080	0.733	rs497678	ENSG00000255239.1	AP002954.6	6.96	2.28e-10	9.39e-07	0.7	0.54	Serum metabolite levels;	chr11:118697172	chr11:118688039~118690600:-
GBM	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	6.95	2.3e-10	9.45e-07	0.55	0.54	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
GBM	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-6.95	2.32e-10	9.55e-07	-0.64	-0.54	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
GBM	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-6.95	2.34e-10	9.61e-07	-0.71	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
GBM	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	6.95	2.36e-10	9.68e-07	0.6	0.54	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
GBM	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-6.95	2.37e-10	9.72e-07	-0.71	-0.54	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
GBM	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-6.95	2.37e-10	9.73e-07	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-6.95	2.37e-10	9.73e-07	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-6.95	2.37e-10	9.73e-07	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-6.95	2.37e-10	9.73e-07	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-6.95	2.37e-10	9.73e-07	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
GBM	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	6.95	2.37e-10	9.74e-07	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
GBM	cis	rs4713118	0.629	rs203888	ENSG00000199851.2	U3	6.95	2.38e-10	9.74e-07	0.82	0.54	Parkinson's disease;	chr6:28053811	chr6:28015568~28015777:+
GBM	cis	rs2486288	0.656	rs11632724	ENSG00000259433.2	CTD-2651B20.4	6.95	2.39e-10	9.78e-07	0.59	0.54	Glomerular filtration rate;	chr15:45258593	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11632651	ENSG00000259433.2	CTD-2651B20.4	6.95	2.39e-10	9.78e-07	0.59	0.54	Glomerular filtration rate;	chr15:45258640	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11637920	ENSG00000259433.2	CTD-2651B20.4	6.95	2.39e-10	9.78e-07	0.59	0.54	Glomerular filtration rate;	chr15:45258707	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11632777	ENSG00000259433.2	CTD-2651B20.4	6.95	2.39e-10	9.78e-07	0.59	0.54	Glomerular filtration rate;	chr15:45258847	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11632778	ENSG00000259433.2	CTD-2651B20.4	6.95	2.39e-10	9.78e-07	0.59	0.54	Glomerular filtration rate;	chr15:45258858	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11632752	ENSG00000259433.2	CTD-2651B20.4	6.95	2.39e-10	9.78e-07	0.59	0.54	Glomerular filtration rate;	chr15:45258942	chr15:45330209~45332634:-
GBM	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-6.95	2.39e-10	9.8e-07	-0.64	-0.54	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
GBM	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-6.95	2.39e-10	9.8e-07	-0.64	-0.54	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
GBM	cis	rs6452524	0.562	rs10474080	ENSG00000248112.1	RP11-78C3.1	6.94	2.44e-10	9.98e-07	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:82919376~82921119:-
GBM	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-6.94	2.44e-10	9.99e-07	-0.52	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-6.94	2.44e-10	9.99e-07	-0.52	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
GBM	cis	rs10935480	0.804	rs9858592	ENSG00000239445.4	ST3GAL6-AS1	-6.94	2.46e-10	1.01e-06	-0.66	-0.54	Blood protein levels;	chr3:98717909	chr3:98714330~98732651:-
GBM	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	6.94	2.47e-10	1.01e-06	1.04	0.54	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
GBM	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-6.94	2.47e-10	1.01e-06	-1.04	-0.54	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
GBM	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-6.94	2.52e-10	1.03e-06	-0.54	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
GBM	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	6.93	2.54e-10	1.04e-06	0.69	0.54	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	6.93	2.54e-10	1.04e-06	0.69	0.54	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
GBM	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	6.93	2.55e-10	1.04e-06	0.58	0.54	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
GBM	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-6.93	2.56e-10	1.04e-06	-0.7	-0.54	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
GBM	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	6.93	2.59e-10	1.06e-06	0.98	0.54	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	6.93	2.59e-10	1.06e-06	0.98	0.54	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
GBM	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-6.93	2.59e-10	1.06e-06	-0.65	-0.54	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
GBM	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-6.93	2.59e-10	1.06e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
GBM	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	6.93	2.6e-10	1.06e-06	0.62	0.54	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	6.93	2.6e-10	1.06e-06	0.62	0.54	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
GBM	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-6.93	2.61e-10	1.06e-06	-0.69	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	6.92	2.68e-10	1.09e-06	0.61	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
GBM	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-6.92	2.68e-10	1.09e-06	-0.66	-0.54	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
GBM	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-6.92	2.68e-10	1.09e-06	-0.66	-0.54	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	6.92	2.68e-10	1.09e-06	0.59	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	6.92	2.68e-10	1.09e-06	0.59	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
GBM	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-6.92	2.68e-10	1.09e-06	-0.57	-0.54	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
GBM	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-6.92	2.69e-10	1.09e-06	-0.64	-0.54	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-6.92	2.69e-10	1.09e-06	-0.64	-0.54	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-6.92	2.69e-10	1.09e-06	-0.64	-0.54	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
GBM	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-6.92	2.69e-10	1.09e-06	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-6.92	2.69e-10	1.09e-06	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
GBM	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	6.92	2.7e-10	1.09e-06	0.62	0.54	Height;	chr11:118781100	chr11:118688039~118690600:-
GBM	cis	rs2486288	0.656	rs6493143	ENSG00000259433.2	CTD-2651B20.4	6.92	2.7e-10	1.1e-06	0.61	0.54	Glomerular filtration rate;	chr15:45278583	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs7166580	ENSG00000259433.2	CTD-2651B20.4	6.92	2.7e-10	1.1e-06	0.61	0.54	Glomerular filtration rate;	chr15:45279011	chr15:45330209~45332634:-
GBM	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	6.92	2.71e-10	1.1e-06	1.03	0.54	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
GBM	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	6.92	2.72e-10	1.1e-06	0.69	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
GBM	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	6.92	2.76e-10	1.11e-06	0.64	0.54	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	6.92	2.76e-10	1.11e-06	0.64	0.54	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
GBM	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-6.92	2.78e-10	1.12e-06	-0.68	-0.54	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
GBM	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-6.92	2.78e-10	1.12e-06	-0.46	-0.54	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
GBM	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-6.92	2.78e-10	1.12e-06	-0.82	-0.54	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
GBM	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-6.91	2.8e-10	1.13e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-6.91	2.81e-10	1.13e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
GBM	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	6.91	2.83e-10	1.14e-06	0.64	0.54	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	6.91	2.83e-10	1.14e-06	0.64	0.54	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
GBM	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	6.91	2.89e-10	1.16e-06	0.64	0.54	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
GBM	cis	rs6597981	0.592	rs28625355	ENSG00000279672.1	CMB9-55F22.1	6.91	2.89e-10	1.16e-06	0.61	0.54	Breast cancer;	chr11:736334	chr11:779617~780755:+
GBM	cis	rs2486288	0.656	rs7171312	ENSG00000259433.2	CTD-2651B20.4	6.91	2.89e-10	1.16e-06	0.61	0.54	Glomerular filtration rate;	chr15:45278027	chr15:45330209~45332634:-
GBM	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	6.91	2.9e-10	1.16e-06	0.66	0.54	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000235689.1	AP000351.13	6.91	2.9e-10	1.17e-06	0.61	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:24006305~24008258:-
GBM	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-6.91	2.91e-10	1.17e-06	-0.52	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.91	2.91e-10	1.17e-06	-0.52	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
GBM	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	6.91	2.93e-10	1.17e-06	1	0.54	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
GBM	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	6.91	2.93e-10	1.18e-06	0.67	0.54	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
GBM	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	6.9	2.97e-10	1.19e-06	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
GBM	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-6.9	2.97e-10	1.19e-06	-0.61	-0.54	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
GBM	cis	rs4713118	0.621	rs9295756	ENSG00000199851.2	U3	6.9	3.02e-10	1.21e-06	0.87	0.54	Parkinson's disease;	chr6:28065618	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.621	rs10484403	ENSG00000199851.2	U3	6.9	3.02e-10	1.21e-06	0.87	0.54	Parkinson's disease;	chr6:28065745	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.621	rs4713132	ENSG00000199851.2	U3	6.9	3.02e-10	1.21e-06	0.87	0.54	Parkinson's disease;	chr6:28066257	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.621	rs4713133	ENSG00000199851.2	U3	6.9	3.02e-10	1.21e-06	0.87	0.54	Parkinson's disease;	chr6:28066263	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.621	rs4713134	ENSG00000199851.2	U3	6.9	3.02e-10	1.21e-06	0.87	0.54	Parkinson's disease;	chr6:28066343	chr6:28015568~28015777:+
GBM	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	6.9	3.07e-10	1.23e-06	0.65	0.54	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
GBM	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	6.9	3.08e-10	1.23e-06	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
GBM	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	6.89	3.09e-10	1.24e-06	0.66	0.54	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
GBM	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	6.89	3.11e-10	1.24e-06	0.65	0.54	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
GBM	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	6.89	3.16e-10	1.26e-06	0.73	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
GBM	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-6.89	3.16e-10	1.26e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-6.89	3.16e-10	1.26e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-6.89	3.16e-10	1.26e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
GBM	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-6.89	3.17e-10	1.26e-06	-0.79	-0.54	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
GBM	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	6.89	3.18e-10	1.26e-06	1.01	0.54	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
GBM	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	6.89	3.18e-10	1.26e-06	1.01	0.54	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
GBM	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-6.89	3.2e-10	1.27e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-6.89	3.2e-10	1.27e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-6.89	3.22e-10	1.28e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-6.89	3.22e-10	1.28e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-6.89	3.22e-10	1.28e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
GBM	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	6.88	3.24e-10	1.28e-06	0.64	0.54	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	6.88	3.24e-10	1.28e-06	0.64	0.54	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	6.88	3.24e-10	1.28e-06	0.64	0.54	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	6.88	3.24e-10	1.28e-06	0.64	0.54	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	6.88	3.24e-10	1.28e-06	0.64	0.54	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
GBM	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	6.88	3.24e-10	1.29e-06	0.94	0.54	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
GBM	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	6.88	3.24e-10	1.29e-06	0.94	0.54	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
GBM	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-6.88	3.25e-10	1.29e-06	-0.64	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
GBM	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-6.88	3.26e-10	1.29e-06	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-6.88	3.26e-10	1.29e-06	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-6.88	3.26e-10	1.29e-06	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-6.88	3.26e-10	1.29e-06	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
GBM	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-6.88	3.31e-10	1.31e-06	-0.71	-0.54	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
GBM	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	6.88	3.31e-10	1.31e-06	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	6.88	3.31e-10	1.31e-06	0.6	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
GBM	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	6.88	3.31e-10	1.31e-06	0.57	0.54	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
GBM	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	6.88	3.32e-10	1.31e-06	0.66	0.54	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
GBM	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	6.88	3.32e-10	1.31e-06	0.69	0.54	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
GBM	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-6.88	3.34e-10	1.32e-06	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
GBM	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-6.88	3.35e-10	1.32e-06	-0.71	-0.54	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
GBM	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-6.88	3.36e-10	1.32e-06	-0.65	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
GBM	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-6.88	3.36e-10	1.33e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-6.88	3.36e-10	1.33e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-6.88	3.36e-10	1.33e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-6.88	3.38e-10	1.33e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-6.88	3.38e-10	1.33e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
GBM	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	6.88	3.39e-10	1.34e-06	0.57	0.54	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
GBM	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	6.87	3.44e-10	1.36e-06	0.65	0.54	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
GBM	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	6.87	3.44e-10	1.36e-06	0.66	0.54	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
GBM	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	6.87	3.49e-10	1.37e-06	0.64	0.54	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	6.87	3.49e-10	1.37e-06	0.64	0.54	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	6.87	3.49e-10	1.37e-06	0.64	0.54	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
GBM	cis	rs2486288	0.656	rs2413773	ENSG00000259433.2	CTD-2651B20.4	6.87	3.5e-10	1.38e-06	0.59	0.54	Glomerular filtration rate;	chr15:45257244	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs12911186	ENSG00000259433.2	CTD-2651B20.4	6.87	3.55e-10	1.4e-06	0.59	0.54	Glomerular filtration rate;	chr15:45259225	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs12915314	ENSG00000259433.2	CTD-2651B20.4	6.87	3.55e-10	1.4e-06	0.59	0.54	Glomerular filtration rate;	chr15:45259293	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs8039138	ENSG00000259433.2	CTD-2651B20.4	6.87	3.55e-10	1.4e-06	0.59	0.54	Glomerular filtration rate;	chr15:45259394	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs8039540	ENSG00000259433.2	CTD-2651B20.4	6.87	3.55e-10	1.4e-06	0.59	0.54	Glomerular filtration rate;	chr15:45259644	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs8040185	ENSG00000259433.2	CTD-2651B20.4	6.87	3.55e-10	1.4e-06	0.59	0.54	Glomerular filtration rate;	chr15:45259883	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs1060896	ENSG00000259433.2	CTD-2651B20.4	6.87	3.55e-10	1.4e-06	0.59	0.54	Glomerular filtration rate;	chr15:45262069	chr15:45330209~45332634:-
GBM	cis	rs6452524	0.692	rs1382367	ENSG00000248112.1	RP11-78C3.1	-6.87	3.57e-10	1.41e-06	-0.7	-0.54	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:82919376~82921119:-
GBM	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	6.86	3.59e-10	1.41e-06	0.97	0.54	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
GBM	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	6.86	3.59e-10	1.41e-06	0.63	0.54	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
GBM	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	6.86	3.59e-10	1.41e-06	0.65	0.54	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
GBM	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	6.86	3.59e-10	1.41e-06	0.65	0.54	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
GBM	cis	rs4273100	0.512	rs1355128	ENSG00000265185.4	SNORD3B-1	-6.86	3.62e-10	1.42e-06	-0.64	-0.54	Schizophrenia;	chr17:19395831	chr17:19061912~19062669:+
GBM	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-6.86	3.62e-10	1.42e-06	-0.61	-0.54	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
GBM	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-6.86	3.63e-10	1.42e-06	-0.63	-0.54	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-6.86	3.66e-10	1.43e-06	-0.65	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
GBM	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-6.86	3.7e-10	1.45e-06	-0.54	-0.54	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
GBM	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	6.86	3.71e-10	1.45e-06	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
GBM	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	6.86	3.72e-10	1.46e-06	0.64	0.54	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
GBM	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	6.86	3.75e-10	1.47e-06	0.63	0.54	Height;	chr11:118747911	chr11:118688039~118690600:-
GBM	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-6.86	3.75e-10	1.47e-06	-0.67	-0.54	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.766	rs2252179	ENSG00000248112.1	RP11-78C3.1	-6.85	3.76e-10	1.47e-06	-0.72	-0.54	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:82919376~82921119:-
GBM	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-6.85	3.77e-10	1.47e-06	-0.67	-0.54	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
GBM	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	6.85	3.77e-10	1.48e-06	0.64	0.54	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
GBM	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	6.85	3.83e-10	1.5e-06	0.77	0.54	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
GBM	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	6.85	3.83e-10	1.5e-06	0.64	0.54	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	6.85	3.83e-10	1.5e-06	0.64	0.54	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
GBM	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-6.85	3.86e-10	1.51e-06	-0.7	-0.54	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
GBM	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-6.85	3.88e-10	1.51e-06	-0.64	-0.54	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-6.85	3.88e-10	1.51e-06	-0.64	-0.54	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
GBM	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-6.85	3.89e-10	1.52e-06	-0.56	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-6.85	3.89e-10	1.52e-06	-0.56	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-6.85	3.89e-10	1.52e-06	-0.56	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
GBM	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-6.85	3.91e-10	1.52e-06	-0.74	-0.54	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
GBM	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-6.85	3.92e-10	1.53e-06	-0.66	-0.54	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
GBM	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-6.84	3.99e-10	1.55e-06	-0.75	-0.54	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
GBM	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-6.84	4.02e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-6.84	4.03e-10	1.56e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
GBM	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-6.84	4.05e-10	1.57e-06	-0.74	-0.54	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
GBM	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-6.84	4.06e-10	1.57e-06	-0.71	-0.54	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
GBM	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-6.84	4.09e-10	1.58e-06	-0.79	-0.54	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
GBM	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	6.84	4.09e-10	1.58e-06	0.6	0.54	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	6.84	4.09e-10	1.58e-06	0.6	0.54	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
GBM	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	6.84	4.1e-10	1.59e-06	0.64	0.54	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	6.84	4.1e-10	1.59e-06	0.64	0.54	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	6.84	4.1e-10	1.59e-06	0.64	0.54	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	6.84	4.1e-10	1.59e-06	0.64	0.54	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	6.84	4.1e-10	1.59e-06	0.64	0.54	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	6.84	4.1e-10	1.59e-06	0.64	0.54	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	6.84	4.1e-10	1.59e-06	0.64	0.54	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
GBM	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-6.83	4.19e-10	1.61e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
GBM	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-6.83	4.22e-10	1.62e-06	-0.75	-0.54	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
GBM	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	6.83	4.22e-10	1.62e-06	0.56	0.54	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
GBM	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-6.83	4.22e-10	1.62e-06	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs2413774	ENSG00000259433.2	CTD-2651B20.4	6.83	4.22e-10	1.62e-06	0.59	0.54	Glomerular filtration rate;	chr15:45257225	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs2413772	ENSG00000259433.2	CTD-2651B20.4	6.83	4.22e-10	1.62e-06	0.59	0.54	Glomerular filtration rate;	chr15:45257664	chr15:45330209~45332634:-
GBM	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-6.83	4.23e-10	1.62e-06	-0.64	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
GBM	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-6.83	4.3e-10	1.65e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
GBM	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-6.83	4.32e-10	1.65e-06	-0.69	-0.54	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
GBM	cis	rs2486288	0.656	rs7165039	ENSG00000259433.2	CTD-2651B20.4	6.83	4.32e-10	1.66e-06	0.6	0.54	Glomerular filtration rate;	chr15:45278215	chr15:45330209~45332634:-
GBM	cis	rs853679	0.517	rs9393884	ENSG00000199851.2	U3	6.83	4.36e-10	1.67e-06	0.86	0.54	Depression;	chr6:28079011	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393887	ENSG00000199851.2	U3	6.83	4.36e-10	1.67e-06	0.86	0.54	Depression;	chr6:28091242	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs6922063	ENSG00000199851.2	U3	6.83	4.36e-10	1.67e-06	0.86	0.54	Depression;	chr6:28126588	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs2275508	ENSG00000199851.2	U3	6.83	4.36e-10	1.67e-06	0.86	0.54	Depression;	chr6:28126953	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs1904841	ENSG00000199851.2	U3	6.83	4.36e-10	1.67e-06	0.86	0.54	Depression;	chr6:28140307	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9380058	ENSG00000199851.2	U3	6.83	4.36e-10	1.67e-06	0.86	0.54	Depression;	chr6:28159666	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs9393898	ENSG00000199851.2	U3	6.83	4.36e-10	1.67e-06	0.86	0.54	Depression;	chr6:28162598	chr6:28015568~28015777:+
GBM	cis	rs853679	0.517	rs6932109	ENSG00000199851.2	U3	-6.83	4.36e-10	1.67e-06	-0.86	-0.54	Depression;	chr6:28110525	chr6:28015568~28015777:+
GBM	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	6.83	4.36e-10	1.67e-06	1.04	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	6.83	4.36e-10	1.67e-06	1.04	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	6.83	4.36e-10	1.67e-06	1.04	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	6.83	4.36e-10	1.67e-06	1.04	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	6.83	4.36e-10	1.67e-06	1.04	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	6.83	4.36e-10	1.67e-06	1.04	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	6.82	4.38e-10	1.67e-06	0.59	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
GBM	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	6.82	4.4e-10	1.68e-06	0.64	0.54	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	6.82	4.4e-10	1.68e-06	0.64	0.54	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	6.82	4.4e-10	1.68e-06	0.64	0.54	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
GBM	cis	rs6452524	0.522	rs13161662	ENSG00000248112.1	RP11-78C3.1	-6.82	4.4e-10	1.68e-06	-0.68	-0.54	Hypertension (SNP x SNP interaction);	chr5:83209777	chr5:82919376~82921119:-
GBM	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-6.82	4.41e-10	1.68e-06	-0.51	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
GBM	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	6.82	4.43e-10	1.69e-06	0.69	0.54	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
GBM	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-6.82	4.43e-10	1.69e-06	-0.63	-0.54	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
GBM	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	6.82	4.46e-10	1.7e-06	0.64	0.54	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	6.82	4.46e-10	1.7e-06	0.64	0.54	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	6.82	4.46e-10	1.7e-06	0.64	0.54	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	6.82	4.46e-10	1.7e-06	0.64	0.54	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	6.82	4.46e-10	1.7e-06	0.64	0.54	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
GBM	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-6.82	4.47e-10	1.7e-06	-0.59	-0.54	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
GBM	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-6.82	4.49e-10	1.71e-06	-0.65	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
GBM	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	6.82	4.5e-10	1.71e-06	0.69	0.54	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
GBM	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	6.82	4.5e-10	1.71e-06	0.59	0.54	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	6.82	4.5e-10	1.71e-06	0.59	0.54	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	6.82	4.5e-10	1.71e-06	0.59	0.54	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	6.82	4.5e-10	1.71e-06	0.59	0.54	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
GBM	cis	rs2486288	0.656	rs9921025	ENSG00000259433.2	CTD-2651B20.4	6.82	4.58e-10	1.74e-06	0.59	0.54	Glomerular filtration rate;	chr15:45254404	chr15:45330209~45332634:-
GBM	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	6.81	4.59e-10	1.74e-06	0.64	0.54	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	6.81	4.59e-10	1.74e-06	0.64	0.54	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	6.81	4.64e-10	1.76e-06	0.63	0.54	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	6.81	4.65e-10	1.76e-06	0.63	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
GBM	cis	rs853679	0.517	rs9283884	ENSG00000199851.2	U3	-6.81	4.68e-10	1.77e-06	-0.86	-0.54	Depression;	chr6:28167882	chr6:28015568~28015777:+
GBM	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-6.81	4.68e-10	1.77e-06	-0.56	-0.54	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
GBM	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-6.81	4.69e-10	1.77e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
GBM	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	6.81	4.69e-10	1.77e-06	0.65	0.54	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
GBM	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	6.81	4.72e-10	1.78e-06	0.63	0.54	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
GBM	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	6.81	4.72e-10	1.78e-06	0.96	0.54	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	6.81	4.72e-10	1.78e-06	0.96	0.54	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
GBM	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-6.81	4.74e-10	1.79e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-6.81	4.74e-10	1.79e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-6.81	4.74e-10	1.79e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-6.81	4.74e-10	1.79e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-6.81	4.74e-10	1.79e-06	-0.69	-0.54	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
GBM	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	6.81	4.77e-10	1.8e-06	0.99	0.54	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
GBM	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-6.81	4.78e-10	1.8e-06	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs11639420	ENSG00000259433.2	CTD-2651B20.4	6.81	4.78e-10	1.8e-06	0.6	0.54	Glomerular filtration rate;	chr15:45267070	chr15:45330209~45332634:-
GBM	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	6.81	4.8e-10	1.81e-06	0.72	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
GBM	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-6.8	4.82e-10	1.82e-06	-0.63	-0.54	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
GBM	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-6.8	4.82e-10	1.82e-06	-0.66	-0.54	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-6.8	4.82e-10	1.82e-06	-0.66	-0.54	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-6.8	4.82e-10	1.82e-06	-0.66	-0.54	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
GBM	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-6.8	4.82e-10	1.82e-06	-0.64	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
GBM	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-6.8	4.84e-10	1.82e-06	-0.74	-0.54	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
GBM	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-6.8	4.86e-10	1.83e-06	-0.73	-0.54	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
GBM	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-6.8	4.86e-10	1.83e-06	-0.7	-0.54	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-6.8	4.86e-10	1.83e-06	-0.7	-0.54	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
GBM	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	6.8	4.89e-10	1.84e-06	0.69	0.54	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
GBM	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-6.8	4.9e-10	1.84e-06	-0.78	-0.54	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-6.8	4.9e-10	1.84e-06	-0.78	-0.54	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
GBM	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-6.8	5e-10	1.88e-06	-0.7	-0.54	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
GBM	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	6.8	5e-10	1.88e-06	0.47	0.54	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
GBM	cis	rs6452524	0.534	rs10061690	ENSG00000248112.1	RP11-78C3.1	6.8	5e-10	1.88e-06	0.66	0.54	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.561	rs4331874	ENSG00000248112.1	RP11-78C3.1	6.8	5e-10	1.88e-06	0.66	0.54	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:82919376~82921119:-
GBM	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-6.8	5.03e-10	1.89e-06	-0.65	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.656	rs11629807	ENSG00000259433.2	CTD-2651B20.4	6.8	5.05e-10	1.89e-06	0.59	0.54	Glomerular filtration rate;	chr15:45254839	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.587	rs12899942	ENSG00000259433.2	CTD-2651B20.4	6.8	5.05e-10	1.89e-06	0.59	0.54	Glomerular filtration rate;	chr15:45255082	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs12899058	ENSG00000259433.2	CTD-2651B20.4	6.8	5.05e-10	1.89e-06	0.59	0.54	Glomerular filtration rate;	chr15:45255126	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs12904150	ENSG00000259433.2	CTD-2651B20.4	6.8	5.05e-10	1.89e-06	0.59	0.54	Glomerular filtration rate;	chr15:45255407	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs9920290	ENSG00000259433.2	CTD-2651B20.4	6.8	5.05e-10	1.89e-06	0.59	0.54	Glomerular filtration rate;	chr15:45255837	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11854325	ENSG00000259433.2	CTD-2651B20.4	6.8	5.05e-10	1.89e-06	0.59	0.54	Glomerular filtration rate;	chr15:45256761	chr15:45330209~45332634:-
GBM	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	6.8	5.06e-10	1.9e-06	0.63	0.54	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
GBM	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	6.8	5.06e-10	1.9e-06	0.63	0.54	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
GBM	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	6.79	5.08e-10	1.9e-06	1.14	0.54	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
GBM	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-6.79	5.09e-10	1.91e-06	-0.83	-0.54	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
GBM	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-6.79	5.1e-10	1.91e-06	-0.51	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-6.79	5.1e-10	1.91e-06	-0.51	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-6.79	5.1e-10	1.91e-06	-0.51	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
GBM	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	6.79	5.11e-10	1.91e-06	0.63	0.54	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	6.79	5.11e-10	1.91e-06	0.63	0.54	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	6.79	5.11e-10	1.91e-06	0.63	0.54	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	6.79	5.11e-10	1.91e-06	0.63	0.54	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
GBM	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-6.79	5.12e-10	1.92e-06	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
GBM	cis	rs172166	0.637	rs1225597	ENSG00000199851.2	U3	6.79	5.14e-10	1.92e-06	0.74	0.54	Cardiac Troponin-T levels;	chr6:28194309	chr6:28015568~28015777:+
GBM	cis	rs172166	0.637	rs1071893	ENSG00000199851.2	U3	6.79	5.14e-10	1.92e-06	0.74	0.54	Cardiac Troponin-T levels;	chr6:28199857	chr6:28015568~28015777:+
GBM	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	6.79	5.16e-10	1.93e-06	0.68	0.54	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-6.79	5.16e-10	1.93e-06	-0.68	-0.54	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
GBM	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-6.79	5.16e-10	1.93e-06	-0.51	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-6.79	5.16e-10	1.93e-06	-0.51	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
GBM	cis	rs2486288	0.656	rs11629858	ENSG00000259433.2	CTD-2651B20.4	6.79	5.17e-10	1.93e-06	0.6	0.54	Glomerular filtration rate;	chr15:45254916	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11629859	ENSG00000259433.2	CTD-2651B20.4	6.79	5.17e-10	1.93e-06	0.6	0.54	Glomerular filtration rate;	chr15:45254923	chr15:45330209~45332634:-
GBM	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-6.79	5.23e-10	1.95e-06	-0.75	-0.53	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
GBM	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	6.79	5.23e-10	1.95e-06	0.63	0.53	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
GBM	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-6.79	5.27e-10	1.97e-06	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
GBM	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	6.78	5.34e-10	1.99e-06	0.63	0.53	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
GBM	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	6.78	5.35e-10	2e-06	0.56	0.53	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
GBM	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-6.78	5.36e-10	2e-06	-0.67	-0.53	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-6.78	5.36e-10	2e-06	-0.67	-0.53	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	6.78	5.36e-10	2e-06	0.67	0.53	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
GBM	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-6.78	5.38e-10	2.01e-06	-1.01	-0.53	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
GBM	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-6.78	5.41e-10	2.02e-06	-0.65	-0.53	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-6.78	5.41e-10	2.02e-06	-0.59	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
GBM	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.78	5.46e-10	2.03e-06	-0.63	-0.53	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
GBM	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	6.78	5.46e-10	2.03e-06	1.02	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	6.78	5.46e-10	2.03e-06	1.02	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
GBM	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-6.78	5.46e-10	2.03e-06	-0.64	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000224205.1	AP000351.4	6.78	5.5e-10	2.05e-06	0.58	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23987320~23991421:-
GBM	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	6.78	5.53e-10	2.05e-06	0.66	0.53	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
GBM	cis	rs7615952	0.611	rs79405914	ENSG00000171084.14	FAM86JP	6.78	5.53e-10	2.06e-06	1.2	0.53	Blood pressure (smoking interaction);	chr3:126004780	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.611	rs78137633	ENSG00000171084.14	FAM86JP	6.78	5.53e-10	2.06e-06	1.2	0.53	Blood pressure (smoking interaction);	chr3:126056218	chr3:125916620~125930024:+
GBM	cis	rs172166	0.694	rs2791332	ENSG00000199851.2	U3	6.78	5.56e-10	2.07e-06	0.8	0.53	Cardiac Troponin-T levels;	chr6:28141010	chr6:28015568~28015777:+
GBM	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	6.78	5.57e-10	2.07e-06	0.63	0.53	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
GBM	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-6.77	5.62e-10	2.09e-06	-0.71	-0.53	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-6.77	5.62e-10	2.09e-06	-0.71	-0.53	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
GBM	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-6.77	5.75e-10	2.13e-06	-0.7	-0.53	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
GBM	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	6.77	5.76e-10	2.13e-06	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
GBM	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	6.77	5.76e-10	2.13e-06	0.64	0.53	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000224205.1	AP000351.4	-6.76	5.87e-10	2.17e-06	-0.59	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23987320~23991421:-
GBM	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	6.76	5.88e-10	2.17e-06	0.97	0.53	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
GBM	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.76	5.89e-10	2.18e-06	0.53	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
GBM	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-6.76	5.9e-10	2.18e-06	-0.61	-0.53	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
GBM	cis	rs6452524	0.836	rs4343818	ENSG00000248112.1	RP11-78C3.1	6.76	5.92e-10	2.19e-06	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:82919376~82921119:-
GBM	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-6.76	5.92e-10	2.19e-06	-0.99	-0.53	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
GBM	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-6.76	5.95e-10	2.2e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-6.76	5.95e-10	2.2e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
GBM	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-6.76	5.98e-10	2.21e-06	-0.71	-0.53	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
GBM	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-6.76	5.99e-10	2.21e-06	-0.66	-0.53	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
GBM	cis	rs6452524	0.87	rs2174976	ENSG00000248112.1	RP11-78C3.1	6.76	6e-10	2.21e-06	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:82919376~82921119:-
GBM	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	6.76	6.08e-10	2.24e-06	0.57	0.53	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
GBM	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-6.75	6.19e-10	2.28e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
GBM	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	6.75	6.2e-10	2.28e-06	0.62	0.53	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	6.75	6.2e-10	2.28e-06	0.62	0.53	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	6.75	6.2e-10	2.28e-06	0.62	0.53	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	6.75	6.2e-10	2.28e-06	0.62	0.53	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
GBM	cis	rs2486288	0.656	rs8039354	ENSG00000259433.2	CTD-2651B20.4	-6.75	6.21e-10	2.29e-06	-0.57	-0.53	Glomerular filtration rate;	chr15:45259558	chr15:45330209~45332634:-
GBM	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-6.75	6.24e-10	2.3e-06	-0.64	-0.53	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
GBM	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-6.75	6.29e-10	2.32e-06	-0.65	-0.53	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
GBM	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-6.75	6.31e-10	2.32e-06	-0.82	-0.53	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
GBM	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-6.75	6.32e-10	2.32e-06	-0.62	-0.53	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
GBM	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-6.75	6.38e-10	2.34e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
GBM	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	6.75	6.38e-10	2.34e-06	0.7	0.53	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
GBM	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-6.75	6.43e-10	2.36e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
GBM	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	6.75	6.48e-10	2.38e-06	0.64	0.53	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
GBM	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	6.74	6.52e-10	2.39e-06	0.64	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
GBM	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-6.74	6.55e-10	2.4e-06	-0.82	-0.53	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
GBM	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	6.74	6.58e-10	2.41e-06	0.63	0.53	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
GBM	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-6.74	6.58e-10	2.41e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
GBM	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-6.74	6.67e-10	2.44e-06	-1.01	-0.53	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
GBM	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-6.74	6.67e-10	2.44e-06	-0.68	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
GBM	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-6.74	6.68e-10	2.44e-06	-0.64	-0.53	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-6.74	6.68e-10	2.44e-06	-0.64	-0.53	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-6.74	6.68e-10	2.44e-06	-0.64	-0.53	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
GBM	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-6.74	6.69e-10	2.44e-06	-0.66	-0.53	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
GBM	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-6.74	6.73e-10	2.46e-06	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-6.74	6.73e-10	2.46e-06	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
GBM	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	6.73	6.87e-10	2.51e-06	0.94	0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
GBM	cis	rs4273100	0.512	rs973650	ENSG00000265185.4	SNORD3B-1	-6.73	6.88e-10	2.51e-06	-0.6	-0.53	Schizophrenia;	chr17:19388472	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.541	rs973649	ENSG00000265185.4	SNORD3B-1	-6.73	6.88e-10	2.51e-06	-0.6	-0.53	Schizophrenia;	chr17:19388755	chr17:19061912~19062669:+
GBM	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	6.73	6.9e-10	2.51e-06	0.99	0.53	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
GBM	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	6.73	6.9e-10	2.51e-06	0.99	0.53	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
GBM	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	6.73	6.9e-10	2.51e-06	0.99	0.53	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
GBM	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	6.73	6.9e-10	2.51e-06	0.99	0.53	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
GBM	cis	rs2486288	0.656	rs62026703	ENSG00000259433.2	CTD-2651B20.4	6.73	6.92e-10	2.52e-06	0.6	0.53	Glomerular filtration rate;	chr15:45277731	chr15:45330209~45332634:-
GBM	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-6.73	6.93e-10	2.52e-06	-1.03	-0.53	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-6.73	6.93e-10	2.52e-06	-1.03	-0.53	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-6.73	6.93e-10	2.52e-06	-1.03	-0.53	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
GBM	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	6.72	7.16e-10	2.61e-06	0.83	0.53	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000235689.1	AP000351.13	6.72	7.18e-10	2.61e-06	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:24006305~24008258:-
GBM	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	6.72	7.19e-10	2.62e-06	0.6	0.53	Height;	chr11:118808920	chr11:118688039~118690600:-
GBM	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	6.72	7.2e-10	2.62e-06	0.63	0.53	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
GBM	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-6.72	7.22e-10	2.63e-06	-0.68	-0.53	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
GBM	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	6.72	7.29e-10	2.64e-06	1.04	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
GBM	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	6.72	7.33e-10	2.65e-06	0.59	0.53	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
GBM	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-6.72	7.34e-10	2.66e-06	-0.52	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
GBM	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-6.72	7.36e-10	2.66e-06	-0.63	-0.53	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
GBM	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-6.72	7.43e-10	2.69e-06	-0.63	-0.53	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
GBM	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-6.72	7.47e-10	2.7e-06	-0.63	-0.53	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
GBM	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-6.71	7.54e-10	2.73e-06	-0.64	-0.53	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
GBM	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-6.71	7.58e-10	2.74e-06	-0.56	-0.53	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
GBM	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	6.71	7.59e-10	2.74e-06	0.64	0.53	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
GBM	cis	rs172166	0.694	rs1225716	ENSG00000199851.2	U3	6.71	7.66e-10	2.76e-06	0.8	0.53	Cardiac Troponin-T levels;	chr6:28145968	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.512	rs2622319	ENSG00000199851.2	U3	6.71	7.66e-10	2.76e-06	0.8	0.53	Parkinson's disease;	chr6:28152623	chr6:28015568~28015777:+
GBM	cis	rs172166	0.694	rs1150666	ENSG00000199851.2	U3	6.71	7.66e-10	2.76e-06	0.8	0.53	Cardiac Troponin-T levels;	chr6:28156150	chr6:28015568~28015777:+
GBM	cis	rs172166	0.694	rs9295760	ENSG00000199851.2	U3	6.71	7.66e-10	2.76e-06	0.8	0.53	Cardiac Troponin-T levels;	chr6:28179607	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs1225591	ENSG00000199851.2	U3	6.71	7.66e-10	2.76e-06	0.8	0.53	Parkinson's disease;	chr6:28180974	chr6:28015568~28015777:+
GBM	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	6.71	7.67e-10	2.77e-06	1	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
GBM	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	6.71	7.69e-10	2.78e-06	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
GBM	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-6.71	7.7e-10	2.78e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-6.71	7.7e-10	2.78e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
GBM	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-6.71	7.71e-10	2.78e-06	-0.64	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-6.71	7.71e-10	2.78e-06	-0.64	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
GBM	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	6.71	7.74e-10	2.79e-06	0.62	0.53	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	6.71	7.74e-10	2.79e-06	0.62	0.53	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
GBM	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-6.71	7.77e-10	2.8e-06	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
GBM	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-6.71	7.79e-10	2.81e-06	-0.64	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
GBM	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-6.71	7.84e-10	2.82e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
GBM	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-6.71	7.88e-10	2.84e-06	-0.55	-0.53	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
GBM	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	6.7	7.96e-10	2.86e-06	0.64	0.53	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
GBM	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-6.7	8e-10	2.88e-06	-1.06	-0.53	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
GBM	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	6.7	8.09e-10	2.91e-06	0.77	0.53	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
GBM	cis	rs172166	0.694	rs203884	ENSG00000199851.2	U3	6.7	8.11e-10	2.91e-06	0.79	0.53	Cardiac Troponin-T levels;	chr6:28109596	chr6:28015568~28015777:+
GBM	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	6.7	8.12e-10	2.92e-06	0.63	0.53	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
GBM	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	6.7	8.15e-10	2.93e-06	0.65	0.53	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
GBM	cis	rs7615952	0.611	rs72979452	ENSG00000171084.14	FAM86JP	6.7	8.16e-10	2.93e-06	1.19	0.53	Blood pressure (smoking interaction);	chr3:126037335	chr3:125916620~125930024:+
GBM	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-6.7	8.17e-10	2.93e-06	-0.74	-0.53	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	6.7	8.19e-10	2.94e-06	0.58	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
GBM	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-6.7	8.27e-10	2.97e-06	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-6.7	8.27e-10	2.97e-06	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000224205.1	AP000351.4	6.7	8.28e-10	2.97e-06	0.57	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23987320~23991421:-
GBM	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-6.69	8.3e-10	2.97e-06	-0.8	-0.53	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-6.69	8.3e-10	2.97e-06	-0.8	-0.53	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-6.69	8.3e-10	2.97e-06	-0.8	-0.53	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
GBM	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-6.69	8.33e-10	2.98e-06	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
GBM	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-6.69	8.34e-10	2.99e-06	-0.85	-0.53	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000224205.1	AP000351.4	6.69	8.36e-10	2.99e-06	0.59	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23987320~23991421:-
GBM	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	6.69	8.39e-10	3e-06	0.66	0.53	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
GBM	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-6.69	8.39e-10	3e-06	-0.55	-0.53	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
GBM	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-6.69	8.39e-10	3e-06	-0.55	-0.53	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
GBM	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	6.69	8.41e-10	3.01e-06	0.63	0.53	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
GBM	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	6.69	8.46e-10	3.02e-06	0.59	0.53	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-6.69	8.46e-10	3.03e-06	-0.71	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
GBM	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	6.69	8.49e-10	3.04e-06	1.02	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
GBM	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-6.69	8.56e-10	3.06e-06	-0.64	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-6.69	8.56e-10	3.06e-06	-0.64	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
GBM	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-6.69	8.56e-10	3.06e-06	-0.72	-0.53	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
GBM	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-6.69	8.62e-10	3.08e-06	-0.55	-0.53	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-6.69	8.62e-10	3.08e-06	-0.7	-0.53	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
GBM	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-6.69	8.62e-10	3.08e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
GBM	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	6.69	8.63e-10	3.08e-06	0.88	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
GBM	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	6.69	8.63e-10	3.08e-06	0.65	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
GBM	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-6.69	8.63e-10	3.08e-06	-0.66	-0.53	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
GBM	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-6.69	8.68e-10	3.1e-06	-0.67	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
GBM	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-6.68	8.71e-10	3.11e-06	-0.64	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
GBM	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-6.68	8.71e-10	3.11e-06	-0.64	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
GBM	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-6.68	8.71e-10	3.11e-06	-0.64	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
GBM	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-6.68	8.72e-10	3.11e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-6.68	8.74e-10	3.12e-06	-0.69	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
GBM	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-6.68	8.75e-10	3.12e-06	-0.58	-0.53	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
GBM	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-6.68	8.75e-10	3.12e-06	-0.65	-0.53	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
GBM	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-6.68	8.75e-10	3.12e-06	-0.65	-0.53	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
GBM	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	6.68	8.76e-10	3.12e-06	0.56	0.53	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	6.68	8.76e-10	3.12e-06	0.56	0.53	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
GBM	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	6.68	8.8e-10	3.14e-06	0.63	0.53	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
GBM	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	6.68	8.97e-10	3.19e-06	0.61	0.53	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
GBM	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-6.68	8.99e-10	3.2e-06	-0.68	-0.53	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
GBM	cis	rs6452524	0.836	rs1015440	ENSG00000248112.1	RP11-78C3.1	6.68	9e-10	3.21e-06	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:82919376~82921119:-
GBM	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-6.68	9e-10	3.21e-06	-0.62	-0.53	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
GBM	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-6.68	9.01e-10	3.21e-06	-0.76	-0.53	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-6.68	9.01e-10	3.21e-06	-0.76	-0.53	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
GBM	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	6.68	9.02e-10	3.21e-06	0.66	0.53	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	6.68	9.02e-10	3.21e-06	0.61	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
GBM	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	6.68	9.12e-10	3.24e-06	0.62	0.53	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
GBM	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	6.67	9.16e-10	3.25e-06	0.58	0.53	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
GBM	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-6.67	9.2e-10	3.26e-06	-0.59	-0.53	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
GBM	cis	rs4273100	0.512	rs2233072	ENSG00000265185.4	SNORD3B-1	-6.67	9.3e-10	3.3e-06	-0.6	-0.53	Schizophrenia;	chr17:19378515	chr17:19061912~19062669:+
GBM	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	6.67	9.3e-10	3.3e-06	0.65	0.53	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
GBM	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	6.67	9.31e-10	3.3e-06	0.63	0.53	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-6.67	9.31e-10	3.3e-06	-0.64	-0.53	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
GBM	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	6.67	9.34e-10	3.31e-06	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
GBM	cis	rs10256972	0.616	rs3802141	ENSG00000229043.2	AC091729.9	-6.67	9.37e-10	3.32e-06	-0.6	-0.53	Endometriosis;Longevity;	chr7:1091720	chr7:1160374~1165267:+
GBM	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	6.67	9.4e-10	3.33e-06	0.66	0.53	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	6.67	9.4e-10	3.33e-06	0.66	0.53	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	6.67	9.4e-10	3.33e-06	0.66	0.53	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
GBM	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	6.67	9.43e-10	3.33e-06	0.63	0.53	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
GBM	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-6.67	9.45e-10	3.34e-06	-0.66	-0.53	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
GBM	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-6.67	9.57e-10	3.38e-06	-0.62	-0.53	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
GBM	cis	rs7301826	0.627	rs7315707	ENSG00000256299.1	RP11-989F5.3	6.66	9.68e-10	3.41e-06	0.61	0.53	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810821~130812622:-
GBM	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	6.66	9.69e-10	3.42e-06	0.66	0.53	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
GBM	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	6.66	9.69e-10	3.42e-06	0.66	0.53	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
GBM	cis	rs2486288	0.656	rs6493145	ENSG00000259433.2	CTD-2651B20.4	6.66	9.71e-10	3.42e-06	0.59	0.53	Glomerular filtration rate;	chr15:45281664	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs8024620	ENSG00000259433.2	CTD-2651B20.4	6.66	9.71e-10	3.42e-06	0.59	0.53	Glomerular filtration rate;	chr15:45282131	chr15:45330209~45332634:-
GBM	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-6.66	9.72e-10	3.43e-06	-0.71	-0.53	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
GBM	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-6.66	9.76e-10	3.44e-06	-0.73	-0.53	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
GBM	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-6.66	9.77e-10	3.44e-06	-0.64	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
GBM	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-6.66	9.77e-10	3.44e-06	-0.64	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
GBM	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-6.66	9.77e-10	3.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-6.66	9.77e-10	3.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-6.66	9.77e-10	3.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-6.66	9.77e-10	3.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-6.66	9.77e-10	3.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-6.66	9.77e-10	3.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-6.66	9.77e-10	3.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
GBM	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	6.66	9.78e-10	3.44e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
GBM	cis	rs4273100	0.541	rs7501702	ENSG00000265185.4	SNORD3B-1	-6.66	9.84e-10	3.46e-06	-0.6	-0.53	Schizophrenia;	chr17:19390414	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.512	rs7502682	ENSG00000265185.4	SNORD3B-1	-6.66	9.84e-10	3.46e-06	-0.6	-0.53	Schizophrenia;	chr17:19392137	chr17:19061912~19062669:+
GBM	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	6.66	9.91e-10	3.48e-06	0.77	0.53	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
GBM	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-6.66	1e-09	3.52e-06	-0.69	-0.53	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-6.65	1.01e-09	3.54e-06	-0.7	-0.53	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-6.65	1.01e-09	3.54e-06	-0.7	-0.53	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-6.65	1.01e-09	3.54e-06	-0.7	-0.53	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
GBM	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-6.65	1.02e-09	3.57e-06	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-6.65	1.02e-09	3.57e-06	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-6.65	1.02e-09	3.57e-06	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
GBM	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-6.65	1.02e-09	3.57e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
GBM	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-6.65	1.02e-09	3.57e-06	-0.62	-0.53	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
GBM	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	6.65	1.02e-09	3.57e-06	0.63	0.53	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
GBM	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	6.65	1.02e-09	3.57e-06	0.58	0.53	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
GBM	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	6.65	1.02e-09	3.58e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	6.65	1.02e-09	3.58e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	6.65	1.02e-09	3.58e-06	0.68	0.53	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	6.65	1.02e-09	3.58e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
GBM	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-6.65	1.02e-09	3.58e-06	-0.69	-0.53	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-6.65	1.02e-09	3.58e-06	-0.69	-0.53	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-6.65	1.02e-09	3.58e-06	-0.69	-0.53	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-6.65	1.02e-09	3.58e-06	-0.69	-0.53	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-6.65	1.02e-09	3.58e-06	-0.69	-0.53	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
GBM	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	6.65	1.04e-09	3.61e-06	0.73	0.53	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
GBM	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	6.65	1.04e-09	3.61e-06	0.73	0.53	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
GBM	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	6.65	1.04e-09	3.61e-06	0.73	0.53	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
GBM	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	6.65	1.04e-09	3.61e-06	0.73	0.53	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
GBM	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	6.65	1.04e-09	3.61e-06	0.73	0.53	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
GBM	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-6.65	1.04e-09	3.61e-06	-0.61	-0.53	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
GBM	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	6.65	1.04e-09	3.62e-06	0.99	0.53	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
GBM	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	6.65	1.06e-09	3.68e-06	0.95	0.53	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-6.65	1.06e-09	3.68e-06	-0.95	-0.53	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
GBM	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-6.64	1.06e-09	3.69e-06	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
GBM	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-6.64	1.07e-09	3.71e-06	-0.54	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
GBM	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	6.64	1.07e-09	3.73e-06	0.56	0.53	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
GBM	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	6.64	1.08e-09	3.73e-06	0.98	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
GBM	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	6.64	1.08e-09	3.73e-06	0.66	0.53	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
GBM	cis	rs4273100	0.646	rs4924990	ENSG00000265185.4	SNORD3B-1	-6.63	1.13e-09	3.89e-06	-0.65	-0.53	Schizophrenia;	chr17:19391511	chr17:19061912~19062669:+
GBM	cis	rs2486288	0.656	rs11632920	ENSG00000259433.2	CTD-2651B20.4	6.63	1.14e-09	3.91e-06	0.57	0.53	Glomerular filtration rate;	chr15:45259066	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	6.63	1.14e-09	3.91e-06	0.63	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
GBM	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	6.63	1.15e-09	3.92e-06	0.69	0.53	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
GBM	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-6.63	1.15e-09	3.92e-06	-0.64	-0.53	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
GBM	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	6.63	1.15e-09	3.93e-06	0.62	0.53	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	6.63	1.15e-09	3.93e-06	0.62	0.53	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
GBM	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-6.63	1.15e-09	3.93e-06	-0.75	-0.53	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-6.63	1.15e-09	3.93e-06	-0.75	-0.53	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-6.63	1.15e-09	3.93e-06	-0.75	-0.53	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
GBM	cis	rs172166	0.637	rs1233708	ENSG00000199851.2	U3	6.63	1.15e-09	3.94e-06	0.71	0.53	Cardiac Troponin-T levels;	chr6:28205441	chr6:28015568~28015777:+
GBM	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	6.63	1.15e-09	3.94e-06	0.97	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	6.63	1.15e-09	3.94e-06	0.97	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
GBM	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	6.63	1.15e-09	3.95e-06	0.98	0.53	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
GBM	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	6.63	1.17e-09	3.98e-06	0.7	0.53	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
GBM	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-6.62	1.17e-09	4.01e-06	-0.7	-0.53	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
GBM	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-6.62	1.17e-09	4.01e-06	-0.7	-0.53	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	6.62	1.18e-09	4.03e-06	0.58	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
GBM	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-6.62	1.18e-09	4.03e-06	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
GBM	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-6.62	1.18e-09	4.04e-06	-0.58	-0.53	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
GBM	cis	rs881375	0.715	rs10818491	ENSG00000226752.6	PSMD5-AS1	-6.62	1.19e-09	4.05e-06	-0.63	-0.53	Rheumatoid arthritis;	chr9:120961073	chr9:120824828~120854385:+
GBM	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-6.62	1.2e-09	4.08e-06	-0.62	-0.53	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
GBM	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	6.62	1.2e-09	4.08e-06	0.62	0.53	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
GBM	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-6.62	1.22e-09	4.15e-06	-0.63	-0.53	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
GBM	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-6.62	1.22e-09	4.16e-06	-0.68	-0.53	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
GBM	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	6.62	1.22e-09	4.16e-06	0.64	0.53	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
GBM	cis	rs4713118	0.699	rs573179	ENSG00000199851.2	U3	6.62	1.22e-09	4.16e-06	0.88	0.53	Parkinson's disease;	chr6:27881898	chr6:28015568~28015777:+
GBM	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	6.61	1.24e-09	4.22e-06	0.65	0.52	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	6.61	1.24e-09	4.22e-06	0.65	0.52	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
GBM	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-6.61	1.25e-09	4.23e-06	-0.69	-0.52	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
GBM	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	6.61	1.25e-09	4.25e-06	0.68	0.52	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
GBM	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	6.61	1.26e-09	4.28e-06	0.58	0.52	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
GBM	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-6.61	1.27e-09	4.29e-06	-0.56	-0.52	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
GBM	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-6.61	1.27e-09	4.29e-06	-0.56	-0.52	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
GBM	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	6.61	1.27e-09	4.3e-06	0.62	0.52	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
GBM	cis	rs7267979	0.565	rs6107060	ENSG00000276952.1	RP5-965G21.6	6.61	1.27e-09	4.31e-06	0.51	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:25284915~25285588:-
GBM	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-6.61	1.28e-09	4.33e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-6.61	1.28e-09	4.33e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-6.61	1.28e-09	4.33e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-6.61	1.28e-09	4.33e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
GBM	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-6.61	1.28e-09	4.33e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
GBM	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-6.61	1.28e-09	4.34e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
GBM	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	6.61	1.28e-09	4.34e-06	0.62	0.52	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
GBM	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-6.6	1.29e-09	4.36e-06	-0.71	-0.52	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
GBM	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-6.6	1.29e-09	4.36e-06	-0.71	-0.52	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
GBM	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-6.6	1.29e-09	4.36e-06	-0.71	-0.52	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
GBM	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-6.6	1.29e-09	4.36e-06	-0.7	-0.52	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
GBM	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-6.6	1.29e-09	4.37e-06	-0.69	-0.52	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
GBM	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-6.6	1.3e-09	4.38e-06	-0.96	-0.52	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
GBM	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-6.6	1.3e-09	4.38e-06	-0.96	-0.52	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
GBM	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-6.6	1.3e-09	4.38e-06	-0.96	-0.52	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
GBM	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-6.6	1.3e-09	4.38e-06	-0.96	-0.52	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
GBM	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-6.6	1.3e-09	4.38e-06	-0.96	-0.52	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
GBM	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-6.6	1.3e-09	4.38e-06	-0.96	-0.52	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
GBM	cis	rs2486288	0.656	rs11631021	ENSG00000259433.2	CTD-2651B20.4	6.6	1.3e-09	4.39e-06	0.58	0.52	Glomerular filtration rate;	chr15:45264631	chr15:45330209~45332634:-
GBM	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-6.6	1.3e-09	4.39e-06	-0.54	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
GBM	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-6.6	1.31e-09	4.41e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-6.6	1.31e-09	4.41e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-6.6	1.31e-09	4.41e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
GBM	cis	rs6452524	0.534	rs10514246	ENSG00000248112.1	RP11-78C3.1	6.6	1.31e-09	4.41e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:82919376~82921119:-
GBM	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	6.6	1.31e-09	4.42e-06	0.84	0.52	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
GBM	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-6.6	1.32e-09	4.46e-06	-0.66	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
GBM	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-6.6	1.33e-09	4.46e-06	-0.54	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-6.6	1.33e-09	4.46e-06	-0.54	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
GBM	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-6.6	1.33e-09	4.47e-06	-0.59	-0.52	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
GBM	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	6.6	1.33e-09	4.47e-06	0.87	0.52	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
GBM	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	6.6	1.33e-09	4.48e-06	0.71	0.52	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
GBM	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	6.6	1.33e-09	4.48e-06	0.85	0.52	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
GBM	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	6.6	1.33e-09	4.48e-06	0.85	0.52	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
GBM	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	6.6	1.34e-09	4.51e-06	0.64	0.52	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
GBM	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	6.6	1.34e-09	4.51e-06	0.5	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
GBM	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	6.6	1.35e-09	4.54e-06	0.96	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	6.6	1.35e-09	4.54e-06	0.96	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
GBM	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-6.59	1.36e-09	4.55e-06	-0.54	-0.52	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
GBM	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-6.59	1.36e-09	4.56e-06	-0.62	-0.52	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
GBM	cis	rs4713118	0.629	rs203887	ENSG00000199851.2	U3	6.59	1.36e-09	4.56e-06	0.8	0.52	Parkinson's disease;	chr6:28053491	chr6:28015568~28015777:+
GBM	cis	rs7267979	0.528	rs34485039	ENSG00000276952.1	RP5-965G21.6	-6.59	1.37e-09	4.58e-06	-0.51	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.565	rs4815437	ENSG00000276952.1	RP5-965G21.6	-6.59	1.37e-09	4.58e-06	-0.51	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.565	rs6107059	ENSG00000276952.1	RP5-965G21.6	-6.59	1.37e-09	4.58e-06	-0.51	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:25284915~25285588:-
GBM	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	6.59	1.38e-09	4.61e-06	0.63	0.52	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs12911861	ENSG00000259433.2	CTD-2651B20.4	6.59	1.39e-09	4.64e-06	0.59	0.52	Glomerular filtration rate;	chr15:45274520	chr15:45330209~45332634:-
GBM	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-6.59	1.39e-09	4.66e-06	-0.75	-0.52	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-6.59	1.39e-09	4.66e-06	-0.75	-0.52	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-6.59	1.39e-09	4.66e-06	-0.75	-0.52	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-6.59	1.39e-09	4.66e-06	-0.75	-0.52	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-6.59	1.39e-09	4.66e-06	-0.75	-0.52	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
GBM	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-6.59	1.4e-09	4.68e-06	-0.54	-0.52	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
GBM	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	6.59	1.4e-09	4.68e-06	0.54	0.52	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
GBM	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-6.59	1.41e-09	4.72e-06	-1.15	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
GBM	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-6.58	1.42e-09	4.75e-06	-0.77	-0.52	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
GBM	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	6.58	1.43e-09	4.78e-06	0.67	0.52	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
GBM	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-6.58	1.45e-09	4.84e-06	-0.67	-0.52	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
GBM	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-6.58	1.45e-09	4.84e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
GBM	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.58	1.46e-09	4.86e-06	-0.61	-0.52	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
GBM	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	6.58	1.47e-09	4.89e-06	0.62	0.52	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
GBM	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-6.58	1.47e-09	4.9e-06	-0.62	-0.52	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
GBM	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	6.58	1.48e-09	4.91e-06	0.67	0.52	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
GBM	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-6.58	1.48e-09	4.92e-06	-1	-0.52	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
GBM	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-6.58	1.49e-09	4.95e-06	-0.75	-0.52	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-6.58	1.49e-09	4.95e-06	-0.75	-0.52	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
GBM	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-6.57	1.5e-09	4.99e-06	-0.65	-0.52	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
GBM	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-6.57	1.5e-09	4.99e-06	-0.5	-0.52	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
GBM	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-6.57	1.5e-09	4.99e-06	-0.5	-0.52	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
GBM	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	6.57	1.51e-09	5.01e-06	0.66	0.52	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	6.57	1.51e-09	5.01e-06	0.66	0.52	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
GBM	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	6.57	1.51e-09	5.02e-06	0.68	0.52	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	6.57	1.51e-09	5.02e-06	0.68	0.52	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
GBM	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-6.57	1.52e-09	5.04e-06	-0.54	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-6.57	1.52e-09	5.04e-06	-0.54	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
GBM	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	6.57	1.52e-09	5.05e-06	0.58	0.52	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
GBM	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-6.57	1.52e-09	5.06e-06	-0.52	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-6.57	1.52e-09	5.06e-06	-0.52	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
GBM	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-6.57	1.53e-09	5.07e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs1706768	ENSG00000259433.2	CTD-2651B20.4	6.57	1.53e-09	5.07e-06	0.58	0.52	Glomerular filtration rate;	chr15:45277245	chr15:45330209~45332634:-
GBM	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	6.57	1.53e-09	5.08e-06	0.82	0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
GBM	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	6.57	1.54e-09	5.1e-06	0.94	0.52	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
GBM	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-6.57	1.54e-09	5.1e-06	-0.77	-0.52	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-6.57	1.54e-09	5.1e-06	-0.77	-0.52	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
GBM	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-6.57	1.54e-09	5.1e-06	-0.77	-0.52	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
GBM	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-6.57	1.54e-09	5.1e-06	-0.77	-0.52	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
GBM	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-6.57	1.54e-09	5.1e-06	-0.77	-0.52	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	6.57	1.56e-09	5.15e-06	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	6.57	1.56e-09	5.15e-06	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	6.57	1.56e-09	5.15e-06	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	6.57	1.56e-09	5.15e-06	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	6.57	1.56e-09	5.15e-06	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
GBM	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-6.57	1.56e-09	5.16e-06	-0.52	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
GBM	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-6.57	1.56e-09	5.17e-06	-0.63	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
GBM	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-6.57	1.57e-09	5.17e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-6.57	1.57e-09	5.17e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-6.57	1.57e-09	5.17e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-6.57	1.57e-09	5.18e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
GBM	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-6.56	1.57e-09	5.18e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
GBM	cis	rs2486288	0.656	rs2461705	ENSG00000259433.2	CTD-2651B20.4	6.56	1.58e-09	5.22e-06	0.59	0.52	Glomerular filtration rate;	chr15:45278043	chr15:45330209~45332634:-
GBM	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	6.56	1.61e-09	5.31e-06	0.57	0.52	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
GBM	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	6.56	1.61e-09	5.32e-06	0.97	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
GBM	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	6.56	1.61e-09	5.32e-06	0.64	0.52	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
GBM	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	6.56	1.62e-09	5.36e-06	0.62	0.52	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
GBM	cis	rs2486288	0.586	rs12909625	ENSG00000259433.2	CTD-2651B20.4	6.56	1.64e-09	5.41e-06	0.59	0.52	Glomerular filtration rate;	chr15:45279855	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.586	rs12909883	ENSG00000259433.2	CTD-2651B20.4	6.56	1.64e-09	5.41e-06	0.59	0.52	Glomerular filtration rate;	chr15:45279856	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs12910009	ENSG00000259433.2	CTD-2651B20.4	6.56	1.64e-09	5.41e-06	0.59	0.52	Glomerular filtration rate;	chr15:45280210	chr15:45330209~45332634:-
GBM	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-6.56	1.64e-09	5.42e-06	-0.78	-0.52	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
GBM	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	6.55	1.65e-09	5.45e-06	0.58	0.52	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
GBM	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-6.55	1.65e-09	5.45e-06	-0.78	-0.52	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
GBM	cis	rs950027	0.549	rs11070452	ENSG00000259433.2	CTD-2651B20.4	6.55	1.65e-09	5.46e-06	0.59	0.52	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45330209~45332634:-
GBM	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	6.55	1.66e-09	5.46e-06	0.73	0.52	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000224205.1	AP000351.4	6.55	1.66e-09	5.48e-06	0.59	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23987320~23991421:-
GBM	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-6.55	1.68e-09	5.53e-06	-0.62	-0.52	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-6.55	1.68e-09	5.53e-06	-0.62	-0.52	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-6.55	1.68e-09	5.53e-06	-0.62	-0.52	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
GBM	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	6.55	1.69e-09	5.55e-06	0.62	0.52	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
GBM	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	6.55	1.7e-09	5.58e-06	0.69	0.52	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
GBM	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	6.55	1.7e-09	5.58e-06	0.97	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
GBM	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-6.55	1.7e-09	5.6e-06	-1.01	-0.52	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
GBM	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	6.54	1.73e-09	5.69e-06	0.65	0.52	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
GBM	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	6.54	1.74e-09	5.71e-06	0.54	0.52	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
GBM	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	6.54	1.77e-09	5.79e-06	0.87	0.52	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
GBM	cis	rs6452524	0.532	rs27363	ENSG00000248112.1	RP11-78C3.1	6.54	1.78e-09	5.83e-06	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.532	rs26263	ENSG00000248112.1	RP11-78C3.1	6.54	1.78e-09	5.83e-06	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:82919376~82921119:-
GBM	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-6.54	1.78e-09	5.83e-06	-0.66	-0.52	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
GBM	cis	rs172166	0.637	rs1225592	ENSG00000199851.2	U3	6.54	1.79e-09	5.84e-06	0.74	0.52	Cardiac Troponin-T levels;	chr6:28182464	chr6:28015568~28015777:+
GBM	cis	rs172166	0.637	rs1225595	ENSG00000199851.2	U3	6.54	1.79e-09	5.84e-06	0.74	0.52	Cardiac Troponin-T levels;	chr6:28183562	chr6:28015568~28015777:+
GBM	cis	rs172166	0.637	rs1233691	ENSG00000199851.2	U3	6.54	1.79e-09	5.84e-06	0.74	0.52	Cardiac Troponin-T levels;	chr6:28186119	chr6:28015568~28015777:+
GBM	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	6.54	1.79e-09	5.85e-06	0.63	0.52	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
GBM	cis	rs453301	0.598	rs2921383	ENSG00000254340.1	RP11-10A14.3	6.54	1.79e-09	5.86e-06	0.67	0.52	Joint mobility (Beighton score);	chr8:9034711	chr8:9141424~9145435:+
GBM	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-6.54	1.79e-09	5.86e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
GBM	cis	rs7267979	0.738	rs2892409	ENSG00000125804.12	FAM182A	-6.53	1.82e-09	5.96e-06	-0.68	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:26054655~26086917:+
GBM	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	6.53	1.84e-09	5.99e-06	0.81	0.52	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
GBM	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-6.53	1.85e-09	6.03e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
GBM	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-6.53	1.86e-09	6.05e-06	-0.6	-0.52	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000235689.1	AP000351.13	6.53	1.86e-09	6.06e-06	0.59	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	6.53	1.86e-09	6.06e-06	0.59	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	6.53	1.86e-09	6.06e-06	0.59	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	6.53	1.86e-09	6.06e-06	0.59	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	6.53	1.86e-09	6.06e-06	0.59	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
GBM	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	6.53	1.86e-09	6.07e-06	0.68	0.52	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
GBM	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-6.53	1.88e-09	6.14e-06	-0.59	-0.52	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
GBM	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	6.53	1.89e-09	6.17e-06	0.67	0.52	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
GBM	cis	rs2486288	0.656	rs12440356	ENSG00000259433.2	CTD-2651B20.4	-6.53	1.89e-09	6.17e-06	-0.58	-0.52	Glomerular filtration rate;	chr15:45275331	chr15:45330209~45332634:-
GBM	cis	rs2486288	0.656	rs11639349	ENSG00000259433.2	CTD-2651B20.4	6.53	1.89e-09	6.17e-06	0.58	0.52	Glomerular filtration rate;	chr15:45276062	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	6.53	1.89e-09	6.17e-06	0.59	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-6.53	1.9e-09	6.17e-06	-0.57	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
GBM	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-6.52	1.92e-09	6.24e-06	-0.65	-0.52	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
GBM	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	6.52	1.92e-09	6.24e-06	0.58	0.52	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	6.52	1.92e-09	6.24e-06	0.58	0.52	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
GBM	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-6.52	1.92e-09	6.24e-06	-0.54	-0.52	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
GBM	cis	rs6452524	0.78	rs10078661	ENSG00000248112.1	RP11-78C3.1	6.52	1.95e-09	6.33e-06	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:82919376~82921119:-
GBM	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-6.52	1.95e-09	6.33e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
GBM	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-6.52	1.95e-09	6.35e-06	-0.72	-0.52	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
GBM	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-6.52	1.96e-09	6.36e-06	-0.63	-0.52	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
GBM	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-6.52	1.96e-09	6.36e-06	-0.59	-0.52	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	6.52	1.96e-09	6.36e-06	0.59	0.52	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-6.52	1.96e-09	6.36e-06	-0.59	-0.52	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-6.52	1.96e-09	6.36e-06	-0.59	-0.52	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-6.52	1.96e-09	6.36e-06	-0.59	-0.52	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	6.52	1.96e-09	6.36e-06	0.59	0.52	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
GBM	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	6.52	1.97e-09	6.38e-06	0.57	0.52	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
GBM	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-6.52	1.98e-09	6.42e-06	-0.95	-0.52	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
GBM	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	6.52	1.98e-09	6.42e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
GBM	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	6.52	2e-09	6.47e-06	0.61	0.52	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
GBM	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-6.51	2.01e-09	6.5e-06	-0.62	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
GBM	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	6.51	2.01e-09	6.51e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	6.51	2.01e-09	6.51e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
GBM	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-6.51	2.01e-09	6.51e-06	-0.64	-0.52	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
GBM	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	6.51	2.02e-09	6.54e-06	0.6	0.52	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
GBM	cis	rs4682868	0.581	rs4682869	ENSG00000273328.4	RP11-141M3.6	-6.51	2.03e-09	6.57e-06	-0.6	-0.52	Monocyte percentage of white cells;	chr3:42882472	chr3:42809414~42908105:+
GBM	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
GBM	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
GBM	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
GBM	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
GBM	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-6.51	2.03e-09	6.57e-06	-0.73	-0.52	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
GBM	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	6.51	2.05e-09	6.6e-06	0.63	0.52	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
GBM	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-6.51	2.05e-09	6.61e-06	-0.7	-0.52	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
GBM	cis	rs950027	0.549	rs9920634	ENSG00000259433.2	CTD-2651B20.4	6.51	2.05e-09	6.61e-06	0.58	0.52	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45330209~45332634:-
GBM	cis	rs950027	0.549	rs2899375	ENSG00000259433.2	CTD-2651B20.4	6.51	2.05e-09	6.61e-06	0.58	0.52	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45330209~45332634:-
GBM	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-6.51	2.05e-09	6.62e-06	-0.59	-0.52	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-6.51	2.05e-09	6.62e-06	-0.59	-0.52	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.51	2.05e-09	6.62e-06	-0.59	-0.52	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
GBM	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.51	2.05e-09	6.62e-06	-0.59	-0.52	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
GBM	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-6.51	2.07e-09	6.68e-06	-0.64	-0.52	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	6.51	2.07e-09	6.68e-06	0.64	0.52	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	6.51	2.07e-09	6.68e-06	0.64	0.52	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
GBM	cis	rs6452524	0.868	rs1564379	ENSG00000248112.1	RP11-78C3.1	6.51	2.1e-09	6.75e-06	0.62	0.52	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:82919376~82921119:-
GBM	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	6.5	2.1e-09	6.77e-06	0.67	0.52	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
GBM	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-09	6.82e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
GBM	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-09	6.82e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-09	6.82e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-09	6.82e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
GBM	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-09	6.82e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-09	6.82e-06	-0.69	-0.52	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
GBM	cis	rs7267979	0.527	rs6076369	ENSG00000276952.1	RP5-965G21.6	-6.5	2.13e-09	6.84e-06	-0.5	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:25284915~25285588:-
GBM	cis	rs6452524	0.537	rs1583	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.506	rs7891	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.534	rs7724935	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.506	rs7707143	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.563	rs10473863	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.534	rs72765386	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.534	rs9293328	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.534	rs11746747	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.534	rs10037377	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.507	rs28592576	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.534	rs7727691	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.87e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.901	rs4571449	ENSG00000248112.1	RP11-78C3.1	6.5	2.14e-09	6.88e-06	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:82919376~82921119:-
GBM	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-6.5	2.16e-09	6.92e-06	-0.64	-0.52	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
GBM	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-6.5	2.17e-09	6.95e-06	-0.94	-0.52	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
GBM	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	6.5	2.18e-09	7e-06	0.78	0.52	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
GBM	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-6.5	2.19e-09	7.03e-06	-0.61	-0.52	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
GBM	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-6.49	2.21e-09	7.09e-06	-0.65	-0.52	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
GBM	cis	rs2486288	0.656	rs12908818	ENSG00000259433.2	CTD-2651B20.4	6.49	2.22e-09	7.12e-06	0.58	0.52	Glomerular filtration rate;	chr15:45279470	chr15:45330209~45332634:-
GBM	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	6.49	2.22e-09	7.12e-06	0.74	0.52	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
GBM	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	6.49	2.24e-09	7.16e-06	0.61	0.52	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
GBM	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	6.49	2.25e-09	7.19e-06	0.66	0.52	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
GBM	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-6.49	2.25e-09	7.19e-06	-0.74	-0.52	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
GBM	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-6.49	2.25e-09	7.19e-06	-0.63	-0.52	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
GBM	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	6.49	2.27e-09	7.25e-06	0.61	0.52	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
GBM	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-6.49	2.29e-09	7.32e-06	-0.67	-0.52	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
GBM	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	6.49	2.29e-09	7.33e-06	0.61	0.52	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
GBM	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-6.49	2.3e-09	7.35e-06	-0.53	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
GBM	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	6.49	2.31e-09	7.37e-06	0.66	0.52	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
GBM	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	6.48	2.33e-09	7.43e-06	0.61	0.52	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
GBM	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-6.48	2.34e-09	7.47e-06	-0.6	-0.52	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
GBM	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	6.48	2.34e-09	7.48e-06	0.62	0.52	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
GBM	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-6.48	2.35e-09	7.5e-06	-0.71	-0.52	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
GBM	cis	rs2486288	0.656	rs2413771	ENSG00000259433.2	CTD-2651B20.4	6.48	2.36e-09	7.51e-06	0.57	0.52	Glomerular filtration rate;	chr15:45260942	chr15:45330209~45332634:-
GBM	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-6.48	2.36e-09	7.54e-06	-0.65	-0.52	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
GBM	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	6.48	2.37e-09	7.55e-06	0.73	0.52	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
GBM	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.39e-09	7.62e-06	-0.62	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
GBM	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.39e-09	7.62e-06	-0.62	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
GBM	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.39e-09	7.62e-06	-0.62	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
GBM	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.39e-09	7.62e-06	-0.62	-0.52	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
GBM	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-6.48	2.4e-09	7.64e-06	-0.64	-0.52	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
GBM	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-6.48	2.4e-09	7.64e-06	-0.64	-0.52	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
GBM	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-6.48	2.42e-09	7.69e-06	-0.64	-0.52	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
GBM	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-6.48	2.42e-09	7.71e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
GBM	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-6.47	2.44e-09	7.77e-06	-0.67	-0.52	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
GBM	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-6.47	2.44e-09	7.77e-06	-0.67	-0.52	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
GBM	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.47	2.45e-09	7.8e-06	-0.74	-0.52	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
GBM	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-6.47	2.47e-09	7.84e-06	-0.5	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-6.47	2.47e-09	7.84e-06	-0.5	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-6.47	2.47e-09	7.84e-06	-0.5	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
GBM	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-6.47	2.48e-09	7.87e-06	-0.59	-0.52	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
GBM	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-6.47	2.49e-09	7.9e-06	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	6.47	2.5e-09	7.94e-06	0.58	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-6.47	2.51e-09	7.96e-06	-0.57	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
GBM	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-6.47	2.52e-09	7.98e-06	-0.67	-0.52	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-6.47	2.52e-09	7.98e-06	-0.67	-0.52	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
GBM	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-6.47	2.52e-09	7.98e-06	-0.67	-0.52	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
GBM	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-6.47	2.52e-09	7.98e-06	-0.67	-0.52	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-6.47	2.52e-09	7.98e-06	-0.67	-0.52	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
GBM	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-6.47	2.52e-09	7.98e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
GBM	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-6.47	2.52e-09	7.98e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
GBM	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	6.47	2.53e-09	8e-06	0.94	0.52	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
GBM	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-6.46	2.58e-09	8.16e-06	-0.65	-0.52	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-6.46	2.58e-09	8.16e-06	-0.65	-0.52	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-6.46	2.58e-09	8.16e-06	-0.65	-0.52	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
GBM	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
GBM	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
GBM	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
GBM	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
GBM	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
GBM	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
GBM	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-6.46	2.6e-09	8.2e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
GBM	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-6.46	2.6e-09	8.21e-06	-0.65	-0.52	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
GBM	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	6.46	2.61e-09	8.22e-06	0.61	0.52	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
GBM	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-6.46	2.61e-09	8.22e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-6.46	2.61e-09	8.22e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-6.46	2.61e-09	8.22e-06	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
GBM	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	6.46	2.62e-09	8.24e-06	0.92	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	6.46	2.62e-09	8.24e-06	0.92	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
GBM	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	6.46	2.62e-09	8.26e-06	0.61	0.52	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
GBM	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-6.46	2.64e-09	8.3e-06	-0.53	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
GBM	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	6.46	2.64e-09	8.32e-06	0.66	0.52	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-6.46	2.65e-09	8.33e-06	-0.62	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
GBM	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-6.46	2.65e-09	8.33e-06	-0.72	-0.52	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
GBM	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-6.46	2.66e-09	8.36e-06	-0.76	-0.52	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
GBM	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-6.46	2.67e-09	8.39e-06	-0.63	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-6.46	2.67e-09	8.39e-06	-0.63	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-6.46	2.67e-09	8.39e-06	-0.63	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
GBM	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	6.45	2.68e-09	8.42e-06	0.55	0.52	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
GBM	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	6.45	2.68e-09	8.42e-06	0.63	0.52	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
GBM	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-6.45	2.69e-09	8.43e-06	-0.73	-0.52	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-6.45	2.69e-09	8.43e-06	-0.73	-0.52	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-6.45	2.69e-09	8.43e-06	-0.73	-0.52	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
GBM	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-6.45	2.7e-09	8.47e-06	-0.63	-0.52	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
GBM	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	6.45	2.7e-09	8.47e-06	0.66	0.52	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
GBM	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	6.45	2.71e-09	8.5e-06	0.69	0.52	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
GBM	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	6.45	2.72e-09	8.54e-06	0.7	0.52	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	6.45	2.74e-09	8.57e-06	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	6.45	2.74e-09	8.57e-06	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	6.45	2.74e-09	8.57e-06	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	6.45	2.74e-09	8.57e-06	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
GBM	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-6.45	2.74e-09	8.57e-06	-0.73	-0.52	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-6.45	2.74e-09	8.57e-06	-0.73	-0.52	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
GBM	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-6.45	2.74e-09	8.58e-06	-0.49	-0.52	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
GBM	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-6.45	2.75e-09	8.6e-06	-0.66	-0.52	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000224205.1	AP000351.4	6.45	2.75e-09	8.61e-06	0.56	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23987320~23991421:-
GBM	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-6.45	2.75e-09	8.61e-06	-0.5	-0.52	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
GBM	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-6.45	2.76e-09	8.63e-06	-0.78	-0.52	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
GBM	cis	rs7829975	0.542	rs7844374	ENSG00000253893.2	FAM85B	6.45	2.77e-09	8.64e-06	0.6	0.52	Mood instability;	chr8:8941174	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.606	rs6601274	ENSG00000253893.2	FAM85B	6.45	2.77e-09	8.64e-06	0.6	0.52	Mood instability;	chr8:8941549	chr8:8167819~8226614:-
GBM	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-6.45	2.77e-09	8.66e-06	-0.78	-0.52	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
GBM	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	6.45	2.78e-09	8.69e-06	0.55	0.52	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
GBM	cis	rs453301	0.652	rs2043129	ENSG00000253893.2	FAM85B	-6.45	2.8e-09	8.73e-06	-0.62	-0.52	Joint mobility (Beighton score);	chr8:8967994	chr8:8167819~8226614:-
GBM	cis	rs2486288	0.656	rs8039153	ENSG00000259433.2	CTD-2651B20.4	6.44	2.86e-09	8.89e-06	0.55	0.51	Glomerular filtration rate;	chr15:45287615	chr15:45330209~45332634:-
GBM	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-6.44	2.86e-09	8.9e-06	-0.74	-0.51	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
GBM	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-6.44	2.87e-09	8.92e-06	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
GBM	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	6.44	2.88e-09	8.93e-06	0.42	0.51	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
GBM	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	6.44	2.89e-09	8.96e-06	0.68	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
GBM	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-6.44	2.91e-09	9.02e-06	-0.94	-0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
GBM	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	6.44	2.93e-09	9.1e-06	0.6	0.51	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
GBM	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	6.44	2.94e-09	9.12e-06	0.64	0.51	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	6.44	2.94e-09	9.12e-06	0.64	0.51	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
GBM	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-6.43	2.96e-09	9.18e-06	-0.69	-0.51	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
GBM	cis	rs7829975	0.508	rs1594437	ENSG00000253893.2	FAM85B	-6.43	2.98e-09	9.24e-06	-0.62	-0.51	Mood instability;	chr8:8968365	chr8:8167819~8226614:-
GBM	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-6.43	2.98e-09	9.25e-06	-0.72	-0.51	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
GBM	cis	rs7267979	0.528	rs6076366	ENSG00000276952.1	RP5-965G21.6	-6.43	3.03e-09	9.37e-06	-0.5	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25284915~25285588:-
GBM	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	6.43	3.05e-09	9.44e-06	0.61	0.51	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
GBM	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-6.43	3.06e-09	9.47e-06	-0.6	-0.51	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
GBM	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	6.43	3.06e-09	9.47e-06	0.59	0.51	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
GBM	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-6.43	3.08e-09	9.52e-06	-0.59	-0.51	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
GBM	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-6.43	3.08e-09	9.52e-06	-0.51	-0.51	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
GBM	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-6.43	3.08e-09	9.53e-06	-0.63	-0.51	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
GBM	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	6.43	3.09e-09	9.55e-06	0.64	0.51	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
GBM	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-6.42	3.13e-09	9.68e-06	-0.64	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
GBM	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-6.42	3.15e-09	9.74e-06	-0.71	-0.51	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
GBM	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-6.42	3.15e-09	9.74e-06	-0.71	-0.51	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
GBM	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-6.42	3.17e-09	9.78e-06	-0.72	-0.51	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
GBM	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-6.42	3.17e-09	9.78e-06	-0.72	-0.51	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
GBM	cis	rs7267979	0.966	rs6050611	ENSG00000125804.12	FAM182A	-6.42	3.17e-09	9.79e-06	-0.63	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:26054655~26086917:+
GBM	cis	rs4713118	0.621	rs9295755	ENSG00000199851.2	U3	-6.42	3.22e-09	9.92e-06	-0.82	-0.51	Parkinson's disease;	chr6:28065396	chr6:28015568~28015777:+
GBM	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-6.42	3.22e-09	9.92e-06	-0.75	-0.51	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-6.42	3.22e-09	9.92e-06	-0.75	-0.51	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
GBM	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	6.42	3.22e-09	9.93e-06	0.62	0.51	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
GBM	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-6.42	3.23e-09	9.95e-06	-0.7	-0.51	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
GBM	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-6.42	3.23e-09	9.95e-06	-0.7	-0.51	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
GBM	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-6.41	3.25e-09	1e-05	-0.6	-0.51	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
GBM	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-6.41	3.27e-09	1e-05	-0.57	-0.51	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
GBM	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	6.41	3.29e-09	1.01e-05	0.61	0.51	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	6.41	3.29e-09	1.01e-05	0.61	0.51	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	6.41	3.29e-09	1.01e-05	0.61	0.51	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
GBM	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-6.41	3.33e-09	1.02e-05	-0.78	-0.51	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
GBM	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-6.41	3.34e-09	1.02e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
GBM	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-6.41	3.36e-09	1.03e-05	-0.64	-0.51	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
GBM	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	6.41	3.36e-09	1.03e-05	0.57	0.51	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	6.41	3.37e-09	1.03e-05	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	6.41	3.37e-09	1.03e-05	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	6.41	3.37e-09	1.03e-05	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
GBM	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	6.41	3.38e-09	1.04e-05	0.78	0.51	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
GBM	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	6.41	3.39e-09	1.04e-05	0.64	0.51	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	6.41	3.39e-09	1.04e-05	0.64	0.51	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	6.41	3.39e-09	1.04e-05	0.64	0.51	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
GBM	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	6.4	3.42e-09	1.05e-05	0.89	0.51	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
GBM	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	6.4	3.46e-09	1.06e-05	0.72	0.51	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
GBM	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-6.4	3.48e-09	1.06e-05	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
GBM	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-6.4	3.48e-09	1.06e-05	-1.09	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
GBM	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	6.4	3.53e-09	1.08e-05	0.62	0.51	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	6.4	3.53e-09	1.08e-05	0.62	0.51	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	6.4	3.53e-09	1.08e-05	0.62	0.51	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	6.4	3.53e-09	1.08e-05	0.62	0.51	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	6.4	3.53e-09	1.08e-05	0.62	0.51	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	6.4	3.53e-09	1.08e-05	0.62	0.51	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
GBM	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-6.4	3.53e-09	1.08e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-6.4	3.53e-09	1.08e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-6.4	3.53e-09	1.08e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
GBM	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
GBM	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
GBM	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
GBM	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
GBM	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
GBM	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
GBM	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
GBM	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
GBM	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
GBM	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
GBM	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
GBM	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-6.4	3.54e-09	1.08e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
GBM	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-6.4	3.57e-09	1.09e-05	-0.7	-0.51	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
GBM	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	6.39	3.58e-09	1.09e-05	0.61	0.51	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
GBM	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	6.39	3.58e-09	1.09e-05	0.61	0.51	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
GBM	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-6.39	3.61e-09	1.1e-05	-0.7	-0.51	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
GBM	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	6.39	3.65e-09	1.11e-05	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
GBM	cis	rs4273100	0.573	rs4924783	ENSG00000265185.4	SNORD3B-1	-6.39	3.65e-09	1.11e-05	-0.56	-0.51	Schizophrenia;	chr17:19350668	chr17:19061912~19062669:+
GBM	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.39	3.7e-09	1.13e-05	-0.61	-0.51	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.39	3.7e-09	1.13e-05	-0.61	-0.51	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
GBM	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-6.39	3.7e-09	1.13e-05	-0.57	-0.51	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
GBM	cis	rs4682868	0.552	rs6771233	ENSG00000273328.4	RP11-141M3.6	-6.39	3.7e-09	1.13e-05	-0.61	-0.51	Monocyte percentage of white cells;	chr3:42881205	chr3:42809414~42908105:+
GBM	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-6.39	3.72e-09	1.13e-05	-0.73	-0.51	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
GBM	cis	rs11098499	0.566	rs7664440	ENSG00000249244.1	RP11-548H18.2	6.39	3.73e-09	1.13e-05	0.63	0.51	Corneal astigmatism;	chr4:119657385	chr4:119391831~119395335:-
GBM	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-6.39	3.73e-09	1.13e-05	-0.73	-0.51	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
GBM	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	6.38	3.76e-09	1.14e-05	0.6	0.51	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	6.38	3.76e-09	1.14e-05	0.6	0.51	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
GBM	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-6.38	3.76e-09	1.14e-05	-0.71	-0.51	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
GBM	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-6.38	3.76e-09	1.14e-05	-0.71	-0.51	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
GBM	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	6.38	3.77e-09	1.14e-05	0.6	0.51	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
GBM	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-6.38	3.81e-09	1.15e-05	-0.62	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
GBM	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	6.38	3.81e-09	1.15e-05	0.63	0.51	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	6.38	3.81e-09	1.15e-05	0.63	0.51	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	6.38	3.81e-09	1.15e-05	0.63	0.51	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-6.38	3.81e-09	1.15e-05	-0.63	-0.51	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
GBM	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-6.38	3.81e-09	1.15e-05	-0.53	-0.51	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
GBM	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	6.38	3.82e-09	1.16e-05	0.65	0.51	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
GBM	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	6.38	3.87e-09	1.17e-05	0.86	0.51	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
GBM	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-6.38	3.88e-09	1.17e-05	-0.62	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
GBM	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-6.38	3.88e-09	1.17e-05	-0.66	-0.51	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	6.38	3.9e-09	1.18e-05	0.58	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
GBM	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	6.38	3.91e-09	1.18e-05	0.54	0.51	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
GBM	cis	rs11098499	0.866	rs3756156	ENSG00000250412.1	KLHL2P1	6.38	3.93e-09	1.19e-05	0.65	0.51	Corneal astigmatism;	chr4:119603686	chr4:119334329~119378233:+
GBM	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-6.37	3.94e-09	1.19e-05	-0.83	-0.51	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
GBM	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-6.37	3.98e-09	1.2e-05	-0.69	-0.51	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
GBM	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-6.37	3.98e-09	1.2e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
GBM	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	6.37	4.01e-09	1.21e-05	0.6	0.51	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
GBM	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-6.37	4.02e-09	1.21e-05	-0.56	-0.51	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
GBM	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-6.37	4.02e-09	1.21e-05	-0.56	-0.51	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
GBM	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-6.37	4.04e-09	1.22e-05	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-6.37	4.04e-09	1.22e-05	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-6.37	4.04e-09	1.22e-05	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
GBM	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-6.37	4.04e-09	1.22e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
GBM	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-6.37	4.04e-09	1.22e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
GBM	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-6.37	4.06e-09	1.22e-05	-0.82	-0.51	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
GBM	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-6.37	4.06e-09	1.22e-05	-0.71	-0.51	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
GBM	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	6.37	4.06e-09	1.22e-05	0.59	0.51	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	6.37	4.06e-09	1.22e-05	0.59	0.51	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	6.37	4.06e-09	1.22e-05	0.59	0.51	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	6.37	4.06e-09	1.22e-05	0.59	0.51	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
GBM	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-6.37	4.09e-09	1.23e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-6.37	4.09e-09	1.23e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-6.37	4.09e-09	1.23e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-6.37	4.09e-09	1.23e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
GBM	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	6.37	4.1e-09	1.23e-05	0.6	0.51	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.82	rs2389885	ENSG00000249244.1	RP11-548H18.2	6.36	4.14e-09	1.24e-05	0.64	0.51	Corneal astigmatism;	chr4:119612776	chr4:119391831~119395335:-
GBM	cis	rs172166	0.611	rs203882	ENSG00000199851.2	U3	6.36	4.14e-09	1.24e-05	0.75	0.51	Cardiac Troponin-T levels;	chr6:28110724	chr6:28015568~28015777:+
GBM	cis	rs172166	0.694	rs1770131	ENSG00000199851.2	U3	6.36	4.14e-09	1.24e-05	0.75	0.51	Cardiac Troponin-T levels;	chr6:28118635	chr6:28015568~28015777:+
GBM	cis	rs172166	0.694	rs1631552	ENSG00000199851.2	U3	6.36	4.14e-09	1.24e-05	0.75	0.51	Cardiac Troponin-T levels;	chr6:28121921	chr6:28015568~28015777:+
GBM	cis	rs172166	0.694	rs536704	ENSG00000199851.2	U3	6.36	4.14e-09	1.24e-05	0.75	0.51	Cardiac Troponin-T levels;	chr6:28124825	chr6:28015568~28015777:+
GBM	cis	rs11098499	0.604	rs34278750	ENSG00000249244.1	RP11-548H18.2	6.36	4.14e-09	1.24e-05	0.63	0.51	Corneal astigmatism;	chr4:119649981	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.604	rs10022185	ENSG00000249244.1	RP11-548H18.2	6.36	4.14e-09	1.24e-05	0.63	0.51	Corneal astigmatism;	chr4:119650610	chr4:119391831~119395335:-
GBM	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-6.36	4.15e-09	1.25e-05	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
GBM	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-6.36	4.17e-09	1.25e-05	-0.64	-0.51	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
GBM	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-6.36	4.2e-09	1.26e-05	-0.73	-0.51	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	6.36	4.2e-09	1.26e-05	0.73	0.51	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
GBM	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	6.36	4.21e-09	1.26e-05	0.66	0.51	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
GBM	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	6.36	4.22e-09	1.27e-05	0.56	0.51	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
GBM	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	6.36	4.23e-09	1.27e-05	0.93	0.51	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	6.36	4.23e-09	1.27e-05	0.93	0.51	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	6.36	4.23e-09	1.27e-05	0.93	0.51	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	6.36	4.23e-09	1.27e-05	0.93	0.51	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
GBM	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	6.36	4.3e-09	1.29e-05	0.68	0.51	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
GBM	cis	rs7267979	0.789	rs2260197	ENSG00000125804.12	FAM182A	-6.36	4.33e-09	1.29e-05	-0.66	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26054655~26086917:+
GBM	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-6.35	4.36e-09	1.3e-05	-0.62	-0.51	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
GBM	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-6.35	4.4e-09	1.31e-05	-0.56	-0.51	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
GBM	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	6.35	4.41e-09	1.31e-05	0.59	0.51	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	6.35	4.41e-09	1.31e-05	0.61	0.51	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
GBM	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	6.35	4.41e-09	1.31e-05	0.63	0.51	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
GBM	cis	rs7267979	0.657	rs6107073	ENSG00000125804.12	FAM182A	-6.35	4.42e-09	1.32e-05	-0.66	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:26054655~26086917:+
GBM	cis	rs950027	0.572	rs12910764	ENSG00000259433.2	CTD-2651B20.4	6.35	4.43e-09	1.32e-05	0.56	0.51	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45330209~45332634:-
GBM	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-6.35	4.43e-09	1.32e-05	-0.72	-0.51	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
GBM	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-6.35	4.44e-09	1.32e-05	-0.58	-0.51	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
GBM	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-6.35	4.47e-09	1.33e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
GBM	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	6.35	4.48e-09	1.33e-05	0.59	0.51	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	6.35	4.48e-09	1.33e-05	0.59	0.51	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	6.35	4.48e-09	1.33e-05	0.59	0.51	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
GBM	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	6.35	4.49e-09	1.34e-05	0.63	0.51	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
GBM	cis	rs7267979	0.753	rs404148	ENSG00000125804.12	FAM182A	-6.35	4.51e-09	1.34e-05	-0.66	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.702	rs449801	ENSG00000125804.12	FAM182A	-6.35	4.51e-09	1.34e-05	-0.66	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:26054655~26086917:+
GBM	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	6.35	4.51e-09	1.34e-05	0.58	0.51	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
GBM	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	6.35	4.51e-09	1.34e-05	0.61	0.51	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
GBM	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-6.35	4.52e-09	1.34e-05	-0.75	-0.51	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
GBM	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	6.35	4.52e-09	1.34e-05	0.63	0.51	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-6.35	4.52e-09	1.34e-05	-0.63	-0.51	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
GBM	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
GBM	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-6.35	4.54e-09	1.34e-05	-0.76	-0.51	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
GBM	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-6.34	4.56e-09	1.35e-05	-0.61	-0.51	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
GBM	cis	rs4682868	0.581	rs13068366	ENSG00000273328.4	RP11-141M3.6	-6.34	4.57e-09	1.35e-05	-0.61	-0.51	Monocyte percentage of white cells;	chr3:42880528	chr3:42809414~42908105:+
GBM	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-6.34	4.57e-09	1.35e-05	-0.92	-0.51	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
GBM	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	6.34	4.57e-09	1.35e-05	0.63	0.51	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	6.34	4.61e-09	1.36e-05	0.66	0.51	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
GBM	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	6.34	4.66e-09	1.38e-05	0.65	0.51	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
GBM	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-6.34	4.68e-09	1.38e-05	-0.71	-0.51	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
GBM	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-6.34	4.68e-09	1.38e-05	-0.71	-0.51	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
GBM	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	6.34	4.68e-09	1.38e-05	0.66	0.51	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	6.34	4.69e-09	1.38e-05	0.63	0.51	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
GBM	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-6.34	4.69e-09	1.38e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-6.34	4.69e-09	1.38e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
GBM	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-6.34	4.69e-09	1.38e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
GBM	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	6.34	4.69e-09	1.39e-05	0.95	0.51	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
GBM	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-6.34	4.7e-09	1.39e-05	-0.63	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	6.34	4.7e-09	1.39e-05	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	6.34	4.7e-09	1.39e-05	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
GBM	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-6.34	4.74e-09	1.4e-05	-0.67	-0.51	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-6.34	4.74e-09	1.4e-05	-0.67	-0.51	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-6.34	4.74e-09	1.4e-05	-0.67	-0.51	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000235689.1	AP000351.13	-6.34	4.74e-09	1.4e-05	-0.58	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:24006305~24008258:-
GBM	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-6.34	4.75e-09	1.4e-05	-0.74	-0.51	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	6.34	4.76e-09	1.4e-05	0.68	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
GBM	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-6.33	4.81e-09	1.42e-05	-0.61	-0.51	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
GBM	cis	rs172166	0.694	rs203876	ENSG00000199851.2	U3	6.33	4.82e-09	1.42e-05	0.71	0.51	Cardiac Troponin-T levels;	chr6:28078895	chr6:28015568~28015777:+
GBM	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	6.33	4.83e-09	1.42e-05	0.71	0.51	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
GBM	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.33	4.83e-09	1.42e-05	0.71	0.51	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
GBM	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	6.33	4.91e-09	1.44e-05	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	6.33	4.91e-09	1.44e-05	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
GBM	cis	rs950027	0.787	rs1547487	ENSG00000259433.2	CTD-2651B20.4	-6.33	4.91e-09	1.45e-05	-0.5	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45330209~45332634:-
GBM	cis	rs11098499	0.73	rs12505735	ENSG00000249244.1	RP11-548H18.2	6.33	4.93e-09	1.45e-05	0.62	0.51	Corneal astigmatism;	chr4:119611801	chr4:119391831~119395335:-
GBM	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	6.33	4.95e-09	1.45e-05	0.49	0.51	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
GBM	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	6.33	4.97e-09	1.46e-05	0.73	0.51	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
GBM	cis	rs11098499	0.604	rs2389882	ENSG00000249244.1	RP11-548H18.2	6.33	4.99e-09	1.47e-05	0.62	0.51	Corneal astigmatism;	chr4:119645578	chr4:119391831~119395335:-
GBM	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-6.32	5.04e-09	1.48e-05	-0.67	-0.51	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-6.32	5.04e-09	1.48e-05	-0.67	-0.51	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
GBM	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	6.32	5.04e-09	1.48e-05	0.66	0.51	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-6.32	5.07e-09	1.49e-05	-0.68	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
GBM	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	6.32	5.08e-09	1.49e-05	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	6.32	5.12e-09	1.5e-05	0.61	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
GBM	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	6.32	5.12e-09	1.5e-05	0.57	0.51	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
GBM	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	6.32	5.14e-09	1.5e-05	0.63	0.51	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
GBM	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	6.32	5.15e-09	1.51e-05	0.61	0.51	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	6.32	5.15e-09	1.51e-05	0.61	0.51	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
GBM	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	6.32	5.17e-09	1.51e-05	0.5	0.51	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	6.32	5.17e-09	1.51e-05	0.5	0.51	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	6.32	5.17e-09	1.51e-05	0.5	0.51	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
GBM	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	6.32	5.24e-09	1.53e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	6.32	5.24e-09	1.53e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	6.32	5.24e-09	1.53e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	6.32	5.24e-09	1.53e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	6.32	5.24e-09	1.53e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	6.32	5.24e-09	1.53e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	6.32	5.24e-09	1.53e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
GBM	cis	rs7267979	0.565	rs4815432	ENSG00000276952.1	RP5-965G21.6	-6.32	5.24e-09	1.53e-05	-0.49	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:25284915~25285588:-
GBM	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	6.32	5.25e-09	1.53e-05	0.72	0.51	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
GBM	cis	rs11098499	0.604	rs2389887	ENSG00000249244.1	RP11-548H18.2	6.31	5.31e-09	1.55e-05	0.62	0.51	Corneal astigmatism;	chr4:119649489	chr4:119391831~119395335:-
GBM	cis	rs7267979	0.527	rs6083891	ENSG00000276952.1	RP5-965G21.6	-6.31	5.31e-09	1.55e-05	-0.49	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25284915~25285588:-
GBM	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-6.31	5.33e-09	1.55e-05	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
GBM	cis	rs7267979	0.565	rs6076364	ENSG00000276952.1	RP5-965G21.6	-6.31	5.33e-09	1.56e-05	-0.49	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.565	rs13040726	ENSG00000276952.1	RP5-965G21.6	-6.31	5.33e-09	1.56e-05	-0.49	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:25284915~25285588:-
GBM	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-6.31	5.37e-09	1.57e-05	-0.64	-0.51	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
GBM	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-6.31	5.38e-09	1.57e-05	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
GBM	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	6.31	5.42e-09	1.58e-05	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
GBM	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-6.31	5.47e-09	1.59e-05	-0.67	-0.51	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	6.31	5.47e-09	1.59e-05	0.67	0.51	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
GBM	cis	rs2486288	0.656	rs10519018	ENSG00000259433.2	CTD-2651B20.4	6.3	5.54e-09	1.61e-05	0.56	0.51	Glomerular filtration rate;	chr15:45257067	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000224205.1	AP000351.4	-6.3	5.54e-09	1.61e-05	-0.55	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23987320~23991421:-
GBM	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-6.3	5.55e-09	1.61e-05	-0.72	-0.51	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-6.3	5.55e-09	1.61e-05	-0.72	-0.51	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-6.3	5.55e-09	1.61e-05	-0.72	-0.51	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
GBM	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	6.3	5.56e-09	1.62e-05	0.62	0.51	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
GBM	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	6.3	5.58e-09	1.62e-05	0.9	0.51	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	6.3	5.58e-09	1.62e-05	0.9	0.51	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
GBM	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	6.3	5.58e-09	1.62e-05	0.92	0.51	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
GBM	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-6.3	5.63e-09	1.63e-05	-0.59	-0.51	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
GBM	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-6.3	5.65e-09	1.64e-05	-0.8	-0.51	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
GBM	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	6.3	5.65e-09	1.64e-05	0.6	0.51	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	6.3	5.71e-09	1.65e-05	0.63	0.51	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	6.3	5.71e-09	1.65e-05	0.63	0.51	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
GBM	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-6.3	5.71e-09	1.65e-05	-0.62	-0.51	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-6.3	5.71e-09	1.65e-05	-0.62	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
GBM	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	6.3	5.72e-09	1.65e-05	0.68	0.51	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	6.3	5.72e-09	1.65e-05	0.68	0.51	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	6.3	5.72e-09	1.65e-05	0.68	0.51	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
GBM	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	6.3	5.72e-09	1.65e-05	0.63	0.51	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
GBM	cis	rs6452524	0.901	rs12514607	ENSG00000249664.1	CTD-2227C6.2	-6.3	5.72e-09	1.65e-05	-0.61	-0.51	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:83012285~83013109:-
GBM	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-6.3	5.73e-09	1.66e-05	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
GBM	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-6.3	5.74e-09	1.66e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-6.3	5.74e-09	1.66e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-6.3	5.74e-09	1.66e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-6.3	5.74e-09	1.66e-05	-0.65	-0.51	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
GBM	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-6.3	5.75e-09	1.66e-05	-0.79	-0.51	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-6.3	5.75e-09	1.66e-05	-0.79	-0.51	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
GBM	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.3	5.76e-09	1.66e-05	-0.6	-0.51	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
GBM	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-6.3	5.76e-09	1.66e-05	-0.56	-0.51	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
GBM	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	6.3	5.77e-09	1.67e-05	0.68	0.51	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
GBM	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-6.3	5.78e-09	1.67e-05	-0.61	-0.51	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
GBM	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	6.29	5.81e-09	1.68e-05	0.6	0.51	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
GBM	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	6.29	5.84e-09	1.69e-05	0.54	0.51	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
GBM	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-6.29	5.85e-09	1.69e-05	-0.75	-0.51	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
GBM	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-6.29	5.93e-09	1.71e-05	-0.42	-0.51	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-6.29	6.02e-09	1.73e-05	-0.55	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
GBM	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	6.29	6.02e-09	1.73e-05	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	6.29	6.02e-09	1.73e-05	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	6.29	6.02e-09	1.73e-05	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	6.29	6.02e-09	1.73e-05	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
GBM	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	6.29	6.04e-09	1.74e-05	0.64	0.51	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
GBM	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	6.28	6.07e-09	1.74e-05	0.59	0.51	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
GBM	cis	rs950027	0.787	rs2433616	ENSG00000259433.2	CTD-2651B20.4	-6.28	6.11e-09	1.75e-05	-0.51	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45330209~45332634:-
GBM	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	6.28	6.13e-09	1.76e-05	0.56	0.51	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
GBM	cis	rs4273100	0.564	rs10445411	ENSG00000265185.4	SNORD3B-1	-6.28	6.17e-09	1.77e-05	-0.58	-0.51	Schizophrenia;	chr17:19362484	chr17:19061912~19062669:+
GBM	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	6.28	6.18e-09	1.77e-05	0.9	0.51	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
GBM	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	6.28	6.21e-09	1.78e-05	0.49	0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
GBM	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-6.27	6.43e-09	1.84e-05	-0.73	-0.5	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-6.27	6.43e-09	1.84e-05	-0.73	-0.5	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-6.27	6.43e-09	1.84e-05	-0.73	-0.5	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-6.27	6.43e-09	1.84e-05	-0.73	-0.5	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
GBM	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-6.27	6.43e-09	1.84e-05	-0.73	-0.5	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
GBM	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	6.27	6.43e-09	1.84e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	6.27	6.43e-09	1.84e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	6.27	6.43e-09	1.84e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	6.27	6.43e-09	1.84e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	6.27	6.43e-09	1.84e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
GBM	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-6.27	6.45e-09	1.84e-05	-0.91	-0.5	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
GBM	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-6.27	6.45e-09	1.84e-05	-0.91	-0.5	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
GBM	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-6.27	6.45e-09	1.84e-05	-0.91	-0.5	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
GBM	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-6.27	6.46e-09	1.85e-05	-0.5	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
GBM	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	6.27	6.47e-09	1.85e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
GBM	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	6.27	6.52e-09	1.86e-05	0.65	0.5	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
GBM	cis	rs2486288	0.656	rs11637364	ENSG00000259433.2	CTD-2651B20.4	6.27	6.61e-09	1.89e-05	0.55	0.5	Glomerular filtration rate;	chr15:45287040	chr15:45330209~45332634:-
GBM	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	6.27	6.66e-09	1.9e-05	0.67	0.5	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
GBM	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	6.27	6.67e-09	1.9e-05	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	6.27	6.67e-09	1.9e-05	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	6.27	6.67e-09	1.9e-05	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	6.27	6.67e-09	1.9e-05	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-6.27	6.67e-09	1.9e-05	-0.66	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
GBM	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	6.26	6.68e-09	1.9e-05	0.58	0.5	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
GBM	cis	rs4713118	0.513	rs149955	ENSG00000199851.2	U3	6.26	6.73e-09	1.92e-05	0.76	0.5	Parkinson's disease;	chr6:28068447	chr6:28015568~28015777:+
GBM	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	6.26	6.75e-09	1.92e-05	0.59	0.5	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
GBM	cis	rs7267979	0.816	rs6076358	ENSG00000125804.12	FAM182A	6.26	6.78e-09	1.93e-05	0.61	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.789	rs4815429	ENSG00000125804.12	FAM182A	6.26	6.78e-09	1.93e-05	0.61	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.789	rs1983974	ENSG00000125804.12	FAM182A	6.26	6.78e-09	1.93e-05	0.61	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.816	rs405822	ENSG00000125804.12	FAM182A	-6.26	6.78e-09	1.93e-05	-0.61	-0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.816	rs6138593	ENSG00000125804.12	FAM182A	-6.26	6.78e-09	1.93e-05	-0.61	-0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.816	rs409853	ENSG00000125804.12	FAM182A	-6.26	6.78e-09	1.93e-05	-0.61	-0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26054655~26086917:+
GBM	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	6.26	6.83e-09	1.94e-05	0.77	0.5	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
GBM	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	6.26	6.84e-09	1.94e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	6.26	6.84e-09	1.94e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
GBM	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	6.26	6.86e-09	1.94e-05	0.63	0.5	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
GBM	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-6.26	6.87e-09	1.95e-05	-0.65	-0.5	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
GBM	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-6.26	6.89e-09	1.95e-05	-0.65	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
GBM	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	6.26	6.92e-09	1.96e-05	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
GBM	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-6.26	6.94e-09	1.97e-05	-0.62	-0.5	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
GBM	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-6.26	6.95e-09	1.97e-05	-0.49	-0.5	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-6.26	6.95e-09	1.97e-05	-0.49	-0.5	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000224205.1	AP000351.4	-6.26	6.98e-09	1.98e-05	-0.55	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23987320~23991421:-
GBM	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	6.25	7.03e-09	1.99e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	6.25	7.03e-09	1.99e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
GBM	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-6.25	7.06e-09	2e-05	-0.74	-0.5	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
GBM	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-6.25	7.07e-09	2e-05	-0.69	-0.5	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
GBM	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-6.25	7.07e-09	2e-05	-0.69	-0.5	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
GBM	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-6.25	7.07e-09	2e-05	-0.69	-0.5	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
GBM	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	6.25	7.15e-09	2.02e-05	0.64	0.5	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
GBM	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-6.25	7.17e-09	2.03e-05	-0.71	-0.5	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
GBM	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-6.25	7.19e-09	2.03e-05	-0.65	-0.5	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
GBM	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	6.25	7.19e-09	2.03e-05	0.94	0.5	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
GBM	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	6.25	7.2e-09	2.03e-05	0.91	0.5	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	6.25	7.2e-09	2.03e-05	0.91	0.5	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	6.25	7.2e-09	2.03e-05	0.91	0.5	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
GBM	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	6.25	7.2e-09	2.03e-05	0.91	0.5	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
GBM	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	6.25	7.21e-09	2.03e-05	0.71	0.5	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
GBM	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-6.25	7.24e-09	2.04e-05	-0.53	-0.5	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
GBM	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	6.25	7.25e-09	2.05e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	6.25	7.25e-09	2.05e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
GBM	cis	rs453301	0.522	rs1964356	ENSG00000253893.2	FAM85B	-6.25	7.26e-09	2.05e-05	-0.65	-0.5	Joint mobility (Beighton score);	chr8:8995760	chr8:8167819~8226614:-
GBM	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-6.25	7.32e-09	2.06e-05	-0.62	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-6.25	7.35e-09	2.07e-05	-0.55	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
GBM	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	6.24	7.37e-09	2.07e-05	0.6	0.5	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
GBM	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	6.24	7.38e-09	2.08e-05	0.75	0.5	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
GBM	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-6.24	7.39e-09	2.08e-05	-0.69	-0.5	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
GBM	cis	rs7267979	0.565	rs3752273	ENSG00000276952.1	RP5-965G21.6	-6.24	7.42e-09	2.09e-05	-0.48	-0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:25284915~25285588:-
GBM	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-6.24	7.43e-09	2.09e-05	-0.57	-0.5	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
GBM	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-6.24	7.44e-09	2.09e-05	-0.56	-0.5	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
GBM	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-6.24	7.44e-09	2.09e-05	-0.55	-0.5	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
GBM	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	6.24	7.44e-09	2.09e-05	0.59	0.5	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
GBM	cis	rs881375	0.967	rs3761849	ENSG00000226752.6	PSMD5-AS1	-6.24	7.46e-09	2.1e-05	-0.66	-0.5	Rheumatoid arthritis;	chr9:120928679	chr9:120824828~120854385:+
GBM	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	6.24	7.46e-09	2.1e-05	0.6	0.5	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
GBM	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-6.24	7.48e-09	2.1e-05	-0.89	-0.5	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
GBM	cis	rs2980439	0.517	rs793753	ENSG00000253893.2	FAM85B	6.24	7.48e-09	2.1e-05	0.63	0.5	Neuroticism;	chr8:8247837	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.863	rs3822192	ENSG00000250412.1	KLHL2P1	6.24	7.53e-09	2.11e-05	0.65	0.5	Corneal astigmatism;	chr4:119524565	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs10019674	ENSG00000250412.1	KLHL2P1	-6.24	7.53e-09	2.11e-05	-0.65	-0.5	Corneal astigmatism;	chr4:119522334	chr4:119334329~119378233:+
GBM	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-6.24	7.55e-09	2.12e-05	-0.62	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
GBM	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-6.24	7.57e-09	2.12e-05	-0.58	-0.5	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
GBM	cis	rs4713118	0.662	rs149970	ENSG00000199851.2	U3	6.24	7.58e-09	2.13e-05	0.78	0.5	Parkinson's disease;	chr6:28012442	chr6:28015568~28015777:+
GBM	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-6.24	7.59e-09	2.13e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
GBM	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-6.24	7.59e-09	2.13e-05	-0.65	-0.5	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
GBM	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	6.24	7.61e-09	2.13e-05	0.59	0.5	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	6.24	7.61e-09	2.13e-05	0.59	0.5	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
GBM	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	6.23	7.71e-09	2.16e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
GBM	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-6.23	7.73e-09	2.17e-05	-0.55	-0.5	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
GBM	cis	rs2486288	0.656	rs8039352	ENSG00000259433.2	CTD-2651B20.4	6.23	7.75e-09	2.17e-05	0.56	0.5	Glomerular filtration rate;	chr15:45259592	chr15:45330209~45332634:-
GBM	cis	rs4814920	0.818	rs6046387	ENSG00000275142.1	RP5-999L4.2	-6.23	7.76e-09	2.17e-05	-0.86	-0.5	Bipolar disorder (body mass index interaction);	chr20:19869186	chr20:19871891~19872284:+
GBM	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	6.23	7.81e-09	2.19e-05	0.57	0.5	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
GBM	cis	rs1964356	0.967	rs2953802	ENSG00000254340.1	RP11-10A14.3	6.23	7.84e-09	2.2e-05	0.69	0.5	Mean corpuscular volume;	chr8:8994371	chr8:9141424~9145435:+
GBM	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	6.23	7.84e-09	2.2e-05	0.56	0.5	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
GBM	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	6.23	7.89e-09	2.21e-05	0.89	0.5	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
GBM	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-6.23	7.89e-09	2.21e-05	-0.64	-0.5	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-6.23	7.89e-09	2.21e-05	-0.64	-0.5	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
GBM	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-6.23	7.89e-09	2.21e-05	-0.64	-0.5	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
GBM	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-6.23	7.89e-09	2.21e-05	-0.64	-0.5	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
GBM	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-6.23	7.9e-09	2.21e-05	-0.64	-0.5	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
GBM	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-6.23	7.92e-09	2.21e-05	-0.62	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	6.23	7.93e-09	2.22e-05	0.56	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
GBM	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-6.23	7.98e-09	2.23e-05	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
GBM	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-6.23	7.99e-09	2.23e-05	-0.69	-0.5	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
GBM	cis	rs2486288	0.656	rs1719232	ENSG00000259433.2	CTD-2651B20.4	6.23	8.03e-09	2.24e-05	0.56	0.5	Glomerular filtration rate;	chr15:45279874	chr15:45330209~45332634:-
GBM	cis	rs11098499	0.604	rs2389886	ENSG00000249244.1	RP11-548H18.2	6.22	8.1e-09	2.26e-05	0.61	0.5	Corneal astigmatism;	chr4:119649267	chr4:119391831~119395335:-
GBM	cis	rs4713118	0.699	rs200969	ENSG00000199851.2	U3	6.22	8.17e-09	2.28e-05	0.81	0.5	Parkinson's disease;	chr6:27891675	chr6:28015568~28015777:+
GBM	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	6.22	8.21e-09	2.29e-05	0.6	0.5	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
GBM	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-6.22	8.21e-09	2.29e-05	-0.49	-0.5	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
GBM	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	6.22	8.23e-09	2.29e-05	0.68	0.5	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
GBM	cis	rs8135665	0.625	rs34385006	ENSG00000233739.1	RP5-1039K5.13	6.22	8.24e-09	2.29e-05	0.61	0.5	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38054284	chr22:38057180~38073940:-
GBM	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	6.22	8.25e-09	2.3e-05	0.69	0.5	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
GBM	cis	rs7267979	0.789	rs6083841	ENSG00000125804.12	FAM182A	6.22	8.27e-09	2.3e-05	0.65	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26054655~26086917:+
GBM	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-6.22	8.3e-09	2.31e-05	-0.55	-0.5	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
GBM	cis	rs2486288	0.656	rs1706770	ENSG00000259433.2	CTD-2651B20.4	6.22	8.3e-09	2.31e-05	0.56	0.5	Glomerular filtration rate;	chr15:45282864	chr15:45330209~45332634:-
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	6.22	8.43e-09	2.34e-05	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
GBM	cis	rs7267979	0.789	rs6083820	ENSG00000125804.12	FAM182A	6.22	8.45e-09	2.35e-05	0.65	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.789	rs62213729	ENSG00000125804.12	FAM182A	6.22	8.45e-09	2.35e-05	0.65	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26054655~26086917:+
GBM	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-6.21	8.48e-09	2.35e-05	-0.84	-0.5	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
GBM	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-6.21	8.48e-09	2.35e-05	-0.84	-0.5	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
GBM	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-6.21	8.48e-09	2.35e-05	-0.84	-0.5	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
GBM	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-6.21	8.48e-09	2.35e-05	-0.84	-0.5	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
GBM	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	6.21	8.52e-09	2.36e-05	0.6	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
GBM	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-6.21	8.54e-09	2.37e-05	-0.92	-0.5	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
GBM	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-6.21	8.61e-09	2.38e-05	-0.61	-0.5	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-6.21	8.61e-09	2.38e-05	-0.61	-0.5	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-6.21	8.61e-09	2.38e-05	-0.61	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
GBM	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	6.21	8.62e-09	2.38e-05	0.93	0.5	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
GBM	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	6.21	8.64e-09	2.39e-05	1.11	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
GBM	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	6.21	8.64e-09	2.39e-05	1.11	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
GBM	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	6.21	8.64e-09	2.39e-05	1.11	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
GBM	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	6.21	8.64e-09	2.39e-05	1.11	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
GBM	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	6.21	8.64e-09	2.39e-05	1.11	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
GBM	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-6.21	8.65e-09	2.39e-05	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-6.21	8.65e-09	2.39e-05	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
GBM	cis	rs11098499	0.604	rs17051352	ENSG00000249244.1	RP11-548H18.2	6.21	8.73e-09	2.41e-05	0.63	0.5	Corneal astigmatism;	chr4:119660272	chr4:119391831~119395335:-
GBM	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-6.21	8.8e-09	2.43e-05	-0.47	-0.5	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
GBM	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	6.21	8.8e-09	2.43e-05	0.61	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
GBM	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	6.2	8.91e-09	2.45e-05	0.77	0.5	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
GBM	cis	rs7267979	0.789	rs6083810	ENSG00000125804.12	FAM182A	6.2	8.97e-09	2.47e-05	0.64	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26054655~26086917:+
GBM	cis	rs6782228	0.675	rs6806687	ENSG00000277250.1	Metazoa_SRP	6.2	9.07e-09	2.5e-05	0.55	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128673681~128674021:-
GBM	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-6.2	9.13e-09	2.51e-05	-0.57	-0.5	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
GBM	cis	rs4713118	0.699	rs200978	ENSG00000199851.2	U3	6.2	9.14e-09	2.51e-05	0.81	0.5	Parkinson's disease;	chr6:27885390	chr6:28015568~28015777:+
GBM	cis	rs453301	0.624	rs2979265	ENSG00000254340.1	RP11-10A14.3	6.2	9.17e-09	2.52e-05	0.64	0.5	Joint mobility (Beighton score);	chr8:9001207	chr8:9141424~9145435:+
GBM	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	6.2	9.26e-09	2.54e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
GBM	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-6.19	9.33e-09	2.56e-05	-0.5	-0.5	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
GBM	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	6.19	9.33e-09	2.56e-05	1.11	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
GBM	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-6.19	9.38e-09	2.57e-05	-0.57	-0.5	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
GBM	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-6.19	9.38e-09	2.57e-05	-0.57	-0.5	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
GBM	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-6.19	9.46e-09	2.59e-05	-0.7	-0.5	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
GBM	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-6.19	9.46e-09	2.59e-05	-0.58	-0.5	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
GBM	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	6.19	9.5e-09	2.61e-05	0.89	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	6.19	9.5e-09	2.61e-05	0.89	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
GBM	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	6.19	9.53e-09	2.61e-05	0.63	0.5	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
GBM	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	6.19	9.53e-09	2.61e-05	0.59	0.5	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	6.19	9.53e-09	2.61e-05	0.59	0.5	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	6.19	9.53e-09	2.61e-05	0.59	0.5	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	6.19	9.53e-09	2.61e-05	0.59	0.5	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
GBM	cis	rs2486288	0.554	rs1719235	ENSG00000259433.2	CTD-2651B20.4	6.19	9.54e-09	2.61e-05	0.56	0.5	Glomerular filtration rate;	chr15:45283910	chr15:45330209~45332634:-
GBM	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-6.19	9.57e-09	2.62e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
GBM	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-6.19	9.68e-09	2.65e-05	-0.62	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-6.19	9.68e-09	2.65e-05	-0.62	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
GBM	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-6.19	9.69e-09	2.65e-05	-0.61	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-6.19	9.69e-09	2.65e-05	-0.61	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-6.19	9.69e-09	2.65e-05	-0.61	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-6.19	9.69e-09	2.65e-05	-0.61	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-6.19	9.69e-09	2.65e-05	-0.61	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
GBM	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-6.19	9.7e-09	2.65e-05	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
GBM	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-6.19	9.7e-09	2.65e-05	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
GBM	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.19	9.78e-09	2.67e-05	-0.48	-0.5	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
GBM	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-6.18	9.85e-09	2.69e-05	-0.69	-0.5	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
GBM	cis	rs172166	0.694	rs203877	ENSG00000199851.2	U3	6.18	9.91e-09	2.7e-05	0.7	0.5	Cardiac Troponin-T levels;	chr6:28080846	chr6:28015568~28015777:+
GBM	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-6.18	1e-08	2.73e-05	-0.61	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-6.18	1e-08	2.73e-05	-0.61	-0.5	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-6.18	1e-08	2.73e-05	-0.61	-0.5	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
GBM	cis	rs453301	0.598	rs10104303	ENSG00000254340.1	RP11-10A14.3	6.18	1e-08	2.74e-05	0.62	0.5	Joint mobility (Beighton score);	chr8:8977018	chr8:9141424~9145435:+
GBM	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	6.18	1.01e-08	2.75e-05	0.59	0.5	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
GBM	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-6.18	1.01e-08	2.75e-05	-0.56	-0.5	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
GBM	cis	rs4713118	0.513	rs149972	ENSG00000199851.2	U3	6.18	1.01e-08	2.76e-05	0.75	0.5	Parkinson's disease;	chr6:28015449	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149975	ENSG00000199851.2	U3	6.18	1.01e-08	2.76e-05	0.75	0.5	Parkinson's disease;	chr6:28018562	chr6:28015568~28015777:+
GBM	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	6.18	1.01e-08	2.76e-05	0.66	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
GBM	cis	rs453301	0.624	rs7014430	ENSG00000253893.2	FAM85B	-6.18	1.02e-08	2.77e-05	-0.6	-0.5	Joint mobility (Beighton score);	chr8:8970227	chr8:8167819~8226614:-
GBM	cis	rs7267979	0.816	rs443009	ENSG00000125804.12	FAM182A	6.18	1.02e-08	2.77e-05	0.6	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26054655~26086917:+
GBM	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	6.18	1.02e-08	2.77e-05	0.58	0.5	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
GBM	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-6.18	1.02e-08	2.78e-05	-0.6	-0.5	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
GBM	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-6.18	1.02e-08	2.78e-05	-0.76	-0.5	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-6.18	1.02e-08	2.78e-05	-0.76	-0.5	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
GBM	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-6.18	1.02e-08	2.78e-05	-0.56	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	6.18	1.02e-08	2.78e-05	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
GBM	cis	rs11098499	0.618	rs35265692	ENSG00000250412.1	KLHL2P1	6.18	1.03e-08	2.79e-05	0.66	0.5	Corneal astigmatism;	chr4:119403980	chr4:119334329~119378233:+
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000224205.1	AP000351.4	6.17	1.03e-08	2.79e-05	0.54	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000224205.1	AP000351.4	6.17	1.03e-08	2.79e-05	0.54	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000224205.1	AP000351.4	6.17	1.03e-08	2.79e-05	0.54	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000224205.1	AP000351.4	6.17	1.03e-08	2.79e-05	0.54	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23987320~23991421:-
GBM	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-6.17	1.03e-08	2.79e-05	-0.72	-0.5	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
GBM	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-6.17	1.03e-08	2.8e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-6.17	1.03e-08	2.8e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-6.17	1.03e-08	2.8e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-6.17	1.03e-08	2.8e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
GBM	cis	rs172166	0.694	rs188105	ENSG00000199851.2	U3	6.17	1.04e-08	2.82e-05	0.74	0.5	Cardiac Troponin-T levels;	chr6:28103615	chr6:28015568~28015777:+
GBM	cis	rs11098499	0.78	rs12504773	ENSG00000250412.1	KLHL2P1	6.17	1.04e-08	2.82e-05	0.63	0.5	Corneal astigmatism;	chr4:119640994	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.78	rs7680914	ENSG00000250412.1	KLHL2P1	6.17	1.04e-08	2.82e-05	0.63	0.5	Corneal astigmatism;	chr4:119641898	chr4:119334329~119378233:+
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	6.17	1.05e-08	2.84e-05	0.56	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
GBM	cis	rs11098499	0.908	rs9995234	ENSG00000250412.1	KLHL2P1	6.17	1.05e-08	2.84e-05	0.65	0.5	Corneal astigmatism;	chr4:119400672	chr4:119334329~119378233:+
GBM	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-6.17	1.05e-08	2.84e-05	-0.62	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
GBM	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.85e-05	0.64	0.5	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.85e-05	0.64	0.5	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.85e-05	0.64	0.5	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.85e-05	0.64	0.5	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.85e-05	0.64	0.5	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.85e-05	0.64	0.5	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.86e-05	0.62	0.5	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	6.17	1.05e-08	2.86e-05	0.62	0.5	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
GBM	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-6.17	1.06e-08	2.86e-05	-0.72	-0.5	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-6.17	1.06e-08	2.86e-05	-0.72	-0.5	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-6.17	1.06e-08	2.86e-05	-0.72	-0.5	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
GBM	cis	rs453301	0.522	rs1964356	ENSG00000254340.1	RP11-10A14.3	6.17	1.06e-08	2.88e-05	0.69	0.5	Joint mobility (Beighton score);	chr8:8995760	chr8:9141424~9145435:+
GBM	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	6.17	1.07e-08	2.89e-05	0.61	0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
GBM	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-6.17	1.07e-08	2.89e-05	-0.76	-0.5	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-6.17	1.07e-08	2.89e-05	-0.76	-0.5	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
GBM	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-6.17	1.07e-08	2.89e-05	-0.76	-0.5	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-6.17	1.07e-08	2.89e-05	-0.76	-0.5	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-6.17	1.07e-08	2.89e-05	-0.76	-0.5	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
GBM	cis	rs4273100	0.688	rs4924980	ENSG00000265185.4	SNORD3B-1	-6.17	1.07e-08	2.89e-05	-0.59	-0.5	Schizophrenia;	chr17:19301550	chr17:19061912~19062669:+
GBM	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	6.17	1.07e-08	2.89e-05	0.65	0.5	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.82	rs28578366	ENSG00000250412.1	KLHL2P1	-6.17	1.07e-08	2.89e-05	-0.61	-0.5	Corneal astigmatism;	chr4:119615750	chr4:119334329~119378233:+
GBM	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	6.16	1.08e-08	2.91e-05	0.61	0.5	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
GBM	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-6.16	1.08e-08	2.92e-05	-0.59	-0.5	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
GBM	cis	rs11098499	0.954	rs3733524	ENSG00000250412.1	KLHL2P1	6.16	1.09e-08	2.94e-05	0.66	0.5	Corneal astigmatism;	chr4:119502574	chr4:119334329~119378233:+
GBM	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-6.16	1.09e-08	2.94e-05	-0.76	-0.5	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-6.16	1.09e-08	2.94e-05	-0.76	-0.5	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
GBM	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-6.16	1.1e-08	2.95e-05	-0.7	-0.5	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
GBM	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-6.16	1.1e-08	2.96e-05	-0.76	-0.5	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
GBM	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	6.16	1.11e-08	2.99e-05	0.56	0.5	Height;	chr11:118809363	chr11:118688039~118690600:-
GBM	cis	rs4273100	0.688	rs4924967	ENSG00000265185.4	SNORD3B-1	6.16	1.12e-08	3.01e-05	0.59	0.5	Schizophrenia;	chr17:19268883	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.688	rs28760541	ENSG00000265185.4	SNORD3B-1	6.16	1.12e-08	3.01e-05	0.59	0.5	Schizophrenia;	chr17:19269192	chr17:19061912~19062669:+
GBM	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	6.16	1.12e-08	3.02e-05	0.63	0.5	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
GBM	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-6.16	1.13e-08	3.03e-05	-0.62	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
GBM	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-6.15	1.14e-08	3.06e-05	-0.64	-0.5	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000224205.1	AP000351.4	-6.15	1.14e-08	3.06e-05	-0.53	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23987320~23991421:-
GBM	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-6.15	1.14e-08	3.06e-05	-0.56	-0.5	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-6.15	1.14e-08	3.06e-05	-0.56	-0.5	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-6.15	1.14e-08	3.06e-05	-0.56	-0.5	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-6.15	1.14e-08	3.06e-05	-0.56	-0.5	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-6.15	1.14e-08	3.06e-05	-0.56	-0.5	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-6.15	1.14e-08	3.06e-05	-0.56	-0.5	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-6.15	1.14e-08	3.06e-05	-0.56	-0.5	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
GBM	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	6.15	1.14e-08	3.07e-05	0.61	0.5	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
GBM	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	6.15	1.14e-08	3.07e-05	0.64	0.5	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
GBM	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-6.15	1.15e-08	3.07e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-6.15	1.15e-08	3.07e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
GBM	cis	rs6452524	0.804	rs1478481	ENSG00000248112.1	RP11-78C3.1	6.15	1.15e-08	3.08e-05	0.61	0.5	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:82919376~82921119:-
GBM	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	6.15	1.15e-08	3.08e-05	1.24	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
GBM	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	6.15	1.15e-08	3.08e-05	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
GBM	cis	rs11098499	0.73	rs12505735	ENSG00000250412.1	KLHL2P1	6.15	1.15e-08	3.09e-05	0.61	0.5	Corneal astigmatism;	chr4:119611801	chr4:119334329~119378233:+
GBM	cis	rs4713118	0.513	rs149954	ENSG00000199851.2	U3	6.15	1.16e-08	3.11e-05	0.75	0.5	Parkinson's disease;	chr6:28067468	chr6:28015568~28015777:+
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000224205.1	AP000351.4	6.15	1.16e-08	3.11e-05	0.56	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23987320~23991421:-
GBM	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-6.15	1.16e-08	3.11e-05	-0.72	-0.5	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
GBM	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	6.15	1.16e-08	3.11e-05	0.47	0.5	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
GBM	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	6.15	1.17e-08	3.13e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	6.15	1.17e-08	3.13e-05	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
GBM	cis	rs2486288	0.656	rs8041702	ENSG00000259433.2	CTD-2651B20.4	6.15	1.17e-08	3.13e-05	0.57	0.5	Glomerular filtration rate;	chr15:45254895	chr15:45330209~45332634:-
GBM	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-6.15	1.18e-08	3.15e-05	-0.55	-0.5	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
GBM	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-6.14	1.18e-08	3.16e-05	-0.55	-0.5	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
GBM	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-6.14	1.18e-08	3.16e-05	-0.53	-0.5	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
GBM	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	6.14	1.19e-08	3.18e-05	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
GBM	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-6.14	1.2e-08	3.19e-05	-0.61	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
GBM	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-6.14	1.2e-08	3.2e-05	-0.6	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
GBM	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	6.14	1.2e-08	3.21e-05	0.63	0.5	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	6.14	1.2e-08	3.21e-05	0.63	0.5	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	6.14	1.2e-08	3.21e-05	0.63	0.5	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	6.14	1.2e-08	3.21e-05	0.63	0.5	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	6.14	1.2e-08	3.21e-05	0.63	0.5	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	6.14	1.2e-08	3.21e-05	0.63	0.5	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
GBM	cis	rs7267979	0.727	rs4815431	ENSG00000125804.12	FAM182A	6.14	1.2e-08	3.21e-05	0.61	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26054655~26086917:+
GBM	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-6.14	1.21e-08	3.22e-05	-1.11	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
GBM	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-6.14	1.22e-08	3.24e-05	-0.58	-0.5	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
GBM	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	6.14	1.22e-08	3.26e-05	0.72	0.5	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
GBM	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	6.14	1.23e-08	3.28e-05	0.53	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
GBM	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-6.14	1.24e-08	3.29e-05	-0.67	-0.5	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
GBM	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	6.14	1.24e-08	3.29e-05	0.64	0.5	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	6.14	1.24e-08	3.29e-05	0.64	0.5	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	6.14	1.24e-08	3.29e-05	0.64	0.5	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
GBM	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	6.13	1.24e-08	3.3e-05	0.66	0.5	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
GBM	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	6.13	1.24e-08	3.3e-05	0.63	0.5	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
GBM	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	6.13	1.24e-08	3.3e-05	0.79	0.5	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
GBM	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-6.13	1.25e-08	3.31e-05	-0.73	-0.5	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
GBM	cis	rs1964356	0.967	rs2953802	ENSG00000253893.2	FAM85B	-6.13	1.25e-08	3.31e-05	-0.64	-0.5	Mean corpuscular volume;	chr8:8994371	chr8:8167819~8226614:-
GBM	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	6.13	1.25e-08	3.31e-05	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
GBM	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-6.13	1.25e-08	3.32e-05	-0.92	-0.5	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
GBM	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	6.13	1.25e-08	3.32e-05	0.77	0.5	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
GBM	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	6.13	1.25e-08	3.33e-05	0.6	0.5	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
GBM	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-6.13	1.26e-08	3.34e-05	-0.49	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
GBM	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-6.13	1.26e-08	3.34e-05	-0.67	-0.5	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
GBM	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-6.13	1.26e-08	3.34e-05	-0.67	-0.5	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
GBM	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-6.13	1.26e-08	3.34e-05	-0.67	-0.5	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
GBM	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-6.13	1.26e-08	3.34e-05	-0.67	-0.5	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
GBM	cis	rs11098499	0.604	rs17051352	ENSG00000250412.1	KLHL2P1	6.13	1.26e-08	3.35e-05	0.63	0.5	Corneal astigmatism;	chr4:119660272	chr4:119334329~119378233:+
GBM	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	6.13	1.26e-08	3.35e-05	0.67	0.5	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
GBM	cis	rs7301826	0.627	rs10744480	ENSG00000256250.1	RP11-989F5.1	-6.13	1.27e-08	3.37e-05	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130792602	chr12:130810606~130812438:+
GBM	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-6.13	1.27e-08	3.38e-05	-0.56	-0.5	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
GBM	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-6.13	1.28e-08	3.39e-05	-0.71	-0.5	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
GBM	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-6.13	1.28e-08	3.39e-05	-0.75	-0.5	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
GBM	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-6.13	1.28e-08	3.39e-05	-0.56	-0.5	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
GBM	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-6.13	1.28e-08	3.4e-05	-0.63	-0.5	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
GBM	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-6.13	1.29e-08	3.41e-05	-0.54	-0.5	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
GBM	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	6.13	1.29e-08	3.41e-05	0.6	0.5	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
GBM	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	6.13	1.29e-08	3.41e-05	0.59	0.5	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
GBM	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-6.13	1.29e-08	3.42e-05	-0.62	-0.5	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
GBM	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	6.13	1.29e-08	3.42e-05	0.62	0.5	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	6.13	1.29e-08	3.42e-05	0.62	0.5	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
GBM	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	6.13	1.29e-08	3.43e-05	0.67	0.5	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
GBM	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	6.13	1.3e-08	3.43e-05	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	6.13	1.3e-08	3.43e-05	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	6.13	1.3e-08	3.43e-05	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	6.13	1.3e-08	3.43e-05	0.56	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000099984.9	GSTT2	6.12	1.3e-08	3.45e-05	0.73	0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23980123~23983911:+
GBM	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	6.12	1.31e-08	3.47e-05	0.67	0.5	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
GBM	cis	rs11098499	0.82	rs28394116	ENSG00000250412.1	KLHL2P1	6.12	1.32e-08	3.48e-05	0.62	0.5	Corneal astigmatism;	chr4:119603128	chr4:119334329~119378233:+
GBM	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	6.12	1.32e-08	3.48e-05	0.67	0.5	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
GBM	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-6.12	1.32e-08	3.48e-05	-0.61	-0.5	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
GBM	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	6.12	1.33e-08	3.51e-05	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	6.12	1.33e-08	3.51e-05	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	6.12	1.33e-08	3.51e-05	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
GBM	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	6.12	1.33e-08	3.51e-05	0.62	0.5	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
GBM	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-6.12	1.33e-08	3.51e-05	-0.81	-0.5	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
GBM	cis	rs11098499	0.644	rs10050092	ENSG00000249244.1	RP11-548H18.2	6.12	1.34e-08	3.54e-05	0.6	0.5	Corneal astigmatism;	chr4:119610930	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs7693919	ENSG00000249244.1	RP11-548H18.2	6.12	1.34e-08	3.54e-05	0.6	0.5	Corneal astigmatism;	chr4:119619416	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.57	rs6832740	ENSG00000249244.1	RP11-548H18.2	6.12	1.34e-08	3.54e-05	0.6	0.5	Corneal astigmatism;	chr4:119624981	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs6855918	ENSG00000249244.1	RP11-548H18.2	6.12	1.34e-08	3.54e-05	0.6	0.5	Corneal astigmatism;	chr4:119625144	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs28787668	ENSG00000249244.1	RP11-548H18.2	6.12	1.34e-08	3.54e-05	0.6	0.5	Corneal astigmatism;	chr4:119633532	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs7676296	ENSG00000249244.1	RP11-548H18.2	6.12	1.34e-08	3.54e-05	0.6	0.5	Corneal astigmatism;	chr4:119634532	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	6.12	1.34e-08	3.54e-05	0.63	0.5	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
GBM	cis	rs6452524	0.806	rs10078084	ENSG00000248112.1	RP11-78C3.1	6.12	1.34e-08	3.55e-05	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs11750836	ENSG00000248112.1	RP11-78C3.1	6.12	1.34e-08	3.55e-05	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:82919376~82921119:-
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	6.12	1.35e-08	3.56e-05	0.61	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
GBM	cis	rs11098499	0.954	rs6849561	ENSG00000250412.1	KLHL2P1	-6.12	1.35e-08	3.56e-05	-0.65	-0.5	Corneal astigmatism;	chr4:119488539	chr4:119334329~119378233:+
GBM	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	6.12	1.35e-08	3.56e-05	0.58	0.5	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.909	rs10017335	ENSG00000250412.1	KLHL2P1	-6.12	1.35e-08	3.57e-05	-0.65	-0.5	Corneal astigmatism;	chr4:119460368	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs6858592	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119537537	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	6.12	1.35e-08	3.57e-05	0.61	0.5	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
GBM	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-6.12	1.36e-08	3.57e-05	-0.8	-0.5	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
GBM	cis	rs7615952	0.605	rs34865555	ENSG00000171084.14	FAM86JP	6.11	1.37e-08	3.6e-05	0.98	0.5	Blood pressure (smoking interaction);	chr3:125585290	chr3:125916620~125930024:+
GBM	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	6.11	1.37e-08	3.6e-05	0.65	0.5	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
GBM	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	6.11	1.37e-08	3.6e-05	0.64	0.5	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
GBM	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	6.11	1.37e-08	3.61e-05	0.63	0.5	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
GBM	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	6.11	1.38e-08	3.61e-05	0.6	0.5	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	6.11	1.38e-08	3.61e-05	0.6	0.5	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	6.11	1.38e-08	3.61e-05	0.6	0.5	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000224205.1	AP000351.4	6.11	1.38e-08	3.63e-05	0.54	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23987320~23991421:-
GBM	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-6.11	1.38e-08	3.63e-05	-0.61	-0.5	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
GBM	cis	rs6993244	1	rs6993244	ENSG00000254340.1	RP11-10A14.3	6.11	1.39e-08	3.64e-05	0.62	0.5	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9141424~9145435:+
GBM	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-6.11	1.4e-08	3.67e-05	-0.6	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
GBM	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	6.11	1.4e-08	3.68e-05	0.41	0.5	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
GBM	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	6.11	1.41e-08	3.69e-05	0.66	0.49	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
GBM	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	6.11	1.42e-08	3.71e-05	0.65	0.49	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
GBM	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-6.11	1.42e-08	3.73e-05	-0.61	-0.49	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
GBM	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-6.11	1.42e-08	3.73e-05	-0.61	-0.49	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
GBM	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	6.11	1.42e-08	3.73e-05	0.55	0.49	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
GBM	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-6.11	1.43e-08	3.73e-05	-0.74	-0.49	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
GBM	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-6.1	1.43e-08	3.73e-05	-0.56	-0.49	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
GBM	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	6.1	1.43e-08	3.74e-05	0.7	0.49	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
GBM	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	6.1	1.43e-08	3.74e-05	0.56	0.49	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
GBM	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-6.1	1.44e-08	3.77e-05	-0.75	-0.49	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
GBM	cis	rs172166	0.611	rs203883	ENSG00000199851.2	U3	6.1	1.45e-08	3.77e-05	0.72	0.49	Cardiac Troponin-T levels;	chr6:28110578	chr6:28015568~28015777:+
GBM	cis	rs11098499	0.82	rs13128602	ENSG00000250412.1	KLHL2P1	-6.1	1.46e-08	3.8e-05	-0.61	-0.49	Corneal astigmatism;	chr4:119538211	chr4:119334329~119378233:+
GBM	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	6.1	1.46e-08	3.81e-05	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	6.1	1.46e-08	3.81e-05	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	6.1	1.46e-08	3.81e-05	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
GBM	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-6.1	1.47e-08	3.84e-05	-0.64	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
GBM	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-6.1	1.48e-08	3.84e-05	-0.63	-0.49	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
GBM	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-6.1	1.48e-08	3.86e-05	-0.46	-0.49	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
GBM	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	6.1	1.49e-08	3.88e-05	0.76	0.49	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
GBM	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-6.1	1.49e-08	3.89e-05	-0.53	-0.49	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
GBM	cis	rs1930961	1	rs6004657	ENSG00000100058.11	CRYBB2P1	6.1	1.5e-08	3.9e-05	1.1	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25448105~25520854:+
GBM	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-6.1	1.5e-08	3.9e-05	-0.57	-0.49	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
GBM	cis	rs11098499	0.863	rs13136462	ENSG00000250412.1	KLHL2P1	6.09	1.5e-08	3.9e-05	0.62	0.49	Corneal astigmatism;	chr4:119622018	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.82	rs13122709	ENSG00000250412.1	KLHL2P1	6.09	1.5e-08	3.9e-05	0.62	0.49	Corneal astigmatism;	chr4:119634201	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.82	rs28535956	ENSG00000250412.1	KLHL2P1	-6.09	1.5e-08	3.9e-05	-0.62	-0.49	Corneal astigmatism;	chr4:119615703	chr4:119334329~119378233:+
GBM	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-6.09	1.51e-08	3.93e-05	-0.57	-0.49	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
GBM	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	6.09	1.51e-08	3.94e-05	0.6	0.49	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
GBM	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-6.09	1.52e-08	3.96e-05	-0.57	-0.49	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
GBM	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	6.09	1.53e-08	3.97e-05	0.56	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	6.09	1.53e-08	3.97e-05	0.56	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	6.09	1.53e-08	3.97e-05	0.56	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	6.09	1.53e-08	3.97e-05	0.56	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	6.09	1.53e-08	3.97e-05	0.56	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
GBM	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-6.09	1.54e-08	3.99e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
GBM	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.09	1.55e-08	4.02e-05	-0.69	-0.49	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
GBM	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	6.09	1.56e-08	4.04e-05	0.49	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
GBM	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-6.09	1.56e-08	4.04e-05	-0.61	-0.49	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
GBM	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-6.09	1.56e-08	4.05e-05	-0.63	-0.49	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
GBM	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	6.08	1.57e-08	4.08e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	6.08	1.57e-08	4.08e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	6.08	1.57e-08	4.08e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	6.08	1.57e-08	4.08e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	6.08	1.57e-08	4.08e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
GBM	cis	rs6452524	0.869	rs10051155	ENSG00000248112.1	RP11-78C3.1	6.08	1.58e-08	4.08e-05	0.62	0.49	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs10043698	ENSG00000248112.1	RP11-78C3.1	6.08	1.58e-08	4.08e-05	0.62	0.49	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:82919376~82921119:-
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	6.08	1.58e-08	4.08e-05	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
GBM	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	6.08	1.58e-08	4.1e-05	0.64	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	6.08	1.58e-08	4.1e-05	0.64	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
GBM	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-6.08	1.59e-08	4.11e-05	-0.7	-0.49	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
GBM	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-6.08	1.59e-08	4.12e-05	-0.68	-0.49	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
GBM	cis	rs4273100	0.607	rs8072587	ENSG00000265185.4	SNORD3B-1	-6.08	1.6e-08	4.14e-05	-0.58	-0.49	Schizophrenia;	chr17:19307760	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.646	rs1472932	ENSG00000265185.4	SNORD3B-1	-6.08	1.6e-08	4.14e-05	-0.58	-0.49	Schizophrenia;	chr17:19317353	chr17:19061912~19062669:+
GBM	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-6.08	1.6e-08	4.14e-05	-0.49	-0.49	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
GBM	cis	rs4713118	0.513	rs9368547	ENSG00000199851.2	U3	6.08	1.6e-08	4.15e-05	0.74	0.49	Parkinson's disease;	chr6:28060289	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs183244	ENSG00000199851.2	U3	6.08	1.6e-08	4.15e-05	0.74	0.49	Parkinson's disease;	chr6:28064060	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149950	ENSG00000199851.2	U3	6.08	1.6e-08	4.15e-05	0.74	0.49	Parkinson's disease;	chr6:28065261	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149951	ENSG00000199851.2	U3	6.08	1.6e-08	4.15e-05	0.74	0.49	Parkinson's disease;	chr6:28065309	chr6:28015568~28015777:+
GBM	cis	rs11098499	0.604	rs12642411	ENSG00000249244.1	RP11-548H18.2	6.08	1.61e-08	4.17e-05	0.6	0.49	Corneal astigmatism;	chr4:119659370	chr4:119391831~119395335:-
GBM	cis	rs7267979	0.528	rs2387976	ENSG00000276952.1	RP5-965G21.6	-6.08	1.61e-08	4.17e-05	-0.48	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:25284915~25285588:-
GBM	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	6.08	1.62e-08	4.18e-05	0.59	0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
GBM	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-6.08	1.62e-08	4.18e-05	-0.77	-0.49	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
GBM	cis	rs11098499	0.863	rs1552095	ENSG00000250412.1	KLHL2P1	6.08	1.62e-08	4.18e-05	0.62	0.49	Corneal astigmatism;	chr4:119539151	chr4:119334329~119378233:+
GBM	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	6.08	1.62e-08	4.18e-05	0.89	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
GBM	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	6.08	1.62e-08	4.19e-05	0.63	0.49	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
GBM	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-6.08	1.62e-08	4.19e-05	-0.75	-0.49	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
GBM	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.08	1.63e-08	4.2e-05	-0.68	-0.49	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-6.08	1.63e-08	4.2e-05	-0.68	-0.49	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-6.08	1.63e-08	4.2e-05	-0.68	-0.49	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
GBM	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	6.08	1.63e-08	4.21e-05	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
GBM	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-6.08	1.63e-08	4.21e-05	-0.68	-0.49	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-6.08	1.63e-08	4.21e-05	-0.68	-0.49	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
GBM	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-6.08	1.63e-08	4.21e-05	-0.69	-0.49	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
GBM	cis	rs11098499	0.532	rs4833624	ENSG00000250412.1	KLHL2P1	6.08	1.64e-08	4.23e-05	0.63	0.49	Corneal astigmatism;	chr4:119664342	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.532	rs12512646	ENSG00000250412.1	KLHL2P1	6.08	1.64e-08	4.23e-05	0.63	0.49	Corneal astigmatism;	chr4:119664578	chr4:119334329~119378233:+
GBM	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	6.07	1.65e-08	4.26e-05	0.68	0.49	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	6.07	1.65e-08	4.26e-05	0.68	0.49	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
GBM	cis	rs4273100	0.605	rs28591622	ENSG00000265185.4	SNORD3B-1	6.07	1.67e-08	4.29e-05	0.59	0.49	Schizophrenia;	chr17:19272004	chr17:19061912~19062669:+
GBM	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	6.07	1.67e-08	4.29e-05	0.57	0.49	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
GBM	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	6.07	1.67e-08	4.29e-05	0.59	0.49	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
GBM	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	6.07	1.68e-08	4.32e-05	0.69	0.49	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
GBM	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	6.07	1.69e-08	4.33e-05	0.57	0.49	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
GBM	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	6.07	1.69e-08	4.33e-05	0.57	0.49	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	6.07	1.69e-08	4.33e-05	0.57	0.49	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	6.07	1.69e-08	4.33e-05	0.57	0.49	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
GBM	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	6.07	1.69e-08	4.35e-05	0.75	0.49	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
GBM	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	6.07	1.7e-08	4.38e-05	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
GBM	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	6.07	1.71e-08	4.38e-05	0.67	0.49	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
GBM	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	6.07	1.71e-08	4.38e-05	0.59	0.49	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
GBM	cis	rs11098499	0.863	rs1010739	ENSG00000249244.1	RP11-548H18.2	6.07	1.71e-08	4.38e-05	0.62	0.49	Corneal astigmatism;	chr4:119542316	chr4:119391831~119395335:-
GBM	cis	rs2486288	0.656	rs8037583	ENSG00000259433.2	CTD-2651B20.4	6.07	1.71e-08	4.39e-05	0.53	0.49	Glomerular filtration rate;	chr15:45254180	chr15:45330209~45332634:-
GBM	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-6.07	1.71e-08	4.4e-05	-0.77	-0.49	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
GBM	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	6.07	1.72e-08	4.4e-05	0.59	0.49	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
GBM	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	6.07	1.72e-08	4.4e-05	0.59	0.49	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	6.07	1.72e-08	4.4e-05	0.59	0.49	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	6.07	1.72e-08	4.4e-05	0.59	0.49	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
GBM	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	6.07	1.72e-08	4.4e-05	0.49	0.49	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	6.07	1.72e-08	4.4e-05	0.49	0.49	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	6.07	1.72e-08	4.4e-05	0.49	0.49	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	6.07	1.72e-08	4.4e-05	0.49	0.49	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	6.07	1.72e-08	4.4e-05	0.49	0.49	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	6.07	1.72e-08	4.4e-05	0.49	0.49	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	6.07	1.72e-08	4.4e-05	0.49	0.49	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
GBM	cis	rs7267979	0.816	rs422148	ENSG00000125804.12	FAM182A	-6.07	1.72e-08	4.41e-05	-0.58	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26054655~26086917:+
GBM	cis	rs2486288	0.656	rs7167146	ENSG00000259433.2	CTD-2651B20.4	-6.06	1.74e-08	4.45e-05	-0.59	-0.49	Glomerular filtration rate;	chr15:45279188	chr15:45330209~45332634:-
GBM	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	6.06	1.74e-08	4.45e-05	0.61	0.49	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
GBM	cis	rs4713118	0.516	rs6931858	ENSG00000199851.2	U3	6.06	1.74e-08	4.45e-05	0.77	0.49	Parkinson's disease;	chr6:28110633	chr6:28015568~28015777:+
GBM	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-6.06	1.74e-08	4.45e-05	-0.67	-0.49	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
GBM	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	6.06	1.74e-08	4.46e-05	0.71	0.49	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
GBM	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	6.06	1.75e-08	4.48e-05	0.57	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	6.06	1.75e-08	4.48e-05	0.57	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
GBM	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	6.06	1.75e-08	4.49e-05	0.62	0.49	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
GBM	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-6.06	1.77e-08	4.52e-05	-0.46	-0.49	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
GBM	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-6.06	1.77e-08	4.52e-05	-0.46	-0.49	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
GBM	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-6.06	1.77e-08	4.52e-05	-0.93	-0.49	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
GBM	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-6.06	1.77e-08	4.52e-05	-0.93	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
GBM	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	6.06	1.77e-08	4.52e-05	0.63	0.49	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
GBM	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-6.06	1.77e-08	4.53e-05	-0.74	-0.49	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
GBM	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-6.06	1.78e-08	4.54e-05	-0.59	-0.49	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
GBM	cis	rs11098499	0.954	rs1480931	ENSG00000250412.1	KLHL2P1	6.05	1.81e-08	4.62e-05	0.64	0.49	Corneal astigmatism;	chr4:119474654	chr4:119334329~119378233:+
GBM	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-6.05	1.82e-08	4.64e-05	-0.46	-0.49	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
GBM	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	6.05	1.82e-08	4.64e-05	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
GBM	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	6.05	1.82e-08	4.65e-05	0.7	0.49	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
GBM	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	6.05	1.83e-08	4.66e-05	0.8	0.49	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
GBM	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-6.05	1.83e-08	4.66e-05	-0.86	-0.49	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
GBM	cis	rs4273100	0.688	rs12939947	ENSG00000265185.4	SNORD3B-1	6.05	1.83e-08	4.67e-05	0.58	0.49	Schizophrenia;	chr17:19301218	chr17:19061912~19062669:+
GBM	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
GBM	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
GBM	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-6.05	1.85e-08	4.71e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
GBM	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-6.05	1.86e-08	4.72e-05	-0.58	-0.49	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	6.05	1.86e-08	4.72e-05	0.58	0.49	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
GBM	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.05	1.87e-08	4.72e-05	0.48	0.49	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
GBM	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-6.05	1.87e-08	4.73e-05	-0.63	-0.49	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
GBM	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-6.05	1.88e-08	4.76e-05	-0.6	-0.49	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-6.05	1.88e-08	4.76e-05	-0.6	-0.49	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
GBM	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	6.05	1.89e-08	4.78e-05	0.58	0.49	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
GBM	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	6.05	1.89e-08	4.78e-05	0.63	0.49	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	6.05	1.89e-08	4.78e-05	0.63	0.49	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
GBM	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	6.04	1.9e-08	4.81e-05	0.61	0.49	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
GBM	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	6.04	1.91e-08	4.81e-05	0.42	0.49	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
GBM	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	6.04	1.91e-08	4.82e-05	0.58	0.49	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
GBM	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	6.04	1.92e-08	4.84e-05	0.53	0.49	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
GBM	cis	rs950027	0.549	rs12909409	ENSG00000259433.2	CTD-2651B20.4	6.04	1.93e-08	4.86e-05	0.55	0.49	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45330209~45332634:-
GBM	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-6.04	1.93e-08	4.86e-05	-0.55	-0.49	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
GBM	cis	rs4273100	0.607	rs1043809	ENSG00000265185.4	SNORD3B-1	-6.04	1.93e-08	4.86e-05	-0.58	-0.49	Schizophrenia;	chr17:19336119	chr17:19061912~19062669:+
GBM	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-6.04	1.93e-08	4.86e-05	-0.75	-0.49	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
GBM	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	6.04	1.94e-08	4.88e-05	0.62	0.49	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
GBM	cis	rs7267979	1	rs4815420	ENSG00000276952.1	RP5-965G21.6	-6.04	1.94e-08	4.88e-05	-0.46	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25284915~25285588:-
GBM	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-6.04	1.95e-08	4.91e-05	-0.87	-0.49	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
GBM	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	6.04	1.96e-08	4.92e-05	0.62	0.49	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	6.04	1.96e-08	4.92e-05	0.62	0.49	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
GBM	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	6.04	1.96e-08	4.92e-05	0.58	0.49	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
GBM	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	6.04	1.96e-08	4.93e-05	0.64	0.49	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
GBM	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-6.04	1.96e-08	4.93e-05	-1	-0.49	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
GBM	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-6.04	1.97e-08	4.95e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
GBM	cis	rs7267979	0.546	rs8115804	ENSG00000125804.12	FAM182A	6.04	1.97e-08	4.95e-05	0.66	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:26054655~26086917:+
GBM	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	6.04	1.98e-08	4.95e-05	0.78	0.49	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
GBM	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	6.03	1.99e-08	4.95e-05	0.62	0.49	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000224205.1	AP000351.4	6.03	1.99e-08	4.95e-05	0.55	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000224205.1	AP000351.4	6.03	1.99e-08	4.95e-05	0.55	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000224205.1	AP000351.4	6.03	1.99e-08	4.95e-05	0.55	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000224205.1	AP000351.4	6.03	1.99e-08	4.95e-05	0.55	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000224205.1	AP000351.4	6.03	1.99e-08	4.95e-05	0.55	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23987320~23991421:-
GBM	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	6.03	1.99e-08	4.96e-05	0.68	0.49	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000224205.1	AP000351.4	6.03	2e-08	4.97e-05	0.54	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23987320~23991421:-
GBM	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-6.03	2.01e-08	4.98e-05	-0.63	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
GBM	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	6.03	2.02e-08	5.02e-05	0.62	0.49	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	6.03	2.02e-08	5.02e-05	0.62	0.49	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
GBM	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-6.03	2.03e-08	5.03e-05	-0.63	-0.49	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
GBM	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-6.03	2.04e-08	5.05e-05	-0.58	-0.49	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
GBM	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	6.03	2.04e-08	5.05e-05	0.89	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
GBM	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	6.03	2.05e-08	5.05e-05	0.63	0.49	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-6.03	2.05e-08	5.05e-05	-0.63	-0.49	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-6.03	2.05e-08	5.05e-05	-0.63	-0.49	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
GBM	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-6.03	2.05e-08	5.06e-05	-0.67	-0.49	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-6.03	2.05e-08	5.06e-05	-0.67	-0.49	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-6.03	2.05e-08	5.06e-05	-0.67	-0.49	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-6.03	2.05e-08	5.06e-05	-0.67	-0.49	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-6.03	2.05e-08	5.06e-05	-0.67	-0.49	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-6.03	2.05e-08	5.06e-05	-0.67	-0.49	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
GBM	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-6.03	2.06e-08	5.06e-05	-0.72	-0.49	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
GBM	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-6.03	2.06e-08	5.08e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-6.03	2.06e-08	5.08e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-6.03	2.06e-08	5.08e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
GBM	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	6.03	2.08e-08	5.11e-05	0.61	0.49	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
GBM	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-6.03	2.08e-08	5.11e-05	-0.59	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-6.03	2.08e-08	5.11e-05	-0.59	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-6.03	2.08e-08	5.11e-05	-0.59	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	6.03	2.08e-08	5.11e-05	0.59	0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
GBM	cis	rs11098499	0.863	rs6534139	ENSG00000250412.1	KLHL2P1	-6.02	2.09e-08	5.13e-05	-0.6	-0.49	Corneal astigmatism;	chr4:119528301	chr4:119334329~119378233:+
GBM	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-6.02	2.09e-08	5.13e-05	-0.66	-0.49	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
GBM	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-6.02	2.09e-08	5.13e-05	-0.62	-0.49	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
GBM	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	6.02	2.1e-08	5.16e-05	0.62	0.49	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	6.02	2.1e-08	5.16e-05	0.62	0.49	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
GBM	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-6.02	2.12e-08	5.21e-05	-0.55	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
GBM	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	6.02	2.14e-08	5.25e-05	0.74	0.49	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
GBM	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-6.02	2.15e-08	5.27e-05	-1.16	-0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
GBM	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	6.02	2.15e-08	5.27e-05	0.61	0.49	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-6.02	2.15e-08	5.27e-05	-0.61	-0.49	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
GBM	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-6.02	2.17e-08	5.32e-05	-0.47	-0.49	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
GBM	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-6.02	2.17e-08	5.32e-05	-0.47	-0.49	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
GBM	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-6.02	2.17e-08	5.32e-05	-0.47	-0.49	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
GBM	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-6.02	2.18e-08	5.34e-05	-0.93	-0.49	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
GBM	cis	rs6452524	0.904	rs10474095	ENSG00000248112.1	RP11-78C3.1	6.02	2.18e-08	5.34e-05	0.61	0.49	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:82919376~82921119:-
GBM	cis	rs7267979	0.668	rs2387977	ENSG00000276952.1	RP5-965G21.6	-6.01	2.19e-08	5.35e-05	-0.48	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:25284915~25285588:-
GBM	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-6.01	2.2e-08	5.37e-05	-0.47	-0.49	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
GBM	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-6.01	2.2e-08	5.38e-05	-0.6	-0.49	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
GBM	cis	rs2013441	0.786	rs4003797	ENSG00000230528.6	NOS2P3	6.01	2.21e-08	5.4e-05	0.55	0.49	Obesity-related traits;	chr17:20385587	chr17:20436337~20447249:+
GBM	cis	rs11098499	0.909	rs79026312	ENSG00000250412.1	KLHL2P1	6.01	2.21e-08	5.4e-05	0.62	0.49	Corneal astigmatism;	chr4:119519522	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs35111518	ENSG00000250412.1	KLHL2P1	6.01	2.21e-08	5.4e-05	0.62	0.49	Corneal astigmatism;	chr4:119519527	chr4:119334329~119378233:+
GBM	cis	rs6452524	0.534	rs17284134	ENSG00000248112.1	RP11-78C3.1	-6.01	2.21e-08	5.4e-05	-0.6	-0.49	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:82919376~82921119:-
GBM	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-6.01	2.21e-08	5.4e-05	-0.62	-0.49	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
GBM	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	6.01	2.22e-08	5.42e-05	0.81	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
GBM	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	6.01	2.22e-08	5.42e-05	0.55	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	6.01	2.22e-08	5.42e-05	0.55	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	6.01	2.22e-08	5.42e-05	0.55	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	6.01	2.22e-08	5.42e-05	0.55	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	6.01	2.22e-08	5.42e-05	0.55	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
GBM	cis	rs7267979	0.565	rs958075	ENSG00000276952.1	RP5-965G21.6	-6.01	2.22e-08	5.42e-05	-0.46	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:25284915~25285588:-
GBM	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	6.01	2.23e-08	5.45e-05	0.62	0.49	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
GBM	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	6.01	2.24e-08	5.46e-05	0.48	0.49	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
GBM	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-6.01	2.24e-08	5.47e-05	-0.57	-0.49	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
GBM	cis	rs4273100	0.646	rs11652784	ENSG00000265185.4	SNORD3B-1	-6.01	2.24e-08	5.47e-05	-0.58	-0.49	Schizophrenia;	chr17:19313948	chr17:19061912~19062669:+
GBM	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-6.01	2.24e-08	5.47e-05	-0.57	-0.49	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
GBM	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	6.01	2.25e-08	5.48e-05	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	6.01	2.25e-08	5.48e-05	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
GBM	cis	rs7267979	1	rs4815417	ENSG00000276952.1	RP5-965G21.6	-6.01	2.25e-08	5.49e-05	-0.44	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25284915~25285588:-
GBM	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	6.01	2.26e-08	5.52e-05	0.47	0.49	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
GBM	cis	rs6782228	0.606	rs2811489	ENSG00000277250.1	Metazoa_SRP	6.01	2.27e-08	5.53e-05	0.54	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128673681~128674021:-
GBM	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	6.01	2.27e-08	5.53e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
GBM	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-6.01	2.27e-08	5.53e-05	-0.62	-0.49	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
GBM	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-6.01	2.28e-08	5.54e-05	-0.63	-0.49	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
GBM	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	6.01	2.28e-08	5.54e-05	0.64	0.49	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
GBM	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	6.01	2.28e-08	5.54e-05	0.59	0.49	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
GBM	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	6.01	2.28e-08	5.54e-05	0.61	0.49	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
GBM	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	6.01	2.28e-08	5.55e-05	0.55	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	6.01	2.28e-08	5.55e-05	0.55	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
GBM	cis	rs11098499	0.566	rs7664440	ENSG00000250412.1	KLHL2P1	6.01	2.28e-08	5.55e-05	0.61	0.49	Corneal astigmatism;	chr4:119657385	chr4:119334329~119378233:+
GBM	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-6.01	2.29e-08	5.55e-05	-0.58	-0.49	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-6.01	2.29e-08	5.55e-05	-0.58	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-6.01	2.29e-08	5.55e-05	-0.58	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-6.01	2.29e-08	5.55e-05	-0.58	-0.49	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-6.01	2.29e-08	5.55e-05	-0.58	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-6.01	2.29e-08	5.55e-05	-0.58	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
GBM	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	6.01	2.29e-08	5.55e-05	0.68	0.49	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
GBM	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-6.01	2.29e-08	5.55e-05	-0.67	-0.49	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
GBM	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-6	2.31e-08	5.59e-05	-0.62	-0.49	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
GBM	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-6	2.31e-08	5.6e-05	-0.68	-0.49	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
GBM	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	6	2.31e-08	5.6e-05	0.58	0.49	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
GBM	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-6	2.33e-08	5.66e-05	-0.69	-0.49	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
GBM	cis	rs7267979	0.816	rs404775	ENSG00000125804.12	FAM182A	-6	2.35e-08	5.69e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.816	rs374701	ENSG00000125804.12	FAM182A	-6	2.35e-08	5.69e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.816	rs6037158	ENSG00000125804.12	FAM182A	-6	2.35e-08	5.69e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26054655~26086917:+
GBM	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-6	2.36e-08	5.7e-05	-0.77	-0.49	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
GBM	cis	rs11098499	0.954	rs12508504	ENSG00000250412.1	KLHL2P1	6	2.36e-08	5.7e-05	0.63	0.49	Corneal astigmatism;	chr4:119489452	chr4:119334329~119378233:+
GBM	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-6	2.36e-08	5.7e-05	-0.56	-0.49	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
GBM	cis	rs4273100	0.688	rs1467028	ENSG00000265185.4	SNORD3B-1	6	2.36e-08	5.71e-05	0.58	0.49	Schizophrenia;	chr17:19271561	chr17:19061912~19062669:+
GBM	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-6	2.36e-08	5.72e-05	-0.52	-0.49	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
GBM	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-6	2.37e-08	5.72e-05	-0.56	-0.49	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
GBM	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-6	2.37e-08	5.73e-05	-0.77	-0.49	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
GBM	cis	rs11098499	0.82	rs11737395	ENSG00000250412.1	KLHL2P1	6	2.37e-08	5.74e-05	0.62	0.49	Corneal astigmatism;	chr4:119599549	chr4:119334329~119378233:+
GBM	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-6	2.38e-08	5.75e-05	-0.56	-0.49	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
GBM	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-6	2.38e-08	5.75e-05	-0.56	-0.49	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
GBM	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	6	2.38e-08	5.77e-05	0.62	0.49	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
GBM	cis	rs7267979	0.844	rs6115188	ENSG00000125804.12	FAM182A	-6	2.39e-08	5.79e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26054655~26086917:+
GBM	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-6	2.4e-08	5.79e-05	-0.68	-0.49	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
GBM	cis	rs11098499	0.82	rs6829903	ENSG00000250412.1	KLHL2P1	5.99	2.42e-08	5.84e-05	0.61	0.49	Corneal astigmatism;	chr4:119585729	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs7669520	ENSG00000250412.1	KLHL2P1	5.99	2.42e-08	5.84e-05	0.61	0.49	Corneal astigmatism;	chr4:119594123	chr4:119334329~119378233:+
GBM	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-5.99	2.42e-08	5.84e-05	-0.52	-0.49	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
GBM	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-5.99	2.42e-08	5.84e-05	-0.64	-0.49	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-5.99	2.42e-08	5.84e-05	-0.64	-0.49	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
GBM	cis	rs2013441	0.965	rs8068720	ENSG00000230528.6	NOS2P3	5.99	2.43e-08	5.85e-05	0.54	0.49	Obesity-related traits;	chr17:20310858	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs8079701	ENSG00000230528.6	NOS2P3	5.99	2.43e-08	5.85e-05	0.54	0.49	Obesity-related traits;	chr17:20313252	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2058971	ENSG00000230528.6	NOS2P3	5.99	2.43e-08	5.85e-05	0.54	0.49	Obesity-related traits;	chr17:20316195	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.804	rs1811453	ENSG00000230528.6	NOS2P3	5.99	2.43e-08	5.85e-05	0.54	0.49	Obesity-related traits;	chr17:20328880	chr17:20436337~20447249:+
GBM	cis	rs6452524	0.836	rs62372713	ENSG00000248112.1	RP11-78C3.1	5.99	2.43e-08	5.86e-05	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs62372714	ENSG00000248112.1	RP11-78C3.1	5.99	2.43e-08	5.86e-05	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs17205699	ENSG00000248112.1	RP11-78C3.1	5.99	2.43e-08	5.86e-05	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.78	rs2386237	ENSG00000248112.1	RP11-78C3.1	5.99	2.43e-08	5.86e-05	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.775	rs10071579	ENSG00000248112.1	RP11-78C3.1	5.99	2.43e-08	5.86e-05	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.839	rs28745307	ENSG00000248112.1	RP11-78C3.1	5.99	2.43e-08	5.86e-05	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.746	rs28745311	ENSG00000248112.1	RP11-78C3.1	5.99	2.43e-08	5.86e-05	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:82919376~82921119:-
GBM	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-5.99	2.43e-08	5.86e-05	-0.62	-0.49	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	5.99	2.43e-08	5.86e-05	0.62	0.49	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	5.99	2.43e-08	5.86e-05	0.62	0.49	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	5.99	2.43e-08	5.86e-05	0.62	0.49	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	5.99	2.43e-08	5.86e-05	0.62	0.49	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	5.99	2.43e-08	5.86e-05	0.62	0.49	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
GBM	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-5.99	2.44e-08	5.89e-05	-0.64	-0.49	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
GBM	cis	rs11098499	0.604	rs34278750	ENSG00000250412.1	KLHL2P1	5.99	2.44e-08	5.89e-05	0.61	0.49	Corneal astigmatism;	chr4:119649981	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.604	rs10022185	ENSG00000250412.1	KLHL2P1	5.99	2.44e-08	5.89e-05	0.61	0.49	Corneal astigmatism;	chr4:119650610	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	5.99	2.45e-08	5.89e-05	0.63	0.49	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
GBM	cis	rs453301	0.653	rs7016139	ENSG00000254340.1	RP11-10A14.3	-5.99	2.45e-08	5.91e-05	-0.63	-0.49	Joint mobility (Beighton score);	chr8:9037960	chr8:9141424~9145435:+
GBM	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	5.99	2.46e-08	5.92e-05	0.9	0.49	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
GBM	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-5.99	2.46e-08	5.93e-05	-0.56	-0.49	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
GBM	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-5.99	2.46e-08	5.93e-05	-0.59	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-5.99	2.46e-08	5.93e-05	-0.59	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
GBM	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-5.99	2.46e-08	5.93e-05	-0.59	-0.49	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
GBM	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-5.99	2.46e-08	5.93e-05	-0.61	-0.49	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
GBM	cis	rs11098499	0.863	rs10004484	ENSG00000250412.1	KLHL2P1	5.99	2.47e-08	5.93e-05	0.62	0.49	Corneal astigmatism;	chr4:119521273	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs1155576	ENSG00000250412.1	KLHL2P1	5.99	2.47e-08	5.93e-05	0.62	0.49	Corneal astigmatism;	chr4:119529004	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs13140391	ENSG00000250412.1	KLHL2P1	5.99	2.47e-08	5.94e-05	0.62	0.49	Corneal astigmatism;	chr4:119582282	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs13140409	ENSG00000250412.1	KLHL2P1	5.99	2.47e-08	5.94e-05	0.62	0.49	Corneal astigmatism;	chr4:119582305	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs6833334	ENSG00000250412.1	KLHL2P1	5.99	2.47e-08	5.94e-05	0.62	0.49	Corneal astigmatism;	chr4:119583072	chr4:119334329~119378233:+
GBM	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	5.99	2.47e-08	5.95e-05	0.52	0.49	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-5.99	2.47e-08	5.95e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
GBM	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-5.99	2.48e-08	5.97e-05	-0.65	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
GBM	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	5.99	2.49e-08	5.97e-05	0.61	0.49	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
GBM	cis	rs7267979	0.78	rs6050679	ENSG00000125804.12	FAM182A	-5.99	2.5e-08	6.01e-05	-0.6	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26054655~26086917:+
GBM	cis	rs4713118	0.614	rs9380007	ENSG00000218016.2	ZNF192P2	-5.99	2.5e-08	6.02e-05	-0.58	-0.49	Parkinson's disease;	chr6:27692729	chr6:28188050~28189432:+
GBM	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-5.99	2.51e-08	6.02e-05	-0.7	-0.49	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
GBM	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-5.99	2.51e-08	6.04e-05	-0.56	-0.49	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
GBM	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.98	2.52e-08	6.05e-05	-0.48	-0.49	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
GBM	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	5.98	2.54e-08	6.09e-05	0.6	0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
GBM	cis	rs453301	0.624	rs2288673	ENSG00000254340.1	RP11-10A14.3	5.98	2.54e-08	6.09e-05	0.62	0.49	Joint mobility (Beighton score);	chr8:9002766	chr8:9141424~9145435:+
GBM	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	5.98	2.55e-08	6.12e-05	0.68	0.49	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
GBM	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-5.98	2.56e-08	6.14e-05	-0.52	-0.49	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
GBM	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-5.98	2.56e-08	6.14e-05	-0.61	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
GBM	cis	rs7267979	0.816	rs376742	ENSG00000125804.12	FAM182A	-5.98	2.57e-08	6.16e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26054655~26086917:+
GBM	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-5.98	2.58e-08	6.18e-05	-0.56	-0.49	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
GBM	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-5.98	2.58e-08	6.19e-05	-0.66	-0.49	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
GBM	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-5.98	2.58e-08	6.19e-05	-0.66	-0.49	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
GBM	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-5.98	2.58e-08	6.19e-05	-0.66	-0.49	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
GBM	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	5.98	2.59e-08	6.2e-05	0.56	0.49	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
GBM	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	5.98	2.59e-08	6.2e-05	1.07	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
GBM	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	5.98	2.59e-08	6.2e-05	1.07	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
GBM	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	5.98	2.59e-08	6.2e-05	1.07	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
GBM	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-5.98	2.6e-08	6.22e-05	-0.63	-0.49	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
GBM	cis	rs7267979	0.844	rs2257649	ENSG00000125804.12	FAM182A	-5.98	2.61e-08	6.25e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs2424703	ENSG00000125804.12	FAM182A	-5.98	2.61e-08	6.25e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.74	rs2259961	ENSG00000125804.12	FAM182A	-5.98	2.61e-08	6.25e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs2474780	ENSG00000125804.12	FAM182A	-5.98	2.61e-08	6.25e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.789	rs4815400	ENSG00000125804.12	FAM182A	5.98	2.61e-08	6.25e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26054655~26086917:+
GBM	cis	rs2013441	0.965	rs7207611	ENSG00000230528.6	NOS2P3	-5.98	2.61e-08	6.25e-05	-0.53	-0.49	Obesity-related traits;	chr17:20301203	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs1373147	ENSG00000230528.6	NOS2P3	5.98	2.61e-08	6.25e-05	0.53	0.49	Obesity-related traits;	chr17:20303332	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs11871945	ENSG00000230528.6	NOS2P3	5.98	2.61e-08	6.25e-05	0.53	0.49	Obesity-related traits;	chr17:20303570	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2120282	ENSG00000230528.6	NOS2P3	5.98	2.61e-08	6.25e-05	0.53	0.49	Obesity-related traits;	chr17:20306161	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2165897	ENSG00000230528.6	NOS2P3	5.98	2.61e-08	6.25e-05	0.53	0.49	Obesity-related traits;	chr17:20306408	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.965	rs8071665	ENSG00000230528.6	NOS2P3	5.98	2.61e-08	6.25e-05	0.53	0.49	Obesity-related traits;	chr17:20306630	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2386429	ENSG00000230528.6	NOS2P3	5.98	2.61e-08	6.25e-05	0.53	0.49	Obesity-related traits;	chr17:20307496	chr17:20436337~20447249:+
GBM	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	5.98	2.62e-08	6.26e-05	0.58	0.49	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	5.98	2.62e-08	6.26e-05	0.58	0.49	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
GBM	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	5.98	2.62e-08	6.26e-05	0.62	0.49	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	5.98	2.62e-08	6.26e-05	0.62	0.49	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	5.98	2.62e-08	6.26e-05	0.62	0.49	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
GBM	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-5.98	2.63e-08	6.27e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-5.98	2.63e-08	6.27e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-5.98	2.63e-08	6.27e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-5.98	2.63e-08	6.27e-05	-0.51	-0.49	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
GBM	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	5.98	2.63e-08	6.29e-05	0.59	0.49	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	5.98	2.63e-08	6.29e-05	0.59	0.49	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
GBM	cis	rs11098499	0.604	rs2389882	ENSG00000250412.1	KLHL2P1	5.97	2.64e-08	6.29e-05	0.6	0.49	Corneal astigmatism;	chr4:119645578	chr4:119334329~119378233:+
GBM	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	5.97	2.64e-08	6.29e-05	0.59	0.49	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	5.97	2.64e-08	6.29e-05	0.59	0.49	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
GBM	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	5.97	2.64e-08	6.3e-05	0.6	0.49	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
GBM	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-5.97	2.64e-08	6.3e-05	-0.61	-0.49	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
GBM	cis	rs11098499	0.69	rs34818745	ENSG00000250412.1	KLHL2P1	5.97	2.64e-08	6.3e-05	0.63	0.49	Corneal astigmatism;	chr4:119335900	chr4:119334329~119378233:+
GBM	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	5.97	2.66e-08	6.35e-05	0.6	0.49	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
GBM	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-5.97	2.66e-08	6.36e-05	-0.57	-0.49	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
GBM	cis	rs6452524	0.904	rs10473867	ENSG00000248112.1	RP11-78C3.1	5.97	2.68e-08	6.38e-05	0.61	0.49	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:82919376~82921119:-
GBM	cis	rs7267979	0.844	rs6083845	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs6083851	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs4423675	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs35735333	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs4815413	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs6083824	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs869358	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.844	rs6076343	ENSG00000125804.12	FAM182A	5.97	2.68e-08	6.38e-05	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26054655~26086917:+
GBM	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-5.97	2.69e-08	6.41e-05	-0.69	-0.49	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-5.97	2.69e-08	6.41e-05	-0.69	-0.49	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
GBM	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	5.97	2.7e-08	6.42e-05	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	5.97	2.7e-08	6.42e-05	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	5.97	2.72e-08	6.47e-05	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
GBM	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-5.97	2.73e-08	6.48e-05	-0.56	-0.49	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
GBM	cis	rs11098499	0.954	rs10017371	ENSG00000250412.1	KLHL2P1	5.97	2.73e-08	6.48e-05	0.63	0.49	Corneal astigmatism;	chr4:119372621	chr4:119334329~119378233:+
GBM	cis	rs1964356	0.967	rs17701675	ENSG00000253893.2	FAM85B	5.97	2.73e-08	6.5e-05	0.62	0.49	Mean corpuscular volume;	chr8:8993123	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.863	rs7699064	ENSG00000250412.1	KLHL2P1	-5.97	2.74e-08	6.51e-05	-0.61	-0.49	Corneal astigmatism;	chr4:119507154	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs4507344	ENSG00000250412.1	KLHL2P1	5.97	2.74e-08	6.51e-05	0.63	0.49	Corneal astigmatism;	chr4:119386330	chr4:119334329~119378233:+
GBM	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-5.97	2.76e-08	6.54e-05	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
GBM	cis	rs7267979	0.844	rs6107027	ENSG00000125804.12	FAM182A	-5.96	2.78e-08	6.6e-05	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	5.96	2.81e-08	6.65e-05	0.62	0.49	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs2389880	ENSG00000249244.1	RP11-548H18.2	5.96	2.81e-08	6.65e-05	0.59	0.49	Corneal astigmatism;	chr4:119638715	chr4:119391831~119395335:-
GBM	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-5.96	2.82e-08	6.66e-05	-0.55	-0.49	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
GBM	cis	rs11098499	0.863	rs6858592	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119537537	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs12498539	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119547215	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs9997631	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119548840	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3822194	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119550493	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3822195	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119550505	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775854	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119550816	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs2306457	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119551684	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs6853998	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119554705	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs6858777	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119554811	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs10018280	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119556984	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs11731756	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119557541	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs34308924	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119560276	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs6534141	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119564068	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs2127823	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119564515	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs2170276	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119564669	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775858	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119564873	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs9884402	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119568827	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.731	rs9995026	ENSG00000250412.1	KLHL2P1	5.96	2.82e-08	6.66e-05	0.61	0.49	Corneal astigmatism;	chr4:119569344	chr4:119334329~119378233:+
GBM	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	5.96	2.82e-08	6.66e-05	0.56	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
GBM	cis	rs2013441	1	rs11871827	ENSG00000230528.6	NOS2P3	5.96	2.83e-08	6.7e-05	0.53	0.49	Obesity-related traits;	chr17:20312592	chr17:20436337~20447249:+
GBM	cis	rs11098499	0.954	rs878373	ENSG00000250412.1	KLHL2P1	5.96	2.84e-08	6.7e-05	0.63	0.49	Corneal astigmatism;	chr4:119316329	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs1546504	ENSG00000250412.1	KLHL2P1	5.96	2.84e-08	6.7e-05	0.63	0.49	Corneal astigmatism;	chr4:119320024	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs1546505	ENSG00000250412.1	KLHL2P1	5.96	2.84e-08	6.7e-05	0.63	0.49	Corneal astigmatism;	chr4:119320069	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10006877	ENSG00000250412.1	KLHL2P1	5.96	2.84e-08	6.7e-05	0.63	0.49	Corneal astigmatism;	chr4:119321638	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs12505469	ENSG00000250412.1	KLHL2P1	5.96	2.84e-08	6.7e-05	0.63	0.49	Corneal astigmatism;	chr4:119328430	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs11722183	ENSG00000250412.1	KLHL2P1	5.96	2.84e-08	6.7e-05	0.63	0.49	Corneal astigmatism;	chr4:119359442	chr4:119334329~119378233:+
GBM	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	5.96	2.86e-08	6.76e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	5.96	2.86e-08	6.76e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	5.96	2.86e-08	6.76e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	5.96	2.86e-08	6.76e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	5.96	2.86e-08	6.76e-05	0.55	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
GBM	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	5.96	2.87e-08	6.78e-05	0.59	0.49	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
GBM	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	5.96	2.88e-08	6.8e-05	0.64	0.49	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
GBM	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	5.95	2.9e-08	6.84e-05	0.57	0.49	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
GBM	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-5.95	2.9e-08	6.84e-05	-0.6	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-5.95	2.9e-08	6.84e-05	-0.6	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-5.95	2.9e-08	6.84e-05	-0.6	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
GBM	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	5.95	2.91e-08	6.85e-05	0.61	0.49	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
GBM	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-5.95	2.91e-08	6.85e-05	-0.65	-0.49	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
GBM	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-5.95	2.92e-08	6.88e-05	-0.62	-0.49	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
GBM	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	5.95	2.93e-08	6.89e-05	0.65	0.49	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
GBM	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-5.95	2.93e-08	6.89e-05	-0.63	-0.49	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
GBM	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	5.95	2.94e-08	6.89e-05	0.58	0.49	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
GBM	cis	rs11098499	0.863	rs3775841	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119504622	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs13134665	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119505275	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775843	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119506689	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775844	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119506878	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3822190	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119506943	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3822191	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119506946	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs7664986	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119508797	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.818	rs10008791	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119510314	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs11736416	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119510506	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775845	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119511292	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs1383533	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119513421	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs2291185	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119513678	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs10030660	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119515549	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs13149407	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119516670	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs34868248	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119521275	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3733525	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119525893	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775847	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119526487	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775848	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119526569	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs10013305	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119529269	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs3775849	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119529753	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.818	rs7688802	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119530513	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs7695620	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119531621	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs12502389	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119533036	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.821	rs3775852	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119533401	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.82	rs6534140	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119534156	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs7657849	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119534339	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs10034450	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119534494	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs1480939	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119535772	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs1480940	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119536527	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs6835635	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119537712	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs58452170	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119538519	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs7678400	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119540802	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs1480936	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119541706	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs1010740	ENSG00000250412.1	KLHL2P1	-5.95	2.94e-08	6.89e-05	-0.62	-0.49	Corneal astigmatism;	chr4:119542254	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs11098531	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119543846	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs28718422	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119545149	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.818	rs12498599	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119547348	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs10009626	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119548850	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs2306456	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119551267	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs11947234	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119553704	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs11933966	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119555560	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs36040693	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119556461	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.818	rs55825515	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119565247	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs1552092	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119567341	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs59732491	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119568433	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs11723090	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119569437	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs11098532	ENSG00000250412.1	KLHL2P1	5.95	2.94e-08	6.89e-05	0.62	0.49	Corneal astigmatism;	chr4:119569571	chr4:119334329~119378233:+
GBM	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	5.95	2.96e-08	6.94e-05	0.57	0.49	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
GBM	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	5.95	2.96e-08	6.94e-05	0.57	0.49	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.604	rs2389887	ENSG00000250412.1	KLHL2P1	5.95	2.97e-08	6.96e-05	0.61	0.49	Corneal astigmatism;	chr4:119649489	chr4:119334329~119378233:+
GBM	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	5.95	2.97e-08	6.96e-05	0.55	0.49	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
GBM	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-5.95	2.98e-08	6.97e-05	-0.66	-0.49	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
GBM	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	5.95	2.99e-08	7.01e-05	0.57	0.49	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
GBM	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	5.95	3e-08	7.02e-05	0.58	0.48	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
GBM	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-5.94	3.06e-08	7.14e-05	-0.56	-0.48	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
GBM	cis	rs2013441	0.76	rs8080827	ENSG00000230528.6	NOS2P3	5.94	3.07e-08	7.15e-05	0.53	0.48	Obesity-related traits;	chr17:20270623	chr17:20436337~20447249:+
GBM	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	5.94	3.07e-08	7.17e-05	0.56	0.48	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
GBM	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	5.94	3.08e-08	7.18e-05	0.58	0.48	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	5.94	3.1e-08	7.21e-05	0.57	0.48	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
GBM	cis	rs11098499	1	rs3749591	ENSG00000250412.1	KLHL2P1	5.94	3.11e-08	7.22e-05	0.63	0.48	Corneal astigmatism;	chr4:119292875	chr4:119334329~119378233:+
GBM	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	5.94	3.11e-08	7.22e-05	0.57	0.48	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	5.94	3.11e-08	7.22e-05	0.57	0.48	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	5.94	3.11e-08	7.22e-05	0.57	0.48	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	5.94	3.11e-08	7.22e-05	0.57	0.48	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	5.94	3.11e-08	7.22e-05	0.57	0.48	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	5.94	3.11e-08	7.22e-05	0.57	0.48	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	5.94	3.11e-08	7.22e-05	0.57	0.48	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
GBM	cis	rs6782228	0.606	rs2712381	ENSG00000277250.1	Metazoa_SRP	-5.94	3.11e-08	7.22e-05	-0.54	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs1127030	ENSG00000277250.1	Metazoa_SRP	-5.94	3.11e-08	7.22e-05	-0.54	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs2712419	ENSG00000277250.1	Metazoa_SRP	-5.94	3.11e-08	7.24e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs2712417	ENSG00000277250.1	Metazoa_SRP	-5.94	3.11e-08	7.24e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128673681~128674021:-
GBM	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-5.94	3.12e-08	7.25e-05	-0.68	-0.48	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
GBM	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	5.94	3.13e-08	7.26e-05	0.91	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	5.94	3.13e-08	7.26e-05	0.91	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	5.94	3.13e-08	7.26e-05	0.91	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
GBM	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	5.94	3.13e-08	7.27e-05	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
GBM	cis	rs453301	0.597	rs7001187	ENSG00000253893.2	FAM85B	5.94	3.16e-08	7.33e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8935272	chr8:8167819~8226614:-
GBM	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	5.93	3.18e-08	7.38e-05	0.6	0.48	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	5.93	3.18e-08	7.38e-05	0.6	0.48	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
GBM	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-5.93	3.19e-08	7.39e-05	-0.56	-0.48	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
GBM	cis	rs7267979	0.816	rs390123	ENSG00000125804.12	FAM182A	-5.93	3.2e-08	7.41e-05	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26054655~26086917:+
GBM	cis	rs2013441	0.866	rs8070401	ENSG00000230528.6	NOS2P3	5.93	3.2e-08	7.41e-05	0.58	0.48	Obesity-related traits;	chr17:20311179	chr17:20436337~20447249:+
GBM	cis	rs7829975	0.51	rs2921073	ENSG00000253893.2	FAM85B	-5.93	3.21e-08	7.44e-05	-0.58	-0.48	Mood instability;	chr8:8450133	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.51	rs2979160	ENSG00000253893.2	FAM85B	-5.93	3.21e-08	7.44e-05	-0.58	-0.48	Mood instability;	chr8:8450156	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.908	rs1002152	ENSG00000250412.1	KLHL2P1	5.93	3.25e-08	7.51e-05	0.63	0.48	Corneal astigmatism;	chr4:119352232	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.604	rs12642411	ENSG00000250412.1	KLHL2P1	5.93	3.29e-08	7.59e-05	0.6	0.48	Corneal astigmatism;	chr4:119659370	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs1022145	ENSG00000250412.1	KLHL2P1	5.93	3.3e-08	7.62e-05	0.63	0.48	Corneal astigmatism;	chr4:119309824	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs11722872	ENSG00000250412.1	KLHL2P1	5.93	3.3e-08	7.62e-05	0.63	0.48	Corneal astigmatism;	chr4:119311875	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs1546502	ENSG00000250412.1	KLHL2P1	5.93	3.3e-08	7.62e-05	0.63	0.48	Corneal astigmatism;	chr4:119314743	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-5.93	3.31e-08	7.63e-05	-0.6	-0.48	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
GBM	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	5.93	3.31e-08	7.64e-05	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
GBM	cis	rs6452524	0.836	rs4343818	ENSG00000249664.1	CTD-2227C6.2	5.93	3.32e-08	7.66e-05	0.56	0.48	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	5.92	3.34e-08	7.68e-05	0.61	0.48	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	5.92	3.34e-08	7.68e-05	0.61	0.48	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
GBM	cis	rs7267979	0.745	rs6132845	ENSG00000125804.12	FAM182A	-5.92	3.34e-08	7.69e-05	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.909	rs10020034	ENSG00000250412.1	KLHL2P1	5.92	3.35e-08	7.71e-05	0.62	0.48	Corneal astigmatism;	chr4:119373176	chr4:119334329~119378233:+
GBM	cis	rs453301	0.631	rs11780774	ENSG00000253893.2	FAM85B	5.92	3.35e-08	7.72e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8941601	chr8:8167819~8226614:-
GBM	cis	rs453301	0.605	rs7843024	ENSG00000253893.2	FAM85B	5.92	3.35e-08	7.72e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8942466	chr8:8167819~8226614:-
GBM	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	5.92	3.38e-08	7.77e-05	0.57	0.48	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
GBM	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-5.92	3.39e-08	7.79e-05	-0.56	-0.48	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
GBM	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	5.92	3.4e-08	7.79e-05	0.63	0.48	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
GBM	cis	rs11098499	0.954	rs13107475	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119471856	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs7436506	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119472614	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs12499324	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119472631	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10008459	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119473076	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs2127821	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119473380	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs9998585	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119475647	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10034623	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119476674	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs6842762	ENSG00000250412.1	KLHL2P1	5.92	3.4e-08	7.79e-05	0.62	0.48	Corneal astigmatism;	chr4:119477081	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs2389803	ENSG00000250412.1	KLHL2P1	-5.92	3.4e-08	7.79e-05	-0.62	-0.48	Corneal astigmatism;	chr4:119472356	chr4:119334329~119378233:+
GBM	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-5.92	3.41e-08	7.79e-05	-0.6	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
GBM	cis	rs11098499	0.954	rs59866101	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119375436	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.618	rs6858383	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119375617	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.697	rs6832410	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119375645	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs1112817	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119376645	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.779	rs10016060	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119377257	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10005644	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119377322	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.697	rs10016448	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119377690	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.657	rs9996569	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119377849	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.908	rs11729050	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119378911	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs28429722	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119378938	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10014845	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119379922	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.779	rs7674500	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119382438	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28884220	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119386056	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28793658	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119386059	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.697	rs4373140	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119386543	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs13113483	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119387884	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.542	rs10440343	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119388632	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28668716	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119388720	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.542	rs7677836	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119389483	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs10002083	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119389997	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10024844	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119390373	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs4345162	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119391804	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.657	rs4463052	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119392103	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs13151285	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119393586	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs4309825	ENSG00000250412.1	KLHL2P1	-5.92	3.41e-08	7.79e-05	-0.63	-0.48	Corneal astigmatism;	chr4:119393726	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs9993199	ENSG00000250412.1	KLHL2P1	-5.92	3.41e-08	7.79e-05	-0.63	-0.48	Corneal astigmatism;	chr4:119471718	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10518328	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119480624	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs6848389	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119481467	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs6822679	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119481547	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs4577559	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119482888	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs7656252	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119483113	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs28845498	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119484031	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs28753180	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119484212	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs56270433	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119484875	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10006525	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119487776	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10006706	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119487997	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs6849171	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119488394	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs7681544	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119490100	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs17005535	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119490407	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs11940028	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119490752	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs11935596	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119491302	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs12507964	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119491906	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs11098530	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119491999	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs6834796	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119493538	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs11729521	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119495633	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs11734241	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119495717	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs17006190	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119497683	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs28685688	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119499179	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs7687843	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119500056	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs2306455	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119500814	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10031483	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119501481	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10031665	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119501697	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs3733519	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119502293	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs3733520	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119502325	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs3733523	ENSG00000250412.1	KLHL2P1	5.92	3.41e-08	7.79e-05	0.63	0.48	Corneal astigmatism;	chr4:119502564	chr4:119334329~119378233:+
GBM	cis	rs4713118	0.513	rs149989	ENSG00000199851.2	U3	5.92	3.41e-08	7.8e-05	0.72	0.48	Parkinson's disease;	chr6:28030406	chr6:28015568~28015777:+
GBM	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	5.92	3.41e-08	7.8e-05	0.65	0.48	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
GBM	cis	rs453301	0.631	rs7843369	ENSG00000253893.2	FAM85B	5.92	3.42e-08	7.81e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8940276	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.618	rs28491261	ENSG00000250412.1	KLHL2P1	5.92	3.43e-08	7.83e-05	0.63	0.48	Corneal astigmatism;	chr4:119373745	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs59394118	ENSG00000250412.1	KLHL2P1	5.92	3.43e-08	7.83e-05	0.63	0.48	Corneal astigmatism;	chr4:119374396	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs9996417	ENSG00000250412.1	KLHL2P1	5.92	3.43e-08	7.83e-05	0.63	0.48	Corneal astigmatism;	chr4:119374707	chr4:119334329~119378233:+
GBM	cis	rs453301	0.631	rs11779804	ENSG00000253893.2	FAM85B	5.92	3.43e-08	7.83e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8940442	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.954	rs6857105	ENSG00000250412.1	KLHL2P1	5.92	3.45e-08	7.87e-05	0.62	0.48	Corneal astigmatism;	chr4:119301143	chr4:119334329~119378233:+
GBM	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	5.92	3.48e-08	7.93e-05	0.58	0.48	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
GBM	cis	rs4273100	0.646	rs2296981	ENSG00000265185.4	SNORD3B-1	-5.92	3.48e-08	7.93e-05	-0.56	-0.48	Schizophrenia;	chr17:19310022	chr17:19061912~19062669:+
GBM	cis	rs17270561	0.541	rs2009610	ENSG00000272810.1	U91328.22	-5.91	3.5e-08	7.97e-05	-0.71	-0.48	Iron status biomarkers;	chr6:25966840	chr6:26013241~26013757:+
GBM	cis	rs2712381	0.797	rs62270806	ENSG00000277250.1	Metazoa_SRP	-5.91	3.5e-08	7.97e-05	-0.56	-0.48	Monocyte count;	chr3:128657426	chr3:128673681~128674021:-
GBM	cis	rs172166	0.694	rs203893	ENSG00000199851.2	U3	5.91	3.52e-08	8.01e-05	0.71	0.48	Cardiac Troponin-T levels;	chr6:28094288	chr6:28015568~28015777:+
GBM	cis	rs172166	0.652	rs476167	ENSG00000199851.2	U3	5.91	3.52e-08	8.01e-05	0.71	0.48	Cardiac Troponin-T levels;	chr6:28098110	chr6:28015568~28015777:+
GBM	cis	rs172166	0.694	rs203892	ENSG00000199851.2	U3	5.91	3.52e-08	8.01e-05	0.71	0.48	Cardiac Troponin-T levels;	chr6:28099418	chr6:28015568~28015777:+
GBM	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	5.91	3.53e-08	8.04e-05	0.53	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
GBM	cis	rs453301	0.631	rs13250781	ENSG00000253893.2	FAM85B	5.91	3.54e-08	8.06e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8935833	chr8:8167819~8226614:-
GBM	cis	rs453301	0.631	rs28572014	ENSG00000253893.2	FAM85B	5.91	3.54e-08	8.06e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8936097	chr8:8167819~8226614:-
GBM	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	5.91	3.54e-08	8.06e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
GBM	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	5.91	3.54e-08	8.06e-05	0.74	0.48	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
GBM	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-5.91	3.55e-08	8.08e-05	-0.56	-0.48	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
GBM	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-5.91	3.6e-08	8.18e-05	-0.59	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
GBM	cis	rs4273100	0.688	rs4143829	ENSG00000265185.4	SNORD3B-1	-5.91	3.61e-08	8.2e-05	-0.55	-0.48	Schizophrenia;	chr17:19338192	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.646	rs4924987	ENSG00000265185.4	SNORD3B-1	-5.91	3.61e-08	8.2e-05	-0.55	-0.48	Schizophrenia;	chr17:19343762	chr17:19061912~19062669:+
GBM	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	5.91	3.61e-08	8.2e-05	0.58	0.48	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
GBM	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	5.91	3.62e-08	8.22e-05	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
GBM	cis	rs453301	0.579	rs10096850	ENSG00000253893.2	FAM85B	5.91	3.62e-08	8.23e-05	0.57	0.48	Joint mobility (Beighton score);	chr8:8940712	chr8:8167819~8226614:-
GBM	cis	rs2486288	0.656	rs6493144	ENSG00000259433.2	CTD-2651B20.4	-5.91	3.63e-08	8.24e-05	-0.54	-0.48	Glomerular filtration rate;	chr15:45281291	chr15:45330209~45332634:-
GBM	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	5.91	3.63e-08	8.25e-05	0.73	0.48	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
GBM	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	5.9	3.65e-08	8.29e-05	0.64	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	5.9	3.65e-08	8.29e-05	0.64	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
GBM	cis	rs6452524	0.868	rs1011981	ENSG00000248112.1	RP11-78C3.1	5.9	3.67e-08	8.33e-05	0.59	0.48	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs17284218	ENSG00000248112.1	RP11-78C3.1	5.9	3.67e-08	8.33e-05	0.59	0.48	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs10079372	ENSG00000248112.1	RP11-78C3.1	5.9	3.67e-08	8.33e-05	0.59	0.48	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:82919376~82921119:-
GBM	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-5.9	3.67e-08	8.33e-05	-0.65	-0.48	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-5.9	3.67e-08	8.33e-05	-0.65	-0.48	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-5.9	3.67e-08	8.33e-05	-0.65	-0.48	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-5.9	3.67e-08	8.33e-05	-0.65	-0.48	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
GBM	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-5.9	3.69e-08	8.36e-05	-0.64	-0.48	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
GBM	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	5.9	3.69e-08	8.36e-05	0.59	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
GBM	cis	rs6782228	0.675	rs9841987	ENSG00000277250.1	Metazoa_SRP	-5.9	3.7e-08	8.39e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.675	rs56141228	ENSG00000277250.1	Metazoa_SRP	-5.9	3.7e-08	8.39e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.651	rs9852825	ENSG00000277250.1	Metazoa_SRP	-5.9	3.7e-08	8.39e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128673681~128674021:-
GBM	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-5.9	3.71e-08	8.4e-05	-0.65	-0.48	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
GBM	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-5.9	3.71e-08	8.4e-05	-0.67	-0.48	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-5.9	3.71e-08	8.4e-05	-0.67	-0.48	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-5.9	3.71e-08	8.4e-05	-0.67	-0.48	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
GBM	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-5.9	3.71e-08	8.41e-05	-0.56	-0.48	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
GBM	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	5.9	3.72e-08	8.42e-05	0.61	0.48	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	5.9	3.72e-08	8.43e-05	0.63	0.48	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
GBM	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	5.9	3.75e-08	8.47e-05	0.53	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
GBM	cis	rs6782228	0.606	rs2811490	ENSG00000277250.1	Metazoa_SRP	-5.9	3.75e-08	8.48e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128673681~128674021:-
GBM	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-5.9	3.75e-08	8.48e-05	-0.64	-0.48	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
GBM	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	5.9	3.76e-08	8.49e-05	0.6	0.48	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	5.9	3.81e-08	8.59e-05	0.61	0.48	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
GBM	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-5.9	3.82e-08	8.59e-05	-0.46	-0.48	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	5.89	3.84e-08	8.59e-05	0.47	0.48	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
GBM	cis	rs11098499	0.863	rs12508173	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119397371	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.908	rs12504149	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119397422	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10008392	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119397684	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.58	rs12509234	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119398279	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs10014719	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119399560	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10017543	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119400265	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.908	rs7695996	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119400878	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs10518331	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119402440	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs13133522	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119403269	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs35091806	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119404374	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs35165976	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119404475	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs2389802	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119404577	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs6846442	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119405168	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs4001305	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119438081	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs67265404	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119438115	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs71614422	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119438185	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.738	rs34566984	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119440115	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.738	rs34965784	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119440431	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs17009122	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119441248	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.505	rs75122014	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119441271	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs9685777	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119444810	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs71614438	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119450097	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs66506550	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119450290	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs7659501	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119450397	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs71629403	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119451412	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.697	rs28655325	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119451844	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28571712	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119454825	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.738	rs28408407	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119454875	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs1809406	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119455967	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs2389809	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119456244	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.657	rs71614442	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119458191	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs2892848	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119460186	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs9994730	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119460409	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs9994810	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119460435	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.697	rs10020027	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119460724	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.779	rs7356491	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119460819	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.697	rs11941899	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119461603	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs7681978	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119462620	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.821	rs28665282	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119463031	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.738	rs10026493	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119463039	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs10026736	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119463167	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs7681214	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119464165	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.908	rs28559989	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119465472	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.908	rs28499576	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119465522	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28632018	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119465575	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.908	rs71614449	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119465900	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs35063680	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119465947	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs34858317	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119465955	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs17046116	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119466104	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs17046118	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119466341	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs7654587	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119467251	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs11098525	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119468997	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs11098526	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119469204	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.821	rs10032151	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119470473	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs10032158	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119470477	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs6838814	ENSG00000250412.1	KLHL2P1	5.89	3.84e-08	8.59e-05	0.62	0.48	Corneal astigmatism;	chr4:119471288	chr4:119334329~119378233:+
GBM	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	5.89	3.84e-08	8.59e-05	0.41	0.48	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
GBM	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-5.89	3.84e-08	8.59e-05	-0.56	-0.48	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-5.89	3.84e-08	8.59e-05	-0.56	-0.48	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-5.89	3.84e-08	8.59e-05	-0.56	-0.48	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-5.89	3.84e-08	8.59e-05	-0.56	-0.48	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-5.89	3.84e-08	8.59e-05	-0.56	-0.48	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-5.89	3.84e-08	8.59e-05	-0.56	-0.48	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
GBM	cis	rs11098499	0.909	rs11723839	ENSG00000250412.1	KLHL2P1	5.89	3.86e-08	8.62e-05	0.63	0.48	Corneal astigmatism;	chr4:119378518	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs12506546	ENSG00000250412.1	KLHL2P1	5.89	3.86e-08	8.62e-05	0.63	0.48	Corneal astigmatism;	chr4:119380463	chr4:119334329~119378233:+
GBM	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-5.89	3.87e-08	8.64e-05	-0.67	-0.48	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
GBM	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-5.89	3.87e-08	8.64e-05	-0.6	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-5.89	3.87e-08	8.64e-05	-0.6	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
GBM	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	5.89	3.87e-08	8.64e-05	0.63	0.48	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
GBM	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-5.89	3.88e-08	8.65e-05	-0.6	-0.48	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
GBM	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	5.89	3.88e-08	8.67e-05	0.54	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
GBM	cis	rs7267979	1	rs2500432	ENSG00000125804.12	FAM182A	-5.89	3.88e-08	8.67e-05	-0.61	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:26054655~26086917:+
GBM	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	5.89	3.89e-08	8.69e-05	0.89	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
GBM	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	5.89	3.91e-08	8.72e-05	0.53	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
GBM	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	5.89	3.91e-08	8.72e-05	0.53	0.48	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
GBM	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-5.89	3.91e-08	8.73e-05	-0.54	-0.48	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
GBM	cis	rs6782228	0.509	rs4481172	ENSG00000277250.1	Metazoa_SRP	-5.89	3.95e-08	8.8e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs6787559	ENSG00000277250.1	Metazoa_SRP	-5.89	3.95e-08	8.8e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128673681~128674021:-
GBM	cis	rs11098499	0.738	rs72918577	ENSG00000250412.1	KLHL2P1	5.89	3.97e-08	8.83e-05	0.62	0.48	Corneal astigmatism;	chr4:119405546	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs72676074	ENSG00000250412.1	KLHL2P1	5.89	3.97e-08	8.83e-05	0.62	0.48	Corneal astigmatism;	chr4:119438686	chr4:119334329~119378233:+
GBM	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-5.89	3.97e-08	8.84e-05	-0.64	-0.48	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-5.89	3.97e-08	8.84e-05	-0.64	-0.48	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
GBM	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	5.89	3.97e-08	8.84e-05	0.54	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	5.89	3.97e-08	8.84e-05	0.54	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	5.89	3.97e-08	8.84e-05	0.54	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
GBM	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	5.89	3.98e-08	8.84e-05	0.61	0.48	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
GBM	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-5.89	3.98e-08	8.84e-05	-0.74	-0.48	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
GBM	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-5.89	3.98e-08	8.85e-05	-0.67	-0.48	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-5.89	3.98e-08	8.85e-05	-0.67	-0.48	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-5.89	3.99e-08	8.86e-05	-0.67	-0.48	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000224205.1	AP000351.4	5.89	3.99e-08	8.86e-05	0.52	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000224205.1	AP000351.4	5.89	3.99e-08	8.86e-05	0.52	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23987320~23991421:-
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000224205.1	AP000351.4	5.89	3.99e-08	8.86e-05	0.52	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23987320~23991421:-
GBM	cis	rs11098499	0.863	rs3736115	ENSG00000250412.1	KLHL2P1	-5.89	4e-08	8.88e-05	-0.6	-0.48	Corneal astigmatism;	chr4:119567548	chr4:119334329~119378233:+
GBM	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-5.88	4.03e-08	8.94e-05	-0.57	-0.48	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
GBM	cis	rs7267979	1	rs6050555	ENSG00000276952.1	RP5-965G21.6	-5.88	4.06e-08	8.98e-05	-0.45	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25284915~25285588:-
GBM	cis	rs11098499	0.644	rs3806808	ENSG00000249244.1	RP11-548H18.2	5.88	4.06e-08	8.99e-05	0.58	0.48	Corneal astigmatism;	chr4:119629930	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs34835603	ENSG00000249244.1	RP11-548H18.2	5.88	4.06e-08	8.99e-05	0.58	0.48	Corneal astigmatism;	chr4:119632273	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.615	rs28850368	ENSG00000249244.1	RP11-548H18.2	5.88	4.06e-08	8.99e-05	0.58	0.48	Corneal astigmatism;	chr4:119633158	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.675	rs11098534	ENSG00000249244.1	RP11-548H18.2	5.88	4.06e-08	8.99e-05	0.58	0.48	Corneal astigmatism;	chr4:119635617	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs10009566	ENSG00000249244.1	RP11-548H18.2	5.88	4.06e-08	8.99e-05	0.58	0.48	Corneal astigmatism;	chr4:119637453	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs10012252	ENSG00000249244.1	RP11-548H18.2	5.88	4.06e-08	8.99e-05	0.58	0.48	Corneal astigmatism;	chr4:119637984	chr4:119391831~119395335:-
GBM	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	5.88	4.09e-08	9.04e-05	0.5	0.48	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
GBM	cis	rs6452524	0.901	rs72767146	ENSG00000248112.1	RP11-78C3.1	5.88	4.09e-08	9.04e-05	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:82919376~82921119:-
GBM	cis	rs380904	0.963	rs410836	ENSG00000254859.1	RP11-661A12.5	-5.88	4.1e-08	9.04e-05	-0.6	-0.48	Venous thromboembolism (SNP x SNP interaction);	chr8:143494679	chr8:143541973~143549729:-
GBM	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	5.88	4.11e-08	9.07e-05	0.52	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
GBM	cis	rs11098499	0.908	rs11098527	ENSG00000250412.1	KLHL2P1	5.88	4.13e-08	9.11e-05	0.63	0.48	Corneal astigmatism;	chr4:119478751	chr4:119334329~119378233:+
GBM	cis	rs4273100	1	rs12602286	ENSG00000265185.4	SNORD3B-1	-5.88	4.13e-08	9.12e-05	-0.61	-0.48	Schizophrenia;	chr17:19333641	chr17:19061912~19062669:+
GBM	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	5.88	4.17e-08	9.19e-05	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	5.88	4.17e-08	9.19e-05	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	5.88	4.17e-08	9.19e-05	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	5.88	4.17e-08	9.19e-05	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
GBM	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-5.88	4.17e-08	9.19e-05	-0.5	-0.48	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-5.88	4.17e-08	9.19e-05	-0.5	-0.48	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-5.88	4.17e-08	9.19e-05	-0.5	-0.48	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
GBM	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-5.88	4.17e-08	9.19e-05	-0.5	-0.48	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
GBM	cis	rs11098499	0.908	rs2017057	ENSG00000250412.1	KLHL2P1	5.88	4.19e-08	9.24e-05	0.62	0.48	Corneal astigmatism;	chr4:119336556	chr4:119334329~119378233:+
GBM	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-5.88	4.19e-08	9.24e-05	-0.66	-0.48	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
GBM	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	5.87	4.2e-08	9.26e-05	0.95	0.48	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
GBM	cis	rs6782228	0.606	rs2001703	ENSG00000277250.1	Metazoa_SRP	-5.87	4.2e-08	9.26e-05	-0.55	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128673681~128674021:-
GBM	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	5.87	4.23e-08	9.31e-05	0.62	0.48	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	5.87	4.23e-08	9.31e-05	0.62	0.48	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	5.87	4.23e-08	9.31e-05	0.62	0.48	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
GBM	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	5.87	4.24e-08	9.32e-05	0.53	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	5.87	4.24e-08	9.32e-05	0.53	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	5.87	4.24e-08	9.32e-05	0.53	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	5.87	4.24e-08	9.32e-05	0.53	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	5.87	4.24e-08	9.32e-05	0.53	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
GBM	cis	rs11098499	0.863	rs1383532	ENSG00000250412.1	KLHL2P1	-5.87	4.25e-08	9.35e-05	-0.6	-0.48	Corneal astigmatism;	chr4:119513249	chr4:119334329~119378233:+
GBM	cis	rs4683346	0.656	rs11129979	ENSG00000273328.4	RP11-141M3.6	-5.87	4.25e-08	9.35e-05	-0.53	-0.48	Granulocyte percentage of myeloid white cells;	chr3:42849239	chr3:42809414~42908105:+
GBM	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-5.87	4.27e-08	9.38e-05	-0.62	-0.48	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000235689.1	AP000351.13	5.87	4.28e-08	9.41e-05	0.54	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:24006305~24008258:-
GBM	cis	rs7267979	1	rs2257991	ENSG00000125804.12	FAM182A	5.87	4.29e-08	9.41e-05	0.61	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:26054655~26086917:+
GBM	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	5.87	4.29e-08	9.42e-05	0.53	0.48	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	5.87	4.29e-08	9.42e-05	0.53	0.48	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
GBM	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	5.87	4.29e-08	9.43e-05	0.6	0.48	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
GBM	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	5.87	4.31e-08	9.46e-05	0.73	0.48	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	5.87	4.31e-08	9.46e-05	0.73	0.48	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	5.87	4.31e-08	9.46e-05	0.73	0.48	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	5.87	4.31e-08	9.46e-05	0.73	0.48	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	5.87	4.31e-08	9.46e-05	0.73	0.48	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
GBM	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	5.87	4.32e-08	9.49e-05	0.85	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
GBM	cis	rs8072100	0.905	rs8078686	ENSG00000228782.6	CTD-2026D20.3	-5.87	4.33e-08	9.5e-05	-0.56	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47658340	chr17:47450568~47492492:-
GBM	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	5.87	4.34e-08	9.51e-05	1.09	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
GBM	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	5.87	4.34e-08	9.51e-05	1.09	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
GBM	cis	rs11098499	0.566	rs17051356	ENSG00000250412.1	KLHL2P1	5.87	4.35e-08	9.54e-05	0.61	0.48	Corneal astigmatism;	chr4:119664153	chr4:119334329~119378233:+
GBM	cis	rs4273100	0.688	rs12938803	ENSG00000265185.4	SNORD3B-1	-5.87	4.37e-08	9.59e-05	-0.56	-0.48	Schizophrenia;	chr17:19301119	chr17:19061912~19062669:+
GBM	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-5.87	4.38e-08	9.6e-05	-0.64	-0.48	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
GBM	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	5.87	4.38e-08	9.6e-05	0.58	0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
GBM	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	5.86	4.42e-08	9.69e-05	0.58	0.48	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
GBM	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-5.86	4.44e-08	9.73e-05	-0.67	-0.48	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-5.86	4.44e-08	9.73e-05	-0.67	-0.48	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
GBM	cis	rs6782228	0.606	rs58977394	ENSG00000277250.1	Metazoa_SRP	-5.86	4.45e-08	9.74e-05	-0.54	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128673681~128674021:-
GBM	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-5.86	4.46e-08	9.77e-05	-0.68	-0.48	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-5.86	4.46e-08	9.77e-05	-0.68	-0.48	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	5.86	4.47e-08	9.79e-05	0.52	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
GBM	cis	rs11098499	0.909	rs9759478	ENSG00000250412.1	KLHL2P1	5.86	4.48e-08	9.81e-05	0.62	0.48	Corneal astigmatism;	chr4:119446843	chr4:119334329~119378233:+
GBM	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	5.86	4.51e-08	9.87e-05	0.51	0.48	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
GBM	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-5.86	4.52e-08	9.89e-05	-0.85	-0.48	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
GBM	cis	rs6782228	0.527	rs2712371	ENSG00000277250.1	Metazoa_SRP	-5.86	4.54e-08	9.92e-05	-0.54	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128673681~128674021:-
GBM	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-5.86	4.54e-08	9.93e-05	-0.67	-0.48	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-5.86	4.54e-08	9.93e-05	-0.67	-0.48	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	5.86	4.57e-08	9.98e-05	0.64	0.48	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
GBM	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-5.86	4.57e-08	9.99e-05	-0.51	-0.48	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
GBM	cis	rs2980439	0.517	rs17594065	ENSG00000253893.2	FAM85B	5.86	4.59e-08	1e-04	0.6	0.48	Neuroticism;	chr8:8247883	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.863	rs1010739	ENSG00000250412.1	KLHL2P1	5.86	4.6e-08	1e-04	0.61	0.48	Corneal astigmatism;	chr4:119542316	chr4:119334329~119378233:+
GBM	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	5.85	4.61e-08	0.000101	0.58	0.48	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	5.85	4.61e-08	0.000101	0.58	0.48	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	5.85	4.61e-08	0.000101	0.58	0.48	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	5.85	4.61e-08	0.000101	0.58	0.48	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
GBM	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	5.85	4.61e-08	0.000101	0.58	0.48	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
GBM	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	5.85	4.62e-08	0.000101	0.57	0.48	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	5.85	4.62e-08	0.000101	0.57	0.48	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
GBM	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	5.85	4.63e-08	0.000101	0.64	0.48	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
GBM	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-5.85	4.63e-08	0.000101	-0.57	-0.48	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
GBM	cis	rs881375	0.902	rs7021880	ENSG00000226752.6	PSMD5-AS1	5.85	4.65e-08	0.000101	0.65	0.48	Rheumatoid arthritis;	chr9:120911612	chr9:120824828~120854385:+
GBM	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	5.85	4.66e-08	0.000102	0.51	0.48	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
GBM	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-5.85	4.66e-08	0.000102	-0.51	-0.48	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
GBM	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	5.85	4.68e-08	0.000102	0.54	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
GBM	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	5.85	4.68e-08	0.000102	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
GBM	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	5.85	4.68e-08	0.000102	0.41	0.48	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
GBM	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-5.85	4.69e-08	0.000102	-0.67	-0.48	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-5.85	4.69e-08	0.000102	-0.67	-0.48	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
GBM	cis	rs380904	0.963	rs410822	ENSG00000254859.1	RP11-661A12.5	-5.85	4.71e-08	0.000102	-0.6	-0.48	Venous thromboembolism (SNP x SNP interaction);	chr8:143492441	chr8:143541973~143549729:-
GBM	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-5.85	4.74e-08	0.000103	-0.55	-0.48	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
GBM	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	5.85	4.74e-08	0.000103	0.61	0.48	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
GBM	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	5.85	4.76e-08	0.000103	0.4	0.48	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
GBM	cis	rs11098499	0.954	rs13145352	ENSG00000250412.1	KLHL2P1	-5.85	4.77e-08	0.000104	-0.62	-0.48	Corneal astigmatism;	chr4:119488808	chr4:119334329~119378233:+
GBM	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-5.85	4.78e-08	0.000104	-0.6	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
GBM	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-5.85	4.78e-08	0.000104	-0.6	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
GBM	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-5.85	4.78e-08	0.000104	-0.55	-0.48	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
GBM	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	5.85	4.79e-08	0.000104	0.73	0.48	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
GBM	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	5.85	4.79e-08	0.000104	0.73	0.48	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
GBM	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-5.85	4.79e-08	0.000104	-0.59	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
GBM	cis	rs950027	0.787	rs1153845	ENSG00000259433.2	CTD-2651B20.4	5.85	4.8e-08	0.000104	0.48	0.48	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45330209~45332634:-
GBM	cis	rs6496932	0.77	rs4843040	ENSG00000218052.5	ADAMTS7P4	5.85	4.81e-08	0.000104	0.63	0.48	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85255369~85330334:-
GBM	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	5.84	4.82e-08	0.000105	0.6	0.48	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
GBM	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	5.84	4.84e-08	0.000105	0.74	0.48	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	5.84	4.84e-08	0.000105	0.74	0.48	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	5.84	4.84e-08	0.000105	0.74	0.48	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	5.84	4.84e-08	0.000105	0.74	0.48	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	5.84	4.84e-08	0.000105	0.74	0.48	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
GBM	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-5.84	4.85e-08	0.000105	-0.6	-0.48	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
GBM	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	5.84	4.85e-08	0.000105	0.61	0.48	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
GBM	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-5.84	4.85e-08	0.000105	-0.63	-0.48	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
GBM	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	5.84	4.85e-08	0.000105	0.68	0.48	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
GBM	cis	rs11696739	0.536	rs11696842	ENSG00000242324.1	RP4-576H24.2	5.84	4.88e-08	0.000106	0.66	0.48	Mean platelet volume;	chr20:1620148	chr20:1516759~1557653:-
GBM	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-5.84	4.89e-08	0.000106	-0.4	-0.48	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
GBM	cis	rs11098499	0.779	rs10011097	ENSG00000250412.1	KLHL2P1	5.84	4.9e-08	0.000106	0.62	0.48	Corneal astigmatism;	chr4:119389204	chr4:119334329~119378233:+
GBM	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	5.84	4.93e-08	0.000107	0.6	0.48	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	5.84	4.93e-08	0.000107	0.6	0.48	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
GBM	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.84	4.95e-08	0.000107	-0.61	-0.48	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
GBM	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-5.84	4.95e-08	0.000107	-0.7	-0.48	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
GBM	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-5.84	4.96e-08	0.000107	-0.74	-0.48	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
GBM	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	5.84	5e-08	0.000108	0.41	0.48	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
GBM	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-5.84	5e-08	0.000108	-0.67	-0.48	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
GBM	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	5.84	5e-08	0.000108	0.67	0.48	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
GBM	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-5.84	5.01e-08	0.000108	-0.58	-0.48	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
GBM	cis	rs67981189	0.727	rs221903	ENSG00000269927.1	RP6-91H8.3	-5.84	5.04e-08	0.000109	-0.56	-0.48	Schizophrenia;	chr14:71133491	chr14:71141125~71143253:-
GBM	cis	rs11098499	0.526	rs10026625	ENSG00000249244.1	RP11-548H18.2	5.84	5.05e-08	0.000109	0.58	0.48	Corneal astigmatism;	chr4:119358981	chr4:119391831~119395335:-
GBM	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	5.83	5.06e-08	0.000109	0.6	0.48	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	5.83	5.06e-08	0.000109	0.6	0.48	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	5.83	5.06e-08	0.000109	0.6	0.48	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	5.83	5.06e-08	0.000109	0.6	0.48	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	5.83	5.06e-08	0.000109	0.67	0.48	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
GBM	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-5.83	5.08e-08	0.00011	-0.45	-0.48	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
GBM	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-5.83	5.08e-08	0.00011	-0.45	-0.48	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
GBM	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	5.83	5.1e-08	0.00011	0.63	0.48	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
GBM	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-5.83	5.11e-08	0.00011	-0.66	-0.48	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-5.83	5.12e-08	0.00011	-0.62	-0.48	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
GBM	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-5.83	5.13e-08	0.00011	-0.87	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
GBM	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	5.83	5.14e-08	0.000111	0.63	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
GBM	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	5.83	5.14e-08	0.000111	0.54	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	5.83	5.14e-08	0.000111	0.54	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
GBM	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-5.83	5.19e-08	0.000112	-0.38	-0.48	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
GBM	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	5.83	5.2e-08	0.000112	0.56	0.48	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
GBM	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	5.83	5.21e-08	0.000112	0.54	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
GBM	cis	rs7615952	0.611	rs114419739	ENSG00000171084.14	FAM86JP	5.83	5.26e-08	0.000113	0.97	0.48	Blood pressure (smoking interaction);	chr3:126003647	chr3:125916620~125930024:+
GBM	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-5.83	5.29e-08	0.000114	-0.38	-0.48	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
GBM	cis	rs11098499	0.779	rs80242894	ENSG00000250412.1	KLHL2P1	5.82	5.29e-08	0.000114	0.61	0.48	Corneal astigmatism;	chr4:119454597	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.779	rs28495013	ENSG00000250412.1	KLHL2P1	5.82	5.29e-08	0.000114	0.61	0.48	Corneal astigmatism;	chr4:119454676	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs12502423	ENSG00000250412.1	KLHL2P1	5.82	5.32e-08	0.000114	0.62	0.48	Corneal astigmatism;	chr4:119503017	chr4:119334329~119378233:+
GBM	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	5.82	5.33e-08	0.000114	0.67	0.48	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-5.82	5.34e-08	0.000115	-0.67	-0.48	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-5.82	5.34e-08	0.000115	-0.67	-0.48	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
GBM	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-5.82	5.34e-08	0.000115	-0.6	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
GBM	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	5.82	5.35e-08	0.000115	0.82	0.48	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
GBM	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	5.82	5.36e-08	0.000115	0.57	0.48	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	5.82	5.36e-08	0.000115	0.57	0.48	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
GBM	cis	rs7267979	1	rs6083844	ENSG00000276952.1	RP5-965G21.6	-5.82	5.44e-08	0.000116	-0.45	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25284915~25285588:-
GBM	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-5.82	5.44e-08	0.000117	-0.54	-0.48	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
GBM	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-5.82	5.45e-08	0.000117	-0.63	-0.48	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
GBM	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-5.82	5.45e-08	0.000117	-0.63	-0.48	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
GBM	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-5.82	5.45e-08	0.000117	-0.63	-0.48	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
GBM	cis	rs453301	0.631	rs7843789	ENSG00000253893.2	FAM85B	5.82	5.46e-08	0.000117	0.56	0.48	Joint mobility (Beighton score);	chr8:8943051	chr8:8167819~8226614:-
GBM	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	5.82	5.49e-08	0.000117	0.67	0.48	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	5.82	5.49e-08	0.000117	0.67	0.48	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	5.82	5.49e-08	0.000117	0.67	0.48	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	5.82	5.49e-08	0.000117	0.67	0.48	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	5.82	5.49e-08	0.000117	0.67	0.48	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	5.82	5.49e-08	0.000117	0.67	0.48	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
GBM	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-5.82	5.49e-08	0.000117	-0.67	-0.48	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
GBM	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	5.82	5.51e-08	0.000118	0.51	0.48	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
GBM	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-5.82	5.52e-08	0.000118	-0.55	-0.48	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
GBM	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	5.82	5.54e-08	0.000118	0.79	0.48	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
GBM	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	5.81	5.55e-08	0.000118	0.6	0.48	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	5.81	5.56e-08	0.000119	0.57	0.48	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	5.81	5.56e-08	0.000119	0.57	0.48	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
GBM	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	5.81	5.57e-08	0.000119	0.62	0.48	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
GBM	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	5.81	5.57e-08	0.000119	0.57	0.48	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
GBM	cis	rs7267979	1	rs6050598	ENSG00000276952.1	RP5-965G21.6	5.81	5.65e-08	0.00012	0.43	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25284915~25285588:-
GBM	cis	rs2013441	0.83	rs2526469	ENSG00000230528.6	NOS2P3	5.81	5.68e-08	0.000121	0.54	0.48	Obesity-related traits;	chr17:20259435	chr17:20436337~20447249:+
GBM	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	5.81	5.69e-08	0.000121	0.5	0.48	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
GBM	cis	rs4683346	0.656	rs4682862	ENSG00000273328.4	RP11-141M3.6	-5.81	5.76e-08	0.000122	-0.51	-0.48	Granulocyte percentage of myeloid white cells;	chr3:42835921	chr3:42809414~42908105:+
GBM	cis	rs4713118	0.662	rs4713120	ENSG00000218016.2	ZNF192P2	-5.81	5.79e-08	0.000123	-0.57	-0.48	Parkinson's disease;	chr6:27754056	chr6:28188050~28189432:+
GBM	cis	rs860818	1	rs858234	ENSG00000226816.2	AC005082.12	-5.81	5.79e-08	0.000123	-1.21	-0.48	Initial pursuit acceleration;	chr7:23201196	chr7:23206013~23208045:+
GBM	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-5.81	5.79e-08	0.000123	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-5.81	5.79e-08	0.000123	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-5.81	5.79e-08	0.000123	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
GBM	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-5.81	5.79e-08	0.000123	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
GBM	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-5.8	5.82e-08	0.000124	-0.52	-0.48	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
GBM	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-5.8	5.84e-08	0.000124	-0.57	-0.48	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
GBM	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-5.8	5.86e-08	0.000124	-0.54	-0.48	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-5.8	5.86e-08	0.000124	-0.54	-0.48	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-5.8	5.86e-08	0.000124	-0.54	-0.48	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-5.8	5.86e-08	0.000124	-0.54	-0.48	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
GBM	cis	rs7267979	1	rs4815418	ENSG00000276952.1	RP5-965G21.6	-5.8	5.88e-08	0.000125	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25284915~25285588:-
GBM	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-5.8	5.9e-08	0.000125	-0.55	-0.48	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
GBM	cis	rs4682868	0.581	rs6774801	ENSG00000273328.4	RP11-141M3.6	5.8	5.91e-08	0.000125	0.53	0.48	Monocyte percentage of white cells;	chr3:42882284	chr3:42809414~42908105:+
GBM	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-5.8	5.93e-08	0.000126	-0.55	-0.48	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-5.8	5.93e-08	0.000126	-0.55	-0.48	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-5.8	5.93e-08	0.000126	-0.55	-0.48	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
GBM	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	5.8	5.93e-08	0.000126	0.68	0.48	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	5.8	5.93e-08	0.000126	0.68	0.48	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	5.8	5.93e-08	0.000126	0.68	0.48	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	5.8	5.93e-08	0.000126	0.68	0.48	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	5.8	5.93e-08	0.000126	0.68	0.48	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
GBM	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	5.8	5.94e-08	0.000126	0.59	0.48	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	5.8	5.94e-08	0.000126	0.59	0.48	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	5.8	5.94e-08	0.000126	0.59	0.48	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.954	rs7437420	ENSG00000250412.1	KLHL2P1	5.8	5.95e-08	0.000126	0.62	0.48	Corneal astigmatism;	chr4:119391748	chr4:119334329~119378233:+
GBM	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	5.8	5.96e-08	0.000126	0.66	0.48	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
GBM	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	5.8	5.98e-08	0.000127	0.64	0.48	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
GBM	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-5.8	5.99e-08	0.000127	-0.54	-0.48	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
GBM	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	5.8	6.01e-08	0.000127	0.53	0.48	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
GBM	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	5.8	6.02e-08	0.000127	0.58	0.48	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
GBM	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-5.8	6.03e-08	0.000128	-0.53	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
GBM	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-5.8	6.04e-08	0.000128	-0.61	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
GBM	cis	rs7267979	1	rs6076345	ENSG00000276952.1	RP5-965G21.6	-5.8	6.07e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050590	ENSG00000276952.1	RP5-965G21.6	-5.8	6.07e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4813566	ENSG00000276952.1	RP5-965G21.6	-5.8	6.07e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815421	ENSG00000276952.1	RP5-965G21.6	-5.8	6.07e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25284915~25285588:-
GBM	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-5.8	6.07e-08	0.000128	-0.54	-0.48	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
GBM	cis	rs7267979	0.934	rs113469203	ENSG00000276952.1	RP5-965G21.6	-5.8	6.07e-08	0.000128	-0.45	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25362622	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6115153	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs7268053	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6083809	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050561	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6083813	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815406	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs6083817	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050564	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs6083818	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815409	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6076339	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815411	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs6107031	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6115159	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4813562	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs6050567	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6037099	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs4815414	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6107033	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6083825	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs34645895	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6083828	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs3827014	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6037105	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2387880	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2387882	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2387884	ENSG00000276952.1	RP5-965G21.6	-5.8	6.08e-08	0.000128	-0.44	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2261795	ENSG00000276952.1	RP5-965G21.6	5.8	6.08e-08	0.000128	0.44	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs10966	ENSG00000276952.1	RP5-965G21.6	5.8	6.08e-08	0.000128	0.44	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815412	ENSG00000276952.1	RP5-965G21.6	5.8	6.08e-08	0.000128	0.44	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25284915~25285588:-
GBM	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-5.79	6.08e-08	0.000128	-0.56	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
GBM	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-5.79	6.1e-08	0.000129	-0.68	-0.48	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
GBM	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	5.79	6.13e-08	0.000129	0.59	0.48	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
GBM	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	5.79	6.23e-08	0.000131	0.53	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
GBM	cis	rs11098499	0.909	rs73842633	ENSG00000250412.1	KLHL2P1	5.79	6.23e-08	0.000131	0.62	0.48	Corneal astigmatism;	chr4:119454309	chr4:119334329~119378233:+
GBM	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-5.79	6.25e-08	0.000131	-0.67	-0.48	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-5.79	6.25e-08	0.000131	-0.67	-0.48	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-5.79	6.25e-08	0.000131	-0.67	-0.48	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
GBM	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-5.79	6.25e-08	0.000131	-0.69	-0.48	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
GBM	cis	rs17270561	0.525	rs12201678	ENSG00000272810.1	U91328.22	-5.79	6.29e-08	0.000132	-0.7	-0.47	Iron status biomarkers;	chr6:25978765	chr6:26013241~26013757:+
GBM	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	5.79	6.3e-08	0.000132	0.59	0.47	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
GBM	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-5.79	6.32e-08	0.000133	-0.62	-0.47	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
GBM	cis	rs4683346	0.702	rs4682863	ENSG00000273328.4	RP11-141M3.6	-5.79	6.34e-08	0.000133	-0.51	-0.47	Granulocyte percentage of myeloid white cells;	chr3:42836219	chr3:42809414~42908105:+
GBM	cis	rs11098499	0.865	rs11098513	ENSG00000250412.1	KLHL2P1	5.79	6.35e-08	0.000133	0.62	0.47	Corneal astigmatism;	chr4:119394920	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.954	rs28572238	ENSG00000250412.1	KLHL2P1	5.79	6.35e-08	0.000133	0.62	0.47	Corneal astigmatism;	chr4:119395531	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28714195	ENSG00000250412.1	KLHL2P1	5.79	6.35e-08	0.000133	0.62	0.47	Corneal astigmatism;	chr4:119395795	chr4:119334329~119378233:+
GBM	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-5.79	6.35e-08	0.000133	-0.63	-0.47	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
GBM	cis	rs6452524	0.868	rs11746977	ENSG00000248112.1	RP11-78C3.1	5.79	6.36e-08	0.000133	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:82919376~82921119:-
GBM	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	5.78	6.37e-08	0.000134	0.4	0.47	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
GBM	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	5.78	6.37e-08	0.000134	0.58	0.47	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
GBM	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	5.78	6.38e-08	0.000134	0.4	0.47	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
GBM	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-5.78	6.42e-08	0.000135	-0.55	-0.47	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
GBM	cis	rs36132109	0.858	rs13081266	ENSG00000273328.4	RP11-141M3.6	5.78	6.46e-08	0.000135	0.54	0.47	Monocyte chemoattractant protein-1 levels;	chr3:42963598	chr3:42809414~42908105:+
GBM	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-5.78	6.48e-08	0.000136	-0.62	-0.47	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
GBM	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	5.78	6.5e-08	0.000136	0.6	0.47	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
GBM	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-5.78	6.51e-08	0.000136	-0.66	-0.47	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
GBM	cis	rs2019137	0.539	rs4849181	ENSG00000274877.1	RP11-65I12.1	-5.78	6.53e-08	0.000137	-0.61	-0.47	Lymphocyte counts;	chr2:113234393	chr2:113237595~113240825:+
GBM	cis	rs11098499	0.955	rs56386062	ENSG00000250412.1	KLHL2P1	5.78	6.53e-08	0.000137	0.62	0.47	Corneal astigmatism;	chr4:119233980	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs4145951	ENSG00000250412.1	KLHL2P1	5.78	6.53e-08	0.000137	0.62	0.47	Corneal astigmatism;	chr4:119234662	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs35916640	ENSG00000250412.1	KLHL2P1	5.78	6.53e-08	0.000137	0.62	0.47	Corneal astigmatism;	chr4:119234697	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs13113112	ENSG00000250412.1	KLHL2P1	5.78	6.53e-08	0.000137	0.62	0.47	Corneal astigmatism;	chr4:119234885	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs13114751	ENSG00000250412.1	KLHL2P1	5.78	6.53e-08	0.000137	0.62	0.47	Corneal astigmatism;	chr4:119235462	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.913	rs35271032	ENSG00000250412.1	KLHL2P1	5.78	6.53e-08	0.000137	0.62	0.47	Corneal astigmatism;	chr4:119235504	chr4:119334329~119378233:+
GBM	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-5.78	6.54e-08	0.000137	-0.57	-0.47	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
GBM	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	5.78	6.57e-08	0.000137	0.66	0.47	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	5.78	6.57e-08	0.000137	0.66	0.47	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	5.78	6.57e-08	0.000137	0.66	0.47	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	5.78	6.57e-08	0.000137	0.66	0.47	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
GBM	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-5.78	6.58e-08	0.000138	-0.56	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
GBM	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	5.78	6.62e-08	0.000138	0.41	0.47	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
GBM	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	5.78	6.63e-08	0.000139	0.61	0.47	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
GBM	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	5.78	6.63e-08	0.000139	0.61	0.47	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
GBM	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	5.78	6.64e-08	0.000139	0.6	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
GBM	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-5.78	6.66e-08	0.000139	-0.59	-0.47	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
GBM	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-5.78	6.66e-08	0.000139	-0.66	-0.47	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
GBM	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	5.77	6.68e-08	0.000139	0.56	0.47	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
GBM	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	5.77	6.7e-08	0.00014	0.87	0.47	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
GBM	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-5.77	6.71e-08	0.00014	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
GBM	cis	rs9987353	0.589	rs1053036	ENSG00000253893.2	FAM85B	5.77	6.72e-08	0.00014	0.56	0.47	Recombination measurement;	chr8:9202567	chr8:8167819~8226614:-
GBM	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-5.77	6.74e-08	0.00014	-0.66	-0.47	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
GBM	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-5.77	6.74e-08	0.000141	-0.69	-0.47	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
GBM	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	5.77	6.75e-08	0.000141	0.56	0.47	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
GBM	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-5.77	6.75e-08	0.000141	-0.85	-0.47	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
GBM	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	5.77	6.75e-08	0.000141	0.6	0.47	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.604	rs2389886	ENSG00000250412.1	KLHL2P1	5.77	6.77e-08	0.000141	0.59	0.47	Corneal astigmatism;	chr4:119649267	chr4:119334329~119378233:+
GBM	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	5.77	6.77e-08	0.000141	0.58	0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-5.77	6.77e-08	0.000141	-0.58	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-5.77	6.77e-08	0.000141	-0.58	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
GBM	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	5.77	6.77e-08	0.000141	0.55	0.47	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
GBM	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	5.77	6.79e-08	0.000141	0.55	0.47	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
GBM	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-5.77	6.8e-08	0.000142	-0.69	-0.47	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
GBM	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	5.77	6.82e-08	0.000142	0.41	0.47	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
GBM	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-5.77	6.82e-08	0.000142	-0.58	-0.47	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
GBM	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	5.77	6.83e-08	0.000142	0.52	0.47	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
GBM	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-5.77	6.86e-08	0.000143	-0.83	-0.47	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
GBM	cis	rs2013441	0.795	rs6587064	ENSG00000230528.6	NOS2P3	5.77	6.87e-08	0.000143	0.54	0.47	Obesity-related traits;	chr17:20304571	chr17:20436337~20447249:+
GBM	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-5.77	6.9e-08	0.000143	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
GBM	cis	rs6496932	1	rs12917518	ENSG00000218052.5	ADAMTS7P4	5.77	6.91e-08	0.000144	0.7	0.47	Central corneal thickness;Corneal structure;	chr15:85284018	chr15:85255369~85330334:-
GBM	cis	rs6496932	1	rs28374025	ENSG00000218052.5	ADAMTS7P4	5.77	6.91e-08	0.000144	0.7	0.47	Central corneal thickness;Corneal structure;	chr15:85284107	chr15:85255369~85330334:-
GBM	cis	rs6496932	1	rs2002642	ENSG00000218052.5	ADAMTS7P4	5.77	6.91e-08	0.000144	0.7	0.47	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85255369~85330334:-
GBM	cis	rs6496932	1	rs4842872	ENSG00000218052.5	ADAMTS7P4	5.77	6.91e-08	0.000144	0.7	0.47	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85255369~85330334:-
GBM	cis	rs6496932	1	rs12917495	ENSG00000218052.5	ADAMTS7P4	5.77	6.91e-08	0.000144	0.7	0.47	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85255369~85330334:-
GBM	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-5.77	6.92e-08	0.000144	-0.8	-0.47	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
GBM	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-5.77	6.93e-08	0.000144	-0.45	-0.47	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
GBM	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-5.77	6.93e-08	0.000144	-0.45	-0.47	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
GBM	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-5.77	6.95e-08	0.000144	-0.58	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
GBM	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	5.77	6.96e-08	0.000145	0.63	0.47	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
GBM	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	5.76	7e-08	0.000145	0.73	0.47	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	5.76	7e-08	0.000145	0.73	0.47	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	5.76	7e-08	0.000145	0.73	0.47	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	5.76	7e-08	0.000145	0.73	0.47	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	5.76	7e-08	0.000145	0.73	0.47	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	5.76	7e-08	0.000145	0.73	0.47	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	5.76	7e-08	0.000145	0.73	0.47	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
GBM	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	5.76	7e-08	0.000145	0.57	0.47	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
GBM	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-5.76	7.02e-08	0.000146	-0.55	-0.47	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
GBM	cis	rs7267979	0.789	rs9927	ENSG00000276952.1	RP5-965G21.6	5.76	7.02e-08	0.000146	0.45	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25284915~25285588:-
GBM	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	5.76	7.03e-08	0.000146	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
GBM	cis	rs11098499	0.865	rs28634456	ENSG00000250412.1	KLHL2P1	5.76	7.03e-08	0.000146	0.61	0.47	Corneal astigmatism;	chr4:119454623	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs78332141	ENSG00000250412.1	KLHL2P1	5.76	7.03e-08	0.000146	0.61	0.47	Corneal astigmatism;	chr4:119454627	chr4:119334329~119378233:+
GBM	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	5.76	7.07e-08	0.000147	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	5.76	7.07e-08	0.000147	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
GBM	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	5.76	7.08e-08	0.000147	0.51	0.47	Height;	chr11:118758322	chr11:118791254~118793137:+
GBM	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	5.76	7.1e-08	0.000147	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
GBM	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	5.76	7.1e-08	0.000147	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
GBM	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-5.76	7.12e-08	0.000147	-0.67	-0.47	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
GBM	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-5.76	7.14e-08	0.000148	-0.54	-0.47	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-5.76	7.14e-08	0.000148	-0.54	-0.47	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-5.76	7.14e-08	0.000148	-0.54	-0.47	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-5.76	7.14e-08	0.000148	-0.54	-0.47	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
GBM	cis	rs141413113	1	rs141413113	ENSG00000273328.4	RP11-141M3.6	5.76	7.14e-08	0.000148	0.49	0.47	Lymphocyte percentage of white cells;	chr3:42865919	chr3:42809414~42908105:+
GBM	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	5.76	7.15e-08	0.000148	0.59	0.47	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
GBM	cis	rs4713118	0.513	rs149941	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28033255	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149942	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28033832	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149944	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28035040	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149945	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28035075	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149897	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28038872	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs156734	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28039579	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs202908	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28043773	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs156739	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28045632	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149958	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28045839	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149959	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28046076	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs156738	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28046247	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.513	rs149962	ENSG00000199851.2	U3	5.76	7.17e-08	0.000148	0.7	0.47	Parkinson's disease;	chr6:28048140	chr6:28015568~28015777:+
GBM	cis	rs4273100	0.688	rs4143829	ENSG00000262319.1	CTC-457L16.2	5.76	7.18e-08	0.000148	0.53	0.47	Schizophrenia;	chr17:19338192	chr17:19141017~19143689:-
GBM	cis	rs4273100	0.646	rs4924987	ENSG00000262319.1	CTC-457L16.2	5.76	7.18e-08	0.000148	0.53	0.47	Schizophrenia;	chr17:19343762	chr17:19141017~19143689:-
GBM	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	5.76	7.21e-08	0.000149	0.72	0.47	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
GBM	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	5.76	7.23e-08	0.000149	0.54	0.47	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
GBM	cis	rs916888	0.61	rs199530	ENSG00000261575.2	RP11-259G18.1	-5.76	7.25e-08	0.00015	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46267037~46268694:+
GBM	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	5.76	7.26e-08	0.00015	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
GBM	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	5.76	7.28e-08	0.00015	0.65	0.47	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
GBM	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	5.76	7.29e-08	0.00015	0.52	0.47	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
GBM	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	5.76	7.3e-08	0.00015	0.57	0.47	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
GBM	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	5.76	7.3e-08	0.000151	0.41	0.47	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
GBM	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	5.75	7.32e-08	0.000151	0.53	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
GBM	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-5.75	7.32e-08	0.000151	-0.57	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
GBM	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	5.75	7.38e-08	0.000152	0.59	0.47	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
GBM	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-5.75	7.38e-08	0.000152	-0.58	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
GBM	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	5.75	7.38e-08	0.000152	0.6	0.47	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
GBM	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	5.75	7.38e-08	0.000152	0.52	0.47	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
GBM	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-5.75	7.4e-08	0.000152	-0.64	-0.47	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
GBM	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-5.75	7.44e-08	0.000153	-0.57	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-5.75	7.44e-08	0.000153	-0.57	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-5.75	7.44e-08	0.000153	-0.57	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
GBM	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-5.75	7.44e-08	0.000153	-0.62	-0.47	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
GBM	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-5.75	7.45e-08	0.000153	-0.58	-0.47	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
GBM	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	5.75	7.46e-08	0.000153	0.52	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	5.75	7.46e-08	0.000153	0.52	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	5.75	7.46e-08	0.000153	0.52	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
GBM	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	5.75	7.47e-08	0.000154	0.58	0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
GBM	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-5.75	7.48e-08	0.000154	-0.55	-0.47	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
GBM	cis	rs36132109	0.82	rs55946409	ENSG00000273328.4	RP11-141M3.6	5.75	7.5e-08	0.000154	0.54	0.47	Monocyte chemoattractant protein-1 levels;	chr3:42952383	chr3:42809414~42908105:+
GBM	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	5.75	7.5e-08	0.000154	0.56	0.47	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
GBM	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-5.75	7.53e-08	0.000155	-0.66	-0.47	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-5.75	7.57e-08	0.000155	-0.65	-0.47	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
GBM	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	5.75	7.57e-08	0.000155	0.4	0.47	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
GBM	cis	rs11098499	0.954	rs3890049	ENSG00000250412.1	KLHL2P1	5.75	7.59e-08	0.000156	0.61	0.47	Corneal astigmatism;	chr4:119405128	chr4:119334329~119378233:+
GBM	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
GBM	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
GBM	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
GBM	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
GBM	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
GBM	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
GBM	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
GBM	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-5.75	7.63e-08	0.000156	-0.66	-0.47	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
GBM	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-5.75	7.63e-08	0.000157	-0.62	-0.47	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
GBM	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	5.74	7.65e-08	0.000157	0.56	0.47	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
GBM	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	5.74	7.68e-08	0.000157	0.57	0.47	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
GBM	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-5.74	7.7e-08	0.000158	-0.53	-0.47	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
GBM	cis	rs11696739	0.513	rs34600126	ENSG00000242324.1	RP4-576H24.2	5.74	7.72e-08	0.000158	0.68	0.47	Mean platelet volume;	chr20:1616787	chr20:1516759~1557653:-
GBM	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-5.74	7.72e-08	0.000158	-0.55	-0.47	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
GBM	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-5.74	7.73e-08	0.000158	-0.66	-0.47	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
GBM	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	5.74	7.73e-08	0.000158	0.49	0.47	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
GBM	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	5.74	7.74e-08	0.000158	0.9	0.47	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
GBM	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	5.74	7.75e-08	0.000159	0.47	0.47	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
GBM	cis	rs11098499	0.779	rs7699346	ENSG00000250412.1	KLHL2P1	5.74	7.76e-08	0.000159	0.62	0.47	Corneal astigmatism;	chr4:119389387	chr4:119334329~119378233:+
GBM	cis	rs7615952	0.605	rs11708269	ENSG00000171084.14	FAM86JP	5.74	7.81e-08	0.00016	0.98	0.47	Blood pressure (smoking interaction);	chr3:125613306	chr3:125916620~125930024:+
GBM	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	5.74	7.87e-08	0.000161	1.11	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
GBM	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	5.74	7.88e-08	0.000161	0.77	0.47	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
GBM	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	5.74	7.9e-08	0.000161	0.57	0.47	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
GBM	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-5.74	7.93e-08	0.000162	-0.61	-0.47	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-5.74	7.93e-08	0.000162	-0.61	-0.47	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
GBM	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	5.74	7.94e-08	0.000162	0.56	0.47	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
GBM	cis	rs7267979	0.966	rs6037097	ENSG00000276952.1	RP5-965G21.6	5.74	7.94e-08	0.000162	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25284915~25285588:-
GBM	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-5.74	7.95e-08	0.000162	-0.68	-0.47	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-5.74	7.95e-08	0.000162	-0.68	-0.47	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
GBM	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	5.74	7.98e-08	0.000162	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
GBM	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-5.74	7.98e-08	0.000163	-0.54	-0.47	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
GBM	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-5.74	7.98e-08	0.000163	-0.54	-0.47	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
GBM	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-5.74	8e-08	0.000163	-0.45	-0.47	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
GBM	cis	rs11098499	0.532	rs4833624	ENSG00000249244.1	RP11-548H18.2	5.73	8.07e-08	0.000164	0.6	0.47	Corneal astigmatism;	chr4:119664342	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.532	rs12512646	ENSG00000249244.1	RP11-548H18.2	5.73	8.07e-08	0.000164	0.6	0.47	Corneal astigmatism;	chr4:119664578	chr4:119391831~119395335:-
GBM	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-5.73	8.08e-08	0.000165	-0.59	-0.47	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
GBM	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-5.73	8.08e-08	0.000165	-0.5	-0.47	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
GBM	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-5.73	8.09e-08	0.000165	-0.55	-0.47	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-5.73	8.09e-08	0.000165	-0.55	-0.47	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
GBM	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	5.73	8.1e-08	0.000165	0.57	0.47	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
GBM	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.73	8.12e-08	0.000165	0.57	0.47	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
GBM	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	5.73	8.13e-08	0.000165	0.58	0.47	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	5.73	8.13e-08	0.000165	0.58	0.47	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	5.73	8.13e-08	0.000165	0.58	0.47	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs2275045	ENSG00000268592.3	RAET1E-AS1	5.73	8.13e-08	0.000165	0.58	0.47	Lung cancer;	chr6:149842775	chr6:149863494~149919507:+
GBM	cis	rs11098499	0.909	rs11723757	ENSG00000250412.1	KLHL2P1	5.73	8.14e-08	0.000166	0.61	0.47	Corneal astigmatism;	chr4:119378514	chr4:119334329~119378233:+
GBM	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	5.73	8.15e-08	0.000166	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	5.73	8.27e-08	0.000168	0.55	0.47	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
GBM	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-5.73	8.29e-08	0.000168	-0.64	-0.47	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
GBM	cis	rs7267979	1	rs2184000	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs4815425	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050599	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050602	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs6083855	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815426	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6115182	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050609	ENSG00000276952.1	RP5-965G21.6	-5.73	8.32e-08	0.000169	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2424712	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2424714	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2424715	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050617	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.933	rs2387887	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050626	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6037121	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs1047171	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050629	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050630	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050632	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2856	ENSG00000276952.1	RP5-965G21.6	5.73	8.32e-08	0.000169	0.44	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25284915~25285588:-
GBM	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	5.73	8.33e-08	0.000169	0.39	0.47	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
GBM	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-5.73	8.34e-08	0.000169	-0.6	-0.47	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-5.73	8.34e-08	0.000169	-0.6	-0.47	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
GBM	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-5.73	8.34e-08	0.000169	-0.61	-0.47	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
GBM	cis	rs7267979	0.966	rs8123949	ENSG00000276952.1	RP5-965G21.6	-5.72	8.39e-08	0.00017	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25284915~25285588:-
GBM	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	5.72	8.4e-08	0.00017	0.57	0.47	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
GBM	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-5.72	8.43e-08	0.000171	-0.38	-0.47	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
GBM	cis	rs7267979	0.753	rs400357	ENSG00000125804.12	FAM182A	-5.72	8.53e-08	0.000172	-0.58	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs3761117	ENSG00000276952.1	RP5-965G21.6	-5.72	8.54e-08	0.000173	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25284915~25285588:-
GBM	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-5.72	8.61e-08	0.000174	-0.61	-0.47	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
GBM	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	5.72	8.64e-08	0.000174	0.56	0.47	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	5.72	8.64e-08	0.000174	0.56	0.47	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	5.72	8.64e-08	0.000174	0.56	0.47	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
GBM	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	5.72	8.65e-08	0.000175	0.52	0.47	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
GBM	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	5.72	8.65e-08	0.000175	0.52	0.47	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
GBM	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	5.72	8.66e-08	0.000175	0.58	0.47	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
GBM	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	5.72	8.67e-08	0.000175	0.5	0.47	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000224205.1	AP000351.4	5.72	8.72e-08	0.000176	0.53	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23987320~23991421:-
GBM	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-5.72	8.74e-08	0.000176	-0.49	-0.47	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
GBM	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-5.72	8.74e-08	0.000176	-0.49	-0.47	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
GBM	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	5.72	8.78e-08	0.000177	0.48	0.47	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	5.72	8.78e-08	0.000177	0.48	0.47	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	5.72	8.78e-08	0.000177	0.48	0.47	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
GBM	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-5.71	8.81e-08	0.000177	-0.55	-0.47	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
GBM	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	5.71	8.82e-08	0.000178	0.65	0.47	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
GBM	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	5.71	8.82e-08	0.000178	0.59	0.47	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
GBM	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	5.71	8.83e-08	0.000178	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
GBM	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	5.71	8.83e-08	0.000178	0.54	0.47	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
GBM	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-5.71	8.85e-08	0.000178	-0.54	-0.47	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
GBM	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	5.71	8.87e-08	0.000179	0.52	0.47	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
GBM	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	5.71	8.89e-08	0.000179	0.74	0.47	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
GBM	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	5.71	8.89e-08	0.000179	0.74	0.47	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
GBM	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	5.71	8.9e-08	0.000179	0.6	0.47	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
GBM	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	5.71	8.9e-08	0.000179	0.52	0.47	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
GBM	cis	rs36132109	0.82	rs17388512	ENSG00000273328.4	RP11-141M3.6	5.71	8.91e-08	0.000179	0.55	0.47	Monocyte chemoattractant protein-1 levels;	chr3:42935325	chr3:42809414~42908105:+
GBM	cis	rs7267979	1	rs6050573	ENSG00000276952.1	RP5-965G21.6	5.71	8.95e-08	0.00018	0.43	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25284915~25285588:-
GBM	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-5.71	8.99e-08	0.000181	-0.65	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
GBM	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-5.71	9e-08	0.000181	-0.58	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
GBM	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	5.71	9.01e-08	0.000181	0.58	0.47	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
GBM	cis	rs916888	0.779	rs199526	ENSG00000261575.2	RP11-259G18.1	-5.71	9.04e-08	0.000182	-0.62	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46267037~46268694:+
GBM	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	5.71	9.04e-08	0.000182	0.83	0.47	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
GBM	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-5.71	9.06e-08	0.000182	-0.54	-0.47	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
GBM	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	5.71	9.09e-08	0.000183	0.6	0.47	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
GBM	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	5.71	9.1e-08	0.000183	0.56	0.47	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	5.71	9.1e-08	0.000183	0.56	0.47	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
GBM	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-5.71	9.12e-08	0.000183	-0.54	-0.47	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-5.71	9.12e-08	0.000183	-0.54	-0.47	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
GBM	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	5.71	9.14e-08	0.000183	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	5.71	9.14e-08	0.000183	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	5.71	9.14e-08	0.000183	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
GBM	cis	rs507080	0.733	rs497678	ENSG00000255422.1	AP002954.4	-5.71	9.16e-08	0.000184	-0.68	-0.47	Serum metabolite levels;	chr11:118697172	chr11:118704607~118750263:+
GBM	cis	rs2013441	1	rs2703774	ENSG00000230528.6	NOS2P3	5.71	9.16e-08	0.000184	0.52	0.47	Obesity-related traits;	chr17:20230225	chr17:20436337~20447249:+
GBM	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-5.7	9.19e-08	0.000184	-0.5	-0.47	Height;	chr11:118786602	chr11:118791254~118793137:+
GBM	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-5.7	9.21e-08	0.000184	-0.55	-0.47	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
GBM	cis	rs4713118	0.568	rs9468213	ENSG00000218016.2	ZNF192P2	-5.7	9.27e-08	0.000186	-0.57	-0.47	Parkinson's disease;	chr6:27738401	chr6:28188050~28189432:+
GBM	cis	rs2013441	1	rs2703792	ENSG00000230528.6	NOS2P3	5.7	9.3e-08	0.000186	0.51	0.47	Obesity-related traits;	chr17:20263637	chr17:20436337~20447249:+
GBM	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	5.7	9.34e-08	0.000187	0.54	0.47	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
GBM	cis	rs11098499	0.697	rs35280960	ENSG00000249244.1	RP11-548H18.2	5.7	9.36e-08	0.000187	0.6	0.47	Corneal astigmatism;	chr4:119335904	chr4:119391831~119395335:-
GBM	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	5.7	9.39e-08	0.000188	0.57	0.47	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
GBM	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-5.7	9.4e-08	0.000188	-0.5	-0.47	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
GBM	cis	rs6782228	0.606	rs7627549	ENSG00000277250.1	Metazoa_SRP	-5.7	9.41e-08	0.000188	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128673681~128674021:-
GBM	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	5.7	9.42e-08	0.000188	0.39	0.47	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
GBM	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-5.7	9.49e-08	0.00019	-0.74	-0.47	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
GBM	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-5.7	9.6e-08	0.000192	-0.5	-0.47	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
GBM	cis	rs67981189	0.766	rs2526852	ENSG00000269927.1	RP6-91H8.3	-5.7	9.6e-08	0.000192	-0.55	-0.47	Schizophrenia;	chr14:70949450	chr14:71141125~71143253:-
GBM	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	5.69	9.68e-08	0.000193	0.57	0.47	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	5.69	9.68e-08	0.000193	0.57	0.47	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
GBM	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-5.69	9.71e-08	0.000193	-0.54	-0.47	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
GBM	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-5.69	9.71e-08	0.000193	-0.39	-0.47	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
GBM	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-5.69	9.76e-08	0.000194	-0.61	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
GBM	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	5.69	9.79e-08	0.000195	0.4	0.47	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
GBM	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	5.69	9.8e-08	0.000195	0.52	0.47	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	5.69	9.8e-08	0.000195	0.52	0.47	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
GBM	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	5.69	9.8e-08	0.000195	0.56	0.47	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	5.69	9.8e-08	0.000195	0.56	0.47	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	5.69	9.81e-08	0.000195	0.58	0.47	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
GBM	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-5.69	9.83e-08	0.000196	-0.62	-0.47	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
GBM	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-5.69	9.85e-08	0.000196	-0.59	-0.47	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	5.69	9.85e-08	0.000196	0.59	0.47	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
GBM	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	5.69	9.89e-08	0.000196	0.63	0.47	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	5.69	9.89e-08	0.000196	0.63	0.47	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
GBM	cis	rs2980439	0.517	rs712253	ENSG00000253893.2	FAM85B	5.69	9.91e-08	0.000197	0.58	0.47	Neuroticism;	chr8:8246260	chr8:8167819~8226614:-
GBM	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	5.69	9.96e-08	0.000197	0.51	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
GBM	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	5.69	9.96e-08	0.000197	0.51	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
GBM	cis	rs2013441	0.932	rs2526479	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20226908	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703772	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20228140	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526475	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20232903	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.901	rs2526474	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20233821	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526472	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20234575	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703778	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20235587	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2158473	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20235777	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703780	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20240359	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703782	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20241486	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703785	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20249105	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703787	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20255352	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703789	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20259610	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.965	rs2703790	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20259896	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703791	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20260216	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526467	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20261741	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2013576	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20264379	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs9897328	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20271539	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs8074047	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20273390	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.965	rs9896221	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20277024	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs9896709	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20277237	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs3850781	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20278626	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.932	rs3850782	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20278627	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs3850784	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20281717	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.932	rs3850785	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20281935	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs9905493	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20285268	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs9900166	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20289656	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.965	rs6587063	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20290627	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs1561974	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20292831	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2034109	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20293320	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs9325894	ENSG00000230528.6	NOS2P3	5.69	9.96e-08	0.000197	0.51	0.47	Obesity-related traits;	chr17:20293788	chr17:20436337~20447249:+
GBM	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	5.69	9.97e-08	0.000198	0.76	0.47	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
GBM	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-5.69	9.98e-08	0.000198	-0.6	-0.47	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
GBM	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-5.69	9.98e-08	0.000198	-0.6	-0.47	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
GBM	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	5.69	1e-07	0.000198	0.52	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
GBM	cis	rs11098499	0.863	rs17050695	ENSG00000250412.1	KLHL2P1	5.69	1e-07	0.000198	0.58	0.47	Corneal astigmatism;	chr4:119568372	chr4:119334329~119378233:+
GBM	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-5.69	1e-07	0.000198	-0.54	-0.47	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
GBM	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	5.69	1e-07	0.000199	0.51	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
GBM	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	5.69	1e-07	0.000199	0.55	0.47	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
GBM	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	5.69	1.01e-07	0.000199	0.4	0.47	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
GBM	cis	rs7267979	1	rs6050573	ENSG00000125804.12	FAM182A	-5.69	1.01e-07	0.000199	-0.58	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:26054655~26086917:+
GBM	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	5.69	1.01e-07	0.000199	0.53	0.47	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
GBM	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	5.68	1.01e-07	0.000199	0.54	0.47	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	5.68	1.01e-07	0.000199	0.54	0.47	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	5.68	1.01e-07	0.000199	0.54	0.47	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	5.68	1.01e-07	0.000199	0.54	0.47	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	5.68	1.01e-07	0.000199	0.54	0.47	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-5.68	1.01e-07	0.000199	-0.54	-0.47	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-5.68	1.01e-07	0.000199	-0.54	-0.47	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-5.68	1.01e-07	0.000199	-0.54	-0.47	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-5.68	1.01e-07	0.000199	-0.54	-0.47	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
GBM	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-5.68	1.01e-07	0.000199	-0.65	-0.47	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
GBM	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-5.68	1.01e-07	0.000199	-0.55	-0.47	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
GBM	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.68	1.01e-07	2e-04	-0.59	-0.47	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
GBM	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	5.68	1.01e-07	2e-04	1.12	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
GBM	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.68	1.01e-07	2e-04	0.75	0.47	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
GBM	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	5.68	1.01e-07	2e-04	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	5.68	1.01e-07	2e-04	0.49	0.47	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
GBM	cis	rs11098499	0.82	rs2389885	ENSG00000250412.1	KLHL2P1	5.68	1.01e-07	2e-04	0.6	0.47	Corneal astigmatism;	chr4:119612776	chr4:119334329~119378233:+
GBM	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-5.68	1.01e-07	2e-04	-0.59	-0.47	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
GBM	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-5.68	1.01e-07	2e-04	-0.56	-0.47	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
GBM	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-5.68	1.02e-07	0.000201	-0.38	-0.47	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
GBM	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-5.68	1.02e-07	0.000201	-0.52	-0.47	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
GBM	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
GBM	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-5.68	1.02e-07	0.000201	-0.66	-0.47	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
GBM	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	5.68	1.02e-07	0.000201	0.51	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
GBM	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-5.68	1.03e-07	0.000202	-0.4	-0.47	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
GBM	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	5.68	1.03e-07	0.000202	0.64	0.47	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
GBM	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-5.68	1.03e-07	0.000203	-0.56	-0.47	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
GBM	cis	rs6782228	0.675	rs4443194	ENSG00000277250.1	Metazoa_SRP	-5.68	1.03e-07	0.000203	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.675	rs4857918	ENSG00000277250.1	Metazoa_SRP	-5.68	1.03e-07	0.000203	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128673681~128674021:-
GBM	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-5.68	1.04e-07	0.000204	-0.58	-0.47	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
GBM	cis	rs7267979	1	rs6050565	ENSG00000276952.1	RP5-965G21.6	-5.68	1.04e-07	0.000204	-0.43	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25284915~25285588:-
GBM	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	5.68	1.04e-07	0.000204	0.56	0.47	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	5.68	1.04e-07	0.000204	0.56	0.47	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	5.68	1.04e-07	0.000204	0.56	0.47	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	5.68	1.04e-07	0.000204	0.56	0.47	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	5.68	1.04e-07	0.000204	0.56	0.47	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
GBM	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	5.68	1.04e-07	0.000205	0.65	0.47	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
GBM	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-5.68	1.04e-07	0.000205	-0.53	-0.47	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
GBM	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-5.68	1.04e-07	0.000205	-0.53	-0.47	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-5.68	1.04e-07	0.000205	-0.53	-0.47	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
GBM	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	5.68	1.05e-07	0.000206	0.29	0.47	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
GBM	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	5.68	1.05e-07	0.000206	0.53	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
GBM	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-5.68	1.05e-07	0.000206	-0.67	-0.47	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
GBM	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-5.67	1.05e-07	0.000207	-0.53	-0.47	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
GBM	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	5.67	1.06e-07	0.000207	0.78	0.47	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
GBM	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	5.67	1.06e-07	0.000207	0.62	0.47	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
GBM	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.67	1.06e-07	0.000208	0.78	0.47	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
GBM	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	5.67	1.06e-07	0.000208	0.58	0.47	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	5.67	1.06e-07	0.000208	0.58	0.47	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	5.67	1.06e-07	0.000208	0.58	0.47	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	5.67	1.06e-07	0.000208	0.58	0.47	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	5.67	1.06e-07	0.000208	0.58	0.47	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	5.67	1.06e-07	0.000208	0.58	0.47	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
GBM	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-5.67	1.06e-07	0.000208	-0.62	-0.47	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
GBM	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-5.67	1.06e-07	0.000208	-0.62	-0.47	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
GBM	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-5.67	1.06e-07	0.000208	-0.62	-0.47	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
GBM	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-5.67	1.06e-07	0.000208	-0.62	-0.47	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
GBM	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-5.67	1.07e-07	0.000209	-0.56	-0.47	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-5.67	1.07e-07	0.000209	-0.56	-0.47	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-5.67	1.07e-07	0.000209	-0.56	-0.47	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-5.67	1.07e-07	0.000209	-0.56	-0.47	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
GBM	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	5.67	1.07e-07	0.000209	0.62	0.47	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
GBM	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-5.67	1.07e-07	0.00021	-0.54	-0.47	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
GBM	cis	rs2013441	1	rs11870147	ENSG00000230528.6	NOS2P3	5.67	1.07e-07	0.00021	0.51	0.47	Obesity-related traits;	chr17:20312782	chr17:20436337~20447249:+
GBM	cis	rs6782228	0.675	rs9813845	ENSG00000277250.1	Metazoa_SRP	-5.67	1.07e-07	0.00021	-0.52	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128673681~128674021:-
GBM	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	5.67	1.07e-07	0.00021	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	5.67	1.07e-07	0.00021	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	5.67	1.07e-07	0.00021	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	5.67	1.07e-07	0.00021	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	5.67	1.07e-07	0.00021	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	5.67	1.07e-07	0.00021	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	5.67	1.07e-07	0.00021	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
GBM	cis	rs453301	0.653	rs7853	ENSG00000254340.1	RP11-10A14.3	5.67	1.08e-07	0.00021	0.59	0.47	Joint mobility (Beighton score);	chr8:9033304	chr8:9141424~9145435:+
GBM	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-5.67	1.08e-07	0.000211	-0.59	-0.47	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-5.67	1.08e-07	0.000211	-0.59	-0.47	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-5.67	1.08e-07	0.000211	-0.59	-0.47	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs12711071	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119319779	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
GBM	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
GBM	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	5.67	1.08e-07	0.000211	0.59	0.47	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
GBM	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-5.67	1.08e-07	0.000211	-0.52	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
GBM	cis	rs6782228	1	rs34890930	ENSG00000277250.1	Metazoa_SRP	5.67	1.09e-07	0.000211	0.56	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128673681~128674021:-
GBM	cis	rs67981189	0.752	rs221902	ENSG00000269927.1	RP6-91H8.3	-5.67	1.09e-07	0.000211	-0.54	-0.47	Schizophrenia;	chr14:71134362	chr14:71141125~71143253:-
GBM	cis	rs453301	0.624	rs2288671	ENSG00000254340.1	RP11-10A14.3	5.67	1.09e-07	0.000212	0.57	0.47	Joint mobility (Beighton score);	chr8:9003384	chr8:9141424~9145435:+
GBM	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-5.67	1.09e-07	0.000212	-0.6	-0.47	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
GBM	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-5.67	1.1e-07	0.000213	-0.56	-0.47	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-5.67	1.1e-07	0.000213	-0.56	-0.47	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
GBM	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-5.67	1.1e-07	0.000214	-0.62	-0.47	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
GBM	cis	rs6496932	0.663	rs7183764	ENSG00000218052.5	ADAMTS7P4	-5.66	1.1e-07	0.000214	-0.66	-0.47	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.663	rs4842878	ENSG00000218052.5	ADAMTS7P4	-5.66	1.1e-07	0.000214	-0.66	-0.47	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.663	rs8040940	ENSG00000218052.5	ADAMTS7P4	-5.66	1.1e-07	0.000214	-0.66	-0.47	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.635	rs12900455	ENSG00000218052.5	ADAMTS7P4	-5.66	1.1e-07	0.000214	-0.66	-0.47	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85255369~85330334:-
GBM	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	5.66	1.11e-07	0.000216	0.64	0.47	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
GBM	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-5.66	1.11e-07	0.000216	-0.53	-0.47	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
GBM	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-5.66	1.11e-07	0.000216	-0.62	-0.47	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
GBM	cis	rs67981189	0.835	rs2526855	ENSG00000269927.1	RP6-91H8.3	-5.66	1.11e-07	0.000216	-0.54	-0.47	Schizophrenia;	chr14:70946629	chr14:71141125~71143253:-
GBM	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-5.66	1.12e-07	0.000217	-0.6	-0.47	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
GBM	cis	rs11696739	0.513	rs2209313	ENSG00000242324.1	RP4-576H24.2	-5.66	1.12e-07	0.000217	-0.67	-0.47	Mean platelet volume;	chr20:1618496	chr20:1516759~1557653:-
GBM	cis	rs950027	0.549	rs11636114	ENSG00000259433.2	CTD-2651B20.4	-5.66	1.12e-07	0.000217	-0.52	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45330209~45332634:-
GBM	cis	rs454217	0.714	rs395142	ENSG00000277851.1	RP11-756G20.1	-5.66	1.12e-07	0.000217	-0.48	-0.47	Smoking quantity;	chr12:92341860	chr12:92247756~92363832:-
GBM	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	5.66	1.12e-07	0.000218	0.51	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
GBM	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	5.66	1.12e-07	0.000218	0.5	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
GBM	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-5.66	1.12e-07	0.000218	-0.62	-0.47	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
GBM	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	5.66	1.13e-07	0.000219	0.54	0.47	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
GBM	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	5.66	1.13e-07	0.000219	0.6	0.47	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
GBM	cis	rs7829975	0.777	rs486781	ENSG00000253893.2	FAM85B	5.66	1.13e-07	0.000219	0.54	0.47	Mood instability;	chr8:8782230	chr8:8167819~8226614:-
GBM	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	5.66	1.13e-07	0.000219	0.52	0.47	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
GBM	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-5.66	1.14e-07	0.00022	-0.38	-0.47	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
GBM	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	5.66	1.14e-07	0.00022	0.55	0.47	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	5.66	1.14e-07	0.00022	0.55	0.47	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	5.66	1.14e-07	0.00022	0.55	0.47	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	5.66	1.14e-07	0.00022	0.55	0.47	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	5.66	1.14e-07	0.00022	0.55	0.47	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	5.66	1.14e-07	0.00022	0.55	0.47	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
GBM	cis	rs2013441	1	rs17686798	ENSG00000230528.6	NOS2P3	5.66	1.14e-07	0.000221	0.53	0.47	Obesity-related traits;	chr17:20125857	chr17:20436337~20447249:+
GBM	cis	rs6782228	1	rs6782228	ENSG00000242551.2	POU5F1P6	5.66	1.14e-07	0.000221	0.51	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128604581	chr3:128674735~128677005:-
GBM	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	5.66	1.15e-07	0.000222	0.53	0.47	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	5.65	1.16e-07	0.000224	0.54	0.47	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
GBM	cis	rs2013441	0.866	rs7207817	ENSG00000230528.6	NOS2P3	5.65	1.16e-07	0.000224	0.55	0.47	Obesity-related traits;	chr17:20318015	chr17:20436337~20447249:+
GBM	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	5.65	1.16e-07	0.000225	0.52	0.47	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
GBM	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	5.65	1.16e-07	0.000225	0.65	0.47	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
GBM	cis	rs6496932	0.663	rs12915663	ENSG00000218052.5	ADAMTS7P4	-5.65	1.16e-07	0.000225	-0.66	-0.47	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85255369~85330334:-
GBM	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-5.65	1.16e-07	0.000225	-0.61	-0.47	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
GBM	cis	rs2013441	1	rs2526480	ENSG00000230528.6	NOS2P3	-5.65	1.16e-07	0.000225	-0.51	-0.47	Obesity-related traits;	chr17:20226761	chr17:20436337~20447249:+
GBM	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-5.65	1.17e-07	0.000226	-0.55	-0.47	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
GBM	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-5.65	1.17e-07	0.000226	-0.58	-0.47	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-5.65	1.17e-07	0.000226	-0.58	-0.47	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
GBM	cis	rs9987353	0.566	rs34491841	ENSG00000253893.2	FAM85B	5.65	1.17e-07	0.000226	0.54	0.47	Recombination measurement;	chr8:9208000	chr8:8167819~8226614:-
GBM	cis	rs9987353	0.566	rs34389718	ENSG00000253893.2	FAM85B	5.65	1.17e-07	0.000226	0.54	0.47	Recombination measurement;	chr8:9208015	chr8:8167819~8226614:-
GBM	cis	rs9987353	0.566	rs6998368	ENSG00000253893.2	FAM85B	5.65	1.17e-07	0.000226	0.54	0.47	Recombination measurement;	chr8:9212778	chr8:8167819~8226614:-
GBM	cis	rs9322193	0.923	rs2184370	ENSG00000268592.3	RAET1E-AS1	5.65	1.17e-07	0.000226	0.57	0.47	Lung cancer;	chr6:149843242	chr6:149863494~149919507:+
GBM	cis	rs916888	0.602	rs199508	ENSG00000261575.2	RP11-259G18.1	-5.65	1.17e-07	0.000226	-0.57	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:46267037~46268694:+
GBM	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-5.65	1.18e-07	0.000228	-0.61	-0.47	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
GBM	cis	rs7267979	1	rs12428	ENSG00000276952.1	RP5-965G21.6	-5.65	1.18e-07	0.000228	-0.44	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25284915~25285588:-
GBM	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	5.65	1.18e-07	0.000228	0.56	0.47	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
GBM	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	5.65	1.19e-07	0.000229	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
GBM	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	5.65	1.19e-07	0.000229	0.6	0.47	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
GBM	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	5.65	1.19e-07	0.00023	0.5	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	5.65	1.19e-07	0.00023	0.5	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
GBM	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	5.65	1.19e-07	0.00023	0.5	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
GBM	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	5.65	1.2e-07	0.000231	0.56	0.47	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
GBM	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	5.65	1.2e-07	0.000232	0.74	0.47	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
GBM	cis	rs67981189	0.896	rs58133478	ENSG00000269927.1	RP6-91H8.3	5.65	1.21e-07	0.000232	0.53	0.47	Schizophrenia;	chr14:71058370	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs17108967	ENSG00000269927.1	RP6-91H8.3	5.65	1.21e-07	0.000232	0.53	0.47	Schizophrenia;	chr14:71075451	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs34763296	ENSG00000269927.1	RP6-91H8.3	5.65	1.21e-07	0.000232	0.53	0.47	Schizophrenia;	chr14:71083458	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.789	rs12101246	ENSG00000269927.1	RP6-91H8.3	5.65	1.21e-07	0.000232	0.53	0.47	Schizophrenia;	chr14:71084618	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs8003227	ENSG00000269927.1	RP6-91H8.3	5.65	1.21e-07	0.000232	0.53	0.47	Schizophrenia;	chr14:71093635	chr14:71141125~71143253:-
GBM	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	5.64	1.21e-07	0.000233	0.53	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	5.64	1.21e-07	0.000233	0.53	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	5.64	1.21e-07	0.000233	0.53	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
GBM	cis	rs17772222	0.56	rs3742681	ENSG00000258983.2	RP11-507K2.2	-5.64	1.21e-07	0.000233	-0.49	-0.47	Coronary artery calcification;	chr14:88554903	chr14:88499334~88515502:+
GBM	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-5.64	1.22e-07	0.000233	-0.38	-0.47	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
GBM	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	5.64	1.22e-07	0.000234	0.53	0.47	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
GBM	cis	rs6782228	0.606	rs7650156	ENSG00000277250.1	Metazoa_SRP	-5.64	1.22e-07	0.000234	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128673681~128674021:-
GBM	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	5.64	1.22e-07	0.000234	0.61	0.47	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	5.64	1.22e-07	0.000234	0.61	0.47	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
GBM	cis	rs17772222	0.63	rs816069	ENSG00000258983.2	RP11-507K2.2	-5.64	1.23e-07	0.000235	-0.47	-0.47	Coronary artery calcification;	chr14:88500992	chr14:88499334~88515502:+
GBM	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-5.64	1.23e-07	0.000235	-0.55	-0.47	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
GBM	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-5.64	1.23e-07	0.000235	-0.75	-0.47	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
GBM	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-5.64	1.23e-07	0.000235	-0.64	-0.47	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
GBM	cis	rs36132109	0.858	rs2288370	ENSG00000273328.4	RP11-141M3.6	5.64	1.23e-07	0.000237	0.53	0.47	Monocyte chemoattractant protein-1 levels;	chr3:42935944	chr3:42809414~42908105:+
GBM	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-5.64	1.24e-07	0.000237	-0.62	-0.47	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
GBM	cis	rs7267979	0.966	rs2257233	ENSG00000125804.12	FAM182A	5.64	1.24e-07	0.000237	0.59	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:26054655~26086917:+
GBM	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	5.64	1.24e-07	0.000237	0.72	0.47	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
GBM	cis	rs6782228	0.651	rs9289332	ENSG00000277250.1	Metazoa_SRP	-5.64	1.24e-07	0.000237	-0.52	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128673681~128674021:-
GBM	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	5.64	1.24e-07	0.000237	0.48	0.47	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
GBM	cis	rs916888	0.647	rs199524	ENSG00000261575.2	RP11-259G18.1	-5.64	1.24e-07	0.000238	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46267037~46268694:+
GBM	cis	rs916888	0.647	rs199523	ENSG00000261575.2	RP11-259G18.1	-5.64	1.24e-07	0.000238	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46267037~46268694:+
GBM	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-5.64	1.25e-07	0.000239	-0.62	-0.47	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
GBM	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	5.64	1.25e-07	0.000239	0.64	0.47	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
GBM	cis	rs1964356	0.967	rs17701675	ENSG00000254340.1	RP11-10A14.3	-5.64	1.25e-07	0.000239	-0.63	-0.47	Mean corpuscular volume;	chr8:8993123	chr8:9141424~9145435:+
GBM	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	5.64	1.25e-07	0.00024	0.54	0.47	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
GBM	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	5.64	1.26e-07	0.000241	0.57	0.47	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
GBM	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	5.63	1.27e-07	0.000242	1.07	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
GBM	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-5.63	1.27e-07	0.000242	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
GBM	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	5.63	1.27e-07	0.000242	0.55	0.47	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
GBM	cis	rs11098499	0.954	rs12510138	ENSG00000250412.1	KLHL2P1	5.63	1.27e-07	0.000243	0.61	0.47	Corneal astigmatism;	chr4:119502780	chr4:119334329~119378233:+
GBM	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	5.63	1.28e-07	0.000243	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
GBM	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-5.63	1.28e-07	0.000244	-0.59	-0.47	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
GBM	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-5.63	1.28e-07	0.000244	-0.59	-0.47	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
GBM	cis	rs9876781	1	rs6784322	ENSG00000244380.1	RP11-24C3.2	5.63	1.28e-07	0.000244	0.53	0.46	Longevity;	chr3:48380745	chr3:48440352~48446656:-
GBM	cis	rs34034915	1	rs34034915	ENSG00000218016.2	ZNF192P2	-5.63	1.29e-07	0.000245	-0.57	-0.46	Hepatitis A;	chr6:27752924	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.527	rs36042294	ENSG00000218016.2	ZNF192P2	-5.63	1.29e-07	0.000245	-0.57	-0.46	Parkinson's disease;	chr6:27752933	chr6:28188050~28189432:+
GBM	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	5.63	1.29e-07	0.000246	0.59	0.46	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
GBM	cis	rs7267979	0.816	rs390123	ENSG00000276952.1	RP5-965G21.6	5.63	1.29e-07	0.000247	0.42	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25284915~25285588:-
GBM	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	5.63	1.3e-07	0.000247	0.51	0.46	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
GBM	cis	rs6496932	1	rs6496932	ENSG00000218052.5	ADAMTS7P4	5.63	1.3e-07	0.000248	0.66	0.46	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85255369~85330334:-
GBM	cis	rs67981189	0.788	rs34093157	ENSG00000269927.1	RP6-91H8.3	5.63	1.3e-07	0.000248	0.53	0.46	Schizophrenia;	chr14:71101966	chr14:71141125~71143253:-
GBM	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	5.63	1.31e-07	0.000249	0.51	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
GBM	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-5.63	1.31e-07	0.000249	-0.54	-0.46	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
GBM	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-5.63	1.31e-07	0.000249	-0.58	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
GBM	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	5.63	1.32e-07	0.00025	0.5	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
GBM	cis	rs7267979	1	rs6115168	ENSG00000276952.1	RP5-965G21.6	-5.63	1.32e-07	0.00025	-0.44	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25284915~25285588:-
GBM	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	5.63	1.32e-07	0.00025	0.64	0.46	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	5.63	1.32e-07	0.00025	0.64	0.46	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
GBM	cis	rs11098499	0.954	rs6847248	ENSG00000250412.1	KLHL2P1	5.63	1.32e-07	0.00025	0.62	0.46	Corneal astigmatism;	chr4:119304800	chr4:119334329~119378233:+
GBM	cis	rs950169	0.92	rs34672825	ENSG00000225151.9	GOLGA2P7	-5.62	1.33e-07	0.000251	-0.58	-0.46	Schizophrenia;	chr15:84034718	chr15:84199311~84230136:-
GBM	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	5.62	1.33e-07	0.000251	0.61	0.46	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
GBM	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	5.62	1.33e-07	0.000251	0.52	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
GBM	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-5.62	1.33e-07	0.000251	-0.5	-0.46	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
GBM	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-5.62	1.33e-07	0.000252	-0.54	-0.46	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
GBM	cis	rs7267979	0.718	rs2983489	ENSG00000125804.12	FAM182A	-5.62	1.34e-07	0.000252	-0.56	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26054655~26086917:+
GBM	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-5.62	1.34e-07	0.000253	-0.65	-0.46	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
GBM	cis	rs6452524	0.904	rs10076056	ENSG00000248112.1	RP11-78C3.1	-5.62	1.34e-07	0.000253	-0.57	-0.46	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:82919376~82921119:-
GBM	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	5.62	1.34e-07	0.000254	0.48	0.46	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
GBM	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	5.62	1.35e-07	0.000254	0.46	0.46	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
GBM	cis	rs6782228	1	rs6782228	ENSG00000277250.1	Metazoa_SRP	5.62	1.35e-07	0.000255	0.56	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128604581	chr3:128673681~128674021:-
GBM	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	5.62	1.35e-07	0.000256	0.39	0.46	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
GBM	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-5.62	1.36e-07	0.000256	-0.63	-0.46	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
GBM	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	5.62	1.36e-07	0.000256	0.57	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
GBM	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	5.62	1.36e-07	0.000256	0.51	0.46	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	5.62	1.36e-07	0.000256	0.51	0.46	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	5.62	1.36e-07	0.000256	0.51	0.46	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
GBM	cis	rs11098499	1	rs10029750	ENSG00000250412.1	KLHL2P1	5.62	1.36e-07	0.000256	0.59	0.46	Corneal astigmatism;	chr4:119251388	chr4:119334329~119378233:+
GBM	cis	rs11098499	1	rs6837898	ENSG00000250412.1	KLHL2P1	5.62	1.36e-07	0.000256	0.59	0.46	Corneal astigmatism;	chr4:119257999	chr4:119334329~119378233:+
GBM	cis	rs11098499	1	rs28374891	ENSG00000250412.1	KLHL2P1	5.62	1.36e-07	0.000256	0.59	0.46	Corneal astigmatism;	chr4:119262395	chr4:119334329~119378233:+
GBM	cis	rs6452524	0.804	rs2048215	ENSG00000248112.1	RP11-78C3.1	-5.62	1.36e-07	0.000257	-0.57	-0.46	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.836	rs11949301	ENSG00000248112.1	RP11-78C3.1	-5.62	1.36e-07	0.000257	-0.57	-0.46	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.836	rs2731849	ENSG00000248112.1	RP11-78C3.1	-5.62	1.36e-07	0.000257	-0.57	-0.46	Hypertension (SNP x SNP interaction);	chr5:83214060	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.836	rs62374402	ENSG00000248112.1	RP11-78C3.1	5.62	1.36e-07	0.000257	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:82919376~82921119:-
GBM	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-5.62	1.36e-07	0.000257	-0.63	-0.46	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
GBM	cis	rs67981189	0.892	rs221899	ENSG00000269927.1	RP6-91H8.3	5.62	1.37e-07	0.000257	0.54	0.46	Schizophrenia;	chr14:71138551	chr14:71141125~71143253:-
GBM	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-5.62	1.37e-07	0.000257	-0.55	-0.46	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
GBM	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	5.62	1.37e-07	0.000258	0.61	0.46	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
GBM	cis	rs7267979	1	rs7020	ENSG00000125804.12	FAM182A	-5.62	1.37e-07	0.000258	-0.59	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:26054655~26086917:+
GBM	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	5.62	1.38e-07	0.000259	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
GBM	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	5.62	1.38e-07	0.000259	0.39	0.46	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
GBM	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-5.62	1.38e-07	0.00026	-0.5	-0.46	Height;	chr11:118791319	chr11:118791254~118793137:+
GBM	cis	rs67981189	0.896	rs2158997	ENSG00000269927.1	RP6-91H8.3	-5.62	1.38e-07	0.00026	-0.54	-0.46	Schizophrenia;	chr14:71031077	chr14:71141125~71143253:-
GBM	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-5.61	1.39e-07	0.000261	-0.6	-0.46	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
GBM	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-5.61	1.39e-07	0.000261	-0.69	-0.46	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
GBM	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-5.61	1.39e-07	0.000262	-0.71	-0.46	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
GBM	cis	rs4273100	0.607	rs1043809	ENSG00000262319.1	CTC-457L16.2	5.61	1.4e-07	0.000264	0.55	0.46	Schizophrenia;	chr17:19336119	chr17:19141017~19143689:-
GBM	cis	rs4373814	0.671	rs2840320	ENSG00000226083.4	SLC39A12-AS1	5.61	1.41e-07	0.000264	0.52	0.46	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18145261	chr10:18001786~18010562:-
GBM	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	5.61	1.41e-07	0.000264	0.55	0.46	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
GBM	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	5.61	1.41e-07	0.000264	0.55	0.46	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	5.61	1.41e-07	0.000264	0.55	0.46	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	5.61	1.41e-07	0.000264	0.55	0.46	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
GBM	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	5.61	1.41e-07	0.000264	0.6	0.46	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
GBM	cis	rs6782228	0.606	rs7613073	ENSG00000277250.1	Metazoa_SRP	-5.61	1.41e-07	0.000265	-0.52	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128673681~128674021:-
GBM	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	5.61	1.41e-07	0.000265	0.53	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
GBM	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	5.61	1.42e-07	0.000266	0.55	0.46	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
GBM	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	5.61	1.42e-07	0.000266	0.63	0.46	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
GBM	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	5.61	1.42e-07	0.000266	0.49	0.46	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
GBM	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-5.61	1.42e-07	0.000266	-0.55	-0.46	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
GBM	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-5.61	1.42e-07	0.000266	-0.55	-0.46	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
GBM	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-5.61	1.42e-07	0.000266	-0.72	-0.46	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-5.61	1.42e-07	0.000266	-0.72	-0.46	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
GBM	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	5.61	1.42e-07	0.000267	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
GBM	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	5.61	1.42e-07	0.000267	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
GBM	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	5.61	1.42e-07	0.000267	0.68	0.46	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	5.61	1.42e-07	0.000267	0.68	0.46	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	5.61	1.42e-07	0.000267	0.68	0.46	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	5.61	1.42e-07	0.000267	0.68	0.46	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	5.61	1.42e-07	0.000267	0.68	0.46	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	5.61	1.42e-07	0.000267	0.68	0.46	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	5.61	1.42e-07	0.000267	0.68	0.46	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-5.61	1.42e-07	0.000267	-0.68	-0.46	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
GBM	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	5.61	1.43e-07	0.000267	0.62	0.46	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
GBM	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	5.61	1.43e-07	0.000268	0.4	0.46	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
GBM	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	5.61	1.44e-07	0.000269	0.59	0.46	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
GBM	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-5.61	1.44e-07	0.000269	-0.54	-0.46	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
GBM	cis	rs6782228	0.606	rs2811500	ENSG00000277250.1	Metazoa_SRP	-5.61	1.44e-07	0.000269	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128673681~128674021:-
GBM	cis	rs11098499	1	rs11098500	ENSG00000250412.1	KLHL2P1	5.61	1.44e-07	0.00027	0.58	0.46	Corneal astigmatism;	chr4:119298084	chr4:119334329~119378233:+
GBM	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	5.6	1.45e-07	0.000272	0.39	0.46	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
GBM	cis	rs4713118	0.615	rs57252182	ENSG00000218016.2	ZNF192P2	-5.6	1.46e-07	0.000272	-0.57	-0.46	Parkinson's disease;	chr6:27752470	chr6:28188050~28189432:+
GBM	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	5.6	1.46e-07	0.000272	0.56	0.46	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
GBM	cis	rs3096299	0.967	rs2965937	ENSG00000260259.1	RP11-368I7.4	5.6	1.46e-07	0.000272	0.5	0.46	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89682620~89686569:-
GBM	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-5.6	1.46e-07	0.000273	-0.54	-0.46	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-5.6	1.46e-07	0.000273	-0.54	-0.46	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
GBM	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	5.6	1.47e-07	0.000274	0.54	0.46	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
GBM	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	5.6	1.47e-07	0.000275	0.6	0.46	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
GBM	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-5.6	1.47e-07	0.000275	-0.65	-0.46	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
GBM	cis	rs6782228	0.606	rs2811488	ENSG00000277250.1	Metazoa_SRP	-5.6	1.48e-07	0.000276	-0.52	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128673681~128674021:-
GBM	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-5.6	1.49e-07	0.000277	-0.38	-0.46	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
GBM	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	5.6	1.49e-07	0.000278	0.76	0.46	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	5.6	1.49e-07	0.000278	0.76	0.46	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
GBM	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-5.6	1.49e-07	0.000278	-0.58	-0.46	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
GBM	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-5.6	1.49e-07	0.000279	-0.58	-0.46	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
GBM	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	5.6	1.5e-07	0.000279	0.55	0.46	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	5.6	1.5e-07	0.000279	0.55	0.46	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	5.6	1.5e-07	0.000279	0.55	0.46	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	5.6	1.5e-07	0.000279	0.55	0.46	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
GBM	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-5.6	1.5e-07	0.00028	-0.55	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
GBM	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	5.6	1.51e-07	0.000281	0.57	0.46	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
GBM	cis	rs4713118	0.513	rs149878	ENSG00000199851.2	U3	5.6	1.51e-07	0.000281	0.64	0.46	Parkinson's disease;	chr6:27910960	chr6:28015568~28015777:+
GBM	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-5.6	1.51e-07	0.000281	-0.48	-0.46	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
GBM	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	5.6	1.51e-07	0.000282	0.39	0.46	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
GBM	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	5.6	1.52e-07	0.000282	0.73	0.46	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	5.6	1.52e-07	0.000282	0.73	0.46	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	5.6	1.52e-07	0.000282	0.73	0.46	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	5.6	1.52e-07	0.000282	0.73	0.46	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	5.6	1.52e-07	0.000282	0.73	0.46	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	5.6	1.52e-07	0.000282	0.73	0.46	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
GBM	cis	rs36132109	1	rs36132109	ENSG00000273328.4	RP11-141M3.6	5.59	1.52e-07	0.000283	0.53	0.46	Monocyte chemoattractant protein-1 levels;	chr3:42985512	chr3:42809414~42908105:+
GBM	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	5.59	1.52e-07	0.000283	0.56	0.46	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
GBM	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	5.59	1.52e-07	0.000283	0.39	0.46	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
GBM	cis	rs2976388	0.967	rs2976397	ENSG00000253741.1	CTD-2292P10.4	5.59	1.52e-07	0.000284	0.49	0.46	Urinary tract infection frequency;	chr8:142683195	chr8:142702252~142726973:-
GBM	cis	rs8081395	0.603	rs1292047	ENSG00000266992.1	DHX40P1	5.59	1.53e-07	0.000284	0.65	0.46	White blood cell count;	chr17:59877805	chr17:59976009~60002384:-
GBM	cis	rs7615952	0.546	rs2976733	ENSG00000171084.14	FAM86JP	5.59	1.53e-07	0.000285	0.73	0.46	Blood pressure (smoking interaction);	chr3:125695294	chr3:125916620~125930024:+
GBM	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-5.59	1.53e-07	0.000285	-0.7	-0.46	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
GBM	cis	rs6782228	0.606	rs6439135	ENSG00000277250.1	Metazoa_SRP	-5.59	1.54e-07	0.000285	-0.54	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.509	rs2811495	ENSG00000277250.1	Metazoa_SRP	-5.59	1.54e-07	0.000285	-0.54	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.565	rs2811496	ENSG00000277250.1	Metazoa_SRP	-5.59	1.54e-07	0.000285	-0.54	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128673681~128674021:-
GBM	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	5.59	1.54e-07	0.000285	0.54	0.46	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
GBM	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-5.59	1.54e-07	0.000285	-0.48	-0.46	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
GBM	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-5.59	1.54e-07	0.000285	-0.48	-0.46	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
GBM	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	5.59	1.54e-07	0.000286	0.64	0.46	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
GBM	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-5.59	1.54e-07	0.000286	-0.57	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
GBM	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	5.59	1.54e-07	0.000286	0.61	0.46	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.913	rs56122576	ENSG00000249244.1	RP11-548H18.2	5.59	1.54e-07	0.000286	0.61	0.46	Corneal astigmatism;	chr4:119208181	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	5.59	1.54e-07	0.000286	0.61	0.46	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	5.59	1.54e-07	0.000286	0.61	0.46	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
GBM	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-5.59	1.54e-07	0.000286	-0.48	-0.46	Height;	chr11:118737823	chr11:118791254~118793137:+
GBM	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-5.59	1.54e-07	0.000286	-0.48	-0.46	Height;	chr11:118737916	chr11:118791254~118793137:+
GBM	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	5.59	1.55e-07	0.000287	0.4	0.46	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
GBM	cis	rs853679	0.513	rs13437444	ENSG00000199851.2	U3	5.59	1.55e-07	0.000288	0.82	0.46	Depression;	chr6:28103220	chr6:28015568~28015777:+
GBM	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-5.59	1.56e-07	0.000288	-0.53	-0.46	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
GBM	cis	rs7267979	0.816	rs376742	ENSG00000276952.1	RP5-965G21.6	5.59	1.56e-07	0.000288	0.42	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25284915~25285588:-
GBM	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	5.59	1.56e-07	0.00029	0.39	0.46	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
GBM	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-5.59	1.57e-07	0.00029	-0.56	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
GBM	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-5.59	1.57e-07	0.00029	-0.55	-0.46	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
GBM	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-5.59	1.57e-07	0.00029	-0.59	-0.46	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
GBM	cis	rs7267979	0.934	rs2261115	ENSG00000125804.12	FAM182A	-5.59	1.57e-07	0.000291	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:26054655~26086917:+
GBM	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-5.59	1.58e-07	0.000291	-0.63	-0.46	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
GBM	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	5.59	1.58e-07	0.000292	0.59	0.46	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
GBM	cis	rs2976388	0.967	rs2585183	ENSG00000253741.1	CTD-2292P10.4	5.58	1.59e-07	0.000294	0.49	0.46	Urinary tract infection frequency;	chr8:142684641	chr8:142702252~142726973:-
GBM	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	5.58	1.59e-07	0.000294	0.5	0.46	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
GBM	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	5.58	1.59e-07	0.000294	0.6	0.46	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	5.58	1.59e-07	0.000294	0.6	0.46	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	5.58	1.59e-07	0.000294	0.6	0.46	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
GBM	cis	rs17772222	0.63	rs1344747	ENSG00000258983.2	RP11-507K2.2	-5.58	1.61e-07	0.000298	-0.48	-0.46	Coronary artery calcification;	chr14:88548091	chr14:88499334~88515502:+
GBM	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-5.58	1.61e-07	0.000298	-0.53	-0.46	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-5.58	1.61e-07	0.000298	-0.53	-0.46	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
GBM	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	5.58	1.63e-07	3e-04	0.57	0.46	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
GBM	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	5.58	1.63e-07	3e-04	0.45	0.46	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
GBM	cis	rs7267979	0.966	rs2151144	ENSG00000125804.12	FAM182A	5.58	1.63e-07	0.000301	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:26054655~26086917:+
GBM	cis	rs11098499	1	rs13435802	ENSG00000250412.1	KLHL2P1	-5.58	1.63e-07	0.000301	-0.59	-0.46	Corneal astigmatism;	chr4:119256805	chr4:119334329~119378233:+
GBM	cis	rs7267979	0.934	rs4815423	ENSG00000125804.12	FAM182A	5.58	1.63e-07	0.000301	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815424	ENSG00000125804.12	FAM182A	5.58	1.63e-07	0.000301	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6515651	ENSG00000125804.12	FAM182A	5.58	1.63e-07	0.000301	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2424716	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs761025	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050631	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6132835	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.933	rs11699203	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.933	rs6138571	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs11087520	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs416745	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs454723	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs398036	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs397119	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs448396	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs453329	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs447722	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs422424	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs422844	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs401166	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs404394	ENSG00000125804.12	FAM182A	-5.58	1.63e-07	0.000301	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:26054655~26086917:+
GBM	cis	rs860818	1	rs1728327	ENSG00000226816.2	AC005082.12	5.58	1.64e-07	0.000302	1.34	0.46	Initial pursuit acceleration;	chr7:23195864	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs1637214	ENSG00000226816.2	AC005082.12	5.58	1.64e-07	0.000302	1.34	0.46	Initial pursuit acceleration;	chr7:23197223	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858237	ENSG00000226816.2	AC005082.12	5.58	1.64e-07	0.000302	1.34	0.46	Initial pursuit acceleration;	chr7:23199604	chr7:23206013~23208045:+
GBM	cis	rs67981189	0.896	rs4048474	ENSG00000269927.1	RP6-91H8.3	5.58	1.64e-07	0.000303	0.53	0.46	Schizophrenia;	chr14:71060982	chr14:71141125~71143253:-
GBM	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	5.58	1.65e-07	0.000303	0.57	0.46	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
GBM	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	5.58	1.65e-07	0.000303	0.57	0.46	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
GBM	cis	rs4273100	0.573	rs4924783	ENSG00000262319.1	CTC-457L16.2	5.58	1.65e-07	0.000303	0.51	0.46	Schizophrenia;	chr17:19350668	chr17:19141017~19143689:-
GBM	cis	rs6452524	0.935	rs72767160	ENSG00000248112.1	RP11-78C3.1	5.58	1.65e-07	0.000303	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs5000997	ENSG00000248112.1	RP11-78C3.1	5.58	1.65e-07	0.000303	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.935	rs6887915	ENSG00000248112.1	RP11-78C3.1	5.58	1.65e-07	0.000303	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:82919376~82921119:-
GBM	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	5.58	1.65e-07	0.000303	0.54	0.46	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
GBM	cis	rs7267979	0.933	rs2261109	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2261698	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2261720	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2227890	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2261747	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.934	rs2261753	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2261790	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2261794	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2145126	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs910996	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2257705	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2227892	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2257712	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2257461	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2257808	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2257809	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs910997	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs1077889	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs3002702	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2257985	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2257988	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2257432	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258066	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258135	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258201	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258563	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2424704	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258617	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2257420	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258769	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs7018	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258879	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2257496	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2258884	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2259837	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2259873	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs11100	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs1046073	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2259926	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2259928	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2259956	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6037083	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs4813557	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2297496	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2297497	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs7267979	ENSG00000125804.12	FAM182A	-5.58	1.65e-07	0.000303	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs7343481	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815404	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6115146	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.934	rs6037085	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6050532	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6083804	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6083805	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815405	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050542	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6076336	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050544	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs8125868	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6037095	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050562	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815407	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815408	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050566	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4813563	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6037103	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2387881	ENSG00000125804.12	FAM182A	5.58	1.65e-07	0.000303	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:26054655~26086917:+
GBM	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-5.58	1.66e-07	0.000304	-1.15	-0.46	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
GBM	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	5.57	1.66e-07	0.000304	0.64	0.46	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
GBM	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-5.57	1.66e-07	0.000305	-0.52	-0.46	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
GBM	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	5.57	1.67e-07	0.000305	0.75	0.46	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
GBM	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	5.57	1.67e-07	0.000306	0.55	0.46	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
GBM	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	5.57	1.67e-07	0.000306	0.52	0.46	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
GBM	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	5.57	1.68e-07	0.000307	0.64	0.46	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
GBM	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-5.57	1.68e-07	0.000307	-0.53	-0.46	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
GBM	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-5.57	1.68e-07	0.000307	-0.53	-0.46	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
GBM	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	5.57	1.68e-07	0.000307	0.5	0.46	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
GBM	cis	rs9828933	0.701	rs7621544	ENSG00000280620.1	SCAANT1	5.57	1.68e-07	0.000308	0.75	0.46	Type 2 diabetes;	chr3:63943005	chr3:63911518~63911772:-
GBM	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-5.57	1.69e-07	0.000308	-0.53	-0.46	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
GBM	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	5.57	1.69e-07	0.000309	0.5	0.46	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
GBM	cis	rs11098499	1	rs12506395	ENSG00000250412.1	KLHL2P1	5.57	1.7e-07	0.00031	0.59	0.46	Corneal astigmatism;	chr4:119263939	chr4:119334329~119378233:+
GBM	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-5.57	1.7e-07	0.000311	-0.59	-0.46	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
GBM	cis	rs6782228	0.606	rs2811497	ENSG00000277250.1	Metazoa_SRP	-5.57	1.7e-07	0.000311	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128673681~128674021:-
GBM	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	5.57	1.7e-07	0.000311	0.58	0.46	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
GBM	cis	rs4713118	0.615	rs9348772	ENSG00000218016.2	ZNF192P2	-5.57	1.7e-07	0.000311	-0.58	-0.46	Parkinson's disease;	chr6:27688311	chr6:28188050~28189432:+
GBM	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-5.57	1.71e-07	0.000312	-0.54	-0.46	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
GBM	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-5.57	1.71e-07	0.000312	-0.8	-0.46	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
GBM	cis	rs9876781	1	rs2885510	ENSG00000244380.1	RP11-24C3.2	-5.57	1.72e-07	0.000313	-0.51	-0.46	Longevity;	chr3:48376736	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs725309	ENSG00000244380.1	RP11-24C3.2	-5.57	1.72e-07	0.000313	-0.51	-0.46	Longevity;	chr3:48377218	chr3:48440352~48446656:-
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-5.57	1.72e-07	0.000313	-0.62	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
GBM	cis	rs11233250	0.697	rs12421066	ENSG00000245832.5	RP11-179A16.1	5.57	1.72e-07	0.000314	0.64	0.46	Glioblastoma;Glioma;	chr11:82703938	chr11:81879851~82718082:-
GBM	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	5.57	1.73e-07	0.000314	0.55	0.46	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
GBM	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	5.57	1.73e-07	0.000315	0.53	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
GBM	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	5.57	1.73e-07	0.000315	0.56	0.46	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
GBM	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-5.57	1.73e-07	0.000316	-0.59	-0.46	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-5.57	1.73e-07	0.000316	-0.59	-0.46	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
GBM	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	5.57	1.73e-07	0.000316	0.74	0.46	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
GBM	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-5.56	1.74e-07	0.000317	-0.54	-0.46	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
GBM	cis	rs6782228	0.585	rs3122175	ENSG00000277250.1	Metazoa_SRP	-5.56	1.74e-07	0.000317	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128673681~128674021:-
GBM	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	5.56	1.75e-07	0.000318	0.44	0.46	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
GBM	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-5.56	1.75e-07	0.000319	-0.5	-0.46	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
GBM	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-5.56	1.76e-07	0.000319	-0.62	-0.46	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
GBM	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-5.56	1.76e-07	0.000319	-0.85	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	5.56	1.76e-07	0.000319	0.85	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
GBM	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	5.56	1.76e-07	0.000319	0.52	0.46	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
GBM	cis	rs3096299	0.933	rs2930219	ENSG00000260259.1	RP11-368I7.4	5.56	1.76e-07	0.00032	0.5	0.46	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89682620~89686569:-
GBM	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	5.56	1.76e-07	0.00032	0.59	0.46	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	5.56	1.76e-07	0.00032	0.59	0.46	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	5.56	1.76e-07	0.00032	0.59	0.46	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
GBM	cis	rs3096299	0.967	rs2911253	ENSG00000260259.1	RP11-368I7.4	5.56	1.76e-07	0.00032	0.5	0.46	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89682620~89686569:-
GBM	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	5.56	1.76e-07	0.00032	0.77	0.46	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
GBM	cis	rs6782228	0.876	rs34198449	ENSG00000277250.1	Metazoa_SRP	5.56	1.77e-07	0.000321	0.59	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128673681~128674021:-
GBM	cis	rs17772222	0.63	rs12437422	ENSG00000258983.2	RP11-507K2.2	-5.56	1.77e-07	0.000322	-0.48	-0.46	Coronary artery calcification;	chr14:88529621	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.605	rs4899955	ENSG00000258983.2	RP11-507K2.2	-5.56	1.77e-07	0.000322	-0.48	-0.46	Coronary artery calcification;	chr14:88530381	chr14:88499334~88515502:+
GBM	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-5.56	1.78e-07	0.000323	-0.63	-0.46	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
GBM	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-5.56	1.78e-07	0.000323	-0.63	-0.46	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
GBM	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	5.56	1.78e-07	0.000323	0.78	0.46	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
GBM	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	5.56	1.78e-07	0.000323	0.55	0.46	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
GBM	cis	rs7267979	0.816	rs443009	ENSG00000276952.1	RP5-965G21.6	-5.56	1.79e-07	0.000325	-0.42	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25284915~25285588:-
GBM	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	5.56	1.79e-07	0.000325	0.68	0.46	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
GBM	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-5.56	1.8e-07	0.000327	-0.55	-0.46	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
GBM	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	5.56	1.81e-07	0.000328	0.55	0.46	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
GBM	cis	rs11098499	1	rs6849889	ENSG00000250412.1	KLHL2P1	5.56	1.82e-07	0.000329	0.58	0.46	Corneal astigmatism;	chr4:119265193	chr4:119334329~119378233:+
GBM	cis	rs11098499	1	rs58601355	ENSG00000250412.1	KLHL2P1	5.56	1.82e-07	0.000329	0.58	0.46	Corneal astigmatism;	chr4:119265212	chr4:119334329~119378233:+
GBM	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	5.55	1.82e-07	0.000329	0.86	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	5.55	1.82e-07	0.000329	0.86	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
GBM	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	5.55	1.82e-07	0.00033	0.62	0.46	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
GBM	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	5.55	1.82e-07	0.00033	0.55	0.46	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
GBM	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	5.55	1.83e-07	0.000331	0.55	0.46	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
GBM	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-5.55	1.83e-07	0.000331	-0.69	-0.46	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
GBM	cis	rs11696739	0.536	rs3761268	ENSG00000242324.1	RP4-576H24.2	5.55	1.83e-07	0.000332	0.65	0.46	Mean platelet volume;	chr20:1620521	chr20:1516759~1557653:-
GBM	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-5.55	1.84e-07	0.000334	-0.59	-0.46	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
GBM	cis	rs6452524	0.772	rs13156510	ENSG00000248112.1	RP11-78C3.1	-5.55	1.85e-07	0.000334	-0.57	-0.46	Hypertension (SNP x SNP interaction);	chr5:83208668	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.836	rs10514249	ENSG00000248112.1	RP11-78C3.1	-5.55	1.85e-07	0.000334	-0.57	-0.46	Hypertension (SNP x SNP interaction);	chr5:83209037	chr5:82919376~82921119:-
GBM	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-5.55	1.85e-07	0.000335	-0.55	-0.46	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
GBM	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	5.55	1.85e-07	0.000335	0.58	0.46	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
GBM	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	5.55	1.86e-07	0.000336	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
GBM	cis	rs7267979	1	rs6050559	ENSG00000125804.12	FAM182A	-5.55	1.86e-07	0.000337	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:26054655~26086917:+
GBM	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	5.55	1.87e-07	0.000337	0.59	0.46	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
GBM	cis	rs17772222	0.63	rs12436642	ENSG00000258983.2	RP11-507K2.2	-5.55	1.87e-07	0.000338	-0.48	-0.46	Coronary artery calcification;	chr14:88559032	chr14:88499334~88515502:+
GBM	cis	rs7267979	0.966	rs2261784	ENSG00000125804.12	FAM182A	-5.55	1.87e-07	0.000338	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2261785	ENSG00000125804.12	FAM182A	-5.55	1.87e-07	0.000338	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.644	rs10050092	ENSG00000250412.1	KLHL2P1	5.55	1.87e-07	0.000338	0.57	0.46	Corneal astigmatism;	chr4:119610930	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.644	rs7693919	ENSG00000250412.1	KLHL2P1	5.55	1.87e-07	0.000338	0.57	0.46	Corneal astigmatism;	chr4:119619416	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.57	rs6832740	ENSG00000250412.1	KLHL2P1	5.55	1.87e-07	0.000338	0.57	0.46	Corneal astigmatism;	chr4:119624981	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.644	rs6855918	ENSG00000250412.1	KLHL2P1	5.55	1.87e-07	0.000338	0.57	0.46	Corneal astigmatism;	chr4:119625144	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.644	rs28787668	ENSG00000250412.1	KLHL2P1	5.55	1.87e-07	0.000338	0.57	0.46	Corneal astigmatism;	chr4:119633532	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.644	rs7676296	ENSG00000250412.1	KLHL2P1	5.55	1.87e-07	0.000338	0.57	0.46	Corneal astigmatism;	chr4:119634532	chr4:119334329~119378233:+
GBM	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-5.55	1.88e-07	0.000338	-0.53	-0.46	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
GBM	cis	rs7267979	0.866	rs2424699	ENSG00000125804.12	FAM182A	-5.55	1.88e-07	0.000339	-0.61	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:26054655~26086917:+
GBM	cis	rs6452524	0.87	rs12152892	ENSG00000248112.1	RP11-78C3.1	5.55	1.88e-07	0.000339	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:82919376~82921119:-
GBM	cis	rs7267979	1	rs6050547	ENSG00000125804.12	FAM182A	5.55	1.88e-07	0.000339	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:26054655~26086917:+
GBM	cis	rs9987353	0.522	rs2929466	ENSG00000253893.2	FAM85B	5.55	1.88e-07	0.00034	0.55	0.46	Recombination measurement;	chr8:9206389	chr8:8167819~8226614:-
GBM	cis	rs7267979	0.934	rs2257464	ENSG00000125804.12	FAM182A	-5.55	1.89e-07	0.00034	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:26054655~26086917:+
GBM	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-5.55	1.9e-07	0.000341	-0.62	-0.46	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
GBM	cis	rs7267979	1	rs2424700	ENSG00000125804.12	FAM182A	-5.55	1.9e-07	0.000342	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.566	rs17051356	ENSG00000249244.1	RP11-548H18.2	5.55	1.9e-07	0.000342	0.58	0.46	Corneal astigmatism;	chr4:119664153	chr4:119391831~119395335:-
GBM	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-5.54	1.9e-07	0.000342	-0.49	-0.46	Height;	chr11:118742526	chr11:118791254~118793137:+
GBM	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-5.54	1.9e-07	0.000342	-0.49	-0.46	Height;	chr11:118746590	chr11:118791254~118793137:+
GBM	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-5.54	1.91e-07	0.000343	-0.64	-0.46	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
GBM	cis	rs9876781	1	rs6442117	ENSG00000244380.1	RP11-24C3.2	-5.54	1.91e-07	0.000344	-0.51	-0.46	Longevity;	chr3:48378407	chr3:48440352~48446656:-
GBM	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-5.54	1.91e-07	0.000344	-0.68	-0.46	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
GBM	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	5.54	1.92e-07	0.000345	0.55	0.46	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	5.54	1.92e-07	0.000345	0.55	0.46	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
GBM	cis	rs9876781	1	rs7653691	ENSG00000244380.1	RP11-24C3.2	-5.54	1.92e-07	0.000345	-0.51	-0.46	Longevity;	chr3:48378199	chr3:48440352~48446656:-
GBM	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	5.54	1.93e-07	0.000347	0.55	0.46	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
GBM	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	5.54	1.94e-07	0.000348	0.68	0.46	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	5.54	1.95e-07	0.000351	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
GBM	cis	rs2013441	0.965	rs2703808	ENSG00000230528.6	NOS2P3	5.54	1.95e-07	0.000351	0.5	0.46	Obesity-related traits;	chr17:20206352	chr17:20436337~20447249:+
GBM	cis	rs7267979	1	rs2482911	ENSG00000125804.12	FAM182A	5.54	1.96e-07	0.000352	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.873	rs6083853	ENSG00000125804.12	FAM182A	5.54	1.96e-07	0.000352	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.934	rs2482913	ENSG00000125804.12	FAM182A	5.54	1.96e-07	0.000352	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2500436	ENSG00000125804.12	FAM182A	5.54	1.96e-07	0.000352	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6083856	ENSG00000125804.12	FAM182A	5.54	1.96e-07	0.000352	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2482918	ENSG00000125804.12	FAM182A	5.54	1.96e-07	0.000352	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2387885	ENSG00000125804.12	FAM182A	5.54	1.96e-07	0.000352	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2424713	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs7270835	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6138572	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6138575	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6115191	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs11087521	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs13038834	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6107045	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6107046	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6107047	ENSG00000125804.12	FAM182A	-5.54	1.96e-07	0.000352	-0.57	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:26054655~26086917:+
GBM	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-5.54	1.96e-07	0.000352	-0.53	-0.46	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
GBM	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-5.54	1.96e-07	0.000352	-0.53	-0.46	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
GBM	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	5.54	1.96e-07	0.000352	0.48	0.46	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
GBM	cis	rs11233250	0.697	rs1390978	ENSG00000245832.5	RP11-179A16.1	5.54	1.96e-07	0.000352	0.67	0.46	Glioblastoma;Glioma;	chr11:82713330	chr11:81879851~82718082:-
GBM	cis	rs11233250	0.697	rs60491498	ENSG00000245832.5	RP11-179A16.1	5.54	1.96e-07	0.000352	0.67	0.46	Glioblastoma;Glioma;	chr11:82722728	chr11:81879851~82718082:-
GBM	cis	rs11098499	1	rs35643470	ENSG00000250412.1	KLHL2P1	5.54	1.97e-07	0.000352	0.58	0.46	Corneal astigmatism;	chr4:119263793	chr4:119334329~119378233:+
GBM	cis	rs11098499	1	rs11098499	ENSG00000250412.1	KLHL2P1	5.54	1.97e-07	0.000352	0.58	0.46	Corneal astigmatism;	chr4:119266456	chr4:119334329~119378233:+
GBM	cis	rs11098499	1	rs7659194	ENSG00000250412.1	KLHL2P1	5.54	1.97e-07	0.000352	0.58	0.46	Corneal astigmatism;	chr4:119285992	chr4:119334329~119378233:+
GBM	cis	rs11098499	1	rs13116504	ENSG00000250412.1	KLHL2P1	5.54	1.97e-07	0.000352	0.58	0.46	Corneal astigmatism;	chr4:119288257	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28555550	ENSG00000250412.1	KLHL2P1	5.54	1.97e-07	0.000352	0.58	0.46	Corneal astigmatism;	chr4:119289885	chr4:119334329~119378233:+
GBM	cis	rs11098499	1	rs28419773	ENSG00000250412.1	KLHL2P1	5.54	1.97e-07	0.000352	0.58	0.46	Corneal astigmatism;	chr4:119289906	chr4:119334329~119378233:+
GBM	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-5.54	1.97e-07	0.000352	-0.59	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
GBM	cis	rs7267979	1	rs2500424	ENSG00000125804.12	FAM182A	5.54	1.97e-07	0.000353	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2500448	ENSG00000125804.12	FAM182A	5.54	1.97e-07	0.000353	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.644	rs2389880	ENSG00000250412.1	KLHL2P1	5.54	1.97e-07	0.000353	0.56	0.46	Corneal astigmatism;	chr4:119638715	chr4:119334329~119378233:+
GBM	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	5.54	1.97e-07	0.000353	0.3	0.46	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	5.54	1.97e-07	0.000353	0.3	0.46	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	5.54	1.97e-07	0.000353	0.3	0.46	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	5.54	1.97e-07	0.000353	0.3	0.46	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	5.54	1.97e-07	0.000353	0.3	0.46	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
GBM	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	5.54	1.97e-07	0.000353	0.79	0.46	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
GBM	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-5.54	1.98e-07	0.000355	-0.38	-0.46	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
GBM	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	5.54	1.99e-07	0.000355	0.71	0.46	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
GBM	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	5.54	1.99e-07	0.000355	0.71	0.46	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
GBM	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-5.53	1.99e-07	0.000355	-0.53	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
GBM	cis	rs7267979	1	rs6050559	ENSG00000276952.1	RP5-965G21.6	5.53	1.99e-07	0.000355	0.44	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258719	ENSG00000125804.12	FAM182A	-5.53	1.99e-07	0.000355	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs7019	ENSG00000125804.12	FAM182A	-5.53	1.99e-07	0.000355	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.933	rs2424708	ENSG00000125804.12	FAM182A	-5.53	1.99e-07	0.000355	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2424710	ENSG00000125804.12	FAM182A	-5.53	1.99e-07	0.000355	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6115140	ENSG00000125804.12	FAM182A	-5.53	1.99e-07	0.000355	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs1888999	ENSG00000125804.12	FAM182A	-5.53	1.99e-07	0.000355	-0.58	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs884613	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs1888998	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2500433	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2482948	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs1888997	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482919	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs3002698	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6037086	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2482923	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482927	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2500443	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482928	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482930	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482931	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2500446	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482937	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482940	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2027003	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2027004	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.934	rs2500399	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.903	rs2500400	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2500404	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2500405	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2482941	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.903	rs2500423	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2263204	ENSG00000125804.12	FAM182A	5.53	1.99e-07	0.000355	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:26054655~26086917:+
GBM	cis	rs6782228	0.585	rs2811492	ENSG00000277250.1	Metazoa_SRP	-5.53	1.99e-07	0.000355	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs1697	ENSG00000277250.1	Metazoa_SRP	-5.53	1.99e-07	0.000355	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128673681~128674021:-
GBM	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	5.53	2e-07	0.000356	0.52	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	5.53	2e-07	0.000356	0.52	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
GBM	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-5.53	2.01e-07	0.000358	-0.63	-0.46	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	5.53	2.02e-07	0.00036	0.57	0.46	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
GBM	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	5.53	2.02e-07	0.00036	0.46	0.46	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
GBM	cis	rs2976388	0.967	rs2976387	ENSG00000253741.1	CTD-2292P10.4	5.53	2.02e-07	0.00036	0.5	0.46	Urinary tract infection frequency;	chr8:142677946	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.904	rs2920281	ENSG00000253741.1	CTD-2292P10.4	5.53	2.02e-07	0.00036	0.5	0.46	Urinary tract infection frequency;	chr8:142679026	chr8:142702252~142726973:-
GBM	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	5.53	2.02e-07	0.00036	0.59	0.46	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
GBM	cis	rs6496932	1	rs34434405	ENSG00000218052.5	ADAMTS7P4	5.53	2.03e-07	0.00036	0.68	0.46	Central corneal thickness;Corneal structure;	chr15:85281437	chr15:85255369~85330334:-
GBM	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	5.53	2.03e-07	0.000361	0.53	0.46	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
GBM	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	5.53	2.04e-07	0.000362	0.77	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
GBM	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-5.53	2.04e-07	0.000362	-0.51	-0.46	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
GBM	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	5.53	2.04e-07	0.000362	0.5	0.46	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
GBM	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-5.53	2.05e-07	0.000363	-0.56	-0.46	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
GBM	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-5.53	2.05e-07	0.000363	-0.62	-0.46	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
GBM	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-5.53	2.05e-07	0.000364	-0.49	-0.46	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
GBM	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	5.53	2.06e-07	0.000366	0.57	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
GBM	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	5.53	2.07e-07	0.000366	0.47	0.46	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
GBM	cis	rs6782228	0.565	rs11719239	ENSG00000277250.1	Metazoa_SRP	-5.53	2.07e-07	0.000367	-0.5	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs2001950	ENSG00000277250.1	Metazoa_SRP	-5.53	2.07e-07	0.000367	-0.5	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128673681~128674021:-
GBM	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	5.52	2.08e-07	0.000368	0.56	0.46	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
GBM	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	5.52	2.08e-07	0.000368	0.56	0.46	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
GBM	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-5.52	2.09e-07	0.000369	-0.48	-0.46	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
GBM	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-5.52	2.09e-07	0.000369	-0.63	-0.46	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
GBM	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	5.52	2.09e-07	0.00037	0.43	0.46	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
GBM	cis	rs7267979	1	rs2482943	ENSG00000125804.12	FAM182A	5.52	2.1e-07	0.00037	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:26054655~26086917:+
GBM	cis	rs2843012	0.529	rs2516815	ENSG00000229921.5	KIF25-AS1	-5.52	2.1e-07	0.00037	-0.6	-0.46	Metabolite levels (5-HIAA);	chr6:168010510	chr6:167992822~167997077:-
GBM	cis	rs2843012	0.529	rs2636358	ENSG00000229921.5	KIF25-AS1	-5.52	2.1e-07	0.00037	-0.6	-0.46	Metabolite levels (5-HIAA);	chr6:168010515	chr6:167992822~167997077:-
GBM	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	5.52	2.11e-07	0.000372	0.58	0.46	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
GBM	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	5.52	2.11e-07	0.000373	0.54	0.46	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	5.52	2.11e-07	0.000373	0.54	0.46	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	5.52	2.11e-07	0.000373	0.54	0.46	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
GBM	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	5.52	2.11e-07	0.000373	0.58	0.46	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
GBM	cis	rs7267979	0.727	rs2474765	ENSG00000125804.12	FAM182A	-5.52	2.11e-07	0.000373	-0.55	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.764	rs2474767	ENSG00000125804.12	FAM182A	-5.52	2.11e-07	0.000373	-0.55	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26054655~26086917:+
GBM	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	5.52	2.12e-07	0.000373	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
GBM	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
GBM	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
GBM	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.12e-07	0.000374	-0.59	-0.46	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
GBM	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	5.52	2.13e-07	0.000374	0.86	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
GBM	cis	rs67981189	0.542	rs17109053	ENSG00000269927.1	RP6-91H8.3	5.52	2.13e-07	0.000375	0.55	0.46	Schizophrenia;	chr14:71142981	chr14:71141125~71143253:-
GBM	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	5.52	2.13e-07	0.000375	0.54	0.46	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
GBM	cis	rs66887589	0.592	rs62320740	ENSG00000249244.1	RP11-548H18.2	5.52	2.14e-07	0.000376	0.54	0.46	Diastolic blood pressure;	chr4:119358331	chr4:119391831~119395335:-
GBM	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	5.52	2.14e-07	0.000376	0.46	0.46	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	5.52	2.14e-07	0.000376	0.46	0.46	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	5.52	2.14e-07	0.000376	0.46	0.46	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
GBM	cis	rs9876781	1	rs725310	ENSG00000244380.1	RP11-24C3.2	-5.52	2.14e-07	0.000376	-0.51	-0.46	Longevity;	chr3:48377081	chr3:48440352~48446656:-
GBM	cis	rs7267979	0.966	rs2500417	ENSG00000125804.12	FAM182A	5.52	2.14e-07	0.000376	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:26054655~26086917:+
GBM	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-5.52	2.14e-07	0.000377	-0.53	-0.46	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
GBM	cis	rs2013441	0.931	rs12937827	ENSG00000230528.6	NOS2P3	-5.52	2.14e-07	0.000377	-0.51	-0.46	Obesity-related traits;	chr17:20129889	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs17686839	ENSG00000230528.6	NOS2P3	-5.52	2.14e-07	0.000377	-0.51	-0.46	Obesity-related traits;	chr17:20135858	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs4924809	ENSG00000230528.6	NOS2P3	-5.52	2.14e-07	0.000377	-0.51	-0.46	Obesity-related traits;	chr17:20141360	chr17:20436337~20447249:+
GBM	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-5.52	2.15e-07	0.000377	-0.45	-0.46	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	5.52	2.15e-07	0.000377	0.45	0.46	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	5.52	2.15e-07	0.000377	0.45	0.46	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	5.52	2.15e-07	0.000377	0.45	0.46	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	5.52	2.15e-07	0.000377	0.45	0.46	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	5.52	2.15e-07	0.000377	0.45	0.46	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
GBM	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-5.52	2.16e-07	0.000378	-0.5	-0.46	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
GBM	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	5.52	2.16e-07	0.000379	0.52	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
GBM	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-5.52	2.16e-07	0.000379	-0.6	-0.46	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
GBM	cis	rs17772222	0.63	rs4904454	ENSG00000258983.2	RP11-507K2.2	-5.52	2.16e-07	0.000379	-0.47	-0.46	Coronary artery calcification;	chr14:88537777	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.63	rs2033418	ENSG00000258983.2	RP11-507K2.2	-5.52	2.16e-07	0.000379	-0.47	-0.46	Coronary artery calcification;	chr14:88539331	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.63	rs10873392	ENSG00000258983.2	RP11-507K2.2	-5.52	2.16e-07	0.000379	-0.47	-0.46	Coronary artery calcification;	chr14:88545124	chr14:88499334~88515502:+
GBM	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	5.52	2.17e-07	0.00038	0.73	0.46	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
GBM	cis	rs7829975	0.742	rs12547493	ENSG00000254340.1	RP11-10A14.3	-5.51	2.18e-07	0.000381	-0.61	-0.46	Mood instability;	chr8:8804024	chr8:9141424~9145435:+
GBM	cis	rs11233250	0.697	rs17144197	ENSG00000245832.5	RP11-179A16.1	5.51	2.18e-07	0.000381	0.66	0.46	Glioblastoma;Glioma;	chr11:82721092	chr11:81879851~82718082:-
GBM	cis	rs2069426	0.591	rs17694493	ENSG00000240498.5	CDKN2B-AS1	5.51	2.18e-07	0.000382	0.66	0.46	Acute lymphoblastic leukemia (childhood);	chr9:22041999	chr9:21994778~22121097:+
GBM	cis	rs3096299	0.967	rs2911255	ENSG00000260259.1	RP11-368I7.4	5.51	2.18e-07	0.000382	0.5	0.46	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89682620~89686569:-
GBM	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-5.51	2.19e-07	0.000383	-0.66	-0.46	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
GBM	cis	rs67981189	0.865	rs2810071	ENSG00000269927.1	RP6-91H8.3	-5.51	2.19e-07	0.000384	-0.53	-0.46	Schizophrenia;	chr14:70920931	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.865	rs2189806	ENSG00000269927.1	RP6-91H8.3	-5.51	2.19e-07	0.000384	-0.53	-0.46	Schizophrenia;	chr14:70921681	chr14:71141125~71143253:-
GBM	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	5.51	2.2e-07	0.000384	0.55	0.46	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
GBM	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-5.51	2.2e-07	0.000384	-0.56	-0.46	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	5.51	2.2e-07	0.000384	0.54	0.46	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	5.51	2.2e-07	0.000384	0.54	0.46	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	5.51	2.2e-07	0.000384	0.54	0.46	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	5.51	2.2e-07	0.000384	0.54	0.46	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	5.51	2.2e-07	0.000384	0.54	0.46	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
GBM	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-5.51	2.22e-07	0.000387	-0.53	-0.46	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
GBM	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-5.51	2.22e-07	0.000387	-0.53	-0.46	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-5.51	2.22e-07	0.000387	-0.53	-0.46	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
GBM	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-5.51	2.22e-07	0.000387	-0.53	-0.46	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-5.51	2.22e-07	0.000387	-0.53	-0.46	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-5.51	2.22e-07	0.000387	-0.53	-0.46	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-5.51	2.22e-07	0.000387	-0.53	-0.46	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
GBM	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	5.51	2.22e-07	0.000387	0.66	0.46	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
GBM	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	5.51	2.22e-07	0.000388	0.55	0.46	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	5.51	2.22e-07	0.000388	0.55	0.46	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	5.51	2.22e-07	0.000388	0.55	0.46	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	5.51	2.22e-07	0.000388	0.55	0.46	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	5.51	2.22e-07	0.000388	0.55	0.46	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	5.51	2.22e-07	0.000388	0.55	0.46	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	5.51	2.22e-07	0.000388	0.55	0.46	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
GBM	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	5.51	2.23e-07	0.000388	0.53	0.46	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	5.51	2.23e-07	0.000388	0.53	0.46	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
GBM	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	5.51	2.23e-07	0.000389	0.54	0.46	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
GBM	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-5.51	2.23e-07	0.000389	-0.65	-0.46	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
GBM	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	5.51	2.24e-07	0.00039	0.45	0.46	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
GBM	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	5.51	2.25e-07	0.000391	0.6	0.46	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	5.51	2.25e-07	0.000391	0.6	0.46	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
GBM	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-5.51	2.25e-07	0.000391	-0.47	-0.46	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
GBM	cis	rs11696739	0.501	rs2243603	ENSG00000242324.1	RP4-576H24.2	5.51	2.25e-07	0.000391	0.61	0.46	Mean platelet volume;	chr20:1566265	chr20:1516759~1557653:-
GBM	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	5.51	2.25e-07	0.000392	0.51	0.46	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
GBM	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	5.51	2.25e-07	0.000392	0.51	0.46	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
GBM	cis	rs12495178	0.574	rs55971481	ENSG00000239519.1	CADM2-AS1	5.51	2.26e-07	0.000393	0.5	0.46	Body mass index;	chr3:85871507	chr3:85992183~86028007:-
GBM	cis	rs2976388	1	rs2976388	ENSG00000253741.1	CTD-2292P10.4	5.51	2.26e-07	0.000393	0.49	0.46	Urinary tract infection frequency;	chr8:142678838	chr8:142702252~142726973:-
GBM	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-5.51	2.26e-07	0.000393	-0.49	-0.46	Height;	chr11:118773873	chr11:118791254~118793137:+
GBM	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	5.51	2.26e-07	0.000394	0.7	0.46	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
GBM	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	5.51	2.27e-07	0.000394	0.54	0.46	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
GBM	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-5.51	2.27e-07	0.000394	-0.58	-0.46	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
GBM	cis	rs11159086	1	rs11159086	ENSG00000270000.1	RP3-449M8.9	5.51	2.27e-07	0.000395	0.66	0.46	Advanced glycation end-product levels;	chr14:74495572	chr14:74471930~74472360:-
GBM	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-5.5	2.29e-07	0.000397	-0.6	-0.46	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	5.5	2.29e-07	0.000397	0.57	0.46	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
GBM	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
GBM	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
GBM	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-5.5	2.29e-07	0.000397	-0.61	-0.46	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
GBM	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	5.5	2.29e-07	0.000397	1.05	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
GBM	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	5.5	2.29e-07	0.000397	1.05	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
GBM	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	5.5	2.29e-07	0.000397	0.54	0.46	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
GBM	cis	rs4072705	1	rs4836991	ENSG00000224020.1	MIR181A2HG	5.5	2.3e-07	0.000398	0.5	0.46	Menarche (age at onset);	chr9:124749761	chr9:124658467~124698631:+
GBM	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-5.5	2.3e-07	0.000398	-0.4	-0.46	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
GBM	cis	rs67981189	0.896	rs17108925	ENSG00000269927.1	RP6-91H8.3	5.5	2.3e-07	0.000398	0.52	0.46	Schizophrenia;	chr14:71033010	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs28374308	ENSG00000269927.1	RP6-91H8.3	5.5	2.3e-07	0.000398	0.52	0.46	Schizophrenia;	chr14:71035040	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs8016506	ENSG00000269927.1	RP6-91H8.3	5.5	2.3e-07	0.000398	0.52	0.46	Schizophrenia;	chr14:71039600	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.858	rs35631530	ENSG00000269927.1	RP6-91H8.3	5.5	2.3e-07	0.000398	0.52	0.46	Schizophrenia;	chr14:71041312	chr14:71141125~71143253:-
GBM	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-5.5	2.3e-07	0.000398	-0.49	-0.46	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
GBM	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-5.5	2.3e-07	0.000398	-0.49	-0.46	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
GBM	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	5.5	2.3e-07	0.000398	0.78	0.46	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	5.5	2.3e-07	0.000398	0.78	0.46	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
GBM	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-5.5	2.3e-07	0.000399	-0.61	-0.46	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
GBM	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-5.5	2.31e-07	4e-04	-0.47	-0.46	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
GBM	cis	rs4713118	0.506	rs9366697	ENSG00000218016.2	ZNF192P2	-5.5	2.31e-07	4e-04	-0.55	-0.46	Parkinson's disease;	chr6:27665239	chr6:28188050~28189432:+
GBM	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-5.5	2.31e-07	4e-04	-0.59	-0.46	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
GBM	cis	rs7267979	0.932	rs449370	ENSG00000125804.12	FAM182A	5.5	2.31e-07	4e-04	0.57	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:26054655~26086917:+
GBM	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	5.5	2.32e-07	0.000401	0.55	0.46	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
GBM	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-5.5	2.32e-07	0.000401	-0.59	-0.46	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
GBM	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-5.5	2.33e-07	0.000402	-0.54	-0.46	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
GBM	cis	rs6496932	0.865	rs4842874	ENSG00000218052.5	ADAMTS7P4	5.5	2.34e-07	0.000404	0.69	0.46	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85255369~85330334:-
GBM	cis	rs2013441	0.866	rs2703773	ENSG00000230528.6	NOS2P3	5.5	2.35e-07	0.000406	0.52	0.46	Obesity-related traits;	chr17:20228501	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.866	rs2526473	ENSG00000230528.6	NOS2P3	5.5	2.35e-07	0.000406	0.52	0.46	Obesity-related traits;	chr17:20234165	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.866	rs2703784	ENSG00000230528.6	NOS2P3	5.5	2.35e-07	0.000406	0.52	0.46	Obesity-related traits;	chr17:20248007	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.866	rs2526471	ENSG00000230528.6	NOS2P3	5.5	2.35e-07	0.000406	0.52	0.46	Obesity-related traits;	chr17:20248360	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.866	rs2526470	ENSG00000230528.6	NOS2P3	5.5	2.35e-07	0.000406	0.52	0.46	Obesity-related traits;	chr17:20256957	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.761	rs2526468	ENSG00000230528.6	NOS2P3	5.5	2.35e-07	0.000406	0.52	0.46	Obesity-related traits;	chr17:20259759	chr17:20436337~20447249:+
GBM	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-5.5	2.35e-07	0.000406	-0.52	-0.46	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
GBM	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-5.5	2.36e-07	0.000407	-0.62	-0.46	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	5.5	2.37e-07	0.000408	0.61	0.46	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
GBM	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-5.5	2.37e-07	0.000409	-0.68	-0.46	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-5.5	2.37e-07	0.000409	-0.68	-0.46	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
GBM	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-5.5	2.37e-07	0.000409	-0.54	-0.46	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-5.5	2.37e-07	0.000409	-0.54	-0.46	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
GBM	cis	rs9987353	0.544	rs2929470	ENSG00000253893.2	FAM85B	5.5	2.38e-07	0.00041	0.53	0.46	Recombination measurement;	chr8:9204980	chr8:8167819~8226614:-
GBM	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-5.49	2.38e-07	0.000411	-0.49	-0.46	Height;	chr11:118761813	chr11:118791254~118793137:+
GBM	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-5.49	2.39e-07	0.000411	-0.58	-0.46	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
GBM	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	5.49	2.39e-07	0.000412	0.46	0.46	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
GBM	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-5.49	2.39e-07	0.000412	-0.57	-0.46	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
GBM	cis	rs6782228	0.585	rs2712392	ENSG00000277250.1	Metazoa_SRP	-5.49	2.4e-07	0.000413	-0.51	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128673681~128674021:-
GBM	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	5.49	2.4e-07	0.000413	0.6	0.46	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
GBM	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	5.49	2.4e-07	0.000413	0.71	0.46	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
GBM	cis	rs11098499	0.697	rs4560394	ENSG00000250412.1	KLHL2P1	5.49	2.4e-07	0.000413	0.61	0.46	Corneal astigmatism;	chr4:119392280	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs938056	ENSG00000250412.1	KLHL2P1	5.49	2.4e-07	0.000413	0.59	0.46	Corneal astigmatism;	chr4:119316298	chr4:119334329~119378233:+
GBM	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	5.49	2.4e-07	0.000414	0.59	0.46	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	5.49	2.4e-07	0.000414	0.59	0.46	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
GBM	cis	rs2013441	1	rs2526484	ENSG00000230528.6	NOS2P3	5.49	2.41e-07	0.000414	0.52	0.46	Obesity-related traits;	chr17:20200447	chr17:20436337~20447249:+
GBM	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-5.49	2.41e-07	0.000414	-0.57	-0.46	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
GBM	cis	rs7267979	0.933	rs1130694	ENSG00000276952.1	RP5-965G21.6	5.49	2.41e-07	0.000414	0.43	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.933	rs2258728	ENSG00000276952.1	RP5-965G21.6	5.49	2.41e-07	0.000414	0.43	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25284915~25285588:-
GBM	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	5.49	2.41e-07	0.000415	0.52	0.46	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
GBM	cis	rs2013441	1	rs4588033	ENSG00000230528.6	NOS2P3	5.49	2.42e-07	0.000415	0.52	0.46	Obesity-related traits;	chr17:20126588	chr17:20436337~20447249:+
GBM	cis	rs453301	0.509	rs7000323	ENSG00000253893.2	FAM85B	5.49	2.42e-07	0.000416	0.56	0.46	Joint mobility (Beighton score);	chr8:8934763	chr8:8167819~8226614:-
GBM	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-5.49	2.43e-07	0.000417	-0.46	-0.46	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
GBM	cis	rs860818	1	rs858238	ENSG00000226816.2	AC005082.12	5.49	2.43e-07	0.000418	1.26	0.46	Initial pursuit acceleration;	chr7:23199514	chr7:23206013~23208045:+
GBM	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	5.49	2.44e-07	0.000418	0.53	0.46	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
GBM	cis	rs7267979	1	rs2474777	ENSG00000276952.1	RP5-965G21.6	5.49	2.44e-07	0.000419	0.41	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25284915~25285588:-
GBM	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-5.49	2.44e-07	0.000419	-0.48	-0.46	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
GBM	cis	rs7267979	1	rs2500418	ENSG00000125804.12	FAM182A	5.49	2.44e-07	0.000419	0.58	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:26054655~26086917:+
GBM	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-5.49	2.45e-07	0.00042	-0.59	-0.46	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
GBM	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	5.49	2.46e-07	0.000421	0.54	0.46	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
GBM	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-5.49	2.46e-07	0.000422	-0.47	-0.46	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
GBM	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	5.49	2.46e-07	0.000422	0.44	0.46	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
GBM	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-5.49	2.47e-07	0.000423	-0.49	-0.46	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
GBM	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-5.49	2.47e-07	0.000423	-0.49	-0.46	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
GBM	cis	rs7615952	0.512	rs4234285	ENSG00000171084.14	FAM86JP	5.49	2.48e-07	0.000425	0.72	0.46	Blood pressure (smoking interaction);	chr3:125685633	chr3:125916620~125930024:+
GBM	cis	rs6782228	0.606	rs4634140	ENSG00000277250.1	Metazoa_SRP	5.49	2.48e-07	0.000425	0.51	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128673681~128674021:-
GBM	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-5.49	2.49e-07	0.000425	-0.61	-0.46	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000224205.1	AP000351.4	5.48	2.49e-07	0.000427	0.51	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23987320~23991421:-
GBM	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	5.48	2.5e-07	0.000428	0.6	0.46	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	5.48	2.5e-07	0.000428	0.6	0.46	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
GBM	cis	rs67981189	0.593	rs7143595	ENSG00000269927.1	RP6-91H8.3	5.48	2.51e-07	0.000429	0.51	0.46	Schizophrenia;	chr14:71055284	chr14:71141125~71143253:-
GBM	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-5.48	2.51e-07	0.000429	-0.66	-0.46	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
GBM	cis	rs172166	0.538	rs1150686	ENSG00000199851.2	U3	5.48	2.51e-07	0.000429	0.56	0.46	Cardiac Troponin-T levels;	chr6:28193493	chr6:28015568~28015777:+
GBM	cis	rs1150688	1	rs1150688	ENSG00000199851.2	U3	5.48	2.51e-07	0.000429	0.56	0.46	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.523	rs2179096	ENSG00000218016.2	ZNF192P2	-5.48	2.52e-07	0.00043	-0.56	-0.46	Parkinson's disease;	chr6:27698141	chr6:28188050~28189432:+
GBM	cis	rs11159086	1	rs3759745	ENSG00000270000.1	RP3-449M8.9	5.48	2.52e-07	0.00043	0.71	0.46	Advanced glycation end-product levels;	chr14:74495967	chr14:74471930~74472360:-
GBM	cis	rs11159086	1	rs4903232	ENSG00000270000.1	RP3-449M8.9	5.48	2.52e-07	0.00043	0.71	0.46	Advanced glycation end-product levels;	chr14:74496585	chr14:74471930~74472360:-
GBM	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	5.48	2.54e-07	0.000433	0.54	0.46	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000224205.1	AP000351.4	-5.48	2.54e-07	0.000433	-0.52	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23987320~23991421:-
GBM	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-5.48	2.54e-07	0.000434	-0.61	-0.46	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
GBM	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-5.48	2.54e-07	0.000434	-0.61	-0.46	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-5.48	2.54e-07	0.000434	-0.52	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
GBM	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	5.48	2.54e-07	0.000434	0.75	0.46	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
GBM	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	5.48	2.55e-07	0.000435	0.53	0.45	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-5.48	2.56e-07	0.000436	-0.55	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
GBM	cis	rs11098499	0.644	rs3806808	ENSG00000250412.1	KLHL2P1	5.48	2.56e-07	0.000436	0.56	0.45	Corneal astigmatism;	chr4:119629930	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.644	rs34835603	ENSG00000250412.1	KLHL2P1	5.48	2.56e-07	0.000436	0.56	0.45	Corneal astigmatism;	chr4:119632273	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.615	rs28850368	ENSG00000250412.1	KLHL2P1	5.48	2.56e-07	0.000436	0.56	0.45	Corneal astigmatism;	chr4:119633158	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.675	rs11098534	ENSG00000250412.1	KLHL2P1	5.48	2.56e-07	0.000436	0.56	0.45	Corneal astigmatism;	chr4:119635617	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.644	rs10009566	ENSG00000250412.1	KLHL2P1	5.48	2.56e-07	0.000436	0.56	0.45	Corneal astigmatism;	chr4:119637453	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.644	rs10012252	ENSG00000250412.1	KLHL2P1	5.48	2.56e-07	0.000436	0.56	0.45	Corneal astigmatism;	chr4:119637984	chr4:119334329~119378233:+
GBM	cis	rs2013441	0.896	rs1812934	ENSG00000230528.6	NOS2P3	5.48	2.56e-07	0.000436	0.51	0.45	Obesity-related traits;	chr17:20127647	chr17:20436337~20447249:+
GBM	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-5.48	2.56e-07	0.000436	-0.55	-0.45	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
GBM	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	5.48	2.56e-07	0.000437	0.71	0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
GBM	cis	rs11159086	0.938	rs11623040	ENSG00000270000.1	RP3-449M8.9	5.48	2.57e-07	0.000437	0.76	0.45	Advanced glycation end-product levels;	chr14:74496743	chr14:74471930~74472360:-
GBM	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	5.48	2.57e-07	0.000438	0.52	0.45	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	5.48	2.57e-07	0.000438	0.52	0.45	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
GBM	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	5.48	2.58e-07	0.000439	0.69	0.45	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
GBM	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	5.48	2.58e-07	0.00044	0.55	0.45	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	5.48	2.58e-07	0.00044	0.55	0.45	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
GBM	cis	rs12460587	0.547	rs4566288	ENSG00000275055.1	CTC-471J1.11	-5.48	2.59e-07	0.000441	-0.55	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52092677	chr19:52049007~52049754:+
GBM	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	5.48	2.59e-07	0.000441	0.61	0.45	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
GBM	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	5.48	2.6e-07	0.000442	0.55	0.45	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
GBM	cis	rs6452524	0.868	rs10057303	ENSG00000248112.1	RP11-78C3.1	5.48	2.6e-07	0.000442	0.56	0.45	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs2386235	ENSG00000248112.1	RP11-78C3.1	5.48	2.6e-07	0.000442	0.56	0.45	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.868	rs10045104	ENSG00000248112.1	RP11-78C3.1	5.48	2.6e-07	0.000442	0.56	0.45	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:82919376~82921119:-
GBM	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	5.48	2.6e-07	0.000443	0.52	0.45	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	5.48	2.6e-07	0.000443	0.52	0.45	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	5.48	2.6e-07	0.000443	0.52	0.45	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	5.48	2.6e-07	0.000443	0.52	0.45	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
GBM	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	5.47	2.6e-07	0.000443	0.43	0.45	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
GBM	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-5.47	2.61e-07	0.000443	-0.65	-0.45	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
GBM	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	5.47	2.61e-07	0.000444	0.86	0.45	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
GBM	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	5.47	2.62e-07	0.000445	0.47	0.45	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
GBM	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	5.47	2.62e-07	0.000445	0.58	0.45	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
GBM	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	5.47	2.62e-07	0.000446	0.54	0.45	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
GBM	cis	rs7267979	1	rs6083844	ENSG00000125804.12	FAM182A	5.47	2.62e-07	0.000446	0.57	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:26054655~26086917:+
GBM	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	5.47	2.62e-07	0.000446	0.47	0.45	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
GBM	cis	rs3096299	0.933	rs2965938	ENSG00000260259.1	RP11-368I7.4	5.47	2.63e-07	0.000447	0.5	0.45	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89682620~89686569:-
GBM	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	5.47	2.64e-07	0.000449	0.48	0.45	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
GBM	cis	rs7267979	1	rs6050598	ENSG00000125804.12	FAM182A	-5.47	2.66e-07	0.000452	-0.55	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:26054655~26086917:+
GBM	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	5.47	2.67e-07	0.000453	0.52	0.45	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	5.47	2.67e-07	0.000453	0.52	0.45	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
GBM	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-5.47	2.67e-07	0.000454	-0.58	-0.45	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
GBM	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	5.47	2.68e-07	0.000454	0.52	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
GBM	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-5.47	2.68e-07	0.000455	-0.61	-0.45	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
GBM	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	5.47	2.68e-07	0.000455	0.46	0.45	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
GBM	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-5.47	2.69e-07	0.000456	-0.67	-0.45	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
GBM	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	5.47	2.69e-07	0.000456	0.45	0.45	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
GBM	cis	rs67981189	0.865	rs2810117	ENSG00000269927.1	RP6-91H8.3	-5.47	2.69e-07	0.000456	-0.52	-0.45	Schizophrenia;	chr14:70924308	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.865	rs2810115	ENSG00000269927.1	RP6-91H8.3	-5.47	2.69e-07	0.000456	-0.52	-0.45	Schizophrenia;	chr14:70928070	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs917065	ENSG00000269927.1	RP6-91H8.3	-5.47	2.69e-07	0.000456	-0.52	-0.45	Schizophrenia;	chr14:70931129	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs1018977	ENSG00000269927.1	RP6-91H8.3	-5.47	2.69e-07	0.000456	-0.52	-0.45	Schizophrenia;	chr14:70933936	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs1859468	ENSG00000269927.1	RP6-91H8.3	-5.47	2.69e-07	0.000456	-0.52	-0.45	Schizophrenia;	chr14:70935573	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.752	rs2332477	ENSG00000269927.1	RP6-91H8.3	-5.47	2.69e-07	0.000456	-0.52	-0.45	Schizophrenia;	chr14:70936594	chr14:71141125~71143253:-
GBM	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-5.47	2.69e-07	0.000457	-0.52	-0.45	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
GBM	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-5.47	2.7e-07	0.000457	-0.57	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
GBM	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-5.47	2.7e-07	0.000457	-0.57	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
GBM	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	5.47	2.7e-07	0.000458	0.45	0.45	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
GBM	cis	rs8067545	0.532	rs35915823	ENSG00000230528.6	NOS2P3	-5.47	2.7e-07	0.000458	-0.55	-0.45	Schizophrenia;	chr17:20070084	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.67	rs12937327	ENSG00000230528.6	NOS2P3	-5.47	2.7e-07	0.000458	-0.55	-0.45	Obesity-related traits;	chr17:20075671	chr17:20436337~20447249:+
GBM	cis	rs860818	1	rs1621012	ENSG00000226816.2	AC005082.12	5.47	2.71e-07	0.000459	1.26	0.45	Initial pursuit acceleration;	chr7:23163714	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs1637244	ENSG00000226816.2	AC005082.12	5.47	2.71e-07	0.000459	1.26	0.45	Initial pursuit acceleration;	chr7:23163715	chr7:23206013~23208045:+
GBM	cis	rs67981189	0.821	rs34257131	ENSG00000269927.1	RP6-91H8.3	5.47	2.71e-07	0.000459	0.52	0.45	Schizophrenia;	chr14:71053723	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.821	rs12896370	ENSG00000269927.1	RP6-91H8.3	5.47	2.71e-07	0.000459	0.52	0.45	Schizophrenia;	chr14:71054623	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.821	rs2286310	ENSG00000269927.1	RP6-91H8.3	5.47	2.71e-07	0.000459	0.52	0.45	Schizophrenia;	chr14:71056888	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.821	rs61990419	ENSG00000269927.1	RP6-91H8.3	5.47	2.71e-07	0.000459	0.52	0.45	Schizophrenia;	chr14:71069570	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.784	rs58984901	ENSG00000269927.1	RP6-91H8.3	5.47	2.71e-07	0.000459	0.52	0.45	Schizophrenia;	chr14:71085271	chr14:71141125~71143253:-
GBM	cis	rs2013441	1	rs2526464	ENSG00000230528.6	NOS2P3	5.47	2.72e-07	0.000459	0.51	0.45	Obesity-related traits;	chr17:20171739	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2189710	ENSG00000230528.6	NOS2P3	5.47	2.72e-07	0.000459	0.51	0.45	Obesity-related traits;	chr17:20175651	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526462	ENSG00000230528.6	NOS2P3	5.47	2.72e-07	0.000459	0.51	0.45	Obesity-related traits;	chr17:20176147	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs34712254	ENSG00000230528.6	NOS2P3	-5.47	2.72e-07	0.000459	-0.51	-0.45	Obesity-related traits;	chr17:20145995	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs34089239	ENSG00000230528.6	NOS2P3	-5.47	2.72e-07	0.000459	-0.51	-0.45	Obesity-related traits;	chr17:20154646	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2080673	ENSG00000230528.6	NOS2P3	-5.47	2.72e-07	0.000459	-0.51	-0.45	Obesity-related traits;	chr17:20159082	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs34644796	ENSG00000230528.6	NOS2P3	-5.47	2.72e-07	0.000459	-0.51	-0.45	Obesity-related traits;	chr17:20160815	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.931	rs4925089	ENSG00000230528.6	NOS2P3	-5.47	2.72e-07	0.000459	-0.51	-0.45	Obesity-related traits;	chr17:20161471	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs4924810	ENSG00000230528.6	NOS2P3	-5.47	2.72e-07	0.000459	-0.51	-0.45	Obesity-related traits;	chr17:20168506	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703794	ENSG00000230528.6	NOS2P3	-5.47	2.72e-07	0.000459	-0.51	-0.45	Obesity-related traits;	chr17:20170025	chr17:20436337~20447249:+
GBM	cis	rs67981189	0.758	rs221921	ENSG00000269927.1	RP6-91H8.3	-5.46	2.73e-07	0.000462	-0.54	-0.45	Schizophrenia;	chr14:71119411	chr14:71141125~71143253:-
GBM	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-5.46	2.74e-07	0.000463	-0.61	-0.45	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
GBM	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	5.46	2.74e-07	0.000463	0.71	0.45	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
GBM	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	5.46	2.74e-07	0.000463	0.54	0.45	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
GBM	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	5.46	2.74e-07	0.000464	0.77	0.45	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
GBM	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	5.46	2.75e-07	0.000464	0.54	0.45	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
GBM	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	5.46	2.75e-07	0.000464	0.55	0.45	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
GBM	cis	rs4713118	0.715	rs200480	ENSG00000218016.2	ZNF192P2	-5.46	2.75e-07	0.000464	-0.55	-0.45	Parkinson's disease;	chr6:27805886	chr6:28188050~28189432:+
GBM	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	5.46	2.75e-07	0.000465	0.55	0.45	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
GBM	cis	rs6496932	0.663	rs4843051	ENSG00000218052.5	ADAMTS7P4	-5.46	2.76e-07	0.000467	-0.64	-0.45	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85255369~85330334:-
GBM	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	5.46	2.77e-07	0.000467	0.52	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
GBM	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	5.46	2.77e-07	0.000467	0.52	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
GBM	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	5.46	2.77e-07	0.000467	0.51	0.45	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
GBM	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-5.46	2.78e-07	0.000469	-0.53	-0.45	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
GBM	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	5.46	2.79e-07	0.00047	0.73	0.45	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	5.46	2.79e-07	0.00047	0.73	0.45	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
GBM	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	5.46	2.79e-07	0.00047	0.6	0.45	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
GBM	cis	rs6782228	0.527	rs2811491	ENSG00000277250.1	Metazoa_SRP	-5.46	2.79e-07	0.00047	-0.52	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128673681~128674021:-
GBM	cis	rs2013441	0.866	rs12949485	ENSG00000230528.6	NOS2P3	-5.46	2.79e-07	0.000471	-0.53	-0.45	Obesity-related traits;	chr17:20118348	chr17:20436337~20447249:+
GBM	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	5.46	2.8e-07	0.000471	0.55	0.45	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
GBM	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-5.46	2.81e-07	0.000473	-0.52	-0.45	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
GBM	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-5.46	2.81e-07	0.000473	-0.52	-0.45	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-5.46	2.81e-07	0.000473	-0.52	-0.45	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-5.46	2.81e-07	0.000473	-0.52	-0.45	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
GBM	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	5.46	2.82e-07	0.000475	0.54	0.45	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
GBM	cis	rs11098499	0.691	rs9996644	ENSG00000249244.1	RP11-548H18.2	5.46	2.83e-07	0.000476	0.58	0.45	Corneal astigmatism;	chr4:119317722	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.691	rs9996494	ENSG00000249244.1	RP11-548H18.2	5.46	2.83e-07	0.000476	0.58	0.45	Corneal astigmatism;	chr4:119317725	chr4:119391831~119395335:-
GBM	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-5.46	2.83e-07	0.000476	-0.58	-0.45	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
GBM	cis	rs8067545	0.532	rs17759609	ENSG00000230528.6	NOS2P3	-5.46	2.83e-07	0.000476	-0.53	-0.45	Schizophrenia;	chr17:20089201	chr17:20436337~20447249:+
GBM	cis	rs7267979	0.933	rs1130694	ENSG00000125804.12	FAM182A	-5.46	2.83e-07	0.000476	-0.57	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.933	rs2258728	ENSG00000125804.12	FAM182A	-5.46	2.83e-07	0.000476	-0.57	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:26054655~26086917:+
GBM	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-5.46	2.83e-07	0.000476	-0.6	-0.45	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
GBM	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-5.46	2.85e-07	0.000478	-0.54	-0.45	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
GBM	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-5.45	2.85e-07	0.000479	-0.6	-0.45	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-5.45	2.85e-07	0.000479	-0.6	-0.45	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-5.45	2.85e-07	0.000479	-0.6	-0.45	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
GBM	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-5.45	2.85e-07	0.000479	-0.5	-0.45	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
GBM	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	5.45	2.86e-07	0.00048	0.56	0.45	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
GBM	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	5.45	2.87e-07	0.000482	0.45	0.45	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
GBM	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	5.45	2.87e-07	0.000483	0.6	0.45	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	5.45	2.87e-07	0.000483	0.6	0.45	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	5.45	2.87e-07	0.000483	0.6	0.45	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
GBM	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	5.45	2.87e-07	0.000483	0.53	0.45	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
GBM	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	5.45	2.89e-07	0.000485	0.49	0.45	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
GBM	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-5.45	2.89e-07	0.000486	-0.8	-0.45	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
GBM	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-5.45	2.9e-07	0.000486	-0.52	-0.45	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-5.45	2.9e-07	0.000486	-0.52	-0.45	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
GBM	cis	rs11098499	0.908	rs7696649	ENSG00000250412.1	KLHL2P1	5.45	2.91e-07	0.000487	0.59	0.45	Corneal astigmatism;	chr4:119401022	chr4:119334329~119378233:+
GBM	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	5.45	2.91e-07	0.000488	0.53	0.45	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
GBM	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-5.45	2.91e-07	0.000488	-0.6	-0.45	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-5.45	2.91e-07	0.000488	-0.6	-0.45	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-5.45	2.91e-07	0.000488	-0.6	-0.45	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
GBM	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	5.45	2.91e-07	0.000488	0.73	0.45	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
GBM	cis	rs860818	1	rs858316	ENSG00000226816.2	AC005082.12	5.45	2.92e-07	0.000488	1.25	0.45	Initial pursuit acceleration;	chr7:23163511	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858315	ENSG00000226816.2	AC005082.12	5.45	2.92e-07	0.000488	1.25	0.45	Initial pursuit acceleration;	chr7:23164348	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858314	ENSG00000226816.2	AC005082.12	5.45	2.92e-07	0.000488	1.25	0.45	Initial pursuit acceleration;	chr7:23164932	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858313	ENSG00000226816.2	AC005082.12	5.45	2.92e-07	0.000488	1.25	0.45	Initial pursuit acceleration;	chr7:23165118	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858256	ENSG00000226816.2	AC005082.12	5.45	2.92e-07	0.000488	1.25	0.45	Initial pursuit acceleration;	chr7:23176017	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs1881202	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23153889	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs2091491	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23153930	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs1406080	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23153985	chr7:23206013~23208045:+
GBM	cis	rs860818	0.557	rs2178138	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23154414	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs1358441	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23154850	chr7:23206013~23208045:+
GBM	cis	rs860818	0.557	rs6961136	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23155343	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs12700418	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23155701	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs6966420	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23156346	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs4722227	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23156399	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs6966929	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23156455	chr7:23206013~23208045:+
GBM	cis	rs860818	0.546	rs4722228	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23156479	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs4722229	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23156485	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs4722230	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23157572	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs4722233	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23157792	chr7:23206013~23208045:+
GBM	cis	rs860818	0.655	rs6461696	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23158225	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs6461697	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23158468	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs6949272	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23158750	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs12700419	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23158881	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs6960118	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23160709	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs6964671	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23161183	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs6461699	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23162679	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs7807516	ENSG00000226816.2	AC005082.12	-5.45	2.92e-07	0.000488	-1.25	-0.45	Initial pursuit acceleration;	chr7:23163147	chr7:23206013~23208045:+
GBM	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	5.45	2.92e-07	0.000488	0.53	0.45	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	5.45	2.92e-07	0.000488	0.53	0.45	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	5.45	2.92e-07	0.000488	0.53	0.45	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	5.45	2.92e-07	0.000488	0.53	0.45	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	5.45	2.92e-07	0.000488	0.53	0.45	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	5.45	2.92e-07	0.000488	0.53	0.45	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
GBM	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	5.45	2.92e-07	0.000488	0.59	0.45	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
GBM	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	5.45	2.92e-07	0.000489	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
GBM	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-5.45	2.92e-07	0.000489	-0.59	-0.45	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
GBM	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	5.45	2.92e-07	0.000489	0.54	0.45	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
GBM	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-5.45	2.92e-07	0.000489	-0.55	-0.45	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
GBM	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-5.45	2.93e-07	0.00049	-0.59	-0.45	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
GBM	cis	rs2843012	0.529	rs2843003	ENSG00000229921.5	KIF25-AS1	-5.45	2.94e-07	0.000491	-0.6	-0.45	Metabolite levels (5-HIAA);	chr6:168010042	chr6:167992822~167997077:-
GBM	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	2.94e-07	0.000491	-0.39	-0.45	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
GBM	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-5.45	2.94e-07	0.000492	-0.65	-0.45	Depression;	chr6:28135913	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	5.45	2.94e-07	0.000492	0.65	0.45	Depression;	chr6:28109824	chr6:28115628~28116551:+
GBM	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	5.45	2.97e-07	0.000496	0.44	0.45	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
GBM	cis	rs67981189	0.896	rs2526890	ENSG00000269927.1	RP6-91H8.3	-5.44	3e-07	0.000501	-0.51	-0.45	Schizophrenia;	chr14:70963410	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs2810100	ENSG00000269927.1	RP6-91H8.3	-5.44	3e-07	0.000501	-0.51	-0.45	Schizophrenia;	chr14:70965455	chr14:71141125~71143253:-
GBM	cis	rs3806843	0.868	rs2531342	ENSG00000202111.1	VTRNA1-2	5.44	3.01e-07	0.000502	0.46	0.45	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.9	rs2563279	ENSG00000202111.1	VTRNA1-2	5.44	3.01e-07	0.000502	0.46	0.45	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr5:140718925~140719013:+
GBM	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	5.44	3.01e-07	0.000503	0.61	0.45	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
GBM	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-5.44	3.02e-07	0.000503	-0.58	-0.45	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
GBM	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-5.44	3.02e-07	0.000503	-0.58	-0.45	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-5.44	3.02e-07	0.000503	-0.58	-0.45	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
GBM	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-5.44	3.03e-07	0.000505	-0.52	-0.45	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
GBM	cis	rs860818	0.793	rs5014167	ENSG00000226816.2	AC005082.12	5.44	3.03e-07	0.000505	1.3	0.45	Initial pursuit acceleration;	chr7:23202684	chr7:23206013~23208045:+
GBM	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-5.44	3.04e-07	0.000506	-0.64	-0.45	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
GBM	cis	rs7267979	0.816	rs6076358	ENSG00000276952.1	RP5-965G21.6	-5.44	3.04e-07	0.000507	-0.41	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.789	rs4815429	ENSG00000276952.1	RP5-965G21.6	-5.44	3.04e-07	0.000507	-0.41	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.789	rs1983974	ENSG00000276952.1	RP5-965G21.6	-5.44	3.04e-07	0.000507	-0.41	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.816	rs405822	ENSG00000276952.1	RP5-965G21.6	5.44	3.04e-07	0.000507	0.41	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.816	rs6138593	ENSG00000276952.1	RP5-965G21.6	5.44	3.04e-07	0.000507	0.41	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.816	rs409853	ENSG00000276952.1	RP5-965G21.6	5.44	3.04e-07	0.000507	0.41	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25284915~25285588:-
GBM	cis	rs5760092	0.572	rs738806	ENSG00000235689.1	AP000351.13	5.44	3.05e-07	0.000508	0.56	0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:24006305~24008258:-
GBM	cis	rs66887589	0.616	rs13113885	ENSG00000249244.1	RP11-548H18.2	5.44	3.07e-07	0.00051	0.55	0.45	Diastolic blood pressure;	chr4:119300021	chr4:119391831~119395335:-
GBM	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	5.44	3.07e-07	0.00051	0.73	0.45	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
GBM	cis	rs67981189	0.896	rs2526878	ENSG00000269927.1	RP6-91H8.3	-5.44	3.07e-07	0.000511	-0.53	-0.45	Schizophrenia;	chr14:70910578	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.865	rs2526876	ENSG00000269927.1	RP6-91H8.3	-5.44	3.07e-07	0.000511	-0.53	-0.45	Schizophrenia;	chr14:70911471	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs2526874	ENSG00000269927.1	RP6-91H8.3	-5.44	3.07e-07	0.000511	-0.53	-0.45	Schizophrenia;	chr14:70914502	chr14:71141125~71143253:-
GBM	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	5.44	3.08e-07	0.000512	0.47	0.45	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
GBM	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	5.44	3.09e-07	0.000514	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
GBM	cis	rs11098499	0.663	rs9996501	ENSG00000249244.1	RP11-548H18.2	5.44	3.09e-07	0.000514	0.58	0.45	Corneal astigmatism;	chr4:119317763	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.697	rs28458294	ENSG00000249244.1	RP11-548H18.2	5.44	3.09e-07	0.000514	0.58	0.45	Corneal astigmatism;	chr4:119317769	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.663	rs28369503	ENSG00000249244.1	RP11-548H18.2	5.44	3.09e-07	0.000514	0.58	0.45	Corneal astigmatism;	chr4:119317770	chr4:119391831~119395335:-
GBM	cis	rs67981189	0.806	rs2810107	ENSG00000269927.1	RP6-91H8.3	-5.44	3.1e-07	0.000515	-0.51	-0.45	Schizophrenia;	chr14:70954340	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs2526846	ENSG00000269927.1	RP6-91H8.3	-5.44	3.1e-07	0.000515	-0.51	-0.45	Schizophrenia;	chr14:70957538	chr14:71141125~71143253:-
GBM	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-5.44	3.11e-07	0.000516	-0.52	-0.45	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
GBM	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	5.43	3.12e-07	0.000518	0.57	0.45	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
GBM	cis	rs6496932	1	rs35156762	ENSG00000218052.5	ADAMTS7P4	5.43	3.12e-07	0.000518	0.67	0.45	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85255369~85330334:-
GBM	cis	rs2013441	0.866	rs12941200	ENSG00000230528.6	NOS2P3	-5.43	3.13e-07	0.00052	-0.55	-0.45	Obesity-related traits;	chr17:20108248	chr17:20436337~20447249:+
GBM	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	5.43	3.14e-07	0.000521	0.57	0.45	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
GBM	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-5.43	3.15e-07	0.000522	-0.46	-0.45	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
GBM	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	5.43	3.15e-07	0.000523	0.77	0.45	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
GBM	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	5.43	3.15e-07	0.000523	0.54	0.45	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
GBM	cis	rs7267979	1	rs6083862	ENSG00000276952.1	RP5-965G21.6	-5.43	3.17e-07	0.000525	-0.39	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25284915~25285588:-
GBM	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-5.43	3.17e-07	0.000525	-0.52	-0.45	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-5.43	3.17e-07	0.000525	-0.52	-0.45	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
GBM	cis	rs9876781	1	rs898225	ENSG00000244380.1	RP11-24C3.2	-5.43	3.17e-07	0.000526	-0.51	-0.45	Longevity;	chr3:48371689	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs1459242	ENSG00000244380.1	RP11-24C3.2	-5.43	3.17e-07	0.000526	-0.51	-0.45	Longevity;	chr3:48372047	chr3:48440352~48446656:-
GBM	cis	rs17270561	0.579	rs10456326	ENSG00000272810.1	U91328.22	-5.43	3.18e-07	0.000527	-0.7	-0.45	Iron status biomarkers;	chr6:25919434	chr6:26013241~26013757:+
GBM	cis	rs11098499	1	rs11726229	ENSG00000250412.1	KLHL2P1	5.43	3.19e-07	0.000529	0.57	0.45	Corneal astigmatism;	chr4:119290425	chr4:119334329~119378233:+
GBM	cis	rs17214007	0.597	rs4781677	ENSG00000279866.1	CTB-193M12.4	5.43	3.21e-07	0.000531	0.56	0.45	Cognitive function;	chr16:15636388	chr16:15704410~15705984:+
GBM	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-5.43	3.21e-07	0.000531	-0.54	-0.45	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
GBM	cis	rs11098499	0.954	rs11098524	ENSG00000249244.1	RP11-548H18.2	5.43	3.21e-07	0.000531	0.58	0.45	Corneal astigmatism;	chr4:119468877	chr4:119391831~119395335:-
GBM	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.43	3.23e-07	0.000534	-0.61	-0.45	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
GBM	cis	rs17214007	0.877	rs7201553	ENSG00000279866.1	CTB-193M12.4	5.43	3.24e-07	0.000536	0.57	0.45	Cognitive function;	chr16:15781186	chr16:15704410~15705984:+
GBM	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	5.42	3.26e-07	0.000538	0.51	0.45	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	5.42	3.26e-07	0.000538	0.51	0.45	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	5.42	3.26e-07	0.000538	0.51	0.45	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	5.42	3.26e-07	0.000538	0.51	0.45	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	5.42	3.26e-07	0.000538	0.51	0.45	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
GBM	cis	rs2486288	0.656	rs1719236	ENSG00000259433.2	CTD-2651B20.4	5.42	3.26e-07	0.000539	0.51	0.45	Glomerular filtration rate;	chr15:45285585	chr15:45330209~45332634:-
GBM	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-5.42	3.27e-07	0.00054	-0.66	-0.45	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
GBM	cis	rs7267979	0.966	rs2261784	ENSG00000276952.1	RP5-965G21.6	5.42	3.27e-07	0.000541	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2261785	ENSG00000276952.1	RP5-965G21.6	5.42	3.27e-07	0.000541	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25284915~25285588:-
GBM	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	5.42	3.28e-07	0.000542	0.6	0.45	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	5.42	3.28e-07	0.000542	0.6	0.45	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
GBM	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-5.42	3.3e-07	0.000544	-0.46	-0.45	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
GBM	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-5.42	3.3e-07	0.000544	-0.46	-0.45	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
GBM	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-5.42	3.3e-07	0.000544	-0.46	-0.45	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
GBM	cis	rs9368481	0.547	rs2093303	ENSG00000224843.5	LINC00240	-5.42	3.3e-07	0.000544	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26956992~27023924:+
GBM	cis	rs7267979	1	rs3761117	ENSG00000125804.12	FAM182A	5.42	3.3e-07	0.000545	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:26054655~26086917:+
GBM	cis	rs67981189	0.613	rs221892	ENSG00000269927.1	RP6-91H8.3	-5.42	3.3e-07	0.000545	-0.51	-0.45	Schizophrenia;	chr14:71144889	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.634	rs221891	ENSG00000269927.1	RP6-91H8.3	-5.42	3.3e-07	0.000545	-0.51	-0.45	Schizophrenia;	chr14:71144910	chr14:71141125~71143253:-
GBM	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	5.42	3.31e-07	0.000546	0.71	0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
GBM	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	5.42	3.31e-07	0.000546	0.71	0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000224205.1	AP000351.4	5.42	3.31e-07	0.000546	0.51	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23987320~23991421:-
GBM	cis	rs66887589	0.592	rs11731571	ENSG00000249244.1	RP11-548H18.2	5.42	3.32e-07	0.000547	0.53	0.45	Diastolic blood pressure;	chr4:119300030	chr4:119391831~119395335:-
GBM	cis	rs7267979	1	rs2500418	ENSG00000276952.1	RP5-965G21.6	-5.42	3.32e-07	0.000547	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25284915~25285588:-
GBM	cis	rs67981189	0.634	rs221896	ENSG00000269927.1	RP6-91H8.3	-5.42	3.32e-07	0.000547	-0.51	-0.45	Schizophrenia;	chr14:71139951	chr14:71141125~71143253:-
GBM	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-5.42	3.32e-07	0.000547	-0.62	-0.45	Height;	chr11:118703185	chr11:118704607~118750263:+
GBM	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-5.42	3.32e-07	0.000547	-0.62	-0.45	Height;	chr11:118703207	chr11:118704607~118750263:+
GBM	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-5.42	3.32e-07	0.000547	-0.62	-0.45	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
GBM	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	5.42	3.32e-07	0.000547	0.62	0.45	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
GBM	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-5.42	3.33e-07	0.000547	-0.48	-0.45	Height;	chr11:118749988	chr11:118791254~118793137:+
GBM	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-5.42	3.33e-07	0.000547	-0.48	-0.45	Height;	chr11:118760944	chr11:118791254~118793137:+
GBM	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-5.42	3.33e-07	0.000547	-0.48	-0.45	Height;	chr11:118764443	chr11:118791254~118793137:+
GBM	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28070115	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28071237	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28071808	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28076559	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28076704	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28078391	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28080757	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28080760	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28082231	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28082261	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28082984	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28083994	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28084025	chr6:28115628~28116551:+
GBM	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28085319	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	5.42	3.34e-07	0.000547	0.65	0.45	Depression;	chr6:28086929	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28089816	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28090857	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28091439	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28091659	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28092227	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28093966	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28094014	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28096077	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28096855	chr6:28115628~28116551:+
GBM	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28099759	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28100648	chr6:28115628~28116551:+
GBM	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28107222	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28108492	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28110254	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28111382	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28111650	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28112175	chr6:28115628~28116551:+
GBM	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28113616	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28113851	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28114487	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28114933	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28115743	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28116411	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
GBM	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28123153	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28124529	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28127577	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28131566	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28133900	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28136698	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28136856	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28138363	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28138981	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28139012	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28139049	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28139876	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28139998	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28140454	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28141189	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28141484	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	5.42	3.34e-07	0.000547	0.65	0.45	Depression;	chr6:28142370	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28143758	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28144784	chr6:28115628~28116551:+
GBM	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28145952	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28147378	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28147406	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28148143	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28149979	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28151096	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28152885	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28153120	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28154567	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28156691	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28158424	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28159056	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28159843	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28159925	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28159932	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28161802	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28162053	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28163375	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28163759	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28164580	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28164825	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28164948	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28165025	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28165528	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28168434	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28169019	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28169249	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28169676	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28169755	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28169791	chr6:28115628~28116551:+
GBM	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28170075	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28173770	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28174809	chr6:28115628~28116551:+
GBM	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28175233	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28176973	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-5.42	3.34e-07	0.000547	-0.65	-0.45	Depression;	chr6:28180209	chr6:28115628~28116551:+
GBM	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	5.42	3.34e-07	0.000548	0.48	0.45	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
GBM	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	5.42	3.34e-07	0.000548	0.7	0.45	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	5.42	3.34e-07	0.000548	0.7	0.45	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
GBM	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	5.42	3.35e-07	0.000548	0.53	0.45	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
GBM	cis	rs3806843	0.864	rs2531343	ENSG00000202111.1	VTRNA1-2	5.42	3.35e-07	0.000548	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.9	rs2531341	ENSG00000202111.1	VTRNA1-2	5.42	3.35e-07	0.000548	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140751309	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.9	rs2531340	ENSG00000202111.1	VTRNA1-2	5.42	3.35e-07	0.000548	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140751461	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.868	rs2563281	ENSG00000202111.1	VTRNA1-2	5.42	3.35e-07	0.000548	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140751634	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.9	rs2563280	ENSG00000202111.1	VTRNA1-2	5.42	3.35e-07	0.000548	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140751945	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.838	rs2262567	ENSG00000202111.1	VTRNA1-2	5.42	3.35e-07	0.000548	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.838	rs2337514	ENSG00000202111.1	VTRNA1-2	5.42	3.35e-07	0.000548	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140753147	chr5:140718925~140719013:+
GBM	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	5.42	3.35e-07	0.000549	0.54	0.45	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
GBM	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	5.42	3.35e-07	0.000549	0.54	0.45	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
GBM	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	5.42	3.35e-07	0.000549	0.54	0.45	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
GBM	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	5.42	3.35e-07	0.00055	1.26	0.45	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
GBM	cis	rs2013441	0.866	rs2703813	ENSG00000230528.6	NOS2P3	5.42	3.36e-07	0.00055	0.55	0.45	Obesity-related traits;	chr17:20212002	chr17:20436337~20447249:+
GBM	cis	rs11098499	0.697	rs35280960	ENSG00000250412.1	KLHL2P1	5.42	3.36e-07	0.00055	0.58	0.45	Corneal astigmatism;	chr4:119335904	chr4:119334329~119378233:+
GBM	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-5.42	3.37e-07	0.000552	-0.56	-0.45	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
GBM	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-5.42	3.39e-07	0.000554	-0.53	-0.45	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
GBM	cis	rs3096299	0.781	rs3102381	ENSG00000260259.1	RP11-368I7.4	5.41	3.41e-07	0.000557	0.5	0.45	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89682620~89686569:-
GBM	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-5.41	3.41e-07	0.000557	-0.52	-0.45	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
GBM	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-5.41	3.41e-07	0.000557	-0.52	-0.45	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
GBM	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	5.41	3.41e-07	0.000558	0.46	0.45	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
GBM	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	5.41	3.42e-07	0.000558	0.38	0.45	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
GBM	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	5.41	3.42e-07	0.000559	0.46	0.45	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
GBM	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	5.41	3.42e-07	0.000559	0.45	0.45	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	5.41	3.42e-07	0.000559	0.45	0.45	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	5.41	3.42e-07	0.000559	0.45	0.45	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	5.41	3.42e-07	0.000559	0.45	0.45	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
GBM	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	5.41	3.42e-07	0.000559	0.59	0.45	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
GBM	cis	rs7267979	0.966	rs2500417	ENSG00000276952.1	RP5-965G21.6	-5.41	3.44e-07	0.000562	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258719	ENSG00000276952.1	RP5-965G21.6	5.41	3.45e-07	0.000563	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs7019	ENSG00000276952.1	RP5-965G21.6	5.41	3.45e-07	0.000563	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.933	rs2424708	ENSG00000276952.1	RP5-965G21.6	5.41	3.45e-07	0.000563	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2424710	ENSG00000276952.1	RP5-965G21.6	5.41	3.45e-07	0.000563	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6115140	ENSG00000276952.1	RP5-965G21.6	5.41	3.45e-07	0.000563	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs1888999	ENSG00000276952.1	RP5-965G21.6	5.41	3.45e-07	0.000563	0.43	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs884613	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs1888998	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2500433	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2482948	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs1888997	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482919	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs3002698	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6037086	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2482923	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482927	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2500443	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482928	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482930	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482931	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2500446	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482937	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482940	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2027003	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2027004	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.934	rs2500399	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.903	rs2500400	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2500404	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2500405	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2482941	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.903	rs2500423	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2263204	ENSG00000276952.1	RP5-965G21.6	-5.41	3.45e-07	0.000563	-0.43	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25284915~25285588:-
GBM	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-5.41	3.45e-07	0.000563	-0.58	-0.45	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
GBM	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-5.41	3.45e-07	0.000563	-0.58	-0.45	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
GBM	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-5.41	3.45e-07	0.000563	-0.58	-0.45	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
GBM	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-5.41	3.46e-07	0.000564	-0.53	-0.45	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
GBM	cis	rs9987353	0.519	rs13276350	ENSG00000253893.2	FAM85B	5.41	3.48e-07	0.000566	0.53	0.45	Recombination measurement;	chr8:9205647	chr8:8167819~8226614:-
GBM	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	5.41	3.48e-07	0.000567	0.52	0.45	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
GBM	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-5.41	3.49e-07	0.000568	-0.52	-0.45	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
GBM	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	5.41	3.49e-07	0.000568	0.54	0.45	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
GBM	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	5.41	3.5e-07	0.000569	0.39	0.45	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
GBM	cis	rs1420956	0.562	rs2287295	ENSG00000264151.4	RP11-739N10.1	5.41	3.5e-07	0.00057	0.6	0.45	Obesity-related traits;	chr18:27595323	chr18:27336379~27595164:-
GBM	cis	rs7267979	0.816	rs404775	ENSG00000276952.1	RP5-965G21.6	5.41	3.5e-07	0.00057	0.41	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.816	rs374701	ENSG00000276952.1	RP5-965G21.6	5.41	3.5e-07	0.00057	0.41	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.816	rs6037158	ENSG00000276952.1	RP5-965G21.6	5.41	3.5e-07	0.00057	0.41	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25284915~25285588:-
GBM	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-5.41	3.5e-07	0.00057	-0.6	-0.45	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
GBM	cis	rs7267979	1	rs2184000	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs4815425	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050599	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050602	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6083855	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815426	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6115182	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050609	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2424712	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2424714	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2424715	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050617	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.933	rs2387887	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050626	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6037121	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs1047171	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050629	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050630	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050632	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2856	ENSG00000125804.12	FAM182A	-5.41	3.51e-07	0.00057	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:26054655~26086917:+
GBM	cis	rs860818	1	rs858253	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23178101	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858252	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23178253	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858250	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23178941	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858243	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23184738	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs1637223	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23189050	chr7:23206013~23208045:+
GBM	cis	rs860818	0.744	rs1728319	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23191580	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	5.41	3.51e-07	0.00057	1.26	0.45	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
GBM	cis	rs2013441	1	rs2703804	ENSG00000230528.6	NOS2P3	5.41	3.51e-07	0.00057	0.5	0.45	Obesity-related traits;	chr17:20203882	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703806	ENSG00000230528.6	NOS2P3	5.41	3.51e-07	0.00057	0.5	0.45	Obesity-related traits;	chr17:20204926	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526483	ENSG00000230528.6	NOS2P3	5.41	3.51e-07	0.00057	0.5	0.45	Obesity-related traits;	chr17:20208903	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703810	ENSG00000230528.6	NOS2P3	5.41	3.51e-07	0.00057	0.5	0.45	Obesity-related traits;	chr17:20210402	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.965	rs1544421	ENSG00000230528.6	NOS2P3	5.41	3.51e-07	0.00057	0.5	0.45	Obesity-related traits;	chr17:20210904	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703816	ENSG00000230528.6	NOS2P3	5.41	3.51e-07	0.00057	0.5	0.45	Obesity-related traits;	chr17:20215574	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703818	ENSG00000230528.6	NOS2P3	5.41	3.51e-07	0.00057	0.5	0.45	Obesity-related traits;	chr17:20216663	chr17:20436337~20447249:+
GBM	cis	rs7267979	0.966	rs8123949	ENSG00000125804.12	FAM182A	5.41	3.51e-07	0.00057	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:26054655~26086917:+
GBM	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	5.41	3.51e-07	0.00057	0.61	0.45	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	5.41	3.51e-07	0.00057	0.61	0.45	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	5.41	3.51e-07	0.00057	0.61	0.45	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
GBM	cis	rs9987353	0.519	rs2929465	ENSG00000253893.2	FAM85B	5.41	3.51e-07	0.00057	0.52	0.45	Recombination measurement;	chr8:9206492	chr8:8167819~8226614:-
GBM	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	5.41	3.52e-07	0.000572	0.54	0.45	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
GBM	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-5.41	3.52e-07	0.000572	-0.51	-0.45	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
GBM	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-5.41	3.52e-07	0.000572	-0.51	-0.45	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
GBM	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-5.41	3.52e-07	0.000572	-0.51	-0.45	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
GBM	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-5.41	3.52e-07	0.000572	-0.51	-0.45	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
GBM	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-5.41	3.55e-07	0.000575	-0.59	-0.45	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
GBM	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-5.41	3.55e-07	0.000575	-0.67	-0.45	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-5.41	3.55e-07	0.000575	-0.67	-0.45	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-5.41	3.55e-07	0.000575	-0.67	-0.45	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	5.41	3.55e-07	0.000575	0.67	0.45	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
GBM	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-5.4	3.56e-07	0.000576	-0.6	-0.45	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-5.4	3.56e-07	0.000576	-0.6	-0.45	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
GBM	cis	rs11098499	0.954	rs11098524	ENSG00000250412.1	KLHL2P1	5.4	3.56e-07	0.000577	0.59	0.45	Corneal astigmatism;	chr4:119468877	chr4:119334329~119378233:+
GBM	cis	rs7267979	0.844	rs6115188	ENSG00000276952.1	RP5-965G21.6	5.4	3.56e-07	0.000577	0.41	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25284915~25285588:-
GBM	cis	rs5760092	0.572	rs738806	ENSG00000099984.9	GSTT2	-5.4	3.57e-07	0.000577	-0.67	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23980123~23983911:+
GBM	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-5.4	3.57e-07	0.000577	-0.53	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
GBM	cis	rs11098499	0.754	rs9999724	ENSG00000250412.1	KLHL2P1	5.4	3.57e-07	0.000577	0.58	0.45	Corneal astigmatism;	chr4:119318789	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs714899	ENSG00000250412.1	KLHL2P1	5.4	3.57e-07	0.000577	0.58	0.45	Corneal astigmatism;	chr4:119321880	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs66900435	ENSG00000250412.1	KLHL2P1	5.4	3.57e-07	0.000577	0.58	0.45	Corneal astigmatism;	chr4:119328270	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs17595608	ENSG00000250412.1	KLHL2P1	5.4	3.57e-07	0.000577	0.58	0.45	Corneal astigmatism;	chr4:119329351	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs1980027	ENSG00000250412.1	KLHL2P1	5.4	3.57e-07	0.000577	0.58	0.45	Corneal astigmatism;	chr4:119330422	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs10213554	ENSG00000250412.1	KLHL2P1	-5.4	3.57e-07	0.000577	-0.58	-0.45	Corneal astigmatism;	chr4:119339630	chr4:119334329~119378233:+
GBM	cis	rs6496932	0.635	rs28559998	ENSG00000218052.5	ADAMTS7P4	-5.4	3.58e-07	0.000579	-0.62	-0.45	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.635	rs8023859	ENSG00000218052.5	ADAMTS7P4	-5.4	3.58e-07	0.000579	-0.62	-0.45	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.663	rs7182814	ENSG00000218052.5	ADAMTS7P4	-5.4	3.58e-07	0.000579	-0.62	-0.45	Central corneal thickness;Corneal structure;	chr15:85362840	chr15:85255369~85330334:-
GBM	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-5.4	3.58e-07	0.000579	-0.39	-0.45	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
GBM	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	5.4	3.59e-07	0.00058	0.52	0.45	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
GBM	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	5.4	3.6e-07	0.000582	0.51	0.45	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	5.4	3.6e-07	0.000582	0.51	0.45	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
GBM	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	5.4	3.61e-07	0.000583	0.53	0.45	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
GBM	cis	rs4604732	0.536	rs4925674	ENSG00000227135.1	GCSAML-AS1	-5.4	3.61e-07	0.000583	-0.64	-0.45	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473604	chr1:247524679~247526752:-
GBM	cis	rs17270561	0.578	rs76182885	ENSG00000272810.1	U91328.22	-5.4	3.61e-07	0.000584	-0.69	-0.45	Iron status biomarkers;	chr6:25903857	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.541	rs12192932	ENSG00000272810.1	U91328.22	-5.4	3.61e-07	0.000584	-0.69	-0.45	Iron status biomarkers;	chr6:25911274	chr6:26013241~26013757:+
GBM	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	5.4	3.62e-07	0.000584	0.52	0.45	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
GBM	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	5.4	3.62e-07	0.000584	0.54	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
GBM	cis	rs7267979	0.789	rs6076347	ENSG00000125804.12	FAM182A	5.4	3.62e-07	0.000584	0.6	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26054655~26086917:+
GBM	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-5.4	3.62e-07	0.000584	-0.52	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
GBM	cis	rs9368481	0.569	rs6907403	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.502	rs3933232	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.524	rs12530345	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.546	rs12664610	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.524	rs9393768	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.569	rs10946868	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.594	rs7768643	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.594	rs7768814	ENSG00000224843.5	LINC00240	-5.4	3.62e-07	0.000584	-0.55	-0.45	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26956992~27023924:+
GBM	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	5.4	3.63e-07	0.000584	0.55	0.45	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	5.4	3.63e-07	0.000584	0.55	0.45	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	5.4	3.63e-07	0.000584	0.55	0.45	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
GBM	cis	rs7267979	1	rs6115153	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs7268053	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6083809	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050561	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6083813	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815406	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6083817	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050564	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6083818	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815409	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6076339	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815411	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6107031	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6115159	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4813562	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs6050567	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6037099	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs4815414	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6107033	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6083825	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs34645895	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6083828	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs3827014	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6037105	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2387880	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2387882	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs2387884	ENSG00000125804.12	FAM182A	5.4	3.63e-07	0.000584	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.966	rs2261795	ENSG00000125804.12	FAM182A	-5.4	3.63e-07	0.000584	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs10966	ENSG00000125804.12	FAM182A	-5.4	3.63e-07	0.000584	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815412	ENSG00000125804.12	FAM182A	-5.4	3.63e-07	0.000584	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.826	rs4472123	ENSG00000250412.1	KLHL2P1	5.4	3.63e-07	0.000584	0.59	0.45	Corneal astigmatism;	chr4:119315475	chr4:119334329~119378233:+
GBM	cis	rs860818	0.655	rs6968416	ENSG00000226816.2	AC005082.12	-5.4	3.64e-07	0.000585	-1.25	-0.45	Initial pursuit acceleration;	chr7:23158042	chr7:23206013~23208045:+
GBM	cis	rs860818	0.793	rs9639457	ENSG00000226816.2	AC005082.12	-5.4	3.64e-07	0.000585	-1.25	-0.45	Initial pursuit acceleration;	chr7:23158090	chr7:23206013~23208045:+
GBM	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-5.4	3.64e-07	0.000585	-0.56	-0.45	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
GBM	cis	rs3806843	0.9	rs2262576	ENSG00000202111.1	VTRNA1-2	5.4	3.64e-07	0.000586	0.47	0.45	Depressive symptoms (multi-trait analysis);	chr5:140755951	chr5:140718925~140719013:+
GBM	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	5.4	3.64e-07	0.000586	0.52	0.45	Height;	chr11:118856623	chr11:118688039~118690600:-
GBM	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	5.4	3.64e-07	0.000586	0.52	0.45	Height;	chr11:118857611	chr11:118688039~118690600:-
GBM	cis	rs11098499	0.754	rs10518300	ENSG00000250412.1	KLHL2P1	-5.4	3.65e-07	0.000587	-0.57	-0.45	Corneal astigmatism;	chr4:119328344	chr4:119334329~119378233:+
GBM	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	5.4	3.65e-07	0.000587	0.38	0.45	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
GBM	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-5.4	3.66e-07	0.000588	-0.56	-0.45	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
GBM	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-5.4	3.67e-07	0.000588	-0.59	-0.45	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
GBM	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-5.4	3.67e-07	0.000588	-0.59	-0.45	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-5.4	3.67e-07	0.000589	-0.62	-0.45	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
GBM	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-5.4	3.68e-07	0.000591	-0.59	-0.45	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
GBM	cis	rs4072705	1	rs4836980	ENSG00000224020.1	MIR181A2HG	-5.4	3.69e-07	0.000592	-0.5	-0.45	Menarche (age at onset);	chr9:124576884	chr9:124658467~124698631:+
GBM	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-5.4	3.69e-07	0.000592	-0.51	-0.45	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
GBM	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	5.4	3.69e-07	0.000592	0.51	0.45	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
GBM	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	5.4	3.7e-07	0.000593	0.53	0.45	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
GBM	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	5.4	3.71e-07	0.000595	0.39	0.45	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
GBM	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-5.4	3.72e-07	0.000596	-0.55	-0.45	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-5.4	3.72e-07	0.000596	-0.55	-0.45	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
GBM	cis	rs6782228	0.527	rs6767383	ENSG00000277250.1	Metazoa_SRP	-5.39	3.72e-07	0.000597	-0.48	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.509	rs6780447	ENSG00000277250.1	Metazoa_SRP	-5.39	3.72e-07	0.000597	-0.48	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128673681~128674021:-
GBM	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	5.39	3.72e-07	0.000597	0.58	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
GBM	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-5.39	3.73e-07	0.000597	-0.67	-0.45	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
GBM	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-5.39	3.73e-07	0.000597	-0.5	-0.45	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
GBM	cis	rs11098499	0.71	rs6851130	ENSG00000249244.1	RP11-548H18.2	-5.39	3.74e-07	0.000598	-0.6	-0.45	Corneal astigmatism;	chr4:119212557	chr4:119391831~119395335:-
GBM	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-5.39	3.76e-07	0.000602	-0.58	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
GBM	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	5.39	3.76e-07	0.000602	0.46	0.45	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
GBM	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-5.39	3.76e-07	0.000602	-0.62	-0.45	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
GBM	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-5.39	3.76e-07	0.000602	-0.62	-0.45	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-5.39	3.76e-07	0.000602	-0.62	-0.45	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
GBM	cis	rs7267979	1	rs4815417	ENSG00000125804.12	FAM182A	5.39	3.77e-07	0.000603	0.55	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:26054655~26086917:+
GBM	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-5.39	3.78e-07	0.000604	-0.53	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
GBM	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs10150696	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74476723	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs11850070	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74487575	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs28378078	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74487940	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	5.39	3.78e-07	0.000604	0.69	0.45	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
GBM	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	5.39	3.78e-07	0.000604	0.68	0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
GBM	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	5.39	3.78e-07	0.000604	0.68	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
GBM	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-5.39	3.8e-07	0.000607	-0.55	-0.45	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
GBM	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	5.39	3.81e-07	0.000608	0.52	0.45	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
GBM	cis	rs4713118	0.615	rs9295747	ENSG00000218016.2	ZNF192P2	5.39	3.82e-07	0.00061	0.57	0.45	Parkinson's disease;	chr6:27769214	chr6:28188050~28189432:+
GBM	cis	rs12699921	0.735	rs4466298	ENSG00000279048.1	RP11-511H23.2	-5.39	3.82e-07	0.000611	-0.35	-0.45	Fibrinogen levels;	chr7:17952391	chr7:17940503~17942922:+
GBM	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-5.39	3.83e-07	0.000612	-0.69	-0.45	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
GBM	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-5.39	3.83e-07	0.000612	-0.69	-0.45	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
GBM	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	5.39	3.85e-07	0.000614	0.76	0.45	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
GBM	cis	rs6782228	0.606	rs2253144	ENSG00000277250.1	Metazoa_SRP	5.39	3.85e-07	0.000615	0.48	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128673681~128674021:-
GBM	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-5.39	3.86e-07	0.000616	-0.6	-0.45	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
GBM	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-5.39	3.86e-07	0.000616	-0.42	-0.45	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-5.39	3.86e-07	0.000616	-0.42	-0.45	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-5.39	3.86e-07	0.000616	-0.42	-0.45	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-5.39	3.86e-07	0.000616	-0.42	-0.45	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
GBM	cis	rs7267979	1	rs6076345	ENSG00000125804.12	FAM182A	5.39	3.86e-07	0.000616	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs6050590	ENSG00000125804.12	FAM182A	5.39	3.86e-07	0.000616	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4813566	ENSG00000125804.12	FAM182A	5.39	3.86e-07	0.000616	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:26054655~26086917:+
GBM	cis	rs7267979	1	rs4815421	ENSG00000125804.12	FAM182A	5.39	3.86e-07	0.000616	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:26054655~26086917:+
GBM	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	5.39	3.86e-07	0.000617	0.52	0.45	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
GBM	cis	rs12495178	0.529	rs112998994	ENSG00000239519.1	CADM2-AS1	5.39	3.87e-07	0.000618	0.48	0.45	Body mass index;	chr3:85927841	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.574	rs36080783	ENSG00000239519.1	CADM2-AS1	5.39	3.87e-07	0.000618	0.48	0.45	Body mass index;	chr3:85935680	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.574	rs11127913	ENSG00000239519.1	CADM2-AS1	5.39	3.87e-07	0.000618	0.48	0.45	Body mass index;	chr3:85937958	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.599	rs4368495	ENSG00000239519.1	CADM2-AS1	5.39	3.87e-07	0.000618	0.48	0.45	Body mass index;	chr3:85964667	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.599	rs2325006	ENSG00000239519.1	CADM2-AS1	5.39	3.87e-07	0.000618	0.48	0.45	Body mass index;	chr3:85970644	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.599	rs12492459	ENSG00000239519.1	CADM2-AS1	5.39	3.87e-07	0.000618	0.48	0.45	Body mass index;	chr3:85972896	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.599	rs12485709	ENSG00000239519.1	CADM2-AS1	5.39	3.87e-07	0.000618	0.48	0.45	Body mass index;	chr3:85976101	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.528	rs9879903	ENSG00000239519.1	CADM2-AS1	-5.39	3.87e-07	0.000618	-0.48	-0.45	Body mass index;	chr3:85948218	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.55	rs28522091	ENSG00000239519.1	CADM2-AS1	-5.39	3.87e-07	0.000618	-0.48	-0.45	Body mass index;	chr3:85954797	chr3:85992183~86028007:-
GBM	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	5.39	3.88e-07	0.000618	0.59	0.45	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	5.39	3.88e-07	0.000618	0.59	0.45	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	5.39	3.88e-07	0.000618	0.59	0.45	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	5.39	3.88e-07	0.000618	0.59	0.45	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
GBM	cis	rs6782228	0.628	rs7641584	ENSG00000277250.1	Metazoa_SRP	-5.38	3.89e-07	0.00062	-0.51	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128673681~128674021:-
GBM	cis	rs67981189	0.858	rs17108877	ENSG00000269927.1	RP6-91H8.3	5.38	3.9e-07	0.000621	0.51	0.45	Schizophrenia;	chr14:71007092	chr14:71141125~71143253:-
GBM	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	5.38	3.9e-07	0.000622	0.44	0.45	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
GBM	cis	rs2976388	0.566	rs4736373	ENSG00000253741.1	CTD-2292P10.4	5.38	3.91e-07	0.000623	0.51	0.45	Urinary tract infection frequency;	chr8:142710939	chr8:142702252~142726973:-
GBM	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-5.38	3.91e-07	0.000623	-0.58	-0.45	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
GBM	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	5.38	3.91e-07	0.000623	0.53	0.45	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
GBM	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-5.38	3.93e-07	0.000626	-0.53	-0.45	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
GBM	cis	rs17214007	0.877	rs2075514	ENSG00000279866.1	CTB-193M12.4	5.38	3.94e-07	0.000627	0.57	0.45	Cognitive function;	chr16:15778752	chr16:15704410~15705984:+
GBM	cis	rs4713118	0.614	rs9468209	ENSG00000218016.2	ZNF192P2	-5.38	3.95e-07	0.000627	-0.53	-0.45	Parkinson's disease;	chr6:27726642	chr6:28188050~28189432:+
GBM	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-5.38	3.95e-07	0.000628	-0.58	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
GBM	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	5.38	3.95e-07	0.000628	0.44	0.45	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
GBM	cis	rs7829975	0.626	rs907183	ENSG00000254340.1	RP11-10A14.3	-5.38	3.97e-07	0.000631	-0.56	-0.45	Mood instability;	chr8:8872251	chr8:9141424~9145435:+
GBM	cis	rs1122900	0.626	rs56162483	ENSG00000250155.1	CTD-2353F22.1	5.38	3.98e-07	0.000632	0.57	0.45	Aggressive periodontitis;	chr5:36710728	chr5:36666214~36725195:-
GBM	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	5.38	3.99e-07	0.000633	0.65	0.45	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
GBM	cis	rs17214007	0.597	rs11649126	ENSG00000279866.1	CTB-193M12.4	5.38	3.99e-07	0.000633	0.56	0.45	Cognitive function;	chr16:15626390	chr16:15704410~15705984:+
GBM	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	5.38	4e-07	0.000634	0.41	0.45	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
GBM	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	5.38	4e-07	0.000634	0.41	0.45	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
GBM	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	5.38	4e-07	0.000634	0.53	0.45	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
GBM	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	5.38	4e-07	0.000634	0.63	0.45	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
GBM	cis	rs11098499	0.754	rs1980025	ENSG00000250412.1	KLHL2P1	-5.38	4.01e-07	0.000634	-0.58	-0.45	Corneal astigmatism;	chr4:119331651	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs9991959	ENSG00000250412.1	KLHL2P1	-5.38	4.01e-07	0.000634	-0.58	-0.45	Corneal astigmatism;	chr4:119332618	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs878376	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119316547	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.789	rs9991166	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119316696	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.708	rs10005237	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119316742	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.575	rs907204	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119317499	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.575	rs907205	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119317509	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs878372	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119317625	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs10213267	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119317919	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs10212775	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119318089	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs11732087	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119318676	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs2964	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119318976	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs1511025	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119319083	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs12711071	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119319779	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs1546503	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119320012	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.708	rs1546506	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119320085	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs12506610	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119320504	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.743	rs10003567	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119320519	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs10006259	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119320990	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs28652763	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119321157	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs28643450	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119324087	chr4:119334329~119378233:+
GBM	cis	rs10028773	0.7	rs7671797	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Educational attainment;	chr4:119327002	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs7672372	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119327251	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs7672594	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119327388	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs7672778	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119327430	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs2036860	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119327779	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs2036857	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119328085	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs2036856	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119328133	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs4443261	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119328146	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs12513083	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119328457	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs12509621	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119328505	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs1511017	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119329650	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.789	rs12498994	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119329663	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs12507565	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119329966	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.826	rs12511640	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119330093	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs1980026	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119330488	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.722	rs28713555	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119330840	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.743	rs11098501	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119330862	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs11098502	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119330908	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.708	rs11732686	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119331175	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs11724409	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119331206	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.789	rs1980024	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119331892	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs34425882	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119332022	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs4107728	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119332755	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs17049949	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119334135	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs10213221	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119334771	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs7689729	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119335037	chr4:119334329~119378233:+
GBM	cis	rs10028773	0.7	rs7690338	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Educational attainment;	chr4:119335313	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.865	rs3956464	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119335609	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.619	rs28502463	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119335868	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.648	rs2002047	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119336073	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.775	rs2002049	ENSG00000250412.1	KLHL2P1	5.38	4.01e-07	0.000634	0.58	0.45	Corneal astigmatism;	chr4:119336262	chr4:119334329~119378233:+
GBM	cis	rs66887589	0.616	rs10032299	ENSG00000249244.1	RP11-548H18.2	5.38	4.01e-07	0.000634	0.54	0.45	Diastolic blood pressure;	chr4:119285264	chr4:119391831~119395335:-
GBM	cis	rs8067545	0.532	rs12946508	ENSG00000230528.6	NOS2P3	-5.38	4.02e-07	0.000635	-0.56	-0.45	Schizophrenia;	chr17:20048746	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.512	rs4925071	ENSG00000230528.6	NOS2P3	-5.38	4.02e-07	0.000635	-0.56	-0.45	Schizophrenia;	chr17:20051186	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.532	rs3862151	ENSG00000230528.6	NOS2P3	-5.38	4.02e-07	0.000635	-0.56	-0.45	Schizophrenia;	chr17:20053976	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.532	rs17759041	ENSG00000230528.6	NOS2P3	-5.38	4.02e-07	0.000635	-0.56	-0.45	Schizophrenia;	chr17:20056653	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.532	rs4925074	ENSG00000230528.6	NOS2P3	-5.38	4.02e-07	0.000635	-0.56	-0.45	Schizophrenia;	chr17:20059241	chr17:20436337~20447249:+
GBM	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	5.38	4.02e-07	0.000636	0.53	0.45	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	5.38	4.02e-07	0.000636	0.53	0.45	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
GBM	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	5.38	4.03e-07	0.000637	0.5	0.45	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
GBM	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	5.38	4.03e-07	0.000637	0.53	0.45	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
GBM	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	5.38	4.04e-07	0.000638	0.62	0.45	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
GBM	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	5.38	4.04e-07	0.000639	0.51	0.45	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
GBM	cis	rs2013441	0.866	rs10438824	ENSG00000230528.6	NOS2P3	-5.38	4.04e-07	0.000639	-0.53	-0.45	Obesity-related traits;	chr17:20155197	chr17:20436337~20447249:+
GBM	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	5.38	4.05e-07	0.000639	0.55	0.45	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
GBM	cis	rs10946940	0.965	rs4713112	ENSG00000218016.2	ZNF192P2	5.38	4.05e-07	0.000639	0.55	0.45	Systemic lupus erythematosus;	chr6:27549054	chr6:28188050~28189432:+
GBM	cis	rs4072705	1	rs721862	ENSG00000224020.1	MIR181A2HG	-5.37	4.07e-07	0.000642	-0.49	-0.45	Menarche (age at onset);	chr9:124773713	chr9:124658467~124698631:+
GBM	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	5.37	4.07e-07	0.000643	0.5	0.45	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
GBM	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	5.37	4.08e-07	0.000644	0.82	0.45	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
GBM	cis	rs453301	0.657	rs36056437	ENSG00000253893.2	FAM85B	5.37	4.09e-07	0.000646	0.54	0.45	Joint mobility (Beighton score);	chr8:8935355	chr8:8167819~8226614:-
GBM	cis	rs11233250	0.697	rs59068249	ENSG00000245832.5	RP11-179A16.1	5.37	4.11e-07	0.000648	0.67	0.45	Glioblastoma;Glioma;	chr11:82707867	chr11:81879851~82718082:-
GBM	cis	rs11233250	0.697	rs78000356	ENSG00000245832.5	RP11-179A16.1	5.37	4.11e-07	0.000648	0.67	0.45	Glioblastoma;Glioma;	chr11:82717577	chr11:81879851~82718082:-
GBM	cis	rs6782228	1	rs35604103	ENSG00000277250.1	Metazoa_SRP	5.37	4.11e-07	0.000648	0.54	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128673681~128674021:-
GBM	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-5.37	4.12e-07	0.000649	-0.51	-0.45	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
GBM	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	5.37	4.13e-07	0.000651	0.47	0.45	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
GBM	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	5.37	4.14e-07	0.000652	0.69	0.45	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
GBM	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-5.37	4.14e-07	0.000652	-0.56	-0.45	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
GBM	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-5.37	4.14e-07	0.000652	-0.56	-0.45	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
GBM	cis	rs7615952	0.512	rs2979351	ENSG00000171084.14	FAM86JP	5.37	4.14e-07	0.000653	0.71	0.45	Blood pressure (smoking interaction);	chr3:125644755	chr3:125916620~125930024:+
GBM	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	5.37	4.15e-07	0.000654	0.39	0.45	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
GBM	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-5.37	4.16e-07	0.000654	-0.52	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
GBM	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-5.37	4.16e-07	0.000654	-0.52	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
GBM	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-5.37	4.16e-07	0.000654	-0.52	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
GBM	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	5.37	4.17e-07	0.000656	0.59	0.45	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	5.37	4.17e-07	0.000656	0.59	0.45	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	5.37	4.17e-07	0.000656	0.59	0.45	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	5.37	4.17e-07	0.000656	0.59	0.45	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
GBM	cis	rs7267979	0.816	rs422148	ENSG00000276952.1	RP5-965G21.6	5.37	4.18e-07	0.000657	0.4	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25284915~25285588:-
GBM	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-5.37	4.18e-07	0.000657	-0.64	-0.45	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
GBM	cis	rs860818	1	rs858254	ENSG00000226816.2	AC005082.12	5.37	4.18e-07	0.000657	1.25	0.45	Initial pursuit acceleration;	chr7:23177584	chr7:23206013~23208045:+
GBM	cis	rs7615952	0.546	rs2979307	ENSG00000171084.14	FAM86JP	-5.37	4.18e-07	0.000658	-0.78	-0.45	Blood pressure (smoking interaction);	chr3:125590730	chr3:125916620~125930024:+
GBM	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-5.37	4.19e-07	0.000659	-0.76	-0.45	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
GBM	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	5.37	4.19e-07	0.000659	0.52	0.45	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
GBM	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-5.37	4.19e-07	0.000659	-0.52	-0.45	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
GBM	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-5.37	4.19e-07	0.000659	-0.61	-0.45	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-5.37	4.19e-07	0.000659	-0.61	-0.45	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-5.37	4.19e-07	0.000659	-0.61	-0.45	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
GBM	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-5.37	4.19e-07	0.000659	-0.62	-0.45	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
GBM	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-5.37	4.19e-07	0.000659	-0.62	-0.45	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
GBM	cis	rs7216064	0.589	rs7213585	ENSG00000278219.1	AC145343.1	-5.37	4.2e-07	0.00066	-0.5	-0.45	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68101538~68101639:+
GBM	cis	rs763121	0.853	rs2281019	ENSG00000273076.1	RP3-508I15.22	5.37	4.21e-07	0.000661	0.52	0.45	Menopause (age at onset);	chr22:38668373	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2281020	ENSG00000273076.1	RP3-508I15.22	5.37	4.21e-07	0.000661	0.52	0.45	Menopause (age at onset);	chr22:38668401	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2281021	ENSG00000273076.1	RP3-508I15.22	5.37	4.21e-07	0.000661	0.52	0.45	Menopause (age at onset);	chr22:38668662	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5995610	ENSG00000273076.1	RP3-508I15.22	5.37	4.21e-07	0.000661	0.52	0.45	Menopause (age at onset);	chr22:38668676	chr22:38743495~38743910:+
GBM	cis	rs67981189	0.896	rs7153237	ENSG00000269927.1	RP6-91H8.3	5.37	4.21e-07	0.000661	0.51	0.45	Schizophrenia;	chr14:71021937	chr14:71141125~71143253:-
GBM	cis	rs860818	0.655	rs1406079	ENSG00000226816.2	AC005082.12	-5.37	4.21e-07	0.000662	-1.29	-0.45	Initial pursuit acceleration;	chr7:23155078	chr7:23206013~23208045:+
GBM	cis	rs7267979	0.934	rs2261115	ENSG00000276952.1	RP5-965G21.6	5.37	4.22e-07	0.000663	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25284915~25285588:-
GBM	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	5.37	4.23e-07	0.000665	0.53	0.45	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
GBM	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-5.37	4.24e-07	0.000666	-0.53	-0.45	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
GBM	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-5.37	4.25e-07	0.000666	-0.53	-0.45	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
GBM	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	5.36	4.25e-07	0.000667	0.37	0.45	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
GBM	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	5.36	4.25e-07	0.000667	0.69	0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
GBM	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-5.36	4.27e-07	0.000669	-0.42	-0.45	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
GBM	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-5.36	4.27e-07	0.00067	-0.52	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
GBM	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-5.36	4.28e-07	0.00067	-0.58	-0.45	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
GBM	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-5.36	4.28e-07	0.00067	-0.58	-0.45	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
GBM	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	5.36	4.28e-07	0.000671	0.47	0.45	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
GBM	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-5.36	4.28e-07	0.000671	-0.38	-0.45	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
GBM	cis	rs7267979	1	rs6050547	ENSG00000276952.1	RP5-965G21.6	-5.36	4.29e-07	0.000672	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25284915~25285588:-
GBM	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	5.36	4.3e-07	0.000674	0.57	0.45	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
GBM	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-5.36	4.31e-07	0.000675	-0.47	-0.45	Height;	chr11:118808920	chr11:118791254~118793137:+
GBM	cis	rs17270561	0.541	rs17586946	ENSG00000272810.1	U91328.22	-5.36	4.31e-07	0.000675	-0.72	-0.45	Iron status biomarkers;	chr6:25938825	chr6:26013241~26013757:+
GBM	cis	rs17772222	0.74	rs10150986	ENSG00000222990.1	RNU4-22P	5.36	4.31e-07	0.000675	0.49	0.45	Coronary artery calcification;	chr14:88517326	chr14:88513498~88513663:+
GBM	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-5.36	4.31e-07	0.000675	-0.61	-0.45	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-5.36	4.31e-07	0.000675	-0.61	-0.45	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-5.36	4.31e-07	0.000675	-0.61	-0.45	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-5.36	4.31e-07	0.000675	-0.61	-0.45	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-5.36	4.31e-07	0.000675	-0.61	-0.45	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-5.36	4.31e-07	0.000675	-0.61	-0.45	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
GBM	cis	rs2013441	0.866	rs12947950	ENSG00000230528.6	NOS2P3	-5.36	4.31e-07	0.000675	-0.53	-0.45	Obesity-related traits;	chr17:20141863	chr17:20436337~20447249:+
GBM	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	5.36	4.32e-07	0.000676	0.6	0.45	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	5.36	4.32e-07	0.000676	0.6	0.45	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
GBM	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	5.36	4.32e-07	0.000676	0.6	0.45	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
GBM	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-5.36	4.33e-07	0.000677	-0.55	-0.45	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
GBM	cis	rs7267979	1	rs4815418	ENSG00000125804.12	FAM182A	5.36	4.34e-07	0.000678	0.56	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:26054655~26086917:+
GBM	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-5.36	4.34e-07	0.000679	-0.65	-0.45	Depression;	chr6:28074687	chr6:28115628~28116551:+
GBM	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	5.36	4.34e-07	0.000679	0.48	0.45	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	5.36	4.34e-07	0.000679	0.48	0.45	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	5.36	4.34e-07	0.000679	0.48	0.45	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
GBM	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	5.36	4.35e-07	0.00068	0.51	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
GBM	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-5.36	4.35e-07	0.000681	-0.6	-0.45	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
GBM	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-5.36	4.36e-07	0.000682	-0.63	-0.45	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
GBM	cis	rs12460587	0.547	rs56244227	ENSG00000275055.1	CTC-471J1.11	-5.36	4.36e-07	0.000682	-0.53	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080439	chr19:52049007~52049754:+
GBM	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	5.36	4.38e-07	0.000684	0.5	0.45	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	5.36	4.38e-07	0.000684	0.5	0.45	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	5.36	4.38e-07	0.000684	0.5	0.45	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
GBM	cis	rs7267979	0.873	rs6115093	ENSG00000125804.12	FAM182A	-5.36	4.38e-07	0.000685	-0.58	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.535	rs7671759	ENSG00000250412.1	KLHL2P1	5.36	4.41e-07	0.000689	0.58	0.45	Corneal astigmatism;	chr4:119326939	chr4:119334329~119378233:+
GBM	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	5.36	4.42e-07	0.00069	0.63	0.45	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
GBM	cis	rs6782228	1	rs35871360	ENSG00000277250.1	Metazoa_SRP	5.36	4.43e-07	0.000691	0.54	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128673681~128674021:-
GBM	cis	rs2013441	1	rs3850783	ENSG00000230528.6	NOS2P3	-5.36	4.43e-07	0.000691	-0.49	-0.45	Obesity-related traits;	chr17:20281188	chr17:20436337~20447249:+
GBM	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	5.36	4.43e-07	0.000691	0.51	0.45	Height;	chr11:118856460	chr11:118688039~118690600:-
GBM	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-5.36	4.43e-07	0.000691	-0.51	-0.45	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
GBM	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-5.36	4.43e-07	0.000691	-0.46	-0.45	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
GBM	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	5.36	4.43e-07	0.000691	0.46	0.45	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
GBM	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	5.36	4.43e-07	0.000692	0.51	0.45	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
GBM	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	5.35	4.45e-07	0.000694	0.54	0.45	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-5.35	4.45e-07	0.000694	-0.54	-0.45	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-5.35	4.45e-07	0.000694	-0.54	-0.45	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
GBM	cis	rs453301	0.653	rs1562211	ENSG00000254340.1	RP11-10A14.3	-5.35	4.45e-07	0.000694	-0.56	-0.45	Joint mobility (Beighton score);	chr8:9044914	chr8:9141424~9145435:+
GBM	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	5.35	4.45e-07	0.000694	0.56	0.45	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
GBM	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	5.35	4.45e-07	0.000694	0.47	0.45	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
GBM	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	5.35	4.45e-07	0.000694	0.77	0.45	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
GBM	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	5.35	4.46e-07	0.000695	0.54	0.45	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
GBM	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	5.35	4.47e-07	0.000696	0.58	0.45	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
GBM	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-5.35	4.47e-07	0.000697	-0.57	-0.45	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
GBM	cis	rs67981189	0.865	rs34488204	ENSG00000269927.1	RP6-91H8.3	5.35	4.47e-07	0.000697	0.5	0.45	Schizophrenia;	chr14:71028571	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs3814869	ENSG00000269927.1	RP6-91H8.3	5.35	4.47e-07	0.000697	0.5	0.45	Schizophrenia;	chr14:71028982	chr14:71141125~71143253:-
GBM	cis	rs17772222	0.638	rs11159859	ENSG00000258983.2	RP11-507K2.2	5.35	4.48e-07	0.000698	0.47	0.45	Coronary artery calcification;	chr14:88561547	chr14:88499334~88515502:+
GBM	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-5.35	4.48e-07	0.000698	-0.63	-0.45	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
GBM	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	5.35	4.48e-07	0.000698	0.61	0.45	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
GBM	cis	rs7267979	0.966	rs6037083	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs4813557	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2297496	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2297497	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs7343481	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815404	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6115146	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.934	rs6037085	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs6050532	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6083804	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6083805	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815405	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050542	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6076336	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050544	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs8125868	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6037095	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050562	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815407	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815408	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050566	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4813563	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs6037103	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2387881	ENSG00000276952.1	RP5-965G21.6	-5.35	4.49e-07	0.000698	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.933	rs2261109	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2261698	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2261720	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2227890	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2261747	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.934	rs2261753	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2261790	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2261794	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2145126	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs910996	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2257705	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2227892	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2257712	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2257461	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2257808	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2257809	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs910997	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs1077889	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs3002702	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2257985	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2257988	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2257432	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258066	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258135	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258201	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258563	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2424704	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258617	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2257420	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258769	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs7018	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258879	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2257496	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2258884	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2259837	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2259873	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs11100	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs1046073	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2259926	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2259928	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2259956	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs7267979	ENSG00000276952.1	RP5-965G21.6	5.35	4.49e-07	0.000698	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25284915~25285588:-
GBM	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-5.35	4.49e-07	0.000698	-0.65	-0.45	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
GBM	cis	rs7267979	0.706	rs6138542	ENSG00000125804.12	FAM182A	-5.35	4.5e-07	0.000699	-0.58	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:26054655~26086917:+
GBM	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	5.35	4.5e-07	0.000699	0.6	0.45	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
GBM	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	5.35	4.5e-07	0.000699	0.51	0.45	Height;	chr11:118859432	chr11:118688039~118690600:-
GBM	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	5.35	4.5e-07	0.000699	0.51	0.45	Height;	chr11:118860890	chr11:118688039~118690600:-
GBM	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	5.35	4.5e-07	0.000699	0.51	0.45	Height;	chr11:118861053	chr11:118688039~118690600:-
GBM	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	5.35	4.51e-07	7e-04	0.5	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
GBM	cis	rs950027	0.549	rs1719250	ENSG00000259433.2	CTD-2651B20.4	-5.35	4.51e-07	7e-04	-0.53	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45330209~45332634:-
GBM	cis	rs7267979	1	rs2257982	ENSG00000125804.12	FAM182A	-5.35	4.52e-07	0.000701	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:26054655~26086917:+
GBM	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	5.35	4.52e-07	0.000701	0.56	0.45	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
GBM	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	5.35	4.52e-07	0.000702	0.56	0.45	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
GBM	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	5.35	4.53e-07	0.000702	0.54	0.45	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
GBM	cis	rs11098499	0.691	rs9996644	ENSG00000250412.1	KLHL2P1	5.35	4.53e-07	0.000703	0.58	0.45	Corneal astigmatism;	chr4:119317722	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.691	rs9996494	ENSG00000250412.1	KLHL2P1	5.35	4.53e-07	0.000703	0.58	0.45	Corneal astigmatism;	chr4:119317725	chr4:119334329~119378233:+
GBM	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-5.35	4.55e-07	0.000705	-0.59	-0.45	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-5.35	4.55e-07	0.000705	-0.59	-0.45	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
GBM	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-5.35	4.55e-07	0.000705	-0.59	-0.45	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
GBM	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-5.35	4.55e-07	0.000706	-0.53	-0.45	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
GBM	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	5.35	4.55e-07	0.000706	0.5	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
GBM	cis	rs11159086	1	rs8006958	ENSG00000270000.1	RP3-449M8.9	5.35	4.56e-07	0.000706	0.69	0.45	Advanced glycation end-product levels;	chr14:74478148	chr14:74471930~74472360:-
GBM	cis	rs3096299	0.933	rs2965939	ENSG00000260259.1	RP11-368I7.4	5.35	4.56e-07	0.000707	0.49	0.45	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89682620~89686569:-
GBM	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-5.35	4.56e-07	0.000707	-0.46	-0.45	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
GBM	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-5.35	4.56e-07	0.000707	-0.52	-0.45	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
GBM	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	5.35	4.57e-07	0.000709	0.53	0.45	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	5.35	4.57e-07	0.000709	0.53	0.45	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
GBM	cis	rs3806843	0.808	rs6893708	ENSG00000202111.1	VTRNA1-2	5.35	4.59e-07	0.000711	0.46	0.45	Depressive symptoms (multi-trait analysis);	chr5:140746337	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.778	rs2531346	ENSG00000202111.1	VTRNA1-2	5.35	4.59e-07	0.000711	0.46	0.45	Depressive symptoms (multi-trait analysis);	chr5:140746554	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.868	rs2531345	ENSG00000202111.1	VTRNA1-2	5.35	4.59e-07	0.000711	0.46	0.45	Depressive symptoms (multi-trait analysis);	chr5:140747196	chr5:140718925~140719013:+
GBM	cis	rs11098499	0.754	rs10212714	ENSG00000250412.1	KLHL2P1	5.35	4.59e-07	0.000711	0.58	0.45	Corneal astigmatism;	chr4:119333147	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.754	rs1849457	ENSG00000250412.1	KLHL2P1	5.35	4.59e-07	0.000711	0.58	0.45	Corneal astigmatism;	chr4:119333200	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.789	rs10212719	ENSG00000250412.1	KLHL2P1	5.35	4.59e-07	0.000711	0.58	0.45	Corneal astigmatism;	chr4:119333282	chr4:119334329~119378233:+
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	5.35	4.59e-07	0.000711	0.51	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
GBM	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-5.35	4.59e-07	0.000711	-0.65	-0.45	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
GBM	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-5.35	4.6e-07	0.000712	-0.58	-0.45	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
GBM	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	5.35	4.6e-07	0.000713	0.49	0.45	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
GBM	cis	rs17772222	0.793	rs7143853	ENSG00000258983.2	RP11-507K2.2	5.35	4.61e-07	0.000713	0.52	0.45	Coronary artery calcification;	chr14:88578477	chr14:88499334~88515502:+
GBM	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	5.35	4.61e-07	0.000714	0.53	0.45	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	5.35	4.61e-07	0.000714	0.53	0.45	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
GBM	cis	rs12495178	0.55	rs35498642	ENSG00000239519.1	CADM2-AS1	5.35	4.62e-07	0.000714	0.48	0.45	Body mass index;	chr3:85879484	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.574	rs11708377	ENSG00000239519.1	CADM2-AS1	5.35	4.62e-07	0.000714	0.48	0.45	Body mass index;	chr3:85882768	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.574	rs62261744	ENSG00000239519.1	CADM2-AS1	5.35	4.62e-07	0.000714	0.48	0.45	Body mass index;	chr3:85884979	chr3:85992183~86028007:-
GBM	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	5.35	4.62e-07	0.000715	0.38	0.45	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
GBM	cis	rs67981189	0.896	rs2526877	ENSG00000269927.1	RP6-91H8.3	-5.35	4.63e-07	0.000716	-0.5	-0.45	Schizophrenia;	chr14:70966605	chr14:71141125~71143253:-
GBM	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	5.35	4.63e-07	0.000716	0.41	0.45	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
GBM	cis	rs7615952	0.512	rs2979336	ENSG00000171084.14	FAM86JP	5.35	4.63e-07	0.000716	0.71	0.45	Blood pressure (smoking interaction);	chr3:125638626	chr3:125916620~125930024:+
GBM	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-5.35	4.63e-07	0.000717	-0.51	-0.45	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
GBM	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	5.35	4.63e-07	0.000717	0.51	0.45	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
GBM	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	5.35	4.63e-07	0.000717	0.51	0.45	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
GBM	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	5.35	4.63e-07	0.000717	0.51	0.45	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
GBM	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	5.34	4.64e-07	0.000718	0.54	0.45	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
GBM	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	5.34	4.65e-07	0.000718	0.65	0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
GBM	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	5.34	4.65e-07	0.000718	0.65	0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
GBM	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-5.34	4.65e-07	0.000718	-0.65	-0.45	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
GBM	cis	rs7267979	1	rs2482911	ENSG00000276952.1	RP5-965G21.6	-5.34	4.65e-07	0.000718	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.873	rs6083853	ENSG00000276952.1	RP5-965G21.6	-5.34	4.65e-07	0.000718	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.934	rs2482913	ENSG00000276952.1	RP5-965G21.6	-5.34	4.65e-07	0.000718	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2500436	ENSG00000276952.1	RP5-965G21.6	-5.34	4.65e-07	0.000718	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6083856	ENSG00000276952.1	RP5-965G21.6	-5.34	4.65e-07	0.000718	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2482918	ENSG00000276952.1	RP5-965G21.6	-5.34	4.65e-07	0.000718	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs2387885	ENSG00000276952.1	RP5-965G21.6	-5.34	4.65e-07	0.000718	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs2424713	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs7270835	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6115191	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6107045	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6107046	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6107047	ENSG00000276952.1	RP5-965G21.6	5.34	4.65e-07	0.000718	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25284915~25285588:-
GBM	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	5.34	4.65e-07	0.000719	0.84	0.45	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
GBM	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	5.34	4.66e-07	0.000719	0.59	0.45	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
GBM	cis	rs17214007	0.877	rs11075281	ENSG00000279866.1	CTB-193M12.4	5.34	4.66e-07	0.00072	0.56	0.45	Cognitive function;	chr16:15780585	chr16:15704410~15705984:+
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	5.34	4.68e-07	0.000722	0.5	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
GBM	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	5.34	4.68e-07	0.000722	0.59	0.45	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
GBM	cis	rs7267979	0.866	rs2424698	ENSG00000276952.1	RP5-965G21.6	5.34	4.69e-07	0.000723	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25284915~25285588:-
GBM	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	5.34	4.69e-07	0.000724	0.58	0.45	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
GBM	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	5.34	4.69e-07	0.000724	0.51	0.45	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
GBM	cis	rs7267979	1	rs2500424	ENSG00000276952.1	RP5-965G21.6	-5.34	4.7e-07	0.000725	-0.42	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25284915~25285588:-
GBM	cis	rs8067545	0.532	rs12449914	ENSG00000230528.6	NOS2P3	-5.34	4.73e-07	0.000729	-0.55	-0.45	Schizophrenia;	chr17:20100656	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.532	rs12943904	ENSG00000230528.6	NOS2P3	-5.34	4.73e-07	0.000729	-0.55	-0.45	Schizophrenia;	chr17:20104254	chr17:20436337~20447249:+
GBM	cis	rs7267979	0.966	rs6037097	ENSG00000125804.12	FAM182A	-5.34	4.74e-07	0.00073	-0.55	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:26054655~26086917:+
GBM	cis	rs4072705	1	rs7032937	ENSG00000224020.1	MIR181A2HG	-5.34	4.74e-07	0.00073	-0.49	-0.45	Menarche (age at onset);	chr9:124575894	chr9:124658467~124698631:+
GBM	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-5.34	4.75e-07	0.000731	-0.41	-0.45	Temperament;	chr17:14003617	chr17:14024514~14025488:+
GBM	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-5.34	4.75e-07	0.000732	-0.53	-0.45	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
GBM	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	5.34	4.75e-07	0.000732	0.47	0.45	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
GBM	cis	rs2013441	0.866	rs17686622	ENSG00000230528.6	NOS2P3	5.34	4.77e-07	0.000735	0.53	0.45	Obesity-related traits;	chr17:20117051	chr17:20436337~20447249:+
GBM	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-5.34	4.78e-07	0.000737	-0.56	-0.45	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
GBM	cis	rs67981189	0.896	rs17108822	ENSG00000269927.1	RP6-91H8.3	5.34	4.79e-07	0.000738	0.51	0.45	Schizophrenia;	chr14:70979189	chr14:71141125~71143253:-
GBM	cis	rs2013441	1	rs1992562	ENSG00000230528.6	NOS2P3	5.34	4.79e-07	0.000738	0.5	0.45	Obesity-related traits;	chr17:20315480	chr17:20436337~20447249:+
GBM	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	5.34	4.81e-07	0.00074	0.44	0.45	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	5.34	4.81e-07	0.00074	0.44	0.45	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	5.34	4.81e-07	0.00074	0.44	0.45	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
GBM	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
GBM	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-5.34	4.81e-07	0.00074	-0.59	-0.45	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
GBM	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	5.34	4.82e-07	0.000742	0.77	0.45	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
GBM	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	5.34	4.82e-07	0.000742	0.51	0.45	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
GBM	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	5.34	4.83e-07	0.000743	0.51	0.45	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	5.34	4.83e-07	0.000743	0.51	0.45	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	5.34	4.83e-07	0.000743	0.51	0.45	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	5.34	4.83e-07	0.000743	0.51	0.45	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	5.34	4.83e-07	0.000743	0.51	0.45	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	5.34	4.83e-07	0.000743	0.51	0.45	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	5.34	4.83e-07	0.000743	0.51	0.45	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
GBM	cis	rs7267979	1	rs7020	ENSG00000276952.1	RP5-965G21.6	5.34	4.85e-07	0.000745	0.42	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25284915~25285588:-
GBM	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	5.33	4.86e-07	0.000746	0.6	0.45	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
GBM	cis	rs3806843	0.868	rs2262573	ENSG00000202111.1	VTRNA1-2	5.33	4.86e-07	0.000747	0.46	0.45	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.9	rs2563286	ENSG00000202111.1	VTRNA1-2	5.33	4.86e-07	0.000747	0.46	0.45	Depressive symptoms (multi-trait analysis);	chr5:140745614	chr5:140718925~140719013:+
GBM	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-5.33	4.87e-07	0.000748	-0.63	-0.45	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
GBM	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	5.33	4.9e-07	0.000753	0.79	0.45	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
GBM	cis	rs2013441	1	rs2703821	ENSG00000230528.6	NOS2P3	5.33	4.91e-07	0.000753	0.49	0.45	Obesity-related traits;	chr17:20218213	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2263175	ENSG00000230528.6	NOS2P3	5.33	4.91e-07	0.000753	0.49	0.45	Obesity-related traits;	chr17:20224716	chr17:20436337~20447249:+
GBM	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-5.33	4.92e-07	0.000754	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
GBM	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-5.33	4.92e-07	0.000755	-0.57	-0.45	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
GBM	cis	rs950169	0.649	rs12901010	ENSG00000225151.9	GOLGA2P7	-5.33	4.92e-07	0.000755	-0.56	-0.45	Schizophrenia;	chr15:84030282	chr15:84199311~84230136:-
GBM	cis	rs950169	0.69	rs12901166	ENSG00000225151.9	GOLGA2P7	-5.33	4.92e-07	0.000755	-0.56	-0.45	Schizophrenia;	chr15:84030361	chr15:84199311~84230136:-
GBM	cis	rs10946940	0.965	rs6915266	ENSG00000218016.2	ZNF192P2	5.33	4.92e-07	0.000755	0.55	0.45	Systemic lupus erythematosus;	chr6:27560864	chr6:28188050~28189432:+
GBM	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	5.33	4.93e-07	0.000756	0.75	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	5.33	4.93e-07	0.000756	0.75	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
GBM	cis	rs17214007	0.877	rs4541094	ENSG00000279866.1	CTB-193M12.4	5.33	4.93e-07	0.000757	0.57	0.45	Cognitive function;	chr16:15776878	chr16:15704410~15705984:+
GBM	cis	rs7267979	0.932	rs1541061	ENSG00000125804.12	FAM182A	-5.33	4.96e-07	0.00076	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs6138600	ENSG00000125804.12	FAM182A	-5.33	4.96e-07	0.00076	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.899	rs2104734	ENSG00000125804.12	FAM182A	-5.33	4.96e-07	0.00076	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs6107052	ENSG00000125804.12	FAM182A	-5.33	4.96e-07	0.00076	-0.56	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:26054655~26086917:+
GBM	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	5.33	4.98e-07	0.000763	0.59	0.45	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
GBM	cis	rs3096299	0.967	rs2965935	ENSG00000260259.1	RP11-368I7.4	-5.33	4.98e-07	0.000763	-0.46	-0.45	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89682620~89686569:-
GBM	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-5.33	5e-07	0.000765	-0.74	-0.44	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
GBM	cis	rs11233250	0.697	rs2888789	ENSG00000245832.5	RP11-179A16.1	5.33	5e-07	0.000766	0.67	0.44	Glioblastoma;Glioma;	chr11:82719127	chr11:81879851~82718082:-
GBM	cis	rs11233250	0.697	rs55862501	ENSG00000245832.5	RP11-179A16.1	5.33	5e-07	0.000766	0.67	0.44	Glioblastoma;Glioma;	chr11:82720554	chr11:81879851~82718082:-
GBM	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-5.33	5.01e-07	0.000767	-0.38	-0.44	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
GBM	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	5.33	5.01e-07	0.000767	0.61	0.44	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
GBM	cis	rs67981189	1	rs67981189	ENSG00000269927.1	RP6-91H8.3	5.33	5.02e-07	0.000768	0.51	0.44	Schizophrenia;	chr14:71005509	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs7145484	ENSG00000269927.1	RP6-91H8.3	5.33	5.02e-07	0.000768	0.51	0.44	Schizophrenia;	chr14:71006820	chr14:71141125~71143253:-
GBM	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	5.33	5.04e-07	0.00077	0.49	0.44	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
GBM	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	5.33	5.04e-07	0.00077	0.53	0.44	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	5.33	5.04e-07	0.00077	0.53	0.44	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	5.33	5.04e-07	0.00077	0.53	0.44	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	5.33	5.04e-07	0.00077	0.53	0.44	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
GBM	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-5.33	5.04e-07	0.00077	-0.37	-0.44	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
GBM	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-5.33	5.04e-07	0.000771	-0.5	-0.44	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
GBM	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-5.33	5.04e-07	0.000771	-0.5	-0.44	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
GBM	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-5.33	5.05e-07	0.000772	-0.55	-0.44	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
GBM	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	5.32	5.07e-07	0.000775	0.61	0.44	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
GBM	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	5.32	5.07e-07	0.000775	0.53	0.44	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
GBM	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-5.32	5.09e-07	0.000777	-0.59	-0.44	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
GBM	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	5.32	5.1e-07	0.000778	0.38	0.44	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
GBM	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-5.32	5.11e-07	0.000781	-0.76	-0.44	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-5.32	5.11e-07	0.000781	-0.76	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
GBM	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	5.32	5.12e-07	0.000782	0.51	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
GBM	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	5.32	5.13e-07	0.000783	0.41	0.44	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
GBM	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	5.32	5.15e-07	0.000786	0.5	0.44	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
GBM	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	5.32	5.15e-07	0.000786	0.5	0.44	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
GBM	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	5.32	5.15e-07	0.000786	0.5	0.44	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
GBM	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	5.32	5.15e-07	0.000786	0.5	0.44	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
GBM	cis	rs67981189	0.896	rs12100737	ENSG00000269927.1	RP6-91H8.3	-5.32	5.16e-07	0.000787	-0.56	-0.44	Schizophrenia;	chr14:71004383	chr14:71141125~71143253:-
GBM	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	5.32	5.17e-07	0.000788	0.76	0.44	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
GBM	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	5.32	5.17e-07	0.000788	0.76	0.44	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
GBM	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	5.32	5.17e-07	0.000788	0.48	0.44	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	5.32	5.17e-07	0.000788	0.48	0.44	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.857	rs11685425	ENSG00000253559.1	OSGEPL1-AS1	5.32	5.17e-07	0.000788	0.48	0.44	Ferritin levels;	chr2:189747977	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.652	rs10210345	ENSG00000253559.1	OSGEPL1-AS1	5.32	5.17e-07	0.000788	0.48	0.44	Ferritin levels;	chr2:189754760	chr2:189762704~189765556:+
GBM	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	5.32	5.17e-07	0.000788	0.51	0.44	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
GBM	cis	rs6782228	1	rs6782407	ENSG00000277250.1	Metazoa_SRP	5.32	5.17e-07	0.000789	0.55	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128673681~128674021:-
GBM	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	5.32	5.18e-07	0.000789	0.52	0.44	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
GBM	cis	rs7267979	1	rs2482943	ENSG00000276952.1	RP5-965G21.6	-5.32	5.19e-07	0.000791	-0.42	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25284915~25285588:-
GBM	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	5.32	5.2e-07	0.000792	0.45	0.44	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
GBM	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	5.32	5.22e-07	0.000795	0.59	0.44	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
GBM	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	5.32	5.24e-07	0.000797	0.53	0.44	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
GBM	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	5.32	5.24e-07	0.000797	0.53	0.44	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
GBM	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	5.32	5.24e-07	0.000797	0.53	0.44	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
GBM	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	5.32	5.24e-07	0.000797	0.45	0.44	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
GBM	cis	rs67981189	0.858	rs221927	ENSG00000269927.1	RP6-91H8.3	-5.32	5.27e-07	0.000802	-0.53	-0.44	Schizophrenia;	chr14:71112024	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.679	rs221901	ENSG00000269927.1	RP6-91H8.3	-5.32	5.27e-07	0.000802	-0.51	-0.44	Schizophrenia;	chr14:71135509	chr14:71141125~71143253:-
GBM	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-5.32	5.28e-07	0.000802	-0.57	-0.44	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
GBM	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	5.32	5.28e-07	0.000803	0.46	0.44	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
GBM	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	5.32	5.28e-07	0.000803	0.32	0.44	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	5.32	5.28e-07	0.000803	0.32	0.44	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
GBM	cis	rs7267979	1	rs2257982	ENSG00000276952.1	RP5-965G21.6	5.32	5.29e-07	0.000804	0.42	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25284915~25285588:-
GBM	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	5.31	5.31e-07	0.000806	0.51	0.44	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
GBM	cis	rs67981189	0.896	rs221922	ENSG00000269927.1	RP6-91H8.3	-5.31	5.31e-07	0.000806	-0.53	-0.44	Schizophrenia;	chr14:71118396	chr14:71141125~71143253:-
GBM	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	5.31	5.31e-07	0.000806	0.41	0.44	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
GBM	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	5.31	5.34e-07	0.000809	0.55	0.44	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	5.31	5.35e-07	0.000811	0.59	0.44	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
GBM	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-5.31	5.35e-07	0.000811	-0.6	-0.44	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
GBM	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-5.31	5.35e-07	0.000812	-0.5	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
GBM	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-5.31	5.36e-07	0.000812	-0.56	-0.44	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
GBM	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	5.31	5.36e-07	0.000812	0.59	0.44	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	5.31	5.36e-07	0.000812	0.59	0.44	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	5.31	5.36e-07	0.000812	0.59	0.44	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
GBM	cis	rs7267979	0.866	rs2424698	ENSG00000125804.12	FAM182A	-5.31	5.36e-07	0.000813	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:26054655~26086917:+
GBM	cis	rs2919917	0.578	rs922928	ENSG00000254352.1	RP11-578O24.2	5.31	5.37e-07	0.000815	0.7	0.44	Lymphocyte counts;	chr8:78645085	chr8:78723796~78724136:-
GBM	cis	rs67981189	0.896	rs7157250	ENSG00000269927.1	RP6-91H8.3	5.31	5.4e-07	0.000818	0.51	0.44	Schizophrenia;	chr14:70991112	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs4132849	ENSG00000269927.1	RP6-91H8.3	5.31	5.4e-07	0.000818	0.51	0.44	Schizophrenia;	chr14:70992806	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.821	rs56021283	ENSG00000269927.1	RP6-91H8.3	5.31	5.4e-07	0.000818	0.51	0.44	Schizophrenia;	chr14:70996042	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs12883437	ENSG00000269927.1	RP6-91H8.3	5.31	5.4e-07	0.000818	0.51	0.44	Schizophrenia;	chr14:70998064	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.821	rs8007026	ENSG00000269927.1	RP6-91H8.3	5.31	5.4e-07	0.000818	0.52	0.44	Schizophrenia;	chr14:70997667	chr14:71141125~71143253:-
GBM	cis	rs5742933	0.744	rs12693557	ENSG00000253559.1	OSGEPL1-AS1	5.31	5.4e-07	0.000818	0.48	0.44	Ferritin levels;	chr2:189726211	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.817	rs13035966	ENSG00000253559.1	OSGEPL1-AS1	5.31	5.4e-07	0.000818	0.48	0.44	Ferritin levels;	chr2:189726507	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	5.31	5.4e-07	0.000818	0.48	0.44	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
GBM	cis	rs36132109	0.826	rs13081156	ENSG00000273328.4	RP11-141M3.6	5.31	5.43e-07	0.000822	0.51	0.44	Monocyte chemoattractant protein-1 levels;	chr3:42963725	chr3:42809414~42908105:+
GBM	cis	rs36132109	0.858	rs13078406	ENSG00000273328.4	RP11-141M3.6	5.31	5.43e-07	0.000822	0.51	0.44	Monocyte chemoattractant protein-1 levels;	chr3:42982513	chr3:42809414~42908105:+
GBM	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	5.31	5.45e-07	0.000824	0.59	0.44	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
GBM	cis	rs4273100	0.646	rs6587216	ENSG00000265185.4	SNORD3B-1	-5.31	5.46e-07	0.000826	-0.53	-0.44	Schizophrenia;	chr17:19321084	chr17:19061912~19062669:+
GBM	cis	rs6782228	0.675	rs2253151	ENSG00000277250.1	Metazoa_SRP	-5.31	5.47e-07	0.000827	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128673681~128674021:-
GBM	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	5.31	5.47e-07	0.000827	0.44	0.44	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	5.31	5.47e-07	0.000827	0.44	0.44	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
GBM	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-5.31	5.49e-07	0.000829	-0.38	-0.44	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
GBM	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-5.31	5.49e-07	0.000829	-0.38	-0.44	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
GBM	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	5.31	5.5e-07	0.00083	0.52	0.44	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
GBM	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	5.31	5.5e-07	0.000831	0.5	0.44	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
GBM	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-5.31	5.51e-07	0.000831	-0.52	-0.44	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
GBM	cis	rs3096299	0.838	rs3102384	ENSG00000260259.1	RP11-368I7.4	5.31	5.51e-07	0.000831	0.49	0.44	Multiple myeloma (IgH translocation);	chr16:89345253	chr16:89682620~89686569:-
GBM	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	5.31	5.52e-07	0.000832	0.53	0.44	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
GBM	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-5.31	5.52e-07	0.000832	-0.4	-0.44	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
GBM	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-5.31	5.52e-07	0.000833	-0.58	-0.44	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
GBM	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-5.31	5.52e-07	0.000833	-0.58	-0.44	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
GBM	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-5.31	5.52e-07	0.000833	-0.58	-0.44	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
GBM	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-5.31	5.52e-07	0.000833	-0.58	-0.44	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
GBM	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-5.31	5.52e-07	0.000833	-0.58	-0.44	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
GBM	cis	rs4072705	0.967	rs4838195	ENSG00000224020.1	MIR181A2HG	-5.31	5.53e-07	0.000834	-0.47	-0.44	Menarche (age at onset);	chr9:124588938	chr9:124658467~124698631:+
GBM	cis	rs3762637	0.769	rs13317855	ENSG00000272758.4	RP11-299J3.8	-5.31	5.53e-07	0.000834	-0.7	-0.44	LDL cholesterol levels;	chr3:122385387	chr3:122416207~122443180:+
GBM	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	5.31	5.53e-07	0.000834	0.5	0.44	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
GBM	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-5.3	5.54e-07	0.000835	-0.58	-0.44	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
GBM	cis	rs9876781	1	rs9311423	ENSG00000244380.1	RP11-24C3.2	5.3	5.54e-07	0.000835	0.5	0.44	Longevity;	chr3:48378818	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs7634377	ENSG00000244380.1	RP11-24C3.2	5.3	5.54e-07	0.000835	0.5	0.44	Longevity;	chr3:48379768	chr3:48440352~48446656:-
GBM	cis	rs9987353	0.544	rs2929469	ENSG00000253893.2	FAM85B	-5.3	5.55e-07	0.000837	-0.52	-0.44	Recombination measurement;	chr8:9205146	chr8:8167819~8226614:-
GBM	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-5.3	5.56e-07	0.000838	-0.69	-0.44	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-5.3	5.56e-07	0.000838	-0.69	-0.44	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-5.3	5.56e-07	0.000838	-0.69	-0.44	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-5.3	5.56e-07	0.000838	-0.69	-0.44	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	5.3	5.56e-07	0.000838	0.69	0.44	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	5.3	5.56e-07	0.000838	0.69	0.44	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	5.3	5.56e-07	0.000838	0.69	0.44	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
GBM	cis	rs763121	0.819	rs4560233	ENSG00000273076.1	RP3-508I15.22	5.3	5.56e-07	0.000838	0.53	0.44	Menopause (age at onset);	chr22:38586437	chr22:38743495~38743910:+
GBM	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	5.3	5.57e-07	0.000839	0.48	0.44	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
GBM	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	5.3	5.58e-07	0.00084	0.48	0.44	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
GBM	cis	rs9876781	1	rs28824259	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48384185	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs12487542	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48384586	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs73074358	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48385757	chr3:48440352~48446656:-
GBM	cis	rs9876781	0.967	rs34761139	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48386489	chr3:48440352~48446656:-
GBM	cis	rs9876781	0.868	rs9875280	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48387420	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs6796491	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48388977	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs6804774	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48389129	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs9826195	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48392157	chr3:48440352~48446656:-
GBM	cis	rs9876781	0.967	rs9864815	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48392588	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs9809843	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48392923	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs1563736	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48395329	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs13071337	ENSG00000244380.1	RP11-24C3.2	5.3	5.59e-07	0.000841	0.5	0.44	Longevity;	chr3:48396724	chr3:48440352~48446656:-
GBM	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	5.3	5.6e-07	0.000842	0.71	0.44	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	5.3	5.6e-07	0.000842	0.71	0.44	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
GBM	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-5.3	5.62e-07	0.000845	-0.52	-0.44	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
GBM	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	5.3	5.62e-07	0.000845	0.52	0.44	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
GBM	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	5.3	5.63e-07	0.000847	0.45	0.44	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	5.3	5.63e-07	0.000847	0.45	0.44	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
GBM	cis	rs7267979	0.966	rs2151144	ENSG00000276952.1	RP5-965G21.6	-5.3	5.64e-07	0.000848	-0.42	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25284915~25285588:-
GBM	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	5.3	5.64e-07	0.000848	0.48	0.44	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
GBM	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	5.3	5.66e-07	0.00085	0.46	0.44	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
GBM	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-5.3	5.66e-07	0.000851	-0.47	-0.44	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
GBM	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-5.3	5.66e-07	0.000851	-0.59	-0.44	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
GBM	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-5.3	5.66e-07	0.000851	-0.51	-0.44	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
GBM	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-5.3	5.67e-07	0.000851	-0.51	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
GBM	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	5.3	5.67e-07	0.000851	0.54	0.44	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
GBM	cis	rs66887589	0.616	rs11098497	ENSG00000249244.1	RP11-548H18.2	5.3	5.67e-07	0.000852	0.53	0.44	Diastolic blood pressure;	chr4:119265913	chr4:119391831~119395335:-
GBM	cis	rs66887589	0.616	rs7659403	ENSG00000249244.1	RP11-548H18.2	5.3	5.67e-07	0.000852	0.53	0.44	Diastolic blood pressure;	chr4:119286099	chr4:119391831~119395335:-
GBM	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-5.3	5.68e-07	0.000852	-0.41	-0.44	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
GBM	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	5.3	5.68e-07	0.000852	0.41	0.44	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
GBM	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	5.3	5.68e-07	0.000852	0.41	0.44	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
GBM	cis	rs9876781	1	rs7630741	ENSG00000244380.1	RP11-24C3.2	5.3	5.69e-07	0.000854	0.5	0.44	Longevity;	chr3:48378233	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs9864371	ENSG00000244380.1	RP11-24C3.2	5.3	5.69e-07	0.000854	0.5	0.44	Longevity;	chr3:48385276	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs11712561	ENSG00000244380.1	RP11-24C3.2	5.3	5.69e-07	0.000854	0.5	0.44	Longevity;	chr3:48393807	chr3:48440352~48446656:-
GBM	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-5.3	5.69e-07	0.000854	-0.53	-0.44	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
GBM	cis	rs17214007	0.877	rs11644832	ENSG00000279866.1	CTB-193M12.4	5.3	5.69e-07	0.000854	0.56	0.44	Cognitive function;	chr16:15778891	chr16:15704410~15705984:+
GBM	cis	rs17214007	0.877	rs11645883	ENSG00000279866.1	CTB-193M12.4	5.3	5.69e-07	0.000854	0.56	0.44	Cognitive function;	chr16:15778950	chr16:15704410~15705984:+
GBM	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	5.3	5.7e-07	0.000855	0.5	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
GBM	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	5.3	5.7e-07	0.000855	0.51	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	5.3	5.7e-07	0.000855	0.51	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
GBM	cis	rs4713118	0.591	rs2056924	ENSG00000218016.2	ZNF192P2	-5.3	5.72e-07	0.000857	-0.55	-0.44	Parkinson's disease;	chr6:27722395	chr6:28188050~28189432:+
GBM	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-5.3	5.72e-07	0.000858	-0.55	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
GBM	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	5.3	5.73e-07	0.000859	0.46	0.44	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
GBM	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	5.3	5.73e-07	0.000859	0.46	0.44	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
GBM	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	5.3	5.73e-07	0.000859	0.46	0.44	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
GBM	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	5.3	5.74e-07	0.000861	0.42	0.44	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
GBM	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	5.3	5.75e-07	0.000861	1.01	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
GBM	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	5.3	5.75e-07	0.000862	0.45	0.44	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	5.3	5.75e-07	0.000862	0.45	0.44	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
GBM	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-5.3	5.76e-07	0.000863	-0.49	-0.44	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
GBM	cis	rs3812049	0.784	rs2250127	ENSG00000245937.6	LINC01184	-5.3	5.76e-07	0.000863	-0.49	-0.44	Lymphocyte counts;Red cell distribution width;	chr5:128053152	chr5:127940426~128083172:-
GBM	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	5.3	5.76e-07	0.000863	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-5.3	5.76e-07	0.000863	-0.55	-0.44	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-5.3	5.76e-07	0.000863	-0.55	-0.44	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.836	rs2731849	ENSG00000249664.1	CTD-2227C6.2	-5.3	5.76e-07	0.000863	-0.55	-0.44	Hypertension (SNP x SNP interaction);	chr5:83214060	chr5:83012285~83013109:-
GBM	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	5.3	5.78e-07	0.000866	0.5	0.44	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
GBM	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	5.29	5.79e-07	0.000867	0.45	0.44	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
GBM	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	5.29	5.81e-07	0.00087	0.51	0.44	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
GBM	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	5.29	5.81e-07	0.00087	0.51	0.44	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
GBM	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-5.29	5.82e-07	0.000872	-0.59	-0.44	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-5.29	5.82e-07	0.000872	-0.59	-0.44	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-5.29	5.82e-07	0.000872	-0.59	-0.44	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
GBM	cis	rs6782228	1	rs12495411	ENSG00000277250.1	Metazoa_SRP	5.29	5.83e-07	0.000873	0.54	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128673681~128674021:-
GBM	cis	rs6782228	1	rs6775011	ENSG00000277250.1	Metazoa_SRP	5.29	5.83e-07	0.000873	0.54	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128673681~128674021:-
GBM	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	5.29	5.84e-07	0.000874	0.51	0.44	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	5.29	5.84e-07	0.000874	0.51	0.44	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
GBM	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	5.29	5.85e-07	0.000875	0.44	0.44	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
GBM	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	5.29	5.86e-07	0.000876	0.64	0.44	Depression;	chr6:28167882	chr6:28115628~28116551:+
GBM	cis	rs11098499	0.955	rs6815725	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119237255	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs1551	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119237345	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs11931312	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119237868	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs1511018	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119240425	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs1397608	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119240589	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs7685268	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119241033	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs7684942	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119241046	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.913	rs10010696	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119243148	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs1511019	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119244852	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.913	rs11098496	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119246311	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs35197422	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119248159	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs35434465	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119248223	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs1511015	ENSG00000250412.1	KLHL2P1	5.29	5.86e-07	0.000877	0.57	0.44	Corneal astigmatism;	chr4:119249318	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.955	rs11944880	ENSG00000250412.1	KLHL2P1	-5.29	5.86e-07	0.000877	-0.57	-0.44	Corneal astigmatism;	chr4:119238179	chr4:119334329~119378233:+
GBM	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-5.29	5.87e-07	0.000877	-0.59	-0.44	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
GBM	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-5.29	5.87e-07	0.000877	-0.59	-0.44	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-5.29	5.87e-07	0.000877	-0.59	-0.44	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
GBM	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	5.29	5.87e-07	0.000878	0.5	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
GBM	cis	rs67981189	0.896	rs4391999	ENSG00000269927.1	RP6-91H8.3	5.29	5.89e-07	0.000879	0.5	0.44	Schizophrenia;	chr14:70978696	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs8012728	ENSG00000269927.1	RP6-91H8.3	5.29	5.89e-07	0.000879	0.5	0.44	Schizophrenia;	chr14:70981231	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs34731365	ENSG00000269927.1	RP6-91H8.3	5.29	5.89e-07	0.000879	0.5	0.44	Schizophrenia;	chr14:70982877	chr14:71141125~71143253:-
GBM	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	5.29	5.89e-07	0.00088	0.36	0.44	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
GBM	cis	rs5742933	0.744	rs13009889	ENSG00000253559.1	OSGEPL1-AS1	5.29	5.89e-07	0.00088	0.48	0.44	Ferritin levels;	chr2:189763842	chr2:189762704~189765556:+
GBM	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	5.29	5.9e-07	0.000881	0.52	0.44	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
GBM	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	5.29	5.92e-07	0.000883	0.53	0.44	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
GBM	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-5.29	5.92e-07	0.000883	-0.58	-0.44	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
GBM	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	5.29	5.92e-07	0.000884	0.68	0.44	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	5.29	5.92e-07	0.000884	0.68	0.44	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
GBM	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	5.29	5.92e-07	0.000884	0.56	0.44	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
GBM	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	5.29	5.93e-07	0.000886	0.58	0.44	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
GBM	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-5.29	5.94e-07	0.000887	-0.52	-0.44	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
GBM	cis	rs3812049	0.784	rs3749748	ENSG00000245937.6	LINC01184	-5.29	5.96e-07	0.000889	-0.49	-0.44	Lymphocyte counts;Red cell distribution width;	chr5:128014857	chr5:127940426~128083172:-
GBM	cis	rs7216064	0.532	rs3890640	ENSG00000278219.1	AC145343.1	5.29	5.97e-07	0.000891	0.49	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.589	rs8072723	ENSG00000278219.1	AC145343.1	5.29	5.97e-07	0.000891	0.49	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68101538~68101639:+
GBM	cis	rs7267979	0.903	rs6115101	ENSG00000276952.1	RP5-965G21.6	5.29	6e-07	0.000895	0.42	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25284915~25285588:-
GBM	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-5.29	6.01e-07	0.000896	-0.59	-0.44	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
GBM	cis	rs7267979	1	rs2424716	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs761025	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6050631	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6132835	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.933	rs11699203	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.933	rs6138571	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs11087520	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs416745	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.966	rs454723	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs398036	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs397119	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs448396	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs453329	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs447722	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs422424	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs422844	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs401166	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs404394	ENSG00000276952.1	RP5-965G21.6	5.29	6.02e-07	0.000896	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.934	rs4815423	ENSG00000276952.1	RP5-965G21.6	-5.29	6.02e-07	0.000896	-0.41	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815424	ENSG00000276952.1	RP5-965G21.6	-5.29	6.02e-07	0.000896	-0.41	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs6515651	ENSG00000276952.1	RP5-965G21.6	-5.29	6.02e-07	0.000896	-0.41	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25284915~25285588:-
GBM	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	5.29	6.03e-07	0.000898	0.53	0.44	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
GBM	cis	rs11098499	0.754	rs12510269	ENSG00000250412.1	KLHL2P1	5.29	6.03e-07	0.000898	0.57	0.44	Corneal astigmatism;	chr4:119320491	chr4:119334329~119378233:+
GBM	cis	rs7216064	0.553	rs62084690	ENSG00000278219.1	AC145343.1	5.29	6.03e-07	0.000899	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68039295	chr17:68101538~68101639:+
GBM	cis	rs7017914	0.714	rs1481796	ENSG00000246366.5	RP11-382J12.1	5.29	6.04e-07	9e-04	0.48	0.44	Bone mineral density;	chr8:71082115	chr8:70608577~70663279:+
GBM	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	5.28	6.05e-07	9e-04	0.51	0.44	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	5.28	6.05e-07	9e-04	0.51	0.44	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
GBM	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	5.28	6.06e-07	0.000901	0.52	0.44	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
GBM	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-5.28	6.07e-07	0.000902	-0.56	-0.44	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
GBM	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	5.28	6.07e-07	0.000902	0.61	0.44	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	5.28	6.07e-07	0.000902	0.61	0.44	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
GBM	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-5.28	6.07e-07	0.000902	-0.52	-0.44	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
GBM	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	5.28	6.08e-07	0.000904	0.65	0.44	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
GBM	cis	rs2013441	0.67	rs4924802	ENSG00000230528.6	NOS2P3	-5.28	6.08e-07	0.000904	-0.55	-0.44	Obesity-related traits;	chr17:20052582	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.67	rs35317166	ENSG00000230528.6	NOS2P3	-5.28	6.08e-07	0.000904	-0.55	-0.44	Obesity-related traits;	chr17:20056507	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.532	rs56371654	ENSG00000230528.6	NOS2P3	-5.28	6.08e-07	0.000904	-0.55	-0.44	Schizophrenia;	chr17:20057049	chr17:20436337~20447249:+
GBM	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-5.28	6.09e-07	0.000905	-0.52	-0.44	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
GBM	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-5.28	6.09e-07	0.000905	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
GBM	cis	rs112374913	1	rs112374913	ENSG00000239519.1	CADM2-AS1	5.28	6.1e-07	0.000906	0.48	0.44	Educational attainment;	chr3:85897356	chr3:85992183~86028007:-
GBM	cis	rs7267979	0.932	rs1985737	ENSG00000125804.12	FAM182A	-5.28	6.1e-07	0.000907	-0.56	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:26054655~26086917:+
GBM	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	5.28	6.13e-07	0.00091	0.56	0.44	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
GBM	cis	rs7267979	0.903	rs6115101	ENSG00000125804.12	FAM182A	-5.28	6.14e-07	0.000912	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:26054655~26086917:+
GBM	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	5.28	6.14e-07	0.000912	0.44	0.44	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	5.28	6.14e-07	0.000912	0.44	0.44	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
GBM	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-5.28	6.15e-07	0.000912	-0.37	-0.44	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
GBM	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	5.28	6.2e-07	0.000919	0.32	0.44	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	5.28	6.2e-07	0.000919	0.32	0.44	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
GBM	cis	rs4072705	1	rs4838196	ENSG00000224020.1	MIR181A2HG	-5.28	6.2e-07	0.000919	-0.48	-0.44	Menarche (age at onset);	chr9:124595399	chr9:124658467~124698631:+
GBM	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	5.28	6.21e-07	0.000921	0.61	0.44	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
GBM	cis	rs172166	0.769	rs149965	ENSG00000199851.2	U3	5.28	6.22e-07	0.000922	0.66	0.44	Cardiac Troponin-T levels;	chr6:28050911	chr6:28015568~28015777:+
GBM	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	5.28	6.22e-07	0.000922	0.72	0.44	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
GBM	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-5.28	6.23e-07	0.000923	-0.59	-0.44	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
GBM	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-5.28	6.26e-07	0.000927	-0.41	-0.44	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
GBM	cis	rs6782228	1	rs11711038	ENSG00000277250.1	Metazoa_SRP	5.28	6.26e-07	0.000927	0.54	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128673681~128674021:-
GBM	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-5.28	6.26e-07	0.000927	-0.6	-0.44	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
GBM	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	5.28	6.26e-07	0.000927	0.51	0.44	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
GBM	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-5.28	6.28e-07	0.00093	-0.56	-0.44	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
GBM	cis	rs2013441	0.866	rs1009082	ENSG00000230528.6	NOS2P3	-5.28	6.28e-07	0.00093	-0.53	-0.44	Obesity-related traits;	chr17:20159646	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.866	rs2703797	ENSG00000230528.6	NOS2P3	5.28	6.28e-07	0.00093	0.53	0.44	Obesity-related traits;	chr17:20176988	chr17:20436337~20447249:+
GBM	cis	rs9368481	0.594	rs2636425	ENSG00000224843.5	LINC00240	-5.28	6.28e-07	0.000931	-0.56	-0.44	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26956992~27023924:+
GBM	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	5.28	6.29e-07	0.000931	0.5	0.44	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
GBM	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	5.28	6.29e-07	0.000931	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	5.28	6.29e-07	0.000931	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	5.28	6.29e-07	0.000931	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
GBM	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-5.28	6.3e-07	0.000931	-0.45	-0.44	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
GBM	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-5.28	6.3e-07	0.000931	-0.67	-0.44	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	5.28	6.3e-07	0.000931	0.67	0.44	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
GBM	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-5.28	6.31e-07	0.000932	-0.58	-0.44	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
GBM	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-5.28	6.31e-07	0.000932	-0.51	-0.44	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
GBM	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-5.28	6.31e-07	0.000932	-0.51	-0.44	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
GBM	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	5.27	6.32e-07	0.000933	0.5	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
GBM	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	5.27	6.32e-07	0.000933	0.5	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
GBM	cis	rs7267979	0.934	rs2257464	ENSG00000276952.1	RP5-965G21.6	5.27	6.33e-07	0.000934	0.42	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25284915~25285588:-
GBM	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	5.27	6.33e-07	0.000935	0.53	0.44	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
GBM	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-5.27	6.34e-07	0.000936	-0.63	-0.44	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
GBM	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-5.27	6.34e-07	0.000936	-0.63	-0.44	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
GBM	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-5.27	6.34e-07	0.000936	-0.52	-0.44	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-5.27	6.34e-07	0.000936	-0.52	-0.44	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
GBM	cis	rs12495178	0.574	rs11127912	ENSG00000239519.1	CADM2-AS1	5.27	6.38e-07	0.00094	0.47	0.44	Body mass index;	chr3:85898333	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.55	rs12633520	ENSG00000239519.1	CADM2-AS1	5.27	6.38e-07	0.00094	0.47	0.44	Body mass index;	chr3:85900754	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.551	rs34803122	ENSG00000239519.1	CADM2-AS1	5.27	6.38e-07	0.00094	0.47	0.44	Body mass index;	chr3:85902571	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.574	rs13082138	ENSG00000239519.1	CADM2-AS1	5.27	6.38e-07	0.00094	0.47	0.44	Body mass index;	chr3:85905217	chr3:85992183~86028007:-
GBM	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-5.27	6.38e-07	0.00094	-0.64	-0.44	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
GBM	cis	rs853679	0.527	rs9461443	ENSG00000199851.2	U3	5.27	6.38e-07	0.00094	0.7	0.44	Depression;	chr6:28226851	chr6:28015568~28015777:+
GBM	cis	rs853679	0.55	rs34477097	ENSG00000199851.2	U3	5.27	6.38e-07	0.00094	0.7	0.44	Depression;	chr6:28229408	chr6:28015568~28015777:+
GBM	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-5.27	6.4e-07	0.000943	-0.57	-0.44	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
GBM	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-5.27	6.4e-07	0.000943	-0.54	-0.44	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
GBM	cis	rs67981189	0.858	rs2526862	ENSG00000269927.1	RP6-91H8.3	-5.27	6.42e-07	0.000946	-0.51	-0.44	Schizophrenia;	chr14:70942897	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.788	rs2526860	ENSG00000269927.1	RP6-91H8.3	-5.27	6.42e-07	0.000946	-0.51	-0.44	Schizophrenia;	chr14:70945161	chr14:71141125~71143253:-
GBM	cis	rs7216064	0.636	rs4638	ENSG00000278219.1	AC145343.1	5.27	6.43e-07	0.000948	0.48	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68101538~68101639:+
GBM	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-5.27	6.46e-07	0.000951	-0.52	-0.44	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
GBM	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	5.27	6.46e-07	0.000951	0.49	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
GBM	cis	rs2486288	0.656	rs1706767	ENSG00000259433.2	CTD-2651B20.4	5.27	6.47e-07	0.000953	0.48	0.44	Glomerular filtration rate;	chr15:45276901	chr15:45330209~45332634:-
GBM	cis	rs67981189	0.789	rs2810073	ENSG00000269927.1	RP6-91H8.3	-5.27	6.47e-07	0.000953	-0.52	-0.44	Schizophrenia;	chr14:70917131	chr14:71141125~71143253:-
GBM	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	5.27	6.52e-07	0.000959	0.36	0.44	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
GBM	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-5.27	6.52e-07	0.000959	-0.54	-0.44	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
GBM	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	5.27	6.53e-07	0.000961	0.71	0.44	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
GBM	cis	rs6782228	1	rs11718130	ENSG00000277250.1	Metazoa_SRP	5.27	6.54e-07	0.000962	0.55	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128673681~128674021:-
GBM	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-5.27	6.55e-07	0.000962	-0.52	-0.44	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
GBM	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-5.27	6.55e-07	0.000963	-0.52	-0.44	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
GBM	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	5.27	6.56e-07	0.000964	0.99	0.44	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
GBM	cis	rs66887589	0.616	rs11098498	ENSG00000249244.1	RP11-548H18.2	5.27	6.58e-07	0.000966	0.53	0.44	Diastolic blood pressure;	chr4:119265964	chr4:119391831~119395335:-
GBM	cis	rs6782228	0.585	rs9841161	ENSG00000277250.1	Metazoa_SRP	-5.27	6.58e-07	0.000967	-0.47	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs2712405	ENSG00000277250.1	Metazoa_SRP	-5.27	6.58e-07	0.000967	-0.47	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs9828893	ENSG00000277250.1	Metazoa_SRP	-5.27	6.58e-07	0.000967	-0.47	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128673681~128674021:-
GBM	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	5.27	6.59e-07	0.000968	0.67	0.44	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
GBM	cis	rs7267979	0.844	rs2257649	ENSG00000276952.1	RP5-965G21.6	5.26	6.64e-07	0.000974	0.4	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs2424703	ENSG00000276952.1	RP5-965G21.6	5.26	6.64e-07	0.000974	0.4	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.74	rs2259961	ENSG00000276952.1	RP5-965G21.6	5.26	6.64e-07	0.000974	0.4	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs2474780	ENSG00000276952.1	RP5-965G21.6	5.26	6.64e-07	0.000974	0.4	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.789	rs4815400	ENSG00000276952.1	RP5-965G21.6	-5.26	6.64e-07	0.000974	-0.4	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25284915~25285588:-
GBM	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-5.26	6.64e-07	0.000974	-0.46	-0.44	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
GBM	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-5.26	6.64e-07	0.000975	-0.52	-0.44	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
GBM	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	5.26	6.65e-07	0.000976	0.73	0.44	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
GBM	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	5.26	6.65e-07	0.000976	0.48	0.44	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	5.26	6.65e-07	0.000976	0.48	0.44	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
GBM	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	5.26	6.68e-07	0.00098	0.7	0.44	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
GBM	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	5.26	6.68e-07	0.00098	0.49	0.44	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
GBM	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	5.26	6.69e-07	0.00098	0.61	0.44	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
GBM	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-5.26	6.69e-07	0.000981	-0.63	-0.44	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
GBM	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	5.26	6.7e-07	0.000983	0.47	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
GBM	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	5.26	6.71e-07	0.000984	0.45	0.44	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	5.26	6.71e-07	0.000984	0.45	0.44	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
GBM	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	5.26	6.71e-07	0.000984	0.45	0.44	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
GBM	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	5.26	6.73e-07	0.000986	0.64	0.44	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
GBM	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	5.26	6.73e-07	0.000986	0.64	0.44	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
GBM	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	5.26	6.74e-07	0.000987	0.48	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
GBM	cis	rs3806843	0.868	rs2531352	ENSG00000202111.1	VTRNA1-2	5.26	6.74e-07	0.000987	0.45	0.44	Depressive symptoms (multi-trait analysis);	chr5:140739949	chr5:140718925~140719013:+
GBM	cis	rs7267979	0.903	rs6132819	ENSG00000276952.1	RP5-965G21.6	5.26	6.74e-07	0.000987	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.868	rs6107019	ENSG00000276952.1	RP5-965G21.6	5.26	6.74e-07	0.000987	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.903	rs6115109	ENSG00000276952.1	RP5-965G21.6	5.26	6.74e-07	0.000987	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.833	rs4619688	ENSG00000276952.1	RP5-965G21.6	5.26	6.74e-07	0.000987	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25284915~25285588:-
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	5.26	6.75e-07	0.000989	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
GBM	cis	rs17214007	0.877	rs10852376	ENSG00000279866.1	CTB-193M12.4	-5.26	6.76e-07	0.00099	-0.56	-0.44	Cognitive function;	chr16:15778216	chr16:15704410~15705984:+
GBM	cis	rs17214007	0.877	rs1569300	ENSG00000279866.1	CTB-193M12.4	5.26	6.76e-07	0.00099	0.56	0.44	Cognitive function;	chr16:15776891	chr16:15704410~15705984:+
GBM	cis	rs17214007	0.877	rs4482303	ENSG00000279866.1	CTB-193M12.4	5.26	6.76e-07	0.00099	0.56	0.44	Cognitive function;	chr16:15777020	chr16:15704410~15705984:+
GBM	cis	rs17214007	0.877	rs2075515	ENSG00000279866.1	CTB-193M12.4	5.26	6.76e-07	0.00099	0.56	0.44	Cognitive function;	chr16:15778462	chr16:15704410~15705984:+
GBM	cis	rs3096299	0.838	rs3102376	ENSG00000260259.1	RP11-368I7.4	5.26	6.76e-07	0.00099	0.48	0.44	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89682620~89686569:-
GBM	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-5.26	6.77e-07	0.00099	-0.53	-0.44	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
GBM	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	5.26	6.77e-07	0.00099	0.5	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
GBM	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	5.26	6.77e-07	0.000991	0.58	0.44	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	5.26	6.77e-07	0.000991	0.58	0.44	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
GBM	cis	rs7267979	0.844	rs35735333	ENSG00000276952.1	RP5-965G21.6	-5.26	6.78e-07	0.000991	-0.4	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs4815413	ENSG00000276952.1	RP5-965G21.6	-5.26	6.78e-07	0.000991	-0.4	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs6083824	ENSG00000276952.1	RP5-965G21.6	-5.26	6.78e-07	0.000991	-0.4	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs869358	ENSG00000276952.1	RP5-965G21.6	-5.26	6.78e-07	0.000991	-0.4	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs6076343	ENSG00000276952.1	RP5-965G21.6	-5.26	6.78e-07	0.000991	-0.4	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25284915~25285588:-
GBM	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	5.26	6.79e-07	0.000993	0.71	0.44	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
GBM	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	5.26	6.8e-07	0.000995	0.58	0.44	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	5.26	6.8e-07	0.000995	0.58	0.44	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
GBM	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-5.26	6.8e-07	0.000995	-0.55	-0.44	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
GBM	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-5.26	6.8e-07	0.000995	-0.55	-0.44	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
GBM	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-5.26	6.8e-07	0.000995	-0.55	-0.44	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
GBM	cis	rs6782228	1	rs7429360	ENSG00000277250.1	Metazoa_SRP	5.26	6.8e-07	0.000995	0.55	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128673681~128674021:-
GBM	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-5.26	6.83e-07	0.000998	-0.49	-0.44	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
GBM	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	5.26	6.84e-07	0.000999	0.66	0.44	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	5.26	6.84e-07	0.000999	0.66	0.44	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	5.26	6.84e-07	0.000999	0.66	0.44	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
GBM	cis	rs7267979	1	rs2500448	ENSG00000276952.1	RP5-965G21.6	-5.26	6.85e-07	0.001	-0.41	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25284915~25285588:-
GBM	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-5.26	6.86e-07	0.001	-0.58	-0.44	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
GBM	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	5.26	6.86e-07	0.001	0.47	0.44	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
GBM	cis	rs2013441	0.866	rs2703811	ENSG00000230528.6	NOS2P3	5.26	6.87e-07	0.001	0.51	0.44	Obesity-related traits;	chr17:20210662	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.866	rs9898295	ENSG00000230528.6	NOS2P3	5.26	6.87e-07	0.001	0.51	0.44	Obesity-related traits;	chr17:20217281	chr17:20436337~20447249:+
GBM	cis	rs17772222	0.638	rs11629164	ENSG00000258983.2	RP11-507K2.2	-5.26	6.87e-07	0.001	-0.46	-0.44	Coronary artery calcification;	chr14:88564740	chr14:88499334~88515502:+
GBM	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-5.26	6.89e-07	0.00101	-0.47	-0.44	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
GBM	cis	rs12495178	0.574	rs4464472	ENSG00000239519.1	CADM2-AS1	5.26	6.89e-07	0.00101	0.47	0.44	Body mass index;	chr3:85909398	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.536	rs34420989	ENSG00000239519.1	CADM2-AS1	5.26	6.89e-07	0.00101	0.47	0.44	Body mass index;	chr3:85914328	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.562	rs12489145	ENSG00000239519.1	CADM2-AS1	5.26	6.89e-07	0.00101	0.47	0.44	Body mass index;	chr3:85923462	chr3:85992183~86028007:-
GBM	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	5.25	6.9e-07	0.00101	0.53	0.44	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	5.25	6.93e-07	0.00101	0.54	0.44	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
GBM	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	5.25	6.94e-07	0.00101	0.58	0.44	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
GBM	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	5.25	6.95e-07	0.00101	0.98	0.44	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
GBM	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	5.25	6.95e-07	0.00101	0.51	0.44	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
GBM	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-5.25	6.96e-07	0.00101	-0.54	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-5.25	6.96e-07	0.00101	-0.54	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-5.25	6.96e-07	0.00101	-0.54	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-5.25	6.96e-07	0.00101	-0.54	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
GBM	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	5.25	6.97e-07	0.00102	0.66	0.44	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
GBM	cis	rs67981189	0.57	rs67188216	ENSG00000269927.1	RP6-91H8.3	5.25	6.98e-07	0.00102	0.52	0.44	Schizophrenia;	chr14:71042607	chr14:71141125~71143253:-
GBM	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	5.25	6.98e-07	0.00102	0.44	0.44	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	5.25	6.98e-07	0.00102	0.44	0.44	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
GBM	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	5.25	6.99e-07	0.00102	1	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
GBM	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	5.25	7e-07	0.00102	0.85	0.44	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	5.25	7e-07	0.00102	0.85	0.44	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	5.25	7e-07	0.00102	0.85	0.44	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
GBM	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-5.25	7e-07	0.00102	-0.64	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
GBM	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	5.25	7.03e-07	0.00102	0.52	0.44	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
GBM	cis	rs12460587	0.568	rs8113376	ENSG00000275055.1	CTC-471J1.11	-5.25	7.03e-07	0.00102	-0.53	-0.44	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52090170	chr19:52049007~52049754:+
GBM	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	5.25	7.04e-07	0.00103	0.52	0.44	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
GBM	cis	rs11098499	0.663	rs9996501	ENSG00000250412.1	KLHL2P1	5.25	7.06e-07	0.00103	0.57	0.44	Corneal astigmatism;	chr4:119317763	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.697	rs28458294	ENSG00000250412.1	KLHL2P1	5.25	7.06e-07	0.00103	0.57	0.44	Corneal astigmatism;	chr4:119317769	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.663	rs28369503	ENSG00000250412.1	KLHL2P1	5.25	7.06e-07	0.00103	0.57	0.44	Corneal astigmatism;	chr4:119317770	chr4:119334329~119378233:+
GBM	cis	rs4713118	0.505	rs156740	ENSG00000199851.2	U3	5.25	7.07e-07	0.00103	0.55	0.44	Parkinson's disease;	chr6:27992657	chr6:28015568~28015777:+
GBM	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-5.25	7.07e-07	0.00103	-0.48	-0.44	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
GBM	cis	rs3096299	0.967	rs2911257	ENSG00000260259.1	RP11-368I7.4	5.25	7.08e-07	0.00103	0.47	0.44	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89682620~89686569:-
GBM	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	5.25	7.09e-07	0.00103	0.57	0.44	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
GBM	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	5.25	7.1e-07	0.00103	0.61	0.44	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
GBM	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	5.25	7.1e-07	0.00103	0.53	0.44	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	5.25	7.1e-07	0.00103	0.53	0.44	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	5.25	7.1e-07	0.00103	0.53	0.44	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
GBM	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	5.25	7.12e-07	0.00103	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
GBM	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	5.25	7.12e-07	0.00104	0.71	0.44	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
GBM	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	5.25	7.16e-07	0.00104	0.44	0.44	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
GBM	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	5.25	7.18e-07	0.00104	0.49	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
GBM	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	5.25	7.18e-07	0.00104	0.57	0.44	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
GBM	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-5.25	7.2e-07	0.00105	-0.57	-0.44	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-5.25	7.2e-07	0.00105	-0.57	-0.44	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
GBM	cis	rs12216125	0.537	rs12207059	ENSG00000272810.1	U91328.22	-5.24	7.2e-07	0.00105	-0.66	-0.44	Iron status biomarkers;	chr6:25922157	chr6:26013241~26013757:+
GBM	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-5.24	7.22e-07	0.00105	-0.58	-0.44	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
GBM	cis	rs2013441	1	rs2703799	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20182455	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526460	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20183039	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2243732	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20185276	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526458	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20188887	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.965	rs2386485	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20191933	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2526490	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20194213	chr17:20436337~20447249:+
GBM	cis	rs2013441	0.932	rs2526488	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20195304	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703801	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20197287	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2703802	ENSG00000230528.6	NOS2P3	5.24	7.23e-07	0.00105	0.49	0.44	Obesity-related traits;	chr17:20197726	chr17:20436337~20447249:+
GBM	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-5.24	7.25e-07	0.00105	-0.58	-0.44	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
GBM	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-5.24	7.27e-07	0.00105	-0.49	-0.44	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
GBM	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-5.24	7.27e-07	0.00105	-0.49	-0.44	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
GBM	cis	rs7017914	0.667	rs13262350	ENSG00000246366.5	RP11-382J12.1	-5.24	7.29e-07	0.00106	-0.49	-0.44	Bone mineral density;	chr8:71069371	chr8:70608577~70663279:+
GBM	cis	rs6782228	1	rs6801509	ENSG00000277250.1	Metazoa_SRP	5.24	7.32e-07	0.00106	0.55	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128673681~128674021:-
GBM	cis	rs453301	0.574	rs10081437	ENSG00000253893.2	FAM85B	5.24	7.32e-07	0.00106	0.5	0.44	Joint mobility (Beighton score);	chr8:9091469	chr8:8167819~8226614:-
GBM	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	5.24	7.33e-07	0.00106	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	5.24	7.33e-07	0.00106	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
GBM	cis	rs10946940	0.965	rs62401383	ENSG00000218016.2	ZNF192P2	5.24	7.34e-07	0.00106	0.52	0.44	Systemic lupus erythematosus;	chr6:27596768	chr6:28188050~28189432:+
GBM	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-5.24	7.34e-07	0.00106	-0.53	-0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
GBM	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	5.24	7.34e-07	0.00106	0.54	0.44	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
GBM	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	5.24	7.34e-07	0.00106	0.52	0.44	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
GBM	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-5.24	7.35e-07	0.00106	-0.65	-0.44	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
GBM	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	5.24	7.35e-07	0.00106	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
GBM	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-5.24	7.35e-07	0.00106	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
GBM	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	5.24	7.36e-07	0.00107	0.45	0.44	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
GBM	cis	rs7927592	0.513	rs901823	ENSG00000212093.1	AP000807.1	5.24	7.37e-07	0.00107	0.5	0.44	Total body bone mineral density;	chr11:68438110	chr11:68506083~68506166:-
GBM	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-5.24	7.39e-07	0.00107	-0.45	-0.44	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
GBM	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-5.24	7.39e-07	0.00107	-0.45	-0.44	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
GBM	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-5.24	7.39e-07	0.00107	-0.58	-0.44	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
GBM	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	5.24	7.4e-07	0.00107	0.54	0.44	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
GBM	cis	rs1420956	0.543	rs12455678	ENSG00000264151.4	RP11-739N10.1	5.24	7.4e-07	0.00107	0.59	0.44	Obesity-related traits;	chr18:27611276	chr18:27336379~27595164:-
GBM	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	5.24	7.42e-07	0.00107	0.51	0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
GBM	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	5.24	7.43e-07	0.00107	0.44	0.44	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
GBM	cis	rs3806843	0.75	rs2563285	ENSG00000202111.1	VTRNA1-2	5.24	7.43e-07	0.00107	0.45	0.44	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr5:140718925~140719013:+
GBM	cis	rs66887589	0.72	rs11724758	ENSG00000249244.1	RP11-548H18.2	5.24	7.43e-07	0.00107	0.52	0.44	Diastolic blood pressure;	chr4:119318723	chr4:119391831~119395335:-
GBM	cis	rs66887589	0.72	rs2036858	ENSG00000249244.1	RP11-548H18.2	5.24	7.43e-07	0.00107	0.52	0.44	Diastolic blood pressure;	chr4:119328082	chr4:119391831~119395335:-
GBM	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	5.24	7.46e-07	0.00108	0.52	0.44	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
GBM	cis	rs7267979	1	rs2500432	ENSG00000276952.1	RP5-965G21.6	5.24	7.46e-07	0.00108	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25284915~25285588:-
GBM	cis	rs4072705	1	rs4524900	ENSG00000224020.1	MIR181A2HG	-5.24	7.46e-07	0.00108	-0.48	-0.44	Menarche (age at onset);	chr9:124580930	chr9:124658467~124698631:+
GBM	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	5.24	7.49e-07	0.00108	0.5	0.44	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
GBM	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-5.24	7.5e-07	0.00108	-0.53	-0.44	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	5.24	7.5e-07	0.00108	0.53	0.44	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
GBM	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-5.24	7.5e-07	0.00108	-0.47	-0.44	Height;	chr11:118781100	chr11:118791254~118793137:+
GBM	cis	rs4072705	1	rs4240487	ENSG00000224020.1	MIR181A2HG	-5.24	7.51e-07	0.00108	-0.48	-0.44	Menarche (age at onset);	chr9:124608028	chr9:124658467~124698631:+
GBM	cis	rs7267979	0.903	rs2474766	ENSG00000125804.12	FAM182A	-5.24	7.51e-07	0.00108	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:26054655~26086917:+
GBM	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-5.24	7.52e-07	0.00109	-0.53	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-5.24	7.52e-07	0.00109	-0.53	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-5.24	7.52e-07	0.00109	-0.53	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
GBM	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	5.23	7.55e-07	0.00109	0.5	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
GBM	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	5.23	7.55e-07	0.00109	0.5	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
GBM	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	5.23	7.55e-07	0.00109	0.5	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
GBM	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	5.23	7.55e-07	0.00109	0.48	0.44	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
GBM	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-5.23	7.55e-07	0.00109	-0.56	-0.44	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
GBM	cis	rs4683346	0.752	rs7647523	ENSG00000273328.4	RP11-141M3.6	-5.23	7.57e-07	0.00109	-0.46	-0.44	Granulocyte percentage of myeloid white cells;	chr3:42845563	chr3:42809414~42908105:+
GBM	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	5.23	7.59e-07	0.0011	0.53	0.44	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
GBM	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	5.23	7.59e-07	0.0011	0.53	0.44	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
GBM	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	5.23	7.62e-07	0.0011	0.56	0.44	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
GBM	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	5.23	7.63e-07	0.0011	0.51	0.44	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
GBM	cis	rs9637599	0.513	rs7678928	ENSG00000246375.2	RP11-10L7.1	-5.23	7.63e-07	0.0011	-0.46	-0.44	Metabolite levels (small molecules and protein measures);	chr4:88301675	chr4:88284942~88331421:+
GBM	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	5.23	7.63e-07	0.0011	0.43	0.44	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	5.23	7.63e-07	0.0011	0.43	0.44	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
GBM	cis	rs5742933	0.75	rs10197331	ENSG00000253559.1	OSGEPL1-AS1	5.23	7.64e-07	0.0011	0.47	0.44	Ferritin levels;	chr2:189768112	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.817	rs1055091	ENSG00000253559.1	OSGEPL1-AS1	5.23	7.64e-07	0.0011	0.47	0.44	Ferritin levels;	chr2:189770417	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.817	rs6942	ENSG00000253559.1	OSGEPL1-AS1	5.23	7.64e-07	0.0011	0.47	0.44	Ferritin levels;	chr2:189771685	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.817	rs3816196	ENSG00000253559.1	OSGEPL1-AS1	5.23	7.64e-07	0.0011	0.47	0.44	Ferritin levels;	chr2:189775749	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.817	rs6738042	ENSG00000253559.1	OSGEPL1-AS1	5.23	7.64e-07	0.0011	0.47	0.44	Ferritin levels;	chr2:189776958	chr2:189762704~189765556:+
GBM	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	5.23	7.65e-07	0.0011	0.54	0.44	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
GBM	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-5.23	7.66e-07	0.0011	-0.46	-0.44	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
GBM	cis	rs3096299	0.967	rs2911256	ENSG00000260259.1	RP11-368I7.4	5.23	7.67e-07	0.0011	0.47	0.44	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89682620~89686569:-
GBM	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	5.23	7.67e-07	0.0011	0.44	0.44	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
GBM	cis	rs4072705	1	rs4836981	ENSG00000224020.1	MIR181A2HG	-5.23	7.68e-07	0.0011	-0.49	-0.44	Menarche (age at onset);	chr9:124577866	chr9:124658467~124698631:+
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000235689.1	AP000351.13	-5.23	7.69e-07	0.00111	-0.54	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:24006305~24008258:-
GBM	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	5.23	7.7e-07	0.00111	0.48	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
GBM	cis	rs7017914	0.559	rs12056347	ENSG00000246366.5	RP11-382J12.1	-5.23	7.75e-07	0.00111	-0.48	-0.44	Bone mineral density;	chr8:71072374	chr8:70608577~70663279:+
GBM	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-5.23	7.78e-07	0.00112	-0.58	-0.44	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
GBM	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	5.23	7.85e-07	0.00113	0.45	0.44	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
GBM	cis	rs6583331	1	rs6583331	ENSG00000273013.1	CTD-2002J20.1	-5.23	7.86e-07	0.00113	-0.47	-0.44	Vitiligo;	chr3:196620382	chr3:196474801~196475394:+
GBM	cis	rs6583331	1	rs34088166	ENSG00000273013.1	CTD-2002J20.1	-5.23	7.86e-07	0.00113	-0.47	-0.44	Vitiligo;	chr3:196620833	chr3:196474801~196475394:+
GBM	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-5.23	7.86e-07	0.00113	-0.56	-0.44	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
GBM	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-5.22	7.87e-07	0.00113	-0.55	-0.44	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
GBM	cis	rs860818	1	rs858298	ENSG00000226816.2	AC005082.12	5.22	7.87e-07	0.00113	1.18	0.44	Initial pursuit acceleration;	chr7:23205301	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858297	ENSG00000226816.2	AC005082.12	5.22	7.87e-07	0.00113	1.18	0.44	Initial pursuit acceleration;	chr7:23205342	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858296	ENSG00000226816.2	AC005082.12	5.22	7.87e-07	0.00113	1.18	0.44	Initial pursuit acceleration;	chr7:23205929	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858293	ENSG00000226816.2	AC005082.12	5.22	7.87e-07	0.00113	1.18	0.44	Initial pursuit acceleration;	chr7:23206705	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858292	ENSG00000226816.2	AC005082.12	5.22	7.87e-07	0.00113	1.18	0.44	Initial pursuit acceleration;	chr7:23207114	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858291	ENSG00000226816.2	AC005082.12	5.22	7.87e-07	0.00113	1.18	0.44	Initial pursuit acceleration;	chr7:23207742	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858285	ENSG00000226816.2	AC005082.12	5.22	7.87e-07	0.00113	1.18	0.44	Initial pursuit acceleration;	chr7:23209899	chr7:23206013~23208045:+
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000235689.1	AP000351.13	-5.22	7.89e-07	0.00113	-0.55	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:24006305~24008258:-
GBM	cis	rs3806843	0.838	rs2563289	ENSG00000202111.1	VTRNA1-2	5.22	7.9e-07	0.00113	0.45	0.44	Depressive symptoms (multi-trait analysis);	chr5:140743181	chr5:140718925~140719013:+
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000224205.1	AP000351.4	-5.22	7.92e-07	0.00114	-0.54	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23987320~23991421:-
GBM	cis	rs12495178	0.574	rs56760958	ENSG00000239519.1	CADM2-AS1	5.22	7.95e-07	0.00114	0.47	0.44	Body mass index;	chr3:85933988	chr3:85992183~86028007:-
GBM	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	5.22	7.95e-07	0.00114	0.66	0.44	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
GBM	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	5.22	7.95e-07	0.00114	0.77	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
GBM	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-5.22	7.97e-07	0.00114	-0.66	-0.44	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
GBM	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-5.22	7.98e-07	0.00114	-0.53	-0.44	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
GBM	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	5.22	7.98e-07	0.00114	0.84	0.44	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	5.22	7.98e-07	0.00114	0.84	0.44	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
GBM	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	5.22	7.99e-07	0.00114	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	5.22	7.99e-07	0.00114	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	5.22	7.99e-07	0.00114	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
GBM	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	5.22	8e-07	0.00115	0.48	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
GBM	cis	rs4683346	0.752	rs2114883	ENSG00000273328.4	RP11-141M3.6	-5.22	8.02e-07	0.00115	-0.46	-0.44	Granulocyte percentage of myeloid white cells;	chr3:42841176	chr3:42809414~42908105:+
GBM	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	5.22	8.02e-07	0.00115	0.65	0.44	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
GBM	cis	rs7017914	0.667	rs1481801	ENSG00000246366.5	RP11-382J12.1	-5.22	8.05e-07	0.00115	-0.48	-0.44	Bone mineral density;	chr8:71077484	chr8:70608577~70663279:+
GBM	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-5.22	8.07e-07	0.00115	-0.66	-0.44	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
GBM	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-5.22	8.08e-07	0.00115	-0.5	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-5.22	8.08e-07	0.00115	-0.5	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
GBM	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-5.22	8.09e-07	0.00116	-0.61	-0.44	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
GBM	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-5.22	8.09e-07	0.00116	-0.61	-0.44	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-5.22	8.09e-07	0.00116	-0.61	-0.44	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
GBM	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	5.22	8.09e-07	0.00116	0.61	0.44	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
GBM	cis	rs10946940	0.93	rs10807029	ENSG00000218016.2	ZNF192P2	5.22	8.13e-07	0.00116	0.52	0.44	Systemic lupus erythematosus;	chr6:27605684	chr6:28188050~28189432:+
GBM	cis	rs10946940	0.965	rs6921256	ENSG00000218016.2	ZNF192P2	-5.22	8.13e-07	0.00116	-0.52	-0.44	Systemic lupus erythematosus;	chr6:27619739	chr6:28188050~28189432:+
GBM	cis	rs17685	0.702	rs6960598	ENSG00000280388.1	RP11-229D13.3	-5.22	8.14e-07	0.00116	-0.41	-0.44	Coffee consumption (cups per day);Coffee consumption;	chr7:76143673	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs10235738	ENSG00000280388.1	RP11-229D13.3	-5.22	8.14e-07	0.00116	-0.41	-0.44	Coffee consumption (cups per day);Coffee consumption;	chr7:76144142	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs6953342	ENSG00000280388.1	RP11-229D13.3	-5.22	8.14e-07	0.00116	-0.41	-0.44	Coffee consumption (cups per day);Coffee consumption;	chr7:76147435	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs10952842	ENSG00000280388.1	RP11-229D13.3	-5.22	8.14e-07	0.00116	-0.41	-0.44	Coffee consumption (cups per day);Coffee consumption;	chr7:76151095	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs6464994	ENSG00000280388.1	RP11-229D13.3	-5.22	8.14e-07	0.00116	-0.41	-0.44	Coffee consumption (cups per day);Coffee consumption;	chr7:76155350	chr7:76043977~76045963:-
GBM	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	5.22	8.14e-07	0.00116	0.35	0.44	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
GBM	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-5.22	8.16e-07	0.00116	-0.46	-0.44	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
GBM	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	5.22	8.16e-07	0.00116	0.46	0.44	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
GBM	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	5.22	8.16e-07	0.00116	0.46	0.44	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
GBM	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-5.22	8.21e-07	0.00117	-0.57	-0.44	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-5.22	8.21e-07	0.00117	-0.57	-0.44	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
GBM	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	5.21	8.22e-07	0.00117	0.52	0.44	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
GBM	cis	rs11159086	0.793	rs10139122	ENSG00000270000.1	RP3-449M8.9	5.21	8.23e-07	0.00117	0.67	0.44	Advanced glycation end-product levels;	chr14:74492353	chr14:74471930~74472360:-
GBM	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	5.21	8.23e-07	0.00117	0.77	0.44	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
GBM	cis	rs7216064	0.684	rs62084675	ENSG00000278219.1	AC145343.1	5.21	8.23e-07	0.00117	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.531	rs62084683	ENSG00000278219.1	AC145343.1	5.21	8.23e-07	0.00117	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.655	rs8078543	ENSG00000278219.1	AC145343.1	5.21	8.23e-07	0.00117	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.636	rs62084696	ENSG00000278219.1	AC145343.1	5.21	8.23e-07	0.00117	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.601	rs35453056	ENSG00000278219.1	AC145343.1	5.21	8.23e-07	0.00117	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.628	rs62084702	ENSG00000278219.1	AC145343.1	5.21	8.23e-07	0.00117	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68101538~68101639:+
GBM	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	5.21	8.23e-07	0.00117	0.57	0.44	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
GBM	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	5.21	8.26e-07	0.00118	0.53	0.44	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	5.21	8.26e-07	0.00118	0.53	0.44	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
GBM	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-5.21	8.27e-07	0.00118	-0.57	-0.44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
GBM	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-5.21	8.3e-07	0.00118	-0.59	-0.44	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
GBM	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-5.21	8.3e-07	0.00118	-0.59	-0.44	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
GBM	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-5.21	8.3e-07	0.00118	-0.59	-0.44	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
GBM	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-5.21	8.3e-07	0.00118	-0.59	-0.44	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
GBM	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-5.21	8.3e-07	0.00118	-0.45	-0.44	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
GBM	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-5.21	8.3e-07	0.00118	-0.45	-0.44	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
GBM	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-5.21	8.3e-07	0.00118	-0.45	-0.44	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
GBM	cis	rs7216064	0.684	rs7406031	ENSG00000278219.1	AC145343.1	5.21	8.3e-07	0.00118	0.47	0.44	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68101538~68101639:+
GBM	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-5.21	8.31e-07	0.00118	-0.69	-0.44	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
GBM	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-5.21	8.31e-07	0.00118	-0.38	-0.44	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
GBM	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-5.21	8.31e-07	0.00118	-0.49	-0.44	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-5.21	8.31e-07	0.00118	-0.49	-0.44	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
GBM	cis	rs7267979	0.789	rs9927	ENSG00000125804.12	FAM182A	-5.21	8.32e-07	0.00118	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:26054655~26086917:+
GBM	cis	rs4072705	1	rs4072705	ENSG00000224020.1	MIR181A2HG	-5.21	8.34e-07	0.00119	-0.48	-0.44	Menarche (age at onset);	chr9:124611184	chr9:124658467~124698631:+
GBM	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	5.21	8.36e-07	0.00119	0.53	0.44	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	5.21	8.36e-07	0.00119	0.53	0.44	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
GBM	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	5.21	8.39e-07	0.00119	0.5	0.44	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
GBM	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-5.21	8.42e-07	0.0012	-0.57	-0.44	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
GBM	cis	rs3806843	0.9	rs2563287	ENSG00000202111.1	VTRNA1-2	-5.21	8.43e-07	0.0012	-0.44	-0.44	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr5:140718925~140719013:+
GBM	cis	rs12495178	0.626	rs12491363	ENSG00000239519.1	CADM2-AS1	-5.21	8.44e-07	0.0012	-0.46	-0.44	Body mass index;	chr3:85971319	chr3:85992183~86028007:-
GBM	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	5.21	8.46e-07	0.0012	0.3	0.44	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	5.21	8.46e-07	0.0012	0.3	0.44	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
GBM	cis	rs7267979	1	rs2424700	ENSG00000276952.1	RP5-965G21.6	5.21	8.49e-07	0.0012	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.868	rs6138546	ENSG00000125804.12	FAM182A	-5.21	8.49e-07	0.0012	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.868	rs6138550	ENSG00000125804.12	FAM182A	-5.21	8.49e-07	0.0012	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.903	rs6050481	ENSG00000125804.12	FAM182A	-5.21	8.49e-07	0.0012	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.834	rs6115100	ENSG00000125804.12	FAM182A	-5.21	8.49e-07	0.0012	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:26054655~26086917:+
GBM	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	5.21	8.51e-07	0.00121	0.53	0.44	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
GBM	cis	rs2013441	1	rs17759959	ENSG00000230528.6	NOS2P3	-5.21	8.54e-07	0.00121	-0.5	-0.44	Obesity-related traits;	chr17:20120782	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs12451216	ENSG00000230528.6	NOS2P3	-5.21	8.54e-07	0.00121	-0.5	-0.44	Obesity-related traits;	chr17:20122527	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs972966	ENSG00000230528.6	NOS2P3	-5.21	8.54e-07	0.00121	-0.5	-0.44	Obesity-related traits;	chr17:20127679	chr17:20436337~20447249:+
GBM	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	5.21	8.55e-07	0.00121	0.65	0.44	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
GBM	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
GBM	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-5.21	8.55e-07	0.00121	-0.65	-0.44	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
GBM	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-5.21	8.55e-07	0.00121	-0.55	-0.44	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
GBM	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-5.2	8.58e-07	0.00121	-0.49	-0.44	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
GBM	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-5.2	8.58e-07	0.00121	-0.45	-0.44	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
GBM	cis	rs2976388	0.647	rs1048831	ENSG00000253741.1	CTD-2292P10.4	-5.2	8.59e-07	0.00122	-0.45	-0.44	Urinary tract infection frequency;	chr8:142700440	chr8:142702252~142726973:-
GBM	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-5.2	8.59e-07	0.00122	-0.5	-0.44	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
GBM	cis	rs10946940	0.965	rs6456799	ENSG00000218016.2	ZNF192P2	5.2	8.6e-07	0.00122	0.52	0.44	Systemic lupus erythematosus;	chr6:27605757	chr6:28188050~28189432:+
GBM	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-5.2	8.61e-07	0.00122	-0.66	-0.44	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
GBM	cis	rs67981189	0.574	rs2526867	ENSG00000269927.1	RP6-91H8.3	-5.2	8.63e-07	0.00122	-0.5	-0.44	Schizophrenia;	chr14:70929249	chr14:71141125~71143253:-
GBM	cis	rs7267979	0.903	rs6132819	ENSG00000125804.12	FAM182A	-5.2	8.64e-07	0.00122	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.868	rs6107019	ENSG00000125804.12	FAM182A	-5.2	8.64e-07	0.00122	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.903	rs6115109	ENSG00000125804.12	FAM182A	-5.2	8.64e-07	0.00122	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.833	rs4619688	ENSG00000125804.12	FAM182A	-5.2	8.64e-07	0.00122	-0.55	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:26054655~26086917:+
GBM	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	5.2	8.66e-07	0.00122	0.58	0.44	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
GBM	cis	rs12495178	0.574	rs4600827	ENSG00000239519.1	CADM2-AS1	5.2	8.68e-07	0.00123	0.46	0.44	Body mass index;	chr3:85909234	chr3:85992183~86028007:-
GBM	cis	rs67981189	0.896	rs17108804	ENSG00000269927.1	RP6-91H8.3	-5.2	8.68e-07	0.00123	-0.5	-0.44	Schizophrenia;	chr14:70974807	chr14:71141125~71143253:-
GBM	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-5.2	8.69e-07	0.00123	-0.47	-0.44	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
GBM	cis	rs4664293	0.867	rs7579206	ENSG00000226266.5	AC009961.3	-5.2	8.71e-07	0.00123	-0.54	-0.44	Monocyte percentage of white cells;	chr2:159715992	chr2:159670708~159712435:-
GBM	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	5.2	8.72e-07	0.00123	0.51	0.44	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	5.2	8.72e-07	0.00123	0.51	0.44	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	5.2	8.72e-07	0.00123	0.51	0.44	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
GBM	cis	rs6782228	0.606	rs4857861	ENSG00000277250.1	Metazoa_SRP	-5.2	8.72e-07	0.00123	-0.47	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs4857919	ENSG00000277250.1	Metazoa_SRP	-5.2	8.72e-07	0.00123	-0.47	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128673681~128674021:-
GBM	cis	rs7267979	1	rs2257991	ENSG00000276952.1	RP5-965G21.6	-5.2	8.72e-07	0.00123	-0.42	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25284915~25285588:-
GBM	cis	rs2976388	0.692	rs2585175	ENSG00000253741.1	CTD-2292P10.4	-5.2	8.72e-07	0.00123	-0.45	-0.44	Urinary tract infection frequency;	chr8:142699871	chr8:142702252~142726973:-
GBM	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	5.2	8.73e-07	0.00123	0.41	0.44	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
GBM	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	5.2	8.75e-07	0.00123	0.51	0.44	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
GBM	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	5.2	8.76e-07	0.00124	0.38	0.44	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
GBM	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-5.2	8.79e-07	0.00124	-0.48	-0.44	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
GBM	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-5.2	8.79e-07	0.00124	-0.48	-0.44	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
GBM	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	5.2	8.82e-07	0.00124	0.56	0.44	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
GBM	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	5.2	8.83e-07	0.00124	0.53	0.44	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
GBM	cis	rs12931792	0.687	rs8057425	ENSG00000183604.13	SMG1P5	5.2	8.84e-07	0.00125	0.52	0.44	Tonsillectomy;	chr16:30171220	chr16:30267553~30335374:-
GBM	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-5.2	8.88e-07	0.00125	-0.56	-0.44	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
GBM	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-5.2	8.88e-07	0.00125	-0.56	-0.44	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
GBM	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	5.2	8.88e-07	0.00125	0.55	0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
GBM	cis	rs4072705	1	rs4838206	ENSG00000224020.1	MIR181A2HG	-5.2	8.89e-07	0.00125	-0.48	-0.44	Menarche (age at onset);	chr9:124749645	chr9:124658467~124698631:+
GBM	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-5.2	8.9e-07	0.00125	-0.59	-0.44	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
GBM	cis	rs7267979	0.844	rs6083845	ENSG00000276952.1	RP5-965G21.6	-5.2	8.9e-07	0.00125	-0.39	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs6083851	ENSG00000276952.1	RP5-965G21.6	-5.2	8.9e-07	0.00125	-0.39	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs4423675	ENSG00000276952.1	RP5-965G21.6	-5.2	8.9e-07	0.00125	-0.39	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25284915~25285588:-
GBM	cis	rs12495178	0.574	rs9860792	ENSG00000239519.1	CADM2-AS1	5.2	8.9e-07	0.00125	0.47	0.44	Body mass index;	chr3:85900539	chr3:85992183~86028007:-
GBM	cis	rs6782228	0.606	rs2712404	ENSG00000277250.1	Metazoa_SRP	5.2	8.91e-07	0.00126	0.47	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128673681~128674021:-
GBM	cis	rs7267979	0.903	rs2474766	ENSG00000276952.1	RP5-965G21.6	5.19	8.96e-07	0.00126	0.41	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25284915~25285588:-
GBM	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-5.19	8.97e-07	0.00126	-0.45	-0.44	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
GBM	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	5.19	9.01e-07	0.00127	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
GBM	cis	rs741668	0.931	rs17428874	ENSG00000235903.6	CPB2-AS1	5.19	9.02e-07	0.00127	0.62	0.44	Cerebrospinal fluid clusterin levels;	chr13:45955427	chr13:46052806~46113332:+
GBM	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	5.19	9.03e-07	0.00127	0.69	0.44	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	5.19	9.03e-07	0.00127	0.69	0.44	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	5.19	9.03e-07	0.00127	0.69	0.44	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	5.19	9.03e-07	0.00127	0.69	0.44	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-5.19	9.03e-07	0.00127	-0.69	-0.44	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	5.19	9.03e-07	0.00127	0.51	0.44	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
GBM	cis	rs9876781	1	rs6442118	ENSG00000244380.1	RP11-24C3.2	5.19	9.05e-07	0.00127	0.49	0.44	Longevity;	chr3:48398582	chr3:48440352~48446656:-
GBM	cis	rs8062405	0.72	rs9926245	ENSG00000271623.1	RP11-435I10.5	-5.19	9.06e-07	0.00127	-0.5	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28364700~28365333:+
GBM	cis	rs2729354	0.681	rs3851117	ENSG00000265566.2	RN7SL605P	5.19	9.1e-07	0.00128	0.69	0.44	Blood protein levels;	chr11:57469640	chr11:57528085~57528365:-
GBM	cis	rs67981189	0.896	rs3814871	ENSG00000269927.1	RP6-91H8.3	5.19	9.14e-07	0.00128	0.5	0.44	Schizophrenia;	chr14:70978071	chr14:71141125~71143253:-
GBM	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	5.19	9.14e-07	0.00128	0.61	0.44	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
GBM	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	5.19	9.15e-07	0.00129	0.52	0.44	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
GBM	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-5.19	9.17e-07	0.00129	-0.5	-0.44	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
GBM	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-5.19	9.17e-07	0.00129	-0.5	-0.44	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
GBM	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-5.19	9.17e-07	0.00129	-0.5	-0.44	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
GBM	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	5.19	9.18e-07	0.00129	0.52	0.44	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	5.19	9.18e-07	0.00129	0.52	0.44	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	5.19	9.18e-07	0.00129	0.52	0.44	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	5.19	9.18e-07	0.00129	0.52	0.44	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	5.19	9.18e-07	0.00129	0.52	0.44	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
GBM	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	5.19	9.2e-07	0.00129	0.56	0.44	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
GBM	cis	rs9876781	1	rs7651407	ENSG00000244380.1	RP11-24C3.2	5.19	9.24e-07	0.0013	0.49	0.44	Longevity;	chr3:48402409	chr3:48440352~48446656:-
GBM	cis	rs5742933	0.857	rs12471217	ENSG00000253559.1	OSGEPL1-AS1	5.19	9.24e-07	0.0013	0.47	0.44	Ferritin levels;	chr2:189707337	chr2:189762704~189765556:+
GBM	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-5.19	9.26e-07	0.0013	-0.53	-0.44	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
GBM	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	5.19	9.3e-07	0.0013	0.57	0.44	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
GBM	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	5.19	9.32e-07	0.00131	0.55	0.44	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	5.19	9.32e-07	0.00131	0.55	0.44	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	5.19	9.32e-07	0.00131	0.55	0.44	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	5.19	9.32e-07	0.00131	0.55	0.44	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	5.19	9.32e-07	0.00131	0.55	0.44	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	5.19	9.32e-07	0.00131	0.55	0.44	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	5.19	9.32e-07	0.00131	0.55	0.44	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
GBM	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	5.19	9.34e-07	0.00131	0.43	0.44	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
GBM	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	5.19	9.35e-07	0.00131	0.61	0.44	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-5.19	9.35e-07	0.00131	-0.67	-0.44	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
GBM	cis	rs73198271	0.813	rs17697237	ENSG00000253893.2	FAM85B	-5.18	9.39e-07	0.00131	-0.6	-0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8167819~8226614:-
GBM	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	5.18	9.39e-07	0.00131	0.6	0.44	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
GBM	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-5.18	9.4e-07	0.00131	-0.5	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-5.18	9.4e-07	0.00131	-0.5	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
GBM	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	5.18	9.4e-07	0.00131	0.48	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
GBM	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-5.18	9.4e-07	0.00131	-0.52	-0.44	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
GBM	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-5.18	9.4e-07	0.00132	-0.44	-0.44	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-5.18	9.4e-07	0.00132	-0.44	-0.44	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-5.18	9.4e-07	0.00132	-0.44	-0.44	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
GBM	cis	rs4713118	0.869	rs9283883	ENSG00000199851.2	U3	5.18	9.41e-07	0.00132	0.6	0.44	Parkinson's disease;	chr6:27747691	chr6:28015568~28015777:+
GBM	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	5.18	9.41e-07	0.00132	0.6	0.44	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
GBM	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	5.18	9.42e-07	0.00132	0.52	0.44	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
GBM	cis	rs17214007	0.877	rs11075280	ENSG00000279866.1	CTB-193M12.4	5.18	9.44e-07	0.00132	0.55	0.44	Cognitive function;	chr16:15776630	chr16:15704410~15705984:+
GBM	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-5.18	9.44e-07	0.00132	-0.6	-0.44	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-5.18	9.44e-07	0.00132	-0.6	-0.44	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
GBM	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-5.18	9.44e-07	0.00132	-0.6	-0.44	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
GBM	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	5.18	9.45e-07	0.00132	0.52	0.44	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
GBM	cis	rs8081395	0.509	rs1292045	ENSG00000266992.1	DHX40P1	5.18	9.46e-07	0.00132	0.53	0.44	White blood cell count;	chr17:59869851	chr17:59976009~60002384:-
GBM	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-5.18	9.46e-07	0.00132	-0.5	-0.44	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
GBM	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	5.18	9.46e-07	0.00132	0.51	0.44	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
GBM	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	5.18	9.46e-07	0.00132	0.44	0.44	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
GBM	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-5.18	9.47e-07	0.00132	-0.65	-0.44	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
GBM	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-5.18	9.47e-07	0.00132	-0.65	-0.44	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
GBM	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-5.18	9.47e-07	0.00132	-0.65	-0.44	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
GBM	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-5.18	9.47e-07	0.00132	-0.65	-0.44	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
GBM	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	5.18	9.47e-07	0.00132	0.53	0.44	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
GBM	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-5.18	9.49e-07	0.00133	-0.48	-0.44	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
GBM	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	5.18	9.51e-07	0.00133	0.46	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
GBM	cis	rs9876781	1	rs9815103	ENSG00000244380.1	RP11-24C3.2	5.18	9.51e-07	0.00133	0.49	0.44	Longevity;	chr3:48372725	chr3:48440352~48446656:-
GBM	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	5.18	9.52e-07	0.00133	0.53	0.44	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
GBM	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	5.18	9.52e-07	0.00133	0.52	0.44	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
GBM	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-5.18	9.53e-07	0.00133	-0.39	-0.44	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
GBM	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	5.18	9.53e-07	0.00133	0.53	0.44	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	5.18	9.53e-07	0.00133	0.53	0.44	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	5.18	9.53e-07	0.00133	0.53	0.44	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	5.18	9.53e-07	0.00133	0.53	0.44	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	5.18	9.53e-07	0.00133	0.53	0.44	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	5.18	9.53e-07	0.00133	0.53	0.44	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
GBM	cis	rs11233250	0.697	rs12419612	ENSG00000245832.5	RP11-179A16.1	5.18	9.54e-07	0.00133	0.66	0.43	Glioblastoma;Glioma;	chr11:82695034	chr11:81879851~82718082:-
GBM	cis	rs11233250	0.697	rs1945794	ENSG00000245832.5	RP11-179A16.1	5.18	9.54e-07	0.00133	0.66	0.43	Glioblastoma;Glioma;	chr11:82697229	chr11:81879851~82718082:-
GBM	cis	rs11233250	0.697	rs57630229	ENSG00000245832.5	RP11-179A16.1	5.18	9.54e-07	0.00133	0.66	0.43	Glioblastoma;Glioma;	chr11:82698589	chr11:81879851~82718082:-
GBM	cis	rs11233250	0.697	rs72942432	ENSG00000245832.5	RP11-179A16.1	5.18	9.54e-07	0.00133	0.66	0.43	Glioblastoma;Glioma;	chr11:82699873	chr11:81879851~82718082:-
GBM	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-5.18	9.55e-07	0.00133	-0.51	-0.43	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
GBM	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-5.18	9.56e-07	0.00133	-0.51	-0.43	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
GBM	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-5.18	9.57e-07	0.00133	-0.65	-0.43	Depression;	chr6:28096845	chr6:28115628~28116551:+
GBM	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	5.18	9.61e-07	0.00134	0.52	0.43	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
GBM	cis	rs67981189	0.529	rs8014273	ENSG00000269927.1	RP6-91H8.3	5.18	9.61e-07	0.00134	0.51	0.43	Schizophrenia;	chr14:71043113	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.529	rs8010063	ENSG00000269927.1	RP6-91H8.3	5.18	9.61e-07	0.00134	0.51	0.43	Schizophrenia;	chr14:71043408	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.529	rs2158996	ENSG00000269927.1	RP6-91H8.3	5.18	9.61e-07	0.00134	0.51	0.43	Schizophrenia;	chr14:71062882	chr14:71141125~71143253:-
GBM	cis	rs860818	1	rs858287	ENSG00000226816.2	AC005082.12	5.18	9.62e-07	0.00134	1.13	0.43	Initial pursuit acceleration;	chr7:23209594	chr7:23206013~23208045:+
GBM	cis	rs860818	1	rs858286	ENSG00000226816.2	AC005082.12	5.18	9.62e-07	0.00134	1.13	0.43	Initial pursuit acceleration;	chr7:23209844	chr7:23206013~23208045:+
GBM	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	5.18	9.65e-07	0.00134	0.47	0.43	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
GBM	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	5.18	9.65e-07	0.00134	0.47	0.43	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
GBM	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	5.18	9.65e-07	0.00134	0.47	0.43	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
GBM	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	5.18	9.65e-07	0.00134	0.47	0.43	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
GBM	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	5.18	9.65e-07	0.00134	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	5.18	9.65e-07	0.00134	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	5.18	9.65e-07	0.00134	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	5.18	9.65e-07	0.00134	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
GBM	cis	rs7267979	0.903	rs6107015	ENSG00000125804.12	FAM182A	-5.18	9.72e-07	0.00135	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.833	rs6138556	ENSG00000125804.12	FAM182A	-5.18	9.72e-07	0.00135	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:26054655~26086917:+
GBM	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-5.18	9.72e-07	0.00135	-0.48	-0.43	Height;	chr11:118747911	chr11:118791254~118793137:+
GBM	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	5.18	9.73e-07	0.00135	0.52	0.43	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
GBM	cis	rs17772222	0.63	rs7146241	ENSG00000258983.2	RP11-507K2.2	-5.18	9.73e-07	0.00135	-0.45	-0.43	Coronary artery calcification;	chr14:88551622	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.63	rs930181	ENSG00000258983.2	RP11-507K2.2	-5.18	9.73e-07	0.00135	-0.45	-0.43	Coronary artery calcification;	chr14:88552364	chr14:88499334~88515502:+
GBM	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
GBM	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
GBM	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-5.18	9.74e-07	0.00135	-0.57	-0.43	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
GBM	cis	rs6583331	1	rs12718061	ENSG00000273013.1	CTD-2002J20.1	-5.18	9.74e-07	0.00135	-0.48	-0.43	Vitiligo;	chr3:196620566	chr3:196474801~196475394:+
GBM	cis	rs10754283	0.84	rs1215501	ENSG00000231613.1	RP5-943J3.1	5.18	9.75e-07	0.00135	0.54	0.43	Amyotrophic lateral sclerosis (sporadic);	chr1:89630131	chr1:89788914~89790492:+
GBM	cis	rs7267979	0.868	rs6138553	ENSG00000276952.1	RP5-965G21.6	5.18	9.76e-07	0.00135	0.41	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25284915~25285588:-
GBM	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-5.17	9.79e-07	0.00136	-0.57	-0.43	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
GBM	cis	rs10754283	0.84	rs1215502	ENSG00000231613.1	RP5-943J3.1	5.17	9.79e-07	0.00136	0.54	0.43	Amyotrophic lateral sclerosis (sporadic);	chr1:89627456	chr1:89788914~89790492:+
GBM	cis	rs4713118	0.525	rs9357042	ENSG00000218016.2	ZNF192P2	-5.17	9.81e-07	0.00136	-0.54	-0.43	Parkinson's disease;	chr6:27615016	chr6:28188050~28189432:+
GBM	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	5.17	9.82e-07	0.00136	0.44	0.43	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	5.17	9.82e-07	0.00136	0.44	0.43	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
GBM	cis	rs7267979	0.934	rs113469203	ENSG00000125804.12	FAM182A	5.17	9.83e-07	0.00136	0.54	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25362622	chr20:26054655~26086917:+
GBM	cis	rs4072705	1	rs722477	ENSG00000224020.1	MIR181A2HG	-5.17	9.86e-07	0.00137	-0.48	-0.43	Menarche (age at onset);	chr9:124712315	chr9:124658467~124698631:+
GBM	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-5.17	9.87e-07	0.00137	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
GBM	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-5.17	9.89e-07	0.00137	-0.65	-0.43	Depression;	chr6:28104824	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-5.17	9.89e-07	0.00137	-0.65	-0.43	Depression;	chr6:28137418	chr6:28115628~28116551:+
GBM	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-5.17	9.9e-07	0.00137	-0.44	-0.43	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
GBM	cis	rs1420956	0.562	rs16943820	ENSG00000264151.4	RP11-739N10.1	5.17	9.93e-07	0.00138	0.58	0.43	Obesity-related traits;	chr18:27599849	chr18:27336379~27595164:-
GBM	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	5.17	9.94e-07	0.00138	0.5	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
GBM	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-5.17	9.94e-07	0.00138	-0.48	-0.43	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
GBM	cis	rs763121	0.706	rs3827356	ENSG00000273076.1	RP3-508I15.22	-5.17	9.96e-07	0.00138	-0.48	-0.43	Menopause (age at onset);	chr22:38668801	chr22:38743495~38743910:+
GBM	cis	rs7267979	0.844	rs6050477	ENSG00000125804.12	FAM182A	5.17	9.97e-07	0.00138	0.59	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26054655~26086917:+
GBM	cis	rs2013441	1	rs4924808	ENSG00000230528.6	NOS2P3	5.17	9.98e-07	0.00138	0.48	0.43	Obesity-related traits;	chr17:20123235	chr17:20436337~20447249:+
GBM	cis	rs67981189	0.896	rs7146591	ENSG00000269927.1	RP6-91H8.3	-5.17	1e-06	0.00139	-0.49	-0.43	Schizophrenia;	chr14:70971511	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.896	rs34049963	ENSG00000269927.1	RP6-91H8.3	5.17	1e-06	0.00139	0.49	0.43	Schizophrenia;	chr14:70974029	chr14:71141125~71143253:-
GBM	cis	rs454217	0.846	rs337661	ENSG00000277851.1	RP11-756G20.1	5.17	1.01e-06	0.00139	0.46	0.43	Smoking quantity;	chr12:92310960	chr12:92247756~92363832:-
GBM	cis	rs17270561	0.525	rs10484432	ENSG00000272810.1	U91328.22	-5.17	1.01e-06	0.00139	-0.66	-0.43	Iron status biomarkers;	chr6:26008648	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.562	rs12199626	ENSG00000272810.1	U91328.22	-5.17	1.01e-06	0.00139	-0.66	-0.43	Iron status biomarkers;	chr6:26013376	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.562	rs74293932	ENSG00000272810.1	U91328.22	-5.17	1.01e-06	0.00139	-0.66	-0.43	Iron status biomarkers;	chr6:26014583	chr6:26013241~26013757:+
GBM	cis	rs17772222	0.63	rs8017811	ENSG00000258983.2	RP11-507K2.2	-5.17	1.01e-06	0.00139	-0.44	-0.43	Coronary artery calcification;	chr14:88534559	chr14:88499334~88515502:+
GBM	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	5.17	1.01e-06	0.0014	0.5	0.43	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
GBM	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	5.17	1.01e-06	0.0014	0.5	0.43	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
GBM	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	5.17	1.01e-06	0.0014	0.5	0.43	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
GBM	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	5.17	1.01e-06	0.0014	0.56	0.43	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
GBM	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-5.17	1.02e-06	0.0014	-0.29	-0.43	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
GBM	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	5.17	1.02e-06	0.00141	0.49	0.43	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
GBM	cis	rs7927592	0.546	rs497261	ENSG00000212093.1	AP000807.1	5.17	1.02e-06	0.00141	0.49	0.43	Total body bone mineral density;	chr11:68424776	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.546	rs599083	ENSG00000212093.1	AP000807.1	5.17	1.02e-06	0.00141	0.49	0.43	Total body bone mineral density;	chr11:68424878	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.546	rs683978	ENSG00000212093.1	AP000807.1	5.17	1.02e-06	0.00141	0.49	0.43	Total body bone mineral density;	chr11:68424953	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.546	rs554734	ENSG00000212093.1	AP000807.1	5.17	1.02e-06	0.00141	0.49	0.43	Total body bone mineral density;	chr11:68425050	chr11:68506083~68506166:-
GBM	cis	rs525592	1	rs525592	ENSG00000212093.1	AP000807.1	5.17	1.02e-06	0.00141	0.49	0.43	Bone mineral density;	chr11:68427636	chr11:68506083~68506166:-
GBM	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-5.17	1.02e-06	0.00141	-0.63	-0.43	Depression;	chr6:28079011	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-5.17	1.02e-06	0.00141	-0.63	-0.43	Depression;	chr6:28091242	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	5.17	1.02e-06	0.00141	0.63	0.43	Depression;	chr6:28110525	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-5.17	1.02e-06	0.00141	-0.63	-0.43	Depression;	chr6:28126588	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-5.17	1.02e-06	0.00141	-0.63	-0.43	Depression;	chr6:28126953	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-5.17	1.02e-06	0.00141	-0.63	-0.43	Depression;	chr6:28140307	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-5.17	1.02e-06	0.00141	-0.63	-0.43	Depression;	chr6:28159666	chr6:28115628~28116551:+
GBM	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-5.17	1.02e-06	0.00141	-0.63	-0.43	Depression;	chr6:28162598	chr6:28115628~28116551:+
GBM	cis	rs2013441	1	rs2703817	ENSG00000230528.6	NOS2P3	5.16	1.02e-06	0.00141	0.49	0.43	Obesity-related traits;	chr17:20216364	chr17:20436337~20447249:+
GBM	cis	rs4887140	0.541	rs2415230	ENSG00000260469.2	C15orf59-AS1	-5.16	1.02e-06	0.00141	-0.79	-0.43	Glucose homeostasis traits;	chr15:73766740	chr15:73752317~73770613:+
GBM	cis	rs12460587	0.622	rs7247612	ENSG00000275055.1	CTC-471J1.11	-5.16	1.02e-06	0.00141	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-5.16	1.02e-06	0.00141	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.537	rs4145658	ENSG00000275055.1	CTC-471J1.11	-5.16	1.02e-06	0.00141	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.537	rs16983434	ENSG00000275055.1	CTC-471J1.11	-5.16	1.02e-06	0.00141	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52049007~52049754:+
GBM	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-5.16	1.02e-06	0.00141	-0.56	-0.43	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-5.16	1.02e-06	0.00141	-0.56	-0.43	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
GBM	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
GBM	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	5.16	1.03e-06	0.00141	0.52	0.43	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
GBM	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	5.16	1.03e-06	0.00141	0.52	0.43	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	5.16	1.03e-06	0.00141	0.52	0.43	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	5.16	1.03e-06	0.00141	0.52	0.43	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	5.16	1.03e-06	0.00141	0.52	0.43	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
GBM	cis	rs7267979	0.932	rs431579	ENSG00000125804.12	FAM182A	-5.16	1.03e-06	0.00142	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:26054655~26086917:+
GBM	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	5.16	1.03e-06	0.00142	0.3	0.43	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
GBM	cis	rs763121	0.853	rs3788544	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38668961	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs4821808	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38669734	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs4821809	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38669738	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs3761454	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38670815	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs3747170	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38671326	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs3747172	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38671519	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750659	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38672784	chr22:38743495~38743910:+
GBM	cis	rs763121	0.819	rs3747173	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38673040	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs3747174	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38673176	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs1065201	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38673505	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757226	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38674545	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757232	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38675672	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs9306329	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38676449	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750662	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38676467	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750664	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38676764	chr22:38743495~38743910:+
GBM	cis	rs763121	0.752	rs6001190	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38677806	chr22:38743495~38743910:+
GBM	cis	rs763121	0.626	rs5757236	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38677819	chr22:38743495~38743910:+
GBM	cis	rs763121	0.819	rs5757237	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38677830	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs6001191	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38678447	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs11704021	ENSG00000273076.1	RP3-508I15.22	5.16	1.03e-06	0.00142	0.5	0.43	Menopause (age at onset);	chr22:38678711	chr22:38743495~38743910:+
GBM	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	5.16	1.03e-06	0.00142	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
GBM	cis	rs6782228	0.848	rs3935016	ENSG00000277250.1	Metazoa_SRP	5.16	1.03e-06	0.00142	0.52	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.848	rs6439141	ENSG00000277250.1	Metazoa_SRP	5.16	1.03e-06	0.00142	0.52	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.883	rs6439142	ENSG00000277250.1	Metazoa_SRP	5.16	1.03e-06	0.00142	0.52	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128673681~128674021:-
GBM	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-5.16	1.03e-06	0.00142	-0.49	-0.43	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
GBM	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-5.16	1.03e-06	0.00142	-0.49	-0.43	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-5.16	1.03e-06	0.00142	-0.49	-0.43	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
GBM	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	5.16	1.03e-06	0.00142	0.66	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
GBM	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	5.16	1.03e-06	0.00142	0.66	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
GBM	cis	rs916888	0.61	rs199454	ENSG00000261575.2	RP11-259G18.1	-5.16	1.03e-06	0.00142	-0.53	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46267037~46268694:+
GBM	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-5.16	1.04e-06	0.00143	-0.65	-0.43	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
GBM	cis	rs7267979	0.903	rs2474769	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:26054655~26086917:+
GBM	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	5.16	1.04e-06	0.00143	0.41	0.43	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
GBM	cis	rs17772222	0.74	rs3783885	ENSG00000222990.1	RNU4-22P	5.16	1.04e-06	0.00143	0.47	0.43	Coronary artery calcification;	chr14:88510714	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs11159857	ENSG00000222990.1	RNU4-22P	5.16	1.04e-06	0.00143	0.47	0.43	Coronary artery calcification;	chr14:88510796	chr14:88513498~88513663:+
GBM	cis	rs7267979	0.866	rs437635	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.899	rs442834	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs417110	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs417130	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs449703	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs372678	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs424487	ENSG00000125804.12	FAM182A	-5.16	1.04e-06	0.00143	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs433352	ENSG00000125804.12	FAM182A	5.16	1.04e-06	0.00143	0.55	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:26054655~26086917:+
GBM	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-5.16	1.04e-06	0.00143	-0.49	-0.43	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
GBM	cis	rs11671005	0.572	rs11669127	ENSG00000269473.1	CTD-2619J13.19	-5.16	1.05e-06	0.00144	-0.51	-0.43	Mean platelet volume;	chr19:58492463	chr19:58440448~58445849:+
GBM	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	5.16	1.05e-06	0.00144	0.75	0.43	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	5.16	1.05e-06	0.00144	0.75	0.43	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
GBM	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	5.16	1.05e-06	0.00144	0.54	0.43	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
GBM	cis	rs4072705	0.967	rs7020358	ENSG00000224020.1	MIR181A2HG	-5.16	1.05e-06	0.00144	-0.48	-0.43	Menarche (age at onset);	chr9:124720192	chr9:124658467~124698631:+
GBM	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	5.16	1.05e-06	0.00144	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
GBM	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-5.16	1.05e-06	0.00144	-0.58	-0.43	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
GBM	cis	rs7615952	0.546	rs2979306	ENSG00000171084.14	FAM86JP	5.16	1.05e-06	0.00144	0.74	0.43	Blood pressure (smoking interaction);	chr3:125593286	chr3:125916620~125930024:+
GBM	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-5.16	1.05e-06	0.00144	-0.51	-0.43	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
GBM	cis	rs893971	0.672	rs13151250	ENSG00000246375.2	RP11-10L7.1	5.16	1.05e-06	0.00144	0.48	0.43	Conduct disorder (maternal expressed emotions interaction);	chr4:88301906	chr4:88284942~88331421:+
GBM	cis	rs4604732	0.588	rs4925552	ENSG00000227135.1	GCSAML-AS1	-5.16	1.05e-06	0.00144	-0.66	-0.43	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468447	chr1:247524679~247526752:-
GBM	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	5.16	1.06e-06	0.00145	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
GBM	cis	rs763121	0.813	rs4821807	ENSG00000273076.1	RP3-508I15.22	5.16	1.06e-06	0.00145	0.5	0.43	Menopause (age at onset);	chr22:38669577	chr22:38743495~38743910:+
GBM	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-5.16	1.06e-06	0.00145	-0.66	-0.43	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
GBM	cis	rs2408955	0.522	rs7139330	ENSG00000258273.1	RP11-370I10.4	5.16	1.06e-06	0.00146	0.54	0.43	Glycated hemoglobin levels;	chr12:48089701	chr12:48333755~48333901:-
GBM	cis	rs2408955	0.522	rs2051851	ENSG00000258273.1	RP11-370I10.4	5.16	1.06e-06	0.00146	0.54	0.43	Glycated hemoglobin levels;	chr12:48092157	chr12:48333755~48333901:-
GBM	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	5.16	1.06e-06	0.00146	0.54	0.43	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
GBM	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	5.16	1.06e-06	0.00146	0.55	0.43	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
GBM	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-5.16	1.06e-06	0.00146	-0.58	-0.43	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
GBM	cis	rs67981189	0.558	rs56043821	ENSG00000269927.1	RP6-91H8.3	5.16	1.07e-06	0.00146	0.51	0.43	Schizophrenia;	chr14:71103835	chr14:71141125~71143253:-
GBM	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	5.15	1.07e-06	0.00146	0.41	0.43	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
GBM	cis	rs67981189	0.656	rs2810113	ENSG00000269927.1	RP6-91H8.3	-5.15	1.07e-06	0.00146	-0.48	-0.43	Schizophrenia;	chr14:70929053	chr14:71141125~71143253:-
GBM	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-5.15	1.07e-06	0.00146	-0.67	-0.43	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
GBM	cis	rs17772222	0.682	rs4904452	ENSG00000258983.2	RP11-507K2.2	-5.15	1.07e-06	0.00146	-0.46	-0.43	Coronary artery calcification;	chr14:88517329	chr14:88499334~88515502:+
GBM	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	5.15	1.07e-06	0.00146	0.49	0.43	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
GBM	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-5.15	1.07e-06	0.00146	-0.55	-0.43	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
GBM	cis	rs11098499	0.913	rs67073020	ENSG00000250412.1	KLHL2P1	5.15	1.07e-06	0.00146	0.57	0.43	Corneal astigmatism;	chr4:119231402	chr4:119334329~119378233:+
GBM	cis	rs11159086	1	rs72730186	ENSG00000270000.1	RP3-449M8.9	5.15	1.07e-06	0.00147	0.74	0.43	Advanced glycation end-product levels;	chr14:74475610	chr14:74471930~74472360:-
GBM	cis	rs4713118	0.869	rs10214440	ENSG00000199851.2	U3	5.15	1.07e-06	0.00147	0.6	0.43	Parkinson's disease;	chr6:27734661	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs6902689	ENSG00000199851.2	U3	5.15	1.07e-06	0.00147	0.6	0.43	Parkinson's disease;	chr6:27741662	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs9468214	ENSG00000199851.2	U3	5.15	1.07e-06	0.00147	0.6	0.43	Parkinson's disease;	chr6:27745520	chr6:28015568~28015777:+
GBM	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	5.15	1.07e-06	0.00147	0.4	0.43	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
GBM	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	5.15	1.08e-06	0.00147	0.53	0.43	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
GBM	cis	rs7267979	0.932	rs367666	ENSG00000125804.12	FAM182A	-5.15	1.08e-06	0.00148	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:26054655~26086917:+
GBM	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	5.15	1.08e-06	0.00148	0.6	0.43	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
GBM	cis	rs7267979	0.932	rs2260997	ENSG00000276952.1	RP5-965G21.6	-5.15	1.08e-06	0.00148	-0.39	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25284915~25285588:-
GBM	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	5.15	1.08e-06	0.00148	0.53	0.43	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	5.15	1.08e-06	0.00148	0.53	0.43	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	5.15	1.08e-06	0.00148	0.53	0.43	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
GBM	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	5.15	1.09e-06	0.00148	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
GBM	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	5.15	1.09e-06	0.00148	0.47	0.43	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	5.15	1.09e-06	0.00148	0.47	0.43	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
GBM	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	5.15	1.09e-06	0.00148	0.47	0.43	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
GBM	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-5.15	1.09e-06	0.00149	-0.96	-0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
GBM	cis	rs7267979	0.966	rs2257233	ENSG00000276952.1	RP5-965G21.6	-5.15	1.09e-06	0.00149	-0.41	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25284915~25285588:-
GBM	cis	rs172166	0.543	rs1150691	ENSG00000199851.2	U3	5.15	1.09e-06	0.00149	0.56	0.43	Cardiac Troponin-T levels;	chr6:28200255	chr6:28015568~28015777:+
GBM	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	5.15	1.09e-06	0.00149	0.64	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
GBM	cis	rs9876781	0.967	rs7618883	ENSG00000244380.1	RP11-24C3.2	5.15	1.09e-06	0.00149	0.49	0.43	Longevity;	chr3:48457056	chr3:48440352~48446656:-
GBM	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-5.15	1.1e-06	0.00149	-0.52	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-5.15	1.1e-06	0.00149	-0.52	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-5.15	1.1e-06	0.00149	-0.52	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
GBM	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	5.15	1.1e-06	0.0015	0.6	0.43	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
GBM	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-5.15	1.1e-06	0.0015	-0.59	-0.43	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
GBM	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	5.15	1.1e-06	0.0015	0.58	0.43	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
GBM	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	5.15	1.1e-06	0.0015	0.58	0.43	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
GBM	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	5.15	1.1e-06	0.0015	0.58	0.43	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
GBM	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	5.15	1.1e-06	0.0015	0.58	0.43	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
GBM	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	5.15	1.1e-06	0.0015	0.48	0.43	QT interval;	chr16:28860645	chr16:28700294~28701540:-
GBM	cis	rs73198271	0.813	rs56007835	ENSG00000253893.2	FAM85B	5.15	1.1e-06	0.0015	0.61	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8167819~8226614:-
GBM	cis	rs741668	0.641	rs4942472	ENSG00000235903.6	CPB2-AS1	-5.15	1.1e-06	0.0015	-0.52	-0.43	Cerebrospinal fluid clusterin levels;	chr13:46070980	chr13:46052806~46113332:+
GBM	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	5.15	1.1e-06	0.0015	0.52	0.43	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
GBM	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-5.15	1.1e-06	0.0015	-0.46	-0.43	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
GBM	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-5.15	1.1e-06	0.0015	-0.46	-0.43	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
GBM	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-5.15	1.1e-06	0.0015	-0.46	-0.43	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
GBM	cis	rs10946940	1	rs10946940	ENSG00000218016.2	ZNF192P2	5.15	1.11e-06	0.00151	0.52	0.43	Systemic lupus erythematosus;	chr6:27592808	chr6:28188050~28189432:+
GBM	cis	rs17270561	0.514	rs10946805	ENSG00000272810.1	U91328.22	-5.15	1.11e-06	0.00151	-0.69	-0.43	Iron status biomarkers;	chr6:26077663	chr6:26013241~26013757:+
GBM	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-5.15	1.11e-06	0.00151	-0.62	-0.43	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-5.15	1.11e-06	0.00151	-0.62	-0.43	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-5.15	1.11e-06	0.00151	-0.62	-0.43	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
GBM	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	5.15	1.11e-06	0.00151	0.65	0.43	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	5.15	1.11e-06	0.00151	0.65	0.43	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	5.15	1.11e-06	0.00151	0.65	0.43	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
GBM	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	5.15	1.11e-06	0.00151	0.51	0.43	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
GBM	cis	rs4273100	0.541	rs7501702	ENSG00000262319.1	CTC-457L16.2	5.14	1.11e-06	0.00151	0.49	0.43	Schizophrenia;	chr17:19390414	chr17:19141017~19143689:-
GBM	cis	rs4273100	0.512	rs7502682	ENSG00000262319.1	CTC-457L16.2	5.14	1.11e-06	0.00151	0.49	0.43	Schizophrenia;	chr17:19392137	chr17:19141017~19143689:-
GBM	cis	rs4072705	0.967	rs12339980	ENSG00000224020.1	MIR181A2HG	-5.14	1.11e-06	0.00151	-0.48	-0.43	Menarche (age at onset);	chr9:124556424	chr9:124658467~124698631:+
GBM	cis	rs4072705	0.967	rs10739650	ENSG00000224020.1	MIR181A2HG	-5.14	1.11e-06	0.00151	-0.48	-0.43	Menarche (age at onset);	chr9:124561497	chr9:124658467~124698631:+
GBM	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	5.14	1.12e-06	0.00152	0.48	0.43	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
GBM	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-5.14	1.12e-06	0.00152	-0.53	-0.43	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-5.14	1.12e-06	0.00152	-0.53	-0.43	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
GBM	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-5.14	1.12e-06	0.00152	-0.63	-0.43	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-5.14	1.12e-06	0.00152	-0.63	-0.43	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-5.14	1.12e-06	0.00152	-0.63	-0.43	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-5.14	1.12e-06	0.00152	-0.63	-0.43	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-5.14	1.12e-06	0.00152	-0.63	-0.43	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
GBM	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	5.14	1.12e-06	0.00152	0.52	0.43	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
GBM	cis	rs6452524	0.901	rs12188673	ENSG00000248112.1	RP11-78C3.1	5.14	1.12e-06	0.00153	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:82919376~82921119:-
GBM	cis	rs6452524	0.87	rs6452511	ENSG00000248112.1	RP11-78C3.1	5.14	1.12e-06	0.00153	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:82919376~82921119:-
GBM	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	5.14	1.13e-06	0.00153	0.45	0.43	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
GBM	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	5.14	1.13e-06	0.00154	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
GBM	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-5.14	1.13e-06	0.00154	-0.51	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
GBM	cis	rs11098499	0.662	rs13108589	ENSG00000250412.1	KLHL2P1	5.14	1.14e-06	0.00154	0.57	0.43	Corneal astigmatism;	chr4:119346947	chr4:119334329~119378233:+
GBM	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	5.14	1.14e-06	0.00154	0.59	0.43	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	5.14	1.14e-06	0.00154	0.59	0.43	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
GBM	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-5.14	1.14e-06	0.00155	-0.56	-0.43	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
GBM	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-5.14	1.14e-06	0.00155	-0.74	-0.43	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
GBM	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-5.14	1.14e-06	0.00155	-0.74	-0.43	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
GBM	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	5.14	1.15e-06	0.00155	0.52	0.43	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	5.14	1.15e-06	0.00155	0.52	0.43	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	5.14	1.15e-06	0.00155	0.52	0.43	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
GBM	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	5.14	1.15e-06	0.00155	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	5.14	1.15e-06	0.00155	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	5.14	1.15e-06	0.00155	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
GBM	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-5.14	1.15e-06	0.00156	-0.46	-0.43	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-5.14	1.15e-06	0.00156	-0.46	-0.43	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
GBM	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-5.14	1.15e-06	0.00156	-0.46	-0.43	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
GBM	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	5.14	1.16e-06	0.00156	0.57	0.43	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
GBM	cis	rs763121	0.853	rs3788545	ENSG00000273076.1	RP3-508I15.22	5.14	1.16e-06	0.00156	0.5	0.43	Menopause (age at onset);	chr22:38669167	chr22:38743495~38743910:+
GBM	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	5.14	1.16e-06	0.00156	0.63	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
GBM	cis	rs7267979	0.932	rs928121	ENSG00000125804.12	FAM182A	-5.14	1.16e-06	0.00157	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:26054655~26086917:+
GBM	cis	rs10946940	0.897	rs6456801	ENSG00000218016.2	ZNF192P2	-5.13	1.16e-06	0.00157	-0.52	-0.43	Systemic lupus erythematosus;	chr6:27657753	chr6:28188050~28189432:+
GBM	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	5.13	1.16e-06	0.00157	0.46	0.43	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
GBM	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-5.13	1.16e-06	0.00157	-0.37	-0.43	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
GBM	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-5.13	1.16e-06	0.00157	-0.37	-0.43	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
GBM	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-5.13	1.16e-06	0.00157	-0.37	-0.43	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
GBM	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	5.13	1.17e-06	0.00157	0.61	0.43	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	5.13	1.17e-06	0.00157	0.61	0.43	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
GBM	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	5.13	1.17e-06	0.00158	0.56	0.43	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
GBM	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	5.13	1.17e-06	0.00158	0.47	0.43	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
GBM	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-5.13	1.17e-06	0.00158	-0.65	-0.43	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
GBM	cis	rs2013441	1	rs11654025	ENSG00000230528.6	NOS2P3	5.13	1.17e-06	0.00158	0.45	0.43	Obesity-related traits;	chr17:20294847	chr17:20436337~20447249:+
GBM	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-5.13	1.18e-06	0.00159	-0.68	-0.43	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
GBM	cis	rs7267979	0.903	rs6115118	ENSG00000125804.12	FAM182A	-5.13	1.18e-06	0.00159	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.903	rs1118963	ENSG00000125804.12	FAM182A	-5.13	1.18e-06	0.00159	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:26054655~26086917:+
GBM	cis	rs11098499	0.739	rs4833612	ENSG00000249244.1	RP11-548H18.2	-5.13	1.18e-06	0.00159	-0.57	-0.43	Corneal astigmatism;	chr4:119226441	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.739	rs10013032	ENSG00000249244.1	RP11-548H18.2	-5.13	1.18e-06	0.00159	-0.57	-0.43	Corneal astigmatism;	chr4:119228264	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.739	rs951570	ENSG00000249244.1	RP11-548H18.2	-5.13	1.18e-06	0.00159	-0.57	-0.43	Corneal astigmatism;	chr4:119229312	chr4:119391831~119395335:-
GBM	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-5.13	1.18e-06	0.00159	-0.48	-0.43	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
GBM	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-5.13	1.18e-06	0.00159	-0.48	-0.43	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-5.13	1.18e-06	0.00159	-0.48	-0.43	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
GBM	cis	rs860818	1	rs858233	ENSG00000226816.2	AC005082.12	5.13	1.18e-06	0.00159	1.25	0.43	Initial pursuit acceleration;	chr7:23201914	chr7:23206013~23208045:+
GBM	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-5.13	1.19e-06	0.0016	-0.58	-0.43	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
GBM	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-5.13	1.19e-06	0.0016	-0.56	-0.43	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-5.13	1.19e-06	0.0016	-0.55	-0.43	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
GBM	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	5.13	1.19e-06	0.0016	0.56	0.43	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
GBM	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	5.13	1.19e-06	0.0016	0.56	0.43	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
GBM	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	5.13	1.19e-06	0.0016	0.56	0.43	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
GBM	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	5.13	1.19e-06	0.0016	0.56	0.43	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
GBM	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	5.13	1.19e-06	0.00161	0.52	0.43	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
GBM	cis	rs3096299	0.781	rs2170839	ENSG00000260259.1	RP11-368I7.4	5.13	1.19e-06	0.00161	0.48	0.43	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89682620~89686569:-
GBM	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	5.13	1.2e-06	0.00161	0.29	0.43	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
GBM	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	5.13	1.2e-06	0.00161	0.49	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
GBM	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.13	1.2e-06	0.00161	-0.48	-0.43	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
GBM	cis	rs9876781	1	rs13314659	ENSG00000244380.1	RP11-24C3.2	-5.13	1.2e-06	0.00161	-0.49	-0.43	Longevity;	chr3:48407742	chr3:48440352~48446656:-
GBM	cis	rs6908917	0.711	rs6902768	ENSG00000219776.2	RPL21P67	5.13	1.2e-06	0.00161	0.56	0.43	IgG glycosylation;	chr6:131011029	chr6:131469059~131469536:+
GBM	cis	rs3806843	0.868	rs2563291	ENSG00000202111.1	VTRNA1-2	5.13	1.21e-06	0.00162	0.45	0.43	Depressive symptoms (multi-trait analysis);	chr5:140740014	chr5:140718925~140719013:+
GBM	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	5.13	1.21e-06	0.00162	0.63	0.43	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
GBM	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-5.13	1.21e-06	0.00163	-0.66	-0.43	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
GBM	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	5.12	1.21e-06	0.00163	0.55	0.43	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
GBM	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	5.12	1.21e-06	0.00163	0.55	0.43	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
GBM	cis	rs7267979	0.903	rs6050482	ENSG00000276952.1	RP5-965G21.6	5.12	1.22e-06	0.00163	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.706	rs6037069	ENSG00000276952.1	RP5-965G21.6	5.12	1.22e-06	0.00163	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.903	rs6107015	ENSG00000276952.1	RP5-965G21.6	5.12	1.22e-06	0.00163	0.41	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.833	rs6138556	ENSG00000276952.1	RP5-965G21.6	5.12	1.22e-06	0.00163	0.41	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25284915~25285588:-
GBM	cis	rs9926296	0.529	rs7195906	ENSG00000260259.1	RP11-368I7.4	-5.12	1.22e-06	0.00163	-0.45	-0.43	Vitiligo;	chr16:89739939	chr16:89682620~89686569:-
GBM	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	5.12	1.22e-06	0.00164	0.48	0.43	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
GBM	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-5.12	1.22e-06	0.00164	-0.54	-0.43	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
GBM	cis	rs8062405	0.823	rs7202948	ENSG00000271623.1	RP11-435I10.5	-5.12	1.22e-06	0.00164	-0.49	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs7191618	ENSG00000271623.1	RP11-435I10.5	-5.12	1.22e-06	0.00164	-0.49	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.754	rs3859172	ENSG00000271623.1	RP11-435I10.5	-5.12	1.22e-06	0.00164	-0.49	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28364700~28365333:+
GBM	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	5.12	1.22e-06	0.00164	0.52	0.43	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
GBM	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	5.12	1.22e-06	0.00164	0.46	0.43	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
GBM	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	5.12	1.22e-06	0.00164	0.46	0.43	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
GBM	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	5.12	1.22e-06	0.00164	0.46	0.43	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
GBM	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	5.12	1.22e-06	0.00164	0.46	0.43	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
GBM	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	5.12	1.22e-06	0.00164	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
GBM	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	5.12	1.22e-06	0.00164	0.5	0.43	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
GBM	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	5.12	1.23e-06	0.00164	0.49	0.43	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
GBM	cis	rs17772222	0.74	rs4390529	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88510853	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.771	rs4516145	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88510953	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs4594187	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511071	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs4514599	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511083	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs61975276	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511193	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs61975277	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511202	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs61984675	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511236	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs73317739	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511400	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.696	rs28666030	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511463	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs28493481	ENSG00000222990.1	RNU4-22P	5.12	1.23e-06	0.00164	0.47	0.43	Coronary artery calcification;	chr14:88511491	chr14:88513498~88513663:+
GBM	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	5.12	1.23e-06	0.00164	0.86	0.43	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
GBM	cis	rs7267979	1	rs6050565	ENSG00000125804.12	FAM182A	5.12	1.23e-06	0.00164	0.53	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:26054655~26086917:+
GBM	cis	rs56262138	0.5	rs35259978	ENSG00000239519.1	CADM2-AS1	5.12	1.23e-06	0.00164	0.47	0.43	Educational attainment (years of education);	chr3:85988801	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs35012249	ENSG00000239519.1	CADM2-AS1	5.12	1.23e-06	0.00164	0.47	0.43	Educational attainment (years of education);	chr3:85989111	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs62261591	ENSG00000239519.1	CADM2-AS1	5.12	1.23e-06	0.00164	0.47	0.43	Educational attainment (years of education);	chr3:85989540	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs62261592	ENSG00000239519.1	CADM2-AS1	5.12	1.23e-06	0.00164	0.47	0.43	Educational attainment (years of education);	chr3:85989612	chr3:85992183~86028007:-
GBM	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-5.12	1.23e-06	0.00165	-0.57	-0.43	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
GBM	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.23e-06	0.00165	-0.55	-0.43	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.23e-06	0.00165	-0.55	-0.43	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.23e-06	0.00165	-0.55	-0.43	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.23e-06	0.00165	-0.55	-0.43	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.23e-06	0.00165	-0.55	-0.43	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.23e-06	0.00165	-0.55	-0.43	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.23e-06	0.00165	-0.55	-0.43	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
GBM	cis	rs763121	0.889	rs9610971	ENSG00000273076.1	RP3-508I15.22	5.12	1.23e-06	0.00165	0.49	0.43	Menopause (age at onset);	chr22:38514805	chr22:38743495~38743910:+
GBM	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-5.12	1.24e-06	0.00165	-0.46	-0.43	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
GBM	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-5.12	1.24e-06	0.00165	-0.41	-0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
GBM	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	5.12	1.24e-06	0.00165	0.41	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
GBM	cis	rs397969	0.646	rs1638527	ENSG00000230528.6	NOS2P3	5.12	1.24e-06	0.00165	0.52	0.43	Platelet count;	chr17:19942080	chr17:20436337~20447249:+
GBM	cis	rs7267979	0.873	rs7453	ENSG00000125804.12	FAM182A	-5.12	1.24e-06	0.00165	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:26054655~26086917:+
GBM	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-5.12	1.24e-06	0.00165	-0.54	-0.43	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
GBM	cis	rs6782228	0.527	rs7426806	ENSG00000277250.1	Metazoa_SRP	-5.12	1.24e-06	0.00166	-0.46	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.585	rs6774515	ENSG00000277250.1	Metazoa_SRP	-5.12	1.24e-06	0.00166	-0.46	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.565	rs12695509	ENSG00000277250.1	Metazoa_SRP	-5.12	1.24e-06	0.00166	-0.46	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128673681~128674021:-
GBM	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	5.12	1.24e-06	0.00166	0.54	0.43	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
GBM	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-5.12	1.24e-06	0.00166	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-5.12	1.24e-06	0.00166	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-5.12	1.24e-06	0.00166	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
GBM	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-5.12	1.25e-06	0.00166	-0.51	-0.43	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
GBM	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	5.12	1.25e-06	0.00166	0.52	0.43	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
GBM	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	5.12	1.25e-06	0.00167	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	5.12	1.25e-06	0.00167	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	5.12	1.25e-06	0.00167	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
GBM	cis	rs5742933	0.817	rs2033870	ENSG00000253559.1	OSGEPL1-AS1	-5.12	1.26e-06	0.00167	-0.48	-0.43	Ferritin levels;	chr2:189739104	chr2:189762704~189765556:+
GBM	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-5.12	1.26e-06	0.00168	-0.57	-0.43	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
GBM	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-5.12	1.26e-06	0.00168	-0.5	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
GBM	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	5.12	1.26e-06	0.00168	0.64	0.43	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	5.12	1.26e-06	0.00168	0.64	0.43	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	5.12	1.26e-06	0.00168	0.64	0.43	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	5.12	1.26e-06	0.00168	0.64	0.43	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	5.12	1.26e-06	0.00168	0.64	0.43	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
GBM	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-5.12	1.26e-06	0.00168	-0.49	-0.43	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
GBM	cis	rs832187	0.704	rs704364	ENSG00000280620.1	SCAANT1	-5.12	1.26e-06	0.00168	-0.58	-0.43	Schizophrenia;	chr3:63889058	chr3:63911518~63911772:-
GBM	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-5.12	1.26e-06	0.00168	-0.57	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
GBM	cis	rs7267979	0.932	rs449370	ENSG00000276952.1	RP5-965G21.6	-5.11	1.27e-06	0.00169	-0.4	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25284915~25285588:-
GBM	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-5.11	1.28e-06	0.00169	-0.49	-0.43	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
GBM	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	5.11	1.28e-06	0.0017	0.38	0.43	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
GBM	cis	rs5742933	0.948	rs7592066	ENSG00000253559.1	OSGEPL1-AS1	5.11	1.28e-06	0.0017	0.46	0.43	Ferritin levels;	chr2:189778792	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.779	rs7595020	ENSG00000253559.1	OSGEPL1-AS1	5.11	1.28e-06	0.0017	0.46	0.43	Ferritin levels;	chr2:189778950	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.681	rs4525728	ENSG00000253559.1	OSGEPL1-AS1	5.11	1.28e-06	0.0017	0.46	0.43	Ferritin levels;	chr2:189780324	chr2:189762704~189765556:+
GBM	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-5.11	1.28e-06	0.0017	-0.52	-0.43	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
GBM	cis	rs9876781	0.624	rs12491849	ENSG00000244380.1	RP11-24C3.2	5.11	1.28e-06	0.0017	0.5	0.43	Longevity;	chr3:48489975	chr3:48440352~48446656:-
GBM	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	5.11	1.28e-06	0.0017	0.49	0.43	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
GBM	cis	rs17685	0.712	rs7794454	ENSG00000280388.1	RP11-229D13.3	5.11	1.28e-06	0.0017	0.4	0.43	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:76043977~76045963:-
GBM	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	5.11	1.28e-06	0.0017	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
GBM	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-5.11	1.29e-06	0.00171	-0.49	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
GBM	cis	rs9876781	1	rs6442119	ENSG00000244380.1	RP11-24C3.2	5.11	1.29e-06	0.00171	0.48	0.43	Longevity;	chr3:48398713	chr3:48440352~48446656:-
GBM	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-5.11	1.29e-06	0.00171	-0.43	-0.43	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
GBM	cis	rs73198271	0.855	rs57301822	ENSG00000253893.2	FAM85B	5.11	1.29e-06	0.00171	0.59	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8167819~8226614:-
GBM	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	5.11	1.29e-06	0.00171	0.63	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
GBM	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	5.11	1.29e-06	0.00171	0.63	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
GBM	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	5.11	1.3e-06	0.00172	0.5	0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
GBM	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-5.11	1.3e-06	0.00173	-0.54	-0.43	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
GBM	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-5.11	1.3e-06	0.00173	-0.47	-0.43	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
GBM	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-5.11	1.3e-06	0.00173	-0.47	-0.43	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
GBM	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-5.11	1.3e-06	0.00173	-0.47	-0.43	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
GBM	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	5.11	1.3e-06	0.00173	0.51	0.43	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
GBM	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-5.11	1.31e-06	0.00173	-0.56	-0.43	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
GBM	cis	rs3096299	0.754	rs3096320	ENSG00000260259.1	RP11-368I7.4	5.11	1.31e-06	0.00173	0.48	0.43	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89682620~89686569:-
GBM	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	5.11	1.31e-06	0.00173	0.43	0.43	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
GBM	cis	rs7267979	0.718	rs2983489	ENSG00000276952.1	RP5-965G21.6	5.11	1.31e-06	0.00173	0.39	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25284915~25285588:-
GBM	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-5.11	1.31e-06	0.00174	-0.56	-0.43	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-5.11	1.31e-06	0.00174	-0.56	-0.43	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-5.11	1.31e-06	0.00174	-0.56	-0.43	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-5.11	1.31e-06	0.00174	-0.56	-0.43	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
GBM	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	5.11	1.31e-06	0.00174	0.53	0.43	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
GBM	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	5.11	1.31e-06	0.00174	0.6	0.43	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	5.11	1.31e-06	0.00174	0.6	0.43	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
GBM	cis	rs17685	0.632	rs1859793	ENSG00000280388.1	RP11-229D13.3	-5.11	1.31e-06	0.00174	-0.41	-0.43	Coffee consumption (cups per day);Coffee consumption;	chr7:76191965	chr7:76043977~76045963:-
GBM	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-5.11	1.31e-06	0.00174	-0.53	-0.43	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
GBM	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	5.11	1.31e-06	0.00174	0.42	0.43	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
GBM	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	5.11	1.31e-06	0.00174	0.49	0.43	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
GBM	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	5.11	1.31e-06	0.00174	0.49	0.43	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
GBM	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	5.11	1.31e-06	0.00174	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	5.11	1.31e-06	0.00174	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	5.11	1.31e-06	0.00174	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	5.11	1.31e-06	0.00174	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
GBM	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	5.11	1.32e-06	0.00174	0.49	0.43	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	5.11	1.32e-06	0.00174	0.49	0.43	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
GBM	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-5.11	1.32e-06	0.00174	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-5.11	1.32e-06	0.00174	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
GBM	cis	rs4683346	0.712	rs4683345	ENSG00000273328.4	RP11-141M3.6	-5.11	1.32e-06	0.00175	-0.46	-0.43	Granulocyte percentage of myeloid white cells;	chr3:42845150	chr3:42809414~42908105:+
GBM	cis	rs9876781	0.967	rs2885509	ENSG00000244380.1	RP11-24C3.2	-5.11	1.32e-06	0.00175	-0.5	-0.43	Longevity;	chr3:48376729	chr3:48440352~48446656:-
GBM	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	5.11	1.32e-06	0.00175	0.48	0.43	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
GBM	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	5.11	1.32e-06	0.00175	0.43	0.43	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
GBM	cis	rs7267979	0.932	rs2260997	ENSG00000125804.12	FAM182A	5.1	1.32e-06	0.00175	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:26054655~26086917:+
GBM	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	5.1	1.32e-06	0.00175	0.52	0.43	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
GBM	cis	rs11233250	0.697	rs1472401	ENSG00000245832.5	RP11-179A16.1	5.1	1.33e-06	0.00175	0.63	0.43	Glioblastoma;Glioma;	chr11:82711904	chr11:81879851~82718082:-
GBM	cis	rs11690935	0.879	rs13017585	ENSG00000228389.1	AC068039.4	5.1	1.33e-06	0.00175	0.43	0.43	Schizophrenia;	chr2:171865298	chr2:171773482~171775844:+
GBM	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	5.1	1.33e-06	0.00176	0.72	0.43	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
GBM	cis	rs11098499	0.739	rs9884728	ENSG00000249244.1	RP11-548H18.2	-5.1	1.33e-06	0.00176	-0.57	-0.43	Corneal astigmatism;	chr4:119205924	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.739	rs7441137	ENSG00000249244.1	RP11-548H18.2	-5.1	1.33e-06	0.00176	-0.57	-0.43	Corneal astigmatism;	chr4:119212066	chr4:119391831~119395335:-
GBM	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-5.1	1.33e-06	0.00176	-0.72	-0.43	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
GBM	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	5.1	1.33e-06	0.00176	0.48	0.43	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
GBM	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	5.1	1.33e-06	0.00176	0.56	0.43	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
GBM	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-5.1	1.34e-06	0.00176	-0.46	-0.43	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
GBM	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	5.1	1.34e-06	0.00176	0.51	0.43	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
GBM	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-5.1	1.34e-06	0.00176	-0.56	-0.43	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
GBM	cis	rs7267979	0.903	rs6115118	ENSG00000276952.1	RP5-965G21.6	5.1	1.34e-06	0.00177	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.903	rs1118963	ENSG00000276952.1	RP5-965G21.6	5.1	1.34e-06	0.00177	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25284915~25285588:-
GBM	cis	rs7267979	1	rs4815420	ENSG00000125804.12	FAM182A	5.1	1.34e-06	0.00177	0.54	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:26054655~26086917:+
GBM	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-5.1	1.34e-06	0.00177	-0.37	-0.43	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
GBM	cis	rs2013441	0.866	rs2526492	ENSG00000230528.6	NOS2P3	5.1	1.35e-06	0.00178	0.51	0.43	Obesity-related traits;	chr17:20192302	chr17:20436337~20447249:+
GBM	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	5.1	1.35e-06	0.00179	0.5	0.43	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	5.1	1.35e-06	0.00179	0.5	0.43	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	5.1	1.35e-06	0.00179	0.5	0.43	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	5.1	1.35e-06	0.00179	0.5	0.43	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	5.1	1.35e-06	0.00179	0.5	0.43	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
GBM	cis	rs56262138	0.5	rs68058340	ENSG00000239519.1	CADM2-AS1	5.1	1.35e-06	0.00179	0.47	0.43	Educational attainment (years of education);	chr3:85980808	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs4688895	ENSG00000239519.1	CADM2-AS1	5.1	1.35e-06	0.00179	0.47	0.43	Educational attainment (years of education);	chr3:85985606	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs56339824	ENSG00000239519.1	CADM2-AS1	5.1	1.35e-06	0.00179	0.47	0.43	Educational attainment (years of education);	chr3:85987159	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs12486982	ENSG00000239519.1	CADM2-AS1	5.1	1.35e-06	0.00179	0.47	0.43	Educational attainment (years of education);	chr3:85988012	chr3:85992183~86028007:-
GBM	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-5.1	1.36e-06	0.00179	-0.53	-0.43	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-5.1	1.36e-06	0.00179	-0.53	-0.43	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
GBM	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	5.1	1.36e-06	0.00179	0.6	0.43	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
GBM	cis	rs10435719	0.867	rs35778860	ENSG00000255556.2	RP11-351I21.6	5.1	1.36e-06	0.00179	0.45	0.43	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.867	rs34465618	ENSG00000255556.2	RP11-351I21.6	5.1	1.36e-06	0.00179	0.45	0.43	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.867	rs34583868	ENSG00000255556.2	RP11-351I21.6	5.1	1.36e-06	0.00179	0.45	0.43	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:12378679~12380265:-
GBM	cis	rs893971	0.672	rs10024717	ENSG00000246375.2	RP11-10L7.1	5.1	1.36e-06	0.00179	0.48	0.43	Conduct disorder (maternal expressed emotions interaction);	chr4:88298493	chr4:88284942~88331421:+
GBM	cis	rs6782228	0.606	rs6775270	ENSG00000277250.1	Metazoa_SRP	-5.1	1.36e-06	0.00179	-0.46	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128673681~128674021:-
GBM	cis	rs6782228	0.606	rs6807019	ENSG00000277250.1	Metazoa_SRP	-5.1	1.36e-06	0.00179	-0.46	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128673681~128674021:-
GBM	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	5.1	1.36e-06	0.0018	0.49	0.43	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	5.1	1.36e-06	0.0018	0.49	0.43	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-5.1	1.36e-06	0.0018	-0.49	-0.43	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
GBM	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	5.1	1.36e-06	0.0018	0.58	0.43	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
GBM	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	5.1	1.36e-06	0.0018	0.58	0.43	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
GBM	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	5.1	1.37e-06	0.0018	0.62	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
GBM	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-5.1	1.37e-06	0.0018	-0.51	-0.43	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
GBM	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-5.1	1.37e-06	0.0018	-0.53	-0.43	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
GBM	cis	rs11098499	0.739	rs2203039	ENSG00000249244.1	RP11-548H18.2	-5.1	1.37e-06	0.00181	-0.57	-0.43	Corneal astigmatism;	chr4:119211192	chr4:119391831~119395335:-
GBM	cis	rs7267979	0.808	rs84816	ENSG00000125804.12	FAM182A	-5.1	1.37e-06	0.00181	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:26054655~26086917:+
GBM	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-5.1	1.38e-06	0.00181	-0.56	-0.43	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
GBM	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-5.1	1.38e-06	0.00181	-0.57	-0.43	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
GBM	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-5.1	1.38e-06	0.00181	-0.57	-0.43	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
GBM	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-5.1	1.38e-06	0.00181	-0.57	-0.43	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
GBM	cis	rs10946940	0.632	rs9366698	ENSG00000216901.1	AL022393.7	5.1	1.38e-06	0.00181	0.58	0.43	Systemic lupus erythematosus;	chr6:27704256	chr6:28176188~28176674:+
GBM	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	5.1	1.38e-06	0.00181	0.57	0.43	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
GBM	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	5.09	1.38e-06	0.00182	0.49	0.43	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
GBM	cis	rs11098499	0.874	rs7661020	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119185827	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs9995277	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119187448	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs17839089	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119189914	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs6826823	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119190943	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	5.09	1.38e-06	0.00182	0.56	0.43	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
GBM	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	5.09	1.38e-06	0.00182	0.72	0.43	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
GBM	cis	rs67981189	0.896	rs2010061	ENSG00000269927.1	RP6-91H8.3	-5.09	1.38e-06	0.00182	-0.5	-0.43	Schizophrenia;	chr14:70899479	chr14:71141125~71143253:-
GBM	cis	rs4683346	0.752	rs4683341	ENSG00000273328.4	RP11-141M3.6	-5.09	1.38e-06	0.00182	-0.47	-0.43	Granulocyte percentage of myeloid white cells;	chr3:42835902	chr3:42809414~42908105:+
GBM	cis	rs2810114	0.916	rs2526851	ENSG00000269927.1	RP6-91H8.3	-5.09	1.39e-06	0.00182	-0.52	-0.43	Alcohol dependence;	chr14:70949563	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.529	rs2526850	ENSG00000269927.1	RP6-91H8.3	-5.09	1.39e-06	0.00182	-0.52	-0.43	Schizophrenia;	chr14:70950532	chr14:71141125~71143253:-
GBM	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-5.09	1.39e-06	0.00183	-0.44	-0.43	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
GBM	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-5.09	1.39e-06	0.00183	-0.44	-0.43	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
GBM	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-5.09	1.39e-06	0.00183	-0.44	-0.43	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
GBM	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	5.09	1.39e-06	0.00183	0.55	0.43	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	5.09	1.39e-06	0.00183	0.55	0.43	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
GBM	cis	rs397969	0.596	rs9901294	ENSG00000230528.6	NOS2P3	-5.09	1.4e-06	0.00183	-0.52	-0.43	Platelet count;	chr17:19985188	chr17:20436337~20447249:+
GBM	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	5.09	1.4e-06	0.00183	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	5.09	1.4e-06	0.00183	0.8	0.43	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	5.09	1.4e-06	0.00183	0.8	0.43	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	5.09	1.4e-06	0.00183	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
GBM	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	5.09	1.4e-06	0.00184	0.54	0.43	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
GBM	cis	rs4683346	0.752	rs1007638	ENSG00000273328.4	RP11-141M3.6	-5.09	1.4e-06	0.00184	-0.46	-0.43	Granulocyte percentage of myeloid white cells;	chr3:42839573	chr3:42809414~42908105:+
GBM	cis	rs4683346	0.752	rs11919717	ENSG00000273328.4	RP11-141M3.6	-5.09	1.4e-06	0.00184	-0.46	-0.43	Granulocyte percentage of myeloid white cells;	chr3:42841510	chr3:42809414~42908105:+
GBM	cis	rs9876781	1	rs4858817	ENSG00000244380.1	RP11-24C3.2	-5.09	1.4e-06	0.00184	-0.49	-0.43	Longevity;	chr3:48375266	chr3:48440352~48446656:-
GBM	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	5.09	1.41e-06	0.00185	0.43	0.43	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
GBM	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	5.09	1.41e-06	0.00185	0.43	0.43	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
GBM	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-5.09	1.41e-06	0.00185	-0.64	-0.43	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
GBM	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-5.09	1.41e-06	0.00185	-0.49	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
GBM	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-5.09	1.41e-06	0.00185	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
GBM	cis	rs6782228	0.565	rs67445542	ENSG00000277250.1	Metazoa_SRP	-5.09	1.41e-06	0.00185	-0.47	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128673681~128674021:-
GBM	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-5.09	1.41e-06	0.00185	-0.59	-0.43	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
GBM	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-5.09	1.41e-06	0.00185	-0.59	-0.43	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
GBM	cis	rs454217	0.773	rs518009	ENSG00000277851.1	RP11-756G20.1	5.09	1.41e-06	0.00185	0.45	0.43	Smoking quantity;	chr12:92339730	chr12:92247756~92363832:-
GBM	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	5.09	1.42e-06	0.00186	0.5	0.43	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
GBM	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	5.09	1.42e-06	0.00186	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	5.09	1.42e-06	0.00186	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	5.09	1.42e-06	0.00186	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
GBM	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	5.09	1.42e-06	0.00186	0.58	0.43	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
GBM	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	5.09	1.42e-06	0.00186	0.46	0.43	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
GBM	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-5.09	1.42e-06	0.00186	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
GBM	cis	rs67981189	0.513	rs221893	ENSG00000269927.1	RP6-91H8.3	-5.09	1.42e-06	0.00186	-0.49	-0.43	Schizophrenia;	chr14:71144697	chr14:71141125~71143253:-
GBM	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	5.09	1.42e-06	0.00186	0.65	0.43	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
GBM	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	5.09	1.42e-06	0.00186	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
GBM	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	5.09	1.42e-06	0.00186	0.49	0.43	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	5.09	1.42e-06	0.00186	0.49	0.43	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	5.09	1.42e-06	0.00186	0.49	0.43	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
GBM	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-5.09	1.42e-06	0.00186	-0.49	-0.43	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
GBM	cis	rs3806843	0.966	rs2337516	ENSG00000202111.1	VTRNA1-2	5.09	1.42e-06	0.00186	0.45	0.43	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr5:140718925~140719013:+
GBM	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	5.09	1.42e-06	0.00186	0.52	0.43	Height;	chr3:53082835	chr3:53064283~53065091:-
GBM	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-5.09	1.42e-06	0.00186	-0.54	-0.43	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
GBM	cis	rs763121	0.853	rs5757231	ENSG00000273076.1	RP3-508I15.22	-5.09	1.42e-06	0.00186	-0.46	-0.43	Menopause (age at onset);	chr22:38675653	chr22:38743495~38743910:+
GBM	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	5.09	1.43e-06	0.00187	0.6	0.43	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
GBM	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-5.09	1.43e-06	0.00187	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-5.09	1.43e-06	0.00187	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
GBM	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-5.09	1.43e-06	0.00187	-0.59	-0.43	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
GBM	cis	rs172166	0.516	rs2791333	ENSG00000199851.2	U3	5.09	1.43e-06	0.00187	0.52	0.43	Cardiac Troponin-T levels;	chr6:28143336	chr6:28015568~28015777:+
GBM	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-5.09	1.43e-06	0.00188	-0.51	-0.43	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
GBM	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-5.09	1.43e-06	0.00188	-0.57	-0.43	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
GBM	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-5.09	1.43e-06	0.00188	-0.57	-0.43	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
GBM	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-5.09	1.43e-06	0.00188	-0.57	-0.43	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
GBM	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	5.09	1.44e-06	0.00188	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	5.09	1.44e-06	0.00188	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
GBM	cis	rs17772222	0.74	rs61975278	ENSG00000222990.1	RNU4-22P	5.09	1.44e-06	0.00188	0.47	0.43	Coronary artery calcification;	chr14:88511223	chr14:88513498~88513663:+
GBM	cis	rs4273100	0.512	rs2233072	ENSG00000262319.1	CTC-457L16.2	5.09	1.44e-06	0.00188	0.48	0.43	Schizophrenia;	chr17:19378515	chr17:19141017~19143689:-
GBM	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	5.08	1.44e-06	0.00189	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
GBM	cis	rs453301	0.538	rs7830804	ENSG00000254340.1	RP11-10A14.3	-5.08	1.44e-06	0.00189	-0.55	-0.43	Joint mobility (Beighton score);	chr8:9113252	chr8:9141424~9145435:+
GBM	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-5.08	1.45e-06	0.00189	-0.56	-0.43	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
GBM	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	5.08	1.45e-06	0.00189	0.7	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
GBM	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	5.08	1.45e-06	0.00189	0.53	0.43	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
GBM	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	5.08	1.45e-06	0.0019	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
GBM	cis	rs7267979	1	rs6115168	ENSG00000125804.12	FAM182A	5.08	1.45e-06	0.0019	0.54	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:26054655~26086917:+
GBM	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-5.08	1.45e-06	0.0019	-0.57	-0.43	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
GBM	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	5.08	1.45e-06	0.0019	0.67	0.43	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
GBM	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
GBM	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.46e-06	0.0019	-0.56	-0.43	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
GBM	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	5.08	1.46e-06	0.0019	0.55	0.43	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
GBM	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-5.08	1.46e-06	0.0019	-0.45	-0.43	Height;	chr11:118809363	chr11:118791254~118793137:+
GBM	cis	rs2810114	0.916	rs2810099	ENSG00000269927.1	RP6-91H8.3	-5.08	1.46e-06	0.00191	-0.51	-0.43	Alcohol dependence;	chr14:70965704	chr14:71141125~71143253:-
GBM	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	5.08	1.46e-06	0.00191	0.37	0.43	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
GBM	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-5.08	1.46e-06	0.00191	-0.58	-0.43	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
GBM	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-5.08	1.46e-06	0.00191	-0.59	-0.43	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
GBM	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-5.08	1.46e-06	0.00191	-0.57	-0.43	Height;	chr11:118747911	chr11:118704607~118750263:+
GBM	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-5.08	1.47e-06	0.00191	-0.51	-0.43	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
GBM	cis	rs3762637	0.765	rs28718697	ENSG00000272758.4	RP11-299J3.8	-5.08	1.47e-06	0.00192	-0.69	-0.43	LDL cholesterol levels;	chr3:122430650	chr3:122416207~122443180:+
GBM	cis	rs4072705	1	rs10760370	ENSG00000224020.1	MIR181A2HG	-5.08	1.48e-06	0.00193	-0.47	-0.43	Menarche (age at onset);	chr9:124655724	chr9:124658467~124698631:+
GBM	cis	rs2288884	0.515	rs9676397	ENSG00000275055.1	CTC-471J1.11	-5.08	1.48e-06	0.00194	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:52049007~52049754:+
GBM	cis	rs8067545	0.64	rs17759083	ENSG00000230528.6	NOS2P3	-5.08	1.49e-06	0.00194	-0.49	-0.43	Schizophrenia;	chr17:20060292	chr17:20436337~20447249:+
GBM	cis	rs3806843	0.9	rs2337984	ENSG00000202111.1	VTRNA1-2	5.08	1.49e-06	0.00195	0.45	0.43	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr5:140718925~140719013:+
GBM	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	5.08	1.49e-06	0.00195	0.6	0.43	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	5.08	1.49e-06	0.00195	0.6	0.43	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	5.08	1.49e-06	0.00195	0.6	0.43	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
GBM	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-5.08	1.49e-06	0.00195	-0.57	-0.43	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-5.08	1.49e-06	0.00195	-0.57	-0.43	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-5.08	1.49e-06	0.00195	-0.57	-0.43	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
GBM	cis	rs7267979	0.932	rs6115214	ENSG00000125804.12	FAM182A	5.08	1.49e-06	0.00195	0.54	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.899	rs2179459	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs2387891	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs6115200	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs6138588	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs4280527	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.899	rs6115213	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs6132848	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.932	rs6115215	ENSG00000125804.12	FAM182A	-5.08	1.49e-06	0.00195	-0.54	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:26054655~26086917:+
GBM	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	5.08	1.5e-06	0.00195	0.29	0.43	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	5.08	1.5e-06	0.00195	0.29	0.43	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	5.08	1.5e-06	0.00195	0.29	0.43	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	5.08	1.5e-06	0.00195	0.29	0.43	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	5.08	1.5e-06	0.00195	0.29	0.43	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	5.08	1.5e-06	0.00195	0.29	0.43	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
GBM	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-5.08	1.5e-06	0.00195	-0.57	-0.43	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
GBM	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-5.08	1.5e-06	0.00195	-0.57	-0.43	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
GBM	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-5.08	1.5e-06	0.00195	-0.57	-0.43	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
GBM	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-5.08	1.5e-06	0.00195	-0.58	-0.43	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-5.08	1.5e-06	0.00195	-0.58	-0.43	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
GBM	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-5.08	1.5e-06	0.00195	-0.58	-0.43	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
GBM	cis	rs7216064	0.532	rs8065296	ENSG00000278219.1	AC145343.1	5.08	1.5e-06	0.00195	0.46	0.43	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68101538~68101639:+
GBM	cis	rs397969	0.646	rs1638526	ENSG00000230528.6	NOS2P3	-5.08	1.5e-06	0.00196	-0.51	-0.43	Platelet count;	chr17:19945137	chr17:20436337~20447249:+
GBM	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-5.07	1.51e-06	0.00196	-0.53	-0.43	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
GBM	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-5.07	1.51e-06	0.00196	-0.5	-0.43	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
GBM	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	5.07	1.51e-06	0.00196	0.49	0.43	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
GBM	cis	rs7176527	0.519	rs12148368	ENSG00000225151.9	GOLGA2P7	5.07	1.51e-06	0.00196	0.54	0.43	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84199311~84230136:-
GBM	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	5.07	1.51e-06	0.00196	0.5	0.43	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	5.07	1.51e-06	0.00196	0.5	0.43	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	5.07	1.51e-06	0.00196	0.5	0.43	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	5.07	1.51e-06	0.00196	0.5	0.43	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	5.07	1.51e-06	0.00196	0.5	0.43	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
GBM	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-5.07	1.51e-06	0.00197	-0.54	-0.43	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
GBM	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	5.07	1.52e-06	0.00197	0.52	0.43	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
GBM	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	5.07	1.52e-06	0.00198	0.41	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
GBM	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	5.07	1.52e-06	0.00198	0.54	0.43	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	5.07	1.52e-06	0.00198	0.54	0.43	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	5.07	1.52e-06	0.00198	0.54	0.43	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
GBM	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-5.07	1.52e-06	0.00198	-0.48	-0.43	QT interval;	chr16:28857143	chr16:28700294~28701540:-
GBM	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-5.07	1.52e-06	0.00198	-0.48	-0.43	QT interval;	chr16:28877088	chr16:28700294~28701540:-
GBM	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-5.07	1.52e-06	0.00198	-0.57	-0.43	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
GBM	cis	rs4072705	0.934	rs4838194	ENSG00000224020.1	MIR181A2HG	-5.07	1.52e-06	0.00198	-0.47	-0.43	Menarche (age at onset);	chr9:124580536	chr9:124658467~124698631:+
GBM	cis	rs5760092	0.755	rs915589	ENSG00000235689.1	AP000351.13	-5.07	1.53e-06	0.00198	-0.56	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:24006305~24008258:-
GBM	cis	rs11671005	0.571	rs56243535	ENSG00000269473.1	CTD-2619J13.19	5.07	1.53e-06	0.00198	0.51	0.43	Mean platelet volume;	chr19:58494783	chr19:58440448~58445849:+
GBM	cis	rs9393777	0.546	rs9366673	ENSG00000224843.5	LINC00240	5.07	1.53e-06	0.00198	0.62	0.43	Intelligence (multi-trait analysis);	chr6:26925550	chr6:26956992~27023924:+
GBM	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	5.07	1.53e-06	0.00199	0.52	0.43	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
GBM	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-5.07	1.53e-06	0.00199	-0.57	-0.43	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
GBM	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	5.07	1.53e-06	0.00199	0.63	0.43	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
GBM	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	5.07	1.54e-06	0.00199	0.52	0.43	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
GBM	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	5.07	1.54e-06	0.00199	0.52	0.43	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
GBM	cis	rs2810114	0.76	rs2810105	ENSG00000269927.1	RP6-91H8.3	-5.07	1.54e-06	0.002	-0.51	-0.43	Alcohol dependence;	chr14:70957934	chr14:71141125~71143253:-
GBM	cis	rs8067545	0.64	rs10083840	ENSG00000230528.6	NOS2P3	-5.07	1.54e-06	0.002	-0.49	-0.43	Schizophrenia;	chr17:20062659	chr17:20436337~20447249:+
GBM	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-5.07	1.55e-06	0.00201	-0.49	-0.43	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
GBM	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	5.07	1.55e-06	0.00201	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
GBM	cis	rs4072705	1	rs10760374	ENSG00000224020.1	MIR181A2HG	-5.07	1.55e-06	0.00201	-0.48	-0.43	Menarche (age at onset);	chr9:124733229	chr9:124658467~124698631:+
GBM	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	5.07	1.55e-06	0.00201	0.5	0.43	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
GBM	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	5.07	1.55e-06	0.00201	0.56	0.43	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
GBM	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-5.07	1.55e-06	0.00201	-0.56	-0.43	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
GBM	cis	rs172166	0.61	rs156737	ENSG00000280107.1	AL022393.9	-5.07	1.55e-06	0.00201	-0.46	-0.43	Cardiac Troponin-T levels;	chr6:27927435	chr6:28170845~28172521:+
GBM	cis	rs172166	0.61	rs276369	ENSG00000280107.1	AL022393.9	-5.07	1.55e-06	0.00201	-0.46	-0.43	Cardiac Troponin-T levels;	chr6:27951465	chr6:28170845~28172521:+
GBM	cis	rs9368481	0.7	rs6911401	ENSG00000224843.5	LINC00240	-5.07	1.55e-06	0.00201	-0.51	-0.43	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.729	rs10946881	ENSG00000224843.5	LINC00240	-5.07	1.55e-06	0.00201	-0.51	-0.43	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.678	rs62402024	ENSG00000224843.5	LINC00240	-5.07	1.55e-06	0.00201	-0.51	-0.43	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26956992~27023924:+
GBM	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-5.07	1.56e-06	0.00201	-0.48	-0.43	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
GBM	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	5.07	1.56e-06	0.00201	0.53	0.43	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
GBM	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-5.07	1.56e-06	0.00201	-0.5	-0.43	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
GBM	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-5.07	1.56e-06	0.00202	-0.43	-0.43	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
GBM	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	5.07	1.56e-06	0.00202	0.45	0.43	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
GBM	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	5.07	1.57e-06	0.00202	0.42	0.43	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
GBM	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	5.07	1.57e-06	0.00203	0.94	0.43	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
GBM	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	5.07	1.57e-06	0.00203	0.94	0.43	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
GBM	cis	rs11233250	0.619	rs1497119	ENSG00000245832.5	RP11-179A16.1	5.07	1.57e-06	0.00203	0.75	0.43	Glioblastoma;Glioma;	chr11:82691866	chr11:81879851~82718082:-
GBM	cis	rs11233250	0.697	rs17144112	ENSG00000245832.5	RP11-179A16.1	5.07	1.57e-06	0.00203	0.75	0.43	Glioblastoma;Glioma;	chr11:82692788	chr11:81879851~82718082:-
GBM	cis	rs6591341	0.515	rs599301	ENSG00000212093.1	AP000807.1	5.06	1.57e-06	0.00203	0.49	0.43	Lean body mass;	chr11:68422477	chr11:68506083~68506166:-
GBM	cis	rs67981189	0.593	rs221904	ENSG00000269927.1	RP6-91H8.3	-5.06	1.57e-06	0.00203	-0.49	-0.43	Schizophrenia;	chr14:71132771	chr14:71141125~71143253:-
GBM	cis	rs893971	0.672	rs28375859	ENSG00000246375.2	RP11-10L7.1	5.06	1.58e-06	0.00203	0.48	0.43	Conduct disorder (maternal expressed emotions interaction);	chr4:88303033	chr4:88284942~88331421:+
GBM	cis	rs4273100	0.646	rs6587216	ENSG00000262319.1	CTC-457L16.2	5.06	1.58e-06	0.00204	0.51	0.43	Schizophrenia;	chr17:19321084	chr17:19141017~19143689:-
GBM	cis	rs9876781	1	rs9838618	ENSG00000244380.1	RP11-24C3.2	5.06	1.58e-06	0.00204	0.48	0.43	Longevity;	chr3:48445949	chr3:48440352~48446656:-
GBM	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	5.06	1.58e-06	0.00204	0.29	0.43	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
GBM	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	5.06	1.58e-06	0.00204	0.49	0.43	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
GBM	cis	rs4072705	0.967	rs2148787	ENSG00000224020.1	MIR181A2HG	-5.06	1.58e-06	0.00204	-0.47	-0.43	Menarche (age at onset);	chr9:124705925	chr9:124658467~124698631:+
GBM	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-5.06	1.58e-06	0.00204	-0.57	-0.43	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
GBM	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-5.06	1.58e-06	0.00204	-0.57	-0.43	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
GBM	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-5.06	1.58e-06	0.00204	-0.57	-0.43	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
GBM	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-5.06	1.58e-06	0.00204	-0.57	-0.43	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
GBM	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-5.06	1.58e-06	0.00204	-0.57	-0.43	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
GBM	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-5.06	1.58e-06	0.00204	-0.51	-0.43	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-5.06	1.58e-06	0.00204	-0.51	-0.43	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
GBM	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-5.06	1.58e-06	0.00204	-0.56	-0.43	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-5.06	1.59e-06	0.00205	-0.57	-0.43	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
GBM	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-5.06	1.59e-06	0.00205	-0.57	-0.43	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-5.06	1.59e-06	0.00205	-0.57	-0.43	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
GBM	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	1.59e-06	0.00205	-0.37	-0.43	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
GBM	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	5.06	1.6e-06	0.00205	0.42	0.43	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
GBM	cis	rs2408955	0.522	rs4760679	ENSG00000258273.1	RP11-370I10.4	5.06	1.6e-06	0.00205	0.54	0.43	Glycated hemoglobin levels;	chr12:48067852	chr12:48333755~48333901:-
GBM	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	5.06	1.6e-06	0.00205	0.56	0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
GBM	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-5.06	1.6e-06	0.00205	-0.51	-0.43	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000224205.1	AP000351.4	-5.06	1.6e-06	0.00205	-0.54	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23987320~23991421:-
GBM	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-5.06	1.6e-06	0.00205	-0.47	-0.43	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
GBM	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	5.06	1.6e-06	0.00206	0.52	0.43	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	5.06	1.6e-06	0.00206	0.52	0.43	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	5.06	1.6e-06	0.00206	0.52	0.43	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	5.06	1.6e-06	0.00206	0.52	0.43	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
GBM	cis	rs7829975	0.626	rs332040	ENSG00000254340.1	RP11-10A14.3	5.06	1.6e-06	0.00206	0.53	0.43	Mood instability;	chr8:8872978	chr8:9141424~9145435:+
GBM	cis	rs4713118	0.868	rs760587	ENSG00000218016.2	ZNF192P2	-5.06	1.6e-06	0.00206	-0.59	-0.43	Parkinson's disease;	chr6:27772521	chr6:28188050~28189432:+
GBM	cis	rs7267979	1	rs12428	ENSG00000125804.12	FAM182A	5.06	1.6e-06	0.00206	0.54	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:26054655~26086917:+
GBM	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	5.06	1.6e-06	0.00206	0.48	0.43	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
GBM	cis	rs9926296	0.585	rs4785595	ENSG00000260259.1	RP11-368I7.4	5.06	1.6e-06	0.00206	0.46	0.43	Vitiligo;	chr16:89769113	chr16:89682620~89686569:-
GBM	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	5.06	1.6e-06	0.00206	0.48	0.43	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	5.06	1.6e-06	0.00206	0.48	0.43	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.513	rs630225	ENSG00000212093.1	AP000807.1	5.06	1.6e-06	0.00206	0.48	0.43	Total body bone mineral density;	chr11:68427143	chr11:68506083~68506166:-
GBM	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-5.06	1.61e-06	0.00206	-0.46	-0.43	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-5.06	1.61e-06	0.00206	-0.46	-0.43	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
GBM	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	5.06	1.61e-06	0.00207	0.28	0.43	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
GBM	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	5.06	1.61e-06	0.00207	0.57	0.43	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
GBM	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	5.06	1.61e-06	0.00207	0.45	0.43	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
GBM	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-5.06	1.62e-06	0.00208	-0.65	-0.43	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
GBM	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-5.06	1.62e-06	0.00208	-0.65	-0.43	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
GBM	cis	rs4072705	1	rs7874367	ENSG00000224020.1	MIR181A2HG	5.06	1.62e-06	0.00209	0.47	0.43	Menarche (age at onset);	chr9:124615501	chr9:124658467~124698631:+
GBM	cis	rs4072705	1	rs4838201	ENSG00000224020.1	MIR181A2HG	-5.06	1.62e-06	0.00209	-0.47	-0.43	Menarche (age at onset);	chr9:124698338	chr9:124658467~124698631:+
GBM	cis	rs172166	0.516	rs2622322	ENSG00000199851.2	U3	5.06	1.62e-06	0.00209	0.51	0.43	Cardiac Troponin-T levels;	chr6:28149665	chr6:28015568~28015777:+
GBM	cis	rs172166	0.516	rs1150670	ENSG00000199851.2	U3	5.06	1.62e-06	0.00209	0.51	0.43	Cardiac Troponin-T levels;	chr6:28162781	chr6:28015568~28015777:+
GBM	cis	rs172166	0.516	rs2021826	ENSG00000199851.2	U3	5.06	1.62e-06	0.00209	0.51	0.43	Cardiac Troponin-T levels;	chr6:28164978	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.835	rs1233696	ENSG00000199851.2	U3	5.06	1.62e-06	0.00209	0.51	0.43	Pubertal anthropometrics;	chr6:28175232	chr6:28015568~28015777:+
GBM	cis	rs4072705	1	rs2416949	ENSG00000224020.1	MIR181A2HG	-5.06	1.63e-06	0.00209	-0.47	-0.43	Menarche (age at onset);	chr9:124712832	chr9:124658467~124698631:+
GBM	cis	rs7267979	0.868	rs6138546	ENSG00000276952.1	RP5-965G21.6	5.06	1.63e-06	0.00209	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.868	rs6138550	ENSG00000276952.1	RP5-965G21.6	5.06	1.63e-06	0.00209	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.903	rs6050481	ENSG00000276952.1	RP5-965G21.6	5.06	1.63e-06	0.00209	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.834	rs6115100	ENSG00000276952.1	RP5-965G21.6	5.06	1.63e-06	0.00209	0.4	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25284915~25285588:-
GBM	cis	rs1150668	0.699	rs1736895	ENSG00000218016.2	ZNF192P2	-5.06	1.63e-06	0.00209	-0.5	-0.43	Pubertal anthropometrics;	chr6:28252048	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.699	rs12214383	ENSG00000218016.2	ZNF192P2	5.06	1.63e-06	0.00209	0.5	0.43	Pubertal anthropometrics;	chr6:28255953	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.699	rs1531681	ENSG00000218016.2	ZNF192P2	-5.06	1.63e-06	0.00209	-0.5	-0.43	Pubertal anthropometrics;	chr6:28259100	chr6:28188050~28189432:+
GBM	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-5.06	1.63e-06	0.00209	-0.56	-0.43	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
GBM	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-5.06	1.63e-06	0.0021	-0.45	-0.43	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
GBM	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-5.06	1.63e-06	0.0021	-0.45	-0.43	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
GBM	cis	rs10946940	0.965	rs9393830	ENSG00000218016.2	ZNF192P2	-5.06	1.64e-06	0.0021	-0.5	-0.43	Systemic lupus erythematosus;	chr6:27619248	chr6:28188050~28189432:+
GBM	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-5.06	1.64e-06	0.0021	-0.87	-0.43	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
GBM	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	5.06	1.64e-06	0.0021	0.56	0.43	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
GBM	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	5.06	1.64e-06	0.0021	0.56	0.43	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
GBM	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	5.05	1.64e-06	0.0021	0.54	0.43	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
GBM	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	5.05	1.64e-06	0.0021	0.62	0.43	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
GBM	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	5.05	1.64e-06	0.0021	0.62	0.43	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
GBM	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-5.05	1.64e-06	0.00211	-0.47	-0.43	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
GBM	cis	rs11098499	0.874	rs13123591	ENSG00000249244.1	RP11-548H18.2	5.05	1.64e-06	0.00211	0.56	0.43	Corneal astigmatism;	chr4:119184835	chr4:119391831~119395335:-
GBM	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	5.05	1.64e-06	0.00211	0.52	0.43	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
GBM	cis	rs3806843	0.931	rs13168670	ENSG00000202111.1	VTRNA1-2	-5.05	1.65e-06	0.00211	-0.45	-0.43	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr5:140718925~140719013:+
GBM	cis	rs7733403	1	rs7733403	ENSG00000202111.1	VTRNA1-2	-5.05	1.65e-06	0.00211	-0.45	-0.43	Schizophrenia;	chr5:140774630	chr5:140718925~140719013:+
GBM	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-5.05	1.65e-06	0.00211	-0.54	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
GBM	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.05	1.66e-06	0.00212	0.68	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	5.05	1.66e-06	0.00212	0.68	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.05	1.66e-06	0.00212	0.68	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
GBM	cis	rs67981189	0.529	rs2526872	ENSG00000269927.1	RP6-91H8.3	-5.05	1.66e-06	0.00212	-0.51	-0.43	Schizophrenia;	chr14:70918168	chr14:71141125~71143253:-
GBM	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	5.05	1.66e-06	0.00213	0.6	0.43	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
GBM	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	5.05	1.66e-06	0.00213	0.5	0.43	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
GBM	cis	rs7567389	0.812	rs6710496	ENSG00000236682.1	AC068282.3	5.05	1.67e-06	0.00213	0.48	0.43	Self-rated health;	chr2:127218798	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.889	rs1504136	ENSG00000236682.1	AC068282.3	5.05	1.67e-06	0.00213	0.48	0.43	Self-rated health;	chr2:127219542	chr2:127389130~127400580:+
GBM	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	5.05	1.67e-06	0.00214	0.49	0.43	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
GBM	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-5.05	1.67e-06	0.00214	-0.52	-0.43	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
GBM	cis	rs4273100	0.512	rs973650	ENSG00000262319.1	CTC-457L16.2	5.05	1.68e-06	0.00215	0.48	0.43	Schizophrenia;	chr17:19388472	chr17:19141017~19143689:-
GBM	cis	rs4273100	0.541	rs973649	ENSG00000262319.1	CTC-457L16.2	5.05	1.68e-06	0.00215	0.48	0.43	Schizophrenia;	chr17:19388755	chr17:19141017~19143689:-
GBM	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-5.05	1.68e-06	0.00215	-0.53	-0.43	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
GBM	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	5.05	1.69e-06	0.00215	0.5	0.43	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	5.05	1.69e-06	0.00215	0.5	0.43	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	5.05	1.69e-06	0.00215	0.5	0.43	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	5.05	1.69e-06	0.00215	0.5	0.43	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	5.05	1.69e-06	0.00215	0.5	0.43	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
GBM	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-5.05	1.69e-06	0.00216	-0.48	-0.43	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
GBM	cis	rs1150668	0.699	rs13408	ENSG00000199851.2	U3	5.05	1.69e-06	0.00216	0.53	0.43	Pubertal anthropometrics;	chr6:28244970	chr6:28015568~28015777:+
GBM	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	5.05	1.69e-06	0.00216	0.61	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
GBM	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	5.05	1.69e-06	0.00216	0.61	0.43	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
GBM	cis	rs916888	0.779	rs199498	ENSG00000261575.2	RP11-259G18.1	5.05	1.69e-06	0.00216	0.56	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46267037~46268694:+
GBM	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	5.05	1.7e-06	0.00217	0.58	0.43	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
GBM	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-5.05	1.7e-06	0.00217	-0.56	-0.43	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
GBM	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-5.05	1.7e-06	0.00217	-0.56	-0.43	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
GBM	cis	rs8081395	0.729	rs12453125	ENSG00000266992.1	DHX40P1	-5.05	1.7e-06	0.00217	-0.54	-0.43	White blood cell count;	chr17:59968715	chr17:59976009~60002384:-
GBM	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-5.05	1.7e-06	0.00217	-0.57	-0.43	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
GBM	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	5.05	1.7e-06	0.00217	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	5.05	1.7e-06	0.00217	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	5.05	1.7e-06	0.00217	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	5.05	1.7e-06	0.00217	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	5.05	1.7e-06	0.00217	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	5.05	1.7e-06	0.00217	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-5.05	1.7e-06	0.00217	-0.48	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
GBM	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	5.05	1.71e-06	0.00217	0.54	0.43	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
GBM	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	5.05	1.71e-06	0.00217	0.54	0.43	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
GBM	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	5.04	1.71e-06	0.00218	0.48	0.43	Height;	chr11:118854014	chr11:118688039~118690600:-
GBM	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	5.04	1.71e-06	0.00218	0.48	0.43	Height;	chr11:118855233	chr11:118688039~118690600:-
GBM	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	5.04	1.71e-06	0.00218	0.48	0.43	Height;	chr11:118855938	chr11:118688039~118690600:-
GBM	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-5.04	1.71e-06	0.00218	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-5.04	1.71e-06	0.00218	-0.51	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
GBM	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	5.04	1.72e-06	0.00219	0.48	0.43	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
GBM	cis	rs11098499	0.739	rs6534130	ENSG00000249244.1	RP11-548H18.2	-5.04	1.72e-06	0.00219	-0.57	-0.43	Corneal astigmatism;	chr4:119210184	chr4:119391831~119395335:-
GBM	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-5.04	1.72e-06	0.00219	-0.57	-0.43	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-5.04	1.72e-06	0.00219	-0.57	-0.43	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
GBM	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	5.04	1.72e-06	0.00219	0.5	0.43	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
GBM	cis	rs916888	0.61	rs142167	ENSG00000261575.2	RP11-259G18.1	-5.04	1.72e-06	0.00219	-0.51	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46267037~46268694:+
GBM	cis	rs12495178	0.549	rs4303861	ENSG00000239519.1	CADM2-AS1	5.04	1.72e-06	0.00219	0.43	0.43	Body mass index;	chr3:85975423	chr3:85992183~86028007:-
GBM	cis	rs11671005	0.611	rs56026876	ENSG00000269473.1	CTD-2619J13.19	5.04	1.72e-06	0.00219	0.51	0.43	Mean platelet volume;	chr19:58494790	chr19:58440448~58445849:+
GBM	cis	rs7267979	1	rs6083862	ENSG00000125804.12	FAM182A	5.04	1.72e-06	0.0022	0.49	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:26054655~26086917:+
GBM	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	5.04	1.73e-06	0.0022	0.6	0.43	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
GBM	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	5.04	1.73e-06	0.0022	0.6	0.43	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	5.04	1.73e-06	0.0022	0.6	0.43	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
GBM	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	5.04	1.73e-06	0.0022	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
GBM	cis	rs4887140	1	rs4887140	ENSG00000260469.2	C15orf59-AS1	-5.04	1.73e-06	0.0022	-0.81	-0.43	Glucose homeostasis traits;	chr15:73754322	chr15:73752317~73770613:+
GBM	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-5.04	1.73e-06	0.0022	-0.44	-0.43	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
GBM	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-5.04	1.73e-06	0.0022	-0.51	-0.43	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
GBM	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-5.04	1.73e-06	0.0022	-0.37	-0.43	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
GBM	cis	rs1420956	0.603	rs12456956	ENSG00000264151.4	RP11-739N10.1	5.04	1.74e-06	0.00221	0.56	0.43	Obesity-related traits;	chr18:27610887	chr18:27336379~27595164:-
GBM	cis	rs56262138	0.5	rs35177461	ENSG00000239519.1	CADM2-AS1	5.04	1.74e-06	0.00221	0.47	0.43	Educational attainment (years of education);	chr3:86030768	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs13073604	ENSG00000239519.1	CADM2-AS1	5.04	1.74e-06	0.00221	0.47	0.43	Educational attainment (years of education);	chr3:86031021	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs62263322	ENSG00000239519.1	CADM2-AS1	5.04	1.74e-06	0.00221	0.47	0.43	Educational attainment (years of education);	chr3:86033155	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs13061174	ENSG00000239519.1	CADM2-AS1	5.04	1.74e-06	0.00221	0.47	0.43	Educational attainment (years of education);	chr3:86037722	chr3:85992183~86028007:-
GBM	cis	rs67340775	0.541	rs200965	ENSG00000199851.2	U3	5.04	1.74e-06	0.00221	0.82	0.43	Lung cancer in ever smokers;	chr6:27898606	chr6:28015568~28015777:+
GBM	cis	rs4273100	0.564	rs10445411	ENSG00000262319.1	CTC-457L16.2	5.04	1.74e-06	0.00221	0.49	0.43	Schizophrenia;	chr17:19362484	chr17:19141017~19143689:-
GBM	cis	rs763121	0.853	rs4821811	ENSG00000273076.1	RP3-508I15.22	5.04	1.74e-06	0.00222	0.5	0.43	Menopause (age at onset);	chr22:38679140	chr22:38743495~38743910:+
GBM	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-5.04	1.75e-06	0.00222	-0.65	-0.43	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
GBM	cis	rs10754283	0.84	rs990040	ENSG00000231613.1	RP5-943J3.1	5.04	1.75e-06	0.00222	0.52	0.43	Amyotrophic lateral sclerosis (sporadic);	chr1:89628800	chr1:89788914~89790492:+
GBM	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	5.04	1.75e-06	0.00222	0.47	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
GBM	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	5.04	1.75e-06	0.00223	0.53	0.43	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	5.04	1.75e-06	0.00223	0.53	0.43	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	5.04	1.75e-06	0.00223	0.53	0.43	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	5.04	1.75e-06	0.00223	0.53	0.43	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
GBM	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	5.04	1.75e-06	0.00223	1	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
GBM	cis	rs2288884	0.515	rs11882053	ENSG00000275055.1	CTC-471J1.11	-5.04	1.76e-06	0.00224	-0.52	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047687	chr19:52049007~52049754:+
GBM	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-5.04	1.76e-06	0.00224	-0.47	-0.43	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
GBM	cis	rs10754283	0.84	rs1215504	ENSG00000231613.1	RP5-943J3.1	5.04	1.76e-06	0.00224	0.52	0.43	Amyotrophic lateral sclerosis (sporadic);	chr1:89626331	chr1:89788914~89790492:+
GBM	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	5.04	1.76e-06	0.00224	0.51	0.43	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
GBM	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-5.04	1.76e-06	0.00224	-0.59	-0.43	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.505	rs276371	ENSG00000280107.1	AL022393.9	-5.04	1.76e-06	0.00224	-0.45	-0.43	Parkinson's disease;	chr6:27942930	chr6:28170845~28172521:+
GBM	cis	rs56262138	0.5	rs35772683	ENSG00000239519.1	CADM2-AS1	5.04	1.77e-06	0.00224	0.46	0.43	Educational attainment (years of education);	chr3:85996916	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs34289000	ENSG00000239519.1	CADM2-AS1	5.04	1.77e-06	0.00224	0.46	0.43	Educational attainment (years of education);	chr3:85997905	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs35242846	ENSG00000239519.1	CADM2-AS1	5.04	1.77e-06	0.00224	0.46	0.43	Educational attainment (years of education);	chr3:85998085	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs12488773	ENSG00000239519.1	CADM2-AS1	5.04	1.77e-06	0.00224	0.46	0.43	Educational attainment (years of education);	chr3:85999097	chr3:85992183~86028007:-
GBM	cis	rs12931792	0.782	rs13331817	ENSG00000183604.13	SMG1P5	5.04	1.77e-06	0.00224	0.51	0.43	Tonsillectomy;	chr16:30161306	chr16:30267553~30335374:-
GBM	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	5.04	1.77e-06	0.00224	0.51	0.43	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
GBM	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-5.04	1.77e-06	0.00225	-0.57	-0.43	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
GBM	cis	rs7267979	0.966	rs6050611	ENSG00000276952.1	RP5-965G21.6	5.04	1.78e-06	0.00225	0.39	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25284915~25285588:-
GBM	cis	rs62402013	1	rs62402013	ENSG00000224843.5	LINC00240	-5.04	1.78e-06	0.00225	-0.51	-0.43	Schizophrenia;	chr6:26947221	chr6:26956992~27023924:+
GBM	cis	rs7829975	0.667	rs1877119	ENSG00000254340.1	RP11-10A14.3	5.04	1.78e-06	0.00226	0.51	0.43	Mood instability;	chr8:8849687	chr8:9141424~9145435:+
GBM	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	5.04	1.78e-06	0.00226	0.51	0.43	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
GBM	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-5.04	1.78e-06	0.00226	-0.56	-0.43	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-5.04	1.78e-06	0.00226	-0.56	-0.43	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-5.04	1.78e-06	0.00226	-0.56	-0.43	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
GBM	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	5.03	1.79e-06	0.00226	0.43	0.43	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	5.03	1.79e-06	0.00226	0.43	0.43	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
GBM	cis	rs1298062	0.861	rs2431821	ENSG00000131401.10	NAPSB	-5.03	1.79e-06	0.00227	-0.5	-0.42	Age of smoking initiation;	chr19:50491841	chr19:50333796~50344767:-
GBM	cis	rs7267979	0.866	rs6138609	ENSG00000125804.12	FAM182A	-5.03	1.79e-06	0.00227	-0.54	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:26054655~26086917:+
GBM	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	5.03	1.79e-06	0.00227	0.53	0.42	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
GBM	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	5.03	1.8e-06	0.00228	0.49	0.42	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
GBM	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	5.03	1.8e-06	0.00228	0.56	0.42	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	5.03	1.8e-06	0.00228	0.56	0.42	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
GBM	cis	rs7267979	0.903	rs2474769	ENSG00000276952.1	RP5-965G21.6	5.03	1.8e-06	0.00228	0.4	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25284915~25285588:-
GBM	cis	rs17211409	1	rs7950878	ENSG00000254479.1	SLC25A1P1	5.03	1.8e-06	0.00228	0.98	0.42	JT interval (sulfonylurea treatment interaction);	chr11:86577245	chr11:85934737~85935663:+
GBM	cis	rs10752881	1	rs6658501	ENSG00000224468.3	RP11-181K3.4	5.03	1.8e-06	0.00228	0.33	0.42	Colorectal cancer;	chr1:183022282	chr1:183138402~183141282:-
GBM	cis	rs73198271	0.74	rs10109886	ENSG00000253893.2	FAM85B	5.03	1.8e-06	0.00228	0.62	0.42	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8167819~8226614:-
GBM	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	5.03	1.81e-06	0.00229	0.52	0.42	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	5.03	1.81e-06	0.00229	0.52	0.42	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
GBM	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	5.03	1.81e-06	0.00229	0.52	0.42	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
GBM	cis	rs3806843	0.966	rs2563261	ENSG00000202111.1	VTRNA1-2	5.03	1.82e-06	0.0023	0.45	0.42	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs2563263	ENSG00000202111.1	VTRNA1-2	-5.03	1.82e-06	0.0023	-0.45	-0.42	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs6891559	ENSG00000202111.1	VTRNA1-2	-5.03	1.82e-06	0.0023	-0.45	-0.42	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs11741994	ENSG00000202111.1	VTRNA1-2	-5.03	1.82e-06	0.0023	-0.45	-0.42	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr5:140718925~140719013:+
GBM	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	5.03	1.82e-06	0.0023	0.55	0.42	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
GBM	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	5.03	1.82e-06	0.0023	0.54	0.42	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
GBM	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	5.03	1.82e-06	0.0023	0.43	0.42	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
GBM	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-5.03	1.82e-06	0.0023	-0.43	-0.42	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
GBM	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-5.03	1.82e-06	0.00231	-0.85	-0.42	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
GBM	cis	rs9987353	0.519	rs11779181	ENSG00000253893.2	FAM85B	-5.03	1.83e-06	0.00231	-0.5	-0.42	Recombination measurement;	chr8:9205517	chr8:8167819~8226614:-
GBM	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-5.03	1.83e-06	0.00231	-0.56	-0.42	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
GBM	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-5.03	1.83e-06	0.00231	-0.6	-0.42	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
GBM	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	5.03	1.83e-06	0.00231	0.51	0.42	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
GBM	cis	rs4713118	0.869	rs9283880	ENSG00000199851.2	U3	5.03	1.83e-06	0.00231	0.57	0.42	Parkinson's disease;	chr6:27747464	chr6:28015568~28015777:+
GBM	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-5.03	1.84e-06	0.00232	-0.57	-0.42	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
GBM	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-5.03	1.84e-06	0.00232	-0.63	-0.42	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
GBM	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-5.03	1.84e-06	0.00233	-0.47	-0.42	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
GBM	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	5.03	1.84e-06	0.00233	0.51	0.42	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
GBM	cis	rs56262138	0.5	rs2324975	ENSG00000239519.1	CADM2-AS1	5.03	1.84e-06	0.00233	0.47	0.42	Educational attainment (years of education);	chr3:86009295	chr3:85992183~86028007:-
GBM	cis	rs56262138	0.5	rs12486099	ENSG00000239519.1	CADM2-AS1	5.03	1.84e-06	0.00233	0.47	0.42	Educational attainment (years of education);	chr3:86011185	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.502	rs13065014	ENSG00000239519.1	CADM2-AS1	5.03	1.84e-06	0.00233	0.47	0.42	Body mass index;	chr3:86011753	chr3:85992183~86028007:-
GBM	cis	rs7267979	1	rs6050555	ENSG00000125804.12	FAM182A	5.03	1.85e-06	0.00233	0.53	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:26054655~26086917:+
GBM	cis	rs867371	0.929	rs1501371	ENSG00000278603.1	RP13-608F4.5	5.03	1.85e-06	0.00233	0.5	0.42	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472203~82472426:+
GBM	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	5.03	1.85e-06	0.00233	0.71	0.42	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
GBM	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	5.03	1.85e-06	0.00234	0.48	0.42	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
GBM	cis	rs11159086	1	rs12433848	ENSG00000270000.1	RP3-449M8.9	5.03	1.86e-06	0.00234	0.66	0.42	Advanced glycation end-product levels;	chr14:74497570	chr14:74471930~74472360:-
GBM	cis	rs200986	1	rs200986	ENSG00000218016.2	ZNF192P2	-5.03	1.86e-06	0.00235	-0.57	-0.42	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.539	rs200951	ENSG00000218016.2	ZNF192P2	-5.03	1.86e-06	0.00235	-0.57	-0.42	Parkinson's disease;	chr6:27868152	chr6:28188050~28189432:+
GBM	cis	rs17685	0.753	rs2302435	ENSG00000280388.1	RP11-229D13.3	5.02	1.87e-06	0.00235	0.4	0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76047669	chr7:76043977~76045963:-
GBM	cis	rs17685	0.725	rs2302436	ENSG00000280388.1	RP11-229D13.3	5.02	1.87e-06	0.00235	0.4	0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76047670	chr7:76043977~76045963:-
GBM	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-5.02	1.87e-06	0.00235	-0.59	-0.42	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-5.02	1.87e-06	0.00235	-0.59	-0.42	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-5.02	1.87e-06	0.00235	-0.59	-0.42	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
GBM	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	5.02	1.87e-06	0.00235	0.54	0.42	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
GBM	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	5.02	1.87e-06	0.00235	0.51	0.42	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	5.02	1.87e-06	0.00235	0.51	0.42	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	5.02	1.87e-06	0.00235	0.51	0.42	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	5.02	1.87e-06	0.00235	0.51	0.42	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
GBM	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-5.02	1.87e-06	0.00235	-0.65	-0.42	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
GBM	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-5.02	1.87e-06	0.00235	-0.65	-0.42	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
GBM	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-5.02	1.88e-06	0.00237	-0.48	-0.42	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
GBM	cis	rs6496932	0.865	rs4843049	ENSG00000218052.5	ADAMTS7P4	5.02	1.89e-06	0.00238	0.65	0.42	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85255369~85330334:-
GBM	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-5.02	1.89e-06	0.00238	-0.58	-0.42	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
GBM	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	5.02	1.89e-06	0.00238	0.48	0.42	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
GBM	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
GBM	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
GBM	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-5.02	1.89e-06	0.00238	-0.56	-0.42	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
GBM	cis	rs67981189	0.529	rs2526868	ENSG00000269927.1	RP6-91H8.3	-5.02	1.89e-06	0.00238	-0.51	-0.42	Schizophrenia;	chr14:70923672	chr14:71141125~71143253:-
GBM	cis	rs2810114	1	rs2810114	ENSG00000269927.1	RP6-91H8.3	-5.02	1.89e-06	0.00238	-0.51	-0.42	Alcohol dependence;	chr14:70928887	chr14:71141125~71143253:-
GBM	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	5.02	1.9e-06	0.00238	0.56	0.42	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
GBM	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	5.02	1.9e-06	0.00238	0.56	0.42	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
GBM	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	5.02	1.9e-06	0.00238	0.56	0.42	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
GBM	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-5.02	1.9e-06	0.00238	-0.53	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
GBM	cis	rs1420956	0.562	rs16943845	ENSG00000264151.4	RP11-739N10.1	5.02	1.9e-06	0.00239	0.56	0.42	Obesity-related traits;	chr18:27611959	chr18:27336379~27595164:-
GBM	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	5.02	1.9e-06	0.00239	0.45	0.42	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	5.02	1.9e-06	0.00239	0.45	0.42	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
GBM	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	5.02	1.9e-06	0.00239	0.45	0.42	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
GBM	cis	rs56262138	0.5	rs62263325	ENSG00000239519.1	CADM2-AS1	5.02	1.9e-06	0.00239	0.46	0.42	Educational attainment (years of education);	chr3:86073373	chr3:85992183~86028007:-
GBM	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	5.02	1.9e-06	0.00239	0.53	0.42	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
GBM	cis	rs763121	0.853	rs5750669	ENSG00000273076.1	RP3-508I15.22	5.02	1.93e-06	0.00242	0.49	0.42	Menopause (age at onset);	chr22:38684633	chr22:38743495~38743910:+
GBM	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	5.02	1.93e-06	0.00242	0.5	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
GBM	cis	rs7615952	0.546	rs2979333	ENSG00000171084.14	FAM86JP	5.02	1.93e-06	0.00243	0.77	0.42	Blood pressure (smoking interaction);	chr3:125641499	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs111812401	ENSG00000171084.14	FAM86JP	5.02	1.93e-06	0.00243	0.77	0.42	Blood pressure (smoking interaction);	chr3:125642651	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs2979350	ENSG00000171084.14	FAM86JP	5.02	1.93e-06	0.00243	0.77	0.42	Blood pressure (smoking interaction);	chr3:125643371	chr3:125916620~125930024:+
GBM	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	5.02	1.94e-06	0.00243	0.58	0.42	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
GBM	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-5.02	1.94e-06	0.00243	-0.6	-0.42	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
GBM	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	5.02	1.94e-06	0.00243	0.57	0.42	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
GBM	cis	rs7267979	0.868	rs6138553	ENSG00000125804.12	FAM182A	-5.02	1.95e-06	0.00244	-0.53	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:26054655~26086917:+
GBM	cis	rs8062405	0.824	rs4788085	ENSG00000271623.1	RP11-435I10.5	-5.02	1.95e-06	0.00244	-0.5	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs28772958	ENSG00000271623.1	RP11-435I10.5	-5.02	1.95e-06	0.00244	-0.5	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.789	rs2106480	ENSG00000271623.1	RP11-435I10.5	-5.02	1.95e-06	0.00244	-0.5	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28364700~28365333:+
GBM	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	5.01	1.95e-06	0.00244	0.57	0.42	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
GBM	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	5.01	1.96e-06	0.00245	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	5.01	1.96e-06	0.00245	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
GBM	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	5.01	1.96e-06	0.00246	0.48	0.42	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
GBM	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-5.01	1.96e-06	0.00246	-0.44	-0.42	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
GBM	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	5.01	1.97e-06	0.00246	0.42	0.42	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	5.01	1.97e-06	0.00246	0.42	0.42	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
GBM	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-5.01	1.97e-06	0.00246	-0.53	-0.42	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
GBM	cis	rs9368481	0.729	rs9379950	ENSG00000224843.5	LINC00240	5.01	1.97e-06	0.00246	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26956992~27023924:+
GBM	cis	rs9368481	1	rs9368481	ENSG00000224843.5	LINC00240	5.01	1.97e-06	0.00246	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.554	rs2754603	ENSG00000224843.5	LINC00240	5.01	1.97e-06	0.00246	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.761	rs9357028	ENSG00000224843.5	LINC00240	5.01	1.97e-06	0.00246	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26956992~27023924:+
GBM	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-5.01	1.97e-06	0.00247	-0.59	-0.42	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
GBM	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-5.01	1.97e-06	0.00247	-0.57	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
GBM	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-5.01	1.97e-06	0.00247	-0.54	-0.42	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-5.01	1.97e-06	0.00247	-0.54	-0.42	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-5.01	1.97e-06	0.00247	-0.54	-0.42	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-5.01	1.97e-06	0.00247	-0.54	-0.42	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
GBM	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-5.01	1.98e-06	0.00247	-0.42	-0.42	Temperament;	chr17:14007198	chr17:14024514~14025488:+
GBM	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-5.01	1.98e-06	0.00247	-0.42	-0.42	Temperament;	chr17:14007316	chr17:14024514~14025488:+
GBM	cis	rs10754283	0.84	rs1229992	ENSG00000231613.1	RP5-943J3.1	5.01	1.98e-06	0.00247	0.51	0.42	Amyotrophic lateral sclerosis (sporadic);	chr1:89628669	chr1:89788914~89790492:+
GBM	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	5.01	1.98e-06	0.00247	0.51	0.42	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
GBM	cis	rs454217	0.846	rs2119575	ENSG00000277851.1	RP11-756G20.1	5.01	1.98e-06	0.00248	0.45	0.42	Smoking quantity;	chr12:92309812	chr12:92247756~92363832:-
GBM	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-5.01	1.99e-06	0.00248	-0.52	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-5.01	1.99e-06	0.00248	-0.52	-0.42	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
GBM	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-5.01	1.99e-06	0.00249	-0.54	-0.42	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
GBM	cis	rs17214007	0.735	rs2075513	ENSG00000279866.1	CTB-193M12.4	5.01	1.99e-06	0.00249	0.53	0.42	Cognitive function;	chr16:15782614	chr16:15704410~15705984:+
GBM	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-5.01	1.99e-06	0.00249	-0.85	-0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
GBM	cis	rs2408955	0.522	rs10875721	ENSG00000258273.1	RP11-370I10.4	5.01	1.99e-06	0.00249	0.54	0.42	Glycated hemoglobin levels;	chr12:48019810	chr12:48333755~48333901:-
GBM	cis	rs1420956	0.562	rs11083216	ENSG00000264151.4	RP11-739N10.1	5.01	1.99e-06	0.00249	0.56	0.42	Obesity-related traits;	chr18:27577684	chr18:27336379~27595164:-
GBM	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	5.01	2e-06	0.00249	0.44	0.42	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
GBM	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	5.01	2e-06	0.00249	0.5	0.42	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
GBM	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-5.01	2e-06	0.0025	-0.5	-0.42	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-5.01	2e-06	0.0025	-0.5	-0.42	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
GBM	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-5.01	2e-06	0.0025	-0.5	-0.42	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
GBM	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-5.01	2e-06	0.0025	-0.5	-0.42	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
GBM	cis	rs4072705	0.646	rs4838187	ENSG00000224020.1	MIR181A2HG	-5.01	2e-06	0.0025	-0.46	-0.42	Menarche (age at onset);	chr9:124479797	chr9:124658467~124698631:+
GBM	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-5.01	2e-06	0.0025	-0.48	-0.42	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
GBM	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	5.01	2e-06	0.0025	0.48	0.42	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
GBM	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-5.01	2e-06	0.0025	-0.54	-0.42	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-5.01	2e-06	0.0025	-0.54	-0.42	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-5.01	2e-06	0.0025	-0.54	-0.42	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-5.01	2e-06	0.0025	-0.54	-0.42	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-5.01	2e-06	0.0025	-0.54	-0.42	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
GBM	cis	rs3742264	0.656	rs9534284	ENSG00000235903.6	CPB2-AS1	-5.01	2.01e-06	0.0025	-0.5	-0.42	Blood protein levels;	chr13:46016926	chr13:46052806~46113332:+
GBM	cis	rs172166	0.516	rs1225618	ENSG00000199851.2	U3	5.01	2.01e-06	0.00251	0.52	0.42	Cardiac Troponin-T levels;	chr6:28161935	chr6:28015568~28015777:+
GBM	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-5.01	2.01e-06	0.00251	-0.52	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
GBM	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-5.01	2.02e-06	0.00251	-0.54	-0.42	Height;	chr11:118749988	chr11:118704607~118750263:+
GBM	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-5.01	2.02e-06	0.00251	-0.54	-0.42	Height;	chr11:118760944	chr11:118704607~118750263:+
GBM	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-5.01	2.02e-06	0.00251	-0.54	-0.42	Height;	chr11:118764443	chr11:118704607~118750263:+
GBM	cis	rs7829975	0.742	rs1533059	ENSG00000254340.1	RP11-10A14.3	-5.01	2.02e-06	0.00251	-0.51	-0.42	Mood instability;	chr8:8827443	chr8:9141424~9145435:+
GBM	cis	rs454217	0.846	rs337663	ENSG00000277851.1	RP11-756G20.1	-5.01	2.02e-06	0.00252	-0.45	-0.42	Smoking quantity;	chr12:92311428	chr12:92247756~92363832:-
GBM	cis	rs454217	0.818	rs381750	ENSG00000277851.1	RP11-756G20.1	5.01	2.02e-06	0.00252	0.45	0.42	Smoking quantity;	chr12:92323106	chr12:92247756~92363832:-
GBM	cis	rs454217	0.846	rs1661029	ENSG00000277851.1	RP11-756G20.1	5.01	2.02e-06	0.00252	0.45	0.42	Smoking quantity;	chr12:92324197	chr12:92247756~92363832:-
GBM	cis	rs9368481	0.761	rs3931464	ENSG00000224843.5	LINC00240	-5.01	2.02e-06	0.00252	-0.5	-0.42	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26956992~27023924:+
GBM	cis	rs2013441	0.866	rs62067558	ENSG00000230528.6	NOS2P3	-5.01	2.02e-06	0.00252	-0.51	-0.42	Obesity-related traits;	chr17:20122393	chr17:20436337~20447249:+
GBM	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	5.01	2.03e-06	0.00252	0.52	0.42	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
GBM	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-5.01	2.03e-06	0.00252	-0.55	-0.42	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
GBM	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	5.01	2.03e-06	0.00252	0.51	0.42	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
GBM	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	5	2.03e-06	0.00253	0.54	0.42	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
GBM	cis	rs6496932	0.503	rs7164354	ENSG00000218052.5	ADAMTS7P4	-5	2.04e-06	0.00254	-0.59	-0.42	Central corneal thickness;Corneal structure;	chr15:85405217	chr15:85255369~85330334:-
GBM	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	5	2.05e-06	0.00254	0.63	0.42	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
GBM	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	5	2.05e-06	0.00254	0.63	0.42	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
GBM	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	5	2.05e-06	0.00254	0.63	0.42	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
GBM	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	5	2.05e-06	0.00255	0.53	0.42	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
GBM	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-5	2.05e-06	0.00255	-0.52	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-5	2.06e-06	0.00255	-0.52	-0.42	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-5	2.06e-06	0.00255	-0.52	-0.42	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
GBM	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-5	2.06e-06	0.00255	-0.52	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
GBM	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-5	2.06e-06	0.00255	-0.52	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
GBM	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-5	2.06e-06	0.00255	-0.52	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
GBM	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-5	2.06e-06	0.00255	-0.52	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
GBM	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-5	2.06e-06	0.00255	-0.58	-0.42	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
GBM	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-5	2.06e-06	0.00255	-0.58	-0.42	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
GBM	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	5	2.06e-06	0.00255	0.29	0.42	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	5	2.06e-06	0.00255	0.29	0.42	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	5	2.06e-06	0.00255	0.29	0.42	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
GBM	cis	rs66887589	0.66	rs4833613	ENSG00000249244.1	RP11-548H18.2	-5	2.06e-06	0.00256	-0.53	-0.42	Diastolic blood pressure;	chr4:119229001	chr4:119391831~119395335:-
GBM	cis	rs6496932	0.635	rs11074191	ENSG00000218052.5	ADAMTS7P4	-5	2.06e-06	0.00256	-0.6	-0.42	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85255369~85330334:-
GBM	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	5	2.07e-06	0.00257	0.57	0.42	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
GBM	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	5	2.07e-06	0.00257	0.57	0.42	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
GBM	cis	rs67981189	0.519	rs2526879	ENSG00000269927.1	RP6-91H8.3	-5	2.07e-06	0.00257	-0.51	-0.42	Schizophrenia;	chr14:70910501	chr14:71141125~71143253:-
GBM	cis	rs4072705	1	rs10986391	ENSG00000224020.1	MIR181A2HG	-5	2.08e-06	0.00258	-0.46	-0.42	Menarche (age at onset);	chr9:124665956	chr9:124658467~124698631:+
GBM	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	5	2.08e-06	0.00258	0.51	0.42	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	5	2.08e-06	0.00258	0.51	0.42	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	5	2.08e-06	0.00258	0.51	0.42	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	5	2.08e-06	0.00258	0.51	0.42	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	5	2.08e-06	0.00258	0.51	0.42	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
GBM	cis	rs4713118	0.869	rs9366700	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27729172	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs9393851	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27731802	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs9461400	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27732780	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs9295742	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27735053	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs9461401	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27735512	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs6914924	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27743751	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs6930992	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27744341	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs6901520	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27746796	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs9461405	ENSG00000199851.2	U3	5	2.08e-06	0.00258	0.57	0.42	Parkinson's disease;	chr6:27751596	chr6:28015568~28015777:+
GBM	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-5	2.08e-06	0.00258	-0.37	-0.42	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
GBM	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-5	2.08e-06	0.00258	-0.37	-0.42	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
GBM	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-5	2.08e-06	0.00258	-0.37	-0.42	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
GBM	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-5	2.08e-06	0.00258	-0.37	-0.42	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
GBM	cis	rs11098499	1	rs1011054	ENSG00000250412.1	KLHL2P1	-5	2.08e-06	0.00258	-0.56	-0.42	Corneal astigmatism;	chr4:119281232	chr4:119334329~119378233:+
GBM	cis	rs7267979	0.932	rs6037125	ENSG00000125804.12	FAM182A	-5	2.09e-06	0.00259	-0.54	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:26054655~26086917:+
GBM	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	5	2.09e-06	0.0026	0.53	0.42	Height;	chr3:53073764	chr3:53064283~53065091:-
GBM	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-5	2.1e-06	0.0026	-0.86	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
GBM	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-5	2.1e-06	0.0026	-0.55	-0.42	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-5	2.1e-06	0.0026	-0.55	-0.42	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
GBM	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	5	2.1e-06	0.0026	0.29	0.42	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	5	2.1e-06	0.0026	0.29	0.42	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	5	2.1e-06	0.0026	0.29	0.42	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	5	2.1e-06	0.0026	0.29	0.42	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	5	2.1e-06	0.0026	0.29	0.42	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	5	2.1e-06	0.0026	0.29	0.42	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	5	2.1e-06	0.0026	0.29	0.42	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
GBM	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	5	2.1e-06	0.0026	0.48	0.42	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	5	2.1e-06	0.0026	0.48	0.42	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	5	2.1e-06	0.0026	0.48	0.42	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	5	2.1e-06	0.0026	0.48	0.42	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
GBM	cis	rs7216064	0.531	rs6504573	ENSG00000278219.1	AC145343.1	-5	2.1e-06	0.0026	-0.45	-0.42	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68019847	chr17:68101538~68101639:+
GBM	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	5	2.11e-06	0.00261	0.32	0.42	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
GBM	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	5	2.11e-06	0.00261	0.54	0.42	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	5	2.11e-06	0.00261	0.54	0.42	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
GBM	cis	rs11098499	0.722	rs7673476	ENSG00000250412.1	KLHL2P1	5	2.11e-06	0.00261	0.54	0.42	Corneal astigmatism;	chr4:119327528	chr4:119334329~119378233:+
GBM	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	5	2.12e-06	0.00262	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	5	2.12e-06	0.00262	0.77	0.42	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	5	2.12e-06	0.00262	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	5	2.12e-06	0.00262	0.77	0.42	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	5	2.12e-06	0.00262	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
GBM	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	5	2.12e-06	0.00262	0.5	0.42	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
GBM	cis	rs2408955	0.561	rs9971924	ENSG00000258273.1	RP11-370I10.4	5	2.12e-06	0.00262	0.53	0.42	Glycated hemoglobin levels;	chr12:48086049	chr12:48333755~48333901:-
GBM	cis	rs7759001	0.602	rs12211424	ENSG00000218016.2	ZNF192P2	4.99	2.12e-06	0.00262	0.7	0.42	Glomerular filtration rate (creatinine);	chr6:27467245	chr6:28188050~28189432:+
GBM	cis	rs67981189	0.574	rs2526848	ENSG00000269927.1	RP6-91H8.3	-4.99	2.12e-06	0.00262	-0.47	-0.42	Schizophrenia;	chr14:70953025	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs2810109	ENSG00000269927.1	RP6-91H8.3	-4.99	2.12e-06	0.00262	-0.47	-0.42	Schizophrenia;	chr14:70953175	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.529	rs2526858	ENSG00000269927.1	RP6-91H8.3	-4.99	2.12e-06	0.00262	-0.51	-0.42	Schizophrenia;	chr14:70945623	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.529	rs2526857	ENSG00000269927.1	RP6-91H8.3	-4.99	2.12e-06	0.00262	-0.51	-0.42	Schizophrenia;	chr14:70945909	chr14:71141125~71143253:-
GBM	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	4.99	2.12e-06	0.00262	0.49	0.42	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
GBM	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-4.99	2.13e-06	0.00263	-0.55	-0.42	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
GBM	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-4.99	2.13e-06	0.00263	-0.54	-0.42	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
GBM	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-4.99	2.13e-06	0.00263	-0.67	-0.42	Depression;	chr6:28103220	chr6:28115628~28116551:+
GBM	cis	rs9876781	1	rs9881491	ENSG00000244380.1	RP11-24C3.2	4.99	2.14e-06	0.00264	0.47	0.42	Longevity;	chr3:48446507	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs13091785	ENSG00000244380.1	RP11-24C3.2	4.99	2.14e-06	0.00264	0.47	0.42	Longevity;	chr3:48452692	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs6776700	ENSG00000244380.1	RP11-24C3.2	4.99	2.14e-06	0.00264	0.47	0.42	Longevity;	chr3:48455358	chr3:48440352~48446656:-
GBM	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	4.99	2.14e-06	0.00264	0.51	0.42	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
GBM	cis	rs4713118	0.826	rs2893929	ENSG00000218016.2	ZNF192P2	-4.99	2.14e-06	0.00264	-0.58	-0.42	Parkinson's disease;	chr6:27770953	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.666	rs4140646	ENSG00000218016.2	ZNF192P2	-4.99	2.14e-06	0.00264	-0.58	-0.42	Parkinson's disease;	chr6:27771022	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.666	rs2893930	ENSG00000218016.2	ZNF192P2	-4.99	2.14e-06	0.00264	-0.58	-0.42	Parkinson's disease;	chr6:27771027	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.868	rs742047	ENSG00000218016.2	ZNF192P2	-4.99	2.14e-06	0.00264	-0.58	-0.42	Parkinson's disease;	chr6:27771601	chr6:28188050~28189432:+
GBM	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	4.99	2.14e-06	0.00265	0.43	0.42	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
GBM	cis	rs8062405	0.824	rs4788083	ENSG00000271623.1	RP11-435I10.5	-4.99	2.14e-06	0.00265	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28364700~28365333:+
GBM	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	4.99	2.15e-06	0.00265	0.54	0.42	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	4.99	2.15e-06	0.00265	0.54	0.42	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	4.99	2.15e-06	0.00265	0.54	0.42	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	4.99	2.15e-06	0.00265	0.54	0.42	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-4.99	2.15e-06	0.00265	-0.54	-0.42	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-4.99	2.15e-06	0.00265	-0.54	-0.42	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-4.99	2.15e-06	0.00265	-0.54	-0.42	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-4.99	2.15e-06	0.00265	-0.54	-0.42	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-4.99	2.15e-06	0.00265	-0.54	-0.42	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-4.99	2.15e-06	0.00265	-0.54	-0.42	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
GBM	cis	rs9601248	0.756	rs928640	ENSG00000227676.3	LINC01068	-4.99	2.15e-06	0.00265	-0.5	-0.42	Major depressive disorder;	chr13:79603348	chr13:79566727~79571436:+
GBM	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
GBM	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
GBM	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
GBM	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
GBM	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
GBM	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
GBM	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
GBM	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
GBM	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
GBM	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
GBM	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
GBM	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
GBM	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
GBM	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
GBM	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-4.99	2.15e-06	0.00265	-0.5	-0.42	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
GBM	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	4.99	2.15e-06	0.00266	0.46	0.42	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757234	ENSG00000273076.1	RP3-508I15.22	4.99	2.15e-06	0.00266	0.46	0.42	Menopause (age at onset);	chr22:38676681	chr22:38743495~38743910:+
GBM	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	4.99	2.16e-06	0.00266	0.45	0.42	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
GBM	cis	rs9947662	0.917	rs11873243	ENSG00000267761.3	CTD-2130O13.1	-4.99	2.17e-06	0.00267	-0.53	-0.42	Migraine;	chr18:47335799	chr18:47285725~47594550:+
GBM	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	4.99	2.17e-06	0.00267	0.49	0.42	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
GBM	cis	rs3096299	0.838	rs4785561	ENSG00000260259.1	RP11-368I7.4	4.99	2.18e-06	0.00268	0.44	0.42	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89682620~89686569:-
GBM	cis	rs12908161	0.683	rs12903256	ENSG00000225151.9	GOLGA2P7	-4.99	2.18e-06	0.00268	-0.45	-0.42	Schizophrenia;	chr15:84764910	chr15:84199311~84230136:-
GBM	cis	rs3742264	0.656	rs4942460	ENSG00000235903.6	CPB2-AS1	-4.99	2.18e-06	0.00268	-0.48	-0.42	Blood protein levels;	chr13:45976308	chr13:46052806~46113332:+
GBM	cis	rs8067545	0.603	rs10083830	ENSG00000230528.6	NOS2P3	-4.99	2.18e-06	0.00268	-0.49	-0.42	Schizophrenia;	chr17:20062570	chr17:20436337~20447249:+
GBM	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	4.99	2.19e-06	0.00269	0.75	0.42	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
GBM	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
GBM	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.51	0.42	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
GBM	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	4.99	2.19e-06	0.00269	0.59	0.42	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
GBM	cis	rs9926296	0.533	rs7190823	ENSG00000260259.1	RP11-368I7.4	-4.99	2.19e-06	0.00269	-0.45	-0.42	Vitiligo;	chr16:89799635	chr16:89682620~89686569:-
GBM	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	4.99	2.19e-06	0.00269	0.52	0.42	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
GBM	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	4.99	2.2e-06	0.00269	0.57	0.42	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
GBM	cis	rs454217	0.846	rs381966	ENSG00000277851.1	RP11-756G20.1	4.99	2.2e-06	0.00269	0.45	0.42	Smoking quantity;	chr12:92335913	chr12:92247756~92363832:-
GBM	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-4.99	2.2e-06	0.00269	-0.54	-0.42	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
GBM	cis	rs454217	0.846	rs428699	ENSG00000277851.1	RP11-756G20.1	4.99	2.2e-06	0.0027	0.45	0.42	Smoking quantity;	chr12:92334822	chr12:92247756~92363832:-
GBM	cis	rs4713118	0.868	rs2893928	ENSG00000218016.2	ZNF192P2	-4.99	2.21e-06	0.0027	-0.6	-0.42	Parkinson's disease;	chr6:27770651	chr6:28188050~28189432:+
GBM	cis	rs2013441	1	rs2703815	ENSG00000230528.6	NOS2P3	-4.99	2.21e-06	0.0027	-0.47	-0.42	Obesity-related traits;	chr17:20215186	chr17:20436337~20447249:+
GBM	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-4.99	2.21e-06	0.0027	-0.58	-0.42	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
GBM	cis	rs67981189	0.896	rs2810098	ENSG00000269927.1	RP6-91H8.3	-4.99	2.21e-06	0.0027	-0.47	-0.42	Schizophrenia;	chr14:70967194	chr14:71141125~71143253:-
GBM	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	4.99	2.21e-06	0.0027	0.5	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
GBM	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
GBM	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
GBM	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-4.98	2.21e-06	0.0027	-0.55	-0.42	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
GBM	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	4.98	2.21e-06	0.0027	0.5	0.42	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
GBM	cis	rs10028773	0.632	rs34481394	ENSG00000249244.1	RP11-548H18.2	4.98	2.21e-06	0.00271	0.55	0.42	Educational attainment;	chr4:119327219	chr4:119391831~119395335:-
GBM	cis	rs10028773	0.666	rs35231872	ENSG00000249244.1	RP11-548H18.2	4.98	2.21e-06	0.00271	0.55	0.42	Educational attainment;	chr4:119327221	chr4:119391831~119395335:-
GBM	cis	rs10028773	0.7	rs35653026	ENSG00000249244.1	RP11-548H18.2	4.98	2.21e-06	0.00271	0.55	0.42	Educational attainment;	chr4:119327223	chr4:119391831~119395335:-
GBM	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	4.98	2.21e-06	0.00271	0.44	0.42	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	4.98	2.21e-06	0.00271	0.44	0.42	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
GBM	cis	rs17772222	0.74	rs10138309	ENSG00000222990.1	RNU4-22P	4.98	2.22e-06	0.00271	0.45	0.42	Coronary artery calcification;	chr14:88510352	chr14:88513498~88513663:+
GBM	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	4.98	2.22e-06	0.00272	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	4.98	2.22e-06	0.00272	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
GBM	cis	rs889122	0.531	rs8113425	ENSG00000267289.1	CTD-2623N2.11	-4.98	2.23e-06	0.00273	-0.48	-0.42	Menarche (age at onset);	chr19:9889630	chr19:9834079~9835013:-
GBM	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	4.98	2.24e-06	0.00273	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
GBM	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-4.98	2.24e-06	0.00273	-0.47	-0.42	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
GBM	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-4.98	2.24e-06	0.00273	-0.47	-0.42	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
GBM	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	4.98	2.24e-06	0.00273	0.49	0.42	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
GBM	cis	rs763121	0.889	rs1837988	ENSG00000273076.1	RP3-508I15.22	4.98	2.24e-06	0.00274	0.49	0.42	Menopause (age at onset);	chr22:38505089	chr22:38743495~38743910:+
GBM	cis	rs2013441	1	rs17759923	ENSG00000230528.6	NOS2P3	-4.98	2.25e-06	0.00274	-0.48	-0.42	Obesity-related traits;	chr17:20118722	chr17:20436337~20447249:+
GBM	cis	rs2013441	1	rs2013441	ENSG00000230528.6	NOS2P3	-4.98	2.25e-06	0.00274	-0.48	-0.42	Obesity-related traits;	chr17:20119786	chr17:20436337~20447249:+
GBM	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-4.98	2.25e-06	0.00274	-0.48	-0.42	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
GBM	cis	rs4072705	1	rs6478671	ENSG00000224020.1	MIR181A2HG	-4.98	2.25e-06	0.00275	-0.47	-0.42	Menarche (age at onset);	chr9:124611716	chr9:124658467~124698631:+
GBM	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-4.98	2.26e-06	0.00275	-0.57	-0.42	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-4.98	2.26e-06	0.00275	-0.57	-0.42	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
GBM	cis	rs67981189	0.613	rs4366661	ENSG00000269927.1	RP6-91H8.3	-4.98	2.26e-06	0.00275	-0.47	-0.42	Schizophrenia;	chr14:70985599	chr14:71141125~71143253:-
GBM	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	4.98	2.26e-06	0.00275	0.55	0.42	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
GBM	cis	rs454217	0.818	rs1661031	ENSG00000277851.1	RP11-756G20.1	4.98	2.26e-06	0.00276	0.45	0.42	Smoking quantity;	chr12:92328010	chr12:92247756~92363832:-
GBM	cis	rs454217	0.846	rs418571	ENSG00000277851.1	RP11-756G20.1	4.98	2.26e-06	0.00276	0.45	0.42	Smoking quantity;	chr12:92330380	chr12:92247756~92363832:-
GBM	cis	rs454217	0.846	rs1661024	ENSG00000277851.1	RP11-756G20.1	4.98	2.26e-06	0.00276	0.45	0.42	Smoking quantity;	chr12:92330771	chr12:92247756~92363832:-
GBM	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	4.98	2.26e-06	0.00276	0.59	0.42	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
GBM	cis	rs9368481	0.761	rs12661756	ENSG00000224843.5	LINC00240	-4.98	2.26e-06	0.00276	-0.52	-0.42	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26956992~27023924:+
GBM	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-4.98	2.26e-06	0.00276	-0.57	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
GBM	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	4.98	2.27e-06	0.00276	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	4.98	2.27e-06	0.00276	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	4.98	2.27e-06	0.00276	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
GBM	cis	rs2579103	0.63	rs825975	ENSG00000258183.4	RP11-753N8.1	4.98	2.28e-06	0.00278	0.64	0.42	Body mass index;	chr12:90314725	chr12:90280894~90300340:+
GBM	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	4.98	2.28e-06	0.00278	0.36	0.42	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
GBM	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-4.98	2.28e-06	0.00278	-0.55	-0.42	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
GBM	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	4.98	2.28e-06	0.00278	0.41	0.42	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
GBM	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-4.98	2.28e-06	0.00278	-0.5	-0.42	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
GBM	cis	rs860818	1	rs10634	ENSG00000226816.2	AC005082.12	-4.98	2.29e-06	0.00279	-0.89	-0.42	Initial pursuit acceleration;	chr7:23200977	chr7:23206013~23208045:+
GBM	cis	rs17772222	0.655	rs816072	ENSG00000258983.2	RP11-507K2.2	-4.98	2.29e-06	0.00279	-0.44	-0.42	Coronary artery calcification;	chr14:88484335	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.655	rs1152376	ENSG00000258983.2	RP11-507K2.2	-4.98	2.29e-06	0.00279	-0.44	-0.42	Coronary artery calcification;	chr14:88495121	chr14:88499334~88515502:+
GBM	cis	rs3096299	0.933	rs2965934	ENSG00000260259.1	RP11-368I7.4	4.98	2.3e-06	0.00279	0.45	0.42	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89682620~89686569:-
GBM	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	4.98	2.3e-06	0.00279	0.43	0.42	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
GBM	cis	rs454217	0.846	rs427600	ENSG00000277851.1	RP11-756G20.1	4.98	2.3e-06	0.0028	0.45	0.42	Smoking quantity;	chr12:92326886	chr12:92247756~92363832:-
GBM	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-4.98	2.3e-06	0.0028	-0.54	-0.42	Height;	chr11:118742526	chr11:118704607~118750263:+
GBM	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-4.98	2.3e-06	0.0028	-0.54	-0.42	Height;	chr11:118746590	chr11:118704607~118750263:+
GBM	cis	rs172166	0.538	rs149956	ENSG00000199851.2	U3	4.98	2.3e-06	0.0028	0.54	0.42	Cardiac Troponin-T levels;	chr6:28068473	chr6:28015568~28015777:+
GBM	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	4.97	2.31e-06	0.00281	0.42	0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
GBM	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-4.97	2.31e-06	0.00281	-0.45	-0.42	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
GBM	cis	rs6782228	0.606	rs10048945	ENSG00000277250.1	Metazoa_SRP	-4.97	2.31e-06	0.00281	-0.44	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128673681~128674021:-
GBM	cis	rs832187	0.704	rs3774720	ENSG00000280620.1	SCAANT1	4.97	2.32e-06	0.00281	0.57	0.42	Schizophrenia;	chr3:63966089	chr3:63911518~63911772:-
GBM	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	4.97	2.33e-06	0.00282	0.36	0.42	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
GBM	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-4.97	2.33e-06	0.00283	-0.57	-0.42	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
GBM	cis	rs67981189	0.634	rs221898	ENSG00000269927.1	RP6-91H8.3	4.97	2.33e-06	0.00283	0.48	0.42	Schizophrenia;	chr14:71138799	chr14:71141125~71143253:-
GBM	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	4.97	2.33e-06	0.00283	0.51	0.42	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
GBM	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	4.97	2.33e-06	0.00283	0.51	0.42	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
GBM	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-4.97	2.34e-06	0.00284	-0.5	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
GBM	cis	rs17772222	0.682	rs1152377	ENSG00000258983.2	RP11-507K2.2	-4.97	2.34e-06	0.00284	-0.45	-0.42	Coronary artery calcification;	chr14:88496243	chr14:88499334~88515502:+
GBM	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	4.97	2.35e-06	0.00285	0.59	0.42	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
GBM	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	4.97	2.35e-06	0.00285	0.6	0.42	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
GBM	cis	rs67340775	0.541	rs200968	ENSG00000199851.2	U3	4.97	2.35e-06	0.00285	0.78	0.42	Lung cancer in ever smokers;	chr6:27891790	chr6:28015568~28015777:+
GBM	cis	rs73198271	1	rs11775821	ENSG00000253893.2	FAM85B	4.97	2.35e-06	0.00285	0.6	0.42	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8167819~8226614:-
GBM	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
GBM	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
GBM	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
GBM	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-4.97	2.36e-06	0.00286	-0.56	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
GBM	cis	rs4887140	0.717	rs9920840	ENSG00000260469.2	C15orf59-AS1	-4.97	2.36e-06	0.00286	-0.85	-0.42	Glucose homeostasis traits;	chr15:73762121	chr15:73752317~73770613:+
GBM	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	4.97	2.36e-06	0.00287	0.29	0.42	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
GBM	cis	rs3742264	0.656	rs9534280	ENSG00000235903.6	CPB2-AS1	-4.97	2.37e-06	0.00287	-0.49	-0.42	Blood protein levels;	chr13:46010916	chr13:46052806~46113332:+
GBM	cis	rs3742264	0.656	rs4941538	ENSG00000235903.6	CPB2-AS1	-4.97	2.37e-06	0.00287	-0.49	-0.42	Blood protein levels;	chr13:46012474	chr13:46052806~46113332:+
GBM	cis	rs3742264	0.656	rs9534281	ENSG00000235903.6	CPB2-AS1	-4.97	2.37e-06	0.00287	-0.49	-0.42	Blood protein levels;	chr13:46012841	chr13:46052806~46113332:+
GBM	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	4.97	2.37e-06	0.00288	0.73	0.42	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
GBM	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	4.97	2.37e-06	0.00288	0.64	0.42	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
GBM	cis	rs9876781	0.933	rs6442124	ENSG00000244380.1	RP11-24C3.2	4.97	2.38e-06	0.00288	0.49	0.42	Longevity;	chr3:48463903	chr3:48440352~48446656:-
GBM	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
GBM	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
GBM	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
GBM	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-4.97	2.38e-06	0.00288	-0.56	-0.42	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
GBM	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	4.97	2.38e-06	0.00288	0.51	0.42	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	4.97	2.38e-06	0.00288	0.51	0.42	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
GBM	cis	rs4072705	0.967	rs4287038	ENSG00000224020.1	MIR181A2HG	4.97	2.38e-06	0.00288	0.44	0.42	Menarche (age at onset);	chr9:124607400	chr9:124658467~124698631:+
GBM	cis	rs5742933	0.69	rs6726636	ENSG00000253559.1	OSGEPL1-AS1	-4.97	2.38e-06	0.00289	-0.56	-0.42	Ferritin levels;	chr2:189653095	chr2:189762704~189765556:+
GBM	cis	rs4713118	0.824	rs9468225	ENSG00000218016.2	ZNF192P2	-4.97	2.39e-06	0.00289	-0.56	-0.42	Parkinson's disease;	chr6:27777940	chr6:28188050~28189432:+
GBM	cis	rs2919917	0.628	rs11776243	ENSG00000254352.1	RP11-578O24.2	4.97	2.39e-06	0.00289	0.67	0.42	Lymphocyte counts;	chr8:78648848	chr8:78723796~78724136:-
GBM	cis	rs2919917	0.628	rs10110524	ENSG00000254352.1	RP11-578O24.2	4.97	2.39e-06	0.00289	0.67	0.42	Lymphocyte counts;	chr8:78648871	chr8:78723796~78724136:-
GBM	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-4.97	2.39e-06	0.00289	-0.55	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
GBM	cis	rs9637599	0.69	rs2869926	ENSG00000246375.2	RP11-10L7.1	4.97	2.4e-06	0.00289	0.47	0.42	Metabolite levels (small molecules and protein measures);	chr4:88280224	chr4:88284942~88331421:+
GBM	cis	rs9637599	0.69	rs881561	ENSG00000246375.2	RP11-10L7.1	4.97	2.4e-06	0.00289	0.47	0.42	Metabolite levels (small molecules and protein measures);	chr4:88281890	chr4:88284942~88331421:+
GBM	cis	rs6499766	1	rs1502007	ENSG00000260135.5	RP11-212I21.2	4.97	2.4e-06	0.00289	0.56	0.42	Thyroid hormone levels;	chr16:55579610	chr16:55426797~55462297:-
GBM	cis	rs2018683	0.834	rs733485	ENSG00000228421.2	AC005013.5	4.97	2.4e-06	0.0029	0.5	0.42	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28957667~28959345:+
GBM	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	4.96	2.41e-06	0.00291	0.29	0.42	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
GBM	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	4.96	2.41e-06	0.00291	0.79	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	4.96	2.41e-06	0.00291	0.79	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	4.96	2.41e-06	0.00291	0.79	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
GBM	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	4.96	2.41e-06	0.00291	0.83	0.42	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
GBM	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	4.96	2.43e-06	0.00293	0.48	0.42	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
GBM	cis	rs11159086	1	rs8006909	ENSG00000270000.1	RP3-449M8.9	4.96	2.43e-06	0.00293	0.65	0.42	Advanced glycation end-product levels;	chr14:74478085	chr14:74471930~74472360:-
GBM	cis	rs67981189	0.529	rs17108862	ENSG00000269927.1	RP6-91H8.3	4.96	2.43e-06	0.00294	0.5	0.42	Schizophrenia;	chr14:70997949	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.529	rs61990379	ENSG00000269927.1	RP6-91H8.3	4.96	2.43e-06	0.00294	0.5	0.42	Schizophrenia;	chr14:71000353	chr14:71141125~71143253:-
GBM	cis	rs9637599	0.69	rs6821589	ENSG00000246375.2	RP11-10L7.1	4.96	2.44e-06	0.00294	0.47	0.42	Metabolite levels (small molecules and protein measures);	chr4:88271640	chr4:88284942~88331421:+
GBM	cis	rs9637599	0.69	rs17789147	ENSG00000246375.2	RP11-10L7.1	4.96	2.44e-06	0.00294	0.47	0.42	Metabolite levels (small molecules and protein measures);	chr4:88272488	chr4:88284942~88331421:+
GBM	cis	rs9637599	0.69	rs34752329	ENSG00000246375.2	RP11-10L7.1	4.96	2.44e-06	0.00294	0.47	0.42	Metabolite levels (small molecules and protein measures);	chr4:88274388	chr4:88284942~88331421:+
GBM	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-4.96	2.44e-06	0.00294	-0.46	-0.42	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
GBM	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	4.96	2.44e-06	0.00294	0.41	0.42	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
GBM	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	4.96	2.44e-06	0.00294	0.48	0.42	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
GBM	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	4.96	2.44e-06	0.00295	0.58	0.42	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	4.96	2.44e-06	0.00295	0.58	0.42	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
GBM	cis	rs4273100	0.646	rs2296981	ENSG00000262319.1	CTC-457L16.2	4.96	2.45e-06	0.00295	0.49	0.42	Schizophrenia;	chr17:19310022	chr17:19141017~19143689:-
GBM	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	4.96	2.45e-06	0.00295	0.4	0.42	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
GBM	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-4.96	2.45e-06	0.00295	-0.88	-0.42	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
GBM	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-4.96	2.46e-06	0.00297	-0.71	-0.42	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
GBM	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-4.96	2.47e-06	0.00297	-0.57	-0.42	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
GBM	cis	rs9601248	0.711	rs9530937	ENSG00000227676.3	LINC01068	-4.96	2.47e-06	0.00297	-0.49	-0.42	Major depressive disorder;	chr13:79603701	chr13:79566727~79571436:+
GBM	cis	rs2018683	0.834	rs2012754	ENSG00000228421.2	AC005013.5	4.96	2.47e-06	0.00298	0.5	0.42	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28957667~28959345:+
GBM	cis	rs763121	0.853	rs4821812	ENSG00000273076.1	RP3-508I15.22	4.96	2.47e-06	0.00298	0.48	0.42	Menopause (age at onset);	chr22:38679230	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs3827357	ENSG00000273076.1	RP3-508I15.22	4.96	2.47e-06	0.00298	0.48	0.42	Menopause (age at onset);	chr22:38683408	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750668	ENSG00000273076.1	RP3-508I15.22	4.96	2.47e-06	0.00298	0.48	0.42	Menopause (age at onset);	chr22:38683959	chr22:38743495~38743910:+
GBM	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-4.96	2.47e-06	0.00298	-0.58	-0.42	Depression;	chr6:28184805	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-4.96	2.47e-06	0.00298	-0.58	-0.42	Depression;	chr6:28197321	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-4.96	2.47e-06	0.00298	-0.58	-0.42	Depression;	chr6:28197412	chr6:28115628~28116551:+
GBM	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-4.96	2.47e-06	0.00298	-0.58	-0.42	Depression;	chr6:28198669	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-4.96	2.47e-06	0.00298	-0.58	-0.42	Depression;	chr6:28201380	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-4.96	2.47e-06	0.00298	-0.58	-0.42	Depression;	chr6:28205175	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	4.96	2.47e-06	0.00298	0.58	0.42	Depression;	chr6:28199145	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	4.96	2.47e-06	0.00298	0.58	0.42	Depression;	chr6:28200948	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	4.96	2.47e-06	0.00298	0.58	0.42	Depression;	chr6:28205232	chr6:28115628~28116551:+
GBM	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	4.96	2.48e-06	0.00298	0.48	0.42	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
GBM	cis	rs4713118	0.868	rs7756968	ENSG00000218016.2	ZNF192P2	-4.96	2.48e-06	0.00298	-0.57	-0.42	Parkinson's disease;	chr6:27767175	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.868	rs35069907	ENSG00000218016.2	ZNF192P2	-4.96	2.48e-06	0.00298	-0.57	-0.42	Parkinson's disease;	chr6:27778913	chr6:28188050~28189432:+
GBM	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-4.96	2.48e-06	0.00299	-0.45	-0.42	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
GBM	cis	rs6583331	1	rs6799977	ENSG00000273013.1	CTD-2002J20.1	-4.96	2.48e-06	0.00299	-0.46	-0.42	Vitiligo;	chr3:196623970	chr3:196474801~196475394:+
GBM	cis	rs6583331	0.967	rs1385331	ENSG00000273013.1	CTD-2002J20.1	-4.96	2.48e-06	0.00299	-0.46	-0.42	Vitiligo;	chr3:196624344	chr3:196474801~196475394:+
GBM	cis	rs916888	0.61	rs199438	ENSG00000261575.2	RP11-259G18.1	4.96	2.49e-06	0.00299	0.52	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46267037~46268694:+
GBM	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	4.96	2.5e-06	0.00301	0.57	0.42	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	4.96	2.5e-06	0.00301	0.57	0.42	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	4.96	2.5e-06	0.00301	0.57	0.42	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	4.96	2.5e-06	0.00301	0.57	0.42	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
GBM	cis	rs11098499	0.739	rs9996382	ENSG00000249244.1	RP11-548H18.2	4.96	2.51e-06	0.00301	0.55	0.42	Corneal astigmatism;	chr4:119229857	chr4:119391831~119395335:-
GBM	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-4.96	2.51e-06	0.00301	-0.55	-0.42	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-4.96	2.51e-06	0.00301	-0.55	-0.42	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
GBM	cis	rs4713118	0.539	rs510987	ENSG00000199851.2	U3	4.96	2.51e-06	0.00302	0.61	0.42	Parkinson's disease;	chr6:27879739	chr6:28015568~28015777:+
GBM	cis	rs59406912	1	rs59406912	ENSG00000261485.1	PAN3-AS1	4.96	2.51e-06	0.00302	0.84	0.42	Hepcidin/transferrin saturation ratio;	chr13:28269628	chr13:28136843~28138193:-
GBM	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-4.95	2.51e-06	0.00302	-0.61	-0.42	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
GBM	cis	rs7615952	0.546	rs11711150	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125596819	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs11717632	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125602286	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs2922197	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125603188	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs2979340	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125622540	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs2979338	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125624282	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs2922171	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125624349	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs112919177	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125627226	chr3:125916620~125930024:+
GBM	cis	rs7615952	0.546	rs4428131	ENSG00000171084.14	FAM86JP	4.95	2.52e-06	0.00302	0.75	0.42	Blood pressure (smoking interaction);	chr3:125627635	chr3:125916620~125930024:+
GBM	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	4.95	2.52e-06	0.00303	0.44	0.42	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	4.95	2.52e-06	0.00303	0.44	0.42	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	4.95	2.52e-06	0.00303	0.44	0.42	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	4.95	2.52e-06	0.00303	0.44	0.42	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	4.95	2.52e-06	0.00303	0.44	0.42	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	4.95	2.52e-06	0.00303	0.44	0.42	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
GBM	cis	rs7429990	0.803	rs13319205	ENSG00000229759.1	MRPS18AP1	4.95	2.52e-06	0.00303	0.54	0.42	Educational attainment (years of education);	chr3:47758726	chr3:48256350~48256938:-
GBM	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-4.95	2.53e-06	0.00303	-0.57	-0.42	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
GBM	cis	rs17772222	0.917	rs61984708	ENSG00000222990.1	RNU4-22P	4.95	2.53e-06	0.00304	0.49	0.42	Coronary artery calcification;	chr14:88565523	chr14:88513498~88513663:+
GBM	cis	rs6908917	0.673	rs1984054	ENSG00000219776.2	RPL21P67	4.95	2.53e-06	0.00304	0.54	0.42	IgG glycosylation;	chr6:131005539	chr6:131469059~131469536:+
GBM	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	4.95	2.54e-06	0.00305	0.54	0.42	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
GBM	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	4.95	2.54e-06	0.00305	0.54	0.42	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
GBM	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	4.95	2.54e-06	0.00305	0.36	0.42	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
GBM	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	4.95	2.54e-06	0.00305	0.47	0.42	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
GBM	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	4.95	2.54e-06	0.00305	0.59	0.42	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
GBM	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-4.95	2.55e-06	0.00305	-0.88	-0.42	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
GBM	cis	rs397969	0.57	rs2108981	ENSG00000230528.6	NOS2P3	-4.95	2.55e-06	0.00306	-0.52	-0.42	Platelet count;	chr17:19975353	chr17:20436337~20447249:+
GBM	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	4.95	2.55e-06	0.00306	0.53	0.42	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
GBM	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-4.95	2.56e-06	0.00307	-0.5	-0.42	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
GBM	cis	rs8067545	0.512	rs34726000	ENSG00000230528.6	NOS2P3	-4.95	2.56e-06	0.00307	-0.52	-0.42	Schizophrenia;	chr17:19984508	chr17:20436337~20447249:+
GBM	cis	rs9368481	0.672	rs3931463	ENSG00000224843.5	LINC00240	-4.95	2.56e-06	0.00307	-0.5	-0.42	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26956992~27023924:+
GBM	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	4.95	2.56e-06	0.00307	0.51	0.42	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
GBM	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	4.95	2.56e-06	0.00307	0.51	0.42	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
GBM	cis	rs9368481	0.761	rs9348746	ENSG00000224843.5	LINC00240	4.95	2.57e-06	0.00307	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.761	rs9357030	ENSG00000224843.5	LINC00240	4.95	2.57e-06	0.00307	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.761	rs9379952	ENSG00000224843.5	LINC00240	4.95	2.57e-06	0.00307	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26956992~27023924:+
GBM	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	4.95	2.57e-06	0.00308	0.67	0.42	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
GBM	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	4.95	2.57e-06	0.00308	0.5	0.42	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
GBM	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	4.95	2.57e-06	0.00308	0.52	0.42	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	4.95	2.57e-06	0.00308	0.52	0.42	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
GBM	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	4.95	2.57e-06	0.00308	0.49	0.42	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
GBM	cis	rs6496932	0.503	rs11074205	ENSG00000218052.5	ADAMTS7P4	-4.95	2.58e-06	0.00309	-0.59	-0.42	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85255369~85330334:-
GBM	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-4.95	2.58e-06	0.00309	-0.51	-0.42	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
GBM	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	4.95	2.58e-06	0.00309	0.5	0.42	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
GBM	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	4.95	2.58e-06	0.00309	0.5	0.42	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
GBM	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	4.95	2.58e-06	0.00309	0.57	0.42	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
GBM	cis	rs4072705	0.646	rs2416933	ENSG00000224020.1	MIR181A2HG	4.95	2.58e-06	0.00309	0.46	0.42	Menarche (age at onset);	chr9:124483250	chr9:124658467~124698631:+
GBM	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	4.95	2.58e-06	0.00309	0.51	0.42	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
GBM	cis	rs17685	0.753	rs4728550	ENSG00000280388.1	RP11-229D13.3	4.95	2.58e-06	0.00309	0.39	0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76041670	chr7:76043977~76045963:-
GBM	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	4.95	2.59e-06	0.0031	0.5	0.42	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
GBM	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	4.95	2.59e-06	0.0031	0.46	0.42	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
GBM	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
GBM	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	4.95	2.59e-06	0.0031	0.57	0.42	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
GBM	cis	rs2013441	0.835	rs2526491	ENSG00000230528.6	NOS2P3	4.95	2.59e-06	0.0031	0.5	0.42	Obesity-related traits;	chr17:20194149	chr17:20436337~20447249:+
GBM	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	4.95	2.59e-06	0.0031	0.53	0.42	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	4.95	2.59e-06	0.0031	0.53	0.42	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	4.95	2.59e-06	0.0031	0.53	0.42	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
GBM	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-4.95	2.59e-06	0.0031	-0.34	-0.42	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
GBM	cis	rs7017914	0.902	rs6472542	ENSG00000246366.5	RP11-382J12.1	4.95	2.59e-06	0.0031	0.45	0.42	Bone mineral density;	chr8:70741852	chr8:70608577~70663279:+
GBM	cis	rs4072705	0.646	rs10120967	ENSG00000224020.1	MIR181A2HG	-4.95	2.59e-06	0.0031	-0.45	-0.42	Menarche (age at onset);	chr9:124481855	chr9:124658467~124698631:+
GBM	cis	rs67981189	0.896	rs7146932	ENSG00000269927.1	RP6-91H8.3	4.95	2.6e-06	0.00311	0.48	0.42	Schizophrenia;	chr14:71010328	chr14:71141125~71143253:-
GBM	cis	rs67340775	0.541	rs200979	ENSG00000199851.2	U3	4.95	2.6e-06	0.00311	0.78	0.42	Lung cancer in ever smokers;	chr6:27884579	chr6:28015568~28015777:+
GBM	cis	rs67340775	0.541	rs200975	ENSG00000199851.2	U3	4.95	2.6e-06	0.00311	0.78	0.42	Lung cancer in ever smokers;	chr6:27887847	chr6:28015568~28015777:+
GBM	cis	rs67340775	0.541	rs200974	ENSG00000199851.2	U3	4.95	2.6e-06	0.00311	0.78	0.42	Lung cancer in ever smokers;	chr6:27888067	chr6:28015568~28015777:+
GBM	cis	rs11159086	1	rs4899516	ENSG00000270000.1	RP3-449M8.9	4.95	2.6e-06	0.00311	0.65	0.42	Advanced glycation end-product levels;	chr14:74492825	chr14:74471930~74472360:-
GBM	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	4.95	2.6e-06	0.00311	0.59	0.42	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
GBM	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-4.95	2.6e-06	0.00311	-0.44	-0.42	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
GBM	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-4.95	2.6e-06	0.00311	-0.44	-0.42	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	4.95	2.6e-06	0.00311	0.46	0.42	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
GBM	cis	rs3096299	0.967	rs3102383	ENSG00000274627.1	RP11-104N10.2	4.95	2.6e-06	0.00311	0.37	0.42	Multiple myeloma (IgH translocation);	chr16:89344887	chr16:89516797~89522217:+
GBM	cis	rs4887140	1	rs4887141	ENSG00000260469.2	C15orf59-AS1	4.95	2.6e-06	0.00311	0.75	0.42	Glucose homeostasis traits;	chr15:73754360	chr15:73752317~73770613:+
GBM	cis	rs9876781	1	rs6810060	ENSG00000244380.1	RP11-24C3.2	4.95	2.61e-06	0.00311	0.48	0.42	Longevity;	chr3:48393284	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs6770470	ENSG00000244380.1	RP11-24C3.2	4.95	2.61e-06	0.00311	0.48	0.42	Longevity;	chr3:48393659	chr3:48440352~48446656:-
GBM	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	4.95	2.61e-06	0.00311	0.51	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
GBM	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	4.95	2.61e-06	0.00311	0.51	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
GBM	cis	rs11233250	0.697	rs72942468	ENSG00000245832.5	RP11-179A16.1	4.95	2.61e-06	0.00312	0.62	0.42	Glioblastoma;Glioma;	chr11:82715694	chr11:81879851~82718082:-
GBM	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	4.95	2.61e-06	0.00312	0.47	0.42	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	4.95	2.61e-06	0.00312	0.47	0.42	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
GBM	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	4.95	2.61e-06	0.00312	0.59	0.42	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	4.95	2.61e-06	0.00312	0.59	0.42	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	4.95	2.61e-06	0.00312	0.59	0.42	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
GBM	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	4.95	2.62e-06	0.00313	0.41	0.42	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
GBM	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	4.94	2.62e-06	0.00313	0.5	0.42	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	4.94	2.62e-06	0.00313	0.5	0.42	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
GBM	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	4.94	2.63e-06	0.00313	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
GBM	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	4.94	2.63e-06	0.00314	0.57	0.42	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
GBM	cis	rs4072705	0.967	rs10217141	ENSG00000224020.1	MIR181A2HG	-4.94	2.63e-06	0.00314	-0.47	-0.42	Menarche (age at onset);	chr9:124641656	chr9:124658467~124698631:+
GBM	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	4.94	2.63e-06	0.00314	0.51	0.42	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
GBM	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-4.94	2.64e-06	0.00314	-0.56	-0.42	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
GBM	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	4.94	2.64e-06	0.00315	0.3	0.42	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	4.94	2.64e-06	0.00315	0.3	0.42	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
GBM	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	4.94	2.64e-06	0.00315	0.51	0.42	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
GBM	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	4.94	2.64e-06	0.00315	0.5	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
GBM	cis	rs4072705	1	rs4838197	ENSG00000224020.1	MIR181A2HG	-4.94	2.66e-06	0.00317	-0.46	-0.42	Menarche (age at onset);	chr9:124602236	chr9:124658467~124698631:+
GBM	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	4.94	2.66e-06	0.00317	0.47	0.42	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
GBM	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	4.94	2.66e-06	0.00317	0.57	0.42	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
GBM	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	4.94	2.66e-06	0.00317	0.57	0.42	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
GBM	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	4.94	2.66e-06	0.00317	0.57	0.42	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
GBM	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	4.94	2.66e-06	0.00317	0.57	0.42	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
GBM	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	4.94	2.66e-06	0.00318	0.49	0.42	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
GBM	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	4.94	2.67e-06	0.00318	0.57	0.42	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	4.94	2.67e-06	0.00318	0.57	0.42	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
GBM	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	4.94	2.67e-06	0.00318	0.62	0.42	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
GBM	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	4.94	2.68e-06	0.00319	0.51	0.42	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	4.94	2.68e-06	0.00319	0.51	0.42	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
GBM	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	4.94	2.68e-06	0.00319	0.51	0.42	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
GBM	cis	rs172166	0.61	rs156737	ENSG00000218016.2	ZNF192P2	-4.94	2.68e-06	0.00319	-0.5	-0.42	Cardiac Troponin-T levels;	chr6:27927435	chr6:28188050~28189432:+
GBM	cis	rs172166	0.61	rs276369	ENSG00000218016.2	ZNF192P2	-4.94	2.68e-06	0.00319	-0.5	-0.42	Cardiac Troponin-T levels;	chr6:27951465	chr6:28188050~28189432:+
GBM	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-4.94	2.68e-06	0.00319	-0.48	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
GBM	cis	rs6496932	1	rs35796484	ENSG00000218052.5	ADAMTS7P4	4.94	2.68e-06	0.00319	0.63	0.42	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85255369~85330334:-
GBM	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	4.94	2.68e-06	0.00319	0.49	0.42	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
GBM	cis	rs9828933	0.507	rs56030924	ENSG00000280620.1	SCAANT1	4.94	2.69e-06	0.0032	0.58	0.42	Type 2 diabetes;	chr3:64009887	chr3:63911518~63911772:-
GBM	cis	rs67981189	0.574	rs8004452	ENSG00000269927.1	RP6-91H8.3	-4.94	2.69e-06	0.0032	-0.47	-0.42	Schizophrenia;	chr14:70949323	chr14:71141125~71143253:-
GBM	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	4.94	2.69e-06	0.0032	0.43	0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
GBM	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-4.94	2.69e-06	0.0032	-0.57	-0.42	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-4.94	2.69e-06	0.0032	-0.57	-0.42	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
GBM	cis	rs17685	0.753	rs13240404	ENSG00000280388.1	RP11-229D13.3	4.94	2.7e-06	0.00321	0.4	0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76046401	chr7:76043977~76045963:-
GBM	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	4.94	2.7e-06	0.00321	0.59	0.42	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	4.94	2.7e-06	0.00321	0.59	0.42	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	4.94	2.7e-06	0.00321	0.59	0.42	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
GBM	cis	rs2288884	0.537	rs12151270	ENSG00000275055.1	CTC-471J1.11	-4.94	2.7e-06	0.00321	-0.5	-0.42	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:52049007~52049754:+
GBM	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	4.94	2.71e-06	0.00322	0.51	0.42	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
GBM	cis	rs2976388	1	rs2572910	ENSG00000253741.1	CTD-2292P10.4	4.94	2.71e-06	0.00322	0.44	0.42	Urinary tract infection frequency;	chr8:142688717	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2585179	ENSG00000253741.1	CTD-2292P10.4	4.94	2.71e-06	0.00322	0.44	0.42	Urinary tract infection frequency;	chr8:142692775	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2717562	ENSG00000253741.1	CTD-2292P10.4	4.94	2.71e-06	0.00322	0.44	0.42	Urinary tract infection frequency;	chr8:142695250	chr8:142702252~142726973:-
GBM	cis	rs35851103	0.6	rs4841662	ENSG00000254527.1	ENPP7P12	-4.94	2.71e-06	0.00322	-0.49	-0.42	Neuroticism;	chr8:11986249	chr8:12205759~12206389:-
GBM	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	4.94	2.71e-06	0.00323	0.54	0.42	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
GBM	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	4.94	2.72e-06	0.00323	0.53	0.42	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
GBM	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-4.94	2.72e-06	0.00323	-0.48	-0.42	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
GBM	cis	rs11671005	0.736	rs11668201	ENSG00000269473.1	CTD-2619J13.19	4.94	2.72e-06	0.00323	0.49	0.42	Mean platelet volume;	chr19:58492265	chr19:58440448~58445849:+
GBM	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-4.94	2.73e-06	0.00324	-0.5	-0.42	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
GBM	cis	rs7267979	1	rs2474777	ENSG00000125804.12	FAM182A	-4.94	2.73e-06	0.00324	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:26054655~26086917:+
GBM	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	4.93	2.74e-06	0.00325	0.52	0.42	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
GBM	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-4.93	2.74e-06	0.00325	-0.39	-0.42	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
GBM	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-4.93	2.74e-06	0.00325	-0.39	-0.42	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
GBM	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-4.93	2.74e-06	0.00325	-0.39	-0.42	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
GBM	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-4.93	2.74e-06	0.00325	-0.39	-0.42	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
GBM	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-4.93	2.74e-06	0.00325	-0.39	-0.42	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
GBM	cis	rs9599293	0.614	rs7999415	ENSG00000276672.1	RP11-142E9.1	4.93	2.74e-06	0.00325	0.8	0.42	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr13:34600174	chr13:33846190~33850825:+
GBM	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-4.93	2.74e-06	0.00325	-0.53	-0.42	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
GBM	cis	rs3742264	0.656	rs9526128	ENSG00000235903.6	CPB2-AS1	-4.93	2.74e-06	0.00325	-0.49	-0.42	Blood protein levels;	chr13:46004219	chr13:46052806~46113332:+
GBM	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	4.93	2.74e-06	0.00325	0.6	0.42	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
GBM	cis	rs11159086	1	rs58384818	ENSG00000270000.1	RP3-449M8.9	4.93	2.75e-06	0.00326	0.65	0.42	Advanced glycation end-product levels;	chr14:74487045	chr14:74471930~74472360:-
GBM	cis	rs11159086	1	rs17100588	ENSG00000270000.1	RP3-449M8.9	4.93	2.75e-06	0.00326	0.65	0.42	Advanced glycation end-product levels;	chr14:74487624	chr14:74471930~74472360:-
GBM	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-4.93	2.75e-06	0.00326	-0.55	-0.42	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-4.93	2.75e-06	0.00326	-0.55	-0.42	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-4.93	2.75e-06	0.00326	-0.55	-0.42	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
GBM	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	4.93	2.76e-06	0.00327	0.82	0.42	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
GBM	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-4.93	2.77e-06	0.00328	-0.65	-0.42	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
GBM	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-4.93	2.77e-06	0.00328	-0.65	-0.42	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
GBM	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-4.93	2.77e-06	0.00328	-0.57	-0.42	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-4.93	2.77e-06	0.00328	-0.57	-0.42	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-4.93	2.77e-06	0.00328	-0.57	-0.42	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
GBM	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	4.93	2.77e-06	0.00329	0.34	0.42	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
GBM	cis	rs7267979	0.739	rs6138555	ENSG00000276952.1	RP5-965G21.6	4.93	2.78e-06	0.0033	0.38	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25284915~25285588:-
GBM	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-4.93	2.78e-06	0.0033	-0.45	-0.42	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-4.93	2.78e-06	0.0033	-0.45	-0.42	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
GBM	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	4.93	2.79e-06	0.0033	0.5	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
GBM	cis	rs7615952	0.546	rs11718647	ENSG00000171084.14	FAM86JP	4.93	2.79e-06	0.0033	0.75	0.42	Blood pressure (smoking interaction);	chr3:125633178	chr3:125916620~125930024:+
GBM	cis	rs893971	0.643	rs17789621	ENSG00000246375.2	RP11-10L7.1	4.93	2.79e-06	0.00331	0.48	0.42	Conduct disorder (maternal expressed emotions interaction);	chr4:88305969	chr4:88284942~88331421:+
GBM	cis	rs4713118	0.868	rs10484401	ENSG00000218016.2	ZNF192P2	4.93	2.79e-06	0.00331	0.56	0.42	Parkinson's disease;	chr6:27778811	chr6:28188050~28189432:+
GBM	cis	rs55720021	1	rs55720021	ENSG00000232871.7	SEC1P	4.93	2.8e-06	0.00331	0.54	0.42	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr19:48640984	chr19:48638071~48682245:+
GBM	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	4.93	2.8e-06	0.00331	0.47	0.42	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
GBM	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	4.93	2.8e-06	0.00331	0.47	0.42	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
GBM	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-4.93	2.8e-06	0.00331	-0.56	-0.42	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
GBM	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-4.93	2.8e-06	0.00331	-0.54	-0.42	Height;	chr11:118791319	chr11:118704607~118750263:+
GBM	cis	rs7615952	0.546	rs2922194	ENSG00000171084.14	FAM86JP	4.93	2.8e-06	0.00332	0.75	0.42	Blood pressure (smoking interaction);	chr3:125613419	chr3:125916620~125930024:+
GBM	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-4.93	2.8e-06	0.00332	-0.55	-0.42	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
GBM	cis	rs7267979	0.565	rs4815432	ENSG00000125804.12	FAM182A	4.93	2.81e-06	0.00332	0.54	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26054655~26086917:+
GBM	cis	rs9637599	0.69	rs6819344	ENSG00000246375.2	RP11-10L7.1	4.93	2.81e-06	0.00332	0.47	0.42	Metabolite levels (small molecules and protein measures);	chr4:88276367	chr4:88284942~88331421:+
GBM	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	4.93	2.81e-06	0.00332	0.6	0.42	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
GBM	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-4.93	2.81e-06	0.00332	-0.59	-0.42	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-4.93	2.81e-06	0.00332	-0.59	-0.42	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-4.93	2.81e-06	0.00332	-0.59	-0.42	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-4.93	2.81e-06	0.00332	-0.59	-0.42	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-4.93	2.81e-06	0.00332	-0.59	-0.42	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	4.93	2.82e-06	0.00333	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
GBM	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-4.93	2.82e-06	0.00333	-0.43	-0.42	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
GBM	cis	rs893971	0.643	rs9998450	ENSG00000246375.2	RP11-10L7.1	4.93	2.82e-06	0.00333	0.48	0.42	Conduct disorder (maternal expressed emotions interaction);	chr4:88309973	chr4:88284942~88331421:+
GBM	cis	rs893971	0.643	rs28884607	ENSG00000246375.2	RP11-10L7.1	4.93	2.82e-06	0.00333	0.48	0.42	Conduct disorder (maternal expressed emotions interaction);	chr4:88310671	chr4:88284942~88331421:+
GBM	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	4.93	2.82e-06	0.00334	0.52	0.42	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	4.93	2.82e-06	0.00334	0.52	0.42	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	4.93	2.82e-06	0.00334	0.52	0.42	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
GBM	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-4.93	2.82e-06	0.00334	-0.47	-0.42	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
GBM	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	4.93	2.82e-06	0.00334	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
GBM	cis	rs7267979	0.932	rs446649	ENSG00000125804.12	FAM182A	-4.93	2.83e-06	0.00334	-0.53	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:26054655~26086917:+
GBM	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	4.93	2.83e-06	0.00334	0.58	0.42	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
GBM	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-4.93	2.84e-06	0.00335	-0.57	-0.42	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
GBM	cis	rs67981189	0.529	rs17093738	ENSG00000269927.1	RP6-91H8.3	4.93	2.84e-06	0.00335	0.5	0.42	Schizophrenia;	chr14:71119931	chr14:71141125~71143253:-
GBM	cis	rs7267979	0.932	rs367666	ENSG00000276952.1	RP5-965G21.6	4.92	2.85e-06	0.00336	0.4	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25284915~25285588:-
GBM	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-4.92	2.86e-06	0.00337	-0.56	-0.42	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-4.92	2.86e-06	0.00337	-0.56	-0.42	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-4.92	2.86e-06	0.00337	-0.56	-0.42	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	4.92	2.86e-06	0.00337	0.56	0.42	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	4.92	2.86e-06	0.00337	0.56	0.42	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	4.92	2.86e-06	0.00337	0.56	0.42	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	4.92	2.86e-06	0.00337	0.56	0.42	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	4.92	2.86e-06	0.00337	0.56	0.42	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	4.92	2.86e-06	0.00337	0.59	0.42	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
GBM	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	4.92	2.86e-06	0.00337	0.51	0.42	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
GBM	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-4.92	2.86e-06	0.00338	-0.55	-0.42	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
GBM	cis	rs66887589	0.87	rs10518336	ENSG00000249244.1	RP11-548H18.2	4.92	2.87e-06	0.00338	0.5	0.42	Diastolic blood pressure;	chr4:119601779	chr4:119391831~119395335:-
GBM	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-4.92	2.87e-06	0.00338	-0.49	-0.42	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
GBM	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-4.92	2.87e-06	0.00338	-0.54	-0.42	Height;	chr11:118761813	chr11:118704607~118750263:+
GBM	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	4.92	2.88e-06	0.00339	0.53	0.42	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	4.92	2.88e-06	0.00339	0.53	0.42	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
GBM	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	4.92	2.88e-06	0.00339	0.82	0.42	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
GBM	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	4.92	2.88e-06	0.0034	0.55	0.42	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
GBM	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	4.92	2.89e-06	0.0034	0.57	0.42	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.868	rs9468220	ENSG00000218016.2	ZNF192P2	4.92	2.89e-06	0.00341	0.56	0.42	Parkinson's disease;	chr6:27765197	chr6:28188050~28189432:+
GBM	cis	rs4072705	0.967	rs4838210	ENSG00000224020.1	MIR181A2HG	4.92	2.9e-06	0.00341	0.45	0.42	Menarche (age at onset);	chr9:124783904	chr9:124658467~124698631:+
GBM	cis	rs524281	0.729	rs12790034	ENSG00000255320.1	RP11-755F10.1	-4.92	2.9e-06	0.00341	-0.69	-0.42	Electroencephalogram traits;	chr11:66018268	chr11:66244840~66246239:-
GBM	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-4.92	2.9e-06	0.00342	-0.71	-0.42	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
GBM	cis	rs950027	1	rs950027	ENSG00000259433.2	CTD-2651B20.4	4.92	2.91e-06	0.00342	0.43	0.42	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45330209~45332634:-
GBM	cis	rs4072705	0.646	rs7865700	ENSG00000224020.1	MIR181A2HG	4.92	2.91e-06	0.00342	0.47	0.42	Menarche (age at onset);	chr9:124483905	chr9:124658467~124698631:+
GBM	cis	rs3096299	0.933	rs2965823	ENSG00000260259.1	RP11-368I7.4	4.92	2.92e-06	0.00343	0.45	0.42	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89682620~89686569:-
GBM	cis	rs832187	0.679	rs9879045	ENSG00000280620.1	SCAANT1	4.92	2.92e-06	0.00343	0.58	0.42	Schizophrenia;	chr3:64016249	chr3:63911518~63911772:-
GBM	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	4.92	2.92e-06	0.00343	0.44	0.42	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
GBM	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	4.92	2.92e-06	0.00343	0.5	0.42	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
GBM	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-4.92	2.92e-06	0.00344	-0.56	-0.42	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
GBM	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-4.92	2.93e-06	0.00345	-0.51	-0.42	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
GBM	cis	rs4887140	0.717	rs8040531	ENSG00000260469.2	C15orf59-AS1	-4.92	2.93e-06	0.00345	-0.84	-0.42	Glucose homeostasis traits;	chr15:73759864	chr15:73752317~73770613:+
GBM	cis	rs12908161	0.853	rs11633788	ENSG00000225151.9	GOLGA2P7	-4.92	2.93e-06	0.00345	-0.45	-0.42	Schizophrenia;	chr15:84761911	chr15:84199311~84230136:-
GBM	cis	rs2980439	0.517	rs793753	ENSG00000173295.6	FAM86B3P	4.92	2.93e-06	0.00345	0.4	0.42	Neuroticism;	chr8:8247837	chr8:8228595~8244865:+
GBM	cis	rs3096299	0.967	rs753852	ENSG00000260259.1	RP11-368I7.4	4.92	2.93e-06	0.00345	0.45	0.42	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89682620~89686569:-
GBM	cis	rs3096299	0.967	rs753853	ENSG00000260259.1	RP11-368I7.4	4.92	2.93e-06	0.00345	0.45	0.42	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89682620~89686569:-
GBM	cis	rs3096299	1	rs3096299	ENSG00000260259.1	RP11-368I7.4	4.92	2.93e-06	0.00345	0.45	0.42	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89682620~89686569:-
GBM	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	4.92	2.94e-06	0.00345	0.59	0.42	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
GBM	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	4.92	2.94e-06	0.00345	0.68	0.42	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
GBM	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	4.92	2.94e-06	0.00345	0.36	0.42	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
GBM	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	4.92	2.94e-06	0.00346	0.44	0.42	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
GBM	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	4.92	2.94e-06	0.00346	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	4.92	2.94e-06	0.00346	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	4.92	2.94e-06	0.00346	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
GBM	cis	rs9876781	1	rs10470686	ENSG00000244380.1	RP11-24C3.2	4.92	2.95e-06	0.00346	0.48	0.42	Longevity;	chr3:48408549	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs3214041	ENSG00000244380.1	RP11-24C3.2	4.92	2.95e-06	0.00346	0.48	0.42	Longevity;	chr3:48413059	chr3:48440352~48446656:-
GBM	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	4.92	2.95e-06	0.00346	0.75	0.42	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
GBM	cis	rs4072705	0.646	rs7037254	ENSG00000224020.1	MIR181A2HG	4.92	2.95e-06	0.00346	0.45	0.42	Menarche (age at onset);	chr9:124483133	chr9:124658467~124698631:+
GBM	cis	rs6782228	0.848	rs6439140	ENSG00000277250.1	Metazoa_SRP	4.92	2.95e-06	0.00346	0.49	0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128673681~128674021:-
GBM	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-4.92	2.95e-06	0.00346	-0.46	-0.42	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
GBM	cis	rs893971	0.698	rs17732955	ENSG00000246375.2	RP11-10L7.1	4.92	2.95e-06	0.00347	0.51	0.42	Conduct disorder (maternal expressed emotions interaction);	chr4:88282941	chr4:88284942~88331421:+
GBM	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-4.92	2.96e-06	0.00348	-0.5	-0.42	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
GBM	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-4.92	2.97e-06	0.00348	-0.46	-0.42	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
GBM	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-4.92	2.97e-06	0.00348	-0.45	-0.42	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
GBM	cis	rs7267979	0.727	rs2474765	ENSG00000276952.1	RP5-965G21.6	4.92	2.97e-06	0.00348	0.38	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.764	rs2474767	ENSG00000276952.1	RP5-965G21.6	4.92	2.97e-06	0.00348	0.38	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25284915~25285588:-
GBM	cis	rs9368481	0.729	rs9379948	ENSG00000224843.5	LINC00240	-4.91	2.98e-06	0.00349	-0.49	-0.42	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26956992~27023924:+
GBM	cis	rs6496932	0.503	rs7170370	ENSG00000218052.5	ADAMTS7P4	-4.91	2.98e-06	0.00349	-0.58	-0.42	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85255369~85330334:-
GBM	cis	rs5742933	0.817	rs7591929	ENSG00000253559.1	OSGEPL1-AS1	4.91	2.98e-06	0.00349	0.44	0.42	Ferritin levels;	chr2:189778531	chr2:189762704~189765556:+
GBM	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	4.91	2.98e-06	0.00349	0.49	0.42	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
GBM	cis	rs922692	0.967	rs11633351	ENSG00000261143.1	ADAMTS7P3	4.91	2.98e-06	0.00349	0.48	0.42	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78764473	chr15:77976042~77993057:+
GBM	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	4.91	2.98e-06	0.00349	0.59	0.42	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	4.91	2.98e-06	0.00349	0.59	0.42	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	4.91	2.98e-06	0.00349	0.59	0.42	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
GBM	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	4.91	2.98e-06	0.00349	0.59	0.42	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
GBM	cis	rs3806843	1	rs7710794	ENSG00000202111.1	VTRNA1-2	-4.91	2.99e-06	0.0035	-0.44	-0.42	Depressive symptoms (multi-trait analysis);	chr5:140829882	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs10038174	ENSG00000202111.1	VTRNA1-2	-4.91	2.99e-06	0.0035	-0.44	-0.42	Depressive symptoms (multi-trait analysis);	chr5:140831031	chr5:140718925~140719013:+
GBM	cis	rs3096299	0.967	rs2965827	ENSG00000260259.1	RP11-368I7.4	-4.91	2.99e-06	0.0035	-0.45	-0.42	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89682620~89686569:-
GBM	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-4.91	2.99e-06	0.0035	-0.44	-0.42	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
GBM	cis	rs67981189	0.593	rs2286311	ENSG00000269927.1	RP6-91H8.3	4.91	3e-06	0.00351	0.46	0.42	Schizophrenia;	chr14:71056238	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs7152845	ENSG00000269927.1	RP6-91H8.3	4.91	3e-06	0.00351	0.46	0.42	Schizophrenia;	chr14:71060506	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs8020480	ENSG00000269927.1	RP6-91H8.3	4.91	3e-06	0.00351	0.46	0.42	Schizophrenia;	chr14:71061327	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs9806042	ENSG00000269927.1	RP6-91H8.3	4.91	3e-06	0.00351	0.46	0.42	Schizophrenia;	chr14:71064276	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs8008111	ENSG00000269927.1	RP6-91H8.3	4.91	3e-06	0.00351	0.46	0.42	Schizophrenia;	chr14:71064529	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs6573994	ENSG00000269927.1	RP6-91H8.3	4.91	3e-06	0.00351	0.46	0.42	Schizophrenia;	chr14:71069945	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.552	rs8021824	ENSG00000269927.1	RP6-91H8.3	4.91	3e-06	0.00351	0.46	0.42	Schizophrenia;	chr14:71070521	chr14:71141125~71143253:-
GBM	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	4.91	3e-06	0.00351	0.84	0.42	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
GBM	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	4.91	3e-06	0.00351	0.58	0.42	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	4.91	3e-06	0.00351	0.58	0.42	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
GBM	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	4.91	3e-06	0.00351	0.58	0.42	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
GBM	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	4.91	3e-06	0.00351	0.58	0.42	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	4.91	3e-06	0.00351	0.58	0.42	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
GBM	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	4.91	3.01e-06	0.00351	0.59	0.42	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	4.91	3.01e-06	0.00351	0.59	0.42	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	4.91	3.01e-06	0.00351	0.59	0.42	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	4.91	3.01e-06	0.00351	0.59	0.42	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	4.91	3.01e-06	0.00351	0.59	0.42	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	4.91	3.01e-06	0.00351	0.59	0.42	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	4.91	3.01e-06	0.00351	0.59	0.42	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
GBM	cis	rs67981189	0.593	rs1468470	ENSG00000269927.1	RP6-91H8.3	4.91	3.01e-06	0.00352	0.46	0.42	Schizophrenia;	chr14:71088814	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs1558097	ENSG00000269927.1	RP6-91H8.3	4.91	3.01e-06	0.00352	0.46	0.42	Schizophrenia;	chr14:71090550	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs7145285	ENSG00000269927.1	RP6-91H8.3	4.91	3.01e-06	0.00352	0.46	0.42	Schizophrenia;	chr14:71094757	chr14:71141125~71143253:-
GBM	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-4.91	3.01e-06	0.00352	-0.47	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-4.91	3.01e-06	0.00352	-0.47	-0.42	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
GBM	cis	rs4713118	0.588	rs200994	ENSG00000199851.2	U3	-4.91	3.01e-06	0.00352	-0.65	-0.42	Parkinson's disease;	chr6:27846035	chr6:28015568~28015777:+
GBM	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-4.91	3.02e-06	0.00352	-0.51	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
GBM	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	4.91	3.02e-06	0.00352	0.56	0.42	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
GBM	cis	rs9876781	1	rs11130170	ENSG00000244380.1	RP11-24C3.2	4.91	3.02e-06	0.00352	0.48	0.42	Longevity;	chr3:48408490	chr3:48440352~48446656:-
GBM	cis	rs67981189	0.513	rs7154395	ENSG00000269927.1	RP6-91H8.3	4.91	3.02e-06	0.00353	0.46	0.42	Schizophrenia;	chr14:71099583	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs2877714	ENSG00000269927.1	RP6-91H8.3	4.91	3.02e-06	0.00353	0.46	0.42	Schizophrenia;	chr14:71101498	chr14:71141125~71143253:-
GBM	cis	rs4273100	0.85	rs11204306	ENSG00000265185.4	SNORD3B-1	4.91	3.02e-06	0.00353	0.57	0.42	Schizophrenia;	chr17:19364058	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.79	rs2048230	ENSG00000265185.4	SNORD3B-1	4.91	3.02e-06	0.00353	0.57	0.42	Schizophrenia;	chr17:19372886	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.79	rs60606605	ENSG00000265185.4	SNORD3B-1	4.91	3.02e-06	0.00353	0.57	0.42	Schizophrenia;	chr17:19373831	chr17:19061912~19062669:+
GBM	cis	rs4273100	0.79	rs60166680	ENSG00000265185.4	SNORD3B-1	4.91	3.02e-06	0.00353	0.57	0.42	Schizophrenia;	chr17:19374231	chr17:19061912~19062669:+
GBM	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	4.91	3.03e-06	0.00353	0.58	0.42	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	4.91	3.03e-06	0.00353	0.58	0.42	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	4.91	3.03e-06	0.00353	0.58	0.42	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	4.91	3.03e-06	0.00353	0.58	0.42	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	4.91	3.03e-06	0.00353	0.58	0.42	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	4.91	3.03e-06	0.00353	0.58	0.42	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
GBM	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	4.91	3.03e-06	0.00353	0.51	0.42	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
GBM	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	4.91	3.04e-06	0.00354	0.51	0.42	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
GBM	cis	rs1420956	0.692	rs1024877	ENSG00000264151.4	RP11-739N10.1	4.91	3.04e-06	0.00355	0.51	0.42	Obesity-related traits;	chr18:27594556	chr18:27336379~27595164:-
GBM	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	4.91	3.04e-06	0.00355	0.36	0.42	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
GBM	cis	rs10911251	0.528	rs10911263	ENSG00000224468.3	RP11-181K3.4	-4.91	3.05e-06	0.00356	-0.35	-0.42	Colorectal cancer;	chr1:183145883	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs10911264	ENSG00000224468.3	RP11-181K3.4	-4.91	3.05e-06	0.00356	-0.35	-0.42	Colorectal cancer;	chr1:183145905	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs10911265	ENSG00000224468.3	RP11-181K3.4	-4.91	3.05e-06	0.00356	-0.35	-0.42	Colorectal cancer;	chr1:183145936	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs10911266	ENSG00000224468.3	RP11-181K3.4	-4.91	3.05e-06	0.00356	-0.35	-0.42	Colorectal cancer;	chr1:183145962	chr1:183138402~183141282:-
GBM	cis	rs2579103	0.708	rs1103370	ENSG00000258183.4	RP11-753N8.1	-4.91	3.05e-06	0.00356	-0.62	-0.42	Body mass index;	chr12:90307356	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.668	rs825965	ENSG00000258183.4	RP11-753N8.1	-4.91	3.05e-06	0.00356	-0.62	-0.42	Body mass index;	chr12:90309031	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs825966	ENSG00000258183.4	RP11-753N8.1	-4.91	3.05e-06	0.00356	-0.62	-0.42	Body mass index;	chr12:90309109	chr12:90280894~90300340:+
GBM	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-4.91	3.06e-06	0.00357	-0.53	-0.42	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
GBM	cis	rs67981189	0.593	rs2810101	ENSG00000269927.1	RP6-91H8.3	-4.91	3.07e-06	0.00357	-0.46	-0.42	Schizophrenia;	chr14:70963110	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.542	rs1012725	ENSG00000269927.1	RP6-91H8.3	-4.91	3.07e-06	0.00357	-0.49	-0.42	Schizophrenia;	chr14:71138994	chr14:71141125~71143253:-
GBM	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	4.91	3.07e-06	0.00357	0.81	0.42	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
GBM	cis	rs150992	0.568	rs34498	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.5	0.42	Body mass index;	chr5:98960690	chr5:98929171~98995013:+
GBM	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
GBM	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
GBM	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
GBM	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
GBM	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
GBM	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
GBM	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
GBM	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
GBM	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
GBM	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
GBM	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
GBM	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	4.91	3.08e-06	0.00358	0.44	0.42	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-4.91	3.08e-06	0.00358	-0.44	-0.42	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
GBM	cis	rs7267979	0.873	rs6037062	ENSG00000276952.1	RP5-965G21.6	4.91	3.08e-06	0.00359	0.4	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25284915~25285588:-
GBM	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-4.91	3.09e-06	0.00359	-0.55	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
GBM	cis	rs4072705	1	rs10760371	ENSG00000224020.1	MIR181A2HG	-4.91	3.09e-06	0.00359	-0.46	-0.42	Menarche (age at onset);	chr9:124690698	chr9:124658467~124698631:+
GBM	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-4.91	3.09e-06	0.00359	-0.49	-0.42	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-4.91	3.09e-06	0.00359	-0.49	-0.42	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
GBM	cis	rs397969	0.596	rs35925051	ENSG00000230528.6	NOS2P3	-4.91	3.09e-06	0.00359	-0.51	-0.42	Platelet count;	chr17:19974056	chr17:20436337~20447249:+
GBM	cis	rs922692	0.696	rs1809420	ENSG00000261143.1	ADAMTS7P3	4.91	3.09e-06	0.00359	0.49	0.42	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78764427	chr15:77976042~77993057:+
GBM	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	4.91	3.09e-06	0.00359	0.78	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	4.91	3.09e-06	0.00359	0.78	0.42	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	4.91	3.09e-06	0.00359	0.78	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
GBM	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	4.91	3.09e-06	0.00359	0.52	0.42	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
GBM	cis	rs9637599	0.513	rs9995984	ENSG00000246375.2	RP11-10L7.1	4.91	3.09e-06	0.00359	0.44	0.42	Metabolite levels (small molecules and protein measures);	chr4:88303936	chr4:88284942~88331421:+
GBM	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	4.91	3.1e-06	0.0036	0.78	0.42	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	4.91	3.1e-06	0.0036	0.78	0.42	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	4.91	3.1e-06	0.0036	0.78	0.42	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	4.91	3.1e-06	0.0036	0.78	0.42	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	4.91	3.1e-06	0.0036	0.78	0.42	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
GBM	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	4.91	3.1e-06	0.0036	0.49	0.42	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
GBM	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	4.91	3.1e-06	0.0036	0.49	0.42	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
GBM	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-4.91	3.1e-06	0.0036	-0.5	-0.42	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
GBM	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	4.9	3.11e-06	0.00361	0.84	0.42	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
GBM	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	4.9	3.11e-06	0.00361	0.47	0.42	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
GBM	cis	rs67981189	0.579	rs2240533	ENSG00000269927.1	RP6-91H8.3	4.9	3.11e-06	0.00361	0.49	0.42	Schizophrenia;	chr14:71074309	chr14:71141125~71143253:-
GBM	cis	rs7208859	0.673	rs9903862	ENSG00000263531.1	RP13-753N3.1	4.9	3.11e-06	0.00361	1.05	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879415	chr17:30863921~30864940:-
GBM	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	4.9	3.11e-06	0.00361	0.62	0.42	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
GBM	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-4.9	3.11e-06	0.00361	-0.34	-0.42	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
GBM	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-4.9	3.11e-06	0.00361	-0.54	-0.42	Height;	chr11:118773873	chr11:118704607~118750263:+
GBM	cis	rs2579103	0.63	rs1222451	ENSG00000258183.4	RP11-753N8.1	-4.9	3.11e-06	0.00361	-0.62	-0.42	Body mass index;	chr12:90314445	chr12:90280894~90300340:+
GBM	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	4.9	3.12e-06	0.00362	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
GBM	cis	rs67981189	0.778	rs2189807	ENSG00000269927.1	RP6-91H8.3	4.9	3.12e-06	0.00362	0.48	0.42	Schizophrenia;	chr14:70896314	chr14:71141125~71143253:-
GBM	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-4.9	3.12e-06	0.00362	-0.52	-0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
GBM	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	4.9	3.13e-06	0.00363	0.5	0.42	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
GBM	cis	rs4713118	0.869	rs9283881	ENSG00000199851.2	U3	4.9	3.14e-06	0.00364	0.55	0.42	Parkinson's disease;	chr6:27747476	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.869	rs9283882	ENSG00000199851.2	U3	4.9	3.14e-06	0.00364	0.55	0.42	Parkinson's disease;	chr6:27747479	chr6:28015568~28015777:+
GBM	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-4.9	3.14e-06	0.00364	-0.44	-0.42	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
GBM	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-4.9	3.14e-06	0.00364	-0.47	-0.42	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
GBM	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-4.9	3.14e-06	0.00364	-0.44	-0.42	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
GBM	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	4.9	3.15e-06	0.00365	0.57	0.42	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
GBM	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	4.9	3.15e-06	0.00365	0.5	0.42	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
GBM	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-4.9	3.15e-06	0.00365	-0.55	-0.42	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
GBM	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-4.9	3.16e-06	0.00366	-0.51	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
GBM	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	4.9	3.16e-06	0.00367	0.47	0.42	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-4.9	3.17e-06	0.00367	-0.49	-0.42	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
GBM	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-4.9	3.17e-06	0.00367	-0.5	-0.42	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
GBM	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-4.9	3.17e-06	0.00367	-0.49	-0.42	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
GBM	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	4.9	3.18e-06	0.00368	0.49	0.42	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
GBM	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	4.9	3.18e-06	0.00368	0.5	0.42	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
GBM	cis	rs2980439	0.517	rs17594065	ENSG00000173295.6	FAM86B3P	4.9	3.19e-06	0.00369	0.39	0.42	Neuroticism;	chr8:8247883	chr8:8228595~8244865:+
GBM	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	4.9	3.19e-06	0.00369	0.45	0.42	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
GBM	cis	rs453301	0.686	rs6601280	ENSG00000254340.1	RP11-10A14.3	4.9	3.19e-06	0.0037	0.52	0.42	Joint mobility (Beighton score);	chr8:9051726	chr8:9141424~9145435:+
GBM	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-4.9	3.2e-06	0.0037	-0.82	-0.42	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
GBM	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	4.9	3.22e-06	0.00372	0.36	0.42	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
GBM	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	4.9	3.22e-06	0.00372	0.64	0.42	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
GBM	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-4.9	3.23e-06	0.00373	-0.47	-0.42	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-4.9	3.23e-06	0.00373	-0.47	-0.42	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
GBM	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-4.9	3.23e-06	0.00373	-0.47	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
GBM	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-4.9	3.23e-06	0.00373	-0.47	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
GBM	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-4.9	3.23e-06	0.00373	-0.47	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
GBM	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-4.9	3.23e-06	0.00373	-0.47	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
GBM	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	4.9	3.23e-06	0.00373	0.8	0.42	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	4.9	3.23e-06	0.00373	0.8	0.42	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	4.9	3.23e-06	0.00373	0.8	0.42	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
GBM	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	4.89	3.24e-06	0.00374	0.48	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
GBM	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-4.89	3.24e-06	0.00374	-0.47	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
GBM	cis	rs17685	0.712	rs60721456	ENSG00000280388.1	RP11-229D13.3	-4.89	3.24e-06	0.00374	-0.4	-0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76114502	chr7:76043977~76045963:-
GBM	cis	rs867371	0.896	rs8033831	ENSG00000278603.1	RP13-608F4.5	4.89	3.25e-06	0.00375	0.48	0.42	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472203~82472426:+
GBM	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	4.89	3.25e-06	0.00375	0.36	0.42	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
GBM	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	4.89	3.25e-06	0.00375	0.5	0.42	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
GBM	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-4.89	3.25e-06	0.00375	-0.49	-0.42	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
GBM	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-4.89	3.26e-06	0.00376	-0.49	-0.42	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
GBM	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	4.89	3.26e-06	0.00376	0.78	0.42	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
GBM	cis	rs397969	0.607	rs169413	ENSG00000230528.6	NOS2P3	-4.89	3.26e-06	0.00376	-0.51	-0.42	Platelet count;	chr17:19946432	chr17:20436337~20447249:+
GBM	cis	rs397969	0.573	rs203475	ENSG00000230528.6	NOS2P3	-4.89	3.26e-06	0.00376	-0.51	-0.42	Platelet count;	chr17:19947662	chr17:20436337~20447249:+
GBM	cis	rs17772222	0.682	rs7142053	ENSG00000258983.2	RP11-507K2.2	4.89	3.27e-06	0.00377	0.44	0.42	Coronary artery calcification;	chr14:88511594	chr14:88499334~88515502:+
GBM	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	4.89	3.27e-06	0.00377	0.52	0.42	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	4.89	3.27e-06	0.00377	0.52	0.42	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
GBM	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	4.89	3.27e-06	0.00377	0.57	0.42	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
GBM	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-4.89	3.28e-06	0.00377	-0.51	-0.42	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
GBM	cis	rs8062405	0.824	rs153106	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.789	rs240704	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs240702	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs62034319	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs28698667	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.754	rs62034323	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs62034324	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs62034326	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.824	rs4788084	ENSG00000271623.1	RP11-435I10.5	-4.89	3.28e-06	0.00378	-0.49	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28364700~28365333:+
GBM	cis	rs1298062	0.717	rs78467973	ENSG00000131401.10	NAPSB	-4.89	3.28e-06	0.00378	-0.5	-0.42	Age of smoking initiation;	chr19:50492314	chr19:50333796~50344767:-
GBM	cis	rs7017914	0.84	rs1481804	ENSG00000246366.5	RP11-382J12.1	-4.89	3.28e-06	0.00378	-0.45	-0.41	Bone mineral density;	chr8:71057195	chr8:70608577~70663279:+
GBM	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-4.89	3.29e-06	0.00378	-0.52	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
GBM	cis	rs172166	0.56	rs203878	ENSG00000199851.2	U3	4.89	3.29e-06	0.00379	0.48	0.41	Cardiac Troponin-T levels;	chr6:28081218	chr6:28015568~28015777:+
GBM	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	4.89	3.3e-06	0.00379	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
GBM	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	4.89	3.3e-06	0.0038	0.58	0.41	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
GBM	cis	rs67981189	0.574	rs221916	ENSG00000269927.1	RP6-91H8.3	-4.89	3.3e-06	0.0038	-0.48	-0.41	Schizophrenia;	chr14:71125361	chr14:71141125~71143253:-
GBM	cis	rs4713118	0.869	rs6456802	ENSG00000199851.2	U3	4.89	3.31e-06	0.00381	0.56	0.41	Parkinson's disease;	chr6:27730576	chr6:28015568~28015777:+
GBM	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	4.89	3.31e-06	0.00381	0.55	0.41	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
GBM	cis	rs67981189	0.501	rs3829954	ENSG00000269927.1	RP6-91H8.3	4.89	3.32e-06	0.00382	0.5	0.41	Schizophrenia;	chr14:70988823	chr14:71141125~71143253:-
GBM	cis	rs6496932	0.503	rs8037726	ENSG00000218052.5	ADAMTS7P4	-4.89	3.32e-06	0.00382	-0.58	-0.41	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85255369~85330334:-
GBM	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	4.89	3.33e-06	0.00383	0.47	0.41	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
GBM	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-4.89	3.34e-06	0.00384	-0.46	-0.41	QT interval;	chr16:28824579	chr16:28700294~28701540:-
GBM	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-4.89	3.35e-06	0.00384	-0.54	-0.41	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
GBM	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-4.89	3.35e-06	0.00384	-0.57	-0.41	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
GBM	cis	rs3806843	1	rs11167600	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140795280	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3756340	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140800866	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3806845	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140801152	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3733707	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140802307	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs7701755	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140802516	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs2240693	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140803740	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs2240692	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140804000	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs6579987	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140804074	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs1030163	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140805547	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs1030164	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140805687	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs1030165	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140805863	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs1030166	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140805888	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs4151680	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140807072	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3822346	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140807737	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.933	rs2337987	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140808798	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.933	rs2879087	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140808990	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs2879089	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140812308	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs11167609	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140820841	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs6885319	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140821026	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs4151682	ENSG00000202111.1	VTRNA1-2	-4.89	3.35e-06	0.00384	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140821679	chr5:140718925~140719013:+
GBM	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-4.89	3.35e-06	0.00385	-0.5	-0.41	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
GBM	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	4.89	3.35e-06	0.00385	0.53	0.41	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	4.89	3.35e-06	0.00385	0.53	0.41	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
GBM	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-4.89	3.36e-06	0.00386	-0.78	-0.41	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
GBM	cis	rs4812048	0.793	rs7266693	ENSG00000268649.3	RP4-806M20.4	-4.89	3.36e-06	0.00386	-0.48	-0.41	Mean platelet volume;	chr20:59018103	chr20:58817132~58817725:-
GBM	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	4.88	3.38e-06	0.00387	0.6	0.41	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	4.88	3.38e-06	0.00387	0.6	0.41	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
GBM	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	4.88	3.38e-06	0.00388	0.5	0.41	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
GBM	cis	rs741668	0.897	rs41284147	ENSG00000235903.6	CPB2-AS1	4.88	3.38e-06	0.00388	0.6	0.41	Cerebrospinal fluid clusterin levels;	chr13:45957558	chr13:46052806~46113332:+
GBM	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	4.88	3.39e-06	0.00388	0.56	0.41	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	4.88	3.39e-06	0.00388	0.56	0.41	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	4.88	3.39e-06	0.00388	0.56	0.41	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
GBM	cis	rs4072705	1	rs10818983	ENSG00000224020.1	MIR181A2HG	-4.88	3.39e-06	0.00388	-0.47	-0.41	Menarche (age at onset);	chr9:124649298	chr9:124658467~124698631:+
GBM	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	4.88	3.39e-06	0.00389	0.42	0.41	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
GBM	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	4.88	3.4e-06	0.0039	0.54	0.41	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
GBM	cis	rs10231759	0.53	rs6971206	ENSG00000273419.1	RP4-751H13.7	-4.88	3.42e-06	0.00392	-0.46	-0.41	Height;	chr7:150835171	chr7:149858400~149862492:-
GBM	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-4.88	3.43e-06	0.00392	-0.57	-0.41	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
GBM	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-4.88	3.43e-06	0.00392	-0.57	-0.41	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
GBM	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-4.88	3.43e-06	0.00393	-0.57	-0.41	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
GBM	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	4.88	3.43e-06	0.00393	0.48	0.41	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
GBM	cis	rs73198271	0.92	rs11781542	ENSG00000253893.2	FAM85B	4.88	3.43e-06	0.00393	0.59	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8759671	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.502	rs7820738	ENSG00000254340.1	RP11-10A14.3	-4.88	3.44e-06	0.00393	-0.5	-0.41	Mood instability;	chr8:8845097	chr8:9141424~9145435:+
GBM	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	4.88	3.44e-06	0.00394	0.65	0.41	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
GBM	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	4.88	3.44e-06	0.00394	0.74	0.41	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
GBM	cis	rs10028773	0.632	rs34481394	ENSG00000250412.1	KLHL2P1	4.88	3.44e-06	0.00394	0.55	0.41	Educational attainment;	chr4:119327219	chr4:119334329~119378233:+
GBM	cis	rs10028773	0.666	rs35231872	ENSG00000250412.1	KLHL2P1	4.88	3.44e-06	0.00394	0.55	0.41	Educational attainment;	chr4:119327221	chr4:119334329~119378233:+
GBM	cis	rs10028773	0.7	rs35653026	ENSG00000250412.1	KLHL2P1	4.88	3.44e-06	0.00394	0.55	0.41	Educational attainment;	chr4:119327223	chr4:119334329~119378233:+
GBM	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	4.88	3.44e-06	0.00394	0.49	0.41	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
GBM	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-4.88	3.45e-06	0.00395	-0.52	-0.41	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
GBM	cis	rs11992162	0.967	rs7461062	ENSG00000255556.2	RP11-351I21.6	4.88	3.46e-06	0.00395	0.42	0.41	Monocyte count;	chr8:11974439	chr8:12378679~12380265:-
GBM	cis	rs11992162	0.933	rs10108075	ENSG00000255556.2	RP11-351I21.6	4.88	3.46e-06	0.00395	0.42	0.41	Monocyte count;	chr8:11974570	chr8:12378679~12380265:-
GBM	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	4.88	3.47e-06	0.00397	0.47	0.41	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
GBM	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	4.88	3.48e-06	0.00397	0.49	0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
GBM	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	4.88	3.48e-06	0.00397	0.57	0.41	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
GBM	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	4.88	3.48e-06	0.00397	0.57	0.41	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
GBM	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-4.88	3.48e-06	0.00398	-0.55	-0.41	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-4.88	3.48e-06	0.00398	-0.55	-0.41	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
GBM	cis	rs3806843	0.868	rs2531349	ENSG00000202111.1	VTRNA1-2	4.88	3.48e-06	0.00398	0.43	0.41	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr5:140718925~140719013:+
GBM	cis	rs17772222	0.682	rs7142053	ENSG00000222990.1	RNU4-22P	4.88	3.48e-06	0.00398	0.45	0.41	Coronary artery calcification;	chr14:88511594	chr14:88513498~88513663:+
GBM	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-4.88	3.49e-06	0.00398	-0.49	-0.41	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
GBM	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-4.88	3.49e-06	0.00398	-0.49	-0.41	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
GBM	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-4.88	3.49e-06	0.00398	-0.49	-0.41	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
GBM	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-4.88	3.49e-06	0.00398	-0.49	-0.41	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
GBM	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-4.88	3.49e-06	0.00398	-0.49	-0.41	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
GBM	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	4.88	3.49e-06	0.00398	0.49	0.41	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
GBM	cis	rs172166	0.516	rs1225710	ENSG00000218016.2	ZNF192P2	4.88	3.49e-06	0.00399	0.48	0.41	Cardiac Troponin-T levels;	chr6:28132862	chr6:28188050~28189432:+
GBM	cis	rs55940216	0.556	rs2739680	ENSG00000245281.5	CTD-2547L16.1	4.88	3.5e-06	0.00399	0.45	0.41	Facial morphology (factor 14, intercanthal width);	chr8:18124757	chr8:18084868~18096394:+
GBM	cis	rs55940216	0.556	rs2739681	ENSG00000245281.5	CTD-2547L16.1	4.88	3.5e-06	0.00399	0.45	0.41	Facial morphology (factor 14, intercanthal width);	chr8:18124760	chr8:18084868~18096394:+
GBM	cis	rs2729354	0.693	rs2584862	ENSG00000265566.2	RN7SL605P	-4.88	3.51e-06	0.004	-0.64	-0.41	Blood protein levels;	chr11:57474483	chr11:57528085~57528365:-
GBM	cis	rs3806843	0.966	rs11958868	ENSG00000202111.1	VTRNA1-2	-4.88	3.51e-06	0.004	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140821835	chr5:140718925~140719013:+
GBM	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	4.88	3.51e-06	0.004	0.5	0.41	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
GBM	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	4.88	3.51e-06	0.004	0.29	0.41	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
GBM	cis	rs2976388	1	rs2920295	ENSG00000253741.1	CTD-2292P10.4	4.88	3.51e-06	0.00401	0.43	0.41	Urinary tract infection frequency;	chr8:142683519	chr8:142702252~142726973:-
GBM	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	4.88	3.51e-06	0.00401	0.46	0.41	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
GBM	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	4.88	3.52e-06	0.00401	0.45	0.41	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
GBM	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	4.88	3.52e-06	0.00401	0.58	0.41	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
GBM	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-4.87	3.52e-06	0.00402	-0.47	-0.41	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
GBM	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	4.87	3.52e-06	0.00402	0.51	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
GBM	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	4.87	3.53e-06	0.00403	0.61	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
GBM	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-4.87	3.53e-06	0.00403	-0.56	-0.41	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
GBM	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-4.87	3.53e-06	0.00403	-0.63	-0.41	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
GBM	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-4.87	3.54e-06	0.00403	-0.55	-0.41	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
GBM	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	4.87	3.54e-06	0.00403	0.5	0.41	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
GBM	cis	rs889122	0.55	rs8108431	ENSG00000267289.1	CTD-2623N2.11	4.87	3.54e-06	0.00403	0.47	0.41	Menarche (age at onset);	chr19:9886011	chr19:9834079~9835013:-
GBM	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	4.87	3.54e-06	0.00403	0.52	0.41	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
GBM	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	4.87	3.55e-06	0.00404	0.83	0.41	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
GBM	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-4.87	3.55e-06	0.00404	-0.45	-0.41	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
GBM	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-4.87	3.55e-06	0.00404	-0.42	-0.41	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
GBM	cis	rs9368481	0.761	rs4713062	ENSG00000224843.5	LINC00240	4.87	3.55e-06	0.00405	0.49	0.41	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26956992~27023924:+
GBM	cis	rs5742933	0.779	rs1899025	ENSG00000253559.1	OSGEPL1-AS1	4.87	3.56e-06	0.00405	0.44	0.41	Ferritin levels;	chr2:189784856	chr2:189762704~189765556:+
GBM	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	4.87	3.56e-06	0.00405	0.46	0.41	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
GBM	cis	rs67981189	0.529	rs17108808	ENSG00000269927.1	RP6-91H8.3	4.87	3.56e-06	0.00406	0.49	0.41	Schizophrenia;	chr14:70974835	chr14:71141125~71143253:-
GBM	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	4.87	3.57e-06	0.00406	0.59	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
GBM	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-4.87	3.57e-06	0.00406	-0.45	-0.41	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
GBM	cis	rs893971	0.643	rs7677533	ENSG00000246375.2	RP11-10L7.1	4.87	3.57e-06	0.00406	0.48	0.41	Conduct disorder (maternal expressed emotions interaction);	chr4:88306766	chr4:88284942~88331421:+
GBM	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-4.87	3.58e-06	0.00407	-0.47	-0.41	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-4.87	3.58e-06	0.00407	-0.47	-0.41	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
GBM	cis	rs2069426	1	rs17756311	ENSG00000240498.5	CDKN2B-AS1	-4.87	3.58e-06	0.00407	-0.78	-0.41	Acute lymphoblastic leukemia (childhood);	chr9:22053896	chr9:21994778~22121097:+
GBM	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	4.87	3.59e-06	0.00408	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	4.87	3.59e-06	0.00408	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
GBM	cis	rs7017914	0.69	rs10453108	ENSG00000246366.5	RP11-382J12.1	-4.87	3.59e-06	0.00408	-0.43	-0.41	Bone mineral density;	chr8:70870705	chr8:70608577~70663279:+
GBM	cis	rs4072705	0.585	rs7852843	ENSG00000224020.1	MIR181A2HG	4.87	3.59e-06	0.00408	0.43	0.41	Menarche (age at onset);	chr9:124471544	chr9:124658467~124698631:+
GBM	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	4.87	3.59e-06	0.00409	0.44	0.41	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
GBM	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	4.87	3.59e-06	0.00409	0.44	0.41	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
GBM	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	4.87	3.59e-06	0.00409	0.44	0.41	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
GBM	cis	rs2739330	0.76	rs5751761	ENSG00000272787.1	KB-226F1.2	-4.87	3.6e-06	0.00409	-0.39	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23969211~23969873:+
GBM	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	4.87	3.6e-06	0.0041	0.56	0.41	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
GBM	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	4.87	3.61e-06	0.0041	0.5	0.41	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
GBM	cis	rs5742933	0.817	rs1233265	ENSG00000253559.1	OSGEPL1-AS1	-4.87	3.61e-06	0.0041	-0.45	-0.41	Ferritin levels;	chr2:189796390	chr2:189762704~189765556:+
GBM	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	4.87	3.63e-06	0.00412	0.69	0.41	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
GBM	cis	rs73198271	0.74	rs3827807	ENSG00000253893.2	FAM85B	4.87	3.63e-06	0.00412	0.61	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8167819~8226614:-
GBM	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	4.87	3.63e-06	0.00412	0.49	0.41	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	4.87	3.63e-06	0.00412	0.49	0.41	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
GBM	cis	rs4072705	0.614	rs1570581	ENSG00000224020.1	MIR181A2HG	-4.87	3.64e-06	0.00412	-0.43	-0.41	Menarche (age at onset);	chr9:124471780	chr9:124658467~124698631:+
GBM	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	4.87	3.64e-06	0.00412	0.49	0.41	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	4.87	3.64e-06	0.00412	0.49	0.41	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	4.87	3.64e-06	0.00412	0.49	0.41	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
GBM	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-4.87	3.64e-06	0.00413	-0.55	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
GBM	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-4.87	3.64e-06	0.00413	-0.47	-0.41	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
GBM	cis	rs10754283	0.84	rs1215500	ENSG00000231613.1	RP5-943J3.1	4.87	3.64e-06	0.00413	0.5	0.41	Amyotrophic lateral sclerosis (sporadic);	chr1:89631695	chr1:89788914~89790492:+
GBM	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	4.87	3.65e-06	0.00414	0.44	0.41	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
GBM	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	4.87	3.65e-06	0.00414	0.49	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
GBM	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-4.87	3.66e-06	0.00415	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
GBM	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	4.87	3.67e-06	0.00415	0.4	0.41	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
GBM	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-4.87	3.67e-06	0.00415	-0.52	-0.41	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
GBM	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	4.86	3.68e-06	0.00416	0.53	0.41	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
GBM	cis	rs6496932	0.909	rs74024818	ENSG00000218052.5	ADAMTS7P4	4.86	3.68e-06	0.00417	0.63	0.41	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85255369~85330334:-
GBM	cis	rs10946940	0.965	rs6910838	ENSG00000218016.2	ZNF192P2	4.86	3.69e-06	0.00417	0.51	0.41	Systemic lupus erythematosus;	chr6:27547740	chr6:28188050~28189432:+
GBM	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	4.86	3.69e-06	0.00417	0.5	0.41	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
GBM	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	4.86	3.7e-06	0.00418	0.44	0.41	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	4.86	3.7e-06	0.00418	0.44	0.41	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
GBM	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-4.86	3.72e-06	0.00421	-0.56	-0.41	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
GBM	cis	rs7267979	0.78	rs6050679	ENSG00000276952.1	RP5-965G21.6	4.86	3.73e-06	0.00422	0.38	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25284915~25285588:-
GBM	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	4.86	3.73e-06	0.00422	0.84	0.41	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
GBM	cis	rs10946940	0.896	rs12208078	ENSG00000218016.2	ZNF192P2	4.86	3.74e-06	0.00422	0.51	0.41	Systemic lupus erythematosus;	chr6:27530802	chr6:28188050~28189432:+
GBM	cis	rs10946940	0.965	rs10946935	ENSG00000218016.2	ZNF192P2	4.86	3.74e-06	0.00422	0.51	0.41	Systemic lupus erythematosus;	chr6:27533566	chr6:28188050~28189432:+
GBM	cis	rs10946940	0.93	rs12215012	ENSG00000218016.2	ZNF192P2	4.86	3.74e-06	0.00422	0.51	0.41	Systemic lupus erythematosus;	chr6:27539715	chr6:28188050~28189432:+
GBM	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	4.86	3.74e-06	0.00422	0.83	0.41	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
GBM	cis	rs4713118	0.869	rs2056925	ENSG00000199851.2	U3	4.86	3.75e-06	0.00423	0.56	0.41	Parkinson's disease;	chr6:27723126	chr6:28015568~28015777:+
GBM	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-4.86	3.75e-06	0.00423	-0.47	-0.41	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
GBM	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-4.86	3.75e-06	0.00423	-0.47	-0.41	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
GBM	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-4.86	3.75e-06	0.00423	-0.47	-0.41	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
GBM	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-4.86	3.75e-06	0.00423	-0.47	-0.41	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
GBM	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-4.86	3.75e-06	0.00423	-0.56	-0.41	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
GBM	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-4.86	3.75e-06	0.00423	-0.56	-0.41	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
GBM	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-4.86	3.75e-06	0.00423	-0.56	-0.41	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
GBM	cis	rs763121	0.853	rs5757141	ENSG00000273076.1	RP3-508I15.22	4.86	3.75e-06	0.00423	0.46	0.41	Menopause (age at onset);	chr22:38561478	chr22:38743495~38743910:+
GBM	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-4.86	3.75e-06	0.00423	-0.46	-0.41	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
GBM	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-4.86	3.75e-06	0.00423	-0.46	-0.41	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
GBM	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-4.86	3.75e-06	0.00423	-0.46	-0.41	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
GBM	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-4.86	3.75e-06	0.00423	-0.46	-0.41	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
GBM	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-4.86	3.75e-06	0.00423	-0.46	-0.41	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
GBM	cis	rs7267979	0.528	rs6076366	ENSG00000125804.12	FAM182A	4.86	3.76e-06	0.00424	0.54	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26054655~26086917:+
GBM	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-4.86	3.77e-06	0.00424	-0.52	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
GBM	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-4.86	3.77e-06	0.00424	-0.55	-0.41	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
GBM	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-4.86	3.77e-06	0.00424	-0.55	-0.41	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
GBM	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	4.86	3.77e-06	0.00424	0.45	0.41	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	4.86	3.77e-06	0.00424	0.45	0.41	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
GBM	cis	rs7267979	0.706	rs6138542	ENSG00000276952.1	RP5-965G21.6	4.86	3.77e-06	0.00424	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25284915~25285588:-
GBM	cis	rs17508449	0.732	rs74610368	ENSG00000232450.1	RP4-730K3.3	-4.86	3.77e-06	0.00424	-0.69	-0.41	Leprosy;	chr1:113742681	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.732	rs74533448	ENSG00000232450.1	RP4-730K3.3	-4.86	3.77e-06	0.00424	-0.69	-0.41	Leprosy;	chr1:113750266	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.732	rs75746385	ENSG00000232450.1	RP4-730K3.3	-4.86	3.77e-06	0.00424	-0.69	-0.41	Leprosy;	chr1:113758270	chr1:113698884~113699631:-
GBM	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-4.86	3.78e-06	0.00425	-0.44	-0.41	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
GBM	cis	rs950776	0.695	rs8025188	ENSG00000261762.1	RP11-650L12.2	-4.86	3.78e-06	0.00426	-0.58	-0.41	Sudden cardiac arrest;	chr15:78619936	chr15:78589123~78591276:-
GBM	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-4.86	3.79e-06	0.00426	-0.42	-0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
GBM	cis	rs3806843	0.966	rs3756338	ENSG00000202111.1	VTRNA1-2	-4.86	3.79e-06	0.00427	-0.43	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140800976	chr5:140718925~140719013:+
GBM	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-4.86	3.8e-06	0.00427	-0.42	-0.41	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
GBM	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-4.86	3.8e-06	0.00427	-0.68	-0.41	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
GBM	cis	rs11159086	1	rs4903233	ENSG00000270000.1	RP3-449M8.9	4.86	3.8e-06	0.00428	0.65	0.41	Advanced glycation end-product levels;	chr14:74497291	chr14:74471930~74472360:-
GBM	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	4.86	3.81e-06	0.00429	0.28	0.41	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
GBM	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
GBM	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
GBM	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	4.86	3.82e-06	0.00429	0.58	0.41	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
GBM	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-4.86	3.82e-06	0.0043	-0.56	-0.41	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
GBM	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-4.86	3.82e-06	0.0043	-0.56	-0.41	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
GBM	cis	rs4713118	0.539	rs200988	ENSG00000218016.2	ZNF192P2	-4.85	3.83e-06	0.0043	-0.56	-0.41	Parkinson's disease;	chr6:27851575	chr6:28188050~28189432:+
GBM	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	4.85	3.83e-06	0.0043	0.55	0.41	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
GBM	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	4.85	3.83e-06	0.0043	0.55	0.41	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
GBM	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	4.85	3.84e-06	0.00431	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
GBM	cis	rs11673344	0.583	rs7254411	ENSG00000226686.6	LINC01535	4.85	3.84e-06	0.00431	0.45	0.41	Obesity-related traits;	chr19:37034969	chr19:37251912~37265535:+
GBM	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	4.85	3.84e-06	0.00431	0.52	0.41	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
GBM	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	4.85	3.84e-06	0.00431	0.48	0.41	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
GBM	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	4.85	3.84e-06	0.00431	0.48	0.41	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
GBM	cis	rs200972	1	rs200972	ENSG00000218016.2	ZNF192P2	-4.85	3.84e-06	0.00431	-0.5	-0.41	Urinary tract infection frequency;	chr6:27891059	chr6:28188050~28189432:+
GBM	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-4.85	3.84e-06	0.00432	-0.46	-0.41	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
GBM	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	4.85	3.85e-06	0.00432	0.54	0.41	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
GBM	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	4.85	3.85e-06	0.00433	0.79	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
GBM	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	4.85	3.85e-06	0.00433	0.48	0.41	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
GBM	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	-4.85	3.86e-06	0.00433	-0.57	-0.41	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
GBM	cis	rs1298062	0.861	rs2431827	ENSG00000131401.10	NAPSB	-4.85	3.86e-06	0.00433	-0.49	-0.41	Age of smoking initiation;	chr19:50490957	chr19:50333796~50344767:-
GBM	cis	rs1298062	0.717	rs74176110	ENSG00000131401.10	NAPSB	-4.85	3.86e-06	0.00433	-0.49	-0.41	Age of smoking initiation;	chr19:50492311	chr19:50333796~50344767:-
GBM	cis	rs1298062	0.771	rs4801833	ENSG00000131401.10	NAPSB	-4.85	3.86e-06	0.00433	-0.49	-0.41	Age of smoking initiation;	chr19:50492675	chr19:50333796~50344767:-
GBM	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-4.85	3.86e-06	0.00434	-0.46	-0.41	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
GBM	cis	rs10911232	0.507	rs4652764	ENSG00000224468.3	RP11-181K3.4	-4.85	3.87e-06	0.00434	-0.33	-0.41	Hypertriglyceridemia;	chr1:183024980	chr1:183138402~183141282:-
GBM	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-4.85	3.87e-06	0.00435	-0.46	-0.41	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
GBM	cis	rs3806843	0.966	rs7710380	ENSG00000202111.1	VTRNA1-2	-4.85	3.88e-06	0.00435	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr5:140718925~140719013:+
GBM	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	4.85	3.88e-06	0.00435	0.47	0.41	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
GBM	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-4.85	3.88e-06	0.00435	-0.47	-0.41	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
GBM	cis	rs172166	0.561	rs149976	ENSG00000199851.2	U3	-4.85	3.88e-06	0.00435	-0.53	-0.41	Cardiac Troponin-T levels;	chr6:28019998	chr6:28015568~28015777:+
GBM	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	4.85	3.89e-06	0.00436	0.63	0.41	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
GBM	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-4.85	3.9e-06	0.00436	-0.46	-0.41	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
GBM	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-4.85	3.9e-06	0.00437	-0.47	-0.41	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
GBM	cis	rs17214007	0.627	rs28593034	ENSG00000279866.1	CTB-193M12.4	4.85	3.91e-06	0.00437	0.51	0.41	Cognitive function;	chr16:15597329	chr16:15704410~15705984:+
GBM	cis	rs3096299	0.754	rs3102382	ENSG00000260259.1	RP11-368I7.4	4.85	3.91e-06	0.00438	0.46	0.41	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89682620~89686569:-
GBM	cis	rs3742264	0.656	rs9526133	ENSG00000235903.6	CPB2-AS1	-4.85	3.91e-06	0.00438	-0.49	-0.41	Blood protein levels;	chr13:46040866	chr13:46052806~46113332:+
GBM	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	4.85	3.91e-06	0.00438	0.47	0.41	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
GBM	cis	rs172166	0.516	rs1225715	ENSG00000199851.2	U3	-4.85	3.91e-06	0.00438	-0.51	-0.41	Cardiac Troponin-T levels;	chr6:28145595	chr6:28015568~28015777:+
GBM	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	4.85	3.93e-06	0.0044	0.55	0.41	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
GBM	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-4.85	3.93e-06	0.0044	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-4.85	3.93e-06	0.0044	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-4.85	3.93e-06	0.0044	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-4.85	3.93e-06	0.0044	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-4.85	3.93e-06	0.0044	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-4.85	3.93e-06	0.0044	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	4.85	3.93e-06	0.0044	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	4.85	3.93e-06	0.0044	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	4.85	3.93e-06	0.0044	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
GBM	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-4.85	3.93e-06	0.0044	-0.49	-0.41	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
GBM	cis	rs2579103	0.668	rs1222456	ENSG00000258183.4	RP11-753N8.1	-4.85	3.93e-06	0.0044	-0.62	-0.41	Body mass index;	chr12:90300134	chr12:90280894~90300340:+
GBM	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	4.85	3.93e-06	0.0044	0.67	0.41	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
GBM	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	4.85	3.95e-06	0.00442	0.57	0.41	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
GBM	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	4.85	3.95e-06	0.00442	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	4.85	3.95e-06	0.00442	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
GBM	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	4.85	3.95e-06	0.00442	0.43	0.41	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
GBM	cis	rs4604732	0.588	rs4356092	ENSG00000227135.1	GCSAML-AS1	-4.85	3.96e-06	0.00443	-0.63	-0.41	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469366	chr1:247524679~247526752:-
GBM	cis	rs3806843	0.868	rs2262574	ENSG00000202111.1	VTRNA1-2	4.85	3.96e-06	0.00443	0.43	0.41	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr5:140718925~140719013:+
GBM	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-4.85	3.97e-06	0.00444	-0.47	-0.41	QT interval;	chr16:28884339	chr16:28700294~28701540:-
GBM	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	4.85	3.97e-06	0.00444	0.51	0.41	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
GBM	cis	rs3806843	0.762	rs3756337	ENSG00000202111.1	VTRNA1-2	-4.85	3.98e-06	0.00445	-0.41	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140806853	chr5:140718925~140719013:+
GBM	cis	rs893971	0.643	rs6532063	ENSG00000246375.2	RP11-10L7.1	4.85	3.98e-06	0.00445	0.47	0.41	Conduct disorder (maternal expressed emotions interaction);	chr4:88310803	chr4:88284942~88331421:+
GBM	cis	rs893971	0.611	rs1595911	ENSG00000246375.2	RP11-10L7.1	4.85	3.98e-06	0.00445	0.47	0.41	Conduct disorder (maternal expressed emotions interaction);	chr4:88311273	chr4:88284942~88331421:+
GBM	cis	rs4273100	0.607	rs8072587	ENSG00000262319.1	CTC-457L16.2	4.85	3.98e-06	0.00445	0.48	0.41	Schizophrenia;	chr17:19307760	chr17:19141017~19143689:-
GBM	cis	rs4273100	0.646	rs1472932	ENSG00000262319.1	CTC-457L16.2	4.85	3.98e-06	0.00445	0.48	0.41	Schizophrenia;	chr17:19317353	chr17:19141017~19143689:-
GBM	cis	rs67981189	0.593	rs8007425	ENSG00000269927.1	RP6-91H8.3	4.85	3.99e-06	0.00445	0.45	0.41	Schizophrenia;	chr14:71041483	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.529	rs2810096	ENSG00000269927.1	RP6-91H8.3	-4.85	3.99e-06	0.00446	-0.49	-0.41	Schizophrenia;	chr14:70968583	chr14:71141125~71143253:-
GBM	cis	rs7267979	0.873	rs6115093	ENSG00000276952.1	RP5-965G21.6	4.85	3.99e-06	0.00446	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.649	rs2500406	ENSG00000125804.12	FAM182A	4.84	3.99e-06	0.00446	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:26054655~26086917:+
GBM	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-4.84	4e-06	0.00447	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-4.84	4e-06	0.00447	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
GBM	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-4.84	4e-06	0.00447	-0.55	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
GBM	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	4.84	4e-06	0.00447	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-4.84	4e-06	0.00447	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
GBM	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-4.84	4.01e-06	0.00448	-0.53	-0.41	Height;	chr11:118786602	chr11:118704607~118750263:+
GBM	cis	rs4713118	0.869	rs6922574	ENSG00000199851.2	U3	4.84	4.01e-06	0.00448	0.57	0.41	Parkinson's disease;	chr6:27725224	chr6:28015568~28015777:+
GBM	cis	rs7829975	0.501	rs4840353	ENSG00000253893.2	FAM85B	4.84	4.02e-06	0.00449	0.51	0.41	Mood instability;	chr8:8723060	chr8:8167819~8226614:-
GBM	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-4.84	4.02e-06	0.00449	-0.47	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
GBM	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-4.84	4.03e-06	0.00449	-0.49	-0.41	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
GBM	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	4.84	4.03e-06	0.00449	0.44	0.41	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
GBM	cis	rs17685	0.753	rs2302438	ENSG00000280388.1	RP11-229D13.3	-4.84	4.03e-06	0.0045	-0.38	-0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76047747	chr7:76043977~76045963:-
GBM	cis	rs17685	0.697	rs2302437	ENSG00000280388.1	RP11-229D13.3	4.84	4.03e-06	0.0045	0.38	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76047698	chr7:76043977~76045963:-
GBM	cis	rs17685	0.796	rs3757594	ENSG00000280388.1	RP11-229D13.3	4.84	4.03e-06	0.0045	0.38	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76049326	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs3757593	ENSG00000280388.1	RP11-229D13.3	4.84	4.03e-06	0.0045	0.38	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76049417	chr7:76043977~76045963:-
GBM	cis	rs397969	0.646	rs1638528	ENSG00000230528.6	NOS2P3	-4.84	4.03e-06	0.0045	-0.5	-0.41	Platelet count;	chr17:19934616	chr17:20436337~20447249:+
GBM	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-4.84	4.04e-06	0.0045	-0.55	-0.41	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
GBM	cis	rs763121	0.853	rs9607566	ENSG00000273076.1	RP3-508I15.22	4.84	4.05e-06	0.00451	0.47	0.41	Menopause (age at onset);	chr22:38679429	chr22:38743495~38743910:+
GBM	cis	rs4072705	1	rs10760373	ENSG00000224020.1	MIR181A2HG	-4.84	4.05e-06	0.00451	-0.46	-0.41	Menarche (age at onset);	chr9:124723166	chr9:124658467~124698631:+
GBM	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	4.84	4.05e-06	0.00452	0.47	0.41	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
GBM	cis	rs10752881	0.652	rs10911262	ENSG00000224468.3	RP11-181K3.4	-4.84	4.06e-06	0.00453	-0.34	-0.41	Colorectal cancer;	chr1:183145821	chr1:183138402~183141282:-
GBM	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-4.84	4.06e-06	0.00453	-0.51	-0.41	Height;	chr3:53074760	chr3:53064283~53065091:-
GBM	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-4.84	4.06e-06	0.00453	-0.55	-0.41	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-4.84	4.06e-06	0.00453	-0.55	-0.41	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
GBM	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-4.84	4.06e-06	0.00453	-0.53	-0.41	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
GBM	cis	rs4713118	0.824	rs9468223	ENSG00000218016.2	ZNF192P2	-4.84	4.06e-06	0.00453	-0.53	-0.41	Parkinson's disease;	chr6:27772887	chr6:28188050~28189432:+
GBM	cis	rs9571757	1	rs9571757	ENSG00000230040.1	LINC00364	4.84	4.07e-06	0.00454	0.51	0.41	Photic sneeze reflex;	chr13:67331105	chr13:67372387~67379976:+
GBM	cis	rs9368481	0.645	rs10456350	ENSG00000224843.5	LINC00240	-4.84	4.07e-06	0.00454	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26956992~27023924:+
GBM	cis	rs9368481	0.761	rs4358615	ENSG00000224843.5	LINC00240	-4.84	4.07e-06	0.00454	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26956992~27023924:+
GBM	cis	rs9987353	0.62	rs34455383	ENSG00000253893.2	FAM85B	4.84	4.07e-06	0.00454	0.5	0.41	Recombination measurement;	chr8:9208948	chr8:8167819~8226614:-
GBM	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	4.84	4.08e-06	0.00454	0.49	0.41	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
GBM	cis	rs4295623	0.816	rs35558975	ENSG00000255556.2	RP11-351I21.6	-4.84	4.08e-06	0.00455	-0.48	-0.41	Morning vs. evening chronotype;	chr8:11726967	chr8:12378679~12380265:-
GBM	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-4.84	4.08e-06	0.00455	-0.46	-0.41	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
GBM	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	4.84	4.09e-06	0.00455	0.6	0.41	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
GBM	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	4.84	4.09e-06	0.00455	0.6	0.41	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
GBM	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	4.84	4.09e-06	0.00455	0.45	0.41	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
GBM	cis	rs12699921	0.761	rs4272266	ENSG00000279048.1	RP11-511H23.2	4.84	4.1e-06	0.00457	0.34	0.41	Fibrinogen levels;	chr7:17951886	chr7:17940503~17942922:+
GBM	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-4.84	4.11e-06	0.00458	-0.43	-0.41	Temperament;	chr17:14019308	chr17:14024514~14025488:+
GBM	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	4.84	4.11e-06	0.00458	0.56	0.41	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
GBM	cis	rs4713118	0.513	rs200971	ENSG00000199851.2	U3	4.84	4.12e-06	0.00459	0.59	0.41	Parkinson's disease;	chr6:27891126	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.539	rs200967	ENSG00000199851.2	U3	4.84	4.12e-06	0.00459	0.59	0.41	Parkinson's disease;	chr6:27894349	chr6:28015568~28015777:+
GBM	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-4.84	4.13e-06	0.00459	-0.94	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
GBM	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	4.84	4.13e-06	0.00459	0.48	0.41	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
GBM	cis	rs7267979	0.866	rs6138609	ENSG00000276952.1	RP5-965G21.6	4.84	4.13e-06	0.00459	0.39	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25284915~25285588:-
GBM	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	4.84	4.13e-06	0.0046	0.57	0.41	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
GBM	cis	rs3096299	0.809	rs2911264	ENSG00000260259.1	RP11-368I7.4	4.84	4.13e-06	0.0046	0.45	0.41	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89682620~89686569:-
GBM	cis	rs11098499	0.821	rs56155624	ENSG00000249244.1	RP11-548H18.2	4.84	4.13e-06	0.0046	0.54	0.41	Corneal astigmatism;	chr4:119369871	chr4:119391831~119395335:-
GBM	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	4.84	4.13e-06	0.0046	0.47	0.41	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
GBM	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	4.84	4.13e-06	0.0046	0.56	0.41	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
GBM	cis	rs1150668	0.835	rs203869	ENSG00000199851.2	U3	4.84	4.14e-06	0.0046	0.48	0.41	Pubertal anthropometrics;	chr6:28073041	chr6:28015568~28015777:+
GBM	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-4.84	4.14e-06	0.00461	-0.42	-0.41	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-4.84	4.14e-06	0.00461	-0.42	-0.41	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
GBM	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	4.84	4.14e-06	0.00461	0.4	0.41	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
GBM	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	4.84	4.14e-06	0.00461	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
GBM	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-4.84	4.14e-06	0.00461	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
GBM	cis	rs526231	0.667	rs187580	ENSG00000175749.11	EIF3KP1	4.84	4.14e-06	0.00461	0.67	0.41	Primary biliary cholangitis;	chr5:103291654	chr5:103032376~103033031:+
GBM	cis	rs3096299	0.967	rs2965932	ENSG00000260259.1	RP11-368I7.4	-4.84	4.15e-06	0.00461	-0.44	-0.41	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89682620~89686569:-
GBM	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	4.84	4.15e-06	0.00461	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
GBM	cis	rs763121	0.819	rs5757126	ENSG00000273076.1	RP3-508I15.22	4.84	4.15e-06	0.00462	0.45	0.41	Menopause (age at onset);	chr22:38527670	chr22:38743495~38743910:+
GBM	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-4.84	4.16e-06	0.00462	-0.45	-0.41	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-4.84	4.16e-06	0.00462	-0.45	-0.41	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
GBM	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-4.83	4.16e-06	0.00463	-0.46	-0.41	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
GBM	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	4.83	4.18e-06	0.00464	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
GBM	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-4.83	4.18e-06	0.00464	-0.34	-0.41	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
GBM	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-4.83	4.18e-06	0.00465	-0.56	-0.41	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
GBM	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	4.83	4.19e-06	0.00465	0.73	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	4.83	4.19e-06	0.00465	0.73	0.41	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
GBM	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-4.83	4.19e-06	0.00465	-0.47	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
GBM	cis	rs2526882	0.562	rs12893492	ENSG00000269927.1	RP6-91H8.3	4.83	4.19e-06	0.00465	0.46	0.41	Schizophrenia;	chr14:71040058	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.572	rs7156009	ENSG00000269927.1	RP6-91H8.3	4.83	4.19e-06	0.00465	0.46	0.41	Schizophrenia;	chr14:71048714	chr14:71141125~71143253:-
GBM	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	4.83	4.2e-06	0.00466	0.48	0.41	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
GBM	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	4.83	4.2e-06	0.00466	0.43	0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
GBM	cis	rs67981189	0.593	rs8006046	ENSG00000269927.1	RP6-91H8.3	4.83	4.2e-06	0.00466	0.46	0.41	Schizophrenia;	chr14:71032274	chr14:71141125~71143253:-
GBM	cis	rs172166	0.561	rs149971	ENSG00000199851.2	U3	4.83	4.2e-06	0.00467	0.54	0.41	Cardiac Troponin-T levels;	chr6:28014374	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.505	rs276371	ENSG00000218016.2	ZNF192P2	-4.83	4.21e-06	0.00467	-0.49	-0.41	Parkinson's disease;	chr6:27942930	chr6:28188050~28189432:+
GBM	cis	rs10028773	0.515	rs9994488	ENSG00000250412.1	KLHL2P1	4.83	4.21e-06	0.00467	0.53	0.41	Educational attainment;	chr4:119666626	chr4:119334329~119378233:+
GBM	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-4.83	4.21e-06	0.00467	-0.48	-0.41	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
GBM	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	4.83	4.21e-06	0.00468	0.54	0.41	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
GBM	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.83	4.23e-06	0.00469	0.51	0.41	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.83	4.23e-06	0.00469	0.51	0.41	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.83	4.23e-06	0.00469	0.51	0.41	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
GBM	cis	rs2976388	0.935	rs2978979	ENSG00000253741.1	CTD-2292P10.4	4.83	4.23e-06	0.00469	0.44	0.41	Urinary tract infection frequency;	chr8:142675868	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.935	rs2978980	ENSG00000253741.1	CTD-2292P10.4	4.83	4.23e-06	0.00469	0.44	0.41	Urinary tract infection frequency;	chr8:142676290	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2920282	ENSG00000253741.1	CTD-2292P10.4	4.83	4.23e-06	0.00469	0.44	0.41	Urinary tract infection frequency;	chr8:142676345	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.874	rs2976389	ENSG00000253741.1	CTD-2292P10.4	4.83	4.23e-06	0.00469	0.44	0.41	Urinary tract infection frequency;	chr8:142679003	chr8:142702252~142726973:-
GBM	cis	rs3096299	0.9	rs3114867	ENSG00000260259.1	RP11-368I7.4	4.83	4.24e-06	0.0047	0.44	0.41	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89682620~89686569:-
GBM	cis	rs9876781	0.563	rs4858821	ENSG00000244380.1	RP11-24C3.2	-4.83	4.24e-06	0.0047	-0.48	-0.41	Longevity;	chr3:48512515	chr3:48440352~48446656:-
GBM	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	4.83	4.24e-06	0.0047	0.65	0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
GBM	cis	rs3096299	0.933	rs28608022	ENSG00000260259.1	RP11-368I7.4	4.83	4.25e-06	0.00471	0.44	0.41	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89682620~89686569:-
GBM	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	4.83	4.25e-06	0.00471	0.43	0.41	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
GBM	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-4.83	4.25e-06	0.00471	-0.39	-0.41	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
GBM	cis	rs7267979	0.727	rs4815431	ENSG00000276952.1	RP5-965G21.6	-4.83	4.26e-06	0.00472	-0.38	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25284915~25285588:-
GBM	cis	rs4072705	0.646	rs915034	ENSG00000224020.1	MIR181A2HG	-4.83	4.26e-06	0.00472	-0.45	-0.41	Menarche (age at onset);	chr9:124482676	chr9:124658467~124698631:+
GBM	cis	rs6496932	0.503	rs4564526	ENSG00000218052.5	ADAMTS7P4	-4.83	4.26e-06	0.00472	-0.58	-0.41	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85255369~85330334:-
GBM	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	4.83	4.26e-06	0.00472	0.65	0.41	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
GBM	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	4.83	4.26e-06	0.00472	0.49	0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
GBM	cis	rs4713118	0.869	rs7773070	ENSG00000199851.2	U3	4.83	4.26e-06	0.00472	0.55	0.41	Parkinson's disease;	chr6:27761048	chr6:28015568~28015777:+
GBM	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	4.83	4.27e-06	0.00473	0.48	0.41	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
GBM	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-4.83	4.27e-06	0.00473	-0.51	-0.41	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
GBM	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	4.83	4.28e-06	0.00474	0.31	0.41	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
GBM	cis	rs7017914	0.69	rs3098872	ENSG00000246366.5	RP11-382J12.1	4.83	4.28e-06	0.00474	0.43	0.41	Bone mineral density;	chr8:71019969	chr8:70608577~70663279:+
GBM	cis	rs172166	0.561	rs149973	ENSG00000199851.2	U3	4.83	4.28e-06	0.00474	0.53	0.41	Cardiac Troponin-T levels;	chr6:28015835	chr6:28015568~28015777:+
GBM	cis	rs172166	0.561	rs149974	ENSG00000199851.2	U3	4.83	4.28e-06	0.00474	0.53	0.41	Cardiac Troponin-T levels;	chr6:28017318	chr6:28015568~28015777:+
GBM	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	4.83	4.29e-06	0.00475	0.55	0.41	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
GBM	cis	rs3806843	1	rs2098058	ENSG00000202111.1	VTRNA1-2	4.83	4.29e-06	0.00475	0.44	0.41	Depressive symptoms (multi-trait analysis);	chr5:140777842	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs10066278	ENSG00000202111.1	VTRNA1-2	-4.83	4.29e-06	0.00475	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs10053945	ENSG00000202111.1	VTRNA1-2	-4.83	4.29e-06	0.00475	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140780542	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs1548700	ENSG00000202111.1	VTRNA1-2	-4.83	4.29e-06	0.00475	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140785304	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs1548699	ENSG00000202111.1	VTRNA1-2	-4.83	4.29e-06	0.00475	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140785333	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs12055222	ENSG00000202111.1	VTRNA1-2	-4.83	4.29e-06	0.00475	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140785983	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs6898939	ENSG00000202111.1	VTRNA1-2	-4.83	4.29e-06	0.00475	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140789770	chr5:140718925~140719013:+
GBM	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	4.83	4.29e-06	0.00475	0.84	0.41	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
GBM	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	4.83	4.29e-06	0.00475	0.84	0.41	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
GBM	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	4.83	4.29e-06	0.00475	0.84	0.41	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
GBM	cis	rs7567389	0.568	rs7568070	ENSG00000236682.1	AC068282.3	-4.83	4.3e-06	0.00475	-0.49	-0.41	Self-rated health;	chr2:127195478	chr2:127389130~127400580:+
GBM	cis	rs11992186	0.57	rs17628941	ENSG00000253893.2	FAM85B	4.83	4.3e-06	0.00476	0.51	0.41	Neuroticism;	chr8:8730024	chr8:8167819~8226614:-
GBM	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-4.83	4.3e-06	0.00476	-0.52	-0.41	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
GBM	cis	rs5742933	0.803	rs1233262	ENSG00000253559.1	OSGEPL1-AS1	-4.83	4.3e-06	0.00476	-0.45	-0.41	Ferritin levels;	chr2:189793107	chr2:189762704~189765556:+
GBM	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	4.83	4.31e-06	0.00476	0.45	0.41	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
GBM	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-4.83	4.32e-06	0.00477	-0.41	-0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
GBM	cis	rs1420956	0.562	rs9956311	ENSG00000264151.4	RP11-739N10.1	4.83	4.32e-06	0.00478	0.54	0.41	Obesity-related traits;	chr18:27582888	chr18:27336379~27595164:-
GBM	cis	rs9926296	0.605	rs6500449	ENSG00000260259.1	RP11-368I7.4	-4.83	4.32e-06	0.00478	-0.45	-0.41	Vitiligo;	chr16:89789985	chr16:89682620~89686569:-
GBM	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-4.83	4.32e-06	0.00478	-0.47	-0.41	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
GBM	cis	rs7267979	0.932	rs1985737	ENSG00000276952.1	RP5-965G21.6	4.83	4.33e-06	0.00478	0.39	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25284915~25285588:-
GBM	cis	rs17772222	0.63	rs7141608	ENSG00000258983.2	RP11-507K2.2	-4.83	4.33e-06	0.00479	-0.43	-0.41	Coronary artery calcification;	chr14:88514045	chr14:88499334~88515502:+
GBM	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	4.83	4.33e-06	0.00479	0.44	0.41	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
GBM	cis	rs4713118	0.5	rs9461434	ENSG00000219392.1	RP1-265C24.5	-4.82	4.34e-06	0.00479	-0.65	-0.41	Parkinson's disease;	chr6:28134687	chr6:28115628~28116551:+
GBM	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	4.82	4.34e-06	0.00479	0.49	0.41	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
GBM	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	4.82	4.34e-06	0.0048	0.48	0.41	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
GBM	cis	rs6046396	1	rs6046404	ENSG00000275142.1	RP5-999L4.2	-4.82	4.34e-06	0.0048	-0.58	-0.41	Bipolar disorder and schizophrenia;	chr20:19882918	chr20:19871891~19872284:+
GBM	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	4.82	4.35e-06	0.0048	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
GBM	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-4.82	4.35e-06	0.0048	-0.88	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
GBM	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	4.82	4.35e-06	0.00481	0.49	0.41	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
GBM	cis	rs4834770	1	rs878375	ENSG00000249244.1	RP11-548H18.2	4.82	4.35e-06	0.00481	0.52	0.41	Blood protein levels;	chr4:119316419	chr4:119391831~119395335:-
GBM	cis	rs2739330	0.76	rs5751760	ENSG00000272787.1	KB-226F1.2	4.82	4.35e-06	0.00481	0.39	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23969211~23969873:+
GBM	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-4.82	4.35e-06	0.00481	-0.48	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-4.82	4.35e-06	0.00481	-0.48	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
GBM	cis	rs397969	0.646	rs8079923	ENSG00000230528.6	NOS2P3	-4.82	4.36e-06	0.00481	-0.51	-0.41	Platelet count;	chr17:19966231	chr17:20436337~20447249:+
GBM	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	4.82	4.37e-06	0.00482	0.57	0.41	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	4.82	4.37e-06	0.00482	0.57	0.41	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
GBM	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	4.82	4.38e-06	0.00483	0.39	0.41	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
GBM	cis	rs11992162	0.967	rs4841661	ENSG00000255556.2	RP11-351I21.6	4.82	4.38e-06	0.00483	0.41	0.41	Monocyte count;	chr8:11975260	chr8:12378679~12380265:-
GBM	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	4.82	4.38e-06	0.00483	0.47	0.41	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	4.82	4.38e-06	0.00483	0.47	0.41	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	4.82	4.38e-06	0.00483	0.47	0.41	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
GBM	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-4.82	4.39e-06	0.00484	-0.55	-0.41	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
GBM	cis	rs4713118	0.824	rs7759217	ENSG00000218016.2	ZNF192P2	-4.82	4.39e-06	0.00485	-0.53	-0.41	Parkinson's disease;	chr6:27762684	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.784	rs9468219	ENSG00000218016.2	ZNF192P2	-4.82	4.39e-06	0.00485	-0.53	-0.41	Parkinson's disease;	chr6:27763976	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.824	rs9366702	ENSG00000218016.2	ZNF192P2	-4.82	4.39e-06	0.00485	-0.53	-0.41	Parkinson's disease;	chr6:27766691	chr6:28188050~28189432:+
GBM	cis	rs17211409	0.744	rs11234698	ENSG00000254479.1	SLC25A1P1	4.82	4.4e-06	0.00485	0.95	0.41	JT interval (sulfonylurea treatment interaction);	chr11:86579753	chr11:85934737~85935663:+
GBM	cis	rs1908814	0.503	rs34657250	ENSG00000255556.2	RP11-351I21.6	-4.82	4.4e-06	0.00486	-0.43	-0.41	Neuroticism;	chr8:11937864	chr8:12378679~12380265:-
GBM	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-4.82	4.41e-06	0.00486	-0.41	-0.41	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
GBM	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	4.82	4.41e-06	0.00486	0.56	0.41	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	4.82	4.41e-06	0.00486	0.56	0.41	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
GBM	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-4.82	4.41e-06	0.00486	-0.57	-0.41	Depression;	chr6:28192182	chr6:28115628~28116551:+
GBM	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-4.82	4.41e-06	0.00486	-0.57	-0.41	Depression;	chr6:28193021	chr6:28115628~28116551:+
GBM	cis	rs1475545	0.934	rs867585	ENSG00000274011.1	Metazoa_SRP	-4.82	4.41e-06	0.00486	-0.4	-0.41	Obesity-related traits;	chr9:97555993	chr9:98115885~98116135:+
GBM	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.82	4.42e-06	0.00487	-0.55	-0.41	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-4.82	4.42e-06	0.00487	-0.55	-0.41	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
GBM	cis	rs1475545	0.967	rs7865885	ENSG00000274011.1	Metazoa_SRP	-4.82	4.43e-06	0.00488	-0.4	-0.41	Obesity-related traits;	chr9:97556457	chr9:98115885~98116135:+
GBM	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	4.82	4.44e-06	0.00489	0.57	0.41	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
GBM	cis	rs73198271	0.737	rs506960	ENSG00000253893.2	FAM85B	4.82	4.45e-06	0.00489	0.57	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8167819~8226614:-
GBM	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-4.82	4.45e-06	0.00489	-0.51	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
GBM	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	4.82	4.45e-06	0.0049	0.43	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
GBM	cis	rs12495178	0.639	rs13071488	ENSG00000239519.1	CADM2-AS1	4.82	4.46e-06	0.0049	0.43	0.41	Body mass index;	chr3:85866747	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.599	rs13099482	ENSG00000239519.1	CADM2-AS1	4.82	4.46e-06	0.0049	0.43	0.41	Body mass index;	chr3:85867392	chr3:85992183~86028007:-
GBM	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-4.82	4.46e-06	0.00491	-0.56	-0.41	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
GBM	cis	rs67981189	0.529	rs8181986	ENSG00000269927.1	RP6-91H8.3	4.82	4.46e-06	0.00491	0.49	0.41	Schizophrenia;	chr14:71115527	chr14:71141125~71143253:-
GBM	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	4.82	4.47e-06	0.00491	0.56	0.41	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
GBM	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	4.82	4.47e-06	0.00491	0.59	0.41	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-4.82	4.47e-06	0.00491	-0.59	-0.41	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
GBM	cis	rs17211409	0.793	rs10501623	ENSG00000254479.1	SLC25A1P1	4.82	4.49e-06	0.00493	0.88	0.41	JT interval (sulfonylurea treatment interaction);	chr11:86580583	chr11:85934737~85935663:+
GBM	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-4.82	4.49e-06	0.00493	-0.66	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
GBM	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-4.82	4.49e-06	0.00493	-0.87	-0.41	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
GBM	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	4.82	4.51e-06	0.00494	0.35	0.41	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
GBM	cis	rs61041384	0.661	rs75589918	ENSG00000256092.2	RP13-942N8.1	-4.82	4.51e-06	0.00495	-0.94	-0.41	Schizophrenia;	chr12:123109855	chr12:123363868~123366113:+
GBM	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	4.82	4.51e-06	0.00495	0.54	0.41	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
GBM	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-4.81	4.52e-06	0.00496	-0.63	-0.41	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
GBM	cis	rs7267979	0.714	rs6132825	ENSG00000276952.1	RP5-965G21.6	4.81	4.52e-06	0.00496	0.37	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:25284915~25285588:-
GBM	cis	rs4713118	0.696	rs2394002	ENSG00000218016.2	ZNF192P2	-4.81	4.53e-06	0.00497	-0.53	-0.41	Parkinson's disease;	chr6:27780236	chr6:28188050~28189432:+
GBM	cis	rs67981189	0.593	rs221917	ENSG00000269927.1	RP6-91H8.3	-4.81	4.53e-06	0.00497	-0.55	-0.41	Schizophrenia;	chr14:71123286	chr14:71141125~71143253:-
GBM	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	4.81	4.54e-06	0.00497	0.42	0.41	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	4.81	4.54e-06	0.00497	0.42	0.41	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
GBM	cis	rs8114671	0.805	rs6060168	ENSG00000269202.1	RP4-614O4.12	-4.81	4.54e-06	0.00498	-0.5	-0.41	Height;	chr20:35033214	chr20:35201747~35203288:-
GBM	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	4.81	4.54e-06	0.00498	0.57	0.41	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
GBM	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-4.81	4.55e-06	0.00498	-0.51	-0.41	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
GBM	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	4.81	4.55e-06	0.00498	0.81	0.41	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
GBM	cis	rs1150668	0.699	rs2394049	ENSG00000218016.2	ZNF192P2	-4.81	4.56e-06	0.00498	-0.48	-0.41	Pubertal anthropometrics;	chr6:28271903	chr6:28188050~28189432:+
GBM	cis	rs2739330	0.76	rs5760095	ENSG00000272787.1	KB-226F1.2	4.81	4.56e-06	0.00498	0.39	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23969211~23969873:+
GBM	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	4.81	4.56e-06	0.00498	0.28	0.41	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
GBM	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
GBM	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	4.81	4.57e-06	0.00498	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
GBM	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-4.81	4.57e-06	0.00498	-0.58	-0.41	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
GBM	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	4.81	4.57e-06	0.00498	0.45	0.41	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
GBM	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	4.81	4.57e-06	0.00499	0.46	0.41	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
GBM	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-4.81	4.58e-06	0.005	-0.52	-0.41	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-4.81	4.58e-06	0.005	-0.52	-0.41	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
GBM	cis	rs10752881	1	rs10911191	ENSG00000224468.3	RP11-181K3.4	-4.81	4.59e-06	0.005	-0.32	-0.41	Colorectal cancer;	chr1:183015389	chr1:183138402~183141282:-
GBM	cis	rs6496932	0.503	rs7170085	ENSG00000218052.5	ADAMTS7P4	-4.81	4.59e-06	0.005	-0.59	-0.41	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85255369~85330334:-
GBM	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-4.81	4.6e-06	0.00501	-0.47	-0.41	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
GBM	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	4.81	4.6e-06	0.00501	0.47	0.41	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
GBM	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	4.81	4.6e-06	0.00501	0.47	0.41	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	4.81	4.6e-06	0.00501	0.47	0.41	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
GBM	cis	rs3806843	1	rs991918	ENSG00000202111.1	VTRNA1-2	-4.81	4.6e-06	0.00501	-0.44	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140815273	chr5:140718925~140719013:+
GBM	cis	rs67981189	0.529	rs61990387	ENSG00000269927.1	RP6-91H8.3	4.81	4.6e-06	0.00501	0.49	0.41	Schizophrenia;	chr14:71024850	chr14:71141125~71143253:-
GBM	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	4.81	4.61e-06	0.00502	0.28	0.41	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
GBM	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	4.81	4.62e-06	0.00503	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
GBM	cis	rs893971	0.568	rs1808860	ENSG00000246375.2	RP11-10L7.1	4.81	4.63e-06	0.00504	0.44	0.41	Conduct disorder (maternal expressed emotions interaction);	chr4:88313557	chr4:88284942~88331421:+
GBM	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-4.81	4.64e-06	0.00504	-0.43	-0.41	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
GBM	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-4.81	4.64e-06	0.00505	-0.34	-0.41	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
GBM	cis	rs172166	0.561	rs149973	ENSG00000280107.1	AL022393.9	-4.81	4.64e-06	0.00505	-0.45	-0.41	Cardiac Troponin-T levels;	chr6:28015835	chr6:28170845~28172521:+
GBM	cis	rs172166	0.561	rs149974	ENSG00000280107.1	AL022393.9	-4.81	4.64e-06	0.00505	-0.45	-0.41	Cardiac Troponin-T levels;	chr6:28017318	chr6:28170845~28172521:+
GBM	cis	rs6496932	0.503	rs10520588	ENSG00000218052.5	ADAMTS7P4	-4.81	4.65e-06	0.00505	-0.57	-0.41	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.503	rs2086756	ENSG00000218052.5	ADAMTS7P4	-4.81	4.65e-06	0.00505	-0.57	-0.41	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85255369~85330334:-
GBM	cis	rs5742933	0.817	rs5742938	ENSG00000253559.1	OSGEPL1-AS1	4.81	4.66e-06	0.00506	0.44	0.41	Ferritin levels;	chr2:189785232	chr2:189762704~189765556:+
GBM	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	4.81	4.66e-06	0.00507	0.49	0.41	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
GBM	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-4.81	4.66e-06	0.00507	-0.55	-0.41	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
GBM	cis	rs922692	1	rs72743199	ENSG00000261143.1	ADAMTS7P3	4.81	4.67e-06	0.00507	0.44	0.41	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78683513	chr15:77976042~77993057:+
GBM	cis	rs7017914	0.69	rs6984056	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70858886	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs4446768	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70865354	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs7003794	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70876911	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.714	rs1982884	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70877318	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs10090230	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70884778	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs10090471	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70885034	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs13255749	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70889586	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs11985482	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70898343	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.583	rs7838671	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70899057	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs13248937	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70906514	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs6992048	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70911636	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs6984663	ENSG00000246366.5	RP11-382J12.1	-4.81	4.67e-06	0.00507	-0.42	-0.41	Bone mineral density;	chr8:70915430	chr8:70608577~70663279:+
GBM	cis	rs3742264	0.656	rs9526126	ENSG00000235903.6	CPB2-AS1	-4.81	4.68e-06	0.00508	-0.48	-0.41	Blood protein levels;	chr13:45991067	chr13:46052806~46113332:+
GBM	cis	rs3742264	0.656	rs9534272	ENSG00000235903.6	CPB2-AS1	-4.81	4.68e-06	0.00508	-0.48	-0.41	Blood protein levels;	chr13:45992688	chr13:46052806~46113332:+
GBM	cis	rs3806843	0.966	rs10036519	ENSG00000202111.1	VTRNA1-2	4.81	4.69e-06	0.00509	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140772116	chr5:140718925~140719013:+
GBM	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	4.81	4.69e-06	0.00509	0.5	0.41	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	4.81	4.69e-06	0.00509	0.5	0.41	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
GBM	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	4.81	4.7e-06	0.0051	0.29	0.41	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-4.81	4.7e-06	0.0051	-0.29	-0.41	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
GBM	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-4.81	4.7e-06	0.0051	-0.7	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-4.81	4.7e-06	0.0051	-0.7	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11742261	ENSG00000248734.2	CTD-2260A17.1	-4.81	4.7e-06	0.0051	-0.7	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96831905	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11748795	ENSG00000248734.2	CTD-2260A17.1	-4.81	4.7e-06	0.0051	-0.7	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96832353	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-4.81	4.7e-06	0.0051	-0.7	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
GBM	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	4.81	4.71e-06	0.00511	0.5	0.41	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	4.81	4.71e-06	0.00511	0.5	0.41	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
GBM	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	4.81	4.71e-06	0.00511	0.5	0.41	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
GBM	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	4.81	4.71e-06	0.00511	0.5	0.41	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
GBM	cis	rs172166	0.516	rs1225715	ENSG00000218016.2	ZNF192P2	4.81	4.71e-06	0.00511	0.48	0.41	Cardiac Troponin-T levels;	chr6:28145595	chr6:28188050~28189432:+
GBM	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	4.8	4.72e-06	0.00511	0.64	0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
GBM	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	4.8	4.72e-06	0.00511	0.64	0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
GBM	cis	rs67981189	0.634	rs221900	ENSG00000269927.1	RP6-91H8.3	4.8	4.72e-06	0.00511	0.48	0.41	Schizophrenia;	chr14:71137637	chr14:71141125~71143253:-
GBM	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	4.8	4.72e-06	0.00512	0.95	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
GBM	cis	rs6908917	0.673	rs7746714	ENSG00000219776.2	RPL21P67	4.8	4.73e-06	0.00512	0.52	0.41	IgG glycosylation;	chr6:131004929	chr6:131469059~131469536:+
GBM	cis	rs11992162	0.967	rs11250185	ENSG00000255556.2	RP11-351I21.6	4.8	4.73e-06	0.00513	0.41	0.41	Monocyte count;	chr8:11975614	chr8:12378679~12380265:-
GBM	cis	rs11992162	1	rs12334769	ENSG00000255556.2	RP11-351I21.6	4.8	4.73e-06	0.00513	0.41	0.41	Monocyte count;	chr8:11975652	chr8:12378679~12380265:-
GBM	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-4.8	4.74e-06	0.00513	-0.46	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
GBM	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	4.8	4.74e-06	0.00513	0.45	0.41	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
GBM	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	4.8	4.74e-06	0.00514	0.57	0.41	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
GBM	cis	rs67981189	0.593	rs2526871	ENSG00000269927.1	RP6-91H8.3	-4.8	4.75e-06	0.00515	-0.46	-0.41	Schizophrenia;	chr14:70918396	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs2810072	ENSG00000269927.1	RP6-91H8.3	-4.8	4.75e-06	0.00515	-0.46	-0.41	Schizophrenia;	chr14:70920476	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.574	rs2810118	ENSG00000269927.1	RP6-91H8.3	-4.8	4.75e-06	0.00515	-0.46	-0.41	Schizophrenia;	chr14:70921858	chr14:71141125~71143253:-
GBM	cis	rs1150668	0.699	rs2394049	ENSG00000199851.2	U3	4.8	4.75e-06	0.00515	0.5	0.41	Pubertal anthropometrics;	chr6:28271903	chr6:28015568~28015777:+
GBM	cis	rs4604732	0.631	rs10925044	ENSG00000227135.1	GCSAML-AS1	-4.8	4.75e-06	0.00515	-0.65	-0.41	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463769	chr1:247524679~247526752:-
GBM	cis	rs3806843	0.832	rs2531360	ENSG00000202111.1	VTRNA1-2	4.8	4.75e-06	0.00515	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr5:140718925~140719013:+
GBM	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	4.8	4.75e-06	0.00515	0.35	0.41	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
GBM	cis	rs10911232	0.524	rs4652773	ENSG00000224468.3	RP11-181K3.4	-4.8	4.76e-06	0.00516	-0.32	-0.41	Hypertriglyceridemia;	chr1:183085692	chr1:183138402~183141282:-
GBM	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-4.8	4.76e-06	0.00516	-0.51	-0.41	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
GBM	cis	rs4072705	1	rs13283284	ENSG00000224020.1	MIR181A2HG	-4.8	4.79e-06	0.00518	-0.44	-0.41	Menarche (age at onset);	chr9:124753898	chr9:124658467~124698631:+
GBM	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-4.8	4.79e-06	0.00519	-0.5	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
GBM	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	4.8	4.79e-06	0.00519	0.39	0.41	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
GBM	cis	rs2235573	0.662	rs2018980	ENSG00000233739.1	RP5-1039K5.13	4.8	4.8e-06	0.00519	0.5	0.41	Glioma;Glioblastoma;	chr22:38054613	chr22:38057180~38073940:-
GBM	cis	rs4713118	0.955	rs9468206	ENSG00000199851.2	U3	4.8	4.8e-06	0.00519	0.57	0.41	Parkinson's disease;	chr6:27722674	chr6:28015568~28015777:+
GBM	cis	rs9467773	0.595	rs12525810	ENSG00000224843.5	LINC00240	4.8	4.82e-06	0.00521	0.63	0.41	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26956992~27023924:+
GBM	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-4.8	4.82e-06	0.00521	-0.45	-0.41	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
GBM	cis	rs3742264	0.656	rs1041166	ENSG00000235903.6	CPB2-AS1	-4.8	4.82e-06	0.00522	-0.48	-0.41	Blood protein levels;	chr13:45981085	chr13:46052806~46113332:+
GBM	cis	rs832187	0.64	rs704367	ENSG00000280620.1	SCAANT1	-4.8	4.84e-06	0.00523	-0.56	-0.41	Schizophrenia;	chr3:63883101	chr3:63911518~63911772:-
GBM	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-4.8	4.84e-06	0.00523	-0.53	-0.41	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
GBM	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-4.8	4.84e-06	0.00524	-0.58	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
GBM	cis	rs8062405	0.792	rs12446550	ENSG00000271623.1	RP11-435I10.5	-4.8	4.85e-06	0.00524	-0.48	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28364700~28365333:+
GBM	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-4.8	4.85e-06	0.00524	-0.52	-0.41	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
GBM	cis	rs9926296	0.605	rs7205053	ENSG00000260259.1	RP11-368I7.4	-4.8	4.85e-06	0.00525	-0.44	-0.41	Vitiligo;	chr16:89790355	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.585	rs8045232	ENSG00000260259.1	RP11-368I7.4	-4.8	4.85e-06	0.00525	-0.44	-0.41	Vitiligo;	chr16:89791140	chr16:89682620~89686569:-
GBM	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	4.8	4.85e-06	0.00525	0.5	0.41	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
GBM	cis	rs3806843	0.932	rs2563269	ENSG00000202111.1	VTRNA1-2	4.8	4.86e-06	0.00525	0.43	0.41	Depressive symptoms (multi-trait analysis);	chr5:140756883	chr5:140718925~140719013:+
GBM	cis	rs5742933	0.803	rs1233302	ENSG00000253559.1	OSGEPL1-AS1	-4.8	4.86e-06	0.00525	-0.44	-0.41	Ferritin levels;	chr2:189804154	chr2:189762704~189765556:+
GBM	cis	rs7829975	0.517	rs12542733	ENSG00000254340.1	RP11-10A14.3	-4.8	4.86e-06	0.00526	-0.51	-0.41	Mood instability;	chr8:8967348	chr8:9141424~9145435:+
GBM	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-4.8	4.87e-06	0.00526	-0.37	-0.41	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-4.8	4.87e-06	0.00526	-0.37	-0.41	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
GBM	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-4.8	4.87e-06	0.00527	-0.36	-0.41	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
GBM	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-4.8	4.88e-06	0.00527	-0.5	-0.41	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
GBM	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	4.8	4.88e-06	0.00527	0.52	0.41	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
GBM	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-4.8	4.88e-06	0.00527	-0.51	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-4.8	4.88e-06	0.00527	-0.51	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-4.8	4.88e-06	0.00527	-0.51	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
GBM	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	4.8	4.88e-06	0.00527	0.81	0.41	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
GBM	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	4.8	4.89e-06	0.00528	0.44	0.41	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
GBM	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	4.8	4.89e-06	0.00528	0.45	0.41	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
GBM	cis	rs2976388	1	rs2976394	ENSG00000253741.1	CTD-2292P10.4	4.8	4.89e-06	0.00528	0.43	0.41	Urinary tract infection frequency;	chr8:142682204	chr8:142702252~142726973:-
GBM	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	4.8	4.9e-06	0.00529	0.44	0.41	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
GBM	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	4.8	4.9e-06	0.00529	0.44	0.41	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
GBM	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-4.8	4.91e-06	0.0053	-0.59	-0.41	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
GBM	cis	rs5742933	0.857	rs13021611	ENSG00000253559.1	OSGEPL1-AS1	4.79	4.91e-06	0.0053	0.44	0.41	Ferritin levels;	chr2:189700038	chr2:189762704~189765556:+
GBM	cis	rs9876781	1	rs6442123	ENSG00000244380.1	RP11-24C3.2	4.79	4.92e-06	0.00531	0.47	0.41	Longevity;	chr3:48458887	chr3:48440352~48446656:-
GBM	cis	rs2976388	1	rs2294010	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142681012	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2976392	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142681514	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2920298	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142681625	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2920297	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142681665	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2920296	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142681691	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2978982	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142682072	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs1045531	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142682129	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs10216533	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142682272	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.967	rs2976395	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142682332	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs1045547	ENSG00000253741.1	CTD-2292P10.4	4.79	4.93e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142682339	chr8:142702252~142726973:-
GBM	cis	rs12908161	0.853	rs12912342	ENSG00000225151.9	GOLGA2P7	-4.79	4.94e-06	0.00532	-0.45	-0.41	Schizophrenia;	chr15:84704985	chr15:84199311~84230136:-
GBM	cis	rs2976388	1	rs2920293	ENSG00000253741.1	CTD-2292P10.4	4.79	4.94e-06	0.00532	0.43	0.41	Urinary tract infection frequency;	chr8:142683996	chr8:142702252~142726973:-
GBM	cis	rs11673344	0.542	rs1667380	ENSG00000226686.6	LINC01535	4.79	4.94e-06	0.00533	0.44	0.41	Obesity-related traits;	chr19:37001848	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.598	rs826326	ENSG00000226686.6	LINC01535	4.79	4.94e-06	0.00533	0.44	0.41	Obesity-related traits;	chr19:37003863	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.542	rs826328	ENSG00000226686.6	LINC01535	4.79	4.94e-06	0.00533	0.44	0.41	Obesity-related traits;	chr19:37004479	chr19:37251912~37265535:+
GBM	cis	rs867371	0.929	rs1045508	ENSG00000278603.1	RP13-608F4.5	-4.79	4.94e-06	0.00533	-0.48	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472203~82472426:+
GBM	cis	rs2976388	1	rs1045605	ENSG00000253741.1	CTD-2292P10.4	4.79	4.96e-06	0.00534	0.43	0.41	Urinary tract infection frequency;	chr8:142682683	chr8:142702252~142726973:-
GBM	cis	rs9876781	1	rs9876781	ENSG00000244380.1	RP11-24C3.2	4.79	4.96e-06	0.00534	0.47	0.41	Longevity;	chr3:48445934	chr3:48440352~48446656:-
GBM	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	4.79	4.96e-06	0.00534	0.61	0.41	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
GBM	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-4.79	4.97e-06	0.00535	-0.45	-0.41	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
GBM	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	4.79	4.97e-06	0.00535	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
GBM	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	4.79	4.97e-06	0.00535	0.5	0.41	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
GBM	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-4.79	4.97e-06	0.00535	-0.42	-0.41	Temperament;	chr17:14015466	chr17:14024514~14025488:+
GBM	cis	rs11673344	0.542	rs826331	ENSG00000226686.6	LINC01535	4.79	4.97e-06	0.00536	0.44	0.41	Obesity-related traits;	chr19:37007360	chr19:37251912~37265535:+
GBM	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-4.79	4.97e-06	0.00536	-0.37	-0.41	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-4.79	4.97e-06	0.00536	-0.37	-0.41	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-4.79	4.97e-06	0.00536	-0.37	-0.41	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-4.79	4.97e-06	0.00536	-0.37	-0.41	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-4.79	4.97e-06	0.00536	-0.37	-0.41	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
GBM	cis	rs2976388	1	rs2976398	ENSG00000253741.1	CTD-2292P10.4	4.79	4.98e-06	0.00536	0.43	0.41	Urinary tract infection frequency;	chr8:142683461	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2920294	ENSG00000253741.1	CTD-2292P10.4	4.79	4.98e-06	0.00536	0.43	0.41	Urinary tract infection frequency;	chr8:142683908	chr8:142702252~142726973:-
GBM	cis	rs2976388	1	rs2920292	ENSG00000253741.1	CTD-2292P10.4	4.79	4.98e-06	0.00536	0.43	0.41	Urinary tract infection frequency;	chr8:142684281	chr8:142702252~142726973:-
GBM	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	4.79	4.98e-06	0.00536	0.57	0.41	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
GBM	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-4.79	4.98e-06	0.00537	-0.52	-0.41	Height;	chr11:118808920	chr11:118704607~118750263:+
GBM	cis	rs2976388	0.967	rs2976393	ENSG00000253741.1	CTD-2292P10.4	4.79	4.99e-06	0.00537	0.43	0.41	Urinary tract infection frequency;	chr8:142682200	chr8:142702252~142726973:-
GBM	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	4.79	5.01e-06	0.00539	0.42	0.41	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
GBM	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	4.79	5.01e-06	0.00539	0.49	0.41	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-4.79	5.01e-06	0.00539	-0.52	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
GBM	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	4.79	5.02e-06	0.0054	0.43	0.41	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
GBM	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-4.79	5.02e-06	0.0054	-0.43	-0.41	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
GBM	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	4.79	5.02e-06	0.0054	0.44	0.41	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
GBM	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	4.79	5.02e-06	0.0054	0.44	0.41	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
GBM	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	4.79	5.02e-06	0.0054	0.44	0.41	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
GBM	cis	rs6565180	1	rs6565180	ENSG00000183604.13	SMG1P5	-4.79	5.02e-06	0.0054	-0.53	-0.41	Tonsillectomy;	chr16:30350020	chr16:30267553~30335374:-
GBM	cis	rs6565180	1	rs11862806	ENSG00000183604.13	SMG1P5	-4.79	5.02e-06	0.0054	-0.53	-0.41	Tonsillectomy;	chr16:30352750	chr16:30267553~30335374:-
GBM	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-4.79	5.03e-06	0.0054	-0.89	-0.41	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
GBM	cis	rs9876781	1	rs13069724	ENSG00000244380.1	RP11-24C3.2	4.79	5.03e-06	0.00541	0.47	0.41	Longevity;	chr3:48436629	chr3:48440352~48446656:-
GBM	cis	rs62560775	0.541	rs12352425	ENSG00000240498.5	CDKN2B-AS1	4.79	5.03e-06	0.00541	0.56	0.41	Lung cancer;Lung adenocarcinoma;	chr9:22042087	chr9:21994778~22121097:+
GBM	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	4.79	5.03e-06	0.00541	0.42	0.41	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
GBM	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	4.79	5.03e-06	0.00541	0.56	0.41	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	4.79	5.03e-06	0.00541	0.56	0.41	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	4.79	5.03e-06	0.00541	0.56	0.41	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	4.79	5.03e-06	0.00541	0.56	0.41	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	4.79	5.03e-06	0.00541	0.56	0.41	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	4.79	5.03e-06	0.00541	0.56	0.41	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
GBM	cis	rs2980439	0.517	rs712253	ENSG00000173295.6	FAM86B3P	4.79	5.04e-06	0.00541	0.39	0.41	Neuroticism;	chr8:8246260	chr8:8228595~8244865:+
GBM	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	4.79	5.04e-06	0.00542	0.55	0.41	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
GBM	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-4.79	5.04e-06	0.00542	-0.53	-0.41	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
GBM	cis	rs12137294	0.866	rs1078362	ENSG00000271580.1	RP11-536L3.4	-4.79	5.04e-06	0.00542	-0.38	-0.41	Red cell distribution width;	chr1:205240402	chr1:205091163~205091946:+
GBM	cis	rs12137294	0.866	rs1077883	ENSG00000271580.1	RP11-536L3.4	-4.79	5.04e-06	0.00542	-0.38	-0.41	Red cell distribution width;	chr1:205241287	chr1:205091163~205091946:+
GBM	cis	rs67981189	0.593	rs8005160	ENSG00000269927.1	RP6-91H8.3	4.79	5.05e-06	0.00542	0.46	0.41	Schizophrenia;	chr14:70979777	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs10145824	ENSG00000269927.1	RP6-91H8.3	4.79	5.05e-06	0.00542	0.46	0.41	Schizophrenia;	chr14:70981015	chr14:71141125~71143253:-
GBM	cis	rs3806843	0.897	rs2531338	ENSG00000202111.1	VTRNA1-2	4.79	5.05e-06	0.00542	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140757372	chr5:140718925~140719013:+
GBM	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-4.79	5.05e-06	0.00542	-0.53	-0.41	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
GBM	cis	rs3736858	1	rs2296093	ENSG00000261105.4	LMO7-AS1	-4.79	5.06e-06	0.00543	-0.72	-0.41	Interleukin-9 levels;	chr13:75856325	chr13:75604700~75635994:-
GBM	cis	rs7927592	0.513	rs556442	ENSG00000212093.1	AP000807.1	-4.79	5.06e-06	0.00543	-0.46	-0.41	Total body bone mineral density;	chr11:68425222	chr11:68506083~68506166:-
GBM	cis	rs4713118	0.869	rs9295743	ENSG00000199851.2	U3	4.79	5.07e-06	0.00544	0.55	0.41	Parkinson's disease;	chr6:27747323	chr6:28015568~28015777:+
GBM	cis	rs8062405	0.721	rs151181	ENSG00000271623.1	RP11-435I10.5	-4.79	5.07e-06	0.00545	-0.48	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28364700~28365333:+
GBM	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-4.79	5.08e-06	0.00545	-0.45	-0.41	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-4.79	5.08e-06	0.00545	-0.45	-0.41	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-4.79	5.08e-06	0.00545	-0.45	-0.41	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-4.79	5.08e-06	0.00545	-0.45	-0.41	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
GBM	cis	rs17767294	0.612	rs9461425	ENSG00000199851.2	U3	4.79	5.08e-06	0.00545	0.93	0.41	Parkinson's disease;	chr6:27951910	chr6:28015568~28015777:+
GBM	cis	rs9876781	1	rs9883759	ENSG00000244380.1	RP11-24C3.2	4.79	5.08e-06	0.00545	0.47	0.41	Longevity;	chr3:48422209	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs6442120	ENSG00000244380.1	RP11-24C3.2	4.79	5.08e-06	0.00545	0.47	0.41	Longevity;	chr3:48423094	chr3:48440352~48446656:-
GBM	cis	rs9876781	0.9	rs1037773	ENSG00000244380.1	RP11-24C3.2	4.79	5.08e-06	0.00545	0.47	0.41	Longevity;	chr3:48426493	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs2279077	ENSG00000244380.1	RP11-24C3.2	4.79	5.08e-06	0.00545	0.47	0.41	Longevity;	chr3:48432839	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs3774808	ENSG00000244380.1	RP11-24C3.2	4.79	5.08e-06	0.00545	0.47	0.41	Longevity;	chr3:48440237	chr3:48440352~48446656:-
GBM	cis	rs7829975	1	rs7829975	ENSG00000254340.1	RP11-10A14.3	-4.79	5.09e-06	0.00546	-0.53	-0.41	Mood instability;	chr8:8690607	chr8:9141424~9145435:+
GBM	cis	rs7267979	0.844	rs1555330	ENSG00000276952.1	RP5-965G21.6	4.79	5.09e-06	0.00546	0.38	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25284915~25285588:-
GBM	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	4.79	5.1e-06	0.00547	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
GBM	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-4.79	5.11e-06	0.00547	-0.72	-0.41	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
GBM	cis	rs12137294	0.866	rs1172140	ENSG00000271580.1	RP11-536L3.4	-4.79	5.11e-06	0.00547	-0.37	-0.41	Red cell distribution width;	chr1:205243896	chr1:205091163~205091946:+
GBM	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-4.79	5.12e-06	0.00548	-0.53	-0.41	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
GBM	cis	rs7615952	0.599	rs60847438	ENSG00000250012.1	RP11-124N2.1	-4.79	5.12e-06	0.00548	-0.47	-0.41	Blood pressure (smoking interaction);	chr3:126027162	chr3:126084220~126095349:+
GBM	cis	rs1298062	0.763	rs921938	ENSG00000131401.10	NAPSB	-4.78	5.13e-06	0.00549	-0.48	-0.41	Age of smoking initiation;	chr19:50478829	chr19:50333796~50344767:-
GBM	cis	rs1298062	0.763	rs2387112	ENSG00000131401.10	NAPSB	-4.78	5.13e-06	0.00549	-0.48	-0.41	Age of smoking initiation;	chr19:50481596	chr19:50333796~50344767:-
GBM	cis	rs11673344	0.543	rs8108429	ENSG00000226686.6	LINC01535	4.78	5.13e-06	0.00549	0.45	0.41	Obesity-related traits;	chr19:37145874	chr19:37251912~37265535:+
GBM	cis	rs2579103	0.63	rs1222610	ENSG00000258183.4	RP11-753N8.1	-4.78	5.14e-06	0.0055	-0.59	-0.41	Body mass index;	chr12:90315578	chr12:90280894~90300340:+
GBM	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	4.78	5.14e-06	0.0055	0.48	0.41	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	4.78	5.14e-06	0.0055	0.48	0.41	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
GBM	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-4.78	5.15e-06	0.00551	-0.48	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
GBM	cis	rs763121	0.853	rs5750621	ENSG00000273076.1	RP3-508I15.22	4.78	5.15e-06	0.00551	0.45	0.41	Menopause (age at onset);	chr22:38560161	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750622	ENSG00000273076.1	RP3-508I15.22	4.78	5.15e-06	0.00551	0.45	0.41	Menopause (age at onset);	chr22:38560459	chr22:38743495~38743910:+
GBM	cis	rs763121	0.744	rs5757140	ENSG00000273076.1	RP3-508I15.22	4.78	5.15e-06	0.00551	0.45	0.41	Menopause (age at onset);	chr22:38561008	chr22:38743495~38743910:+
GBM	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	4.78	5.15e-06	0.00552	0.55	0.41	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
GBM	cis	rs6908034	0.769	rs6916589	ENSG00000228412.5	RP4-625H18.2	4.78	5.16e-06	0.00552	0.79	0.41	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19802164~19804752:-
GBM	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	4.78	5.16e-06	0.00552	0.32	0.41	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
GBM	cis	rs172166	0.516	rs1225710	ENSG00000199851.2	U3	-4.78	5.17e-06	0.00553	-0.49	-0.41	Cardiac Troponin-T levels;	chr6:28132862	chr6:28015568~28015777:+
GBM	cis	rs11992162	0.967	rs4840601	ENSG00000255556.2	RP11-351I21.6	4.78	5.18e-06	0.00554	0.42	0.41	Monocyte count;	chr8:11971221	chr8:12378679~12380265:-
GBM	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	4.78	5.18e-06	0.00554	0.5	0.41	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
GBM	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-4.78	5.18e-06	0.00554	-0.47	-0.41	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
GBM	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-4.78	5.19e-06	0.00555	-0.38	-0.41	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
GBM	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-4.78	5.19e-06	0.00555	-0.37	-0.41	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
GBM	cis	rs10857712	0.528	rs2265638	ENSG00000214279.11	SCART1	-4.78	5.19e-06	0.00555	-0.29	-0.41	Systemic lupus erythematosus;	chr10:133403671	chr10:133453928~133523558:+
GBM	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-4.78	5.19e-06	0.00555	-0.56	-0.41	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
GBM	cis	rs8177876	0.749	rs804885	ENSG00000261838.4	RP11-303E16.6	-4.78	5.19e-06	0.00555	-0.75	-0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061758	chr16:81069854~81076598:+
GBM	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-4.78	5.21e-06	0.00557	-0.43	-0.41	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
GBM	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-4.78	5.22e-06	0.00557	-0.61	-0.41	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
GBM	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-4.78	5.22e-06	0.00557	-0.61	-0.41	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
GBM	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-4.78	5.22e-06	0.00557	-0.61	-0.41	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
GBM	cis	rs7017914	0.69	rs7013495	ENSG00000246366.5	RP11-382J12.1	-4.78	5.22e-06	0.00557	-0.42	-0.41	Bone mineral density;	chr8:70781282	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs10429277	ENSG00000246366.5	RP11-382J12.1	-4.78	5.22e-06	0.00557	-0.42	-0.41	Bone mineral density;	chr8:70789156	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.714	rs13273979	ENSG00000246366.5	RP11-382J12.1	-4.78	5.22e-06	0.00557	-0.42	-0.41	Bone mineral density;	chr8:70825087	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs13255849	ENSG00000246366.5	RP11-382J12.1	-4.78	5.22e-06	0.00557	-0.42	-0.41	Bone mineral density;	chr8:70840518	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.653	rs6472548	ENSG00000246366.5	RP11-382J12.1	-4.78	5.22e-06	0.00557	-0.42	-0.41	Bone mineral density;	chr8:70842064	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs1156956	ENSG00000246366.5	RP11-382J12.1	-4.78	5.22e-06	0.00557	-0.42	-0.41	Bone mineral density;	chr8:70842803	chr8:70608577~70663279:+
GBM	cis	rs10435719	0.867	rs6999030	ENSG00000255556.2	RP11-351I21.6	4.78	5.22e-06	0.00557	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:12378679~12380265:-
GBM	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-4.78	5.22e-06	0.00558	-0.68	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-4.78	5.22e-06	0.00558	-0.68	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-4.78	5.22e-06	0.00558	-0.68	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-4.78	5.22e-06	0.00558	-0.68	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-4.78	5.22e-06	0.00558	-0.68	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-4.78	5.22e-06	0.00558	-0.68	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-4.78	5.22e-06	0.00558	-0.68	-0.41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
GBM	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
GBM	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	4.78	5.23e-06	0.00558	0.56	0.41	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
GBM	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-4.78	5.23e-06	0.00558	-0.55	-0.41	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-4.78	5.23e-06	0.00558	-0.55	-0.41	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-4.78	5.23e-06	0.00558	-0.55	-0.41	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-4.78	5.23e-06	0.00558	-0.55	-0.41	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
GBM	cis	rs4604732	0.536	rs12049066	ENSG00000227135.1	GCSAML-AS1	-4.78	5.23e-06	0.00559	-0.59	-0.41	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247479353	chr1:247524679~247526752:-
GBM	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	4.78	5.24e-06	0.00559	0.56	0.41	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	4.78	5.24e-06	0.00559	0.56	0.41	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	4.78	5.24e-06	0.00559	0.56	0.41	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	4.78	5.24e-06	0.00559	0.56	0.41	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	4.78	5.24e-06	0.00559	0.56	0.41	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	4.78	5.24e-06	0.00559	0.56	0.41	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	4.78	5.24e-06	0.00559	0.56	0.41	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
GBM	cis	rs4072705	0.616	rs915033	ENSG00000224020.1	MIR181A2HG	-4.78	5.24e-06	0.00559	-0.45	-0.41	Menarche (age at onset);	chr9:124483279	chr9:124658467~124698631:+
GBM	cis	rs1150668	0.796	rs2247002	ENSG00000199851.2	U3	4.78	5.25e-06	0.00559	0.5	0.41	Pubertal anthropometrics;	chr6:28430174	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.796	rs728122	ENSG00000199851.2	U3	4.78	5.25e-06	0.00559	0.5	0.41	Pubertal anthropometrics;	chr6:28431347	chr6:28015568~28015777:+
GBM	cis	rs2976388	0.566	rs13250661	ENSG00000253741.1	CTD-2292P10.4	4.78	5.25e-06	0.0056	0.47	0.41	Urinary tract infection frequency;	chr8:142722716	chr8:142702252~142726973:-
GBM	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	4.78	5.26e-06	0.0056	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	4.78	5.26e-06	0.0056	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
GBM	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	4.78	5.27e-06	0.00561	0.56	0.41	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
GBM	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-4.78	5.27e-06	0.00561	-0.48	-0.41	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
GBM	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	4.78	5.27e-06	0.00561	0.78	0.41	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
GBM	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	4.78	5.27e-06	0.00561	0.53	0.41	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	4.78	5.27e-06	0.00561	0.53	0.41	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	4.78	5.27e-06	0.00561	0.53	0.41	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
GBM	cis	rs2579103	0.708	rs825964	ENSG00000258183.4	RP11-753N8.1	4.78	5.28e-06	0.00562	0.61	0.41	Body mass index;	chr12:90306962	chr12:90280894~90300340:+
GBM	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-4.78	5.29e-06	0.00563	-0.37	-0.41	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-4.78	5.29e-06	0.00563	-0.37	-0.41	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-4.78	5.29e-06	0.00563	-0.37	-0.41	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-4.78	5.29e-06	0.00563	-0.37	-0.41	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-4.78	5.29e-06	0.00563	-0.37	-0.41	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-4.78	5.29e-06	0.00563	-0.37	-0.41	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-4.78	5.29e-06	0.00563	-0.37	-0.41	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
GBM	cis	rs17685	0.753	rs1637045	ENSG00000280388.1	RP11-229D13.3	-4.78	5.3e-06	0.00564	-0.37	-0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76074577	chr7:76043977~76045963:-
GBM	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	4.78	5.31e-06	0.00564	0.38	0.41	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
GBM	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs17100414	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74467918	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
GBM	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	4.78	5.31e-06	0.00565	0.62	0.41	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
GBM	cis	rs9532669	0.889	rs9549302	ENSG00000176268.5	CYCSP34	4.78	5.32e-06	0.00565	0.47	0.41	Cervical cancer;	chr13:40843278	chr13:40863599~40863902:-
GBM	cis	rs4713118	0.869	rs4713121	ENSG00000218016.2	ZNF192P2	-4.78	5.32e-06	0.00566	-0.52	-0.41	Parkinson's disease;	chr6:27754285	chr6:28188050~28189432:+
GBM	cis	rs5742933	0.69	rs62183657	ENSG00000253559.1	OSGEPL1-AS1	-4.78	5.33e-06	0.00566	-0.53	-0.41	Ferritin levels;	chr2:189669448	chr2:189762704~189765556:+
GBM	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	4.78	5.33e-06	0.00566	0.73	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
GBM	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	4.78	5.33e-06	0.00566	0.44	0.41	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
GBM	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	4.78	5.33e-06	0.00566	0.53	0.41	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
GBM	cis	rs7605378	1	rs769958	ENSG00000232732.8	AC073043.1	-4.77	5.34e-06	0.00567	-0.53	-0.41	Osteoporosis;	chr2:199831178	chr2:199867396~199911159:-
GBM	cis	rs7605378	1	rs2689766	ENSG00000232732.8	AC073043.1	-4.77	5.34e-06	0.00567	-0.53	-0.41	Osteoporosis;	chr2:199832816	chr2:199867396~199911159:-
GBM	cis	rs7267979	0.745	rs6132845	ENSG00000276952.1	RP5-965G21.6	4.77	5.34e-06	0.00567	0.37	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25284915~25285588:-
GBM	cis	rs8062405	0.964	rs11860513	ENSG00000271623.1	RP11-435I10.5	-4.77	5.34e-06	0.00567	-0.49	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs1987472	ENSG00000271623.1	RP11-435I10.5	-4.77	5.34e-06	0.00567	-0.49	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.895	rs56186137	ENSG00000271623.1	RP11-435I10.5	-4.77	5.34e-06	0.00567	-0.49	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28364700~28365333:+
GBM	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	4.77	5.35e-06	0.00568	0.39	0.41	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
GBM	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-4.77	5.35e-06	0.00568	-0.47	-0.41	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
GBM	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	4.77	5.37e-06	0.00569	0.46	0.41	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
GBM	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	4.77	5.38e-06	0.0057	0.42	0.41	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	4.77	5.38e-06	0.0057	0.42	0.41	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
GBM	cis	rs4713118	0.869	rs10214440	ENSG00000218016.2	ZNF192P2	-4.77	5.38e-06	0.0057	-0.53	-0.41	Parkinson's disease;	chr6:27734661	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs6902689	ENSG00000218016.2	ZNF192P2	-4.77	5.38e-06	0.0057	-0.53	-0.41	Parkinson's disease;	chr6:27741662	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs9468214	ENSG00000218016.2	ZNF192P2	-4.77	5.38e-06	0.0057	-0.53	-0.41	Parkinson's disease;	chr6:27745520	chr6:28188050~28189432:+
GBM	cis	rs67981189	0.546	rs2810075	ENSG00000269927.1	RP6-91H8.3	-4.77	5.39e-06	0.00571	-0.47	-0.41	Schizophrenia;	chr14:70908363	chr14:71141125~71143253:-
GBM	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-4.77	5.39e-06	0.00571	-0.47	-0.41	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
GBM	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-4.77	5.4e-06	0.00572	-0.5	-0.41	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
GBM	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	4.77	5.4e-06	0.00572	0.5	0.41	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
GBM	cis	rs2013441	1	rs2107566	ENSG00000230528.6	NOS2P3	4.77	5.4e-06	0.00573	0.44	0.41	Obesity-related traits;	chr17:20199939	chr17:20436337~20447249:+
GBM	cis	rs17685	0.753	rs10262501	ENSG00000280388.1	RP11-229D13.3	4.77	5.42e-06	0.00574	0.38	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76038854	chr7:76043977~76045963:-
GBM	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	4.77	5.42e-06	0.00574	0.41	0.41	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
GBM	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	4.77	5.42e-06	0.00574	0.41	0.41	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
GBM	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	4.77	5.42e-06	0.00574	0.51	0.41	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
GBM	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	4.77	5.42e-06	0.00575	0.46	0.41	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
GBM	cis	rs10435719	0.834	rs11250176	ENSG00000255556.2	RP11-351I21.6	4.77	5.43e-06	0.00576	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:12378679~12380265:-
GBM	cis	rs73198271	1	rs73198279	ENSG00000253893.2	FAM85B	4.77	5.44e-06	0.00576	0.58	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8167819~8226614:-
GBM	cis	rs73198271	1	rs11776513	ENSG00000253893.2	FAM85B	4.77	5.44e-06	0.00576	0.58	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8167819~8226614:-
GBM	cis	rs3806843	0.966	rs2563264	ENSG00000202111.1	VTRNA1-2	4.77	5.44e-06	0.00576	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140757918	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs2563262	ENSG00000202111.1	VTRNA1-2	4.77	5.44e-06	0.00576	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140758127	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.932	rs2563257	ENSG00000202111.1	VTRNA1-2	4.77	5.44e-06	0.00576	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140760944	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.932	rs2563256	ENSG00000202111.1	VTRNA1-2	4.77	5.44e-06	0.00576	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140762194	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs2563255	ENSG00000202111.1	VTRNA1-2	4.77	5.44e-06	0.00576	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140762962	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.9	rs2563254	ENSG00000202111.1	VTRNA1-2	4.77	5.44e-06	0.00576	0.42	0.41	Depressive symptoms (multi-trait analysis);	chr5:140763116	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs7737424	ENSG00000202111.1	VTRNA1-2	-4.77	5.44e-06	0.00576	-0.42	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140766760	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs12659129	ENSG00000202111.1	VTRNA1-2	-4.77	5.44e-06	0.00576	-0.42	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140767663	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs11953833	ENSG00000202111.1	VTRNA1-2	-4.77	5.44e-06	0.00576	-0.42	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140775538	chr5:140718925~140719013:+
GBM	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.77	5.44e-06	0.00576	0.51	0.41	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
GBM	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	4.77	5.44e-06	0.00576	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	4.77	5.44e-06	0.00576	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	4.77	5.44e-06	0.00576	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	4.77	5.44e-06	0.00576	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
GBM	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	4.77	5.44e-06	0.00576	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
GBM	cis	rs8067545	0.574	rs62067483	ENSG00000230528.6	NOS2P3	-4.77	5.44e-06	0.00576	-0.51	-0.41	Schizophrenia;	chr17:20045081	chr17:20436337~20447249:+
GBM	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	4.77	5.45e-06	0.00577	0.47	0.41	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	4.77	5.45e-06	0.00577	0.47	0.41	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
GBM	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-4.77	5.46e-06	0.00578	-0.5	-0.41	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
GBM	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	4.77	5.46e-06	0.00578	0.51	0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
GBM	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	4.77	5.46e-06	0.00578	0.4	0.41	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
GBM	cis	rs741668	0.931	rs17428825	ENSG00000235903.6	CPB2-AS1	4.77	5.46e-06	0.00578	0.58	0.41	Cerebrospinal fluid clusterin levels;	chr13:45948541	chr13:46052806~46113332:+
GBM	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-4.77	5.47e-06	0.00578	-0.56	-0.41	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
GBM	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	4.77	5.47e-06	0.00578	0.59	0.41	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
GBM	cis	rs17772222	0.958	rs17798341	ENSG00000222990.1	RNU4-22P	4.77	5.48e-06	0.00579	0.5	0.41	Coronary artery calcification;	chr14:88548201	chr14:88513498~88513663:+
GBM	cis	rs1298062	0.757	rs1673039	ENSG00000131401.10	NAPSB	-4.77	5.48e-06	0.00579	-0.48	-0.41	Age of smoking initiation;	chr19:50474700	chr19:50333796~50344767:-
GBM	cis	rs1150668	0.799	rs1150707	ENSG00000199851.2	U3	4.77	5.48e-06	0.00579	0.5	0.41	Pubertal anthropometrics;	chr6:28229827	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.768	rs1233713	ENSG00000199851.2	U3	4.77	5.48e-06	0.00579	0.5	0.41	Pubertal anthropometrics;	chr6:28230503	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.799	rs7206	ENSG00000199851.2	U3	4.77	5.48e-06	0.00579	0.5	0.41	Pubertal anthropometrics;	chr6:28233360	chr6:28015568~28015777:+
GBM	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	4.77	5.48e-06	0.00579	0.28	0.41	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	4.77	5.48e-06	0.00579	0.28	0.41	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	4.77	5.48e-06	0.00579	0.28	0.41	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	4.77	5.48e-06	0.00579	0.28	0.41	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
GBM	cis	rs67981189	0.593	rs2240531	ENSG00000269927.1	RP6-91H8.3	4.77	5.48e-06	0.00579	0.46	0.41	Schizophrenia;	chr14:71086889	chr14:71141125~71143253:-
GBM	cis	rs172166	0.538	rs149956	ENSG00000280107.1	AL022393.9	-4.77	5.48e-06	0.00579	-0.45	-0.41	Cardiac Troponin-T levels;	chr6:28068473	chr6:28170845~28172521:+
GBM	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	4.77	5.49e-06	0.0058	0.45	0.41	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
GBM	cis	rs916888	0.779	rs199526	ENSG00000262500.1	RP11-259G18.2	-4.77	5.49e-06	0.0058	-0.57	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46243606~46245044:+
GBM	cis	rs11671005	0.737	rs11673101	ENSG00000269473.1	CTD-2619J13.19	4.77	5.5e-06	0.00581	0.47	0.41	Mean platelet volume;	chr19:58483686	chr19:58440448~58445849:+
GBM	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	4.77	5.5e-06	0.00581	0.78	0.41	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
GBM	cis	rs4713118	0.869	rs9348775	ENSG00000199851.2	U3	4.77	5.5e-06	0.00581	0.57	0.41	Parkinson's disease;	chr6:27727550	chr6:28015568~28015777:+
GBM	cis	rs1420956	0.766	rs8086623	ENSG00000264151.4	RP11-739N10.1	4.77	5.51e-06	0.00582	0.49	0.41	Obesity-related traits;	chr18:27590232	chr18:27336379~27595164:-
GBM	cis	rs922692	0.744	rs11639044	ENSG00000261143.1	ADAMTS7P3	4.77	5.51e-06	0.00582	0.45	0.41	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78791472	chr15:77976042~77993057:+
GBM	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	4.77	5.51e-06	0.00582	0.56	0.41	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	4.77	5.51e-06	0.00582	0.56	0.41	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
GBM	cis	rs12495178	0.639	rs17879296	ENSG00000239519.1	CADM2-AS1	4.77	5.52e-06	0.00582	0.43	0.41	Body mass index;	chr3:85862400	chr3:85992183~86028007:-
GBM	cis	rs12495178	0.599	rs7620825	ENSG00000239519.1	CADM2-AS1	4.77	5.52e-06	0.00582	0.43	0.41	Body mass index;	chr3:85868139	chr3:85992183~86028007:-
GBM	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	4.77	5.52e-06	0.00582	0.5	0.41	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
GBM	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	4.77	5.52e-06	0.00583	0.61	0.41	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
GBM	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-4.77	5.53e-06	0.00584	-0.48	-0.41	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
GBM	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
GBM	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
GBM	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
GBM	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
GBM	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
GBM	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
GBM	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
GBM	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
GBM	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
GBM	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
GBM	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
GBM	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
GBM	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
GBM	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
GBM	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	4.77	5.54e-06	0.00584	0.49	0.41	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
GBM	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	4.77	5.54e-06	0.00584	0.57	0.41	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
GBM	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	4.77	5.55e-06	0.00585	0.46	0.41	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	4.77	5.55e-06	0.00585	0.46	0.41	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	4.77	5.55e-06	0.00585	0.46	0.41	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	4.77	5.55e-06	0.00585	0.46	0.41	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
GBM	cis	rs922692	1	rs4887077	ENSG00000261143.1	ADAMTS7P3	-4.77	5.56e-06	0.00586	-0.43	-0.41	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78686022	chr15:77976042~77993057:+
GBM	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	4.76	5.57e-06	0.00586	0.39	0.41	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
GBM	cis	rs67981189	0.593	rs221915	ENSG00000269927.1	RP6-91H8.3	-4.76	5.57e-06	0.00587	-0.47	-0.41	Schizophrenia;	chr14:71125425	chr14:71141125~71143253:-
GBM	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	4.76	5.57e-06	0.00587	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
GBM	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	4.76	5.58e-06	0.00588	0.53	0.41	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
GBM	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-4.76	5.58e-06	0.00588	-0.5	-0.41	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
GBM	cis	rs3096299	0.933	rs747485	ENSG00000260259.1	RP11-368I7.4	4.76	5.58e-06	0.00588	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89682620~89686569:-
GBM	cis	rs1691562	0.652	rs1610206	ENSG00000231121.3	RP1-34H18.1	4.76	5.58e-06	0.00588	0.57	0.41	Adult asthma;	chr12:76885727	chr12:77324641~77572275:+
GBM	cis	rs73198271	1	rs55971558	ENSG00000253893.2	FAM85B	4.76	5.59e-06	0.00589	0.59	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756893	chr8:8167819~8226614:-
GBM	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	4.76	5.6e-06	0.00589	0.48	0.41	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
GBM	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	4.76	5.6e-06	0.00589	0.49	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
GBM	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	4.76	5.6e-06	0.00589	0.42	0.41	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	4.76	5.6e-06	0.00589	0.42	0.41	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	4.76	5.6e-06	0.00589	0.42	0.41	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	4.76	5.6e-06	0.00589	0.42	0.41	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	4.76	5.6e-06	0.00589	0.42	0.41	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	4.76	5.6e-06	0.00589	0.42	0.41	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	4.76	5.6e-06	0.00589	0.42	0.41	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-4.76	5.6e-06	0.00589	-0.42	-0.41	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
GBM	cis	rs7267979	0.773	rs6132821	ENSG00000276952.1	RP5-965G21.6	4.76	5.61e-06	0.0059	0.37	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs6107017	ENSG00000276952.1	RP5-965G21.6	4.76	5.61e-06	0.0059	0.37	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.844	rs6132824	ENSG00000276952.1	RP5-965G21.6	4.76	5.61e-06	0.0059	0.37	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25284915~25285588:-
GBM	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-4.76	5.62e-06	0.00591	-0.63	-0.41	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
GBM	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	4.76	5.64e-06	0.00592	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	4.76	5.64e-06	0.00592	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
GBM	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	4.76	5.64e-06	0.00592	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	4.76	5.64e-06	0.00592	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
GBM	cis	rs6452524	0.772	rs13156510	ENSG00000249664.1	CTD-2227C6.2	-4.76	5.65e-06	0.00593	-0.51	-0.41	Hypertension (SNP x SNP interaction);	chr5:83208668	chr5:83012285~83013109:-
GBM	cis	rs6452524	0.836	rs10514249	ENSG00000249664.1	CTD-2227C6.2	-4.76	5.65e-06	0.00593	-0.51	-0.41	Hypertension (SNP x SNP interaction);	chr5:83209037	chr5:83012285~83013109:-
GBM	cis	rs2013441	0.965	rs2703820	ENSG00000230528.6	NOS2P3	4.76	5.65e-06	0.00594	0.45	0.41	Obesity-related traits;	chr17:20218166	chr17:20436337~20447249:+
GBM	cis	rs16937	0.518	rs1172149	ENSG00000271580.1	RP11-536L3.4	-4.76	5.66e-06	0.00594	-0.38	-0.41	Schizophrenia;	chr1:205255630	chr1:205091163~205091946:+
GBM	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	4.76	5.66e-06	0.00594	0.46	0.41	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	4.76	5.66e-06	0.00594	0.46	0.41	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
GBM	cis	rs67981189	0.593	rs221919	ENSG00000269927.1	RP6-91H8.3	-4.76	5.66e-06	0.00594	-0.46	-0.41	Schizophrenia;	chr14:71121512	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs221918	ENSG00000269927.1	RP6-91H8.3	-4.76	5.66e-06	0.00594	-0.46	-0.41	Schizophrenia;	chr14:71121698	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs10132984	ENSG00000269927.1	RP6-91H8.3	4.76	5.67e-06	0.00595	0.46	0.41	Schizophrenia;	chr14:71010510	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs3784067	ENSG00000269927.1	RP6-91H8.3	4.76	5.67e-06	0.00595	0.46	0.41	Schizophrenia;	chr14:71013461	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs10132789	ENSG00000269927.1	RP6-91H8.3	4.76	5.67e-06	0.00595	0.46	0.41	Schizophrenia;	chr14:71013562	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs2097975	ENSG00000269927.1	RP6-91H8.3	4.76	5.67e-06	0.00595	0.46	0.41	Schizophrenia;	chr14:71013687	chr14:71141125~71143253:-
GBM	cis	rs853679	0.546	rs200949	ENSG00000199851.2	U3	4.76	5.67e-06	0.00595	0.85	0.41	Depression;	chr6:27867657	chr6:28015568~28015777:+
GBM	cis	rs7267979	0.873	rs6037062	ENSG00000125804.12	FAM182A	-4.76	5.68e-06	0.00596	-0.52	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:26054655~26086917:+
GBM	cis	rs4713118	0.866	rs2179094	ENSG00000218016.2	ZNF192P2	-4.76	5.68e-06	0.00596	-0.52	-0.41	Parkinson's disease;	chr6:27774046	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.739	rs2893931	ENSG00000218016.2	ZNF192P2	-4.76	5.68e-06	0.00596	-0.52	-0.41	Parkinson's disease;	chr6:27780231	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.824	rs2092075	ENSG00000218016.2	ZNF192P2	-4.76	5.68e-06	0.00596	-0.52	-0.41	Parkinson's disease;	chr6:27781551	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.824	rs13211701	ENSG00000218016.2	ZNF192P2	-4.76	5.68e-06	0.00596	-0.52	-0.41	Parkinson's disease;	chr6:27782300	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.824	rs9468229	ENSG00000218016.2	ZNF192P2	-4.76	5.68e-06	0.00596	-0.52	-0.41	Parkinson's disease;	chr6:27782307	chr6:28188050~28189432:+
GBM	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	4.76	5.68e-06	0.00596	0.63	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
GBM	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	4.76	5.69e-06	0.00597	0.57	0.41	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
GBM	cis	rs7829975	0.742	rs1533058	ENSG00000254340.1	RP11-10A14.3	4.76	5.7e-06	0.00597	0.5	0.41	Mood instability;	chr8:8827680	chr8:9141424~9145435:+
GBM	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	4.76	5.7e-06	0.00597	0.3	0.41	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
GBM	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	4.76	5.71e-06	0.00598	0.56	0.41	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	4.76	5.71e-06	0.00598	0.56	0.41	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	4.76	5.71e-06	0.00598	0.56	0.41	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	4.76	5.71e-06	0.00598	0.56	0.41	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	4.76	5.71e-06	0.00598	0.56	0.41	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	4.76	5.71e-06	0.00598	0.56	0.41	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
GBM	cis	rs4713118	0.738	rs200465	ENSG00000218016.2	ZNF192P2	-4.76	5.71e-06	0.00598	-0.52	-0.41	Parkinson's disease;	chr6:27789875	chr6:28188050~28189432:+
GBM	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-4.76	5.71e-06	0.00598	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
GBM	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	4.76	5.72e-06	0.00599	0.74	0.41	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
GBM	cis	rs67981189	0.593	rs4147077	ENSG00000269927.1	RP6-91H8.3	4.76	5.72e-06	0.00599	0.46	0.41	Schizophrenia;	chr14:70988153	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs4132848	ENSG00000269927.1	RP6-91H8.3	4.76	5.72e-06	0.00599	0.46	0.41	Schizophrenia;	chr14:70992642	chr14:71141125~71143253:-
GBM	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-4.76	5.72e-06	0.00599	-0.64	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
GBM	cis	rs922692	1	rs922692	ENSG00000261143.1	ADAMTS7P3	4.76	5.72e-06	0.00599	0.43	0.41	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78691872	chr15:77976042~77993057:+
GBM	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	4.76	5.72e-06	0.00599	0.49	0.41	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
GBM	cis	rs67981189	0.552	rs9323556	ENSG00000269927.1	RP6-91H8.3	4.76	5.72e-06	0.00599	0.46	0.41	Schizophrenia;	chr14:71002795	chr14:71141125~71143253:-
GBM	cis	rs7267979	0.873	rs6132822	ENSG00000276952.1	RP5-965G21.6	4.76	5.72e-06	0.00599	0.37	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25284915~25285588:-
GBM	cis	rs4604732	0.631	rs12038793	ENSG00000227135.1	GCSAML-AS1	4.76	5.73e-06	0.00599	0.62	0.41	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460960	chr1:247524679~247526752:-
GBM	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	4.76	5.73e-06	0.006	0.42	0.41	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
GBM	cis	rs7605378	1	rs2346662	ENSG00000232732.8	AC073043.1	-4.76	5.73e-06	0.006	-0.53	-0.41	Osteoporosis;	chr2:199814435	chr2:199867396~199911159:-
GBM	cis	rs7605378	1	rs796363	ENSG00000232732.8	AC073043.1	-4.76	5.73e-06	0.006	-0.53	-0.41	Osteoporosis;	chr2:199828945	chr2:199867396~199911159:-
GBM	cis	rs7605378	1	rs769957	ENSG00000232732.8	AC073043.1	-4.76	5.73e-06	0.006	-0.53	-0.41	Osteoporosis;	chr2:199830801	chr2:199867396~199911159:-
GBM	cis	rs763121	1	rs763121	ENSG00000273076.1	RP3-508I15.22	-4.76	5.73e-06	0.006	-0.45	-0.41	Menopause (age at onset);	chr22:38483935	chr22:38743495~38743910:+
GBM	cis	rs1908814	0.516	rs13281077	ENSG00000255556.2	RP11-351I21.6	4.76	5.74e-06	0.006	0.43	0.41	Neuroticism;	chr8:11937305	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs13281315	ENSG00000255556.2	RP11-351I21.6	4.76	5.74e-06	0.006	0.43	0.41	Neuroticism;	chr8:11937346	chr8:12378679~12380265:-
GBM	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-4.76	5.74e-06	0.006	-0.38	-0.41	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
GBM	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	4.76	5.74e-06	0.00601	0.76	0.41	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-4.76	5.74e-06	0.00601	-0.76	-0.41	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
GBM	cis	rs7017914	0.69	rs11779364	ENSG00000246366.5	RP11-382J12.1	4.76	5.74e-06	0.00601	0.42	0.41	Bone mineral density;	chr8:71042361	chr8:70608577~70663279:+
GBM	cis	rs2965260	0.621	rs17305073	ENSG00000237017.1	AC012314.8	4.76	5.75e-06	0.00601	0.87	0.41	IgG glycosylation;	chr19:53264900	chr19:54119511~54125343:-
GBM	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-4.76	5.75e-06	0.00601	-0.43	-0.41	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
GBM	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	4.76	5.75e-06	0.00601	0.55	0.41	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	4.76	5.75e-06	0.00601	0.55	0.41	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	4.76	5.75e-06	0.00601	0.55	0.41	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	4.76	5.75e-06	0.00601	0.55	0.41	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	4.76	5.75e-06	0.00601	0.55	0.41	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
GBM	cis	rs73198271	0.96	rs11776546	ENSG00000253893.2	FAM85B	4.76	5.78e-06	0.00604	0.59	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751671	chr8:8167819~8226614:-
GBM	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-4.76	5.79e-06	0.00605	-0.47	-0.41	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
GBM	cis	rs6908917	0.62	rs4897479	ENSG00000219776.2	RPL21P67	4.76	5.79e-06	0.00605	0.51	0.41	IgG glycosylation;	chr6:130992659	chr6:131469059~131469536:+
GBM	cis	rs10911232	0.507	rs6660111	ENSG00000224468.3	RP11-181K3.4	-4.76	5.79e-06	0.00605	-0.33	-0.41	Hypertriglyceridemia;	chr1:183045154	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4266836	ENSG00000224468.3	RP11-181K3.4	-4.76	5.79e-06	0.00605	-0.33	-0.41	Hypertriglyceridemia;	chr1:183059935	chr1:183138402~183141282:-
GBM	cis	rs67981189	0.593	rs221906	ENSG00000269927.1	RP6-91H8.3	4.76	5.79e-06	0.00605	0.44	0.41	Schizophrenia;	chr14:71130676	chr14:71141125~71143253:-
GBM	cis	rs2858942	0.575	rs2858011	ENSG00000268836.1	LA16c-OS12.2	4.75	5.8e-06	0.00606	0.39	0.41	Mean corpuscular hemoglobin;	chr16:197939	chr16:185748~186294:-
GBM	cis	rs922692	1	rs12901913	ENSG00000261143.1	ADAMTS7P3	4.75	5.81e-06	0.00607	0.43	0.41	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78689006	chr15:77976042~77993057:+
GBM	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	4.75	5.81e-06	0.00607	0.62	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
GBM	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-4.75	5.81e-06	0.00607	-0.53	-0.41	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
GBM	cis	rs5742933	0.817	rs1233299	ENSG00000253559.1	OSGEPL1-AS1	-4.75	5.82e-06	0.00607	-0.44	-0.41	Ferritin levels;	chr2:189799912	chr2:189762704~189765556:+
GBM	cis	rs804280	0.543	rs13261205	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	Myopia (pathological);	chr8:11933707	chr8:12378679~12380265:-
GBM	cis	rs804280	0.518	rs34266352	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	Myopia (pathological);	chr8:11933953	chr8:12378679~12380265:-
GBM	cis	rs804280	0.542	rs35647515	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	Myopia (pathological);	chr8:11934120	chr8:12378679~12380265:-
GBM	cis	rs804280	0.542	rs36100659	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	Myopia (pathological);	chr8:11934144	chr8:12378679~12380265:-
GBM	cis	rs804280	0.517	rs7815179	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	Myopia (pathological);	chr8:11934539	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.871	rs7815186	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs7833079	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	Neuroticism;	chr8:11934620	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.899	rs7815595	ENSG00000255556.2	RP11-351I21.6	4.75	5.82e-06	0.00607	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:12378679~12380265:-
GBM	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	4.75	5.82e-06	0.00607	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
GBM	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	4.75	5.82e-06	0.00607	0.47	0.41	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
GBM	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	4.75	5.82e-06	0.00608	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	4.75	5.82e-06	0.00608	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
GBM	cis	rs1908814	0.516	rs10113062	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11935740	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs10113145	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11935786	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs4367597	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11936020	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.899	rs9329251	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.773	rs7842810	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.541	rs7824267	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11936770	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs7825529	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11936935	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs7812563	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11936979	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.718	rs7813935	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.504	rs7830734	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11938130	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs4840597	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11938559	chr8:12378679~12380265:-
GBM	cis	rs804280	0.509	rs4841639	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Myopia (pathological);	chr8:11938584	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs60176945	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11939165	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs56102998	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11939166	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs35391955	ENSG00000255556.2	RP11-351I21.6	4.75	5.83e-06	0.00608	0.43	0.41	Neuroticism;	chr8:11939219	chr8:12378679~12380265:-
GBM	cis	rs397969	0.596	rs17605101	ENSG00000230528.6	NOS2P3	-4.75	5.83e-06	0.00608	-0.49	-0.41	Platelet count;	chr17:19974321	chr17:20436337~20447249:+
GBM	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	4.75	5.84e-06	0.00608	0.53	0.41	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	4.75	5.84e-06	0.00608	0.53	0.41	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
GBM	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	4.75	5.84e-06	0.00609	0.49	0.41	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
GBM	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	4.75	5.86e-06	0.0061	0.48	0.41	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
GBM	cis	rs67981189	0.529	rs2810097	ENSG00000269927.1	RP6-91H8.3	-4.75	5.86e-06	0.00611	-0.5	-0.41	Schizophrenia;	chr14:70967397	chr14:71141125~71143253:-
GBM	cis	rs1150668	0.799	rs1736891	ENSG00000199851.2	U3	4.75	5.86e-06	0.00611	0.5	0.41	Pubertal anthropometrics;	chr6:28219323	chr6:28015568~28015777:+
GBM	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-4.75	5.86e-06	0.00611	-0.48	-0.41	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
GBM	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-4.75	5.87e-06	0.00611	-0.42	-0.41	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
GBM	cis	rs7267979	0.586	rs6050445	ENSG00000276952.1	RP5-965G21.6	4.75	5.87e-06	0.00611	0.38	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25284915~25285588:-
GBM	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	4.75	5.87e-06	0.00611	0.48	0.41	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
GBM	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	4.75	5.87e-06	0.00611	0.48	0.41	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
GBM	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	4.75	5.88e-06	0.00612	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
GBM	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	4.75	5.88e-06	0.00612	0.59	0.41	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
GBM	cis	rs4842666	0.915	rs117742247	ENSG00000258302.2	RP11-981P6.1	4.75	5.88e-06	0.00612	0.53	0.41	Blood pressure;	chr12:89597536	chr12:89561129~89594878:+
GBM	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	4.75	5.88e-06	0.00613	0.75	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
GBM	cis	rs2729354	0.729	rs2258835	ENSG00000265566.2	RN7SL605P	-4.75	5.88e-06	0.00613	-0.64	-0.41	Blood protein levels;	chr11:57476115	chr11:57528085~57528365:-
GBM	cis	rs7267979	0.528	rs34485039	ENSG00000125804.12	FAM182A	4.75	5.89e-06	0.00613	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.565	rs4815437	ENSG00000125804.12	FAM182A	4.75	5.89e-06	0.00613	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.565	rs6107059	ENSG00000125804.12	FAM182A	4.75	5.89e-06	0.00613	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26054655~26086917:+
GBM	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	4.75	5.89e-06	0.00613	0.48	0.41	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
GBM	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	4.75	5.9e-06	0.00614	0.45	0.41	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
GBM	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-4.75	5.9e-06	0.00614	-0.37	-0.41	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
GBM	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	4.75	5.9e-06	0.00614	0.42	0.41	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
GBM	cis	rs7759001	0.649	rs12212404	ENSG00000218016.2	ZNF192P2	4.75	5.9e-06	0.00614	0.66	0.41	Glomerular filtration rate (creatinine);	chr6:27504247	chr6:28188050~28189432:+
GBM	cis	rs9637599	0.69	rs893971	ENSG00000246375.2	RP11-10L7.1	-4.75	5.91e-06	0.00615	-0.45	-0.41	Metabolite levels (small molecules and protein measures);	chr4:88282518	chr4:88284942~88331421:+
GBM	cis	rs10435719	0.744	rs11250175	ENSG00000255556.2	RP11-351I21.6	4.75	5.92e-06	0.00615	0.43	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs13252853	ENSG00000255556.2	RP11-351I21.6	4.75	5.92e-06	0.00615	0.43	0.41	Neuroticism;	chr8:11935465	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs13252854	ENSG00000255556.2	RP11-351I21.6	4.75	5.92e-06	0.00615	0.43	0.41	Neuroticism;	chr8:11935469	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs13279577	ENSG00000255556.2	RP11-351I21.6	4.75	5.92e-06	0.00615	0.43	0.41	Neuroticism;	chr8:11935587	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs10112958	ENSG00000255556.2	RP11-351I21.6	4.75	5.92e-06	0.00615	0.43	0.41	Neuroticism;	chr8:11935631	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs10113042	ENSG00000255556.2	RP11-351I21.6	4.75	5.92e-06	0.00615	0.43	0.41	Neuroticism;	chr8:11935669	chr8:12378679~12380265:-
GBM	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	4.75	5.92e-06	0.00616	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
GBM	cis	rs3096299	0.967	rs2965830	ENSG00000260259.1	RP11-368I7.4	4.75	5.93e-06	0.00617	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89682620~89686569:-
GBM	cis	rs3096299	0.967	rs11648663	ENSG00000260259.1	RP11-368I7.4	4.75	5.93e-06	0.00617	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89682620~89686569:-
GBM	cis	rs3096299	0.967	rs16965692	ENSG00000260259.1	RP11-368I7.4	4.75	5.93e-06	0.00617	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89682620~89686569:-
GBM	cis	rs3096299	0.967	rs28644774	ENSG00000260259.1	RP11-368I7.4	4.75	5.93e-06	0.00617	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89682620~89686569:-
GBM	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	4.75	5.94e-06	0.00617	0.31	0.4	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
GBM	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-4.75	5.95e-06	0.00618	-0.48	-0.4	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
GBM	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-4.75	5.95e-06	0.00618	-0.48	-0.4	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
GBM	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-4.75	5.95e-06	0.00618	-0.48	-0.4	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
GBM	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	4.75	5.95e-06	0.00618	0.47	0.4	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	4.75	5.95e-06	0.00618	0.47	0.4	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
GBM	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-4.75	5.96e-06	0.00619	-0.58	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
GBM	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	4.75	5.96e-06	0.0062	0.86	0.4	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	4.75	5.96e-06	0.0062	0.86	0.4	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
GBM	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	4.75	5.97e-06	0.0062	0.56	0.4	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
GBM	cis	rs4072705	0.646	rs915032	ENSG00000224020.1	MIR181A2HG	-4.75	5.97e-06	0.0062	-0.45	-0.4	Menarche (age at onset);	chr9:124483403	chr9:124658467~124698631:+
GBM	cis	rs1298062	0.79	rs1274597	ENSG00000131401.10	NAPSB	-4.75	5.98e-06	0.00621	-0.48	-0.4	Age of smoking initiation;	chr19:50470002	chr19:50333796~50344767:-
GBM	cis	rs1298062	0.79	rs1274596	ENSG00000131401.10	NAPSB	-4.75	5.98e-06	0.00621	-0.48	-0.4	Age of smoking initiation;	chr19:50470219	chr19:50333796~50344767:-
GBM	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-4.75	6e-06	0.00622	-0.53	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
GBM	cis	rs9450351	0.744	rs9362271	ENSG00000203875.9	SNHG5	-4.75	6e-06	0.00622	-1.03	-0.4	Interferon gamma-induced protein 10 levels;	chr6:86108616	chr6:85660950~85678736:-
GBM	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	4.75	6.01e-06	0.00623	0.52	0.4	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	4.75	6.01e-06	0.00623	0.52	0.4	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	4.75	6.01e-06	0.00623	0.52	0.4	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-4.75	6.01e-06	0.00623	-0.52	-0.4	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	4.75	6.01e-06	0.00623	0.52	0.4	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-4.75	6.01e-06	0.00623	-0.52	-0.4	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-4.75	6.01e-06	0.00623	-0.52	-0.4	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-4.75	6.01e-06	0.00623	-0.52	-0.4	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
GBM	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	4.75	6.03e-06	0.00625	0.58	0.4	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
GBM	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-4.74	6.04e-06	0.00626	-0.69	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
GBM	cis	rs2408955	0.522	rs4760612	ENSG00000258273.1	RP11-370I10.4	4.74	6.05e-06	0.00627	0.53	0.4	Glycated hemoglobin levels;	chr12:48028073	chr12:48333755~48333901:-
GBM	cis	rs11671005	0.696	rs73066211	ENSG00000269473.1	CTD-2619J13.19	4.74	6.05e-06	0.00627	0.47	0.4	Mean platelet volume;	chr19:58485712	chr19:58440448~58445849:+
GBM	cis	rs7017914	0.69	rs2639942	ENSG00000246366.5	RP11-382J12.1	-4.74	6.05e-06	0.00627	-0.42	-0.4	Bone mineral density;	chr8:71000939	chr8:70608577~70663279:+
GBM	cis	rs7267979	0.565	rs6107060	ENSG00000125804.12	FAM182A	-4.74	6.05e-06	0.00627	-0.52	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26054655~26086917:+
GBM	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-4.74	6.05e-06	0.00627	-0.37	-0.4	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-4.74	6.05e-06	0.00627	-0.37	-0.4	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
GBM	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	4.74	6.05e-06	0.00627	0.6	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	4.74	6.05e-06	0.00627	0.6	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
GBM	cis	rs1150668	0.83	rs2531831	ENSG00000199851.2	U3	4.74	6.06e-06	0.00627	0.5	0.4	Pubertal anthropometrics;	chr6:28420988	chr6:28015568~28015777:+
GBM	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	4.74	6.06e-06	0.00628	0.96	0.4	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
GBM	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	4.74	6.07e-06	0.00628	0.48	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
GBM	cis	rs17685	0.753	rs4732542	ENSG00000280388.1	RP11-229D13.3	-4.74	6.07e-06	0.00629	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76033885	chr7:76043977~76045963:-
GBM	cis	rs4388249	0.687	rs10038829	ENSG00000271849.1	CTC-332L22.1	4.74	6.08e-06	0.00629	0.48	0.4	Schizophrenia;	chr5:109769002	chr5:109687802~109688329:-
GBM	cis	rs11631955	1	rs11631955	ENSG00000261143.1	ADAMTS7P3	4.74	6.09e-06	0.0063	0.44	0.4	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78793573	chr15:77976042~77993057:+
GBM	cis	rs922692	0.715	rs11632102	ENSG00000261143.1	ADAMTS7P3	4.74	6.09e-06	0.0063	0.44	0.4	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78793715	chr15:77976042~77993057:+
GBM	cis	rs7829975	0.714	rs12544992	ENSG00000254340.1	RP11-10A14.3	4.74	6.1e-06	0.00631	0.5	0.4	Mood instability;	chr8:8804171	chr8:9141424~9145435:+
GBM	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-4.74	6.1e-06	0.00631	-0.51	-0.4	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
GBM	cis	rs7267979	0.903	rs6050482	ENSG00000125804.12	FAM182A	-4.74	6.14e-06	0.00634	-0.5	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.706	rs6037069	ENSG00000125804.12	FAM182A	-4.74	6.14e-06	0.00634	-0.5	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:26054655~26086917:+
GBM	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-4.74	6.14e-06	0.00635	-0.55	-0.4	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
GBM	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-4.74	6.15e-06	0.00635	-0.45	-0.4	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
GBM	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	4.74	6.15e-06	0.00635	0.47	0.4	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
GBM	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-4.74	6.17e-06	0.00637	-0.48	-0.4	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
GBM	cis	rs1420956	0.562	rs16943800	ENSG00000264151.4	RP11-739N10.1	4.74	6.18e-06	0.00637	0.55	0.4	Obesity-related traits;	chr18:27593566	chr18:27336379~27595164:-
GBM	cis	rs7615952	0.599	rs12486459	ENSG00000250012.1	RP11-124N2.1	-4.74	6.18e-06	0.00637	-0.47	-0.4	Blood pressure (smoking interaction);	chr3:126022622	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs67575510	ENSG00000250012.1	RP11-124N2.1	-4.74	6.18e-06	0.00637	-0.47	-0.4	Blood pressure (smoking interaction);	chr3:126023512	chr3:126084220~126095349:+
GBM	cis	rs73198271	1	rs4840356	ENSG00000253893.2	FAM85B	4.74	6.18e-06	0.00638	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750017	chr8:8167819~8226614:-
GBM	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	4.74	6.2e-06	0.00639	0.55	0.4	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	4.74	6.2e-06	0.00639	0.55	0.4	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
GBM	cis	rs172166	0.585	rs149963	ENSG00000280107.1	AL022393.9	-4.74	6.2e-06	0.00639	-0.44	-0.4	Cardiac Troponin-T levels;	chr6:28049354	chr6:28170845~28172521:+
GBM	cis	rs3096299	0.935	rs3114890	ENSG00000260259.1	RP11-368I7.4	4.74	6.21e-06	0.0064	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89682620~89686569:-
GBM	cis	rs4713118	0.588	rs200994	ENSG00000218016.2	ZNF192P2	4.74	6.22e-06	0.0064	0.6	0.4	Parkinson's disease;	chr6:27846035	chr6:28188050~28189432:+
GBM	cis	rs6452524	0.522	rs13161662	ENSG00000249664.1	CTD-2227C6.2	-4.74	6.22e-06	0.00641	-0.51	-0.4	Hypertension (SNP x SNP interaction);	chr5:83209777	chr5:83012285~83013109:-
GBM	cis	rs454217	0.846	rs413415	ENSG00000277851.1	RP11-756G20.1	4.74	6.22e-06	0.00641	0.44	0.4	Smoking quantity;	chr12:92327115	chr12:92247756~92363832:-
GBM	cis	rs7017914	0.69	rs7837005	ENSG00000246366.5	RP11-382J12.1	-4.74	6.22e-06	0.00641	-0.44	-0.4	Bone mineral density;	chr8:71086797	chr8:70608577~70663279:+
GBM	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	4.74	6.22e-06	0.00641	0.48	0.4	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
GBM	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	4.74	6.22e-06	0.00641	0.56	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
GBM	cis	rs1150668	0.83	rs2859365	ENSG00000199851.2	U3	-4.74	6.23e-06	0.00642	-0.5	-0.4	Pubertal anthropometrics;	chr6:28423688	chr6:28015568~28015777:+
GBM	cis	rs3806843	0.966	rs10060640	ENSG00000202111.1	VTRNA1-2	-4.74	6.24e-06	0.00642	-0.42	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr5:140718925~140719013:+
GBM	cis	rs9876781	1	rs9812647	ENSG00000244380.1	RP11-24C3.2	-4.74	6.24e-06	0.00643	-0.47	-0.4	Longevity;	chr3:48407507	chr3:48440352~48446656:-
GBM	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	4.74	6.24e-06	0.00643	0.48	0.4	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
GBM	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	4.74	6.24e-06	0.00643	0.59	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
GBM	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	4.74	6.24e-06	0.00643	0.48	0.4	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
GBM	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	4.74	6.24e-06	0.00643	0.69	0.4	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
GBM	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	4.74	6.24e-06	0.00643	0.69	0.4	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
GBM	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	4.74	6.24e-06	0.00643	0.69	0.4	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
GBM	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	4.74	6.24e-06	0.00643	0.69	0.4	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
GBM	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	4.74	6.25e-06	0.00643	0.46	0.4	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
GBM	cis	rs11673344	0.523	rs10420330	ENSG00000226686.6	LINC01535	4.74	6.25e-06	0.00643	0.44	0.4	Obesity-related traits;	chr19:37111269	chr19:37251912~37265535:+
GBM	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	4.74	6.25e-06	0.00644	0.46	0.4	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
GBM	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-4.74	6.25e-06	0.00644	-0.55	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
GBM	cis	rs2739330	0.703	rs5760112	ENSG00000272787.1	KB-226F1.2	4.74	6.26e-06	0.00644	0.38	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23969211~23969873:+
GBM	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	4.74	6.26e-06	0.00644	0.58	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
GBM	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	4.74	6.26e-06	0.00644	0.49	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
GBM	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-4.74	6.28e-06	0.00646	-0.56	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
GBM	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-4.74	6.28e-06	0.00646	-0.53	-0.4	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
GBM	cis	rs3768617	0.51	rs35968946	ENSG00000224468.3	RP11-181K3.4	-4.74	6.29e-06	0.00646	-0.34	-0.4	Fuchs's corneal dystrophy;	chr1:183145736	chr1:183138402~183141282:-
GBM	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
GBM	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-4.73	6.31e-06	0.00647	-0.6	-0.4	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
GBM	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
GBM	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
GBM	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-4.73	6.31e-06	0.00647	-0.6	-0.4	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	4.73	6.31e-06	0.00647	0.6	0.4	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
GBM	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	4.73	6.31e-06	0.00647	0.51	0.4	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
GBM	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	4.73	6.31e-06	0.00647	0.77	0.4	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
GBM	cis	rs55940216	0.524	rs17126237	ENSG00000245281.5	CTD-2547L16.1	4.73	6.31e-06	0.00647	0.51	0.4	Facial morphology (factor 14, intercanthal width);	chr8:18123580	chr8:18084868~18096394:+
GBM	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-4.73	6.33e-06	0.00648	-0.53	-0.4	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
GBM	cis	rs1150668	0.699	rs1736895	ENSG00000199851.2	U3	4.73	6.33e-06	0.00648	0.5	0.4	Pubertal anthropometrics;	chr6:28252048	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.699	rs12214383	ENSG00000199851.2	U3	-4.73	6.33e-06	0.00648	-0.5	-0.4	Pubertal anthropometrics;	chr6:28255953	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.699	rs1531681	ENSG00000199851.2	U3	4.73	6.33e-06	0.00648	0.5	0.4	Pubertal anthropometrics;	chr6:28259100	chr6:28015568~28015777:+
GBM	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-4.73	6.33e-06	0.00648	-0.46	-0.4	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
GBM	cis	rs10752881	1	rs10797812	ENSG00000224468.3	RP11-181K3.4	4.73	6.34e-06	0.00649	0.31	0.4	Colorectal cancer;	chr1:183015462	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4652772	ENSG00000224468.3	RP11-181K3.4	4.73	6.34e-06	0.00649	0.33	0.4	Hypertriglyceridemia;	chr1:183054561	chr1:183138402~183141282:-
GBM	cis	rs7267979	0.932	rs6037125	ENSG00000276952.1	RP5-965G21.6	4.73	6.35e-06	0.0065	0.39	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25284915~25285588:-
GBM	cis	rs816535	1	rs816535	ENSG00000276952.1	RP5-965G21.6	4.73	6.35e-06	0.0065	0.43	0.4	Parkinson disease and lewy body pathology;	chr20:26275360	chr20:25284915~25285588:-
GBM	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	4.73	6.36e-06	0.00651	0.48	0.4	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
GBM	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	4.73	6.36e-06	0.00651	0.48	0.4	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
GBM	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	4.73	6.36e-06	0.00651	0.48	0.4	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
GBM	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	4.73	6.36e-06	0.00651	0.48	0.4	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
GBM	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	4.73	6.36e-06	0.00651	0.48	0.4	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
GBM	cis	rs1009077	0.61	rs2389869	ENSG00000248280.1	RP11-33B1.2	-4.73	6.37e-06	0.00652	-0.59	-0.4	Endometriosis;	chr4:119596336	chr4:119440561~119450157:-
GBM	cis	rs3096299	0.933	rs889576	ENSG00000260259.1	RP11-368I7.4	-4.73	6.38e-06	0.00653	-0.43	-0.4	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89682620~89686569:-
GBM	cis	rs454217	0.846	rs1948656	ENSG00000277851.1	RP11-756G20.1	4.73	6.38e-06	0.00653	0.42	0.4	Smoking quantity;	chr12:92337508	chr12:92247756~92363832:-
GBM	cis	rs7605378	1	rs797163	ENSG00000232732.8	AC073043.1	-4.73	6.38e-06	0.00653	-0.52	-0.4	Osteoporosis;	chr2:199831664	chr2:199867396~199911159:-
GBM	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
GBM	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-4.73	6.38e-06	0.00653	-0.54	-0.4	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
GBM	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	4.73	6.39e-06	0.00654	0.56	0.4	Depression;	chr6:28187640	chr6:28115628~28116551:+
GBM	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-4.73	6.39e-06	0.00654	-0.51	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
GBM	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	4.73	6.4e-06	0.00655	0.35	0.4	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
GBM	cis	rs5742933	0.597	rs12471663	ENSG00000253559.1	OSGEPL1-AS1	4.73	6.41e-06	0.00655	0.45	0.4	Ferritin levels;	chr2:189642372	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.597	rs6761923	ENSG00000253559.1	OSGEPL1-AS1	4.73	6.41e-06	0.00655	0.45	0.4	Ferritin levels;	chr2:189642873	chr2:189762704~189765556:+
GBM	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-4.73	6.41e-06	0.00655	-0.49	-0.4	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
GBM	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-4.73	6.43e-06	0.00657	-0.41	-0.4	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
GBM	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-4.73	6.43e-06	0.00657	-0.58	-0.4	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
GBM	cis	rs4273100	0.646	rs11652784	ENSG00000262319.1	CTC-457L16.2	4.73	6.44e-06	0.00658	0.48	0.4	Schizophrenia;	chr17:19313948	chr17:19141017~19143689:-
GBM	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	4.73	6.45e-06	0.00659	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
GBM	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	4.73	6.45e-06	0.00659	0.47	0.4	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
GBM	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	4.73	6.45e-06	0.00659	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
GBM	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	4.73	6.45e-06	0.00659	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
GBM	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	4.73	6.45e-06	0.00659	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
GBM	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	4.73	6.45e-06	0.00659	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
GBM	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	4.73	6.45e-06	0.00659	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
GBM	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	4.73	6.45e-06	0.00659	0.48	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
GBM	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-4.73	6.46e-06	0.0066	-0.53	-0.4	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
GBM	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-4.73	6.46e-06	0.0066	-0.37	-0.4	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-4.73	6.46e-06	0.0066	-0.37	-0.4	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-4.73	6.46e-06	0.0066	-0.37	-0.4	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-4.73	6.46e-06	0.0066	-0.37	-0.4	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
GBM	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	4.73	6.46e-06	0.0066	0.81	0.4	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
GBM	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	4.73	6.47e-06	0.0066	0.48	0.4	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
GBM	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	4.73	6.47e-06	0.0066	0.43	0.4	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
GBM	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	4.73	6.47e-06	0.0066	0.82	0.4	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	4.73	6.47e-06	0.0066	0.82	0.4	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	4.73	6.47e-06	0.0066	0.82	0.4	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	4.73	6.47e-06	0.0066	0.82	0.4	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
GBM	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-4.73	6.48e-06	0.00661	-0.48	-0.4	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-4.73	6.48e-06	0.00661	-0.48	-0.4	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-4.73	6.48e-06	0.00661	-0.48	-0.4	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-4.73	6.48e-06	0.00661	-0.48	-0.4	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-4.73	6.48e-06	0.00661	-0.48	-0.4	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
GBM	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	4.73	6.49e-06	0.00662	0.47	0.4	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
GBM	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	4.73	6.5e-06	0.00662	0.61	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
GBM	cis	rs7567389	0.853	rs7585314	ENSG00000236682.1	AC068282.3	4.73	6.5e-06	0.00663	0.44	0.4	Self-rated health;	chr2:127204917	chr2:127389130~127400580:+
GBM	cis	rs7605378	1	rs7577763	ENSG00000232732.8	AC073043.1	-4.73	6.5e-06	0.00663	-0.53	-0.4	Osteoporosis;	chr2:199817030	chr2:199867396~199911159:-
GBM	cis	rs7605378	1	rs2577852	ENSG00000232732.8	AC073043.1	-4.73	6.5e-06	0.00663	-0.53	-0.4	Osteoporosis;	chr2:199822525	chr2:199867396~199911159:-
GBM	cis	rs7605378	0.964	rs2689763	ENSG00000232732.8	AC073043.1	-4.73	6.5e-06	0.00663	-0.53	-0.4	Osteoporosis;	chr2:199824832	chr2:199867396~199911159:-
GBM	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-4.73	6.52e-06	0.00665	-0.55	-0.4	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
GBM	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	4.73	6.53e-06	0.00666	0.46	0.4	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	4.73	6.53e-06	0.00666	0.46	0.4	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
GBM	cis	rs893363	0.517	rs6445606	ENSG00000271916.1	RP11-884K10.6	-4.73	6.53e-06	0.00666	-0.49	-0.4	Axial length;	chr3:53822023	chr3:53797764~53798019:-
GBM	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-4.73	6.54e-06	0.00666	-0.41	-0.4	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
GBM	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	4.73	6.55e-06	0.00667	0.39	0.4	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
GBM	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	4.73	6.56e-06	0.00668	0.48	0.4	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
GBM	cis	rs4273100	0.688	rs12938803	ENSG00000262319.1	CTC-457L16.2	4.73	6.56e-06	0.00668	0.47	0.4	Schizophrenia;	chr17:19301119	chr17:19141017~19143689:-
GBM	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-4.73	6.56e-06	0.00668	-0.49	-0.4	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
GBM	cis	rs10911232	0.507	rs10797816	ENSG00000224468.3	RP11-181K3.4	-4.73	6.56e-06	0.00668	-0.32	-0.4	Hypertriglyceridemia;	chr1:183029351	chr1:183138402~183141282:-
GBM	cis	rs7181230	0.845	rs4923852	ENSG00000275636.1	RP11-521C20.5	-4.72	6.57e-06	0.00669	-0.47	-0.4	Dehydroepiandrosterone sulphate levels;	chr15:40085664	chr15:40078892~40079347:+
GBM	cis	rs17772222	0.958	rs10134008	ENSG00000222990.1	RNU4-22P	4.72	6.58e-06	0.00669	0.49	0.4	Coronary artery calcification;	chr14:88549183	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.958	rs891750	ENSG00000222990.1	RNU4-22P	4.72	6.58e-06	0.00669	0.49	0.4	Coronary artery calcification;	chr14:88550856	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.958	rs891749	ENSG00000222990.1	RNU4-22P	4.72	6.58e-06	0.00669	0.49	0.4	Coronary artery calcification;	chr14:88550893	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs61984683	ENSG00000222990.1	RNU4-22P	4.72	6.58e-06	0.00669	0.49	0.4	Coronary artery calcification;	chr14:88553162	chr14:88513498~88513663:+
GBM	cis	rs804280	0.542	rs34117651	ENSG00000255556.2	RP11-351I21.6	4.72	6.58e-06	0.0067	0.43	0.4	Myopia (pathological);	chr8:11934108	chr8:12378679~12380265:-
GBM	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	4.72	6.59e-06	0.0067	0.49	0.4	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
GBM	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-4.72	6.61e-06	0.00672	-0.5	-0.4	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
GBM	cis	rs2579103	0.63	rs862233	ENSG00000258183.4	RP11-753N8.1	-4.72	6.61e-06	0.00672	-0.58	-0.4	Body mass index;	chr12:90312060	chr12:90280894~90300340:+
GBM	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-4.72	6.61e-06	0.00672	-0.47	-0.4	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
GBM	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-4.72	6.61e-06	0.00672	-0.47	-0.4	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
GBM	cis	rs3753275	0.624	rs10864366	ENSG00000230679.1	ENO1-AS1	-4.72	6.62e-06	0.00673	-0.48	-0.4	Educational attainment;	chr1:8772440	chr1:8878835~8879894:+
GBM	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-4.72	6.62e-06	0.00673	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-4.72	6.62e-06	0.00673	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-4.72	6.62e-06	0.00673	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-4.72	6.62e-06	0.00673	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-4.72	6.62e-06	0.00673	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-4.72	6.62e-06	0.00673	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-4.72	6.62e-06	0.00673	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
GBM	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	4.72	6.65e-06	0.00676	0.57	0.4	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
GBM	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	4.72	6.66e-06	0.00677	0.55	0.4	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
GBM	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	4.72	6.67e-06	0.00677	0.51	0.4	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
GBM	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	4.72	6.67e-06	0.00677	0.51	0.4	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
GBM	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	4.72	6.67e-06	0.00677	0.46	0.4	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
GBM	cis	rs4713118	0.824	rs2179095	ENSG00000218016.2	ZNF192P2	4.72	6.67e-06	0.00677	0.51	0.4	Parkinson's disease;	chr6:27783079	chr6:28188050~28189432:+
GBM	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-4.72	6.68e-06	0.00677	-0.48	-0.4	QT interval;	chr16:28845498	chr16:28700294~28701540:-
GBM	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	4.72	6.68e-06	0.00677	0.47	0.4	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
GBM	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-4.72	6.68e-06	0.00677	-0.32	-0.4	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
GBM	cis	rs2025751	0.512	rs6935608	ENSG00000230204.1	FTH1P5	-4.72	6.69e-06	0.00678	-0.46	-0.4	Intraocular pressure;	chr6:51822479	chr6:50912712~50913256:-
GBM	cis	rs5760092	0.755	rs915589	ENSG00000224205.1	AP000351.4	-4.72	6.69e-06	0.00678	-0.52	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23987320~23991421:-
GBM	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	4.72	6.69e-06	0.00678	0.49	0.4	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	4.72	6.69e-06	0.00678	0.49	0.4	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
GBM	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-4.72	6.69e-06	0.00679	-0.72	-0.4	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
GBM	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-4.72	6.69e-06	0.00679	-0.72	-0.4	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
GBM	cis	rs3096299	0.967	rs28689480	ENSG00000260259.1	RP11-368I7.4	4.72	6.69e-06	0.00679	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89682620~89686569:-
GBM	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-4.72	6.7e-06	0.00679	-0.56	-0.4	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
GBM	cis	rs7267979	0.844	rs8184820	ENSG00000276952.1	RP5-965G21.6	-4.72	6.71e-06	0.00679	-0.37	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25284915~25285588:-
GBM	cis	rs73198271	1	rs11774744	ENSG00000253893.2	FAM85B	4.72	6.71e-06	0.0068	0.57	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:8167819~8226614:-
GBM	cis	rs4713118	0.911	rs9295746	ENSG00000218016.2	ZNF192P2	-4.72	6.71e-06	0.0068	-0.54	-0.4	Parkinson's disease;	chr6:27762285	chr6:28188050~28189432:+
GBM	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-4.72	6.72e-06	0.0068	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-4.72	6.72e-06	0.0068	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
GBM	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-4.72	6.72e-06	0.0068	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
GBM	cis	rs10754283	0.967	rs4658308	ENSG00000231613.1	RP5-943J3.1	4.72	6.74e-06	0.00682	0.48	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89657372	chr1:89788914~89790492:+
GBM	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	4.72	6.74e-06	0.00682	0.55	0.4	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
GBM	cis	rs397969	0.596	rs7209653	ENSG00000230528.6	NOS2P3	-4.72	6.75e-06	0.00683	-0.45	-0.4	Platelet count;	chr17:19978771	chr17:20436337~20447249:+
GBM	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-4.72	6.76e-06	0.00684	-0.42	-0.4	Temperament;	chr17:14018109	chr17:14024514~14025488:+
GBM	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	4.72	6.76e-06	0.00684	0.44	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
GBM	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	4.72	6.77e-06	0.00684	0.28	0.4	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
GBM	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-4.72	6.77e-06	0.00684	-0.55	-0.4	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
GBM	cis	rs3096299	0.933	rs3096297	ENSG00000260259.1	RP11-368I7.4	4.72	6.78e-06	0.00685	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89682620~89686569:-
GBM	cis	rs7267979	0.714	rs3787082	ENSG00000276952.1	RP5-965G21.6	4.72	6.78e-06	0.00685	0.36	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.714	rs6115107	ENSG00000276952.1	RP5-965G21.6	4.72	6.78e-06	0.00685	0.36	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.78	rs2500413	ENSG00000276952.1	RP5-965G21.6	4.72	6.78e-06	0.00685	0.36	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.714	rs2474763	ENSG00000276952.1	RP5-965G21.6	4.72	6.78e-06	0.00685	0.36	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25284915~25285588:-
GBM	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	4.72	6.78e-06	0.00686	0.47	0.4	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
GBM	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	4.72	6.8e-06	0.00687	0.53	0.4	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
GBM	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	4.72	6.81e-06	0.00688	0.74	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	4.72	6.81e-06	0.00688	0.74	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	4.72	6.81e-06	0.00688	0.74	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
GBM	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	4.72	6.82e-06	0.00688	0.49	0.4	Axial length;	chr3:53815483	chr3:53797764~53798019:-
GBM	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	4.72	6.82e-06	0.00689	0.59	0.4	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
GBM	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	4.72	6.82e-06	0.00689	0.59	0.4	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
GBM	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-4.72	6.83e-06	0.0069	-0.52	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-4.72	6.83e-06	0.0069	-0.52	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
GBM	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	4.71	6.84e-06	0.0069	0.42	0.4	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
GBM	cis	rs4245535	1	rs17069274	ENSG00000225174.1	OSTM1-AS1	4.71	6.86e-06	0.00692	0.74	0.4	Major depressive disorder;	chr6:108124819	chr6:108123515~108159392:+
GBM	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-4.71	6.87e-06	0.00693	-0.53	-0.4	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
GBM	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	4.71	6.88e-06	0.00693	0.55	0.4	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
GBM	cis	rs763121	0.853	rs138702	ENSG00000273076.1	RP3-508I15.22	-4.71	6.89e-06	0.00694	-0.42	-0.4	Menopause (age at onset);	chr22:38736596	chr22:38743495~38743910:+
GBM	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-4.71	6.9e-06	0.00695	-0.53	-0.4	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-4.71	6.9e-06	0.00695	-0.53	-0.4	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-4.71	6.9e-06	0.00695	-0.53	-0.4	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-4.71	6.9e-06	0.00695	-0.53	-0.4	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-4.71	6.9e-06	0.00695	-0.53	-0.4	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
GBM	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-4.71	6.9e-06	0.00695	-0.53	-0.4	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
GBM	cis	rs867371	0.929	rs7173852	ENSG00000278603.1	RP13-608F4.5	4.71	6.92e-06	0.00697	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472203~82472426:+
GBM	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	4.71	6.92e-06	0.00697	0.58	0.4	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
GBM	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	4.71	6.92e-06	0.00697	0.58	0.4	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
GBM	cis	rs7017914	0.6	rs12678625	ENSG00000246366.5	RP11-382J12.1	-4.71	6.94e-06	0.00699	-0.45	-0.4	Bone mineral density;	chr8:70576107	chr8:70608577~70663279:+
GBM	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	4.71	6.95e-06	0.007	0.5	0.4	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
GBM	cis	rs4604732	0.754	rs12080212	ENSG00000227135.1	GCSAML-AS1	-4.71	6.96e-06	0.007	-0.56	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468304	chr1:247524679~247526752:-
GBM	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-4.71	6.96e-06	0.007	-0.53	-0.4	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
GBM	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	4.71	6.96e-06	0.00701	0.47	0.4	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
GBM	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	4.71	6.96e-06	0.00701	0.47	0.4	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
GBM	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	4.71	6.96e-06	0.00701	0.47	0.4	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
GBM	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	4.71	6.96e-06	0.00701	0.47	0.4	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
GBM	cis	rs11671005	0.779	rs3794971	ENSG00000269473.1	CTD-2619J13.19	4.71	6.96e-06	0.00701	0.46	0.4	Mean platelet volume;	chr19:58474499	chr19:58440448~58445849:+
GBM	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	4.71	6.97e-06	0.00701	0.4	0.4	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
GBM	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	4.71	6.97e-06	0.00701	0.4	0.4	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
GBM	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	4.71	6.97e-06	0.00701	0.4	0.4	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
GBM	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	4.71	6.99e-06	0.00702	0.35	0.4	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
GBM	cis	rs3096299	0.9	rs2911258	ENSG00000260259.1	RP11-368I7.4	4.71	6.99e-06	0.00702	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89682620~89686569:-
GBM	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	4.71	6.99e-06	0.00703	0.75	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	4.71	6.99e-06	0.00703	0.75	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	4.71	6.99e-06	0.00703	0.75	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
GBM	cis	rs11098499	0.739	rs10031033	ENSG00000250412.1	KLHL2P1	4.71	7e-06	0.00703	0.53	0.4	Corneal astigmatism;	chr4:119230297	chr4:119334329~119378233:+
GBM	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	4.71	7.01e-06	0.00704	0.52	0.4	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
GBM	cis	rs7615952	0.534	rs1503072	ENSG00000250012.1	RP11-124N2.1	-4.71	7.01e-06	0.00704	-0.46	-0.4	Blood pressure (smoking interaction);	chr3:126035848	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs7631268	ENSG00000250012.1	RP11-124N2.1	-4.71	7.01e-06	0.00704	-0.46	-0.4	Blood pressure (smoking interaction);	chr3:126036821	chr3:126084220~126095349:+
GBM	cis	rs804280	0.509	rs12719915	ENSG00000255556.2	RP11-351I21.6	-4.71	7.02e-06	0.00705	-0.44	-0.4	Myopia (pathological);	chr8:11928746	chr8:12378679~12380265:-
GBM	cis	rs9393777	0.513	rs9379893	ENSG00000224843.5	LINC00240	-4.71	7.03e-06	0.00706	-0.59	-0.4	Intelligence (multi-trait analysis);	chr6:26584440	chr6:26956992~27023924:+
GBM	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-4.71	7.04e-06	0.00707	-0.6	-0.4	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
GBM	cis	rs3742264	0.656	rs1409436	ENSG00000235903.6	CPB2-AS1	-4.71	7.05e-06	0.00707	-0.49	-0.4	Blood protein levels;	chr13:46040515	chr13:46052806~46113332:+
GBM	cis	rs3806843	0.801	rs801171	ENSG00000202111.1	VTRNA1-2	4.71	7.05e-06	0.00707	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140735718	chr5:140718925~140719013:+
GBM	cis	rs10752881	0.74	rs1889307	ENSG00000224468.3	RP11-181K3.4	-4.71	7.05e-06	0.00708	-0.33	-0.4	Colorectal cancer;	chr1:183080254	chr1:183138402~183141282:-
GBM	cis	rs4664293	0.833	rs3764969	ENSG00000226266.5	AC009961.3	-4.71	7.05e-06	0.00708	-0.51	-0.4	Monocyte percentage of white cells;	chr2:159764337	chr2:159670708~159712435:-
GBM	cis	rs4713118	0.824	rs742046	ENSG00000218016.2	ZNF192P2	-4.71	7.06e-06	0.00708	-0.52	-0.4	Parkinson's disease;	chr6:27771475	chr6:28188050~28189432:+
GBM	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-4.71	7.06e-06	0.00709	-0.51	-0.4	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
GBM	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	4.71	7.07e-06	0.00709	0.51	0.4	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
GBM	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	4.71	7.07e-06	0.00709	0.43	0.4	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
GBM	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	4.71	7.08e-06	0.0071	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
GBM	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	4.71	7.08e-06	0.0071	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
GBM	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-4.71	7.1e-06	0.00712	-0.53	-0.4	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-4.71	7.1e-06	0.00712	-0.53	-0.4	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
GBM	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-4.71	7.11e-06	0.00713	-0.52	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
GBM	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	4.71	7.12e-06	0.00714	0.28	0.4	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
GBM	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-4.7	7.13e-06	0.00715	-0.56	-0.4	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
GBM	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
GBM	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-4.7	7.13e-06	0.00715	-0.5	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
GBM	cis	rs4713118	0.866	rs9468217	ENSG00000218016.2	ZNF192P2	-4.7	7.15e-06	0.00716	-0.53	-0.4	Parkinson's disease;	chr6:27758688	chr6:28188050~28189432:+
GBM	cis	rs17685	0.753	rs10245584	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76116548	chr7:76043977~76045963:-
GBM	cis	rs17685	0.736	rs4732594	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76123955	chr7:76043977~76045963:-
GBM	cis	rs17685	0.671	rs60303271	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76130690	chr7:76043977~76045963:-
GBM	cis	rs17685	0.735	rs11763339	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76132223	chr7:76043977~76045963:-
GBM	cis	rs17685	0.775	rs11761172	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76132229	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs11764129	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76132572	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs28506984	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76134166	chr7:76043977~76045963:-
GBM	cis	rs17685	0.816	rs11763076	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76136645	chr7:76043977~76045963:-
GBM	cis	rs17685	0.623	rs7782808	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76139327	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs6953665	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76139731	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs7778735	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76140919	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs10275521	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76141654	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs6951808	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76143095	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs6951943	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76143134	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs10952840	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76143560	chr7:76043977~76045963:-
GBM	cis	rs17685	0.672	rs10952841	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76149308	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs2108274	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76152318	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1806885	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76156294	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1859791	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76156725	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs6464999	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76157997	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs6465000	ENSG00000280388.1	RP11-229D13.3	-4.7	7.16e-06	0.00716	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76158099	chr7:76043977~76045963:-
GBM	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-4.7	7.16e-06	0.00717	-0.54	-0.4	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
GBM	cis	rs1150668	0.699	rs13408	ENSG00000218016.2	ZNF192P2	-4.7	7.16e-06	0.00717	-0.47	-0.4	Pubertal anthropometrics;	chr6:28244970	chr6:28188050~28189432:+
GBM	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	4.7	7.16e-06	0.00717	0.68	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
GBM	cis	rs4713118	0.955	rs9468203	ENSG00000199851.2	U3	4.7	7.17e-06	0.00717	0.56	0.4	Parkinson's disease;	chr6:27720888	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9468204	ENSG00000199851.2	U3	4.7	7.17e-06	0.00717	0.56	0.4	Parkinson's disease;	chr6:27721030	chr6:28015568~28015777:+
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-4.7	7.17e-06	0.00718	-0.54	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
GBM	cis	rs9601248	0.756	rs2146592	ENSG00000227676.3	LINC01068	-4.7	7.17e-06	0.00718	-0.48	-0.4	Major depressive disorder;	chr13:79606146	chr13:79566727~79571436:+
GBM	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-4.7	7.18e-06	0.00718	-0.55	-0.4	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
GBM	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	4.7	7.18e-06	0.00719	0.73	0.4	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
GBM	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	4.7	7.18e-06	0.00719	0.73	0.4	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
GBM	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	4.7	7.18e-06	0.00719	0.59	0.4	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
GBM	cis	rs11098499	0.913	rs10006304	ENSG00000250412.1	KLHL2P1	4.7	7.19e-06	0.00719	0.54	0.4	Corneal astigmatism;	chr4:119203150	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.913	rs56122576	ENSG00000250412.1	KLHL2P1	4.7	7.19e-06	0.00719	0.54	0.4	Corneal astigmatism;	chr4:119208181	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.913	rs68128210	ENSG00000250412.1	KLHL2P1	4.7	7.19e-06	0.00719	0.54	0.4	Corneal astigmatism;	chr4:119216664	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.913	rs13126596	ENSG00000250412.1	KLHL2P1	4.7	7.19e-06	0.00719	0.54	0.4	Corneal astigmatism;	chr4:119219574	chr4:119334329~119378233:+
GBM	cis	rs7267979	0.586	rs6083776	ENSG00000276952.1	RP5-965G21.6	4.7	7.19e-06	0.0072	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.586	rs1473695	ENSG00000276952.1	RP5-965G21.6	4.7	7.19e-06	0.0072	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.586	rs1007707	ENSG00000276952.1	RP5-965G21.6	4.7	7.19e-06	0.0072	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.586	rs1007708	ENSG00000276952.1	RP5-965G21.6	4.7	7.19e-06	0.0072	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.586	rs6050439	ENSG00000276952.1	RP5-965G21.6	4.7	7.19e-06	0.0072	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25284915~25285588:-
GBM	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	4.7	7.2e-06	0.0072	0.48	0.4	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
GBM	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	4.7	7.21e-06	0.0072	0.45	0.4	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
GBM	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-4.7	7.22e-06	0.00721	-0.47	-0.4	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
GBM	cis	rs17508449	0.819	rs78394484	ENSG00000232450.1	RP4-730K3.3	-4.7	7.23e-06	0.00722	-0.68	-0.4	Leprosy;	chr1:113740136	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs79198040	ENSG00000232450.1	RP4-730K3.3	-4.7	7.23e-06	0.00722	-0.68	-0.4	Leprosy;	chr1:113746069	chr1:113698884~113699631:-
GBM	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	4.7	7.24e-06	0.00722	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
GBM	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	4.7	7.24e-06	0.00723	0.48	0.4	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
GBM	cis	rs67340775	0.541	rs200964	ENSG00000199851.2	U3	4.7	7.26e-06	0.00724	0.76	0.4	Lung cancer in ever smokers;	chr6:27899165	chr6:28015568~28015777:+
GBM	cis	rs17772222	0.958	rs17203789	ENSG00000222990.1	RNU4-22P	4.7	7.26e-06	0.00724	0.48	0.4	Coronary artery calcification;	chr14:88541362	chr14:88513498~88513663:+
GBM	cis	rs7267979	0.873	rs7453	ENSG00000276952.1	RP5-965G21.6	4.7	7.26e-06	0.00724	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25284915~25285588:-
GBM	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	4.7	7.29e-06	0.00727	0.59	0.4	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	4.7	7.29e-06	0.00727	0.59	0.4	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
GBM	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	4.7	7.29e-06	0.00727	0.54	0.4	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	4.7	7.31e-06	0.00729	0.56	0.4	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	4.7	7.31e-06	0.00729	0.56	0.4	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
GBM	cis	rs4266144	0.563	rs61124401	ENSG00000243629.1	LINC00880	-4.7	7.31e-06	0.00729	-0.51	-0.4	Coronary artery disease;	chr3:157123130	chr3:157081667~157123004:-
GBM	cis	rs67981189	0.513	rs2526856	ENSG00000269927.1	RP6-91H8.3	4.7	7.32e-06	0.00729	0.44	0.4	Schizophrenia;	chr14:70946000	chr14:71141125~71143253:-
GBM	cis	rs7017914	0.667	rs2732098	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71008762	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs3098869	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71017597	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs3098875	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71022453	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs3098878	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71025234	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.653	rs3098882	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71027859	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.653	rs3110260	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71028253	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs3110261	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71029216	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs3110262	ENSG00000246366.5	RP11-382J12.1	-4.7	7.33e-06	0.00731	-0.41	-0.4	Bone mineral density;	chr8:71029395	chr8:70608577~70663279:+
GBM	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-4.7	7.33e-06	0.00731	-0.62	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	4.7	7.33e-06	0.00731	0.62	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	4.7	7.33e-06	0.00731	0.62	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
GBM	cis	rs6496932	0.503	rs10220820	ENSG00000218052.5	ADAMTS7P4	-4.7	7.34e-06	0.00731	-0.56	-0.4	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85255369~85330334:-
GBM	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-4.7	7.35e-06	0.00733	-0.45	-0.4	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
GBM	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-4.7	7.35e-06	0.00733	-0.45	-0.4	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
GBM	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-4.7	7.35e-06	0.00733	-0.45	-0.4	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
GBM	cis	rs11773103	0.708	rs55825235	ENSG00000224046.1	AC005076.5	4.7	7.35e-06	0.00733	0.57	0.4	Bipolar disorder or major depressive disorder (combined);	chr7:87130385	chr7:87151423~87152420:-
GBM	cis	rs2976388	0.669	rs1836633	ENSG00000253741.1	CTD-2292P10.4	-4.7	7.36e-06	0.00733	-0.42	-0.4	Urinary tract infection frequency;	chr8:142693174	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.692	rs1435453	ENSG00000253741.1	CTD-2292P10.4	-4.7	7.36e-06	0.00733	-0.42	-0.4	Urinary tract infection frequency;	chr8:142699357	chr8:142702252~142726973:-
GBM	cis	rs10946940	0.632	rs9366698	ENSG00000218016.2	ZNF192P2	-4.7	7.38e-06	0.00735	-0.56	-0.4	Systemic lupus erythematosus;	chr6:27704256	chr6:28188050~28189432:+
GBM	cis	rs10028773	0.515	rs9994488	ENSG00000249244.1	RP11-548H18.2	4.7	7.38e-06	0.00735	0.5	0.4	Educational attainment;	chr4:119666626	chr4:119391831~119395335:-
GBM	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	4.7	7.38e-06	0.00735	0.53	0.4	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
GBM	cis	rs9599293	0.764	rs7325039	ENSG00000276672.1	RP11-142E9.1	-4.7	7.38e-06	0.00735	-0.81	-0.4	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr13:34594471	chr13:33846190~33850825:+
GBM	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-4.7	7.39e-06	0.00735	-0.74	-0.4	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
GBM	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-4.7	7.39e-06	0.00735	-0.74	-0.4	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
GBM	cis	rs4812048	0.793	rs62205397	ENSG00000268649.3	RP4-806M20.4	-4.7	7.39e-06	0.00735	-0.46	-0.4	Mean platelet volume;	chr20:59021956	chr20:58817132~58817725:-
GBM	cis	rs12137294	0.829	rs1172154	ENSG00000271580.1	RP11-536L3.4	-4.7	7.39e-06	0.00736	-0.38	-0.4	Red cell distribution width;	chr1:205251511	chr1:205091163~205091946:+
GBM	cis	rs12137294	0.866	rs1172153	ENSG00000271580.1	RP11-536L3.4	-4.7	7.39e-06	0.00736	-0.38	-0.4	Red cell distribution width;	chr1:205251533	chr1:205091163~205091946:+
GBM	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	4.7	7.39e-06	0.00736	0.71	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
GBM	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	4.7	7.4e-06	0.00736	0.48	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
GBM	cis	rs6782228	0.883	rs11712115	ENSG00000277250.1	Metazoa_SRP	4.7	7.4e-06	0.00736	0.47	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128673681~128674021:-
GBM	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	4.7	7.41e-06	0.00737	0.4	0.4	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
GBM	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	4.7	7.41e-06	0.00737	0.4	0.4	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
GBM	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	4.7	7.42e-06	0.00738	0.56	0.4	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
GBM	cis	rs3096299	0.967	rs28575874	ENSG00000260259.1	RP11-368I7.4	4.69	7.43e-06	0.00738	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89682620~89686569:-
GBM	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	4.69	7.43e-06	0.00738	0.48	0.4	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
GBM	cis	rs6496932	1	rs11638110	ENSG00000218052.5	ADAMTS7P4	4.69	7.44e-06	0.00739	0.62	0.4	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85255369~85330334:-
GBM	cis	rs922692	1	rs11638372	ENSG00000261143.1	ADAMTS7P3	-4.69	7.45e-06	0.0074	-0.42	-0.4	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78691217	chr15:77976042~77993057:+
GBM	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	4.69	7.45e-06	0.0074	0.46	0.4	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
GBM	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-4.69	7.45e-06	0.0074	-0.46	-0.4	Height;	chr11:118703185	chr11:118791254~118793137:+
GBM	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-4.69	7.45e-06	0.0074	-0.46	-0.4	Height;	chr11:118703207	chr11:118791254~118793137:+
GBM	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-4.69	7.45e-06	0.0074	-0.46	-0.4	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
GBM	cis	rs867371	0.82	rs12443224	ENSG00000278603.1	RP13-608F4.5	4.69	7.45e-06	0.0074	0.47	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82472203~82472426:+
GBM	cis	rs3742264	0.656	rs6561275	ENSG00000235903.6	CPB2-AS1	-4.69	7.46e-06	0.0074	-0.49	-0.4	Blood protein levels;	chr13:45944164	chr13:46052806~46113332:+
GBM	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	4.69	7.47e-06	0.00741	0.47	0.4	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
GBM	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	4.69	7.48e-06	0.00743	0.5	0.4	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
GBM	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-4.69	7.49e-06	0.00743	-0.58	-0.4	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
GBM	cis	rs1420956	0.603	rs62080908	ENSG00000264151.4	RP11-739N10.1	4.69	7.49e-06	0.00743	0.54	0.4	Obesity-related traits;	chr18:27569224	chr18:27336379~27595164:-
GBM	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	4.69	7.49e-06	0.00743	0.47	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
GBM	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	4.69	7.49e-06	0.00743	0.53	0.4	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
GBM	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-4.69	7.49e-06	0.00743	-0.54	-0.4	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
GBM	cis	rs11673344	0.563	rs55825113	ENSG00000226686.6	LINC01535	4.69	7.49e-06	0.00744	0.43	0.4	Obesity-related traits;	chr19:37191523	chr19:37251912~37265535:+
GBM	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	4.69	7.5e-06	0.00744	0.48	0.4	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	4.69	7.5e-06	0.00744	0.48	0.4	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	4.69	7.5e-06	0.00744	0.48	0.4	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
GBM	cis	rs4713118	0.539	rs510987	ENSG00000218016.2	ZNF192P2	-4.69	7.5e-06	0.00744	-0.56	-0.4	Parkinson's disease;	chr6:27879739	chr6:28188050~28189432:+
GBM	cis	rs4373814	0.698	rs10764325	ENSG00000226083.4	SLC39A12-AS1	-4.69	7.5e-06	0.00744	-0.46	-0.4	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18151804	chr10:18001786~18010562:-
GBM	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-4.69	7.52e-06	0.00745	-0.55	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
GBM	cis	rs4273100	0.688	rs4924980	ENSG00000262319.1	CTC-457L16.2	4.69	7.52e-06	0.00746	0.47	0.4	Schizophrenia;	chr17:19301550	chr17:19141017~19143689:-
GBM	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	4.69	7.53e-06	0.00747	0.66	0.4	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
GBM	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-4.69	7.54e-06	0.00748	-0.39	-0.4	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
GBM	cis	rs645901	1	rs645901	ENSG00000254851.1	RP11-109L13.1	-4.69	7.55e-06	0.00748	-0.76	-0.4	Plateletcrit;	chr11:116831646	chr11:117135528~117138582:+
GBM	cis	rs10435719	0.805	rs13269417	ENSG00000255556.2	RP11-351I21.6	4.69	7.55e-06	0.00749	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:12378679~12380265:-
GBM	cis	rs7017914	0.905	rs3110255	ENSG00000246366.5	RP11-382J12.1	-4.69	7.55e-06	0.00749	-0.42	-0.4	Bone mineral density;	chr8:71025815	chr8:70608577~70663279:+
GBM	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	4.69	7.55e-06	0.00749	0.3	0.4	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
GBM	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	4.69	7.56e-06	0.00749	0.55	0.4	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
GBM	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	4.69	7.56e-06	0.00749	0.55	0.4	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
GBM	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	4.69	7.56e-06	0.00749	0.55	0.4	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
GBM	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	4.69	7.56e-06	0.0075	0.47	0.4	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
GBM	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	4.69	7.58e-06	0.00751	0.56	0.4	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	4.69	7.58e-06	0.00751	0.56	0.4	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	4.69	7.58e-06	0.00751	0.56	0.4	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
GBM	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	4.69	7.58e-06	0.00751	0.56	0.4	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
GBM	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	4.69	7.58e-06	0.00751	0.56	0.4	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
GBM	cis	rs2976388	1	rs2294008	ENSG00000253741.1	CTD-2292P10.4	4.69	7.58e-06	0.00751	0.43	0.4	Urinary tract infection frequency;	chr8:142680513	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.934	rs2920279	ENSG00000253741.1	CTD-2292P10.4	4.69	7.58e-06	0.00751	0.43	0.4	Urinary tract infection frequency;	chr8:142680717	chr8:142702252~142726973:-
GBM	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	4.69	7.58e-06	0.00751	0.45	0.4	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
GBM	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	4.69	7.59e-06	0.00752	0.73	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
GBM	cis	rs3096299	0.967	rs3102383	ENSG00000260259.1	RP11-368I7.4	4.69	7.59e-06	0.00752	0.45	0.4	Multiple myeloma (IgH translocation);	chr16:89344887	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.605	rs3743859	ENSG00000260259.1	RP11-368I7.4	4.69	7.6e-06	0.00753	0.43	0.4	Vitiligo;	chr16:89779642	chr16:89682620~89686569:-
GBM	cis	rs4604732	0.631	rs1106719	ENSG00000227135.1	GCSAML-AS1	4.69	7.62e-06	0.00755	0.61	0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461411	chr1:247524679~247526752:-
GBM	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	4.69	7.62e-06	0.00755	0.55	0.4	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
GBM	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-4.69	7.63e-06	0.00755	-0.65	-0.4	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
GBM	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-4.69	7.64e-06	0.00757	-0.53	-0.4	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
GBM	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-4.69	7.65e-06	0.00757	-0.41	-0.4	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
GBM	cis	rs3096299	0.933	rs3114848	ENSG00000260259.1	RP11-368I7.4	4.69	7.65e-06	0.00757	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89682620~89686569:-
GBM	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-4.69	7.65e-06	0.00757	-0.33	-0.4	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
GBM	cis	rs9393777	0.513	rs13190754	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26587178	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9379895	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26592479	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs11967852	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26612642	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs7754159	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26620084	chr6:26956992~27023924:+
GBM	cis	rs9379850	0.73	rs9393738	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26620430	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9379905	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26630762	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9295702	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26633812	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9348728	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26634208	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs6936555	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26640658	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.582	rs6936561	ENSG00000224843.5	LINC00240	4.69	7.65e-06	0.00757	0.59	0.4	Intelligence (multi-trait analysis);	chr6:26640667	chr6:26956992~27023924:+
GBM	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	4.69	7.65e-06	0.00757	0.48	0.4	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
GBM	cis	rs2919917	1	rs1966115	ENSG00000254352.1	RP11-578O24.2	4.69	7.66e-06	0.00758	0.49	0.4	Lymphocyte counts;	chr8:78644656	chr8:78723796~78724136:-
GBM	cis	rs2919917	1	rs4609182	ENSG00000254352.1	RP11-578O24.2	4.69	7.66e-06	0.00758	0.49	0.4	Lymphocyte counts;	chr8:78644992	chr8:78723796~78724136:-
GBM	cis	rs2579103	0.708	rs825981	ENSG00000258183.4	RP11-753N8.1	4.69	7.66e-06	0.00758	0.59	0.4	Body mass index;	chr12:90306162	chr12:90280894~90300340:+
GBM	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-4.69	7.66e-06	0.00758	-0.53	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
GBM	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
GBM	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
GBM	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-4.69	7.69e-06	0.0076	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
GBM	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	4.69	7.69e-06	0.0076	0.73	0.4	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
GBM	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	4.69	7.69e-06	0.0076	0.56	0.4	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
GBM	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	4.69	7.7e-06	0.0076	0.47	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	4.69	7.7e-06	0.0076	0.47	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	4.69	7.7e-06	0.0076	0.47	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-4.69	7.7e-06	0.0076	-0.47	-0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
GBM	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	4.69	7.7e-06	0.00761	0.57	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
GBM	cis	rs7017914	0.582	rs7012796	ENSG00000246366.5	RP11-382J12.1	-4.69	7.72e-06	0.00763	-0.43	-0.4	Bone mineral density;	chr8:70763958	chr8:70608577~70663279:+
GBM	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-4.69	7.73e-06	0.00764	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
GBM	cis	rs2976388	1	rs1045574	ENSG00000253741.1	CTD-2292P10.4	4.69	7.73e-06	0.00764	0.41	0.4	Urinary tract infection frequency;	chr8:142682540	chr8:142702252~142726973:-
GBM	cis	rs5742933	0.597	rs6756913	ENSG00000253559.1	OSGEPL1-AS1	4.69	7.73e-06	0.00764	0.44	0.4	Ferritin levels;	chr2:189641040	chr2:189762704~189765556:+
GBM	cis	rs8062405	0.754	rs151179	ENSG00000271623.1	RP11-435I10.5	-4.68	7.74e-06	0.00764	-0.47	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28364700~28365333:+
GBM	cis	rs17685	0.712	rs2158867	ENSG00000280388.1	RP11-229D13.3	-4.68	7.74e-06	0.00764	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76185823	chr7:76043977~76045963:-
GBM	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	4.68	7.75e-06	0.00765	0.55	0.4	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
GBM	cis	rs1908814	0.516	rs4841641	ENSG00000255556.2	RP11-351I21.6	4.68	7.75e-06	0.00765	0.42	0.4	Neuroticism;	chr8:11940718	chr8:12378679~12380265:-
GBM	cis	rs12495178	0.639	rs7627287	ENSG00000239519.1	CADM2-AS1	-4.68	7.76e-06	0.00765	-0.42	-0.4	Body mass index;	chr3:85863363	chr3:85992183~86028007:-
GBM	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-4.68	7.76e-06	0.00766	-0.48	-0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
GBM	cis	rs3960554	0.53	rs6954252	ENSG00000280388.1	RP11-229D13.3	-4.68	7.77e-06	0.00766	-0.41	-0.4	Eotaxin levels;	chr7:76230391	chr7:76043977~76045963:-
GBM	cis	rs9532669	0.89	rs2149570	ENSG00000176268.5	CYCSP34	4.68	7.78e-06	0.00767	0.48	0.4	Cervical cancer;	chr13:40858533	chr13:40863599~40863902:-
GBM	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-4.68	7.78e-06	0.00767	-0.55	-0.4	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
GBM	cis	rs73198271	0.96	rs12155530	ENSG00000253893.2	FAM85B	4.68	7.8e-06	0.00769	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8753454	chr8:8167819~8226614:-
GBM	cis	rs5742933	0.857	rs1233272	ENSG00000253559.1	OSGEPL1-AS1	-4.68	7.8e-06	0.00769	-0.45	-0.4	Ferritin levels;	chr2:189814968	chr2:189762704~189765556:+
GBM	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-4.68	7.8e-06	0.00769	-0.44	-0.4	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
GBM	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	4.68	7.8e-06	0.00769	0.48	0.4	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	4.68	7.8e-06	0.00769	0.48	0.4	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
GBM	cis	rs5752326	0.764	rs5997093	ENSG00000261188.1	CTA-445C9.14	-4.68	7.83e-06	0.00772	-0.62	-0.4	Ischemic stroke;	chr22:26455862	chr22:26512537~26514568:+
GBM	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-4.68	7.84e-06	0.00772	-0.34	-0.4	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
GBM	cis	rs11654801	0.836	rs11654932	ENSG00000233098.7	CCDC144NL-AS1	-4.68	7.84e-06	0.00773	-0.54	-0.4	Mosquito bite size;	chr17:20969634	chr17:20868433~21002276:+
GBM	cis	rs11654801	0.812	rs62056764	ENSG00000233098.7	CCDC144NL-AS1	-4.68	7.84e-06	0.00773	-0.54	-0.4	Mosquito bite size;	chr17:20971832	chr17:20868433~21002276:+
GBM	cis	rs7267979	0.932	rs1541061	ENSG00000276952.1	RP5-965G21.6	4.68	7.87e-06	0.00775	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs6138600	ENSG00000276952.1	RP5-965G21.6	4.68	7.87e-06	0.00775	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.899	rs2104734	ENSG00000276952.1	RP5-965G21.6	4.68	7.87e-06	0.00775	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs6107052	ENSG00000276952.1	RP5-965G21.6	4.68	7.87e-06	0.00775	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25284915~25285588:-
GBM	cis	rs4834770	1	rs4336213	ENSG00000250412.1	KLHL2P1	4.68	7.87e-06	0.00775	0.54	0.4	Blood protein levels;	chr4:119315314	chr4:119334329~119378233:+
GBM	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-4.68	7.87e-06	0.00775	-0.49	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
GBM	cis	rs4273100	0.688	rs12939947	ENSG00000262319.1	CTC-457L16.2	-4.68	7.88e-06	0.00776	-0.47	-0.4	Schizophrenia;	chr17:19301218	chr17:19141017~19143689:-
GBM	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	4.68	7.89e-06	0.00777	0.4	0.4	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	4.68	7.89e-06	0.00777	0.4	0.4	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
GBM	cis	rs4604732	0.536	rs12090434	ENSG00000227135.1	GCSAML-AS1	-4.68	7.89e-06	0.00777	-0.59	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247495984	chr1:247524679~247526752:-
GBM	cis	rs804280	0.509	rs7461273	ENSG00000255556.2	RP11-351I21.6	4.68	7.91e-06	0.00778	0.42	0.4	Myopia (pathological);	chr8:11920468	chr8:12378679~12380265:-
GBM	cis	rs4072705	0.967	rs10818979	ENSG00000224020.1	MIR181A2HG	-4.68	7.91e-06	0.00779	-0.42	-0.4	Menarche (age at onset);	chr9:124574634	chr9:124658467~124698631:+
GBM	cis	rs8067545	0.553	rs35254155	ENSG00000230528.6	NOS2P3	-4.68	7.92e-06	0.00779	-0.51	-0.4	Schizophrenia;	chr17:20020320	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.553	rs4577147	ENSG00000230528.6	NOS2P3	-4.68	7.92e-06	0.00779	-0.51	-0.4	Schizophrenia;	chr17:20040710	chr17:20436337~20447249:+
GBM	cis	rs8067545	0.536	rs62067482	ENSG00000230528.6	NOS2P3	-4.68	7.92e-06	0.00779	-0.51	-0.4	Schizophrenia;	chr17:20043962	chr17:20436337~20447249:+
GBM	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	4.68	7.92e-06	0.00779	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
GBM	cis	rs4604732	0.536	rs61184655	ENSG00000227135.1	GCSAML-AS1	-4.68	7.92e-06	0.00779	-0.58	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247488040	chr1:247524679~247526752:-
GBM	cis	rs4295623	0.789	rs12541318	ENSG00000255556.2	RP11-351I21.6	-4.68	7.92e-06	0.00779	-0.46	-0.4	Morning vs. evening chronotype;	chr8:11737461	chr8:12378679~12380265:-
GBM	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	4.68	7.93e-06	0.0078	0.34	0.4	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
GBM	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	4.68	7.93e-06	0.0078	0.72	0.4	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
GBM	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	4.68	7.94e-06	0.00781	0.48	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
GBM	cis	rs763121	0.853	rs6001188	ENSG00000273076.1	RP3-508I15.22	4.68	7.94e-06	0.00781	0.45	0.4	Menopause (age at onset);	chr22:38666189	chr22:38743495~38743910:+
GBM	cis	rs4713118	0.869	rs9283883	ENSG00000218016.2	ZNF192P2	-4.68	7.94e-06	0.00781	-0.52	-0.4	Parkinson's disease;	chr6:27747691	chr6:28188050~28189432:+
GBM	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	4.68	7.95e-06	0.00782	0.83	0.4	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
GBM	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	4.68	7.95e-06	0.00782	0.83	0.4	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
GBM	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	4.68	7.95e-06	0.00782	0.55	0.4	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
GBM	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	4.68	7.97e-06	0.00783	0.46	0.4	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
GBM	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	4.68	7.97e-06	0.00783	0.46	0.4	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	4.68	7.97e-06	0.00783	0.46	0.4	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
GBM	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-4.68	7.97e-06	0.00783	-0.46	-0.4	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
GBM	cis	rs3096299	0.589	rs3114898	ENSG00000260259.1	RP11-368I7.4	4.68	7.97e-06	0.00783	0.44	0.4	Multiple myeloma (IgH translocation);	chr16:89325907	chr16:89682620~89686569:-
GBM	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-4.68	7.97e-06	0.00783	-0.45	-0.4	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
GBM	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	4.68	7.99e-06	0.00785	0.39	0.4	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	4.68	7.99e-06	0.00785	0.39	0.4	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	4.68	7.99e-06	0.00785	0.39	0.4	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
GBM	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-4.68	8.01e-06	0.00786	-0.5	-0.4	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
GBM	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-4.68	8.02e-06	0.00786	-0.52	-0.4	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
GBM	cis	rs763121	0.853	rs35565791	ENSG00000273076.1	RP3-508I15.22	4.68	8.02e-06	0.00786	0.45	0.4	Menopause (age at onset);	chr22:38667006	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs35522482	ENSG00000273076.1	RP3-508I15.22	4.68	8.02e-06	0.00786	0.45	0.4	Menopause (age at onset);	chr22:38667010	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2072796	ENSG00000273076.1	RP3-508I15.22	4.68	8.02e-06	0.00786	0.45	0.4	Menopause (age at onset);	chr22:38668225	chr22:38743495~38743910:+
GBM	cis	rs4604732	0.578	rs12038656	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460514	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.578	rs112449432	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460878	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.527	rs12031949	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461161	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs1106721	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461374	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs1106720	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461379	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs12039596	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461464	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.578	rs12036417	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461503	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs12039642	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461596	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.574	rs111928142	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461927	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs75600450	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462190	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs74154672	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462323	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs74154673	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462327	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.678	rs74154674	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462383	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs11490198	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462401	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs11490199	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462435	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs74154675	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462534	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs74154676	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462592	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs11490200	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462613	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs56704806	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462846	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs74154678	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462900	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs11490201	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462960	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.589	rs78689516	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462972	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs76761880	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463075	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.536	rs78019731	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463128	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.527	rs77361748	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463173	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.527	rs79329288	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463211	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.578	rs79203328	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463279	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs75320597	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463449	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs35046441	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463510	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs80319072	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463533	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs34330532	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463542	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs34924545	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463590	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs34443739	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463611	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs12036460	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463626	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs10925043	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463699	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs10802509	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463856	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.631	rs7546720	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463927	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.527	rs7539082	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463958	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.578	rs7525209	ENSG00000227135.1	GCSAML-AS1	-4.68	8.02e-06	0.00786	-0.63	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464102	chr1:247524679~247526752:-
GBM	cis	rs7017914	0.905	rs2639898	ENSG00000246366.5	RP11-382J12.1	-4.68	8.02e-06	0.00786	-0.42	-0.4	Bone mineral density;	chr8:71008075	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.84	rs2732099	ENSG00000246366.5	RP11-382J12.1	-4.68	8.02e-06	0.00786	-0.42	-0.4	Bone mineral density;	chr8:71008815	chr8:70608577~70663279:+
GBM	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-4.68	8.02e-06	0.00787	-0.53	-0.4	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-4.68	8.02e-06	0.00787	-0.53	-0.4	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-4.68	8.02e-06	0.00787	-0.53	-0.4	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
GBM	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-4.68	8.03e-06	0.00787	-0.52	-0.4	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
GBM	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	4.68	8.03e-06	0.00787	0.48	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
GBM	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	4.68	8.04e-06	0.00788	0.54	0.4	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
GBM	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	4.68	8.04e-06	0.00788	0.54	0.4	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	4.68	8.04e-06	0.00788	0.54	0.4	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
GBM	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-4.68	8.05e-06	0.00789	-0.5	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
GBM	cis	rs7017914	0.714	rs3110264	ENSG00000246366.5	RP11-382J12.1	-4.67	8.07e-06	0.0079	-0.41	-0.4	Bone mineral density;	chr8:71032045	chr8:70608577~70663279:+
GBM	cis	rs9876781	1	rs6794875	ENSG00000244380.1	RP11-24C3.2	4.67	8.08e-06	0.00791	0.47	0.4	Longevity;	chr3:48414217	chr3:48440352~48446656:-
GBM	cis	rs3845817	0.801	rs2438102	ENSG00000237979.1	AC007389.1	4.67	8.08e-06	0.00791	0.57	0.4	Bipolar disorder;	chr2:65530223	chr2:65500993~65502138:-
GBM	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	4.67	8.09e-06	0.00792	0.48	0.4	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
GBM	cis	rs172166	0.561	rs149976	ENSG00000280107.1	AL022393.9	4.67	8.1e-06	0.00793	0.44	0.4	Cardiac Troponin-T levels;	chr6:28019998	chr6:28170845~28172521:+
GBM	cis	rs9393777	0.513	rs9393737	ENSG00000224843.5	LINC00240	-4.67	8.1e-06	0.00793	-0.59	-0.4	Intelligence (multi-trait analysis);	chr6:26617078	chr6:26956992~27023924:+
GBM	cis	rs67981189	0.593	rs2526847	ENSG00000269927.1	RP6-91H8.3	-4.67	8.1e-06	0.00793	-0.45	-0.4	Schizophrenia;	chr14:70955557	chr14:71141125~71143253:-
GBM	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-4.67	8.11e-06	0.00793	-0.47	-0.4	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	4.67	8.11e-06	0.00793	0.47	0.4	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
GBM	cis	rs9876781	1	rs1109227	ENSG00000244380.1	RP11-24C3.2	4.67	8.11e-06	0.00793	0.46	0.4	Longevity;	chr3:48437797	chr3:48440352~48446656:-
GBM	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-4.67	8.12e-06	0.00794	-0.42	-0.4	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
GBM	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	4.67	8.12e-06	0.00794	0.49	0.4	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
GBM	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	4.67	8.12e-06	0.00794	0.71	0.4	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
GBM	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-4.67	8.13e-06	0.00794	-0.4	-0.4	Temperament;	chr17:13999319	chr17:14024514~14025488:+
GBM	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	4.67	8.14e-06	0.00795	0.47	0.4	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
GBM	cis	rs3096299	0.838	rs3096319	ENSG00000260259.1	RP11-368I7.4	4.67	8.15e-06	0.00795	0.44	0.4	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89682620~89686569:-
GBM	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-4.67	8.16e-06	0.00796	-0.41	-0.4	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-4.67	8.16e-06	0.00796	-0.41	-0.4	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-4.67	8.16e-06	0.00796	-0.41	-0.4	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-4.67	8.16e-06	0.00796	-0.41	-0.4	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-4.67	8.16e-06	0.00796	-0.41	-0.4	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-4.67	8.16e-06	0.00796	-0.41	-0.4	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-4.67	8.16e-06	0.00796	-0.41	-0.4	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
GBM	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	4.67	8.16e-06	0.00796	0.48	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
GBM	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	4.67	8.16e-06	0.00796	0.79	0.4	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
GBM	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	4.67	8.17e-06	0.00797	0.54	0.4	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
GBM	cis	rs4642101	0.64	rs3901666	ENSG00000213943.3	KRT18P17	-4.67	8.18e-06	0.00798	-0.41	-0.4	QRS complex (12-leadsum);	chr3:12782864	chr3:12787393~12788671:-
GBM	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	4.67	8.18e-06	0.00798	0.6	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
GBM	cis	rs4812048	0.793	rs6070693	ENSG00000268649.3	RP4-806M20.4	-4.67	8.19e-06	0.00799	-0.46	-0.4	Mean platelet volume;	chr20:59014461	chr20:58817132~58817725:-
GBM	cis	rs73198271	0.96	rs73198286	ENSG00000253893.2	FAM85B	4.67	8.19e-06	0.00799	0.6	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8754512	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.96	rs73198287	ENSG00000253893.2	FAM85B	4.67	8.19e-06	0.00799	0.6	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8755276	chr8:8167819~8226614:-
GBM	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-4.67	8.2e-06	0.00799	-0.54	-0.4	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-4.67	8.2e-06	0.00799	-0.54	-0.4	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
GBM	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-4.67	8.2e-06	0.00799	-0.54	-0.4	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
GBM	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-4.67	8.2e-06	0.00799	-0.54	-0.4	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-4.67	8.2e-06	0.00799	-0.54	-0.4	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
GBM	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-4.67	8.2e-06	0.00799	-0.56	-0.4	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
GBM	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-4.67	8.21e-06	0.008	-0.53	-0.4	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
GBM	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	4.67	8.22e-06	0.00801	0.62	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	4.67	8.22e-06	0.00801	0.62	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
GBM	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-4.67	8.22e-06	0.00801	-0.48	-0.4	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
GBM	cis	rs11159086	1	rs17100451	ENSG00000270000.1	RP3-449M8.9	4.67	8.24e-06	0.00803	0.6	0.4	Advanced glycation end-product levels;	chr14:74476210	chr14:74471930~74472360:-
GBM	cis	rs950027	0.967	rs2643718	ENSG00000259433.2	CTD-2651B20.4	-4.67	8.25e-06	0.00803	-0.41	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45330209~45332634:-
GBM	cis	rs4713118	0.911	rs9461406	ENSG00000199851.2	U3	-4.67	8.25e-06	0.00804	-0.56	-0.4	Parkinson's disease;	chr6:27751985	chr6:28015568~28015777:+
GBM	cis	rs2965260	0.621	rs17305059	ENSG00000237017.1	AC012314.8	4.67	8.26e-06	0.00804	0.85	0.4	IgG glycosylation;	chr19:53257505	chr19:54119511~54125343:-
GBM	cis	rs11654801	0.812	rs62056765	ENSG00000233098.7	CCDC144NL-AS1	-4.67	8.27e-06	0.00805	-0.54	-0.4	Mosquito bite size;	chr17:20975715	chr17:20868433~21002276:+
GBM	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-4.67	8.27e-06	0.00805	-0.47	-0.4	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
GBM	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	4.67	8.28e-06	0.00806	0.57	0.4	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
GBM	cis	rs7017914	0.967	rs6993170	ENSG00000246366.5	RP11-382J12.1	-4.67	8.29e-06	0.00808	-0.42	-0.4	Bone mineral density;	chr8:70781284	chr8:70608577~70663279:+
GBM	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-4.67	8.3e-06	0.00808	-0.56	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
GBM	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	4.67	8.31e-06	0.00809	0.52	0.4	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
GBM	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	4.67	8.32e-06	0.00809	0.39	0.4	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
GBM	cis	rs10435719	0.61	rs76311455	ENSG00000255556.2	RP11-351I21.6	4.67	8.32e-06	0.0081	0.43	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933017	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.61	rs80269926	ENSG00000255556.2	RP11-351I21.6	4.67	8.32e-06	0.0081	0.43	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933018	chr8:12378679~12380265:-
GBM	cis	rs4664293	0.631	rs13024749	ENSG00000226266.5	AC009961.3	4.67	8.32e-06	0.0081	0.51	0.4	Monocyte percentage of white cells;	chr2:159799606	chr2:159670708~159712435:-
GBM	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	4.67	8.33e-06	0.0081	0.48	0.4	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
GBM	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	4.67	8.33e-06	0.0081	0.44	0.4	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
GBM	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	4.67	8.34e-06	0.00811	0.59	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
GBM	cis	rs3806843	0.766	rs801399	ENSG00000202111.1	VTRNA1-2	4.67	8.34e-06	0.00811	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.766	rs2251860	ENSG00000202111.1	VTRNA1-2	4.67	8.34e-06	0.00811	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.766	rs702397	ENSG00000202111.1	VTRNA1-2	4.67	8.34e-06	0.00811	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs2563333	ENSG00000202111.1	VTRNA1-2	4.67	8.34e-06	0.00811	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140672686	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.766	rs2530239	ENSG00000202111.1	VTRNA1-2	4.67	8.34e-06	0.00811	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr5:140718925~140719013:+
GBM	cis	rs2976388	0.566	rs2585141	ENSG00000253741.1	CTD-2292P10.4	4.67	8.34e-06	0.00811	0.47	0.4	Urinary tract infection frequency;	chr8:142724925	chr8:142702252~142726973:-
GBM	cis	rs763121	0.853	rs2076028	ENSG00000273076.1	RP3-508I15.22	4.67	8.35e-06	0.00812	0.42	0.4	Menopause (age at onset);	chr22:38754445	chr22:38743495~38743910:+
GBM	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-4.67	8.36e-06	0.00813	-0.36	-0.4	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
GBM	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	4.67	8.36e-06	0.00813	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
GBM	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-4.67	8.37e-06	0.00814	-0.45	-0.4	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
GBM	cis	rs7267979	0.866	rs2424699	ENSG00000276952.1	RP5-965G21.6	4.67	8.37e-06	0.00814	0.39	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25284915~25285588:-
GBM	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-4.67	8.37e-06	0.00814	-0.59	-0.4	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
GBM	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	4.67	8.39e-06	0.00815	0.71	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
GBM	cis	rs3096299	0.933	rs2965824	ENSG00000260259.1	RP11-368I7.4	4.67	8.39e-06	0.00816	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89682620~89686569:-
GBM	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-4.67	8.39e-06	0.00816	-0.57	-0.4	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
GBM	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-4.66	8.4e-06	0.00816	-0.44	-0.4	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
GBM	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-4.66	8.41e-06	0.00817	-0.66	-0.4	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
GBM	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-4.66	8.41e-06	0.00818	-0.36	-0.4	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
GBM	cis	rs433852	0.75	rs386243	ENSG00000232871.7	SEC1P	-4.66	8.42e-06	0.00818	-0.53	-0.4	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48624233	chr19:48638071~48682245:+
GBM	cis	rs7267979	0.527	rs6083891	ENSG00000125804.12	FAM182A	4.66	8.42e-06	0.00819	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26054655~26086917:+
GBM	cis	rs893971	0.508	rs1899132	ENSG00000246375.2	RP11-10L7.1	4.66	8.43e-06	0.00819	0.42	0.4	Conduct disorder (maternal expressed emotions interaction);	chr4:88308185	chr4:88284942~88331421:+
GBM	cis	rs12137294	0.866	rs896320	ENSG00000271580.1	RP11-536L3.4	-4.66	8.44e-06	0.0082	-0.38	-0.4	Red cell distribution width;	chr1:205236219	chr1:205091163~205091946:+
GBM	cis	rs12137294	0.866	rs896318	ENSG00000271580.1	RP11-536L3.4	-4.66	8.44e-06	0.0082	-0.38	-0.4	Red cell distribution width;	chr1:205236656	chr1:205091163~205091946:+
GBM	cis	rs12137294	0.794	rs1172160	ENSG00000271580.1	RP11-536L3.4	-4.66	8.44e-06	0.0082	-0.38	-0.4	Red cell distribution width;	chr1:205237887	chr1:205091163~205091946:+
GBM	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-4.66	8.44e-06	0.0082	-0.47	-0.4	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
GBM	cis	rs2720460	0.502	rs223374	ENSG00000248971.2	KRT8P46	-4.66	8.45e-06	0.00821	-0.42	-0.4	Testicular germ cell tumor;	chr4:102837144	chr4:102728746~102730171:-
GBM	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-4.66	8.46e-06	0.00821	-0.42	-0.4	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
GBM	cis	rs17685	0.523	rs10246583	ENSG00000280388.1	RP11-229D13.3	-4.66	8.49e-06	0.00824	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76117349	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs55812043	ENSG00000280388.1	RP11-229D13.3	-4.66	8.49e-06	0.00824	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76117923	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs10264760	ENSG00000280388.1	RP11-229D13.3	-4.66	8.49e-06	0.00824	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76120376	chr7:76043977~76045963:-
GBM	cis	rs7829975	0.774	rs57312668	ENSG00000254340.1	RP11-10A14.3	4.66	8.49e-06	0.00824	0.5	0.4	Mood instability;	chr8:8822967	chr8:9141424~9145435:+
GBM	cis	rs7829975	0.744	rs2409092	ENSG00000254340.1	RP11-10A14.3	4.66	8.49e-06	0.00824	0.5	0.4	Mood instability;	chr8:8824682	chr8:9141424~9145435:+
GBM	cis	rs4713118	0.539	rs200988	ENSG00000199851.2	U3	4.66	8.49e-06	0.00824	0.57	0.4	Parkinson's disease;	chr6:27851575	chr6:28015568~28015777:+
GBM	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-4.66	8.49e-06	0.00824	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
GBM	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	4.66	8.52e-06	0.00826	0.48	0.4	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
GBM	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	4.66	8.52e-06	0.00826	0.48	0.4	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	4.66	8.52e-06	0.00826	0.48	0.4	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	4.66	8.52e-06	0.00826	0.48	0.4	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	4.66	8.52e-06	0.00826	0.48	0.4	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	4.66	8.52e-06	0.00826	0.48	0.4	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	4.66	8.52e-06	0.00826	0.48	0.4	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	4.66	8.52e-06	0.00826	0.48	0.4	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
GBM	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-4.66	8.52e-06	0.00826	-0.56	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
GBM	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-4.66	8.54e-06	0.00828	-0.36	-0.4	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-4.66	8.54e-06	0.00828	-0.36	-0.4	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
GBM	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	4.66	8.54e-06	0.00828	0.36	0.4	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
GBM	cis	rs1908814	0.516	rs58869268	ENSG00000255556.2	RP11-351I21.6	4.66	8.54e-06	0.00828	0.42	0.4	Neuroticism;	chr8:11939586	chr8:12378679~12380265:-
GBM	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	4.66	8.56e-06	0.00829	0.42	0.4	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	4.66	8.56e-06	0.00829	0.42	0.4	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	4.66	8.56e-06	0.00829	0.42	0.4	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	4.66	8.56e-06	0.00829	0.42	0.4	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
GBM	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	4.66	8.56e-06	0.0083	0.47	0.4	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
GBM	cis	rs4834770	1	rs878375	ENSG00000250412.1	KLHL2P1	4.66	8.58e-06	0.00831	0.52	0.4	Blood protein levels;	chr4:119316419	chr4:119334329~119378233:+
GBM	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	4.66	8.58e-06	0.00831	0.48	0.4	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	4.66	8.58e-06	0.00831	0.48	0.4	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	4.66	8.58e-06	0.00831	0.48	0.4	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	4.66	8.58e-06	0.00831	0.48	0.4	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
GBM	cis	rs17685	0.593	rs56265719	ENSG00000280388.1	RP11-229D13.3	-4.66	8.59e-06	0.00831	-0.37	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:76043977~76045963:-
GBM	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	4.66	8.59e-06	0.00832	0.45	0.4	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
GBM	cis	rs3742264	0.656	rs9534258	ENSG00000235903.6	CPB2-AS1	4.66	8.59e-06	0.00832	0.48	0.4	Blood protein levels;	chr13:45946738	chr13:46052806~46113332:+
GBM	cis	rs7267979	0.932	rs928121	ENSG00000276952.1	RP5-965G21.6	4.66	8.6e-06	0.00833	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25284915~25285588:-
GBM	cis	rs2579103	0.625	rs1726065	ENSG00000258183.4	RP11-753N8.1	-4.66	8.6e-06	0.00833	-0.59	-0.4	Body mass index;	chr12:90319369	chr12:90280894~90300340:+
GBM	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-4.66	8.6e-06	0.00833	-0.48	-0.4	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-4.66	8.6e-06	0.00833	-0.48	-0.4	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-4.66	8.6e-06	0.00833	-0.48	-0.4	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
GBM	cis	rs4713118	0.669	rs200997	ENSG00000218016.2	ZNF192P2	-4.66	8.62e-06	0.00834	-0.5	-0.4	Parkinson's disease;	chr6:27844037	chr6:28188050~28189432:+
GBM	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-4.66	8.63e-06	0.00835	-0.61	-0.4	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
GBM	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	4.66	8.64e-06	0.00835	0.7	0.4	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	4.66	8.64e-06	0.00835	0.7	0.4	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
GBM	cis	rs1908814	0.516	rs11996277	ENSG00000255556.2	RP11-351I21.6	4.66	8.64e-06	0.00836	0.42	0.4	Neuroticism;	chr8:11942522	chr8:12378679~12380265:-
GBM	cis	rs1908814	0.516	rs11250178	ENSG00000255556.2	RP11-351I21.6	4.66	8.64e-06	0.00836	0.42	0.4	Neuroticism;	chr8:11942725	chr8:12378679~12380265:-
GBM	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	4.66	8.64e-06	0.00836	0.4	0.4	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
GBM	cis	rs741668	0.931	rs12431359	ENSG00000235903.6	CPB2-AS1	4.66	8.65e-06	0.00836	0.54	0.4	Cerebrospinal fluid clusterin levels;	chr13:45972048	chr13:46052806~46113332:+
GBM	cis	rs4841097	0.806	rs6992247	ENSG00000253893.2	FAM85B	-4.66	8.65e-06	0.00836	-0.5	-0.4	Platelet distribution width;	chr8:9090959	chr8:8167819~8226614:-
GBM	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	4.66	8.66e-06	0.00837	0.38	0.4	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
GBM	cis	rs7267979	0.565	rs6076364	ENSG00000125804.12	FAM182A	4.66	8.66e-06	0.00837	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.565	rs13040726	ENSG00000125804.12	FAM182A	4.66	8.66e-06	0.00837	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26054655~26086917:+
GBM	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-4.66	8.67e-06	0.00838	-0.53	-0.4	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-4.66	8.67e-06	0.00838	-0.53	-0.4	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
GBM	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	4.66	8.67e-06	0.00838	0.54	0.4	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
GBM	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	4.66	8.69e-06	0.00839	0.49	0.4	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
GBM	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	4.66	8.7e-06	0.0084	0.56	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
GBM	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	4.66	8.72e-06	0.00842	0.48	0.4	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
GBM	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	4.66	8.72e-06	0.00842	0.52	0.4	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
GBM	cis	rs10752881	0.905	rs10797830	ENSG00000224468.3	RP11-181K3.4	-4.66	8.74e-06	0.00843	-0.32	-0.4	Colorectal cancer;	chr1:183067139	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.52	rs10797831	ENSG00000224468.3	RP11-181K3.4	-4.66	8.74e-06	0.00843	-0.32	-0.4	Hypertriglyceridemia;	chr1:183067681	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911222	ENSG00000224468.3	RP11-181K3.4	-4.66	8.74e-06	0.00843	-0.32	-0.4	Hypertriglyceridemia;	chr1:183078228	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.935	rs10797834	ENSG00000224468.3	RP11-181K3.4	-4.66	8.74e-06	0.00843	-0.32	-0.4	Colorectal cancer;	chr1:183079614	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.542	rs12128323	ENSG00000224468.3	RP11-181K3.4	-4.66	8.74e-06	0.00843	-0.32	-0.4	Hypertriglyceridemia;	chr1:183080952	chr1:183138402~183141282:-
GBM	cis	rs741668	0.931	rs61953332	ENSG00000235903.6	CPB2-AS1	4.66	8.74e-06	0.00843	0.55	0.4	Cerebrospinal fluid clusterin levels;	chr13:46016139	chr13:46052806~46113332:+
GBM	cis	rs741668	0.894	rs6561282	ENSG00000235903.6	CPB2-AS1	4.66	8.74e-06	0.00843	0.55	0.4	Cerebrospinal fluid clusterin levels;	chr13:46022607	chr13:46052806~46113332:+
GBM	cis	rs741668	0.897	rs56223000	ENSG00000235903.6	CPB2-AS1	4.66	8.74e-06	0.00843	0.55	0.4	Cerebrospinal fluid clusterin levels;	chr13:46028500	chr13:46052806~46113332:+
GBM	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	4.65	8.75e-06	0.00844	0.55	0.4	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
GBM	cis	rs10435719	0.809	rs77601743	ENSG00000255556.2	RP11-351I21.6	4.65	8.76e-06	0.00845	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933060	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.678	rs74724594	ENSG00000255556.2	RP11-351I21.6	4.65	8.76e-06	0.00845	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933067	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.702	rs77055881	ENSG00000255556.2	RP11-351I21.6	4.65	8.76e-06	0.00845	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933072	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.899	rs11250177	ENSG00000255556.2	RP11-351I21.6	4.65	8.77e-06	0.00845	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:12378679~12380265:-
GBM	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	4.65	8.77e-06	0.00845	0.28	0.4	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	4.65	8.77e-06	0.00845	0.28	0.4	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	4.65	8.77e-06	0.00845	0.28	0.4	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	4.65	8.77e-06	0.00845	0.28	0.4	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
GBM	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	4.65	8.78e-06	0.00846	0.55	0.4	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
GBM	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-4.65	8.78e-06	0.00846	-0.41	-0.4	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	4.65	8.78e-06	0.00846	0.41	0.4	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	4.65	8.78e-06	0.00846	0.41	0.4	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
GBM	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-4.65	8.79e-06	0.00846	-0.47	-0.4	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
GBM	cis	rs5742933	0.597	rs7568449	ENSG00000253559.1	OSGEPL1-AS1	4.65	8.8e-06	0.00847	0.45	0.4	Ferritin levels;	chr2:189656328	chr2:189762704~189765556:+
GBM	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-4.65	8.8e-06	0.00847	-0.47	-0.4	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	4.65	8.8e-06	0.00847	0.47	0.4	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	4.65	8.8e-06	0.00847	0.47	0.4	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	4.65	8.8e-06	0.00847	0.47	0.4	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
GBM	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-4.65	8.81e-06	0.00847	-0.5	-0.4	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
GBM	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	4.65	8.81e-06	0.00848	0.56	0.4	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
GBM	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-4.65	8.81e-06	0.00848	-0.44	-0.4	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-4.65	8.81e-06	0.00848	-0.44	-0.4	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
GBM	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-4.65	8.81e-06	0.00848	-0.53	-0.4	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
GBM	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-4.65	8.81e-06	0.00848	-0.53	-0.4	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-4.65	8.81e-06	0.00848	-0.53	-0.4	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
GBM	cis	rs10435719	0.867	rs62493601	ENSG00000255556.2	RP11-351I21.6	4.65	8.82e-06	0.00848	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.753	rs9694940	ENSG00000255556.2	RP11-351I21.6	4.65	8.82e-06	0.00848	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.78	rs9692662	ENSG00000255556.2	RP11-351I21.6	4.65	8.82e-06	0.00848	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.899	rs9693925	ENSG00000255556.2	RP11-351I21.6	4.65	8.82e-06	0.00848	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:12378679~12380265:-
GBM	cis	rs7829975	0.658	rs907181	ENSG00000254340.1	RP11-10A14.3	4.65	8.82e-06	0.00848	0.49	0.4	Mood instability;	chr8:8845365	chr8:9141424~9145435:+
GBM	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	4.65	8.82e-06	0.00848	0.53	0.4	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
GBM	cis	rs7829975	0.774	rs1039915	ENSG00000254340.1	RP11-10A14.3	4.65	8.84e-06	0.0085	0.5	0.4	Mood instability;	chr8:8822104	chr8:9141424~9145435:+
GBM	cis	rs893971	0.527	rs10018448	ENSG00000246375.2	RP11-10L7.1	4.65	8.85e-06	0.0085	0.42	0.4	Conduct disorder (maternal expressed emotions interaction);	chr4:88304019	chr4:88284942~88331421:+
GBM	cis	rs10911232	0.507	rs4652762	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183024825	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4652763	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183024949	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4652765	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183025012	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4651137	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183025165	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4652766	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183025201	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911196	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183026098	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.935	rs10911197	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Colorectal cancer;	chr1:183026264	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs61081633	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183026473	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4642853	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183027107	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4369195	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183027156	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797815	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183027692	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911198	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183028183	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs5022057	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183028626	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911199	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183028901	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797817	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183030001	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs12037585	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183030906	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs12037623	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183031013	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4651138	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183032177	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.901	rs10911201	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Colorectal cancer;	chr1:183032487	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4652767	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183033348	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4129857	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183035412	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797819	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183037776	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4652769	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183040061	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797820	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183042231	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911206	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183043288	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797821	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183043424	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.524	rs10911209	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183044853	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs6664995	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183048210	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797822	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183048634	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs6668980	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183049722	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs28477876	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183050747	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4422969	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183051627	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10752890	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183052775	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10752891	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183054148	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.935	rs4652771	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Colorectal cancer;	chr1:183054368	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.875	rs10797825	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Colorectal cancer;	chr1:183055446	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.524	rs10737238	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183056168	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10732271	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183056763	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs3934578	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183058081	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs3934579	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183058297	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs3934697	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183058377	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4072709	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183059720	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs3935384	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183059835	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10737239	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183061035	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs7547953	ENSG00000224468.3	RP11-181K3.4	-4.65	8.86e-06	0.0085	-0.32	-0.4	Hypertriglyceridemia;	chr1:183062506	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797829	ENSG00000224468.3	RP11-181K3.4	4.65	8.86e-06	0.0085	0.32	0.4	Hypertriglyceridemia;	chr1:183064093	chr1:183138402~183141282:-
GBM	cis	rs4713118	0.869	rs6922574	ENSG00000218016.2	ZNF192P2	-4.65	8.86e-06	0.0085	-0.52	-0.4	Parkinson's disease;	chr6:27725224	chr6:28188050~28189432:+
GBM	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	4.65	8.87e-06	0.00851	0.81	0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
GBM	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-4.65	8.89e-06	0.00853	-0.6	-0.4	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
GBM	cis	rs67981189	0.593	rs7154437	ENSG00000269927.1	RP6-91H8.3	4.65	8.9e-06	0.00854	0.44	0.4	Schizophrenia;	chr14:70974668	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs7160958	ENSG00000269927.1	RP6-91H8.3	4.65	8.9e-06	0.00854	0.44	0.4	Schizophrenia;	chr14:70975809	chr14:71141125~71143253:-
GBM	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	4.65	8.9e-06	0.00854	0.41	0.4	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
GBM	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	4.65	8.9e-06	0.00854	0.48	0.4	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
GBM	cis	rs10028773	0.515	rs9994651	ENSG00000250412.1	KLHL2P1	4.65	8.91e-06	0.00854	0.51	0.4	Educational attainment;	chr4:119666648	chr4:119334329~119378233:+
GBM	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	4.65	8.91e-06	0.00855	0.55	0.4	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
GBM	cis	rs9926296	0.512	rs11076626	ENSG00000260259.1	RP11-368I7.4	-4.65	8.92e-06	0.00855	-0.43	-0.4	Vitiligo;	chr16:89798695	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.533	rs10852623	ENSG00000260259.1	RP11-368I7.4	-4.65	8.92e-06	0.00855	-0.43	-0.4	Vitiligo;	chr16:89798834	chr16:89682620~89686569:-
GBM	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	4.65	8.92e-06	0.00855	0.47	0.4	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
GBM	cis	rs3806843	0.9	rs2261651	ENSG00000202111.1	VTRNA1-2	4.65	8.92e-06	0.00855	0.41	0.4	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.9	rs2337983	ENSG00000202111.1	VTRNA1-2	4.65	8.92e-06	0.00855	0.41	0.4	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr5:140718925~140719013:+
GBM	cis	rs9926296	0.527	rs1800335	ENSG00000260259.1	RP11-368I7.4	-4.65	8.92e-06	0.00855	-0.43	-0.4	Vitiligo;	chr16:89779787	chr16:89682620~89686569:-
GBM	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	4.65	8.93e-06	0.00856	0.28	0.4	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	4.65	8.93e-06	0.00856	0.28	0.4	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
GBM	cis	rs7615952	0.599	rs2279821	ENSG00000250012.1	RP11-124N2.1	-4.65	8.94e-06	0.00857	-0.46	-0.4	Blood pressure (smoking interaction);	chr3:126015465	chr3:126084220~126095349:+
GBM	cis	rs17772222	0.56	rs3742681	ENSG00000222990.1	RNU4-22P	-4.65	8.94e-06	0.00857	-0.42	-0.4	Coronary artery calcification;	chr14:88554903	chr14:88513498~88513663:+
GBM	cis	rs6496932	0.635	rs11632761	ENSG00000218052.5	ADAMTS7P4	-4.65	8.94e-06	0.00857	-0.57	-0.4	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85255369~85330334:-
GBM	cis	rs6496932	0.635	rs67659163	ENSG00000218052.5	ADAMTS7P4	-4.65	8.94e-06	0.00857	-0.57	-0.4	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85255369~85330334:-
GBM	cis	rs7017914	0.69	rs4623462	ENSG00000246366.5	RP11-382J12.1	4.65	8.94e-06	0.00857	0.41	0.4	Bone mineral density;	chr8:71034149	chr8:70608577~70663279:+
GBM	cis	rs73198271	0.96	rs73198290	ENSG00000253893.2	FAM85B	4.65	8.94e-06	0.00857	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758499	chr8:8167819~8226614:-
GBM	cis	rs61041384	0.661	rs77193970	ENSG00000256092.2	RP13-942N8.1	-4.65	8.94e-06	0.00857	-0.91	-0.4	Schizophrenia;	chr12:123031770	chr12:123363868~123366113:+
GBM	cis	rs67981189	0.593	rs2251394	ENSG00000269927.1	RP6-91H8.3	-4.65	8.98e-06	0.0086	-0.44	-0.4	Schizophrenia;	chr14:70969357	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs7147862	ENSG00000269927.1	RP6-91H8.3	-4.65	8.98e-06	0.0086	-0.44	-0.4	Schizophrenia;	chr14:70971485	chr14:71141125~71143253:-
GBM	cis	rs9450351	0.744	rs7741914	ENSG00000203875.9	SNHG5	-4.65	8.98e-06	0.0086	-0.98	-0.4	Interferon gamma-induced protein 10 levels;	chr6:86095057	chr6:85660950~85678736:-
GBM	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-4.65	8.98e-06	0.0086	-0.54	-0.4	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
GBM	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-4.65	8.99e-06	0.00861	-0.5	-0.4	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
GBM	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-4.65	8.99e-06	0.00861	-0.45	-0.4	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
GBM	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-4.65	9e-06	0.00862	-0.55	-0.4	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
GBM	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	4.65	9e-06	0.00862	0.44	0.4	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	4.65	9e-06	0.00862	0.44	0.4	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	4.65	9e-06	0.00862	0.44	0.4	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	4.65	9e-06	0.00862	0.44	0.4	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	4.65	9e-06	0.00862	0.44	0.4	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
GBM	cis	rs3096299	0.566	rs4129126	ENSG00000260259.1	RP11-368I7.4	4.65	9.01e-06	0.00862	0.46	0.4	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89682620~89686569:-
GBM	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
GBM	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
GBM	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-4.65	9.01e-06	0.00862	-0.53	-0.4	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
GBM	cis	rs17772222	0.793	rs7143853	ENSG00000222990.1	RNU4-22P	4.65	9.01e-06	0.00862	0.47	0.4	Coronary artery calcification;	chr14:88578477	chr14:88513498~88513663:+
GBM	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	4.65	9.02e-06	0.00863	0.54	0.4	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
GBM	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	4.65	9.02e-06	0.00863	0.72	0.4	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
GBM	cis	rs7017914	0.69	rs7838421	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70760088	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs2008517	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70944285	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.642	rs2732143	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70963007	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs2639929	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70972413	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs2732133	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70978741	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.629	rs2732120	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70992758	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.714	rs2732119	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70996142	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs2732117	ENSG00000246366.5	RP11-382J12.1	-4.65	9.02e-06	0.00863	-0.41	-0.4	Bone mineral density;	chr8:70996843	chr8:70608577~70663279:+
GBM	cis	rs4568518	0.616	rs17661083	ENSG00000279048.1	RP11-511H23.2	4.65	9.03e-06	0.00864	0.31	0.4	Measles;	chr7:17965230	chr7:17940503~17942922:+
GBM	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-4.65	9.05e-06	0.00865	-0.62	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
GBM	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	4.65	9.05e-06	0.00865	0.54	0.4	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
GBM	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-4.65	9.09e-06	0.00868	-0.52	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
GBM	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	4.65	9.11e-06	0.0087	0.46	0.4	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
GBM	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	4.65	9.11e-06	0.0087	0.46	0.4	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
GBM	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-4.64	9.12e-06	0.0087	-0.53	-0.4	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
GBM	cis	rs7267979	0.932	rs6115214	ENSG00000276952.1	RP5-965G21.6	-4.64	9.12e-06	0.0087	-0.38	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.899	rs2179459	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs2387891	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs6115200	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs6138588	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs4280527	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.899	rs6115213	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs6132848	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs6115215	ENSG00000276952.1	RP5-965G21.6	4.64	9.12e-06	0.0087	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25284915~25285588:-
GBM	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	4.64	9.13e-06	0.00872	0.59	0.4	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
GBM	cis	rs7605378	1	rs7605378	ENSG00000232732.8	AC073043.1	-4.64	9.14e-06	0.00872	-0.52	-0.4	Osteoporosis;	chr2:199812203	chr2:199867396~199911159:-
GBM	cis	rs7605378	1	rs10194076	ENSG00000232732.8	AC073043.1	-4.64	9.14e-06	0.00872	-0.52	-0.4	Osteoporosis;	chr2:199812940	chr2:199867396~199911159:-
GBM	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-4.64	9.14e-06	0.00872	-0.58	-0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs1039911	ENSG00000253893.2	FAM85B	4.64	9.14e-06	0.00872	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	4.64	9.14e-06	0.00872	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	4.64	9.14e-06	0.00872	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	4.64	9.14e-06	0.00872	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
GBM	cis	rs73198271	1	rs4841031	ENSG00000253893.2	FAM85B	4.64	9.14e-06	0.00872	0.57	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749885	chr8:8167819~8226614:-
GBM	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-4.64	9.15e-06	0.00873	-0.47	-0.4	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
GBM	cis	rs16937	0.662	rs12137294	ENSG00000271580.1	RP11-536L3.4	-4.64	9.18e-06	0.00876	-0.37	-0.4	Schizophrenia;	chr1:205213744	chr1:205091163~205091946:+
GBM	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-4.64	9.19e-06	0.00876	-0.52	-0.4	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	4.64	9.19e-06	0.00876	0.52	0.4	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
GBM	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	4.64	9.2e-06	0.00877	0.44	0.4	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
GBM	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-4.64	9.22e-06	0.00878	-0.47	-0.4	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
GBM	cis	rs3742264	0.656	rs9316177	ENSG00000235903.6	CPB2-AS1	-4.64	9.24e-06	0.00879	-0.47	-0.4	Blood protein levels;	chr13:45987676	chr13:46052806~46113332:+
GBM	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-4.64	9.25e-06	0.00881	-0.49	-0.4	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
GBM	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-4.64	9.28e-06	0.00882	-0.49	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
GBM	cis	rs10435719	0.834	rs6985792	ENSG00000255556.2	RP11-351I21.6	4.64	9.29e-06	0.00884	0.42	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:12378679~12380265:-
GBM	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-4.64	9.3e-06	0.00885	-0.52	-0.4	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
GBM	cis	rs11671005	0.735	rs12977592	ENSG00000269473.1	CTD-2619J13.19	4.64	9.31e-06	0.00885	0.42	0.4	Mean platelet volume;	chr19:58449689	chr19:58440448~58445849:+
GBM	cis	rs11098499	1	rs1011054	ENSG00000249244.1	RP11-548H18.2	-4.64	9.32e-06	0.00886	-0.52	-0.4	Corneal astigmatism;	chr4:119281232	chr4:119391831~119395335:-
GBM	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-4.64	9.33e-06	0.00887	-0.39	-0.4	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
GBM	cis	rs73198271	0.722	rs488566	ENSG00000253893.2	FAM85B	4.64	9.35e-06	0.00888	0.56	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8782065	chr8:8167819~8226614:-
GBM	cis	rs28374715	0.51	rs8034073	ENSG00000223313.1	RNU6-516P	4.64	9.36e-06	0.00889	0.51	0.4	Ulcerative colitis;	chr15:41253415	chr15:40529570~40529673:+
GBM	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	4.64	9.36e-06	0.00889	0.54	0.4	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
GBM	cis	rs2712431	0.554	rs2010054	ENSG00000277250.1	Metazoa_SRP	-4.64	9.37e-06	0.0089	-0.42	-0.4	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128673681~128674021:-
GBM	cis	rs7829975	0.686	rs907180	ENSG00000254340.1	RP11-10A14.3	4.64	9.37e-06	0.0089	0.49	0.4	Mood instability;	chr8:8845317	chr8:9141424~9145435:+
GBM	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	4.64	9.37e-06	0.0089	0.47	0.4	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
GBM	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-4.64	9.38e-06	0.00891	-0.48	-0.4	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-4.64	9.38e-06	0.00891	-0.48	-0.4	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
GBM	cis	rs7829975	0.774	rs11775523	ENSG00000254340.1	RP11-10A14.3	4.64	9.39e-06	0.00892	0.5	0.4	Mood instability;	chr8:8821666	chr8:9141424~9145435:+
GBM	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	4.64	9.39e-06	0.00892	0.82	0.4	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	4.64	9.39e-06	0.00892	0.82	0.4	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
GBM	cis	rs832187	0.704	rs832195	ENSG00000280620.1	SCAANT1	-4.64	9.4e-06	0.00892	-0.55	-0.4	Schizophrenia;	chr3:63878936	chr3:63911518~63911772:-
GBM	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	4.64	9.41e-06	0.00893	0.41	0.4	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
GBM	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-4.64	9.41e-06	0.00893	-0.55	-0.4	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
GBM	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-4.64	9.43e-06	0.00895	-0.49	-0.4	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
GBM	cis	rs8114671	0.836	rs6060165	ENSG00000269202.1	RP4-614O4.12	4.64	9.43e-06	0.00895	0.49	0.4	Height;	chr20:35031677	chr20:35201747~35203288:-
GBM	cis	rs3806843	0.966	rs2563267	ENSG00000202111.1	VTRNA1-2	4.64	9.44e-06	0.00895	0.41	0.4	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs2563266	ENSG00000202111.1	VTRNA1-2	4.64	9.44e-06	0.00895	0.41	0.4	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr5:140718925~140719013:+
GBM	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	4.64	9.44e-06	0.00895	0.52	0.4	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
GBM	cis	rs4713118	0.911	rs9461406	ENSG00000218016.2	ZNF192P2	4.64	9.44e-06	0.00896	0.53	0.4	Parkinson's disease;	chr6:27751985	chr6:28188050~28189432:+
GBM	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-4.64	9.46e-06	0.00897	-0.48	-0.4	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
GBM	cis	rs7615952	0.512	rs4679430	ENSG00000242001.1	GS1-388B5.1	4.64	9.46e-06	0.00897	0.59	0.4	Blood pressure (smoking interaction);	chr3:125639049	chr3:125681305~125681453:+
GBM	cis	rs7615952	0.512	rs34651730	ENSG00000242001.1	GS1-388B5.1	4.64	9.46e-06	0.00897	0.59	0.4	Blood pressure (smoking interaction);	chr3:125639796	chr3:125681305~125681453:+
GBM	cis	rs7615952	0.512	rs2979334	ENSG00000242001.1	GS1-388B5.1	4.64	9.46e-06	0.00897	0.59	0.4	Blood pressure (smoking interaction);	chr3:125639980	chr3:125681305~125681453:+
GBM	cis	rs7615952	0.512	rs11929125	ENSG00000242001.1	GS1-388B5.1	4.64	9.46e-06	0.00897	0.59	0.4	Blood pressure (smoking interaction);	chr3:125640599	chr3:125681305~125681453:+
GBM	cis	rs7615952	0.512	rs11921452	ENSG00000242001.1	GS1-388B5.1	4.64	9.46e-06	0.00897	0.59	0.4	Blood pressure (smoking interaction);	chr3:125640906	chr3:125681305~125681453:+
GBM	cis	rs7615952	0.512	rs2922175	ENSG00000242001.1	GS1-388B5.1	4.64	9.46e-06	0.00897	0.59	0.4	Blood pressure (smoking interaction);	chr3:125642516	chr3:125681305~125681453:+
GBM	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-4.64	9.46e-06	0.00897	-0.78	-0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	4.64	9.46e-06	0.00897	0.78	0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	4.64	9.46e-06	0.00897	0.78	0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
GBM	cis	rs67981189	0.593	rs2877708	ENSG00000269927.1	RP6-91H8.3	4.64	9.47e-06	0.00897	0.45	0.4	Schizophrenia;	chr14:71017409	chr14:71141125~71143253:-
GBM	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	4.64	9.47e-06	0.00897	0.55	0.4	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
GBM	cis	rs4072705	1	rs4836985	ENSG00000224020.1	MIR181A2HG	-4.64	9.47e-06	0.00897	-0.44	-0.4	Menarche (age at onset);	chr9:124645615	chr9:124658467~124698631:+
GBM	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-4.64	9.49e-06	0.00899	-0.52	-0.4	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
GBM	cis	rs67981189	0.593	rs10140225	ENSG00000269927.1	RP6-91H8.3	4.64	9.49e-06	0.00899	0.45	0.4	Schizophrenia;	chr14:71024404	chr14:71141125~71143253:-
GBM	cis	rs67981189	0.593	rs10140917	ENSG00000269927.1	RP6-91H8.3	4.64	9.49e-06	0.00899	0.45	0.4	Schizophrenia;	chr14:71025103	chr14:71141125~71143253:-
GBM	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	4.64	9.49e-06	0.00899	0.45	0.4	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
GBM	cis	rs3096299	0.617	rs2353030	ENSG00000260259.1	RP11-368I7.4	-4.63	9.5e-06	0.009	-0.43	-0.4	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89682620~89686569:-
GBM	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-4.63	9.51e-06	0.00901	-0.52	-0.4	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-4.63	9.51e-06	0.00901	-0.52	-0.4	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-4.63	9.51e-06	0.00901	-0.52	-0.4	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
GBM	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-4.63	9.51e-06	0.00901	-0.47	-0.4	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
GBM	cis	rs4713118	0.869	rs9295743	ENSG00000218016.2	ZNF192P2	-4.63	9.52e-06	0.00902	-0.5	-0.4	Parkinson's disease;	chr6:27747323	chr6:28188050~28189432:+
GBM	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	4.63	9.53e-06	0.00902	0.64	0.4	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	4.63	9.53e-06	0.00902	0.64	0.4	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
GBM	cis	rs7267979	0.932	rs431579	ENSG00000276952.1	RP5-965G21.6	4.63	9.53e-06	0.00902	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25284915~25285588:-
GBM	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	4.63	9.54e-06	0.00902	0.54	0.4	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
GBM	cis	rs11098499	0.588	rs2389874	ENSG00000249244.1	RP11-548H18.2	-4.63	9.54e-06	0.00902	-0.46	-0.4	Corneal astigmatism;	chr4:119633836	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.562	rs13101722	ENSG00000249244.1	RP11-548H18.2	-4.63	9.54e-06	0.00902	-0.46	-0.4	Corneal astigmatism;	chr4:119634820	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.562	rs58583086	ENSG00000249244.1	RP11-548H18.2	-4.63	9.54e-06	0.00902	-0.46	-0.4	Corneal astigmatism;	chr4:119635207	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.615	rs59867181	ENSG00000249244.1	RP11-548H18.2	-4.63	9.54e-06	0.00902	-0.46	-0.4	Corneal astigmatism;	chr4:119635312	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.562	rs2389879	ENSG00000249244.1	RP11-548H18.2	-4.63	9.54e-06	0.00902	-0.46	-0.4	Corneal astigmatism;	chr4:119636529	chr4:119391831~119395335:-
GBM	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	4.63	9.54e-06	0.00903	0.68	0.4	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
GBM	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-4.63	9.55e-06	0.00903	-0.57	-0.4	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
GBM	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-4.63	9.57e-06	0.00904	-0.49	-0.4	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
GBM	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	4.63	9.57e-06	0.00905	0.46	0.4	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
GBM	cis	rs67981189	0.529	rs61990380	ENSG00000269927.1	RP6-91H8.3	4.63	9.57e-06	0.00905	0.48	0.4	Schizophrenia;	chr14:71005229	chr14:71141125~71143253:-
GBM	cis	rs4072705	1	rs4838207	ENSG00000224020.1	MIR181A2HG	-4.63	9.58e-06	0.00905	-0.43	-0.4	Menarche (age at onset);	chr9:124756855	chr9:124658467~124698631:+
GBM	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-4.63	9.58e-06	0.00906	-0.49	-0.4	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
GBM	cis	rs3806843	0.735	rs778595	ENSG00000202111.1	VTRNA1-2	4.63	9.6e-06	0.00907	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs2530242	ENSG00000202111.1	VTRNA1-2	4.63	9.6e-06	0.00907	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs2530241	ENSG00000202111.1	VTRNA1-2	4.63	9.6e-06	0.00907	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs2530235	ENSG00000202111.1	VTRNA1-2	4.63	9.6e-06	0.00907	0.42	0.4	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr5:140718925~140719013:+
GBM	cis	rs73198271	1	rs11784958	ENSG00000253893.2	FAM85B	4.63	9.61e-06	0.00908	0.57	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr8:8167819~8226614:-
GBM	cis	rs73198271	1	rs11775476	ENSG00000253893.2	FAM85B	4.63	9.61e-06	0.00908	0.57	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr8:8167819~8226614:-
GBM	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	4.63	9.62e-06	0.00908	0.94	0.4	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
GBM	cis	rs3812049	0.532	rs251390	ENSG00000245937.6	LINC01184	4.63	9.63e-06	0.00909	0.42	0.4	Lymphocyte counts;Red cell distribution width;	chr5:128202654	chr5:127940426~128083172:-
GBM	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	4.63	9.63e-06	0.00909	0.28	0.4	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
GBM	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	4.63	9.64e-06	0.0091	0.5	0.4	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
GBM	cis	rs8177876	0.749	rs804895	ENSG00000261838.4	RP11-303E16.6	-4.63	9.66e-06	0.00912	-0.8	-0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81066108	chr16:81069854~81076598:+
GBM	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	4.63	9.66e-06	0.00912	0.53	0.4	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
GBM	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	4.63	9.67e-06	0.00912	0.65	0.4	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
GBM	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	4.63	9.67e-06	0.00912	0.52	0.4	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
GBM	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-4.63	9.68e-06	0.00913	-0.51	-0.4	Height;	chr11:118781100	chr11:118704607~118750263:+
GBM	cis	rs7615952	0.546	rs2976733	ENSG00000242001.1	GS1-388B5.1	4.63	9.69e-06	0.00914	0.6	0.4	Blood pressure (smoking interaction);	chr3:125695294	chr3:125681305~125681453:+
GBM	cis	rs2526882	0.541	rs2526859	ENSG00000269927.1	RP6-91H8.3	-4.63	9.7e-06	0.00915	-0.44	-0.4	Schizophrenia;	chr14:70945490	chr14:71141125~71143253:-
GBM	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	4.63	9.7e-06	0.00915	0.75	0.4	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
GBM	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	4.63	9.71e-06	0.00915	0.54	0.4	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	4.63	9.71e-06	0.00915	0.54	0.4	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	4.63	9.71e-06	0.00915	0.54	0.4	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	4.63	9.71e-06	0.00915	0.54	0.4	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	4.63	9.71e-06	0.00915	0.54	0.4	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
GBM	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	4.63	9.71e-06	0.00915	0.28	0.4	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	4.63	9.71e-06	0.00915	0.28	0.4	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
GBM	cis	rs1298062	0.756	rs2463241	ENSG00000131401.10	NAPSB	4.63	9.72e-06	0.00916	0.46	0.4	Age of smoking initiation;	chr19:50493704	chr19:50333796~50344767:-
GBM	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-4.63	9.72e-06	0.00916	-0.76	-0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
GBM	cis	rs7267979	0.932	rs433352	ENSG00000276952.1	RP5-965G21.6	-4.63	9.72e-06	0.00916	-0.38	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.866	rs437635	ENSG00000276952.1	RP5-965G21.6	4.63	9.72e-06	0.00916	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.899	rs442834	ENSG00000276952.1	RP5-965G21.6	4.63	9.72e-06	0.00916	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs417110	ENSG00000276952.1	RP5-965G21.6	4.63	9.72e-06	0.00916	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs417130	ENSG00000276952.1	RP5-965G21.6	4.63	9.72e-06	0.00916	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs449703	ENSG00000276952.1	RP5-965G21.6	4.63	9.72e-06	0.00916	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs372678	ENSG00000276952.1	RP5-965G21.6	4.63	9.72e-06	0.00916	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.932	rs424487	ENSG00000276952.1	RP5-965G21.6	4.63	9.72e-06	0.00916	0.38	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25284915~25285588:-
GBM	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	4.63	9.74e-06	0.00917	0.49	0.4	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	4.63	9.74e-06	0.00917	0.49	0.4	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	4.63	9.74e-06	0.00917	0.49	0.4	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
GBM	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	4.63	9.77e-06	0.0092	0.48	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
GBM	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-4.63	9.77e-06	0.0092	-0.51	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
GBM	cis	rs7267979	0.527	rs6076369	ENSG00000125804.12	FAM182A	4.63	9.78e-06	0.0092	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26054655~26086917:+
GBM	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	4.63	9.78e-06	0.00921	0.48	0.4	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
GBM	cis	rs9926296	0.605	rs12448860	ENSG00000260259.1	RP11-368I7.4	-4.63	9.78e-06	0.00921	-0.44	-0.4	Vitiligo;	chr16:89783221	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.605	rs8046243	ENSG00000260259.1	RP11-368I7.4	-4.63	9.78e-06	0.00921	-0.44	-0.4	Vitiligo;	chr16:89785725	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.605	rs12709094	ENSG00000260259.1	RP11-368I7.4	-4.63	9.78e-06	0.00921	-0.44	-0.4	Vitiligo;	chr16:89786609	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.605	rs8047486	ENSG00000260259.1	RP11-368I7.4	-4.63	9.78e-06	0.00921	-0.44	-0.4	Vitiligo;	chr16:89787617	chr16:89682620~89686569:-
GBM	cis	rs2976388	0.566	rs2585146	ENSG00000253741.1	CTD-2292P10.4	-4.63	9.78e-06	0.00921	-0.46	-0.4	Urinary tract infection frequency;	chr8:142717223	chr8:142702252~142726973:-
GBM	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	4.63	9.79e-06	0.00921	0.52	0.4	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
GBM	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	4.63	9.8e-06	0.00922	0.54	0.4	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
GBM	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	4.63	9.8e-06	0.00922	0.54	0.4	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
GBM	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	4.63	9.8e-06	0.00922	0.54	0.4	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
GBM	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	4.63	9.8e-06	0.00922	0.54	0.4	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
GBM	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	4.63	9.8e-06	0.00922	0.54	0.4	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	4.63	9.8e-06	0.00922	0.54	0.4	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
GBM	cis	rs7829975	0.774	rs35039922	ENSG00000254340.1	RP11-10A14.3	4.63	9.81e-06	0.00923	0.5	0.4	Mood instability;	chr8:8817815	chr8:9141424~9145435:+
GBM	cis	rs1150668	0.768	rs1150716	ENSG00000199851.2	U3	4.63	9.81e-06	0.00923	0.5	0.4	Pubertal anthropometrics;	chr6:28294921	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.799	rs2142730	ENSG00000199851.2	U3	4.63	9.81e-06	0.00923	0.5	0.4	Pubertal anthropometrics;	chr6:28298372	chr6:28015568~28015777:+
GBM	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	4.63	9.82e-06	0.00923	0.45	0.4	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	4.63	9.82e-06	0.00923	0.45	0.4	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	4.63	9.82e-06	0.00923	0.45	0.4	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
GBM	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	4.63	9.82e-06	0.00923	0.48	0.4	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
GBM	cis	rs12819124	0.502	rs10875718	ENSG00000258273.1	RP11-370I10.4	-4.63	9.82e-06	0.00924	-0.49	-0.4	Glycated hemoglobin levels;	chr12:48017319	chr12:48333755~48333901:-
GBM	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	4.63	9.82e-06	0.00924	0.45	0.4	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
GBM	cis	rs11098499	0.739	rs10031033	ENSG00000249244.1	RP11-548H18.2	4.63	9.83e-06	0.00925	0.51	0.4	Corneal astigmatism;	chr4:119230297	chr4:119391831~119395335:-
GBM	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	4.63	9.84e-06	0.00925	0.55	0.4	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
GBM	cis	rs3806843	1	rs10053586	ENSG00000202111.1	VTRNA1-2	-4.63	9.85e-06	0.00926	-0.4	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr5:140718925~140719013:+
GBM	cis	rs2681472	0.524	rs7314459	ENSG00000258302.2	RP11-981P6.1	4.63	9.85e-06	0.00926	0.46	0.4	Hypertension;Coronary artery disease;Myocardial infarction;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Systolic blood pressure;Diastolic blood pressure;	chr12:89562564	chr12:89561129~89594878:+
GBM	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-4.63	9.86e-06	0.00927	-0.34	-0.4	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
GBM	cis	rs67340775	0.541	rs200966	ENSG00000199851.2	U3	4.63	9.86e-06	0.00927	0.72	0.4	Lung cancer in ever smokers;	chr6:27894374	chr6:28015568~28015777:+
GBM	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-4.63	9.86e-06	0.00927	-0.47	-0.4	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
GBM	cis	rs4713118	0.669	rs200997	ENSG00000199851.2	U3	4.63	9.88e-06	0.00928	0.53	0.4	Parkinson's disease;	chr6:27844037	chr6:28015568~28015777:+
GBM	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	4.63	9.88e-06	0.00928	0.61	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
GBM	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-4.63	9.88e-06	0.00928	-0.46	-0.4	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
GBM	cis	rs10752881	0.967	rs12404594	ENSG00000224468.3	RP11-181K3.4	-4.62	9.89e-06	0.00929	-0.32	-0.4	Colorectal cancer;	chr1:183018892	chr1:183138402~183141282:-
GBM	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-4.62	9.92e-06	0.00931	-0.68	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
GBM	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	4.62	9.94e-06	0.00933	0.63	0.4	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
GBM	cis	rs4273100	0.512	rs1355128	ENSG00000262319.1	CTC-457L16.2	4.62	9.94e-06	0.00933	0.47	0.4	Schizophrenia;	chr17:19395831	chr17:19141017~19143689:-
GBM	cis	rs4713118	0.911	rs9295746	ENSG00000199851.2	U3	4.62	9.94e-06	0.00933	0.56	0.4	Parkinson's disease;	chr6:27762285	chr6:28015568~28015777:+
GBM	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-4.62	9.96e-06	0.00934	-0.52	-0.4	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
GBM	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	4.62	9.96e-06	0.00935	0.56	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
GBM	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	4.62	9.98e-06	0.00935	0.49	0.4	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
GBM	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	4.62	9.98e-06	0.00936	0.47	0.4	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
GBM	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	4.62	9.99e-06	0.00937	0.53	0.4	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	4.62	9.99e-06	0.00937	0.53	0.4	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
GBM	cis	rs1150668	0.835	rs203869	ENSG00000218016.2	ZNF192P2	-4.62	1e-05	0.00937	-0.44	-0.4	Pubertal anthropometrics;	chr6:28073041	chr6:28188050~28189432:+
GBM	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	4.62	1e-05	0.00937	0.5	0.4	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
GBM	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-4.62	1e-05	0.00938	-0.42	-0.4	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
GBM	cis	rs977747	1	rs61782665	ENSG00000232022.5	FAAHP1	-4.62	1e-05	0.00938	-0.4	-0.4	Body mass index;	chr1:47226363	chr1:46432129~46445521:+
GBM	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-4.62	1e-05	0.00939	-0.47	-0.4	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
GBM	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	4.62	1e-05	0.00939	0.47	0.4	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	4.62	1e-05	0.00939	0.47	0.4	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
GBM	cis	rs17772222	0.917	rs61984684	ENSG00000222990.1	RNU4-22P	4.62	1e-05	0.0094	0.5	0.4	Coronary artery calcification;	chr14:88559104	chr14:88513498~88513663:+
GBM	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-4.62	1e-05	0.0094	-0.59	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
GBM	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	4.62	1e-05	0.0094	0.51	0.4	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
GBM	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	4.62	1e-05	0.0094	0.43	0.4	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
GBM	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	4.62	1e-05	0.00941	0.42	0.4	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
GBM	cis	rs9425766	0.64	rs61827925	ENSG00000270084.1	GAS5-AS1	-4.62	1e-05	0.00941	-0.46	-0.4	Life satisfaction;	chr1:173862619	chr1:173863248~173863941:+
GBM	cis	rs9425766	0.64	rs2067079	ENSG00000270084.1	GAS5-AS1	-4.62	1e-05	0.00941	-0.46	-0.4	Life satisfaction;	chr1:173866073	chr1:173863248~173863941:+
GBM	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	4.62	1.01e-05	0.00941	0.41	0.4	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
GBM	cis	rs2965260	0.621	rs117943561	ENSG00000237017.1	AC012314.8	4.62	1.01e-05	0.00942	0.89	0.4	IgG glycosylation;	chr19:53261469	chr19:54119511~54125343:-
GBM	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-4.62	1.01e-05	0.00942	-0.48	-0.4	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-4.62	1.01e-05	0.00942	-0.48	-0.4	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-4.62	1.01e-05	0.00942	-0.48	-0.4	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-4.62	1.01e-05	0.00942	-0.48	-0.4	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-4.62	1.01e-05	0.00942	-0.48	-0.4	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
GBM	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
GBM	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-4.62	1.01e-05	0.00942	-0.45	-0.4	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
GBM	cis	rs17685	0.712	rs1859794	ENSG00000280388.1	RP11-229D13.3	-4.62	1.01e-05	0.00943	-0.38	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76192226	chr7:76043977~76045963:-
GBM	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	4.62	1.01e-05	0.00943	0.64	0.4	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
GBM	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-4.62	1.01e-05	0.00943	-0.49	-0.4	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
GBM	cis	rs9393777	0.513	rs7740197	ENSG00000224843.5	LINC00240	-4.62	1.01e-05	0.00944	-0.56	-0.4	Intelligence (multi-trait analysis);	chr6:26663250	chr6:26956992~27023924:+
GBM	cis	rs7017914	0.69	rs4074908	ENSG00000246366.5	RP11-382J12.1	4.62	1.01e-05	0.00944	0.41	0.4	Bone mineral density;	chr8:71043097	chr8:70608577~70663279:+
GBM	cis	rs1061377	0.748	rs12506723	ENSG00000249685.1	RP11-360F5.3	4.62	1.01e-05	0.00944	0.51	0.4	Uric acid levels;	chr4:39103152	chr4:39133913~39135608:+
GBM	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-4.62	1.01e-05	0.00945	-0.52	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
GBM	cis	rs3096299	0.934	rs9927904	ENSG00000260259.1	RP11-368I7.4	4.62	1.02e-05	0.00948	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89682620~89686569:-
GBM	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	4.62	1.02e-05	0.0095	0.48	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
GBM	cis	rs4604732	0.536	rs12058821	ENSG00000227135.1	GCSAML-AS1	-4.62	1.02e-05	0.0095	-0.57	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247486349	chr1:247524679~247526752:-
GBM	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-4.62	1.02e-05	0.0095	-0.51	-0.4	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-4.62	1.02e-05	0.0095	-0.51	-0.4	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-4.62	1.02e-05	0.0095	-0.51	-0.4	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-4.62	1.02e-05	0.0095	-0.51	-0.4	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
GBM	cis	rs10911251	0.546	rs20560	ENSG00000224468.3	RP11-181K3.4	-4.62	1.02e-05	0.00951	-0.33	-0.4	Colorectal cancer;	chr1:183136399	chr1:183138402~183141282:-
GBM	cis	rs853679	0.766	rs9368561	ENSG00000199851.2	U3	4.62	1.02e-05	0.00952	0.8	0.4	Depression;	chr6:28200565	chr6:28015568~28015777:+
GBM	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-4.62	1.02e-05	0.00952	-0.45	-0.4	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
GBM	cis	rs11992162	0.967	rs7836456	ENSG00000255556.2	RP11-351I21.6	4.62	1.02e-05	0.00953	0.41	0.4	Monocyte count;	chr8:11971666	chr8:12378679~12380265:-
GBM	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	4.62	1.02e-05	0.00953	0.56	0.4	Depression;	chr6:28251492	chr6:28176188~28176674:+
GBM	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	4.62	1.02e-05	0.00955	0.47	0.4	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
GBM	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-4.62	1.02e-05	0.00955	-0.46	-0.4	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
GBM	cis	rs73198271	0.737	rs565203	ENSG00000253893.2	FAM85B	4.62	1.02e-05	0.00955	0.55	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:8167819~8226614:-
GBM	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-4.62	1.02e-05	0.00956	-0.55	-0.4	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-4.62	1.03e-05	0.00956	-0.55	-0.4	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
GBM	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-4.62	1.03e-05	0.00956	-0.52	-0.4	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
GBM	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-4.62	1.03e-05	0.00956	-0.52	-0.4	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
GBM	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-4.62	1.03e-05	0.00956	-0.52	-0.4	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
GBM	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-4.62	1.03e-05	0.00956	-0.52	-0.4	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
GBM	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-4.62	1.03e-05	0.00957	-0.52	-0.4	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
GBM	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-4.62	1.03e-05	0.00957	-0.42	-0.4	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
GBM	cis	rs5742933	0.857	rs1233284	ENSG00000253559.1	OSGEPL1-AS1	-4.62	1.03e-05	0.00957	-0.44	-0.4	Ferritin levels;	chr2:189825045	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.817	rs1233288	ENSG00000253559.1	OSGEPL1-AS1	-4.62	1.03e-05	0.00957	-0.44	-0.4	Ferritin levels;	chr2:189825999	chr2:189762704~189765556:+
GBM	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-4.62	1.03e-05	0.00959	-0.46	-0.4	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
GBM	cis	rs9786986	0.609	rs16832331	ENSG00000207181.1	SNORA14B	-4.61	1.03e-05	0.00959	-0.67	-0.4	Body mass index;	chr1:235539720	chr1:235127803~235127937:-
GBM	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	4.61	1.03e-05	0.0096	0.48	0.4	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
GBM	cis	rs11992186	0.597	rs11781841	ENSG00000253893.2	FAM85B	4.61	1.03e-05	0.0096	0.48	0.4	Neuroticism;	chr8:8737753	chr8:8167819~8226614:-
GBM	cis	rs10911251	0.546	rs12034436	ENSG00000224468.3	RP11-181K3.4	-4.61	1.03e-05	0.00962	-0.33	-0.4	Colorectal cancer;	chr1:183145662	chr1:183138402~183141282:-
GBM	cis	rs17772222	0.917	rs7157149	ENSG00000222990.1	RNU4-22P	4.61	1.03e-05	0.00963	0.49	0.4	Coronary artery calcification;	chr14:88765501	chr14:88513498~88513663:+
GBM	cis	rs7829975	0.742	rs882462	ENSG00000254340.1	RP11-10A14.3	4.61	1.03e-05	0.00963	0.5	0.4	Mood instability;	chr8:8821020	chr8:9141424~9145435:+
GBM	cis	rs3806843	0.9	rs3756334	ENSG00000202111.1	VTRNA1-2	-4.61	1.03e-05	0.00963	-0.42	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140834211	chr5:140718925~140719013:+
GBM	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	4.61	1.03e-05	0.00963	0.41	0.4	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
GBM	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-4.61	1.03e-05	0.00963	-0.51	-0.4	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
GBM	cis	rs1150668	0.796	rs9468372	ENSG00000199851.2	U3	4.61	1.03e-05	0.00963	0.48	0.4	Pubertal anthropometrics;	chr6:28411584	chr6:28015568~28015777:+
GBM	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	4.61	1.04e-05	0.00964	0.44	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
GBM	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	4.61	1.04e-05	0.00964	0.44	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
GBM	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	4.61	1.04e-05	0.00964	0.5	0.4	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
GBM	cis	rs10911251	0.546	rs7473	ENSG00000224468.3	RP11-181K3.4	-4.61	1.04e-05	0.00964	-0.33	-0.4	Colorectal cancer;	chr1:183145499	chr1:183138402~183141282:-
GBM	cis	rs3806843	0.966	rs2563265	ENSG00000202111.1	VTRNA1-2	4.61	1.04e-05	0.00965	0.41	0.4	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs2563260	ENSG00000202111.1	VTRNA1-2	4.61	1.04e-05	0.00965	0.41	0.4	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr5:140718925~140719013:+
GBM	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-4.61	1.04e-05	0.00967	-0.44	-0.4	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
GBM	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-4.61	1.04e-05	0.00967	-0.44	-0.4	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
GBM	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-4.61	1.04e-05	0.00968	-0.4	-0.4	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
GBM	cis	rs172166	0.561	rs149973	ENSG00000218016.2	ZNF192P2	-4.61	1.04e-05	0.0097	-0.49	-0.4	Cardiac Troponin-T levels;	chr6:28015835	chr6:28188050~28189432:+
GBM	cis	rs172166	0.561	rs149974	ENSG00000218016.2	ZNF192P2	-4.61	1.04e-05	0.0097	-0.49	-0.4	Cardiac Troponin-T levels;	chr6:28017318	chr6:28188050~28189432:+
GBM	cis	rs9393777	0.513	rs13195210	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26646293	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9368447	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26646446	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9393739	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26646738	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9368448	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26649127	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs3999471	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26650078	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9368450	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26652261	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9393741	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26653961	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9379907	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26654090	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs9368451	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26654105	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs13210025	ENSG00000224843.5	LINC00240	4.61	1.04e-05	0.0097	0.57	0.4	Intelligence (multi-trait analysis);	chr6:26654589	chr6:26956992~27023924:+
GBM	cis	rs7615952	0.543	rs4645102	ENSG00000242001.1	GS1-388B5.1	4.61	1.05e-05	0.0097	0.6	0.4	Blood pressure (smoking interaction);	chr3:125705597	chr3:125681305~125681453:+
GBM	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-4.61	1.05e-05	0.00973	-0.68	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
GBM	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	4.61	1.05e-05	0.00973	0.51	0.39	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
GBM	cis	rs17685	0.753	rs4398845	ENSG00000280388.1	RP11-229D13.3	-4.61	1.05e-05	0.00974	-0.36	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76087463	chr7:76043977~76045963:-
GBM	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	4.61	1.05e-05	0.00974	0.5	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
GBM	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	4.61	1.05e-05	0.00974	0.38	0.39	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	4.61	1.05e-05	0.00974	0.38	0.39	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
GBM	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-4.61	1.05e-05	0.00974	-0.53	-0.39	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
GBM	cis	rs2018683	0.803	rs12700920	ENSG00000228421.2	AC005013.5	4.61	1.05e-05	0.00975	0.45	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28957667~28959345:+
GBM	cis	rs2018683	0.933	rs12536127	ENSG00000228421.2	AC005013.5	4.61	1.05e-05	0.00975	0.45	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28957667~28959345:+
GBM	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	4.61	1.05e-05	0.00975	0.52	0.39	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
GBM	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-4.61	1.05e-05	0.00975	-0.52	-0.39	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
GBM	cis	rs9450351	0.744	rs9362247	ENSG00000203875.9	SNHG5	-4.61	1.05e-05	0.00975	-0.93	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85822546	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs6913958	ENSG00000203875.9	SNHG5	-4.61	1.05e-05	0.00975	-0.93	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85825481	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.546	rs9344550	ENSG00000203875.9	SNHG5	-4.61	1.05e-05	0.00975	-0.93	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85829000	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9362248	ENSG00000203875.9	SNHG5	-4.61	1.05e-05	0.00975	-0.93	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85847249	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs6937582	ENSG00000203875.9	SNHG5	-4.61	1.05e-05	0.00975	-0.93	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85855880	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9362250	ENSG00000203875.9	SNHG5	-4.61	1.05e-05	0.00975	-0.93	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85867970	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9342047	ENSG00000203875.9	SNHG5	-4.61	1.05e-05	0.00975	-0.93	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85869115	chr6:85660950~85678736:-
GBM	cis	rs763121	0.719	rs9610995	ENSG00000273076.1	RP3-508I15.22	4.61	1.05e-05	0.00975	0.44	0.39	Menopause (age at onset);	chr22:38661758	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs8142098	ENSG00000273076.1	RP3-508I15.22	4.61	1.05e-05	0.00975	0.44	0.39	Menopause (age at onset);	chr22:38662752	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2413544	ENSG00000273076.1	RP3-508I15.22	4.61	1.05e-05	0.00975	0.44	0.39	Menopause (age at onset);	chr22:38663399	chr22:38743495~38743910:+
GBM	cis	rs763121	0.752	rs5757222	ENSG00000273076.1	RP3-508I15.22	4.61	1.05e-05	0.00975	0.44	0.39	Menopause (age at onset);	chr22:38664468	chr22:38743495~38743910:+
GBM	cis	rs763121	0.819	rs5750658	ENSG00000273076.1	RP3-508I15.22	4.61	1.05e-05	0.00975	0.44	0.39	Menopause (age at onset);	chr22:38664912	chr22:38743495~38743910:+
GBM	cis	rs763121	0.819	rs8137829	ENSG00000273076.1	RP3-508I15.22	4.61	1.05e-05	0.00975	0.44	0.39	Menopause (age at onset);	chr22:38665025	chr22:38743495~38743910:+
GBM	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	4.61	1.05e-05	0.00975	0.5	0.39	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
GBM	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	4.61	1.06e-05	0.00977	0.56	0.39	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
GBM	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-4.61	1.06e-05	0.00977	-0.45	-0.39	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
GBM	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-4.61	1.06e-05	0.00977	-0.45	-0.39	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
GBM	cis	rs1964356	0.524	rs7839585	ENSG00000253893.2	FAM85B	4.61	1.06e-05	0.00977	0.46	0.39	Mean corpuscular volume;	chr8:8996725	chr8:8167819~8226614:-
GBM	cis	rs7017914	0.967	rs59992214	ENSG00000246366.5	RP11-382J12.1	-4.61	1.06e-05	0.00977	-0.43	-0.39	Bone mineral density;	chr8:70687310	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.935	rs35564237	ENSG00000246366.5	RP11-382J12.1	-4.61	1.06e-05	0.00977	-0.43	-0.39	Bone mineral density;	chr8:70688239	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6987007	ENSG00000246366.5	RP11-382J12.1	-4.61	1.06e-05	0.00977	-0.43	-0.39	Bone mineral density;	chr8:70688707	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs62530772	ENSG00000246366.5	RP11-382J12.1	-4.61	1.06e-05	0.00977	-0.43	-0.39	Bone mineral density;	chr8:70689306	chr8:70608577~70663279:+
GBM	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-4.61	1.06e-05	0.00979	-0.48	-0.39	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
GBM	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	4.61	1.06e-05	0.00981	0.61	0.39	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
GBM	cis	rs893363	0.621	rs14165	ENSG00000271916.1	RP11-884K10.6	-4.61	1.06e-05	0.00981	-0.48	-0.39	Axial length;	chr3:53813381	chr3:53797764~53798019:-
GBM	cis	rs3806843	0.733	rs801181	ENSG00000202111.1	VTRNA1-2	4.61	1.06e-05	0.00982	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr5:140718925~140719013:+
GBM	cis	rs3096299	0.702	rs2086824	ENSG00000260259.1	RP11-368I7.4	-4.61	1.06e-05	0.00982	-0.42	-0.39	Multiple myeloma (IgH translocation);	chr16:89404838	chr16:89682620~89686569:-
GBM	cis	rs7267979	0.808	rs84816	ENSG00000276952.1	RP5-965G21.6	4.61	1.06e-05	0.00983	0.37	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25284915~25285588:-
GBM	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	4.61	1.06e-05	0.00983	0.64	0.39	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	4.61	1.06e-05	0.00983	0.64	0.39	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	4.61	1.06e-05	0.00983	0.64	0.39	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	4.61	1.06e-05	0.00983	0.64	0.39	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	4.61	1.06e-05	0.00983	0.64	0.39	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	4.61	1.06e-05	0.00983	0.64	0.39	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
GBM	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	4.61	1.07e-05	0.00984	0.54	0.39	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
GBM	cis	rs4713118	0.786	rs200503	ENSG00000199851.2	U3	4.61	1.07e-05	0.00984	0.57	0.39	Parkinson's disease;	chr6:27818104	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.786	rs200502	ENSG00000199851.2	U3	4.61	1.07e-05	0.00984	0.57	0.39	Parkinson's disease;	chr6:27820284	chr6:28015568~28015777:+
GBM	cis	rs10246939	0.543	rs9640357	ENSG00000261797.1	RP11-744I24.3	-4.61	1.07e-05	0.00984	-0.47	-0.39	Bitter taste perception;	chr7:141843298	chr7:141512698~141513183:-
GBM	cis	rs172166	0.516	rs1225618	ENSG00000218016.2	ZNF192P2	-4.61	1.07e-05	0.00985	-0.46	-0.39	Cardiac Troponin-T levels;	chr6:28161935	chr6:28188050~28189432:+
GBM	cis	rs9876781	1	rs2362452	ENSG00000244380.1	RP11-24C3.2	-4.61	1.07e-05	0.00988	-0.45	-0.39	Longevity;	chr3:48376724	chr3:48440352~48446656:-
GBM	cis	rs6565180	1	rs68051857	ENSG00000183604.13	SMG1P5	-4.61	1.07e-05	0.00989	-0.51	-0.39	Tonsillectomy;	chr16:30348690	chr16:30267553~30335374:-
GBM	cis	rs172166	0.585	rs149963	ENSG00000218016.2	ZNF192P2	-4.6	1.07e-05	0.0099	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28049354	chr6:28188050~28189432:+
GBM	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	4.6	1.07e-05	0.0099	0.55	0.39	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
GBM	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	4.6	1.07e-05	0.0099	0.55	0.39	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
GBM	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	4.6	1.07e-05	0.0099	0.55	0.39	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
GBM	cis	rs7309	0.87	rs2358016	ENSG00000227403.1	AC009299.3	4.6	1.07e-05	0.0099	0.45	0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161244739~161249050:+
GBM	cis	rs832187	0.64	rs3774729	ENSG00000280620.1	SCAANT1	4.6	1.07e-05	0.0099	0.52	0.39	Schizophrenia;	chr3:63996406	chr3:63911518~63911772:-
GBM	cis	rs763121	0.853	rs5757181	ENSG00000273076.1	RP3-508I15.22	4.6	1.07e-05	0.00991	0.44	0.39	Menopause (age at onset);	chr22:38617517	chr22:38743495~38743910:+
GBM	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-4.6	1.07e-05	0.00991	-0.48	-0.39	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
GBM	cis	rs4604732	0.642	rs6426252	ENSG00000227135.1	GCSAML-AS1	-4.6	1.08e-05	0.00992	-0.52	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476585	chr1:247524679~247526752:-
GBM	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	4.6	1.08e-05	0.00995	0.41	0.39	Temperament;	chr17:13996939	chr17:14024514~14025488:+
GBM	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-4.6	1.08e-05	0.00995	-0.46	-0.39	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
GBM	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-4.6	1.08e-05	0.00995	-0.46	-0.39	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
GBM	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-4.6	1.08e-05	0.00995	-0.61	-0.39	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
GBM	cis	rs5742933	0.857	rs1233282	ENSG00000253559.1	OSGEPL1-AS1	-4.6	1.08e-05	0.00996	-0.45	-0.39	Ferritin levels;	chr2:189823518	chr2:189762704~189765556:+
GBM	cis	rs832187	0.629	rs7624403	ENSG00000280620.1	SCAANT1	4.6	1.08e-05	0.00996	0.51	0.39	Schizophrenia;	chr3:63984401	chr3:63911518~63911772:-
GBM	cis	rs12922040	1	rs2075516	ENSG00000279866.1	CTB-193M12.4	-4.6	1.08e-05	0.00997	-0.46	-0.39	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15704410~15705984:+
GBM	cis	rs6496932	0.635	rs4356428	ENSG00000218052.5	ADAMTS7P4	-4.6	1.08e-05	0.00998	-0.57	-0.39	Central corneal thickness;Corneal structure;	chr15:85386349	chr15:85255369~85330334:-
GBM	cis	rs3742264	0.615	rs4941536	ENSG00000235903.6	CPB2-AS1	-4.6	1.08e-05	0.00998	-0.47	-0.39	Blood protein levels;	chr13:45949309	chr13:46052806~46113332:+
GBM	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	4.6	1.08e-05	0.00999	0.77	0.39	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	4.6	1.08e-05	0.00999	0.77	0.39	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
GBM	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-4.6	1.08e-05	0.00999	-0.56	-0.39	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
GBM	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-4.6	1.09e-05	0.01	-0.75	-0.39	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
GBM	cis	rs9876781	0.967	rs9876891	ENSG00000244380.1	RP11-24C3.2	4.6	1.09e-05	0.01	0.45	0.39	Longevity;	chr3:48440024	chr3:48440352~48446656:-
GBM	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	4.6	1.09e-05	0.01	0.53	0.39	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
GBM	cis	rs7605378	1	rs769954	ENSG00000232732.8	AC073043.1	4.6	1.09e-05	0.01	0.51	0.39	Osteoporosis;	chr2:199827436	chr2:199867396~199911159:-
GBM	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	4.6	1.09e-05	0.01	0.51	0.39	Height;	chr11:118758322	chr11:118704607~118750263:+
GBM	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	4.6	1.09e-05	0.01	0.54	0.39	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
GBM	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	4.6	1.09e-05	0.01	0.54	0.39	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
GBM	cis	rs9926296	0.605	rs886952	ENSG00000260259.1	RP11-368I7.4	-4.6	1.09e-05	0.01	-0.42	-0.39	Vitiligo;	chr16:89770373	chr16:89682620~89686569:-
GBM	cis	rs4604732	0.642	rs10925048	ENSG00000227135.1	GCSAML-AS1	-4.6	1.09e-05	0.01	-0.51	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247477434	chr1:247524679~247526752:-
GBM	cis	rs9637599	0.69	rs34813495	ENSG00000246375.2	RP11-10L7.1	4.6	1.09e-05	0.0101	0.45	0.39	Metabolite levels (small molecules and protein measures);	chr4:88291925	chr4:88284942~88331421:+
GBM	cis	rs9637599	0.622	rs7655241	ENSG00000246375.2	RP11-10L7.1	4.6	1.09e-05	0.0101	0.45	0.39	Metabolite levels (small molecules and protein measures);	chr4:88292919	chr4:88284942~88331421:+
GBM	cis	rs453301	0.574	rs10081437	ENSG00000254340.1	RP11-10A14.3	-4.6	1.09e-05	0.0101	-0.47	-0.39	Joint mobility (Beighton score);	chr8:9091469	chr8:9141424~9145435:+
GBM	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-4.6	1.09e-05	0.0101	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
GBM	cis	rs3096299	0.874	rs3102342	ENSG00000260259.1	RP11-368I7.4	4.6	1.09e-05	0.0101	0.42	0.39	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89682620~89686569:-
GBM	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	4.6	1.1e-05	0.0101	0.55	0.39	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
GBM	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	4.6	1.1e-05	0.0101	0.28	0.39	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
GBM	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-4.6	1.1e-05	0.0101	-0.46	-0.39	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
GBM	cis	rs67981189	0.613	rs4531677	ENSG00000269927.1	RP6-91H8.3	4.6	1.1e-05	0.0101	0.44	0.39	Schizophrenia;	chr14:70985144	chr14:71141125~71143253:-
GBM	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	4.6	1.1e-05	0.0101	0.4	0.39	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	4.6	1.1e-05	0.0101	0.4	0.39	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	4.6	1.1e-05	0.0101	0.4	0.39	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	4.6	1.1e-05	0.0101	0.4	0.39	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
GBM	cis	rs11671005	0.61	rs2305122	ENSG00000269600.1	AC016629.3	-4.6	1.1e-05	0.0101	-0.57	-0.39	Mean platelet volume;	chr19:58545385	chr19:58593896~58599355:-
GBM	cis	rs17685	0.712	rs6976236	ENSG00000280388.1	RP11-229D13.3	-4.6	1.1e-05	0.0101	-0.37	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76111769	chr7:76043977~76045963:-
GBM	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	4.6	1.1e-05	0.0101	0.45	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
GBM	cis	rs67340775	0.541	rs169287	ENSG00000199851.2	U3	4.6	1.1e-05	0.0101	0.72	0.39	Lung cancer in ever smokers;	chr6:27886982	chr6:28015568~28015777:+
GBM	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-4.6	1.1e-05	0.0101	-0.44	-0.39	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
GBM	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-4.6	1.1e-05	0.0101	-0.44	-0.39	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
GBM	cis	rs7017914	0.967	rs2933853	ENSG00000246366.5	RP11-382J12.1	-4.6	1.1e-05	0.0101	-0.42	-0.39	Bone mineral density;	chr8:70996987	chr8:70608577~70663279:+
GBM	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	4.6	1.1e-05	0.0101	0.56	0.39	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
GBM	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	4.6	1.1e-05	0.0101	0.52	0.39	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
GBM	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-4.6	1.1e-05	0.0101	-0.52	-0.39	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
GBM	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-4.6	1.1e-05	0.0101	-0.52	-0.39	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
GBM	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-4.6	1.1e-05	0.0101	-0.52	-0.39	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
GBM	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-4.6	1.1e-05	0.0101	-0.52	-0.39	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
GBM	cis	rs1150668	0.796	rs2531825	ENSG00000199851.2	U3	4.6	1.1e-05	0.0101	0.48	0.39	Pubertal anthropometrics;	chr6:28381487	chr6:28015568~28015777:+
GBM	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-4.6	1.1e-05	0.0101	-0.59	-0.39	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
GBM	cis	rs9393777	0.513	rs7759969	ENSG00000224843.5	LINC00240	4.6	1.1e-05	0.0101	0.57	0.39	Intelligence (multi-trait analysis);	chr6:26662868	chr6:26956992~27023924:+
GBM	cis	rs9348729	1	rs9348729	ENSG00000224843.5	LINC00240	4.6	1.1e-05	0.0101	0.57	0.39	Intelligence (multi-trait analysis);	chr6:26664040	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.513	rs1104871	ENSG00000224843.5	LINC00240	4.6	1.1e-05	0.0101	0.57	0.39	Intelligence (multi-trait analysis);	chr6:26665007	chr6:26956992~27023924:+
GBM	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-4.6	1.1e-05	0.0101	-0.44	-0.39	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
GBM	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-4.6	1.1e-05	0.0101	-0.5	-0.39	Height;	chr11:118737823	chr11:118704607~118750263:+
GBM	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-4.6	1.1e-05	0.0101	-0.5	-0.39	Height;	chr11:118737916	chr11:118704607~118750263:+
GBM	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	4.6	1.1e-05	0.0101	0.55	0.39	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	4.6	1.1e-05	0.0101	0.55	0.39	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	4.6	1.1e-05	0.0101	0.55	0.39	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	4.6	1.1e-05	0.0101	0.55	0.39	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	4.6	1.1e-05	0.0101	0.55	0.39	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
GBM	cis	rs4664293	0.867	rs34392518	ENSG00000226266.5	AC009961.3	-4.6	1.1e-05	0.0101	-0.5	-0.39	Monocyte percentage of white cells;	chr2:159749367	chr2:159670708~159712435:-
GBM	cis	rs409045	0.525	rs452688	ENSG00000271874.1	CTD-2024P10.2	-4.6	1.11e-05	0.0102	-0.5	-0.39	Left ventricular mass;	chr5:34628325	chr5:34651457~34651888:-
GBM	cis	rs4273100	0.688	rs1467028	ENSG00000262319.1	CTC-457L16.2	-4.6	1.11e-05	0.0102	-0.47	-0.39	Schizophrenia;	chr17:19271561	chr17:19141017~19143689:-
GBM	cis	rs10971721	0.643	rs7040130	ENSG00000281128.1	PTENP1-AS	4.6	1.11e-05	0.0102	0.85	0.39	Body mass index;	chr9:33785075	chr9:33677268~33688011:+
GBM	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	4.6	1.11e-05	0.0102	0.43	0.39	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
GBM	cis	rs3806843	0.766	rs6848	ENSG00000202111.1	VTRNA1-2	4.6	1.11e-05	0.0102	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr5:140718925~140719013:+
GBM	cis	rs4834770	0.504	rs35703745	ENSG00000250412.1	KLHL2P1	-4.6	1.11e-05	0.0102	-0.54	-0.39	Blood protein levels;	chr4:119398642	chr4:119334329~119378233:+
GBM	cis	rs172166	0.61	rs156737	ENSG00000199851.2	U3	4.6	1.11e-05	0.0102	0.5	0.39	Cardiac Troponin-T levels;	chr6:27927435	chr6:28015568~28015777:+
GBM	cis	rs172166	0.61	rs276369	ENSG00000199851.2	U3	4.6	1.11e-05	0.0102	0.5	0.39	Cardiac Troponin-T levels;	chr6:27951465	chr6:28015568~28015777:+
GBM	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-4.6	1.11e-05	0.0102	-0.47	-0.39	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
GBM	cis	rs8062405	1	rs62036617	ENSG00000271623.1	RP11-435I10.5	-4.59	1.12e-05	0.0102	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28364700~28365333:+
GBM	cis	rs453301	0.686	rs7814328	ENSG00000254340.1	RP11-10A14.3	-4.59	1.12e-05	0.0102	-0.51	-0.39	Joint mobility (Beighton score);	chr8:9018719	chr8:9141424~9145435:+
GBM	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	4.59	1.12e-05	0.0103	0.28	0.39	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
GBM	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-4.59	1.12e-05	0.0103	-0.69	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
GBM	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-4.59	1.12e-05	0.0103	-0.49	-0.39	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
GBM	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	4.59	1.12e-05	0.0103	0.44	0.39	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
GBM	cis	rs454217	0.765	rs392929	ENSG00000277851.1	RP11-756G20.1	4.59	1.12e-05	0.0103	0.42	0.39	Smoking quantity;	chr12:92338016	chr12:92247756~92363832:-
GBM	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	4.59	1.12e-05	0.0103	0.55	0.39	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
GBM	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-4.59	1.12e-05	0.0103	-0.46	-0.39	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
GBM	cis	rs4834770	1	rs4834770	ENSG00000250412.1	KLHL2P1	4.59	1.12e-05	0.0103	0.51	0.39	Blood protein levels;	chr4:119320694	chr4:119334329~119378233:+
GBM	cis	rs4834770	1	rs6823963	ENSG00000250412.1	KLHL2P1	4.59	1.12e-05	0.0103	0.51	0.39	Blood protein levels;	chr4:119321009	chr4:119334329~119378233:+
GBM	cis	rs4834770	1	rs2282688	ENSG00000250412.1	KLHL2P1	4.59	1.12e-05	0.0103	0.51	0.39	Blood protein levels;	chr4:119322567	chr4:119334329~119378233:+
GBM	cis	rs4834770	1	rs10034579	ENSG00000250412.1	KLHL2P1	4.59	1.12e-05	0.0103	0.51	0.39	Blood protein levels;	chr4:119322874	chr4:119334329~119378233:+
GBM	cis	rs17772222	0.701	rs845757	ENSG00000258983.2	RP11-507K2.2	-4.59	1.13e-05	0.0103	-0.41	-0.39	Coronary artery calcification;	chr14:88455372	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.675	rs845769	ENSG00000258983.2	RP11-507K2.2	-4.59	1.13e-05	0.0103	-0.41	-0.39	Coronary artery calcification;	chr14:88461455	chr14:88499334~88515502:+
GBM	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-4.59	1.13e-05	0.0103	-0.51	-0.39	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-4.59	1.13e-05	0.0103	-0.51	-0.39	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-4.59	1.13e-05	0.0103	-0.51	-0.39	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
GBM	cis	rs10028773	0.515	rs9994651	ENSG00000249244.1	RP11-548H18.2	4.59	1.13e-05	0.0103	0.49	0.39	Educational attainment;	chr4:119666648	chr4:119391831~119395335:-
GBM	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-4.59	1.13e-05	0.0103	-0.45	-0.39	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
GBM	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-4.59	1.13e-05	0.0103	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-4.59	1.13e-05	0.0103	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-4.59	1.13e-05	0.0103	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
GBM	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-4.59	1.13e-05	0.0103	-0.49	-0.39	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
GBM	cis	rs7017914	0.811	rs4272413	ENSG00000246366.5	RP11-382J12.1	-4.59	1.14e-05	0.0104	-0.43	-0.39	Bone mineral density;	chr8:70723952	chr8:70608577~70663279:+
GBM	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	4.59	1.14e-05	0.0104	0.5	0.39	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
GBM	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	4.59	1.14e-05	0.0104	0.52	0.39	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
GBM	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	4.59	1.14e-05	0.0104	0.52	0.39	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
GBM	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	4.59	1.14e-05	0.0104	0.52	0.39	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
GBM	cis	rs4713118	0.911	rs2394000	ENSG00000199851.2	U3	4.59	1.14e-05	0.0104	0.56	0.39	Parkinson's disease;	chr6:27719212	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9393847	ENSG00000199851.2	U3	4.59	1.14e-05	0.0104	0.56	0.39	Parkinson's disease;	chr6:27720194	chr6:28015568~28015777:+
GBM	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-4.59	1.14e-05	0.0104	-0.49	-0.39	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
GBM	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-4.59	1.14e-05	0.0104	-0.49	-0.39	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
GBM	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-4.59	1.14e-05	0.0104	-0.45	-0.39	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
GBM	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-4.59	1.14e-05	0.0104	-0.45	-0.39	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
GBM	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-4.59	1.14e-05	0.0104	-0.75	-0.39	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
GBM	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-4.59	1.14e-05	0.0104	-0.75	-0.39	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
GBM	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-4.59	1.14e-05	0.0104	-0.75	-0.39	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
GBM	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-4.59	1.14e-05	0.0104	-0.39	-0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
GBM	cis	rs2086824	0.702	rs3114891	ENSG00000260259.1	RP11-368I7.4	4.59	1.14e-05	0.0104	0.43	0.39	Multiple myeloma (IgH translocation);	chr16:89333047	chr16:89682620~89686569:-
GBM	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	4.59	1.14e-05	0.0104	0.4	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
GBM	cis	rs8062405	0.721	rs151303	ENSG00000271623.1	RP11-435I10.5	-4.59	1.14e-05	0.0104	-0.46	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28364700~28365333:+
GBM	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	4.59	1.14e-05	0.0104	0.42	0.39	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.546	rs7187436	ENSG00000260259.1	RP11-368I7.4	-4.59	1.15e-05	0.0104	-0.43	-0.39	Vitiligo;	chr16:89778702	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.585	rs1800337	ENSG00000260259.1	RP11-368I7.4	-4.59	1.15e-05	0.0104	-0.43	-0.39	Vitiligo;	chr16:89778786	chr16:89682620~89686569:-
GBM	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
GBM	cis	rs11654801	0.812	rs11204325	ENSG00000233098.7	CCDC144NL-AS1	-4.59	1.15e-05	0.0104	-0.52	-0.39	Mosquito bite size;	chr17:20948733	chr17:20868433~21002276:+
GBM	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
GBM	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	4.59	1.15e-05	0.0105	0.4	0.39	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	4.59	1.15e-05	0.0105	0.4	0.39	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	4.59	1.15e-05	0.0105	0.4	0.39	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	4.59	1.15e-05	0.0105	0.4	0.39	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	4.59	1.15e-05	0.0105	0.4	0.39	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
GBM	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-4.59	1.15e-05	0.0105	-0.46	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	4.59	1.15e-05	0.0105	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
GBM	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-4.59	1.15e-05	0.0105	-0.72	-0.39	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
GBM	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-4.59	1.15e-05	0.0105	-0.54	-0.39	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
GBM	cis	rs9637599	0.69	rs13128713	ENSG00000246375.2	RP11-10L7.1	4.59	1.15e-05	0.0105	0.45	0.39	Metabolite levels (small molecules and protein measures);	chr4:88289453	chr4:88284942~88331421:+
GBM	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	4.59	1.15e-05	0.0105	0.54	0.39	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
GBM	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	4.59	1.16e-05	0.0105	0.51	0.39	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
GBM	cis	rs4072705	0.967	rs6478677	ENSG00000224020.1	MIR181A2HG	-4.59	1.16e-05	0.0105	-0.42	-0.39	Menarche (age at onset);	chr9:124659900	chr9:124658467~124698631:+
GBM	cis	rs10911232	0.507	rs6672306	ENSG00000224468.3	RP11-181K3.4	-4.59	1.16e-05	0.0106	-0.31	-0.39	Hypertriglyceridemia;	chr1:183089763	chr1:183138402~183141282:-
GBM	cis	rs172166	0.585	rs149963	ENSG00000199851.2	U3	4.58	1.16e-05	0.0106	0.5	0.39	Cardiac Troponin-T levels;	chr6:28049354	chr6:28015568~28015777:+
GBM	cis	rs7829975	0.714	rs59046059	ENSG00000254340.1	RP11-10A14.3	4.58	1.17e-05	0.0106	0.49	0.39	Mood instability;	chr8:8813226	chr8:9141424~9145435:+
GBM	cis	rs73198271	0.96	rs11778970	ENSG00000253893.2	FAM85B	4.58	1.17e-05	0.0106	0.58	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.96	rs10503392	ENSG00000253893.2	FAM85B	4.58	1.17e-05	0.0106	0.58	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.96	rs73198288	ENSG00000253893.2	FAM85B	4.58	1.17e-05	0.0106	0.58	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756430	chr8:8167819~8226614:-
GBM	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-4.58	1.17e-05	0.0106	-0.4	-0.39	Temperament;	chr17:14033087	chr17:14024514~14025488:+
GBM	cis	rs4604732	0.631	rs12031721	ENSG00000227135.1	GCSAML-AS1	-4.58	1.17e-05	0.0106	-0.62	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460471	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs12045675	ENSG00000227135.1	GCSAML-AS1	-4.58	1.17e-05	0.0106	-0.62	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460613	chr1:247524679~247526752:-
GBM	cis	rs893971	0.646	rs1595910	ENSG00000246375.2	RP11-10L7.1	4.58	1.17e-05	0.0106	0.45	0.39	Conduct disorder (maternal expressed emotions interaction);	chr4:88311420	chr4:88284942~88331421:+
GBM	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-4.58	1.18e-05	0.0107	-0.48	-0.39	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
GBM	cis	rs4604732	0.536	rs10925056	ENSG00000227135.1	GCSAML-AS1	-4.58	1.18e-05	0.0107	-0.57	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247487170	chr1:247524679~247526752:-
GBM	cis	rs4266144	0.592	rs1545854	ENSG00000243629.1	LINC00880	4.58	1.18e-05	0.0107	0.49	0.39	Coronary artery disease;	chr3:157122349	chr3:157081667~157123004:-
GBM	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	4.58	1.18e-05	0.0107	0.65	0.39	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	4.58	1.18e-05	0.0107	0.65	0.39	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
GBM	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	4.58	1.18e-05	0.0107	0.51	0.39	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
GBM	cis	rs9876781	1	rs9883927	ENSG00000244380.1	RP11-24C3.2	4.58	1.18e-05	0.0107	0.46	0.39	Longevity;	chr3:48422302	chr3:48440352~48446656:-
GBM	cis	rs17685	0.712	rs11770149	ENSG00000280388.1	RP11-229D13.3	-4.58	1.18e-05	0.0107	-0.36	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:76043977~76045963:-
GBM	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	4.58	1.18e-05	0.0107	0.39	0.39	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
GBM	cis	rs3812049	0.532	rs251216	ENSG00000245937.6	LINC01184	4.58	1.18e-05	0.0107	0.43	0.39	Lymphocyte counts;Red cell distribution width;	chr5:128207588	chr5:127940426~128083172:-
GBM	cis	rs11671005	0.735	rs45617039	ENSG00000269473.1	CTD-2619J13.19	4.58	1.18e-05	0.0107	0.43	0.39	Mean platelet volume;	chr19:58439729	chr19:58440448~58445849:+
GBM	cis	rs763121	0.853	rs5750627	ENSG00000273076.1	RP3-508I15.22	4.58	1.18e-05	0.0107	0.43	0.39	Menopause (age at onset);	chr22:38586316	chr22:38743495~38743910:+
GBM	cis	rs453301	0.658	rs6986044	ENSG00000254340.1	RP11-10A14.3	-4.58	1.19e-05	0.0107	-0.5	-0.39	Joint mobility (Beighton score);	chr8:9017276	chr8:9141424~9145435:+
GBM	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-4.58	1.19e-05	0.0107	-0.52	-0.39	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
GBM	cis	rs3806843	0.712	rs2530244	ENSG00000202111.1	VTRNA1-2	4.58	1.19e-05	0.0107	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140729570	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.801	rs801170	ENSG00000202111.1	VTRNA1-2	4.58	1.19e-05	0.0107	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140735758	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs10477033	ENSG00000202111.1	VTRNA1-2	-4.58	1.19e-05	0.0107	-0.4	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140790018	chr5:140718925~140719013:+
GBM	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	4.58	1.19e-05	0.0107	0.44	0.39	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
GBM	cis	rs4713118	0.869	rs9366700	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27729172	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs9393851	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27731802	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs9461400	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27732780	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs9295742	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27735053	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs9461401	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27735512	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs6914924	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27743751	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs6930992	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27744341	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs6901520	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27746796	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs9461405	ENSG00000218016.2	ZNF192P2	-4.58	1.19e-05	0.0107	-0.5	-0.39	Parkinson's disease;	chr6:27751596	chr6:28188050~28189432:+
GBM	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-4.58	1.19e-05	0.0107	-0.47	-0.39	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
GBM	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	4.58	1.19e-05	0.0108	0.46	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
GBM	cis	rs3806843	0.766	rs801176	ENSG00000202111.1	VTRNA1-2	-4.58	1.19e-05	0.0108	-0.41	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140707425	chr5:140718925~140719013:+
GBM	cis	rs9450351	0.744	rs9344559	ENSG00000203875.9	SNHG5	-4.58	1.19e-05	0.0108	-0.94	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86012192	chr6:85660950~85678736:-
GBM	cis	rs55940216	0.615	rs2027924	ENSG00000245281.5	CTD-2547L16.1	4.58	1.19e-05	0.0108	0.45	0.39	Facial morphology (factor 14, intercanthal width);	chr8:18126214	chr8:18084868~18096394:+
GBM	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	4.58	1.19e-05	0.0108	0.48	0.39	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.714	rs11784052	ENSG00000254340.1	RP11-10A14.3	4.58	1.2e-05	0.0108	0.48	0.39	Mood instability;	chr8:8814452	chr8:9141424~9145435:+
GBM	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	4.58	1.2e-05	0.0108	0.41	0.39	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
GBM	cis	rs9876781	1	rs11130171	ENSG00000244380.1	RP11-24C3.2	4.58	1.2e-05	0.0108	0.46	0.39	Longevity;	chr3:48421052	chr3:48440352~48446656:-
GBM	cis	rs16937	0.64	rs6664706	ENSG00000271580.1	RP11-536L3.4	-4.58	1.2e-05	0.0108	-0.36	-0.39	Schizophrenia;	chr1:205213435	chr1:205091163~205091946:+
GBM	cis	rs9876781	1	rs9817615	ENSG00000244380.1	RP11-24C3.2	4.58	1.2e-05	0.0108	0.46	0.39	Longevity;	chr3:48429347	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs2290822	ENSG00000244380.1	RP11-24C3.2	4.58	1.2e-05	0.0108	0.46	0.39	Longevity;	chr3:48431794	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs13076076	ENSG00000244380.1	RP11-24C3.2	4.58	1.2e-05	0.0108	0.46	0.39	Longevity;	chr3:48437629	chr3:48440352~48446656:-
GBM	cis	rs17767294	0.612	rs9461424	ENSG00000199851.2	U3	4.58	1.2e-05	0.0108	0.9	0.39	Parkinson's disease;	chr6:27951623	chr6:28015568~28015777:+
GBM	cis	rs4834770	1	rs4834771	ENSG00000250412.1	KLHL2P1	4.58	1.2e-05	0.0108	0.5	0.39	Blood protein levels;	chr4:119321617	chr4:119334329~119378233:+
GBM	cis	rs4834770	1	rs1397613	ENSG00000250412.1	KLHL2P1	4.58	1.2e-05	0.0108	0.5	0.39	Blood protein levels;	chr4:119321774	chr4:119334329~119378233:+
GBM	cis	rs4834770	1	rs6857641	ENSG00000250412.1	KLHL2P1	4.58	1.2e-05	0.0108	0.5	0.39	Blood protein levels;	chr4:119322356	chr4:119334329~119378233:+
GBM	cis	rs7017914	0.967	rs1477944	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70703365	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs17760497	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70704810	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs34677078	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70705480	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs62530792	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70706532	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs35893260	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70707838	chr8:70608577~70663279:+
GBM	cis	rs7017914	1	rs13253842	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70713268	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13254908	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70713863	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13264669	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70714537	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs34508469	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70716228	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6472539	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70717575	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs56043721	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70718192	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.935	rs6981435	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70724913	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6999739	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70724977	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs7013657	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70725324	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs7006615	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70727572	chr8:70608577~70663279:+
GBM	cis	rs7017914	1	rs7007450	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70728034	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs11989553	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70728664	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13272523	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70729237	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs62530826	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70729408	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs35295900	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70729826	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs35115527	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70730774	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs11991273	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70733625	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.869	rs11987511	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70733636	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs7015035	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70741366	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6982406	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70742373	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs1902614	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70743932	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs34905858	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70747215	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs6998024	ENSG00000246366.5	RP11-382J12.1	-4.58	1.2e-05	0.0108	-0.43	-0.39	Bone mineral density;	chr8:70748605	chr8:70608577~70663279:+
GBM	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-4.58	1.2e-05	0.0108	-0.53	-0.39	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
GBM	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	4.58	1.2e-05	0.0108	0.54	0.39	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
GBM	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-4.58	1.2e-05	0.0108	-0.53	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
GBM	cis	rs7181230	0.885	rs3923235	ENSG00000275636.1	RP11-521C20.5	4.58	1.2e-05	0.0108	0.5	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40078920	chr15:40078892~40079347:+
GBM	cis	rs1555322	1	rs2425041	ENSG00000126005.14	MMP24-AS1	-4.58	1.21e-05	0.0108	-0.68	-0.39	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35216462~35278131:-
GBM	cis	rs741668	0.931	rs17350833	ENSG00000235903.6	CPB2-AS1	4.58	1.21e-05	0.0109	0.53	0.39	Cerebrospinal fluid clusterin levels;	chr13:45963622	chr13:46052806~46113332:+
GBM	cis	rs1555322	0.932	rs1205411	ENSG00000126005.14	MMP24-AS1	-4.58	1.21e-05	0.0109	-0.68	-0.39	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35216462~35278131:-
GBM	cis	rs8114671	0.836	rs1885114	ENSG00000269202.1	RP4-614O4.12	4.58	1.21e-05	0.0109	0.5	0.39	Height;	chr20:34989558	chr20:35201747~35203288:-
GBM	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	4.58	1.21e-05	0.0109	0.44	0.39	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
GBM	cis	rs7267979	0.528	rs2387976	ENSG00000125804.12	FAM182A	4.58	1.21e-05	0.0109	0.51	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26054655~26086917:+
GBM	cis	rs9876781	1	rs2242150	ENSG00000244380.1	RP11-24C3.2	-4.58	1.21e-05	0.0109	-0.45	-0.39	Longevity;	chr3:48464565	chr3:48440352~48446656:-
GBM	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	4.58	1.21e-05	0.0109	0.49	0.39	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
GBM	cis	rs832187	0.64	rs831692	ENSG00000280620.1	SCAANT1	4.58	1.21e-05	0.0109	0.53	0.39	Schizophrenia;	chr3:64018307	chr3:63911518~63911772:-
GBM	cis	rs893971	0.674	rs28789746	ENSG00000246375.2	RP11-10L7.1	4.57	1.21e-05	0.0109	0.44	0.39	Conduct disorder (maternal expressed emotions interaction);	chr4:88309350	chr4:88284942~88331421:+
GBM	cis	rs950169	1	rs950169	ENSG00000275120.1	RP11-182J1.17	4.57	1.22e-05	0.0109	0.52	0.39	Schizophrenia;	chr15:84037709	chr15:84599434~84606463:-
GBM	cis	rs950169	0.92	rs2135551	ENSG00000275120.1	RP11-182J1.17	4.57	1.22e-05	0.0109	0.52	0.39	Schizophrenia;	chr15:84039099	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs12902672	ENSG00000275120.1	RP11-182J1.17	4.57	1.22e-05	0.0109	0.52	0.39	Schizophrenia;	chr15:84048234	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs12903820	ENSG00000275120.1	RP11-182J1.17	4.57	1.22e-05	0.0109	0.52	0.39	Schizophrenia;	chr15:84055068	chr15:84599434~84606463:-
GBM	cis	rs7017914	0.967	rs7814648	ENSG00000246366.5	RP11-382J12.1	-4.57	1.22e-05	0.0109	-0.43	-0.39	Bone mineral density;	chr8:70691749	chr8:70608577~70663279:+
GBM	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	4.57	1.22e-05	0.0109	0.41	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
GBM	cis	rs17214007	0.518	rs56374730	ENSG00000279866.1	CTB-193M12.4	4.57	1.22e-05	0.0109	0.51	0.39	Cognitive function;	chr16:15773795	chr16:15704410~15705984:+
GBM	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-4.57	1.22e-05	0.0109	-0.51	-0.39	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
GBM	cis	rs2287838	0.668	rs12979274	ENSG00000267289.1	CTD-2623N2.11	4.57	1.22e-05	0.0109	0.45	0.39	Sleep duration;	chr19:9890249	chr19:9834079~9835013:-
GBM	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	4.57	1.22e-05	0.011	0.5	0.39	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
GBM	cis	rs7017914	0.69	rs62508859	ENSG00000246366.5	RP11-382J12.1	-4.57	1.22e-05	0.011	-0.41	-0.39	Bone mineral density;	chr8:70828699	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.653	rs6983845	ENSG00000246366.5	RP11-382J12.1	-4.57	1.22e-05	0.011	-0.41	-0.39	Bone mineral density;	chr8:70834245	chr8:70608577~70663279:+
GBM	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	4.57	1.22e-05	0.011	0.45	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
GBM	cis	rs3742264	0.656	rs6561274	ENSG00000235903.6	CPB2-AS1	4.57	1.23e-05	0.011	0.48	0.39	Blood protein levels;	chr13:45943961	chr13:46052806~46113332:+
GBM	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-4.57	1.23e-05	0.011	-0.52	-0.39	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
GBM	cis	rs11992162	0.967	rs10088415	ENSG00000255556.2	RP11-351I21.6	-4.57	1.23e-05	0.011	-0.39	-0.39	Monocyte count;	chr8:11973316	chr8:12378679~12380265:-
GBM	cis	rs17361889	0.727	rs62440406	ENSG00000224683.1	RPL36AP29	4.57	1.23e-05	0.011	0.45	0.39	Pediatric bone mineral content (hip);	chr7:16245394	chr7:16208945~16209265:+
GBM	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	4.57	1.23e-05	0.011	0.65	0.39	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
GBM	cis	rs3096299	0.935	rs3102387	ENSG00000260259.1	RP11-368I7.4	4.57	1.23e-05	0.011	0.43	0.39	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89682620~89686569:-
GBM	cis	rs12137294	0.866	rs1172156	ENSG00000271580.1	RP11-536L3.4	-4.57	1.23e-05	0.011	-0.38	-0.39	Red cell distribution width;	chr1:205250959	chr1:205091163~205091946:+
GBM	cis	rs11992162	0.967	rs10112888	ENSG00000255556.2	RP11-351I21.6	4.57	1.23e-05	0.011	0.4	0.39	Monocyte count;	chr8:11972699	chr8:12378679~12380265:-
GBM	cis	rs2579103	1	rs2918621	ENSG00000258183.4	RP11-753N8.1	-4.57	1.23e-05	0.011	-0.53	-0.39	Body mass index;	chr12:90213775	chr12:90280894~90300340:+
GBM	cis	rs7017914	0.967	rs3954897	ENSG00000246366.5	RP11-382J12.1	-4.57	1.23e-05	0.011	-0.42	-0.39	Bone mineral density;	chr8:70723720	chr8:70608577~70663279:+
GBM	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-4.57	1.23e-05	0.011	-0.44	-0.39	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-4.57	1.23e-05	0.011	-0.44	-0.39	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-4.57	1.23e-05	0.011	-0.44	-0.39	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-4.57	1.23e-05	0.011	-0.44	-0.39	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-4.57	1.23e-05	0.011	-0.44	-0.39	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
GBM	cis	rs3131337	1	rs3131337	ENSG00000219392.1	RP1-265C24.5	-4.57	1.23e-05	0.0111	-0.95	-0.39	Cold sores;	chr6:28828294	chr6:28115628~28116551:+
GBM	cis	rs7267979	0.714	rs6132825	ENSG00000125804.12	FAM182A	-4.57	1.24e-05	0.0111	-0.47	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:26054655~26086917:+
GBM	cis	rs2980439	0.517	rs17594093	ENSG00000253893.2	FAM85B	4.57	1.24e-05	0.0111	0.52	0.39	Neuroticism;	chr8:8248884	chr8:8167819~8226614:-
GBM	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
GBM	cis	rs950776	0.695	rs1878399	ENSG00000261762.1	RP11-650L12.2	-4.57	1.24e-05	0.0111	-0.56	-0.39	Sudden cardiac arrest;	chr15:78619661	chr15:78589123~78591276:-
GBM	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	4.57	1.24e-05	0.0111	0.77	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	4.57	1.24e-05	0.0111	0.77	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs1563077	ENSG00000261838.4	RP11-303E16.6	4.57	1.24e-05	0.0111	0.77	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	4.57	1.24e-05	0.0111	0.77	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	4.57	1.24e-05	0.0111	0.77	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
GBM	cis	rs11992162	1	rs11784499	ENSG00000255556.2	RP11-351I21.6	4.57	1.24e-05	0.0111	0.41	0.39	Monocyte count;	chr8:11977030	chr8:12378679~12380265:-
GBM	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	4.57	1.24e-05	0.0111	0.33	0.39	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
GBM	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	4.57	1.24e-05	0.0111	0.48	0.39	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
GBM	cis	rs9601248	0.756	rs9601251	ENSG00000227676.3	LINC01068	-4.57	1.24e-05	0.0111	-0.46	-0.39	Major depressive disorder;	chr13:79615582	chr13:79566727~79571436:+
GBM	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	4.57	1.24e-05	0.0111	0.71	0.39	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
GBM	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	4.57	1.24e-05	0.0111	0.71	0.39	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
GBM	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	4.57	1.24e-05	0.0111	0.71	0.39	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
GBM	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	4.57	1.24e-05	0.0111	0.58	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	4.57	1.24e-05	0.0111	0.58	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
GBM	cis	rs7829975	0.682	rs7013471	ENSG00000254340.1	RP11-10A14.3	-4.57	1.25e-05	0.0111	-0.47	-0.39	Mood instability;	chr8:8829815	chr8:9141424~9145435:+
GBM	cis	rs4713118	0.869	rs7773070	ENSG00000218016.2	ZNF192P2	-4.57	1.25e-05	0.0111	-0.5	-0.39	Parkinson's disease;	chr6:27761048	chr6:28188050~28189432:+
GBM	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-4.57	1.25e-05	0.0111	-0.42	-0.39	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
GBM	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-4.57	1.25e-05	0.0111	-0.47	-0.39	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
GBM	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	4.57	1.25e-05	0.0111	0.77	0.39	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
GBM	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	4.57	1.25e-05	0.0111	0.55	0.39	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
GBM	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	4.57	1.25e-05	0.0111	0.55	0.39	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
GBM	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-4.57	1.25e-05	0.0112	-0.52	-0.39	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
GBM	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	4.57	1.25e-05	0.0112	0.39	0.39	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
GBM	cis	rs6504622	0.818	rs28451958	ENSG00000262879.4	RP11-156P1.3	4.57	1.25e-05	0.0112	0.36	0.39	Orofacial clefts;	chr17:46968528	chr17:46984045~47100323:-
GBM	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	4.57	1.25e-05	0.0112	0.48	0.39	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	4.57	1.25e-05	0.0112	0.48	0.39	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	4.57	1.25e-05	0.0112	0.48	0.39	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
GBM	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	4.57	1.25e-05	0.0112	0.48	0.39	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
GBM	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	4.57	1.25e-05	0.0112	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
GBM	cis	rs17685	0.712	rs10271413	ENSG00000280388.1	RP11-229D13.3	-4.57	1.25e-05	0.0112	-0.37	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76125540	chr7:76043977~76045963:-
GBM	cis	rs7017914	0.667	rs2639925	ENSG00000246366.5	RP11-382J12.1	-4.57	1.25e-05	0.0112	-0.4	-0.39	Bone mineral density;	chr8:70991937	chr8:70608577~70663279:+
GBM	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	4.57	1.25e-05	0.0112	0.47	0.39	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	4.57	1.25e-05	0.0112	0.47	0.39	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	4.57	1.25e-05	0.0112	0.47	0.39	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	4.57	1.25e-05	0.0112	0.47	0.39	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
GBM	cis	rs2408955	0.522	rs6580650	ENSG00000258273.1	RP11-370I10.4	4.57	1.25e-05	0.0112	0.51	0.39	Glycated hemoglobin levels;	chr12:48024773	chr12:48333755~48333901:-
GBM	cis	rs67981189	0.593	rs221926	ENSG00000269927.1	RP6-91H8.3	-4.57	1.25e-05	0.0112	-0.45	-0.39	Schizophrenia;	chr14:71112418	chr14:71141125~71143253:-
GBM	cis	rs9947662	0.778	rs1019990	ENSG00000267761.3	CTD-2130O13.1	-4.57	1.26e-05	0.0112	-0.49	-0.39	Migraine;	chr18:47340365	chr18:47285725~47594550:+
GBM	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-4.57	1.26e-05	0.0112	-0.54	-0.39	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
GBM	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	4.57	1.26e-05	0.0112	0.55	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
GBM	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	4.57	1.26e-05	0.0112	0.55	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
GBM	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	4.57	1.26e-05	0.0112	0.51	0.39	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
GBM	cis	rs67981189	0.593	rs12896829	ENSG00000269927.1	RP6-91H8.3	4.57	1.26e-05	0.0112	0.44	0.39	Schizophrenia;	chr14:70996959	chr14:71141125~71143253:-
GBM	cis	rs4713118	0.955	rs9468200	ENSG00000218016.2	ZNF192P2	-4.57	1.26e-05	0.0112	-0.53	-0.39	Parkinson's disease;	chr6:27715284	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs34752872	ENSG00000218016.2	ZNF192P2	-4.57	1.26e-05	0.0112	-0.53	-0.39	Parkinson's disease;	chr6:27715465	chr6:28188050~28189432:+
GBM	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-4.57	1.26e-05	0.0112	-0.48	-0.39	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
GBM	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	4.56	1.26e-05	0.0112	0.71	0.39	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
GBM	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-4.56	1.26e-05	0.0112	-0.45	-0.39	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
GBM	cis	rs812925	0.519	rs1186706	ENSG00000271889.1	RP11-493E12.1	4.56	1.26e-05	0.0113	0.4	0.39	Immature fraction of reticulocytes;	chr2:61446259	chr2:61151433~61162105:-
GBM	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	4.56	1.26e-05	0.0113	0.5	0.39	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
GBM	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	4.56	1.27e-05	0.0113	0.41	0.39	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
GBM	cis	rs2278702	1	rs2278702	ENSG00000259495.2	RP11-210M15.2	-4.56	1.27e-05	0.0113	-0.39	-0.39	Bipolar disorder;	chr15:80402580	chr15:80344853~80403575:-
GBM	cis	rs453301	0.624	rs7014430	ENSG00000254340.1	RP11-10A14.3	4.56	1.27e-05	0.0113	0.5	0.39	Joint mobility (Beighton score);	chr8:8970227	chr8:9141424~9145435:+
GBM	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	4.56	1.27e-05	0.0113	0.63	0.39	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
GBM	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	4.56	1.27e-05	0.0113	0.45	0.39	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
GBM	cis	rs853679	0.882	rs9468300	ENSG00000199851.2	U3	4.56	1.27e-05	0.0113	0.79	0.39	Depression;	chr6:28159062	chr6:28015568~28015777:+
GBM	cis	rs853679	0.825	rs8180562	ENSG00000199851.2	U3	4.56	1.27e-05	0.0113	0.79	0.39	Depression;	chr6:28173682	chr6:28015568~28015777:+
GBM	cis	rs853679	0.882	rs9380064	ENSG00000199851.2	U3	4.56	1.27e-05	0.0113	0.79	0.39	Depression;	chr6:28175340	chr6:28015568~28015777:+
GBM	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	4.56	1.27e-05	0.0113	0.33	0.39	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
GBM	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	4.56	1.27e-05	0.0113	0.8	0.39	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
GBM	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-4.56	1.27e-05	0.0113	-0.52	-0.39	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
GBM	cis	rs10463554	0.675	rs444020	ENSG00000175749.11	EIF3KP1	4.56	1.27e-05	0.0113	0.53	0.39	Parkinson's disease;	chr5:103092139	chr5:103032376~103033031:+
GBM	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	4.56	1.27e-05	0.0113	0.7	0.39	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
GBM	cis	rs1387259	0.64	rs10783243	ENSG00000258273.1	RP11-370I10.4	4.56	1.27e-05	0.0113	0.44	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48333755~48333901:-
GBM	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-4.56	1.27e-05	0.0113	-0.45	-0.39	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
GBM	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	4.56	1.27e-05	0.0113	0.49	0.39	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
GBM	cis	rs7267979	0.932	rs446649	ENSG00000276952.1	RP5-965G21.6	4.56	1.28e-05	0.0113	0.37	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25284915~25285588:-
GBM	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	4.56	1.28e-05	0.0113	0.46	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
GBM	cis	rs3806843	1	rs4451093	ENSG00000202111.1	VTRNA1-2	4.56	1.28e-05	0.0113	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr5:140718925~140719013:+
GBM	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	4.56	1.28e-05	0.0114	0.58	0.39	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
GBM	cis	rs3096299	0.606	rs2965946	ENSG00000260259.1	RP11-368I7.4	4.56	1.28e-05	0.0114	0.46	0.39	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89682620~89686569:-
GBM	cis	rs4072705	1	rs4836988	ENSG00000224020.1	MIR181A2HG	-4.56	1.28e-05	0.0114	-0.44	-0.39	Menarche (age at onset);	chr9:124735294	chr9:124658467~124698631:+
GBM	cis	rs67981189	0.593	rs221925	ENSG00000269927.1	RP6-91H8.3	-4.56	1.28e-05	0.0114	-0.45	-0.39	Schizophrenia;	chr14:71112912	chr14:71141125~71143253:-
GBM	cis	rs17685	0.753	rs10085567	ENSG00000280388.1	RP11-229D13.3	-4.56	1.28e-05	0.0114	-0.37	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76104888	chr7:76043977~76045963:-
GBM	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	4.56	1.28e-05	0.0114	0.33	0.39	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
GBM	cis	rs12130219	0.913	rs10443208	ENSG00000237975.5	FLG-AS1	4.56	1.28e-05	0.0114	0.71	0.39	Inflammatory skin disease;	chr1:152253907	chr1:152168125~152445456:+
GBM	cis	rs17767294	0.708	rs72848752	ENSG00000199851.2	U3	4.56	1.28e-05	0.0114	1.16	0.39	Parkinson's disease;	chr6:27910490	chr6:28015568~28015777:+
GBM	cis	rs7267979	0.714	rs1555329	ENSG00000276952.1	RP5-965G21.6	4.56	1.29e-05	0.0114	0.36	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25284915~25285588:-
GBM	cis	rs8062405	0.754	rs149299	ENSG00000271623.1	RP11-435I10.5	-4.56	1.29e-05	0.0114	-0.46	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28364700~28365333:+
GBM	cis	rs7267979	0.565	rs3752273	ENSG00000125804.12	FAM182A	4.56	1.29e-05	0.0114	0.5	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26054655~26086917:+
GBM	cis	rs17772222	0.839	rs2274735	ENSG00000258983.2	RP11-507K2.2	4.56	1.29e-05	0.0114	0.4	0.39	Coronary artery calcification;	chr14:88505414	chr14:88499334~88515502:+
GBM	cis	rs1420956	0.505	rs11083217	ENSG00000264151.4	RP11-739N10.1	4.56	1.29e-05	0.0114	0.52	0.39	Obesity-related traits;	chr18:27584396	chr18:27336379~27595164:-
GBM	cis	rs1420956	0.524	rs11083218	ENSG00000264151.4	RP11-739N10.1	4.56	1.29e-05	0.0114	0.52	0.39	Obesity-related traits;	chr18:27584397	chr18:27336379~27595164:-
GBM	cis	rs67981189	0.593	rs221924	ENSG00000269927.1	RP6-91H8.3	-4.56	1.29e-05	0.0114	-0.45	-0.39	Schizophrenia;	chr14:71114061	chr14:71141125~71143253:-
GBM	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	4.56	1.29e-05	0.0114	0.51	0.39	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
GBM	cis	rs11098499	0.738	rs28687057	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119359657	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.73	rs78971550	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119359886	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.645	rs78422072	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119359887	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.775	rs67281037	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119360002	chr4:119391831~119395335:-
GBM	cis	rs10028773	0.506	rs12374346	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Educational attainment;	chr4:119360550	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs12374244	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119360817	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs12374352	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119360822	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.775	rs10021601	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119361408	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs6857892	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119361541	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.909	rs28581362	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119362393	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.82	rs12503082	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119363162	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs12499602	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119363232	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.774	rs11098505	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119363472	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs13105020	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119364533	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs6824111	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119364813	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.779	rs10857066	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119365441	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.775	rs10029303	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119365600	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs9995136	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119365690	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.687	rs71610270	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119366281	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs13125526	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119366864	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs12513310	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119366884	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.564	rs11098507	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119367131	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs12510451	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119367988	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.774	rs73842616	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119369528	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.645	rs72676059	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119369673	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.569	rs55845118	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119369758	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs7677068	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119370549	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs9991221	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119370952	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.78	rs10013652	ENSG00000249244.1	RP11-548H18.2	4.56	1.29e-05	0.0115	0.48	0.39	Corneal astigmatism;	chr4:119371101	chr4:119391831~119395335:-
GBM	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	4.56	1.3e-05	0.0115	0.42	0.39	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
GBM	cis	rs7615952	0.599	rs6438953	ENSG00000250012.1	RP11-124N2.1	-4.56	1.3e-05	0.0115	-0.42	-0.39	Blood pressure (smoking interaction);	chr3:126006108	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs1044215	ENSG00000250012.1	RP11-124N2.1	-4.56	1.3e-05	0.0115	-0.42	-0.39	Blood pressure (smoking interaction);	chr3:126006716	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs6438955	ENSG00000250012.1	RP11-124N2.1	-4.56	1.3e-05	0.0115	-0.42	-0.39	Blood pressure (smoking interaction);	chr3:126011490	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs66532274	ENSG00000250012.1	RP11-124N2.1	-4.56	1.3e-05	0.0115	-0.42	-0.39	Blood pressure (smoking interaction);	chr3:126013002	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs2333408	ENSG00000250012.1	RP11-124N2.1	-4.56	1.3e-05	0.0115	-0.42	-0.39	Blood pressure (smoking interaction);	chr3:126013255	chr3:126084220~126095349:+
GBM	cis	rs10971721	0.554	rs55917897	ENSG00000281128.1	PTENP1-AS	4.56	1.3e-05	0.0115	0.85	0.39	Body mass index;	chr9:33795952	chr9:33677268~33688011:+
GBM	cis	rs10971721	0.643	rs12378415	ENSG00000281128.1	PTENP1-AS	4.56	1.3e-05	0.0115	0.85	0.39	Body mass index;	chr9:33797335	chr9:33677268~33688011:+
GBM	cis	rs7829975	0.755	rs3789849	ENSG00000254340.1	RP11-10A14.3	4.56	1.3e-05	0.0115	0.49	0.39	Mood instability;	chr8:8829544	chr8:9141424~9145435:+
GBM	cis	rs67981189	0.574	rs2526884	ENSG00000269927.1	RP6-91H8.3	-4.56	1.3e-05	0.0115	-0.43	-0.39	Schizophrenia;	chr14:70901250	chr14:71141125~71143253:-
GBM	cis	rs9926296	0.605	rs12599180	ENSG00000260259.1	RP11-368I7.4	4.56	1.3e-05	0.0115	0.42	0.39	Vitiligo;	chr16:89772898	chr16:89682620~89686569:-
GBM	cis	rs950169	0.922	rs12912934	ENSG00000275120.1	RP11-182J1.17	4.56	1.3e-05	0.0115	0.5	0.39	Schizophrenia;	chr15:84571216	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs62021167	ENSG00000275120.1	RP11-182J1.17	4.56	1.3e-05	0.0115	0.5	0.39	Schizophrenia;	chr15:84574820	chr15:84599434~84606463:-
GBM	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	4.56	1.31e-05	0.0116	0.55	0.39	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
GBM	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-4.56	1.31e-05	0.0116	-0.49	-0.39	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
GBM	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	4.56	1.31e-05	0.0116	0.44	0.39	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
GBM	cis	rs17214007	0.778	rs17213271	ENSG00000279866.1	CTB-193M12.4	4.56	1.31e-05	0.0116	0.54	0.39	Cognitive function;	chr16:15770487	chr16:15704410~15705984:+
GBM	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	4.55	1.31e-05	0.0116	0.7	0.39	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
GBM	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	4.55	1.31e-05	0.0116	0.7	0.39	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
GBM	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	4.55	1.31e-05	0.0116	0.51	0.39	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
GBM	cis	rs4713118	0.869	rs7776351	ENSG00000218016.2	ZNF192P2	4.55	1.31e-05	0.0116	0.49	0.39	Parkinson's disease;	chr6:27758952	chr6:28188050~28189432:+
GBM	cis	rs4245535	1	rs4245535	ENSG00000225174.1	OSTM1-AS1	4.55	1.31e-05	0.0116	0.73	0.39	Major depressive disorder;	chr6:108128008	chr6:108123515~108159392:+
GBM	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	4.55	1.31e-05	0.0116	0.57	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
GBM	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
GBM	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	4.55	1.31e-05	0.0116	0.51	0.39	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
GBM	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	4.55	1.31e-05	0.0116	0.8	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
GBM	cis	rs1908814	0.51	rs57655799	ENSG00000255556.2	RP11-351I21.6	4.55	1.31e-05	0.0116	0.41	0.39	Neuroticism;	chr8:11924908	chr8:12378679~12380265:-
GBM	cis	rs1061377	0.748	rs1964345	ENSG00000249685.1	RP11-360F5.3	4.55	1.31e-05	0.0116	0.5	0.39	Uric acid levels;	chr4:39104793	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.748	rs1964347	ENSG00000249685.1	RP11-360F5.3	4.55	1.31e-05	0.0116	0.5	0.39	Uric acid levels;	chr4:39104956	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.748	rs1036033	ENSG00000249685.1	RP11-360F5.3	4.55	1.31e-05	0.0116	0.5	0.39	Uric acid levels;	chr4:39105295	chr4:39133913~39135608:+
GBM	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	4.55	1.32e-05	0.0116	0.4	0.39	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
GBM	cis	rs7017914	0.967	rs1348535	ENSG00000246366.5	RP11-382J12.1	-4.55	1.32e-05	0.0116	-0.42	-0.39	Bone mineral density;	chr8:70750506	chr8:70608577~70663279:+
GBM	cis	rs8177876	0.731	rs4889227	ENSG00000261838.4	RP11-303E16.6	-4.55	1.32e-05	0.0116	-0.71	-0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81069854~81076598:+
GBM	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	4.55	1.32e-05	0.0116	0.56	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
GBM	cis	rs12495178	0.608	rs9863150	ENSG00000239519.1	CADM2-AS1	4.55	1.32e-05	0.0116	0.38	0.39	Body mass index;	chr3:85865885	chr3:85992183~86028007:-
GBM	cis	rs3806843	0.741	rs2563293	ENSG00000202111.1	VTRNA1-2	4.55	1.32e-05	0.0116	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.771	rs801174	ENSG00000202111.1	VTRNA1-2	4.55	1.32e-05	0.0116	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr5:140718925~140719013:+
GBM	cis	rs10971721	0.643	rs10971699	ENSG00000281128.1	PTENP1-AS	4.55	1.32e-05	0.0117	0.84	0.39	Body mass index;	chr9:33777186	chr9:33677268~33688011:+
GBM	cis	rs10971721	0.643	rs10971701	ENSG00000281128.1	PTENP1-AS	4.55	1.32e-05	0.0117	0.84	0.39	Body mass index;	chr9:33781900	chr9:33677268~33688011:+
GBM	cis	rs10971721	0.643	rs10971702	ENSG00000281128.1	PTENP1-AS	4.55	1.32e-05	0.0117	0.84	0.39	Body mass index;	chr9:33784104	chr9:33677268~33688011:+
GBM	cis	rs10971721	0.643	rs12375483	ENSG00000281128.1	PTENP1-AS	4.55	1.32e-05	0.0117	0.84	0.39	Body mass index;	chr9:33784910	chr9:33677268~33688011:+
GBM	cis	rs10971721	0.643	rs72711741	ENSG00000281128.1	PTENP1-AS	4.55	1.32e-05	0.0117	0.84	0.39	Body mass index;	chr9:33785113	chr9:33677268~33688011:+
GBM	cis	rs731565	0.867	rs118089518	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147668836	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs117781995	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147668861	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs76768888	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147669327	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs77376398	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147669382	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs77064727	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147669455	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs74596644	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147669690	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs117267807	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147669939	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs77574224	ENSG00000232391.1	RANP2	4.55	1.32e-05	0.0117	0.75	0.39	Diabetic kidney disease;	chr7:147670488	chr7:147167344~147167572:+
GBM	cis	rs7017914	0.967	rs4628281	ENSG00000246366.5	RP11-382J12.1	-4.55	1.32e-05	0.0117	-0.42	-0.39	Bone mineral density;	chr8:70926929	chr8:70608577~70663279:+
GBM	cis	rs2579103	0.631	rs2731257	ENSG00000258183.4	RP11-753N8.1	-4.55	1.33e-05	0.0117	-0.57	-0.39	Body mass index;	chr12:90288161	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs1561423	ENSG00000258183.4	RP11-753N8.1	-4.55	1.33e-05	0.0117	-0.57	-0.39	Body mass index;	chr12:90280416	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs2731260	ENSG00000258183.4	RP11-753N8.1	-4.55	1.33e-05	0.0117	-0.57	-0.39	Body mass index;	chr12:90283433	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs1371080	ENSG00000258183.4	RP11-753N8.1	-4.55	1.33e-05	0.0117	-0.57	-0.39	Body mass index;	chr12:90288622	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs2731256	ENSG00000258183.4	RP11-753N8.1	-4.55	1.33e-05	0.0117	-0.57	-0.39	Body mass index;	chr12:90289196	chr12:90280894~90300340:+
GBM	cis	rs11654801	0.812	rs9972887	ENSG00000233098.7	CCDC144NL-AS1	-4.55	1.33e-05	0.0117	-0.55	-0.39	Mosquito bite size;	chr17:20973159	chr17:20868433~21002276:+
GBM	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	4.55	1.33e-05	0.0117	0.64	0.39	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
GBM	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	4.55	1.33e-05	0.0117	0.46	0.39	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
GBM	cis	rs741668	0.931	rs2806924	ENSG00000235903.6	CPB2-AS1	-4.55	1.33e-05	0.0117	-0.56	-0.39	Cerebrospinal fluid clusterin levels;	chr13:45944831	chr13:46052806~46113332:+
GBM	cis	rs8014671	0.532	rs1953800	ENSG00000235812.4	ADAM21P1	4.55	1.33e-05	0.0117	0.47	0.39	Prostate cancer;	chr14:70491979	chr14:70245491~70247801:-
GBM	cis	rs7615952	0.512	rs4234285	ENSG00000242001.1	GS1-388B5.1	4.55	1.33e-05	0.0117	0.59	0.39	Blood pressure (smoking interaction);	chr3:125685633	chr3:125681305~125681453:+
GBM	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-4.55	1.33e-05	0.0118	-0.52	-0.39	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
GBM	cis	rs73198271	0.74	rs1039910	ENSG00000253893.2	FAM85B	4.55	1.34e-05	0.0118	0.57	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8167819~8226614:-
GBM	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	4.55	1.34e-05	0.0118	0.46	0.39	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
GBM	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-4.55	1.34e-05	0.0118	-0.52	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
GBM	cis	rs1009077	0.61	rs2248236	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119572782	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs2622499	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119574695	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs2622500	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119574951	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs12646525	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119581306	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs12503853	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119582008	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs12648259	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119583024	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.578	rs6834347	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119583524	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.578	rs2389863	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119586509	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.531	rs10012485	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119587143	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs28412979	ENSG00000248280.1	RP11-33B1.2	-4.55	1.34e-05	0.0118	-0.55	-0.39	Endometriosis;	chr4:119588726	chr4:119440561~119450157:-
GBM	cis	rs67981189	0.593	rs7144986	ENSG00000269927.1	RP6-91H8.3	4.55	1.34e-05	0.0118	0.44	0.39	Schizophrenia;	chr14:71006714	chr14:71141125~71143253:-
GBM	cis	rs73198271	0.737	rs535094	ENSG00000253893.2	FAM85B	4.55	1.34e-05	0.0118	0.55	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.765	rs534103	ENSG00000253893.2	FAM85B	4.55	1.34e-05	0.0118	0.55	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:8167819~8226614:-
GBM	cis	rs2013441	0.711	rs1682297	ENSG00000230528.6	NOS2P3	-4.55	1.34e-05	0.0118	-0.42	-0.39	Obesity-related traits;	chr17:20481607	chr17:20436337~20447249:+
GBM	cis	rs4245535	1	rs62427094	ENSG00000225174.1	OSTM1-AS1	4.55	1.34e-05	0.0118	0.73	0.39	Major depressive disorder;	chr6:108133026	chr6:108123515~108159392:+
GBM	cis	rs4245535	1	rs4946906	ENSG00000225174.1	OSTM1-AS1	4.55	1.34e-05	0.0118	0.73	0.39	Major depressive disorder;	chr6:108135980	chr6:108123515~108159392:+
GBM	cis	rs3806843	1	rs7732179	ENSG00000202111.1	VTRNA1-2	-4.55	1.34e-05	0.0118	-0.4	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140819454	chr5:140718925~140719013:+
GBM	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	4.55	1.34e-05	0.0118	0.62	0.39	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
GBM	cis	rs10752881	1	rs4233192	ENSG00000224468.3	RP11-181K3.4	4.55	1.34e-05	0.0118	0.32	0.39	Colorectal cancer;	chr1:183001702	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs4233193	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183001730	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10911185	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183002612	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10737235	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183002681	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.967	rs10911186	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183003407	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10797802	ENSG00000224468.3	RP11-181K3.4	4.55	1.34e-05	0.0118	0.32	0.39	Colorectal cancer;	chr1:183004023	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs8179262	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183004051	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10752881	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183004356	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.967	rs8179284	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183005572	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.967	rs4652757	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183005615	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.967	rs4652758	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183005965	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4575047	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Hypertriglyceridemia;	chr1:183006893	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4596846	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Hypertriglyceridemia;	chr1:183006899	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs4420053	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183006998	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs6701400	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183008062	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs9787327	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Hypertriglyceridemia;	chr1:183009324	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10797807	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183009738	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10911190	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183009945	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10797808	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183010488	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10797810	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183011815	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10752883	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183011828	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.524	rs4487994	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Hypertriglyceridemia;	chr1:183013038	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs4454510	ENSG00000224468.3	RP11-181K3.4	4.55	1.34e-05	0.0118	0.32	0.39	Colorectal cancer;	chr1:183013168	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4442336	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Hypertriglyceridemia;	chr1:183013403	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10752885	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183013743	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs6673559	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183014062	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs6697739	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183014198	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs12403189	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183014697	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10797811	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183015297	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs4593781	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183015848	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs12028732	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183016390	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs12028740	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183016446	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs12035773	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183016581	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs4402094	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183017306	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs6424879	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183017457	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs6424880	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183017544	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10752886	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183018113	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs12133714	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183019117	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4483371	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Hypertriglyceridemia;	chr1:183019217	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs12126434	ENSG00000224468.3	RP11-181K3.4	4.55	1.34e-05	0.0118	0.32	0.39	Colorectal cancer;	chr1:183019279	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10737236	ENSG00000224468.3	RP11-181K3.4	4.55	1.34e-05	0.0118	0.32	0.39	Colorectal cancer;	chr1:183019473	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10737237	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183020134	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10797813	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183020231	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.905	rs12132262	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183020814	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10752887	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183021699	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797814	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Hypertriglyceridemia;	chr1:183021794	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.967	rs6695746	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183022220	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.967	rs6695837	ENSG00000224468.3	RP11-181K3.4	-4.55	1.34e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183022327	chr1:183138402~183141282:-
GBM	cis	rs804280	0.509	rs13276433	ENSG00000255556.2	RP11-351I21.6	4.55	1.35e-05	0.0118	0.41	0.39	Myopia (pathological);	chr8:11925527	chr8:12378679~12380265:-
GBM	cis	rs804280	0.509	rs13268030	ENSG00000255556.2	RP11-351I21.6	4.55	1.35e-05	0.0118	0.41	0.39	Myopia (pathological);	chr8:11925564	chr8:12378679~12380265:-
GBM	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0118	0.63	0.39	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0118	0.63	0.39	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
GBM	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0118	0.63	0.39	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0118	0.63	0.39	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0118	0.63	0.39	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0118	0.63	0.39	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0118	0.63	0.39	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
GBM	cis	rs10752881	0.967	rs8179361	ENSG00000224468.3	RP11-181K3.4	-4.55	1.35e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183005437	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs8179282	ENSG00000224468.3	RP11-181K3.4	-4.55	1.35e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183005463	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs8179283	ENSG00000224468.3	RP11-181K3.4	-4.55	1.35e-05	0.0118	-0.32	-0.39	Colorectal cancer;	chr1:183005467	chr1:183138402~183141282:-
GBM	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	4.55	1.35e-05	0.0118	0.45	0.39	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
GBM	cis	rs11992162	1	rs11994417	ENSG00000255556.2	RP11-351I21.6	4.55	1.35e-05	0.0118	0.41	0.39	Monocyte count;	chr8:11975753	chr8:12378679~12380265:-
GBM	cis	rs73198271	0.751	rs617813	ENSG00000253893.2	FAM85B	4.55	1.35e-05	0.0118	0.55	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8167819~8226614:-
GBM	cis	rs2115630	0.905	rs6496401	ENSG00000225151.9	GOLGA2P7	4.55	1.35e-05	0.0118	0.41	0.39	P wave terminal force;	chr15:84754562	chr15:84199311~84230136:-
GBM	cis	rs2115630	0.967	rs11073702	ENSG00000225151.9	GOLGA2P7	4.55	1.35e-05	0.0118	0.41	0.39	P wave terminal force;	chr15:84766840	chr15:84199311~84230136:-
GBM	cis	rs2018683	0.932	rs4386882	ENSG00000228421.2	AC005013.5	4.55	1.35e-05	0.0119	0.48	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28949653	chr7:28957667~28959345:+
GBM	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	4.55	1.35e-05	0.0119	0.45	0.39	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	4.55	1.35e-05	0.0119	0.45	0.39	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	4.55	1.35e-05	0.0119	0.45	0.39	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	4.55	1.35e-05	0.0119	0.45	0.39	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	4.55	1.35e-05	0.0119	0.45	0.39	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
GBM	cis	rs11654801	0.812	rs62056770	ENSG00000233098.7	CCDC144NL-AS1	-4.55	1.35e-05	0.0119	-0.56	-0.39	Mosquito bite size;	chr17:20993854	chr17:20868433~21002276:+
GBM	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	4.55	1.35e-05	0.0119	0.41	0.39	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
GBM	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0119	0.66	0.39	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	4.55	1.35e-05	0.0119	0.66	0.39	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-4.55	1.35e-05	0.0119	-0.66	-0.39	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
GBM	cis	rs73198271	0.74	rs67766414	ENSG00000253893.2	FAM85B	4.55	1.36e-05	0.0119	0.58	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8167819~8226614:-
GBM	cis	rs8114671	0.869	rs2038503	ENSG00000269202.1	RP4-614O4.12	4.55	1.36e-05	0.0119	0.49	0.39	Height;	chr20:35088097	chr20:35201747~35203288:-
GBM	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	4.55	1.36e-05	0.0119	0.45	0.39	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-4.55	1.37e-05	0.012	-0.51	-0.39	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
GBM	cis	rs1009077	0.61	rs7684899	ENSG00000248280.1	RP11-33B1.2	-4.54	1.37e-05	0.012	-0.55	-0.39	Endometriosis;	chr4:119600474	chr4:119440561~119450157:-
GBM	cis	rs922692	0.744	rs12903203	ENSG00000261143.1	ADAMTS7P3	4.54	1.37e-05	0.012	0.41	0.39	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78792591	chr15:77976042~77993057:+
GBM	cis	rs10995505	0.589	rs1553789	ENSG00000232075.1	MRPL35P2	4.54	1.37e-05	0.012	0.56	0.39	Intelligence (multi-trait analysis);	chr10:63119469	chr10:63634317~63634827:-
GBM	cis	rs4478147	0.548	rs4693140	ENSG00000261496.1	RP13-514E23.1	-4.54	1.37e-05	0.012	-0.49	-0.39	Migraine - clinic-based;	chr4:86319646	chr4:86012296~86013874:-
GBM	cis	rs9890032	0.618	rs55872374	ENSG00000266490.1	CTD-2349P21.9	4.54	1.37e-05	0.012	0.31	0.39	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30792372~30792833:+
GBM	cis	rs2115630	1	rs11854313	ENSG00000225151.9	GOLGA2P7	4.54	1.37e-05	0.012	0.41	0.39	P wave terminal force;	chr15:84760817	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-4.54	1.37e-05	0.012	-0.44	-0.39	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-4.54	1.37e-05	0.012	-0.44	-0.39	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-4.54	1.37e-05	0.012	-0.44	-0.39	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-4.54	1.37e-05	0.012	-0.44	-0.39	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
GBM	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	4.54	1.37e-05	0.012	0.3	0.39	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
GBM	cis	rs3096299	0.606	rs4785573	ENSG00000260259.1	RP11-368I7.4	4.54	1.37e-05	0.012	0.45	0.39	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89682620~89686569:-
GBM	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	4.54	1.37e-05	0.012	0.57	0.39	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
GBM	cis	rs5742933	0.557	rs1233276	ENSG00000253559.1	OSGEPL1-AS1	-4.54	1.37e-05	0.012	-0.49	-0.39	Ferritin levels;	chr2:189820056	chr2:189762704~189765556:+
GBM	cis	rs172166	0.56	rs203878	ENSG00000218016.2	ZNF192P2	-4.54	1.38e-05	0.012	-0.43	-0.39	Cardiac Troponin-T levels;	chr6:28081218	chr6:28188050~28189432:+
GBM	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-4.54	1.38e-05	0.012	-0.45	-0.39	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
GBM	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-4.54	1.38e-05	0.012	-0.52	-0.39	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
GBM	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	4.54	1.38e-05	0.0121	0.39	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
GBM	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	4.54	1.38e-05	0.0121	0.47	0.39	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
GBM	cis	rs2965260	0.621	rs12609049	ENSG00000237017.1	AC012314.8	-4.54	1.38e-05	0.0121	-0.79	-0.39	IgG glycosylation;	chr19:53259284	chr19:54119511~54125343:-
GBM	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-4.54	1.38e-05	0.0121	-0.51	-0.39	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
GBM	cis	rs10911232	0.507	rs11582514	ENSG00000224468.3	RP11-181K3.4	-4.54	1.38e-05	0.0121	-0.32	-0.39	Hypertriglyceridemia;	chr1:183023026	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911194	ENSG00000224468.3	RP11-181K3.4	-4.54	1.38e-05	0.0121	-0.32	-0.39	Hypertriglyceridemia;	chr1:183023890	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911195	ENSG00000224468.3	RP11-181K3.4	-4.54	1.38e-05	0.0121	-0.32	-0.39	Hypertriglyceridemia;	chr1:183024303	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10752888	ENSG00000224468.3	RP11-181K3.4	-4.54	1.38e-05	0.0121	-0.32	-0.39	Hypertriglyceridemia;	chr1:183024616	chr1:183138402~183141282:-
GBM	cis	rs7017914	0.967	rs12675271	ENSG00000246366.5	RP11-382J12.1	-4.54	1.39e-05	0.0121	-0.42	-0.39	Bone mineral density;	chr8:70689774	chr8:70608577~70663279:+
GBM	cis	rs4072705	0.614	rs35929043	ENSG00000224020.1	MIR181A2HG	-4.54	1.39e-05	0.0121	-0.42	-0.39	Menarche (age at onset);	chr9:124472077	chr9:124658467~124698631:+
GBM	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	4.54	1.39e-05	0.0121	0.52	0.39	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
GBM	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	4.54	1.39e-05	0.0121	0.43	0.39	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	4.54	1.39e-05	0.0121	0.43	0.39	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
GBM	cis	rs7338174	0.655	rs9316535	ENSG00000243406.5	MRPS31P5	4.54	1.39e-05	0.0122	0.67	0.39	Mitochondrial DNA levels;	chr13:51329329	chr13:52167709~52194465:-
GBM	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-4.54	1.39e-05	0.0122	-0.45	-0.39	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
GBM	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	4.54	1.4e-05	0.0122	0.4	0.39	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	4.54	1.4e-05	0.0122	0.4	0.39	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	4.54	1.4e-05	0.0122	0.4	0.39	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	4.54	1.4e-05	0.0122	0.4	0.39	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
GBM	cis	rs10911232	0.524	rs10911229	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Hypertriglyceridemia;	chr1:183081233	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.875	rs10752894	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Colorectal cancer;	chr1:183081475	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911230	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Hypertriglyceridemia;	chr1:183081983	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs35782443	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Hypertriglyceridemia;	chr1:183082367	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.935	rs12082051	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Colorectal cancer;	chr1:183082479	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911231	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Hypertriglyceridemia;	chr1:183082610	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10911234	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Hypertriglyceridemia;	chr1:183083866	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs4397624	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Hypertriglyceridemia;	chr1:183083996	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.935	rs10911235	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Colorectal cancer;	chr1:183084611	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs2151669	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Hypertriglyceridemia;	chr1:183086263	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.933	rs2027086	ENSG00000224468.3	RP11-181K3.4	-4.54	1.41e-05	0.0122	-0.31	-0.39	Colorectal cancer;	chr1:183088798	chr1:183138402~183141282:-
GBM	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-4.54	1.41e-05	0.0123	-0.49	-0.39	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
GBM	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	4.54	1.41e-05	0.0123	0.71	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
GBM	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	4.54	1.41e-05	0.0123	0.47	0.39	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
GBM	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	4.54	1.41e-05	0.0123	0.4	0.39	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
GBM	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-4.54	1.41e-05	0.0123	-0.7	-0.39	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
GBM	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-4.54	1.41e-05	0.0123	-0.53	-0.39	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
GBM	cis	rs17772222	0.917	rs2224333	ENSG00000222990.1	RNU4-22P	4.54	1.41e-05	0.0123	0.47	0.39	Coronary artery calcification;	chr14:88768748	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs12590826	ENSG00000222990.1	RNU4-22P	4.54	1.41e-05	0.0123	0.47	0.39	Coronary artery calcification;	chr14:88769357	chr14:88513498~88513663:+
GBM	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-4.54	1.41e-05	0.0123	-0.43	-0.39	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
GBM	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	4.54	1.42e-05	0.0123	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	4.54	1.42e-05	0.0123	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
GBM	cis	rs853679	0.666	rs200956	ENSG00000199851.2	U3	4.54	1.42e-05	0.0123	0.68	0.39	Depression;	chr6:27871968	chr6:28015568~28015777:+
GBM	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	4.54	1.42e-05	0.0123	0.43	0.39	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
GBM	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	4.54	1.42e-05	0.0123	0.43	0.39	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
GBM	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	4.54	1.42e-05	0.0124	0.45	0.39	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
GBM	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-4.54	1.42e-05	0.0124	-0.55	-0.39	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
GBM	cis	rs17685	0.712	rs10235086	ENSG00000280388.1	RP11-229D13.3	-4.53	1.42e-05	0.0124	-0.37	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76203820	chr7:76043977~76045963:-
GBM	cis	rs11098499	0.526	rs10026625	ENSG00000250412.1	KLHL2P1	4.53	1.42e-05	0.0124	0.48	0.39	Corneal astigmatism;	chr4:119358981	chr4:119334329~119378233:+
GBM	cis	rs1298062	0.79	rs2463245	ENSG00000131401.10	NAPSB	-4.53	1.42e-05	0.0124	-0.46	-0.39	Age of smoking initiation;	chr19:50463993	chr19:50333796~50344767:-
GBM	cis	rs3806843	0.801	rs2531358	ENSG00000202111.1	VTRNA1-2	4.53	1.42e-05	0.0124	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr5:140718925~140719013:+
GBM	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-4.53	1.42e-05	0.0124	-0.56	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
GBM	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-4.53	1.43e-05	0.0124	-0.56	-0.39	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
GBM	cis	rs3096299	0.9	rs4785663	ENSG00000260259.1	RP11-368I7.4	4.53	1.43e-05	0.0124	0.44	0.39	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89682620~89686569:-
GBM	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	4.53	1.43e-05	0.0124	0.44	0.39	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
GBM	cis	rs1009077	0.61	rs13115778	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119589380	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs2389864	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119589595	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs7659250	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119590820	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs6842674	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119591353	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs2389866	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119594108	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.579	rs10032993	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119595462	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.579	rs10021460	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119595464	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.504	rs9998919	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119595538	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs3756154	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119597174	chr4:119440561~119450157:-
GBM	cis	rs1009077	0.61	rs7670921	ENSG00000248280.1	RP11-33B1.2	-4.53	1.43e-05	0.0124	-0.55	-0.39	Endometriosis;	chr4:119597867	chr4:119440561~119450157:-
GBM	cis	rs5742933	0.557	rs6756571	ENSG00000253559.1	OSGEPL1-AS1	4.53	1.43e-05	0.0124	0.43	0.39	Ferritin levels;	chr2:189640971	chr2:189762704~189765556:+
GBM	cis	rs4713118	0.911	rs2394000	ENSG00000218016.2	ZNF192P2	-4.53	1.43e-05	0.0124	-0.52	-0.39	Parkinson's disease;	chr6:27719212	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9393847	ENSG00000218016.2	ZNF192P2	-4.53	1.43e-05	0.0124	-0.52	-0.39	Parkinson's disease;	chr6:27720194	chr6:28188050~28189432:+
GBM	cis	rs11159086	0.793	rs1029701	ENSG00000270000.1	RP3-449M8.9	4.53	1.43e-05	0.0124	0.58	0.39	Advanced glycation end-product levels;	chr14:74474112	chr14:74471930~74472360:-
GBM	cis	rs4072705	0.617	rs10283445	ENSG00000224020.1	MIR181A2HG	-4.53	1.43e-05	0.0124	-0.43	-0.39	Menarche (age at onset);	chr9:124481358	chr9:124658467~124698631:+
GBM	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-4.53	1.43e-05	0.0125	-0.4	-0.39	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
GBM	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	4.53	1.43e-05	0.0125	0.51	0.39	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
GBM	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-4.53	1.44e-05	0.0125	-0.7	-0.39	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
GBM	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	4.53	1.44e-05	0.0125	0.7	0.39	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
GBM	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	4.53	1.44e-05	0.0125	0.7	0.39	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
GBM	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	4.53	1.44e-05	0.0125	0.7	0.39	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
GBM	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	4.53	1.44e-05	0.0125	0.7	0.39	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
GBM	cis	rs7315956	0.929	rs6581924	ENSG00000257139.1	RP11-320P7.2	-4.53	1.44e-05	0.0125	-0.46	-0.39	Testicular germ cell tumor;	chr12:70168208	chr12:70180338~70202004:+
GBM	cis	rs7315956	0.929	rs10879101	ENSG00000257139.1	RP11-320P7.2	-4.53	1.44e-05	0.0125	-0.46	-0.39	Testicular germ cell tumor;	chr12:70168344	chr12:70180338~70202004:+
GBM	cis	rs7315956	0.964	rs735309	ENSG00000257139.1	RP11-320P7.2	-4.53	1.44e-05	0.0125	-0.46	-0.39	Testicular germ cell tumor;	chr12:70178637	chr12:70180338~70202004:+
GBM	cis	rs7315956	1	rs1036537	ENSG00000257139.1	RP11-320P7.2	-4.53	1.44e-05	0.0125	-0.46	-0.39	Testicular germ cell tumor;	chr12:70182167	chr12:70180338~70202004:+
GBM	cis	rs7315956	1	rs983787	ENSG00000257139.1	RP11-320P7.2	-4.53	1.44e-05	0.0125	-0.46	-0.39	Testicular germ cell tumor;	chr12:70190275	chr12:70180338~70202004:+
GBM	cis	rs7315956	0.963	rs7954979	ENSG00000257139.1	RP11-320P7.2	-4.53	1.44e-05	0.0125	-0.46	-0.39	Testicular germ cell tumor;	chr12:70206116	chr12:70180338~70202004:+
GBM	cis	rs7315956	0.892	rs7978439	ENSG00000257139.1	RP11-320P7.2	-4.53	1.44e-05	0.0125	-0.46	-0.39	Testicular germ cell tumor;	chr12:70208668	chr12:70180338~70202004:+
GBM	cis	rs4604732	0.631	rs12038880	ENSG00000227135.1	GCSAML-AS1	-4.53	1.44e-05	0.0125	-0.6	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461301	chr1:247524679~247526752:-
GBM	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-4.53	1.44e-05	0.0125	-0.49	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
GBM	cis	rs7829975	0.714	rs6994038	ENSG00000254340.1	RP11-10A14.3	4.53	1.44e-05	0.0125	0.48	0.39	Mood instability;	chr8:8803028	chr8:9141424~9145435:+
GBM	cis	rs9353324	1	rs9450372	ENSG00000203875.9	SNHG5	-4.53	1.44e-05	0.0125	-0.96	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86027230	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs6919244	ENSG00000203875.9	SNHG5	-4.53	1.44e-05	0.0125	-0.96	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86045035	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs56344601	ENSG00000203875.9	SNHG5	-4.53	1.44e-05	0.0125	-0.96	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86057967	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs6901489	ENSG00000203875.9	SNHG5	-4.53	1.44e-05	0.0125	-0.96	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86066343	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs6913399	ENSG00000203875.9	SNHG5	-4.53	1.44e-05	0.0125	-0.96	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86068202	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs73751283	ENSG00000203875.9	SNHG5	-4.53	1.44e-05	0.0125	-0.96	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86072398	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9450383	ENSG00000203875.9	SNHG5	-4.53	1.44e-05	0.0125	-0.96	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86073540	chr6:85660950~85678736:-
GBM	cis	rs4072705	0.967	rs10739651	ENSG00000224020.1	MIR181A2HG	-4.53	1.44e-05	0.0125	-0.41	-0.39	Menarche (age at onset);	chr9:124561794	chr9:124658467~124698631:+
GBM	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-4.53	1.44e-05	0.0125	-0.5	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
GBM	cis	rs10435719	0.764	rs10103485	ENSG00000255556.2	RP11-351I21.6	4.53	1.45e-05	0.0125	0.41	0.39	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:12378679~12380265:-
GBM	cis	rs8062405	1	rs4788095	ENSG00000271623.1	RP11-435I10.5	-4.53	1.45e-05	0.0125	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.964	rs72793809	ENSG00000271623.1	RP11-435I10.5	-4.53	1.45e-05	0.0125	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62036620	ENSG00000271623.1	RP11-435I10.5	-4.53	1.45e-05	0.0125	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62036621	ENSG00000271623.1	RP11-435I10.5	-4.53	1.45e-05	0.0125	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs4451951	ENSG00000271623.1	RP11-435I10.5	-4.53	1.45e-05	0.0125	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28364700~28365333:+
GBM	cis	rs7216064	0.7	rs4791295	ENSG00000278219.1	AC145343.1	-4.53	1.45e-05	0.0125	-0.45	-0.39	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68101538~68101639:+
GBM	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-4.53	1.45e-05	0.0125	-0.47	-0.39	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
GBM	cis	rs763121	0.853	rs9622833	ENSG00000273076.1	RP3-508I15.22	4.53	1.45e-05	0.0126	0.43	0.39	Menopause (age at onset);	chr22:38604392	chr22:38743495~38743910:+
GBM	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-4.53	1.45e-05	0.0126	-0.4	-0.39	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
GBM	cis	rs8014671	0.553	rs8019852	ENSG00000235812.4	ADAM21P1	-4.53	1.45e-05	0.0126	-0.47	-0.39	Prostate cancer;	chr14:70417226	chr14:70245491~70247801:-
GBM	cis	rs9926296	0.533	rs9938865	ENSG00000260259.1	RP11-368I7.4	-4.53	1.45e-05	0.0126	-0.42	-0.39	Vitiligo;	chr16:89801389	chr16:89682620~89686569:-
GBM	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	4.53	1.46e-05	0.0126	0.52	0.39	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
GBM	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	4.53	1.46e-05	0.0126	0.47	0.39	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
GBM	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	4.53	1.46e-05	0.0126	0.47	0.39	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
GBM	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	4.53	1.46e-05	0.0126	0.47	0.39	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
GBM	cis	rs3806843	0.735	rs801188	ENSG00000202111.1	VTRNA1-2	4.53	1.46e-05	0.0126	0.41	0.39	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr5:140718925~140719013:+
GBM	cis	rs7017914	0.69	rs17699455	ENSG00000246366.5	RP11-382J12.1	-4.53	1.46e-05	0.0126	-0.42	-0.39	Bone mineral density;	chr8:71060138	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs7013793	ENSG00000246366.5	RP11-382J12.1	-4.53	1.46e-05	0.0126	-0.42	-0.39	Bone mineral density;	chr8:71061317	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs35201629	ENSG00000246366.5	RP11-382J12.1	-4.53	1.46e-05	0.0126	-0.42	-0.39	Bone mineral density;	chr8:71062264	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.644	rs55970604	ENSG00000246366.5	RP11-382J12.1	-4.53	1.46e-05	0.0126	-0.42	-0.39	Bone mineral density;	chr8:71065538	chr8:70608577~70663279:+
GBM	cis	rs11671005	0.651	rs55716128	ENSG00000269600.1	AC016629.3	-4.53	1.46e-05	0.0127	-0.56	-0.39	Mean platelet volume;	chr19:58537387	chr19:58593896~58599355:-
GBM	cis	rs3096299	0.866	rs4238829	ENSG00000260259.1	RP11-368I7.4	4.53	1.46e-05	0.0127	0.42	0.39	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89682620~89686569:-
GBM	cis	rs397969	0.596	rs12450857	ENSG00000230528.6	NOS2P3	-4.53	1.47e-05	0.0127	-0.5	-0.39	Platelet count;	chr17:19991935	chr17:20436337~20447249:+
GBM	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	4.53	1.47e-05	0.0127	0.55	0.39	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
GBM	cis	rs2976388	0.647	rs2572898	ENSG00000253741.1	CTD-2292P10.4	-4.53	1.47e-05	0.0127	-0.4	-0.39	Urinary tract infection frequency;	chr8:142700856	chr8:142702252~142726973:-
GBM	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-4.53	1.47e-05	0.0127	-0.44	-0.39	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
GBM	cis	rs7017914	0.967	rs35960437	ENSG00000246366.5	RP11-382J12.1	-4.53	1.47e-05	0.0127	-0.42	-0.39	Bone mineral density;	chr8:70749725	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs34409123	ENSG00000246366.5	RP11-382J12.1	-4.53	1.47e-05	0.0127	-0.42	-0.39	Bone mineral density;	chr8:70749881	chr8:70608577~70663279:+
GBM	cis	rs763121	0.886	rs1013339	ENSG00000273076.1	RP3-508I15.22	4.53	1.48e-05	0.0127	0.41	0.39	Menopause (age at onset);	chr22:38578675	chr22:38743495~38743910:+
GBM	cis	rs893971	0.508	rs1440581	ENSG00000246375.2	RP11-10L7.1	4.53	1.48e-05	0.0127	0.4	0.39	Conduct disorder (maternal expressed emotions interaction);	chr4:88305270	chr4:88284942~88331421:+
GBM	cis	rs7267979	0.649	rs2500406	ENSG00000276952.1	RP5-965G21.6	-4.53	1.48e-05	0.0128	-0.37	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:25284915~25285588:-
GBM	cis	rs9393777	0.588	rs11967935	ENSG00000224843.5	LINC00240	4.53	1.48e-05	0.0128	0.57	0.39	Intelligence (multi-trait analysis);	chr6:26560444	chr6:26956992~27023924:+
GBM	cis	rs7017914	0.628	rs1389198	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70921872	chr8:70608577~70663279:+
GBM	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-4.52	1.48e-05	0.0128	-0.51	-0.39	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-4.52	1.48e-05	0.0128	-0.51	-0.39	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-4.52	1.48e-05	0.0128	-0.51	-0.39	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
GBM	cis	rs17508449	0.547	rs79100402	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113803538	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs3195954	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113812032	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs55940960	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113813474	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs3811021	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113814041	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs17463292	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113828618	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs3761935	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113829906	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.504	rs17509844	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113835147	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs6658523	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113843437	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs3765598	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113851841	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.602	rs3789608	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113855166	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs55646484	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113856152	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs35173468	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113856199	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.547	rs11582409	ENSG00000232450.1	RP4-730K3.3	-4.52	1.48e-05	0.0128	-0.62	-0.39	Leprosy;	chr1:113856811	chr1:113698884~113699631:-
GBM	cis	rs7869524	0.549	rs10970468	ENSG00000231808.2	LINC01388	-4.52	1.48e-05	0.0128	-0.47	-0.39	Mean platelet volume;	chr9:326448	chr9:112713~113754:-
GBM	cis	rs4842666	0.915	rs12579302	ENSG00000258302.2	RP11-981P6.1	-4.52	1.48e-05	0.0128	-0.47	-0.39	Blood pressure;	chr12:89656726	chr12:89561129~89594878:+
GBM	cis	rs588177	1	rs588177	ENSG00000236935.1	AP003774.1	4.52	1.48e-05	0.0128	0.44	0.39	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64256584	chr11:64325050~64329504:-
GBM	cis	rs7017914	0.967	rs7825446	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70751939	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6472543	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70752173	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs7819332	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70756030	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs7012404	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70756463	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs7018381	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70757882	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13258584	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70759344	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs7009297	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70760131	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs7014012	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70760508	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs1471114	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70763312	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs12680166	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70766403	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs17688313	ENSG00000246366.5	RP11-382J12.1	4.52	1.48e-05	0.0128	0.42	0.39	Bone mineral density;	chr8:70771629	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs1373480	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70774732	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs10448014	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70775930	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs7000647	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70776173	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13254801	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70776749	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.783	rs13252584	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70776796	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.84	rs13254851	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70776799	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs62508771	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70780453	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6998786	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70782395	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs12680988	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70783655	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs1596566	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70786341	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6993115	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70786948	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs6992879	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70787048	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs10504481	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70787282	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs1838393	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70790356	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.935	rs7826483	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70790658	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs35207116	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70796736	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs62508819	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70805871	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs34042354	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70818726	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13261712	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70820029	chr8:70608577~70663279:+
GBM	cis	rs7017914	1	rs13252719	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70822334	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs13274062	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70824852	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13274381	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70852859	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.935	rs6472551	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70869614	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs17689585	ENSG00000246366.5	RP11-382J12.1	-4.52	1.48e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70906566	chr8:70608577~70663279:+
GBM	cis	rs8062405	0.723	rs4788079	ENSG00000271623.1	RP11-435I10.5	-4.52	1.49e-05	0.0128	-0.47	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28364700~28365333:+
GBM	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-4.52	1.49e-05	0.0128	-0.46	-0.39	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
GBM	cis	rs853679	0.824	rs34712084	ENSG00000199851.2	U3	4.52	1.49e-05	0.0128	0.78	0.39	Depression;	chr6:28076050	chr6:28015568~28015777:+
GBM	cis	rs853679	0.824	rs1321505	ENSG00000199851.2	U3	4.52	1.49e-05	0.0128	0.78	0.39	Depression;	chr6:28085045	chr6:28015568~28015777:+
GBM	cis	rs853679	0.882	rs9468287	ENSG00000199851.2	U3	4.52	1.49e-05	0.0128	0.78	0.39	Depression;	chr6:28111963	chr6:28015568~28015777:+
GBM	cis	rs4664293	0.867	rs7566584	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159728284	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs7566802	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159728480	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs3732289	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159728887	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs3821299	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159729229	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs13415100	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159729716	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs13415025	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159729799	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs13389662	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159729926	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs7562060	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159730618	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs4665110	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159731014	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs34893664	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159732266	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs34795915	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159732420	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs10204867	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159732674	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs35196716	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159733266	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs6432557	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159735699	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs7603274	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159736179	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs13403371	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159736603	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs13428679	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159736687	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs12623283	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159736959	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2098976	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159737264	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2081723	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159737649	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2081722	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159737697	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs10166694	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159738380	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs10190704	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159738451	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2357529	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159738922	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs12692562	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159739199	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs12998291	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159739392	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs10194483	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159739883	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2357531	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159740907	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2357532	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159740916	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs16844269	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159742569	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs4664300	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159743927	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs16822556	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159744392	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs16822558	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159744496	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs1834761	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159745278	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs6432558	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159745397	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs7567818	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159746186	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs12692563	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159746300	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs12620924	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159746452	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs13397597	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159747084	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.805	rs7593273	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159749349	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.805	rs6432559	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159750649	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs6432560	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159750758	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs3863924	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159758247	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs11681565	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159760362	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs11687502	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159760464	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.836	rs13401087	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159760957	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs12692564	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159761326	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs1427328	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159762064	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.613	rs9784044	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159765854	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs4664301	ENSG00000226266.5	AC009961.3	-4.52	1.49e-05	0.0128	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159766855	chr2:159670708~159712435:-
GBM	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-4.52	1.49e-05	0.0128	-0.51	-0.39	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
GBM	cis	rs17685	0.753	rs4732595	ENSG00000280388.1	RP11-229D13.3	-4.52	1.49e-05	0.0128	-0.37	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76125821	chr7:76043977~76045963:-
GBM	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-4.52	1.49e-05	0.0128	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
GBM	cis	rs4834770	1	rs878374	ENSG00000250412.1	KLHL2P1	4.52	1.49e-05	0.0128	0.5	0.39	Blood protein levels;	chr4:119316409	chr4:119334329~119378233:+
GBM	cis	rs7017914	0.652	rs56099911	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70710156	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6987515	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70728067	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs56156614	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70730816	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs56094661	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70732493	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.592	rs6980835	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70733691	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6994488	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70741229	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35931247	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70743849	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs7015947	ENSG00000246366.5	RP11-382J12.1	-4.52	1.49e-05	0.0128	-0.42	-0.39	Bone mineral density;	chr8:70748711	chr8:70608577~70663279:+
GBM	cis	rs3096299	0.967	rs7205785	ENSG00000260259.1	RP11-368I7.4	4.52	1.49e-05	0.0128	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89682620~89686569:-
GBM	cis	rs11642862	1	rs75231191	ENSG00000260911.2	RP11-196G11.2	4.52	1.49e-05	0.0128	0.56	0.39	Tonsillectomy;	chr16:30777280	chr16:31043150~31049868:+
GBM	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	4.52	1.5e-05	0.0128	0.52	0.39	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
GBM	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-4.52	1.5e-05	0.0128	-0.43	-0.39	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
GBM	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
GBM	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	4.52	1.5e-05	0.0129	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
GBM	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	4.52	1.5e-05	0.0129	0.78	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
GBM	cis	rs7017914	0.652	rs62533063	ENSG00000246366.5	RP11-382J12.1	-4.52	1.5e-05	0.0129	-0.41	-0.39	Bone mineral density;	chr8:70673824	chr8:70608577~70663279:+
GBM	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-4.52	1.5e-05	0.0129	-0.47	-0.39	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
GBM	cis	rs2069426	0.591	rs17694493	ENSG00000265194.1	RP11-70L8.4	4.52	1.51e-05	0.0129	0.44	0.39	Acute lymphoblastic leukemia (childhood);	chr9:22041999	chr9:21858910~21861926:-
GBM	cis	rs4273100	0.688	rs4924967	ENSG00000262319.1	CTC-457L16.2	-4.52	1.51e-05	0.0129	-0.46	-0.39	Schizophrenia;	chr17:19268883	chr17:19141017~19143689:-
GBM	cis	rs4273100	0.688	rs28760541	ENSG00000262319.1	CTC-457L16.2	-4.52	1.51e-05	0.0129	-0.46	-0.39	Schizophrenia;	chr17:19269192	chr17:19141017~19143689:-
GBM	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	4.52	1.51e-05	0.013	0.53	0.39	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
GBM	cis	rs172166	0.516	rs2622322	ENSG00000218016.2	ZNF192P2	-4.52	1.51e-05	0.013	-0.44	-0.39	Cardiac Troponin-T levels;	chr6:28149665	chr6:28188050~28189432:+
GBM	cis	rs172166	0.516	rs1150670	ENSG00000218016.2	ZNF192P2	-4.52	1.51e-05	0.013	-0.44	-0.39	Cardiac Troponin-T levels;	chr6:28162781	chr6:28188050~28189432:+
GBM	cis	rs172166	0.516	rs2021826	ENSG00000218016.2	ZNF192P2	-4.52	1.51e-05	0.013	-0.44	-0.39	Cardiac Troponin-T levels;	chr6:28164978	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.835	rs1233696	ENSG00000218016.2	ZNF192P2	-4.52	1.51e-05	0.013	-0.44	-0.39	Pubertal anthropometrics;	chr6:28175232	chr6:28188050~28189432:+
GBM	cis	rs17361889	0.502	rs10807780	ENSG00000224683.1	RPL36AP29	-4.52	1.51e-05	0.013	-0.43	-0.39	Pediatric bone mineral content (hip);	chr7:16179743	chr7:16208945~16209265:+
GBM	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	4.52	1.51e-05	0.013	0.62	0.39	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
GBM	cis	rs741668	0.897	rs12429980	ENSG00000235903.6	CPB2-AS1	4.52	1.51e-05	0.013	0.53	0.39	Cerebrospinal fluid clusterin levels;	chr13:45976003	chr13:46052806~46113332:+
GBM	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-4.52	1.51e-05	0.013	-0.47	-0.39	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
GBM	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-4.52	1.52e-05	0.013	-0.45	-0.39	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
GBM	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-4.52	1.52e-05	0.013	-0.44	-0.39	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
GBM	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	4.52	1.52e-05	0.013	0.39	0.39	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
GBM	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-4.52	1.52e-05	0.013	-0.72	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
GBM	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	4.52	1.52e-05	0.013	0.41	0.39	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	4.52	1.52e-05	0.013	0.41	0.39	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
GBM	cis	rs7267979	0.586	rs11087505	ENSG00000125804.12	FAM182A	-4.52	1.52e-05	0.013	-0.49	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:26054655~26086917:+
GBM	cis	rs17685	0.725	rs6947068	ENSG00000280388.1	RP11-229D13.3	4.52	1.52e-05	0.013	0.37	0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76032738	chr7:76043977~76045963:-
GBM	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-4.52	1.52e-05	0.013	-0.44	-0.39	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
GBM	cis	rs12460587	0.587	rs10415150	ENSG00000275055.1	CTC-471J1.11	-4.52	1.53e-05	0.0131	-0.44	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:52049007~52049754:+
GBM	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-4.52	1.53e-05	0.0131	-0.51	-0.39	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
GBM	cis	rs10819861	1	rs10819861	ENSG00000175611.10	LINC00476	-4.52	1.53e-05	0.0131	-0.45	-0.39	Electrocardiographic traits;	chr9:96105531	chr9:95759231~95875977:-
GBM	cis	rs950169	1	rs1818950	ENSG00000275120.1	RP11-182J1.17	4.52	1.53e-05	0.0131	0.51	0.39	Schizophrenia;	chr15:84053769	chr15:84599434~84606463:-
GBM	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-4.52	1.53e-05	0.0131	-0.47	-0.39	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
GBM	cis	rs11671005	0.779	rs11670125	ENSG00000269473.1	CTD-2619J13.19	4.52	1.53e-05	0.0131	0.44	0.39	Mean platelet volume;	chr19:58476023	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.779	rs731259	ENSG00000269473.1	CTD-2619J13.19	4.52	1.53e-05	0.0131	0.44	0.39	Mean platelet volume;	chr19:58478057	chr19:58440448~58445849:+
GBM	cis	rs66887589	0.967	rs59516282	ENSG00000249244.1	RP11-548H18.2	-4.52	1.53e-05	0.0131	-0.46	-0.39	Diastolic blood pressure;	chr4:119580861	chr4:119391831~119395335:-
GBM	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	4.52	1.53e-05	0.0131	0.41	0.39	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	4.52	1.53e-05	0.0131	0.41	0.39	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
GBM	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	4.52	1.54e-05	0.0131	0.45	0.39	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
GBM	cis	rs1150668	0.799	rs9301	ENSG00000199851.2	U3	4.52	1.54e-05	0.0131	0.48	0.39	Pubertal anthropometrics;	chr6:28324929	chr6:28015568~28015777:+
GBM	cis	rs2976388	0.647	rs13272904	ENSG00000253741.1	CTD-2292P10.4	-4.51	1.54e-05	0.0132	-0.4	-0.39	Urinary tract infection frequency;	chr8:142701196	chr8:142702252~142726973:-
GBM	cis	rs7017914	0.628	rs7833211	ENSG00000246366.5	RP11-382J12.1	-4.51	1.54e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70691903	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs12156043	ENSG00000246366.5	RP11-382J12.1	-4.51	1.54e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70701808	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.644	rs6472564	ENSG00000246366.5	RP11-382J12.1	-4.51	1.54e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:71066165	chr8:70608577~70663279:+
GBM	cis	rs4664293	0.867	rs7565297	ENSG00000226266.5	AC009961.3	-4.51	1.54e-05	0.0132	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159716008	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs7594329	ENSG00000226266.5	AC009961.3	-4.51	1.54e-05	0.0132	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159716207	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs7582124	ENSG00000226266.5	AC009961.3	-4.51	1.54e-05	0.0132	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159716326	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs7606046	ENSG00000226266.5	AC009961.3	-4.51	1.54e-05	0.0132	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159719647	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.802	rs13025347	ENSG00000226266.5	AC009961.3	-4.51	1.54e-05	0.0132	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159721056	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs6432554	ENSG00000226266.5	AC009961.3	-4.51	1.54e-05	0.0132	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159722573	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs6760485	ENSG00000226266.5	AC009961.3	-4.51	1.54e-05	0.0132	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159723179	chr2:159670708~159712435:-
GBM	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-4.51	1.54e-05	0.0132	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-4.51	1.54e-05	0.0132	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-4.51	1.54e-05	0.0132	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-4.51	1.54e-05	0.0132	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-4.51	1.54e-05	0.0132	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-4.51	1.54e-05	0.0132	-0.67	-0.39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
GBM	cis	rs4072705	0.967	rs4838208	ENSG00000224020.1	MIR181A2HG	-4.51	1.55e-05	0.0132	-0.41	-0.39	Menarche (age at onset);	chr9:124765756	chr9:124658467~124698631:+
GBM	cis	rs4072705	0.967	rs4838209	ENSG00000224020.1	MIR181A2HG	-4.51	1.55e-05	0.0132	-0.41	-0.39	Menarche (age at onset);	chr9:124766563	chr9:124658467~124698631:+
GBM	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-4.51	1.55e-05	0.0132	-0.52	-0.39	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
GBM	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-4.51	1.55e-05	0.0132	-0.52	-0.39	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
GBM	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	4.51	1.55e-05	0.0132	0.5	0.39	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
GBM	cis	rs4072705	0.967	rs4838200	ENSG00000224020.1	MIR181A2HG	4.51	1.55e-05	0.0132	0.41	0.39	Menarche (age at onset);	chr9:124688778	chr9:124658467~124698631:+
GBM	cis	rs4072705	0.967	rs10818985	ENSG00000224020.1	MIR181A2HG	-4.51	1.55e-05	0.0132	-0.41	-0.39	Menarche (age at onset);	chr9:124688292	chr9:124658467~124698631:+
GBM	cis	rs7017914	0.967	rs2100908	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70671075	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13271442	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70672934	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs34558600	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70673917	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6472538	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70674736	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs7001162	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70675235	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs56112621	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70676159	chr8:70608577~70663279:+
GBM	cis	rs7017914	1	rs7017914	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70678968	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs6991329	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70681190	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13256250	ENSG00000246366.5	RP11-382J12.1	-4.51	1.55e-05	0.0132	-0.42	-0.39	Bone mineral density;	chr8:70683958	chr8:70608577~70663279:+
GBM	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	4.51	1.55e-05	0.0132	0.45	0.39	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
GBM	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-4.51	1.55e-05	0.0132	-0.72	-0.39	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
GBM	cis	rs73198271	1	rs73198271	ENSG00000253893.2	FAM85B	4.51	1.55e-05	0.0132	0.56	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749297	chr8:8167819~8226614:-
GBM	cis	rs73198271	1	rs73198272	ENSG00000253893.2	FAM85B	4.51	1.55e-05	0.0132	0.56	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749298	chr8:8167819~8226614:-
GBM	cis	rs73198271	1	rs4841030	ENSG00000253893.2	FAM85B	4.51	1.55e-05	0.0132	0.56	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749501	chr8:8167819~8226614:-
GBM	cis	rs4072705	0.904	rs721863	ENSG00000224020.1	MIR181A2HG	-4.51	1.55e-05	0.0132	-0.43	-0.39	Menarche (age at onset);	chr9:124773988	chr9:124658467~124698631:+
GBM	cis	rs763121	0.853	rs5757193	ENSG00000273076.1	RP3-508I15.22	-4.51	1.55e-05	0.0132	-0.45	-0.39	Menopause (age at onset);	chr22:38638862	chr22:38743495~38743910:+
GBM	cis	rs1009077	0.61	rs1987179	ENSG00000248280.1	RP11-33B1.2	4.51	1.55e-05	0.0132	0.55	0.39	Endometriosis;	chr4:119598779	chr4:119440561~119450157:-
GBM	cis	rs7017914	0.702	rs13278019	ENSG00000246366.5	RP11-382J12.1	-4.51	1.56e-05	0.0133	-0.42	-0.39	Bone mineral density;	chr8:70621109	chr8:70608577~70663279:+
GBM	cis	rs11671005	0.693	rs34230465	ENSG00000269473.1	CTD-2619J13.19	4.51	1.56e-05	0.0133	0.43	0.39	Mean platelet volume;	chr19:58432209	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs3764529	ENSG00000269473.1	CTD-2619J13.19	4.51	1.56e-05	0.0133	0.43	0.39	Mean platelet volume;	chr19:58433722	chr19:58440448~58445849:+
GBM	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-4.51	1.56e-05	0.0133	-0.52	-0.39	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
GBM	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-4.51	1.56e-05	0.0133	-0.63	-0.39	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
GBM	cis	rs6600671	0.934	rs12131379	ENSG00000223345.3	HIST2H2BA	4.51	1.56e-05	0.0133	0.51	0.39	Hip geometry;	chr1:121551639	chr1:121108210~121117257:-
GBM	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-4.51	1.56e-05	0.0133	-0.56	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
GBM	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-4.51	1.56e-05	0.0133	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
GBM	cis	rs9532669	0.511	rs3783164	ENSG00000168852.11	TPTE2P5	-4.51	1.56e-05	0.0133	-0.56	-0.39	Cervical cancer;	chr13:40806227	chr13:40822296~40921749:-
GBM	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	4.51	1.57e-05	0.0133	0.59	0.39	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
GBM	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	4.51	1.57e-05	0.0133	0.59	0.39	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
GBM	cis	rs7017914	0.934	rs13255886	ENSG00000246366.5	RP11-382J12.1	-4.51	1.57e-05	0.0133	-0.42	-0.39	Bone mineral density;	chr8:70653719	chr8:70608577~70663279:+
GBM	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-4.51	1.57e-05	0.0133	-0.49	-0.39	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
GBM	cis	rs9468199	0.505	rs72847381	ENSG00000199851.2	U3	4.51	1.57e-05	0.0133	1.14	0.39	Parkinson's disease;	chr6:27906153	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.799	rs1150707	ENSG00000218016.2	ZNF192P2	-4.51	1.57e-05	0.0133	-0.45	-0.39	Pubertal anthropometrics;	chr6:28229827	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.768	rs1233713	ENSG00000218016.2	ZNF192P2	-4.51	1.57e-05	0.0133	-0.45	-0.39	Pubertal anthropometrics;	chr6:28230503	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.799	rs7206	ENSG00000218016.2	ZNF192P2	-4.51	1.57e-05	0.0133	-0.45	-0.39	Pubertal anthropometrics;	chr6:28233360	chr6:28188050~28189432:+
GBM	cis	rs9450351	0.744	rs1447157	ENSG00000203875.9	SNHG5	-4.51	1.57e-05	0.0134	-0.92	-0.39	Interferon gamma-induced protein 10 levels;	chr6:85879434	chr6:85660950~85678736:-
GBM	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
GBM	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
GBM	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	4.51	1.57e-05	0.0134	0.63	0.39	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-4.51	1.57e-05	0.0134	-0.63	-0.39	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
GBM	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-4.51	1.57e-05	0.0134	-0.46	-0.39	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
GBM	cis	rs7615952	0.546	rs16836896	ENSG00000171084.14	FAM86JP	4.51	1.57e-05	0.0134	0.65	0.39	Blood pressure (smoking interaction);	chr3:125592418	chr3:125916620~125930024:+
GBM	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	4.51	1.57e-05	0.0134	0.64	0.39	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
GBM	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	4.51	1.57e-05	0.0134	0.47	0.39	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
GBM	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	4.51	1.58e-05	0.0134	0.52	0.39	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
GBM	cis	rs16937	0.662	rs10900472	ENSG00000271580.1	RP11-536L3.4	-4.51	1.58e-05	0.0134	-0.35	-0.39	Schizophrenia;	chr1:205212398	chr1:205091163~205091946:+
GBM	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-4.51	1.58e-05	0.0134	-0.46	-0.39	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
GBM	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	4.51	1.58e-05	0.0134	0.48	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
GBM	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	4.51	1.58e-05	0.0134	0.48	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
GBM	cis	rs172166	0.561	rs149976	ENSG00000218016.2	ZNF192P2	4.51	1.58e-05	0.0134	0.47	0.39	Cardiac Troponin-T levels;	chr6:28019998	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.799	rs853684	ENSG00000218016.2	ZNF192P2	-4.51	1.58e-05	0.0134	-0.45	-0.39	Pubertal anthropometrics;	chr6:28326773	chr6:28188050~28189432:+
GBM	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	4.51	1.58e-05	0.0134	0.53	0.39	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	4.51	1.58e-05	0.0134	0.53	0.39	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	4.51	1.58e-05	0.0134	0.53	0.39	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
GBM	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	4.51	1.58e-05	0.0134	0.49	0.39	Height;	chr3:53072864	chr3:53064283~53065091:-
GBM	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	4.51	1.58e-05	0.0134	0.45	0.39	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-4.51	1.58e-05	0.0134	-0.45	-0.39	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-4.51	1.58e-05	0.0134	-0.45	-0.39	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-4.51	1.58e-05	0.0134	-0.44	-0.39	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
GBM	cis	rs858239	0.669	rs10950940	ENSG00000230042.1	AK3P3	4.51	1.59e-05	0.0135	0.44	0.39	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23129178~23129841:+
GBM	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-4.51	1.59e-05	0.0135	-0.56	-0.39	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
GBM	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-4.51	1.59e-05	0.0135	-0.5	-0.39	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-4.51	1.59e-05	0.0135	-0.5	-0.39	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
GBM	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-4.51	1.59e-05	0.0135	-0.52	-0.39	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
GBM	cis	rs8062405	0.965	rs8049439	ENSG00000271623.1	RP11-435I10.5	-4.51	1.59e-05	0.0135	-0.46	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28364700~28365333:+
GBM	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	4.51	1.59e-05	0.0135	0.48	0.39	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
GBM	cis	rs10911251	0.546	rs10911260	ENSG00000224468.3	RP11-181K3.4	4.51	1.59e-05	0.0135	0.31	0.39	Colorectal cancer;	chr1:183137095	chr1:183138402~183141282:-
GBM	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-4.51	1.59e-05	0.0135	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
GBM	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	4.51	1.59e-05	0.0135	0.59	0.39	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
GBM	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	4.51	1.59e-05	0.0135	0.59	0.39	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
GBM	cis	rs4273100	0.605	rs28591622	ENSG00000262319.1	CTC-457L16.2	-4.51	1.59e-05	0.0135	-0.46	-0.39	Schizophrenia;	chr17:19272004	chr17:19141017~19143689:-
GBM	cis	rs7017914	0.652	rs7841286	ENSG00000246366.5	RP11-382J12.1	-4.51	1.59e-05	0.0135	-0.41	-0.39	Bone mineral density;	chr8:70890908	chr8:70608577~70663279:+
GBM	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	4.51	1.59e-05	0.0135	0.43	0.39	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
GBM	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-4.51	1.6e-05	0.0135	-0.63	-0.39	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
GBM	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-4.51	1.6e-05	0.0135	-0.27	-0.39	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
GBM	cis	rs9876781	1	rs9849509	ENSG00000244380.1	RP11-24C3.2	4.51	1.6e-05	0.0135	0.46	0.39	Longevity;	chr3:48442021	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs60512868	ENSG00000244380.1	RP11-24C3.2	4.51	1.6e-05	0.0135	0.46	0.39	Longevity;	chr3:48442035	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs7636044	ENSG00000244380.1	RP11-24C3.2	4.51	1.6e-05	0.0135	0.46	0.39	Longevity;	chr3:48443151	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs4490383	ENSG00000244380.1	RP11-24C3.2	4.51	1.6e-05	0.0135	0.46	0.39	Longevity;	chr3:48443275	chr3:48440352~48446656:-
GBM	cis	rs1009077	0.61	rs6822275	ENSG00000248280.1	RP11-33B1.2	-4.51	1.6e-05	0.0135	-0.56	-0.39	Endometriosis;	chr4:119588472	chr4:119440561~119450157:-
GBM	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	4.51	1.6e-05	0.0136	0.47	0.39	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
GBM	cis	rs3845817	0.868	rs702890	ENSG00000237979.1	AC007389.1	-4.51	1.6e-05	0.0136	-0.54	-0.39	Bipolar disorder;	chr2:65530517	chr2:65500993~65502138:-
GBM	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	4.51	1.6e-05	0.0136	0.58	0.39	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	4.51	1.6e-05	0.0136	0.58	0.39	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
GBM	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-4.51	1.6e-05	0.0136	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-4.51	1.6e-05	0.0136	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-4.51	1.6e-05	0.0136	-0.49	-0.39	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
GBM	cis	rs338389	0.542	rs7182139	ENSG00000260657.2	RP11-315D16.4	-4.51	1.6e-05	0.0136	-0.56	-0.39	Survival in rectal cancer;	chr15:67993116	chr15:68267792~68277994:-
GBM	cis	rs4713118	0.955	rs9468200	ENSG00000199851.2	U3	4.5	1.61e-05	0.0136	0.55	0.39	Parkinson's disease;	chr6:27715284	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs34752872	ENSG00000199851.2	U3	4.5	1.61e-05	0.0136	0.55	0.39	Parkinson's disease;	chr6:27715465	chr6:28015568~28015777:+
GBM	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	4.5	1.61e-05	0.0136	0.59	0.39	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
GBM	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-4.5	1.61e-05	0.0136	-0.4	-0.39	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-4.5	1.61e-05	0.0136	-0.4	-0.39	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-4.5	1.61e-05	0.0136	-0.4	-0.39	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
GBM	cis	rs2579103	0.708	rs1438988	ENSG00000258183.4	RP11-753N8.1	-4.5	1.61e-05	0.0136	-0.57	-0.39	Body mass index;	chr12:90290693	chr12:90280894~90300340:+
GBM	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-4.5	1.61e-05	0.0136	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-4.5	1.61e-05	0.0136	-0.48	-0.39	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
GBM	cis	rs6545883	0.542	rs7584500	ENSG00000271889.1	RP11-493E12.1	4.5	1.61e-05	0.0136	0.4	0.39	Tuberculosis;	chr2:61464980	chr2:61151433~61162105:-
GBM	cis	rs1908814	0.516	rs13275143	ENSG00000255556.2	RP11-351I21.6	4.5	1.61e-05	0.0136	0.41	0.39	Neuroticism;	chr8:11939481	chr8:12378679~12380265:-
GBM	cis	rs1150668	0.796	rs1005125	ENSG00000199851.2	U3	4.5	1.61e-05	0.0136	0.47	0.39	Pubertal anthropometrics;	chr6:28399578	chr6:28015568~28015777:+
GBM	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	4.5	1.61e-05	0.0136	0.7	0.39	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
GBM	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	4.5	1.61e-05	0.0136	0.55	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	4.5	1.61e-05	0.0136	0.55	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
GBM	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	4.5	1.61e-05	0.0136	0.61	0.39	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
GBM	cis	rs397969	0.646	rs203454	ENSG00000230528.6	NOS2P3	-4.5	1.62e-05	0.0137	-0.45	-0.39	Platelet count;	chr17:19918200	chr17:20436337~20447249:+
GBM	cis	rs397969	0.621	rs203449	ENSG00000230528.6	NOS2P3	-4.5	1.62e-05	0.0137	-0.45	-0.39	Platelet count;	chr17:19921308	chr17:20436337~20447249:+
GBM	cis	rs4842666	0.915	rs11105352	ENSG00000258302.2	RP11-981P6.1	4.5	1.62e-05	0.0137	0.48	0.39	Blood pressure;	chr12:89632685	chr12:89561129~89594878:+
GBM	cis	rs4842666	0.915	rs11105353	ENSG00000258302.2	RP11-981P6.1	4.5	1.62e-05	0.0137	0.48	0.39	Blood pressure;	chr12:89632686	chr12:89561129~89594878:+
GBM	cis	rs4842666	0.915	rs11105354	ENSG00000258302.2	RP11-981P6.1	4.5	1.62e-05	0.0137	0.48	0.39	Blood pressure;	chr12:89632746	chr12:89561129~89594878:+
GBM	cis	rs3096299	0.583	rs2965949	ENSG00000260259.1	RP11-368I7.4	4.5	1.62e-05	0.0137	0.46	0.39	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89682620~89686569:-
GBM	cis	rs9353324	1	rs7745560	ENSG00000203875.9	SNHG5	4.5	1.62e-05	0.0137	0.95	0.39	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85660950~85678736:-
GBM	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	4.5	1.62e-05	0.0137	0.45	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
GBM	cis	rs3806843	1	rs10223116	ENSG00000202111.1	VTRNA1-2	-4.5	1.62e-05	0.0137	-0.4	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140813058	chr5:140718925~140719013:+
GBM	cis	rs17772222	0.74	rs7160647	ENSG00000222990.1	RNU4-22P	4.5	1.62e-05	0.0137	0.43	0.39	Coronary artery calcification;	chr14:88507340	chr14:88513498~88513663:+
GBM	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	4.5	1.63e-05	0.0137	0.64	0.39	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
GBM	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-4.5	1.63e-05	0.0137	-0.46	-0.39	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-4.5	1.63e-05	0.0137	-0.46	-0.39	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-4.5	1.63e-05	0.0137	-0.46	-0.39	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-4.5	1.63e-05	0.0137	-0.46	-0.39	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-4.5	1.63e-05	0.0137	-0.46	-0.39	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-4.5	1.63e-05	0.0137	-0.46	-0.39	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
GBM	cis	rs3096299	0.606	rs4785674	ENSG00000260259.1	RP11-368I7.4	4.5	1.63e-05	0.0137	0.45	0.39	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89682620~89686569:-
GBM	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-4.5	1.63e-05	0.0138	-0.42	-0.39	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
GBM	cis	rs7017914	0.902	rs34856835	ENSG00000246366.5	RP11-382J12.1	-4.5	1.63e-05	0.0138	-0.42	-0.39	Bone mineral density;	chr8:71058376	chr8:70608577~70663279:+
GBM	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	4.5	1.63e-05	0.0138	0.74	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
GBM	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	4.5	1.64e-05	0.0138	0.57	0.39	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
GBM	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-4.5	1.64e-05	0.0138	-0.43	-0.39	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	4.5	1.64e-05	0.0138	0.43	0.39	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
GBM	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	4.5	1.64e-05	0.0138	0.58	0.39	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
GBM	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	4.5	1.64e-05	0.0138	0.47	0.39	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
GBM	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	4.5	1.64e-05	0.0138	0.47	0.39	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
GBM	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	4.5	1.64e-05	0.0138	0.47	0.39	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
GBM	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	4.5	1.65e-05	0.0139	0.53	0.39	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
GBM	cis	rs7017914	0.652	rs7003788	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70876889	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs13272343	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70882272	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6984618	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70883334	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs12675094	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70884968	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs12675116	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70885056	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs13252230	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70886081	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6996049	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70887771	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.629	rs35762981	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70889405	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs4629903	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70892897	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs13271286	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70894364	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs12156041	ENSG00000246366.5	RP11-382J12.1	-4.5	1.65e-05	0.0139	-0.41	-0.39	Bone mineral density;	chr8:70914690	chr8:70608577~70663279:+
GBM	cis	rs10911251	0.546	rs1051473	ENSG00000224468.3	RP11-181K3.4	-4.5	1.65e-05	0.0139	-0.31	-0.39	Colorectal cancer;	chr1:183145011	chr1:183138402~183141282:-
GBM	cis	rs7315956	0.865	rs7296613	ENSG00000257139.1	RP11-320P7.2	-4.5	1.65e-05	0.0139	-0.46	-0.39	Testicular germ cell tumor;	chr12:70155737	chr12:70180338~70202004:+
GBM	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	4.5	1.65e-05	0.0139	0.62	0.39	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
GBM	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	4.5	1.65e-05	0.0139	0.51	0.39	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
GBM	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	4.5	1.65e-05	0.0139	0.47	0.39	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
GBM	cis	rs4713118	0.869	rs6456802	ENSG00000218016.2	ZNF192P2	-4.5	1.66e-05	0.0139	-0.5	-0.39	Parkinson's disease;	chr6:27730576	chr6:28188050~28189432:+
GBM	cis	rs7017914	0.702	rs62531711	ENSG00000246366.5	RP11-382J12.1	-4.5	1.66e-05	0.0139	-0.42	-0.39	Bone mineral density;	chr8:70618265	chr8:70608577~70663279:+
GBM	cis	rs4373814	0.857	rs12570727	ENSG00000226083.4	SLC39A12-AS1	4.5	1.66e-05	0.0139	0.49	0.39	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18136590	chr10:18001786~18010562:-
GBM	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	4.5	1.66e-05	0.0139	0.44	0.39	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
GBM	cis	rs1257344	1	rs2890729	ENSG00000231758.2	AC092652.1	4.5	1.66e-05	0.0139	0.39	0.39	Diisocyanate-induced asthma;	chr2:143834300	chr2:143640756~143656179:-
GBM	cis	rs1257344	1	rs2178734	ENSG00000231758.2	AC092652.1	4.5	1.66e-05	0.0139	0.39	0.39	Diisocyanate-induced asthma;	chr2:143834537	chr2:143640756~143656179:-
GBM	cis	rs1257344	1	rs2593719	ENSG00000231758.2	AC092652.1	-4.5	1.66e-05	0.0139	-0.39	-0.39	Diisocyanate-induced asthma;	chr2:143835592	chr2:143640756~143656179:-
GBM	cis	rs1257344	1	rs2593718	ENSG00000231758.2	AC092652.1	-4.5	1.66e-05	0.0139	-0.39	-0.39	Diisocyanate-induced asthma;	chr2:143835816	chr2:143640756~143656179:-
GBM	cis	rs1257344	1	rs1882627	ENSG00000231758.2	AC092652.1	-4.5	1.66e-05	0.0139	-0.39	-0.39	Diisocyanate-induced asthma;	chr2:143837483	chr2:143640756~143656179:-
GBM	cis	rs1257344	1	rs1257345	ENSG00000231758.2	AC092652.1	-4.5	1.66e-05	0.0139	-0.39	-0.39	Diisocyanate-induced asthma;	chr2:143839899	chr2:143640756~143656179:-
GBM	cis	rs1257344	1	rs1257344	ENSG00000231758.2	AC092652.1	-4.5	1.66e-05	0.0139	-0.39	-0.39	Diisocyanate-induced asthma;	chr2:143840863	chr2:143640756~143656179:-
GBM	cis	rs1257344	1	rs1257343	ENSG00000231758.2	AC092652.1	-4.5	1.66e-05	0.0139	-0.39	-0.39	Diisocyanate-induced asthma;	chr2:143842228	chr2:143640756~143656179:-
GBM	cis	rs2739330	0.685	rs4822453	ENSG00000272787.1	KB-226F1.2	4.5	1.66e-05	0.014	0.37	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23969211~23969873:+
GBM	cis	rs4834770	1	rs4834770	ENSG00000249244.1	RP11-548H18.2	4.5	1.66e-05	0.014	0.49	0.39	Blood protein levels;	chr4:119320694	chr4:119391831~119395335:-
GBM	cis	rs4834770	1	rs6823963	ENSG00000249244.1	RP11-548H18.2	4.5	1.66e-05	0.014	0.49	0.39	Blood protein levels;	chr4:119321009	chr4:119391831~119395335:-
GBM	cis	rs4834770	1	rs2282688	ENSG00000249244.1	RP11-548H18.2	4.5	1.66e-05	0.014	0.49	0.39	Blood protein levels;	chr4:119322567	chr4:119391831~119395335:-
GBM	cis	rs4834770	1	rs10034579	ENSG00000249244.1	RP11-548H18.2	4.5	1.66e-05	0.014	0.49	0.39	Blood protein levels;	chr4:119322874	chr4:119391831~119395335:-
GBM	cis	rs4604732	0.603	rs10925051	ENSG00000227135.1	GCSAML-AS1	-4.5	1.66e-05	0.014	-0.51	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247478532	chr1:247524679~247526752:-
GBM	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	4.5	1.66e-05	0.014	0.57	0.39	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
GBM	cis	rs7017914	0.69	rs7845516	ENSG00000246366.5	RP11-382J12.1	4.5	1.66e-05	0.014	0.4	0.39	Bone mineral density;	chr8:70773587	chr8:70608577~70663279:+
GBM	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	4.5	1.67e-05	0.014	0.48	0.39	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
GBM	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	4.5	1.67e-05	0.014	0.32	0.39	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
GBM	cis	rs731565	1	rs117004893	ENSG00000232391.1	RANP2	4.5	1.67e-05	0.014	0.75	0.39	Diabetic kidney disease;	chr7:147709971	chr7:147167344~147167572:+
GBM	cis	rs731565	1	rs76726484	ENSG00000232391.1	RANP2	4.5	1.67e-05	0.014	0.75	0.39	Diabetic kidney disease;	chr7:147714916	chr7:147167344~147167572:+
GBM	cis	rs731565	1	rs79763756	ENSG00000232391.1	RANP2	4.5	1.67e-05	0.014	0.75	0.39	Diabetic kidney disease;	chr7:147716645	chr7:147167344~147167572:+
GBM	cis	rs731565	1	rs75560221	ENSG00000232391.1	RANP2	4.5	1.67e-05	0.014	0.75	0.39	Diabetic kidney disease;	chr7:147716758	chr7:147167344~147167572:+
GBM	cis	rs2018683	0.834	rs733485	ENSG00000272568.4	CTB-113D17.1	4.5	1.67e-05	0.014	0.45	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28979967~29013367:+
GBM	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	4.49	1.67e-05	0.014	0.44	0.39	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
GBM	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-4.49	1.67e-05	0.014	-0.39	-0.39	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
GBM	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	4.49	1.68e-05	0.0141	0.4	0.39	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
GBM	cis	rs2579103	0.708	rs2579101	ENSG00000258183.4	RP11-753N8.1	-4.49	1.68e-05	0.0141	-0.57	-0.39	Body mass index;	chr12:90293325	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.626	rs2579099	ENSG00000258183.4	RP11-753N8.1	-4.49	1.68e-05	0.0141	-0.57	-0.39	Body mass index;	chr12:90293578	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs2579095	ENSG00000258183.4	RP11-753N8.1	-4.49	1.68e-05	0.0141	-0.57	-0.39	Body mass index;	chr12:90294499	chr12:90280894~90300340:+
GBM	cis	rs11673344	0.542	rs826325	ENSG00000226686.6	LINC01535	4.49	1.68e-05	0.0141	0.41	0.39	Obesity-related traits;	chr19:37003580	chr19:37251912~37265535:+
GBM	cis	rs3741404	0.609	rs687581	ENSG00000231680.1	AP003774.6	4.49	1.68e-05	0.0141	0.44	0.39	Platelet count;	chr11:64104061	chr11:64394342~64395831:-
GBM	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-4.49	1.68e-05	0.0141	-0.51	-0.39	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
GBM	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	4.49	1.68e-05	0.0141	0.44	0.39	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
GBM	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	4.49	1.68e-05	0.0141	0.46	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
GBM	cis	rs1501911	0.611	rs1875529	ENSG00000248489.1	CTD-2007H13.3	-4.49	1.68e-05	0.0141	-0.45	-0.39	Lung function (FEV1/FVC);	chr5:99033350	chr5:98929171~98995013:+
GBM	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	4.49	1.68e-05	0.0141	0.57	0.39	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
GBM	cis	rs4642101	0.535	rs55692304	ENSG00000213943.3	KRT18P17	4.49	1.69e-05	0.0141	0.42	0.39	QRS complex (12-leadsum);	chr3:12798558	chr3:12787393~12788671:-
GBM	cis	rs763121	0.776	rs4820346	ENSG00000273076.1	RP3-508I15.22	-4.49	1.69e-05	0.0141	-0.42	-0.39	Menopause (age at onset);	chr22:38729069	chr22:38743495~38743910:+
GBM	cis	rs2018683	0.834	rs2012754	ENSG00000272568.4	CTB-113D17.1	4.49	1.69e-05	0.0141	0.45	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28979967~29013367:+
GBM	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-4.49	1.69e-05	0.0142	-0.48	-0.39	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
GBM	cis	rs17772222	0.74	rs11847417	ENSG00000222990.1	RNU4-22P	-4.49	1.69e-05	0.0142	-0.41	-0.39	Coronary artery calcification;	chr14:88510606	chr14:88513498~88513663:+
GBM	cis	rs1150668	0.799	rs853684	ENSG00000199851.2	U3	4.49	1.69e-05	0.0142	0.47	0.39	Pubertal anthropometrics;	chr6:28326773	chr6:28015568~28015777:+
GBM	cis	rs763121	0.819	rs5757133	ENSG00000273076.1	RP3-508I15.22	-4.49	1.69e-05	0.0142	-0.41	-0.39	Menopause (age at onset);	chr22:38551830	chr22:38743495~38743910:+
GBM	cis	rs4713118	0.615	rs9348772	ENSG00000216901.1	AL022393.7	4.49	1.69e-05	0.0142	0.48	0.39	Parkinson's disease;	chr6:27688311	chr6:28176188~28176674:+
GBM	cis	rs7267979	0.753	rs400357	ENSG00000276952.1	RP5-965G21.6	4.49	1.69e-05	0.0142	0.36	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25284915~25285588:-
GBM	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	4.49	1.69e-05	0.0142	0.4	0.39	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
GBM	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-4.49	1.7e-05	0.0142	-0.41	-0.39	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-4.49	1.7e-05	0.0142	-0.41	-0.39	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-4.49	1.7e-05	0.0142	-0.41	-0.39	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
GBM	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	4.49	1.7e-05	0.0142	0.41	0.39	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
GBM	cis	rs763121	0.853	rs2413546	ENSG00000273076.1	RP3-508I15.22	4.49	1.7e-05	0.0142	0.44	0.39	Menopause (age at onset);	chr22:38710996	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2413547	ENSG00000273076.1	RP3-508I15.22	4.49	1.7e-05	0.0142	0.44	0.39	Menopause (age at onset);	chr22:38711333	chr22:38743495~38743910:+
GBM	cis	rs1501911	0.611	rs7712408	ENSG00000248489.1	CTD-2007H13.3	-4.49	1.7e-05	0.0142	-0.44	-0.39	Lung function (FEV1/FVC);	chr5:99020633	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-4.49	1.7e-05	0.0142	-0.44	-0.39	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-4.49	1.7e-05	0.0142	-0.44	-0.39	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
GBM	cis	rs6679677	0.543	rs1230680	ENSG00000232450.1	RP4-730K3.3	-4.49	1.7e-05	0.0142	-0.65	-0.39	Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis;	chr1:113754148	chr1:113698884~113699631:-
GBM	cis	rs7017914	0.905	rs2732106	ENSG00000246366.5	RP11-382J12.1	-4.49	1.7e-05	0.0142	-0.41	-0.39	Bone mineral density;	chr8:71011604	chr8:70608577~70663279:+
GBM	cis	rs67981189	0.574	rs4467005	ENSG00000269927.1	RP6-91H8.3	4.49	1.7e-05	0.0142	0.43	0.39	Schizophrenia;	chr14:71031939	chr14:71141125~71143253:-
GBM	cis	rs61041384	1	rs4148865	ENSG00000256092.2	RP13-942N8.1	-4.49	1.7e-05	0.0142	-0.9	-0.39	Schizophrenia;	chr12:123111202	chr12:123363868~123366113:+
GBM	cis	rs8114671	0.836	rs2425012	ENSG00000269202.1	RP4-614O4.12	4.49	1.7e-05	0.0142	0.48	0.39	Height;	chr20:34994152	chr20:35201747~35203288:-
GBM	cis	rs9400180	1	rs9400179	ENSG00000271734.1	RP1-111B22.3	4.49	1.7e-05	0.0142	0.4	0.39	Major depressive disorder;	chr6:108029391	chr6:108030249~108030718:-
GBM	cis	rs11671005	0.735	rs1122955	ENSG00000269473.1	CTD-2619J13.19	4.49	1.71e-05	0.0143	0.42	0.39	Mean platelet volume;	chr19:58434836	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11668814	ENSG00000269473.1	CTD-2619J13.19	4.49	1.71e-05	0.0143	0.42	0.39	Mean platelet volume;	chr19:58435466	chr19:58440448~58445849:+
GBM	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	4.49	1.71e-05	0.0143	0.47	0.39	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
GBM	cis	rs2018683	0.87	rs13232487	ENSG00000228421.2	AC005013.5	4.49	1.71e-05	0.0143	0.47	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28957667~28959345:+
GBM	cis	rs7017914	0.652	rs13262205	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70659690	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs2279128	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70669324	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.583	rs1477943	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70670528	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs7831507	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70682991	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs13256093	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70684142	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.524	rs35544920	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70687552	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs34719517	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70687866	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.667	rs34972504	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70689486	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs12681588	ENSG00000246366.5	RP11-382J12.1	-4.49	1.71e-05	0.0143	-0.41	-0.39	Bone mineral density;	chr8:70689652	chr8:70608577~70663279:+
GBM	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-4.49	1.71e-05	0.0143	-0.43	-0.39	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
GBM	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	4.49	1.71e-05	0.0143	0.42	0.39	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.528	rs4785721	ENSG00000260259.1	RP11-368I7.4	-4.49	1.72e-05	0.0143	-0.44	-0.39	Vitiligo;	chr16:89773589	chr16:89682620~89686569:-
GBM	cis	rs11671005	0.61	rs11669345	ENSG00000269600.1	AC016629.3	-4.49	1.72e-05	0.0143	-0.56	-0.39	Mean platelet volume;	chr19:58550892	chr19:58593896~58599355:-
GBM	cis	rs7017914	0.69	rs7844508	ENSG00000246366.5	RP11-382J12.1	-4.49	1.72e-05	0.0143	-0.4	-0.39	Bone mineral density;	chr8:70690760	chr8:70608577~70663279:+
GBM	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-4.49	1.72e-05	0.0144	-0.46	-0.39	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
GBM	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	4.49	1.72e-05	0.0144	0.41	0.39	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	4.49	1.72e-05	0.0144	0.41	0.39	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	4.49	1.72e-05	0.0144	0.41	0.39	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	4.49	1.72e-05	0.0144	0.41	0.39	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
GBM	cis	rs10911232	0.507	rs7515822	ENSG00000224468.3	RP11-181K3.4	-4.49	1.72e-05	0.0144	-0.31	-0.39	Hypertriglyceridemia;	chr1:183068668	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797832	ENSG00000224468.3	RP11-181K3.4	-4.49	1.72e-05	0.0144	-0.31	-0.39	Hypertriglyceridemia;	chr1:183074899	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.507	rs10797833	ENSG00000224468.3	RP11-181K3.4	-4.49	1.72e-05	0.0144	-0.31	-0.39	Hypertriglyceridemia;	chr1:183074932	chr1:183138402~183141282:-
GBM	cis	rs597539	0.652	rs564849	ENSG00000250508.1	RP11-757G1.6	-4.49	1.72e-05	0.0144	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68853972	chr11:68870664~68874542:+
GBM	cis	rs1150668	0.83	rs2023493	ENSG00000199851.2	U3	4.49	1.72e-05	0.0144	0.47	0.39	Pubertal anthropometrics;	chr6:28432385	chr6:28015568~28015777:+
GBM	cis	rs10911251	0.546	rs3359	ENSG00000224468.3	RP11-181K3.4	-4.49	1.72e-05	0.0144	-0.31	-0.39	Colorectal cancer;	chr1:183142906	chr1:183138402~183141282:-
GBM	cis	rs4713118	0.869	rs9283880	ENSG00000218016.2	ZNF192P2	-4.49	1.72e-05	0.0144	-0.49	-0.39	Parkinson's disease;	chr6:27747464	chr6:28188050~28189432:+
GBM	cis	rs9467711	0.675	rs58825580	ENSG00000224843.5	LINC00240	4.49	1.73e-05	0.0144	0.84	0.39	Autism spectrum disorder or schizophrenia;	chr6:26365451	chr6:26956992~27023924:+
GBM	cis	rs950169	0.919	rs12915589	ENSG00000275120.1	RP11-182J1.17	4.49	1.73e-05	0.0144	0.51	0.39	Schizophrenia;	chr15:84065712	chr15:84599434~84606463:-
GBM	cis	rs950169	0.959	rs66801143	ENSG00000275120.1	RP11-182J1.17	4.49	1.73e-05	0.0144	0.51	0.39	Schizophrenia;	chr15:84067905	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs35648189	ENSG00000275120.1	RP11-182J1.17	4.49	1.73e-05	0.0144	0.51	0.39	Schizophrenia;	chr15:84071996	chr15:84599434~84606463:-
GBM	cis	rs950169	0.92	rs17300048	ENSG00000275120.1	RP11-182J1.17	4.49	1.73e-05	0.0144	0.51	0.39	Schizophrenia;	chr15:84080725	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs1848093	ENSG00000275120.1	RP11-182J1.17	4.49	1.73e-05	0.0144	0.51	0.39	Schizophrenia;	chr15:84086775	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs12915234	ENSG00000275120.1	RP11-182J1.17	4.49	1.73e-05	0.0144	0.51	0.39	Schizophrenia;	chr15:84089549	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs34751999	ENSG00000275120.1	RP11-182J1.17	4.49	1.73e-05	0.0144	0.51	0.39	Schizophrenia;	chr15:84089667	chr15:84599434~84606463:-
GBM	cis	rs5742933	1	rs7557519	ENSG00000253559.1	OSGEPL1-AS1	-4.49	1.73e-05	0.0144	-0.43	-0.39	Ferritin levels;	chr2:189718461	chr2:189762704~189765556:+
GBM	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-4.49	1.73e-05	0.0144	-0.5	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
GBM	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	4.49	1.73e-05	0.0144	0.42	0.39	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
GBM	cis	rs763121	0.651	rs738249	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38641974	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757196	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38643850	chr22:38743495~38743910:+
GBM	cis	rs763121	0.785	rs5757199	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38644612	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs7289577	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38646209	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs9610993	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38646813	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757200	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38647486	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757203	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38648147	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2205802	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38650322	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757204	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38650695	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs8138996	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38651430	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs6001182	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38651438	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757208	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38653225	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757211	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38655700	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs6001184	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38656111	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs6001185	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38656150	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2294296	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38657044	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2064088	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38657377	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757213	ENSG00000273076.1	RP3-508I15.22	4.49	1.73e-05	0.0144	0.43	0.39	Menopause (age at onset);	chr22:38657883	chr22:38743495~38743910:+
GBM	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-4.49	1.73e-05	0.0144	-0.47	-0.39	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
GBM	cis	rs10435719	0.902	rs12681142	ENSG00000255556.2	RP11-351I21.6	4.49	1.73e-05	0.0144	0.41	0.39	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:12378679~12380265:-
GBM	cis	rs7017914	0.616	rs12681114	ENSG00000246366.5	RP11-382J12.1	-4.49	1.73e-05	0.0144	-0.42	-0.39	Bone mineral density;	chr8:70750263	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.616	rs12679132	ENSG00000246366.5	RP11-382J12.1	-4.49	1.73e-05	0.0144	-0.42	-0.39	Bone mineral density;	chr8:70750270	chr8:70608577~70663279:+
GBM	cis	rs67981189	0.572	rs2810077	ENSG00000269927.1	RP6-91H8.3	-4.49	1.74e-05	0.0144	-0.41	-0.39	Schizophrenia;	chr14:70897097	chr14:71141125~71143253:-
GBM	cis	rs1298062	0.663	rs1274685	ENSG00000131401.10	NAPSB	-4.49	1.74e-05	0.0144	-0.45	-0.39	Age of smoking initiation;	chr19:50494571	chr19:50333796~50344767:-
GBM	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-4.49	1.74e-05	0.0145	-0.54	-0.39	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
GBM	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	4.48	1.74e-05	0.0145	0.4	0.39	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
GBM	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
GBM	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
GBM	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
GBM	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
GBM	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
GBM	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
GBM	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	4.48	1.74e-05	0.0145	0.41	0.39	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
GBM	cis	rs12946454	0.696	rs4792819	ENSG00000267288.2	RP13-890H12.2	-4.48	1.74e-05	0.0145	-0.46	-0.39	Systolic blood pressure;	chr17:45170590	chr17:45168800~45171584:-
GBM	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-4.48	1.74e-05	0.0145	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
GBM	cis	rs977747	1	rs2984618	ENSG00000232022.5	FAAHP1	4.48	1.74e-05	0.0145	0.39	0.39	Body mass index;	chr1:47224766	chr1:46432129~46445521:+
GBM	cis	rs7017914	0.652	rs7842091	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70702546	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1477945	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70703318	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs17760532	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70708052	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs56173818	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70710138	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs34643336	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70715718	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.629	rs35621553	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70715840	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs78322467	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70716439	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.605	rs13269410	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70725773	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.583	rs11986334	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70732239	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2290702	ENSG00000246366.5	RP11-382J12.1	-4.48	1.74e-05	0.0145	-0.41	-0.39	Bone mineral density;	chr8:70734745	chr8:70608577~70663279:+
GBM	cis	rs4834770	1	rs4834771	ENSG00000249244.1	RP11-548H18.2	4.48	1.74e-05	0.0145	0.49	0.39	Blood protein levels;	chr4:119321617	chr4:119391831~119395335:-
GBM	cis	rs4834770	1	rs1397613	ENSG00000249244.1	RP11-548H18.2	4.48	1.74e-05	0.0145	0.49	0.39	Blood protein levels;	chr4:119321774	chr4:119391831~119395335:-
GBM	cis	rs4834770	1	rs6857641	ENSG00000249244.1	RP11-548H18.2	4.48	1.74e-05	0.0145	0.49	0.39	Blood protein levels;	chr4:119322356	chr4:119391831~119395335:-
GBM	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	4.48	1.75e-05	0.0145	0.62	0.39	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
GBM	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-4.48	1.75e-05	0.0145	-0.43	-0.39	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
GBM	cis	rs8114671	0.836	rs3746432	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35004960	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs62213676	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35024873	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.742	rs6058161	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35032223	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs6142280	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35034439	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs4911461	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35042190	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.804	rs3803936	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35044972	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs13042358	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35046676	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs6142284	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35053564	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs2038504	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35060384	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs2104083	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35061330	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.839	rs2104084	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35061414	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.869	rs1407202	ENSG00000269202.1	RP4-614O4.12	4.48	1.75e-05	0.0145	0.48	0.39	Height;	chr20:35064164	chr20:35201747~35203288:-
GBM	cis	rs8014671	0.553	rs34866539	ENSG00000235812.4	ADAM21P1	-4.48	1.75e-05	0.0145	-0.47	-0.39	Prostate cancer;	chr14:70407046	chr14:70245491~70247801:-
GBM	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	4.48	1.75e-05	0.0145	0.76	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
GBM	cis	rs1009077	0.563	rs10518335	ENSG00000248280.1	RP11-33B1.2	4.48	1.75e-05	0.0145	0.55	0.39	Endometriosis;	chr4:119601017	chr4:119440561~119450157:-
GBM	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-4.48	1.75e-05	0.0145	-0.46	-0.39	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
GBM	cis	rs9450351	0.744	rs9344570	ENSG00000203875.9	SNHG5	-4.48	1.75e-05	0.0146	-0.95	-0.39	Interferon gamma-induced protein 10 levels;	chr6:86084062	chr6:85660950~85678736:-
GBM	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-4.48	1.76e-05	0.0146	-0.37	-0.39	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
GBM	cis	rs804280	0.509	rs10109241	ENSG00000255556.2	RP11-351I21.6	4.48	1.76e-05	0.0146	0.41	0.39	Myopia (pathological);	chr8:11927476	chr8:12378679~12380265:-
GBM	cis	rs7017914	0.652	rs6988053	ENSG00000246366.5	RP11-382J12.1	-4.48	1.76e-05	0.0146	-0.42	-0.39	Bone mineral density;	chr8:70634728	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.702	rs13258368	ENSG00000246366.5	RP11-382J12.1	-4.48	1.76e-05	0.0146	-0.42	-0.39	Bone mineral density;	chr8:70636516	chr8:70608577~70663279:+
GBM	cis	rs3768617	0.51	rs10797852	ENSG00000224468.3	RP11-181K3.4	-4.48	1.76e-05	0.0146	-0.32	-0.39	Fuchs's corneal dystrophy;	chr1:183132167	chr1:183138402~183141282:-
GBM	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	4.48	1.76e-05	0.0146	0.5	0.39	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
GBM	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-4.48	1.76e-05	0.0146	-0.55	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
GBM	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	4.48	1.76e-05	0.0146	0.51	0.39	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
GBM	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	4.48	1.76e-05	0.0146	0.56	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
GBM	cis	rs7927592	0.673	rs2510392	ENSG00000212093.1	AP000807.1	4.48	1.76e-05	0.0146	0.44	0.39	Total body bone mineral density;	chr11:68626989	chr11:68506083~68506166:-
GBM	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-4.48	1.76e-05	0.0146	-0.52	-0.39	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
GBM	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	4.48	1.77e-05	0.0146	0.45	0.39	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	4.48	1.77e-05	0.0146	0.45	0.39	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
GBM	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	4.48	1.77e-05	0.0146	0.45	0.39	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-4.48	1.77e-05	0.0146	-0.45	-0.39	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-4.48	1.77e-05	0.0146	-0.45	-0.39	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-4.48	1.77e-05	0.0146	-0.45	-0.39	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
GBM	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	4.48	1.77e-05	0.0146	0.47	0.39	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
GBM	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	4.48	1.77e-05	0.0147	0.27	0.39	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
GBM	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-4.48	1.77e-05	0.0147	-0.45	-0.39	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	4.48	1.77e-05	0.0147	0.46	0.39	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	4.48	1.77e-05	0.0147	0.46	0.39	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	4.48	1.77e-05	0.0147	0.46	0.39	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
GBM	cis	rs397969	0.646	rs17604987	ENSG00000230528.6	NOS2P3	4.48	1.77e-05	0.0147	0.45	0.39	Platelet count;	chr17:19964018	chr17:20436337~20447249:+
GBM	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	4.48	1.77e-05	0.0147	0.43	0.39	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
GBM	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-4.48	1.78e-05	0.0147	-0.52	-0.39	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
GBM	cis	rs984222	0.617	rs4659152	ENSG00000231365.4	RP11-418J17.1	4.48	1.78e-05	0.0148	0.39	0.39	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119216235	chr1:119140396~119275973:+
GBM	cis	rs984222	0.617	rs2003365	ENSG00000231365.4	RP11-418J17.1	4.48	1.78e-05	0.0148	0.39	0.39	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119219414	chr1:119140396~119275973:+
GBM	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	4.48	1.79e-05	0.0148	0.37	0.39	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
GBM	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-4.48	1.79e-05	0.0148	-0.51	-0.39	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
GBM	cis	rs453301	0.606	rs6601279	ENSG00000254340.1	RP11-10A14.3	-4.48	1.79e-05	0.0148	-0.5	-0.39	Joint mobility (Beighton score);	chr8:9050721	chr8:9141424~9145435:+
GBM	cis	rs453301	0.606	rs6981060	ENSG00000254340.1	RP11-10A14.3	-4.48	1.79e-05	0.0148	-0.5	-0.39	Joint mobility (Beighton score);	chr8:9050725	chr8:9141424~9145435:+
GBM	cis	rs2579103	0.63	rs10506985	ENSG00000258183.4	RP11-753N8.1	-4.48	1.79e-05	0.0148	-0.57	-0.39	Body mass index;	chr12:90318265	chr12:90280894~90300340:+
GBM	cis	rs55940216	0.524	rs28864811	ENSG00000245281.5	CTD-2547L16.1	4.48	1.79e-05	0.0148	0.5	0.39	Facial morphology (factor 14, intercanthal width);	chr8:18122698	chr8:18084868~18096394:+
GBM	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	4.48	1.79e-05	0.0148	0.37	0.39	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
GBM	cis	rs73198271	0.74	rs11781430	ENSG00000253893.2	FAM85B	4.48	1.79e-05	0.0148	0.56	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8167819~8226614:-
GBM	cis	rs8014671	0.553	rs34273029	ENSG00000235812.4	ADAM21P1	-4.48	1.79e-05	0.0148	-0.47	-0.39	Prostate cancer;	chr14:70425508	chr14:70245491~70247801:-
GBM	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	4.48	1.79e-05	0.0148	0.54	0.39	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
GBM	cis	rs4072705	0.586	rs7855247	ENSG00000224020.1	MIR181A2HG	4.48	1.79e-05	0.0148	0.42	0.39	Menarche (age at onset);	chr9:124484365	chr9:124658467~124698631:+
GBM	cis	rs4072705	0.586	rs7869042	ENSG00000224020.1	MIR181A2HG	4.48	1.79e-05	0.0148	0.42	0.39	Menarche (age at onset);	chr9:124484472	chr9:124658467~124698631:+
GBM	cis	rs17685	0.712	rs4732578	ENSG00000280388.1	RP11-229D13.3	-4.48	1.79e-05	0.0148	-0.35	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76092214	chr7:76043977~76045963:-
GBM	cis	rs3096299	0.606	rs2965960	ENSG00000260259.1	RP11-368I7.4	4.48	1.8e-05	0.0148	0.44	0.39	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89682620~89686569:-
GBM	cis	rs61041384	0.661	rs75338281	ENSG00000256092.2	RP13-942N8.1	-4.48	1.8e-05	0.0149	-0.9	-0.39	Schizophrenia;	chr12:123022937	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs4148857	ENSG00000256092.2	RP13-942N8.1	-4.48	1.8e-05	0.0149	-0.9	-0.39	Schizophrenia;	chr12:123055408	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs4148858	ENSG00000256092.2	RP13-942N8.1	-4.48	1.8e-05	0.0149	-0.9	-0.39	Schizophrenia;	chr12:123055475	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs7967118	ENSG00000256092.2	RP13-942N8.1	-4.48	1.8e-05	0.0149	-0.9	-0.39	Schizophrenia;	chr12:123086956	chr12:123363868~123366113:+
GBM	cis	rs4812048	1	rs6070696	ENSG00000268649.3	RP4-806M20.4	-4.48	1.8e-05	0.0149	-0.42	-0.39	Mean platelet volume;	chr20:59022590	chr20:58817132~58817725:-
GBM	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-4.48	1.8e-05	0.0149	-0.51	-0.39	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-4.48	1.8e-05	0.0149	-0.51	-0.39	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-4.48	1.8e-05	0.0149	-0.51	-0.39	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-4.48	1.8e-05	0.0149	-0.51	-0.39	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-4.48	1.8e-05	0.0149	-0.51	-0.39	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-4.48	1.8e-05	0.0149	-0.51	-0.39	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
GBM	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-4.48	1.8e-05	0.0149	-0.4	-0.39	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
GBM	cis	rs11671005	0.61	rs3816329	ENSG00000269600.1	AC016629.3	-4.48	1.8e-05	0.0149	-0.55	-0.39	Mean platelet volume;	chr19:58547326	chr19:58593896~58599355:-
GBM	cis	rs7829975	0.711	rs4841051	ENSG00000254340.1	RP11-10A14.3	-4.48	1.8e-05	0.0149	-0.47	-0.39	Mood instability;	chr8:8828136	chr8:9141424~9145435:+
GBM	cis	rs11671005	0.656	rs55652736	ENSG00000269473.1	CTD-2619J13.19	4.48	1.8e-05	0.0149	0.49	0.39	Mean platelet volume;	chr19:58496199	chr19:58440448~58445849:+
GBM	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	4.48	1.8e-05	0.0149	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	4.48	1.8e-05	0.0149	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
GBM	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	4.48	1.8e-05	0.0149	0.42	0.39	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
GBM	cis	rs7017914	0.617	rs111678999	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70755748	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs17760766	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70758954	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1444343	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70760749	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs35074484	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70762526	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs62508777	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70782769	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6986479	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70785323	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35115647	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70785777	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1444339	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70788407	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.616	rs55855305	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70790642	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs7822474	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70793498	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35323776	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70797931	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs35767277	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70806262	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs13261146	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70814684	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs13263047	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70815061	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs62508827	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70815820	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs62508828	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70815974	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs56108781	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70816519	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs34751830	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70818239	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs13281838	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70822207	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1822651	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70824426	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6982838	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70830504	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs754846	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70832304	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1457198	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70834934	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35921782	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70836689	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1156955	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70842724	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35380538	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70845432	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs10957532	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70845775	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs13274981	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70853045	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6985251	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70853620	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs11991584	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70859112	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs11991605	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70859117	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs11994581	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70862172	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs34301443	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70863161	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs34768553	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70864755	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35343840	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70865160	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs7015825	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70866438	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs2380691	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70872942	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6998354	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70873934	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.644	rs12156377	ENSG00000246366.5	RP11-382J12.1	-4.48	1.8e-05	0.0149	-0.41	-0.39	Bone mineral density;	chr8:70875457	chr8:70608577~70663279:+
GBM	cis	rs10231759	0.53	rs6464110	ENSG00000273419.1	RP4-751H13.7	-4.48	1.8e-05	0.0149	-0.41	-0.39	Height;	chr7:150833726	chr7:149858400~149862492:-
GBM	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	4.47	1.81e-05	0.0149	0.44	0.39	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
GBM	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-4.47	1.81e-05	0.0149	-0.61	-0.39	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
GBM	cis	rs3806843	1	rs13157397	ENSG00000202111.1	VTRNA1-2	-4.47	1.81e-05	0.0149	-0.4	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs4141841	ENSG00000202111.1	VTRNA1-2	-4.47	1.81e-05	0.0149	-0.4	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs10050455	ENSG00000202111.1	VTRNA1-2	-4.47	1.81e-05	0.0149	-0.4	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr5:140718925~140719013:+
GBM	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-4.47	1.81e-05	0.0149	-0.52	-0.39	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-4.47	1.81e-05	0.0149	-0.52	-0.39	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
GBM	cis	rs922692	0.715	rs2277546	ENSG00000261143.1	ADAMTS7P3	4.47	1.81e-05	0.0149	0.41	0.39	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78791034	chr15:77976042~77993057:+
GBM	cis	rs922692	0.744	rs2277545	ENSG00000261143.1	ADAMTS7P3	4.47	1.81e-05	0.0149	0.41	0.39	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78791249	chr15:77976042~77993057:+
GBM	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-4.47	1.82e-05	0.015	-0.44	-0.39	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
GBM	cis	rs11654801	0.755	rs11658791	ENSG00000233098.7	CCDC144NL-AS1	-4.47	1.82e-05	0.015	-0.54	-0.39	Mosquito bite size;	chr17:20978385	chr17:20868433~21002276:+
GBM	cis	rs11654801	0.812	rs11656525	ENSG00000233098.7	CCDC144NL-AS1	-4.47	1.82e-05	0.015	-0.54	-0.39	Mosquito bite size;	chr17:20978432	chr17:20868433~21002276:+
GBM	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	4.47	1.82e-05	0.015	0.57	0.39	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
GBM	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	4.47	1.82e-05	0.015	0.44	0.39	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
GBM	cis	rs7017914	0.652	rs56352991	ENSG00000246366.5	RP11-382J12.1	-4.47	1.82e-05	0.015	-0.41	-0.38	Bone mineral density;	chr8:70655843	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6994814	ENSG00000246366.5	RP11-382J12.1	-4.47	1.82e-05	0.015	-0.41	-0.38	Bone mineral density;	chr8:70656903	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs7830515	ENSG00000246366.5	RP11-382J12.1	-4.47	1.82e-05	0.015	-0.41	-0.38	Bone mineral density;	chr8:70657999	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs12674694	ENSG00000246366.5	RP11-382J12.1	-4.47	1.82e-05	0.015	-0.41	-0.38	Bone mineral density;	chr8:70658599	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35863913	ENSG00000246366.5	RP11-382J12.1	-4.47	1.82e-05	0.015	-0.41	-0.38	Bone mineral density;	chr8:70661024	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs10504480	ENSG00000246366.5	RP11-382J12.1	-4.47	1.82e-05	0.015	-0.41	-0.38	Bone mineral density;	chr8:70666012	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs11987501	ENSG00000246366.5	RP11-382J12.1	-4.47	1.82e-05	0.015	-0.41	-0.38	Bone mineral density;	chr8:70666283	chr8:70608577~70663279:+
GBM	cis	rs4604732	0.578	rs12040725	ENSG00000227135.1	GCSAML-AS1	-4.47	1.82e-05	0.015	-0.56	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247481395	chr1:247524679~247526752:-
GBM	cis	rs804280	0.509	rs9886639	ENSG00000255556.2	RP11-351I21.6	4.47	1.82e-05	0.015	0.41	0.38	Myopia (pathological);	chr8:11927020	chr8:12378679~12380265:-
GBM	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-4.47	1.83e-05	0.015	-0.34	-0.38	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
GBM	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	4.47	1.83e-05	0.015	0.43	0.38	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	4.47	1.83e-05	0.015	0.43	0.38	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
GBM	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	4.47	1.83e-05	0.015	0.4	0.38	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
GBM	cis	rs7615952	0.512	rs2979351	ENSG00000242001.1	GS1-388B5.1	4.47	1.83e-05	0.0151	0.58	0.38	Blood pressure (smoking interaction);	chr3:125644755	chr3:125681305~125681453:+
GBM	cis	rs17685	0.633	rs3801471	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76066870	chr7:76043977~76045963:-
GBM	cis	rs17685	0.784	rs1637043	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76069781	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1639617	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76072410	chr7:76043977~76045963:-
GBM	cis	rs17685	0.672	rs1639618	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76072669	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs7804598	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76073260	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1637044	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76074426	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs1639620	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76074772	chr7:76043977~76045963:-
GBM	cis	rs17685	0.671	rs10274404	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76077316	chr7:76043977~76045963:-
GBM	cis	rs17685	0.672	rs1639623	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76078633	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs59659102	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76080796	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs11982200	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76085565	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs4552844	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76088777	chr7:76043977~76045963:-
GBM	cis	rs17685	0.725	rs6467993	ENSG00000280388.1	RP11-229D13.3	-4.47	1.83e-05	0.0151	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76090032	chr7:76043977~76045963:-
GBM	cis	rs3806843	0.966	rs3806842	ENSG00000202111.1	VTRNA1-2	-4.47	1.83e-05	0.0151	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140833091	chr5:140718925~140719013:+
GBM	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	4.47	1.83e-05	0.0151	0.4	0.38	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
GBM	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-4.47	1.83e-05	0.0151	-0.33	-0.38	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
GBM	cis	rs3096299	0.584	rs3114889	ENSG00000260259.1	RP11-368I7.4	4.47	1.83e-05	0.0151	0.41	0.38	Multiple myeloma (IgH translocation);	chr16:89349097	chr16:89682620~89686569:-
GBM	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	4.47	1.83e-05	0.0151	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
GBM	cis	rs11654801	0.812	rs16962470	ENSG00000233098.7	CCDC144NL-AS1	-4.47	1.84e-05	0.0151	-0.51	-0.38	Mosquito bite size;	chr17:20951462	chr17:20868433~21002276:+
GBM	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-4.47	1.84e-05	0.0151	-0.56	-0.38	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
GBM	cis	rs731565	1	rs78914962	ENSG00000232391.1	RANP2	4.47	1.84e-05	0.0151	0.75	0.38	Diabetic kidney disease;	chr7:147709984	chr7:147167344~147167572:+
GBM	cis	rs4373814	0.624	rs10764332	ENSG00000226083.4	SLC39A12-AS1	4.47	1.84e-05	0.0151	0.45	0.38	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18163040	chr10:18001786~18010562:-
GBM	cis	rs9947662	1	rs9947662	ENSG00000267761.3	CTD-2130O13.1	-4.47	1.84e-05	0.0151	-0.49	-0.38	Migraine;	chr18:47333893	chr18:47285725~47594550:+
GBM	cis	rs7017914	0.702	rs36047866	ENSG00000246366.5	RP11-382J12.1	-4.47	1.84e-05	0.0151	-0.42	-0.38	Bone mineral density;	chr8:70644815	chr8:70608577~70663279:+
GBM	cis	rs397969	0.646	rs850622	ENSG00000230528.6	NOS2P3	-4.47	1.84e-05	0.0151	-0.46	-0.38	Platelet count;	chr17:19934223	chr17:20436337~20447249:+
GBM	cis	rs4499344	0.633	rs259229	ENSG00000201388.1	SNORA68	-4.47	1.84e-05	0.0151	-0.4	-0.38	Mean platelet volume;	chr19:32643519	chr19:32608337~32608469:-
GBM	cis	rs3768617	0.51	rs10911247	ENSG00000224468.3	RP11-181K3.4	-4.47	1.84e-05	0.0151	-0.32	-0.38	Fuchs's corneal dystrophy;	chr1:183107858	chr1:183138402~183141282:-
GBM	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	4.47	1.84e-05	0.0151	0.48	0.38	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
GBM	cis	rs8014671	0.532	rs12893988	ENSG00000235812.4	ADAM21P1	-4.47	1.84e-05	0.0151	-0.47	-0.38	Prostate cancer;	chr14:70455425	chr14:70245491~70247801:-
GBM	cis	rs11642862	1	rs11645367	ENSG00000260911.2	RP11-196G11.2	4.47	1.84e-05	0.0151	0.53	0.38	Tonsillectomy;	chr16:30758753	chr16:31043150~31049868:+
GBM	cis	rs11642862	1	rs112234000	ENSG00000260911.2	RP11-196G11.2	4.47	1.84e-05	0.0151	0.53	0.38	Tonsillectomy;	chr16:30767487	chr16:31043150~31049868:+
GBM	cis	rs11642862	1	rs11642466	ENSG00000260911.2	RP11-196G11.2	4.47	1.84e-05	0.0151	0.53	0.38	Tonsillectomy;	chr16:30770621	chr16:31043150~31049868:+
GBM	cis	rs11642862	1	rs75500538	ENSG00000260911.2	RP11-196G11.2	4.47	1.84e-05	0.0151	0.53	0.38	Tonsillectomy;	chr16:30771128	chr16:31043150~31049868:+
GBM	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-4.47	1.84e-05	0.0151	-0.66	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-4.47	1.84e-05	0.0151	-0.66	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-4.47	1.84e-05	0.0151	-0.66	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-4.47	1.84e-05	0.0151	-0.66	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-4.47	1.84e-05	0.0151	-0.66	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-4.47	1.84e-05	0.0151	-0.66	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-4.47	1.84e-05	0.0151	-0.66	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
GBM	cis	rs11098499	0.588	rs6534149	ENSG00000249244.1	RP11-548H18.2	-4.47	1.84e-05	0.0151	-0.45	-0.38	Corneal astigmatism;	chr4:119638137	chr4:119391831~119395335:-
GBM	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-4.47	1.84e-05	0.0151	-0.45	-0.38	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
GBM	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-4.47	1.84e-05	0.0151	-0.38	-0.38	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
GBM	cis	rs10435719	0.902	rs11250179	ENSG00000255556.2	RP11-351I21.6	4.47	1.84e-05	0.0151	0.41	0.38	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:12378679~12380265:-
GBM	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	4.47	1.84e-05	0.0151	0.42	0.38	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
GBM	cis	rs7017914	0.652	rs1908032	ENSG00000246366.5	RP11-382J12.1	-4.47	1.85e-05	0.0151	-0.41	-0.38	Bone mineral density;	chr8:70876735	chr8:70608577~70663279:+
GBM	cis	rs11671005	0.656	rs73066226	ENSG00000269473.1	CTD-2619J13.19	4.47	1.85e-05	0.0152	0.49	0.38	Mean platelet volume;	chr19:58496846	chr19:58440448~58445849:+
GBM	cis	rs12681420	0.665	rs67705199	ENSG00000246366.5	RP11-382J12.1	-4.47	1.85e-05	0.0152	-0.4	-0.38	Erythrocyte cadmium concentration in never smokers;	chr8:70695170	chr8:70608577~70663279:+
GBM	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	4.47	1.85e-05	0.0152	0.45	0.38	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	4.47	1.85e-05	0.0152	0.45	0.38	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
GBM	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	4.47	1.85e-05	0.0152	0.45	0.38	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
GBM	cis	rs3806843	0.735	rs778596	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.705	rs35614340	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs2563314	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs2530240	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs801189	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.706	rs1089305	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs801185	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs2563306	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs813897	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.676	rs2563304	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs3776129	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.706	rs2563302	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs801168	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs809635	ENSG00000202111.1	VTRNA1-2	4.47	1.85e-05	0.0152	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs801167	ENSG00000202111.1	VTRNA1-2	-4.47	1.85e-05	0.0152	-0.41	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr5:140718925~140719013:+
GBM	cis	rs11671005	0.652	rs11670864	ENSG00000269600.1	AC016629.3	-4.47	1.85e-05	0.0152	-0.56	-0.38	Mean platelet volume;	chr19:58519213	chr19:58593896~58599355:-
GBM	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	4.47	1.85e-05	0.0152	0.79	0.38	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	4.47	1.85e-05	0.0152	0.79	0.38	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
GBM	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	4.47	1.85e-05	0.0152	0.79	0.38	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
GBM	cis	rs893363	0.61	rs893362	ENSG00000271916.1	RP11-884K10.6	-4.47	1.85e-05	0.0152	-0.46	-0.38	Axial length;	chr3:53813767	chr3:53797764~53798019:-
GBM	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-4.47	1.85e-05	0.0152	-0.49	-0.38	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-4.47	1.85e-05	0.0152	-0.49	-0.38	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-4.47	1.85e-05	0.0152	-0.49	-0.38	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
GBM	cis	rs10911251	0.508	rs2296297	ENSG00000224468.3	RP11-181K3.4	-4.47	1.85e-05	0.0152	-0.32	-0.38	Colorectal cancer;	chr1:183136189	chr1:183138402~183141282:-
GBM	cis	rs977747	0.872	rs34087210	ENSG00000232022.5	FAAHP1	-4.47	1.86e-05	0.0152	-0.39	-0.38	Body mass index;	chr1:47224170	chr1:46432129~46445521:+
GBM	cis	rs7017914	0.69	rs10504492	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0152	-0.42	-0.38	Bone mineral density;	chr8:71065724	chr8:70608577~70663279:+
GBM	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-4.47	1.86e-05	0.0152	-0.44	-0.38	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
GBM	cis	rs2025751	0.512	rs6903511	ENSG00000230204.1	FTH1P5	-4.47	1.86e-05	0.0152	-0.44	-0.38	Intraocular pressure;	chr6:51827792	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs6903662	ENSG00000230204.1	FTH1P5	-4.47	1.86e-05	0.0152	-0.44	-0.38	Intraocular pressure;	chr6:51827830	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs6923773	ENSG00000230204.1	FTH1P5	-4.47	1.86e-05	0.0152	-0.44	-0.38	Intraocular pressure;	chr6:51827874	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs6924098	ENSG00000230204.1	FTH1P5	-4.47	1.86e-05	0.0152	-0.44	-0.38	Intraocular pressure;	chr6:51827886	chr6:50912712~50913256:-
GBM	cis	rs11098499	0.731	rs6846966	ENSG00000249244.1	RP11-548H18.2	4.47	1.86e-05	0.0152	0.47	0.38	Corneal astigmatism;	chr4:119372053	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs6847778	ENSG00000249244.1	RP11-548H18.2	4.47	1.86e-05	0.0152	0.47	0.38	Corneal astigmatism;	chr4:119372427	chr4:119391831~119395335:-
GBM	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	4.47	1.86e-05	0.0152	0.43	0.38	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
GBM	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	4.47	1.86e-05	0.0152	0.8	0.38	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
GBM	cis	rs9393777	0.557	rs9358949	ENSG00000224843.5	LINC00240	4.47	1.86e-05	0.0152	0.71	0.38	Intelligence (multi-trait analysis);	chr6:26485489	chr6:26956992~27023924:+
GBM	cis	rs3096299	0.73	rs3102373	ENSG00000260259.1	RP11-368I7.4	4.47	1.86e-05	0.0152	0.43	0.38	Multiple myeloma (IgH translocation);	chr16:89332214	chr16:89682620~89686569:-
GBM	cis	rs8014671	0.553	rs17476399	ENSG00000235812.4	ADAM21P1	-4.47	1.86e-05	0.0152	-0.47	-0.38	Prostate cancer;	chr14:70453613	chr14:70245491~70247801:-
GBM	cis	rs7017914	0.934	rs1993862	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70667127	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs34282253	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70670131	chr8:70608577~70663279:+
GBM	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-4.47	1.86e-05	0.0153	-0.52	-0.38	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
GBM	cis	rs763121	0.853	rs5750630	ENSG00000273076.1	RP3-508I15.22	4.47	1.86e-05	0.0153	0.43	0.38	Menopause (age at onset);	chr22:38589813	chr22:38743495~38743910:+
GBM	cis	rs7017914	0.652	rs12681420	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.41	-0.38	Bone mineral density;	chr8:70680963	chr8:70608577~70663279:+
GBM	cis	rs3806843	0.705	rs2530230	ENSG00000202111.1	VTRNA1-2	4.47	1.86e-05	0.0153	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr5:140718925~140719013:+
GBM	cis	rs748404	0.518	rs2927085	ENSG00000249839.1	AC011330.5	-4.47	1.86e-05	0.0153	-0.51	-0.38	Lung cancer;	chr15:43697332	chr15:43663654~43684339:-
GBM	cis	rs4478147	0.506	rs2869433	ENSG00000261496.1	RP13-514E23.1	-4.47	1.86e-05	0.0153	-0.47	-0.38	Migraine - clinic-based;	chr4:86357943	chr4:86012296~86013874:-
GBM	cis	rs4478147	0.506	rs56255533	ENSG00000261496.1	RP13-514E23.1	-4.47	1.86e-05	0.0153	-0.47	-0.38	Migraine - clinic-based;	chr4:86363080	chr4:86012296~86013874:-
GBM	cis	rs7017914	0.69	rs13280922	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.4	-0.38	Bone mineral density;	chr8:70713163	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs11989644	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.4	-0.38	Bone mineral density;	chr8:70728961	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.568	rs13272884	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.4	-0.38	Bone mineral density;	chr8:70729413	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.677	rs7010889	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.4	-0.38	Bone mineral density;	chr8:70741136	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs7016334	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.4	-0.38	Bone mineral density;	chr8:70742171	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.714	rs28376252	ENSG00000246366.5	RP11-382J12.1	-4.47	1.86e-05	0.0153	-0.4	-0.38	Bone mineral density;	chr8:70747652	chr8:70608577~70663279:+
GBM	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	4.47	1.87e-05	0.0153	0.54	0.38	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
GBM	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	4.47	1.87e-05	0.0153	0.26	0.38	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
GBM	cis	rs17685	0.725	rs4476928	ENSG00000280388.1	RP11-229D13.3	4.47	1.87e-05	0.0153	0.36	0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76012789	chr7:76043977~76045963:-
GBM	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-4.47	1.87e-05	0.0153	-0.49	-0.38	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-4.47	1.87e-05	0.0153	-0.49	-0.38	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
GBM	cis	rs763121	0.853	rs6519120	ENSG00000273076.1	RP3-508I15.22	-4.47	1.87e-05	0.0153	-0.42	-0.38	Menopause (age at onset);	chr22:38595388	chr22:38743495~38743910:+
GBM	cis	rs7017914	0.902	rs7831792	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70653121	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs34882924	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70654073	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs6987313	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70658754	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs35580034	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70659838	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs17760050	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70662016	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs35214141	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70662329	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs10504479	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70665280	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs35109143	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70665665	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs13269513	ENSG00000246366.5	RP11-382J12.1	-4.47	1.87e-05	0.0153	-0.42	-0.38	Bone mineral density;	chr8:70665844	chr8:70608577~70663279:+
GBM	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	4.47	1.88e-05	0.0153	0.45	0.38	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
GBM	cis	rs3824488	0.765	rs10512247	ENSG00000175611.10	LINC00476	-4.47	1.88e-05	0.0153	-0.64	-0.38	Neuroticism;	chr9:95534121	chr9:95759231~95875977:-
GBM	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	4.47	1.88e-05	0.0154	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	4.47	1.88e-05	0.0154	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	4.47	1.88e-05	0.0154	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	4.47	1.88e-05	0.0154	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
GBM	cis	rs10435719	0.902	rs7459545	ENSG00000255556.2	RP11-351I21.6	4.47	1.88e-05	0.0154	0.41	0.38	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:12378679~12380265:-
GBM	cis	rs10435719	0.902	rs7006538	ENSG00000255556.2	RP11-351I21.6	4.47	1.88e-05	0.0154	0.41	0.38	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:12378679~12380265:-
GBM	cis	rs11654801	0.812	rs16962469	ENSG00000233098.7	CCDC144NL-AS1	-4.46	1.88e-05	0.0154	-0.54	-0.38	Mosquito bite size;	chr17:20955119	chr17:20868433~21002276:+
GBM	cis	rs67981189	0.501	rs2810104	ENSG00000269927.1	RP6-91H8.3	4.46	1.88e-05	0.0154	0.47	0.38	Schizophrenia;	chr14:70958096	chr14:71141125~71143253:-
GBM	cis	rs950169	1	rs35297609	ENSG00000275120.1	RP11-182J1.17	4.46	1.88e-05	0.0154	0.51	0.38	Schizophrenia;	chr15:84104144	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs62026530	ENSG00000275120.1	RP11-182J1.17	4.46	1.88e-05	0.0154	0.51	0.38	Schizophrenia;	chr15:84107088	chr15:84599434~84606463:-
GBM	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	4.46	1.88e-05	0.0154	0.46	0.38	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	4.46	1.88e-05	0.0154	0.46	0.38	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
GBM	cis	rs200986	1	rs200986	ENSG00000199851.2	U3	4.46	1.89e-05	0.0154	0.54	0.38	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.539	rs200951	ENSG00000199851.2	U3	4.46	1.89e-05	0.0154	0.54	0.38	Parkinson's disease;	chr6:27868152	chr6:28015568~28015777:+
GBM	cis	rs588177	0.919	rs2244625	ENSG00000236935.1	AP003774.1	4.46	1.89e-05	0.0154	0.44	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64258672	chr11:64325050~64329504:-
GBM	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-4.46	1.89e-05	0.0154	-0.56	-0.38	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
GBM	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-4.46	1.89e-05	0.0154	-0.56	-0.38	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
GBM	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-4.46	1.89e-05	0.0154	-0.56	-0.38	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
GBM	cis	rs753955	0.553	rs1886973	ENSG00000205861.10	C1QTNF9B-AS1	-4.46	1.89e-05	0.0154	-0.47	-0.38	Lung cancer;	chr13:23848931	chr13:23888889~23897263:+
GBM	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	4.46	1.89e-05	0.0154	0.27	0.38	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	4.46	1.89e-05	0.0154	0.27	0.38	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	4.46	1.89e-05	0.0154	0.27	0.38	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
GBM	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	4.46	1.89e-05	0.0154	0.38	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
GBM	cis	rs17772222	0.74	rs10138139	ENSG00000222990.1	RNU4-22P	4.46	1.89e-05	0.0155	0.41	0.38	Coronary artery calcification;	chr14:88510027	chr14:88513498~88513663:+
GBM	cis	rs1555322	1	rs2425040	ENSG00000126005.14	MMP24-AS1	-4.46	1.89e-05	0.0155	-0.66	-0.38	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35216462~35278131:-
GBM	cis	rs1555322	1	rs6058219	ENSG00000126005.14	MMP24-AS1	-4.46	1.89e-05	0.0155	-0.66	-0.38	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35216462~35278131:-
GBM	cis	rs10435719	0.647	rs10092605	ENSG00000255556.2	RP11-351I21.6	4.46	1.9e-05	0.0155	0.41	0.38	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:12378679~12380265:-
GBM	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	4.46	1.9e-05	0.0155	0.44	0.38	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
GBM	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	4.46	1.9e-05	0.0155	0.45	0.38	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
GBM	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-4.46	1.9e-05	0.0155	-0.45	-0.38	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-4.46	1.9e-05	0.0155	-0.45	-0.38	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-4.46	1.9e-05	0.0155	-0.45	-0.38	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-4.46	1.9e-05	0.0155	-0.45	-0.38	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-4.46	1.9e-05	0.0155	-0.45	-0.38	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
GBM	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-4.46	1.9e-05	0.0155	-0.45	-0.38	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
GBM	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-4.46	1.9e-05	0.0155	-0.45	-0.38	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
GBM	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	4.46	1.9e-05	0.0155	0.79	0.38	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
GBM	cis	rs1298062	0.79	rs25668	ENSG00000131401.10	NAPSB	-4.46	1.9e-05	0.0155	-0.45	-0.38	Age of smoking initiation;	chr19:50462015	chr19:50333796~50344767:-
GBM	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-4.46	1.9e-05	0.0155	-0.52	-0.38	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
GBM	cis	rs36715	1	rs40527	ENSG00000245937.6	LINC01184	4.46	1.9e-05	0.0155	0.4	0.38	Breast cancer;	chr5:128214560	chr5:127940426~128083172:-
GBM	cis	rs1298062	0.825	rs1673019	ENSG00000131401.10	NAPSB	-4.46	1.9e-05	0.0155	-0.46	-0.38	Age of smoking initiation;	chr19:50484518	chr19:50333796~50344767:-
GBM	cis	rs1298062	0.825	rs1673020	ENSG00000131401.10	NAPSB	-4.46	1.9e-05	0.0155	-0.46	-0.38	Age of smoking initiation;	chr19:50484590	chr19:50333796~50344767:-
GBM	cis	rs11654801	0.812	rs3891644	ENSG00000233098.7	CCDC144NL-AS1	-4.46	1.91e-05	0.0155	-0.54	-0.38	Mosquito bite size;	chr17:20967181	chr17:20868433~21002276:+
GBM	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-4.46	1.91e-05	0.0155	-0.46	-0.38	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
GBM	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-4.46	1.91e-05	0.0155	-0.46	-0.38	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
GBM	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-4.46	1.91e-05	0.0155	-0.46	-0.38	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
GBM	cis	rs10246939	0.505	rs13236432	ENSG00000261797.1	RP11-744I24.3	-4.46	1.91e-05	0.0156	-0.48	-0.38	Bitter taste perception;	chr7:141850980	chr7:141512698~141513183:-
GBM	cis	rs7017914	0.652	rs62530770	ENSG00000246366.5	RP11-382J12.1	-4.46	1.91e-05	0.0156	-0.41	-0.38	Bone mineral density;	chr8:70688761	chr8:70608577~70663279:+
GBM	cis	rs3096299	0.9	rs744327	ENSG00000260259.1	RP11-368I7.4	4.46	1.91e-05	0.0156	0.42	0.38	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89682620~89686569:-
GBM	cis	rs17711722	0.523	rs365896	ENSG00000235421.1	RP11-667F9.1	-4.46	1.91e-05	0.0156	-0.45	-0.38	Calcium levels;	chr7:66045710	chr7:65525629~65554744:-
GBM	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	4.46	1.92e-05	0.0156	0.57	0.38	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
GBM	cis	rs172166	0.538	rs149956	ENSG00000218016.2	ZNF192P2	-4.46	1.92e-05	0.0156	-0.47	-0.38	Cardiac Troponin-T levels;	chr6:28068473	chr6:28188050~28189432:+
GBM	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	4.46	1.92e-05	0.0156	0.43	0.38	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
GBM	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	4.46	1.92e-05	0.0156	0.44	0.38	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
GBM	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-4.46	1.92e-05	0.0156	-0.54	-0.38	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
GBM	cis	rs172166	0.516	rs2791333	ENSG00000218016.2	ZNF192P2	-4.46	1.92e-05	0.0156	-0.44	-0.38	Cardiac Troponin-T levels;	chr6:28143336	chr6:28188050~28189432:+
GBM	cis	rs3096299	0.967	rs3102341	ENSG00000260259.1	RP11-368I7.4	4.46	1.92e-05	0.0156	0.41	0.38	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89682620~89686569:-
GBM	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-4.46	1.92e-05	0.0157	-0.51	-0.38	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
GBM	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-4.46	1.93e-05	0.0157	-0.43	-0.38	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
GBM	cis	rs11098499	0.739	rs9996382	ENSG00000250412.1	KLHL2P1	4.46	1.93e-05	0.0157	0.51	0.38	Corneal astigmatism;	chr4:119229857	chr4:119334329~119378233:+
GBM	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	4.46	1.93e-05	0.0157	0.47	0.38	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
GBM	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	4.46	1.93e-05	0.0157	0.42	0.38	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
GBM	cis	rs4713118	0.869	rs7776351	ENSG00000199851.2	U3	-4.46	1.93e-05	0.0157	-0.51	-0.38	Parkinson's disease;	chr6:27758952	chr6:28015568~28015777:+
GBM	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-4.46	1.93e-05	0.0157	-0.45	-0.38	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
GBM	cis	rs3096299	0.9	rs4785666	ENSG00000260259.1	RP11-368I7.4	4.46	1.93e-05	0.0157	0.41	0.38	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89682620~89686569:-
GBM	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	4.46	1.93e-05	0.0157	0.42	0.38	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
GBM	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-4.46	1.93e-05	0.0157	-0.5	-0.38	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
GBM	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	4.46	1.93e-05	0.0157	0.5	0.38	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
GBM	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	4.46	1.93e-05	0.0157	0.5	0.38	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
GBM	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-4.46	1.94e-05	0.0157	-0.48	-0.38	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
GBM	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-4.46	1.94e-05	0.0157	-0.41	-0.38	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-4.46	1.94e-05	0.0157	-0.41	-0.38	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
GBM	cis	rs10754283	0.967	rs10801764	ENSG00000231613.1	RP5-943J3.1	4.46	1.94e-05	0.0157	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89656192	chr1:89788914~89790492:+
GBM	cis	rs10231759	0.53	rs4725952	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150831150	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs4725368	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150831259	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs4725369	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150831445	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs9648658	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150831738	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs9648659	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150831782	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs9648660	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150831838	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs12540770	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150832260	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs12540772	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150832275	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs10282083	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150832518	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs10282142	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150832734	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs10282362	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150832748	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs10085672	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150833074	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs6978544	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150833339	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs6978826	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150833396	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs6464109	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150833654	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs6464111	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150833785	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs6464112	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150833908	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs6464113	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150834080	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs6946098	ENSG00000273419.1	RP4-751H13.7	-4.46	1.94e-05	0.0158	-0.42	-0.38	Height;	chr7:150834354	chr7:149858400~149862492:-
GBM	cis	rs8114671	0.836	rs6058154	ENSG00000269202.1	RP4-614O4.12	4.46	1.94e-05	0.0158	0.47	0.38	Height;	chr20:34998031	chr20:35201747~35203288:-
GBM	cis	rs9637599	0.69	rs4423843	ENSG00000246375.2	RP11-10L7.1	4.46	1.94e-05	0.0158	0.43	0.38	Metabolite levels (small molecules and protein measures);	chr4:88285604	chr4:88284942~88331421:+
GBM	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	4.46	1.95e-05	0.0158	0.43	0.38	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
GBM	cis	rs8177876	0.749	rs2602407	ENSG00000261838.4	RP11-303E16.6	-4.46	1.95e-05	0.0158	-0.7	-0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059141	chr16:81069854~81076598:+
GBM	cis	rs922692	0.744	rs4886592	ENSG00000261143.1	ADAMTS7P3	4.46	1.95e-05	0.0158	0.41	0.38	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78790205	chr15:77976042~77993057:+
GBM	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	4.46	1.95e-05	0.0158	0.64	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
GBM	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	4.46	1.95e-05	0.0158	0.68	0.38	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	4.46	1.95e-05	0.0158	0.68	0.38	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-4.46	1.95e-05	0.0158	-0.68	-0.38	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
GBM	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-4.46	1.95e-05	0.0158	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
GBM	cis	rs6788497	0.643	rs11709536	ENSG00000242551.2	POU5F1P6	4.46	1.95e-05	0.0158	0.67	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128392270	chr3:128674735~128677005:-
GBM	cis	rs4713118	0.869	rs2056925	ENSG00000218016.2	ZNF192P2	-4.46	1.95e-05	0.0158	-0.49	-0.38	Parkinson's disease;	chr6:27723126	chr6:28188050~28189432:+
GBM	cis	rs4812048	1	rs55905547	ENSG00000268649.3	RP4-806M20.4	-4.46	1.96e-05	0.0158	-0.44	-0.38	Mean platelet volume;	chr20:59014940	chr20:58817132~58817725:-
GBM	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-4.46	1.96e-05	0.0158	-0.49	-0.38	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
GBM	cis	rs3806843	0.966	rs3806844	ENSG00000202111.1	VTRNA1-2	-4.46	1.96e-05	0.0158	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr5:140718925~140719013:+
GBM	cis	rs7017914	0.69	rs13269690	ENSG00000246366.5	RP11-382J12.1	-4.46	1.96e-05	0.0159	-0.39	-0.38	Bone mineral density;	chr8:70732572	chr8:70608577~70663279:+
GBM	cis	rs2288884	0.559	rs9636139	ENSG00000275055.1	CTC-471J1.11	-4.45	1.96e-05	0.0159	-0.49	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018043	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.559	rs12610953	ENSG00000275055.1	CTC-471J1.11	-4.45	1.96e-05	0.0159	-0.49	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018675	chr19:52049007~52049754:+
GBM	cis	rs4842666	0.834	rs2681492	ENSG00000258302.2	RP11-981P6.1	4.45	1.96e-05	0.0159	0.47	0.38	Blood pressure;	chr12:89619312	chr12:89561129~89594878:+
GBM	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	4.45	1.96e-05	0.0159	0.53	0.38	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
GBM	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-4.45	1.96e-05	0.0159	-0.31	-0.38	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
GBM	cis	rs17772222	1	rs17772222	ENSG00000222990.1	RNU4-22P	-4.45	1.97e-05	0.0159	-0.47	-0.38	Coronary artery calcification;	chr14:88360138	chr14:88513498~88513663:+
GBM	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-4.45	1.97e-05	0.0159	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
GBM	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-4.45	1.97e-05	0.0159	-0.51	-0.38	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
GBM	cis	rs741668	0.931	rs4417456	ENSG00000235903.6	CPB2-AS1	4.45	1.97e-05	0.016	0.53	0.38	Cerebrospinal fluid clusterin levels;	chr13:46014273	chr13:46052806~46113332:+
GBM	cis	rs741668	0.931	rs61953330	ENSG00000235903.6	CPB2-AS1	4.45	1.97e-05	0.016	0.53	0.38	Cerebrospinal fluid clusterin levels;	chr13:46014741	chr13:46052806~46113332:+
GBM	cis	rs741668	0.931	rs61953331	ENSG00000235903.6	CPB2-AS1	4.45	1.97e-05	0.016	0.53	0.38	Cerebrospinal fluid clusterin levels;	chr13:46015336	chr13:46052806~46113332:+
GBM	cis	rs741668	0.894	rs2031633	ENSG00000235903.6	CPB2-AS1	4.45	1.97e-05	0.016	0.53	0.38	Cerebrospinal fluid clusterin levels;	chr13:46022005	chr13:46052806~46113332:+
GBM	cis	rs741668	0.931	rs61953335	ENSG00000235903.6	CPB2-AS1	4.45	1.97e-05	0.016	0.53	0.38	Cerebrospinal fluid clusterin levels;	chr13:46024681	chr13:46052806~46113332:+
GBM	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	4.45	1.97e-05	0.016	0.47	0.38	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
GBM	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	4.45	1.97e-05	0.016	0.38	0.38	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
GBM	cis	rs4072705	1	rs10818987	ENSG00000224020.1	MIR181A2HG	-4.45	1.97e-05	0.016	-0.41	-0.38	Menarche (age at onset);	chr9:124758450	chr9:124658467~124698631:+
GBM	cis	rs7017914	0.87	rs2639953	ENSG00000246366.5	RP11-382J12.1	-4.45	1.97e-05	0.016	-0.41	-0.38	Bone mineral density;	chr8:71013425	chr8:70608577~70663279:+
GBM	cis	rs6908917	0.673	rs1412540	ENSG00000219776.2	RPL21P67	-4.45	1.98e-05	0.016	-0.47	-0.38	IgG glycosylation;	chr6:131005252	chr6:131469059~131469536:+
GBM	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-4.45	1.98e-05	0.016	-0.48	-0.38	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
GBM	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	4.45	1.98e-05	0.016	0.45	0.38	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	4.45	1.98e-05	0.016	0.45	0.38	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
GBM	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-4.45	1.98e-05	0.016	-0.58	-0.38	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
GBM	cis	rs6452524	0.935	rs2386241	ENSG00000248112.1	RP11-78C3.1	-4.45	1.98e-05	0.016	-0.48	-0.38	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:82919376~82921119:-
GBM	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	4.45	1.98e-05	0.016	0.43	0.38	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
GBM	cis	rs17772222	0.63	rs1344747	ENSG00000222990.1	RNU4-22P	-4.45	1.98e-05	0.016	-0.4	-0.38	Coronary artery calcification;	chr14:88548091	chr14:88513498~88513663:+
GBM	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	4.45	1.98e-05	0.016	0.43	0.38	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
GBM	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	4.45	1.98e-05	0.016	0.4	0.38	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
GBM	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	4.45	1.98e-05	0.016	0.68	0.38	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
GBM	cis	rs454217	0.74	rs430709	ENSG00000277851.1	RP11-756G20.1	4.45	1.99e-05	0.016	0.42	0.38	Smoking quantity;	chr12:92325836	chr12:92247756~92363832:-
GBM	cis	rs454217	0.74	rs373627	ENSG00000277851.1	RP11-756G20.1	4.45	1.99e-05	0.016	0.42	0.38	Smoking quantity;	chr12:92325837	chr12:92247756~92363832:-
GBM	cis	rs731565	0.867	rs78654554	ENSG00000232391.1	RANP2	4.45	1.99e-05	0.0161	0.72	0.38	Diabetic kidney disease;	chr7:147671212	chr7:147167344~147167572:+
GBM	cis	rs950169	0.92	rs11637666	ENSG00000275120.1	RP11-182J1.17	4.45	1.99e-05	0.0161	0.53	0.38	Schizophrenia;	chr15:84035122	chr15:84599434~84606463:-
GBM	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-4.45	1.99e-05	0.0161	-0.43	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
GBM	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-4.45	1.99e-05	0.0161	-0.49	-0.38	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
GBM	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-4.45	1.99e-05	0.0161	-0.51	-0.38	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
GBM	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	4.45	1.99e-05	0.0161	0.42	0.38	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
GBM	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-4.45	2e-05	0.0161	-0.45	-0.38	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-4.45	2e-05	0.0161	-0.45	-0.38	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-4.45	2e-05	0.0161	-0.45	-0.38	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-4.45	2e-05	0.0161	-0.45	-0.38	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-4.45	2e-05	0.0161	-0.45	-0.38	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-4.45	2e-05	0.0161	-0.45	-0.38	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
GBM	cis	rs7017914	0.905	rs1353058	ENSG00000246366.5	RP11-382J12.1	-4.45	2e-05	0.0161	-0.41	-0.38	Bone mineral density;	chr8:71009783	chr8:70608577~70663279:+
GBM	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	4.45	2e-05	0.0161	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
GBM	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	4.45	2e-05	0.0161	0.63	0.38	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
GBM	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	4.45	2e-05	0.0161	0.41	0.38	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
GBM	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	4.45	2e-05	0.0161	0.4	0.38	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
GBM	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	4.45	2e-05	0.0161	0.46	0.38	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
GBM	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-4.45	2e-05	0.0162	-0.42	-0.38	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
GBM	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	4.45	2.01e-05	0.0162	0.38	0.38	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
GBM	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	4.45	2.01e-05	0.0162	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
GBM	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	4.45	2.01e-05	0.0162	0.61	0.38	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	4.45	2.01e-05	0.0162	0.61	0.38	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	4.45	2.01e-05	0.0162	0.61	0.38	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
GBM	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	4.45	2.01e-05	0.0162	0.42	0.38	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
GBM	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	4.45	2.01e-05	0.0162	0.64	0.38	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
GBM	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	4.45	2.01e-05	0.0162	0.64	0.38	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
GBM	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-4.45	2.01e-05	0.0162	-0.43	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
GBM	cis	rs11671005	0.735	rs11670871	ENSG00000269473.1	CTD-2619J13.19	-4.45	2.01e-05	0.0162	-0.41	-0.38	Mean platelet volume;	chr19:58429147	chr19:58440448~58445849:+
GBM	cis	rs6598955	0.671	rs11247910	ENSG00000236782.4	RP11-96L14.7	4.45	2.02e-05	0.0162	0.55	0.38	Obesity-related traits;	chr1:26319175	chr1:26169947~26171821:-
GBM	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	4.45	2.02e-05	0.0162	0.36	0.38	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
GBM	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-4.45	2.02e-05	0.0162	-0.53	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
GBM	cis	rs950169	0.686	rs12906474	ENSG00000275120.1	RP11-182J1.17	4.45	2.02e-05	0.0162	0.49	0.38	Schizophrenia;	chr15:84566006	chr15:84599434~84606463:-
GBM	cis	rs950169	0.81	rs2879976	ENSG00000275120.1	RP11-182J1.17	4.45	2.02e-05	0.0162	0.49	0.38	Schizophrenia;	chr15:84566347	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs12915832	ENSG00000275120.1	RP11-182J1.17	4.45	2.02e-05	0.0162	0.49	0.38	Schizophrenia;	chr15:84568226	chr15:84599434~84606463:-
GBM	cis	rs7017914	0.652	rs11987148	ENSG00000246366.5	RP11-382J12.1	-4.45	2.02e-05	0.0163	-0.41	-0.38	Bone mineral density;	chr8:70749075	chr8:70608577~70663279:+
GBM	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-4.45	2.03e-05	0.0163	-0.53	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
GBM	cis	rs10911232	0.507	rs10911212	ENSG00000224468.3	RP11-181K3.4	-4.45	2.03e-05	0.0163	-0.31	-0.38	Hypertriglyceridemia;	chr1:183055334	chr1:183138402~183141282:-
GBM	cis	rs10411262	0.506	rs11083845	ENSG00000245598.5	DACT3-AS1	-4.45	2.03e-05	0.0163	-0.46	-0.38	Tonsillectomy;	chr19:46683398	chr19:46660364~46677447:+
GBM	cis	rs10411262	0.506	rs6509291	ENSG00000245598.5	DACT3-AS1	-4.45	2.03e-05	0.0163	-0.46	-0.38	Tonsillectomy;	chr19:46683704	chr19:46660364~46677447:+
GBM	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	4.45	2.03e-05	0.0163	0.55	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
GBM	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	4.45	2.03e-05	0.0163	0.55	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
GBM	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	4.45	2.03e-05	0.0164	0.63	0.38	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
GBM	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	4.45	2.04e-05	0.0164	0.58	0.38	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
GBM	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	4.45	2.04e-05	0.0164	0.82	0.38	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	4.45	2.04e-05	0.0164	0.82	0.38	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
GBM	cis	rs11642862	1	rs11645175	ENSG00000260911.2	RP11-196G11.2	4.44	2.04e-05	0.0164	0.54	0.38	Tonsillectomy;	chr16:30791978	chr16:31043150~31049868:+
GBM	cis	rs950169	0.922	rs17531523	ENSG00000275120.1	RP11-182J1.17	4.44	2.04e-05	0.0164	0.49	0.38	Schizophrenia;	chr15:84589218	chr15:84599434~84606463:-
GBM	cis	rs17270561	0.779	rs17271767	ENSG00000272462.2	U91328.19	-4.44	2.04e-05	0.0164	-0.59	-0.38	Iron status biomarkers;	chr6:25886693	chr6:25992662~26001775:+
GBM	cis	rs17270561	0.779	rs12209218	ENSG00000272462.2	U91328.19	-4.44	2.04e-05	0.0164	-0.59	-0.38	Iron status biomarkers;	chr6:25887548	chr6:25992662~26001775:+
GBM	cis	rs17270561	0.723	rs12213243	ENSG00000272462.2	U91328.19	-4.44	2.04e-05	0.0164	-0.59	-0.38	Iron status biomarkers;	chr6:25889880	chr6:25992662~26001775:+
GBM	cis	rs922692	0.744	rs12899147	ENSG00000261143.1	ADAMTS7P3	4.44	2.04e-05	0.0164	0.41	0.38	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78787170	chr15:77976042~77993057:+
GBM	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	4.44	2.04e-05	0.0164	0.48	0.38	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	4.44	2.04e-05	0.0164	0.48	0.38	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
GBM	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-4.44	2.04e-05	0.0164	-0.37	-0.38	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
GBM	cis	rs4664293	0.867	rs12617546	ENSG00000226266.5	AC009961.3	-4.44	2.04e-05	0.0164	-0.49	-0.38	Monocyte percentage of white cells;	chr2:159767079	chr2:159670708~159712435:-
GBM	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	4.44	2.04e-05	0.0164	0.46	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
GBM	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-4.44	2.05e-05	0.0164	-0.64	-0.38	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
GBM	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	4.44	2.05e-05	0.0164	0.39	0.38	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	4.44	2.05e-05	0.0164	0.39	0.38	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	4.44	2.05e-05	0.0164	0.39	0.38	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
GBM	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	4.44	2.05e-05	0.0164	0.39	0.38	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
GBM	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-4.44	2.05e-05	0.0165	-0.44	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
GBM	cis	rs8114671	0.836	rs2425006	ENSG00000269202.1	RP4-614O4.12	4.44	2.05e-05	0.0165	0.48	0.38	Height;	chr20:34983425	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs734308	ENSG00000269202.1	RP4-614O4.12	4.44	2.05e-05	0.0165	0.48	0.38	Height;	chr20:34984293	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs745849	ENSG00000269202.1	RP4-614O4.12	4.44	2.05e-05	0.0165	0.48	0.38	Height;	chr20:34984375	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.804	rs6088666	ENSG00000269202.1	RP4-614O4.12	-4.44	2.05e-05	0.0165	-0.48	-0.38	Height;	chr20:34976767	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs6120778	ENSG00000269202.1	RP4-614O4.12	-4.44	2.05e-05	0.0165	-0.48	-0.38	Height;	chr20:34977366	chr20:35201747~35203288:-
GBM	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	4.44	2.05e-05	0.0165	0.26	0.38	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
GBM	cis	rs812925	0.519	rs1186696	ENSG00000271889.1	RP11-493E12.1	4.44	2.05e-05	0.0165	0.4	0.38	Immature fraction of reticulocytes;	chr2:61433348	chr2:61151433~61162105:-
GBM	cis	rs812925	0.502	rs6545868	ENSG00000271889.1	RP11-493E12.1	-4.44	2.05e-05	0.0165	-0.4	-0.38	Immature fraction of reticulocytes;	chr2:61428230	chr2:61151433~61162105:-
GBM	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	4.44	2.05e-05	0.0165	0.58	0.38	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
GBM	cis	rs796364	0.694	rs1653299	ENSG00000232732.8	AC073043.1	-4.44	2.05e-05	0.0165	-0.46	-0.38	Schizophrenia;	chr2:200210888	chr2:199867396~199911159:-
GBM	cis	rs4642101	0.669	rs1467026	ENSG00000213943.3	KRT18P17	4.44	2.06e-05	0.0165	0.4	0.38	QRS complex (12-leadsum);	chr3:12789276	chr3:12787393~12788671:-
GBM	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
GBM	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	4.44	2.06e-05	0.0165	0.4	0.38	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	4.44	2.06e-05	0.0165	0.4	0.38	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
GBM	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	4.44	2.06e-05	0.0165	0.51	0.38	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
GBM	cis	rs11671005	0.693	rs11668821	ENSG00000269473.1	CTD-2619J13.19	4.44	2.06e-05	0.0165	0.42	0.38	Mean platelet volume;	chr19:58444446	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.616	rs12980907	ENSG00000269473.1	CTD-2619J13.19	4.44	2.06e-05	0.0165	0.42	0.38	Mean platelet volume;	chr19:58444959	chr19:58440448~58445849:+
GBM	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	4.44	2.06e-05	0.0165	0.44	0.38	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	4.44	2.06e-05	0.0165	0.44	0.38	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	4.44	2.06e-05	0.0165	0.44	0.38	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
GBM	cis	rs2025751	0.512	rs9474091	ENSG00000230204.1	FTH1P5	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intraocular pressure;	chr6:51821997	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463719	ENSG00000230204.1	FTH1P5	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intraocular pressure;	chr6:51823564	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9474093	ENSG00000230204.1	FTH1P5	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intraocular pressure;	chr6:51823709	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463721	ENSG00000230204.1	FTH1P5	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intraocular pressure;	chr6:51823870	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9474094	ENSG00000230204.1	FTH1P5	-4.44	2.06e-05	0.0165	-0.44	-0.38	Intraocular pressure;	chr6:51824828	chr6:50912712~50913256:-
GBM	cis	rs17508449	0.547	rs3789604	ENSG00000232450.1	RP4-730K3.3	-4.44	2.06e-05	0.0165	-0.62	-0.38	Leprosy;	chr1:113812320	chr1:113698884~113699631:-
GBM	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	4.44	2.06e-05	0.0165	0.42	0.38	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
GBM	cis	rs9788721	0.501	rs1021071	ENSG00000261143.1	ADAMTS7P3	4.44	2.06e-05	0.0165	0.42	0.38	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78675837	chr15:77976042~77993057:+
GBM	cis	rs951266	0.505	rs11072785	ENSG00000261143.1	ADAMTS7P3	4.44	2.06e-05	0.0165	0.42	0.38	Post bronchodilator FEV1/FVC ratio;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Pre bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78675887	chr15:77976042~77993057:+
GBM	cis	rs951266	0.505	rs4886579	ENSG00000261143.1	ADAMTS7P3	4.44	2.06e-05	0.0165	0.42	0.38	Post bronchodilator FEV1/FVC ratio;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Pre bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78676914	chr15:77976042~77993057:+
GBM	cis	rs7615952	0.599	rs7652883	ENSG00000250012.1	RP11-124N2.1	-4.44	2.07e-05	0.0166	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:125989134	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs6803160	ENSG00000250012.1	RP11-124N2.1	-4.44	2.07e-05	0.0166	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:125990711	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs6779141	ENSG00000250012.1	RP11-124N2.1	-4.44	2.07e-05	0.0166	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:125991152	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.688	rs12485622	ENSG00000250012.1	RP11-124N2.1	-4.44	2.07e-05	0.0166	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:125991896	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs6766327	ENSG00000250012.1	RP11-124N2.1	-4.44	2.07e-05	0.0166	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:126004834	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs12491577	ENSG00000250012.1	RP11-124N2.1	-4.44	2.07e-05	0.0166	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:126012288	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs1875683	ENSG00000250012.1	RP11-124N2.1	-4.44	2.07e-05	0.0166	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:126013638	chr3:126084220~126095349:+
GBM	cis	rs324457	1	rs324457	ENSG00000225706.1	PTPRD-AS1	4.44	2.07e-05	0.0166	0.4	0.38	Loneliness;Loneliness (linear analysis);Loneliness (multivariate analysis);	chr9:9054621	chr9:8858130~8862255:+
GBM	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	4.44	2.07e-05	0.0166	0.51	0.38	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
GBM	cis	rs7017914	0.617	rs34917985	ENSG00000246366.5	RP11-382J12.1	-4.44	2.07e-05	0.0166	-0.4	-0.38	Bone mineral density;	chr8:70662426	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs6993326	ENSG00000246366.5	RP11-382J12.1	-4.44	2.07e-05	0.0166	-0.4	-0.38	Bone mineral density;	chr8:70663365	chr8:70608577~70663279:+
GBM	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-4.44	2.07e-05	0.0166	-0.37	-0.38	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
GBM	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	4.44	2.07e-05	0.0166	0.51	0.38	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
GBM	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	4.44	2.07e-05	0.0166	0.51	0.38	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
GBM	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	4.44	2.07e-05	0.0166	0.51	0.38	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
GBM	cis	rs11168351	0.926	rs10875719	ENSG00000258273.1	RP11-370I10.4	-4.44	2.07e-05	0.0166	-0.49	-0.38	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48333755~48333901:-
GBM	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	4.44	2.07e-05	0.0166	0.47	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
GBM	cis	rs3845817	0.832	rs702950	ENSG00000237979.1	AC007389.1	4.44	2.07e-05	0.0166	0.53	0.38	Bipolar disorder;	chr2:65537776	chr2:65500993~65502138:-
GBM	cis	rs11168936	1	rs11168936	ENSG00000257464.1	RP11-161H23.8	-4.44	2.08e-05	0.0166	-0.42	-0.38	Cancer (pleiotropy);	chr12:49251457	chr12:49442424~49442652:-
GBM	cis	rs17772222	0.701	rs1627444	ENSG00000258983.2	RP11-507K2.2	-4.44	2.08e-05	0.0166	-0.4	-0.38	Coronary artery calcification;	chr14:88413784	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.565	rs845759	ENSG00000258983.2	RP11-507K2.2	-4.44	2.08e-05	0.0166	-0.4	-0.38	Coronary artery calcification;	chr14:88415538	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.545	rs1758846	ENSG00000258983.2	RP11-507K2.2	-4.44	2.08e-05	0.0166	-0.4	-0.38	Coronary artery calcification;	chr14:88449288	chr14:88499334~88515502:+
GBM	cis	rs853679	0.599	rs149949	ENSG00000199851.2	U3	4.44	2.08e-05	0.0167	0.73	0.38	Depression;	chr6:28043738	chr6:28015568~28015777:+
GBM	cis	rs8114671	0.904	rs6060197	ENSG00000269202.1	RP4-614O4.12	4.44	2.08e-05	0.0167	0.47	0.38	Height;	chr20:35066512	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.839	rs6142290	ENSG00000269202.1	RP4-614O4.12	4.44	2.08e-05	0.0167	0.47	0.38	Height;	chr20:35066869	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.869	rs6060199	ENSG00000269202.1	RP4-614O4.12	4.44	2.08e-05	0.0167	0.47	0.38	Height;	chr20:35066970	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.869	rs66535333	ENSG00000269202.1	RP4-614O4.12	4.44	2.08e-05	0.0167	0.47	0.38	Height;	chr20:35068863	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.869	rs1544047	ENSG00000269202.1	RP4-614O4.12	4.44	2.08e-05	0.0167	0.47	0.38	Height;	chr20:35082950	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs6142294	ENSG00000269202.1	RP4-614O4.12	4.44	2.08e-05	0.0167	0.47	0.38	Height;	chr20:35083694	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs17404569	ENSG00000269202.1	RP4-614O4.12	4.44	2.08e-05	0.0167	0.47	0.38	Height;	chr20:35086274	chr20:35201747~35203288:-
GBM	cis	rs4072705	1	rs10760372	ENSG00000224020.1	MIR181A2HG	-4.44	2.08e-05	0.0167	-0.4	-0.38	Menarche (age at onset);	chr9:124706537	chr9:124658467~124698631:+
GBM	cis	rs17772222	0.876	rs61983303	ENSG00000222990.1	RNU4-22P	4.44	2.09e-05	0.0167	0.46	0.38	Coronary artery calcification;	chr14:88764459	chr14:88513498~88513663:+
GBM	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	4.44	2.09e-05	0.0167	0.51	0.38	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
GBM	cis	rs12681420	0.754	rs34471605	ENSG00000246366.5	RP11-382J12.1	-4.44	2.09e-05	0.0167	-0.41	-0.38	Erythrocyte cadmium concentration in never smokers;	chr8:70849983	chr8:70608577~70663279:+
GBM	cis	rs4713118	0.955	rs9380010	ENSG00000199851.2	U3	4.44	2.09e-05	0.0167	0.53	0.38	Parkinson's disease;	chr6:27715793	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9368528	ENSG00000199851.2	U3	4.44	2.09e-05	0.0167	0.53	0.38	Parkinson's disease;	chr6:27716019	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9380011	ENSG00000199851.2	U3	4.44	2.09e-05	0.0167	0.53	0.38	Parkinson's disease;	chr6:27716145	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9368529	ENSG00000199851.2	U3	4.44	2.09e-05	0.0167	0.53	0.38	Parkinson's disease;	chr6:27716852	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9380012	ENSG00000199851.2	U3	4.44	2.09e-05	0.0167	0.53	0.38	Parkinson's disease;	chr6:27716875	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9468201	ENSG00000199851.2	U3	4.44	2.09e-05	0.0167	0.53	0.38	Parkinson's disease;	chr6:27719256	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.955	rs9393848	ENSG00000199851.2	U3	4.44	2.09e-05	0.0167	0.53	0.38	Parkinson's disease;	chr6:27720590	chr6:28015568~28015777:+
GBM	cis	rs3845817	0.868	rs702942	ENSG00000237979.1	AC007389.1	4.44	2.09e-05	0.0167	0.53	0.38	Bipolar disorder;	chr2:65529831	chr2:65500993~65502138:-
GBM	cis	rs3845817	0.832	rs702945	ENSG00000237979.1	AC007389.1	4.44	2.09e-05	0.0167	0.53	0.38	Bipolar disorder;	chr2:65534098	chr2:65500993~65502138:-
GBM	cis	rs3845817	0.808	rs702895	ENSG00000237979.1	AC007389.1	4.44	2.09e-05	0.0167	0.53	0.38	Bipolar disorder;	chr2:65534933	chr2:65500993~65502138:-
GBM	cis	rs3845817	0.868	rs702896	ENSG00000237979.1	AC007389.1	4.44	2.09e-05	0.0167	0.53	0.38	Bipolar disorder;	chr2:65535089	chr2:65500993~65502138:-
GBM	cis	rs6583331	0.818	rs7614184	ENSG00000273013.1	CTD-2002J20.1	-4.44	2.09e-05	0.0167	-0.42	-0.38	Vitiligo;	chr3:196619326	chr3:196474801~196475394:+
GBM	cis	rs4887140	0.867	rs12899897	ENSG00000260469.2	C15orf59-AS1	-4.44	2.09e-05	0.0167	-0.71	-0.38	Glucose homeostasis traits;	chr15:73762850	chr15:73752317~73770613:+
GBM	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-4.44	2.09e-05	0.0167	-0.43	-0.38	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-4.44	2.09e-05	0.0167	-0.43	-0.38	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
GBM	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-4.44	2.09e-05	0.0167	-0.43	-0.38	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
GBM	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-4.44	2.09e-05	0.0167	-0.46	-0.38	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-4.44	2.09e-05	0.0167	-0.46	-0.38	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-4.44	2.09e-05	0.0167	-0.46	-0.38	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
GBM	cis	rs950169	0.922	rs11630760	ENSG00000275120.1	RP11-182J1.17	4.44	2.1e-05	0.0167	0.49	0.38	Schizophrenia;	chr15:84570106	chr15:84599434~84606463:-
GBM	cis	rs950169	0.887	rs71395453	ENSG00000275120.1	RP11-182J1.17	4.44	2.1e-05	0.0167	0.49	0.38	Schizophrenia;	chr15:84570259	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs11633075	ENSG00000275120.1	RP11-182J1.17	4.44	2.1e-05	0.0167	0.49	0.38	Schizophrenia;	chr15:84570741	chr15:84599434~84606463:-
GBM	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-4.44	2.1e-05	0.0167	-0.46	-0.38	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
GBM	cis	rs11098499	0.866	rs12501602	ENSG00000249244.1	RP11-548H18.2	4.44	2.1e-05	0.0167	0.48	0.38	Corneal astigmatism;	chr4:119366780	chr4:119391831~119395335:-
GBM	cis	rs7017914	0.837	rs2732105	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0167	-0.4	-0.38	Bone mineral density;	chr8:71011410	chr8:70608577~70663279:+
GBM	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	4.44	2.1e-05	0.0167	0.52	0.38	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
GBM	cis	rs7017914	0.677	rs1973364	ENSG00000246366.5	RP11-382J12.1	4.44	2.1e-05	0.0168	0.4	0.38	Bone mineral density;	chr8:70955007	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs62532068	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70750952	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.653	rs13273718	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70757485	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs12674966	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70772175	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs11992027	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70776635	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs62508770	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70780269	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs55862702	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70781502	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs6998989	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70782296	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs6981149	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70782447	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1596565	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70786597	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.605	rs55865599	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70792351	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs35318824	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70820387	chr8:70608577~70663279:+
GBM	cis	rs763121	0.889	rs9607557	ENSG00000273076.1	RP3-508I15.22	4.44	2.1e-05	0.0168	0.4	0.38	Menopause (age at onset);	chr22:38644274	chr22:38743495~38743910:+
GBM	cis	rs7017914	0.69	rs6991708	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.39	-0.38	Bone mineral density;	chr8:70756293	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs1838392	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.39	-0.38	Bone mineral density;	chr8:70770348	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.653	rs2732130	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70981238	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs2732127	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70984584	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.667	rs2732124	ENSG00000246366.5	RP11-382J12.1	-4.44	2.1e-05	0.0168	-0.4	-0.38	Bone mineral density;	chr8:70986447	chr8:70608577~70663279:+
GBM	cis	rs8114671	0.804	rs6060139	ENSG00000269202.1	RP4-614O4.12	-4.44	2.1e-05	0.0168	-0.48	-0.38	Height;	chr20:34978696	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.836	rs6060140	ENSG00000269202.1	RP4-614O4.12	-4.44	2.1e-05	0.0168	-0.48	-0.38	Height;	chr20:34978704	chr20:35201747~35203288:-
GBM	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-4.44	2.1e-05	0.0168	-0.84	-0.38	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
GBM	cis	rs17772222	0.917	rs2004329	ENSG00000222990.1	RNU4-22P	4.44	2.1e-05	0.0168	0.46	0.38	Coronary artery calcification;	chr14:88532965	chr14:88513498~88513663:+
GBM	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-4.44	2.1e-05	0.0168	-0.34	-0.38	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
GBM	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0168	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0168	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0168	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
GBM	cis	rs853679	0.76	rs9357067	ENSG00000199851.2	U3	4.44	2.11e-05	0.0168	0.66	0.38	Depression;	chr6:28242515	chr6:28015568~28015777:+
GBM	cis	rs853679	0.76	rs967005	ENSG00000199851.2	U3	4.44	2.11e-05	0.0168	0.66	0.38	Depression;	chr6:28242910	chr6:28015568~28015777:+
GBM	cis	rs67981189	0.555	rs11623266	ENSG00000269927.1	RP6-91H8.3	-4.44	2.11e-05	0.0168	-0.43	-0.38	Schizophrenia;	chr14:70899223	chr14:71141125~71143253:-
GBM	cis	rs8177376	0.581	rs512577	ENSG00000254905.1	RP11-712L6.7	-4.44	2.11e-05	0.0168	-0.5	-0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126222046	chr11:126292922~126294254:-
GBM	cis	rs11098499	0.78	rs7692994	ENSG00000249244.1	RP11-548H18.2	4.44	2.11e-05	0.0168	0.46	0.38	Corneal astigmatism;	chr4:119506334	chr4:119391831~119395335:-
GBM	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-4.44	2.11e-05	0.0168	-0.55	-0.38	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
GBM	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-4.44	2.11e-05	0.0168	-0.55	-0.38	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
GBM	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-4.44	2.11e-05	0.0168	-0.46	-0.38	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
GBM	cis	rs7017914	0.935	rs2732093	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71006844	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2639899	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71007227	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732094	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71007683	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732095	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71007711	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs2732096	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71007745	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.935	rs2732097	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71007778	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.875	rs2639897	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71008441	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2639896	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71008548	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs1353057	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71009862	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2639960	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71009904	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2639958	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71009915	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs1908036	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71010089	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs1908035	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71010173	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs1908033	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71010564	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2639957	ENSG00000246366.5	RP11-382J12.1	-4.44	2.11e-05	0.0169	-0.4	-0.38	Bone mineral density;	chr8:71010967	chr8:70608577~70663279:+
GBM	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-4.44	2.11e-05	0.0169	-0.53	-0.38	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
GBM	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0169	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0169	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0169	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0169	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0169	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
GBM	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	4.44	2.11e-05	0.0169	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
GBM	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-4.44	2.12e-05	0.0169	-0.39	-0.38	Temperament;	chr17:14042870	chr17:14024514~14025488:+
GBM	cis	rs5742933	0.948	rs6434365	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189707695	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs1966729	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189721105	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.842	rs1225101	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189740695	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs12052909	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189742484	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs16831955	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189745811	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs2289404	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189771288	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs12622902	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189776263	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs12619808	ENSG00000253559.1	OSGEPL1-AS1	-4.44	2.12e-05	0.0169	-0.44	-0.38	Ferritin levels;	chr2:189776458	chr2:189762704~189765556:+
GBM	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	4.44	2.12e-05	0.0169	0.48	0.38	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
GBM	cis	rs11673344	0.504	rs2595555	ENSG00000226686.6	LINC01535	4.44	2.12e-05	0.0169	0.41	0.38	Obesity-related traits;	chr19:37000219	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.504	rs1667377	ENSG00000226686.6	LINC01535	4.44	2.12e-05	0.0169	0.41	0.38	Obesity-related traits;	chr19:37000966	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.523	rs1667379	ENSG00000226686.6	LINC01535	4.44	2.12e-05	0.0169	0.41	0.38	Obesity-related traits;	chr19:37001192	chr19:37251912~37265535:+
GBM	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	4.43	2.12e-05	0.0169	0.43	0.38	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
GBM	cis	rs7176527	0.579	rs366717	ENSG00000225151.9	GOLGA2P7	4.43	2.12e-05	0.0169	0.51	0.38	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84199311~84230136:-
GBM	cis	rs7017914	0.616	rs11987260	ENSG00000246366.5	RP11-382J12.1	-4.43	2.12e-05	0.0169	-0.41	-0.38	Bone mineral density;	chr8:70861647	chr8:70608577~70663279:+
GBM	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	4.43	2.12e-05	0.0169	0.41	0.38	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
GBM	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	4.43	2.12e-05	0.0169	0.41	0.38	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
GBM	cis	rs11992162	1	rs7460395	ENSG00000255556.2	RP11-351I21.6	4.43	2.12e-05	0.0169	0.39	0.38	Monocyte count;	chr8:11977866	chr8:12378679~12380265:-
GBM	cis	rs10911251	0.509	rs4652780	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183136788	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.809	rs3768613	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183137161	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.508	rs10797854	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183137604	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.508	rs2245784	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183138530	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs2147578	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183138564	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.508	rs729672	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183140101	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs2027084	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183141666	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs1062044	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183143277	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs944971	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183143370	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.508	rs944970	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183143431	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.508	rs6424890	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183143629	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.809	rs3738829	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183144727	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs1547715	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183144817	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs1547714	ENSG00000224468.3	RP11-181K3.4	-4.43	2.13e-05	0.0169	-0.31	-0.38	Colorectal cancer;	chr1:183144984	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs2027085	ENSG00000224468.3	RP11-181K3.4	4.43	2.13e-05	0.0169	0.31	0.38	Colorectal cancer;	chr1:183139476	chr1:183138402~183141282:-
GBM	cis	rs8014671	0.531	rs12880777	ENSG00000235812.4	ADAM21P1	-4.43	2.13e-05	0.0169	-0.47	-0.38	Prostate cancer;	chr14:70407978	chr14:70245491~70247801:-
GBM	cis	rs977747	0.933	rs10789504	ENSG00000232022.5	FAAHP1	-4.43	2.13e-05	0.0169	-0.38	-0.38	Body mass index;	chr1:47210859	chr1:46432129~46445521:+
GBM	cis	rs977747	0.966	rs741959	ENSG00000232022.5	FAAHP1	4.43	2.13e-05	0.0169	0.38	0.38	Body mass index;	chr1:47210561	chr1:46432129~46445521:+
GBM	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-4.43	2.13e-05	0.0169	-0.48	-0.38	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
GBM	cis	rs17685	0.753	rs1637039	ENSG00000280388.1	RP11-229D13.3	-4.43	2.13e-05	0.017	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76063691	chr7:76043977~76045963:-
GBM	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-4.43	2.14e-05	0.017	-0.54	-0.38	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-4.43	2.14e-05	0.017	-0.54	-0.38	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
GBM	cis	rs763121	0.853	rs5757166	ENSG00000273076.1	RP3-508I15.22	4.43	2.14e-05	0.017	0.41	0.38	Menopause (age at onset);	chr22:38599380	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs1569716	ENSG00000273076.1	RP3-508I15.22	4.43	2.14e-05	0.017	0.41	0.38	Menopause (age at onset);	chr22:38602514	chr22:38743495~38743910:+
GBM	cis	rs763121	0.819	rs5757169	ENSG00000273076.1	RP3-508I15.22	4.43	2.14e-05	0.017	0.41	0.38	Menopause (age at onset);	chr22:38607490	chr22:38743495~38743910:+
GBM	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	4.43	2.14e-05	0.017	0.42	0.38	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
GBM	cis	rs763121	0.853	rs138705	ENSG00000273076.1	RP3-508I15.22	4.43	2.14e-05	0.017	0.4	0.38	Menopause (age at onset);	chr22:38737798	chr22:38743495~38743910:+
GBM	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	4.43	2.14e-05	0.017	0.47	0.38	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
GBM	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	4.43	2.14e-05	0.017	0.45	0.38	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
GBM	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-4.43	2.15e-05	0.0171	-0.52	-0.38	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
GBM	cis	rs9926296	0.508	rs1558184	ENSG00000260259.1	RP11-368I7.4	-4.43	2.15e-05	0.0171	-0.42	-0.38	Vitiligo;	chr16:89775966	chr16:89682620~89686569:-
GBM	cis	rs8062405	0.964	rs62036614	ENSG00000271623.1	RP11-435I10.5	-4.43	2.15e-05	0.0171	-0.47	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62036616	ENSG00000271623.1	RP11-435I10.5	-4.43	2.15e-05	0.0171	-0.47	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28364700~28365333:+
GBM	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-4.43	2.15e-05	0.0171	-0.43	-0.38	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
GBM	cis	rs8014671	0.519	rs12884918	ENSG00000235812.4	ADAM21P1	-4.43	2.15e-05	0.0171	-0.46	-0.38	Prostate cancer;	chr14:70424061	chr14:70245491~70247801:-
GBM	cis	rs3742264	0.816	rs9534319	ENSG00000235903.6	CPB2-AS1	4.43	2.15e-05	0.0171	0.5	0.38	Blood protein levels;	chr13:46090309	chr13:46052806~46113332:+
GBM	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-4.43	2.16e-05	0.0171	-0.37	-0.38	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-4.43	2.16e-05	0.0171	-0.37	-0.38	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
GBM	cis	rs2025751	0.666	rs10214608	ENSG00000230204.1	FTH1P5	-4.43	2.16e-05	0.0171	-0.44	-0.38	Intraocular pressure;	chr6:51821455	chr6:50912712~50913256:-
GBM	cis	rs9926296	0.548	rs6500439	ENSG00000260259.1	RP11-368I7.4	-4.43	2.16e-05	0.0171	-0.41	-0.38	Vitiligo;	chr16:89741867	chr16:89682620~89686569:-
GBM	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-4.43	2.16e-05	0.0172	-0.49	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
GBM	cis	rs731565	1	rs113756567	ENSG00000232391.1	RANP2	4.43	2.16e-05	0.0172	0.7	0.38	Diabetic kidney disease;	chr7:147722051	chr7:147167344~147167572:+
GBM	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-4.43	2.17e-05	0.0172	-0.43	-0.38	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
GBM	cis	rs7017914	0.818	rs13252808	ENSG00000246366.5	RP11-382J12.1	-4.43	2.17e-05	0.0172	-0.39	-0.38	Bone mineral density;	chr8:70704420	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.667	rs13281864	ENSG00000246366.5	RP11-382J12.1	-4.43	2.17e-05	0.0172	-0.39	-0.38	Bone mineral density;	chr8:70730338	chr8:70608577~70663279:+
GBM	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-4.43	2.17e-05	0.0172	-0.75	-0.38	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
GBM	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-4.43	2.17e-05	0.0172	-0.45	-0.38	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
GBM	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	4.43	2.17e-05	0.0172	0.47	0.38	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
GBM	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	4.43	2.17e-05	0.0172	0.47	0.38	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
GBM	cis	rs950169	0.919	rs17300292	ENSG00000275120.1	RP11-182J1.17	4.43	2.17e-05	0.0172	0.5	0.38	Schizophrenia;	chr15:84093816	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs12916348	ENSG00000275120.1	RP11-182J1.17	4.43	2.17e-05	0.0172	0.5	0.38	Schizophrenia;	chr15:84096775	chr15:84599434~84606463:-
GBM	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-4.43	2.18e-05	0.0172	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-4.43	2.18e-05	0.0172	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
GBM	cis	rs599083	0.59	rs10791984	ENSG00000212093.1	AP000807.1	-4.43	2.18e-05	0.0172	-0.43	-0.38	Bone mineral density (spine);	chr11:68640367	chr11:68506083~68506166:-
GBM	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	4.43	2.18e-05	0.0172	0.57	0.38	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
GBM	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	4.43	2.18e-05	0.0173	0.44	0.38	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
GBM	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	4.43	2.18e-05	0.0173	0.48	0.38	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
GBM	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	4.43	2.18e-05	0.0173	0.43	0.38	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
GBM	cis	rs1528149	0.504	rs6943936	ENSG00000224683.1	RPL36AP29	-4.43	2.18e-05	0.0173	-0.41	-0.38	Sitting height ratio;	chr7:16128648	chr7:16208945~16209265:+
GBM	cis	rs1528149	0.504	rs6968537	ENSG00000224683.1	RPL36AP29	-4.43	2.18e-05	0.0173	-0.41	-0.38	Sitting height ratio;	chr7:16129083	chr7:16208945~16209265:+
GBM	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	4.43	2.18e-05	0.0173	0.42	0.38	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
GBM	cis	rs11771526	0.551	rs2392053	ENSG00000273014.1	RP11-225B17.2	4.43	2.18e-05	0.0173	0.69	0.38	Body mass index;	chr7:32219444	chr7:32758882~32759353:+
GBM	cis	rs763121	0.853	rs5750673	ENSG00000273076.1	RP3-508I15.22	4.43	2.18e-05	0.0173	0.43	0.38	Menopause (age at onset);	chr22:38714119	chr22:38743495~38743910:+
GBM	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	4.43	2.18e-05	0.0173	0.43	0.38	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
GBM	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	4.43	2.18e-05	0.0173	0.43	0.38	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
GBM	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	4.43	2.18e-05	0.0173	0.43	0.38	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
GBM	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	4.43	2.18e-05	0.0173	0.43	0.38	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
GBM	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-4.43	2.18e-05	0.0173	-0.59	-0.38	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
GBM	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-4.43	2.18e-05	0.0173	-0.38	-0.38	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
GBM	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	4.43	2.19e-05	0.0173	0.47	0.38	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
GBM	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	4.43	2.19e-05	0.0173	0.47	0.38	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
GBM	cis	rs453301	0.686	rs7017868	ENSG00000254340.1	RP11-10A14.3	-4.43	2.19e-05	0.0173	-0.48	-0.38	Joint mobility (Beighton score);	chr8:9015783	chr8:9141424~9145435:+
GBM	cis	rs453301	0.686	rs3895823	ENSG00000254340.1	RP11-10A14.3	-4.43	2.19e-05	0.0173	-0.48	-0.38	Joint mobility (Beighton score);	chr8:9016136	chr8:9141424~9145435:+
GBM	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-4.43	2.19e-05	0.0173	-0.45	-0.38	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-4.43	2.19e-05	0.0173	-0.45	-0.38	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-4.43	2.19e-05	0.0173	-0.45	-0.38	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-4.43	2.19e-05	0.0173	-0.45	-0.38	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-4.43	2.19e-05	0.0173	-0.45	-0.38	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-4.43	2.19e-05	0.0173	-0.45	-0.38	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
GBM	cis	rs4887140	0.681	rs4886597	ENSG00000260469.2	C15orf59-AS1	-4.43	2.19e-05	0.0173	-0.64	-0.38	Glucose homeostasis traits;	chr15:73763639	chr15:73752317~73770613:+
GBM	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	4.43	2.2e-05	0.0174	0.43	0.38	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
GBM	cis	rs3845817	0.798	rs702952	ENSG00000237979.1	AC007389.1	4.43	2.2e-05	0.0174	0.53	0.38	Bipolar disorder;	chr2:65537915	chr2:65500993~65502138:-
GBM	cis	rs4869313	0.905	rs38039	ENSG00000248734.2	CTD-2260A17.1	-4.43	2.2e-05	0.0174	-0.46	-0.38	Pediatric autoimmune diseases;	chr5:96991585	chr5:96784777~96785999:+
GBM	cis	rs5742933	0.696	rs17271246	ENSG00000273240.1	RP11-455J20.3	-4.43	2.2e-05	0.0174	-0.57	-0.38	Ferritin levels;	chr2:189781481	chr2:189763859~189764456:-
GBM	cis	rs4072705	0.967	rs10760369	ENSG00000224020.1	MIR181A2HG	-4.43	2.2e-05	0.0174	-0.4	-0.38	Menarche (age at onset);	chr9:124635121	chr9:124658467~124698631:+
GBM	cis	rs61041384	0.661	rs4148864	ENSG00000256092.2	RP13-942N8.1	-4.43	2.2e-05	0.0174	-0.9	-0.38	Schizophrenia;	chr12:123096110	chr12:123363868~123366113:+
GBM	cis	rs11098499	0.71	rs6851130	ENSG00000250412.1	KLHL2P1	-4.42	2.21e-05	0.0174	-0.52	-0.38	Corneal astigmatism;	chr4:119212557	chr4:119334329~119378233:+
GBM	cis	rs4713118	0.869	rs4713121	ENSG00000199851.2	U3	4.42	2.21e-05	0.0175	0.52	0.38	Parkinson's disease;	chr6:27754285	chr6:28015568~28015777:+
GBM	cis	rs17685	0.753	rs2868203	ENSG00000280388.1	RP11-229D13.3	4.42	2.21e-05	0.0175	0.35	0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76050708	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1104879	ENSG00000280388.1	RP11-229D13.3	-4.42	2.21e-05	0.0175	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76056250	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1104878	ENSG00000280388.1	RP11-229D13.3	-4.42	2.21e-05	0.0175	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76056275	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs869805	ENSG00000280388.1	RP11-229D13.3	-4.42	2.21e-05	0.0175	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76059278	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1637037	ENSG00000280388.1	RP11-229D13.3	-4.42	2.21e-05	0.0175	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76063609	chr7:76043977~76045963:-
GBM	cis	rs3806843	1	rs10057161	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs2337985	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs2337986	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.933	rs10069930	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs1548701	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs10073974	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3756342	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3733710	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.933	rs2240696	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs2240695	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs6579965	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs6898906	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs10477034	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.966	rs3756341	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs12717860	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs6870764	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs6891995	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs13184940	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs1476768	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs9686540	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3756339	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs3733708	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr5:140718925~140719013:+
GBM	cis	rs3806843	1	rs2240694	ENSG00000202111.1	VTRNA1-2	-4.42	2.21e-05	0.0175	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr5:140718925~140719013:+
GBM	cis	rs11671005	0.735	rs11667591	ENSG00000269473.1	CTD-2619J13.19	4.42	2.21e-05	0.0175	0.42	0.38	Mean platelet volume;	chr19:58426270	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11084544	ENSG00000269473.1	CTD-2619J13.19	4.42	2.21e-05	0.0175	0.42	0.38	Mean platelet volume;	chr19:58428760	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.779	rs55875034	ENSG00000269473.1	CTD-2619J13.19	4.42	2.21e-05	0.0175	0.44	0.38	Mean platelet volume;	chr19:58472191	chr19:58440448~58445849:+
GBM	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-4.42	2.22e-05	0.0175	-0.35	-0.38	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
GBM	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	4.42	2.22e-05	0.0175	0.4	0.38	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
GBM	cis	rs11671005	0.735	rs11668420	ENSG00000269473.1	CTD-2619J13.19	4.42	2.22e-05	0.0175	0.42	0.38	Mean platelet volume;	chr19:58426469	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs34873624	ENSG00000269473.1	CTD-2619J13.19	4.42	2.22e-05	0.0175	0.42	0.38	Mean platelet volume;	chr19:58432035	chr19:58440448~58445849:+
GBM	cis	rs138249	0.505	rs138218	ENSG00000273253.2	RP3-402G11.26	-4.42	2.22e-05	0.0175	-0.46	-0.38	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50109129	chr22:50199090~50200837:-
GBM	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	4.42	2.22e-05	0.0175	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	4.42	2.22e-05	0.0175	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	4.42	2.22e-05	0.0175	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
GBM	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	4.42	2.22e-05	0.0175	0.65	0.38	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
GBM	cis	rs1508798	0.539	rs3798092	ENSG00000250786.1	SNHG18	-4.42	2.22e-05	0.0175	-0.52	-0.38	Coronary artery disease;	chr5:9541581	chr5:9546200~9550609:+
GBM	cis	rs2810114	0.834	rs36559	ENSG00000269927.1	RP6-91H8.3	4.42	2.22e-05	0.0175	0.46	0.38	Alcohol dependence;	chr14:70888232	chr14:71141125~71143253:-
GBM	cis	rs4072705	0.967	rs4144630	ENSG00000224020.1	MIR181A2HG	-4.42	2.22e-05	0.0175	-0.4	-0.38	Menarche (age at onset);	chr9:124676921	chr9:124658467~124698631:+
GBM	cis	rs1150668	0.799	rs1736891	ENSG00000218016.2	ZNF192P2	-4.42	2.22e-05	0.0175	-0.44	-0.38	Pubertal anthropometrics;	chr6:28219323	chr6:28188050~28189432:+
GBM	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	4.42	2.22e-05	0.0175	0.66	0.38	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
GBM	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	4.42	2.22e-05	0.0175	0.53	0.38	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
GBM	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	4.42	2.23e-05	0.0175	0.41	0.38	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
GBM	cis	rs10971721	0.643	rs41315997	ENSG00000281128.1	PTENP1-AS	4.42	2.23e-05	0.0175	0.81	0.38	Body mass index;	chr9:33798840	chr9:33677268~33688011:+
GBM	cis	rs35612822	0.65	rs6743973	ENSG00000233143.1	DIRC3-AS1	4.42	2.23e-05	0.0176	0.53	0.38	Kidney disease (early stage) in type 1 diabetes;	chr2:216405370	chr2:217282739~217336120:+
GBM	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-4.42	2.23e-05	0.0176	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
GBM	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	4.42	2.23e-05	0.0176	0.69	0.38	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
GBM	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-4.42	2.23e-05	0.0176	-0.6	-0.38	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
GBM	cis	rs893363	0.559	rs877484	ENSG00000271916.1	RP11-884K10.6	4.42	2.23e-05	0.0176	0.44	0.38	Axial length;	chr3:53812897	chr3:53797764~53798019:-
GBM	cis	rs2280018	0.581	rs7404524	ENSG00000260735.1	RP11-72I8.1	-4.42	2.23e-05	0.0176	-0.41	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15094411~15109197:+
GBM	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-4.42	2.23e-05	0.0176	-0.41	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
GBM	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-4.42	2.24e-05	0.0176	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-4.42	2.24e-05	0.0176	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
GBM	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	4.42	2.24e-05	0.0176	0.42	0.38	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
GBM	cis	rs926937	0.622	rs6005500	ENSG00000235954.5	TTC28-AS1	-4.42	2.24e-05	0.0176	-0.67	-0.38	Age-related cataracts;	chr22:27529117	chr22:27919376~28008581:+
GBM	cis	rs10231759	0.53	rs6952268	ENSG00000273419.1	RP4-751H13.7	-4.42	2.24e-05	0.0177	-0.41	-0.38	Height;	chr7:150835759	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs12537755	ENSG00000273419.1	RP4-751H13.7	-4.42	2.24e-05	0.0177	-0.41	-0.38	Height;	chr7:150835766	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.53	rs4725371	ENSG00000273419.1	RP4-751H13.7	-4.42	2.24e-05	0.0177	-0.41	-0.38	Height;	chr7:150836236	chr7:149858400~149862492:-
GBM	cis	rs1190596	0.689	rs2224460	ENSG00000259088.1	CTD-2017C7.2	-4.42	2.24e-05	0.0177	-0.49	-0.38	Behavioural disinhibition (generation interaction);	chr14:102097460	chr14:101796555~101810321:-
GBM	cis	rs763121	0.925	rs5750654	ENSG00000273076.1	RP3-508I15.22	4.42	2.24e-05	0.0177	0.4	0.38	Menopause (age at onset);	chr22:38655423	chr22:38743495~38743910:+
GBM	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-4.42	2.25e-05	0.0177	-0.56	-0.38	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
GBM	cis	rs17685	0.753	rs869804	ENSG00000280388.1	RP11-229D13.3	-4.42	2.25e-05	0.0177	-0.34	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76059636	chr7:76043977~76045963:-
GBM	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-4.42	2.25e-05	0.0177	-0.45	-0.38	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
GBM	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	4.42	2.25e-05	0.0177	0.4	0.38	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
GBM	cis	rs17685	0.753	rs13240967	ENSG00000280388.1	RP11-229D13.3	4.42	2.25e-05	0.0177	0.36	0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76028879	chr7:76043977~76045963:-
GBM	cis	rs731565	1	rs75553756	ENSG00000232391.1	RANP2	4.42	2.25e-05	0.0177	0.73	0.38	Diabetic kidney disease;	chr7:147717146	chr7:147167344~147167572:+
GBM	cis	rs731565	1	rs116986272	ENSG00000232391.1	RANP2	4.42	2.25e-05	0.0177	0.73	0.38	Diabetic kidney disease;	chr7:147720638	chr7:147167344~147167572:+
GBM	cis	rs731565	1	rs117781501	ENSG00000232391.1	RANP2	4.42	2.25e-05	0.0177	0.73	0.38	Diabetic kidney disease;	chr7:147720714	chr7:147167344~147167572:+
GBM	cis	rs3806843	0.735	rs2563335	ENSG00000202111.1	VTRNA1-2	-4.42	2.25e-05	0.0177	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr5:140718925~140719013:+
GBM	cis	rs10847980	0.623	rs7955367	ENSG00000256092.2	RP13-942N8.1	4.42	2.26e-05	0.0177	0.95	0.38	Adiponectin levels;	chr12:123344245	chr12:123363868~123366113:+
GBM	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-4.42	2.26e-05	0.0177	-0.47	-0.38	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
GBM	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-4.42	2.26e-05	0.0177	-0.47	-0.38	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
GBM	cis	rs7829975	0.659	rs4382480	ENSG00000254340.1	RP11-10A14.3	4.42	2.26e-05	0.0177	0.47	0.38	Mood instability;	chr8:8863963	chr8:9141424~9145435:+
GBM	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	4.42	2.26e-05	0.0178	0.39	0.38	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
GBM	cis	rs7729723	0.837	rs11745596	ENSG00000246323.2	RP11-325L7.1	4.42	2.26e-05	0.0178	0.46	0.38	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138498450	chr5:138032774~138037266:+
GBM	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	4.42	2.26e-05	0.0178	0.61	0.38	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	4.42	2.26e-05	0.0178	0.61	0.38	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	4.42	2.26e-05	0.0178	0.61	0.38	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	4.42	2.26e-05	0.0178	0.61	0.38	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	4.42	2.26e-05	0.0178	0.61	0.38	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	4.42	2.26e-05	0.0178	0.61	0.38	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	4.42	2.26e-05	0.0178	0.61	0.38	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
GBM	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	4.42	2.26e-05	0.0178	0.54	0.38	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
GBM	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	4.42	2.26e-05	0.0178	0.54	0.38	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
GBM	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	4.42	2.26e-05	0.0178	0.54	0.38	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	4.42	2.26e-05	0.0178	0.54	0.38	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
GBM	cis	rs11654801	0.755	rs62056768	ENSG00000233098.7	CCDC144NL-AS1	-4.42	2.26e-05	0.0178	-0.54	-0.38	Mosquito bite size;	chr17:20983881	chr17:20868433~21002276:+
GBM	cis	rs893363	0.539	rs3774614	ENSG00000271916.1	RP11-884K10.6	-4.42	2.27e-05	0.0178	-0.45	-0.38	Axial length;	chr3:53807437	chr3:53797764~53798019:-
GBM	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	4.42	2.27e-05	0.0178	0.56	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
GBM	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	4.42	2.27e-05	0.0178	0.63	0.38	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	4.42	2.27e-05	0.0178	0.63	0.38	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	4.42	2.27e-05	0.0178	0.63	0.38	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	4.42	2.27e-05	0.0178	0.63	0.38	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	4.42	2.27e-05	0.0178	0.63	0.38	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
GBM	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	4.42	2.27e-05	0.0178	0.63	0.38	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	4.42	2.27e-05	0.0178	0.63	0.38	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-4.42	2.27e-05	0.0178	-0.63	-0.38	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
GBM	cis	rs950169	1	rs35658069	ENSG00000275120.1	RP11-182J1.17	4.42	2.27e-05	0.0178	0.5	0.38	Schizophrenia;	chr15:84111394	chr15:84599434~84606463:-
GBM	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-4.42	2.27e-05	0.0178	-0.47	-0.38	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
GBM	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-4.42	2.27e-05	0.0178	-0.55	-0.38	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
GBM	cis	rs10969557	0.542	rs1980876	ENSG00000231808.2	LINC01388	4.42	2.27e-05	0.0178	0.47	0.38	Lung cancer;	chr9:318153	chr9:112713~113754:-
GBM	cis	rs3742264	0.656	rs9534261	ENSG00000235903.6	CPB2-AS1	-4.42	2.27e-05	0.0178	-0.46	-0.38	Blood protein levels;	chr13:45959923	chr13:46052806~46113332:+
GBM	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-4.42	2.27e-05	0.0178	-0.45	-0.38	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
GBM	cis	rs2976388	0.566	rs6998746	ENSG00000253741.1	CTD-2292P10.4	-4.42	2.27e-05	0.0178	-0.46	-0.38	Urinary tract infection frequency;	chr8:142721038	chr8:142702252~142726973:-
GBM	cis	rs453301	0.686	rs4840389	ENSG00000254340.1	RP11-10A14.3	-4.42	2.28e-05	0.0178	-0.48	-0.38	Joint mobility (Beighton score);	chr8:9026993	chr8:9141424~9145435:+
GBM	cis	rs453301	0.658	rs13271797	ENSG00000254340.1	RP11-10A14.3	-4.42	2.28e-05	0.0178	-0.48	-0.38	Joint mobility (Beighton score);	chr8:9028444	chr8:9141424~9145435:+
GBM	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-4.42	2.28e-05	0.0178	-0.43	-0.38	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
GBM	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-4.42	2.28e-05	0.0179	-0.55	-0.38	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
GBM	cis	rs8014671	0.553	rs2877661	ENSG00000235812.4	ADAM21P1	-4.42	2.28e-05	0.0179	-0.46	-0.38	Prostate cancer;	chr14:70449842	chr14:70245491~70247801:-
GBM	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-4.42	2.29e-05	0.0179	-0.48	-0.38	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
GBM	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-4.42	2.29e-05	0.0179	-0.45	-0.38	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
GBM	cis	rs11642862	1	rs74483355	ENSG00000260911.2	RP11-196G11.2	4.41	2.29e-05	0.0179	0.54	0.38	Tonsillectomy;	chr16:30825109	chr16:31043150~31049868:+
GBM	cis	rs8014671	0.553	rs11628785	ENSG00000235812.4	ADAM21P1	-4.41	2.3e-05	0.018	-0.47	-0.38	Prostate cancer;	chr14:70441500	chr14:70245491~70247801:-
GBM	cis	rs6723226	0.503	rs4952262	ENSG00000276334.1	AL133243.1	-4.41	2.3e-05	0.018	-0.47	-0.38	Intelligence (multi-trait analysis);	chr2:32372166	chr2:32521927~32523547:+
GBM	cis	rs6723226	0.521	rs1991626	ENSG00000276334.1	AL133243.1	-4.41	2.3e-05	0.018	-0.47	-0.38	Intelligence (multi-trait analysis);	chr2:32377382	chr2:32521927~32523547:+
GBM	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	4.41	2.3e-05	0.018	0.45	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
GBM	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	4.41	2.3e-05	0.018	0.45	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
GBM	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	4.41	2.3e-05	0.018	0.45	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
GBM	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	4.41	2.3e-05	0.018	0.45	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
GBM	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	4.41	2.3e-05	0.018	0.45	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
GBM	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	4.41	2.3e-05	0.018	0.45	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
GBM	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-4.41	2.3e-05	0.018	-0.45	-0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
GBM	cis	rs7829975	0.742	rs7832968	ENSG00000254340.1	RP11-10A14.3	4.41	2.3e-05	0.018	0.47	0.38	Mood instability;	chr8:8795379	chr8:9141424~9145435:+
GBM	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-4.41	2.31e-05	0.018	-0.47	-0.38	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
GBM	cis	rs16937	0.711	rs3851289	ENSG00000271580.1	RP11-536L3.4	-4.41	2.31e-05	0.018	-0.35	-0.38	Schizophrenia;	chr1:205180529	chr1:205091163~205091946:+
GBM	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-4.41	2.31e-05	0.018	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
GBM	cis	rs8062405	1	rs62036622	ENSG00000271623.1	RP11-435I10.5	-4.41	2.31e-05	0.018	-0.47	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28364700~28365333:+
GBM	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	4.41	2.31e-05	0.0181	0.41	0.38	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
GBM	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	4.41	2.31e-05	0.0181	0.41	0.38	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	4.41	2.31e-05	0.0181	0.41	0.38	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
GBM	cis	rs8062405	0.755	rs4788080	ENSG00000271623.1	RP11-435I10.5	-4.41	2.32e-05	0.0181	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs4787456	ENSG00000271623.1	RP11-435I10.5	-4.41	2.32e-05	0.0181	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs4788078	ENSG00000271623.1	RP11-435I10.5	-4.41	2.32e-05	0.0181	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs62034350	ENSG00000271623.1	RP11-435I10.5	-4.41	2.32e-05	0.0181	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28364700~28365333:+
GBM	cis	rs4869313	0.905	rs2549794	ENSG00000248734.2	CTD-2260A17.1	-4.41	2.32e-05	0.0181	-0.47	-0.38	Pediatric autoimmune diseases;	chr5:96908845	chr5:96784777~96785999:+
GBM	cis	rs763121	0.853	rs2072795	ENSG00000273076.1	RP3-508I15.22	-4.41	2.32e-05	0.0181	-0.42	-0.38	Menopause (age at onset);	chr22:38668204	chr22:38743495~38743910:+
GBM	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-4.41	2.32e-05	0.0181	-0.45	-0.38	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-4.41	2.32e-05	0.0181	-0.45	-0.38	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
GBM	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-4.41	2.32e-05	0.0181	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
GBM	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	4.41	2.32e-05	0.0181	0.46	0.38	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
GBM	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-4.41	2.32e-05	0.0181	-0.46	-0.38	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
GBM	cis	rs8062405	1	rs62036657	ENSG00000271623.1	RP11-435I10.5	-4.41	2.33e-05	0.0182	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs12444171	ENSG00000271623.1	RP11-435I10.5	-4.41	2.33e-05	0.0182	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs56404918	ENSG00000271623.1	RP11-435I10.5	-4.41	2.33e-05	0.0182	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs55719896	ENSG00000271623.1	RP11-435I10.5	-4.41	2.33e-05	0.0182	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs55830740	ENSG00000271623.1	RP11-435I10.5	-4.41	2.33e-05	0.0182	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28364700~28365333:+
GBM	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	4.41	2.33e-05	0.0182	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
GBM	cis	rs4664293	0.867	rs1126842	ENSG00000226266.5	AC009961.3	-4.41	2.33e-05	0.0182	-0.47	-0.38	Monocyte percentage of white cells;	chr2:159770806	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-4.41	2.33e-05	0.0182	-0.47	-0.38	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-4.41	2.33e-05	0.0182	-0.47	-0.38	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-4.41	2.33e-05	0.0182	-0.47	-0.38	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-4.41	2.33e-05	0.0182	-0.47	-0.38	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	4.41	2.33e-05	0.0182	0.47	0.38	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
GBM	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-4.41	2.34e-05	0.0182	-0.41	-0.38	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
GBM	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	4.41	2.34e-05	0.0182	0.41	0.38	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
GBM	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	4.41	2.34e-05	0.0182	0.41	0.38	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
GBM	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	4.41	2.34e-05	0.0182	0.41	0.38	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
GBM	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	4.41	2.34e-05	0.0182	0.41	0.38	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
GBM	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	4.41	2.34e-05	0.0182	0.41	0.38	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
GBM	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	4.41	2.34e-05	0.0182	0.41	0.38	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
GBM	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	4.41	2.34e-05	0.0182	0.41	0.38	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
GBM	cis	rs741668	0.895	rs61953326	ENSG00000235903.6	CPB2-AS1	4.41	2.34e-05	0.0182	0.52	0.38	Cerebrospinal fluid clusterin levels;	chr13:45994147	chr13:46052806~46113332:+
GBM	cis	rs741668	0.931	rs7317990	ENSG00000235903.6	CPB2-AS1	4.41	2.34e-05	0.0182	0.52	0.38	Cerebrospinal fluid clusterin levels;	chr13:45994362	chr13:46052806~46113332:+
GBM	cis	rs741668	0.897	rs17429573	ENSG00000235903.6	CPB2-AS1	4.41	2.34e-05	0.0182	0.52	0.38	Cerebrospinal fluid clusterin levels;	chr13:45995923	chr13:46052806~46113332:+
GBM	cis	rs3806843	0.741	rs4912597	ENSG00000202111.1	VTRNA1-2	4.41	2.34e-05	0.0182	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.771	rs2563334	ENSG00000202111.1	VTRNA1-2	4.41	2.34e-05	0.0182	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr5:140718925~140719013:+
GBM	cis	rs17772222	0.675	rs1099698	ENSG00000258983.2	RP11-507K2.2	-4.41	2.34e-05	0.0182	-0.41	-0.38	Coronary artery calcification;	chr14:88414904	chr14:88499334~88515502:+
GBM	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-4.41	2.34e-05	0.0182	-0.54	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
GBM	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-4.41	2.34e-05	0.0182	-0.54	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
GBM	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-4.41	2.34e-05	0.0182	-0.47	-0.38	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
GBM	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	4.41	2.34e-05	0.0182	0.58	0.38	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
GBM	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	4.41	2.34e-05	0.0182	0.4	0.38	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
GBM	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	4.41	2.34e-05	0.0183	0.44	0.38	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
GBM	cis	rs3806843	0.735	rs702394	ENSG00000202111.1	VTRNA1-2	4.41	2.35e-05	0.0183	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.735	rs801183	ENSG00000202111.1	VTRNA1-2	-4.41	2.35e-05	0.0183	-0.4	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr5:140718925~140719013:+
GBM	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	4.41	2.35e-05	0.0183	0.51	0.38	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	4.41	2.35e-05	0.0183	0.51	0.38	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
GBM	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	4.41	2.36e-05	0.0183	0.42	0.38	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	4.41	2.36e-05	0.0183	0.42	0.38	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
GBM	cis	rs867371	1	rs8042464	ENSG00000278603.1	RP13-608F4.5	4.41	2.36e-05	0.0184	0.45	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472203~82472426:+
GBM	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	4.41	2.36e-05	0.0184	0.51	0.38	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	4.41	2.36e-05	0.0184	0.51	0.38	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	4.41	2.36e-05	0.0184	0.51	0.38	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	4.41	2.36e-05	0.0184	0.51	0.38	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	4.41	2.36e-05	0.0184	0.51	0.38	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
GBM	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	4.41	2.36e-05	0.0184	0.64	0.38	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	4.41	2.36e-05	0.0184	0.64	0.38	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
GBM	cis	rs867371	1	rs7173339	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs1501372	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs1846911	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472203~82472426:+
GBM	cis	rs867371	0.929	rs7176075	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs8041868	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs8041924	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs2088858	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs4778982	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs2867579	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs881308	ENSG00000278603.1	RP13-608F4.5	4.41	2.37e-05	0.0184	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472203~82472426:+
GBM	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	4.41	2.37e-05	0.0184	0.4	0.38	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
GBM	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	4.41	2.37e-05	0.0184	0.27	0.38	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
GBM	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	4.41	2.37e-05	0.0184	0.55	0.38	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
GBM	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-4.41	2.38e-05	0.0184	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-4.41	2.38e-05	0.0184	-0.52	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
GBM	cis	rs7615952	0.512	rs2979336	ENSG00000242001.1	GS1-388B5.1	4.41	2.38e-05	0.0184	0.57	0.38	Blood pressure (smoking interaction);	chr3:125638626	chr3:125681305~125681453:+
GBM	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-4.41	2.38e-05	0.0184	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-4.41	2.38e-05	0.0184	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-4.41	2.38e-05	0.0184	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-4.41	2.38e-05	0.0184	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-4.41	2.38e-05	0.0184	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	4.41	2.38e-05	0.0184	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
GBM	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	4.41	2.38e-05	0.0184	0.47	0.38	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
GBM	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	4.41	2.38e-05	0.0184	0.47	0.38	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
GBM	cis	rs950169	0.92	rs34672825	ENSG00000275120.1	RP11-182J1.17	4.4	2.39e-05	0.0185	0.54	0.38	Schizophrenia;	chr15:84034718	chr15:84599434~84606463:-
GBM	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	4.4	2.39e-05	0.0185	0.6	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
GBM	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.39e-05	0.0185	-0.41	-0.38	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.39e-05	0.0185	-0.41	-0.38	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
GBM	cis	rs763567	0.605	rs647438	ENSG00000271811.1	RP1-79C4.4	-4.4	2.39e-05	0.0185	-0.41	-0.38	Tonsillectomy;	chr1:170608094	chr1:170667381~170669425:+
GBM	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	4.4	2.39e-05	0.0185	0.45	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
GBM	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	4.4	2.39e-05	0.0185	0.51	0.38	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
GBM	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	4.4	2.39e-05	0.0185	0.51	0.38	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
GBM	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	4.4	2.39e-05	0.0185	0.51	0.38	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
GBM	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	4.4	2.4e-05	0.0186	0.49	0.38	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
GBM	cis	rs9876781	1	rs922075	ENSG00000244380.1	RP11-24C3.2	-4.4	2.4e-05	0.0186	-0.43	-0.38	Longevity;	chr3:48447994	chr3:48440352~48446656:-
GBM	cis	rs9876781	1	rs2045554	ENSG00000244380.1	RP11-24C3.2	-4.4	2.4e-05	0.0186	-0.43	-0.38	Longevity;	chr3:48453142	chr3:48440352~48446656:-
GBM	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-4.4	2.4e-05	0.0186	-0.45	-0.38	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
GBM	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	4.4	2.4e-05	0.0186	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
GBM	cis	rs9287604	1	rs2568569	ENSG00000231546.1	RPL3P5	4.4	2.4e-05	0.0186	0.55	0.38	Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;White blood cell count;	chr2:236887749	chr2:236407846~236409077:-
GBM	cis	rs7017914	0.702	rs12678320	ENSG00000246366.5	RP11-382J12.1	-4.4	2.4e-05	0.0186	-0.42	-0.38	Bone mineral density;	chr8:70624957	chr8:70608577~70663279:+
GBM	cis	rs6887276	0.504	rs1003136	ENSG00000245937.6	LINC01184	4.4	2.4e-05	0.0186	0.37	0.38	Height;	chr5:128012123	chr5:127940426~128083172:-
GBM	cis	rs11654801	0.812	rs11658742	ENSG00000233098.7	CCDC144NL-AS1	-4.4	2.4e-05	0.0186	-0.51	-0.38	Mosquito bite size;	chr17:20948199	chr17:20868433~21002276:+
GBM	cis	rs812925	0.519	rs2463099	ENSG00000271889.1	RP11-493E12.1	-4.4	2.41e-05	0.0186	-0.39	-0.38	Immature fraction of reticulocytes;	chr2:61391176	chr2:61151433~61162105:-
GBM	cis	rs853679	0.76	rs9393909	ENSG00000216901.1	AL022393.7	-4.4	2.41e-05	0.0186	-0.59	-0.38	Depression;	chr6:28239422	chr6:28176188~28176674:+
GBM	cis	rs62184315	0.58	rs62185872	ENSG00000273240.1	RP11-455J20.3	-4.4	2.41e-05	0.0186	-0.56	-0.38	Alcohol dependence (age at onset);	chr2:189690033	chr2:189763859~189764456:-
GBM	cis	rs16937	0.521	rs78176224	ENSG00000271580.1	RP11-536L3.4	-4.4	2.41e-05	0.0186	-0.35	-0.38	Schizophrenia;	chr1:205209481	chr1:205091163~205091946:+
GBM	cis	rs16937	0.503	rs76939335	ENSG00000271580.1	RP11-536L3.4	-4.4	2.41e-05	0.0186	-0.35	-0.38	Schizophrenia;	chr1:205209482	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs11240390	ENSG00000271580.1	RP11-536L3.4	-4.4	2.41e-05	0.0186	-0.35	-0.38	Schizophrenia;	chr1:205210329	chr1:205091163~205091946:+
GBM	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	4.4	2.41e-05	0.0187	0.4	0.38	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
GBM	cis	rs11671005	0.693	rs11669665	ENSG00000269473.1	CTD-2619J13.19	4.4	2.41e-05	0.0187	0.42	0.38	Mean platelet volume;	chr19:58420518	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11084543	ENSG00000269473.1	CTD-2619J13.19	4.4	2.41e-05	0.0187	0.42	0.38	Mean platelet volume;	chr19:58421334	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11881000	ENSG00000269473.1	CTD-2619J13.19	4.4	2.41e-05	0.0187	0.42	0.38	Mean platelet volume;	chr19:58421421	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.695	rs11673069	ENSG00000269473.1	CTD-2619J13.19	4.4	2.41e-05	0.0187	0.42	0.38	Mean platelet volume;	chr19:58423551	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs12981875	ENSG00000269473.1	CTD-2619J13.19	4.4	2.41e-05	0.0187	0.42	0.38	Mean platelet volume;	chr19:58423763	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.57	rs73062110	ENSG00000269473.1	CTD-2619J13.19	4.4	2.41e-05	0.0187	0.42	0.38	Mean platelet volume;	chr19:58425275	chr19:58440448~58445849:+
GBM	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	4.4	2.41e-05	0.0187	0.43	0.38	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
GBM	cis	rs454217	0.875	rs7958204	ENSG00000277851.1	RP11-756G20.1	4.4	2.42e-05	0.0187	0.44	0.38	Smoking quantity;	chr12:92323167	chr12:92247756~92363832:-
GBM	cis	rs454217	1	rs454217	ENSG00000277851.1	RP11-756G20.1	4.4	2.42e-05	0.0187	0.44	0.38	Smoking quantity;	chr12:92324782	chr12:92247756~92363832:-
GBM	cis	rs3096299	0.646	rs918722	ENSG00000260259.1	RP11-368I7.4	4.4	2.42e-05	0.0187	0.41	0.38	Multiple myeloma (IgH translocation);	chr16:89348673	chr16:89682620~89686569:-
GBM	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-4.4	2.42e-05	0.0187	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
GBM	cis	rs11671005	0.693	rs11668757	ENSG00000269473.1	CTD-2619J13.19	4.4	2.42e-05	0.0187	0.41	0.38	Mean platelet volume;	chr19:58416932	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11668789	ENSG00000269473.1	CTD-2619J13.19	4.4	2.42e-05	0.0187	0.41	0.38	Mean platelet volume;	chr19:58416942	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs35652377	ENSG00000269473.1	CTD-2619J13.19	4.4	2.42e-05	0.0187	0.41	0.38	Mean platelet volume;	chr19:58417833	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs3764532	ENSG00000269473.1	CTD-2619J13.19	4.4	2.42e-05	0.0187	0.41	0.38	Mean platelet volume;	chr19:58417855	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs3088284	ENSG00000269473.1	CTD-2619J13.19	4.4	2.42e-05	0.0187	0.41	0.38	Mean platelet volume;	chr19:58418060	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs12981649	ENSG00000269473.1	CTD-2619J13.19	4.4	2.42e-05	0.0187	0.41	0.38	Mean platelet volume;	chr19:58418676	chr19:58440448~58445849:+
GBM	cis	rs17772222	0.74	rs10138002	ENSG00000222990.1	RNU4-22P	-4.4	2.42e-05	0.0187	-0.4	-0.38	Coronary artery calcification;	chr14:88510071	chr14:88513498~88513663:+
GBM	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-4.4	2.42e-05	0.0187	-0.54	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
GBM	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-4.4	2.42e-05	0.0187	-0.54	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
GBM	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	4.4	2.42e-05	0.0187	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
GBM	cis	rs867371	1	rs1392976	ENSG00000278603.1	RP13-608F4.5	-4.4	2.42e-05	0.0187	-0.44	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs11855089	ENSG00000278603.1	RP13-608F4.5	4.4	2.42e-05	0.0187	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs1174543	ENSG00000278603.1	RP13-608F4.5	-4.4	2.42e-05	0.0187	-0.44	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs9944197	ENSG00000278603.1	RP13-608F4.5	4.4	2.42e-05	0.0187	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472203~82472426:+
GBM	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	4.4	2.43e-05	0.0187	0.27	0.38	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	4.4	2.43e-05	0.0187	0.27	0.38	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	4.4	2.43e-05	0.0187	0.27	0.38	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	4.4	2.43e-05	0.0187	0.27	0.38	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	4.4	2.43e-05	0.0187	0.27	0.38	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	4.4	2.43e-05	0.0187	0.27	0.38	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
GBM	cis	rs453301	0.624	rs330049	ENSG00000254340.1	RP11-10A14.3	4.4	2.43e-05	0.0188	0.49	0.38	Joint mobility (Beighton score);	chr8:9229789	chr8:9141424~9145435:+
GBM	cis	rs763121	0.853	rs2072794	ENSG00000273076.1	RP3-508I15.22	4.4	2.43e-05	0.0188	0.4	0.38	Menopause (age at onset);	chr22:38754538	chr22:38743495~38743910:+
GBM	cis	rs73198271	0.681	rs35457364	ENSG00000253893.2	FAM85B	4.4	2.44e-05	0.0188	0.55	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.641	rs34473848	ENSG00000253893.2	FAM85B	4.4	2.44e-05	0.0188	0.55	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.601	rs11997731	ENSG00000253893.2	FAM85B	4.4	2.44e-05	0.0188	0.55	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.681	rs11987924	ENSG00000253893.2	FAM85B	4.4	2.44e-05	0.0188	0.55	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8167819~8226614:-
GBM	cis	rs453301	0.507	rs2929306	ENSG00000254340.1	RP11-10A14.3	-4.4	2.44e-05	0.0188	-0.45	-0.38	Joint mobility (Beighton score);	chr8:9227399	chr8:9141424~9145435:+
GBM	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	4.4	2.44e-05	0.0188	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
GBM	cis	rs867371	0.896	rs6495647	ENSG00000278603.1	RP13-608F4.5	4.4	2.44e-05	0.0188	0.43	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472203~82472426:+
GBM	cis	rs7615952	0.641	rs12488180	ENSG00000250012.1	RP11-124N2.1	-4.4	2.44e-05	0.0188	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:126063393	chr3:126084220~126095349:+
GBM	cis	rs977747	1	rs7664	ENSG00000232022.5	FAAHP1	-4.4	2.44e-05	0.0188	-0.38	-0.38	Body mass index;	chr1:47216345	chr1:46432129~46445521:+
GBM	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	4.4	2.44e-05	0.0188	0.58	0.38	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
GBM	cis	rs520525	1	rs520525	ENSG00000271811.1	RP1-79C4.4	4.4	2.44e-05	0.0188	0.46	0.38	Atrial fibrillation;	chr1:170669192	chr1:170667381~170669425:+
GBM	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-4.4	2.44e-05	0.0188	-0.43	-0.38	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-4.4	2.44e-05	0.0188	-0.43	-0.38	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-4.4	2.44e-05	0.0188	-0.43	-0.38	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-4.4	2.44e-05	0.0188	-0.43	-0.38	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
GBM	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.44e-05	0.0188	-0.41	-0.38	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.44e-05	0.0188	-0.41	-0.38	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
GBM	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-4.4	2.45e-05	0.0189	-0.54	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
GBM	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	4.4	2.45e-05	0.0189	0.43	0.38	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
GBM	cis	rs875971	0.545	rs73376394	ENSG00000222364.1	RNU6-96P	-4.4	2.45e-05	0.0189	-0.44	-0.38	Aortic root size;	chr7:66172694	chr7:66395191~66395286:+
GBM	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-4.4	2.45e-05	0.0189	-0.38	-0.38	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
GBM	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	4.4	2.45e-05	0.0189	0.55	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
GBM	cis	rs2976388	0.692	rs2978983	ENSG00000253741.1	CTD-2292P10.4	-4.4	2.45e-05	0.0189	-0.39	-0.38	Urinary tract infection frequency;	chr8:142684424	chr8:142702252~142726973:-
GBM	cis	rs7267979	0.816	rs8115257	ENSG00000276952.1	RP5-965G21.6	4.4	2.45e-05	0.0189	0.36	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25284915~25285588:-
GBM	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	4.4	2.45e-05	0.0189	0.64	0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
GBM	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-4.4	2.45e-05	0.0189	-0.54	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
GBM	cis	rs2018683	1	rs2018683	ENSG00000228421.2	AC005013.5	4.4	2.45e-05	0.0189	0.44	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28957667~28959345:+
GBM	cis	rs66887589	0.592	rs28580295	ENSG00000250412.1	KLHL2P1	4.4	2.46e-05	0.0189	0.46	0.38	Diastolic blood pressure;	chr4:119357718	chr4:119334329~119378233:+
GBM	cis	rs4713118	0.869	rs9283881	ENSG00000218016.2	ZNF192P2	-4.4	2.46e-05	0.019	-0.47	-0.38	Parkinson's disease;	chr6:27747476	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.869	rs9283882	ENSG00000218016.2	ZNF192P2	-4.4	2.46e-05	0.019	-0.47	-0.38	Parkinson's disease;	chr6:27747479	chr6:28188050~28189432:+
GBM	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	4.4	2.47e-05	0.019	0.49	0.38	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
GBM	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-4.4	2.47e-05	0.019	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
GBM	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-4.4	2.47e-05	0.019	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
GBM	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-4.4	2.47e-05	0.019	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
GBM	cis	rs17270561	0.514	rs10946805	ENSG00000272462.2	U91328.19	-4.4	2.47e-05	0.019	-0.6	-0.38	Iron status biomarkers;	chr6:26077663	chr6:25992662~26001775:+
GBM	cis	rs1257344	0.935	rs1257361	ENSG00000231758.2	AC092652.1	-4.4	2.47e-05	0.019	-0.38	-0.38	Diisocyanate-induced asthma;	chr2:143851003	chr2:143640756~143656179:-
GBM	cis	rs977747	0.933	rs6669341	ENSG00000232022.5	FAAHP1	-4.4	2.47e-05	0.019	-0.38	-0.38	Body mass index;	chr1:47212786	chr1:46432129~46445521:+
GBM	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	4.4	2.48e-05	0.019	0.43	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
GBM	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	4.4	2.48e-05	0.0191	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
GBM	cis	rs951266	0.505	rs12902602	ENSG00000261143.1	ADAMTS7P3	4.4	2.48e-05	0.0191	0.41	0.38	Post bronchodilator FEV1/FVC ratio;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Pre bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78675059	chr15:77976042~77993057:+
GBM	cis	rs11673344	0.523	rs2082010	ENSG00000226686.6	LINC01535	4.4	2.48e-05	0.0191	0.41	0.38	Obesity-related traits;	chr19:37039874	chr19:37251912~37265535:+
GBM	cis	rs9368481	0.761	rs7775041	ENSG00000224843.5	LINC00240	4.4	2.48e-05	0.0191	0.46	0.38	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26956992~27023924:+
GBM	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-4.4	2.48e-05	0.0191	-0.41	-0.38	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
GBM	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-4.4	2.48e-05	0.0191	-0.5	-0.38	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-4.39	2.48e-05	0.0191	-0.51	-0.38	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
GBM	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	4.39	2.48e-05	0.0191	0.51	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
GBM	cis	rs3806843	0.648	rs2530233	ENSG00000202111.1	VTRNA1-2	4.39	2.48e-05	0.0191	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr5:140718925~140719013:+
GBM	cis	rs6723108	0.626	rs1530559	ENSG00000224043.6	CCNT2-AS1	4.39	2.48e-05	0.0191	0.46	0.38	Type 2 diabetes;	chr2:134998059	chr2:134735464~134918710:-
GBM	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	4.39	2.49e-05	0.0191	0.36	0.38	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
GBM	cis	rs7267979	0.744	rs6050463	ENSG00000276952.1	RP5-965G21.6	4.39	2.49e-05	0.0191	0.36	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.816	rs6115094	ENSG00000276952.1	RP5-965G21.6	4.39	2.49e-05	0.0191	0.36	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25284915~25285588:-
GBM	cis	rs7017914	0.967	rs2732091	ENSG00000246366.5	RP11-382J12.1	4.39	2.49e-05	0.0191	0.41	0.38	Bone mineral density;	chr8:71006188	chr8:70608577~70663279:+
GBM	cis	rs3096299	0.73	rs6500546	ENSG00000260259.1	RP11-368I7.4	4.39	2.49e-05	0.0191	0.43	0.38	Multiple myeloma (IgH translocation);	chr16:89324684	chr16:89682620~89686569:-
GBM	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-4.39	2.49e-05	0.0191	-0.4	-0.38	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
GBM	cis	rs5742933	1	rs1550388	ENSG00000253559.1	OSGEPL1-AS1	4.39	2.49e-05	0.0191	0.43	0.38	Ferritin levels;	chr2:189739054	chr2:189762704~189765556:+
GBM	cis	rs3806843	0.569	rs753279	ENSG00000202111.1	VTRNA1-2	4.39	2.49e-05	0.0191	0.38	0.38	Depressive symptoms (multi-trait analysis);	chr5:140644233	chr5:140718925~140719013:+
GBM	cis	rs12922040	0.701	rs12149912	ENSG00000279866.1	CTB-193M12.4	4.39	2.49e-05	0.0191	0.45	0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15704410~15705984:+
GBM	cis	rs6600671	0.934	rs4259688	ENSG00000223345.3	HIST2H2BA	4.39	2.49e-05	0.0191	0.5	0.38	Hip geometry;	chr1:121563523	chr1:121108210~121117257:-
GBM	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	4.39	2.5e-05	0.0192	0.37	0.38	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
GBM	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-4.39	2.5e-05	0.0192	-0.51	-0.38	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
GBM	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	4.39	2.5e-05	0.0192	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
GBM	cis	rs2025751	0.512	rs10456648	ENSG00000230204.1	FTH1P5	-4.39	2.5e-05	0.0192	-0.43	-0.38	Intraocular pressure;	chr6:51828066	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs10456649	ENSG00000230204.1	FTH1P5	-4.39	2.5e-05	0.0192	-0.43	-0.38	Intraocular pressure;	chr6:51828460	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9296665	ENSG00000230204.1	FTH1P5	-4.39	2.5e-05	0.0192	-0.43	-0.38	Intraocular pressure;	chr6:51828508	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs10456650	ENSG00000230204.1	FTH1P5	-4.39	2.5e-05	0.0192	-0.43	-0.38	Intraocular pressure;	chr6:51828576	chr6:50912712~50913256:-
GBM	cis	rs4662986	0.579	rs3108975	ENSG00000226915.1	AC068137.13	4.39	2.51e-05	0.0192	0.7	0.38	Age at smoking initiation in chronic obstructive pulmonary disease;	chr2:129608160	chr2:130293822~130294405:+
GBM	cis	rs867371	1	rs13380319	ENSG00000278603.1	RP13-608F4.5	4.39	2.51e-05	0.0192	0.43	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs13380317	ENSG00000278603.1	RP13-608F4.5	-4.39	2.51e-05	0.0192	-0.43	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472203~82472426:+
GBM	cis	rs8177876	0.915	rs8059692	ENSG00000278985.1	RP11-303E16.9	4.39	2.51e-05	0.0193	0.36	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:80982319~80984094:-
GBM	cis	rs8041227	0.509	rs4779847	ENSG00000260693.1	AC026150.8	4.39	2.51e-05	0.0193	0.44	0.38	Eosinophilic esophagitis;	chr15:31236884	chr15:30540093~30545969:+
GBM	cis	rs3742264	1	rs9567613	ENSG00000235903.6	CPB2-AS1	4.39	2.51e-05	0.0193	0.44	0.38	Blood protein levels;	chr13:46075263	chr13:46052806~46113332:+
GBM	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	4.39	2.52e-05	0.0193	0.46	0.38	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
GBM	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-4.39	2.52e-05	0.0193	-0.51	-0.38	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
GBM	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-4.39	2.52e-05	0.0193	-0.49	-0.38	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
GBM	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	4.39	2.52e-05	0.0193	0.42	0.38	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	4.39	2.52e-05	0.0193	0.42	0.38	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
GBM	cis	rs7726839	0.54	rs28364691	ENSG00000260774.1	CTD-2083E4.4	4.39	2.52e-05	0.0193	0.58	0.38	Obesity-related traits;	chr5:663969	chr5:213898~217279:-
GBM	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	4.39	2.52e-05	0.0193	0.57	0.38	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
GBM	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-4.39	2.52e-05	0.0193	-0.37	-0.38	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
GBM	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	4.39	2.52e-05	0.0193	0.9	0.38	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
GBM	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-4.39	2.52e-05	0.0193	-0.46	-0.38	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
GBM	cis	rs12137294	0.761	rs1172150	ENSG00000271580.1	RP11-536L3.4	-4.39	2.52e-05	0.0193	-0.36	-0.38	Red cell distribution width;	chr1:205252733	chr1:205091163~205091946:+
GBM	cis	rs5742933	0.948	rs2264018	ENSG00000253559.1	OSGEPL1-AS1	-4.39	2.52e-05	0.0193	-0.44	-0.38	Ferritin levels;	chr2:189712052	chr2:189762704~189765556:+
GBM	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	4.39	2.52e-05	0.0193	0.42	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	4.39	2.52e-05	0.0193	0.42	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
GBM	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-4.39	2.53e-05	0.0194	-0.5	-0.38	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-4.39	2.53e-05	0.0194	-0.5	-0.38	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-4.39	2.53e-05	0.0194	-0.5	-0.38	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
GBM	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-4.39	2.53e-05	0.0194	-0.56	-0.38	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
GBM	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	4.39	2.53e-05	0.0194	0.44	0.38	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
GBM	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	4.39	2.53e-05	0.0194	0.42	0.38	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
GBM	cis	rs172166	0.561	rs149971	ENSG00000280107.1	AL022393.9	-4.39	2.53e-05	0.0194	-0.42	-0.38	Cardiac Troponin-T levels;	chr6:28014374	chr6:28170845~28172521:+
GBM	cis	rs62560775	0.541	rs12352425	ENSG00000229298.1	TUBB8P1	4.39	2.53e-05	0.0194	0.46	0.38	Lung cancer;Lung adenocarcinoma;	chr9:22042087	chr9:21811621~21812347:-
GBM	cis	rs7829975	0.714	rs60315134	ENSG00000254340.1	RP11-10A14.3	4.39	2.53e-05	0.0194	0.46	0.38	Mood instability;	chr8:8813089	chr8:9141424~9145435:+
GBM	cis	rs11771526	0.551	rs6462344	ENSG00000273014.1	RP11-225B17.2	4.39	2.54e-05	0.0194	0.67	0.38	Body mass index;	chr7:32215277	chr7:32758882~32759353:+
GBM	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-4.39	2.54e-05	0.0194	-0.32	-0.38	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
GBM	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-4.39	2.54e-05	0.0194	-0.32	-0.38	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
GBM	cis	rs1298062	0.79	rs1274604	ENSG00000131401.10	NAPSB	-4.39	2.54e-05	0.0194	-0.44	-0.38	Age of smoking initiation;	chr19:50466068	chr19:50333796~50344767:-
GBM	cis	rs7267979	0.586	rs6083776	ENSG00000125804.12	FAM182A	-4.39	2.54e-05	0.0194	-0.47	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.586	rs1473695	ENSG00000125804.12	FAM182A	-4.39	2.54e-05	0.0194	-0.47	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.586	rs1007707	ENSG00000125804.12	FAM182A	-4.39	2.54e-05	0.0194	-0.47	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.586	rs1007708	ENSG00000125804.12	FAM182A	-4.39	2.54e-05	0.0194	-0.47	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.586	rs6050439	ENSG00000125804.12	FAM182A	-4.39	2.54e-05	0.0194	-0.47	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:26054655~26086917:+
GBM	cis	rs8062405	0.964	rs78613234	ENSG00000271623.1	RP11-435I10.5	-4.39	2.54e-05	0.0194	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62036624	ENSG00000271623.1	RP11-435I10.5	-4.39	2.54e-05	0.0194	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs55991577	ENSG00000271623.1	RP11-435I10.5	-4.39	2.54e-05	0.0194	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs56358680	ENSG00000271623.1	RP11-435I10.5	-4.39	2.54e-05	0.0194	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62036626	ENSG00000271623.1	RP11-435I10.5	-4.39	2.54e-05	0.0194	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28364700~28365333:+
GBM	cis	rs11098499	0.874	rs7661020	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119185827	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs9995277	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119187448	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs17839089	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119189914	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs6826823	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119190943	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs12509054	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119193920	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs10022508	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119194073	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs12502503	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119195100	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs6851169	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119196355	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs6832670	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119197637	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.874	rs6822498	ENSG00000250412.1	KLHL2P1	4.39	2.54e-05	0.0194	0.51	0.38	Corneal astigmatism;	chr4:119199028	chr4:119334329~119378233:+
GBM	cis	rs3806843	0.735	rs6849	ENSG00000202111.1	VTRNA1-2	4.39	2.54e-05	0.0194	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr5:140718925~140719013:+
GBM	cis	rs11098499	0.866	rs11098506	ENSG00000249244.1	RP11-548H18.2	4.39	2.54e-05	0.0195	0.47	0.38	Corneal astigmatism;	chr4:119363816	chr4:119391831~119395335:-
GBM	cis	rs17211409	0.793	rs79285589	ENSG00000254479.1	SLC25A1P1	4.39	2.54e-05	0.0195	0.88	0.38	JT interval (sulfonylurea treatment interaction);	chr11:86581257	chr11:85934737~85935663:+
GBM	cis	rs4604732	0.631	rs12091081	ENSG00000227135.1	GCSAML-AS1	-4.39	2.54e-05	0.0195	-0.61	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459762	chr1:247524679~247526752:-
GBM	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-4.39	2.55e-05	0.0195	-0.51	-0.38	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
GBM	cis	rs17772222	0.958	rs60878614	ENSG00000222990.1	RNU4-22P	4.39	2.55e-05	0.0195	0.46	0.38	Coronary artery calcification;	chr14:88513871	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.958	rs76559451	ENSG00000222990.1	RNU4-22P	4.39	2.55e-05	0.0195	0.46	0.38	Coronary artery calcification;	chr14:88523193	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.958	rs1123421	ENSG00000222990.1	RNU4-22P	4.39	2.55e-05	0.0195	0.46	0.38	Coronary artery calcification;	chr14:88524651	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.958	rs12436326	ENSG00000222990.1	RNU4-22P	4.39	2.55e-05	0.0195	0.46	0.38	Coronary artery calcification;	chr14:88533632	chr14:88513498~88513663:+
GBM	cis	rs858239	1	rs156425	ENSG00000230042.1	AK3P3	4.39	2.55e-05	0.0195	0.43	0.38	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23129178~23129841:+
GBM	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	4.39	2.55e-05	0.0195	0.52	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
GBM	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-4.39	2.55e-05	0.0195	-0.78	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
GBM	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	4.39	2.55e-05	0.0195	0.48	0.38	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
GBM	cis	rs867371	0.826	rs2047678	ENSG00000278603.1	RP13-608F4.5	4.39	2.55e-05	0.0195	0.45	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472203~82472426:+
GBM	cis	rs2288884	0.559	rs12461141	ENSG00000275055.1	CTC-471J1.11	-4.39	2.56e-05	0.0195	-0.47	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.559	rs12459079	ENSG00000275055.1	CTC-471J1.11	-4.39	2.56e-05	0.0195	-0.47	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.559	rs12461226	ENSG00000275055.1	CTC-471J1.11	-4.39	2.56e-05	0.0195	-0.47	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:52049007~52049754:+
GBM	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	4.39	2.56e-05	0.0195	0.52	0.38	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
GBM	cis	rs867371	0.964	rs7169961	ENSG00000278603.1	RP13-608F4.5	4.39	2.56e-05	0.0195	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs6495643	ENSG00000278603.1	RP13-608F4.5	4.39	2.56e-05	0.0195	0.44	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472203~82472426:+
GBM	cis	rs977747	0.933	rs2008713	ENSG00000232022.5	FAAHP1	-4.39	2.56e-05	0.0195	-0.39	-0.38	Body mass index;	chr1:47236696	chr1:46432129~46445521:+
GBM	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	4.39	2.56e-05	0.0195	0.41	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	4.39	2.56e-05	0.0195	0.41	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
GBM	cis	rs11671005	0.656	rs11672609	ENSG00000269473.1	CTD-2619J13.19	4.39	2.56e-05	0.0196	0.49	0.38	Mean platelet volume;	chr19:58495557	chr19:58440448~58445849:+
GBM	cis	rs4245535	1	rs9486817	ENSG00000225174.1	OSTM1-AS1	4.39	2.56e-05	0.0196	0.67	0.38	Major depressive disorder;	chr6:108138806	chr6:108123515~108159392:+
GBM	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	4.39	2.56e-05	0.0196	0.48	0.38	Height;	chr3:53073584	chr3:53064283~53065091:-
GBM	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-4.39	2.56e-05	0.0196	-0.5	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
GBM	cis	rs7588746	0.868	rs12104649	ENSG00000232732.8	AC073043.1	4.39	2.56e-05	0.0196	0.51	0.38	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:200264109	chr2:199867396~199911159:-
GBM	cis	rs3806843	0.735	rs801180	ENSG00000202111.1	VTRNA1-2	4.39	2.57e-05	0.0196	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr5:140718925~140719013:+
GBM	cis	rs7017914	0.902	rs3098866	ENSG00000246366.5	RP11-382J12.1	-4.39	2.57e-05	0.0196	-0.4	-0.38	Bone mineral density;	chr8:71004339	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs3110239	ENSG00000246366.5	RP11-382J12.1	-4.39	2.57e-05	0.0196	-0.4	-0.38	Bone mineral density;	chr8:71004510	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs3098867	ENSG00000246366.5	RP11-382J12.1	-4.39	2.57e-05	0.0196	-0.4	-0.38	Bone mineral density;	chr8:71004636	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs2639904	ENSG00000246366.5	RP11-382J12.1	-4.39	2.57e-05	0.0196	-0.4	-0.38	Bone mineral density;	chr8:71004895	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs2639901	ENSG00000246366.5	RP11-382J12.1	-4.39	2.57e-05	0.0196	-0.4	-0.38	Bone mineral density;	chr8:71005516	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs2732092	ENSG00000246366.5	RP11-382J12.1	-4.39	2.57e-05	0.0196	-0.4	-0.38	Bone mineral density;	chr8:71006364	chr8:70608577~70663279:+
GBM	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	4.39	2.57e-05	0.0196	0.43	0.38	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
GBM	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-4.39	2.57e-05	0.0196	-0.42	-0.38	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
GBM	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	4.39	2.57e-05	0.0196	0.44	0.38	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	4.39	2.57e-05	0.0196	0.44	0.38	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	4.39	2.57e-05	0.0196	0.44	0.38	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	4.39	2.57e-05	0.0196	0.44	0.38	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
GBM	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	4.38	2.58e-05	0.0197	0.32	0.38	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
GBM	cis	rs2712381	0.517	rs62273237	ENSG00000277250.1	Metazoa_SRP	-4.38	2.58e-05	0.0197	-0.4	-0.38	Monocyte count;	chr3:128591264	chr3:128673681~128674021:-
GBM	cis	rs9786986	0.609	rs10802790	ENSG00000207181.1	SNORA14B	-4.38	2.58e-05	0.0197	-0.65	-0.38	Body mass index;	chr1:235538564	chr1:235127803~235127937:-
GBM	cis	rs9786986	0.609	rs10802791	ENSG00000207181.1	SNORA14B	-4.38	2.58e-05	0.0197	-0.65	-0.38	Body mass index;	chr1:235538612	chr1:235127803~235127937:-
GBM	cis	rs17360053	1	rs7534624	ENSG00000218510.5	LINC00339	4.38	2.58e-05	0.0197	0.39	0.38	Obesity-related traits;	chr1:22168134	chr1:22025188~22031223:+
GBM	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	4.38	2.58e-05	0.0197	0.39	0.38	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
GBM	cis	rs984222	0.586	rs12742258	ENSG00000231365.4	RP11-418J17.1	4.38	2.59e-05	0.0197	0.39	0.38	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119199678	chr1:119140396~119275973:+
GBM	cis	rs950169	0.8	rs34302901	ENSG00000275120.1	RP11-182J1.17	4.38	2.59e-05	0.0197	0.48	0.38	Schizophrenia;	chr15:84567712	chr15:84599434~84606463:-
GBM	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-4.38	2.59e-05	0.0197	-0.56	-0.38	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
GBM	cis	rs7829975	0.564	rs2921060	ENSG00000233609.3	RP11-62H7.2	-4.38	2.59e-05	0.0197	-0.46	-0.38	Mood instability;	chr8:8460307	chr8:8961200~8979025:+
GBM	cis	rs7017914	0.967	rs7842851	ENSG00000246366.5	RP11-382J12.1	-4.38	2.59e-05	0.0198	-0.4	-0.38	Bone mineral density;	chr8:70751570	chr8:70608577~70663279:+
GBM	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	4.38	2.6e-05	0.0198	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	4.38	2.6e-05	0.0198	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	4.38	2.6e-05	0.0198	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
GBM	cis	rs17772222	0.63	rs2778936	ENSG00000258983.2	RP11-507K2.2	-4.38	2.6e-05	0.0198	-0.38	-0.38	Coronary artery calcification;	chr14:88505959	chr14:88499334~88515502:+
GBM	cis	rs8062405	0.755	rs17640009	ENSG00000271623.1	RP11-435I10.5	-4.38	2.6e-05	0.0198	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28364700~28365333:+
GBM	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.5	-0.38	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
GBM	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	4.38	2.6e-05	0.0198	0.43	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
GBM	cis	rs17772222	0.63	rs12436642	ENSG00000222990.1	RNU4-22P	-4.38	2.6e-05	0.0198	-0.4	-0.38	Coronary artery calcification;	chr14:88559032	chr14:88513498~88513663:+
GBM	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-4.38	2.6e-05	0.0198	-0.65	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-4.38	2.6e-05	0.0198	-0.65	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-4.38	2.6e-05	0.0198	-0.65	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-4.38	2.6e-05	0.0198	-0.65	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	4.38	2.6e-05	0.0198	0.65	0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
GBM	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.49	-0.38	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-4.38	2.6e-05	0.0198	-0.49	-0.38	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
GBM	cis	rs17685	0.753	rs869806	ENSG00000280388.1	RP11-229D13.3	-4.38	2.6e-05	0.0198	-0.34	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76059305	chr7:76043977~76045963:-
GBM	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-4.38	2.6e-05	0.0198	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
GBM	cis	rs67981189	0.593	rs116016	ENSG00000269927.1	RP6-91H8.3	-4.38	2.62e-05	0.0199	-0.43	-0.38	Schizophrenia;	chr14:71110763	chr14:71141125~71143253:-
GBM	cis	rs62355901	0.505	rs62356568	ENSG00000271828.1	CTD-2310F14.1	4.38	2.62e-05	0.0199	0.92	0.38	Breast cancer;	chr5:56955617	chr5:56927874~56929573:+
GBM	cis	rs9532669	0.926	rs4356344	ENSG00000176268.5	CYCSP34	4.38	2.62e-05	0.0199	0.47	0.38	Cervical cancer;	chr13:40874086	chr13:40863599~40863902:-
GBM	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	4.38	2.62e-05	0.0199	0.37	0.38	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
GBM	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	4.38	2.62e-05	0.0199	0.5	0.38	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	4.38	2.62e-05	0.0199	0.5	0.38	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	4.38	2.62e-05	0.0199	0.5	0.38	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
GBM	cis	rs1555322	1	rs2425032	ENSG00000126005.14	MMP24-AS1	-4.38	2.62e-05	0.0199	-0.65	-0.38	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35216462~35278131:-
GBM	cis	rs741668	0.931	rs2806926	ENSG00000235903.6	CPB2-AS1	4.38	2.62e-05	0.0199	0.56	0.38	Cerebrospinal fluid clusterin levels;	chr13:45947532	chr13:46052806~46113332:+
GBM	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	4.38	2.62e-05	0.02	0.48	0.38	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
GBM	cis	rs853679	0.599	rs202906	ENSG00000199851.2	U3	-4.38	2.62e-05	0.02	-0.72	-0.38	Depression;	chr6:28043874	chr6:28015568~28015777:+
GBM	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-4.38	2.63e-05	0.02	-0.44	-0.38	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
GBM	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-4.38	2.63e-05	0.02	-0.59	-0.38	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
GBM	cis	rs73198271	0.653	rs10099808	ENSG00000253893.2	FAM85B	-4.38	2.63e-05	0.02	-0.51	-0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8167819~8226614:-
GBM	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-4.38	2.63e-05	0.02	-0.5	-0.38	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-4.38	2.63e-05	0.02	-0.5	-0.38	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
GBM	cis	rs17270561	0.541	rs2009610	ENSG00000272462.2	U91328.19	-4.38	2.63e-05	0.02	-0.55	-0.38	Iron status biomarkers;	chr6:25966840	chr6:25992662~26001775:+
GBM	cis	rs1555322	1	rs2425027	ENSG00000126005.14	MMP24-AS1	-4.38	2.63e-05	0.02	-0.65	-0.38	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35216462~35278131:-
GBM	cis	rs67981189	0.537	rs1978164	ENSG00000269927.1	RP6-91H8.3	-4.38	2.63e-05	0.02	-0.42	-0.38	Schizophrenia;	chr14:70894650	chr14:71141125~71143253:-
GBM	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-4.38	2.64e-05	0.02	-0.48	-0.38	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
GBM	cis	rs984222	0.62	rs10923763	ENSG00000231365.4	RP11-418J17.1	4.38	2.64e-05	0.02	0.39	0.38	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119175597	chr1:119140396~119275973:+
GBM	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	4.38	2.64e-05	0.02	0.44	0.38	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
GBM	cis	rs17508449	0.69	rs4839333	ENSG00000232450.1	RP4-730K3.3	-4.38	2.64e-05	0.0201	-0.65	-0.38	Leprosy;	chr1:113676539	chr1:113698884~113699631:-
GBM	cis	rs11654801	0.646	rs35597750	ENSG00000233098.7	CCDC144NL-AS1	-4.38	2.64e-05	0.0201	-0.5	-0.38	Mosquito bite size;	chr17:20948323	chr17:20868433~21002276:+
GBM	cis	rs9368481	0.594	rs2636425	ENSG00000238621.1	TRI-TAT2-2	-4.38	2.65e-05	0.0201	-0.43	-0.38	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:27020335~27020447:+
GBM	cis	rs7017914	0.934	rs2639921	ENSG00000246366.5	RP11-382J12.1	-4.38	2.65e-05	0.0201	-0.41	-0.38	Bone mineral density;	chr8:70962599	chr8:70608577~70663279:+
GBM	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-4.38	2.65e-05	0.0201	-0.39	-0.38	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
GBM	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-4.38	2.65e-05	0.0201	-0.39	-0.38	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
GBM	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-4.38	2.65e-05	0.0201	-0.39	-0.38	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
GBM	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-4.38	2.65e-05	0.0201	-0.39	-0.38	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
GBM	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-4.38	2.65e-05	0.0201	-0.39	-0.38	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
GBM	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	4.38	2.65e-05	0.0201	0.42	0.38	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
GBM	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-4.38	2.65e-05	0.0201	-0.46	-0.38	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
GBM	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	4.38	2.66e-05	0.0201	0.64	0.38	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	4.38	2.66e-05	0.0201	0.64	0.38	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
GBM	cis	rs7267979	0.586	rs6050431	ENSG00000276952.1	RP5-965G21.6	4.38	2.66e-05	0.0202	0.36	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.586	rs6050432	ENSG00000276952.1	RP5-965G21.6	4.38	2.66e-05	0.0202	0.36	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25284915~25285588:-
GBM	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-4.38	2.66e-05	0.0202	-0.48	-0.38	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-4.38	2.66e-05	0.0202	-0.48	-0.38	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
GBM	cis	rs6496932	0.874	rs11074061	ENSG00000218052.5	ADAMTS7P4	4.38	2.66e-05	0.0202	0.58	0.38	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:85255369~85330334:-
GBM	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	4.38	2.67e-05	0.0203	0.44	0.38	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
GBM	cis	rs17756712	0.697	rs2294669	ENSG00000281809.1	LINC01394	-4.38	2.67e-05	0.0203	-0.48	-0.38	Vertical cup-disc ratio;	chr6:625673	chr6:1321698~1324022:-
GBM	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-4.38	2.67e-05	0.0203	-0.64	-0.38	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
GBM	cis	rs8062405	0.722	rs3785354	ENSG00000271623.1	RP11-435I10.5	-4.38	2.67e-05	0.0203	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs4787457	ENSG00000271623.1	RP11-435I10.5	-4.38	2.67e-05	0.0203	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28364700~28365333:+
GBM	cis	rs17772222	0.63	rs4904454	ENSG00000222990.1	RNU4-22P	-4.38	2.68e-05	0.0203	-0.39	-0.38	Coronary artery calcification;	chr14:88537777	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.63	rs2033418	ENSG00000222990.1	RNU4-22P	-4.38	2.68e-05	0.0203	-0.39	-0.38	Coronary artery calcification;	chr14:88539331	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.63	rs10873392	ENSG00000222990.1	RNU4-22P	-4.38	2.68e-05	0.0203	-0.39	-0.38	Coronary artery calcification;	chr14:88545124	chr14:88513498~88513663:+
GBM	cis	rs4812048	1	rs6070697	ENSG00000268649.3	RP4-806M20.4	-4.38	2.68e-05	0.0203	-0.44	-0.38	Mean platelet volume;	chr20:59024347	chr20:58817132~58817725:-
GBM	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-4.38	2.68e-05	0.0203	-0.54	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
GBM	cis	rs763121	0.853	rs7289855	ENSG00000273076.1	RP3-508I15.22	4.38	2.68e-05	0.0203	0.43	0.38	Menopause (age at onset);	chr22:38646216	chr22:38743495~38743910:+
GBM	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-4.37	2.69e-05	0.0203	-0.41	-0.38	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	4.37	2.69e-05	0.0203	0.41	0.38	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
GBM	cis	rs11654801	0.853	rs11658389	ENSG00000233098.7	CCDC144NL-AS1	-4.37	2.69e-05	0.0204	-0.53	-0.38	Mosquito bite size;	chr17:20977405	chr17:20868433~21002276:+
GBM	cis	rs763121	0.626	rs5750643	ENSG00000273076.1	RP3-508I15.22	4.37	2.69e-05	0.0204	0.41	0.38	Menopause (age at onset);	chr22:38613012	chr22:38743495~38743910:+
GBM	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-4.37	2.69e-05	0.0204	-0.56	-0.38	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
GBM	cis	rs17685	0.753	rs6976532	ENSG00000280388.1	RP11-229D13.3	-4.37	2.69e-05	0.0204	-0.34	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76043977~76045963:-
GBM	cis	rs10246939	0.579	rs13232651	ENSG00000261797.1	RP11-744I24.3	-4.37	2.7e-05	0.0204	-0.48	-0.38	Bitter taste perception;	chr7:141862624	chr7:141512698~141513183:-
GBM	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-4.37	2.7e-05	0.0204	-0.6	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
GBM	cis	rs950169	0.84	rs12905223	ENSG00000275120.1	RP11-182J1.17	4.37	2.7e-05	0.0205	0.49	0.38	Schizophrenia;	chr15:84571037	chr15:84599434~84606463:-
GBM	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	4.37	2.71e-05	0.0205	0.37	0.38	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
GBM	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-4.37	2.71e-05	0.0205	-0.37	-0.38	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
GBM	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-4.37	2.71e-05	0.0205	-0.34	-0.38	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
GBM	cis	rs17508449	0.865	rs4838994	ENSG00000232450.1	RP4-730K3.3	4.37	2.71e-05	0.0205	0.65	0.38	Leprosy;	chr1:113608984	chr1:113698884~113699631:-
GBM	cis	rs3806843	0.568	rs2530232	ENSG00000202111.1	VTRNA1-2	4.37	2.72e-05	0.0205	0.41	0.38	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr5:140718925~140719013:+
GBM	cis	rs977747	0.933	rs12407157	ENSG00000232022.5	FAAHP1	-4.37	2.72e-05	0.0206	-0.4	-0.38	Body mass index;	chr1:47241355	chr1:46432129~46445521:+
GBM	cis	rs950169	0.887	rs220333	ENSG00000275120.1	RP11-182J1.17	4.37	2.72e-05	0.0206	0.49	0.38	Schizophrenia;	chr15:84547902	chr15:84599434~84606463:-
GBM	cis	rs4853012	0.887	rs7570950	ENSG00000257800.1	FNBP1P1	4.37	2.72e-05	0.0206	0.61	0.38	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74120680~74123218:+
GBM	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-4.37	2.72e-05	0.0206	-0.43	-0.38	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
GBM	cis	rs8177876	0.749	rs935942	ENSG00000261838.4	RP11-303E16.6	-4.37	2.72e-05	0.0206	-0.69	-0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81069854~81076598:+
GBM	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	4.37	2.72e-05	0.0206	0.31	0.38	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
GBM	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	4.37	2.72e-05	0.0206	0.31	0.38	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
GBM	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	4.37	2.72e-05	0.0206	0.31	0.38	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
GBM	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	4.37	2.72e-05	0.0206	0.31	0.38	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
GBM	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	4.37	2.72e-05	0.0206	0.41	0.38	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
GBM	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-4.37	2.72e-05	0.0206	-0.39	-0.38	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
GBM	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	4.37	2.72e-05	0.0206	0.46	0.38	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
GBM	cis	rs4713118	0.955	rs9468206	ENSG00000218016.2	ZNF192P2	-4.37	2.73e-05	0.0206	-0.5	-0.38	Parkinson's disease;	chr6:27722674	chr6:28188050~28189432:+
GBM	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-4.37	2.73e-05	0.0206	-0.46	-0.38	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
GBM	cis	rs763121	0.853	rs1043441	ENSG00000273076.1	RP3-508I15.22	4.37	2.74e-05	0.0207	0.4	0.38	Menopause (age at onset);	chr22:38734959	chr22:38743495~38743910:+
GBM	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	4.37	2.74e-05	0.0207	0.44	0.38	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
GBM	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	4.37	2.74e-05	0.0207	0.43	0.38	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	4.37	2.74e-05	0.0207	0.43	0.38	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
GBM	cis	rs17685	0.753	rs11972240	ENSG00000280388.1	RP11-229D13.3	-4.37	2.74e-05	0.0207	-0.35	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76064761	chr7:76043977~76045963:-
GBM	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-4.37	2.74e-05	0.0207	-0.52	-0.38	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
GBM	cis	rs1150668	0.799	rs9301	ENSG00000218016.2	ZNF192P2	-4.37	2.74e-05	0.0207	-0.44	-0.38	Pubertal anthropometrics;	chr6:28324929	chr6:28188050~28189432:+
GBM	cis	rs763121	0.853	rs8140617	ENSG00000273076.1	RP3-508I15.22	-4.37	2.75e-05	0.0207	-0.42	-0.38	Menopause (age at onset);	chr22:38574434	chr22:38743495~38743910:+
GBM	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-4.37	2.75e-05	0.0207	-0.43	-0.38	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-4.37	2.75e-05	0.0207	-0.43	-0.38	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
GBM	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-4.37	2.75e-05	0.0207	-0.47	-0.38	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
GBM	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-4.37	2.75e-05	0.0207	-0.43	-0.38	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
GBM	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-4.37	2.75e-05	0.0207	-0.43	-0.38	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
GBM	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-4.37	2.75e-05	0.0208	-0.47	-0.38	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-4.37	2.75e-05	0.0208	-0.47	-0.38	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-4.37	2.75e-05	0.0208	-0.47	-0.38	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-4.37	2.75e-05	0.0208	-0.47	-0.38	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-4.37	2.75e-05	0.0208	-0.47	-0.38	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-4.37	2.75e-05	0.0208	-0.47	-0.38	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-4.37	2.75e-05	0.0208	-0.47	-0.38	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
GBM	cis	rs1555322	0.818	rs2425022	ENSG00000126005.14	MMP24-AS1	-4.37	2.75e-05	0.0208	-0.56	-0.38	Attention deficit hyperactivity disorder;	chr20:35243384	chr20:35216462~35278131:-
GBM	cis	rs66887589	0.934	rs12648182	ENSG00000249244.1	RP11-548H18.2	-4.37	2.76e-05	0.0208	-0.44	-0.38	Diastolic blood pressure;	chr4:119582736	chr4:119391831~119395335:-
GBM	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	4.37	2.76e-05	0.0208	0.36	0.38	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
GBM	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	4.37	2.76e-05	0.0208	0.63	0.38	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
GBM	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-4.37	2.76e-05	0.0208	-0.63	-0.38	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-4.37	2.76e-05	0.0208	-0.63	-0.38	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
GBM	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-4.37	2.76e-05	0.0208	-0.63	-0.38	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-4.37	2.76e-05	0.0208	-0.63	-0.38	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
GBM	cis	rs7035589	1	rs10820752	ENSG00000230013.1	RP11-217B7.3	4.37	2.76e-05	0.0208	0.48	0.38	Pelvic organ prolapse;	chr9:104985855	chr9:104990796~104991781:-
GBM	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	4.37	2.76e-05	0.0208	0.68	0.38	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
GBM	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	4.37	2.76e-05	0.0208	0.41	0.38	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	4.37	2.76e-05	0.0208	0.41	0.38	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
GBM	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	4.37	2.77e-05	0.0208	0.42	0.38	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
GBM	cis	rs8062405	0.691	rs743590	ENSG00000271623.1	RP11-435I10.5	-4.37	2.77e-05	0.0209	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28364700~28365333:+
GBM	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	4.37	2.77e-05	0.0209	0.39	0.38	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	4.37	2.77e-05	0.0209	0.39	0.38	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
GBM	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	4.37	2.77e-05	0.0209	0.39	0.38	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
GBM	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	4.37	2.77e-05	0.0209	0.39	0.38	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
GBM	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	4.37	2.77e-05	0.0209	1.04	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
GBM	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	4.37	2.77e-05	0.0209	1.04	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
GBM	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	4.37	2.78e-05	0.0209	0.76	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
GBM	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	4.37	2.78e-05	0.0209	0.51	0.38	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
GBM	cis	rs2115630	0.936	rs11073663	ENSG00000225151.9	GOLGA2P7	4.37	2.78e-05	0.0209	0.42	0.38	P wave terminal force;	chr15:84717037	chr15:84199311~84230136:-
GBM	cis	rs950169	0.922	rs11630507	ENSG00000275120.1	RP11-182J1.17	4.37	2.78e-05	0.0209	0.5	0.38	Schizophrenia;	chr15:84552494	chr15:84599434~84606463:-
GBM	cis	rs6600671	0.899	rs11249432	ENSG00000223345.3	HIST2H2BA	4.37	2.78e-05	0.0209	0.5	0.38	Hip geometry;	chr1:121541678	chr1:121108210~121117257:-
GBM	cis	rs858239	0.899	rs2268745	ENSG00000230042.1	AK3P3	-4.37	2.78e-05	0.0209	-0.46	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23129178~23129841:+
GBM	cis	rs2235573	0.673	rs5756894	ENSG00000233739.1	RP5-1039K5.13	4.37	2.78e-05	0.0209	0.45	0.38	Glioma;Glioblastoma;	chr22:38054129	chr22:38057180~38073940:-
GBM	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	4.37	2.78e-05	0.0209	0.27	0.38	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
GBM	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	4.37	2.78e-05	0.0209	0.68	0.38	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
GBM	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	4.37	2.78e-05	0.0209	0.68	0.38	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
GBM	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	4.37	2.78e-05	0.0209	1.04	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
GBM	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	4.37	2.78e-05	0.0209	1.04	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
GBM	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-4.37	2.78e-05	0.0209	-0.49	-0.38	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
GBM	cis	rs4604732	0.631	rs12080860	ENSG00000227135.1	GCSAML-AS1	-4.37	2.78e-05	0.0209	-0.6	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459751	chr1:247524679~247526752:-
GBM	cis	rs8177876	0.822	rs7206814	ENSG00000261838.4	RP11-303E16.6	-4.37	2.79e-05	0.021	-0.7	-0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81069854~81076598:+
GBM	cis	rs4713118	0.866	rs9468217	ENSG00000199851.2	U3	4.36	2.79e-05	0.021	0.53	0.38	Parkinson's disease;	chr6:27758688	chr6:28015568~28015777:+
GBM	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	4.36	2.79e-05	0.021	0.44	0.38	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	4.36	2.79e-05	0.021	0.44	0.38	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
GBM	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	4.36	2.79e-05	0.021	0.44	0.38	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
GBM	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	4.36	2.79e-05	0.021	0.44	0.38	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	4.36	2.79e-05	0.021	0.44	0.38	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
GBM	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-4.36	2.79e-05	0.021	-0.43	-0.38	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
GBM	cis	rs763121	0.819	rs6001205	ENSG00000273076.1	RP3-508I15.22	4.36	2.79e-05	0.021	0.43	0.38	Menopause (age at onset);	chr22:38704259	chr22:38743495~38743910:+
GBM	cis	rs3768617	0.51	rs6666259	ENSG00000224468.3	RP11-181K3.4	-4.36	2.8e-05	0.021	-0.31	-0.38	Fuchs's corneal dystrophy;	chr1:183133720	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768615	ENSG00000224468.3	RP11-181K3.4	-4.36	2.8e-05	0.021	-0.31	-0.38	Fuchs's corneal dystrophy;	chr1:183134469	chr1:183138402~183141282:-
GBM	cis	rs1190596	0.83	rs2298877	ENSG00000259088.1	CTD-2017C7.2	-4.36	2.8e-05	0.021	-0.51	-0.38	Behavioural disinhibition (generation interaction);	chr14:102081887	chr14:101796555~101810321:-
GBM	cis	rs4388249	1	rs4388249	ENSG00000271849.1	CTC-332L22.1	4.36	2.8e-05	0.0211	0.56	0.38	Schizophrenia;	chr5:109700365	chr5:109687802~109688329:-
GBM	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	4.36	2.81e-05	0.0211	0.46	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
GBM	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-4.36	2.81e-05	0.0211	-0.45	-0.38	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
GBM	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-4.36	2.81e-05	0.0211	-0.57	-0.38	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
GBM	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	4.36	2.81e-05	0.0211	0.47	0.38	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
GBM	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	4.36	2.81e-05	0.0211	0.47	0.38	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
GBM	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
GBM	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
GBM	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	4.36	2.82e-05	0.0211	0.57	0.38	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
GBM	cis	rs9303029	0.611	rs2306753	ENSG00000279744.1	RP13-20L14.10	-4.36	2.82e-05	0.0211	-0.36	-0.38	Protein quantitative trait loci;	chr17:82469114	chr17:82462601~82464255:+
GBM	cis	rs977747	0.898	rs911910	ENSG00000232022.5	FAAHP1	-4.36	2.82e-05	0.0211	-0.4	-0.38	Body mass index;	chr1:47241298	chr1:46432129~46445521:+
GBM	cis	rs17772222	0.63	rs12437422	ENSG00000222990.1	RNU4-22P	-4.36	2.82e-05	0.0212	-0.4	-0.38	Coronary artery calcification;	chr14:88529621	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.605	rs4899955	ENSG00000222990.1	RNU4-22P	-4.36	2.82e-05	0.0212	-0.4	-0.38	Coronary artery calcification;	chr14:88530381	chr14:88513498~88513663:+
GBM	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-4.36	2.83e-05	0.0212	-0.39	-0.38	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
GBM	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-4.36	2.83e-05	0.0212	-0.39	-0.38	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
GBM	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-4.36	2.84e-05	0.0212	-0.32	-0.38	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
GBM	cis	rs7487075	0.79	rs11183527	ENSG00000257261.4	RP11-96H19.1	4.36	2.84e-05	0.0212	0.37	0.38	Itch intensity from mosquito bite;	chr12:46552580	chr12:46383679~46876159:+
GBM	cis	rs9393777	0.513	rs6924727	ENSG00000224843.5	LINC00240	4.36	2.84e-05	0.0213	0.57	0.38	Intelligence (multi-trait analysis);	chr6:26491006	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.588	rs6941920	ENSG00000224843.5	LINC00240	4.36	2.84e-05	0.0213	0.57	0.38	Intelligence (multi-trait analysis);	chr6:26491921	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.588	rs6933213	ENSG00000224843.5	LINC00240	4.36	2.84e-05	0.0213	0.57	0.38	Intelligence (multi-trait analysis);	chr6:26493681	chr6:26956992~27023924:+
GBM	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-4.36	2.84e-05	0.0213	-0.49	-0.38	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-4.36	2.84e-05	0.0213	-0.49	-0.38	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
GBM	cis	rs2018683	0.691	rs4722881	ENSG00000228421.2	AC005013.5	-4.36	2.84e-05	0.0213	-0.44	-0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28961944	chr7:28957667~28959345:+
GBM	cis	rs10911251	0.528	rs4652779	ENSG00000224468.3	RP11-181K3.4	-4.36	2.84e-05	0.0213	-0.31	-0.38	Colorectal cancer;	chr1:183135417	chr1:183138402~183141282:-
GBM	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	4.36	2.85e-05	0.0213	0.41	0.38	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
GBM	cis	rs858239	1	rs156407	ENSG00000230042.1	AK3P3	-4.36	2.85e-05	0.0213	-0.43	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23129178~23129841:+
GBM	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	4.36	2.85e-05	0.0213	0.4	0.38	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750626	ENSG00000273076.1	RP3-508I15.22	4.36	2.85e-05	0.0213	0.42	0.38	Menopause (age at onset);	chr22:38581885	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs6519119	ENSG00000273076.1	RP3-508I15.22	4.36	2.85e-05	0.0213	0.42	0.38	Menopause (age at onset);	chr22:38593002	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5757162	ENSG00000273076.1	RP3-508I15.22	4.36	2.85e-05	0.0213	0.42	0.38	Menopause (age at onset);	chr22:38597365	chr22:38743495~38743910:+
GBM	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-4.36	2.85e-05	0.0213	-0.43	-0.38	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-4.36	2.85e-05	0.0213	-0.43	-0.38	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
GBM	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-4.36	2.85e-05	0.0214	-0.44	-0.38	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
GBM	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-4.36	2.85e-05	0.0214	-0.44	-0.38	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
GBM	cis	rs9425766	0.64	rs2281486	ENSG00000270084.1	GAS5-AS1	-4.36	2.86e-05	0.0214	-0.44	-0.38	Life satisfaction;	chr1:173853083	chr1:173863248~173863941:+
GBM	cis	rs9425766	0.64	rs16846439	ENSG00000270084.1	GAS5-AS1	-4.36	2.86e-05	0.0214	-0.44	-0.38	Life satisfaction;	chr1:173854900	chr1:173863248~173863941:+
GBM	cis	rs10463554	0.501	rs6860813	ENSG00000175749.11	EIF3KP1	4.36	2.86e-05	0.0214	0.52	0.38	Parkinson's disease;	chr5:103353125	chr5:103032376~103033031:+
GBM	cis	rs397969	0.646	rs403021	ENSG00000230528.6	NOS2P3	-4.36	2.86e-05	0.0214	-0.44	-0.38	Platelet count;	chr17:19903516	chr17:20436337~20447249:+
GBM	cis	rs1555322	1	rs2425031	ENSG00000126005.14	MMP24-AS1	-4.36	2.86e-05	0.0214	-0.65	-0.38	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35216462~35278131:-
GBM	cis	rs1555322	1	rs2425034	ENSG00000126005.14	MMP24-AS1	-4.36	2.86e-05	0.0214	-0.65	-0.38	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35216462~35278131:-
GBM	cis	rs1555322	0.858	rs2425035	ENSG00000126005.14	MMP24-AS1	-4.36	2.86e-05	0.0214	-0.65	-0.38	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35216462~35278131:-
GBM	cis	rs1555322	1	rs2425036	ENSG00000126005.14	MMP24-AS1	-4.36	2.86e-05	0.0214	-0.65	-0.38	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35216462~35278131:-
GBM	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-4.36	2.86e-05	0.0214	-0.45	-0.38	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
GBM	cis	rs7829975	0.714	rs4840362	ENSG00000254340.1	RP11-10A14.3	-4.36	2.86e-05	0.0214	-0.46	-0.38	Mood instability;	chr8:8812572	chr8:9141424~9145435:+
GBM	cis	rs9926296	0.546	rs6500442	ENSG00000260259.1	RP11-368I7.4	-4.36	2.86e-05	0.0214	-0.4	-0.38	Vitiligo;	chr16:89762454	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.548	rs12447465	ENSG00000260259.1	RP11-368I7.4	-4.36	2.86e-05	0.0214	-0.4	-0.38	Vitiligo;	chr16:89763487	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.565	rs8055825	ENSG00000260259.1	RP11-368I7.4	-4.36	2.86e-05	0.0214	-0.4	-0.38	Vitiligo;	chr16:89766440	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.568	rs7203907	ENSG00000260259.1	RP11-368I7.4	-4.36	2.86e-05	0.0214	-0.4	-0.38	Vitiligo;	chr16:89767366	chr16:89682620~89686569:-
GBM	cis	rs2255336	0.938	rs10161486	ENSG00000245648.1	RP11-277P12.20	-4.36	2.87e-05	0.0214	-0.5	-0.38	Blood protein levels;	chr12:10457167	chr12:10363769~10398506:+
GBM	cis	rs2255336	0.938	rs73070924	ENSG00000245648.1	RP11-277P12.20	-4.36	2.87e-05	0.0214	-0.5	-0.38	Blood protein levels;	chr12:10457386	chr12:10363769~10398506:+
GBM	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	4.36	2.87e-05	0.0214	0.41	0.38	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
GBM	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-4.36	2.87e-05	0.0214	-0.44	-0.38	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
GBM	cis	rs4604732	0.536	rs4433437	ENSG00000227135.1	GCSAML-AS1	-4.36	2.87e-05	0.0214	-0.54	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473278	chr1:247524679~247526752:-
GBM	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	4.36	2.87e-05	0.0214	0.37	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
GBM	cis	rs7615952	0.641	rs4490307	ENSG00000250012.1	RP11-124N2.1	-4.36	2.87e-05	0.0214	-0.4	-0.38	Blood pressure (smoking interaction);	chr3:125993833	chr3:126084220~126095349:+
GBM	cis	rs2963463	0.683	rs6862472	ENSG00000253519.1	AC106801.1	4.36	2.87e-05	0.0215	0.52	0.38	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158489706	chr5:157565964~157569098:+
GBM	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-4.36	2.87e-05	0.0215	-0.31	-0.38	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
GBM	cis	rs16937	0.711	rs4951172	ENSG00000271580.1	RP11-536L3.4	4.36	2.87e-05	0.0215	0.34	0.38	Schizophrenia;	chr1:205168450	chr1:205091163~205091946:+
GBM	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	4.36	2.87e-05	0.0215	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
GBM	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	4.36	2.87e-05	0.0215	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
GBM	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	4.36	2.88e-05	0.0215	0.44	0.38	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
GBM	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	4.36	2.88e-05	0.0215	0.44	0.38	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
GBM	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.36	2.88e-05	0.0215	0.47	0.38	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
GBM	cis	rs2018683	1	rs740252	ENSG00000228421.2	AC005013.5	4.36	2.88e-05	0.0215	0.44	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28958149	chr7:28957667~28959345:+
GBM	cis	rs3824488	0.92	rs16909902	ENSG00000271314.1	RP11-435O5.6	-4.36	2.88e-05	0.0215	-0.38	-0.38	Neuroticism;	chr9:95473920	chr9:95494924~95495379:+
GBM	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-4.36	2.89e-05	0.0215	-0.4	-0.38	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
GBM	cis	rs17482078	0.885	rs10045403	ENSG00000248734.2	CTD-2260A17.1	4.36	2.89e-05	0.0215	0.51	0.38	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96784777~96785999:+
GBM	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	4.36	2.89e-05	0.0216	0.48	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
GBM	cis	rs7017914	0.677	rs7012577	ENSG00000246366.5	RP11-382J12.1	-4.36	2.89e-05	0.0216	-0.41	-0.38	Bone mineral density;	chr8:70559809	chr8:70608577~70663279:+
GBM	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	4.36	2.89e-05	0.0216	0.35	0.38	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
GBM	cis	rs8062405	0.755	rs4788073	ENSG00000271623.1	RP11-435I10.5	-4.36	2.89e-05	0.0216	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs55792032	ENSG00000271623.1	RP11-435I10.5	-4.36	2.89e-05	0.0216	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28364700~28365333:+
GBM	cis	rs36715	1	rs36693	ENSG00000245937.6	LINC01184	4.36	2.9e-05	0.0216	0.4	0.38	Breast cancer;	chr5:128213008	chr5:127940426~128083172:-
GBM	cis	rs3812049	0.506	rs36694	ENSG00000245937.6	LINC01184	4.36	2.9e-05	0.0216	0.4	0.38	Lymphocyte counts;Red cell distribution width;	chr5:128213263	chr5:127940426~128083172:-
GBM	cis	rs1298062	0.689	rs12985344	ENSG00000131401.10	NAPSB	-4.36	2.9e-05	0.0216	-0.46	-0.38	Age of smoking initiation;	chr19:50451493	chr19:50333796~50344767:-
GBM	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	4.36	2.9e-05	0.0216	0.42	0.38	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
GBM	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	4.36	2.9e-05	0.0216	0.42	0.38	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
GBM	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	4.36	2.9e-05	0.0216	0.42	0.38	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
GBM	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	4.36	2.9e-05	0.0217	0.42	0.38	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
GBM	cis	rs950169	0.922	rs11633534	ENSG00000275120.1	RP11-182J1.17	4.35	2.9e-05	0.0217	0.48	0.38	Schizophrenia;	chr15:84581411	chr15:84599434~84606463:-
GBM	cis	rs950169	0.65	rs12902052	ENSG00000275120.1	RP11-182J1.17	4.35	2.9e-05	0.0217	0.48	0.38	Schizophrenia;	chr15:84582607	chr15:84599434~84606463:-
GBM	cis	rs7017914	0.629	rs2732111	ENSG00000246366.5	RP11-382J12.1	-4.35	2.9e-05	0.0217	-0.4	-0.38	Bone mineral density;	chr8:71015194	chr8:70608577~70663279:+
GBM	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-4.35	2.91e-05	0.0217	-0.45	-0.38	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
GBM	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	4.35	2.91e-05	0.0217	0.44	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
GBM	cis	rs4072705	0.967	rs4240486	ENSG00000224020.1	MIR181A2HG	-4.35	2.91e-05	0.0217	-0.4	-0.38	Menarche (age at onset);	chr9:124578831	chr9:124658467~124698631:+
GBM	cis	rs4072705	0.615	rs7851737	ENSG00000224020.1	MIR181A2HG	4.35	2.91e-05	0.0217	0.42	0.38	Menarche (age at onset);	chr9:124485652	chr9:124658467~124698631:+
GBM	cis	rs4072705	0.586	rs7023736	ENSG00000224020.1	MIR181A2HG	-4.35	2.91e-05	0.0217	-0.42	-0.38	Menarche (age at onset);	chr9:124485667	chr9:124658467~124698631:+
GBM	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-4.35	2.91e-05	0.0217	-0.44	-0.38	Height;	chr20:35186641	chr20:35201747~35203288:-
GBM	cis	rs9828933	0.752	rs12633353	ENSG00000280620.1	SCAANT1	4.35	2.91e-05	0.0217	0.69	0.38	Type 2 diabetes;	chr3:63984604	chr3:63911518~63911772:-
GBM	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-4.35	2.91e-05	0.0217	-0.51	-0.38	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
GBM	cis	rs977747	1	rs11211481	ENSG00000232022.5	FAAHP1	4.35	2.91e-05	0.0217	0.38	0.38	Body mass index;	chr1:47228495	chr1:46432129~46445521:+
GBM	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-4.35	2.92e-05	0.0217	-0.44	-0.38	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-4.35	2.92e-05	0.0217	-0.44	-0.38	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
GBM	cis	rs17685	0.753	rs1639609	ENSG00000280388.1	RP11-229D13.3	-4.35	2.92e-05	0.0218	-0.34	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76054263	chr7:76043977~76045963:-
GBM	cis	rs17772222	0.74	rs7151164	ENSG00000222990.1	RNU4-22P	4.35	2.93e-05	0.0218	0.4	0.38	Coronary artery calcification;	chr14:88509329	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs12433026	ENSG00000222990.1	RNU4-22P	4.35	2.93e-05	0.0218	0.4	0.38	Coronary artery calcification;	chr14:88509495	chr14:88513498~88513663:+
GBM	cis	rs9425766	0.64	rs9660881	ENSG00000270084.1	GAS5-AS1	-4.35	2.93e-05	0.0218	-0.44	-0.38	Life satisfaction;	chr1:173867378	chr1:173863248~173863941:+
GBM	cis	rs9425766	0.678	rs55829688	ENSG00000270084.1	GAS5-AS1	-4.35	2.93e-05	0.0218	-0.44	-0.38	Life satisfaction;	chr1:173868168	chr1:173863248~173863941:+
GBM	cis	rs3806843	0.657	rs2563283	ENSG00000202111.1	VTRNA1-2	4.35	2.93e-05	0.0218	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.771	rs2563336	ENSG00000202111.1	VTRNA1-2	4.35	2.93e-05	0.0218	0.4	0.38	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr5:140718925~140719013:+
GBM	cis	rs11654801	0.812	rs11204327	ENSG00000233098.7	CCDC144NL-AS1	-4.35	2.93e-05	0.0218	-0.54	-0.38	Mosquito bite size;	chr17:20959253	chr17:20868433~21002276:+
GBM	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	4.35	2.93e-05	0.0218	0.43	0.38	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
GBM	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	4.35	2.93e-05	0.0218	0.39	0.38	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
GBM	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	4.35	2.94e-05	0.0218	0.62	0.38	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	4.35	2.94e-05	0.0218	0.62	0.38	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	4.35	2.94e-05	0.0218	0.62	0.38	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
GBM	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	4.35	2.94e-05	0.0218	0.62	0.38	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
GBM	cis	rs7017914	0.605	rs13267098	ENSG00000246366.5	RP11-382J12.1	-4.35	2.94e-05	0.0218	-0.4	-0.38	Bone mineral density;	chr8:70899651	chr8:70608577~70663279:+
GBM	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	4.35	2.94e-05	0.0219	0.55	0.38	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
GBM	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-4.35	2.94e-05	0.0219	-0.54	-0.38	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
GBM	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-4.35	2.94e-05	0.0219	-0.48	-0.38	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
GBM	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-4.35	2.94e-05	0.0219	-0.48	-0.38	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
GBM	cis	rs3768617	0.51	rs3768616	ENSG00000224468.3	RP11-181K3.4	-4.35	2.94e-05	0.0219	-0.31	-0.38	Fuchs's corneal dystrophy;	chr1:183134416	chr1:183138402~183141282:-
GBM	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	4.35	2.94e-05	0.0219	0.43	0.38	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	4.35	2.94e-05	0.0219	0.43	0.38	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
GBM	cis	rs11654801	0.812	rs11655512	ENSG00000233098.7	CCDC144NL-AS1	-4.35	2.94e-05	0.0219	-0.53	-0.38	Mosquito bite size;	chr17:20948422	chr17:20868433~21002276:+
GBM	cis	rs7267979	0.586	rs6050445	ENSG00000125804.12	FAM182A	-4.35	2.94e-05	0.0219	-0.47	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:26054655~26086917:+
GBM	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	4.35	2.95e-05	0.0219	0.43	0.38	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
GBM	cis	rs2025751	0.666	rs10214606	ENSG00000230204.1	FTH1P5	-4.35	2.95e-05	0.0219	-0.44	-0.38	Intraocular pressure;	chr6:51821283	chr6:50912712~50913256:-
GBM	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	4.35	2.95e-05	0.0219	0.55	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
GBM	cis	rs11654801	0.812	rs11658722	ENSG00000233098.7	CCDC144NL-AS1	-4.35	2.96e-05	0.022	-0.51	-0.38	Mosquito bite size;	chr17:20955373	chr17:20868433~21002276:+
GBM	cis	rs11654801	0.755	rs11650623	ENSG00000233098.7	CCDC144NL-AS1	-4.35	2.96e-05	0.022	-0.51	-0.38	Mosquito bite size;	chr17:20956307	chr17:20868433~21002276:+
GBM	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	4.35	2.96e-05	0.022	0.91	0.38	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
GBM	cis	rs62355901	0.505	rs56309635	ENSG00000271828.1	CTD-2310F14.1	4.35	2.96e-05	0.022	0.91	0.38	Breast cancer;	chr5:56789589	chr5:56927874~56929573:+
GBM	cis	rs4072705	0.935	rs2184219	ENSG00000224020.1	MIR181A2HG	-4.35	2.96e-05	0.022	-0.41	-0.38	Menarche (age at onset);	chr9:124770625	chr9:124658467~124698631:+
GBM	cis	rs4373814	0.698	rs10828280	ENSG00000226083.4	SLC39A12-AS1	4.35	2.96e-05	0.022	0.43	0.38	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18160426	chr10:18001786~18010562:-
GBM	cis	rs3806843	0.933	rs12659980	ENSG00000202111.1	VTRNA1-2	-4.35	2.96e-05	0.022	-0.41	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140839243	chr5:140718925~140719013:+
GBM	cis	rs3845817	0.868	rs702891	ENSG00000237979.1	AC007389.1	-4.35	2.96e-05	0.022	-0.52	-0.38	Bipolar disorder;	chr2:65531316	chr2:65500993~65502138:-
GBM	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	4.35	2.96e-05	0.022	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
GBM	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-4.35	2.96e-05	0.022	-0.41	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
GBM	cis	rs11671005	0.656	rs11671092	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.022	0.48	0.38	Mean platelet volume;	chr19:58497742	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.656	rs55928441	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.022	0.48	0.38	Mean platelet volume;	chr19:58498307	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.656	rs73066228	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.022	0.48	0.38	Mean platelet volume;	chr19:58501829	chr19:58440448~58445849:+
GBM	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-4.35	2.97e-05	0.022	-0.45	-0.38	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
GBM	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-4.35	2.97e-05	0.022	-0.43	-0.38	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
GBM	cis	rs17664713	0.714	rs17732246	ENSG00000259134.4	LINC00924	4.35	2.97e-05	0.0221	0.9	0.38	Response to mTOR inhibitor (rapamycin);	chr15:94776557	chr15:95433095~95507847:+
GBM	cis	rs7824557	0.675	rs2736265	ENSG00000255020.1	AF131216.5	4.35	2.97e-05	0.0221	0.4	0.38	Retinal vascular caliber;	chr8:11329165	chr8:11345748~11347502:-
GBM	cis	rs11671005	0.695	rs8106061	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58406623	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs56292587	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58407699	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs56290606	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58407953	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.651	rs11878203	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58408683	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11878198	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58408935	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11666716	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58409585	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs34511020	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58409929	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11666303	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58411135	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs12986387	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58415848	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs11667723	ENSG00000269473.1	CTD-2619J13.19	4.35	2.97e-05	0.0221	0.41	0.38	Mean platelet volume;	chr19:58416122	chr19:58440448~58445849:+
GBM	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	4.35	2.98e-05	0.0221	0.27	0.38	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
GBM	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	4.35	2.98e-05	0.0221	0.27	0.38	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
GBM	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-4.35	2.98e-05	0.0221	-0.52	-0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
GBM	cis	rs2018683	0.691	rs4722881	ENSG00000272568.4	CTB-113D17.1	-4.35	2.98e-05	0.0221	-0.44	-0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28961944	chr7:28979967~29013367:+
GBM	cis	rs5752326	0.717	rs739290	ENSG00000261188.1	CTA-445C9.14	4.35	2.98e-05	0.0221	0.53	0.38	Ischemic stroke;	chr22:26468692	chr22:26512537~26514568:+
GBM	cis	rs922692	0.71	rs1994016	ENSG00000261143.1	ADAMTS7P3	4.35	2.99e-05	0.0222	0.41	0.38	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78787892	chr15:77976042~77993057:+
GBM	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	4.35	2.99e-05	0.0222	0.45	0.38	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
GBM	cis	rs3845817	0.868	rs702938	ENSG00000237979.1	AC007389.1	-4.35	3e-05	0.0222	-0.52	-0.38	Bipolar disorder;	chr2:65520308	chr2:65500993~65502138:-
GBM	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	4.35	3e-05	0.0223	0.46	0.38	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
GBM	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-4.35	3.01e-05	0.0223	-0.5	-0.38	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-4.35	3.01e-05	0.0223	-0.5	-0.38	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-4.35	3.01e-05	0.0223	-0.5	-0.38	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
GBM	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	4.35	3.01e-05	0.0223	0.31	0.38	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
GBM	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	4.35	3.02e-05	0.0223	0.42	0.38	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	4.35	3.02e-05	0.0223	0.42	0.38	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
GBM	cis	rs753955	0.923	rs9580741	ENSG00000205861.10	C1QTNF9B-AS1	-4.34	3.02e-05	0.0224	-0.49	-0.38	Lung cancer;	chr13:23716482	chr13:23888889~23897263:+
GBM	cis	rs7017914	0.905	rs2732103	ENSG00000246366.5	RP11-382J12.1	-4.34	3.02e-05	0.0224	-0.4	-0.38	Bone mineral density;	chr8:71011261	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732104	ENSG00000246366.5	RP11-382J12.1	-4.34	3.02e-05	0.0224	-0.4	-0.38	Bone mineral density;	chr8:71011284	chr8:70608577~70663279:+
GBM	cis	rs8177876	0.658	rs16954513	ENSG00000261838.4	RP11-303E16.6	4.34	3.03e-05	0.0224	0.83	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81069854~81076598:+
GBM	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	4.34	3.03e-05	0.0224	0.31	0.38	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
GBM	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-4.34	3.03e-05	0.0225	-0.43	-0.38	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
GBM	cis	rs8114671	0.933	rs6142327	ENSG00000269202.1	RP4-614O4.12	4.34	3.04e-05	0.0225	0.43	0.38	Height;	chr20:35205344	chr20:35201747~35203288:-
GBM	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-4.34	3.04e-05	0.0225	-0.54	-0.38	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
GBM	cis	rs4887140	0.717	rs7183428	ENSG00000260469.2	C15orf59-AS1	4.34	3.04e-05	0.0225	0.83	0.38	Glucose homeostasis traits;	chr15:73757257	chr15:73752317~73770613:+
GBM	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-4.34	3.04e-05	0.0225	-0.51	-0.38	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
GBM	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-4.34	3.04e-05	0.0225	-0.41	-0.38	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
GBM	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	4.34	3.05e-05	0.0225	0.4	0.38	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	4.34	3.05e-05	0.0225	0.4	0.38	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	4.34	3.05e-05	0.0225	0.4	0.38	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	4.34	3.05e-05	0.0225	0.4	0.38	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
GBM	cis	rs7615952	0.599	rs16834938	ENSG00000250012.1	RP11-124N2.1	-4.34	3.05e-05	0.0225	-0.42	-0.38	Blood pressure (smoking interaction);	chr3:125987203	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs6438951	ENSG00000250012.1	RP11-124N2.1	-4.34	3.05e-05	0.0225	-0.41	-0.38	Blood pressure (smoking interaction);	chr3:125978156	chr3:126084220~126095349:+
GBM	cis	rs4664293	0.632	rs7588230	ENSG00000226266.5	AC009961.3	4.34	3.05e-05	0.0226	0.47	0.38	Monocyte percentage of white cells;	chr2:159797209	chr2:159670708~159712435:-
GBM	cis	rs3742264	0.656	rs4941537	ENSG00000235903.6	CPB2-AS1	4.34	3.05e-05	0.0226	0.49	0.38	Blood protein levels;	chr13:45968441	chr13:46052806~46113332:+
GBM	cis	rs4713118	0.955	rs9468203	ENSG00000218016.2	ZNF192P2	-4.34	3.05e-05	0.0226	-0.5	-0.38	Parkinson's disease;	chr6:27720888	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9468204	ENSG00000218016.2	ZNF192P2	-4.34	3.05e-05	0.0226	-0.5	-0.38	Parkinson's disease;	chr6:27721030	chr6:28188050~28189432:+
GBM	cis	rs731565	0.867	rs76979648	ENSG00000232391.1	RANP2	4.34	3.05e-05	0.0226	0.71	0.38	Diabetic kidney disease;	chr7:147678697	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs75621293	ENSG00000232391.1	RANP2	4.34	3.05e-05	0.0226	0.71	0.38	Diabetic kidney disease;	chr7:147684563	chr7:147167344~147167572:+
GBM	cis	rs731565	0.867	rs77772876	ENSG00000232391.1	RANP2	4.34	3.05e-05	0.0226	0.71	0.38	Diabetic kidney disease;	chr7:147691352	chr7:147167344~147167572:+
GBM	cis	rs731565	1	rs79733390	ENSG00000232391.1	RANP2	4.34	3.05e-05	0.0226	0.71	0.38	Diabetic kidney disease;	chr7:147708765	chr7:147167344~147167572:+
GBM	cis	rs875971	0.862	rs778734	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66349862	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778686	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66370923	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778684	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66371416	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778680	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66375427	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs1695820	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66379576	chr7:65840212~65840596:+
GBM	cis	rs875971	0.83	rs778715	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66384222	chr7:65840212~65840596:+
GBM	cis	rs875971	0.83	rs809025	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66384832	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778702	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66399848	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs1643375	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66407690	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6962717	ENSG00000236529.1	RP13-254B10.1	4.34	3.05e-05	0.0226	0.4	0.38	Aortic root size;	chr7:66418748	chr7:65840212~65840596:+
GBM	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-4.34	3.06e-05	0.0226	-0.39	-0.38	Temperament;	chr17:14007232	chr17:14024514~14025488:+
GBM	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	4.34	3.06e-05	0.0226	0.49	0.38	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	4.34	3.06e-05	0.0226	0.49	0.38	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
GBM	cis	rs3741404	0.609	rs641430	ENSG00000231680.1	AP003774.6	4.34	3.06e-05	0.0226	0.43	0.38	Platelet count;	chr11:64102059	chr11:64394342~64395831:-
GBM	cis	rs3741404	0.583	rs640999	ENSG00000231680.1	AP003774.6	-4.34	3.06e-05	0.0226	-0.43	-0.38	Platelet count;	chr11:64101953	chr11:64394342~64395831:-
GBM	cis	rs3741404	0.609	rs641378	ENSG00000231680.1	AP003774.6	-4.34	3.06e-05	0.0226	-0.43	-0.38	Platelet count;	chr11:64102021	chr11:64394342~64395831:-
GBM	cis	rs3741404	0.609	rs666497	ENSG00000231680.1	AP003774.6	-4.34	3.06e-05	0.0226	-0.43	-0.38	Platelet count;	chr11:64102349	chr11:64394342~64395831:-
GBM	cis	rs3741404	0.609	rs669913	ENSG00000231680.1	AP003774.6	-4.34	3.06e-05	0.0226	-0.43	-0.38	Platelet count;	chr11:64102407	chr11:64394342~64395831:-
GBM	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	4.34	3.06e-05	0.0226	0.57	0.38	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
GBM	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	4.34	3.07e-05	0.0227	0.63	0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
GBM	cis	rs10231759	0.617	rs7809861	ENSG00000273419.1	RP4-751H13.7	-4.34	3.07e-05	0.0227	-0.42	-0.38	Height;	chr7:150815973	chr7:149858400~149862492:-
GBM	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-4.34	3.08e-05	0.0227	-0.35	-0.38	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
GBM	cis	rs4072705	0.615	rs7869829	ENSG00000224020.1	MIR181A2HG	4.34	3.08e-05	0.0227	0.42	0.38	Menarche (age at onset);	chr9:124484898	chr9:124658467~124698631:+
GBM	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-4.34	3.08e-05	0.0227	-0.5	-0.38	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
GBM	cis	rs875971	0.862	rs2909688	ENSG00000236529.1	RP13-254B10.1	4.34	3.08e-05	0.0228	0.4	0.38	Aortic root size;	chr7:66376625	chr7:65840212~65840596:+
GBM	cis	rs853679	1	rs1936365	ENSG00000219392.1	RP1-265C24.5	4.34	3.09e-05	0.0228	0.64	0.38	Depression;	chr6:28300675	chr6:28115628~28116551:+
GBM	cis	rs853679	1	rs853694	ENSG00000219392.1	RP1-265C24.5	-4.34	3.09e-05	0.0228	-0.64	-0.38	Depression;	chr6:28311323	chr6:28115628~28116551:+
GBM	cis	rs853679	1	rs853685	ENSG00000219392.1	RP1-265C24.5	-4.34	3.09e-05	0.0228	-0.64	-0.38	Depression;	chr6:28321008	chr6:28115628~28116551:+
GBM	cis	rs853679	1	rs853679	ENSG00000219392.1	RP1-265C24.5	-4.34	3.09e-05	0.0228	-0.64	-0.38	Depression;	chr6:28329086	chr6:28115628~28116551:+
GBM	cis	rs853679	1	rs853678	ENSG00000219392.1	RP1-265C24.5	-4.34	3.09e-05	0.0228	-0.64	-0.38	Depression;	chr6:28329536	chr6:28115628~28116551:+
GBM	cis	rs8062405	0.723	rs35175818	ENSG00000271623.1	RP11-435I10.5	-4.34	3.09e-05	0.0228	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28364700~28365333:+
GBM	cis	rs62184315	0.536	rs5742985	ENSG00000273240.1	RP11-455J20.3	-4.34	3.09e-05	0.0228	-0.57	-0.38	Alcohol dependence (age at onset);	chr2:189796383	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs56324258	ENSG00000273240.1	RP11-455J20.3	-4.34	3.09e-05	0.0228	-0.57	-0.38	Alcohol dependence (age at onset);	chr2:189811589	chr2:189763859~189764456:-
GBM	cis	rs2018683	1	rs4719962	ENSG00000228421.2	AC005013.5	4.34	3.09e-05	0.0228	0.44	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28957667~28959345:+
GBM	cis	rs7315956	0.963	rs7960641	ENSG00000257139.1	RP11-320P7.2	-4.34	3.09e-05	0.0228	-0.43	-0.38	Testicular germ cell tumor;	chr12:70216357	chr12:70180338~70202004:+
GBM	cis	rs7267979	0.668	rs4815398	ENSG00000125804.12	FAM182A	4.34	3.1e-05	0.0229	0.48	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26054655~26086917:+
GBM	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-4.34	3.1e-05	0.0229	-0.5	-0.37	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
GBM	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-4.34	3.1e-05	0.0229	-0.43	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
GBM	cis	rs7829975	0.714	rs7823757	ENSG00000254340.1	RP11-10A14.3	4.34	3.11e-05	0.0229	0.46	0.37	Mood instability;	chr8:8812667	chr8:9141424~9145435:+
GBM	cis	rs812925	0.502	rs2084318	ENSG00000271889.1	RP11-493E12.1	-4.34	3.11e-05	0.0229	-0.39	-0.37	Immature fraction of reticulocytes;	chr2:61425466	chr2:61151433~61162105:-
GBM	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	4.34	3.11e-05	0.0229	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	4.34	3.11e-05	0.0229	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	4.34	3.11e-05	0.0229	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	4.34	3.11e-05	0.0229	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
GBM	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	4.34	3.11e-05	0.0229	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
GBM	cis	rs7824557	0.628	rs2572387	ENSG00000255020.1	AF131216.5	4.34	3.11e-05	0.0229	0.4	0.37	Retinal vascular caliber;	chr8:11346656	chr8:11345748~11347502:-
GBM	cis	rs875971	0.545	rs10950029	ENSG00000222364.1	RNU6-96P	-4.34	3.12e-05	0.023	-0.39	-0.37	Aortic root size;	chr7:66169334	chr7:66395191~66395286:+
GBM	cis	rs731565	1	rs74589653	ENSG00000232391.1	RANP2	4.34	3.12e-05	0.023	0.7	0.37	Diabetic kidney disease;	chr7:147720185	chr7:147167344~147167572:+
GBM	cis	rs73198271	0.583	rs11781985	ENSG00000253893.2	FAM85B	-4.34	3.12e-05	0.023	-0.57	-0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8167819~8226614:-
GBM	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	4.34	3.12e-05	0.023	0.77	0.37	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
GBM	cis	rs453301	0.624	rs330056	ENSG00000254340.1	RP11-10A14.3	-4.34	3.12e-05	0.023	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9232185	chr8:9141424~9145435:+
GBM	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
GBM	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
GBM	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	4.34	3.12e-05	0.023	0.62	0.37	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
GBM	cis	rs875971	0.545	rs1796222	ENSG00000236529.1	RP13-254B10.1	-4.34	3.13e-05	0.023	-0.42	-0.37	Aortic root size;	chr7:66592167	chr7:65840212~65840596:+
GBM	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	4.34	3.13e-05	0.023	0.32	0.37	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
GBM	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-4.34	3.13e-05	0.023	-0.44	-0.37	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
GBM	cis	rs453301	0.624	rs330058	ENSG00000254340.1	RP11-10A14.3	-4.34	3.13e-05	0.0231	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9232299	chr8:9141424~9145435:+
GBM	cis	rs7017914	0.652	rs2639911	ENSG00000246366.5	RP11-382J12.1	-4.34	3.14e-05	0.0231	-0.39	-0.37	Bone mineral density;	chr8:70948477	chr8:70608577~70663279:+
GBM	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-4.34	3.14e-05	0.0231	-0.43	-0.37	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
GBM	cis	rs7716219	0.731	rs7704138	ENSG00000227908.3	FLJ31104	4.33	3.14e-05	0.0231	0.29	0.37	Height;	chr5:55648434	chr5:55995167~56003649:+
GBM	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	4.33	3.14e-05	0.0231	0.45	0.37	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
GBM	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-4.33	3.14e-05	0.0231	-0.42	-0.37	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
GBM	cis	rs4072705	0.615	rs7043551	ENSG00000224020.1	MIR181A2HG	-4.33	3.15e-05	0.0232	-0.44	-0.37	Menarche (age at onset);	chr9:124486145	chr9:124658467~124698631:+
GBM	cis	rs7176527	1	rs7176527	ENSG00000259774.1	RP11-182J1.13	4.33	3.15e-05	0.0232	0.59	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84422618~84425882:+
GBM	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-4.33	3.15e-05	0.0232	-0.42	-0.37	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
GBM	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-4.33	3.15e-05	0.0232	-0.42	-0.37	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
GBM	cis	rs7017914	0.905	rs1908034	ENSG00000246366.5	RP11-382J12.1	-4.33	3.15e-05	0.0232	-0.4	-0.37	Bone mineral density;	chr8:71010319	chr8:70608577~70663279:+
GBM	cis	rs4713118	0.505	rs156740	ENSG00000218016.2	ZNF192P2	-4.33	3.15e-05	0.0232	-0.44	-0.37	Parkinson's disease;	chr6:27992657	chr6:28188050~28189432:+
GBM	cis	rs453301	0.571	rs330057	ENSG00000254340.1	RP11-10A14.3	-4.33	3.16e-05	0.0232	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9232283	chr8:9141424~9145435:+
GBM	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-4.33	3.16e-05	0.0232	-0.51	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
GBM	cis	rs7829975	0.774	rs35431455	ENSG00000254340.1	RP11-10A14.3	4.33	3.16e-05	0.0232	0.47	0.37	Mood instability;	chr8:8816226	chr8:9141424~9145435:+
GBM	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	4.33	3.16e-05	0.0233	0.52	0.37	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
GBM	cis	rs3806843	1	rs4404730	ENSG00000202111.1	VTRNA1-2	-4.33	3.17e-05	0.0233	-0.39	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr5:140718925~140719013:+
GBM	cis	rs66887589	0.616	rs11098497	ENSG00000250412.1	KLHL2P1	4.33	3.17e-05	0.0233	0.46	0.37	Diastolic blood pressure;	chr4:119265913	chr4:119334329~119378233:+
GBM	cis	rs66887589	0.616	rs7659403	ENSG00000250412.1	KLHL2P1	4.33	3.17e-05	0.0233	0.46	0.37	Diastolic blood pressure;	chr4:119286099	chr4:119334329~119378233:+
GBM	cis	rs7829975	0.508	rs1594437	ENSG00000254340.1	RP11-10A14.3	4.33	3.17e-05	0.0233	0.48	0.37	Mood instability;	chr8:8968365	chr8:9141424~9145435:+
GBM	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	4.33	3.17e-05	0.0233	0.53	0.37	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
GBM	cis	rs875971	0.83	rs778711	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66386670	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs1083554	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66387354	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778707	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66392040	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778705	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66396128	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778697	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66405439	chr7:65840212~65840596:+
GBM	cis	rs875971	0.798	rs7789615	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66413674	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6978028	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66421313	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6947339	ENSG00000236529.1	RP13-254B10.1	4.33	3.17e-05	0.0233	0.4	0.37	Aortic root size;	chr7:66423483	chr7:65840212~65840596:+
GBM	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-4.33	3.17e-05	0.0233	-0.43	-0.37	Height;	chr2:231516587	chr2:231501990~231502201:-
GBM	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-4.33	3.17e-05	0.0233	-0.44	-0.37	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
GBM	cis	rs7017914	0.935	rs56289931	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70925519	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs12679261	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70932414	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs17689955	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70936629	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs10089583	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70937249	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs1493198	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70939722	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs1389202	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70940050	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.934	rs13255152	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70947384	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs13255735	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70947504	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs2732087	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70948204	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.967	rs2639919	ENSG00000246366.5	RP11-382J12.1	-4.33	3.17e-05	0.0233	-0.4	-0.37	Bone mineral density;	chr8:70962893	chr8:70608577~70663279:+
GBM	cis	rs7267979	0.744	rs6050464	ENSG00000276952.1	RP5-965G21.6	4.33	3.17e-05	0.0233	0.36	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25284915~25285588:-
GBM	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	4.33	3.18e-05	0.0233	0.6	0.37	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
GBM	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	4.33	3.18e-05	0.0233	0.6	0.37	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
GBM	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	4.33	3.18e-05	0.0233	0.6	0.37	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	4.33	3.18e-05	0.0233	0.6	0.37	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
GBM	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	4.33	3.18e-05	0.0233	0.6	0.37	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
GBM	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	4.33	3.18e-05	0.0233	0.45	0.37	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
GBM	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	4.33	3.18e-05	0.0234	0.43	0.37	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
GBM	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	4.33	3.18e-05	0.0234	0.41	0.37	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
GBM	cis	rs893363	0.522	rs2241807	ENSG00000271916.1	RP11-884K10.6	-4.33	3.19e-05	0.0234	-0.43	-0.37	Axial length;	chr3:53823131	chr3:53797764~53798019:-
GBM	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-4.33	3.19e-05	0.0234	-0.42	-0.37	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
GBM	cis	rs7267979	0.816	rs3746337	ENSG00000276952.1	RP5-965G21.6	4.33	3.19e-05	0.0234	0.36	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25284915~25285588:-
GBM	cis	rs10752881	0.935	rs3935221	ENSG00000224468.3	RP11-181K3.4	-4.33	3.19e-05	0.0234	-0.31	-0.37	Colorectal cancer;	chr1:182999875	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs10797800	ENSG00000224468.3	RP11-181K3.4	-4.33	3.19e-05	0.0234	-0.31	-0.37	Colorectal cancer;	chr1:183000693	chr1:183138402~183141282:-
GBM	cis	rs10752881	1	rs4304541	ENSG00000224468.3	RP11-181K3.4	-4.33	3.19e-05	0.0234	-0.31	-0.37	Colorectal cancer;	chr1:183001103	chr1:183138402~183141282:-
GBM	cis	rs3741404	0.574	rs638227	ENSG00000231680.1	AP003774.6	-4.33	3.2e-05	0.0235	-0.43	-0.37	Platelet count;	chr11:64104077	chr11:64394342~64395831:-
GBM	cis	rs3741404	0.609	rs592271	ENSG00000231680.1	AP003774.6	-4.33	3.2e-05	0.0235	-0.43	-0.37	Platelet count;	chr11:64104557	chr11:64394342~64395831:-
GBM	cis	rs3741404	0.609	rs635139	ENSG00000231680.1	AP003774.6	-4.33	3.2e-05	0.0235	-0.43	-0.37	Platelet count;	chr11:64104738	chr11:64394342~64395831:-
GBM	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	4.33	3.2e-05	0.0235	0.44	0.37	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
GBM	cis	rs66887589	0.616	rs10032299	ENSG00000250412.1	KLHL2P1	4.33	3.2e-05	0.0235	0.46	0.37	Diastolic blood pressure;	chr4:119285264	chr4:119334329~119378233:+
GBM	cis	rs4713118	0.955	rs9380010	ENSG00000218016.2	ZNF192P2	-4.33	3.2e-05	0.0235	-0.49	-0.37	Parkinson's disease;	chr6:27715793	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9368528	ENSG00000218016.2	ZNF192P2	-4.33	3.2e-05	0.0235	-0.49	-0.37	Parkinson's disease;	chr6:27716019	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9380011	ENSG00000218016.2	ZNF192P2	-4.33	3.2e-05	0.0235	-0.49	-0.37	Parkinson's disease;	chr6:27716145	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9368529	ENSG00000218016.2	ZNF192P2	-4.33	3.2e-05	0.0235	-0.49	-0.37	Parkinson's disease;	chr6:27716852	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9380012	ENSG00000218016.2	ZNF192P2	-4.33	3.2e-05	0.0235	-0.49	-0.37	Parkinson's disease;	chr6:27716875	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9468201	ENSG00000218016.2	ZNF192P2	-4.33	3.2e-05	0.0235	-0.49	-0.37	Parkinson's disease;	chr6:27719256	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.955	rs9393848	ENSG00000218016.2	ZNF192P2	-4.33	3.2e-05	0.0235	-0.49	-0.37	Parkinson's disease;	chr6:27720590	chr6:28188050~28189432:+
GBM	cis	rs2086824	0.702	rs3114896	ENSG00000260259.1	RP11-368I7.4	-4.33	3.21e-05	0.0235	-0.41	-0.37	Multiple myeloma (IgH translocation);	chr16:89327154	chr16:89682620~89686569:-
GBM	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-4.33	3.21e-05	0.0235	-0.38	-0.37	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
GBM	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-4.33	3.21e-05	0.0235	-0.38	-0.37	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
GBM	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	4.33	3.21e-05	0.0235	0.49	0.37	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
GBM	cis	rs796364	0.589	rs6743217	ENSG00000232732.8	AC073043.1	4.33	3.21e-05	0.0235	0.54	0.37	Schizophrenia;	chr2:200270191	chr2:199867396~199911159:-
GBM	cis	rs796364	0.589	rs55700082	ENSG00000232732.8	AC073043.1	4.33	3.21e-05	0.0235	0.54	0.37	Schizophrenia;	chr2:200270946	chr2:199867396~199911159:-
GBM	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	4.33	3.21e-05	0.0235	0.36	0.37	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
GBM	cis	rs10507419	0.901	rs9541336	ENSG00000276672.1	RP11-142E9.1	-4.33	3.21e-05	0.0235	-0.44	-0.37	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34602911	chr13:33846190~33850825:+
GBM	cis	rs8062405	0.755	rs4788076	ENSG00000271623.1	RP11-435I10.5	-4.33	3.21e-05	0.0235	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs7193402	ENSG00000271623.1	RP11-435I10.5	-4.33	3.21e-05	0.0235	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs62034358	ENSG00000271623.1	RP11-435I10.5	-4.33	3.21e-05	0.0235	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs12445823	ENSG00000271623.1	RP11-435I10.5	-4.33	3.21e-05	0.0235	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.723	rs12445744	ENSG00000271623.1	RP11-435I10.5	-4.33	3.21e-05	0.0235	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs4787455	ENSG00000271623.1	RP11-435I10.5	-4.33	3.21e-05	0.0235	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs4788074	ENSG00000271623.1	RP11-435I10.5	4.33	3.21e-05	0.0235	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28364700~28365333:+
GBM	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	4.33	3.21e-05	0.0235	0.51	0.37	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
GBM	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	4.33	3.21e-05	0.0235	0.51	0.37	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
GBM	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	4.33	3.21e-05	0.0235	0.51	0.37	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
GBM	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	4.33	3.21e-05	0.0235	0.51	0.37	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
GBM	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	4.33	3.21e-05	0.0235	0.51	0.37	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
GBM	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	4.33	3.21e-05	0.0235	0.51	0.37	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
GBM	cis	rs6600671	0.691	rs6600662	ENSG00000223345.3	HIST2H2BA	4.33	3.22e-05	0.0235	0.48	0.37	Hip geometry;	chr1:121488992	chr1:121108210~121117257:-
GBM	cis	rs10507419	1	rs17753659	ENSG00000276672.1	RP11-142E9.1	-4.33	3.22e-05	0.0236	-0.41	-0.37	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34613479	chr13:33846190~33850825:+
GBM	cis	rs12449000	1	rs12449000	ENSG00000260259.1	RP11-368I7.4	-4.33	3.22e-05	0.0236	-0.41	-0.37	Schizophrenia;	chr16:89806562	chr16:89682620~89686569:-
GBM	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	4.33	3.22e-05	0.0236	1.03	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
GBM	cis	rs7615952	0.599	rs2270986	ENSG00000250012.1	RP11-124N2.1	-4.33	3.23e-05	0.0236	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:125982256	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.599	rs12496921	ENSG00000250012.1	RP11-124N2.1	-4.33	3.23e-05	0.0236	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:125983105	chr3:126084220~126095349:+
GBM	cis	rs9926296	0.585	rs8058009	ENSG00000260259.1	RP11-368I7.4	-4.33	3.23e-05	0.0236	-0.46	-0.37	Vitiligo;	chr16:89790031	chr16:89682620~89686569:-
GBM	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-4.33	3.23e-05	0.0236	-0.48	-0.37	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
GBM	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	4.33	3.23e-05	0.0236	0.49	0.37	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
GBM	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	4.33	3.23e-05	0.0236	0.44	0.37	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
GBM	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	4.33	3.23e-05	0.0236	0.44	0.37	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.597	rs17700521	ENSG00000258983.2	RP11-507K2.2	4.33	3.24e-05	0.0237	0.43	0.37	Coronary artery calcification;	chr14:88849531	chr14:88499334~88515502:+
GBM	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-4.33	3.25e-05	0.0237	-0.46	-0.37	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
GBM	cis	rs11673344	0.523	rs7248948	ENSG00000226686.6	LINC01535	4.33	3.25e-05	0.0237	0.4	0.37	Obesity-related traits;	chr19:37056317	chr19:37251912~37265535:+
GBM	cis	rs6600671	0.899	rs6674392	ENSG00000223345.3	HIST2H2BA	4.33	3.25e-05	0.0238	0.49	0.37	Hip geometry;	chr1:121518864	chr1:121108210~121117257:-
GBM	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	4.33	3.25e-05	0.0238	0.27	0.37	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
GBM	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-4.33	3.25e-05	0.0238	-0.53	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
GBM	cis	rs1555322	1	rs2425037	ENSG00000126005.14	MMP24-AS1	4.33	3.25e-05	0.0238	0.64	0.37	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35216462~35278131:-
GBM	cis	rs9481169	0.557	rs34896684	ENSG00000255389.1	C6orf3	-4.33	3.26e-05	0.0238	-0.82	-0.37	Inflammatory skin disease;	chr6:111572034	chr6:111599875~111602295:+
GBM	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-4.33	3.26e-05	0.0238	-0.82	-0.37	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
GBM	cis	rs8114671	0.967	rs4911478	ENSG00000269202.1	RP4-614O4.12	4.33	3.26e-05	0.0238	0.43	0.37	Height;	chr20:35194822	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.935	rs35193912	ENSG00000269202.1	RP4-614O4.12	4.33	3.26e-05	0.0238	0.43	0.37	Height;	chr20:35197247	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs34515766	ENSG00000269202.1	RP4-614O4.12	4.33	3.26e-05	0.0238	0.43	0.37	Height;	chr20:35197418	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6142322	ENSG00000269202.1	RP4-614O4.12	4.33	3.26e-05	0.0238	0.43	0.37	Height;	chr20:35200735	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6142324	ENSG00000269202.1	RP4-614O4.12	4.33	3.26e-05	0.0238	0.43	0.37	Height;	chr20:35201240	chr20:35201747~35203288:-
GBM	cis	rs8114671	1	rs8114671	ENSG00000269202.1	RP4-614O4.12	4.33	3.26e-05	0.0238	0.43	0.37	Height;	chr20:35201339	chr20:35201747~35203288:-
GBM	cis	rs11098499	0.866	rs10518329	ENSG00000249244.1	RP11-548H18.2	4.32	3.27e-05	0.0238	0.45	0.37	Corneal astigmatism;	chr4:119480680	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.866	rs7665125	ENSG00000249244.1	RP11-548H18.2	4.32	3.27e-05	0.0238	0.45	0.37	Corneal astigmatism;	chr4:119480924	chr4:119391831~119395335:-
GBM	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	4.32	3.27e-05	0.0238	0.55	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
GBM	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	4.32	3.27e-05	0.0238	0.54	0.37	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
GBM	cis	rs853679	1	rs6905391	ENSG00000219392.1	RP1-265C24.5	-4.32	3.27e-05	0.0238	-0.64	-0.37	Depression;	chr6:28294909	chr6:28115628~28116551:+
GBM	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	4.32	3.27e-05	0.0239	0.38	0.37	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
GBM	cis	rs7674212	0.507	rs223413	ENSG00000248971.2	KRT8P46	4.32	3.28e-05	0.0239	0.4	0.37	Type 2 diabetes;	chr4:102811709	chr4:102728746~102730171:-
GBM	cis	rs7674212	0.556	rs223401	ENSG00000248971.2	KRT8P46	-4.32	3.28e-05	0.0239	-0.4	-0.37	Type 2 diabetes;	chr4:102817815	chr4:102728746~102730171:-
GBM	cis	rs7674212	0.507	rs223361	ENSG00000248971.2	KRT8P46	-4.32	3.28e-05	0.0239	-0.4	-0.37	Type 2 diabetes;	chr4:102848147	chr4:102728746~102730171:-
GBM	cis	rs867371	1	rs8037224	ENSG00000278603.1	RP13-608F4.5	4.32	3.28e-05	0.0239	0.43	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs7166570	ENSG00000278603.1	RP13-608F4.5	4.32	3.28e-05	0.0239	0.43	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472203~82472426:+
GBM	cis	rs12908161	0.96	rs34452033	ENSG00000275120.1	RP11-182J1.17	4.32	3.28e-05	0.0239	0.48	0.37	Schizophrenia;	chr15:84678762	chr15:84599434~84606463:-
GBM	cis	rs6496932	0.913	rs34896088	ENSG00000218052.5	ADAMTS7P4	4.32	3.28e-05	0.0239	0.55	0.37	Central corneal thickness;Corneal structure;	chr15:85278393	chr15:85255369~85330334:-
GBM	cis	rs588177	0.613	rs3782101	ENSG00000236935.1	AP003774.1	-4.32	3.28e-05	0.0239	-0.47	-0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64363808	chr11:64325050~64329504:-
GBM	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	4.32	3.28e-05	0.0239	0.47	0.37	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
GBM	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-4.32	3.29e-05	0.0239	-0.62	-0.37	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
GBM	cis	rs1298062	0.79	rs2445841	ENSG00000131401.10	NAPSB	-4.32	3.29e-05	0.0239	-0.44	-0.37	Age of smoking initiation;	chr19:50463274	chr19:50333796~50344767:-
GBM	cis	rs137699	0.5	rs137646	ENSG00000230149.2	RP3-508I15.19	-4.32	3.29e-05	0.024	-0.36	-0.37	IgG glycosylation;	chr22:39332709	chr22:38734730~38738990:+
GBM	cis	rs4842666	0.915	rs2681472	ENSG00000258302.2	RP11-981P6.1	4.32	3.29e-05	0.024	0.46	0.37	Blood pressure;	chr12:89615182	chr12:89561129~89594878:+
GBM	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	4.32	3.29e-05	0.024	0.56	0.37	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
GBM	cis	rs4869313	0.905	rs1477364	ENSG00000248734.2	CTD-2260A17.1	4.32	3.29e-05	0.024	0.46	0.37	Pediatric autoimmune diseases;	chr5:96949188	chr5:96784777~96785999:+
GBM	cis	rs7017914	0.967	rs13257800	ENSG00000246366.5	RP11-382J12.1	-4.32	3.3e-05	0.024	-0.4	-0.37	Bone mineral density;	chr8:70801898	chr8:70608577~70663279:+
GBM	cis	rs10807026	1	rs10807026	ENSG00000218016.2	ZNF192P2	4.32	3.3e-05	0.024	0.5	0.37	Lung adenocarcinoma;	chr6:27587740	chr6:28188050~28189432:+
GBM	cis	rs7017914	0.934	rs7814274	ENSG00000246366.5	RP11-382J12.1	4.32	3.3e-05	0.0241	0.4	0.37	Bone mineral density;	chr8:70658176	chr8:70608577~70663279:+
GBM	cis	rs8062405	0.755	rs12447461	ENSG00000271623.1	RP11-435I10.5	-4.32	3.31e-05	0.0241	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs111693583	ENSG00000271623.1	RP11-435I10.5	-4.32	3.31e-05	0.0241	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs7186573	ENSG00000271623.1	RP11-435I10.5	-4.32	3.31e-05	0.0241	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28364700~28365333:+
GBM	cis	rs11671005	0.735	rs34152946	ENSG00000269473.1	CTD-2619J13.19	4.32	3.31e-05	0.0241	0.41	0.37	Mean platelet volume;	chr19:58411896	chr19:58440448~58445849:+
GBM	cis	rs7035589	1	rs10820753	ENSG00000230013.1	RP11-217B7.3	4.32	3.31e-05	0.0241	0.46	0.37	Pelvic organ prolapse;	chr9:104988475	chr9:104990796~104991781:-
GBM	cis	rs73198271	0.71	rs7837843	ENSG00000253893.2	FAM85B	4.32	3.31e-05	0.0241	0.51	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.64	rs7838012	ENSG00000253893.2	FAM85B	4.32	3.31e-05	0.0241	0.51	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8167819~8226614:-
GBM	cis	rs7615952	0.515	rs4441610	ENSG00000250012.1	RP11-124N2.1	-4.32	3.32e-05	0.0241	-0.43	-0.37	Blood pressure (smoking interaction);	chr3:125962464	chr3:126084220~126095349:+
GBM	cis	rs1150668	0.83	rs213240	ENSG00000218016.2	ZNF192P2	-4.32	3.32e-05	0.0241	-0.44	-0.37	Pubertal anthropometrics;	chr6:28348098	chr6:28188050~28189432:+
GBM	cis	rs453301	0.652	rs2043129	ENSG00000254340.1	RP11-10A14.3	4.32	3.32e-05	0.0241	0.48	0.37	Joint mobility (Beighton score);	chr8:8967994	chr8:9141424~9145435:+
GBM	cis	rs812925	0.555	rs12616433	ENSG00000271889.1	RP11-493E12.1	4.32	3.32e-05	0.0242	0.38	0.37	Immature fraction of reticulocytes;	chr2:61469353	chr2:61151433~61162105:-
GBM	cis	rs5742933	1	rs1898560	ENSG00000253559.1	OSGEPL1-AS1	-4.32	3.32e-05	0.0242	-0.43	-0.37	Ferritin levels;	chr2:189747601	chr2:189762704~189765556:+
GBM	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	4.32	3.33e-05	0.0242	1.03	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
GBM	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-4.32	3.33e-05	0.0242	-0.44	-0.37	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-4.32	3.33e-05	0.0242	-0.44	-0.37	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-4.32	3.33e-05	0.0242	-0.44	-0.37	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-4.32	3.33e-05	0.0242	-0.44	-0.37	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-4.32	3.33e-05	0.0242	-0.44	-0.37	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-4.32	3.33e-05	0.0242	-0.44	-0.37	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-4.32	3.33e-05	0.0242	-0.44	-0.37	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
GBM	cis	rs66887589	0.592	rs11731571	ENSG00000250412.1	KLHL2P1	4.32	3.33e-05	0.0242	0.45	0.37	Diastolic blood pressure;	chr4:119300030	chr4:119334329~119378233:+
GBM	cis	rs7017914	0.902	rs6472562	ENSG00000246366.5	RP11-382J12.1	-4.32	3.33e-05	0.0242	-0.4	-0.37	Bone mineral density;	chr8:71057643	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.902	rs6472563	ENSG00000246366.5	RP11-382J12.1	-4.32	3.33e-05	0.0242	-0.4	-0.37	Bone mineral density;	chr8:71057672	chr8:70608577~70663279:+
GBM	cis	rs6539247	0.509	rs4275717	ENSG00000257890.1	RP11-114F10.2	-4.32	3.34e-05	0.0242	-0.45	-0.37	Attention function in attention deficit hyperactive disorder;	chr12:106052074	chr12:106050961~106058254:-
GBM	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-4.32	3.34e-05	0.0243	-0.39	-0.37	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
GBM	cis	rs11098499	0.657	rs10434028	ENSG00000249244.1	RP11-548H18.2	4.32	3.34e-05	0.0243	0.47	0.37	Corneal astigmatism;	chr4:119373309	chr4:119391831~119395335:-
GBM	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	4.32	3.34e-05	0.0243	0.45	0.37	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
GBM	cis	rs4568518	0.619	rs13238312	ENSG00000279048.1	RP11-511H23.2	4.32	3.34e-05	0.0243	0.29	0.37	Measles;	chr7:17968821	chr7:17940503~17942922:+
GBM	cis	rs7017914	0.69	rs12674838	ENSG00000246366.5	RP11-382J12.1	-4.32	3.34e-05	0.0243	-0.41	-0.37	Bone mineral density;	chr8:71078045	chr8:70608577~70663279:+
GBM	cis	rs3768617	0.51	rs10911242	ENSG00000224468.3	RP11-181K3.4	-4.32	3.35e-05	0.0243	-0.32	-0.37	Fuchs's corneal dystrophy;	chr1:183103012	chr1:183138402~183141282:-
GBM	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
GBM	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
GBM	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
GBM	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
GBM	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-4.32	3.35e-05	0.0243	-0.42	-0.37	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
GBM	cis	rs858239	0.899	rs7794684	ENSG00000230042.1	AK3P3	-4.32	3.35e-05	0.0243	-0.44	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23129178~23129841:+
GBM	cis	rs66887589	0.616	rs11098498	ENSG00000250412.1	KLHL2P1	4.32	3.35e-05	0.0243	0.46	0.37	Diastolic blood pressure;	chr4:119265964	chr4:119334329~119378233:+
GBM	cis	rs10246939	0.553	rs34894166	ENSG00000261797.1	RP11-744I24.3	-4.32	3.35e-05	0.0243	-0.47	-0.37	Bitter taste perception;	chr7:141852158	chr7:141512698~141513183:-
GBM	cis	rs10246939	0.579	rs58093678	ENSG00000261797.1	RP11-744I24.3	-4.32	3.35e-05	0.0243	-0.47	-0.37	Bitter taste perception;	chr7:141856719	chr7:141512698~141513183:-
GBM	cis	rs10246939	0.579	rs17133534	ENSG00000261797.1	RP11-744I24.3	-4.32	3.35e-05	0.0243	-0.47	-0.37	Bitter taste perception;	chr7:141860855	chr7:141512698~141513183:-
GBM	cis	rs10246939	0.529	rs60165685	ENSG00000261797.1	RP11-744I24.3	-4.32	3.35e-05	0.0243	-0.47	-0.37	Bitter taste perception;	chr7:141861190	chr7:141512698~141513183:-
GBM	cis	rs17711722	0.503	rs453835	ENSG00000235421.1	RP11-667F9.1	-4.32	3.35e-05	0.0243	-0.43	-0.37	Calcium levels;	chr7:66046172	chr7:65525629~65554744:-
GBM	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-4.32	3.35e-05	0.0243	-0.48	-0.37	Height;	chr11:118809363	chr11:118704607~118750263:+
GBM	cis	rs11159086	0.941	rs12434836	ENSG00000270000.1	RP3-449M8.9	4.32	3.36e-05	0.0244	0.57	0.37	Advanced glycation end-product levels;	chr14:74468887	chr14:74471930~74472360:-
GBM	cis	rs11159086	1	rs11626856	ENSG00000270000.1	RP3-449M8.9	4.32	3.36e-05	0.0244	0.57	0.37	Advanced glycation end-product levels;	chr14:74469665	chr14:74471930~74472360:-
GBM	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-4.32	3.36e-05	0.0244	-0.48	-0.37	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-4.32	3.36e-05	0.0244	-0.48	-0.37	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-4.32	3.36e-05	0.0244	-0.48	-0.37	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
GBM	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	4.32	3.37e-05	0.0244	0.43	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
GBM	cis	rs8114671	0.935	rs6142313	ENSG00000269202.1	RP4-614O4.12	4.32	3.37e-05	0.0244	0.43	0.37	Height;	chr20:35192624	chr20:35201747~35203288:-
GBM	cis	rs860554	1	rs860554	ENSG00000238003.1	RP11-465N4.2	4.32	3.37e-05	0.0244	0.49	0.37	Panic disorder;	chr1:201293304	chr1:201978642~201978949:+
GBM	cis	rs8114671	0.967	rs4911476	ENSG00000269202.1	RP4-614O4.12	4.32	3.37e-05	0.0244	0.43	0.37	Height;	chr20:35192965	chr20:35201747~35203288:-
GBM	cis	rs1150668	0.796	rs1124132	ENSG00000199851.2	U3	4.32	3.37e-05	0.0244	0.45	0.37	Pubertal anthropometrics;	chr6:28412544	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.764	rs9368565	ENSG00000199851.2	U3	-4.32	3.37e-05	0.0244	-0.45	-0.37	Pubertal anthropometrics;	chr6:28377433	chr6:28015568~28015777:+
GBM	cis	rs1150668	0.796	rs1052215	ENSG00000199851.2	U3	-4.32	3.37e-05	0.0244	-0.45	-0.37	Pubertal anthropometrics;	chr6:28380381	chr6:28015568~28015777:+
GBM	cis	rs977747	1	rs7525145	ENSG00000232022.5	FAAHP1	-4.32	3.37e-05	0.0244	-0.38	-0.37	Body mass index;	chr1:47228142	chr1:46432129~46445521:+
GBM	cis	rs977747	1	rs7534271	ENSG00000232022.5	FAAHP1	4.32	3.37e-05	0.0244	0.38	0.37	Body mass index;	chr1:47228309	chr1:46432129~46445521:+
GBM	cis	rs2311126	0.965	rs2018709	ENSG00000264350.1	SNRPGP2	4.32	3.37e-05	0.0245	0.31	0.37	Serum uric acid levels in response to allopurinol in gout;	chr18:54869493	chr18:54406889~54407114:-
GBM	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	4.32	3.38e-05	0.0245	0.39	0.37	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
GBM	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	4.32	3.38e-05	0.0245	0.28	0.37	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
GBM	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	4.32	3.38e-05	0.0245	0.28	0.37	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
GBM	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	4.32	3.38e-05	0.0245	0.35	0.37	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
GBM	cis	rs7829975	0.714	rs11777085	ENSG00000254340.1	RP11-10A14.3	4.32	3.39e-05	0.0245	0.46	0.37	Mood instability;	chr8:8814919	chr8:9141424~9145435:+
GBM	cis	rs3768617	0.51	rs10797842	ENSG00000224468.3	RP11-181K3.4	-4.32	3.39e-05	0.0245	-0.31	-0.37	Fuchs's corneal dystrophy;	chr1:183112732	chr1:183138402~183141282:-
GBM	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-4.32	3.39e-05	0.0245	-0.43	-0.37	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
GBM	cis	rs17508449	0.819	rs78552134	ENSG00000232450.1	RP4-730K3.3	-4.32	3.39e-05	0.0246	-0.63	-0.37	Leprosy;	chr1:113727044	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs4839000	ENSG00000232450.1	RP4-730K3.3	-4.32	3.39e-05	0.0246	-0.63	-0.37	Leprosy;	chr1:113737513	chr1:113698884~113699631:-
GBM	cis	rs7674212	0.507	rs223471	ENSG00000248971.2	KRT8P46	-4.31	3.4e-05	0.0246	-0.4	-0.37	Type 2 diabetes;	chr4:102777629	chr4:102728746~102730171:-
GBM	cis	rs16937	0.711	rs12130817	ENSG00000271580.1	RP11-536L3.4	-4.31	3.4e-05	0.0246	-0.34	-0.37	Schizophrenia;	chr1:205171177	chr1:205091163~205091946:+
GBM	cis	rs4604732	0.603	rs4546958	ENSG00000227135.1	GCSAML-AS1	-4.31	3.4e-05	0.0246	-0.49	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476176	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.642	rs7515859	ENSG00000227135.1	GCSAML-AS1	-4.31	3.4e-05	0.0246	-0.49	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476755	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.642	rs7549312	ENSG00000227135.1	GCSAML-AS1	-4.31	3.4e-05	0.0246	-0.49	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476776	chr1:247524679~247526752:-
GBM	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-4.31	3.4e-05	0.0246	-0.46	-0.37	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
GBM	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	4.31	3.4e-05	0.0246	0.4	0.37	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
GBM	cis	rs4713118	0.824	rs742046	ENSG00000199851.2	U3	4.31	3.41e-05	0.0247	0.51	0.37	Parkinson's disease;	chr6:27771475	chr6:28015568~28015777:+
GBM	cis	rs11642862	1	rs112691371	ENSG00000260911.2	RP11-196G11.2	4.31	3.41e-05	0.0247	0.55	0.37	Tonsillectomy;	chr16:30856895	chr16:31043150~31049868:+
GBM	cis	rs11642862	1	rs11641321	ENSG00000260911.2	RP11-196G11.2	4.31	3.41e-05	0.0247	0.55	0.37	Tonsillectomy;	chr16:30868998	chr16:31043150~31049868:+
GBM	cis	rs11642862	1	rs11642603	ENSG00000260911.2	RP11-196G11.2	4.31	3.41e-05	0.0247	0.55	0.37	Tonsillectomy;	chr16:30874900	chr16:31043150~31049868:+
GBM	cis	rs7017914	0.905	rs3110246	ENSG00000246366.5	RP11-382J12.1	-4.31	3.41e-05	0.0247	-0.4	-0.37	Bone mineral density;	chr8:71022378	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110250	ENSG00000246366.5	RP11-382J12.1	-4.31	3.41e-05	0.0247	-0.4	-0.37	Bone mineral density;	chr8:71024149	chr8:70608577~70663279:+
GBM	cis	rs875971	0.825	rs6951503	ENSG00000236529.1	RP13-254B10.1	-4.31	3.41e-05	0.0247	-0.39	-0.37	Aortic root size;	chr7:66253949	chr7:65840212~65840596:+
GBM	cis	rs875971	0.928	rs2036263	ENSG00000236529.1	RP13-254B10.1	-4.31	3.41e-05	0.0247	-0.39	-0.37	Aortic root size;	chr7:66335210	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10240949	ENSG00000236529.1	RP13-254B10.1	-4.31	3.41e-05	0.0247	-0.39	-0.37	Aortic root size;	chr7:66339430	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs7782704	ENSG00000236529.1	RP13-254B10.1	-4.31	3.41e-05	0.0247	-0.39	-0.37	Aortic root size;	chr7:66340379	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6959268	ENSG00000236529.1	RP13-254B10.1	-4.31	3.41e-05	0.0247	-0.39	-0.37	Aortic root size;	chr7:66347979	chr7:65840212~65840596:+
GBM	cis	rs7017914	0.905	rs2732115	ENSG00000246366.5	RP11-382J12.1	-4.31	3.42e-05	0.0247	-0.4	-0.37	Bone mineral density;	chr8:71016619	chr8:70608577~70663279:+
GBM	cis	rs8062405	0.755	rs62031607	ENSG00000271623.1	RP11-435I10.5	-4.31	3.42e-05	0.0247	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28364700~28365333:+
GBM	cis	rs2311126	0.965	rs2018668	ENSG00000264350.1	SNRPGP2	-4.31	3.42e-05	0.0247	-0.31	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr18:54870093	chr18:54406889~54407114:-
GBM	cis	rs2311126	0.965	rs56184107	ENSG00000264350.1	SNRPGP2	-4.31	3.42e-05	0.0247	-0.31	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr18:54870399	chr18:54406889~54407114:-
GBM	cis	rs6496932	0.913	rs7403354	ENSG00000218052.5	ADAMTS7P4	4.31	3.42e-05	0.0247	0.55	0.37	Central corneal thickness;Corneal structure;	chr15:85277624	chr15:85255369~85330334:-
GBM	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	4.31	3.42e-05	0.0248	0.4	0.37	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	4.31	3.42e-05	0.0248	0.4	0.37	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
GBM	cis	rs10969557	0.6	rs7028627	ENSG00000231808.2	LINC01388	4.31	3.43e-05	0.0248	0.47	0.37	Lung cancer;	chr9:315394	chr9:112713~113754:-
GBM	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-4.31	3.43e-05	0.0248	-0.39	-0.37	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
GBM	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	4.31	3.43e-05	0.0248	0.53	0.37	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
GBM	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-4.31	3.43e-05	0.0248	-0.44	-0.37	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
GBM	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-4.31	3.43e-05	0.0248	-0.44	-0.37	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
GBM	cis	rs5742933	0.696	rs17271246	ENSG00000253559.1	OSGEPL1-AS1	-4.31	3.43e-05	0.0248	-0.55	-0.37	Ferritin levels;	chr2:189781481	chr2:189762704~189765556:+
GBM	cis	rs984222	0.617	rs12123458	ENSG00000231365.4	RP11-418J17.1	4.31	3.43e-05	0.0248	0.38	0.37	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119211635	chr1:119140396~119275973:+
GBM	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	4.31	3.44e-05	0.0248	0.36	0.37	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	4.31	3.44e-05	0.0248	0.36	0.37	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	4.31	3.44e-05	0.0248	0.36	0.37	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	4.31	3.44e-05	0.0248	0.36	0.37	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	4.31	3.44e-05	0.0248	0.36	0.37	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	4.31	3.44e-05	0.0248	0.36	0.37	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
GBM	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	4.31	3.44e-05	0.0248	0.47	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
GBM	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	4.31	3.44e-05	0.0248	0.43	0.37	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
GBM	cis	rs4604732	0.631	rs12031694	ENSG00000227135.1	GCSAML-AS1	-4.31	3.44e-05	0.0248	-0.59	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460351	chr1:247524679~247526752:-
GBM	cis	rs6435862	0.636	rs717548	ENSG00000227769.6	AC072062.3	4.31	3.45e-05	0.0249	0.48	0.37	Neuroblastoma (high-risk);	chr2:214812181	chr2:215004782~215085488:+
GBM	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	4.31	3.46e-05	0.025	0.5	0.37	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
GBM	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-4.31	3.46e-05	0.025	-0.43	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
GBM	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	4.31	3.46e-05	0.025	0.47	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
GBM	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	4.31	3.46e-05	0.025	0.32	0.37	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
GBM	cis	rs763121	0.853	rs2413545	ENSG00000273076.1	RP3-508I15.22	4.31	3.46e-05	0.025	0.43	0.37	Menopause (age at onset);	chr22:38696519	chr22:38743495~38743910:+
GBM	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	4.31	3.47e-05	0.025	0.43	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
GBM	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-4.31	3.47e-05	0.025	-0.36	-0.37	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
GBM	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-4.31	3.48e-05	0.0251	-0.49	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
GBM	cis	rs143626010	1	rs143626010	ENSG00000271623.1	RP11-435I10.5	-4.31	3.48e-05	0.0251	-0.46	-0.37	Mosquito bite size;	chr16:28528081	chr16:28364700~28365333:+
GBM	cis	rs1009077	0.68	rs28540362	ENSG00000248280.1	RP11-33B1.2	4.31	3.48e-05	0.0251	0.53	0.37	Endometriosis;	chr4:119570722	chr4:119440561~119450157:-
GBM	cis	rs11168351	0.927	rs7971880	ENSG00000258273.1	RP11-370I10.4	-4.31	3.48e-05	0.0251	-0.49	-0.37	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48333755~48333901:-
GBM	cis	rs7017914	0.628	rs55740254	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70928325	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2017035	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70929571	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs10504487	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70931364	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs34366597	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70932658	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs7839977	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70933067	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1493199	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70934269	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs7814774	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70934881	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs62506898	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70935267	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.616	rs17689943	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70936145	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs17689989	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70936769	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs17768191	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70939642	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.629	rs17690181	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70942231	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs13273873	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70942984	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs13280740	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70946286	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639910	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70949649	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs3098858	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70951038	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs3098859	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70952797	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.545	rs3110268	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70953933	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.617	rs2732144	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70954384	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.617	rs2639949	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70954781	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.617	rs2639950	ENSG00000246366.5	RP11-382J12.1	-4.31	3.49e-05	0.0251	-0.39	-0.37	Bone mineral density;	chr8:70954823	chr8:70608577~70663279:+
GBM	cis	rs11671005	0.693	rs11084542	ENSG00000269473.1	CTD-2619J13.19	4.31	3.49e-05	0.0251	0.41	0.37	Mean platelet volume;	chr19:58420732	chr19:58440448~58445849:+
GBM	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	4.31	3.49e-05	0.0251	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
GBM	cis	rs10901212	0.911	rs932886	ENSG00000119440.8	LCN1P1	4.31	3.49e-05	0.0252	0.67	0.37	Obesity-related traits;	chr9:132776493	chr9:133224905~133228591:-
GBM	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
GBM	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-4.31	3.5e-05	0.0252	-0.43	-0.37	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	4.31	3.5e-05	0.0252	0.43	0.37	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	4.31	3.5e-05	0.0252	0.43	0.37	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	4.31	3.5e-05	0.0252	0.43	0.37	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	4.31	3.5e-05	0.0252	0.43	0.37	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	4.31	3.5e-05	0.0252	0.43	0.37	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	4.31	3.5e-05	0.0252	0.43	0.37	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
GBM	cis	rs8114671	0.836	rs6141526	ENSG00000269202.1	RP4-614O4.12	4.31	3.5e-05	0.0252	0.46	0.37	Height;	chr20:35027452	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.869	rs2145559	ENSG00000269202.1	RP4-614O4.12	4.31	3.5e-05	0.0252	0.46	0.37	Height;	chr20:35063922	chr20:35201747~35203288:-
GBM	cis	rs393155	0.517	rs330050	ENSG00000254340.1	RP11-10A14.3	-4.31	3.5e-05	0.0252	-0.45	-0.37	Neuroticism;	chr8:9230169	chr8:9141424~9145435:+
GBM	cis	rs453301	0.571	rs330054	ENSG00000254340.1	RP11-10A14.3	-4.31	3.5e-05	0.0252	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9230781	chr8:9141424~9145435:+
GBM	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	4.31	3.51e-05	0.0252	0.36	0.37	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
GBM	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	4.31	3.51e-05	0.0252	0.36	0.37	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
GBM	cis	rs10246939	0.505	rs10952508	ENSG00000261797.1	RP11-744I24.3	-4.31	3.51e-05	0.0252	-0.49	-0.37	Bitter taste perception;	chr7:141879415	chr7:141512698~141513183:-
GBM	cis	rs6598955	0.671	rs59143843	ENSG00000236782.4	RP11-96L14.7	4.31	3.51e-05	0.0252	0.53	0.37	Obesity-related traits;	chr1:26315104	chr1:26169947~26171821:-
GBM	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-4.31	3.51e-05	0.0252	-0.4	-0.37	Height;	chr11:118856460	chr11:118791254~118793137:+
GBM	cis	rs3732481	0.867	rs6791036	ENSG00000242767.1	ZBTB20-AS4	4.31	3.51e-05	0.0252	0.63	0.37	Mitochondrial DNA levels;	chr3:114776159	chr3:115100423~115103061:+
GBM	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-4.31	3.52e-05	0.0253	-0.44	-0.37	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
GBM	cis	rs6539247	0.509	rs2374584	ENSG00000257890.1	RP11-114F10.2	-4.31	3.52e-05	0.0253	-0.45	-0.37	Attention function in attention deficit hyperactive disorder;	chr12:106052210	chr12:106050961~106058254:-
GBM	cis	rs9876781	1	rs7635522	ENSG00000244380.1	RP11-24C3.2	4.31	3.52e-05	0.0253	0.43	0.37	Longevity;	chr3:48382166	chr3:48440352~48446656:-
GBM	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	4.31	3.52e-05	0.0253	0.44	0.37	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
GBM	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-4.31	3.52e-05	0.0253	-0.35	-0.37	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
GBM	cis	rs875971	0.862	rs12537823	ENSG00000236529.1	RP13-254B10.1	4.31	3.53e-05	0.0253	0.39	0.37	Aortic root size;	chr7:66255897	chr7:65840212~65840596:+
GBM	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-4.31	3.53e-05	0.0253	-0.56	-0.37	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
GBM	cis	rs893363	0.623	rs877483	ENSG00000271916.1	RP11-884K10.6	4.3	3.54e-05	0.0254	0.44	0.37	Axial length;	chr3:53812714	chr3:53797764~53798019:-
GBM	cis	rs9876781	1	rs7636782	ENSG00000244380.1	RP11-24C3.2	4.3	3.54e-05	0.0254	0.43	0.37	Longevity;	chr3:48379897	chr3:48440352~48446656:-
GBM	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	4.3	3.54e-05	0.0254	0.62	0.37	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
GBM	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	4.3	3.54e-05	0.0254	0.44	0.37	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	4.3	3.54e-05	0.0254	0.44	0.37	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
GBM	cis	rs4478147	0.506	rs17451111	ENSG00000261496.1	RP13-514E23.1	-4.3	3.54e-05	0.0254	-0.46	-0.37	Migraine - clinic-based;	chr4:86353021	chr4:86012296~86013874:-
GBM	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	4.3	3.55e-05	0.0254	0.38	0.37	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
GBM	cis	rs7985	1	rs5761672	ENSG00000206028.1	CTA-373H7.7	4.3	3.55e-05	0.0255	0.37	0.37	Electroencephalogram traits;	chr22:26673476	chr22:26667693~26672654:-
GBM	cis	rs17772222	0.917	rs57889459	ENSG00000222990.1	RNU4-22P	4.3	3.55e-05	0.0255	0.45	0.37	Coronary artery calcification;	chr14:88770820	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs58550317	ENSG00000222990.1	RNU4-22P	4.3	3.55e-05	0.0255	0.45	0.37	Coronary artery calcification;	chr14:88775243	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs61982733	ENSG00000222990.1	RNU4-22P	4.3	3.55e-05	0.0255	0.45	0.37	Coronary artery calcification;	chr14:88776244	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs2145120	ENSG00000222990.1	RNU4-22P	4.3	3.55e-05	0.0255	0.45	0.37	Coronary artery calcification;	chr14:88777699	chr14:88513498~88513663:+
GBM	cis	rs1150668	0.764	rs9368565	ENSG00000218016.2	ZNF192P2	4.3	3.55e-05	0.0255	0.43	0.37	Pubertal anthropometrics;	chr6:28377433	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.796	rs1052215	ENSG00000218016.2	ZNF192P2	4.3	3.55e-05	0.0255	0.43	0.37	Pubertal anthropometrics;	chr6:28380381	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.796	rs1124132	ENSG00000218016.2	ZNF192P2	-4.3	3.55e-05	0.0255	-0.43	-0.37	Pubertal anthropometrics;	chr6:28412544	chr6:28188050~28189432:+
GBM	cis	rs3806843	1	rs10037757	ENSG00000202111.1	VTRNA1-2	-4.3	3.55e-05	0.0255	-0.39	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140817637	chr5:140718925~140719013:+
GBM	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-4.3	3.55e-05	0.0255	-0.44	-0.37	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
GBM	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	4.3	3.55e-05	0.0255	0.42	0.37	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	4.3	3.55e-05	0.0255	0.42	0.37	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
GBM	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	4.3	3.55e-05	0.0255	0.54	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
GBM	cis	rs172166	0.769	rs149965	ENSG00000218016.2	ZNF192P2	-4.3	3.55e-05	0.0255	-0.53	-0.37	Cardiac Troponin-T levels;	chr6:28050911	chr6:28188050~28189432:+
GBM	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	4.3	3.55e-05	0.0255	0.44	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
GBM	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	4.3	3.56e-05	0.0255	0.46	0.37	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
GBM	cis	rs453301	0.686	rs13252797	ENSG00000254340.1	RP11-10A14.3	4.3	3.56e-05	0.0255	0.47	0.37	Joint mobility (Beighton score);	chr8:9003920	chr8:9141424~9145435:+
GBM	cis	rs338389	0.542	rs7494835	ENSG00000260657.2	RP11-315D16.4	-4.3	3.56e-05	0.0255	-0.54	-0.37	Survival in rectal cancer;	chr15:68001993	chr15:68267792~68277994:-
GBM	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	4.3	3.56e-05	0.0255	0.47	0.37	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
GBM	cis	rs7017914	0.714	rs13268251	ENSG00000246366.5	RP11-382J12.1	4.3	3.56e-05	0.0255	0.39	0.37	Bone mineral density;	chr8:71066579	chr8:70608577~70663279:+
GBM	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-4.3	3.57e-05	0.0256	-0.44	-0.37	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
GBM	cis	rs950169	0.881	rs72750843	ENSG00000275120.1	RP11-182J1.17	4.3	3.57e-05	0.0256	0.47	0.37	Schizophrenia;	chr15:84592552	chr15:84599434~84606463:-
GBM	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-4.3	3.57e-05	0.0256	-0.64	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
GBM	cis	rs11098499	0.874	rs13123591	ENSG00000250412.1	KLHL2P1	4.3	3.57e-05	0.0256	0.5	0.37	Corneal astigmatism;	chr4:119184835	chr4:119334329~119378233:+
GBM	cis	rs853679	1	rs735765	ENSG00000199851.2	U3	4.3	3.57e-05	0.0256	0.71	0.37	Depression;	chr6:28202519	chr6:28015568~28015777:+
GBM	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-4.3	3.57e-05	0.0256	-0.5	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
GBM	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-4.3	3.57e-05	0.0256	-0.5	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
GBM	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-4.3	3.57e-05	0.0256	-0.51	-0.37	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
GBM	cis	rs8062405	0.755	rs62034325	ENSG00000271623.1	RP11-435I10.5	-4.3	3.58e-05	0.0256	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28364700~28365333:+
GBM	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	4.3	3.58e-05	0.0256	0.56	0.37	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
GBM	cis	rs62103177	0.564	rs1864529	ENSG00000261126.6	RP11-795F19.1	-4.3	3.58e-05	0.0257	-0.34	-0.37	Opioid sensitivity;	chr18:79988975	chr18:80046900~80095482:+
GBM	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	4.3	3.59e-05	0.0257	0.45	0.37	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
GBM	cis	rs6499766	1	rs9940227	ENSG00000260135.5	RP11-212I21.2	-4.3	3.59e-05	0.0257	-0.46	-0.37	Thyroid hormone levels;	chr16:55580882	chr16:55426797~55462297:-
GBM	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	4.3	3.59e-05	0.0257	0.39	0.37	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
GBM	cis	rs858239	0.899	rs28635122	ENSG00000230042.1	AK3P3	-4.3	3.6e-05	0.0257	-0.44	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23129178~23129841:+
GBM	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-4.3	3.61e-05	0.0258	-0.5	-0.37	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
GBM	cis	rs4072705	1	rs3739760	ENSG00000224020.1	MIR181A2HG	-4.3	3.61e-05	0.0258	-0.41	-0.37	Menarche (age at onset);	chr9:124690925	chr9:124658467~124698631:+
GBM	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-4.3	3.61e-05	0.0258	-0.4	-0.37	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-4.3	3.61e-05	0.0258	-0.4	-0.37	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-4.3	3.61e-05	0.0258	-0.4	-0.37	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
GBM	cis	rs672059	1	rs566625	ENSG00000224468.3	RP11-181K3.4	-4.3	3.61e-05	0.0258	-0.3	-0.37	Hypertriglyceridemia;	chr1:183192306	chr1:183138402~183141282:-
GBM	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	4.3	3.61e-05	0.0258	0.35	0.37	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
GBM	cis	rs763121	0.813	rs2179143	ENSG00000273076.1	RP3-508I15.22	4.3	3.62e-05	0.0258	0.37	0.37	Menopause (age at onset);	chr22:38641979	chr22:38743495~38743910:+
GBM	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-4.3	3.62e-05	0.0259	-0.38	-0.37	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
GBM	cis	rs853679	1	rs853676	ENSG00000219392.1	RP1-265C24.5	-4.3	3.63e-05	0.0259	-0.64	-0.37	Depression;	chr6:28331910	chr6:28115628~28116551:+
GBM	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	4.3	3.63e-05	0.0259	0.31	0.37	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
GBM	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	4.3	3.64e-05	0.026	0.45	0.37	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
GBM	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.3	3.64e-05	0.026	0.42	0.37	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-4.3	3.64e-05	0.026	-0.42	-0.37	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	4.3	3.64e-05	0.026	0.42	0.37	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.3	3.64e-05	0.026	0.42	0.37	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	4.3	3.64e-05	0.026	0.42	0.37	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	4.3	3.64e-05	0.026	0.42	0.37	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	4.3	3.64e-05	0.026	0.42	0.37	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
GBM	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	4.3	3.64e-05	0.026	0.42	0.37	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
GBM	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-4.3	3.64e-05	0.026	-0.38	-0.37	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-4.3	3.64e-05	0.026	-0.38	-0.37	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-4.3	3.64e-05	0.026	-0.38	-0.37	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
GBM	cis	rs7017914	0.667	rs3098862	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70965706	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639914	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70967418	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs2732139	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70967802	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639913	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70967929	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639928	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70971414	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2933847	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70972946	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639931	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70974202	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639932	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70974216	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2956615	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70974519	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.583	rs2732129	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70982734	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639912	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70983134	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs1845217	ENSG00000246366.5	RP11-382J12.1	-4.3	3.65e-05	0.026	-0.39	-0.37	Bone mineral density;	chr8:70985016	chr8:70608577~70663279:+
GBM	cis	rs11671005	0.779	rs3794970	ENSG00000269473.1	CTD-2619J13.19	-4.3	3.65e-05	0.026	-0.42	-0.37	Mean platelet volume;	chr19:58474893	chr19:58440448~58445849:+
GBM	cis	rs4869313	0.905	rs27660	ENSG00000248734.2	CTD-2260A17.1	-4.3	3.65e-05	0.026	-0.45	-0.37	Pediatric autoimmune diseases;	chr5:97012071	chr5:96784777~96785999:+
GBM	cis	rs977747	1	rs977747	ENSG00000232022.5	FAAHP1	-4.3	3.65e-05	0.026	-0.37	-0.37	Body mass index;	chr1:47219005	chr1:46432129~46445521:+
GBM	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-4.3	3.66e-05	0.026	-0.55	-0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
GBM	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	4.3	3.66e-05	0.026	0.35	0.37	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
GBM	cis	rs3755899	0.51	rs73139409	ENSG00000260296.1	RP11-395I6.3	4.3	3.66e-05	0.026	0.4	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr4:39521826	chr4:40166675~40167831:+
GBM	cis	rs16863064	0.66	rs1007308	ENSG00000279891.1	FLJ42393	-4.3	3.66e-05	0.026	-0.51	-0.37	Schizophrenia;	chr3:188171935	chr3:188178543~188180812:+
GBM	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	4.3	3.66e-05	0.0261	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
GBM	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	4.3	3.66e-05	0.0261	0.42	0.37	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
GBM	cis	rs8062405	0.69	rs62034351	ENSG00000271623.1	RP11-435I10.5	-4.3	3.67e-05	0.0261	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28364700~28365333:+
GBM	cis	rs6908917	0.673	rs946348	ENSG00000219776.2	RPL21P67	4.29	3.67e-05	0.0261	0.47	0.37	IgG glycosylation;	chr6:131055889	chr6:131469059~131469536:+
GBM	cis	rs6908917	0.664	rs12199897	ENSG00000219776.2	RPL21P67	4.29	3.67e-05	0.0261	0.47	0.37	IgG glycosylation;	chr6:131056534	chr6:131469059~131469536:+
GBM	cis	rs7932813	0.574	rs7113286	ENSG00000246820.2	RP11-379P15.1	4.29	3.67e-05	0.0261	0.38	0.37	Waist circumference;	chr11:7686727	chr11:8169167~8178903:+
GBM	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	4.29	3.67e-05	0.0261	0.56	0.37	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
GBM	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	4.29	3.68e-05	0.0262	0.63	0.37	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
GBM	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	4.29	3.68e-05	0.0262	0.26	0.37	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
GBM	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	4.29	3.68e-05	0.0262	0.44	0.37	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
GBM	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-4.29	3.69e-05	0.0262	-0.46	-0.37	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
GBM	cis	rs17772222	0.917	rs61986669	ENSG00000222990.1	RNU4-22P	4.29	3.69e-05	0.0262	0.45	0.37	Coronary artery calcification;	chr14:88727121	chr14:88513498~88513663:+
GBM	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	4.29	3.69e-05	0.0262	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
GBM	cis	rs10159302	0.85	rs17838097	ENSG00000223956.1	RP4-710M16.2	-4.29	3.69e-05	0.0262	-0.49	-0.37	HIV-1 control;	chr1:57397066	chr1:56414963~56415966:+
GBM	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-4.29	3.69e-05	0.0262	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
GBM	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	4.29	3.69e-05	0.0262	0.44	0.37	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
GBM	cis	rs8114671	0.805	rs4616	ENSG00000269202.1	RP4-614O4.12	4.29	3.69e-05	0.0262	0.46	0.37	Height;	chr20:35002555	chr20:35201747~35203288:-
GBM	cis	rs858239	0.965	rs156429	ENSG00000230042.1	AK3P3	-4.29	3.69e-05	0.0262	-0.42	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23129178~23129841:+
GBM	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-4.29	3.7e-05	0.0262	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-4.29	3.7e-05	0.0262	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
GBM	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	4.29	3.7e-05	0.0262	0.45	0.37	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
GBM	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	4.29	3.7e-05	0.0263	0.58	0.37	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
GBM	cis	rs7017914	0.967	rs2639903	ENSG00000246366.5	RP11-382J12.1	-4.29	3.7e-05	0.0263	-0.39	-0.37	Bone mineral density;	chr8:71005209	chr8:70608577~70663279:+
GBM	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	4.29	3.71e-05	0.0263	0.38	0.37	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
GBM	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	4.29	3.71e-05	0.0263	0.52	0.37	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
GBM	cis	rs453301	0.658	rs3855900	ENSG00000254340.1	RP11-10A14.3	-4.29	3.71e-05	0.0263	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9044411	chr8:9141424~9145435:+
GBM	cis	rs453301	0.658	rs12114954	ENSG00000254340.1	RP11-10A14.3	-4.29	3.71e-05	0.0263	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9047352	chr8:9141424~9145435:+
GBM	cis	rs8114671	0.967	rs1577924	ENSG00000269202.1	RP4-614O4.12	4.29	3.71e-05	0.0263	0.42	0.37	Height;	chr20:35196485	chr20:35201747~35203288:-
GBM	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-4.29	3.71e-05	0.0263	-0.41	-0.37	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
GBM	cis	rs397969	0.621	rs203480	ENSG00000230528.6	NOS2P3	-4.29	3.71e-05	0.0263	-0.46	-0.37	Platelet count;	chr17:19925646	chr17:20436337~20447249:+
GBM	cis	rs397969	0.646	rs203478	ENSG00000230528.6	NOS2P3	-4.29	3.71e-05	0.0263	-0.46	-0.37	Platelet count;	chr17:19926529	chr17:20436337~20447249:+
GBM	cis	rs453301	0.658	rs6983877	ENSG00000254340.1	RP11-10A14.3	-4.29	3.71e-05	0.0263	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9047129	chr8:9141424~9145435:+
GBM	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-4.29	3.71e-05	0.0263	-0.43	-0.37	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
GBM	cis	rs3768617	0.51	rs7525917	ENSG00000224468.3	RP11-181K3.4	-4.29	3.71e-05	0.0263	-0.3	-0.37	Fuchs's corneal dystrophy;	chr1:183096271	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797849	ENSG00000224468.3	RP11-181K3.4	-4.29	3.71e-05	0.0263	-0.3	-0.37	Fuchs's corneal dystrophy;	chr1:183119853	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768622	ENSG00000224468.3	RP11-181K3.4	-4.29	3.71e-05	0.0263	-0.3	-0.37	Fuchs's corneal dystrophy;	chr1:183120876	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2093984	ENSG00000224468.3	RP11-181K3.4	-4.29	3.71e-05	0.0263	-0.3	-0.37	Fuchs's corneal dystrophy;	chr1:183125179	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1413387	ENSG00000224468.3	RP11-181K3.4	-4.29	3.71e-05	0.0263	-0.3	-0.37	Fuchs's corneal dystrophy;	chr1:183127639	chr1:183138402~183141282:-
GBM	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-4.29	3.71e-05	0.0263	-0.37	-0.37	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
GBM	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-4.29	3.71e-05	0.0263	-0.37	-0.37	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
GBM	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-4.29	3.71e-05	0.0263	-0.37	-0.37	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
GBM	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	4.29	3.71e-05	0.0263	0.46	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
GBM	cis	rs950169	0.84	rs62019457	ENSG00000275120.1	RP11-182J1.17	4.29	3.72e-05	0.0263	0.49	0.37	Schizophrenia;	chr15:84558911	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs67804993	ENSG00000275120.1	RP11-182J1.17	4.29	3.72e-05	0.0263	0.49	0.37	Schizophrenia;	chr15:84560799	chr15:84599434~84606463:-
GBM	cis	rs6598955	0.671	rs11247909	ENSG00000236782.4	RP11-96L14.7	4.29	3.72e-05	0.0264	0.53	0.37	Obesity-related traits;	chr1:26313644	chr1:26169947~26171821:-
GBM	cis	rs6598955	0.671	rs12088858	ENSG00000236782.4	RP11-96L14.7	4.29	3.72e-05	0.0264	0.53	0.37	Obesity-related traits;	chr1:26317217	chr1:26169947~26171821:-
GBM	cis	rs6598955	0.671	rs41285347	ENSG00000236782.4	RP11-96L14.7	4.29	3.72e-05	0.0264	0.53	0.37	Obesity-related traits;	chr1:26317908	chr1:26169947~26171821:-
GBM	cis	rs6598955	0.671	rs12090258	ENSG00000236782.4	RP11-96L14.7	4.29	3.72e-05	0.0264	0.53	0.37	Obesity-related traits;	chr1:26318207	chr1:26169947~26171821:-
GBM	cis	rs5742933	0.69	rs6726636	ENSG00000273240.1	RP11-455J20.3	-4.29	3.72e-05	0.0264	-0.5	-0.37	Ferritin levels;	chr2:189653095	chr2:189763859~189764456:-
GBM	cis	rs454217	0.715	rs400708	ENSG00000277851.1	RP11-756G20.1	4.29	3.72e-05	0.0264	0.4	0.37	Smoking quantity;	chr12:92320502	chr12:92247756~92363832:-
GBM	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	4.29	3.72e-05	0.0264	0.42	0.37	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
GBM	cis	rs11098499	0.739	rs2203039	ENSG00000250412.1	KLHL2P1	-4.29	3.72e-05	0.0264	-0.5	-0.37	Corneal astigmatism;	chr4:119211192	chr4:119334329~119378233:+
GBM	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	4.29	3.72e-05	0.0264	0.41	0.37	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
GBM	cis	rs1559777	0.938	rs17240167	ENSG00000259250.1	RP11-50C13.1	4.29	3.73e-05	0.0264	0.53	0.37	Myopia (pathological);	chr15:57789020	chr15:58587507~58591676:+
GBM	cis	rs763121	0.853	rs1013338	ENSG00000273076.1	RP3-508I15.22	4.29	3.73e-05	0.0264	0.4	0.37	Menopause (age at onset);	chr22:38578149	chr22:38743495~38743910:+
GBM	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-4.29	3.73e-05	0.0264	-0.44	-0.37	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
GBM	cis	rs7615952	0.512	rs1077621	ENSG00000250012.1	RP11-124N2.1	-4.29	3.73e-05	0.0264	-0.42	-0.37	Blood pressure (smoking interaction);	chr3:126100956	chr3:126084220~126095349:+
GBM	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	4.29	3.73e-05	0.0264	0.41	0.37	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
GBM	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-4.29	3.73e-05	0.0264	-0.54	-0.37	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
GBM	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-4.29	3.73e-05	0.0264	-0.51	-0.37	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
GBM	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-4.29	3.73e-05	0.0264	-0.55	-0.37	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
GBM	cis	rs867371	0.82	rs7164362	ENSG00000278603.1	RP13-608F4.5	4.29	3.73e-05	0.0264	0.44	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472203~82472426:+
GBM	cis	rs8114671	0.967	rs12481169	ENSG00000269202.1	RP4-614O4.12	4.29	3.73e-05	0.0264	0.43	0.37	Height;	chr20:35206707	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs2180568	ENSG00000269202.1	RP4-614O4.12	4.29	3.73e-05	0.0264	0.43	0.37	Height;	chr20:35206991	chr20:35201747~35203288:-
GBM	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	4.29	3.73e-05	0.0264	0.39	0.37	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
GBM	cis	rs8067287	0.635	rs4343329	ENSG00000227158.1	AC073621.2	-4.29	3.74e-05	0.0265	-0.48	-0.37	Diabetic kidney disease;	chr17:16937575	chr17:17422681~17423704:+
GBM	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	4.29	3.74e-05	0.0265	0.32	0.37	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
GBM	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-4.29	3.74e-05	0.0265	-0.52	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
GBM	cis	rs11642862	0.901	rs11647243	ENSG00000260911.2	RP11-196G11.2	4.29	3.74e-05	0.0265	0.49	0.37	Tonsillectomy;	chr16:30953987	chr16:31043150~31049868:+
GBM	cis	rs11642862	0.901	rs11642733	ENSG00000260911.2	RP11-196G11.2	4.29	3.74e-05	0.0265	0.49	0.37	Tonsillectomy;	chr16:30957740	chr16:31043150~31049868:+
GBM	cis	rs11642862	0.901	rs112190455	ENSG00000260911.2	RP11-196G11.2	4.29	3.74e-05	0.0265	0.49	0.37	Tonsillectomy;	chr16:30960116	chr16:31043150~31049868:+
GBM	cis	rs11642862	0.792	rs75586365	ENSG00000260911.2	RP11-196G11.2	4.29	3.74e-05	0.0265	0.49	0.37	Tonsillectomy;	chr16:30985042	chr16:31043150~31049868:+
GBM	cis	rs11642862	0.685	rs79974799	ENSG00000260911.2	RP11-196G11.2	4.29	3.74e-05	0.0265	0.49	0.37	Tonsillectomy;	chr16:30985474	chr16:31043150~31049868:+
GBM	cis	rs11642862	0.71	rs17849880	ENSG00000260911.2	RP11-196G11.2	4.29	3.74e-05	0.0265	0.49	0.37	Tonsillectomy;	chr16:30987877	chr16:31043150~31049868:+
GBM	cis	rs6991838	0.593	rs953593	ENSG00000272010.1	CTD-3025N20.3	-4.29	3.74e-05	0.0265	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65719737	chr8:65591850~65592472:-
GBM	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	4.29	3.74e-05	0.0265	0.56	0.37	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
GBM	cis	rs1150668	0.796	rs2531832	ENSG00000218016.2	ZNF192P2	-4.29	3.75e-05	0.0265	-0.43	-0.37	Pubertal anthropometrics;	chr6:28421445	chr6:28188050~28189432:+
GBM	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	4.29	3.75e-05	0.0265	0.41	0.37	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
GBM	cis	rs433598	0.55	rs757303	ENSG00000180747.14	SMG1P3	4.29	3.75e-05	0.0265	0.46	0.37	Schizophrenia;	chr16:20809248	chr16:21446683~21520444:-
GBM	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-4.29	3.75e-05	0.0265	-0.38	-0.37	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
GBM	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-4.29	3.76e-05	0.0266	-0.43	-0.37	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
GBM	cis	rs7829975	0.774	rs13259216	ENSG00000254340.1	RP11-10A14.3	4.29	3.76e-05	0.0266	0.46	0.37	Mood instability;	chr8:8816091	chr8:9141424~9145435:+
GBM	cis	rs950169	1	rs79318564	ENSG00000275120.1	RP11-182J1.17	4.29	3.76e-05	0.0266	0.48	0.37	Schizophrenia;	chr15:84117398	chr15:84599434~84606463:-
GBM	cis	rs950169	1	rs1911155	ENSG00000275120.1	RP11-182J1.17	4.29	3.76e-05	0.0266	0.48	0.37	Schizophrenia;	chr15:84118883	chr15:84599434~84606463:-
GBM	cis	rs950169	0.92	rs12915390	ENSG00000275120.1	RP11-182J1.17	4.29	3.76e-05	0.0266	0.48	0.37	Schizophrenia;	chr15:84123317	chr15:84599434~84606463:-
GBM	cis	rs950169	0.959	rs12902070	ENSG00000275120.1	RP11-182J1.17	4.29	3.76e-05	0.0266	0.48	0.37	Schizophrenia;	chr15:84124806	chr15:84599434~84606463:-
GBM	cis	rs4713118	0.505	rs156740	ENSG00000280107.1	AL022393.9	-4.29	3.76e-05	0.0266	-0.39	-0.37	Parkinson's disease;	chr6:27992657	chr6:28170845~28172521:+
GBM	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-4.29	3.77e-05	0.0266	-0.46	-0.37	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
GBM	cis	rs11072805	1	rs11072805	ENSG00000261143.1	ADAMTS7P3	4.29	3.77e-05	0.0266	0.41	0.37	Post bronchodilator FEV1/FVC ratio;	chr15:78786176	chr15:77976042~77993057:+
GBM	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	4.29	3.77e-05	0.0266	0.41	0.37	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
GBM	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	4.29	3.77e-05	0.0266	0.41	0.37	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
GBM	cis	rs2255336	0.873	rs11053806	ENSG00000245648.1	RP11-277P12.20	-4.29	3.77e-05	0.0266	-0.49	-0.37	Blood protein levels;	chr12:10455822	chr12:10363769~10398506:+
GBM	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-4.29	3.77e-05	0.0267	-0.5	-0.37	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
GBM	cis	rs11654801	0.812	rs9914432	ENSG00000233098.7	CCDC144NL-AS1	-4.29	3.77e-05	0.0267	-0.5	-0.37	Mosquito bite size;	chr17:20954043	chr17:20868433~21002276:+
GBM	cis	rs10847980	1	rs75438052	ENSG00000256092.2	RP13-942N8.1	-4.29	3.78e-05	0.0267	-0.85	-0.37	Adiponectin levels;	chr12:122911008	chr12:123363868~123366113:+
GBM	cis	rs73198271	0.74	rs10094270	ENSG00000253893.2	FAM85B	4.29	3.78e-05	0.0267	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.773	rs66618176	ENSG00000253893.2	FAM85B	4.29	3.78e-05	0.0267	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs28521727	ENSG00000253893.2	FAM85B	4.29	3.78e-05	0.0267	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs28402110	ENSG00000253893.2	FAM85B	4.29	3.78e-05	0.0267	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10098636	ENSG00000253893.2	FAM85B	4.29	3.78e-05	0.0267	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10112989	ENSG00000253893.2	FAM85B	4.29	3.78e-05	0.0267	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10113326	ENSG00000253893.2	FAM85B	4.29	3.78e-05	0.0267	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8167819~8226614:-
GBM	cis	rs984222	0.563	rs7518538	ENSG00000231365.4	RP11-418J17.1	4.29	3.78e-05	0.0267	0.38	0.37	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119207788	chr1:119140396~119275973:+
GBM	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-4.29	3.78e-05	0.0267	-0.55	-0.37	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
GBM	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	4.29	3.78e-05	0.0267	0.4	0.37	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
GBM	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	4.29	3.78e-05	0.0267	0.4	0.37	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
GBM	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	4.29	3.78e-05	0.0267	0.39	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
GBM	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	4.29	3.79e-05	0.0267	0.41	0.37	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	4.29	3.79e-05	0.0267	0.41	0.37	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	4.29	3.79e-05	0.0267	0.41	0.37	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
GBM	cis	rs812925	0.519	rs967968	ENSG00000271889.1	RP11-493E12.1	-4.29	3.79e-05	0.0267	-0.39	-0.37	Immature fraction of reticulocytes;	chr2:61428921	chr2:61151433~61162105:-
GBM	cis	rs1150668	0.796	rs2531832	ENSG00000199851.2	U3	4.29	3.79e-05	0.0267	0.45	0.37	Pubertal anthropometrics;	chr6:28421445	chr6:28015568~28015777:+
GBM	cis	rs17772222	0.92	rs61975260	ENSG00000258983.2	RP11-507K2.2	4.29	3.79e-05	0.0267	0.45	0.37	Coronary artery calcification;	chr14:88429597	chr14:88499334~88515502:+
GBM	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	4.29	3.79e-05	0.0268	0.41	0.37	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
GBM	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	4.29	3.79e-05	0.0268	0.4	0.37	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	4.29	3.79e-05	0.0268	0.4	0.37	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
GBM	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	4.29	3.79e-05	0.0268	0.26	0.37	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
GBM	cis	rs2025751	0.512	rs9474102	ENSG00000230204.1	FTH1P5	4.29	3.79e-05	0.0268	0.42	0.37	Intraocular pressure;	chr6:51832038	chr6:50912712~50913256:-
GBM	cis	rs79349575	0.783	rs2112617	ENSG00000270781.1	RP11-501C14.9	-4.29	3.8e-05	0.0268	-0.45	-0.37	Type 2 diabetes;	chr17:48899763	chr17:48899131~48899748:+
GBM	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	4.29	3.81e-05	0.0269	0.46	0.37	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
GBM	cis	rs5742933	0.948	rs6434363	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.81e-05	0.0269	-0.44	-0.37	Ferritin levels;	chr2:189707565	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs6717922	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.81e-05	0.0269	-0.44	-0.37	Ferritin levels;	chr2:189721497	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs4667306	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.81e-05	0.0269	-0.44	-0.37	Ferritin levels;	chr2:189725630	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs16831925	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.81e-05	0.0269	-0.44	-0.37	Ferritin levels;	chr2:189731178	chr2:189762704~189765556:+
GBM	cis	rs5742933	1	rs16831939	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.81e-05	0.0269	-0.44	-0.37	Ferritin levels;	chr2:189739282	chr2:189762704~189765556:+
GBM	cis	rs344364	0.552	rs388928	ENSG00000269937.1	RP11-20I23.8	-4.29	3.81e-05	0.0269	-0.47	-0.37	Glomerular filtration rate in chronic kidney disease;	chr16:1859656	chr16:2561471~2565096:-
GBM	cis	rs344364	0.602	rs2983907	ENSG00000269937.1	RP11-20I23.8	-4.29	3.81e-05	0.0269	-0.47	-0.37	Glomerular filtration rate in chronic kidney disease;	chr16:1863335	chr16:2561471~2565096:-
GBM	cis	rs3741404	0.665	rs594461	ENSG00000231680.1	AP003774.6	-4.29	3.81e-05	0.0269	-0.43	-0.37	Platelet count;	chr11:64105071	chr11:64394342~64395831:-
GBM	cis	rs763121	0.776	rs5757177	ENSG00000273076.1	RP3-508I15.22	4.29	3.81e-05	0.0269	0.4	0.37	Menopause (age at onset);	chr22:38611169	chr22:38743495~38743910:+
GBM	cis	rs73198271	0.74	rs10100066	ENSG00000253893.2	FAM85B	4.29	3.81e-05	0.0269	0.52	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10110711	ENSG00000253893.2	FAM85B	4.29	3.81e-05	0.0269	0.52	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.74	rs10103163	ENSG00000253893.2	FAM85B	4.29	3.81e-05	0.0269	0.52	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.599	rs10103169	ENSG00000253893.2	FAM85B	4.29	3.81e-05	0.0269	0.52	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.7	rs10103282	ENSG00000253893.2	FAM85B	4.29	3.81e-05	0.0269	0.52	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.564	rs2921057	ENSG00000233609.3	RP11-62H7.2	4.28	3.82e-05	0.0269	0.44	0.37	Mood instability;	chr8:8461157	chr8:8961200~8979025:+
GBM	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	4.28	3.82e-05	0.0269	0.51	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
GBM	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	4.28	3.82e-05	0.0269	0.4	0.37	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
GBM	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	4.28	3.82e-05	0.0269	0.69	0.37	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
GBM	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	4.28	3.82e-05	0.0269	0.69	0.37	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
GBM	cis	rs3753275	0.624	rs4908514	ENSG00000230679.1	ENO1-AS1	4.28	3.82e-05	0.0269	0.43	0.37	Educational attainment;	chr1:8784541	chr1:8878835~8879894:+
GBM	cis	rs7176527	1	rs3762168	ENSG00000229212.6	RP11-561C5.4	4.28	3.82e-05	0.0269	0.61	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85205440~85234795:-
GBM	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	4.28	3.83e-05	0.0269	0.44	0.37	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
GBM	cis	rs3806843	0.898	rs3756335	ENSG00000202111.1	VTRNA1-2	-4.28	3.83e-05	0.027	-0.38	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140833925	chr5:140718925~140719013:+
GBM	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	4.28	3.83e-05	0.027	0.26	0.37	Breast cancer;	chr11:750849	chr11:781645~782105:+
GBM	cis	rs9468186	1	rs9468186	ENSG00000218016.2	ZNF192P2	-4.28	3.83e-05	0.027	-0.51	-0.37	Neuroticism;	chr6:27658852	chr6:28188050~28189432:+
GBM	cis	rs9983113	0.903	rs9976714	ENSG00000231123.1	SPATA20P1	-4.28	3.83e-05	0.027	-0.38	-0.37	Body mass index;	chr21:38941421	chr21:38238227~38238664:-
GBM	cis	rs763121	0.819	rs5750629	ENSG00000273076.1	RP3-508I15.22	4.28	3.84e-05	0.027	0.39	0.37	Menopause (age at onset);	chr22:38589060	chr22:38743495~38743910:+
GBM	cis	rs763121	0.819	rs5757160	ENSG00000273076.1	RP3-508I15.22	4.28	3.84e-05	0.027	0.39	0.37	Menopause (age at onset);	chr22:38593641	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750633	ENSG00000273076.1	RP3-508I15.22	4.28	3.84e-05	0.027	0.39	0.37	Menopause (age at onset);	chr22:38597462	chr22:38743495~38743910:+
GBM	cis	rs7017914	0.652	rs62510667	ENSG00000246366.5	RP11-382J12.1	-4.28	3.84e-05	0.027	-0.4	-0.37	Bone mineral density;	chr8:70850458	chr8:70608577~70663279:+
GBM	cis	rs875971	0.798	rs12698522	ENSG00000236529.1	RP13-254B10.1	4.28	3.84e-05	0.027	0.39	0.37	Aortic root size;	chr7:66502354	chr7:65840212~65840596:+
GBM	cis	rs875971	0.83	rs28714531	ENSG00000236529.1	RP13-254B10.1	4.28	3.84e-05	0.027	0.39	0.37	Aortic root size;	chr7:66503250	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs12698526	ENSG00000236529.1	RP13-254B10.1	4.28	3.84e-05	0.027	0.39	0.37	Aortic root size;	chr7:66504118	chr7:65840212~65840596:+
GBM	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	4.28	3.84e-05	0.027	0.56	0.37	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
GBM	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	4.28	3.84e-05	0.027	0.39	0.37	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
GBM	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	4.28	3.84e-05	0.027	0.52	0.37	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
GBM	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	4.28	3.84e-05	0.027	0.52	0.37	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
GBM	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	4.28	3.84e-05	0.027	0.52	0.37	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
GBM	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	4.28	3.84e-05	0.027	0.52	0.37	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
GBM	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-4.28	3.84e-05	0.027	-0.49	-0.37	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-4.28	3.84e-05	0.027	-0.49	-0.37	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-4.28	3.84e-05	0.027	-0.49	-0.37	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-4.28	3.84e-05	0.027	-0.49	-0.37	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-4.28	3.84e-05	0.027	-0.49	-0.37	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
GBM	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-4.28	3.85e-05	0.0271	-0.44	-0.37	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
GBM	cis	rs7315956	0.892	rs4761184	ENSG00000257139.1	RP11-320P7.2	4.28	3.85e-05	0.0271	0.43	0.37	Testicular germ cell tumor;	chr12:70213887	chr12:70180338~70202004:+
GBM	cis	rs7829975	0.577	rs7816329	ENSG00000253893.2	FAM85B	4.28	3.85e-05	0.0271	0.48	0.37	Mood instability;	chr8:8686333	chr8:8167819~8226614:-
GBM	cis	rs2579103	0.708	rs2579102	ENSG00000258183.4	RP11-753N8.1	-4.28	3.85e-05	0.0271	-0.54	-0.37	Body mass index;	chr12:90291557	chr12:90280894~90300340:+
GBM	cis	rs7315956	0.963	rs4761186	ENSG00000257139.1	RP11-320P7.2	-4.28	3.85e-05	0.0271	-0.43	-0.37	Testicular germ cell tumor;	chr12:70232545	chr12:70180338~70202004:+
GBM	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	4.28	3.85e-05	0.0271	0.41	0.37	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
GBM	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-4.28	3.86e-05	0.0271	-0.56	-0.37	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
GBM	cis	rs3742264	0.656	rs4460970	ENSG00000235903.6	CPB2-AS1	-4.28	3.86e-05	0.0271	-0.46	-0.37	Blood protein levels;	chr13:45966158	chr13:46052806~46113332:+
GBM	cis	rs7176527	1	rs3762168	ENSG00000259774.1	RP11-182J1.13	4.28	3.86e-05	0.0271	0.58	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:84422618~84425882:+
GBM	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	4.28	3.86e-05	0.0271	0.37	0.37	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
GBM	cis	rs17685	0.587	rs1623759	ENSG00000280388.1	RP11-229D13.3	-4.28	3.86e-05	0.0271	-0.35	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76095361	chr7:76043977~76045963:-
GBM	cis	rs17685	0.625	rs1639630	ENSG00000280388.1	RP11-229D13.3	-4.28	3.86e-05	0.0271	-0.35	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76101181	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs1637051	ENSG00000280388.1	RP11-229D13.3	-4.28	3.86e-05	0.0271	-0.35	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76101341	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs4573217	ENSG00000280388.1	RP11-229D13.3	-4.28	3.86e-05	0.0271	-0.35	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76104628	chr7:76043977~76045963:-
GBM	cis	rs17685	0.784	rs1613890	ENSG00000280388.1	RP11-229D13.3	-4.28	3.86e-05	0.0271	-0.35	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76105719	chr7:76043977~76045963:-
GBM	cis	rs397969	0.596	rs12453720	ENSG00000230528.6	NOS2P3	4.28	3.87e-05	0.0272	0.48	0.37	Platelet count;	chr17:19991889	chr17:20436337~20447249:+
GBM	cis	rs17772222	0.582	rs12050316	ENSG00000258983.2	RP11-507K2.2	4.28	3.87e-05	0.0272	0.39	0.37	Coronary artery calcification;	chr14:88522097	chr14:88499334~88515502:+
GBM	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	4.28	3.88e-05	0.0272	0.55	0.37	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
GBM	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	4.28	3.88e-05	0.0272	0.42	0.37	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
GBM	cis	rs8062405	0.69	rs7187604	ENSG00000271623.1	RP11-435I10.5	-4.28	3.88e-05	0.0272	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28364700~28365333:+
GBM	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	4.28	3.88e-05	0.0272	0.58	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
GBM	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	4.28	3.88e-05	0.0273	0.41	0.37	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
GBM	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	4.28	3.88e-05	0.0273	0.41	0.37	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
GBM	cis	rs1150668	0.768	rs1150716	ENSG00000218016.2	ZNF192P2	-4.28	3.88e-05	0.0273	-0.44	-0.37	Pubertal anthropometrics;	chr6:28294921	chr6:28188050~28189432:+
GBM	cis	rs1150668	0.799	rs2142730	ENSG00000218016.2	ZNF192P2	-4.28	3.88e-05	0.0273	-0.44	-0.37	Pubertal anthropometrics;	chr6:28298372	chr6:28188050~28189432:+
GBM	cis	rs17767294	0.612	rs12332927	ENSG00000199851.2	U3	4.28	3.88e-05	0.0273	0.76	0.37	Parkinson's disease;	chr6:27987337	chr6:28015568~28015777:+
GBM	cis	rs10911232	0.56	rs6697320	ENSG00000224468.3	RP11-181K3.4	-4.28	3.89e-05	0.0273	-0.3	-0.37	Hypertriglyceridemia;	chr1:183068242	chr1:183138402~183141282:-
GBM	cis	rs10911232	0.56	rs10911221	ENSG00000224468.3	RP11-181K3.4	-4.28	3.89e-05	0.0273	-0.3	-0.37	Hypertriglyceridemia;	chr1:183077602	chr1:183138402~183141282:-
GBM	cis	rs17508449	0.505	rs78491726	ENSG00000232450.1	RP4-730K3.3	-4.28	3.89e-05	0.0273	-0.6	-0.37	Leprosy;	chr1:113784847	chr1:113698884~113699631:-
GBM	cis	rs62184315	0.536	rs62183651	ENSG00000253559.1	OSGEPL1-AS1	-4.28	3.89e-05	0.0273	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189647251	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs62183652	ENSG00000253559.1	OSGEPL1-AS1	-4.28	3.89e-05	0.0273	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189648877	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs62183653	ENSG00000253559.1	OSGEPL1-AS1	-4.28	3.89e-05	0.0273	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189650099	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs72920421	ENSG00000253559.1	OSGEPL1-AS1	-4.28	3.89e-05	0.0273	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189650292	chr2:189762704~189765556:+
GBM	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	4.28	3.89e-05	0.0273	0.44	0.37	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
GBM	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
GBM	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
GBM	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-4.28	3.9e-05	0.0273	-0.5	-0.37	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
GBM	cis	rs3213958	0.574	rs11916285	ENSG00000249274.1	PDLIM1P4	-4.28	3.9e-05	0.0274	-0.61	-0.37	Blood protein levels;	chr3:98818497	chr3:98782188~98783193:+
GBM	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-4.28	3.9e-05	0.0274	-0.44	-0.37	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
GBM	cis	rs9393777	0.623	rs9358945	ENSG00000224843.5	LINC00240	-4.28	3.9e-05	0.0274	-0.59	-0.37	Intelligence (multi-trait analysis);	chr6:26471886	chr6:26956992~27023924:+
GBM	cis	rs73198271	0.653	rs10087633	ENSG00000253893.2	FAM85B	4.28	3.9e-05	0.0274	0.5	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.653	rs10087742	ENSG00000253893.2	FAM85B	4.28	3.9e-05	0.0274	0.5	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8167819~8226614:-
GBM	cis	rs3845817	0.832	rs702883	ENSG00000237979.1	AC007389.1	4.28	3.9e-05	0.0274	0.52	0.37	Bipolar disorder;	chr2:65524951	chr2:65500993~65502138:-
GBM	cis	rs3845817	0.838	rs702886	ENSG00000237979.1	AC007389.1	4.28	3.9e-05	0.0274	0.52	0.37	Bipolar disorder;	chr2:65526176	chr2:65500993~65502138:-
GBM	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-4.28	3.91e-05	0.0274	-0.44	-0.37	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
GBM	cis	rs7487075	0.592	rs11615015	ENSG00000257261.4	RP11-96H19.1	4.28	3.91e-05	0.0274	0.37	0.37	Itch intensity from mosquito bite;	chr12:46668503	chr12:46383679~46876159:+
GBM	cis	rs7216064	0.953	rs62086043	ENSG00000267472.1	LOC440461	4.28	3.91e-05	0.0274	0.46	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971887	chr17:68198921~68199596:+
GBM	cis	rs66887589	0.616	rs6843509	ENSG00000250412.1	KLHL2P1	4.28	3.91e-05	0.0274	0.45	0.37	Diastolic blood pressure;	chr4:119299041	chr4:119334329~119378233:+
GBM	cis	rs9926296	0.605	rs886951	ENSG00000260259.1	RP11-368I7.4	-4.28	3.91e-05	0.0274	-0.4	-0.37	Vitiligo;	chr16:89770457	chr16:89682620~89686569:-
GBM	cis	rs9926296	0.568	rs886950	ENSG00000260259.1	RP11-368I7.4	-4.28	3.91e-05	0.0274	-0.4	-0.37	Vitiligo;	chr16:89770464	chr16:89682620~89686569:-
GBM	cis	rs2282300	0.91	rs528292	ENSG00000242353.1	RP4-710M3.1	4.28	3.91e-05	0.0274	0.5	0.37	Morning vs. evening chronotype;	chr11:30368163	chr11:30368148~30368646:+
GBM	cis	rs2282300	0.956	rs594937	ENSG00000242353.1	RP4-710M3.1	4.28	3.91e-05	0.0274	0.5	0.37	Morning vs. evening chronotype;	chr11:30368585	chr11:30368148~30368646:+
GBM	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	4.28	3.92e-05	0.0274	0.41	0.37	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
GBM	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-4.28	3.92e-05	0.0274	-0.41	-0.37	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
GBM	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	4.28	3.92e-05	0.0274	0.39	0.37	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
GBM	cis	rs2436845	0.531	rs1806299	ENSG00000253320.4	KB-1507C5.2	-4.28	3.92e-05	0.0274	-0.4	-0.37	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102886303	chr8:102864300~102977876:+
GBM	cis	rs2436845	0.554	rs10104704	ENSG00000253320.4	KB-1507C5.2	-4.28	3.92e-05	0.0274	-0.4	-0.37	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102888657	chr8:102864300~102977876:+
GBM	cis	rs2436845	0.521	rs1714399	ENSG00000253320.4	KB-1507C5.2	-4.28	3.92e-05	0.0274	-0.4	-0.37	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102892525	chr8:102864300~102977876:+
GBM	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-4.28	3.92e-05	0.0274	-0.55	-0.37	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
GBM	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-4.28	3.92e-05	0.0274	-0.55	-0.37	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
GBM	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-4.28	3.92e-05	0.0275	-0.5	-0.37	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
GBM	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-4.28	3.92e-05	0.0275	-0.5	-0.37	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
GBM	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-4.28	3.92e-05	0.0275	-0.44	-0.37	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
GBM	cis	rs11159086	1	rs11159087	ENSG00000270000.1	RP3-449M8.9	4.28	3.92e-05	0.0275	0.54	0.37	Advanced glycation end-product levels;	chr14:74504671	chr14:74471930~74472360:-
GBM	cis	rs11992162	0.967	rs10108320	ENSG00000255556.2	RP11-351I21.6	-4.28	3.92e-05	0.0275	-0.37	-0.37	Monocyte count;	chr8:11974754	chr8:12378679~12380265:-
GBM	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-4.28	3.93e-05	0.0275	-0.45	-0.37	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
GBM	cis	rs321358	0.731	rs516110	ENSG00000271584.1	RP11-89C3.4	4.28	3.93e-05	0.0275	0.54	0.37	Body mass index;	chr11:111166525	chr11:111091932~111097357:-
GBM	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-4.28	3.93e-05	0.0275	-0.66	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
GBM	cis	rs11098499	0.874	rs13139045	ENSG00000249244.1	RP11-548H18.2	4.28	3.93e-05	0.0275	0.46	0.37	Corneal astigmatism;	chr4:119247433	chr4:119391831~119395335:-
GBM	cis	rs7017914	0.632	rs2035196	ENSG00000246366.5	RP11-382J12.1	-4.28	3.93e-05	0.0275	-0.41	-0.37	Bone mineral density;	chr8:70573115	chr8:70608577~70663279:+
GBM	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	4.28	3.93e-05	0.0275	0.53	0.37	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-4.28	3.93e-05	0.0275	-0.53	-0.37	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
GBM	cis	rs526231	0.764	rs2569014	ENSG00000175749.11	EIF3KP1	4.28	3.94e-05	0.0275	0.54	0.37	Primary biliary cholangitis;	chr5:103302398	chr5:103032376~103033031:+
GBM	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	4.28	3.94e-05	0.0276	0.43	0.37	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
GBM	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-4.28	3.94e-05	0.0276	-0.64	-0.37	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
GBM	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	4.28	3.94e-05	0.0276	0.4	0.37	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
GBM	cis	rs17772222	0.597	rs17700296	ENSG00000258983.2	RP11-507K2.2	4.28	3.95e-05	0.0276	0.44	0.37	Coronary artery calcification;	chr14:88840976	chr14:88499334~88515502:+
GBM	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-4.28	3.95e-05	0.0276	-0.38	-0.37	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
GBM	cis	rs338389	0.542	rs8036189	ENSG00000260657.2	RP11-315D16.4	-4.28	3.95e-05	0.0276	-0.54	-0.37	Survival in rectal cancer;	chr15:68000614	chr15:68267792~68277994:-
GBM	cis	rs950169	0.922	rs11631096	ENSG00000275120.1	RP11-182J1.17	4.28	3.95e-05	0.0276	0.5	0.37	Schizophrenia;	chr15:84557698	chr15:84599434~84606463:-
GBM	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	4.28	3.95e-05	0.0276	0.45	0.37	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
GBM	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	4.28	3.95e-05	0.0276	0.5	0.37	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
GBM	cis	rs9393777	0.588	rs6926677	ENSG00000224843.5	LINC00240	4.28	3.95e-05	0.0276	0.56	0.37	Intelligence (multi-trait analysis);	chr6:26478597	chr6:26956992~27023924:+
GBM	cis	rs2018683	0.899	rs10479816	ENSG00000228421.2	AC005013.5	4.28	3.96e-05	0.0277	0.41	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28957667~28959345:+
GBM	cis	rs2018683	0.899	rs10479817	ENSG00000228421.2	AC005013.5	4.28	3.96e-05	0.0277	0.41	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938531	chr7:28957667~28959345:+
GBM	cis	rs73198271	0.694	rs73201840	ENSG00000253893.2	FAM85B	4.28	3.96e-05	0.0277	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.694	rs113694763	ENSG00000253893.2	FAM85B	4.28	3.96e-05	0.0277	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.694	rs115037021	ENSG00000253893.2	FAM85B	4.28	3.96e-05	0.0277	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8167819~8226614:-
GBM	cis	rs73198271	0.694	rs114184516	ENSG00000253893.2	FAM85B	4.28	3.96e-05	0.0277	0.55	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8167819~8226614:-
GBM	cis	rs11471957	1	rs11471957	ENSG00000268649.3	RP4-806M20.4	-4.27	3.97e-05	0.0277	-0.43	-0.37	Mean platelet volume;Platelet count;	chr20:59023277	chr20:58817132~58817725:-
GBM	cis	rs2599510	0.693	rs2754514	ENSG00000276334.1	AL133243.1	4.27	3.97e-05	0.0277	0.42	0.37	Interleukin-18 levels;	chr2:32563769	chr2:32521927~32523547:+
GBM	cis	rs7017914	0.905	rs1389206	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71012627	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2639955	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71013107	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.869	rs2639954	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71013340	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.837	rs2639952	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71013495	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732108	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71013864	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732109	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71013988	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs1493203	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71014272	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732110	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71014576	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2639951	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71014990	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732112	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71015606	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.811	rs1389204	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71016063	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732113	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71016314	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732114	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71016477	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2732116	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71017092	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs2956610	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71017298	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3098868	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71017457	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3098870	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71017700	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110240	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71017869	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.875	rs3098871	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71018180	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3098873	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71020351	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110241	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71020729	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110242	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71020732	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110243	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71020834	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs3098874	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71022103	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110247	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71022652	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110248	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71022700	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110249	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71023310	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3098876	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71024009	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs3098877	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71024211	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.875	rs3110251	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71024739	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110252	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71024985	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110253	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71025318	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110254	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71025627	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs3110256	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71025901	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3110257	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71025916	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3098879	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71026225	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.935	rs3110258	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71026297	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs3098880	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71026686	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs3098881	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71027455	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.87	rs3098883	ENSG00000246366.5	RP11-382J12.1	-4.27	3.97e-05	0.0277	-0.39	-0.37	Bone mineral density;	chr8:71031332	chr8:70608577~70663279:+
GBM	cis	rs10911251	0.546	rs3768625	ENSG00000224468.3	RP11-181K3.4	-4.27	3.97e-05	0.0277	-0.3	-0.37	Colorectal cancer;	chr1:183109577	chr1:183138402~183141282:-
GBM	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-4.27	3.98e-05	0.0277	-0.42	-0.37	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
GBM	cis	rs6598955	1	rs10902728	ENSG00000236782.4	RP11-96L14.7	4.27	3.98e-05	0.0277	0.43	0.37	Obesity-related traits;	chr1:26271790	chr1:26169947~26171821:-
GBM	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-4.27	3.98e-05	0.0277	-0.5	-0.37	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
GBM	cis	rs8114671	0.967	rs6088734	ENSG00000269202.1	RP4-614O4.12	-4.27	3.98e-05	0.0277	-0.44	-0.37	Height;	chr20:35157243	chr20:35201747~35203288:-
GBM	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-4.27	3.98e-05	0.0277	-0.4	-0.37	Height;	chr11:118856623	chr11:118791254~118793137:+
GBM	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-4.27	3.98e-05	0.0277	-0.4	-0.37	Height;	chr11:118857611	chr11:118791254~118793137:+
GBM	cis	rs10463554	0.892	rs1438687	ENSG00000175749.11	EIF3KP1	4.27	3.99e-05	0.0278	0.53	0.37	Parkinson's disease;	chr5:102968792	chr5:103032376~103033031:+
GBM	cis	rs9300255	0.507	rs1727302	ENSG00000256092.2	RP13-942N8.1	4.27	3.99e-05	0.0278	0.44	0.37	Neutrophil percentage of white cells;	chr12:123148383	chr12:123363868~123366113:+
GBM	cis	rs2025751	0.512	rs9463723	ENSG00000230204.1	FTH1P5	-4.27	3.99e-05	0.0278	-0.43	-0.37	Intraocular pressure;	chr6:51829338	chr6:50912712~50913256:-
GBM	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	4.27	3.99e-05	0.0278	0.42	0.37	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	4.27	3.99e-05	0.0278	0.42	0.37	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	4.27	3.99e-05	0.0278	0.42	0.37	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
GBM	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	4.27	3.99e-05	0.0278	0.33	0.37	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
GBM	cis	rs338389	0.542	rs6494709	ENSG00000260657.2	RP11-315D16.4	-4.27	3.99e-05	0.0278	-0.53	-0.37	Survival in rectal cancer;	chr15:68001672	chr15:68267792~68277994:-
GBM	cis	rs17772222	0.917	rs1950806	ENSG00000222990.1	RNU4-22P	4.27	3.99e-05	0.0278	0.49	0.37	Coronary artery calcification;	chr14:88774412	chr14:88513498~88513663:+
GBM	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-4.27	3.99e-05	0.0278	-0.42	-0.37	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-4.27	3.99e-05	0.0278	-0.42	-0.37	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-4.27	3.99e-05	0.0278	-0.42	-0.37	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
GBM	cis	rs513088	0.681	rs556498	ENSG00000225171.2	DUTP6	4.27	4e-05	0.0278	0.48	0.37	Schizophrenia;	chr1:166719963	chr1:166868748~166869209:+
GBM	cis	rs7017914	0.69	rs7825815	ENSG00000246366.5	RP11-382J12.1	-4.27	4e-05	0.0278	-0.4	-0.37	Bone mineral density;	chr8:71074170	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.558	rs4526394	ENSG00000246366.5	RP11-382J12.1	-4.27	4e-05	0.0278	-0.4	-0.37	Bone mineral density;	chr8:71076092	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs17778232	ENSG00000246366.5	RP11-382J12.1	-4.27	4e-05	0.0278	-0.4	-0.37	Bone mineral density;	chr8:71079283	chr8:70608577~70663279:+
GBM	cis	rs8062405	1	rs72793811	ENSG00000271623.1	RP11-435I10.5	-4.27	4e-05	0.0278	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs72793812	ENSG00000271623.1	RP11-435I10.5	-4.27	4e-05	0.0278	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs12443881	ENSG00000271623.1	RP11-435I10.5	-4.27	4e-05	0.0278	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28364700~28365333:+
GBM	cis	rs453301	0.571	rs2929452	ENSG00000254340.1	RP11-10A14.3	-4.27	4e-05	0.0278	-0.44	-0.37	Joint mobility (Beighton score);	chr8:9226955	chr8:9141424~9145435:+
GBM	cis	rs453301	0.571	rs2929305	ENSG00000254340.1	RP11-10A14.3	-4.27	4e-05	0.0278	-0.44	-0.37	Joint mobility (Beighton score);	chr8:9227707	chr8:9141424~9145435:+
GBM	cis	rs10231759	0.617	rs56077833	ENSG00000273419.1	RP4-751H13.7	-4.27	4e-05	0.0279	-0.42	-0.37	Height;	chr7:150815958	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.617	rs4463336	ENSG00000273419.1	RP4-751H13.7	-4.27	4e-05	0.0279	-0.42	-0.37	Height;	chr7:150816494	chr7:149858400~149862492:-
GBM	cis	rs10231759	0.583	rs35792015	ENSG00000273419.1	RP4-751H13.7	-4.27	4e-05	0.0279	-0.42	-0.37	Height;	chr7:150816753	chr7:149858400~149862492:-
GBM	cis	rs5742933	0.817	rs1233297	ENSG00000253559.1	OSGEPL1-AS1	-4.27	4e-05	0.0279	-0.41	-0.37	Ferritin levels;	chr2:189829449	chr2:189762704~189765556:+
GBM	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-4.27	4.01e-05	0.0279	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
GBM	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-4.27	4.01e-05	0.0279	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
GBM	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-4.27	4.01e-05	0.0279	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
GBM	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-4.27	4.01e-05	0.0279	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
GBM	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-4.27	4.01e-05	0.0279	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
GBM	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-4.27	4.01e-05	0.0279	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
GBM	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-4.27	4.01e-05	0.0279	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
GBM	cis	rs7034139	0.956	rs10980800	ENSG00000259953.1	RP11-4O1.2	4.27	4.01e-05	0.0279	0.56	0.37	Myeloid white cell count;	chr9:111153625	chr9:112032555~112037730:-
GBM	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-4.27	4.01e-05	0.0279	-0.44	-0.37	Height;	chr20:35179263	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-4.27	4.01e-05	0.0279	-0.44	-0.37	Height;	chr20:35179488	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-4.27	4.01e-05	0.0279	-0.44	-0.37	Height;	chr20:35179887	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-4.27	4.01e-05	0.0279	-0.44	-0.37	Height;	chr20:35180449	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-4.27	4.01e-05	0.0279	-0.44	-0.37	Height;	chr20:35182684	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-4.27	4.01e-05	0.0279	-0.44	-0.37	Height;	chr20:35183632	chr20:35201747~35203288:-
GBM	cis	rs6600671	1	rs7532615	ENSG00000223345.3	HIST2H2BA	-4.27	4.01e-05	0.0279	-0.48	-0.37	Hip geometry;	chr1:121430980	chr1:121108210~121117257:-
GBM	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-4.27	4.01e-05	0.0279	-0.67	-0.37	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
GBM	cis	rs7267979	0.604	rs242130	ENSG00000276952.1	RP5-965G21.6	-4.27	4.01e-05	0.0279	-0.4	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:25284915~25285588:-
GBM	cis	rs832187	0.594	rs832197	ENSG00000280620.1	SCAANT1	-4.27	4.01e-05	0.0279	-0.49	-0.37	Schizophrenia;	chr3:63898616	chr3:63911518~63911772:-
GBM	cis	rs7017914	0.905	rs3110244	ENSG00000246366.5	RP11-382J12.1	4.27	4.01e-05	0.0279	0.39	0.37	Bone mineral density;	chr8:71020962	chr8:70608577~70663279:+
GBM	cis	rs1153858	1	rs2453541	ENSG00000259433.2	CTD-2651B20.4	-4.27	4.01e-05	0.0279	-0.43	-0.37	Homoarginine levels;	chr15:45353180	chr15:45330209~45332634:-
GBM	cis	rs1153858	1	rs2461702	ENSG00000259433.2	CTD-2651B20.4	-4.27	4.01e-05	0.0279	-0.43	-0.37	Homoarginine levels;	chr15:45355229	chr15:45330209~45332634:-
GBM	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-4.27	4.02e-05	0.0279	-0.48	-0.37	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
GBM	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-4.27	4.02e-05	0.0279	-0.48	-0.37	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
GBM	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-4.27	4.02e-05	0.0279	-0.48	-0.37	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
GBM	cis	rs7017914	0.652	rs10957533	ENSG00000246366.5	RP11-382J12.1	4.27	4.02e-05	0.0279	0.39	0.37	Bone mineral density;	chr8:70912872	chr8:70608577~70663279:+
GBM	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	4.27	4.02e-05	0.0279	0.62	0.37	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
GBM	cis	rs62367758	0.683	rs543569	ENSG00000247763.2	RP11-447H19.1	4.27	4.02e-05	0.0279	0.45	0.37	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);	chr5:43045620	chr5:43231812~43233173:-
GBM	cis	rs3096299	0.702	rs2086825	ENSG00000260259.1	RP11-368I7.4	4.27	4.02e-05	0.028	0.4	0.37	Multiple myeloma (IgH translocation);	chr16:89405134	chr16:89682620~89686569:-
GBM	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-4.27	4.03e-05	0.028	-0.41	-0.37	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
GBM	cis	rs34975555	0.614	rs6586675	ENSG00000254054.2	RP11-156K13.3	4.27	4.03e-05	0.028	0.55	0.37	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17983648	chr8:17905756~17907887:+
GBM	cis	rs7829975	0.714	rs4841040	ENSG00000254340.1	RP11-10A14.3	4.27	4.03e-05	0.028	0.45	0.37	Mood instability;	chr8:8797017	chr8:9141424~9145435:+
GBM	cis	rs17270561	1	rs17270561	ENSG00000272810.1	U91328.22	4.27	4.03e-05	0.028	0.56	0.37	Iron status biomarkers;	chr6:25820211	chr6:26013241~26013757:+
GBM	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-4.27	4.04e-05	0.028	-0.59	-0.37	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
GBM	cis	rs7829975	0.591	rs12677543	ENSG00000254340.1	RP11-10A14.3	4.27	4.04e-05	0.028	0.45	0.37	Mood instability;	chr8:8786764	chr8:9141424~9145435:+
GBM	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	4.27	4.04e-05	0.0281	0.53	0.37	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	4.27	4.04e-05	0.0281	0.53	0.37	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	4.27	4.04e-05	0.0281	0.53	0.37	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	4.27	4.04e-05	0.0281	0.53	0.37	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
GBM	cis	rs17361889	0.634	rs6954901	ENSG00000224683.1	RPL36AP29	-4.27	4.04e-05	0.0281	-0.4	-0.37	Pediatric bone mineral content (hip);	chr7:16267078	chr7:16208945~16209265:+
GBM	cis	rs62184315	0.536	rs62185897	ENSG00000273240.1	RP11-455J20.3	-4.27	4.04e-05	0.0281	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189721279	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs2278591	ENSG00000273240.1	RP11-455J20.3	-4.27	4.04e-05	0.0281	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189755778	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs62184265	ENSG00000273240.1	RP11-455J20.3	-4.27	4.04e-05	0.0281	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189756231	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs16831972	ENSG00000273240.1	RP11-455J20.3	-4.27	4.04e-05	0.0281	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189756707	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.52	rs62184268	ENSG00000273240.1	RP11-455J20.3	-4.27	4.04e-05	0.0281	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189767451	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs2289405	ENSG00000273240.1	RP11-455J20.3	-4.27	4.04e-05	0.0281	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189771313	chr2:189763859~189764456:-
GBM	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-4.27	4.04e-05	0.0281	-0.49	-0.37	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
GBM	cis	rs4388249	1	rs13172735	ENSG00000271849.1	CTC-332L22.1	4.27	4.05e-05	0.0281	0.53	0.37	Schizophrenia;	chr5:109724132	chr5:109687802~109688329:-
GBM	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-4.27	4.05e-05	0.0281	-0.43	-0.37	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
GBM	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-4.27	4.05e-05	0.0281	-0.43	-0.37	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
GBM	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-4.27	4.05e-05	0.0281	-0.52	-0.37	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
GBM	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	4.27	4.05e-05	0.0281	0.27	0.37	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	4.27	4.05e-05	0.0281	0.27	0.37	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
GBM	cis	rs2579103	0.708	rs2731266	ENSG00000258183.4	RP11-753N8.1	4.27	4.05e-05	0.0281	0.52	0.37	Body mass index;	chr12:90278930	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs1470032	ENSG00000258183.4	RP11-753N8.1	-4.27	4.05e-05	0.0281	-0.52	-0.37	Body mass index;	chr12:90277350	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.668	rs1909552	ENSG00000258183.4	RP11-753N8.1	-4.27	4.05e-05	0.0281	-0.52	-0.37	Body mass index;	chr12:90282067	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs2731261	ENSG00000258183.4	RP11-753N8.1	-4.27	4.05e-05	0.0281	-0.52	-0.37	Body mass index;	chr12:90283399	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.668	rs2253621	ENSG00000258183.4	RP11-753N8.1	-4.27	4.05e-05	0.0281	-0.52	-0.37	Body mass index;	chr12:90283940	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.668	rs2253289	ENSG00000258183.4	RP11-753N8.1	-4.27	4.05e-05	0.0281	-0.52	-0.37	Body mass index;	chr12:90286943	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.631	rs2579113	ENSG00000258183.4	RP11-753N8.1	-4.27	4.05e-05	0.0281	-0.52	-0.37	Body mass index;	chr12:90288844	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs2731254	ENSG00000258183.4	RP11-753N8.1	-4.27	4.05e-05	0.0281	-0.52	-0.37	Body mass index;	chr12:90289830	chr12:90280894~90300340:+
GBM	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-4.27	4.05e-05	0.0281	-0.49	-0.37	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-4.27	4.05e-05	0.0281	-0.49	-0.37	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-4.27	4.05e-05	0.0281	-0.49	-0.37	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
GBM	cis	rs2963463	0.715	rs11135036	ENSG00000253519.1	AC106801.1	-4.27	4.05e-05	0.0281	-0.5	-0.37	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158474016	chr5:157565964~157569098:+
GBM	cis	rs1190596	0.732	rs7156564	ENSG00000259088.1	CTD-2017C7.2	-4.27	4.06e-05	0.0281	-0.52	-0.37	Behavioural disinhibition (generation interaction);	chr14:102092251	chr14:101796555~101810321:-
GBM	cis	rs1190596	0.549	rs11621083	ENSG00000259088.1	CTD-2017C7.2	-4.27	4.06e-05	0.0281	-0.52	-0.37	Behavioural disinhibition (generation interaction);	chr14:102093201	chr14:101796555~101810321:-
GBM	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-4.27	4.06e-05	0.0282	-0.44	-0.37	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
GBM	cis	rs61041384	0.661	rs74240770	ENSG00000256092.2	RP13-942N8.1	-4.27	4.06e-05	0.0282	-0.89	-0.37	Schizophrenia;	chr12:123207195	chr12:123363868~123366113:+
GBM	cis	rs11098499	0.739	rs9884728	ENSG00000250412.1	KLHL2P1	-4.27	4.06e-05	0.0282	-0.5	-0.37	Corneal astigmatism;	chr4:119205924	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.739	rs7441137	ENSG00000250412.1	KLHL2P1	-4.27	4.06e-05	0.0282	-0.5	-0.37	Corneal astigmatism;	chr4:119212066	chr4:119334329~119378233:+
GBM	cis	rs2025751	0.512	rs1326606	ENSG00000230204.1	FTH1P5	-4.27	4.07e-05	0.0282	-0.43	-0.37	Intraocular pressure;	chr6:51834955	chr6:50912712~50913256:-
GBM	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	4.27	4.07e-05	0.0282	0.38	0.37	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
GBM	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	4.27	4.07e-05	0.0282	0.26	0.37	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
GBM	cis	rs8062405	0.723	rs113208333	ENSG00000271623.1	RP11-435I10.5	-4.27	4.07e-05	0.0282	-0.44	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28364700~28365333:+
GBM	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-4.27	4.07e-05	0.0282	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-4.27	4.07e-05	0.0282	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
GBM	cis	rs526231	0.725	rs487937	ENSG00000175749.11	EIF3KP1	4.27	4.07e-05	0.0282	0.54	0.37	Primary biliary cholangitis;	chr5:103302541	chr5:103032376~103033031:+
GBM	cis	rs6908917	0.673	rs9388877	ENSG00000219776.2	RPL21P67	4.27	4.08e-05	0.0283	0.46	0.37	IgG glycosylation;	chr6:131026144	chr6:131469059~131469536:+
GBM	cis	rs11671005	0.695	rs12972898	ENSG00000269473.1	CTD-2619J13.19	4.27	4.08e-05	0.0283	0.41	0.37	Mean platelet volume;	chr19:58445521	chr19:58440448~58445849:+
GBM	cis	rs59104589	0.583	rs73018185	ENSG00000235351.1	AC114730.11	-4.27	4.08e-05	0.0283	-0.33	-0.37	Fibrinogen levels;	chr2:241302291	chr2:241724615~241725693:-
GBM	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-4.27	4.08e-05	0.0283	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
GBM	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-4.27	4.08e-05	0.0283	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
GBM	cis	rs453301	0.571	rs2929453	ENSG00000254340.1	RP11-10A14.3	-4.27	4.08e-05	0.0283	-0.44	-0.37	Joint mobility (Beighton score);	chr8:9226831	chr8:9141424~9145435:+
GBM	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	4.27	4.08e-05	0.0283	0.47	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
GBM	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	4.27	4.08e-05	0.0283	0.45	0.37	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
GBM	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	4.27	4.08e-05	0.0283	0.45	0.37	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
GBM	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	-4.27	4.08e-05	0.0283	-0.34	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
GBM	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
GBM	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
GBM	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
GBM	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
GBM	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
GBM	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
GBM	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
GBM	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
GBM	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
GBM	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-4.27	4.08e-05	0.0283	-0.56	-0.37	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
GBM	cis	rs875971	0.862	rs11769079	ENSG00000236529.1	RP13-254B10.1	4.27	4.09e-05	0.0283	0.39	0.37	Aortic root size;	chr7:66377141	chr7:65840212~65840596:+
GBM	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-4.27	4.09e-05	0.0283	-0.46	-0.37	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
GBM	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-4.27	4.09e-05	0.0283	-0.61	-0.37	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
GBM	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-4.27	4.09e-05	0.0283	-0.45	-0.37	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
GBM	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-4.27	4.09e-05	0.0283	-0.45	-0.37	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
GBM	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-4.27	4.09e-05	0.0283	-0.41	-0.37	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
GBM	cis	rs67981189	0.593	rs9323557	ENSG00000269927.1	RP6-91H8.3	-4.27	4.09e-05	0.0283	-0.43	-0.37	Schizophrenia;	chr14:71004123	chr14:71141125~71143253:-
GBM	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	4.27	4.09e-05	0.0283	0.5	0.37	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
GBM	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	4.27	4.1e-05	0.0284	0.49	0.37	Depression;	chr6:28363475	chr6:28943877~28944537:+
GBM	cis	rs1386478	0.522	rs7643104	ENSG00000241889.1	RP11-435F17.3	-4.27	4.1e-05	0.0284	-0.43	-0.37	Crohn's disease and psoriasis;	chr3:114090526	chr3:113885298~113886031:+
GBM	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	4.27	4.11e-05	0.0284	0.41	0.37	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	4.27	4.11e-05	0.0284	0.41	0.37	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
GBM	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
GBM	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
GBM	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-4.27	4.11e-05	0.0284	-0.5	-0.37	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
GBM	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-4.27	4.11e-05	0.0284	-0.65	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-4.27	4.11e-05	0.0284	-0.65	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-4.27	4.11e-05	0.0284	-0.65	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-4.27	4.11e-05	0.0284	-0.65	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-4.27	4.11e-05	0.0284	-0.65	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
GBM	cis	rs7017914	0.69	rs17699685	ENSG00000246366.5	RP11-382J12.1	-4.27	4.11e-05	0.0285	-0.4	-0.37	Bone mineral density;	chr8:71066769	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs62506037	ENSG00000246366.5	RP11-382J12.1	-4.27	4.11e-05	0.0285	-0.4	-0.37	Bone mineral density;	chr8:71066959	chr8:70608577~70663279:+
GBM	cis	rs66887589	0.592	rs62320740	ENSG00000250412.1	KLHL2P1	4.27	4.11e-05	0.0285	0.45	0.37	Diastolic blood pressure;	chr4:119358331	chr4:119334329~119378233:+
GBM	cis	rs2898290	0.5	rs11998678	ENSG00000255556.2	RP11-351I21.6	-4.27	4.11e-05	0.0285	-0.38	-0.37	Systolic blood pressure;	chr8:11972641	chr8:12378679~12380265:-
GBM	cis	rs804280	0.509	rs35626932	ENSG00000255556.2	RP11-351I21.6	4.27	4.12e-05	0.0285	0.4	0.37	Myopia (pathological);	chr8:11929423	chr8:12378679~12380265:-
GBM	cis	rs4664293	0.667	rs2042782	ENSG00000226266.5	AC009961.3	4.27	4.12e-05	0.0285	0.47	0.37	Monocyte percentage of white cells;	chr2:159789781	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.642	rs6732598	ENSG00000226266.5	AC009961.3	4.27	4.12e-05	0.0285	0.47	0.37	Monocyte percentage of white cells;	chr2:159790370	chr2:159670708~159712435:-
GBM	cis	rs3781264	0.687	rs12217597	ENSG00000273450.1	RP11-76P2.4	-4.27	4.12e-05	0.0285	-0.42	-0.37	Esophageal cancer and gastric cancer;	chr10:94351055	chr10:94314907~94315327:-
GBM	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-4.27	4.12e-05	0.0285	-0.42	-0.37	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
GBM	cis	rs14165	0.67	rs2359133	ENSG00000271916.1	RP11-884K10.6	4.26	4.13e-05	0.0285	0.43	0.37	Refractive error;	chr3:53802715	chr3:53797764~53798019:-
GBM	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	4.26	4.13e-05	0.0285	0.43	0.37	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	4.26	4.13e-05	0.0285	0.43	0.37	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	4.26	4.13e-05	0.0285	0.43	0.37	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	4.26	4.13e-05	0.0285	0.43	0.37	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-4.26	4.13e-05	0.0285	-0.42	-0.37	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
GBM	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-4.26	4.13e-05	0.0285	-0.42	-0.37	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
GBM	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-4.26	4.13e-05	0.0285	-0.42	-0.37	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
GBM	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-4.26	4.13e-05	0.0285	-0.4	-0.37	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
GBM	cis	rs977747	0.966	rs1543502	ENSG00000232022.5	FAAHP1	-4.26	4.13e-05	0.0285	-0.37	-0.37	Body mass index;	chr1:47211417	chr1:46432129~46445521:+
GBM	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-4.26	4.13e-05	0.0286	-0.4	-0.37	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
GBM	cis	rs11673344	0.523	rs7245520	ENSG00000226686.6	LINC01535	4.26	4.13e-05	0.0286	0.39	0.37	Obesity-related traits;	chr19:37036416	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.523	rs7256380	ENSG00000226686.6	LINC01535	4.26	4.13e-05	0.0286	0.39	0.37	Obesity-related traits;	chr19:37041178	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.523	rs7245453	ENSG00000226686.6	LINC01535	4.26	4.13e-05	0.0286	0.39	0.37	Obesity-related traits;	chr19:37043447	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.523	rs36096221	ENSG00000226686.6	LINC01535	4.26	4.13e-05	0.0286	0.39	0.37	Obesity-related traits;	chr19:37060838	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.523	rs6510585	ENSG00000226686.6	LINC01535	4.26	4.13e-05	0.0286	0.39	0.37	Obesity-related traits;	chr19:37063081	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.523	rs17206540	ENSG00000226686.6	LINC01535	4.26	4.13e-05	0.0286	0.39	0.37	Obesity-related traits;	chr19:37069009	chr19:37251912~37265535:+
GBM	cis	rs1799949	1	rs4793236	ENSG00000267681.1	CTD-3199J23.6	-4.26	4.13e-05	0.0286	-0.42	-0.37	Menopause (age at onset);	chr17:43359072	chr17:43144956~43145255:+
GBM	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-4.26	4.13e-05	0.0286	-0.36	-0.37	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
GBM	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	4.26	4.14e-05	0.0286	0.48	0.37	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
GBM	cis	rs732716	0.504	rs9352	ENSG00000267769.1	CTB-50L17.9	-4.26	4.14e-05	0.0286	-0.36	-0.37	Mean corpuscular volume;	chr19:4442339	chr19:4454014~4455286:+
GBM	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	4.26	4.14e-05	0.0286	0.44	0.37	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
GBM	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	4.26	4.14e-05	0.0286	0.44	0.37	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
GBM	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-4.26	4.14e-05	0.0286	-0.47	-0.37	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
GBM	cis	rs8177876	0.749	rs12927828	ENSG00000261838.4	RP11-303E16.6	4.26	4.14e-05	0.0286	0.67	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81069854~81076598:+
GBM	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-4.26	4.14e-05	0.0286	-0.51	-0.37	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
GBM	cis	rs763121	0.853	rs5750672	ENSG00000273076.1	RP3-508I15.22	-4.26	4.15e-05	0.0286	-0.4	-0.37	Menopause (age at onset);	chr22:38708163	chr22:38743495~38743910:+
GBM	cis	rs2278702	0.848	rs77593396	ENSG00000259495.2	RP11-210M15.2	-4.26	4.15e-05	0.0286	-0.38	-0.37	Bipolar disorder;	chr15:80387970	chr15:80344853~80403575:-
GBM	cis	rs3806843	1	rs10072015	ENSG00000202111.1	VTRNA1-2	4.26	4.15e-05	0.0286	0.38	0.37	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr5:140718925~140719013:+
GBM	cis	rs4295623	0.504	rs11250160	ENSG00000255556.2	RP11-351I21.6	-4.26	4.15e-05	0.0287	-0.4	-0.37	Morning vs. evening chronotype;	chr8:11735208	chr8:12378679~12380265:-
GBM	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	4.26	4.15e-05	0.0287	0.51	0.37	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	4.26	4.15e-05	0.0287	0.51	0.37	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
GBM	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	4.26	4.16e-05	0.0287	0.39	0.37	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
GBM	cis	rs66887589	0.616	rs11732621	ENSG00000250412.1	KLHL2P1	4.26	4.16e-05	0.0287	0.45	0.37	Diastolic blood pressure;	chr4:119291728	chr4:119334329~119378233:+
GBM	cis	rs66887589	0.616	rs1052633	ENSG00000250412.1	KLHL2P1	4.26	4.16e-05	0.0287	0.45	0.37	Diastolic blood pressure;	chr4:119294159	chr4:119334329~119378233:+
GBM	cis	rs66887589	0.592	rs2175383	ENSG00000250412.1	KLHL2P1	4.26	4.16e-05	0.0287	0.45	0.37	Diastolic blood pressure;	chr4:119294681	chr4:119334329~119378233:+
GBM	cis	rs11773103	0.786	rs6979269	ENSG00000224046.1	AC005076.5	4.26	4.16e-05	0.0287	0.58	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87125666	chr7:87151423~87152420:-
GBM	cis	rs11773103	0.786	rs734607	ENSG00000224046.1	AC005076.5	4.26	4.16e-05	0.0287	0.58	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87125842	chr7:87151423~87152420:-
GBM	cis	rs950169	0.881	rs34117475	ENSG00000275120.1	RP11-182J1.17	4.26	4.17e-05	0.0287	0.48	0.37	Schizophrenia;	chr15:84565212	chr15:84599434~84606463:-
GBM	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-4.26	4.17e-05	0.0287	-0.4	-0.37	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
GBM	cis	rs2025751	0.512	rs1326600	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51828732	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463722	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51829301	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9474096	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51829531	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463724	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51829708	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs12204614	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51829954	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.578	rs2025752	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51830415	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs1571083	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51830772	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs1571084	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51830849	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs1571085	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51831258	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs1571086	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51831276	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9474101	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51831958	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs1326603	ENSG00000230204.1	FTH1P5	-4.26	4.17e-05	0.0287	-0.43	-0.37	Intraocular pressure;	chr6:51832382	chr6:50912712~50913256:-
GBM	cis	rs17685	0.753	rs1574107	ENSG00000280388.1	RP11-229D13.3	-4.26	4.17e-05	0.0288	-0.34	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76055729	chr7:76043977~76045963:-
GBM	cis	rs7829975	0.557	rs7816427	ENSG00000253893.2	FAM85B	4.26	4.17e-05	0.0288	0.48	0.37	Mood instability;	chr8:8688374	chr8:8167819~8226614:-
GBM	cis	rs6600671	0.934	rs11249429	ENSG00000223345.3	HIST2H2BA	-4.26	4.18e-05	0.0288	-0.48	-0.37	Hip geometry;	chr1:121549282	chr1:121108210~121117257:-
GBM	cis	rs4604732	0.642	rs4266925	ENSG00000227135.1	GCSAML-AS1	-4.26	4.18e-05	0.0288	-0.48	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247475863	chr1:247524679~247526752:-
GBM	cis	rs34375054	0.525	rs7398636	ENSG00000279233.1	RP11-158L12.4	4.26	4.18e-05	0.0288	0.39	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125114058	chr12:125138245~125141711:+
GBM	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	4.26	4.18e-05	0.0288	0.36	0.37	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
GBM	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-4.26	4.19e-05	0.0288	-0.65	-0.37	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
GBM	cis	rs4499344	0.73	rs259279	ENSG00000201388.1	SNORA68	-4.26	4.19e-05	0.0289	-0.42	-0.37	Mean platelet volume;	chr19:32670368	chr19:32608337~32608469:-
GBM	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	4.26	4.19e-05	0.0289	0.45	0.37	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
GBM	cis	rs875971	0.767	rs12668005	ENSG00000236529.1	RP13-254B10.1	4.26	4.2e-05	0.0289	0.39	0.37	Aortic root size;	chr7:66444034	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs11765791	ENSG00000236529.1	RP13-254B10.1	4.26	4.2e-05	0.0289	0.39	0.37	Aortic root size;	chr7:66471587	chr7:65840212~65840596:+
GBM	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-4.26	4.2e-05	0.0289	-0.43	-0.37	Height;	chr20:35176829	chr20:35201747~35203288:-
GBM	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-4.26	4.2e-05	0.0289	-0.49	-0.37	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
GBM	cis	rs875971	0.83	rs6976714	ENSG00000236529.1	RP13-254B10.1	4.26	4.21e-05	0.0289	0.39	0.37	Aortic root size;	chr7:66426474	chr7:65840212~65840596:+
GBM	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	4.26	4.21e-05	0.0289	0.39	0.37	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	4.26	4.21e-05	0.0289	0.39	0.37	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	4.26	4.21e-05	0.0289	0.39	0.37	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	4.26	4.21e-05	0.0289	0.39	0.37	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
GBM	cis	rs73198271	0.92	rs11783112	ENSG00000253893.2	FAM85B	4.26	4.21e-05	0.0289	0.53	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748683	chr8:8167819~8226614:-
GBM	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	4.26	4.21e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	4.26	4.21e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	4.26	4.21e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.965	rs7460287	ENSG00000253982.1	CTD-2336O2.1	4.26	4.21e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr8:1760108	chr8:1761990~1764502:-
GBM	cis	rs8062405	0.755	rs56209193	ENSG00000271623.1	RP11-435I10.5	-4.26	4.21e-05	0.0289	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28364700~28365333:+
GBM	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	4.26	4.22e-05	0.029	0.49	0.37	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
GBM	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-4.26	4.22e-05	0.029	-0.42	-0.37	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
GBM	cis	rs1420956	0.562	rs8088837	ENSG00000264151.4	RP11-739N10.1	4.26	4.22e-05	0.029	0.5	0.37	Obesity-related traits;	chr18:27569676	chr18:27336379~27595164:-
GBM	cis	rs55940216	0.685	rs2517353	ENSG00000245281.5	CTD-2547L16.1	4.26	4.22e-05	0.029	0.43	0.37	Facial morphology (factor 14, intercanthal width);	chr8:18125289	chr8:18084868~18096394:+
GBM	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	4.26	4.23e-05	0.029	0.44	0.37	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
GBM	cis	rs6496932	0.913	rs4843037	ENSG00000218052.5	ADAMTS7P4	4.26	4.23e-05	0.0291	0.55	0.37	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:85255369~85330334:-
GBM	cis	rs4604732	1	rs4604732	ENSG00000227135.1	GCSAML-AS1	4.26	4.23e-05	0.0291	0.53	0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460570	chr1:247524679~247526752:-
GBM	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-4.26	4.23e-05	0.0291	-0.38	-0.37	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
GBM	cis	rs8114671	0.967	rs3746427	ENSG00000269202.1	RP4-614O4.12	-4.26	4.23e-05	0.0291	-0.44	-0.37	Height;	chr20:35142661	chr20:35201747~35203288:-
GBM	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-4.26	4.23e-05	0.0291	-0.38	-0.37	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
GBM	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-4.26	4.23e-05	0.0291	-0.38	-0.37	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
GBM	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	4.26	4.24e-05	0.0291	0.42	0.37	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
GBM	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	4.26	4.24e-05	0.0291	0.42	0.37	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
GBM	cis	rs3744061	0.557	rs9889862	ENSG00000277382.1	RP11-318A15.8	4.26	4.24e-05	0.0291	0.45	0.37	Retinal arteriolar caliber;	chr17:76651894	chr17:76709760~76710045:+
GBM	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	4.26	4.24e-05	0.0291	0.44	0.37	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
GBM	cis	rs8114671	0.935	rs6058198	ENSG00000269202.1	RP4-614O4.12	-4.26	4.24e-05	0.0291	-0.44	-0.37	Height;	chr20:35160450	chr20:35201747~35203288:-
GBM	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	4.26	4.24e-05	0.0291	0.43	0.37	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
GBM	cis	rs7315956	0.929	rs10879100	ENSG00000257139.1	RP11-320P7.2	-4.26	4.24e-05	0.0291	-0.43	-0.37	Testicular germ cell tumor;	chr12:70167411	chr12:70180338~70202004:+
GBM	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	4.26	4.25e-05	0.0292	0.49	0.37	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
GBM	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	4.26	4.25e-05	0.0292	0.41	0.37	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
GBM	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	4.26	4.25e-05	0.0292	0.41	0.37	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
GBM	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	4.26	4.25e-05	0.0292	0.41	0.37	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	4.26	4.25e-05	0.0292	0.41	0.37	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	4.26	4.25e-05	0.0292	0.41	0.37	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	4.26	4.25e-05	0.0292	0.41	0.37	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
GBM	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	4.26	4.25e-05	0.0292	0.44	0.37	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
GBM	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	4.26	4.26e-05	0.0292	0.44	0.37	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
GBM	cis	rs7267979	0.586	rs11087505	ENSG00000276952.1	RP5-965G21.6	4.26	4.26e-05	0.0292	0.35	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25284915~25285588:-
GBM	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-4.26	4.27e-05	0.0293	-0.69	-0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
GBM	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	4.26	4.27e-05	0.0293	0.31	0.37	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
GBM	cis	rs763121	0.853	rs2235230	ENSG00000273076.1	RP3-508I15.22	-4.26	4.27e-05	0.0293	-0.41	-0.37	Menopause (age at onset);	chr22:38728462	chr22:38743495~38743910:+
GBM	cis	rs4642101	0.537	rs4997708	ENSG00000213943.3	KRT18P17	4.26	4.27e-05	0.0293	0.39	0.37	QRS complex (12-leadsum);	chr3:12798104	chr3:12787393~12788671:-
GBM	cis	rs4642101	0.56	rs4535210	ENSG00000213943.3	KRT18P17	4.26	4.27e-05	0.0293	0.39	0.37	QRS complex (12-leadsum);	chr3:12798118	chr3:12787393~12788671:-
GBM	cis	rs7017914	0.875	rs2732107	ENSG00000246366.5	RP11-382J12.1	-4.26	4.27e-05	0.0293	-0.39	-0.37	Bone mineral density;	chr8:71013073	chr8:70608577~70663279:+
GBM	cis	rs17508449	0.819	rs74524050	ENSG00000232450.1	RP4-730K3.3	-4.26	4.27e-05	0.0293	-0.63	-0.37	Leprosy;	chr1:113688585	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.775	rs4839336	ENSG00000232450.1	RP4-730K3.3	-4.26	4.27e-05	0.0293	-0.63	-0.37	Leprosy;	chr1:113691523	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs77551704	ENSG00000232450.1	RP4-730K3.3	-4.26	4.27e-05	0.0293	-0.63	-0.37	Leprosy;	chr1:113692564	chr1:113698884~113699631:-
GBM	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	4.26	4.27e-05	0.0293	0.38	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
GBM	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	4.26	4.28e-05	0.0293	0.37	0.37	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
GBM	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	4.26	4.28e-05	0.0294	0.42	0.37	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
GBM	cis	rs11654801	0.812	rs8080233	ENSG00000233098.7	CCDC144NL-AS1	-4.25	4.29e-05	0.0294	-0.5	-0.37	Mosquito bite size;	chr17:20963541	chr17:20868433~21002276:+
GBM	cis	rs875971	0.545	rs6950988	ENSG00000222364.1	RNU6-96P	-4.25	4.29e-05	0.0294	-0.43	-0.37	Aortic root size;	chr7:66511428	chr7:66395191~66395286:+
GBM	cis	rs977747	0.689	rs7545034	ENSG00000232022.5	FAAHP1	4.25	4.29e-05	0.0294	0.37	0.37	Body mass index;	chr1:47193773	chr1:46432129~46445521:+
GBM	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	4.25	4.3e-05	0.0294	0.5	0.37	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	4.25	4.3e-05	0.0294	0.5	0.37	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	4.25	4.3e-05	0.0294	0.5	0.37	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
GBM	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-4.25	4.3e-05	0.0295	-0.3	-0.37	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
GBM	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	4.25	4.3e-05	0.0295	0.53	0.37	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
GBM	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	4.25	4.3e-05	0.0295	0.26	0.37	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
GBM	cis	rs875971	0.767	rs1643394	ENSG00000236529.1	RP13-254B10.1	4.25	4.3e-05	0.0295	0.4	0.37	Aortic root size;	chr7:66371107	chr7:65840212~65840596:+
GBM	cis	rs3742264	1	rs9316180	ENSG00000235903.6	CPB2-AS1	4.25	4.31e-05	0.0295	0.44	0.37	Blood protein levels;	chr13:46067550	chr13:46052806~46113332:+
GBM	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	4.25	4.31e-05	0.0295	0.43	0.37	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
GBM	cis	rs1420956	0.624	rs62080906	ENSG00000264151.4	RP11-739N10.1	4.25	4.32e-05	0.0296	0.49	0.37	Obesity-related traits;	chr18:27569099	chr18:27336379~27595164:-
GBM	cis	rs1420956	0.624	rs62080907	ENSG00000264151.4	RP11-739N10.1	4.25	4.32e-05	0.0296	0.49	0.37	Obesity-related traits;	chr18:27569221	chr18:27336379~27595164:-
GBM	cis	rs1420956	0.603	rs62080909	ENSG00000264151.4	RP11-739N10.1	4.25	4.32e-05	0.0296	0.49	0.37	Obesity-related traits;	chr18:27569247	chr18:27336379~27595164:-
GBM	cis	rs1420956	0.624	rs62080910	ENSG00000264151.4	RP11-739N10.1	4.25	4.32e-05	0.0296	0.49	0.37	Obesity-related traits;	chr18:27569294	chr18:27336379~27595164:-
GBM	cis	rs1420956	0.603	rs8092173	ENSG00000264151.4	RP11-739N10.1	4.25	4.32e-05	0.0296	0.49	0.37	Obesity-related traits;	chr18:27569506	chr18:27336379~27595164:-
GBM	cis	rs9368481	0.547	rs2093303	ENSG00000238621.1	TRI-TAT2-2	-4.25	4.32e-05	0.0296	-0.41	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:27020335~27020447:+
GBM	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-4.25	4.32e-05	0.0296	-0.31	-0.37	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
GBM	cis	rs17772222	0.582	rs1288122	ENSG00000258983.2	RP11-507K2.2	-4.25	4.32e-05	0.0296	-0.39	-0.37	Coronary artery calcification;	chr14:88472736	chr14:88499334~88515502:+
GBM	cis	rs763121	0.853	rs9610986	ENSG00000273076.1	RP3-508I15.22	4.25	4.32e-05	0.0296	0.4	0.37	Menopause (age at onset);	chr22:38629272	chr22:38743495~38743910:+
GBM	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-4.25	4.32e-05	0.0296	-0.56	-0.37	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
GBM	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-4.25	4.32e-05	0.0296	-0.56	-0.37	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
GBM	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-4.25	4.32e-05	0.0296	-0.56	-0.37	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
GBM	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	4.25	4.32e-05	0.0296	0.4	0.37	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
GBM	cis	rs2963463	0.715	rs2964487	ENSG00000253519.1	AC106801.1	4.25	4.33e-05	0.0296	0.51	0.37	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158486832	chr5:157565964~157569098:+
GBM	cis	rs1865760	0.686	rs12210098	ENSG00000272810.1	U91328.22	-4.25	4.34e-05	0.0297	-0.48	-0.37	Height;	chr6:25963738	chr6:26013241~26013757:+
GBM	cis	rs875971	0.862	rs778736	ENSG00000236529.1	RP13-254B10.1	4.25	4.34e-05	0.0297	0.39	0.37	Aortic root size;	chr7:66348861	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs3893216	ENSG00000236529.1	RP13-254B10.1	-4.25	4.34e-05	0.0297	-0.39	-0.37	Aortic root size;	chr7:66325720	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs2088655	ENSG00000236529.1	RP13-254B10.1	-4.25	4.34e-05	0.0297	-0.39	-0.37	Aortic root size;	chr7:66330724	chr7:65840212~65840596:+
GBM	cis	rs875971	0.895	rs10447522	ENSG00000236529.1	RP13-254B10.1	-4.25	4.34e-05	0.0297	-0.39	-0.37	Aortic root size;	chr7:66331087	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs2088653	ENSG00000236529.1	RP13-254B10.1	-4.25	4.34e-05	0.0297	-0.39	-0.37	Aortic root size;	chr7:66343621	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6460293	ENSG00000236529.1	RP13-254B10.1	-4.25	4.34e-05	0.0297	-0.39	-0.37	Aortic root size;	chr7:66345205	chr7:65840212~65840596:+
GBM	cis	rs7925523	0.891	rs2903825	ENSG00000255553.1	RP11-810P12.5	-4.25	4.35e-05	0.0297	-0.77	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr11:61721496	chr11:62077277~62082184:-
GBM	cis	rs4713118	0.513	rs200971	ENSG00000218016.2	ZNF192P2	-4.25	4.35e-05	0.0297	-0.5	-0.37	Parkinson's disease;	chr6:27891126	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.539	rs200967	ENSG00000218016.2	ZNF192P2	-4.25	4.35e-05	0.0297	-0.5	-0.37	Parkinson's disease;	chr6:27894349	chr6:28188050~28189432:+
GBM	cis	rs875971	0.798	rs6460304	ENSG00000236529.1	RP13-254B10.1	4.25	4.35e-05	0.0298	0.39	0.37	Aortic root size;	chr7:66499741	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6945775	ENSG00000236529.1	RP13-254B10.1	4.25	4.35e-05	0.0298	0.39	0.37	Aortic root size;	chr7:66503987	chr7:65840212~65840596:+
GBM	cis	rs875971	0.798	rs57739047	ENSG00000236529.1	RP13-254B10.1	4.25	4.35e-05	0.0298	0.39	0.37	Aortic root size;	chr7:66507579	chr7:65840212~65840596:+
GBM	cis	rs10435719	0.902	rs4840599	ENSG00000255556.2	RP11-351I21.6	-4.25	4.36e-05	0.0298	-0.38	-0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12378679~12380265:-
GBM	cis	rs9425766	0.64	rs3791020	ENSG00000270084.1	GAS5-AS1	4.25	4.36e-05	0.0298	0.43	0.37	Life satisfaction;	chr1:173844059	chr1:173863248~173863941:+
GBM	cis	rs2013441	1	rs9915059	ENSG00000230528.6	NOS2P3	4.25	4.36e-05	0.0298	0.45	0.37	Obesity-related traits;	chr17:20273791	chr17:20436337~20447249:+
GBM	cis	rs9393777	0.623	rs1884943	ENSG00000224843.5	LINC00240	4.25	4.36e-05	0.0298	0.59	0.37	Intelligence (multi-trait analysis);	chr6:26485497	chr6:26956992~27023924:+
GBM	cis	rs17685	0.712	rs7785025	ENSG00000280388.1	RP11-229D13.3	4.25	4.36e-05	0.0298	0.35	0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:75998783	chr7:76043977~76045963:-
GBM	cis	rs11168351	1	rs11168351	ENSG00000258273.1	RP11-370I10.4	-4.25	4.36e-05	0.0298	-0.48	-0.37	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48333755~48333901:-
GBM	cis	rs3845817	1	rs11126042	ENSG00000237979.1	AC007389.1	-4.25	4.36e-05	0.0298	-0.53	-0.37	Bipolar disorder;	chr2:65536511	chr2:65500993~65502138:-
GBM	cis	rs8062405	0.757	rs2411453	ENSG00000271623.1	RP11-435I10.5	4.25	4.36e-05	0.0298	0.43	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28364700~28365333:+
GBM	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-4.25	4.37e-05	0.0298	-0.43	-0.37	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
GBM	cis	rs2115630	1	rs11073730	ENSG00000225151.9	GOLGA2P7	4.25	4.37e-05	0.0298	0.39	0.37	P wave terminal force;	chr15:84811365	chr15:84199311~84230136:-
GBM	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	4.25	4.37e-05	0.0299	0.41	0.37	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
GBM	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-4.25	4.37e-05	0.0299	-0.5	-0.37	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
GBM	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	4.25	4.38e-05	0.0299	0.4	0.37	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	4.25	4.38e-05	0.0299	0.4	0.37	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
GBM	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	4.25	4.38e-05	0.0299	0.4	0.37	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	4.25	4.38e-05	0.0299	0.4	0.37	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
GBM	cis	rs7176527	1	rs7176527	ENSG00000225151.9	GOLGA2P7	4.25	4.38e-05	0.0299	0.55	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84199311~84230136:-
GBM	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	4.25	4.38e-05	0.0299	0.45	0.37	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
GBM	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	4.25	4.38e-05	0.0299	0.49	0.37	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
GBM	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	4.25	4.38e-05	0.0299	0.55	0.37	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
GBM	cis	rs7017914	0.652	rs13264053	ENSG00000246366.5	RP11-382J12.1	-4.25	4.38e-05	0.0299	-0.4	-0.37	Bone mineral density;	chr8:71079101	chr8:70608577~70663279:+
GBM	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	4.25	4.38e-05	0.0299	0.35	0.37	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
GBM	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	4.25	4.38e-05	0.0299	0.35	0.37	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
GBM	cis	rs7315956	1	rs7315956	ENSG00000257139.1	RP11-320P7.2	-4.25	4.38e-05	0.0299	-0.43	-0.37	Testicular germ cell tumor;	chr12:70170085	chr12:70180338~70202004:+
GBM	cis	rs9368481	0.743	rs9368480	ENSG00000224843.5	LINC00240	-4.25	4.38e-05	0.0299	-0.45	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26956992~27023924:+
GBM	cis	rs2311126	0.965	rs9954811	ENSG00000264350.1	SNRPGP2	-4.25	4.39e-05	0.0299	-0.3	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr18:54878658	chr18:54406889~54407114:-
GBM	cis	rs1150668	0.799	rs1150705	ENSG00000218016.2	ZNF192P2	-4.25	4.39e-05	0.0299	-0.42	-0.37	Pubertal anthropometrics;	chr6:28226008	chr6:28188050~28189432:+
GBM	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-4.25	4.39e-05	0.03	-0.43	-0.37	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
GBM	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	4.25	4.39e-05	0.03	0.44	0.37	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
GBM	cis	rs2963463	0.683	rs2946167	ENSG00000253519.1	AC106801.1	4.25	4.39e-05	0.03	0.5	0.37	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158491334	chr5:157565964~157569098:+
GBM	cis	rs2963463	0.715	rs2946169	ENSG00000253519.1	AC106801.1	4.25	4.39e-05	0.03	0.5	0.37	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158491951	chr5:157565964~157569098:+
GBM	cis	rs2963463	0.715	rs2964488	ENSG00000253519.1	AC106801.1	4.25	4.39e-05	0.03	0.5	0.37	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158492064	chr5:157565964~157569098:+
GBM	cis	rs3845817	1	rs3911863	ENSG00000237979.1	AC007389.1	-4.25	4.39e-05	0.03	-0.53	-0.37	Bipolar disorder;	chr2:65532630	chr2:65500993~65502138:-
GBM	cis	rs3845817	0.966	rs3845818	ENSG00000237979.1	AC007389.1	-4.25	4.39e-05	0.03	-0.53	-0.37	Bipolar disorder;	chr2:65533349	chr2:65500993~65502138:-
GBM	cis	rs8062405	0.69	rs4787458	ENSG00000271623.1	RP11-435I10.5	-4.25	4.4e-05	0.03	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28364700~28365333:+
GBM	cis	rs597539	0.69	rs7104351	ENSG00000250508.1	RP11-757G1.6	-4.25	4.4e-05	0.03	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68850418	chr11:68870664~68874542:+
GBM	cis	rs597539	0.69	rs1272609	ENSG00000250508.1	RP11-757G1.6	-4.25	4.4e-05	0.03	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68850714	chr11:68870664~68874542:+
GBM	cis	rs597539	0.69	rs1249359	ENSG00000250508.1	RP11-757G1.6	-4.25	4.4e-05	0.03	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68850811	chr11:68870664~68874542:+
GBM	cis	rs597539	0.69	rs659465	ENSG00000250508.1	RP11-757G1.6	-4.25	4.4e-05	0.03	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68851496	chr11:68870664~68874542:+
GBM	cis	rs597539	0.727	rs632984	ENSG00000250508.1	RP11-757G1.6	-4.25	4.4e-05	0.03	-0.52	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68852803	chr11:68870664~68874542:+
GBM	cis	rs66887589	0.616	rs11731675	ENSG00000250412.1	KLHL2P1	4.25	4.4e-05	0.03	0.45	0.37	Diastolic blood pressure;	chr4:119291359	chr4:119334329~119378233:+
GBM	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	4.25	4.41e-05	0.03	0.39	0.37	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
GBM	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	4.25	4.41e-05	0.03	0.43	0.37	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
GBM	cis	rs17772222	0.874	rs78077739	ENSG00000222990.1	RNU4-22P	4.25	4.41e-05	0.03	0.44	0.37	Coronary artery calcification;	chr14:88741176	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs61983300	ENSG00000222990.1	RNU4-22P	4.25	4.41e-05	0.03	0.44	0.37	Coronary artery calcification;	chr14:88754047	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.876	rs78068036	ENSG00000222990.1	RNU4-22P	4.25	4.41e-05	0.03	0.44	0.37	Coronary artery calcification;	chr14:88754817	chr14:88513498~88513663:+
GBM	cis	rs1065656	0.589	rs391543	ENSG00000269937.1	RP11-20I23.8	-4.25	4.41e-05	0.03	-0.47	-0.37	Insulin-like growth factors;	chr16:1865582	chr16:2561471~2565096:-
GBM	cis	rs7615952	0.515	rs7637246	ENSG00000250012.1	RP11-124N2.1	-4.25	4.41e-05	0.0301	-0.44	-0.37	Blood pressure (smoking interaction);	chr3:125959863	chr3:126084220~126095349:+
GBM	cis	rs4965869	0.703	rs2643356	ENSG00000259376.1	RP11-505E24.3	4.25	4.41e-05	0.0301	0.45	0.37	Platelet-derived growth factor BB levels;	chr15:101431183	chr15:101043716~101049456:-
GBM	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	4.25	4.42e-05	0.0301	0.54	0.37	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
GBM	cis	rs7925523	0.891	rs9735635	ENSG00000255553.1	RP11-810P12.5	-4.25	4.42e-05	0.0301	-0.76	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr11:61723408	chr11:62077277~62082184:-
GBM	cis	rs11671005	0.571	rs56243535	ENSG00000269600.1	AC016629.3	-4.25	4.42e-05	0.0301	-0.52	-0.37	Mean platelet volume;	chr19:58494783	chr19:58593896~58599355:-
GBM	cis	rs7017914	0.905	rs2732102	ENSG00000246366.5	RP11-382J12.1	4.25	4.42e-05	0.0301	0.39	0.37	Bone mineral density;	chr8:71010637	chr8:70608577~70663279:+
GBM	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	4.25	4.42e-05	0.0301	0.76	0.37	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
GBM	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	4.25	4.42e-05	0.0301	0.31	0.37	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
GBM	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	4.25	4.43e-05	0.0301	0.49	0.37	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
GBM	cis	rs4713118	0.513	rs149941	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28033255	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149942	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28033832	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149944	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28035040	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149945	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28035075	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149897	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28038872	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs156734	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28039579	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs202908	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28043773	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs156739	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28045632	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149958	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28045839	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149959	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28046076	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs156738	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28046247	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149962	ENSG00000218016.2	ZNF192P2	-4.25	4.43e-05	0.0301	-0.52	-0.37	Parkinson's disease;	chr6:28048140	chr6:28188050~28189432:+
GBM	cis	rs7826238	0.72	rs12546760	ENSG00000225725.4	FAM66E	4.25	4.43e-05	0.0301	0.45	0.37	Systolic blood pressure;	chr8:8517326	chr8:7955014~8008755:+
GBM	cis	rs9983113	0.903	rs1029003	ENSG00000231123.1	SPATA20P1	-4.25	4.43e-05	0.0302	-0.37	-0.37	Body mass index;	chr21:38937198	chr21:38238227~38238664:-
GBM	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-4.25	4.43e-05	0.0302	-0.34	-0.37	Temperament;	chr17:14048649	chr17:14024514~14025488:+
GBM	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	4.25	4.44e-05	0.0302	0.43	0.37	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
GBM	cis	rs875971	0.862	rs4149461	ENSG00000236529.1	RP13-254B10.1	-4.25	4.44e-05	0.0302	-0.39	-0.37	Aortic root size;	chr7:66279745	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs4236208	ENSG00000236529.1	RP13-254B10.1	-4.25	4.44e-05	0.0302	-0.39	-0.37	Aortic root size;	chr7:66284091	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10261398	ENSG00000236529.1	RP13-254B10.1	-4.25	4.44e-05	0.0302	-0.39	-0.37	Aortic root size;	chr7:66285177	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10224872	ENSG00000236529.1	RP13-254B10.1	-4.25	4.44e-05	0.0302	-0.39	-0.37	Aortic root size;	chr7:66294786	chr7:65840212~65840596:+
GBM	cis	rs7487075	0.535	rs7979810	ENSG00000257261.4	RP11-96H19.1	4.25	4.44e-05	0.0302	0.36	0.37	Itch intensity from mosquito bite;	chr12:46691737	chr12:46383679~46876159:+
GBM	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	4.25	4.44e-05	0.0302	0.57	0.37	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
GBM	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-4.25	4.44e-05	0.0302	-0.41	-0.37	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-4.25	4.44e-05	0.0302	-0.41	-0.37	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-4.25	4.44e-05	0.0302	-0.41	-0.37	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
GBM	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	4.25	4.44e-05	0.0302	0.64	0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-4.25	4.44e-05	0.0302	-0.64	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
GBM	cis	rs34975555	0.614	rs12056629	ENSG00000254054.2	RP11-156K13.3	4.25	4.45e-05	0.0302	0.54	0.37	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:18003354	chr8:17905756~17907887:+
GBM	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	4.25	4.45e-05	0.0302	0.46	0.37	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
GBM	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	4.25	4.45e-05	0.0302	0.36	0.37	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
GBM	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	4.25	4.45e-05	0.0302	0.36	0.37	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
GBM	cis	rs1413299	0.77	rs4743308	ENSG00000237461.1	RP11-554F20.1	-4.25	4.45e-05	0.0302	-0.53	-0.37	Epithelial ovarian cancer;	chr9:99017157	chr9:99585786~99819889:-
GBM	cis	rs1823874	0.72	rs7162911	ENSG00000182397.13	DNM1P46	-4.24	4.46e-05	0.0303	-0.41	-0.37	IgG glycosylation;	chr15:99814845	chr15:99790156~99806927:-
GBM	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	4.24	4.46e-05	0.0303	0.48	0.37	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
GBM	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-4.24	4.46e-05	0.0303	-0.47	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
GBM	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	4.24	4.46e-05	0.0303	0.62	0.37	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
GBM	cis	rs66887589	0.616	rs6822808	ENSG00000250412.1	KLHL2P1	4.24	4.46e-05	0.0303	0.45	0.37	Diastolic blood pressure;	chr4:119296210	chr4:119334329~119378233:+
GBM	cis	rs62184315	0.58	rs62185872	ENSG00000253559.1	OSGEPL1-AS1	-4.24	4.46e-05	0.0303	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189690033	chr2:189762704~189765556:+
GBM	cis	rs1974653	0.567	rs7284822	ENSG00000277950.1	Metazoa_SRP	4.24	4.46e-05	0.0303	0.51	0.37	Schizophrenia;	chr22:20069555	chr22:20070716~20070965:+
GBM	cis	rs2976388	0.625	rs2257840	ENSG00000253741.1	CTD-2292P10.4	-4.24	4.47e-05	0.0304	-0.38	-0.37	Urinary tract infection frequency;	chr8:142727775	chr8:142702252~142726973:-
GBM	cis	rs10231759	0.53	rs741065	ENSG00000273419.1	RP4-751H13.7	-4.24	4.48e-05	0.0304	-0.43	-0.37	Height;	chr7:150803488	chr7:149858400~149862492:-
GBM	cis	rs1441264	0.565	rs1596033	ENSG00000230584.1	CCT5P2	-4.24	4.48e-05	0.0304	-0.35	-0.37	Body mass index;Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);	chr13:79018327	chr13:78908919~78910542:+
GBM	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-4.24	4.48e-05	0.0304	-0.49	-0.37	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
GBM	cis	rs11098499	0.739	rs4833612	ENSG00000250412.1	KLHL2P1	-4.24	4.48e-05	0.0304	-0.5	-0.37	Corneal astigmatism;	chr4:119226441	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.739	rs10013032	ENSG00000250412.1	KLHL2P1	-4.24	4.48e-05	0.0304	-0.5	-0.37	Corneal astigmatism;	chr4:119228264	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.739	rs951570	ENSG00000250412.1	KLHL2P1	-4.24	4.48e-05	0.0304	-0.5	-0.37	Corneal astigmatism;	chr4:119229312	chr4:119334329~119378233:+
GBM	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	4.24	4.48e-05	0.0304	0.38	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
GBM	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	4.24	4.48e-05	0.0304	0.38	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
GBM	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	4.24	4.48e-05	0.0304	0.38	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
GBM	cis	rs11773103	0.786	rs73202985	ENSG00000224046.1	AC005076.5	4.24	4.49e-05	0.0304	0.58	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87126604	chr7:87151423~87152420:-
GBM	cis	rs11773103	0.581	rs73202987	ENSG00000224046.1	AC005076.5	4.24	4.49e-05	0.0304	0.58	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87126637	chr7:87151423~87152420:-
GBM	cis	rs11773103	0.786	rs73202988	ENSG00000224046.1	AC005076.5	4.24	4.49e-05	0.0304	0.58	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87127087	chr7:87151423~87152420:-
GBM	cis	rs11773103	0.786	rs73202994	ENSG00000224046.1	AC005076.5	4.24	4.49e-05	0.0304	0.58	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87127312	chr7:87151423~87152420:-
GBM	cis	rs11773103	0.786	rs73202997	ENSG00000224046.1	AC005076.5	4.24	4.49e-05	0.0304	0.58	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87127363	chr7:87151423~87152420:-
GBM	cis	rs17772222	0.917	rs12588535	ENSG00000222990.1	RNU4-22P	4.24	4.49e-05	0.0304	0.45	0.37	Coronary artery calcification;	chr14:88781900	chr14:88513498~88513663:+
GBM	cis	rs4664293	0.667	rs10169681	ENSG00000226266.5	AC009961.3	4.24	4.49e-05	0.0304	0.46	0.37	Monocyte percentage of white cells;	chr2:159782065	chr2:159670708~159712435:-
GBM	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-4.24	4.49e-05	0.0305	-0.49	-0.37	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
GBM	cis	rs9548119	1	rs9548119	ENSG00000223685.4	LINC00571	-4.24	4.5e-05	0.0305	-0.56	-0.37	Self-rated health;	chr13:37957444	chr13:38050817~38143232:-
GBM	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	4.24	4.5e-05	0.0305	0.35	0.37	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
GBM	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-4.24	4.5e-05	0.0305	-0.35	-0.37	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
GBM	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-4.24	4.5e-05	0.0305	-0.35	-0.37	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
GBM	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-4.24	4.5e-05	0.0305	-0.51	-0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
GBM	cis	rs9303029	0.551	rs72859131	ENSG00000279744.1	RP13-20L14.10	-4.24	4.5e-05	0.0305	-0.36	-0.37	Protein quantitative trait loci;	chr17:82471977	chr17:82462601~82464255:+
GBM	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	4.24	4.51e-05	0.0306	0.4	0.37	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	4.24	4.51e-05	0.0306	0.4	0.37	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	4.24	4.51e-05	0.0306	0.4	0.37	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
GBM	cis	rs2288884	0.634	rs17835649	ENSG00000275055.1	CTC-471J1.11	-4.24	4.52e-05	0.0306	-0.56	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997362	chr19:52049007~52049754:+
GBM	cis	rs858239	0.899	rs5850	ENSG00000230042.1	AK3P3	-4.24	4.52e-05	0.0306	-0.43	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23129178~23129841:+
GBM	cis	rs875971	0.862	rs1968126	ENSG00000236529.1	RP13-254B10.1	-4.24	4.52e-05	0.0306	-0.39	-0.37	Aortic root size;	chr7:66592017	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6460306	ENSG00000236529.1	RP13-254B10.1	-4.24	4.52e-05	0.0306	-0.39	-0.37	Aortic root size;	chr7:66595806	chr7:65840212~65840596:+
GBM	cis	rs8062405	0.755	rs2077031	ENSG00000271623.1	RP11-435I10.5	-4.24	4.52e-05	0.0306	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28364700~28365333:+
GBM	cis	rs9601248	0.756	rs7997134	ENSG00000227676.3	LINC01068	-4.24	4.52e-05	0.0306	-0.45	-0.37	Major depressive disorder;	chr13:79619594	chr13:79566727~79571436:+
GBM	cis	rs685782	0.516	rs616762	ENSG00000182048.10	TRPC2	-4.24	4.52e-05	0.0306	-0.43	-0.37	Metabolite levels (Dihydroxy docosatrienoic acid);	chr11:3769752	chr11:3609901~3637559:+
GBM	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	4.24	4.52e-05	0.0306	0.47	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
GBM	cis	rs8062405	0.755	rs56272201	ENSG00000271623.1	RP11-435I10.5	-4.24	4.53e-05	0.0306	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.755	rs62034355	ENSG00000271623.1	RP11-435I10.5	-4.24	4.53e-05	0.0306	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28364700~28365333:+
GBM	cis	rs61041384	1	rs4759367	ENSG00000256092.2	RP13-942N8.1	-4.24	4.53e-05	0.0307	-0.89	-0.37	Schizophrenia;	chr12:123171997	chr12:123363868~123366113:+
GBM	cis	rs2115630	0.791	rs2008262	ENSG00000225151.9	GOLGA2P7	4.24	4.53e-05	0.0307	0.41	0.37	P wave terminal force;	chr15:84762039	chr15:84199311~84230136:-
GBM	cis	rs172166	0.538	rs1150686	ENSG00000218016.2	ZNF192P2	-4.24	4.53e-05	0.0307	-0.43	-0.37	Cardiac Troponin-T levels;	chr6:28193493	chr6:28188050~28189432:+
GBM	cis	rs1150688	1	rs1150688	ENSG00000218016.2	ZNF192P2	-4.24	4.53e-05	0.0307	-0.43	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28188050~28189432:+
GBM	cis	rs3741404	0.609	rs651855	ENSG00000231680.1	AP003774.6	-4.24	4.53e-05	0.0307	-0.42	-0.37	Platelet count;	chr11:64103338	chr11:64394342~64395831:-
GBM	cis	rs17772222	0.917	rs61986670	ENSG00000222990.1	RNU4-22P	4.24	4.54e-05	0.0307	0.44	0.37	Coronary artery calcification;	chr14:88730875	chr14:88513498~88513663:+
GBM	cis	rs12922040	0.651	rs35288467	ENSG00000279866.1	CTB-193M12.4	4.24	4.54e-05	0.0307	0.44	0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15704410~15705984:+
GBM	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	4.24	4.54e-05	0.0307	0.46	0.37	Height;	chr3:53091453	chr3:53064283~53065091:-
GBM	cis	rs7824557	0.628	rs11250129	ENSG00000255020.1	AF131216.5	4.24	4.54e-05	0.0307	0.38	0.37	Retinal vascular caliber;	chr8:11344645	chr8:11345748~11347502:-
GBM	cis	rs2888875	0.632	rs35645305	ENSG00000231826.4	AC016735.2	4.24	4.55e-05	0.0308	0.67	0.37	Glomerular filtration rate (creatinine);	chr2:43569339	chr2:43027853~43039547:-
GBM	cis	rs2888875	0.632	rs17031056	ENSG00000231826.4	AC016735.2	4.24	4.55e-05	0.0308	0.67	0.37	Glomerular filtration rate (creatinine);	chr2:43570480	chr2:43027853~43039547:-
GBM	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-4.24	4.56e-05	0.0308	-0.31	-0.37	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
GBM	cis	rs2018683	1	rs740252	ENSG00000272568.4	CTB-113D17.1	4.24	4.56e-05	0.0308	0.43	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28958149	chr7:28979967~29013367:+
GBM	cis	rs893363	0.522	rs11130381	ENSG00000271916.1	RP11-884K10.6	-4.24	4.57e-05	0.0308	-0.42	-0.37	Axial length;	chr3:53815978	chr3:53797764~53798019:-
GBM	cis	rs875971	0.862	rs13232191	ENSG00000236529.1	RP13-254B10.1	4.24	4.57e-05	0.0308	0.39	0.37	Aortic root size;	chr7:66521661	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs35378740	ENSG00000236529.1	RP13-254B10.1	4.24	4.57e-05	0.0308	0.39	0.37	Aortic root size;	chr7:66522725	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10950043	ENSG00000236529.1	RP13-254B10.1	4.24	4.57e-05	0.0308	0.39	0.37	Aortic root size;	chr7:66523623	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs17747530	ENSG00000236529.1	RP13-254B10.1	4.24	4.57e-05	0.0308	0.39	0.37	Aortic root size;	chr7:66529742	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs13226170	ENSG00000236529.1	RP13-254B10.1	4.24	4.57e-05	0.0308	0.39	0.37	Aortic root size;	chr7:66534311	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs2420611	ENSG00000236529.1	RP13-254B10.1	4.24	4.57e-05	0.0308	0.39	0.37	Aortic root size;	chr7:66534333	chr7:65840212~65840596:+
GBM	cis	rs875971	0.767	rs61348003	ENSG00000236529.1	RP13-254B10.1	4.24	4.57e-05	0.0308	0.39	0.37	Aortic root size;	chr7:66540947	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	4.24	4.57e-05	0.0309	0.41	0.37	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
GBM	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	4.24	4.57e-05	0.0309	0.56	0.37	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
GBM	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	4.24	4.57e-05	0.0309	0.3	0.37	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
GBM	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-4.24	4.58e-05	0.0309	-0.49	-0.37	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-4.24	4.58e-05	0.0309	-0.49	-0.37	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
GBM	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	4.24	4.58e-05	0.0309	0.39	0.37	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
GBM	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	4.24	4.58e-05	0.0309	0.39	0.37	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
GBM	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	4.24	4.58e-05	0.0309	0.39	0.37	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
GBM	cis	rs2278702	0.79	rs11858943	ENSG00000259495.2	RP11-210M15.2	-4.24	4.58e-05	0.0309	-0.37	-0.37	Bipolar disorder;	chr15:80388289	chr15:80344853~80403575:-
GBM	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-4.24	4.58e-05	0.0309	-0.42	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
GBM	cis	rs80130819	0.686	rs78239819	ENSG00000279875.1	RP11-474C8.7	-4.24	4.58e-05	0.0309	-0.7	-0.37	Prostate cancer;	chr12:48018767	chr12:48189349~48191207:+
GBM	cis	rs6545883	0.558	rs7587389	ENSG00000271889.1	RP11-493E12.1	-4.24	4.58e-05	0.0309	-0.37	-0.37	Tuberculosis;	chr2:61422656	chr2:61151433~61162105:-
GBM	cis	rs763121	0.853	rs5750649	ENSG00000273076.1	RP3-508I15.22	4.24	4.58e-05	0.0309	0.4	0.37	Menopause (age at onset);	chr22:38640764	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs6519124	ENSG00000273076.1	RP3-508I15.22	4.24	4.58e-05	0.0309	0.4	0.37	Menopause (age at onset);	chr22:38649094	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs5750652	ENSG00000273076.1	RP3-508I15.22	4.24	4.58e-05	0.0309	0.4	0.37	Menopause (age at onset);	chr22:38652311	chr22:38743495~38743910:+
GBM	cis	rs763121	0.814	rs5757212	ENSG00000273076.1	RP3-508I15.22	4.24	4.58e-05	0.0309	0.4	0.37	Menopause (age at onset);	chr22:38657752	chr22:38743495~38743910:+
GBM	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-4.24	4.58e-05	0.0309	-0.41	-0.37	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
GBM	cis	rs9548119	0.941	rs9576404	ENSG00000223685.4	LINC00571	-4.24	4.59e-05	0.0309	-0.56	-0.37	Self-rated health;	chr13:37953276	chr13:38050817~38143232:-
GBM	cis	rs10875943	0.751	rs11168962	ENSG00000258017.1	RP11-386G11.10	-4.24	4.59e-05	0.031	-0.42	-0.37	Prostate cancer;	chr12:49278956	chr12:49127782~49147869:+
GBM	cis	rs453301	0.686	rs1045527	ENSG00000254340.1	RP11-10A14.3	-4.24	4.59e-05	0.031	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9032531	chr8:9141424~9145435:+
GBM	cis	rs7017914	0.652	rs2035929	ENSG00000246366.5	RP11-382J12.1	4.24	4.59e-05	0.031	0.38	0.37	Bone mineral density;	chr8:71001137	chr8:70608577~70663279:+
GBM	cis	rs61041384	0.661	rs74954864	ENSG00000256092.2	RP13-942N8.1	-4.24	4.6e-05	0.031	-0.82	-0.37	Schizophrenia;	chr12:122995776	chr12:123363868~123366113:+
GBM	cis	rs6600671	0.719	rs9728991	ENSG00000223345.3	HIST2H2BA	4.24	4.61e-05	0.0311	0.46	0.37	Hip geometry;	chr1:121522281	chr1:121108210~121117257:-
GBM	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	4.24	4.61e-05	0.0311	0.41	0.37	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
GBM	cis	rs2025751	0.512	rs9463725	ENSG00000230204.1	FTH1P5	-4.24	4.61e-05	0.0311	-0.42	-0.37	Intraocular pressure;	chr6:51832860	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463726	ENSG00000230204.1	FTH1P5	-4.24	4.61e-05	0.0311	-0.42	-0.37	Intraocular pressure;	chr6:51832873	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463727	ENSG00000230204.1	FTH1P5	-4.24	4.61e-05	0.0311	-0.42	-0.37	Intraocular pressure;	chr6:51832880	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463728	ENSG00000230204.1	FTH1P5	-4.24	4.61e-05	0.0311	-0.42	-0.37	Intraocular pressure;	chr6:51833169	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463729	ENSG00000230204.1	FTH1P5	-4.24	4.61e-05	0.0311	-0.42	-0.37	Intraocular pressure;	chr6:51833186	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs7750125	ENSG00000230204.1	FTH1P5	-4.24	4.61e-05	0.0311	-0.42	-0.37	Intraocular pressure;	chr6:51834182	chr6:50912712~50913256:-
GBM	cis	rs2025751	0.512	rs9463730	ENSG00000230204.1	FTH1P5	-4.24	4.61e-05	0.0311	-0.42	-0.37	Intraocular pressure;	chr6:51835760	chr6:50912712~50913256:-
GBM	cis	rs1045529	0.524	rs34251783	ENSG00000254340.1	RP11-10A14.3	-4.24	4.61e-05	0.0311	-0.45	-0.37	Myopia (pathological);Myopia;	chr8:9033866	chr8:9141424~9145435:+
GBM	cis	rs453301	0.719	rs34004903	ENSG00000254340.1	RP11-10A14.3	-4.24	4.61e-05	0.0311	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9035094	chr8:9141424~9145435:+
GBM	cis	rs453301	0.686	rs6987107	ENSG00000254340.1	RP11-10A14.3	-4.24	4.61e-05	0.0311	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9036071	chr8:9141424~9145435:+
GBM	cis	rs453301	0.686	rs10217044	ENSG00000254340.1	RP11-10A14.3	-4.24	4.61e-05	0.0311	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9037242	chr8:9141424~9145435:+
GBM	cis	rs867371	1	rs7181655	ENSG00000278603.1	RP13-608F4.5	4.24	4.62e-05	0.0311	0.43	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs7180584	ENSG00000278603.1	RP13-608F4.5	4.24	4.62e-05	0.0311	0.43	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472203~82472426:+
GBM	cis	rs867371	1	rs6495642	ENSG00000278603.1	RP13-608F4.5	4.24	4.62e-05	0.0311	0.43	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472203~82472426:+
GBM	cis	rs875971	0.862	rs1875057	ENSG00000236529.1	RP13-254B10.1	-4.24	4.62e-05	0.0311	-0.39	-0.37	Aortic root size;	chr7:66266868	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6960446	ENSG00000236529.1	RP13-254B10.1	-4.24	4.62e-05	0.0311	-0.39	-0.37	Aortic root size;	chr7:66268272	chr7:65840212~65840596:+
GBM	cis	rs875971	0.79	rs10257911	ENSG00000236529.1	RP13-254B10.1	-4.24	4.62e-05	0.0311	-0.39	-0.37	Aortic root size;	chr7:66278783	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs7796162	ENSG00000236529.1	RP13-254B10.1	-4.24	4.62e-05	0.0311	-0.39	-0.37	Aortic root size;	chr7:66280771	chr7:65840212~65840596:+
GBM	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	4.24	4.62e-05	0.0311	0.39	0.37	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
GBM	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	4.24	4.62e-05	0.0311	0.43	0.37	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.917	rs17260415	ENSG00000222990.1	RNU4-22P	4.24	4.63e-05	0.0312	0.43	0.37	Coronary artery calcification;	chr14:88745629	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	4.24	4.63e-05	0.0312	0.43	0.37	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
GBM	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	4.24	4.63e-05	0.0312	0.43	0.37	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
GBM	cis	rs3096299	0.73	rs3114895	ENSG00000260259.1	RP11-368I7.4	4.23	4.63e-05	0.0312	0.41	0.37	Multiple myeloma (IgH translocation);	chr16:89328402	chr16:89682620~89686569:-
GBM	cis	rs8114671	0.773	rs3746438	ENSG00000269202.1	RP4-614O4.12	4.23	4.63e-05	0.0312	0.43	0.37	Height;	chr20:34996486	chr20:35201747~35203288:-
GBM	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-4.23	4.64e-05	0.0312	-0.51	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
GBM	cis	rs4568518	0.502	rs4543441	ENSG00000279048.1	RP11-511H23.2	4.23	4.64e-05	0.0312	0.29	0.37	Measles;	chr7:17943674	chr7:17940503~17942922:+
GBM	cis	rs17685	0.712	rs6954569	ENSG00000280388.1	RP11-229D13.3	-4.23	4.64e-05	0.0312	-0.34	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76109567	chr7:76043977~76045963:-
GBM	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	4.23	4.64e-05	0.0313	0.39	0.37	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
GBM	cis	rs1528149	0.504	rs1990364	ENSG00000224683.1	RPL36AP29	4.23	4.64e-05	0.0313	0.41	0.37	Sitting height ratio;	chr7:16129300	chr7:16208945~16209265:+
GBM	cis	rs453301	0.686	rs2409120	ENSG00000254340.1	RP11-10A14.3	-4.23	4.64e-05	0.0313	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9025061	chr8:9141424~9145435:+
GBM	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-4.23	4.65e-05	0.0313	-0.34	-0.37	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
GBM	cis	rs7267979	0.546	rs8115804	ENSG00000276952.1	RP5-965G21.6	-4.23	4.65e-05	0.0313	-0.37	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:25284915~25285588:-
GBM	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	4.23	4.65e-05	0.0313	0.42	0.37	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
GBM	cis	rs7017914	0.652	rs13273773	ENSG00000246366.5	RP11-382J12.1	-4.23	4.65e-05	0.0313	-0.39	-0.37	Bone mineral density;	chr8:70867012	chr8:70608577~70663279:+
GBM	cis	rs7102494	1	rs7102494	ENSG00000255465.3	RP11-264E20.1	-4.23	4.65e-05	0.0313	-0.68	-0.37	Breast cancer;	chr11:129360950	chr11:128615867~128621806:-
GBM	cis	rs8041863	1	rs11633371	ENSG00000279945.1	RP11-97O12.5	-4.23	4.65e-05	0.0313	-0.39	-0.37	Height;	chr15:88813601	chr15:88477871~88478387:-
GBM	cis	rs17772222	0.655	rs7160717	ENSG00000258983.2	RP11-507K2.2	4.23	4.65e-05	0.0313	0.39	0.37	Coronary artery calcification;	chr14:88498232	chr14:88499334~88515502:+
GBM	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
GBM	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
GBM	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
GBM	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
GBM	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
GBM	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
GBM	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-4.23	4.66e-05	0.0313	-0.41	-0.37	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
GBM	cis	rs6788497	0.643	rs11705891	ENSG00000242551.2	POU5F1P6	4.23	4.66e-05	0.0313	0.54	0.37	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128401512	chr3:128674735~128677005:-
GBM	cis	rs8062405	0.723	rs762633	ENSG00000271623.1	RP11-435I10.5	-4.23	4.66e-05	0.0313	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28364700~28365333:+
GBM	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	4.23	4.66e-05	0.0313	0.48	0.37	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
GBM	cis	rs672059	1	rs3120034	ENSG00000224468.3	RP11-181K3.4	-4.23	4.66e-05	0.0314	-0.29	-0.37	Hypertriglyceridemia;	chr1:183197916	chr1:183138402~183141282:-
GBM	cis	rs6479901	0.639	rs10995450	ENSG00000232075.1	MRPL35P2	4.23	4.66e-05	0.0314	0.53	0.37	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63634317~63634827:-
GBM	cis	rs2018683	0.899	rs10269454	ENSG00000228421.2	AC005013.5	4.23	4.67e-05	0.0314	0.41	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28957667~28959345:+
GBM	cis	rs875971	0.545	rs73152714	ENSG00000222364.1	RNU6-96P	-4.23	4.67e-05	0.0314	-0.43	-0.37	Aortic root size;	chr7:66534641	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs4718364	ENSG00000222364.1	RNU6-96P	-4.23	4.67e-05	0.0314	-0.43	-0.37	Aortic root size;	chr7:66536353	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs6961853	ENSG00000222364.1	RNU6-96P	-4.23	4.67e-05	0.0314	-0.43	-0.37	Aortic root size;	chr7:66537035	chr7:66395191~66395286:+
GBM	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	4.23	4.67e-05	0.0314	0.51	0.37	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
GBM	cis	rs439731	0.518	rs2260241	ENSG00000261207.1	LA16c-361A3.3	4.23	4.67e-05	0.0314	0.42	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr16:1025147	chr16:1751559~1752262:-
GBM	cis	rs2739330	0.627	rs9608219	ENSG00000272787.1	KB-226F1.2	4.23	4.67e-05	0.0314	0.34	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23969211~23969873:+
GBM	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	4.23	4.67e-05	0.0314	0.43	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
GBM	cis	rs10752881	1	rs12753817	ENSG00000224468.3	RP11-181K3.4	-4.23	4.68e-05	0.0314	-0.29	-0.37	Colorectal cancer;	chr1:183001202	chr1:183138402~183141282:-
GBM	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-4.23	4.68e-05	0.0314	-0.42	-0.37	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
GBM	cis	rs1528149	0.504	rs10227232	ENSG00000224683.1	RPL36AP29	-4.23	4.68e-05	0.0314	-0.41	-0.37	Sitting height ratio;	chr7:16138475	chr7:16208945~16209265:+
GBM	cis	rs17685	0.725	rs7807647	ENSG00000280388.1	RP11-229D13.3	4.23	4.68e-05	0.0314	0.35	0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:75999351	chr7:76043977~76045963:-
GBM	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	4.23	4.68e-05	0.0315	0.49	0.37	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
GBM	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-4.23	4.68e-05	0.0315	-0.49	-0.37	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
GBM	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-4.23	4.69e-05	0.0315	-0.41	-0.37	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
GBM	cis	rs2288884	0.634	rs80309583	ENSG00000275055.1	CTC-471J1.11	-4.23	4.69e-05	0.0315	-0.54	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51996949	chr19:52049007~52049754:+
GBM	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	4.23	4.69e-05	0.0315	0.26	0.37	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
GBM	cis	rs950169	0.649	rs12901010	ENSG00000275120.1	RP11-182J1.17	4.23	4.69e-05	0.0315	0.53	0.37	Schizophrenia;	chr15:84030282	chr15:84599434~84606463:-
GBM	cis	rs950169	0.69	rs12901166	ENSG00000275120.1	RP11-182J1.17	4.23	4.69e-05	0.0315	0.53	0.37	Schizophrenia;	chr15:84030361	chr15:84599434~84606463:-
GBM	cis	rs7267979	0.565	rs958075	ENSG00000125804.12	FAM182A	4.23	4.7e-05	0.0316	0.46	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26054655~26086917:+
GBM	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-4.23	4.71e-05	0.0316	-0.41	-0.37	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
GBM	cis	rs17685	0.753	rs4728586	ENSG00000280388.1	RP11-229D13.3	-4.23	4.71e-05	0.0316	-0.34	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76173551	chr7:76043977~76045963:-
GBM	cis	rs2288884	0.559	rs12461230	ENSG00000275055.1	CTC-471J1.11	-4.23	4.72e-05	0.0316	-0.46	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:52049007~52049754:+
GBM	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-4.23	4.72e-05	0.0316	-0.47	-0.37	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
GBM	cis	rs66624999	0.817	rs4889038	ENSG00000261390.4	RP11-345M22.2	4.23	4.72e-05	0.0316	0.61	0.37	Prostate-specific antigen levels (conditioned on lead SNPs);	chr16:79815859	chr16:79715232~79770563:-
GBM	cis	rs11099864	0.583	rs12501574	ENSG00000243417.1	RP11-555K12.1	4.23	4.72e-05	0.0317	0.47	0.37	Amyotrophic lateral sclerosis;	chr4:152972113	chr4:152551277~152552364:-
GBM	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-4.23	4.72e-05	0.0317	-0.37	-0.37	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-4.23	4.72e-05	0.0317	-0.37	-0.37	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-4.23	4.72e-05	0.0317	-0.37	-0.37	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
GBM	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-4.23	4.72e-05	0.0317	-0.37	-0.37	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
GBM	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	4.23	4.72e-05	0.0317	0.36	0.37	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
GBM	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-4.23	4.72e-05	0.0317	-0.47	-0.37	Height;	chr3:53070344	chr3:53064283~53065091:-
GBM	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	4.23	4.73e-05	0.0317	0.48	0.37	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
GBM	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	4.23	4.73e-05	0.0317	0.44	0.37	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
GBM	cis	rs6479901	0.512	rs11817169	ENSG00000232075.1	MRPL35P2	4.23	4.73e-05	0.0317	0.65	0.37	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63634317~63634827:-
GBM	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-4.23	4.73e-05	0.0317	-0.49	-0.37	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
GBM	cis	rs17685	0.712	rs1637049	ENSG00000280388.1	RP11-229D13.3	-4.23	4.73e-05	0.0317	-0.34	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76100657	chr7:76043977~76045963:-
GBM	cis	rs17264034	0.5	rs10475468	ENSG00000250786.1	SNHG18	-4.23	4.73e-05	0.0317	-0.52	-0.37	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9538645	chr5:9546200~9550609:+
GBM	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	4.23	4.74e-05	0.0317	0.38	0.37	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
GBM	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	4.23	4.74e-05	0.0318	0.42	0.37	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
GBM	cis	rs17772222	0.917	rs10143767	ENSG00000222990.1	RNU4-22P	4.23	4.74e-05	0.0318	0.46	0.37	Coronary artery calcification;	chr14:88514867	chr14:88513498~88513663:+
GBM	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	4.23	4.75e-05	0.0318	0.47	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
GBM	cis	rs875971	0.862	rs709596	ENSG00000236529.1	RP13-254B10.1	4.23	4.76e-05	0.0319	0.39	0.37	Aortic root size;	chr7:66360926	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs778724	ENSG00000236529.1	RP13-254B10.1	4.23	4.76e-05	0.0319	0.39	0.37	Aortic root size;	chr7:66364304	chr7:65840212~65840596:+
GBM	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	4.23	4.76e-05	0.0319	0.54	0.37	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
GBM	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	4.23	4.76e-05	0.0319	0.54	0.37	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
GBM	cis	rs7017914	0.905	rs2639956	ENSG00000246366.5	RP11-382J12.1	-4.23	4.76e-05	0.0319	-0.38	-0.37	Bone mineral density;	chr8:71011856	chr8:70608577~70663279:+
GBM	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-4.23	4.77e-05	0.0319	-0.7	-0.37	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
GBM	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-4.23	4.77e-05	0.0319	-0.5	-0.37	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-4.23	4.77e-05	0.0319	-0.5	-0.37	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-4.23	4.77e-05	0.0319	-0.5	-0.37	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-4.23	4.77e-05	0.0319	-0.5	-0.37	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-4.23	4.77e-05	0.0319	-0.5	-0.37	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-4.23	4.77e-05	0.0319	-0.5	-0.37	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
GBM	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	4.23	4.78e-05	0.032	0.73	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
GBM	cis	rs73198271	0.7	rs10090152	ENSG00000253893.2	FAM85B	4.23	4.78e-05	0.032	0.53	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8167819~8226614:-
GBM	cis	rs7615916	0.955	rs11128597	ENSG00000236062.1	GSTM5P1	4.23	4.78e-05	0.032	0.48	0.37	Eosinophil percentage of white cells;	chr3:12303137	chr3:12257801~12258460:-
GBM	cis	rs10246939	0.505	rs12703409	ENSG00000261797.1	RP11-744I24.3	-4.23	4.78e-05	0.032	-0.48	-0.37	Bitter taste perception;	chr7:141812058	chr7:141512698~141513183:-
GBM	cis	rs10246939	0.505	rs6967189	ENSG00000261797.1	RP11-744I24.3	-4.23	4.78e-05	0.032	-0.48	-0.37	Bitter taste perception;	chr7:141826220	chr7:141512698~141513183:-
GBM	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	4.23	4.78e-05	0.032	0.46	0.37	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
GBM	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	4.23	4.79e-05	0.032	0.42	0.37	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
GBM	cis	rs1927790	0.727	rs16953068	ENSG00000247400.3	DNAJC3-AS1	-4.23	4.79e-05	0.032	-0.39	-0.37	Body mass index;	chr13:96297073	chr13:95648733~95676925:-
GBM	cis	rs9393777	0.623	rs34313099	ENSG00000224843.5	LINC00240	4.23	4.79e-05	0.032	0.59	0.37	Intelligence (multi-trait analysis);	chr6:26489379	chr6:26956992~27023924:+
GBM	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-4.23	4.8e-05	0.032	-0.51	-0.37	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
GBM	cis	rs3742264	0.656	rs9534263	ENSG00000235903.6	CPB2-AS1	-4.23	4.8e-05	0.0321	-0.44	-0.37	Blood protein levels;	chr13:45967315	chr13:46052806~46113332:+
GBM	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	4.23	4.8e-05	0.0321	0.41	0.37	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	4.23	4.8e-05	0.0321	0.41	0.37	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	4.23	4.8e-05	0.0321	0.41	0.37	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	4.23	4.8e-05	0.0321	0.41	0.37	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
GBM	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-4.22	4.82e-05	0.0322	-0.54	-0.37	Depression;	chr6:28206812	chr6:28115628~28116551:+
GBM	cis	rs763121	0.853	rs4820345	ENSG00000273076.1	RP3-508I15.22	4.22	4.82e-05	0.0322	0.42	0.37	Menopause (age at onset);	chr22:38695146	chr22:38743495~38743910:+
GBM	cis	rs10497721	1	rs4306668	ENSG00000227542.1	AC092614.2	-4.22	4.82e-05	0.0322	-0.75	-0.37	Diabetes (incident);	chr2:192043858	chr2:191229165~191246172:-
GBM	cis	rs8014671	0.552	rs4899359	ENSG00000235812.4	ADAM21P1	4.22	4.82e-05	0.0322	0.45	0.37	Prostate cancer;	chr14:70561247	chr14:70245491~70247801:-
GBM	cis	rs6496932	0.865	rs10520600	ENSG00000218052.5	ADAMTS7P4	4.22	4.82e-05	0.0322	0.58	0.37	Central corneal thickness;Corneal structure;	chr15:85365171	chr15:85255369~85330334:-
GBM	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	4.22	4.82e-05	0.0322	0.45	0.37	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
GBM	cis	rs875971	0.651	rs2420596	ENSG00000236529.1	RP13-254B10.1	4.22	4.82e-05	0.0322	0.39	0.37	Aortic root size;	chr7:66450996	chr7:65840212~65840596:+
GBM	cis	rs875971	0.52	rs2420597	ENSG00000236529.1	RP13-254B10.1	4.22	4.82e-05	0.0322	0.39	0.37	Aortic root size;	chr7:66450999	chr7:65840212~65840596:+
GBM	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	4.22	4.82e-05	0.0322	0.49	0.37	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
GBM	cis	rs16937	0.711	rs10900461	ENSG00000271580.1	RP11-536L3.4	-4.22	4.83e-05	0.0322	-0.33	-0.37	Schizophrenia;	chr1:205184080	chr1:205091163~205091946:+
GBM	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-4.22	4.83e-05	0.0322	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
GBM	cis	rs5821446	1	rs5821446	ENSG00000267472.1	LOC440461	-4.22	4.83e-05	0.0322	-0.45	-0.37	Eosinophil percentage of granulocytes;	chr17:67966422	chr17:68198921~68199596:+
GBM	cis	rs7216064	1	rs7210027	ENSG00000267472.1	LOC440461	-4.22	4.83e-05	0.0322	-0.45	-0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67980937	chr17:68198921~68199596:+
GBM	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-4.22	4.84e-05	0.0323	-0.46	-0.37	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
GBM	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	4.22	4.84e-05	0.0323	0.41	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
GBM	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	4.22	4.84e-05	0.0323	0.5	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
GBM	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	4.22	4.84e-05	0.0323	0.43	0.37	Height;	chr20:35198453	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	4.22	4.84e-05	0.0323	0.43	0.37	Height;	chr20:35200390	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	4.22	4.84e-05	0.0323	0.43	0.37	Height;	chr20:35200671	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	4.22	4.84e-05	0.0323	0.43	0.37	Height;	chr20:35201180	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs2093058	ENSG00000269202.1	RP4-614O4.12	4.22	4.84e-05	0.0323	0.43	0.37	Height;	chr20:35203478	chr20:35201747~35203288:-
GBM	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	4.22	4.84e-05	0.0323	0.4	0.37	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
GBM	cis	rs875971	0.83	rs12673450	ENSG00000236529.1	RP13-254B10.1	4.22	4.84e-05	0.0323	0.39	0.37	Aortic root size;	chr7:66544233	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs13311962	ENSG00000236529.1	RP13-254B10.1	-4.22	4.84e-05	0.0323	-0.4	-0.37	Aortic root size;	chr7:66603142	chr7:65840212~65840596:+
GBM	cis	rs17270561	0.723	rs12192635	ENSG00000272462.2	U91328.19	-4.22	4.84e-05	0.0323	-0.55	-0.37	Iron status biomarkers;	chr6:25880679	chr6:25992662~26001775:+
GBM	cis	rs17270561	0.779	rs78589800	ENSG00000272462.2	U91328.19	-4.22	4.84e-05	0.0323	-0.55	-0.37	Iron status biomarkers;	chr6:25883272	chr6:25992662~26001775:+
GBM	cis	rs17270561	0.779	rs12210620	ENSG00000272462.2	U91328.19	-4.22	4.84e-05	0.0323	-0.55	-0.37	Iron status biomarkers;	chr6:25884557	chr6:25992662~26001775:+
GBM	cis	rs7017914	0.967	rs2732090	ENSG00000246366.5	RP11-382J12.1	4.22	4.84e-05	0.0323	0.39	0.37	Bone mineral density;	chr8:71006022	chr8:70608577~70663279:+
GBM	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	4.22	4.85e-05	0.0323	0.35	0.37	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
GBM	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	4.22	4.85e-05	0.0323	0.43	0.37	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
GBM	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	4.22	4.85e-05	0.0324	0.41	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	4.22	4.85e-05	0.0324	0.41	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
GBM	cis	rs10497721	1	rs4308083	ENSG00000227542.1	AC092614.2	-4.22	4.86e-05	0.0324	-0.81	-0.37	Diabetes (incident);	chr2:192054965	chr2:191229165~191246172:-
GBM	cis	rs3755899	0.51	rs13435734	ENSG00000260296.1	RP11-395I6.3	4.22	4.87e-05	0.0324	0.39	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr4:39517527	chr4:40166675~40167831:+
GBM	cis	rs3755899	0.51	rs10031932	ENSG00000260296.1	RP11-395I6.3	4.22	4.87e-05	0.0324	0.39	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr4:39517994	chr4:40166675~40167831:+
GBM	cis	rs3755899	0.51	rs6829418	ENSG00000260296.1	RP11-395I6.3	4.22	4.87e-05	0.0324	0.39	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr4:39523945	chr4:40166675~40167831:+
GBM	cis	rs4957048	0.577	rs56294732	ENSG00000260774.1	CTD-2083E4.4	4.22	4.87e-05	0.0324	0.5	0.37	Ulcerative colitis;	chr5:568029	chr5:213898~217279:-
GBM	cis	rs57221529	0.655	rs11948381	ENSG00000260774.1	CTD-2083E4.4	4.22	4.87e-05	0.0324	0.5	0.37	Lung disease severity in cystic fibrosis;	chr5:568298	chr5:213898~217279:-
GBM	cis	rs7726839	0.526	rs11960159	ENSG00000260774.1	CTD-2083E4.4	4.22	4.87e-05	0.0324	0.5	0.37	Obesity-related traits;	chr5:568570	chr5:213898~217279:-
GBM	cis	rs17508449	0.819	rs4839332	ENSG00000232450.1	RP4-730K3.3	-4.22	4.87e-05	0.0324	-0.64	-0.37	Leprosy;	chr1:113619569	chr1:113698884~113699631:-
GBM	cis	rs11671005	0.736	rs11668201	ENSG00000269600.1	AC016629.3	-4.22	4.87e-05	0.0324	-0.51	-0.37	Mean platelet volume;	chr19:58492265	chr19:58593896~58599355:-
GBM	cis	rs2963463	0.715	rs2964485	ENSG00000253519.1	AC106801.1	-4.22	4.87e-05	0.0324	-0.5	-0.37	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158477831	chr5:157565964~157569098:+
GBM	cis	rs559928	0.553	rs508326	ENSG00000231680.1	AP003774.6	4.22	4.87e-05	0.0325	0.41	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64408557	chr11:64394342~64395831:-
GBM	cis	rs264	0.725	rs269	ENSG00000254242.1	RP11-1080G15.2	-4.22	4.87e-05	0.0325	-0.51	-0.37	Coronary artery disease;	chr8:19956156	chr8:19091733~19115024:+
GBM	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	4.22	4.88e-05	0.0325	0.42	0.37	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
GBM	cis	rs7017914	0.652	rs13250391	ENSG00000246366.5	RP11-382J12.1	-4.22	4.88e-05	0.0325	-0.39	-0.37	Bone mineral density;	chr8:70885537	chr8:70608577~70663279:+
GBM	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	4.22	4.88e-05	0.0325	0.46	0.37	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
GBM	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	4.22	4.88e-05	0.0325	0.46	0.37	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
GBM	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	4.22	4.88e-05	0.0325	0.41	0.37	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
GBM	cis	rs2018683	0.768	rs10282015	ENSG00000228421.2	AC005013.5	4.22	4.88e-05	0.0325	0.46	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28957667~28959345:+
GBM	cis	rs2018683	0.77	rs10951208	ENSG00000228421.2	AC005013.5	4.22	4.88e-05	0.0325	0.46	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28957667~28959345:+
GBM	cis	rs66887589	1	rs66887589	ENSG00000249244.1	RP11-548H18.2	-4.22	4.89e-05	0.0325	-0.43	-0.37	Diastolic blood pressure;	chr4:119588124	chr4:119391831~119395335:-
GBM	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	4.22	4.89e-05	0.0325	0.55	0.37	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
GBM	cis	rs12137294	0.866	rs1172151	ENSG00000271580.1	RP11-536L3.4	-4.22	4.89e-05	0.0325	-0.34	-0.37	Red cell distribution width;	chr1:205252531	chr1:205091163~205091946:+
GBM	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	4.22	4.89e-05	0.0325	0.51	0.37	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
GBM	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-4.22	4.89e-05	0.0326	-0.41	-0.37	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
GBM	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	4.22	4.89e-05	0.0326	0.46	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
GBM	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	4.22	4.89e-05	0.0326	0.46	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
GBM	cis	rs66887589	0.967	rs7678973	ENSG00000249244.1	RP11-548H18.2	-4.22	4.9e-05	0.0326	-0.43	-0.37	Diastolic blood pressure;	chr4:119590662	chr4:119391831~119395335:-
GBM	cis	rs66887589	0.934	rs56843000	ENSG00000249244.1	RP11-548H18.2	-4.22	4.9e-05	0.0326	-0.43	-0.37	Diastolic blood pressure;	chr4:119595442	chr4:119391831~119395335:-
GBM	cis	rs66887589	0.967	rs2892869	ENSG00000249244.1	RP11-548H18.2	-4.22	4.9e-05	0.0326	-0.43	-0.37	Diastolic blood pressure;	chr4:119600142	chr4:119391831~119395335:-
GBM	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-4.22	4.9e-05	0.0326	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
GBM	cis	rs9947662	0.879	rs1036350	ENSG00000267761.3	CTD-2130O13.1	-4.22	4.9e-05	0.0326	-0.47	-0.37	Migraine;	chr18:47357284	chr18:47285725~47594550:+
GBM	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	4.22	4.9e-05	0.0326	0.44	0.37	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
GBM	cis	rs10411262	0.527	rs314672	ENSG00000245598.5	DACT3-AS1	-4.22	4.91e-05	0.0326	-0.45	-0.37	Tonsillectomy;	chr19:46690997	chr19:46660364~46677447:+
GBM	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-4.22	4.91e-05	0.0326	-0.36	-0.37	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-4.22	4.91e-05	0.0326	-0.36	-0.37	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-4.22	4.91e-05	0.0326	-0.36	-0.37	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-4.22	4.91e-05	0.0326	-0.36	-0.37	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
GBM	cis	rs875971	0.862	rs6971059	ENSG00000236529.1	RP13-254B10.1	-4.22	4.91e-05	0.0326	-0.39	-0.37	Aortic root size;	chr7:66602045	chr7:65840212~65840596:+
GBM	cis	rs875971	0.789	rs7808013	ENSG00000236529.1	RP13-254B10.1	-4.22	4.91e-05	0.0326	-0.39	-0.37	Aortic root size;	chr7:66606209	chr7:65840212~65840596:+
GBM	cis	rs875971	0.825	rs7384021	ENSG00000236529.1	RP13-254B10.1	-4.22	4.91e-05	0.0326	-0.39	-0.37	Aortic root size;	chr7:66612917	chr7:65840212~65840596:+
GBM	cis	rs875971	0.825	rs66981195	ENSG00000236529.1	RP13-254B10.1	-4.22	4.91e-05	0.0326	-0.39	-0.37	Aortic root size;	chr7:66614048	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs3926380	ENSG00000236529.1	RP13-254B10.1	-4.22	4.91e-05	0.0326	-0.39	-0.37	Aortic root size;	chr7:66615658	chr7:65840212~65840596:+
GBM	cis	rs875971	0.825	rs1860472	ENSG00000236529.1	RP13-254B10.1	-4.22	4.91e-05	0.0326	-0.39	-0.37	Aortic root size;	chr7:66617736	chr7:65840212~65840596:+
GBM	cis	rs453301	0.686	rs6601281	ENSG00000254340.1	RP11-10A14.3	-4.22	4.91e-05	0.0326	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9053494	chr8:9141424~9145435:+
GBM	cis	rs66887589	0.967	rs1155577	ENSG00000249244.1	RP11-548H18.2	-4.22	4.92e-05	0.0327	-0.43	-0.37	Diastolic blood pressure;	chr4:119528655	chr4:119391831~119395335:-
GBM	cis	rs11295209	1	rs11295209	ENSG00000249244.1	RP11-548H18.2	-4.22	4.92e-05	0.0327	-0.43	-0.37	Plateletcrit;	chr4:119559079	chr4:119391831~119395335:-
GBM	cis	rs939563	0.894	rs2302460	ENSG00000275084.2	SNORD91B	-4.22	4.92e-05	0.0327	-0.42	-0.37	Mean platelet volume;	chr17:1541408	chr17:2329016~2329237:-
GBM	cis	rs397969	0.646	rs203467	ENSG00000230528.6	NOS2P3	-4.22	4.92e-05	0.0327	-0.45	-0.37	Platelet count;	chr17:19906436	chr17:20436337~20447249:+
GBM	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	4.22	4.92e-05	0.0327	0.43	0.37	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
GBM	cis	rs6600671	1	rs4844381	ENSG00000223345.3	HIST2H2BA	4.22	4.92e-05	0.0327	0.48	0.37	Hip geometry;	chr1:121443040	chr1:121108210~121117257:-
GBM	cis	rs453301	0.686	rs28482034	ENSG00000254340.1	RP11-10A14.3	-4.22	4.92e-05	0.0327	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9012154	chr8:9141424~9145435:+
GBM	cis	rs453301	0.686	rs11785819	ENSG00000254340.1	RP11-10A14.3	-4.22	4.92e-05	0.0327	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9012868	chr8:9141424~9145435:+
GBM	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	4.22	4.92e-05	0.0327	0.4	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
GBM	cis	rs875971	0.571	rs78668714	ENSG00000236529.1	RP13-254B10.1	4.22	4.93e-05	0.0327	0.41	0.37	Aortic root size;	chr7:66474464	chr7:65840212~65840596:+
GBM	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	4.22	4.93e-05	0.0327	0.34	0.37	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
GBM	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	4.22	4.93e-05	0.0327	0.34	0.37	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
GBM	cis	rs8062405	0.723	rs62031562	ENSG00000271623.1	RP11-435I10.5	-4.22	4.93e-05	0.0327	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28364700~28365333:+
GBM	cis	rs3096299	0.73	rs11076780	ENSG00000260259.1	RP11-368I7.4	4.22	4.93e-05	0.0327	0.4	0.37	Multiple myeloma (IgH translocation);	chr16:89331546	chr16:89682620~89686569:-
GBM	cis	rs3096299	0.757	rs3102372	ENSG00000260259.1	RP11-368I7.4	4.22	4.93e-05	0.0327	0.4	0.37	Multiple myeloma (IgH translocation);	chr16:89331863	chr16:89682620~89686569:-
GBM	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	4.22	4.93e-05	0.0328	0.55	0.37	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	4.22	4.93e-05	0.0328	0.55	0.37	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	4.22	4.93e-05	0.0328	0.55	0.37	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	4.22	4.93e-05	0.0328	0.55	0.37	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	4.22	4.93e-05	0.0328	0.55	0.37	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
GBM	cis	rs2117029	0.965	rs2241726	ENSG00000258017.1	RP11-386G11.10	-4.22	4.94e-05	0.0328	-0.43	-0.37	Intelligence (multi-trait analysis);	chr12:49050762	chr12:49127782~49147869:+
GBM	cis	rs5769707	0.967	rs9616327	ENSG00000235111.1	RP1-29C18.8	-4.22	4.94e-05	0.0328	-0.41	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49612657~49615716:-
GBM	cis	rs17772222	0.63	rs7146241	ENSG00000222990.1	RNU4-22P	-4.22	4.94e-05	0.0328	-0.38	-0.37	Coronary artery calcification;	chr14:88551622	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.63	rs930181	ENSG00000222990.1	RNU4-22P	-4.22	4.94e-05	0.0328	-0.38	-0.37	Coronary artery calcification;	chr14:88552364	chr14:88513498~88513663:+
GBM	cis	rs6887276	0.708	rs251215	ENSG00000245937.6	LINC01184	-4.22	4.94e-05	0.0328	-0.35	-0.37	Height;	chr5:128207930	chr5:127940426~128083172:-
GBM	cis	rs62184315	0.536	rs62185897	ENSG00000253559.1	OSGEPL1-AS1	-4.22	4.95e-05	0.0328	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189721279	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs2278591	ENSG00000253559.1	OSGEPL1-AS1	-4.22	4.95e-05	0.0328	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189755778	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs62184265	ENSG00000253559.1	OSGEPL1-AS1	-4.22	4.95e-05	0.0328	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189756231	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs16831972	ENSG00000253559.1	OSGEPL1-AS1	-4.22	4.95e-05	0.0328	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189756707	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.52	rs62184268	ENSG00000253559.1	OSGEPL1-AS1	-4.22	4.95e-05	0.0328	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189767451	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs2289405	ENSG00000253559.1	OSGEPL1-AS1	-4.22	4.95e-05	0.0328	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189771313	chr2:189762704~189765556:+
GBM	cis	rs16937	0.711	rs3851284	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205186952	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs10900465	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205189055	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs10900467	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205190946	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs12129162	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205195522	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs11240382	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205199441	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs4333898	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205200485	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs11240384	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205203047	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs11240385	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205203973	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs10900471	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205204006	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs6682400	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205204391	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs11240388	ENSG00000271580.1	RP11-536L3.4	-4.22	4.95e-05	0.0328	-0.33	-0.37	Schizophrenia;	chr1:205208489	chr1:205091163~205091946:+
GBM	cis	rs66887589	0.967	rs56173225	ENSG00000249244.1	RP11-548H18.2	-4.22	4.95e-05	0.0329	-0.43	-0.37	Diastolic blood pressure;	chr4:119588817	chr4:119391831~119395335:-
GBM	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	4.22	4.96e-05	0.0329	0.39	0.37	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
GBM	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	4.22	4.96e-05	0.0329	0.4	0.37	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
GBM	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-4.22	4.96e-05	0.0329	-0.47	-0.37	Height;	chr3:53097932	chr3:53064283~53065091:-
GBM	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-4.22	4.96e-05	0.0329	-0.38	-0.37	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
GBM	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	4.22	4.97e-05	0.0329	0.43	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
GBM	cis	rs875971	0.545	rs1909508	ENSG00000222364.1	RNU6-96P	-4.22	4.97e-05	0.0329	-0.41	-0.37	Aortic root size;	chr7:66301366	chr7:66395191~66395286:+
GBM	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	4.22	4.97e-05	0.0329	0.5	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
GBM	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	4.22	4.97e-05	0.033	0.42	0.37	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	4.22	4.97e-05	0.033	0.42	0.37	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
GBM	cis	rs7615952	0.641	rs12487875	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126068381	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs7618515	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126071735	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.576	rs66671308	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126074683	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs61048217	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126089062	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs60839048	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126089095	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs7640158	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126089168	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs2365019	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126089292	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.576	rs6780025	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126096781	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.576	rs6804482	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126096919	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.576	rs12497295	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126099807	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.512	rs4646765	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126101864	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.576	rs4646763	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126103286	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.576	rs4646759	ENSG00000250012.1	RP11-124N2.1	-4.22	4.98e-05	0.033	-0.41	-0.37	Blood pressure (smoking interaction);	chr3:126104103	chr3:126084220~126095349:+
GBM	cis	rs10857712	0.754	rs2297031	ENSG00000214279.11	SCART1	-4.22	4.98e-05	0.033	-0.31	-0.37	Systemic lupus erythematosus;	chr10:133419150	chr10:133453928~133523558:+
GBM	cis	rs17318866	0.579	rs34628866	ENSG00000217385.1	PSMC1P11	-4.22	4.98e-05	0.033	-0.49	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);	chr6:3809171	chr6:4702463~4703779:+
GBM	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	4.22	4.99e-05	0.033	0.53	0.37	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
GBM	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	4.22	4.99e-05	0.033	0.53	0.37	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
GBM	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	4.22	4.99e-05	0.033	0.53	0.37	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
GBM	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	4.22	4.99e-05	0.033	0.53	0.37	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
GBM	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	4.22	4.99e-05	0.033	0.53	0.37	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
GBM	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	4.22	4.99e-05	0.033	0.41	0.37	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
GBM	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	4.22	4.99e-05	0.033	0.41	0.37	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
GBM	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	4.22	4.99e-05	0.033	0.4	0.37	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
GBM	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	4.22	4.99e-05	0.0331	0.39	0.37	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
GBM	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	4.21	5e-05	0.0331	0.27	0.37	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
GBM	cis	rs8114671	0.935	rs633198	ENSG00000269202.1	RP4-614O4.12	4.21	5e-05	0.0331	0.43	0.37	Height;	chr20:35190631	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-4.21	5e-05	0.0331	-0.43	-0.37	Height;	chr20:35185886	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-4.21	5e-05	0.0331	-0.43	-0.37	Height;	chr20:35187574	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs6058202	ENSG00000269202.1	RP4-614O4.12	-4.21	5e-05	0.0331	-0.43	-0.37	Height;	chr20:35190180	chr20:35201747~35203288:-
GBM	cis	rs6600671	0.693	rs1853731	ENSG00000223345.3	HIST2H2BA	4.21	5e-05	0.0331	0.47	0.37	Hip geometry;	chr1:121510262	chr1:121108210~121117257:-
GBM	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	4.21	5e-05	0.0331	0.41	0.37	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
GBM	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-4.21	5e-05	0.0331	-0.37	-0.37	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
GBM	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-4.21	5.01e-05	0.0331	-0.37	-0.37	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
GBM	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-4.21	5.01e-05	0.0331	-0.37	-0.37	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
GBM	cis	rs7181230	0.848	rs62004114	ENSG00000275636.1	RP11-521C20.5	4.21	5.01e-05	0.0332	0.46	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40041154	chr15:40078892~40079347:+
GBM	cis	rs7181230	0.848	rs75509561	ENSG00000275636.1	RP11-521C20.5	4.21	5.01e-05	0.0332	0.46	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40041268	chr15:40078892~40079347:+
GBM	cis	rs7181230	0.848	rs7497289	ENSG00000275636.1	RP11-521C20.5	4.21	5.01e-05	0.0332	0.46	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40041456	chr15:40078892~40079347:+
GBM	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-4.21	5.02e-05	0.0332	-0.41	-0.37	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
GBM	cis	rs2579103	0.708	rs2579105	ENSG00000258183.4	RP11-753N8.1	-4.21	5.02e-05	0.0332	-0.51	-0.37	Body mass index;	chr12:90290980	chr12:90280894~90300340:+
GBM	cis	rs2579103	0.708	rs2579104	ENSG00000258183.4	RP11-753N8.1	-4.21	5.02e-05	0.0332	-0.51	-0.37	Body mass index;	chr12:90291037	chr12:90280894~90300340:+
GBM	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	4.21	5.02e-05	0.0332	0.42	0.37	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
GBM	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-4.21	5.02e-05	0.0332	-0.54	-0.37	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
GBM	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-4.21	5.02e-05	0.0332	-0.47	-0.37	Height;	chr3:53052712	chr3:53064283~53065091:-
GBM	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-4.21	5.02e-05	0.0332	-0.47	-0.37	Height;	chr3:53064759	chr3:53064283~53065091:-
GBM	cis	rs9450351	0.744	rs9450294	ENSG00000203875.9	SNHG5	-4.21	5.03e-05	0.0332	-0.89	-0.37	Interferon gamma-induced protein 10 levels;	chr6:85540712	chr6:85660950~85678736:-
GBM	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	4.21	5.03e-05	0.0332	0.49	0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
GBM	cis	rs9601248	0.627	rs2146593	ENSG00000227676.3	LINC01068	4.21	5.03e-05	0.0333	0.53	0.37	Major depressive disorder;	chr13:79605977	chr13:79566727~79571436:+
GBM	cis	rs9786986	0.516	rs12401892	ENSG00000207181.1	SNORA14B	-4.21	5.04e-05	0.0333	-0.62	-0.37	Body mass index;	chr1:235538093	chr1:235127803~235127937:-
GBM	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-4.21	5.04e-05	0.0333	-0.41	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-4.21	5.04e-05	0.0333	-0.41	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
GBM	cis	rs922692	0.715	rs11072803	ENSG00000261143.1	ADAMTS7P3	4.21	5.04e-05	0.0333	0.4	0.37	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78785536	chr15:77976042~77993057:+
GBM	cis	rs7818688	1	rs11786878	ENSG00000253528.2	RP11-347C18.4	-4.21	5.05e-05	0.0333	-0.59	-0.37	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021064	chr8:94974573~94974853:-
GBM	cis	rs7818688	1	rs77257477	ENSG00000253528.2	RP11-347C18.4	-4.21	5.05e-05	0.0333	-0.59	-0.37	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95033171	chr8:94974573~94974853:-
GBM	cis	rs7818688	0.79	rs74395342	ENSG00000253528.2	RP11-347C18.4	-4.21	5.05e-05	0.0333	-0.59	-0.37	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95034723	chr8:94974573~94974853:-
GBM	cis	rs7818688	1	rs6651271	ENSG00000253528.2	RP11-347C18.4	-4.21	5.05e-05	0.0333	-0.59	-0.37	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95035393	chr8:94974573~94974853:-
GBM	cis	rs17685	0.725	rs7795291	ENSG00000280388.1	RP11-229D13.3	-4.21	5.05e-05	0.0334	-0.34	-0.37	Coffee consumption (cups per day);Coffee consumption;	chr7:76095888	chr7:76043977~76045963:-
GBM	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	4.21	5.05e-05	0.0334	0.43	0.37	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
GBM	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	4.21	5.05e-05	0.0334	0.43	0.37	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	4.21	5.05e-05	0.0334	0.43	0.37	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
GBM	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	4.21	5.05e-05	0.0334	0.43	0.37	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	4.21	5.05e-05	0.0334	0.43	0.37	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	4.21	5.05e-05	0.0334	0.43	0.37	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	4.21	5.05e-05	0.0334	0.43	0.37	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
GBM	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	4.21	5.05e-05	0.0334	0.44	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
GBM	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-4.21	5.06e-05	0.0334	-0.53	-0.37	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
GBM	cis	rs796364	0.789	rs1653297	ENSG00000232732.8	AC073043.1	-4.21	5.06e-05	0.0334	-0.47	-0.37	Schizophrenia;	chr2:200210760	chr2:199867396~199911159:-
GBM	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	4.21	5.06e-05	0.0334	0.39	0.37	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
GBM	cis	rs2436845	0.554	rs667927	ENSG00000253320.4	KB-1507C5.2	-4.21	5.06e-05	0.0334	-0.39	-0.37	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102900186	chr8:102864300~102977876:+
GBM	cis	rs2436845	0.521	rs601588	ENSG00000253320.4	KB-1507C5.2	-4.21	5.06e-05	0.0334	-0.39	-0.37	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102902518	chr8:102864300~102977876:+
GBM	cis	rs2436845	0.554	rs647313	ENSG00000253320.4	KB-1507C5.2	-4.21	5.06e-05	0.0334	-0.39	-0.37	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102904426	chr8:102864300~102977876:+
GBM	cis	rs977747	0.966	rs6700838	ENSG00000232022.5	FAAHP1	-4.21	5.06e-05	0.0334	-0.37	-0.37	Body mass index;	chr1:47234355	chr1:46432129~46445521:+
GBM	cis	rs977747	0.933	rs1015890	ENSG00000232022.5	FAAHP1	-4.21	5.06e-05	0.0334	-0.37	-0.37	Body mass index;	chr1:47236557	chr1:46432129~46445521:+
GBM	cis	rs9532669	0.889	rs9525397	ENSG00000176268.5	CYCSP34	4.21	5.06e-05	0.0334	0.45	0.37	Cervical cancer;	chr13:40851575	chr13:40863599~40863902:-
GBM	cis	rs2025751	0.512	rs9474104	ENSG00000230204.1	FTH1P5	-4.21	5.06e-05	0.0334	-0.42	-0.37	Intraocular pressure;	chr6:51836260	chr6:50912712~50913256:-
GBM	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-4.21	5.06e-05	0.0334	-0.4	-0.37	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
GBM	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	4.21	5.06e-05	0.0334	0.55	0.37	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	4.21	5.06e-05	0.0334	0.55	0.37	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	4.21	5.06e-05	0.0334	0.55	0.37	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	4.21	5.06e-05	0.0334	0.55	0.37	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-4.21	5.06e-05	0.0334	-0.55	-0.37	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
GBM	cis	rs67340775	0.541	rs200973	ENSG00000199851.2	U3	4.21	5.07e-05	0.0334	0.64	0.37	Lung cancer in ever smokers;	chr6:27890643	chr6:28015568~28015777:+
GBM	cis	rs2018683	1	rs4719962	ENSG00000272568.4	CTB-113D17.1	4.21	5.07e-05	0.0335	0.42	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28979967~29013367:+
GBM	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	4.21	5.08e-05	0.0335	0.6	0.37	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
GBM	cis	rs1153858	1	rs1145091	ENSG00000259433.2	CTD-2651B20.4	-4.21	5.08e-05	0.0335	-0.42	-0.37	Homoarginine levels;	chr15:45357798	chr15:45330209~45332634:-
GBM	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-4.21	5.08e-05	0.0335	-0.5	-0.37	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
GBM	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-4.21	5.08e-05	0.0335	-0.5	-0.37	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
GBM	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-4.21	5.08e-05	0.0335	-0.5	-0.37	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
GBM	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-4.21	5.08e-05	0.0335	-0.5	-0.37	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
GBM	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-4.21	5.08e-05	0.0335	-0.5	-0.37	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
GBM	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-4.21	5.08e-05	0.0335	-0.5	-0.37	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
GBM	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-4.21	5.08e-05	0.0335	-0.5	-0.37	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
GBM	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-4.21	5.08e-05	0.0335	-0.44	-0.37	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-4.21	5.08e-05	0.0335	-0.44	-0.37	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-4.21	5.08e-05	0.0335	-0.44	-0.37	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
GBM	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	4.21	5.08e-05	0.0335	0.61	0.37	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
GBM	cis	rs11098499	0.71	rs4145952	ENSG00000249244.1	RP11-548H18.2	4.21	5.09e-05	0.0335	0.45	0.37	Corneal astigmatism;	chr4:119234651	chr4:119391831~119395335:-
GBM	cis	rs10159302	0.852	rs3738552	ENSG00000223956.1	RP4-710M16.2	4.21	5.09e-05	0.0335	0.53	0.37	HIV-1 control;	chr1:57386841	chr1:56414963~56415966:+
GBM	cis	rs3806843	0.518	rs2563310	ENSG00000202111.1	VTRNA1-2	4.21	5.09e-05	0.0335	0.36	0.37	Depressive symptoms (multi-trait analysis);	chr5:140636156	chr5:140718925~140719013:+
GBM	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	4.21	5.09e-05	0.0336	0.55	0.37	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
GBM	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-4.21	5.09e-05	0.0336	-0.49	-0.37	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
GBM	cis	rs875971	0.862	rs7783779	ENSG00000236529.1	RP13-254B10.1	-4.21	5.09e-05	0.0336	-0.38	-0.37	Aortic root size;	chr7:66331639	chr7:65840212~65840596:+
GBM	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-4.21	5.09e-05	0.0336	-0.43	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
GBM	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-4.21	5.09e-05	0.0336	-0.43	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
GBM	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-4.21	5.09e-05	0.0336	-0.43	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
GBM	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-4.21	5.1e-05	0.0336	-0.44	-0.37	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
GBM	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	4.21	5.1e-05	0.0336	0.42	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
GBM	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	4.21	5.1e-05	0.0336	0.42	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
GBM	cis	rs66624999	0.935	rs28639441	ENSG00000261390.4	RP11-345M22.2	-4.21	5.1e-05	0.0336	-0.61	-0.37	Prostate-specific antigen levels (conditioned on lead SNPs);	chr16:79823758	chr16:79715232~79770563:-
GBM	cis	rs6906287	0.718	rs6906332	ENSG00000225549.3	RP11-210H10__A.1	-4.21	5.1e-05	0.0336	-0.44	-0.37	Electrocardiographic conduction measures;	chr6:118332173	chr6:118757518~118783420:+
GBM	cis	rs6906287	0.718	rs6911035	ENSG00000225549.3	RP11-210H10__A.1	-4.21	5.1e-05	0.0336	-0.44	-0.37	Electrocardiographic conduction measures;	chr6:118332542	chr6:118757518~118783420:+
GBM	cis	rs3736858	1	rs3736858	ENSG00000261105.4	LMO7-AS1	4.21	5.11e-05	0.0336	0.66	0.37	Interleukin-9 levels;	chr13:75841243	chr13:75604700~75635994:-
GBM	cis	rs338389	0.542	rs12594726	ENSG00000260657.2	RP11-315D16.4	-4.21	5.11e-05	0.0336	-0.53	-0.37	Survival in rectal cancer;	chr15:67994440	chr15:68267792~68277994:-
GBM	cis	rs7136259	0.844	rs2681485	ENSG00000258302.2	RP11-981P6.1	-4.21	5.11e-05	0.0336	-0.39	-0.37	Coronary heart disease;	chr12:89631845	chr12:89561129~89594878:+
GBM	cis	rs10411262	0.506	rs6509290	ENSG00000245598.5	DACT3-AS1	-4.21	5.11e-05	0.0337	-0.46	-0.37	Tonsillectomy;	chr19:46680583	chr19:46660364~46677447:+
GBM	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	4.21	5.11e-05	0.0337	0.43	0.37	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
GBM	cis	rs7017914	0.629	rs2956611	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70985633	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.629	rs2732126	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70986257	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.629	rs2732125	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70986266	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs958605	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70988356	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2732122	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70988908	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639926	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70988976	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2933859	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70993894	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2933858	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70994109	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639948	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70996251	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2732118	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70996430	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.593	rs2732140	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70998491	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2732141	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70998672	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639947	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70999202	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2732145	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70999834	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2732146	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:70999883	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2732147	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71000179	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639946	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71000265	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs2732149	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71000267	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639945	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71000304	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.54	rs2639944	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71000512	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2732088	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71000542	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639943	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71000905	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.606	rs2035928	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71001320	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.606	rs2035927	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71001325	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.606	rs2035926	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71001339	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.606	rs2639941	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71001670	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.644	rs2639940	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71001686	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.606	rs2639939	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71001688	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs2035925	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71001981	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639938	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71002117	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2639937	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71002121	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs2035924	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71002218	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs36162059	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71002471	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.583	rs2639936	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71002500	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.628	rs2732089	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71002929	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.652	rs3098865	ENSG00000246366.5	RP11-382J12.1	-4.21	5.12e-05	0.0337	-0.38	-0.37	Bone mineral density;	chr8:71003749	chr8:70608577~70663279:+
GBM	cis	rs67981189	0.572	rs2810079	ENSG00000269927.1	RP6-91H8.3	-4.21	5.12e-05	0.0337	-0.41	-0.37	Schizophrenia;	chr14:70892554	chr14:71141125~71143253:-
GBM	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-4.21	5.12e-05	0.0337	-0.4	-0.37	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
GBM	cis	rs10186029	0.657	rs11689895	ENSG00000270659.1	RP11-105N14.1	-4.21	5.13e-05	0.0337	-0.38	-0.37	Systemic sclerosis;	chr2:213073829	chr2:213152970~213153659:+
GBM	cis	rs3096299	0.748	rs2965822	ENSG00000260259.1	RP11-368I7.4	4.21	5.13e-05	0.0337	0.4	0.37	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89682620~89686569:-
GBM	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	4.21	5.13e-05	0.0337	0.52	0.37	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	4.21	5.13e-05	0.0337	0.52	0.37	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	4.21	5.13e-05	0.0337	0.52	0.37	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	4.21	5.13e-05	0.0337	0.52	0.37	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	4.21	5.13e-05	0.0337	0.52	0.37	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	4.21	5.13e-05	0.0337	0.52	0.37	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
GBM	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-4.21	5.13e-05	0.0337	-0.51	-0.37	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
GBM	cis	rs12922040	1	rs12922040	ENSG00000279866.1	CTB-193M12.4	4.21	5.13e-05	0.0337	0.43	0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15704410~15705984:+
GBM	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	4.21	5.13e-05	0.0337	0.47	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
GBM	cis	rs8062405	0.558	rs3743963	ENSG00000259982.1	CDC37P1	4.21	5.13e-05	0.0337	0.37	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28593365	chr16:28700294~28701540:-
GBM	cis	rs875971	0.755	rs76288834	ENSG00000236529.1	RP13-254B10.1	-4.21	5.13e-05	0.0337	-0.39	-0.37	Aortic root size;	chr7:66604815	chr7:65840212~65840596:+
GBM	cis	rs812925	0.537	rs10865324	ENSG00000271889.1	RP11-493E12.1	-4.21	5.15e-05	0.0338	-0.36	-0.37	Immature fraction of reticulocytes;	chr2:61394172	chr2:61151433~61162105:-
GBM	cis	rs7035589	1	rs12337928	ENSG00000230013.1	RP11-217B7.3	4.21	5.15e-05	0.0339	0.46	0.37	Pelvic organ prolapse;	chr9:104988279	chr9:104990796~104991781:-
GBM	cis	rs526231	0.736	rs6886092	ENSG00000175749.11	EIF3KP1	4.21	5.15e-05	0.0339	0.53	0.37	Primary biliary cholangitis;	chr5:103298328	chr5:103032376~103033031:+
GBM	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-4.21	5.15e-05	0.0339	-0.37	-0.37	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
GBM	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-4.21	5.15e-05	0.0339	-0.37	-0.37	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
GBM	cis	rs11673344	0.503	rs703531	ENSG00000226686.6	LINC01535	4.21	5.15e-05	0.0339	0.39	0.37	Obesity-related traits;	chr19:37010050	chr19:37251912~37265535:+
GBM	cis	rs11773103	0.786	rs56365880	ENSG00000224046.1	AC005076.5	4.21	5.16e-05	0.0339	0.57	0.37	Bipolar disorder or major depressive disorder (combined);	chr7:87126354	chr7:87151423~87152420:-
GBM	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	4.21	5.16e-05	0.0339	0.28	0.37	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
GBM	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	4.21	5.16e-05	0.0339	0.28	0.37	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
GBM	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	4.21	5.16e-05	0.0339	0.44	0.37	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
GBM	cis	rs59104589	0.583	rs62186399	ENSG00000235351.1	AC114730.11	-4.21	5.16e-05	0.0339	-0.33	-0.37	Fibrinogen levels;	chr2:241285910	chr2:241724615~241725693:-
GBM	cis	rs59104589	0.583	rs57576464	ENSG00000235351.1	AC114730.11	-4.21	5.16e-05	0.0339	-0.33	-0.37	Fibrinogen levels;	chr2:241301282	chr2:241724615~241725693:-
GBM	cis	rs59104589	0.583	rs61689231	ENSG00000235351.1	AC114730.11	-4.21	5.16e-05	0.0339	-0.33	-0.37	Fibrinogen levels;	chr2:241305168	chr2:241724615~241725693:-
GBM	cis	rs59104589	0.583	rs12618809	ENSG00000235351.1	AC114730.11	-4.21	5.16e-05	0.0339	-0.33	-0.37	Fibrinogen levels;	chr2:241309707	chr2:241724615~241725693:-
GBM	cis	rs4664293	0.51	rs2042776	ENSG00000226266.5	AC009961.3	4.21	5.17e-05	0.034	0.56	0.37	Monocyte percentage of white cells;	chr2:159653793	chr2:159670708~159712435:-
GBM	cis	rs7487075	0.718	rs4768735	ENSG00000257261.4	RP11-96H19.1	-4.21	5.17e-05	0.034	-0.36	-0.37	Itch intensity from mosquito bite;	chr12:46550351	chr12:46383679~46876159:+
GBM	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-4.21	5.17e-05	0.034	-0.34	-0.37	Temperament;	chr17:14046511	chr17:14024514~14025488:+
GBM	cis	rs4803480	1	rs11882144	ENSG00000270164.1	LINC01480	-4.21	5.18e-05	0.034	-0.66	-0.37	Schizophrenia;	chr19:41566244	chr19:41535183~41536904:+
GBM	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-4.21	5.18e-05	0.034	-0.43	-0.37	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
GBM	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-4.21	5.18e-05	0.034	-0.48	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-4.21	5.18e-05	0.034	-0.48	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
GBM	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-4.21	5.18e-05	0.034	-0.48	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
GBM	cis	rs17772222	0.682	rs2401751	ENSG00000222990.1	RNU4-22P	-4.21	5.18e-05	0.034	-0.4	-0.37	Coronary artery calcification;	chr14:88480278	chr14:88513498~88513663:+
GBM	cis	rs3753275	0.624	rs10864364	ENSG00000230679.1	ENO1-AS1	-4.21	5.18e-05	0.034	-0.43	-0.37	Educational attainment;	chr1:8707721	chr1:8878835~8879894:+
GBM	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-4.21	5.18e-05	0.034	-0.46	-0.37	Height;	chr3:53094335	chr3:53064283~53065091:-
GBM	cis	rs17318866	0.552	rs9378385	ENSG00000217385.1	PSMC1P11	-4.21	5.19e-05	0.034	-0.46	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);	chr6:3816160	chr6:4702463~4703779:+
GBM	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-4.2	5.19e-05	0.0341	-0.43	-0.37	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
GBM	cis	rs2115630	0.936	rs8033459	ENSG00000225151.9	GOLGA2P7	4.2	5.2e-05	0.0341	0.4	0.37	P wave terminal force;	chr15:84710027	chr15:84199311~84230136:-
GBM	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	4.2	5.2e-05	0.0341	0.46	0.37	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	4.2	5.2e-05	0.0341	0.46	0.37	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
GBM	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	4.2	5.2e-05	0.0341	0.34	0.37	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
GBM	cis	rs9368481	0.569	rs6907403	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:27020335~27020447:+
GBM	cis	rs9368481	0.502	rs3933232	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:27020335~27020447:+
GBM	cis	rs9368481	0.524	rs12530345	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:27020335~27020447:+
GBM	cis	rs9368481	0.546	rs12664610	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:27020335~27020447:+
GBM	cis	rs9368481	0.524	rs9393768	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:27020335~27020447:+
GBM	cis	rs9368481	0.569	rs10946868	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:27020335~27020447:+
GBM	cis	rs9368481	0.594	rs7768643	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:27020335~27020447:+
GBM	cis	rs9368481	0.594	rs7768814	ENSG00000238621.1	TRI-TAT2-2	-4.2	5.2e-05	0.0341	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:27020335~27020447:+
GBM	cis	rs79349575	0.729	rs62075824	ENSG00000270781.1	RP11-501C14.9	-4.2	5.21e-05	0.0341	-0.44	-0.36	Type 2 diabetes;	chr17:48909317	chr17:48899131~48899748:+
GBM	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-4.2	5.21e-05	0.0341	-0.43	-0.36	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
GBM	cis	rs11771526	0.901	rs2191000	ENSG00000273014.1	RP11-225B17.2	-4.2	5.21e-05	0.0342	-0.71	-0.36	Body mass index;	chr7:32235486	chr7:32758882~32759353:+
GBM	cis	rs453301	0.579	rs10096850	ENSG00000233609.3	RP11-62H7.2	-4.2	5.22e-05	0.0342	-0.41	-0.36	Joint mobility (Beighton score);	chr8:8940712	chr8:8961200~8979025:+
GBM	cis	rs9532669	0.926	rs2183144	ENSG00000168852.11	TPTE2P5	-4.2	5.22e-05	0.0342	-0.47	-0.36	Cervical cancer;	chr13:40862129	chr13:40822296~40921749:-
GBM	cis	rs7824557	0.603	rs6995404	ENSG00000255020.1	AF131216.5	4.2	5.22e-05	0.0342	0.37	0.36	Retinal vascular caliber;	chr8:11324639	chr8:11345748~11347502:-
GBM	cis	rs264	0.769	rs263	ENSG00000254242.1	RP11-1080G15.2	4.2	5.23e-05	0.0342	0.5	0.36	Coronary artery disease;	chr8:19955301	chr8:19091733~19115024:+
GBM	cis	rs3768617	0.51	rs12078729	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183090937	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10911239	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183093315	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs10911240	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183093813	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs7542640	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183094603	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10458355	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183094858	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs4491025	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183096048	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs6424884	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183096769	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs6424885	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183097119	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10752895	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183099370	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797835	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183103773	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2027075	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183104131	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2027076	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183104272	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2027078	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183104343	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.565	rs2027080	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183105280	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.546	rs2027081	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183105441	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768629	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183105447	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs2147584	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183105629	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.775	rs2147585	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183105740	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs2182020	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183105829	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs7414273	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183105882	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797837	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183105986	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10911243	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183106280	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs2333622	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183106321	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs12091137	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183106597	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs723014	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183107152	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3765521	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183108480	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3765522	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183108483	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797839	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183108662	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.565	rs3768626	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183109327	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768624	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183110117	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3818417	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183110241	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2296290	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183110277	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2296291	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183110374	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs6672093	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183110718	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs6686682	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183111404	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs10911248	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183111429	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10911249	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183111555	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10752899	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183112106	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797843	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183112860	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797844	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183112932	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs6669199	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183113286	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs3736888	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183115472	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs2027082	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183115473	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.839	rs6692207	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183116169	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10752900	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183117103	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2296292	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183117622	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797846	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183118350	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1547712	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183118878	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2027083	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183119195	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10911254	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183119492	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs10911255	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183119733	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768621	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183120922	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10752902	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183121130	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2333621	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183121616	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs6424889	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183122661	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs4652776	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183122785	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs4651139	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183122828	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs4652777	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183122857	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768620	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183123102	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768619	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183123269	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs3768618	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183123356	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs20557	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183124740	chr1:183138402~183141282:-
GBM	cis	rs10911251	0.528	rs2093982	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183125056	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.839	rs2093983	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183125075	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2093985	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183125187	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs20558	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183125412	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1886499	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183125889	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1886500	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183125913	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1886501	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183126099	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2296293	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183126342	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2296294	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183126461	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2224933	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183126630	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1413390	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183127499	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1413389	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183127533	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs1413388	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183127559	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs7529465	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183127745	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs4651140	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183127817	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs7549768	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183128247	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs4651142	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183128251	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs4651143	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183128263	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs4652778	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183128285	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs4651144	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183128286	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10797851	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183128866	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.528	rs10737242	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183129114	chr1:183138402~183141282:-
GBM	cis	rs10752881	0.743	rs10737244	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Colorectal cancer;	chr1:183129282	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs4651145	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183129765	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2296300	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183130566	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs6691755	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183130686	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs2333620	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183131420	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10752903	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183131728	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10737245	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183131749	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs10752904	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183131903	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs12061219	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183132336	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs12095664	ENSG00000224468.3	RP11-181K3.4	-4.2	5.23e-05	0.0342	-0.3	-0.36	Fuchs's corneal dystrophy;	chr1:183132551	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs12086466	ENSG00000224468.3	RP11-181K3.4	4.2	5.23e-05	0.0342	0.3	0.36	Fuchs's corneal dystrophy;	chr1:183106643	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs6424888	ENSG00000224468.3	RP11-181K3.4	4.2	5.23e-05	0.0342	0.3	0.36	Fuchs's corneal dystrophy;	chr1:183116561	chr1:183138402~183141282:-
GBM	cis	rs3768617	0.51	rs20563	ENSG00000224468.3	RP11-181K3.4	4.2	5.23e-05	0.0342	0.3	0.36	Fuchs's corneal dystrophy;	chr1:183116620	chr1:183138402~183141282:-
GBM	cis	rs7726839	0.526	rs11960158	ENSG00000260774.1	CTD-2083E4.4	4.2	5.25e-05	0.0343	0.5	0.36	Obesity-related traits;	chr5:568550	chr5:213898~217279:-
GBM	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-4.2	5.25e-05	0.0343	-0.41	-0.36	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-4.2	5.25e-05	0.0343	-0.41	-0.36	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-4.2	5.25e-05	0.0343	-0.41	-0.36	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-4.2	5.25e-05	0.0343	-0.41	-0.36	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-4.2	5.25e-05	0.0343	-0.41	-0.36	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-4.2	5.25e-05	0.0343	-0.41	-0.36	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-4.2	5.25e-05	0.0343	-0.41	-0.36	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
GBM	cis	rs916888	0.647	rs199524	ENSG00000262500.1	RP11-259G18.2	-4.2	5.25e-05	0.0343	-0.49	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46243606~46245044:+
GBM	cis	rs916888	0.647	rs199523	ENSG00000262500.1	RP11-259G18.2	-4.2	5.25e-05	0.0343	-0.49	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46243606~46245044:+
GBM	cis	rs8062405	1	rs7205323	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs4788101	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62037364	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.929	rs11150609	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.737	rs11861132	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs11861174	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs4788102	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62037367	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs7198606	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.929	rs11864750	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.964	rs7193733	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs8055982	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs7498665	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.964	rs11864107	ENSG00000271623.1	RP11-435I10.5	-4.2	5.25e-05	0.0343	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28364700~28365333:+
GBM	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
GBM	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	4.2	5.26e-05	0.0343	0.55	0.36	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
GBM	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	4.2	5.26e-05	0.0343	0.39	0.36	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
GBM	cis	rs875971	0.862	rs6460290	ENSG00000236529.1	RP13-254B10.1	-4.2	5.26e-05	0.0343	-0.38	-0.36	Aortic root size;	chr7:66344119	chr7:65840212~65840596:+
GBM	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	4.2	5.26e-05	0.0343	0.47	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
GBM	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	4.2	5.26e-05	0.0343	0.47	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
GBM	cis	rs11773103	0.786	rs73203002	ENSG00000224046.1	AC005076.5	4.2	5.26e-05	0.0343	0.57	0.36	Bipolar disorder or major depressive disorder (combined);	chr7:87129584	chr7:87151423~87152420:-
GBM	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	4.2	5.27e-05	0.0344	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
GBM	cis	rs7083	0.716	rs574603	ENSG00000254851.1	RP11-109L13.1	4.2	5.27e-05	0.0344	0.52	0.36	Blood protein levels;	chr11:117307025	chr11:117135528~117138582:+
GBM	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	4.2	5.27e-05	0.0344	0.42	0.36	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
GBM	cis	rs2579103	1	rs2408222	ENSG00000258183.4	RP11-753N8.1	-4.2	5.27e-05	0.0344	-0.49	-0.36	Body mass index;	chr12:90208355	chr12:90280894~90300340:+
GBM	cis	rs2579103	1	rs2731228	ENSG00000258183.4	RP11-753N8.1	-4.2	5.27e-05	0.0344	-0.49	-0.36	Body mass index;	chr12:90211011	chr12:90280894~90300340:+
GBM	cis	rs2579103	1	rs2579121	ENSG00000258183.4	RP11-753N8.1	-4.2	5.27e-05	0.0344	-0.49	-0.36	Body mass index;	chr12:90211227	chr12:90280894~90300340:+
GBM	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-4.2	5.27e-05	0.0344	-0.53	-0.36	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
GBM	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	4.2	5.27e-05	0.0344	0.53	0.36	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
GBM	cis	rs61041384	0.661	rs79033960	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123196388	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs77015199	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123197090	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs74240768	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123199429	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs74240769	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123203681	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs74917517	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123204258	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs4759407	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123205127	chr12:123363868~123366113:+
GBM	cis	rs61041384	1	rs76872194	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123208816	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs74240771	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123212416	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs4474478	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123249821	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs4759411	ENSG00000256092.2	RP13-942N8.1	-4.2	5.27e-05	0.0344	-0.88	-0.36	Schizophrenia;	chr12:123256296	chr12:123363868~123366113:+
GBM	cis	rs61041384	0.661	rs3759111	ENSG00000256092.2	RP13-942N8.1	4.2	5.27e-05	0.0344	0.88	0.36	Schizophrenia;	chr12:123203227	chr12:123363868~123366113:+
GBM	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	4.2	5.27e-05	0.0344	0.44	0.36	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
GBM	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	4.2	5.27e-05	0.0344	0.49	0.36	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
GBM	cis	rs1153858	1	rs7169818	ENSG00000259433.2	CTD-2651B20.4	-4.2	5.27e-05	0.0344	-0.42	-0.36	Homoarginine levels;	chr15:45347993	chr15:45330209~45332634:-
GBM	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-4.2	5.27e-05	0.0344	-0.5	-0.36	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
GBM	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	4.2	5.28e-05	0.0344	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
GBM	cis	rs853679	0.76	rs9468317	ENSG00000199851.2	U3	4.2	5.28e-05	0.0344	0.62	0.36	Depression;	chr6:28230678	chr6:28015568~28015777:+
GBM	cis	rs853679	0.723	rs9366718	ENSG00000199851.2	U3	4.2	5.28e-05	0.0344	0.62	0.36	Depression;	chr6:28237724	chr6:28015568~28015777:+
GBM	cis	rs853679	0.76	rs9393910	ENSG00000199851.2	U3	4.2	5.28e-05	0.0344	0.62	0.36	Depression;	chr6:28240414	chr6:28015568~28015777:+
GBM	cis	rs853679	0.76	rs9368563	ENSG00000199851.2	U3	4.2	5.28e-05	0.0344	0.62	0.36	Depression;	chr6:28240780	chr6:28015568~28015777:+
GBM	cis	rs853679	0.76	rs9295768	ENSG00000199851.2	U3	4.2	5.28e-05	0.0344	0.62	0.36	Depression;	chr6:28241324	chr6:28015568~28015777:+
GBM	cis	rs853679	0.699	rs9468318	ENSG00000199851.2	U3	4.2	5.28e-05	0.0344	0.62	0.36	Depression;	chr6:28241753	chr6:28015568~28015777:+
GBM	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	4.2	5.28e-05	0.0344	0.38	0.36	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
GBM	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-4.2	5.29e-05	0.0344	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
GBM	cis	rs11671005	0.735	rs11671591	ENSG00000269473.1	CTD-2619J13.19	-4.2	5.29e-05	0.0344	-0.4	-0.36	Mean platelet volume;	chr19:58406970	chr19:58440448~58445849:+
GBM	cis	rs2933343	0.621	rs4927921	ENSG00000231305.3	RP11-723O4.2	-4.2	5.29e-05	0.0344	-0.34	-0.36	IgG glycosylation;	chr3:128850025	chr3:128861313~128871540:-
GBM	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-4.2	5.29e-05	0.0345	-0.42	-0.36	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
GBM	cis	rs7829975	0.681	rs2271342	ENSG00000254340.1	RP11-10A14.3	4.2	5.29e-05	0.0345	0.45	0.36	Mood instability;	chr8:8786428	chr8:9141424~9145435:+
GBM	cis	rs4148008	1	rs4148008	ENSG00000265100.1	RP11-147L13.2	4.2	5.3e-05	0.0345	0.29	0.36	HDL cholesterol;	chr17:68879153	chr17:68246629~68247938:-
GBM	cis	rs73198271	0.96	rs17154702	ENSG00000253893.2	FAM85B	4.2	5.3e-05	0.0345	0.5	0.36	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752370	chr8:8167819~8226614:-
GBM	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	4.2	5.3e-05	0.0345	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
GBM	cis	rs2014572	0.933	rs8109882	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57244250	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.901	rs35658377	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57244259	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.967	rs10427146	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57244630	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.967	rs11084492	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57244658	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.967	rs10426174	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57244687	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.87	rs10426580	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57244853	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.933	rs8107516	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57247077	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.967	rs8111977	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57247790	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.967	rs8112572	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57248244	chr19:57267220~57280334:-
GBM	cis	rs2014572	1	rs2014572	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57248650	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.967	rs7248000	ENSG00000267871.4	CTC-444N24.6	4.2	5.31e-05	0.0345	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57250771	chr19:57267220~57280334:-
GBM	cis	rs6600671	0.899	rs2319971	ENSG00000223345.3	HIST2H2BA	4.2	5.31e-05	0.0345	0.46	0.36	Hip geometry;	chr1:121485184	chr1:121108210~121117257:-
GBM	cis	rs3744061	0.557	rs9889902	ENSG00000277382.1	RP11-318A15.8	4.2	5.31e-05	0.0346	0.46	0.36	Retinal arteriolar caliber;	chr17:76651952	chr17:76709760~76710045:+
GBM	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-4.2	5.31e-05	0.0346	-0.42	-0.36	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
GBM	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-4.2	5.31e-05	0.0346	-0.24	-0.36	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
GBM	cis	rs7083	1	rs535602	ENSG00000254851.1	RP11-109L13.1	4.2	5.32e-05	0.0346	0.52	0.36	Blood protein levels;	chr11:117237059	chr11:117135528~117138582:+
GBM	cis	rs4664293	0.632	rs2059697	ENSG00000226266.5	AC009961.3	4.2	5.32e-05	0.0346	0.46	0.36	Monocyte percentage of white cells;	chr2:159799079	chr2:159670708~159712435:-
GBM	cis	rs4478147	0.506	rs17417758	ENSG00000261496.1	RP13-514E23.1	-4.2	5.32e-05	0.0346	-0.45	-0.36	Migraine - clinic-based;	chr4:86386245	chr4:86012296~86013874:-
GBM	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-4.2	5.32e-05	0.0346	-0.48	-0.36	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
GBM	cis	rs9303029	0.611	rs8008	ENSG00000279744.1	RP13-20L14.10	4.2	5.33e-05	0.0346	0.37	0.36	Protein quantitative trait loci;	chr17:82442879	chr17:82462601~82464255:+
GBM	cis	rs4604732	0.812	rs6663238	ENSG00000227135.1	GCSAML-AS1	4.2	5.33e-05	0.0346	0.53	0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461669	chr1:247524679~247526752:-
GBM	cis	rs4642101	0.68	rs6442330	ENSG00000213943.3	KRT18P17	4.2	5.33e-05	0.0346	0.38	0.36	QRS complex (12-leadsum);	chr3:12779002	chr3:12787393~12788671:-
GBM	cis	rs4642101	0.64	rs7629354	ENSG00000213943.3	KRT18P17	4.2	5.33e-05	0.0346	0.38	0.36	QRS complex (12-leadsum);	chr3:12786247	chr3:12787393~12788671:-
GBM	cis	rs7083	0.716	rs687740	ENSG00000254851.1	RP11-109L13.1	-4.2	5.33e-05	0.0346	-0.51	-0.36	Blood protein levels;	chr11:117306887	chr11:117135528~117138582:+
GBM	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-4.2	5.33e-05	0.0347	-0.49	-0.36	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
GBM	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	4.2	5.33e-05	0.0347	0.43	0.36	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
GBM	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-4.2	5.34e-05	0.0347	-0.5	-0.36	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
GBM	cis	rs9450351	0.744	rs9353339	ENSG00000203875.9	SNHG5	4.2	5.34e-05	0.0347	0.9	0.36	Interferon gamma-induced protein 10 levels;	chr6:85794480	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs6913147	ENSG00000203875.9	SNHG5	-4.2	5.34e-05	0.0347	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85800641	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs7764843	ENSG00000203875.9	SNHG5	-4.2	5.34e-05	0.0347	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85903875	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs7752222	ENSG00000203875.9	SNHG5	-4.2	5.34e-05	0.0347	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85913874	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9351072	ENSG00000203875.9	SNHG5	-4.2	5.34e-05	0.0347	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85917611	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs7738777	ENSG00000203875.9	SNHG5	-4.2	5.34e-05	0.0347	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85923468	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9444371	ENSG00000203875.9	SNHG5	-4.2	5.34e-05	0.0347	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85950676	chr6:85660950~85678736:-
GBM	cis	rs9353324	1	rs58334368	ENSG00000203875.9	SNHG5	-4.2	5.34e-05	0.0347	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85971591	chr6:85660950~85678736:-
GBM	cis	rs11098499	0.698	rs4422403	ENSG00000249244.1	RP11-548H18.2	4.2	5.35e-05	0.0347	0.45	0.36	Corneal astigmatism;	chr4:119337039	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.569	rs10023641	ENSG00000249244.1	RP11-548H18.2	4.2	5.35e-05	0.0347	0.45	0.36	Corneal astigmatism;	chr4:119337255	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.644	rs3986377	ENSG00000249244.1	RP11-548H18.2	4.2	5.35e-05	0.0347	0.45	0.36	Corneal astigmatism;	chr4:119339115	chr4:119391831~119395335:-
GBM	cis	rs10028773	0.556	rs4473640	ENSG00000249244.1	RP11-548H18.2	4.2	5.35e-05	0.0347	0.45	0.36	Educational attainment;	chr4:119339282	chr4:119391831~119395335:-
GBM	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-4.2	5.35e-05	0.0347	-0.49	-0.36	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
GBM	cis	rs2025751	0.512	rs1326601	ENSG00000230204.1	FTH1P5	-4.2	5.36e-05	0.0348	-0.42	-0.36	Intraocular pressure;	chr6:51828907	chr6:50912712~50913256:-
GBM	cis	rs10748180	0.568	rs4760805	ENSG00000257302.1	FAHD2P1	4.2	5.36e-05	0.0348	0.54	0.36	Economic and political preferences (time);	chr12:71670067	chr12:70671918~70672856:+
GBM	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-4.2	5.36e-05	0.0348	-0.5	-0.36	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
GBM	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	4.2	5.36e-05	0.0348	0.26	0.36	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
GBM	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	4.2	5.36e-05	0.0348	0.47	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
GBM	cis	rs885518	0.852	rs10965124	ENSG00000265194.1	RP11-70L8.4	4.2	5.36e-05	0.0348	0.45	0.36	Lung adenocarcinoma;	chr9:21776616	chr9:21858910~21861926:-
GBM	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-4.2	5.37e-05	0.0348	-0.41	-0.36	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
GBM	cis	rs875971	0.545	rs10950036	ENSG00000236529.1	RP13-254B10.1	4.2	5.38e-05	0.0349	0.4	0.36	Aortic root size;	chr7:66353241	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs6460298	ENSG00000236529.1	RP13-254B10.1	4.2	5.38e-05	0.0349	0.4	0.36	Aortic root size;	chr7:66442783	chr7:65840212~65840596:+
GBM	cis	rs17685	0.753	rs10233282	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76160763	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs10251863	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76160874	chr7:76043977~76045963:-
GBM	cis	rs17685	0.753	rs9691174	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76161087	chr7:76043977~76045963:-
GBM	cis	rs17685	0.664	rs9801113	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76162713	chr7:76043977~76045963:-
GBM	cis	rs17685	0.558	rs60787921	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76163526	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs56965035	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76166352	chr7:76043977~76045963:-
GBM	cis	rs17685	0.672	rs56343450	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76166917	chr7:76043977~76045963:-
GBM	cis	rs17685	0.712	rs60232511	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76170764	chr7:76043977~76045963:-
GBM	cis	rs17685	0.743	rs10277259	ENSG00000280388.1	RP11-229D13.3	-4.2	5.38e-05	0.0349	-0.34	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76173356	chr7:76043977~76045963:-
GBM	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-4.2	5.38e-05	0.0349	-0.37	-0.36	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
GBM	cis	rs2255336	0.808	rs59611026	ENSG00000245648.1	RP11-277P12.20	-4.2	5.39e-05	0.0349	-0.47	-0.36	Blood protein levels;	chr12:10445387	chr12:10363769~10398506:+
GBM	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	4.2	5.39e-05	0.0349	0.4	0.36	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
GBM	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-4.2	5.39e-05	0.0349	-0.61	-0.36	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
GBM	cis	rs8040855	0.658	rs3862411	ENSG00000259295.5	CSPG4P12	4.2	5.39e-05	0.0349	0.43	0.36	Bulimia nervosa;	chr15:85007770	chr15:85191438~85213905:+
GBM	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-4.2	5.39e-05	0.0349	-0.53	-0.36	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
GBM	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-4.2	5.39e-05	0.0349	-0.47	-0.36	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-4.2	5.39e-05	0.0349	-0.47	-0.36	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-4.2	5.39e-05	0.0349	-0.47	-0.36	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
GBM	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-4.19	5.39e-05	0.035	-0.43	-0.36	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-4.19	5.39e-05	0.035	-0.43	-0.36	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-4.19	5.39e-05	0.035	-0.43	-0.36	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
GBM	cis	rs4713118	0.824	rs9468225	ENSG00000199851.2	U3	4.19	5.4e-05	0.035	0.51	0.36	Parkinson's disease;	chr6:27777940	chr6:28015568~28015777:+
GBM	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	4.19	5.4e-05	0.035	0.76	0.36	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
GBM	cis	rs4499344	0.633	rs259251	ENSG00000201388.1	SNORA68	4.19	5.4e-05	0.035	0.37	0.36	Mean platelet volume;	chr19:32658862	chr19:32608337~32608469:-
GBM	cis	rs11671005	0.572	rs11669127	ENSG00000269600.1	AC016629.3	4.19	5.4e-05	0.035	0.51	0.36	Mean platelet volume;	chr19:58492463	chr19:58593896~58599355:-
GBM	cis	rs11773103	0.786	rs17161323	ENSG00000224046.1	AC005076.5	4.19	5.4e-05	0.035	0.53	0.36	Bipolar disorder or major depressive disorder (combined);	chr7:87129922	chr7:87151423~87152420:-
GBM	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	4.19	5.4e-05	0.035	0.44	0.36	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
GBM	cis	rs79349575	0.749	rs519537	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48893778	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs832410	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48895503	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs318095	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48897372	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs318096	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48898008	chr17:48899131~48899748:+
GBM	cis	rs2436845	0.589	rs2570950	ENSG00000253320.4	KB-1507C5.2	-4.19	5.41e-05	0.035	-0.43	-0.36	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102871637	chr8:102864300~102977876:+
GBM	cis	rs79349575	0.783	rs903567	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48902956	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs62075818	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48904965	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs9912829	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48905387	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs62075820	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48905809	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs4294857	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48906029	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs61576918	ENSG00000270781.1	RP11-501C14.9	-4.19	5.41e-05	0.035	-0.44	-0.36	Type 2 diabetes;	chr17:48908231	chr17:48899131~48899748:+
GBM	cis	rs17508449	0.865	rs75419513	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113590174	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.865	rs4838993	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113592511	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs4839329	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113593083	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.865	rs4839330	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113594960	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.865	rs75296543	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113595664	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.865	rs76308249	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113605059	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.779	rs78703286	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113605493	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.865	rs76112502	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113607074	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.865	rs80348557	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113608494	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs79220465	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113628719	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs17359281	ENSG00000232450.1	RP4-730K3.3	4.19	5.42e-05	0.035	0.63	0.36	Leprosy;	chr1:113643337	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs3761934	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113646445	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs41352847	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113647258	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs79667495	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113648707	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs2146018	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113652708	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs76726048	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113664077	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs17359378	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113674087	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs17274627	ENSG00000232450.1	RP4-730K3.3	-4.19	5.42e-05	0.035	-0.63	-0.36	Leprosy;	chr1:113674773	chr1:113698884~113699631:-
GBM	cis	rs1257344	0.762	rs2707797	ENSG00000231758.2	AC092652.1	4.19	5.42e-05	0.0351	0.37	0.36	Diisocyanate-induced asthma;	chr2:143854710	chr2:143640756~143656179:-
GBM	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	4.19	5.42e-05	0.0351	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
GBM	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	4.19	5.42e-05	0.0351	0.28	0.36	Breast size;	chr12:9228263	chr12:9277235~9313241:+
GBM	cis	rs7829975	0.593	rs2921061	ENSG00000233609.3	RP11-62H7.2	4.19	5.42e-05	0.0351	0.44	0.36	Mood instability;	chr8:8460105	chr8:8961200~8979025:+
GBM	cis	rs61041384	0.661	rs74240781	ENSG00000256092.2	RP13-942N8.1	-4.19	5.43e-05	0.0351	-0.88	-0.36	Schizophrenia;	chr12:123308154	chr12:123363868~123366113:+
GBM	cis	rs3096299	0.748	rs3102339	ENSG00000260259.1	RP11-368I7.4	4.19	5.43e-05	0.0351	0.4	0.36	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89682620~89686569:-
GBM	cis	rs8114671	0.662	rs6088664	ENSG00000269202.1	RP4-614O4.12	-4.19	5.43e-05	0.0351	-0.45	-0.36	Height;	chr20:34963297	chr20:35201747~35203288:-
GBM	cis	rs1298062	0.605	rs10409679	ENSG00000131401.10	NAPSB	-4.19	5.43e-05	0.0351	-0.44	-0.36	Age of smoking initiation;	chr19:50480673	chr19:50333796~50344767:-
GBM	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	4.19	5.43e-05	0.0351	0.34	0.36	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
GBM	cis	rs79349575	0.777	rs28517720	ENSG00000270781.1	RP11-501C14.9	-4.19	5.43e-05	0.0351	-0.44	-0.36	Type 2 diabetes;	chr17:48899394	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.756	rs2643361	ENSG00000270781.1	RP11-501C14.9	-4.19	5.43e-05	0.0351	-0.44	-0.36	Type 2 diabetes;	chr17:48900100	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.749	rs2546491	ENSG00000270781.1	RP11-501C14.9	-4.19	5.43e-05	0.0351	-0.44	-0.36	Type 2 diabetes;	chr17:48900554	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.783	rs962272	ENSG00000270781.1	RP11-501C14.9	-4.19	5.43e-05	0.0351	-0.44	-0.36	Type 2 diabetes;	chr17:48900921	chr17:48899131~48899748:+
GBM	cis	rs9983113	1	rs2836768	ENSG00000231123.1	SPATA20P1	4.19	5.43e-05	0.0351	0.39	0.36	Body mass index;	chr21:38939569	chr21:38238227~38238664:-
GBM	cis	rs950169	0.763	rs35372971	ENSG00000275120.1	RP11-182J1.17	4.19	5.43e-05	0.0351	0.49	0.36	Schizophrenia;	chr15:84387097	chr15:84599434~84606463:-
GBM	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-4.19	5.43e-05	0.0351	-0.65	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
GBM	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.43e-05	0.0351	-0.41	-0.36	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
GBM	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-4.19	5.43e-05	0.0351	-0.48	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
GBM	cis	rs5742933	0.69	rs62183656	ENSG00000253559.1	OSGEPL1-AS1	-4.19	5.44e-05	0.0351	-0.53	-0.36	Ferritin levels;	chr2:189669387	chr2:189762704~189765556:+
GBM	cis	rs5742933	0.69	rs62183658	ENSG00000253559.1	OSGEPL1-AS1	-4.19	5.44e-05	0.0351	-0.53	-0.36	Ferritin levels;	chr2:189669491	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs56137655	ENSG00000253559.1	OSGEPL1-AS1	-4.19	5.44e-05	0.0351	-0.53	-0.36	Alcohol dependence (age at onset);	chr2:189675844	chr2:189762704~189765556:+
GBM	cis	rs11771526	0.901	rs10282699	ENSG00000273014.1	RP11-225B17.2	-4.19	5.44e-05	0.0351	-0.68	-0.36	Body mass index;	chr7:32258355	chr7:32758882~32759353:+
GBM	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-4.19	5.44e-05	0.0351	-0.41	-0.36	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
GBM	cis	rs950169	0.922	rs11635505	ENSG00000275120.1	RP11-182J1.17	-4.19	5.44e-05	0.0351	-0.46	-0.36	Schizophrenia;	chr15:84553803	chr15:84599434~84606463:-
GBM	cis	rs4834770	1	rs4336213	ENSG00000249244.1	RP11-548H18.2	4.19	5.44e-05	0.0351	0.48	0.36	Blood protein levels;	chr4:119315314	chr4:119391831~119395335:-
GBM	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	4.19	5.44e-05	0.0352	0.6	0.36	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
GBM	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	4.19	5.44e-05	0.0352	0.4	0.36	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	4.19	5.44e-05	0.0352	0.4	0.36	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
GBM	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-4.19	5.45e-05	0.0352	-0.47	-0.36	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
GBM	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-4.19	5.45e-05	0.0352	-0.47	-0.36	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
GBM	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-4.19	5.45e-05	0.0352	-0.47	-0.36	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
GBM	cis	rs308403	0.532	rs309386	ENSG00000224786.1	CETN4P	4.19	5.45e-05	0.0352	0.48	0.36	Blood protein levels;	chr4:122744836	chr4:122730548~122732193:-
GBM	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	4.19	5.45e-05	0.0352	0.54	0.36	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
GBM	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	4.19	5.46e-05	0.0352	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
GBM	cis	rs2976388	0.556	rs4736300	ENSG00000253741.1	CTD-2292P10.4	4.19	5.46e-05	0.0353	0.4	0.36	Urinary tract infection frequency;	chr8:142747851	chr8:142702252~142726973:-
GBM	cis	rs1816537	0.625	rs10891510	ENSG00000214264.4	KCTD9P4	-4.19	5.46e-05	0.0353	-0.4	-0.36	Body mass index;	chr11:113137438	chr11:112180773~112183191:+
GBM	cis	rs853679	0.513	rs13437444	ENSG00000280107.1	AL022393.9	-4.19	5.46e-05	0.0353	-0.55	-0.36	Depression;	chr6:28103220	chr6:28170845~28172521:+
GBM	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.46e-05	0.0353	-0.39	-0.36	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
GBM	cis	rs763121	0.853	rs2179142	ENSG00000273076.1	RP3-508I15.22	4.19	5.46e-05	0.0353	0.41	0.36	Menopause (age at onset);	chr22:38641949	chr22:38743495~38743910:+
GBM	cis	rs916888	0.61	rs199438	ENSG00000262500.1	RP11-259G18.2	4.19	5.47e-05	0.0353	0.48	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46243606~46245044:+
GBM	cis	rs7829975	0.577	rs17684466	ENSG00000253893.2	FAM85B	4.19	5.47e-05	0.0353	0.47	0.36	Mood instability;	chr8:8687723	chr8:8167819~8226614:-
GBM	cis	rs2976388	0.669	rs2976391	ENSG00000253741.1	CTD-2292P10.4	-4.19	5.47e-05	0.0353	-0.38	-0.36	Urinary tract infection frequency;	chr8:142681306	chr8:142702252~142726973:-
GBM	cis	rs5742933	0.512	rs80277863	ENSG00000273240.1	RP11-455J20.3	-4.19	5.47e-05	0.0353	-0.41	-0.36	Ferritin levels;	chr2:189766733	chr2:189763859~189764456:-
GBM	cis	rs11098499	0.722	rs1814814	ENSG00000249244.1	RP11-548H18.2	4.19	5.47e-05	0.0353	0.46	0.36	Corneal astigmatism;	chr4:119336969	chr4:119391831~119395335:-
GBM	cis	rs36715	0.953	rs251214	ENSG00000245937.6	LINC01184	4.19	5.48e-05	0.0354	0.39	0.36	Breast cancer;	chr5:128209046	chr5:127940426~128083172:-
GBM	cis	rs36715	1	rs251213	ENSG00000245937.6	LINC01184	4.19	5.48e-05	0.0354	0.39	0.36	Breast cancer;	chr5:128209913	chr5:127940426~128083172:-
GBM	cis	rs36715	1	rs251212	ENSG00000245937.6	LINC01184	4.19	5.48e-05	0.0354	0.39	0.36	Breast cancer;	chr5:128210218	chr5:127940426~128083172:-
GBM	cis	rs36715	1	rs2617621	ENSG00000245937.6	LINC01184	4.19	5.48e-05	0.0354	0.39	0.36	Breast cancer;	chr5:128210574	chr5:127940426~128083172:-
GBM	cis	rs36715	1	rs251386	ENSG00000245937.6	LINC01184	4.19	5.48e-05	0.0354	0.39	0.36	Breast cancer;	chr5:128211606	chr5:127940426~128083172:-
GBM	cis	rs36715	1	rs181850	ENSG00000245937.6	LINC01184	4.19	5.48e-05	0.0354	0.39	0.36	Breast cancer;	chr5:128211795	chr5:127940426~128083172:-
GBM	cis	rs36715	0.953	rs185177	ENSG00000245937.6	LINC01184	4.19	5.48e-05	0.0354	0.39	0.36	Breast cancer;	chr5:128212118	chr5:127940426~128083172:-
GBM	cis	rs2836950	0.545	rs11700813	ENSG00000238141.2	BRWD1-AS1	-4.19	5.48e-05	0.0354	-0.38	-0.36	Menarche (age at onset);	chr21:39145543	chr21:39315707~39323218:+
GBM	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-4.19	5.48e-05	0.0354	-0.51	-0.36	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
GBM	cis	rs62184315	0.536	rs5743047	ENSG00000253559.1	OSGEPL1-AS1	4.19	5.49e-05	0.0354	0.53	0.36	Alcohol dependence (age at onset);	chr2:189819942	chr2:189762704~189765556:+
GBM	cis	rs7267979	0.586	rs6050431	ENSG00000125804.12	FAM182A	-4.19	5.5e-05	0.0354	-0.47	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.586	rs6050432	ENSG00000125804.12	FAM182A	-4.19	5.5e-05	0.0354	-0.47	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:26054655~26086917:+
GBM	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-4.19	5.5e-05	0.0354	-0.41	-0.36	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
GBM	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	4.19	5.5e-05	0.0355	0.44	0.36	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
GBM	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	4.19	5.5e-05	0.0355	0.39	0.36	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
GBM	cis	rs55704346	0.565	rs4697551	ENSG00000281501.1	SEPSECS-AS1	4.19	5.5e-05	0.0355	0.44	0.36	Tonsillectomy;	chr4:25126938	chr4:25160641~25201440:+
GBM	cis	rs1850744	0.702	rs7666466	ENSG00000250268.3	ALG1L14P	-4.19	5.51e-05	0.0355	-0.96	-0.36	Economic and political preferences;	chr4:9627879	chr4:9166297~9170270:-
GBM	cis	rs1850744	0.609	rs11729458	ENSG00000250268.3	ALG1L14P	-4.19	5.51e-05	0.0355	-0.96	-0.36	Economic and political preferences;	chr4:9628447	chr4:9166297~9170270:-
GBM	cis	rs1850744	0.609	rs11939928	ENSG00000250268.3	ALG1L14P	-4.19	5.51e-05	0.0355	-0.96	-0.36	Economic and political preferences;	chr4:9628867	chr4:9166297~9170270:-
GBM	cis	rs1850744	0.826	rs11933525	ENSG00000250268.3	ALG1L14P	-4.19	5.51e-05	0.0355	-0.96	-0.36	Economic and political preferences;	chr4:9628880	chr4:9166297~9170270:-
GBM	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	4.19	5.51e-05	0.0355	0.48	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
GBM	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	4.19	5.51e-05	0.0355	0.48	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
GBM	cis	rs6903823	0.508	rs1150726	ENSG00000218016.2	ZNF192P2	-4.19	5.51e-05	0.0355	-0.42	-0.36	Pulmonary function;	chr6:28275265	chr6:28188050~28189432:+
GBM	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-4.19	5.51e-05	0.0355	-0.55	-0.36	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
GBM	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	4.19	5.52e-05	0.0355	0.42	0.36	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
GBM	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	4.19	5.52e-05	0.0355	0.42	0.36	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
GBM	cis	rs17270561	0.609	rs9348692	ENSG00000272810.1	U91328.22	-4.19	5.53e-05	0.0356	-0.5	-0.36	Iron status biomarkers;	chr6:25720584	chr6:26013241~26013757:+
GBM	cis	rs11642862	1	rs113454775	ENSG00000260911.2	RP11-196G11.2	4.19	5.53e-05	0.0356	0.53	0.36	Tonsillectomy;	chr16:30798213	chr16:31043150~31049868:+
GBM	cis	rs4478147	0.506	rs17449582	ENSG00000261496.1	RP13-514E23.1	-4.19	5.53e-05	0.0356	-0.46	-0.36	Migraine - clinic-based;	chr4:86319004	chr4:86012296~86013874:-
GBM	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	4.19	5.53e-05	0.0356	0.5	0.36	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
GBM	cis	rs4869313	0.87	rs2548532	ENSG00000248734.2	CTD-2260A17.1	-4.19	5.53e-05	0.0356	-0.44	-0.36	Pediatric autoimmune diseases;	chr5:96902874	chr5:96784777~96785999:+
GBM	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-4.19	5.53e-05	0.0356	-0.5	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
GBM	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-4.19	5.53e-05	0.0356	-0.46	-0.36	Height;	chr3:53093751	chr3:53064283~53065091:-
GBM	cis	rs57221529	0.563	rs4957057	ENSG00000260774.1	CTD-2083E4.4	4.19	5.54e-05	0.0356	0.5	0.36	Lung disease severity in cystic fibrosis;	chr5:569115	chr5:213898~217279:-
GBM	cis	rs2014572	1	rs3746231	ENSG00000267871.4	CTC-444N24.6	4.19	5.54e-05	0.0356	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57248689	chr19:57267220~57280334:-
GBM	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-4.19	5.54e-05	0.0356	-0.53	-0.36	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
GBM	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	4.19	5.54e-05	0.0356	0.4	0.36	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	4.19	5.54e-05	0.0356	0.4	0.36	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	4.19	5.54e-05	0.0356	0.4	0.36	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	4.19	5.54e-05	0.0356	0.4	0.36	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	4.19	5.54e-05	0.0356	0.4	0.36	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
GBM	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	5.54e-05	0.0356	-0.3	-0.36	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
GBM	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	5.54e-05	0.0356	-0.3	-0.36	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
GBM	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	5.54e-05	0.0356	-0.3	-0.36	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
GBM	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	5.54e-05	0.0356	-0.3	-0.36	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
GBM	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	5.54e-05	0.0356	-0.3	-0.36	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
GBM	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	5.54e-05	0.0356	-0.3	-0.36	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
GBM	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	5.54e-05	0.0356	-0.3	-0.36	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
GBM	cis	rs59104589	0.583	rs12624195	ENSG00000235351.1	AC114730.11	-4.19	5.54e-05	0.0356	-0.33	-0.36	Fibrinogen levels;	chr2:241315319	chr2:241724615~241725693:-
GBM	cis	rs59104589	0.617	rs12233133	ENSG00000235351.1	AC114730.11	-4.19	5.54e-05	0.0356	-0.33	-0.36	Fibrinogen levels;	chr2:241317397	chr2:241724615~241725693:-
GBM	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	4.19	5.55e-05	0.0357	0.41	0.36	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
GBM	cis	rs172166	0.516	rs1225710	ENSG00000280107.1	AL022393.9	4.19	5.55e-05	0.0357	0.38	0.36	Cardiac Troponin-T levels;	chr6:28132862	chr6:28170845~28172521:+
GBM	cis	rs7726839	0.54	rs72703080	ENSG00000260774.1	CTD-2083E4.4	4.19	5.55e-05	0.0357	0.51	0.36	Obesity-related traits;	chr5:595123	chr5:213898~217279:-
GBM	cis	rs11098499	0.731	rs6846966	ENSG00000250412.1	KLHL2P1	4.19	5.55e-05	0.0357	0.46	0.36	Corneal astigmatism;	chr4:119372053	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs6847778	ENSG00000250412.1	KLHL2P1	4.19	5.55e-05	0.0357	0.46	0.36	Corneal astigmatism;	chr4:119372427	chr4:119334329~119378233:+
GBM	cis	rs6906287	0.718	rs6911339	ENSG00000225549.3	RP11-210H10__A.1	-4.19	5.55e-05	0.0357	-0.42	-0.36	Electrocardiographic conduction measures;	chr6:118332458	chr6:118757518~118783420:+
GBM	cis	rs4869313	0.905	rs27307	ENSG00000248734.2	CTD-2260A17.1	4.19	5.55e-05	0.0357	0.44	0.36	Pediatric autoimmune diseases;	chr5:97002801	chr5:96784777~96785999:+
GBM	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-4.19	5.55e-05	0.0357	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
GBM	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	4.19	5.56e-05	0.0358	0.4	0.36	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
GBM	cis	rs9494145	0.59	rs9376090	ENSG00000232876.1	CTA-212D2.2	-4.19	5.56e-05	0.0358	-0.49	-0.36	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135090090	chr6:135055033~135060550:+
GBM	cis	rs4568518	0.616	rs4721675	ENSG00000279048.1	RP11-511H23.2	4.19	5.57e-05	0.0358	0.29	0.36	Measles;	chr7:17965079	chr7:17940503~17942922:+
GBM	cis	rs4568518	0.619	rs9648238	ENSG00000279048.1	RP11-511H23.2	4.19	5.57e-05	0.0358	0.29	0.36	Measles;	chr7:17965614	chr7:17940503~17942922:+
GBM	cis	rs4568518	0.616	rs10950691	ENSG00000279048.1	RP11-511H23.2	4.19	5.57e-05	0.0358	0.29	0.36	Measles;	chr7:17966511	chr7:17940503~17942922:+
GBM	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-4.19	5.57e-05	0.0358	-0.5	-0.36	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
GBM	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-4.19	5.59e-05	0.0358	-0.41	-0.36	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
GBM	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	4.19	5.59e-05	0.0359	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
GBM	cis	rs6499129	0.702	rs16957210	ENSG00000270049.1	RP11-297D21.4	-4.19	5.6e-05	0.0359	-0.7	-0.36	Waist-to-hip ratio adjusted for body mass index;	chr16:67184472	chr16:67481314~67487250:+
GBM	cis	rs62184315	0.536	rs5743047	ENSG00000273240.1	RP11-455J20.3	4.19	5.6e-05	0.0359	0.54	0.36	Alcohol dependence (age at onset);	chr2:189819942	chr2:189763859~189764456:-
GBM	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	4.18	5.61e-05	0.036	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
GBM	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-4.18	5.61e-05	0.036	-0.35	-0.36	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
GBM	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	4.18	5.61e-05	0.036	0.55	0.36	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
GBM	cis	rs11098499	0.78	rs7692994	ENSG00000250412.1	KLHL2P1	4.18	5.62e-05	0.036	0.45	0.36	Corneal astigmatism;	chr4:119506334	chr4:119334329~119378233:+
GBM	cis	rs17772222	0.638	rs11159859	ENSG00000222990.1	RNU4-22P	4.18	5.62e-05	0.036	0.38	0.36	Coronary artery calcification;	chr14:88561547	chr14:88513498~88513663:+
GBM	cis	rs2436845	0.554	rs491770	ENSG00000253320.4	KB-1507C5.2	-4.18	5.62e-05	0.036	-0.39	-0.36	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102895800	chr8:102864300~102977876:+
GBM	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	4.18	5.62e-05	0.036	0.42	0.36	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	4.18	5.62e-05	0.036	0.42	0.36	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
GBM	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	4.18	5.62e-05	0.036	0.42	0.36	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
GBM	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	4.18	5.62e-05	0.036	0.42	0.36	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
GBM	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	4.18	5.62e-05	0.036	0.42	0.36	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
GBM	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-4.18	5.62e-05	0.036	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
GBM	cis	rs6598955	0.671	rs10902735	ENSG00000236782.4	RP11-96L14.7	4.18	5.62e-05	0.036	0.53	0.36	Obesity-related traits;	chr1:26291445	chr1:26169947~26171821:-
GBM	cis	rs4842666	0.915	rs73437358	ENSG00000258302.2	RP11-981P6.1	4.18	5.62e-05	0.036	0.45	0.36	Blood pressure;	chr12:89678299	chr12:89561129~89594878:+
GBM	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	4.18	5.63e-05	0.0361	0.36	0.36	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
GBM	cis	rs7017914	0.69	rs55915640	ENSG00000246366.5	RP11-382J12.1	-4.18	5.63e-05	0.0361	-0.39	-0.36	Bone mineral density;	chr8:71052423	chr8:70608577~70663279:+
GBM	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	4.18	5.63e-05	0.0361	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
GBM	cis	rs7829975	0.593	rs2921051	ENSG00000233609.3	RP11-62H7.2	4.18	5.63e-05	0.0361	0.44	0.36	Mood instability;	chr8:8462594	chr8:8961200~8979025:+
GBM	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	4.18	5.63e-05	0.0361	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
GBM	cis	rs17685	0.672	rs55807301	ENSG00000280388.1	RP11-229D13.3	-4.18	5.64e-05	0.0361	-0.33	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76178083	chr7:76043977~76045963:-
GBM	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-4.18	5.64e-05	0.0361	-0.48	-0.36	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
GBM	cis	rs4713118	0.513	rs149989	ENSG00000218016.2	ZNF192P2	-4.18	5.64e-05	0.0361	-0.51	-0.36	Parkinson's disease;	chr6:28030406	chr6:28188050~28189432:+
GBM	cis	rs846111	1	rs846111	ENSG00000225077.2	LINC00337	-4.18	5.65e-05	0.0361	-0.52	-0.36	QT interval;	chr1:6219310	chr1:6236240~6239444:+
GBM	cis	rs7726839	0.561	rs11955068	ENSG00000260774.1	CTD-2083E4.4	4.18	5.65e-05	0.0361	0.49	0.36	Obesity-related traits;	chr5:582209	chr5:213898~217279:-
GBM	cis	rs7726839	0.561	rs72703050	ENSG00000260774.1	CTD-2083E4.4	4.18	5.65e-05	0.0361	0.49	0.36	Obesity-related traits;	chr5:582802	chr5:213898~217279:-
GBM	cis	rs7726839	0.561	rs56410216	ENSG00000260774.1	CTD-2083E4.4	4.18	5.65e-05	0.0361	0.49	0.36	Obesity-related traits;	chr5:583101	chr5:213898~217279:-
GBM	cis	rs7726839	0.561	rs4957048	ENSG00000260774.1	CTD-2083E4.4	4.18	5.65e-05	0.0361	0.49	0.36	Obesity-related traits;	chr5:583327	chr5:213898~217279:-
GBM	cis	rs7726839	0.561	rs72703058	ENSG00000260774.1	CTD-2083E4.4	4.18	5.65e-05	0.0361	0.49	0.36	Obesity-related traits;	chr5:584404	chr5:213898~217279:-
GBM	cis	rs7017914	0.652	rs950903	ENSG00000246366.5	RP11-382J12.1	-4.18	5.65e-05	0.0362	-0.38	-0.36	Bone mineral density;	chr8:70988539	chr8:70608577~70663279:+
GBM	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	4.18	5.66e-05	0.0362	0.42	0.36	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
GBM	cis	rs17270561	0.636	rs7453371	ENSG00000272810.1	U91328.22	-4.18	5.66e-05	0.0362	-0.5	-0.36	Iron status biomarkers;	chr6:25719028	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs7450798	ENSG00000272810.1	U91328.22	-4.18	5.66e-05	0.0362	-0.5	-0.36	Iron status biomarkers;	chr6:25719052	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4712957	ENSG00000272810.1	U91328.22	-4.18	5.66e-05	0.0362	-0.5	-0.36	Iron status biomarkers;	chr6:25719586	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.666	rs17320090	ENSG00000272810.1	U91328.22	-4.18	5.66e-05	0.0362	-0.5	-0.36	Iron status biomarkers;	chr6:25719987	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs9393656	ENSG00000272810.1	U91328.22	-4.18	5.66e-05	0.0362	-0.5	-0.36	Iron status biomarkers;	chr6:25721831	chr6:26013241~26013757:+
GBM	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	4.18	5.66e-05	0.0362	0.4	0.36	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
GBM	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	4.18	5.66e-05	0.0362	0.4	0.36	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
GBM	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	4.18	5.66e-05	0.0362	0.4	0.36	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
GBM	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	4.18	5.66e-05	0.0362	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
GBM	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.18	5.66e-05	0.0362	0.38	0.36	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
GBM	cis	rs10497721	1	rs6743150	ENSG00000227542.1	AC092614.2	4.18	5.67e-05	0.0362	0.82	0.36	Diabetes (incident);	chr2:192039051	chr2:191229165~191246172:-
GBM	cis	rs10497721	1	rs4241288	ENSG00000227542.1	AC092614.2	4.18	5.67e-05	0.0362	0.82	0.36	Diabetes (incident);	chr2:192040368	chr2:191229165~191246172:-
GBM	cis	rs10497721	1	rs4853656	ENSG00000227542.1	AC092614.2	-4.18	5.67e-05	0.0362	-0.82	-0.36	Diabetes (incident);	chr2:192037679	chr2:191229165~191246172:-
GBM	cis	rs4713118	0.505	rs276371	ENSG00000199851.2	U3	4.18	5.67e-05	0.0363	0.45	0.36	Parkinson's disease;	chr6:27942930	chr6:28015568~28015777:+
GBM	cis	rs61823972	0.51	rs11240351	ENSG00000281406.1	BLACAT1	-4.18	5.67e-05	0.0363	-0.49	-0.36	Mean corpuscular volume;High light scatter reticulocyte count;Mean corpuscular hemoglobin concentration;Mean corpuscular hemoglobin;Immature fraction of reticulocytes;	chr1:205075211	chr1:205434886~205437879:-
GBM	cis	rs875971	0.825	rs1129531	ENSG00000236529.1	RP13-254B10.1	-4.18	5.67e-05	0.0363	-0.34	-0.36	Aortic root size;	chr7:66154117	chr7:65840212~65840596:+
GBM	cis	rs10875943	0.751	rs56222401	ENSG00000258017.1	RP11-386G11.10	-4.18	5.67e-05	0.0363	-0.41	-0.36	Prostate cancer;	chr12:49278931	chr12:49127782~49147869:+
GBM	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	4.18	5.68e-05	0.0363	0.41	0.36	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
GBM	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	4.18	5.68e-05	0.0363	0.41	0.36	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
GBM	cis	rs11098499	0.644	rs17517414	ENSG00000249244.1	RP11-548H18.2	4.18	5.68e-05	0.0363	0.46	0.36	Corneal astigmatism;	chr4:119340946	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.722	rs17595727	ENSG00000249244.1	RP11-548H18.2	-4.18	5.68e-05	0.0363	-0.46	-0.36	Corneal astigmatism;	chr4:119340919	chr4:119391831~119395335:-
GBM	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
GBM	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	4.18	5.68e-05	0.0363	0.7	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
GBM	cis	rs853679	0.76	rs9357067	ENSG00000204789.4	ZNF204P	4.18	5.69e-05	0.0363	0.66	0.36	Depression;	chr6:28242515	chr6:27357825~27360221:-
GBM	cis	rs853679	0.76	rs967005	ENSG00000204789.4	ZNF204P	4.18	5.69e-05	0.0363	0.66	0.36	Depression;	chr6:28242910	chr6:27357825~27360221:-
GBM	cis	rs893363	0.522	rs2241808	ENSG00000271916.1	RP11-884K10.6	-4.18	5.69e-05	0.0363	-0.42	-0.36	Axial length;	chr3:53822626	chr3:53797764~53798019:-
GBM	cis	rs10507419	0.931	rs55964921	ENSG00000276672.1	RP11-142E9.1	-4.18	5.69e-05	0.0363	-0.4	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34613690	chr13:33846190~33850825:+
GBM	cis	rs10507419	1	rs55981648	ENSG00000276672.1	RP11-142E9.1	-4.18	5.69e-05	0.0363	-0.4	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34613696	chr13:33846190~33850825:+
GBM	cis	rs10507419	0.965	rs61947292	ENSG00000276672.1	RP11-142E9.1	-4.18	5.69e-05	0.0363	-0.4	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34614216	chr13:33846190~33850825:+
GBM	cis	rs10507419	0.83	rs9529347	ENSG00000276672.1	RP11-142E9.1	-4.18	5.69e-05	0.0363	-0.4	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34614321	chr13:33846190~33850825:+
GBM	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	4.18	5.69e-05	0.0363	0.41	0.36	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
GBM	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	4.18	5.69e-05	0.0363	0.52	0.36	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
GBM	cis	rs7615952	0.576	rs4646748	ENSG00000250012.1	RP11-124N2.1	-4.18	5.69e-05	0.0363	-0.39	-0.36	Blood pressure (smoking interaction);	chr3:126107486	chr3:126084220~126095349:+
GBM	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.69e-05	0.0364	-0.4	-0.36	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.69e-05	0.0364	-0.4	-0.36	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
GBM	cis	rs4072705	0.615	rs7028021	ENSG00000224020.1	MIR181A2HG	-4.18	5.7e-05	0.0364	-0.4	-0.36	Menarche (age at onset);	chr9:124486743	chr9:124658467~124698631:+
GBM	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	4.18	5.7e-05	0.0364	0.51	0.36	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
GBM	cis	rs7267979	0.844	rs6107027	ENSG00000276952.1	RP5-965G21.6	4.18	5.71e-05	0.0365	0.33	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25284915~25285588:-
GBM	cis	rs984222	0.648	rs6428801	ENSG00000231365.4	RP11-418J17.1	-4.18	5.72e-05	0.0365	-0.38	-0.36	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119140396~119275973:+
GBM	cis	rs4841097	0.876	rs6601288	ENSG00000253893.2	FAM85B	-4.18	5.72e-05	0.0365	-0.47	-0.36	Platelet distribution width;	chr8:9085920	chr8:8167819~8226614:-
GBM	cis	rs875971	0.545	rs4441996	ENSG00000222364.1	RNU6-96P	4.18	5.72e-05	0.0365	0.41	0.36	Aortic root size;	chr7:66123233	chr7:66395191~66395286:+
GBM	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-4.18	5.72e-05	0.0365	-0.7	-0.36	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
GBM	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-4.18	5.73e-05	0.0365	-0.43	-0.36	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-4.18	5.73e-05	0.0365	-0.43	-0.36	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-4.18	5.73e-05	0.0365	-0.43	-0.36	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-4.18	5.73e-05	0.0365	-0.43	-0.36	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-4.18	5.73e-05	0.0365	-0.43	-0.36	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-4.18	5.73e-05	0.0365	-0.43	-0.36	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
GBM	cis	rs4072705	0.835	rs7855360	ENSG00000224020.1	MIR181A2HG	-4.18	5.73e-05	0.0365	-0.41	-0.36	Menarche (age at onset);	chr9:124794425	chr9:124658467~124698631:+
GBM	cis	rs13217239	0.646	rs12527111	ENSG00000224843.5	LINC00240	-4.18	5.73e-05	0.0365	-0.43	-0.36	Schizophrenia;	chr6:27038696	chr6:26956992~27023924:+
GBM	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	4.18	5.73e-05	0.0365	0.36	0.36	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
GBM	cis	rs9876781	1	rs4858793	ENSG00000244380.1	RP11-24C3.2	-4.18	5.73e-05	0.0365	-0.45	-0.36	Longevity;	chr3:48373517	chr3:48440352~48446656:-
GBM	cis	rs4604732	0.588	rs7549495	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464504	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.536	rs76191272	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464753	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.536	rs7528219	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465005	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs7549955	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465019	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs7552443	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465281	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs7552461	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465342	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs6677477	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466109	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs9943231	ENSG00000227135.1	GCSAML-AS1	-4.18	5.73e-05	0.0365	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466527	chr1:247524679~247526752:-
GBM	cis	rs911186	0.73	rs2393911	ENSG00000224843.5	LINC00240	4.18	5.73e-05	0.0365	0.49	0.36	Autism spectrum disorder or schizophrenia;	chr6:27089300	chr6:26956992~27023924:+
GBM	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-4.18	5.73e-05	0.0366	-0.39	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
GBM	cis	rs453301	0.658	rs9329175	ENSG00000254340.1	RP11-10A14.3	-4.18	5.74e-05	0.0366	-0.47	-0.36	Joint mobility (Beighton score);	chr8:9009151	chr8:9141424~9145435:+
GBM	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	4.18	5.75e-05	0.0366	0.42	0.36	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	4.18	5.75e-05	0.0366	0.42	0.36	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
GBM	cis	rs7176527	1	rs3762169	ENSG00000259774.1	RP11-182J1.13	4.18	5.75e-05	0.0366	0.57	0.36	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84422618~84425882:+
GBM	cis	rs4568518	0.53	rs4721672	ENSG00000279048.1	RP11-511H23.2	4.18	5.75e-05	0.0366	0.29	0.36	Measles;	chr7:17946475	chr7:17940503~17942922:+
GBM	cis	rs7615952	0.515	rs7630575	ENSG00000250012.1	RP11-124N2.1	-4.18	5.75e-05	0.0367	-0.41	-0.36	Blood pressure (smoking interaction);	chr3:125963487	chr3:126084220~126095349:+
GBM	cis	rs10231759	0.617	rs4725947	ENSG00000273419.1	RP4-751H13.7	-4.18	5.76e-05	0.0367	-0.41	-0.36	Height;	chr7:150817441	chr7:149858400~149862492:-
GBM	cis	rs875971	0.83	rs6950137	ENSG00000236529.1	RP13-254B10.1	4.18	5.76e-05	0.0367	0.39	0.36	Aortic root size;	chr7:66511623	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs11763189	ENSG00000236529.1	RP13-254B10.1	4.18	5.76e-05	0.0367	0.39	0.36	Aortic root size;	chr7:66518542	chr7:65840212~65840596:+
GBM	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	4.18	5.76e-05	0.0367	0.55	0.36	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
GBM	cis	rs11654801	0.812	rs11658671	ENSG00000233098.7	CCDC144NL-AS1	-4.18	5.77e-05	0.0367	-0.51	-0.36	Mosquito bite size;	chr17:20978078	chr17:20868433~21002276:+
GBM	cis	rs10901212	1	rs7857089	ENSG00000119440.8	LCN1P1	4.18	5.77e-05	0.0367	0.65	0.36	Obesity-related traits;	chr9:132777900	chr9:133224905~133228591:-
GBM	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	4.18	5.77e-05	0.0368	0.38	0.36	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
GBM	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-4.18	5.78e-05	0.0368	-0.35	-0.36	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
GBM	cis	rs977747	0.872	rs6658125	ENSG00000232022.5	FAAHP1	-4.18	5.78e-05	0.0368	-0.37	-0.36	Body mass index;	chr1:47211343	chr1:46432129~46445521:+
GBM	cis	rs17772222	0.63	rs8017811	ENSG00000222990.1	RNU4-22P	-4.18	5.78e-05	0.0368	-0.38	-0.36	Coronary artery calcification;	chr14:88534559	chr14:88513498~88513663:+
GBM	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-4.18	5.78e-05	0.0368	-0.41	-0.36	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
GBM	cis	rs875971	0.545	rs73142233	ENSG00000222364.1	RNU6-96P	-4.18	5.79e-05	0.0368	-0.41	-0.36	Aortic root size;	chr7:66221293	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs73142245	ENSG00000222364.1	RNU6-96P	-4.18	5.79e-05	0.0368	-0.41	-0.36	Aortic root size;	chr7:66226662	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs73142265	ENSG00000222364.1	RNU6-96P	-4.18	5.79e-05	0.0368	-0.41	-0.36	Aortic root size;	chr7:66234510	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs4145009	ENSG00000236529.1	RP13-254B10.1	-4.18	5.79e-05	0.0368	-0.39	-0.36	Aortic root size;	chr7:66261628	chr7:65840212~65840596:+
GBM	cis	rs9425766	0.927	rs5878	ENSG00000270084.1	GAS5-AS1	-4.18	5.79e-05	0.0368	-0.4	-0.36	Life satisfaction;	chr1:173909694	chr1:173863248~173863941:+
GBM	cis	rs7267979	0.714	rs3787082	ENSG00000125804.12	FAM182A	-4.18	5.8e-05	0.0368	-0.44	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.714	rs6115107	ENSG00000125804.12	FAM182A	-4.18	5.8e-05	0.0368	-0.44	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.78	rs2500413	ENSG00000125804.12	FAM182A	-4.18	5.8e-05	0.0368	-0.44	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.714	rs2474763	ENSG00000125804.12	FAM182A	-4.18	5.8e-05	0.0368	-0.44	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:26054655~26086917:+
GBM	cis	rs2115630	1	rs2115630	ENSG00000225151.9	GOLGA2P7	4.18	5.8e-05	0.0368	0.38	0.36	P wave terminal force;	chr15:84821285	chr15:84199311~84230136:-
GBM	cis	rs17270561	0.887	rs9358870	ENSG00000272810.1	U91328.22	-4.18	5.8e-05	0.0368	-0.56	-0.36	Iron status biomarkers;	chr6:25718982	chr6:26013241~26013757:+
GBM	cis	rs2282300	0.739	rs35229181	ENSG00000254532.1	RP11-624D11.2	4.18	5.8e-05	0.0369	0.5	0.36	Morning vs. evening chronotype;	chr11:30220151	chr11:30044058~30084343:-
GBM	cis	rs2282300	0.739	rs34234618	ENSG00000254532.1	RP11-624D11.2	4.18	5.8e-05	0.0369	0.5	0.36	Morning vs. evening chronotype;	chr11:30220154	chr11:30044058~30084343:-
GBM	cis	rs858239	0.636	rs28706766	ENSG00000230042.1	AK3P3	-4.18	5.81e-05	0.0369	-0.41	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23129178~23129841:+
GBM	cis	rs7746199	0.736	rs72845070	ENSG00000219392.1	RP1-265C24.5	-4.18	5.81e-05	0.0369	-0.86	-0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28115628~28116551:+
GBM	cis	rs1198872	0.558	rs10929699	ENSG00000272275.1	RP11-791G15.2	-4.18	5.81e-05	0.0369	-0.45	-0.36	Cardiac Troponin-T levels;	chr2:10778083	chr2:10767875~10770058:-
GBM	cis	rs9315786	0.924	rs7323436	ENSG00000168852.11	TPTE2P5	-4.18	5.81e-05	0.0369	-0.49	-0.36	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40822296~40921749:-
GBM	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-4.18	5.82e-05	0.0369	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-4.18	5.82e-05	0.0369	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-4.18	5.82e-05	0.0369	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
GBM	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-4.18	5.82e-05	0.0369	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-4.18	5.82e-05	0.0369	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
GBM	cis	rs875971	0.545	rs3735147	ENSG00000222364.1	RNU6-96P	-4.18	5.82e-05	0.0369	-0.42	-0.36	Aortic root size;	chr7:66505541	chr7:66395191~66395286:+
GBM	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-4.18	5.82e-05	0.0369	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
GBM	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-4.17	5.82e-05	0.037	-0.49	-0.36	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
GBM	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	4.17	5.82e-05	0.037	0.42	0.36	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
GBM	cis	rs3096299	0.606	rs8052103	ENSG00000260259.1	RP11-368I7.4	-4.17	5.83e-05	0.037	-0.42	-0.36	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89682620~89686569:-
GBM	cis	rs2288884	0.559	rs6509611	ENSG00000275055.1	CTC-471J1.11	-4.17	5.83e-05	0.037	-0.46	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:52049007~52049754:+
GBM	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	4.17	5.83e-05	0.037	0.4	0.36	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
GBM	cis	rs6600671	0.934	rs7528274	ENSG00000223345.3	HIST2H2BA	4.17	5.83e-05	0.037	0.47	0.36	Hip geometry;	chr1:121545103	chr1:121108210~121117257:-
GBM	cis	rs9947662	0.879	rs9958629	ENSG00000267761.3	CTD-2130O13.1	-4.17	5.83e-05	0.037	-0.47	-0.36	Migraine;	chr18:47378025	chr18:47285725~47594550:+
GBM	cis	rs9947662	0.879	rs9959021	ENSG00000267761.3	CTD-2130O13.1	-4.17	5.83e-05	0.037	-0.47	-0.36	Migraine;	chr18:47378461	chr18:47285725~47594550:+
GBM	cis	rs8062405	0.755	rs17707300	ENSG00000271623.1	RP11-435I10.5	-4.17	5.83e-05	0.037	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28364700~28365333:+
GBM	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-4.17	5.83e-05	0.037	-0.4	-0.36	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
GBM	cis	rs4784054	0.667	rs71400028	ENSG00000276166.1	CTD-2600O9.2	4.17	5.83e-05	0.037	0.69	0.36	Blood metabolite levels;	chr16:58748369	chr16:57759358~57760024:+
GBM	cis	rs4784054	0.685	rs118064851	ENSG00000276166.1	CTD-2600O9.2	4.17	5.83e-05	0.037	0.69	0.36	Blood metabolite levels;	chr16:58749345	chr16:57759358~57760024:+
GBM	cis	rs4784054	0.803	rs12921819	ENSG00000276166.1	CTD-2600O9.2	4.17	5.83e-05	0.037	0.69	0.36	Blood metabolite levels;	chr16:58753239	chr16:57759358~57760024:+
GBM	cis	rs4784054	0.655	rs8050744	ENSG00000276166.1	CTD-2600O9.2	4.17	5.83e-05	0.037	0.69	0.36	Blood metabolite levels;	chr16:58758580	chr16:57759358~57760024:+
GBM	cis	rs4784054	0.73	rs8055234	ENSG00000276166.1	CTD-2600O9.2	4.17	5.83e-05	0.037	0.69	0.36	Blood metabolite levels;	chr16:58758616	chr16:57759358~57760024:+
GBM	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-4.17	5.84e-05	0.037	-0.42	-0.36	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
GBM	cis	rs10231759	0.617	rs2080054	ENSG00000273419.1	RP4-751H13.7	-4.17	5.85e-05	0.0371	-0.41	-0.36	Height;	chr7:150818586	chr7:149858400~149862492:-
GBM	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-4.17	5.85e-05	0.0371	-0.31	-0.36	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
GBM	cis	rs1555322	1	rs1555322	ENSG00000126005.14	MMP24-AS1	-4.17	5.85e-05	0.0371	-0.6	-0.36	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35216462~35278131:-
GBM	cis	rs13217239	0.646	rs10946888	ENSG00000224843.5	LINC00240	-4.17	5.86e-05	0.0371	-0.43	-0.36	Schizophrenia;	chr6:26983899	chr6:26956992~27023924:+
GBM	cis	rs1167832	0.645	rs1167829	ENSG00000127957.15	PMS2P3	-4.17	5.86e-05	0.0371	-0.46	-0.36	Ankle injury;	chr7:75535697	chr7:75502930~75528148:-
GBM	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-4.17	5.86e-05	0.0371	-0.34	-0.36	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
GBM	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-4.17	5.86e-05	0.0372	-0.46	-0.36	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
GBM	cis	rs875971	0.545	rs316328	ENSG00000222364.1	RNU6-96P	4.17	5.86e-05	0.0372	0.39	0.36	Aortic root size;	chr7:66143851	chr7:66395191~66395286:+
GBM	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-4.17	5.86e-05	0.0372	-0.48	-0.36	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
GBM	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-4.17	5.87e-05	0.0372	-0.37	-0.36	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
GBM	cis	rs181553	0.532	rs2044550	ENSG00000266696.1	RP11-30L3.2	-4.17	5.87e-05	0.0372	-0.39	-0.36	Hip circumference adjusted for BMI;	chr18:49055730	chr18:49205912~49208781:+
GBM	cis	rs9947662	0.879	rs754859	ENSG00000267761.3	CTD-2130O13.1	-4.17	5.88e-05	0.0372	-0.47	-0.36	Migraine;	chr18:47357703	chr18:47285725~47594550:+
GBM	cis	rs9947662	0.879	rs56291872	ENSG00000267761.3	CTD-2130O13.1	-4.17	5.88e-05	0.0372	-0.47	-0.36	Migraine;	chr18:47357849	chr18:47285725~47594550:+
GBM	cis	rs9947662	0.879	rs6507726	ENSG00000267761.3	CTD-2130O13.1	-4.17	5.88e-05	0.0372	-0.47	-0.36	Migraine;	chr18:47358503	chr18:47285725~47594550:+
GBM	cis	rs17318866	0.579	rs4499973	ENSG00000217385.1	PSMC1P11	4.17	5.88e-05	0.0372	0.46	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);	chr6:3816895	chr6:4702463~4703779:+
GBM	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	4.17	5.88e-05	0.0373	0.44	0.36	Height;	chr3:53085313	chr3:53064283~53065091:-
GBM	cis	rs753955	0.962	rs745069	ENSG00000205861.10	C1QTNF9B-AS1	-4.17	5.89e-05	0.0373	-0.47	-0.36	Lung cancer;	chr13:23717833	chr13:23888889~23897263:+
GBM	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-4.17	5.89e-05	0.0373	-0.38	-0.36	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
GBM	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	4.17	5.89e-05	0.0373	0.36	0.36	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
GBM	cis	rs2014572	0.967	rs10411941	ENSG00000267871.4	CTC-444N24.6	4.17	5.89e-05	0.0373	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57251518	chr19:57267220~57280334:-
GBM	cis	rs2014572	0.967	rs11667407	ENSG00000267871.4	CTC-444N24.6	4.17	5.89e-05	0.0373	0.35	0.36	Hyperactive-impulsive symptoms;	chr19:57251754	chr19:57267220~57280334:-
GBM	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	4.17	5.89e-05	0.0373	0.51	0.36	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
GBM	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	4.17	5.9e-05	0.0373	0.42	0.36	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	4.17	5.9e-05	0.0373	0.42	0.36	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	4.17	5.9e-05	0.0373	0.42	0.36	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
GBM	cis	rs10857712	0.687	rs11101742	ENSG00000214279.11	SCART1	-4.17	5.9e-05	0.0373	-0.25	-0.36	Systemic lupus erythematosus;	chr10:133410868	chr10:133453928~133523558:+
GBM	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-4.17	5.9e-05	0.0373	-0.45	-0.36	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
GBM	cis	rs7017914	0.69	rs11987409	ENSG00000246366.5	RP11-382J12.1	-4.17	5.9e-05	0.0374	-0.39	-0.36	Bone mineral density;	chr8:71067825	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.69	rs17699710	ENSG00000246366.5	RP11-382J12.1	-4.17	5.9e-05	0.0374	-0.39	-0.36	Bone mineral density;	chr8:71067975	chr8:70608577~70663279:+
GBM	cis	rs9393777	0.588	rs9467772	ENSG00000224843.5	LINC00240	4.17	5.91e-05	0.0374	0.54	0.36	Intelligence (multi-trait analysis);	chr6:26496350	chr6:26956992~27023924:+
GBM	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-4.17	5.91e-05	0.0374	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
GBM	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	4.17	5.91e-05	0.0374	0.41	0.36	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
GBM	cis	rs7017914	0.934	rs7830550	ENSG00000246366.5	RP11-382J12.1	-4.17	5.92e-05	0.0375	-0.4	-0.36	Bone mineral density;	chr8:70658196	chr8:70608577~70663279:+
GBM	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	4.17	5.93e-05	0.0375	0.42	0.36	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
GBM	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-4.17	5.93e-05	0.0375	-0.55	-0.36	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
GBM	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	4.17	5.94e-05	0.0375	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	4.17	5.94e-05	0.0375	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
GBM	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-4.17	5.94e-05	0.0375	-0.44	-0.36	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
GBM	cis	rs7726839	0.526	rs55647623	ENSG00000260774.1	CTD-2083E4.4	4.17	5.95e-05	0.0376	0.49	0.36	Obesity-related traits;	chr5:567632	chr5:213898~217279:-
GBM	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-4.17	5.95e-05	0.0376	-0.42	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
GBM	cis	rs16937	0.618	rs6659069	ENSG00000271580.1	RP11-536L3.4	-4.17	5.95e-05	0.0376	-0.33	-0.36	Schizophrenia;	chr1:205212903	chr1:205091163~205091946:+
GBM	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	4.17	5.95e-05	0.0376	0.41	0.36	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
GBM	cis	rs742614	0.533	rs6059499	ENSG00000206582.1	Y_RNA	4.17	5.95e-05	0.0376	0.39	0.36	Stearic acid (18:0) levels;	chr20:33860114	chr20:34526510~34526606:-
GBM	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	4.17	5.95e-05	0.0376	0.39	0.36	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
GBM	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	4.17	5.95e-05	0.0376	0.5	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
GBM	cis	rs17772222	0.727	rs3179969	ENSG00000258983.2	RP11-507K2.2	4.17	5.96e-05	0.0376	0.37	0.36	Coronary artery calcification;	chr14:88396185	chr14:88499334~88515502:+
GBM	cis	rs79349575	0.783	rs15563	ENSG00000270781.1	RP11-501C14.9	-4.17	5.96e-05	0.0377	-0.44	-0.36	Type 2 diabetes;	chr17:48927831	chr17:48899131~48899748:+
GBM	cis	rs875971	0.861	rs801215	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66546951	chr7:65840212~65840596:+
GBM	cis	rs875971	0.756	rs2901210	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66552518	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs13536	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66554203	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs801209	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66554403	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs801206	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66556979	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs801204	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66557934	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs801203	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66558025	chr7:65840212~65840596:+
GBM	cis	rs875971	0.825	rs801202	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66558942	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs801195	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66561128	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs801194	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66563508	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs2024192	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66576460	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6955837	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66578155	chr7:65840212~65840596:+
GBM	cis	rs875971	0.825	rs10281499	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66583979	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs4718377	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66584691	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10278014	ENSG00000236529.1	RP13-254B10.1	-4.17	5.96e-05	0.0377	-0.39	-0.36	Aortic root size;	chr7:66586277	chr7:65840212~65840596:+
GBM	cis	rs4568518	0.53	rs6967917	ENSG00000279048.1	RP11-511H23.2	4.17	5.97e-05	0.0377	0.29	0.36	Measles;	chr7:17944674	chr7:17940503~17942922:+
GBM	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	4.17	5.97e-05	0.0377	0.38	0.36	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
GBM	cis	rs2526882	0.542	rs714421	ENSG00000269927.1	RP6-91H8.3	-4.17	5.97e-05	0.0377	-0.4	-0.36	Schizophrenia;	chr14:70892868	chr14:71141125~71143253:-
GBM	cis	rs36715	1	rs36697	ENSG00000245937.6	LINC01184	4.17	5.97e-05	0.0377	0.38	0.36	Breast cancer;	chr5:128213921	chr5:127940426~128083172:-
GBM	cis	rs36715	0.951	rs36698	ENSG00000245937.6	LINC01184	4.17	5.97e-05	0.0377	0.38	0.36	Breast cancer;	chr5:128214057	chr5:127940426~128083172:-
GBM	cis	rs7017914	0.667	rs3816745	ENSG00000246366.5	RP11-382J12.1	4.17	5.98e-05	0.0377	0.4	0.36	Bone mineral density;	chr8:70594399	chr8:70608577~70663279:+
GBM	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	4.17	5.98e-05	0.0377	0.46	0.36	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
GBM	cis	rs832540	0.669	rs173764	ENSG00000225230.1	AC008937.3	4.17	5.98e-05	0.0377	0.48	0.36	Coronary artery disease;	chr5:56903093	chr5:56900041~56910714:-
GBM	cis	rs832540	0.669	rs832538	ENSG00000225230.1	AC008937.3	4.17	5.98e-05	0.0377	0.48	0.36	Coronary artery disease;	chr5:56904189	chr5:56900041~56910714:-
GBM	cis	rs832540	0.695	rs702686	ENSG00000225230.1	AC008937.3	4.17	5.98e-05	0.0377	0.48	0.36	Coronary artery disease;	chr5:56905523	chr5:56900041~56910714:-
GBM	cis	rs7017914	0.905	rs10091471	ENSG00000246366.5	RP11-382J12.1	-4.17	5.98e-05	0.0377	-0.38	-0.36	Bone mineral density;	chr8:71041520	chr8:70608577~70663279:+
GBM	cis	rs13217239	0.646	rs35691005	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27004291	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs10946891	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27005436	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs12201393	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27007911	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs12209886	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27016978	chr6:26956992~27023924:+
GBM	cis	rs6940638	0.531	rs12211984	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs10456351	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27019013	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs10456352	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27022579	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs4583981	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27024244	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs10946897	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27027472	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs4403259	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27029838	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs6937880	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27032457	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.621	rs12527231	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27033509	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs12523820	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27033723	chr6:26956992~27023924:+
GBM	cis	rs13217239	0.646	rs10946898	ENSG00000224843.5	LINC00240	-4.17	5.98e-05	0.0377	-0.43	-0.36	Schizophrenia;	chr6:27036105	chr6:26956992~27023924:+
GBM	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	4.17	5.98e-05	0.0377	0.34	0.36	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
GBM	cis	rs11671005	0.656	rs11671092	ENSG00000269600.1	AC016629.3	-4.17	5.99e-05	0.0378	-0.55	-0.36	Mean platelet volume;	chr19:58497742	chr19:58593896~58599355:-
GBM	cis	rs11671005	0.656	rs55928441	ENSG00000269600.1	AC016629.3	-4.17	5.99e-05	0.0378	-0.55	-0.36	Mean platelet volume;	chr19:58498307	chr19:58593896~58599355:-
GBM	cis	rs11671005	0.656	rs73066228	ENSG00000269600.1	AC016629.3	-4.17	5.99e-05	0.0378	-0.55	-0.36	Mean platelet volume;	chr19:58501829	chr19:58593896~58599355:-
GBM	cis	rs7017914	0.846	rs6472561	ENSG00000246366.5	RP11-382J12.1	4.17	5.99e-05	0.0378	0.38	0.36	Bone mineral density;	chr8:71042948	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs4074909	ENSG00000246366.5	RP11-382J12.1	4.17	5.99e-05	0.0378	0.38	0.36	Bone mineral density;	chr8:71043592	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs4078067	ENSG00000246366.5	RP11-382J12.1	4.17	5.99e-05	0.0378	0.38	0.36	Bone mineral density;	chr8:71044236	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs4504667	ENSG00000246366.5	RP11-382J12.1	4.17	5.99e-05	0.0378	0.38	0.36	Bone mineral density;	chr8:71044557	chr8:70608577~70663279:+
GBM	cis	rs7017914	0.905	rs4571761	ENSG00000246366.5	RP11-382J12.1	4.17	5.99e-05	0.0378	0.38	0.36	Bone mineral density;	chr8:71044938	chr8:70608577~70663279:+
GBM	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	4.17	5.99e-05	0.0378	0.53	0.36	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
GBM	cis	rs4072705	0.615	rs6478666	ENSG00000224020.1	MIR181A2HG	4.17	5.99e-05	0.0378	0.41	0.36	Menarche (age at onset);	chr9:124487064	chr9:124658467~124698631:+
GBM	cis	rs12908161	1	rs62019469	ENSG00000275120.1	RP11-182J1.17	4.17	5.99e-05	0.0378	0.47	0.36	Schizophrenia;	chr15:84777989	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs12908549	ENSG00000275120.1	RP11-182J1.17	4.17	5.99e-05	0.0378	0.47	0.36	Schizophrenia;	chr15:84779120	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.959	rs12906348	ENSG00000275120.1	RP11-182J1.17	4.17	5.99e-05	0.0378	0.47	0.36	Schizophrenia;	chr15:84786190	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.959	rs34342559	ENSG00000275120.1	RP11-182J1.17	4.17	5.99e-05	0.0378	0.47	0.36	Schizophrenia;	chr15:84788040	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.959	rs35557864	ENSG00000275120.1	RP11-182J1.17	4.17	5.99e-05	0.0378	0.47	0.36	Schizophrenia;	chr15:84788398	chr15:84599434~84606463:-
GBM	cis	rs17270561	0.579	rs10456326	ENSG00000272462.2	U91328.19	-4.17	5.99e-05	0.0378	-0.55	-0.36	Iron status biomarkers;	chr6:25919434	chr6:25992662~26001775:+
GBM	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-4.17	6e-05	0.0378	-0.49	-0.36	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-4.17	6e-05	0.0378	-0.5	-0.36	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-4.17	6e-05	0.0378	-0.5	-0.36	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-4.17	6e-05	0.0378	-0.5	-0.36	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
GBM	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	4.17	6e-05	0.0378	0.5	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
GBM	cis	rs453301	0.686	rs6748	ENSG00000254340.1	RP11-10A14.3	-4.17	6e-05	0.0378	-0.45	-0.36	Joint mobility (Beighton score);	chr8:9033292	chr8:9141424~9145435:+
GBM	cis	rs3753275	0.624	rs7551149	ENSG00000230679.1	ENO1-AS1	4.17	6.01e-05	0.0379	0.44	0.36	Educational attainment;	chr1:8701243	chr1:8878835~8879894:+
GBM	cis	rs11673344	0.504	rs10402907	ENSG00000226686.6	LINC01535	4.17	6.01e-05	0.0379	0.39	0.36	Obesity-related traits;	chr19:37112874	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.563	rs4805199	ENSG00000226686.6	LINC01535	4.17	6.01e-05	0.0379	0.39	0.36	Obesity-related traits;	chr19:37115527	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.504	rs4806407	ENSG00000226686.6	LINC01535	-4.17	6.01e-05	0.0379	-0.39	-0.36	Obesity-related traits;	chr19:37097849	chr19:37251912~37265535:+
GBM	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-4.17	6.02e-05	0.0379	-0.47	-0.36	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
GBM	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	4.17	6.02e-05	0.0379	0.52	0.36	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
GBM	cis	rs7985	0.901	rs5761679	ENSG00000206028.1	CTA-373H7.7	4.17	6.02e-05	0.0379	0.35	0.36	Electroencephalogram traits;	chr22:26681268	chr22:26667693~26672654:-
GBM	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	4.17	6.02e-05	0.0379	0.48	0.36	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	4.17	6.02e-05	0.0379	0.48	0.36	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
GBM	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	4.17	6.02e-05	0.0379	0.48	0.36	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
GBM	cis	rs875971	0.862	rs10282433	ENSG00000236529.1	RP13-254B10.1	-4.17	6.03e-05	0.038	-0.38	-0.36	Aortic root size;	chr7:66256452	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10276077	ENSG00000236529.1	RP13-254B10.1	-4.17	6.03e-05	0.038	-0.38	-0.36	Aortic root size;	chr7:66263424	chr7:65840212~65840596:+
GBM	cis	rs5769707	0.632	rs135876	ENSG00000235111.1	RP1-29C18.8	-4.17	6.03e-05	0.038	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49612657~49615716:-
GBM	cis	rs5769707	0.632	rs135877	ENSG00000235111.1	RP1-29C18.8	-4.17	6.03e-05	0.038	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49612657~49615716:-
GBM	cis	rs5769707	0.616	rs6009786	ENSG00000235111.1	RP1-29C18.8	-4.17	6.03e-05	0.038	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49612657~49615716:-
GBM	cis	rs1153858	1	rs4775911	ENSG00000259433.2	CTD-2651B20.4	4.17	6.03e-05	0.038	0.43	0.36	Homoarginine levels;	chr15:45357589	chr15:45330209~45332634:-
GBM	cis	rs7980687	0.657	rs10744151	ENSG00000256092.2	RP13-942N8.1	4.17	6.03e-05	0.038	0.45	0.36	Head circumference (infant);Educational attainment;Height;	chr12:123239188	chr12:123363868~123366113:+
GBM	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-4.17	6.04e-05	0.038	-0.4	-0.36	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
GBM	cis	rs9393777	0.623	rs2093169	ENSG00000224843.5	LINC00240	4.17	6.04e-05	0.038	0.58	0.36	Intelligence (multi-trait analysis);	chr6:26494871	chr6:26956992~27023924:+
GBM	cis	rs2579103	0.708	rs2250237	ENSG00000258183.4	RP11-753N8.1	-4.17	6.04e-05	0.038	-0.5	-0.36	Body mass index;	chr12:90289234	chr12:90280894~90300340:+
GBM	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-4.17	6.04e-05	0.038	-0.47	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
GBM	cis	rs893363	0.559	rs893365	ENSG00000271916.1	RP11-884K10.6	-4.17	6.05e-05	0.0381	-0.42	-0.36	Axial length;	chr3:53807119	chr3:53797764~53798019:-
GBM	cis	rs8114671	0.662	rs3761143	ENSG00000269202.1	RP4-614O4.12	-4.16	6.05e-05	0.0381	-0.44	-0.36	Height;	chr20:34957942	chr20:35201747~35203288:-
GBM	cis	rs11098499	0.691	rs10010355	ENSG00000249244.1	RP11-548H18.2	4.16	6.06e-05	0.0381	0.46	0.36	Corneal astigmatism;	chr4:119339888	chr4:119391831~119395335:-
GBM	cis	rs11098499	0.691	rs9307471	ENSG00000249244.1	RP11-548H18.2	4.16	6.06e-05	0.0381	0.46	0.36	Corneal astigmatism;	chr4:119340107	chr4:119391831~119395335:-
GBM	cis	rs4604732	0.536	rs12037221	ENSG00000227135.1	GCSAML-AS1	-4.16	6.07e-05	0.0382	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247467910	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.536	rs12074913	ENSG00000227135.1	GCSAML-AS1	-4.16	6.07e-05	0.0382	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468305	chr1:247524679~247526752:-
GBM	cis	rs4604732	0.588	rs4925551	ENSG00000227135.1	GCSAML-AS1	-4.16	6.07e-05	0.0382	-0.55	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468422	chr1:247524679~247526752:-
GBM	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-4.16	6.07e-05	0.0382	-0.41	-0.36	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-4.16	6.07e-05	0.0382	-0.41	-0.36	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
GBM	cis	rs11673344	0.504	rs8099987	ENSG00000226686.6	LINC01535	4.16	6.07e-05	0.0382	0.39	0.36	Obesity-related traits;	chr19:37132570	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.504	rs8110796	ENSG00000226686.6	LINC01535	4.16	6.07e-05	0.0382	0.39	0.36	Obesity-related traits;	chr19:37132682	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.504	rs8111285	ENSG00000226686.6	LINC01535	4.16	6.07e-05	0.0382	0.39	0.36	Obesity-related traits;	chr19:37132747	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.504	rs6510591	ENSG00000226686.6	LINC01535	4.16	6.07e-05	0.0382	0.39	0.36	Obesity-related traits;	chr19:37133186	chr19:37251912~37265535:+
GBM	cis	rs11673344	0.504	rs6510592	ENSG00000226686.6	LINC01535	4.16	6.07e-05	0.0382	0.39	0.36	Obesity-related traits;	chr19:37133430	chr19:37251912~37265535:+
GBM	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-4.16	6.07e-05	0.0382	-0.51	-0.36	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
GBM	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	4.16	6.07e-05	0.0382	0.4	0.36	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
GBM	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	4.16	6.07e-05	0.0382	0.4	0.36	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
GBM	cis	rs9786986	0.665	rs12402210	ENSG00000207181.1	SNORA14B	-4.16	6.07e-05	0.0382	-0.65	-0.36	Body mass index;	chr1:235538408	chr1:235127803~235127937:-
GBM	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-4.16	6.08e-05	0.0382	-0.44	-0.36	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
GBM	cis	rs3736858	1	rs9544053	ENSG00000261105.4	LMO7-AS1	-4.16	6.08e-05	0.0382	-0.65	-0.36	Interleukin-9 levels;	chr13:75853716	chr13:75604700~75635994:-
GBM	cis	rs3736858	1	rs61959583	ENSG00000261105.4	LMO7-AS1	-4.16	6.08e-05	0.0382	-0.65	-0.36	Interleukin-9 levels;	chr13:75854458	chr13:75604700~75635994:-
GBM	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	4.16	6.08e-05	0.0382	0.39	0.36	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
GBM	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	4.16	6.08e-05	0.0382	0.39	0.36	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
GBM	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	4.16	6.08e-05	0.0382	0.39	0.36	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
GBM	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	4.16	6.08e-05	0.0382	0.39	0.36	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
GBM	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	4.16	6.08e-05	0.0382	0.39	0.36	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
GBM	cis	rs11051970	0.636	rs325421	ENSG00000274964.1	RP11-817I4.1	-4.16	6.08e-05	0.0382	-0.43	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32418661	chr12:32339368~32340724:+
GBM	cis	rs11051970	0.636	rs325420	ENSG00000274964.1	RP11-817I4.1	-4.16	6.08e-05	0.0382	-0.43	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32419060	chr12:32339368~32340724:+
GBM	cis	rs11051970	0.553	rs325419	ENSG00000274964.1	RP11-817I4.1	-4.16	6.08e-05	0.0382	-0.43	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32419526	chr12:32339368~32340724:+
GBM	cis	rs11051970	0.594	rs325418	ENSG00000274964.1	RP11-817I4.1	-4.16	6.08e-05	0.0382	-0.43	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32419583	chr12:32339368~32340724:+
GBM	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	4.16	6.09e-05	0.0383	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
GBM	cis	rs2311126	0.965	rs11152031	ENSG00000264350.1	SNRPGP2	-4.16	6.09e-05	0.0383	-0.29	-0.36	Serum uric acid levels in response to allopurinol in gout;	chr18:54865807	chr18:54406889~54407114:-
GBM	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	4.16	6.1e-05	0.0383	0.38	0.36	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
GBM	cis	rs9450351	0.744	rs6910543	ENSG00000203875.9	SNHG5	-4.16	6.1e-05	0.0383	-0.93	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85519023	chr6:85660950~85678736:-
GBM	cis	rs3845817	0.838	rs697150	ENSG00000237979.1	AC007389.1	4.16	6.1e-05	0.0383	0.5	0.36	Bipolar disorder;	chr2:65522950	chr2:65500993~65502138:-
GBM	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-4.16	6.1e-05	0.0383	-0.43	-0.36	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
GBM	cis	rs17270561	0.636	rs9379782	ENSG00000272810.1	U91328.22	-4.16	6.1e-05	0.0383	-0.5	-0.36	Iron status biomarkers;	chr6:25714795	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.666	rs3923725	ENSG00000272810.1	U91328.22	-4.16	6.1e-05	0.0383	-0.5	-0.36	Iron status biomarkers;	chr6:25734692	chr6:26013241~26013757:+
GBM	cis	rs753955	0.962	rs12867512	ENSG00000205861.10	C1QTNF9B-AS1	-4.16	6.11e-05	0.0384	-0.47	-0.36	Lung cancer;	chr13:23715710	chr13:23888889~23897263:+
GBM	cis	rs753955	0.962	rs11617518	ENSG00000205861.10	C1QTNF9B-AS1	-4.16	6.11e-05	0.0384	-0.47	-0.36	Lung cancer;	chr13:23716128	chr13:23888889~23897263:+
GBM	cis	rs17772222	0.917	rs1956406	ENSG00000222990.1	RNU4-22P	4.16	6.11e-05	0.0384	0.44	0.36	Coronary artery calcification;	chr14:88749711	chr14:88513498~88513663:+
GBM	cis	rs9786986	0.665	rs12401438	ENSG00000207181.1	SNORA14B	-4.16	6.11e-05	0.0384	-0.66	-0.36	Body mass index;	chr1:235538432	chr1:235127803~235127937:-
GBM	cis	rs916888	0.602	rs199508	ENSG00000262500.1	RP11-259G18.2	-4.16	6.11e-05	0.0384	-0.47	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:46243606~46245044:+
GBM	cis	rs9481169	0.85	rs4947129	ENSG00000255389.1	C6orf3	-4.16	6.12e-05	0.0384	-0.71	-0.36	Inflammatory skin disease;	chr6:111609703	chr6:111599875~111602295:+
GBM	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	4.16	6.12e-05	0.0384	0.43	0.36	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
GBM	cis	rs858239	1	rs156421	ENSG00000230042.1	AK3P3	-4.16	6.13e-05	0.0385	-0.41	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23129178~23129841:+
GBM	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-4.16	6.13e-05	0.0385	-0.43	-0.36	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
GBM	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	4.16	6.14e-05	0.0385	0.25	0.36	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
GBM	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-4.16	6.14e-05	0.0385	-0.4	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
GBM	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-4.16	6.14e-05	0.0385	-0.36	-0.36	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
GBM	cis	rs172166	0.694	rs203893	ENSG00000218016.2	ZNF192P2	-4.16	6.14e-05	0.0385	-0.51	-0.36	Cardiac Troponin-T levels;	chr6:28094288	chr6:28188050~28189432:+
GBM	cis	rs172166	0.652	rs476167	ENSG00000218016.2	ZNF192P2	-4.16	6.14e-05	0.0385	-0.51	-0.36	Cardiac Troponin-T levels;	chr6:28098110	chr6:28188050~28189432:+
GBM	cis	rs172166	0.694	rs203892	ENSG00000218016.2	ZNF192P2	-4.16	6.14e-05	0.0385	-0.51	-0.36	Cardiac Troponin-T levels;	chr6:28099418	chr6:28188050~28189432:+
GBM	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	4.16	6.14e-05	0.0385	0.43	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
GBM	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-4.16	6.14e-05	0.0385	-0.34	-0.36	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
GBM	cis	rs7267979	0.549	rs11698185	ENSG00000125804.12	FAM182A	-4.16	6.15e-05	0.0386	-0.46	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.549	rs6138536	ENSG00000125804.12	FAM182A	-4.16	6.15e-05	0.0386	-0.46	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:26054655~26086917:+
GBM	cis	rs4812048	1	rs4812048	ENSG00000268649.3	RP4-806M20.4	-4.16	6.15e-05	0.0386	-0.42	-0.36	Mean platelet volume;	chr20:59012716	chr20:58817132~58817725:-
GBM	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	4.16	6.15e-05	0.0386	0.51	0.36	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
GBM	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	4.16	6.16e-05	0.0386	0.54	0.36	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
GBM	cis	rs4568518	0.616	rs13223642	ENSG00000279048.1	RP11-511H23.2	4.16	6.16e-05	0.0386	0.28	0.36	Measles;	chr7:17965352	chr7:17940503~17942922:+
GBM	cis	rs8177876	0.686	rs804897	ENSG00000261838.4	RP11-303E16.6	-4.16	6.16e-05	0.0386	-0.73	-0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067590	chr16:81069854~81076598:+
GBM	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-4.16	6.16e-05	0.0386	-0.43	-0.36	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
GBM	cis	rs4568518	0.53	rs4493811	ENSG00000279048.1	RP11-511H23.2	4.16	6.16e-05	0.0387	0.29	0.36	Measles;	chr7:17943746	chr7:17940503~17942922:+
GBM	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	4.16	6.16e-05	0.0387	0.49	0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
GBM	cis	rs17270561	0.609	rs1937131	ENSG00000272810.1	U91328.22	4.16	6.17e-05	0.0387	0.5	0.36	Iron status biomarkers;	chr6:25744603	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9393655	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25711110	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4132072	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25717615	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.553	rs9379784	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25725278	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9379785	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25725985	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9358871	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25726447	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4711095	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25726546	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4711096	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25726826	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4712959	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25726829	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4712960	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25727037	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4712961	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25727106	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9358872	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25727289	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9356985	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25727870	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs12194699	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25729001	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs17267614	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25729799	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9379786	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25730027	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9393658	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25730210	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4711097	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25732086	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs12203927	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25732462	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs12192077	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25732566	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4464787	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25733330	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4711098	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25734111	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs4360128	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25734330	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs3922699	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25734741	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs6924782	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25735588	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs6924794	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25735646	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs3922842	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25736336	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.608	rs9358875	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25737780	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4131670	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25738391	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9358876	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25738728	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.583	rs9393661	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25738852	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9356986	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25738891	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.666	rs9356987	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25738959	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9358877	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25739000	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs12663099	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25739290	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9393662	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25739442	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9358878	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25740045	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4712964	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25740594	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9366629	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25740988	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.553	rs6456696	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741180	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs6456697	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741206	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs6456698	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741436	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.666	rs4711099	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741581	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4711100	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741726	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4711101	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741742	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4712965	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741794	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.608	rs4711102	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741847	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4711103	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25741996	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9379788	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25742531	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9358879	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25742690	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs9358880	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25742933	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4145216	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25743331	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs4145217	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25743769	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9393665	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25744056	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs7754296	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25744650	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs7754733	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25744821	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs7754814	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25745015	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs7775354	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25745038	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9379789	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25745351	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs6941933	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25745474	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs6923367	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25745624	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs6923839	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25745625	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.636	rs4145218	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25745855	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs1892255	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25750126	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs1892254	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25750302	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9348694	ENSG00000272810.1	U91328.22	-4.16	6.17e-05	0.0387	-0.5	-0.36	Iron status biomarkers;	chr6:25753412	chr6:26013241~26013757:+
GBM	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	4.16	6.18e-05	0.0387	0.47	0.36	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
GBM	cis	rs6598955	1	rs6598955	ENSG00000236782.4	RP11-96L14.7	4.16	6.18e-05	0.0387	0.42	0.36	Obesity-related traits;	chr1:26293158	chr1:26169947~26171821:-
GBM	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	4.16	6.18e-05	0.0387	0.41	0.36	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
GBM	cis	rs875971	0.597	rs11763224	ENSG00000222364.1	RNU6-96P	-4.16	6.18e-05	0.0387	-0.43	-0.36	Aortic root size;	chr7:66518628	chr7:66395191~66395286:+
GBM	cis	rs875971	0.528	rs801213	ENSG00000222364.1	RNU6-96P	4.16	6.18e-05	0.0387	0.42	0.36	Aortic root size;	chr7:66549931	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs801212	ENSG00000222364.1	RNU6-96P	4.16	6.18e-05	0.0387	0.42	0.36	Aortic root size;	chr7:66550643	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs801199	ENSG00000222364.1	RNU6-96P	4.16	6.18e-05	0.0387	0.42	0.36	Aortic root size;	chr7:66560286	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs1638724	ENSG00000222364.1	RNU6-96P	4.16	6.18e-05	0.0387	0.42	0.36	Aortic root size;	chr7:66575494	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs1267814	ENSG00000222364.1	RNU6-96P	4.16	6.18e-05	0.0387	0.42	0.36	Aortic root size;	chr7:66579422	chr7:66395191~66395286:+
GBM	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	4.16	6.19e-05	0.0387	0.5	0.36	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	4.16	6.19e-05	0.0387	0.5	0.36	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	4.16	6.19e-05	0.0387	0.5	0.36	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	4.16	6.19e-05	0.0387	0.5	0.36	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
GBM	cis	rs2436845	0.521	rs2570948	ENSG00000253320.4	KB-1507C5.2	-4.16	6.2e-05	0.0388	-0.38	-0.36	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102870430	chr8:102864300~102977876:+
GBM	cis	rs453301	0.686	rs11787026	ENSG00000254340.1	RP11-10A14.3	4.16	6.2e-05	0.0388	0.44	0.36	Joint mobility (Beighton score);	chr8:9044861	chr8:9141424~9145435:+
GBM	cis	rs2739330	0.587	rs4820571	ENSG00000272787.1	KB-226F1.2	4.16	6.2e-05	0.0388	0.34	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23969211~23969873:+
GBM	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-4.16	6.2e-05	0.0388	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	4.16	6.2e-05	0.0388	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
GBM	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-4.16	6.21e-05	0.0388	-0.4	-0.36	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-4.16	6.21e-05	0.0388	-0.4	-0.36	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-4.16	6.21e-05	0.0388	-0.4	-0.36	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
GBM	cis	rs950169	0.656	rs748455	ENSG00000275120.1	RP11-182J1.17	4.16	6.21e-05	0.0388	0.46	0.36	Schizophrenia;	chr15:84606344	chr15:84599434~84606463:-
GBM	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	4.16	6.21e-05	0.0388	0.43	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
GBM	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	4.16	6.21e-05	0.0388	0.41	0.36	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
GBM	cis	rs9786986	0.609	rs12401387	ENSG00000207181.1	SNORA14B	-4.16	6.21e-05	0.0389	-0.61	-0.36	Body mass index;	chr1:235538014	chr1:235127803~235127937:-
GBM	cis	rs17270561	0.779	rs17271767	ENSG00000272810.1	U91328.22	-4.16	6.21e-05	0.0389	-0.56	-0.36	Iron status biomarkers;	chr6:25886693	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.779	rs12209218	ENSG00000272810.1	U91328.22	-4.16	6.21e-05	0.0389	-0.56	-0.36	Iron status biomarkers;	chr6:25887548	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.723	rs12213243	ENSG00000272810.1	U91328.22	-4.16	6.21e-05	0.0389	-0.56	-0.36	Iron status biomarkers;	chr6:25889880	chr6:26013241~26013757:+
GBM	cis	rs16937	0.574	rs10900455	ENSG00000271580.1	RP11-536L3.4	-4.16	6.22e-05	0.0389	-0.32	-0.36	Schizophrenia;	chr1:205154406	chr1:205091163~205091946:+
GBM	cis	rs16937	0.711	rs10751431	ENSG00000271580.1	RP11-536L3.4	-4.16	6.22e-05	0.0389	-0.32	-0.36	Schizophrenia;	chr1:205158931	chr1:205091163~205091946:+
GBM	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	4.16	6.22e-05	0.0389	0.5	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
GBM	cis	rs200972	1	rs200972	ENSG00000199851.2	U3	4.16	6.23e-05	0.0389	0.46	0.36	Urinary tract infection frequency;	chr6:27891059	chr6:28015568~28015777:+
GBM	cis	rs6558530	0.579	rs6558528	ENSG00000253982.1	CTD-2336O2.1	4.16	6.23e-05	0.0389	0.49	0.36	Systolic blood pressure;	chr8:1754897	chr8:1761990~1764502:-
GBM	cis	rs8114671	0.628	rs6060130	ENSG00000269202.1	RP4-614O4.12	-4.16	6.23e-05	0.0389	-0.46	-0.36	Height;	chr20:34961516	chr20:35201747~35203288:-
GBM	cis	rs7246657	0.551	rs11084873	ENSG00000276846.1	CTD-3220F14.3	4.16	6.24e-05	0.039	0.56	0.36	Coronary artery calcification;	chr19:37093008	chr19:37314868~37315620:-
GBM	cis	rs7246657	0.551	rs12978093	ENSG00000276846.1	CTD-3220F14.3	4.16	6.24e-05	0.039	0.56	0.36	Coronary artery calcification;	chr19:37093514	chr19:37314868~37315620:-
GBM	cis	rs1555322	0.872	rs2425033	ENSG00000126005.14	MMP24-AS1	-4.16	6.24e-05	0.039	-0.58	-0.36	Attention deficit hyperactivity disorder;	chr20:35267823	chr20:35216462~35278131:-
GBM	cis	rs7017914	0.677	rs67781030	ENSG00000246366.5	RP11-382J12.1	-4.16	6.24e-05	0.039	-0.39	-0.36	Bone mineral density;	chr8:70836619	chr8:70608577~70663279:+
GBM	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	4.16	6.25e-05	0.039	0.49	0.36	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	4.16	6.25e-05	0.039	0.49	0.36	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	4.16	6.25e-05	0.039	0.49	0.36	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
GBM	cis	rs344364	0.602	rs2437745	ENSG00000269937.1	RP11-20I23.8	-4.16	6.25e-05	0.039	-0.45	-0.36	Glomerular filtration rate in chronic kidney disease;	chr16:1858430	chr16:2561471~2565096:-
GBM	cis	rs3742264	0.656	rs9534265	ENSG00000235903.6	CPB2-AS1	-4.16	6.25e-05	0.039	-0.44	-0.36	Blood protein levels;	chr13:45972887	chr13:46052806~46113332:+
GBM	cis	rs344364	0.602	rs2437744	ENSG00000269937.1	RP11-20I23.8	-4.16	6.25e-05	0.0391	-0.45	-0.36	Glomerular filtration rate in chronic kidney disease;	chr16:1858450	chr16:2561471~2565096:-
GBM	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-4.16	6.25e-05	0.0391	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
GBM	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	4.16	6.26e-05	0.0391	0.3	0.36	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
GBM	cis	rs4842666	0.915	rs11105376	ENSG00000258302.2	RP11-981P6.1	4.16	6.27e-05	0.0391	0.45	0.36	Blood pressure;	chr12:89694991	chr12:89561129~89594878:+
GBM	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	4.16	6.27e-05	0.0391	0.45	0.36	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
GBM	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-4.16	6.27e-05	0.0391	-0.32	-0.36	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
GBM	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-4.16	6.28e-05	0.0392	-0.48	-0.36	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-4.16	6.28e-05	0.0392	-0.48	-0.36	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
GBM	cis	rs11012350	1	rs11012350	ENSG00000234961.1	RP11-124N14.3	4.15	6.28e-05	0.0392	0.55	0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18043063	chr10:17233325~17234833:-
GBM	cis	rs7674212	0.581	rs11946020	ENSG00000248971.2	KRT8P46	-4.15	6.28e-05	0.0392	-0.39	-0.36	Type 2 diabetes;	chr4:103023585	chr4:102728746~102730171:-
GBM	cis	rs4568518	0.53	rs6970593	ENSG00000279048.1	RP11-511H23.2	-4.15	6.28e-05	0.0392	-0.28	-0.36	Measles;	chr7:17949736	chr7:17940503~17942922:+
GBM	cis	rs3742264	0.731	rs7318648	ENSG00000235903.6	CPB2-AS1	-4.15	6.28e-05	0.0392	-0.47	-0.36	Blood protein levels;	chr13:46032497	chr13:46052806~46113332:+
GBM	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	4.15	6.28e-05	0.0392	0.43	0.36	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
GBM	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	4.15	6.28e-05	0.0392	0.43	0.36	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	4.15	6.28e-05	0.0392	0.43	0.36	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
GBM	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	4.15	6.28e-05	0.0392	0.43	0.36	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
GBM	cis	rs7980687	0.628	rs2102949	ENSG00000256092.2	RP13-942N8.1	4.15	6.29e-05	0.0392	0.45	0.36	Head circumference (infant);Educational attainment;Height;	chr12:123192216	chr12:123363868~123366113:+
GBM	cis	rs9300255	0.596	rs4460848	ENSG00000256092.2	RP13-942N8.1	4.15	6.29e-05	0.0392	0.45	0.36	Neutrophil percentage of white cells;	chr12:123193263	chr12:123363868~123366113:+
GBM	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	4.15	6.29e-05	0.0392	0.48	0.36	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	4.15	6.29e-05	0.0392	0.48	0.36	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	4.15	6.29e-05	0.0392	0.48	0.36	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
GBM	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-4.15	6.29e-05	0.0393	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
GBM	cis	rs10869777	1	rs10869777	ENSG00000225937.1	PCA3	4.15	6.3e-05	0.0393	0.39	0.36	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76434241	chr9:76764436~76787569:+
GBM	cis	rs10507419	0.965	rs4943235	ENSG00000276672.1	RP11-142E9.1	-4.15	6.31e-05	0.0393	-0.4	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34612762	chr13:33846190~33850825:+
GBM	cis	rs10507419	1	rs55902196	ENSG00000276672.1	RP11-142E9.1	-4.15	6.31e-05	0.0393	-0.4	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34613594	chr13:33846190~33850825:+
GBM	cis	rs875971	0.545	rs35459055	ENSG00000222364.1	RNU6-96P	-4.15	6.31e-05	0.0393	-0.42	-0.36	Aortic root size;	chr7:66479399	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs75577046	ENSG00000222364.1	RNU6-96P	-4.15	6.31e-05	0.0393	-0.42	-0.36	Aortic root size;	chr7:66493729	chr7:66395191~66395286:+
GBM	cis	rs433598	0.515	rs4783505	ENSG00000180747.14	SMG1P3	4.15	6.31e-05	0.0393	0.45	0.36	Schizophrenia;	chr16:20808216	chr16:21446683~21520444:-
GBM	cis	rs433598	0.55	rs4783506	ENSG00000180747.14	SMG1P3	-4.15	6.31e-05	0.0393	-0.45	-0.36	Schizophrenia;	chr16:20811745	chr16:21446683~21520444:-
GBM	cis	rs9601248	0.756	rs9601252	ENSG00000227676.3	LINC01068	-4.15	6.31e-05	0.0394	-0.42	-0.36	Major depressive disorder;	chr13:79615607	chr13:79566727~79571436:+
GBM	cis	rs8062405	1	rs3088215	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs28403629	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs61737565	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs4788099	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs9972693	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.964	rs9972768	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.965	rs56040780	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.965	rs62037363	ENSG00000271623.1	RP11-435I10.5	-4.15	6.31e-05	0.0394	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28364700~28365333:+
GBM	cis	rs2933343	0.729	rs813732	ENSG00000231305.3	RP11-723O4.2	4.15	6.32e-05	0.0394	0.34	0.36	IgG glycosylation;	chr3:128900514	chr3:128861313~128871540:-
GBM	cis	rs7246657	0.943	rs6508732	ENSG00000226686.6	LINC01535	-4.15	6.32e-05	0.0394	-0.52	-0.36	Coronary artery calcification;	chr19:37509566	chr19:37251912~37265535:+
GBM	cis	rs853679	0.527	rs9461443	ENSG00000216901.1	AL022393.7	4.15	6.32e-05	0.0394	0.53	0.36	Depression;	chr6:28226851	chr6:28176188~28176674:+
GBM	cis	rs853679	0.55	rs34477097	ENSG00000216901.1	AL022393.7	4.15	6.32e-05	0.0394	0.53	0.36	Depression;	chr6:28229408	chr6:28176188~28176674:+
GBM	cis	rs6558530	0.692	rs6981804	ENSG00000253982.1	CTD-2336O2.1	4.15	6.32e-05	0.0394	0.49	0.36	Systolic blood pressure;	chr8:1752118	chr8:1761990~1764502:-
GBM	cis	rs4321325	1	rs4321325	ENSG00000236682.1	AC068282.3	-4.15	6.32e-05	0.0394	-0.45	-0.36	Protein C levels;	chr2:127193421	chr2:127389130~127400580:+
GBM	cis	rs763121	0.889	rs6001209	ENSG00000273076.1	RP3-508I15.22	-4.15	6.32e-05	0.0394	-0.38	-0.36	Menopause (age at onset);	chr22:38725247	chr22:38743495~38743910:+
GBM	cis	rs12908161	1	rs35808647	ENSG00000225151.9	GOLGA2P7	-4.15	6.32e-05	0.0394	-0.41	-0.36	Schizophrenia;	chr15:84834210	chr15:84199311~84230136:-
GBM	cis	rs4853012	0.752	rs13413795	ENSG00000257800.1	FNBP1P1	4.15	6.33e-05	0.0394	0.51	0.36	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74120680~74123218:+
GBM	cis	rs9947662	0.879	rs28578653	ENSG00000267761.3	CTD-2130O13.1	-4.15	6.33e-05	0.0394	-0.47	-0.36	Migraine;	chr18:47368212	chr18:47285725~47594550:+
GBM	cis	rs9947662	0.708	rs9953407	ENSG00000267761.3	CTD-2130O13.1	-4.15	6.33e-05	0.0394	-0.47	-0.36	Migraine;	chr18:47371344	chr18:47285725~47594550:+
GBM	cis	rs9947662	0.879	rs9948413	ENSG00000267761.3	CTD-2130O13.1	-4.15	6.33e-05	0.0394	-0.47	-0.36	Migraine;	chr18:47374572	chr18:47285725~47594550:+
GBM	cis	rs9947662	0.879	rs4986219	ENSG00000267761.3	CTD-2130O13.1	-4.15	6.33e-05	0.0394	-0.47	-0.36	Migraine;	chr18:47376694	chr18:47285725~47594550:+
GBM	cis	rs17807624	1	rs17807624	ENSG00000255556.2	RP11-351I21.6	-4.15	6.34e-05	0.0395	-0.37	-0.36	Systemic lupus erythematosus;	chr8:11605506	chr8:12378679~12380265:-
GBM	cis	rs17270561	0.609	rs12529272	ENSG00000272810.1	U91328.22	-4.15	6.34e-05	0.0395	-0.5	-0.36	Iron status biomarkers;	chr6:25731114	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9393659	ENSG00000272810.1	U91328.22	-4.15	6.34e-05	0.0395	-0.5	-0.36	Iron status biomarkers;	chr6:25731130	chr6:26013241~26013757:+
GBM	cis	rs1865760	0.622	rs9295685	ENSG00000272462.2	U91328.19	-4.15	6.34e-05	0.0395	-0.45	-0.36	Height;	chr6:26071497	chr6:25992662~26001775:+
GBM	cis	rs2018683	0.523	rs1499227	ENSG00000228421.2	AC005013.5	4.15	6.35e-05	0.0395	0.43	0.36	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985999	chr7:28957667~28959345:+
GBM	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-4.15	6.35e-05	0.0395	-0.36	-0.36	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
GBM	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-4.15	6.35e-05	0.0395	-0.36	-0.36	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
GBM	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-4.15	6.36e-05	0.0395	-0.39	-0.36	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
GBM	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	4.15	6.36e-05	0.0395	0.5	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
GBM	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-4.15	6.36e-05	0.0396	-0.4	-0.36	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
GBM	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	4.15	6.36e-05	0.0396	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
GBM	cis	rs867371	0.762	rs1846910	ENSG00000278603.1	RP13-608F4.5	4.15	6.36e-05	0.0396	0.42	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472203~82472426:+
GBM	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-4.15	6.36e-05	0.0396	-0.4	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-4.15	6.36e-05	0.0396	-0.4	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
GBM	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-4.15	6.37e-05	0.0396	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-4.15	6.37e-05	0.0396	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
GBM	cis	rs7035589	1	rs7035589	ENSG00000230013.1	RP11-217B7.3	4.15	6.37e-05	0.0396	0.44	0.36	Pelvic organ prolapse;	chr9:104990077	chr9:104990796~104991781:-
GBM	cis	rs7035589	0.921	rs1836921	ENSG00000230013.1	RP11-217B7.3	4.15	6.37e-05	0.0396	0.44	0.36	Pelvic organ prolapse;	chr9:104991756	chr9:104990796~104991781:-
GBM	cis	rs7035589	1	rs7870986	ENSG00000230013.1	RP11-217B7.3	4.15	6.37e-05	0.0396	0.44	0.36	Pelvic organ prolapse;	chr9:104992552	chr9:104990796~104991781:-
GBM	cis	rs977747	0.931	rs12141363	ENSG00000232022.5	FAAHP1	-4.15	6.38e-05	0.0397	-0.37	-0.36	Body mass index;	chr1:47230909	chr1:46432129~46445521:+
GBM	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	4.15	6.38e-05	0.0397	0.43	0.36	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
GBM	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	4.15	6.38e-05	0.0397	0.43	0.36	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
GBM	cis	rs4803480	1	rs3745937	ENSG00000270164.1	LINC01480	-4.15	6.38e-05	0.0397	-0.66	-0.36	Schizophrenia;	chr19:41564935	chr19:41535183~41536904:+
GBM	cis	rs4803480	0.872	rs10420470	ENSG00000270164.1	LINC01480	-4.15	6.38e-05	0.0397	-0.66	-0.36	Schizophrenia;	chr19:41567075	chr19:41535183~41536904:+
GBM	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-4.15	6.38e-05	0.0397	-0.47	-0.36	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
GBM	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	4.15	6.39e-05	0.0397	0.45	0.36	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
GBM	cis	rs4957048	0.891	rs11960196	ENSG00000260774.1	CTD-2083E4.4	4.15	6.39e-05	0.0397	0.49	0.36	Ulcerative colitis;	chr5:568742	chr5:213898~217279:-
GBM	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	4.15	6.39e-05	0.0397	0.53	0.36	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
GBM	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-4.15	6.4e-05	0.0397	-0.48	-0.36	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
GBM	cis	rs950169	0.84	rs72748702	ENSG00000275120.1	RP11-182J1.17	4.15	6.4e-05	0.0397	0.49	0.36	Schizophrenia;	chr15:84246494	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs4338765	ENSG00000275120.1	RP11-182J1.17	4.15	6.4e-05	0.0397	0.49	0.36	Schizophrenia;	chr15:84248084	chr15:84599434~84606463:-
GBM	cis	rs950169	0.723	rs17589320	ENSG00000275120.1	RP11-182J1.17	4.15	6.4e-05	0.0397	0.49	0.36	Schizophrenia;	chr15:84251244	chr15:84599434~84606463:-
GBM	cis	rs950169	0.845	rs4502182	ENSG00000275120.1	RP11-182J1.17	4.15	6.4e-05	0.0397	0.49	0.36	Schizophrenia;	chr15:84254768	chr15:84599434~84606463:-
GBM	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	4.15	6.4e-05	0.0398	0.38	0.36	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
GBM	cis	rs748404	0.556	rs7166467	ENSG00000249839.1	AC011330.5	4.15	6.41e-05	0.0398	0.46	0.36	Lung cancer;	chr15:43148324	chr15:43663654~43684339:-
GBM	cis	rs2282300	0.956	rs1222212	ENSG00000242353.1	RP4-710M3.1	-4.15	6.42e-05	0.0398	-0.49	-0.36	Morning vs. evening chronotype;	chr11:30353096	chr11:30368148~30368646:+
GBM	cis	rs2282300	0.956	rs1717779	ENSG00000242353.1	RP4-710M3.1	-4.15	6.42e-05	0.0398	-0.49	-0.36	Morning vs. evening chronotype;	chr11:30355151	chr11:30368148~30368646:+
GBM	cis	rs4604732	0.642	rs10925047	ENSG00000227135.1	GCSAML-AS1	-4.15	6.42e-05	0.0398	-0.48	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476841	chr1:247524679~247526752:-
GBM	cis	rs17772222	0.682	rs4904452	ENSG00000222990.1	RNU4-22P	-4.15	6.42e-05	0.0399	-0.38	-0.36	Coronary artery calcification;	chr14:88517329	chr14:88513498~88513663:+
GBM	cis	rs5742933	0.69	rs16831821	ENSG00000253559.1	OSGEPL1-AS1	-4.15	6.43e-05	0.0399	-0.52	-0.36	Ferritin levels;	chr2:189641087	chr2:189762704~189765556:+
GBM	cis	rs62184315	0.536	rs16831873	ENSG00000253559.1	OSGEPL1-AS1	-4.15	6.43e-05	0.0399	-0.52	-0.36	Alcohol dependence (age at onset);	chr2:189692172	chr2:189762704~189765556:+
GBM	cis	rs4148008	1	rs4148005	ENSG00000265100.1	RP11-147L13.2	4.15	6.44e-05	0.0399	0.28	0.36	HDL cholesterol;	chr17:68886325	chr17:68246629~68247938:-
GBM	cis	rs11098499	0.738	rs28687057	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119359657	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.73	rs78971550	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119359886	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.645	rs78422072	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119359887	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.775	rs67281037	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119360002	chr4:119334329~119378233:+
GBM	cis	rs10028773	0.506	rs12374346	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Educational attainment;	chr4:119360550	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs12374244	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119360817	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs12374352	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119360822	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.775	rs10021601	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119361408	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs6857892	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119361541	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.909	rs28581362	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119362393	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.82	rs12503082	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119363162	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs12499602	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119363232	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.774	rs11098505	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119363472	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs13105020	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119364533	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs6824111	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119364813	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.779	rs10857066	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119365441	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.775	rs10029303	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119365600	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs9995136	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119365690	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.687	rs71610270	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119366281	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs13125526	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119366864	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs12513310	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119366884	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.564	rs11098507	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119367131	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs12510451	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119367988	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.774	rs73842616	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119369528	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.645	rs72676059	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119369673	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.569	rs55845118	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119369758	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs7677068	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119370549	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.866	rs9991221	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119370952	chr4:119334329~119378233:+
GBM	cis	rs11098499	0.78	rs10013652	ENSG00000250412.1	KLHL2P1	4.15	6.44e-05	0.0399	0.45	0.36	Corneal astigmatism;	chr4:119371101	chr4:119334329~119378233:+
GBM	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-4.15	6.44e-05	0.0399	-0.42	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
GBM	cis	rs11858210	1	rs11858210	ENSG00000261143.1	ADAMTS7P3	4.15	6.44e-05	0.0399	0.39	0.36	Post bronchodilator FEV1/FVC ratio;	chr15:78786016	chr15:77976042~77993057:+
GBM	cis	rs11072804	1	rs11072804	ENSG00000261143.1	ADAMTS7P3	4.15	6.44e-05	0.0399	0.39	0.36	Post bronchodilator FEV1/FVC ratio;	chr15:78786144	chr15:77976042~77993057:+
GBM	cis	rs922692	0.744	rs11072806	ENSG00000261143.1	ADAMTS7P3	4.15	6.44e-05	0.0399	0.39	0.36	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78786732	chr15:77976042~77993057:+
GBM	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	4.15	6.44e-05	0.0399	0.26	0.36	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
GBM	cis	rs7726839	0.561	rs6555357	ENSG00000260774.1	CTD-2083E4.4	4.15	6.45e-05	0.04	0.49	0.36	Obesity-related traits;	chr5:560808	chr5:213898~217279:-
GBM	cis	rs3753275	0.624	rs7518204	ENSG00000230679.1	ENO1-AS1	4.15	6.45e-05	0.04	0.44	0.36	Educational attainment;	chr1:8728577	chr1:8878835~8879894:+
GBM	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-4.15	6.46e-05	0.04	-0.31	-0.36	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
GBM	cis	rs7017914	0.905	rs4738105	ENSG00000246366.5	RP11-382J12.1	4.15	6.46e-05	0.04	0.38	0.36	Bone mineral density;	chr8:71046683	chr8:70608577~70663279:+
GBM	cis	rs11098499	0.954	rs6820115	ENSG00000249244.1	RP11-548H18.2	4.15	6.46e-05	0.04	0.44	0.36	Corneal astigmatism;	chr4:119477027	chr4:119391831~119395335:-
GBM	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-4.15	6.46e-05	0.04	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-4.15	6.46e-05	0.04	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-4.15	6.46e-05	0.04	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-4.15	6.46e-05	0.04	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-4.15	6.46e-05	0.04	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-4.15	6.46e-05	0.04	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	4.15	6.46e-05	0.04	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	4.15	6.46e-05	0.04	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	4.15	6.46e-05	0.04	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
GBM	cis	rs17270561	0.585	rs9393663	ENSG00000272810.1	U91328.22	-4.15	6.46e-05	0.04	-0.5	-0.36	Iron status biomarkers;	chr6:25740805	chr6:26013241~26013757:+
GBM	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-4.15	6.46e-05	0.04	-0.42	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
GBM	cis	rs875971	0.545	rs66594357	ENSG00000236529.1	RP13-254B10.1	4.15	6.47e-05	0.0401	0.4	0.36	Aortic root size;	chr7:66327797	chr7:65840212~65840596:+
GBM	cis	rs12140703	0.51	rs1572993	ENSG00000281406.1	BLACAT1	4.15	6.47e-05	0.0401	0.48	0.36	Reticulocyte count;	chr1:205075959	chr1:205434886~205437879:-
GBM	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-4.15	6.47e-05	0.0401	-0.41	-0.36	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
GBM	cis	rs7017914	0.905	rs4434651	ENSG00000246366.5	RP11-382J12.1	-4.15	6.47e-05	0.0401	-0.36	-0.36	Bone mineral density;	chr8:71034952	chr8:70608577~70663279:+
GBM	cis	rs4713118	0.699	rs573179	ENSG00000216901.1	AL022393.7	4.15	6.47e-05	0.0401	0.56	0.36	Parkinson's disease;	chr6:27881898	chr6:28176188~28176674:+
GBM	cis	rs2579103	0.898	rs2263480	ENSG00000258183.4	RP11-753N8.1	-4.15	6.48e-05	0.0401	-0.48	-0.36	Body mass index;	chr12:90222950	chr12:90280894~90300340:+
GBM	cis	rs2579103	1	rs2731251	ENSG00000258183.4	RP11-753N8.1	-4.15	6.48e-05	0.0401	-0.48	-0.36	Body mass index;	chr12:90227881	chr12:90280894~90300340:+
GBM	cis	rs2579103	1	rs2731278	ENSG00000258183.4	RP11-753N8.1	-4.15	6.48e-05	0.0401	-0.48	-0.36	Body mass index;	chr12:90230046	chr12:90280894~90300340:+
GBM	cis	rs2579103	1	rs2731277	ENSG00000258183.4	RP11-753N8.1	-4.15	6.48e-05	0.0401	-0.48	-0.36	Body mass index;	chr12:90230184	chr12:90280894~90300340:+
GBM	cis	rs2579103	1	rs1371086	ENSG00000258183.4	RP11-753N8.1	-4.15	6.48e-05	0.0401	-0.48	-0.36	Body mass index;	chr12:90231669	chr12:90280894~90300340:+
GBM	cis	rs12908161	1	rs12903134	ENSG00000275120.1	RP11-182J1.17	4.15	6.48e-05	0.0401	0.47	0.36	Schizophrenia;	chr15:84794468	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs35726233	ENSG00000275120.1	RP11-182J1.17	4.15	6.48e-05	0.0401	0.47	0.36	Schizophrenia;	chr15:84794569	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs35960805	ENSG00000275120.1	RP11-182J1.17	4.15	6.48e-05	0.0401	0.47	0.36	Schizophrenia;	chr15:84800749	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs12912388	ENSG00000275120.1	RP11-182J1.17	4.15	6.48e-05	0.0401	0.47	0.36	Schizophrenia;	chr15:84801319	chr15:84599434~84606463:-
GBM	cis	rs7296418	0.961	rs7957096	ENSG00000256092.2	RP13-942N8.1	4.15	6.48e-05	0.0401	0.42	0.36	Platelet count;	chr12:123060331	chr12:123363868~123366113:+
GBM	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	4.15	6.48e-05	0.0401	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
GBM	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	4.15	6.49e-05	0.0402	0.42	0.36	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
GBM	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	4.15	6.5e-05	0.0402	0.55	0.36	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
GBM	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-4.15	6.5e-05	0.0402	-0.39	-0.36	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-4.15	6.5e-05	0.0402	-0.39	-0.36	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-4.15	6.5e-05	0.0402	-0.39	-0.36	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-4.15	6.5e-05	0.0402	-0.39	-0.36	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-4.15	6.5e-05	0.0402	-0.39	-0.36	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-4.15	6.5e-05	0.0402	-0.39	-0.36	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
GBM	cis	rs7216064	0.953	rs10445361	ENSG00000267472.1	LOC440461	-4.15	6.5e-05	0.0402	-0.45	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67966122	chr17:68198921~68199596:+
GBM	cis	rs7216064	0.953	rs62086044	ENSG00000267472.1	LOC440461	4.15	6.5e-05	0.0402	0.45	0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68198921~68199596:+
GBM	cis	rs4072705	0.967	rs10818984	ENSG00000224020.1	MIR181A2HG	-4.15	6.5e-05	0.0402	-0.39	-0.36	Menarche (age at onset);	chr9:124651272	chr9:124658467~124698631:+
GBM	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	4.15	6.51e-05	0.0402	0.3	0.36	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
GBM	cis	rs893363	0.559	rs3774611	ENSG00000271916.1	RP11-884K10.6	-4.15	6.51e-05	0.0402	-0.41	-0.36	Axial length;	chr3:53806638	chr3:53797764~53798019:-
GBM	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	4.15	6.51e-05	0.0403	0.34	0.36	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
GBM	cis	rs11671005	0.735	rs3826684	ENSG00000269473.1	CTD-2619J13.19	4.15	6.51e-05	0.0403	0.4	0.36	Mean platelet volume;	chr19:58407338	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs3826683	ENSG00000269473.1	CTD-2619J13.19	4.15	6.51e-05	0.0403	0.4	0.36	Mean platelet volume;	chr19:58407366	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs3826682	ENSG00000269473.1	CTD-2619J13.19	4.15	6.51e-05	0.0403	0.4	0.36	Mean platelet volume;	chr19:58407381	chr19:58440448~58445849:+
GBM	cis	rs11671005	0.735	rs3826681	ENSG00000269473.1	CTD-2619J13.19	4.15	6.51e-05	0.0403	0.4	0.36	Mean platelet volume;	chr19:58407397	chr19:58440448~58445849:+
GBM	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	4.15	6.52e-05	0.0403	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
GBM	cis	rs4388249	1	rs11241032	ENSG00000271849.1	CTC-332L22.1	-4.15	6.52e-05	0.0403	-0.55	-0.36	Schizophrenia;	chr5:109723507	chr5:109687802~109688329:-
GBM	cis	rs9300255	0.698	rs4759416	ENSG00000235423.7	RP11-282O18.3	4.15	6.52e-05	0.0403	0.49	0.36	Neutrophil percentage of white cells;	chr12:123261810	chr12:123252030~123261483:-
GBM	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	4.14	6.54e-05	0.0404	0.42	0.36	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
GBM	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	4.14	6.54e-05	0.0404	0.42	0.36	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
GBM	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	4.14	6.54e-05	0.0404	0.4	0.36	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	4.14	6.54e-05	0.0404	0.4	0.36	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
GBM	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	4.14	6.55e-05	0.0404	0.41	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
GBM	cis	rs3744061	0.53	rs12450896	ENSG00000277382.1	RP11-318A15.8	-4.14	6.55e-05	0.0405	-0.47	-0.36	Retinal arteriolar caliber;	chr17:76633785	chr17:76709760~76710045:+
GBM	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	4.14	6.55e-05	0.0405	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
GBM	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-4.14	6.55e-05	0.0405	-0.39	-0.36	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
GBM	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	4.14	6.56e-05	0.0405	0.35	0.36	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	4.14	6.56e-05	0.0405	0.35	0.36	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	4.14	6.56e-05	0.0405	0.35	0.36	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
GBM	cis	rs853679	1	rs7740487	ENSG00000199851.2	U3	4.14	6.56e-05	0.0405	0.71	0.36	Depression;	chr6:28248708	chr6:28015568~28015777:+
GBM	cis	rs2018683	0.768	rs10282015	ENSG00000272568.4	CTB-113D17.1	4.14	6.56e-05	0.0405	0.45	0.36	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28979967~29013367:+
GBM	cis	rs2018683	0.77	rs10951208	ENSG00000272568.4	CTB-113D17.1	4.14	6.56e-05	0.0405	0.45	0.36	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28979967~29013367:+
GBM	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-4.14	6.56e-05	0.0405	-0.45	-0.36	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
GBM	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	4.14	6.56e-05	0.0405	0.41	0.36	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
GBM	cis	rs3753275	0.624	rs6577525	ENSG00000230679.1	ENO1-AS1	-4.14	6.56e-05	0.0405	-0.42	-0.36	Educational attainment;	chr1:8797045	chr1:8878835~8879894:+
GBM	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-4.14	6.57e-05	0.0405	-0.38	-0.36	Height;	chr11:118859432	chr11:118791254~118793137:+
GBM	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-4.14	6.57e-05	0.0405	-0.38	-0.36	Height;	chr11:118860890	chr11:118791254~118793137:+
GBM	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-4.14	6.57e-05	0.0405	-0.38	-0.36	Height;	chr11:118861053	chr11:118791254~118793137:+
GBM	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-4.14	6.57e-05	0.0405	-0.51	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
GBM	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-4.14	6.57e-05	0.0406	-0.37	-0.36	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
GBM	cis	rs17154702	0.506	rs74525088	ENSG00000253893.2	FAM85B	4.14	6.57e-05	0.0406	0.65	0.36	Neurocognitive impairment in HIV-1 infection (continuous);	chr8:8770903	chr8:8167819~8226614:-
GBM	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	4.14	6.58e-05	0.0406	0.5	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	4.14	6.58e-05	0.0406	0.5	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
GBM	cis	rs9450351	0.744	rs9444353	ENSG00000203875.9	SNHG5	-4.14	6.59e-05	0.0407	-0.92	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85566986	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9351063	ENSG00000203875.9	SNHG5	-4.14	6.59e-05	0.0407	-0.92	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85567123	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs6923017	ENSG00000203875.9	SNHG5	-4.14	6.59e-05	0.0407	-0.92	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85592619	chr6:85660950~85678736:-
GBM	cis	rs9353324	1	rs7775788	ENSG00000203875.9	SNHG5	-4.14	6.59e-05	0.0407	-0.92	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85595761	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs111533912	ENSG00000203875.9	SNHG5	-4.14	6.59e-05	0.0407	-0.92	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85622231	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9450308	ENSG00000203875.9	SNHG5	-4.14	6.59e-05	0.0407	-0.92	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85638820	chr6:85660950~85678736:-
GBM	cis	rs6600671	0.692	rs11249430	ENSG00000223345.3	HIST2H2BA	4.14	6.59e-05	0.0407	0.47	0.36	Hip geometry;	chr1:121547115	chr1:121108210~121117257:-
GBM	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-4.14	6.59e-05	0.0407	-0.46	-0.36	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
GBM	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	4.14	6.6e-05	0.0407	0.47	0.36	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
GBM	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	4.14	6.6e-05	0.0407	0.47	0.36	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
GBM	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-4.14	6.6e-05	0.0407	-0.41	-0.36	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
GBM	cis	rs10507419	1	rs9541392	ENSG00000276672.1	RP11-142E9.1	-4.14	6.6e-05	0.0407	-0.39	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34616027	chr13:33846190~33850825:+
GBM	cis	rs7083	0.653	rs573442	ENSG00000254851.1	RP11-109L13.1	4.14	6.6e-05	0.0407	0.51	0.36	Blood protein levels;	chr11:117307204	chr11:117135528~117138582:+
GBM	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	4.14	6.61e-05	0.0407	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	4.14	6.61e-05	0.0407	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
GBM	cis	rs858239	0.899	rs2268747	ENSG00000230042.1	AK3P3	-4.14	6.61e-05	0.0407	-0.43	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23129178~23129841:+
GBM	cis	rs4713118	0.824	rs9468223	ENSG00000199851.2	U3	4.14	6.61e-05	0.0407	0.49	0.36	Parkinson's disease;	chr6:27772887	chr6:28015568~28015777:+
GBM	cis	rs893363	0.61	rs920252	ENSG00000271916.1	RP11-884K10.6	-4.14	6.61e-05	0.0407	-0.43	-0.36	Axial length;	chr3:53814645	chr3:53797764~53798019:-
GBM	cis	rs138453830	1	rs138453830	ENSG00000261485.1	PAN3-AS1	4.14	6.61e-05	0.0407	0.79	0.36	Hepcidin/transferrin saturation ratio;	chr13:28164927	chr13:28136843~28138193:-
GBM	cis	rs11673344	0.523	rs2891766	ENSG00000226686.6	LINC01535	4.14	6.61e-05	0.0407	0.38	0.36	Obesity-related traits;	chr19:37037057	chr19:37251912~37265535:+
GBM	cis	rs950169	0.881	rs4842852	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84387263	chr15:84599434~84606463:-
GBM	cis	rs950169	0.84	rs4842853	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84387606	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs4842946	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84387633	chr15:84599434~84606463:-
GBM	cis	rs950169	0.84	rs4842854	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84387641	chr15:84599434~84606463:-
GBM	cis	rs950169	0.84	rs2896002	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84390423	chr15:84599434~84606463:-
GBM	cis	rs950169	0.887	rs3860265	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84390487	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs2033284	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84391575	chr15:84599434~84606463:-
GBM	cis	rs950169	0.724	rs11632668	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84393989	chr15:84599434~84606463:-
GBM	cis	rs950169	0.881	rs34591918	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84396135	chr15:84599434~84606463:-
GBM	cis	rs950169	0.887	rs12903946	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84399732	chr15:84599434~84606463:-
GBM	cis	rs950169	0.887	rs62029593	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84400482	chr15:84599434~84606463:-
GBM	cis	rs950169	0.81	rs62029594	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84400554	chr15:84599434~84606463:-
GBM	cis	rs950169	0.84	rs62029595	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84400603	chr15:84599434~84606463:-
GBM	cis	rs950169	0.881	rs62029596	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84400736	chr15:84599434~84606463:-
GBM	cis	rs950169	0.881	rs4081123	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84401537	chr15:84599434~84606463:-
GBM	cis	rs950169	0.881	rs62029599	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84401867	chr15:84599434~84606463:-
GBM	cis	rs950169	0.8	rs4099846	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84402196	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs12910334	ENSG00000275120.1	RP11-182J1.17	4.14	6.61e-05	0.0407	0.49	0.36	Schizophrenia;	chr15:84403620	chr15:84599434~84606463:-
GBM	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	4.14	6.61e-05	0.0407	0.39	0.36	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
GBM	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-4.14	6.61e-05	0.0407	-0.53	-0.36	Depression;	chr6:28206179	chr6:28115628~28116551:+
GBM	cis	rs57221529	0.664	rs72704802	ENSG00000260774.1	CTD-2083E4.4	4.14	6.61e-05	0.0407	0.5	0.36	Lung disease severity in cystic fibrosis;	chr5:554096	chr5:213898~217279:-
GBM	cis	rs57221529	0.766	rs28563961	ENSG00000260774.1	CTD-2083E4.4	4.14	6.61e-05	0.0407	0.5	0.36	Lung disease severity in cystic fibrosis;	chr5:554383	chr5:213898~217279:-
GBM	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	4.14	6.62e-05	0.0408	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
GBM	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	4.14	6.62e-05	0.0408	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
GBM	cis	rs453301	0.571	rs330048	ENSG00000254340.1	RP11-10A14.3	-4.14	6.62e-05	0.0408	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9229768	chr8:9141424~9145435:+
GBM	cis	rs17270561	0.578	rs76182885	ENSG00000272462.2	U91328.19	-4.14	6.63e-05	0.0408	-0.55	-0.36	Iron status biomarkers;	chr6:25903857	chr6:25992662~26001775:+
GBM	cis	rs17270561	0.541	rs12192932	ENSG00000272462.2	U91328.19	-4.14	6.63e-05	0.0408	-0.55	-0.36	Iron status biomarkers;	chr6:25911274	chr6:25992662~26001775:+
GBM	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-4.14	6.63e-05	0.0408	-0.37	-0.36	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
GBM	cis	rs2836950	0.545	rs1888489	ENSG00000238141.2	BRWD1-AS1	-4.14	6.64e-05	0.0409	-0.36	-0.36	Menarche (age at onset);	chr21:39161238	chr21:39315707~39323218:+
GBM	cis	rs2836950	0.52	rs8130240	ENSG00000238141.2	BRWD1-AS1	-4.14	6.64e-05	0.0409	-0.36	-0.36	Menarche (age at onset);	chr21:39166182	chr21:39315707~39323218:+
GBM	cis	rs2836950	0.565	rs8134214	ENSG00000238141.2	BRWD1-AS1	-4.14	6.64e-05	0.0409	-0.36	-0.36	Menarche (age at onset);	chr21:39170441	chr21:39315707~39323218:+
GBM	cis	rs2836950	0.52	rs1980407	ENSG00000238141.2	BRWD1-AS1	-4.14	6.64e-05	0.0409	-0.36	-0.36	Menarche (age at onset);	chr21:39172035	chr21:39315707~39323218:+
GBM	cis	rs2836950	0.565	rs2836930	ENSG00000238141.2	BRWD1-AS1	-4.14	6.64e-05	0.0409	-0.36	-0.36	Menarche (age at onset);	chr21:39173730	chr21:39315707~39323218:+
GBM	cis	rs2836950	0.565	rs2836931	ENSG00000238141.2	BRWD1-AS1	-4.14	6.64e-05	0.0409	-0.36	-0.36	Menarche (age at onset);	chr21:39174643	chr21:39315707~39323218:+
GBM	cis	rs10497721	1	rs2884022	ENSG00000227542.1	AC092614.2	4.14	6.64e-05	0.0409	0.79	0.36	Diabetes (incident);	chr2:192048148	chr2:191229165~191246172:-
GBM	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-4.14	6.64e-05	0.0409	-0.47	-0.36	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-4.14	6.64e-05	0.0409	-0.47	-0.36	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
GBM	cis	rs2282300	0.739	rs1222219	ENSG00000254532.1	RP11-624D11.2	4.14	6.64e-05	0.0409	0.49	0.36	Morning vs. evening chronotype;	chr11:30322798	chr11:30044058~30084343:-
GBM	cis	rs896854	0.654	rs13274945	ENSG00000253528.2	RP11-347C18.4	4.14	6.64e-05	0.0409	0.4	0.36	Type 2 diabetes;	chr8:94974398	chr8:94974573~94974853:-
GBM	cis	rs896854	0.714	rs6471503	ENSG00000253528.2	RP11-347C18.4	4.14	6.64e-05	0.0409	0.4	0.36	Type 2 diabetes;	chr8:94978055	chr8:94974573~94974853:-
GBM	cis	rs896854	0.684	rs2340534	ENSG00000253528.2	RP11-347C18.4	4.14	6.64e-05	0.0409	0.4	0.36	Type 2 diabetes;	chr8:94980102	chr8:94974573~94974853:-
GBM	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
GBM	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
GBM	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
GBM	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	4.14	6.65e-05	0.0409	0.41	0.36	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
GBM	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	4.14	6.65e-05	0.0409	0.46	0.36	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
GBM	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	4.14	6.65e-05	0.0409	0.71	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
GBM	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-4.14	6.65e-05	0.0409	-0.71	-0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
GBM	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	4.14	6.65e-05	0.0409	0.56	0.36	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
GBM	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	4.14	6.65e-05	0.0409	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	4.14	6.65e-05	0.0409	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	4.14	6.65e-05	0.0409	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	4.14	6.65e-05	0.0409	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	4.14	6.65e-05	0.0409	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
GBM	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-4.14	6.66e-05	0.0409	-0.47	-0.36	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
GBM	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-4.14	6.66e-05	0.0409	-0.34	-0.36	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
GBM	cis	rs9876781	0.967	rs1870444	ENSG00000244380.1	RP11-24C3.2	4.14	6.66e-05	0.0409	0.41	0.36	Longevity;	chr3:48445369	chr3:48440352~48446656:-
GBM	cis	rs875971	0.528	rs801213	ENSG00000236529.1	RP13-254B10.1	-4.14	6.66e-05	0.0409	-0.4	-0.36	Aortic root size;	chr7:66549931	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs801212	ENSG00000236529.1	RP13-254B10.1	-4.14	6.66e-05	0.0409	-0.4	-0.36	Aortic root size;	chr7:66550643	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs801199	ENSG00000236529.1	RP13-254B10.1	-4.14	6.66e-05	0.0409	-0.4	-0.36	Aortic root size;	chr7:66560286	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs1638724	ENSG00000236529.1	RP13-254B10.1	-4.14	6.66e-05	0.0409	-0.4	-0.36	Aortic root size;	chr7:66575494	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs1267814	ENSG00000236529.1	RP13-254B10.1	-4.14	6.66e-05	0.0409	-0.4	-0.36	Aortic root size;	chr7:66579422	chr7:65840212~65840596:+
GBM	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-4.14	6.67e-05	0.041	-0.41	-0.36	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
GBM	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	4.14	6.67e-05	0.041	0.25	0.36	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
GBM	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	4.14	6.67e-05	0.041	0.46	0.36	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
GBM	cis	rs2278702	0.943	rs78285258	ENSG00000259495.2	RP11-210M15.2	-4.14	6.68e-05	0.041	-0.38	-0.36	Bipolar disorder;	chr15:80392771	chr15:80344853~80403575:-
GBM	cis	rs172166	0.694	rs188105	ENSG00000218016.2	ZNF192P2	-4.14	6.68e-05	0.041	-0.5	-0.36	Cardiac Troponin-T levels;	chr6:28103615	chr6:28188050~28189432:+
GBM	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-4.14	6.69e-05	0.041	-0.35	-0.36	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
GBM	cis	rs8062405	0.69	rs762634	ENSG00000271623.1	RP11-435I10.5	-4.14	6.69e-05	0.041	-0.45	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28364700~28365333:+
GBM	cis	rs62034325	0.697	rs710410	ENSG00000271623.1	RP11-435I10.5	-4.14	6.69e-05	0.041	-0.45	-0.36	Body mass index;	chr16:28592021	chr16:28364700~28365333:+
GBM	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	4.14	6.69e-05	0.0411	0.47	0.36	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	4.14	6.69e-05	0.0411	0.47	0.36	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	4.14	6.69e-05	0.0411	0.47	0.36	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	4.14	6.69e-05	0.0411	0.47	0.36	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
GBM	cis	rs11671005	0.656	rs55652736	ENSG00000269600.1	AC016629.3	-4.14	6.7e-05	0.0411	-0.55	-0.36	Mean platelet volume;	chr19:58496199	chr19:58593896~58599355:-
GBM	cis	rs6788497	0.643	rs11718942	ENSG00000242551.2	POU5F1P6	4.14	6.7e-05	0.0411	0.57	0.36	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128402552	chr3:128674735~128677005:-
GBM	cis	rs6788497	0.643	rs11715947	ENSG00000242551.2	POU5F1P6	4.14	6.7e-05	0.0411	0.57	0.36	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128403737	chr3:128674735~128677005:-
GBM	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-4.14	6.7e-05	0.0411	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
GBM	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-4.14	6.7e-05	0.0411	-0.49	-0.36	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
GBM	cis	rs1528149	0.504	rs1527215	ENSG00000224683.1	RPL36AP29	-4.14	6.71e-05	0.0411	-0.4	-0.36	Sitting height ratio;	chr7:16127184	chr7:16208945~16209265:+
GBM	cis	rs1528149	0.504	rs12537888	ENSG00000224683.1	RPL36AP29	-4.14	6.71e-05	0.0411	-0.4	-0.36	Sitting height ratio;	chr7:16127873	chr7:16208945~16209265:+
GBM	cis	rs6600671	1	rs6600672	ENSG00000223345.3	HIST2H2BA	4.14	6.71e-05	0.0411	0.47	0.36	Hip geometry;	chr1:121454268	chr1:121108210~121117257:-
GBM	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	4.14	6.71e-05	0.0412	0.42	0.36	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
GBM	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-4.14	6.72e-05	0.0412	-0.42	-0.36	Height;	chr20:35177782	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs1415774	ENSG00000269202.1	RP4-614O4.12	4.14	6.72e-05	0.0412	0.42	0.36	Height;	chr20:35177813	chr20:35201747~35203288:-
GBM	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-4.14	6.72e-05	0.0412	-0.47	-0.36	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-4.14	6.72e-05	0.0412	-0.47	-0.36	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
GBM	cis	rs5742933	1	rs5742933	ENSG00000253559.1	OSGEPL1-AS1	-4.14	6.72e-05	0.0412	-0.42	-0.36	Ferritin levels;	chr2:189784590	chr2:189762704~189765556:+
GBM	cis	rs7246657	0.551	rs10404069	ENSG00000276846.1	CTD-3220F14.3	4.14	6.73e-05	0.0412	0.57	0.36	Coronary artery calcification;	chr19:37147502	chr19:37314868~37315620:-
GBM	cis	rs2976388	1	rs2976396	ENSG00000253741.1	CTD-2292P10.4	-4.14	6.73e-05	0.0412	-0.38	-0.36	Urinary tract infection frequency;	chr8:142682583	chr8:142702252~142726973:-
GBM	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-4.14	6.73e-05	0.0412	-0.5	-0.36	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
GBM	cis	rs9983113	0.868	rs2836766	ENSG00000231123.1	SPATA20P1	4.14	6.73e-05	0.0412	0.36	0.36	Body mass index;	chr21:38938776	chr21:38238227~38238664:-
GBM	cis	rs7181230	0.848	rs1010879	ENSG00000275636.1	RP11-521C20.5	4.14	6.73e-05	0.0412	0.45	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40041714	chr15:40078892~40079347:+
GBM	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	4.14	6.73e-05	0.0412	0.45	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
GBM	cis	rs172166	0.561	rs149971	ENSG00000218016.2	ZNF192P2	-4.14	6.74e-05	0.0412	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28014374	chr6:28188050~28189432:+
GBM	cis	rs520525	0.963	rs627848	ENSG00000271811.1	RP1-79C4.4	4.14	6.74e-05	0.0413	0.43	0.36	Atrial fibrillation;	chr1:170662279	chr1:170667381~170669425:+
GBM	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-4.14	6.74e-05	0.0413	-0.5	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
GBM	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	4.14	6.74e-05	0.0413	0.35	0.36	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
GBM	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	4.14	6.74e-05	0.0413	0.43	0.36	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
GBM	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-4.14	6.75e-05	0.0413	-0.48	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
GBM	cis	rs12908161	1	rs12905057	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84667534	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs11638290	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84684405	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.959	rs34028043	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84688354	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.959	rs34784022	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84688675	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs12911736	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84696777	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.959	rs12908699	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84697172	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs35316992	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84704902	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs4643294	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84707022	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs62021219	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84712928	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs34900908	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84714368	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs35524990	ENSG00000275120.1	RP11-182J1.17	4.14	6.75e-05	0.0413	0.47	0.36	Schizophrenia;	chr15:84714972	chr15:84599434~84606463:-
GBM	cis	rs7567389	0.511	rs61185143	ENSG00000236682.1	AC068282.3	4.14	6.75e-05	0.0413	0.37	0.36	Self-rated health;	chr2:127407902	chr2:127389130~127400580:+
GBM	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	4.14	6.75e-05	0.0413	0.54	0.36	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
GBM	cis	rs853679	0.882	rs9461432	ENSG00000199851.2	U3	4.14	6.75e-05	0.0413	0.71	0.36	Depression;	chr6:28119105	chr6:28015568~28015777:+
GBM	cis	rs853679	0.882	rs4713139	ENSG00000199851.2	U3	4.14	6.75e-05	0.0413	0.71	0.36	Depression;	chr6:28124907	chr6:28015568~28015777:+
GBM	cis	rs853679	0.882	rs4713140	ENSG00000199851.2	U3	4.14	6.75e-05	0.0413	0.71	0.36	Depression;	chr6:28129415	chr6:28015568~28015777:+
GBM	cis	rs853679	0.882	rs3757188	ENSG00000199851.2	U3	4.14	6.75e-05	0.0413	0.71	0.36	Depression;	chr6:28139579	chr6:28015568~28015777:+
GBM	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-4.14	6.75e-05	0.0413	-0.39	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
GBM	cis	rs308403	0.509	rs309357	ENSG00000224786.1	CETN4P	4.14	6.75e-05	0.0413	0.48	0.36	Blood protein levels;	chr4:122732421	chr4:122730548~122732193:-
GBM	cis	rs172166	0.516	rs1225618	ENSG00000280107.1	AL022393.9	-4.14	6.76e-05	0.0413	-0.37	-0.36	Cardiac Troponin-T levels;	chr6:28161935	chr6:28170845~28172521:+
GBM	cis	rs35767	0.841	rs2607986	ENSG00000258230.2	RP11-511H9.3	-4.14	6.76e-05	0.0413	-0.53	-0.36	Homeostasis model assessment of insulin resistance;Fasting blood insulin;	chr12:102508000	chr12:101773114~101773755:-
GBM	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	4.14	6.76e-05	0.0413	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
GBM	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-4.14	6.77e-05	0.0414	-0.31	-0.36	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
GBM	cis	rs6504622	0.935	rs62075889	ENSG00000262879.4	RP11-156P1.3	-4.14	6.77e-05	0.0414	-0.31	-0.36	Orofacial clefts;	chr17:46950671	chr17:46984045~47100323:-
GBM	cis	rs6504622	1	rs12940071	ENSG00000262879.4	RP11-156P1.3	-4.14	6.77e-05	0.0414	-0.31	-0.36	Orofacial clefts;	chr17:46950686	chr17:46984045~47100323:-
GBM	cis	rs6504622	0.935	rs17608961	ENSG00000262879.4	RP11-156P1.3	-4.14	6.77e-05	0.0414	-0.31	-0.36	Orofacial clefts;	chr17:46952302	chr17:46984045~47100323:-
GBM	cis	rs7017914	0.69	rs17699084	ENSG00000246366.5	RP11-382J12.1	4.14	6.77e-05	0.0414	0.38	0.36	Bone mineral density;	chr8:71051176	chr8:70608577~70663279:+
GBM	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-4.14	6.77e-05	0.0414	-0.46	-0.36	Height;	chr3:53047596	chr3:53064283~53065091:-
GBM	cis	rs10901212	0.559	rs932887	ENSG00000119440.8	LCN1P1	4.14	6.77e-05	0.0414	0.47	0.36	Obesity-related traits;	chr9:132773518	chr9:133224905~133228591:-
GBM	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-4.14	6.78e-05	0.0414	-0.41	-0.36	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
GBM	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	4.13	6.78e-05	0.0414	0.38	0.36	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	4.13	6.78e-05	0.0414	0.38	0.36	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
GBM	cis	rs6599077	0.618	rs73067622	ENSG00000231873.1	RP11-761N21.1	4.13	6.79e-05	0.0414	0.47	0.36	Sleep-related phenotypes;	chr3:40149413	chr3:40766207~40862626:+
GBM	cis	rs17264034	0.821	rs422309	ENSG00000250786.1	SNHG18	4.13	6.79e-05	0.0414	0.57	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544284	chr5:9546200~9550609:+
GBM	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	4.13	6.8e-05	0.0415	0.69	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
GBM	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	4.13	6.8e-05	0.0415	0.47	0.36	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
GBM	cis	rs3096299	0.73	rs3102380	ENSG00000260259.1	RP11-368I7.4	4.13	6.8e-05	0.0415	0.4	0.36	Multiple myeloma (IgH translocation);	chr16:89324008	chr16:89682620~89686569:-
GBM	cis	rs11773103	0.881	rs73204826	ENSG00000224046.1	AC005076.5	4.13	6.81e-05	0.0415	0.55	0.36	Bipolar disorder or major depressive disorder (combined);	chr7:87144942	chr7:87151423~87152420:-
GBM	cis	rs440932	1	rs365309	ENSG00000253893.2	FAM85B	4.13	6.81e-05	0.0416	0.45	0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8167819~8226614:-
GBM	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	4.13	6.81e-05	0.0416	0.7	0.36	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
GBM	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	4.13	6.82e-05	0.0416	0.35	0.36	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
GBM	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	4.13	6.82e-05	0.0416	0.35	0.36	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
GBM	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	4.13	6.82e-05	0.0416	0.35	0.36	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
GBM	cis	rs6598955	0.585	rs6659822	ENSG00000236782.4	RP11-96L14.7	4.13	6.82e-05	0.0416	0.52	0.36	Obesity-related traits;	chr1:26299917	chr1:26169947~26171821:-
GBM	cis	rs9400180	0.879	rs12567	ENSG00000271734.1	RP1-111B22.3	-4.13	6.83e-05	0.0416	-0.4	-0.36	Major depressive disorder;	chr6:108043378	chr6:108030249~108030718:-
GBM	cis	rs3096299	0.754	rs3096320	ENSG00000274627.1	RP11-104N10.2	4.13	6.85e-05	0.0417	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89516797~89522217:+
GBM	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	4.13	6.85e-05	0.0418	0.34	0.36	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
GBM	cis	rs950169	0.519	rs7237	ENSG00000275120.1	RP11-182J1.17	4.13	6.85e-05	0.0418	0.48	0.36	Schizophrenia;	chr15:84643346	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs4842940	ENSG00000275120.1	RP11-182J1.17	-4.13	6.86e-05	0.0418	-0.47	-0.36	Schizophrenia;	chr15:84162473	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs4842941	ENSG00000275120.1	RP11-182J1.17	-4.13	6.86e-05	0.0418	-0.47	-0.36	Schizophrenia;	chr15:84162560	chr15:84599434~84606463:-
GBM	cis	rs950169	0.922	rs12911223	ENSG00000275120.1	RP11-182J1.17	-4.13	6.86e-05	0.0418	-0.47	-0.36	Schizophrenia;	chr15:84162919	chr15:84599434~84606463:-
GBM	cis	rs950169	0.845	rs4106951	ENSG00000275120.1	RP11-182J1.17	4.13	6.86e-05	0.0418	0.47	0.36	Schizophrenia;	chr15:84164642	chr15:84599434~84606463:-
GBM	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-4.13	6.86e-05	0.0418	-0.52	-0.36	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
GBM	cis	rs11671005	0.656	rs73066226	ENSG00000269600.1	AC016629.3	-4.13	6.86e-05	0.0418	-0.55	-0.36	Mean platelet volume;	chr19:58496846	chr19:58593896~58599355:-
GBM	cis	rs9393777	0.528	rs7745603	ENSG00000224843.5	LINC00240	4.13	6.87e-05	0.0419	0.49	0.36	Intelligence (multi-trait analysis);	chr6:27122625	chr6:26956992~27023924:+
GBM	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-4.13	6.87e-05	0.0419	-0.36	-0.36	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
GBM	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	4.13	6.88e-05	0.0419	0.33	0.36	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
GBM	cis	rs6969780	1	rs6973182	ENSG00000240990.8	HOXA11-AS	-4.13	6.88e-05	0.0419	-0.55	-0.36	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27184518~27189293:+
GBM	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	4.13	6.88e-05	0.0419	0.4	0.36	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
GBM	cis	rs5752326	0.51	rs5752333	ENSG00000261188.1	CTA-445C9.14	4.13	6.88e-05	0.0419	0.46	0.36	Ischemic stroke;	chr22:26483001	chr22:26512537~26514568:+
GBM	cis	rs7612209	0.607	rs4478092	ENSG00000225790.1	RP11-2L8.1	-4.13	6.9e-05	0.042	-0.41	-0.36	Cognitive performance;	chr3:177889805	chr3:177934823~177937662:+
GBM	cis	rs71636213	0.881	rs17260885	ENSG00000248794.1	CTD-2248H3.1	4.13	6.9e-05	0.042	0.73	0.36	Alzheimer's disease in APOE e4- carriers;	chr5:80291732	chr5:81242330~81242599:-
GBM	cis	rs2579103	0.595	rs7301703	ENSG00000258183.4	RP11-753N8.1	-4.13	6.9e-05	0.042	-0.48	-0.36	Body mass index;	chr12:90313548	chr12:90280894~90300340:+
GBM	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-4.13	6.9e-05	0.042	-0.41	-0.36	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-4.13	6.9e-05	0.042	-0.41	-0.36	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-4.13	6.9e-05	0.042	-0.41	-0.36	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-4.13	6.9e-05	0.042	-0.41	-0.36	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-4.13	6.9e-05	0.042	-0.41	-0.36	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-4.13	6.9e-05	0.042	-0.41	-0.36	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
GBM	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-4.13	6.9e-05	0.042	-0.41	-0.36	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
GBM	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	4.13	6.91e-05	0.0421	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	4.13	6.91e-05	0.0421	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
GBM	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	4.13	6.91e-05	0.0421	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
GBM	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	4.13	6.91e-05	0.0421	0.41	0.36	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
GBM	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	4.13	6.92e-05	0.0421	0.34	0.36	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
GBM	cis	rs875971	0.825	rs1000464	ENSG00000236529.1	RP13-254B10.1	-4.13	6.92e-05	0.0421	-0.37	-0.36	Aortic root size;	chr7:66312922	chr7:65840212~65840596:+
GBM	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-4.13	6.92e-05	0.0421	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
GBM	cis	rs11098499	0.954	rs6820115	ENSG00000250412.1	KLHL2P1	4.13	6.93e-05	0.0422	0.44	0.36	Corneal astigmatism;	chr4:119477027	chr4:119334329~119378233:+
GBM	cis	rs4713118	0.738	rs200465	ENSG00000199851.2	U3	4.13	6.93e-05	0.0422	0.49	0.36	Parkinson's disease;	chr6:27789875	chr6:28015568~28015777:+
GBM	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	4.13	6.93e-05	0.0422	0.43	0.36	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
GBM	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	4.13	6.93e-05	0.0422	0.46	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
GBM	cis	rs853679	0.567	rs16894091	ENSG00000199851.2	U3	-4.13	6.94e-05	0.0422	-0.48	-0.36	Depression;	chr6:28422360	chr6:28015568~28015777:+
GBM	cis	rs4842666	0.667	rs1401981	ENSG00000258302.2	RP11-981P6.1	4.13	6.95e-05	0.0422	0.45	0.36	Blood pressure;	chr12:89697669	chr12:89561129~89594878:+
GBM	cis	rs1719271	0.908	rs1684050	ENSG00000277351.1	RP11-325L12.6	-4.13	6.95e-05	0.0423	-0.61	-0.36	Platelet count;	chr15:64905973	chr15:65049188~65049802:-
GBM	cis	rs1719271	0.908	rs1684052	ENSG00000277351.1	RP11-325L12.6	-4.13	6.95e-05	0.0423	-0.61	-0.36	Platelet count;	chr15:64906312	chr15:65049188~65049802:-
GBM	cis	rs1719271	0.908	rs1631677	ENSG00000277351.1	RP11-325L12.6	-4.13	6.95e-05	0.0423	-0.61	-0.36	Platelet count;	chr15:64906392	chr15:65049188~65049802:-
GBM	cis	rs9649213	0.593	rs7812180	ENSG00000272950.1	RP11-307C18.1	-4.13	6.95e-05	0.0423	-0.49	-0.36	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr7:98322853~98323430:+
GBM	cis	rs4266144	0.562	rs2086667	ENSG00000243629.1	LINC00880	-4.13	6.95e-05	0.0423	-0.44	-0.36	Coronary artery disease;	chr3:157118728	chr3:157081667~157123004:-
GBM	cis	rs10507419	1	rs9541398	ENSG00000276672.1	RP11-142E9.1	-4.13	6.95e-05	0.0423	-0.39	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34616160	chr13:33846190~33850825:+
GBM	cis	rs4273100	1	rs4924986	ENSG00000265185.4	SNORD3B-1	-4.13	6.95e-05	0.0423	-0.48	-0.36	Schizophrenia;	chr17:19339154	chr17:19061912~19062669:+
GBM	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	4.13	6.96e-05	0.0423	0.36	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
GBM	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	4.13	6.96e-05	0.0423	0.53	0.36	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
GBM	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-4.13	6.96e-05	0.0423	-0.46	-0.36	Height;	chr11:118859432	chr11:118704607~118750263:+
GBM	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-4.13	6.96e-05	0.0423	-0.46	-0.36	Height;	chr11:118860890	chr11:118704607~118750263:+
GBM	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-4.13	6.96e-05	0.0423	-0.46	-0.36	Height;	chr11:118861053	chr11:118704607~118750263:+
GBM	cis	rs6788497	0.643	rs11705709	ENSG00000242551.2	POU5F1P6	-4.13	6.96e-05	0.0423	-0.56	-0.36	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128401031	chr3:128674735~128677005:-
GBM	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	4.13	6.97e-05	0.0423	0.65	0.36	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
GBM	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	4.13	6.97e-05	0.0423	0.65	0.36	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
GBM	cis	rs6499766	1	rs4784549	ENSG00000260135.5	RP11-212I21.2	-4.13	6.97e-05	0.0423	-0.43	-0.36	Thyroid hormone levels;	chr16:55579006	chr16:55426797~55462297:-
GBM	cis	rs11773103	0.881	rs56404754	ENSG00000224046.1	AC005076.5	4.13	6.97e-05	0.0423	0.57	0.36	Bipolar disorder or major depressive disorder (combined);	chr7:87137693	chr7:87151423~87152420:-
GBM	cis	rs17685	0.712	rs11770149	ENSG00000127957.15	PMS2P3	-4.13	6.98e-05	0.0424	-0.43	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:75502930~75528148:-
GBM	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	4.13	6.98e-05	0.0424	0.37	0.36	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
GBM	cis	rs5742933	0.69	rs62183656	ENSG00000273240.1	RP11-455J20.3	-4.13	6.99e-05	0.0424	-0.53	-0.36	Ferritin levels;	chr2:189669387	chr2:189763859~189764456:-
GBM	cis	rs5742933	0.69	rs62183658	ENSG00000273240.1	RP11-455J20.3	-4.13	6.99e-05	0.0424	-0.53	-0.36	Ferritin levels;	chr2:189669491	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs56137655	ENSG00000273240.1	RP11-455J20.3	-4.13	6.99e-05	0.0424	-0.53	-0.36	Alcohol dependence (age at onset);	chr2:189675844	chr2:189763859~189764456:-
GBM	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-4.13	6.99e-05	0.0424	-0.39	-0.36	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-4.13	6.99e-05	0.0424	-0.39	-0.36	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-4.13	6.99e-05	0.0424	-0.39	-0.36	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
GBM	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	4.13	6.99e-05	0.0424	0.43	0.36	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
GBM	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	4.13	6.99e-05	0.0424	0.4	0.36	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
GBM	cis	rs73198271	0.71	rs11779565	ENSG00000253893.2	FAM85B	4.13	7e-05	0.0424	0.49	0.36	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:8167819~8226614:-
GBM	cis	rs950169	0.544	rs2036949	ENSG00000275120.1	RP11-182J1.17	4.13	7e-05	0.0424	0.47	0.36	Schizophrenia;	chr15:84620374	chr15:84599434~84606463:-
GBM	cis	rs950169	0.58	rs11635597	ENSG00000275120.1	RP11-182J1.17	4.13	7e-05	0.0424	0.47	0.36	Schizophrenia;	chr15:84622468	chr15:84599434~84606463:-
GBM	cis	rs79349575	0.87	rs12941262	ENSG00000270781.1	RP11-501C14.9	-4.13	7e-05	0.0425	-0.44	-0.36	Type 2 diabetes;	chr17:48889675	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.778	rs12950328	ENSG00000270781.1	RP11-501C14.9	-4.13	7e-05	0.0425	-0.44	-0.36	Type 2 diabetes;	chr17:48889699	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.594	rs1985785	ENSG00000270781.1	RP11-501C14.9	-4.13	7e-05	0.0425	-0.44	-0.36	Type 2 diabetes;	chr17:48890426	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.685	rs1124829	ENSG00000270781.1	RP11-501C14.9	-4.13	7e-05	0.0425	-0.44	-0.36	Type 2 diabetes;	chr17:48890435	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.721	rs1008834	ENSG00000270781.1	RP11-501C14.9	-4.13	7e-05	0.0425	-0.44	-0.36	Type 2 diabetes;	chr17:48890646	chr17:48899131~48899748:+
GBM	cis	rs79349575	0.721	rs9904645	ENSG00000270781.1	RP11-501C14.9	-4.13	7e-05	0.0425	-0.44	-0.36	Type 2 diabetes;	chr17:48892303	chr17:48899131~48899748:+
GBM	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-4.13	7e-05	0.0425	-0.46	-0.36	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-4.13	7e-05	0.0425	-0.46	-0.36	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
GBM	cis	rs875971	0.545	rs2279757	ENSG00000236529.1	RP13-254B10.1	4.13	7e-05	0.0425	0.4	0.36	Aortic root size;	chr7:66363676	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs6969224	ENSG00000236529.1	RP13-254B10.1	4.13	7e-05	0.0425	0.4	0.36	Aortic root size;	chr7:66370011	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs11766183	ENSG00000236529.1	RP13-254B10.1	4.13	7e-05	0.0425	0.4	0.36	Aortic root size;	chr7:66374173	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs1065265	ENSG00000236529.1	RP13-254B10.1	4.13	7e-05	0.0425	0.4	0.36	Aortic root size;	chr7:66376216	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs7811204	ENSG00000236529.1	RP13-254B10.1	4.13	7e-05	0.0425	0.4	0.36	Aortic root size;	chr7:66387213	chr7:65840212~65840596:+
GBM	cis	rs4373814	0.595	rs1891393	ENSG00000226083.4	SLC39A12-AS1	4.13	7e-05	0.0425	0.45	0.36	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18138501	chr10:18001786~18010562:-
GBM	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	4.13	7e-05	0.0425	0.48	0.36	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
GBM	cis	rs9983113	0.903	rs2836770	ENSG00000231123.1	SPATA20P1	4.13	7e-05	0.0425	0.35	0.36	Body mass index;	chr21:38942780	chr21:38238227~38238664:-
GBM	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	4.13	7.01e-05	0.0425	0.38	0.36	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
GBM	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	4.13	7.01e-05	0.0425	0.42	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
GBM	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	4.13	7.01e-05	0.0425	0.42	0.36	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
GBM	cis	rs1555322	0.932	rs2425018	ENSG00000126005.14	MMP24-AS1	-4.13	7.01e-05	0.0425	-0.6	-0.36	Attention deficit hyperactivity disorder;	chr20:35230963	chr20:35216462~35278131:-
GBM	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-4.13	7.01e-05	0.0425	-0.41	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
GBM	cis	rs80130819	0.892	rs7966139	ENSG00000279875.1	RP11-474C8.7	4.13	7.02e-05	0.0425	0.64	0.36	Prostate cancer;	chr12:48234974	chr12:48189349~48191207:+
GBM	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	4.13	7.02e-05	0.0425	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
GBM	cis	rs7824557	0.628	rs7841394	ENSG00000255020.1	AF131216.5	4.13	7.02e-05	0.0426	0.38	0.36	Retinal vascular caliber;	chr8:11328162	chr8:11345748~11347502:-
GBM	cis	rs1035275	0.626	rs167787	ENSG00000280620.1	SCAANT1	4.13	7.02e-05	0.0426	0.46	0.36	IgG glycosylation;	chr3:64171355	chr3:63911518~63911772:-
GBM	cis	rs10246939	0.579	rs10464444	ENSG00000261797.1	RP11-744I24.3	4.13	7.04e-05	0.0426	0.44	0.36	Bitter taste perception;	chr7:141832387	chr7:141512698~141513183:-
GBM	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	4.12	7.04e-05	0.0427	0.47	0.36	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
GBM	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	4.12	7.04e-05	0.0427	0.38	0.36	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
GBM	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	4.12	7.04e-05	0.0427	0.37	0.36	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
GBM	cis	rs6887276	0.538	rs35897671	ENSG00000245937.6	LINC01184	-4.12	7.04e-05	0.0427	-0.35	-0.36	Height;	chr5:128014053	chr5:127940426~128083172:-
GBM	cis	rs8062405	0.723	rs4788077	ENSG00000271623.1	RP11-435I10.5	-4.12	7.05e-05	0.0427	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28364700~28365333:+
GBM	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	4.12	7.05e-05	0.0427	0.47	0.36	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
GBM	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-4.12	7.06e-05	0.0428	-0.39	-0.36	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
GBM	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-4.12	7.06e-05	0.0428	-0.39	-0.36	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
GBM	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-4.12	7.06e-05	0.0428	-0.43	-0.36	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
GBM	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	4.12	7.06e-05	0.0428	0.38	0.36	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	4.12	7.06e-05	0.0428	0.38	0.36	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
GBM	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-4.12	7.07e-05	0.0428	-0.39	-0.36	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-4.12	7.07e-05	0.0428	-0.39	-0.36	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
GBM	cis	rs2963463	0.715	rs2963458	ENSG00000253519.1	AC106801.1	-4.12	7.08e-05	0.0428	-0.49	-0.36	Gestational age at birth (maternal effect);Preterm birth (maternal effect);	chr5:158479765	chr5:157565964~157569098:+
GBM	cis	rs17772222	0.917	rs61986664	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88711251	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.876	rs61986665	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88711354	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs8018755	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88714249	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs8018630	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88714250	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs8020072	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88714332	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs17260408	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88715464	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs12589982	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88716861	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs8021690	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88717806	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs61986671	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88732917	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.917	rs17188228	ENSG00000222990.1	RNU4-22P	4.12	7.08e-05	0.0429	0.43	0.36	Coronary artery calcification;	chr14:88738921	chr14:88513498~88513663:+
GBM	cis	rs10507419	1	rs4129985	ENSG00000276672.1	RP11-142E9.1	-4.12	7.08e-05	0.0429	-0.39	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34614858	chr13:33846190~33850825:+
GBM	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-4.12	7.09e-05	0.0429	-0.39	-0.36	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-4.12	7.09e-05	0.0429	-0.39	-0.36	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-4.12	7.09e-05	0.0429	-0.39	-0.36	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-4.12	7.09e-05	0.0429	-0.39	-0.36	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
GBM	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-4.12	7.09e-05	0.0429	-0.39	-0.36	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
GBM	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	4.12	7.09e-05	0.0429	0.63	0.36	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
GBM	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-4.12	7.09e-05	0.0429	-0.47	-0.36	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-4.12	7.09e-05	0.0429	-0.47	-0.36	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-4.12	7.09e-05	0.0429	-0.47	-0.36	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
GBM	cis	rs2579103	1	rs1438994	ENSG00000258183.4	RP11-753N8.1	-4.12	7.1e-05	0.0429	-0.49	-0.36	Body mass index;	chr12:90200612	chr12:90280894~90300340:+
GBM	cis	rs4072705	1	rs2067791	ENSG00000224020.1	MIR181A2HG	-4.12	7.1e-05	0.0429	-0.39	-0.36	Menarche (age at onset);	chr9:124676015	chr9:124658467~124698631:+
GBM	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	4.12	7.1e-05	0.0429	0.34	0.36	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
GBM	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	4.12	7.1e-05	0.0429	0.34	0.36	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
GBM	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	4.12	7.1e-05	0.0429	0.34	0.36	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
GBM	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	4.12	7.1e-05	0.0429	0.34	0.36	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
GBM	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-4.12	7.1e-05	0.0429	-0.37	-0.36	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-4.12	7.1e-05	0.0429	-0.37	-0.36	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
GBM	cis	rs11051970	0.679	rs2733696	ENSG00000274964.1	RP11-817I4.1	-4.12	7.1e-05	0.043	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32401701	chr12:32339368~32340724:+
GBM	cis	rs11051970	0.704	rs7312698	ENSG00000274964.1	RP11-817I4.1	-4.12	7.1e-05	0.043	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32401761	chr12:32339368~32340724:+
GBM	cis	rs11051970	0.704	rs2733694	ENSG00000274964.1	RP11-817I4.1	-4.12	7.1e-05	0.043	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32402296	chr12:32339368~32340724:+
GBM	cis	rs11051970	0.679	rs2931554	ENSG00000274964.1	RP11-817I4.1	-4.12	7.1e-05	0.043	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32403228	chr12:32339368~32340724:+
GBM	cis	rs11051970	0.679	rs2651377	ENSG00000274964.1	RP11-817I4.1	-4.12	7.1e-05	0.043	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32403985	chr12:32339368~32340724:+
GBM	cis	rs3845817	1	rs3845817	ENSG00000237979.1	AC007389.1	-4.12	7.1e-05	0.043	-0.51	-0.36	Bipolar disorder;	chr2:65531391	chr2:65500993~65502138:-
GBM	cis	rs12936587	0.714	rs9890064	ENSG00000231458.2	RNASEH1P2	-4.12	7.11e-05	0.043	-0.39	-0.36	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17634694	chr17:16683438~16684227:+
GBM	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-4.12	7.11e-05	0.043	-0.62	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
GBM	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-4.12	7.11e-05	0.043	-0.62	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
GBM	cis	rs6504622	0.934	rs3760377	ENSG00000262879.4	RP11-156P1.3	-4.12	7.11e-05	0.043	-0.31	-0.36	Orofacial clefts;	chr17:46964713	chr17:46984045~47100323:-
GBM	cis	rs6504622	1	rs11079745	ENSG00000262879.4	RP11-156P1.3	-4.12	7.11e-05	0.043	-0.31	-0.36	Orofacial clefts;	chr17:46966781	chr17:46984045~47100323:-
GBM	cis	rs875971	0.545	rs10261710	ENSG00000222364.1	RNU6-96P	-4.12	7.11e-05	0.043	-0.41	-0.36	Aortic root size;	chr7:66249202	chr7:66395191~66395286:+
GBM	cis	rs17772222	0.651	rs1950280	ENSG00000258983.2	RP11-507K2.2	-4.12	7.12e-05	0.043	-0.37	-0.36	Coronary artery calcification;	chr14:88366259	chr14:88499334~88515502:+
GBM	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-4.12	7.12e-05	0.043	-0.41	-0.36	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
GBM	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-4.12	7.12e-05	0.043	-0.49	-0.36	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
GBM	cis	rs16937	0.711	rs12142514	ENSG00000271580.1	RP11-536L3.4	-4.12	7.12e-05	0.0431	-0.32	-0.36	Schizophrenia;	chr1:205153401	chr1:205091163~205091946:+
GBM	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	4.12	7.13e-05	0.0431	0.42	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
GBM	cis	rs5742933	0.948	rs10195109	ENSG00000253559.1	OSGEPL1-AS1	4.12	7.14e-05	0.0431	0.42	0.36	Ferritin levels;	chr2:189704465	chr2:189762704~189765556:+
GBM	cis	rs4820834	0.542	rs5749062	ENSG00000275258.1	AC004832.1	-4.12	7.14e-05	0.0431	-0.38	-0.36	Coronary artery calcification;	chr22:30325011	chr22:30411646~30411755:+
GBM	cis	rs10507419	0.83	rs73163846	ENSG00000276672.1	RP11-142E9.1	-4.12	7.14e-05	0.0432	-0.43	-0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34597684	chr13:33846190~33850825:+
GBM	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	4.12	7.14e-05	0.0432	0.35	0.36	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	4.12	7.14e-05	0.0432	0.35	0.36	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	4.12	7.14e-05	0.0432	0.35	0.36	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	4.12	7.14e-05	0.0432	0.35	0.36	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	4.12	7.14e-05	0.0432	0.35	0.36	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	4.12	7.14e-05	0.0432	0.35	0.36	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
GBM	cis	rs54211	0.572	rs137626	ENSG00000230149.2	RP3-508I15.19	-4.12	7.15e-05	0.0432	-0.35	-0.36	Sudden cardiac arrest;	chr22:39320266	chr22:38734730~38738990:+
GBM	cis	rs2579103	0.683	rs10777234	ENSG00000258183.4	RP11-753N8.1	-4.12	7.15e-05	0.0432	-0.39	-0.36	Body mass index;	chr12:90213380	chr12:90280894~90300340:+
GBM	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-4.12	7.15e-05	0.0432	-0.39	-0.36	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
GBM	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-4.12	7.15e-05	0.0432	-0.44	-0.36	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
GBM	cis	rs7035589	1	rs10991446	ENSG00000230013.1	RP11-217B7.3	4.12	7.16e-05	0.0432	0.43	0.36	Pelvic organ prolapse;	chr9:104989290	chr9:104990796~104991781:-
GBM	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	4.12	7.16e-05	0.0432	0.41	0.36	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
GBM	cis	rs2904967	0.778	rs77130160	ENSG00000255468.5	RP11-867G23.8	-4.12	7.16e-05	0.0432	-0.63	-0.36	Mean corpuscular volume;	chr11:65355223	chr11:66347950~66364804:+
GBM	cis	rs875971	0.545	rs1796219	ENSG00000236529.1	RP13-254B10.1	-4.12	7.16e-05	0.0432	-0.39	-0.36	Aortic root size;	chr7:66645977	chr7:65840212~65840596:+
GBM	cis	rs875971	0.502	rs6460311	ENSG00000236529.1	RP13-254B10.1	-4.12	7.16e-05	0.0432	-0.39	-0.36	Aortic root size;	chr7:66646886	chr7:65840212~65840596:+
GBM	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-4.12	7.17e-05	0.0433	-0.46	-0.36	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
GBM	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-4.12	7.17e-05	0.0433	-0.46	-0.36	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
GBM	cis	rs7017914	0.905	rs12542300	ENSG00000246366.5	RP11-382J12.1	4.12	7.17e-05	0.0433	0.37	0.36	Bone mineral density;	chr8:71039160	chr8:70608577~70663279:+
GBM	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	4.12	7.17e-05	0.0433	0.47	0.36	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
GBM	cis	rs6598955	0.671	rs17257169	ENSG00000236782.4	RP11-96L14.7	4.12	7.17e-05	0.0433	0.46	0.36	Obesity-related traits;	chr1:26243518	chr1:26169947~26171821:-
GBM	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	4.12	7.18e-05	0.0433	0.42	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
GBM	cis	rs7216064	1	rs7209675	ENSG00000278219.1	AC145343.1	-4.12	7.18e-05	0.0433	-0.41	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67835142	chr17:68101538~68101639:+
GBM	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	4.12	7.18e-05	0.0433	0.4	0.36	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
GBM	cis	rs6558530	0.653	rs7001282	ENSG00000253982.1	CTD-2336O2.1	4.12	7.18e-05	0.0434	0.48	0.36	Systolic blood pressure;	chr8:1752022	chr8:1761990~1764502:-
GBM	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-4.12	7.19e-05	0.0434	-0.49	-0.36	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
GBM	cis	rs7315956	0.826	rs6581921	ENSG00000257139.1	RP11-320P7.2	-4.12	7.19e-05	0.0434	-0.41	-0.36	Testicular germ cell tumor;	chr12:70145123	chr12:70180338~70202004:+
GBM	cis	rs863750	0.687	rs825461	ENSG00000275389.1	RP11-214K3.24	-4.12	7.19e-05	0.0434	-0.45	-0.36	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124077256	chr12:124085761~124088598:+
GBM	cis	rs853679	0.599	rs156743	ENSG00000199851.2	U3	4.12	7.19e-05	0.0434	0.7	0.36	Depression;	chr6:27999311	chr6:28015568~28015777:+
GBM	cis	rs853679	0.599	rs149990	ENSG00000199851.2	U3	4.12	7.19e-05	0.0434	0.7	0.36	Depression;	chr6:28030480	chr6:28015568~28015777:+
GBM	cis	rs853679	0.599	rs149943	ENSG00000199851.2	U3	4.12	7.19e-05	0.0434	0.7	0.36	Depression;	chr6:28034610	chr6:28015568~28015777:+
GBM	cis	rs853679	0.545	rs35949109	ENSG00000199851.2	U3	4.12	7.19e-05	0.0434	0.7	0.36	Depression;	chr6:28058148	chr6:28015568~28015777:+
GBM	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	4.12	7.2e-05	0.0434	0.43	0.36	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	4.12	7.2e-05	0.0434	0.43	0.36	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
GBM	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-4.12	7.21e-05	0.0435	-0.42	-0.36	Height;	chr20:35174686	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-4.12	7.21e-05	0.0435	-0.42	-0.36	Height;	chr20:35175051	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-4.12	7.21e-05	0.0435	-0.42	-0.36	Height;	chr20:35176148	chr20:35201747~35203288:-
GBM	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	4.12	7.22e-05	0.0435	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
GBM	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-4.12	7.23e-05	0.0436	-0.39	-0.36	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-4.12	7.23e-05	0.0436	-0.39	-0.36	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
GBM	cis	rs324126	0.78	rs2059817	ENSG00000277977.1	CTD-3018O17.5	4.12	7.23e-05	0.0436	0.36	0.36	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52392659~52392755:+
GBM	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-4.12	7.23e-05	0.0436	-0.36	-0.36	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
GBM	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-4.12	7.24e-05	0.0436	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-4.12	7.24e-05	0.0436	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
GBM	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-4.12	7.24e-05	0.0436	-0.5	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
GBM	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	4.12	7.24e-05	0.0436	0.37	0.36	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
GBM	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-4.12	7.25e-05	0.0436	-0.46	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
GBM	cis	rs7216064	0.906	rs1976052	ENSG00000278219.1	AC145343.1	-4.12	7.25e-05	0.0436	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834462	chr17:68101538~68101639:+
GBM	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	4.12	7.25e-05	0.0436	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
GBM	cis	rs17270561	0.609	rs9358873	ENSG00000272810.1	U91328.22	-4.12	7.26e-05	0.0437	-0.49	-0.36	Iron status biomarkers;	chr6:25731555	chr6:26013241~26013757:+
GBM	cis	rs17685	0.632	rs1859793	ENSG00000127957.15	PMS2P3	-4.12	7.26e-05	0.0437	-0.44	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76191965	chr7:75502930~75528148:-
GBM	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	4.12	7.26e-05	0.0437	0.53	0.36	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
GBM	cis	rs6499129	0.571	rs9939768	ENSG00000270049.1	RP11-297D21.4	-4.12	7.27e-05	0.0437	-0.72	-0.36	Waist-to-hip ratio adjusted for body mass index;	chr16:67185204	chr16:67481314~67487250:+
GBM	cis	rs4812048	0.894	rs236729	ENSG00000268649.3	RP4-806M20.4	-4.12	7.27e-05	0.0438	-0.41	-0.36	Mean platelet volume;	chr20:59004920	chr20:58817132~58817725:-
GBM	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-4.12	7.27e-05	0.0438	-0.47	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
GBM	cis	rs875971	0.545	rs75840613	ENSG00000222364.1	RNU6-96P	-4.12	7.27e-05	0.0438	-0.42	-0.36	Aortic root size;	chr7:66376399	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs73148639	ENSG00000222364.1	RNU6-96P	-4.12	7.27e-05	0.0438	-0.42	-0.36	Aortic root size;	chr7:66390342	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-4.12	7.28e-05	0.0438	-0.4	-0.36	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-4.12	7.28e-05	0.0438	-0.4	-0.36	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
GBM	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
GBM	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
GBM	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
GBM	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
GBM	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	4.12	7.28e-05	0.0438	0.42	0.36	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
GBM	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-4.12	7.28e-05	0.0438	-0.43	-0.36	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
GBM	cis	rs899997	1	rs12899201	ENSG00000261143.1	ADAMTS7P3	4.12	7.28e-05	0.0438	0.41	0.36	Coronary artery disease or large artery stroke;	chr15:78741192	chr15:77976042~77993057:+
GBM	cis	rs7615952	0.599	rs67566088	ENSG00000250012.1	RP11-124N2.1	-4.12	7.29e-05	0.0438	-0.39	-0.36	Blood pressure (smoking interaction);	chr3:126050130	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs12495947	ENSG00000250012.1	RP11-124N2.1	-4.12	7.29e-05	0.0438	-0.39	-0.36	Blood pressure (smoking interaction);	chr3:126052855	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs6805074	ENSG00000250012.1	RP11-124N2.1	-4.12	7.29e-05	0.0438	-0.39	-0.36	Blood pressure (smoking interaction);	chr3:126053431	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs4422257	ENSG00000250012.1	RP11-124N2.1	-4.12	7.29e-05	0.0438	-0.39	-0.36	Blood pressure (smoking interaction);	chr3:126055520	chr3:126084220~126095349:+
GBM	cis	rs7615952	0.641	rs66520539	ENSG00000250012.1	RP11-124N2.1	-4.12	7.29e-05	0.0438	-0.39	-0.36	Blood pressure (smoking interaction);	chr3:126061531	chr3:126084220~126095349:+
GBM	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	4.12	7.29e-05	0.0438	0.43	0.36	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
GBM	cis	rs7534016	1	rs835422	ENSG00000230812.4	LINC01358	-4.12	7.3e-05	0.0439	-0.4	-0.36	Obesity-related traits;	chr1:59396337	chr1:59020387~59044614:+
GBM	cis	rs3213958	0.574	rs56075614	ENSG00000249274.1	PDLIM1P4	-4.12	7.3e-05	0.0439	-0.57	-0.36	Blood protein levels;	chr3:98819973	chr3:98782188~98783193:+
GBM	cis	rs3213958	0.574	rs6440159	ENSG00000249274.1	PDLIM1P4	-4.12	7.3e-05	0.0439	-0.57	-0.36	Blood protein levels;	chr3:98823350	chr3:98782188~98783193:+
GBM	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-4.12	7.31e-05	0.0439	-0.41	-0.36	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
GBM	cis	rs11771526	0.901	rs10239582	ENSG00000273014.1	RP11-225B17.2	-4.11	7.32e-05	0.044	-0.71	-0.36	Body mass index;	chr7:32258504	chr7:32758882~32759353:+
GBM	cis	rs11771526	0.792	rs17161105	ENSG00000273014.1	RP11-225B17.2	-4.11	7.32e-05	0.044	-0.71	-0.36	Body mass index;	chr7:32259575	chr7:32758882~32759353:+
GBM	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	4.11	7.32e-05	0.044	0.48	0.36	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
GBM	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	4.11	7.32e-05	0.044	0.48	0.36	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
GBM	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	4.11	7.32e-05	0.044	0.48	0.36	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
GBM	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	4.11	7.32e-05	0.044	0.48	0.36	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
GBM	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	4.11	7.32e-05	0.044	0.43	0.36	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	4.11	7.32e-05	0.044	0.43	0.36	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
GBM	cis	rs2115630	0.967	rs8027779	ENSG00000225151.9	GOLGA2P7	4.11	7.33e-05	0.044	0.38	0.36	P wave terminal force;	chr15:84712154	chr15:84199311~84230136:-
GBM	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-4.11	7.33e-05	0.044	-0.34	-0.36	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
GBM	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-4.11	7.33e-05	0.0441	-0.56	-0.36	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
GBM	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-4.11	7.34e-05	0.0441	-0.43	-0.36	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
GBM	cis	rs10435719	0.902	rs7459983	ENSG00000255556.2	RP11-351I21.6	4.11	7.34e-05	0.0441	0.37	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:12378679~12380265:-
GBM	cis	rs950776	0.79	rs2067808	ENSG00000261762.1	RP11-650L12.2	4.11	7.34e-05	0.0441	0.56	0.36	Sudden cardiac arrest;	chr15:78619438	chr15:78589123~78591276:-
GBM	cis	rs651907	0.557	rs1031710	ENSG00000256628.3	ZBTB11-AS1	4.11	7.34e-05	0.0441	0.52	0.36	Colorectal cancer;	chr3:101745051	chr3:101676475~101679217:+
GBM	cis	rs651907	0.535	rs13065944	ENSG00000256628.3	ZBTB11-AS1	4.11	7.34e-05	0.0441	0.52	0.36	Colorectal cancer;	chr3:101754244	chr3:101676475~101679217:+
GBM	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	4.11	7.34e-05	0.0441	0.44	0.36	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
GBM	cis	rs433598	0.55	rs8063878	ENSG00000180747.14	SMG1P3	4.11	7.34e-05	0.0441	0.45	0.36	Schizophrenia;	chr16:20837104	chr16:21446683~21520444:-
GBM	cis	rs950169	0.922	rs11635505	ENSG00000229212.6	RP11-561C5.4	4.11	7.35e-05	0.0441	0.44	0.36	Schizophrenia;	chr15:84553803	chr15:85205440~85234795:-
GBM	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	4.11	7.35e-05	0.0441	0.42	0.36	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
GBM	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	4.11	7.36e-05	0.0441	0.54	0.36	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
GBM	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	4.11	7.36e-05	0.0441	0.41	0.36	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
GBM	cis	rs453301	0.657	rs36056437	ENSG00000254340.1	RP11-10A14.3	-4.11	7.36e-05	0.0441	-0.46	-0.36	Joint mobility (Beighton score);	chr8:8935355	chr8:9141424~9145435:+
GBM	cis	rs6600671	1	rs11249350	ENSG00000223345.3	HIST2H2BA	4.11	7.36e-05	0.0441	0.47	0.36	Hip geometry;	chr1:121436587	chr1:121108210~121117257:-
GBM	cis	rs6600671	1	rs2185281	ENSG00000223345.3	HIST2H2BA	4.11	7.36e-05	0.0441	0.47	0.36	Hip geometry;	chr1:121438132	chr1:121108210~121117257:-
GBM	cis	rs6600671	1	rs10903159	ENSG00000223345.3	HIST2H2BA	4.11	7.36e-05	0.0441	0.47	0.36	Hip geometry;	chr1:121440138	chr1:121108210~121117257:-
GBM	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	4.11	7.37e-05	0.0442	0.55	0.36	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
GBM	cis	rs12457997	0.839	rs11664784	ENSG00000177337.6	DLGAP1-AS1	-4.11	7.37e-05	0.0442	-0.34	-0.36	Periodontitis (DPAL);	chr18:3419465	chr18:3593732~3598352:+
GBM	cis	rs853679	0.538	rs13199081	ENSG00000199851.2	U3	4.11	7.37e-05	0.0442	0.49	0.36	Depression;	chr6:28364057	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.662	rs149901	ENSG00000216901.1	AL022393.7	4.11	7.38e-05	0.0442	0.52	0.36	Parkinson's disease;	chr6:27997725	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.662	rs464312	ENSG00000216901.1	AL022393.7	4.11	7.38e-05	0.0442	0.52	0.36	Parkinson's disease;	chr6:27999813	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.662	rs469228	ENSG00000216901.1	AL022393.7	4.11	7.38e-05	0.0442	0.52	0.36	Parkinson's disease;	chr6:28002926	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.54	rs469227	ENSG00000216901.1	AL022393.7	4.11	7.38e-05	0.0442	0.52	0.36	Parkinson's disease;	chr6:28002927	chr6:28176188~28176674:+
GBM	cis	rs4713118	0.662	rs149948	ENSG00000216901.1	AL022393.7	4.11	7.38e-05	0.0442	0.52	0.36	Parkinson's disease;	chr6:28007039	chr6:28176188~28176674:+
GBM	cis	rs7985	0.901	rs6005133	ENSG00000206028.1	CTA-373H7.7	4.11	7.38e-05	0.0442	0.34	0.36	Electroencephalogram traits;	chr22:26681021	chr22:26667693~26672654:-
GBM	cis	rs812925	0.519	rs10199672	ENSG00000271889.1	RP11-493E12.1	-4.11	7.38e-05	0.0442	-0.37	-0.36	Immature fraction of reticulocytes;	chr2:61400499	chr2:61151433~61162105:-
GBM	cis	rs6600671	1	rs4844616	ENSG00000223345.3	HIST2H2BA	4.11	7.38e-05	0.0443	0.47	0.36	Hip geometry;	chr1:121429348	chr1:121108210~121117257:-
GBM	cis	rs2436845	0.554	rs567395	ENSG00000253320.4	KB-1507C5.2	-4.11	7.39e-05	0.0443	-0.39	-0.36	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102902262	chr8:102864300~102977876:+
GBM	cis	rs3809912	0.693	rs12605081	ENSG00000280302.1	RP11-64C12.1	-4.11	7.39e-05	0.0443	-0.42	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:12999965	chr18:12279427~12282739:+
GBM	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-4.11	7.39e-05	0.0443	-0.45	-0.36	Height;	chr3:53080524	chr3:53064283~53065091:-
GBM	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	4.11	7.39e-05	0.0443	0.49	0.36	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
GBM	cis	rs642803	0.613	rs565427	ENSG00000214659.4	KRT8P26	-4.11	7.4e-05	0.0443	-0.36	-0.36	Urate levels;	chr11:65765354	chr11:65726939~65728214:+
GBM	cis	rs7615952	0.599	rs12485717	ENSG00000250012.1	RP11-124N2.1	4.11	7.41e-05	0.0444	0.38	0.36	Blood pressure (smoking interaction);	chr3:125988232	chr3:126084220~126095349:+
GBM	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-4.11	7.41e-05	0.0444	-0.37	-0.36	Height;	chr6:109360458	chr6:109382795~109383666:+
GBM	cis	rs453301	0.686	rs3989373	ENSG00000254340.1	RP11-10A14.3	-4.11	7.41e-05	0.0444	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9053798	chr8:9141424~9145435:+
GBM	cis	rs17270561	0.609	rs9358883	ENSG00000272810.1	U91328.22	-4.11	7.41e-05	0.0444	-0.5	-0.36	Iron status biomarkers;	chr6:25755287	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs1937132	ENSG00000272810.1	U91328.22	-4.11	7.41e-05	0.0444	-0.5	-0.36	Iron status biomarkers;	chr6:25756789	chr6:26013241~26013757:+
GBM	cis	rs17270561	0.609	rs9358885	ENSG00000272810.1	U91328.22	-4.11	7.41e-05	0.0444	-0.5	-0.36	Iron status biomarkers;	chr6:25757796	chr6:26013241~26013757:+
GBM	cis	rs10420951	0.535	rs79557920	ENSG00000268030.1	AC005253.2	-4.11	7.41e-05	0.0444	-0.43	-0.36	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18417552	chr19:18557775~18561560:-
GBM	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	4.11	7.41e-05	0.0444	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
GBM	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-4.11	7.42e-05	0.0444	-0.39	-0.36	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
GBM	cis	rs454217	0.521	rs11106512	ENSG00000277851.1	RP11-756G20.1	-4.11	7.42e-05	0.0444	-0.43	-0.36	Smoking quantity;	chr12:92333017	chr12:92247756~92363832:-
GBM	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-4.11	7.43e-05	0.0445	-0.46	-0.36	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
GBM	cis	rs9393777	0.528	rs9467989	ENSG00000224843.5	LINC00240	4.11	7.43e-05	0.0445	0.48	0.36	Intelligence (multi-trait analysis);	chr6:27096496	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.557	rs6933999	ENSG00000224843.5	LINC00240	4.11	7.43e-05	0.0445	0.48	0.36	Intelligence (multi-trait analysis);	chr6:27107150	chr6:26956992~27023924:+
GBM	cis	rs1941023	0.615	rs2298556	ENSG00000279632.1	RP11-286N22.6	4.11	7.43e-05	0.0445	0.79	0.36	Congenital heart disease (maternal effect);	chr11:60503852	chr11:61426448~61427325:-
GBM	cis	rs4869313	0.905	rs27712	ENSG00000248734.2	CTD-2260A17.1	4.11	7.44e-05	0.0445	0.43	0.36	Pediatric autoimmune diseases;	chr5:97028359	chr5:96784777~96785999:+
GBM	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-4.11	7.44e-05	0.0445	-0.4	-0.36	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
GBM	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	4.11	7.44e-05	0.0445	0.5	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
GBM	cis	rs7267979	0.586	rs6037057	ENSG00000276952.1	RP5-965G21.6	4.11	7.44e-05	0.0445	0.35	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25284915~25285588:-
GBM	cis	rs7267979	0.586	rs6050429	ENSG00000276952.1	RP5-965G21.6	4.11	7.44e-05	0.0445	0.35	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25284915~25285588:-
GBM	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-4.11	7.45e-05	0.0446	-0.52	-0.36	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
GBM	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-4.11	7.45e-05	0.0446	-0.52	-0.36	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-4.11	7.45e-05	0.0446	-0.52	-0.36	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-4.11	7.45e-05	0.0446	-0.52	-0.36	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
GBM	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-4.11	7.45e-05	0.0446	-0.52	-0.36	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
GBM	cis	rs1555322	0.932	rs6119593	ENSG00000126005.14	MMP24-AS1	-4.11	7.45e-05	0.0446	-0.61	-0.36	Attention deficit hyperactivity disorder;	chr20:35245926	chr20:35216462~35278131:-
GBM	cis	rs1555322	0.932	rs6060321	ENSG00000126005.14	MMP24-AS1	-4.11	7.45e-05	0.0446	-0.61	-0.36	Attention deficit hyperactivity disorder;	chr20:35245978	chr20:35216462~35278131:-
GBM	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	4.11	7.45e-05	0.0446	0.39	0.36	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	4.11	7.45e-05	0.0446	0.39	0.36	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	4.11	7.45e-05	0.0446	0.39	0.36	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
GBM	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	4.11	7.46e-05	0.0446	0.42	0.36	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
GBM	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-4.11	7.46e-05	0.0446	-0.49	-0.36	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
GBM	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-4.11	7.46e-05	0.0446	-0.49	-0.36	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
GBM	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	4.11	7.46e-05	0.0446	0.46	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
GBM	cis	rs2115630	0.967	rs7171167	ENSG00000225151.9	GOLGA2P7	4.11	7.46e-05	0.0446	0.38	0.36	P wave terminal force;	chr15:84695892	chr15:84199311~84230136:-
GBM	cis	rs3096299	0.685	rs4785571	ENSG00000260259.1	RP11-368I7.4	4.11	7.47e-05	0.0447	0.38	0.36	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89682620~89686569:-
GBM	cis	rs7869524	0.578	rs10970464	ENSG00000231808.2	LINC01388	-4.11	7.48e-05	0.0447	-0.42	-0.36	Mean platelet volume;	chr9:326400	chr9:112713~113754:-
GBM	cis	rs6598955	0.95	rs6700455	ENSG00000236782.4	RP11-96L14.7	4.11	7.48e-05	0.0447	0.42	0.36	Obesity-related traits;	chr1:26219373	chr1:26169947~26171821:-
GBM	cis	rs7831492	0.548	rs10958699	ENSG00000253133.1	RP11-360L9.4	4.11	7.48e-05	0.0447	0.51	0.36	Colorectal cancer;	chr8:41790840	chr8:41534155~41578368:-
GBM	cis	rs2287838	0.716	rs7254559	ENSG00000267289.1	CTD-2623N2.11	-4.11	7.48e-05	0.0447	-0.45	-0.36	Sleep duration;	chr19:9892443	chr19:9834079~9835013:-
GBM	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-4.11	7.49e-05	0.0448	-0.3	-0.36	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
GBM	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	4.11	7.49e-05	0.0448	0.39	0.36	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
GBM	cis	rs3768617	0.51	rs7518957	ENSG00000224468.3	RP11-181K3.4	4.11	7.49e-05	0.0448	0.3	0.36	Fuchs's corneal dystrophy;	chr1:183123893	chr1:183138402~183141282:-
GBM	cis	rs3808502	0.563	rs10098664	ENSG00000255556.2	RP11-351I21.6	4.11	7.49e-05	0.0448	0.38	0.36	Neuroticism;	chr8:11559984	chr8:12378679~12380265:-
GBM	cis	rs2282300	0.739	rs1765133	ENSG00000254532.1	RP11-624D11.2	4.11	7.49e-05	0.0448	0.48	0.36	Morning vs. evening chronotype;	chr11:30317853	chr11:30044058~30084343:-
GBM	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-4.11	7.5e-05	0.0448	-0.4	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
GBM	cis	rs10246939	0.543	rs11765575	ENSG00000261797.1	RP11-744I24.3	-4.11	7.51e-05	0.0448	-0.45	-0.36	Bitter taste perception;	chr7:141838168	chr7:141512698~141513183:-
GBM	cis	rs858239	0.699	rs1881201	ENSG00000230042.1	AK3P3	4.11	7.51e-05	0.0448	0.39	0.36	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23129178~23129841:+
GBM	cis	rs3809912	0.509	rs4499304	ENSG00000280302.1	RP11-64C12.1	-4.11	7.51e-05	0.0449	-0.42	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:13001513	chr18:12279427~12282739:+
GBM	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	4.11	7.51e-05	0.0449	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
GBM	cis	rs4713118	0.513	rs149972	ENSG00000218016.2	ZNF192P2	-4.11	7.52e-05	0.0449	-0.51	-0.36	Parkinson's disease;	chr6:28015449	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149975	ENSG00000218016.2	ZNF192P2	-4.11	7.52e-05	0.0449	-0.51	-0.36	Parkinson's disease;	chr6:28018562	chr6:28188050~28189432:+
GBM	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-4.11	7.52e-05	0.0449	-0.4	-0.36	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-4.11	7.52e-05	0.0449	-0.4	-0.36	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-4.11	7.52e-05	0.0449	-0.4	-0.36	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
GBM	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	4.11	7.52e-05	0.0449	0.34	0.36	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	4.11	7.52e-05	0.0449	0.34	0.36	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	4.11	7.52e-05	0.0449	0.34	0.36	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	4.11	7.52e-05	0.0449	0.34	0.36	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	4.11	7.52e-05	0.0449	0.34	0.36	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	4.11	7.52e-05	0.0449	0.34	0.36	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	4.11	7.52e-05	0.0449	0.34	0.36	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.818	rs6764681	ENSG00000231305.3	RP11-723O4.2	-4.11	7.53e-05	0.0449	-0.37	-0.36	IgG glycosylation;	chr3:128849537	chr3:128861313~128871540:-
GBM	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	4.11	7.53e-05	0.0449	0.54	0.36	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
GBM	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-4.11	7.53e-05	0.0449	-0.4	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
GBM	cis	rs4072705	0.615	rs4838189	ENSG00000224020.1	MIR181A2HG	-4.11	7.53e-05	0.045	-0.41	-0.36	Menarche (age at onset);	chr9:124486647	chr9:124658467~124698631:+
GBM	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-4.11	7.54e-05	0.045	-0.4	-0.36	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-4.11	7.54e-05	0.045	-0.4	-0.36	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
GBM	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-4.11	7.54e-05	0.045	-0.51	-0.36	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
GBM	cis	rs7605378	0.528	rs281791	ENSG00000232732.8	AC073043.1	4.11	7.55e-05	0.045	0.46	0.36	Osteoporosis;	chr2:199985679	chr2:199867396~199911159:-
GBM	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	4.11	7.55e-05	0.045	0.59	0.36	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
GBM	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	4.11	7.55e-05	0.045	0.59	0.36	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
GBM	cis	rs16937	0.711	rs6682229	ENSG00000271580.1	RP11-536L3.4	-4.11	7.55e-05	0.045	-0.32	-0.36	Schizophrenia;	chr1:205183804	chr1:205091163~205091946:+
GBM	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	4.11	7.55e-05	0.045	0.46	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
GBM	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	4.11	7.55e-05	0.045	0.46	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
GBM	cis	rs7176527	1	rs3762169	ENSG00000225151.9	GOLGA2P7	4.11	7.55e-05	0.045	0.53	0.36	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84199311~84230136:-
GBM	cis	rs17685	0.593	rs56265719	ENSG00000127957.15	PMS2P3	-4.11	7.56e-05	0.0451	-0.42	-0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:75502930~75528148:-
GBM	cis	rs875971	0.895	rs12531677	ENSG00000236529.1	RP13-254B10.1	-4.11	7.56e-05	0.0451	-0.37	-0.36	Aortic root size;	chr7:66304099	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs7798630	ENSG00000236529.1	RP13-254B10.1	-4.11	7.56e-05	0.0451	-0.37	-0.36	Aortic root size;	chr7:66306492	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs11984115	ENSG00000236529.1	RP13-254B10.1	-4.11	7.56e-05	0.0451	-0.37	-0.36	Aortic root size;	chr7:66308872	chr7:65840212~65840596:+
GBM	cis	rs875971	0.755	rs10228885	ENSG00000236529.1	RP13-254B10.1	-4.11	7.56e-05	0.0451	-0.37	-0.36	Aortic root size;	chr7:66315542	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6958294	ENSG00000236529.1	RP13-254B10.1	-4.11	7.56e-05	0.0451	-0.37	-0.36	Aortic root size;	chr7:66329809	chr7:65840212~65840596:+
GBM	cis	rs7312933	0.558	rs1796381	ENSG00000257225.1	RP11-328C8.4	-4.11	7.56e-05	0.0451	-0.4	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42448673	chr12:42459366~42466128:+
GBM	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	4.11	7.56e-05	0.0451	0.39	0.36	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
GBM	cis	rs17772222	0.74	rs10143744	ENSG00000222990.1	RNU4-22P	4.11	7.57e-05	0.0451	0.37	0.36	Coronary artery calcification;	chr14:88508073	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs1999177	ENSG00000222990.1	RNU4-22P	4.11	7.57e-05	0.0451	0.37	0.36	Coronary artery calcification;	chr14:88508298	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs1999176	ENSG00000222990.1	RNU4-22P	4.11	7.57e-05	0.0451	0.37	0.36	Coronary artery calcification;	chr14:88508371	chr14:88513498~88513663:+
GBM	cis	rs17772222	0.74	rs1864747	ENSG00000222990.1	RNU4-22P	4.11	7.57e-05	0.0451	0.37	0.36	Coronary artery calcification;	chr14:88508523	chr14:88513498~88513663:+
GBM	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-4.11	7.57e-05	0.0451	-0.4	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
GBM	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-4.11	7.57e-05	0.0451	-0.4	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
GBM	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
GBM	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	4.11	7.57e-05	0.0451	0.44	0.36	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
GBM	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-4.11	7.57e-05	0.0451	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
GBM	cis	rs7034139	0.956	rs62569716	ENSG00000259953.1	RP11-4O1.2	-4.11	7.58e-05	0.0451	-0.54	-0.36	Myeloid white cell count;	chr9:111155393	chr9:112032555~112037730:-
GBM	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-4.11	7.58e-05	0.0452	-0.41	-0.36	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
GBM	cis	rs1153858	1	rs2467864	ENSG00000259433.2	CTD-2651B20.4	4.11	7.58e-05	0.0452	0.42	0.36	Homoarginine levels;	chr15:45348900	chr15:45330209~45332634:-
GBM	cis	rs10050311	0.8	rs2230600	ENSG00000261496.1	RP13-514E23.1	4.11	7.58e-05	0.0452	0.59	0.36	Insulin-related traits;	chr4:86769845	chr4:86012296~86013874:-
GBM	cis	rs28599928	0.502	rs926350	ENSG00000227370.1	RP4-669P10.19	4.11	7.58e-05	0.0452	0.39	0.36	Breast cancer;	chr22:43075942	chr22:42132543~42132998:+
GBM	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-4.11	7.59e-05	0.0452	-0.55	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
GBM	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	4.11	7.59e-05	0.0452	0.48	0.36	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
GBM	cis	rs7312933	0.558	rs2178753	ENSG00000257225.1	RP11-328C8.4	4.11	7.59e-05	0.0452	0.4	0.36	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42339002	chr12:42459366~42466128:+
GBM	cis	rs7312933	0.558	rs7965743	ENSG00000257225.1	RP11-328C8.4	4.11	7.59e-05	0.0452	0.4	0.36	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42343020	chr12:42459366~42466128:+
GBM	cis	rs7312933	0.558	rs4768399	ENSG00000257225.1	RP11-328C8.4	4.11	7.59e-05	0.0452	0.4	0.36	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42348894	chr12:42459366~42466128:+
GBM	cis	rs7312933	0.566	rs11181454	ENSG00000257225.1	RP11-328C8.4	4.11	7.59e-05	0.0452	0.4	0.36	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42352684	chr12:42459366~42466128:+
GBM	cis	rs3806843	0.676	rs778593	ENSG00000202111.1	VTRNA1-2	4.1	7.6e-05	0.0452	0.37	0.36	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.676	rs778594	ENSG00000202111.1	VTRNA1-2	4.1	7.6e-05	0.0452	0.37	0.36	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr5:140718925~140719013:+
GBM	cis	rs3806843	0.619	rs2569160	ENSG00000202111.1	VTRNA1-2	4.1	7.6e-05	0.0452	0.37	0.36	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr5:140718925~140719013:+
GBM	cis	rs5752326	1	rs5761530	ENSG00000261188.1	CTA-445C9.14	4.1	7.6e-05	0.0452	0.55	0.36	Ischemic stroke;	chr22:26447950	chr22:26512537~26514568:+
GBM	cis	rs5752326	0.867	rs5761531	ENSG00000261188.1	CTA-445C9.14	4.1	7.6e-05	0.0452	0.55	0.36	Ischemic stroke;	chr22:26448180	chr22:26512537~26514568:+
GBM	cis	rs753955	0.962	rs2861539	ENSG00000205861.10	C1QTNF9B-AS1	-4.1	7.61e-05	0.0453	-0.47	-0.36	Lung cancer;	chr13:23715644	chr13:23888889~23897263:+
GBM	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	4.1	7.61e-05	0.0453	0.39	0.36	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
GBM	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	4.1	7.61e-05	0.0453	0.39	0.36	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
GBM	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
GBM	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-4.1	7.61e-05	0.0453	-0.5	-0.36	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
GBM	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	4.1	7.61e-05	0.0453	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
GBM	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-4.1	7.62e-05	0.0453	-0.42	-0.36	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	4.1	7.62e-05	0.0453	0.42	0.36	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	4.1	7.62e-05	0.0453	0.42	0.36	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	4.1	7.62e-05	0.0453	0.42	0.36	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	4.1	7.62e-05	0.0453	0.42	0.36	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	4.1	7.62e-05	0.0453	0.42	0.36	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
GBM	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-4.1	7.62e-05	0.0453	-0.41	-0.36	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
GBM	cis	rs7017914	0.549	rs3098863	ENSG00000246366.5	RP11-382J12.1	-4.1	7.62e-05	0.0453	-0.38	-0.36	Bone mineral density;	chr8:70965931	chr8:70608577~70663279:+
GBM	cis	rs59104589	0.617	rs62186409	ENSG00000235351.1	AC114730.11	-4.1	7.62e-05	0.0453	-0.32	-0.36	Fibrinogen levels;	chr2:241296295	chr2:241724615~241725693:-
GBM	cis	rs7726839	0.561	rs3915384	ENSG00000260774.1	CTD-2083E4.4	4.1	7.62e-05	0.0453	0.49	0.36	Obesity-related traits;	chr5:573280	chr5:213898~217279:-
GBM	cis	rs2025751	0.692	rs1326602	ENSG00000230204.1	FTH1P5	-4.1	7.62e-05	0.0453	-0.42	-0.36	Intraocular pressure;	chr6:51828938	chr6:50912712~50913256:-
GBM	cis	rs875971	0.545	rs66594357	ENSG00000222364.1	RNU6-96P	-4.1	7.63e-05	0.0453	-0.41	-0.36	Aortic root size;	chr7:66327797	chr7:66395191~66395286:+
GBM	cis	rs832187	0.615	rs9865811	ENSG00000280620.1	SCAANT1	4.1	7.63e-05	0.0453	0.49	0.36	Schizophrenia;	chr3:64008829	chr3:63911518~63911772:-
GBM	cis	rs832187	0.615	rs2037119	ENSG00000280620.1	SCAANT1	4.1	7.63e-05	0.0453	0.49	0.36	Schizophrenia;	chr3:64009203	chr3:63911518~63911772:-
GBM	cis	rs832187	0.615	rs9875198	ENSG00000280620.1	SCAANT1	4.1	7.63e-05	0.0453	0.49	0.36	Schizophrenia;	chr3:64010239	chr3:63911518~63911772:-
GBM	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-4.1	7.64e-05	0.0454	-0.39	-0.36	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	4.1	7.64e-05	0.0454	0.39	0.36	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	4.1	7.64e-05	0.0454	0.39	0.36	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	4.1	7.64e-05	0.0454	0.39	0.36	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	4.1	7.64e-05	0.0454	0.39	0.36	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	4.1	7.64e-05	0.0454	0.39	0.36	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
GBM	cis	rs9659323	0.689	rs10923716	ENSG00000231365.4	RP11-418J17.1	-4.1	7.65e-05	0.0454	-0.43	-0.36	Body mass index;	chr1:118993496	chr1:119140396~119275973:+
GBM	cis	rs9659323	0.717	rs61806238	ENSG00000231365.4	RP11-418J17.1	-4.1	7.65e-05	0.0454	-0.43	-0.36	Body mass index;	chr1:118993755	chr1:119140396~119275973:+
GBM	cis	rs2018683	1	rs4719963	ENSG00000228421.2	AC005013.5	-4.1	7.65e-05	0.0454	-0.39	-0.36	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28957667~28959345:+
GBM	cis	rs4834770	1	rs878374	ENSG00000249244.1	RP11-548H18.2	4.1	7.65e-05	0.0454	0.45	0.36	Blood protein levels;	chr4:119316409	chr4:119391831~119395335:-
GBM	cis	rs7083	1	rs507880	ENSG00000254851.1	RP11-109L13.1	4.1	7.65e-05	0.0455	0.5	0.36	Blood protein levels;	chr11:117266539	chr11:117135528~117138582:+
GBM	cis	rs36715	0.953	rs36700	ENSG00000245937.6	LINC01184	4.1	7.65e-05	0.0455	0.38	0.36	Breast cancer;	chr5:128215581	chr5:127940426~128083172:-
GBM	cis	rs36715	0.909	rs152906	ENSG00000245937.6	LINC01184	4.1	7.65e-05	0.0455	0.38	0.36	Breast cancer;	chr5:128216148	chr5:127940426~128083172:-
GBM	cis	rs36715	1	rs36705	ENSG00000245937.6	LINC01184	4.1	7.65e-05	0.0455	0.38	0.36	Breast cancer;	chr5:128218794	chr5:127940426~128083172:-
GBM	cis	rs4842666	0.915	rs11105368	ENSG00000258302.2	RP11-981P6.1	4.1	7.66e-05	0.0455	0.44	0.36	Blood pressure;	chr12:89680664	chr12:89561129~89594878:+
GBM	cis	rs4842666	0.765	rs4842675	ENSG00000258302.2	RP11-981P6.1	4.1	7.66e-05	0.0455	0.44	0.36	Blood pressure;	chr12:89681466	chr12:89561129~89594878:+
GBM	cis	rs2025751	0.512	rs12194557	ENSG00000230204.1	FTH1P5	-4.1	7.66e-05	0.0455	-0.4	-0.36	Intraocular pressure;	chr6:51831470	chr6:50912712~50913256:-
GBM	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	4.1	7.67e-05	0.0455	0.44	0.36	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
GBM	cis	rs1816537	0.625	rs7112548	ENSG00000214264.4	KCTD9P4	4.1	7.67e-05	0.0456	0.39	0.36	Body mass index;	chr11:113136138	chr11:112180773~112183191:+
GBM	cis	rs1420956	0.624	rs16943751	ENSG00000264151.4	RP11-739N10.1	4.1	7.68e-05	0.0456	0.47	0.36	Obesity-related traits;	chr18:27568961	chr18:27336379~27595164:-
GBM	cis	rs2436845	0.627	rs1055376	ENSG00000253320.4	KB-1507C5.2	-4.1	7.68e-05	0.0456	-0.4	-0.36	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102865206	chr8:102864300~102977876:+
GBM	cis	rs7208859	0.614	rs4794874	ENSG00000264538.5	SUZ12P1	4.1	7.68e-05	0.0456	0.43	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30709299~30790908:+
GBM	cis	rs3753275	0.568	rs7533113	ENSG00000230679.1	ENO1-AS1	4.1	7.68e-05	0.0456	0.42	0.36	Educational attainment;	chr1:8753184	chr1:8878835~8879894:+
GBM	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-4.1	7.68e-05	0.0456	-0.37	-0.36	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
GBM	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-4.1	7.68e-05	0.0456	-0.42	-0.36	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-4.1	7.68e-05	0.0456	-0.42	-0.36	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-4.1	7.68e-05	0.0456	-0.42	-0.36	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-4.1	7.68e-05	0.0456	-0.42	-0.36	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
GBM	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-4.1	7.68e-05	0.0456	-0.42	-0.36	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
GBM	cis	rs875971	0.825	rs4587224	ENSG00000236529.1	RP13-254B10.1	-4.1	7.68e-05	0.0456	-0.37	-0.36	Aortic root size;	chr7:66271195	chr7:65840212~65840596:+
GBM	cis	rs875971	0.792	rs6971752	ENSG00000236529.1	RP13-254B10.1	-4.1	7.68e-05	0.0456	-0.37	-0.36	Aortic root size;	chr7:66272999	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10950033	ENSG00000236529.1	RP13-254B10.1	-4.1	7.68e-05	0.0456	-0.37	-0.36	Aortic root size;	chr7:66274686	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs11760844	ENSG00000236529.1	RP13-254B10.1	-4.1	7.68e-05	0.0456	-0.37	-0.36	Aortic root size;	chr7:66274896	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs949930	ENSG00000236529.1	RP13-254B10.1	-4.1	7.68e-05	0.0456	-0.37	-0.36	Aortic root size;	chr7:66301835	chr7:65840212~65840596:+
GBM	cis	rs1816537	0.573	rs7932647	ENSG00000214264.4	KCTD9P4	4.1	7.69e-05	0.0456	0.39	0.36	Body mass index;	chr11:113130588	chr11:112180773~112183191:+
GBM	cis	rs4713118	0.869	rs9348775	ENSG00000218016.2	ZNF192P2	-4.1	7.69e-05	0.0456	-0.48	-0.36	Parkinson's disease;	chr6:27727550	chr6:28188050~28189432:+
GBM	cis	rs875971	0.545	rs75840613	ENSG00000236529.1	RP13-254B10.1	4.1	7.7e-05	0.0457	0.39	0.36	Aortic root size;	chr7:66376399	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs73148639	ENSG00000236529.1	RP13-254B10.1	4.1	7.7e-05	0.0457	0.39	0.36	Aortic root size;	chr7:66390342	chr7:65840212~65840596:+
GBM	cis	rs1153858	1	rs2668747	ENSG00000259433.2	CTD-2651B20.4	-4.1	7.7e-05	0.0457	-0.43	-0.36	Homoarginine levels;	chr15:45325018	chr15:45330209~45332634:-
GBM	cis	rs17723470	0.513	rs2902426	ENSG00000254427.1	RP11-430H10.1	4.1	7.7e-05	0.0457	0.44	0.36	Thyroid hormone levels;	chr11:45207548	chr11:45355371~45366121:+
GBM	cis	rs17772222	0.74	rs1864746	ENSG00000222990.1	RNU4-22P	4.1	7.7e-05	0.0457	0.37	0.36	Coronary artery calcification;	chr14:88508455	chr14:88513498~88513663:+
GBM	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-4.1	7.7e-05	0.0457	-0.45	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
GBM	cis	rs7674212	0.507	rs223331	ENSG00000248971.2	KRT8P46	-4.1	7.7e-05	0.0457	-0.39	-0.36	Type 2 diabetes;	chr4:102872408	chr4:102728746~102730171:-
GBM	cis	rs6600671	0.967	rs4844613	ENSG00000223345.3	HIST2H2BA	4.1	7.71e-05	0.0457	0.47	0.36	Hip geometry;	chr1:121431913	chr1:121108210~121117257:-
GBM	cis	rs4427176	0.714	rs4560795	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9605738	chr8:8933721~8934006:-
GBM	cis	rs4427176	0.714	rs28464158	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9606262	chr8:8933721~8934006:-
GBM	cis	rs4427176	0.714	rs28437757	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9606295	chr8:8933721~8934006:-
GBM	cis	rs4427176	0.714	rs28615758	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9606428	chr8:8933721~8934006:-
GBM	cis	rs4427176	0.714	rs62493913	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9606799	chr8:8933721~8934006:-
GBM	cis	rs4427176	0.714	rs10104247	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9607676	chr8:8933721~8934006:-
GBM	cis	rs4427176	0.714	rs4562329	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9608642	chr8:8933721~8934006:-
GBM	cis	rs4427176	0.714	rs4265191	ENSG00000270966.1	RP11-62H7.3	4.1	7.71e-05	0.0457	0.71	0.36	Mosquito bite size;	chr8:9608875	chr8:8933721~8934006:-
GBM	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-4.1	7.72e-05	0.0458	-0.4	-0.36	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
GBM	cis	rs56114371	0.53	rs2056923	ENSG00000219392.1	RP1-265C24.5	-4.1	7.72e-05	0.0458	-0.5	-0.36	Breast cancer;	chr6:27722160	chr6:28115628~28116551:+
GBM	cis	rs453301	0.606	rs7462373	ENSG00000254340.1	RP11-10A14.3	-4.1	7.72e-05	0.0458	-0.45	-0.36	Joint mobility (Beighton score);	chr8:9041808	chr8:9141424~9145435:+
GBM	cis	rs1298062	0.535	rs2463240	ENSG00000131401.10	NAPSB	-4.1	7.72e-05	0.0458	-0.44	-0.36	Age of smoking initiation;	chr19:50438648	chr19:50333796~50344767:-
GBM	cis	rs9450351	0.744	rs6906618	ENSG00000203875.9	SNHG5	-4.1	7.74e-05	0.0458	-0.92	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85741719	chr6:85660950~85678736:-
GBM	cis	rs4642101	0.765	rs1985428	ENSG00000213943.3	KRT18P17	-4.1	7.74e-05	0.0459	-0.38	-0.36	QRS complex (12-leadsum);	chr3:12787816	chr3:12787393~12788671:-
GBM	cis	rs8062405	0.755	rs1074631	ENSG00000271623.1	RP11-435I10.5	4.1	7.75e-05	0.0459	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28364700~28365333:+
GBM	cis	rs36715	0.953	rs2546146	ENSG00000245937.6	LINC01184	4.1	7.75e-05	0.0459	0.38	0.36	Breast cancer;	chr5:128210847	chr5:127940426~128083172:-
GBM	cis	rs36715	0.868	rs251387	ENSG00000245937.6	LINC01184	4.1	7.75e-05	0.0459	0.38	0.36	Breast cancer;	chr5:128211488	chr5:127940426~128083172:-
GBM	cis	rs3742264	0.961	rs11620308	ENSG00000235903.6	CPB2-AS1	-4.1	7.75e-05	0.0459	-0.44	-0.36	Blood protein levels;	chr13:46075588	chr13:46052806~46113332:+
GBM	cis	rs4664293	0.867	rs6432553	ENSG00000226266.5	AC009961.3	-4.1	7.75e-05	0.0459	-0.45	-0.36	Monocyte percentage of white cells;	chr2:159720499	chr2:159670708~159712435:-
GBM	cis	rs57221529	0.766	rs1399381	ENSG00000260774.1	CTD-2083E4.4	4.1	7.75e-05	0.0459	0.49	0.36	Lung disease severity in cystic fibrosis;	chr5:589738	chr5:213898~217279:-
GBM	cis	rs57221529	0.766	rs72703070	ENSG00000260774.1	CTD-2083E4.4	4.1	7.75e-05	0.0459	0.49	0.36	Lung disease severity in cystic fibrosis;	chr5:590343	chr5:213898~217279:-
GBM	cis	rs57221529	0.713	rs72703072	ENSG00000260774.1	CTD-2083E4.4	4.1	7.75e-05	0.0459	0.49	0.36	Lung disease severity in cystic fibrosis;	chr5:590511	chr5:213898~217279:-
GBM	cis	rs57221529	0.713	rs12521091	ENSG00000260774.1	CTD-2083E4.4	4.1	7.75e-05	0.0459	0.49	0.36	Lung disease severity in cystic fibrosis;	chr5:590595	chr5:213898~217279:-
GBM	cis	rs57221529	0.713	rs12522724	ENSG00000260774.1	CTD-2083E4.4	4.1	7.75e-05	0.0459	0.49	0.36	Lung disease severity in cystic fibrosis;	chr5:590627	chr5:213898~217279:-
GBM	cis	rs57221529	0.713	rs56328416	ENSG00000260774.1	CTD-2083E4.4	4.1	7.75e-05	0.0459	0.49	0.36	Lung disease severity in cystic fibrosis;	chr5:591023	chr5:213898~217279:-
GBM	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-4.1	7.76e-05	0.0459	-0.43	-0.36	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
GBM	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-4.1	7.76e-05	0.0459	-0.43	-0.36	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
GBM	cis	rs150992	0.631	rs79399563	ENSG00000248489.1	CTD-2007H13.3	4.1	7.76e-05	0.0459	0.39	0.36	Body mass index;	chr5:98993275	chr5:98929171~98995013:+
GBM	cis	rs10911251	0.527	rs1537520	ENSG00000224468.3	RP11-181K3.4	-4.1	7.76e-05	0.0459	-0.3	-0.36	Colorectal cancer;	chr1:183115094	chr1:183138402~183141282:-
GBM	cis	rs9303029	0.611	rs9909476	ENSG00000279744.1	RP13-20L14.10	4.1	7.77e-05	0.046	0.33	0.36	Protein quantitative trait loci;	chr17:82481857	chr17:82462601~82464255:+
GBM	cis	rs3845817	0.966	rs13028180	ENSG00000237979.1	AC007389.1	-4.1	7.77e-05	0.046	-0.52	-0.36	Bipolar disorder;	chr2:65536906	chr2:65500993~65502138:-
GBM	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	4.1	7.77e-05	0.046	0.62	0.36	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
GBM	cis	rs6558530	0.666	rs11136422	ENSG00000253982.1	CTD-2336O2.1	4.1	7.77e-05	0.046	0.5	0.36	Systolic blood pressure;	chr8:1747743	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.666	rs28376731	ENSG00000253982.1	CTD-2336O2.1	4.1	7.77e-05	0.046	0.5	0.36	Systolic blood pressure;	chr8:1748086	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.666	rs6558518	ENSG00000253982.1	CTD-2336O2.1	4.1	7.77e-05	0.046	0.5	0.36	Systolic blood pressure;	chr8:1749143	chr8:1761990~1764502:-
GBM	cis	rs6558530	0.666	rs6558520	ENSG00000253982.1	CTD-2336O2.1	4.1	7.77e-05	0.046	0.5	0.36	Systolic blood pressure;	chr8:1749407	chr8:1761990~1764502:-
GBM	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	4.1	7.78e-05	0.046	0.42	0.36	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
GBM	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	4.1	7.78e-05	0.046	0.47	0.36	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
GBM	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	4.1	7.78e-05	0.046	0.39	0.36	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	4.1	7.78e-05	0.046	0.39	0.36	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	4.1	7.78e-05	0.046	0.39	0.36	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
GBM	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	4.1	7.78e-05	0.046	0.39	0.36	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	4.1	7.78e-05	0.046	0.39	0.36	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
GBM	cis	rs3845817	1	rs3845816	ENSG00000237979.1	AC007389.1	-4.1	7.79e-05	0.0461	-0.52	-0.36	Bipolar disorder;	chr2:65531221	chr2:65500993~65502138:-
GBM	cis	rs453301	0.571	rs2929456	ENSG00000254340.1	RP11-10A14.3	-4.1	7.79e-05	0.0461	-0.43	-0.36	Joint mobility (Beighton score);	chr8:9225906	chr8:9141424~9145435:+
GBM	cis	rs453301	0.571	rs2929454	ENSG00000254340.1	RP11-10A14.3	-4.1	7.79e-05	0.0461	-0.43	-0.36	Joint mobility (Beighton score);	chr8:9226344	chr8:9141424~9145435:+
GBM	cis	rs875971	0.825	rs28480509	ENSG00000236529.1	RP13-254B10.1	-4.1	7.79e-05	0.0461	-0.38	-0.36	Aortic root size;	chr7:66634237	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs9791712	ENSG00000236529.1	RP13-254B10.1	-4.1	7.79e-05	0.0461	-0.38	-0.36	Aortic root size;	chr7:66640176	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs9791713	ENSG00000236529.1	RP13-254B10.1	-4.1	7.79e-05	0.0461	-0.38	-0.36	Aortic root size;	chr7:66640211	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs1860469	ENSG00000236529.1	RP13-254B10.1	-4.1	7.79e-05	0.0461	-0.38	-0.36	Aortic root size;	chr7:66641888	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs4718383	ENSG00000236529.1	RP13-254B10.1	-4.1	7.79e-05	0.0461	-0.38	-0.36	Aortic root size;	chr7:66643422	chr7:65840212~65840596:+
GBM	cis	rs12922040	0.607	rs11641649	ENSG00000279866.1	CTB-193M12.4	4.1	7.79e-05	0.0461	0.44	0.36	Serum uric acid levels in response to allopurinol in gout;	chr16:15773707	chr16:15704410~15705984:+
GBM	cis	rs761746	0.543	rs5998122	ENSG00000240591.1	RP11-247I13.11	4.1	7.79e-05	0.0461	0.37	0.36	Intelligence;	chr22:31777067	chr22:31454251~31464204:+
GBM	cis	rs761746	0.579	rs5998126	ENSG00000240591.1	RP11-247I13.11	4.1	7.79e-05	0.0461	0.37	0.36	Intelligence;	chr22:31782416	chr22:31454251~31464204:+
GBM	cis	rs761746	0.614	rs2108108	ENSG00000240591.1	RP11-247I13.11	4.1	7.79e-05	0.0461	0.37	0.36	Intelligence;	chr22:31785951	chr22:31454251~31464204:+
GBM	cis	rs761746	0.614	rs8141214	ENSG00000240591.1	RP11-247I13.11	4.1	7.79e-05	0.0461	0.37	0.36	Intelligence;	chr22:31800195	chr22:31454251~31464204:+
GBM	cis	rs595244	0.908	rs2015637	ENSG00000259705.1	RP11-227D13.1	4.1	7.8e-05	0.0461	0.62	0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48424656	chr15:48645951~48652016:+
GBM	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-4.1	7.8e-05	0.0461	-0.43	-0.36	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
GBM	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	4.1	7.8e-05	0.0461	0.3	0.36	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
GBM	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	4.1	7.8e-05	0.0461	0.44	0.36	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
GBM	cis	rs4604732	0.631	rs4411161	ENSG00000227135.1	GCSAML-AS1	-4.1	7.8e-05	0.0461	-0.54	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469072	chr1:247524679~247526752:-
GBM	cis	rs17772222	0.917	rs11159868	ENSG00000222990.1	RNU4-22P	4.1	7.8e-05	0.0461	0.43	0.36	Coronary artery calcification;	chr14:88760528	chr14:88513498~88513663:+
GBM	cis	rs3806843	0.735	rs778597	ENSG00000202111.1	VTRNA1-2	-4.1	7.8e-05	0.0461	-0.37	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr5:140718925~140719013:+
GBM	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-4.1	7.81e-05	0.0461	-0.48	-0.36	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
GBM	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	4.1	7.81e-05	0.0461	0.41	0.36	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
GBM	cis	rs6600671	1	rs1591882	ENSG00000223345.3	HIST2H2BA	4.1	7.81e-05	0.0461	0.47	0.36	Hip geometry;	chr1:121441455	chr1:121108210~121117257:-
GBM	cis	rs6600671	1	rs12047116	ENSG00000223345.3	HIST2H2BA	4.1	7.81e-05	0.0461	0.47	0.36	Hip geometry;	chr1:121443912	chr1:121108210~121117257:-
GBM	cis	rs6600671	0.967	rs11249347	ENSG00000223345.3	HIST2H2BA	4.1	7.81e-05	0.0461	0.47	0.36	Hip geometry;	chr1:121446489	chr1:121108210~121117257:-
GBM	cis	rs748404	0.601	rs530118	ENSG00000249839.1	AC011330.5	4.1	7.81e-05	0.0462	0.44	0.36	Lung cancer;	chr15:43186313	chr15:43663654~43684339:-
GBM	cis	rs853679	0.76	rs9468317	ENSG00000204789.4	ZNF204P	4.1	7.81e-05	0.0462	0.64	0.36	Depression;	chr6:28230678	chr6:27357825~27360221:-
GBM	cis	rs853679	0.723	rs9366718	ENSG00000204789.4	ZNF204P	4.1	7.81e-05	0.0462	0.64	0.36	Depression;	chr6:28237724	chr6:27357825~27360221:-
GBM	cis	rs853679	0.76	rs9393910	ENSG00000204789.4	ZNF204P	4.1	7.81e-05	0.0462	0.64	0.36	Depression;	chr6:28240414	chr6:27357825~27360221:-
GBM	cis	rs853679	0.76	rs9368563	ENSG00000204789.4	ZNF204P	4.1	7.81e-05	0.0462	0.64	0.36	Depression;	chr6:28240780	chr6:27357825~27360221:-
GBM	cis	rs853679	0.76	rs9295768	ENSG00000204789.4	ZNF204P	4.1	7.81e-05	0.0462	0.64	0.36	Depression;	chr6:28241324	chr6:27357825~27360221:-
GBM	cis	rs853679	0.699	rs9468318	ENSG00000204789.4	ZNF204P	4.1	7.81e-05	0.0462	0.64	0.36	Depression;	chr6:28241753	chr6:27357825~27360221:-
GBM	cis	rs2069426	1	rs17694572	ENSG00000240498.5	CDKN2B-AS1	-4.1	7.81e-05	0.0462	-0.63	-0.36	Acute lymphoblastic leukemia (childhood);	chr9:22054357	chr9:21994778~22121097:+
GBM	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	4.1	7.81e-05	0.0462	0.39	0.36	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
GBM	cis	rs172166	0.543	rs1150691	ENSG00000218016.2	ZNF192P2	-4.1	7.82e-05	0.0462	-0.44	-0.36	Cardiac Troponin-T levels;	chr6:28200255	chr6:28188050~28189432:+
GBM	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	4.1	7.82e-05	0.0462	0.59	0.36	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
GBM	cis	rs9595908	0.965	rs8000071	ENSG00000212293.1	SNORA16	4.1	7.83e-05	0.0462	0.38	0.36	Body mass index;	chr13:32551236	chr13:32420390~32420516:-
GBM	cis	rs9595908	0.965	rs7984903	ENSG00000212293.1	SNORA16	4.1	7.83e-05	0.0462	0.38	0.36	Body mass index;	chr13:32552002	chr13:32420390~32420516:-
GBM	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-4.1	7.83e-05	0.0462	-0.48	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
GBM	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-4.1	7.83e-05	0.0463	-0.57	-0.36	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
GBM	cis	rs761746	0.579	rs5998121	ENSG00000240591.1	RP11-247I13.11	4.1	7.84e-05	0.0463	0.37	0.36	Intelligence;	chr22:31776381	chr22:31454251~31464204:+
GBM	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-4.1	7.84e-05	0.0463	-0.48	-0.36	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
GBM	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-4.1	7.85e-05	0.0463	-0.41	-0.36	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
GBM	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	4.1	7.85e-05	0.0463	0.42	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
GBM	cis	rs17772222	0.92	rs61975260	ENSG00000222990.1	RNU4-22P	4.1	7.85e-05	0.0463	0.44	0.36	Coronary artery calcification;	chr14:88429597	chr14:88513498~88513663:+
GBM	cis	rs7267979	0.714	rs1555329	ENSG00000125804.12	FAM182A	-4.1	7.85e-05	0.0463	-0.43	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:26054655~26086917:+
GBM	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-4.1	7.85e-05	0.0463	-0.56	-0.36	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
GBM	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	4.1	7.85e-05	0.0463	0.39	0.36	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
GBM	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	4.1	7.85e-05	0.0463	0.3	0.36	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
GBM	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	4.1	7.85e-05	0.0463	0.5	0.36	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
GBM	cis	rs4295623	0.585	rs13259242	ENSG00000255556.2	RP11-351I21.6	-4.1	7.86e-05	0.0464	-0.39	-0.36	Morning vs. evening chronotype;	chr8:11735524	chr8:12378679~12380265:-
GBM	cis	rs4295623	0.553	rs34962960	ENSG00000255556.2	RP11-351I21.6	-4.1	7.86e-05	0.0464	-0.39	-0.36	Morning vs. evening chronotype;	chr8:11737088	chr8:12378679~12380265:-
GBM	cis	rs812925	0.502	rs2053750	ENSG00000271889.1	RP11-493E12.1	-4.1	7.86e-05	0.0464	-0.36	-0.36	Immature fraction of reticulocytes;	chr2:61429138	chr2:61151433~61162105:-
GBM	cis	rs4664293	0.669	rs1549387	ENSG00000226266.5	AC009961.3	4.1	7.86e-05	0.0464	0.43	0.36	Monocyte percentage of white cells;	chr2:159561029	chr2:159670708~159712435:-
GBM	cis	rs4664293	0.669	rs1863219	ENSG00000226266.5	AC009961.3	4.1	7.86e-05	0.0464	0.43	0.36	Monocyte percentage of white cells;	chr2:159561660	chr2:159670708~159712435:-
GBM	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-4.1	7.87e-05	0.0464	-0.33	-0.36	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-4.1	7.87e-05	0.0464	-0.33	-0.36	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
GBM	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-4.1	7.87e-05	0.0464	-0.33	-0.36	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
GBM	cis	rs853679	0.76	rs9357067	ENSG00000216901.1	AL022393.7	4.1	7.87e-05	0.0464	0.57	0.36	Depression;	chr6:28242515	chr6:28176188~28176674:+
GBM	cis	rs853679	0.76	rs967005	ENSG00000216901.1	AL022393.7	4.1	7.87e-05	0.0464	0.57	0.36	Depression;	chr6:28242910	chr6:28176188~28176674:+
GBM	cis	rs1153858	0.945	rs2467854	ENSG00000259433.2	CTD-2651B20.4	-4.1	7.88e-05	0.0464	-0.41	-0.36	Homoarginine levels;	chr15:45409399	chr15:45330209~45332634:-
GBM	cis	rs1153858	1	rs2461701	ENSG00000259433.2	CTD-2651B20.4	-4.1	7.88e-05	0.0464	-0.41	-0.36	Homoarginine levels;	chr15:45411193	chr15:45330209~45332634:-
GBM	cis	rs1153858	1	rs2467858	ENSG00000259433.2	CTD-2651B20.4	-4.1	7.88e-05	0.0464	-0.41	-0.36	Homoarginine levels;	chr15:45419294	chr15:45330209~45332634:-
GBM	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	4.1	7.88e-05	0.0465	0.45	0.36	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
GBM	cis	rs7534016	0.901	rs11586894	ENSG00000230812.4	LINC01358	-4.09	7.89e-05	0.0465	-0.4	-0.36	Obesity-related traits;	chr1:59403819	chr1:59020387~59044614:+
GBM	cis	rs7534016	0.901	rs17119431	ENSG00000230812.4	LINC01358	-4.09	7.89e-05	0.0465	-0.4	-0.36	Obesity-related traits;	chr1:59408552	chr1:59020387~59044614:+
GBM	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-4.09	7.89e-05	0.0465	-0.48	-0.36	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
GBM	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-4.09	7.9e-05	0.0465	-0.38	-0.36	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-4.09	7.9e-05	0.0465	-0.38	-0.36	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
GBM	cis	rs7017914	0.714	rs12155783	ENSG00000246366.5	RP11-382J12.1	4.09	7.9e-05	0.0465	0.38	0.36	Bone mineral density;	chr8:71086891	chr8:70608577~70663279:+
GBM	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-4.09	7.9e-05	0.0466	-0.34	-0.36	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	4.09	7.9e-05	0.0466	0.34	0.36	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
GBM	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	4.09	7.9e-05	0.0466	0.34	0.36	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
GBM	cis	rs9393777	0.623	rs7773938	ENSG00000224843.5	LINC00240	4.09	7.9e-05	0.0466	0.56	0.36	Intelligence (multi-trait analysis);	chr6:26473816	chr6:26956992~27023924:+
GBM	cis	rs4148008	1	rs1156340	ENSG00000265100.1	RP11-147L13.2	4.09	7.9e-05	0.0466	0.28	0.36	HDL cholesterol;	chr17:68892979	chr17:68246629~68247938:-
GBM	cis	rs4148008	0.83	rs4148000	ENSG00000265100.1	RP11-147L13.2	4.09	7.9e-05	0.0466	0.28	0.36	HDL cholesterol;	chr17:68893976	chr17:68246629~68247938:-
GBM	cis	rs4148008	1	rs8065105	ENSG00000265100.1	RP11-147L13.2	4.09	7.9e-05	0.0466	0.28	0.36	HDL cholesterol;	chr17:68897031	chr17:68246629~68247938:-
GBM	cis	rs17214007	0.735	rs8045778	ENSG00000279866.1	CTB-193M12.4	-4.09	7.91e-05	0.0466	-0.43	-0.36	Cognitive function;	chr16:15784395	chr16:15704410~15705984:+
GBM	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-4.09	7.91e-05	0.0466	-0.41	-0.36	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-4.09	7.91e-05	0.0466	-0.41	-0.36	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-4.09	7.91e-05	0.0466	-0.41	-0.36	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-4.09	7.91e-05	0.0466	-0.41	-0.36	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
GBM	cis	rs66887589	0.934	rs41464847	ENSG00000249244.1	RP11-548H18.2	-4.09	7.91e-05	0.0466	-0.42	-0.36	Diastolic blood pressure;	chr4:119611246	chr4:119391831~119395335:-
GBM	cis	rs17361889	0.514	rs10251171	ENSG00000224683.1	RPL36AP29	4.09	7.91e-05	0.0466	0.47	0.36	Pediatric bone mineral content (hip);	chr7:16353495	chr7:16208945~16209265:+
GBM	cis	rs11671005	0.611	rs56026876	ENSG00000269600.1	AC016629.3	-4.09	7.91e-05	0.0466	-0.5	-0.36	Mean platelet volume;	chr19:58494790	chr19:58593896~58599355:-
GBM	cis	rs17270561	0.887	rs717551	ENSG00000272810.1	U91328.22	-4.09	7.92e-05	0.0466	-0.56	-0.36	Iron status biomarkers;	chr6:25855396	chr6:26013241~26013757:+
GBM	cis	rs7824557	0.628	rs11777746	ENSG00000255020.1	AF131216.5	4.09	7.92e-05	0.0466	0.38	0.36	Retinal vascular caliber;	chr8:11347246	chr8:11345748~11347502:-
GBM	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-4.09	7.92e-05	0.0467	-0.46	-0.36	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
GBM	cis	rs1420956	0.646	rs7243150	ENSG00000264151.4	RP11-739N10.1	4.09	7.92e-05	0.0467	0.43	0.36	Obesity-related traits;	chr18:27617983	chr18:27336379~27595164:-
GBM	cis	rs9303542	0.729	rs7218848	ENSG00000230148.7	HOXB-AS1	4.09	7.93e-05	0.0467	0.55	0.36	Epithelial ovarian cancer;Ovarian cancer;	chr17:48341227	chr17:48543551~48551250:+
GBM	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	4.09	7.93e-05	0.0467	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
GBM	cis	rs9649213	0.511	rs6950994	ENSG00000272950.1	RP11-307C18.1	4.09	7.93e-05	0.0467	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98258560	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	4.09	7.94e-05	0.0467	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	4.09	7.94e-05	0.0467	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	4.09	7.94e-05	0.0467	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	4.09	7.94e-05	0.0467	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
GBM	cis	rs1413299	0.894	rs10988451	ENSG00000237461.1	RP11-554F20.1	4.09	7.94e-05	0.0467	0.43	0.36	Epithelial ovarian cancer;	chr9:98979384	chr9:99585786~99819889:-
GBM	cis	rs4873772	0.558	rs6472452	ENSG00000253817.1	RP11-1134I14.6	-4.09	7.94e-05	0.0467	-0.47	-0.36	Lobe attachment (rater-scored or self-reported);	chr8:47464657	chr8:47198032~47198323:-
GBM	cis	rs2836950	0.545	rs8132424	ENSG00000238141.2	BRWD1-AS1	4.09	7.95e-05	0.0468	0.35	0.36	Menarche (age at onset);	chr21:39212486	chr21:39315707~39323218:+
GBM	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-4.09	7.95e-05	0.0468	-0.55	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
GBM	cis	rs11773103	0.881	rs73204816	ENSG00000224046.1	AC005076.5	4.09	7.96e-05	0.0468	0.57	0.36	Bipolar disorder or major depressive disorder (combined);	chr7:87139556	chr7:87151423~87152420:-
GBM	cis	rs1153858	1	rs1145081	ENSG00000259433.2	CTD-2651B20.4	-4.09	7.96e-05	0.0468	-0.42	-0.36	Homoarginine levels;	chr15:45387469	chr15:45330209~45332634:-
GBM	cis	rs7034139	0.779	rs10980779	ENSG00000259953.1	RP11-4O1.2	-4.09	7.96e-05	0.0468	-0.59	-0.36	Myeloid white cell count;	chr9:111121841	chr9:112032555~112037730:-
GBM	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-4.09	7.97e-05	0.0469	-0.56	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
GBM	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	4.09	7.97e-05	0.0469	0.45	0.36	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	4.09	7.97e-05	0.0469	0.45	0.36	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
GBM	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	4.09	7.97e-05	0.0469	0.45	0.36	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
GBM	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-4.09	7.97e-05	0.0469	-0.3	-0.36	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
GBM	cis	rs875971	0.789	rs10260426	ENSG00000236529.1	RP13-254B10.1	-4.09	7.98e-05	0.0469	-0.37	-0.36	Aortic root size;	chr7:66271055	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs2901152	ENSG00000236529.1	RP13-254B10.1	-4.09	7.98e-05	0.0469	-0.37	-0.36	Aortic root size;	chr7:66300017	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10263690	ENSG00000236529.1	RP13-254B10.1	-4.09	7.98e-05	0.0469	-0.37	-0.36	Aortic root size;	chr7:66301466	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs10250544	ENSG00000236529.1	RP13-254B10.1	-4.09	7.98e-05	0.0469	-0.37	-0.36	Aortic root size;	chr7:66301574	chr7:65840212~65840596:+
GBM	cis	rs172166	0.611	rs203883	ENSG00000218016.2	ZNF192P2	-4.09	7.98e-05	0.0469	-0.49	-0.36	Cardiac Troponin-T levels;	chr6:28110578	chr6:28188050~28189432:+
GBM	cis	rs12908161	0.959	rs17534709	ENSG00000275120.1	RP11-182J1.17	4.09	7.98e-05	0.0469	0.46	0.36	Schizophrenia;	chr15:84771166	chr15:84599434~84606463:-
GBM	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-4.09	7.98e-05	0.0469	-0.5	-0.36	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-4.09	7.98e-05	0.0469	-0.5	-0.36	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	4.09	7.98e-05	0.0469	0.5	0.36	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
GBM	cis	rs983545	0.8	rs1441039	ENSG00000271964.1	RP11-415F23.2	4.09	7.98e-05	0.0469	0.4	0.36	Blood protein levels;	chr3:16917827	chr3:16314439~16314987:+
GBM	cis	rs2117029	0.767	rs11168838	ENSG00000258017.1	RP11-386G11.10	-4.09	7.99e-05	0.047	-0.45	-0.36	Intelligence (multi-trait analysis);	chr12:49061223	chr12:49127782~49147869:+
GBM	cis	rs4568518	0.502	rs10268632	ENSG00000279048.1	RP11-511H23.2	4.09	7.99e-05	0.047	0.29	0.36	Measles;	chr7:17940658	chr7:17940503~17942922:+
GBM	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-4.09	7.99e-05	0.047	-0.43	-0.36	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
GBM	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	4.09	7.99e-05	0.047	0.39	0.36	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
GBM	cis	rs2287838	0.704	rs12979606	ENSG00000267289.1	CTD-2623N2.11	-4.09	7.99e-05	0.047	-0.43	-0.36	Sleep duration;	chr19:9889322	chr19:9834079~9835013:-
GBM	cis	rs418939	0.506	rs405161	ENSG00000246316.6	RP11-492A10.1	4.09	8e-05	0.047	0.53	0.36	Intelligence (multi-trait analysis);	chr5:114510849	chr5:114488997~114668410:-
GBM	cis	rs12936587	0.595	rs9911672	ENSG00000231458.2	RNASEH1P2	4.09	8e-05	0.047	0.39	0.36	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17625356	chr17:16683438~16684227:+
GBM	cis	rs59104589	0.617	rs59487360	ENSG00000235351.1	AC114730.11	-4.09	8e-05	0.047	-0.32	-0.36	Fibrinogen levels;	chr2:241331018	chr2:241724615~241725693:-
GBM	cis	rs59104589	0.617	rs60614486	ENSG00000235351.1	AC114730.11	-4.09	8e-05	0.047	-0.32	-0.36	Fibrinogen levels;	chr2:241335583	chr2:241724615~241725693:-
GBM	cis	rs9300255	0.506	rs11057251	ENSG00000235423.7	RP11-282O18.3	-4.09	8e-05	0.047	-0.42	-0.36	Neutrophil percentage of white cells;	chr12:123306680	chr12:123252030~123261483:-
GBM	cis	rs7017914	0.644	rs13251367	ENSG00000246366.5	RP11-382J12.1	-4.09	8.01e-05	0.0471	-0.4	-0.36	Bone mineral density;	chr8:71089696	chr8:70608577~70663279:+
GBM	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-4.09	8.01e-05	0.0471	-0.4	-0.36	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
GBM	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-4.09	8.01e-05	0.0471	-0.4	-0.36	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
GBM	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-4.09	8.01e-05	0.0471	-0.45	-0.36	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
GBM	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-4.09	8.01e-05	0.0471	-0.67	-0.36	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
GBM	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-4.09	8.01e-05	0.0471	-0.44	-0.36	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
GBM	cis	rs5742933	1	rs5743052	ENSG00000253559.1	OSGEPL1-AS1	-4.09	8.02e-05	0.0471	-0.43	-0.36	Ferritin levels;	chr2:189824558	chr2:189762704~189765556:+
GBM	cis	rs733592	0.507	rs56129148	ENSG00000258273.1	RP11-370I10.4	4.09	8.03e-05	0.0471	0.38	0.36	Plateletcrit;	chr12:48091747	chr12:48333755~48333901:-
GBM	cis	rs12908161	0.959	rs3748376	ENSG00000275120.1	RP11-182J1.17	4.09	8.03e-05	0.0472	0.47	0.36	Schizophrenia;	chr15:84785121	chr15:84599434~84606463:-
GBM	cis	rs7246657	0.943	rs10404945	ENSG00000276846.1	CTD-3220F14.3	4.09	8.04e-05	0.0472	0.52	0.36	Coronary artery calcification;	chr19:37531456	chr19:37314868~37315620:-
GBM	cis	rs2836950	0.565	rs2150413	ENSG00000238141.2	BRWD1-AS1	-4.09	8.04e-05	0.0472	-0.36	-0.36	Menarche (age at onset);	chr21:39242952	chr21:39315707~39323218:+
GBM	cis	rs2836950	0.565	rs2150414	ENSG00000238141.2	BRWD1-AS1	-4.09	8.04e-05	0.0472	-0.36	-0.36	Menarche (age at onset);	chr21:39243062	chr21:39315707~39323218:+
GBM	cis	rs57481061	1	rs57481061	ENSG00000258302.2	RP11-981P6.1	4.09	8.05e-05	0.0472	0.44	0.36	Coronary artery disease;	chr12:89625401	chr12:89561129~89594878:+
GBM	cis	rs8062405	0.964	rs7187333	ENSG00000271623.1	RP11-435I10.5	-4.09	8.05e-05	0.0472	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs12446589	ENSG00000271623.1	RP11-435I10.5	-4.09	8.05e-05	0.0472	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28364700~28365333:+
GBM	cis	rs8062405	1	rs62037369	ENSG00000271623.1	RP11-435I10.5	-4.09	8.05e-05	0.0472	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28364700~28365333:+
GBM	cis	rs8062405	0.965	rs7359397	ENSG00000271623.1	RP11-435I10.5	-4.09	8.05e-05	0.0472	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28364700~28365333:+
GBM	cis	rs7829975	0.902	rs777707	ENSG00000254340.1	RP11-10A14.3	4.09	8.06e-05	0.0473	0.45	0.36	Mood instability;	chr8:8726834	chr8:9141424~9145435:+
GBM	cis	rs6600671	1	rs6600669	ENSG00000223345.3	HIST2H2BA	4.09	8.06e-05	0.0473	0.47	0.36	Hip geometry;	chr1:121471785	chr1:121108210~121117257:-
GBM	cis	rs6499129	0.571	rs2346676	ENSG00000270049.1	RP11-297D21.4	-4.09	8.06e-05	0.0473	-0.78	-0.36	Waist-to-hip ratio adjusted for body mass index;	chr16:67189900	chr16:67481314~67487250:+
GBM	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	4.09	8.07e-05	0.0473	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
GBM	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-4.09	8.07e-05	0.0473	-0.43	-0.36	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
GBM	cis	rs4842666	0.831	rs12230074	ENSG00000258302.2	RP11-981P6.1	4.09	8.07e-05	0.0473	0.44	0.36	Blood pressure;	chr12:89697090	chr12:89561129~89594878:+
GBM	cis	rs2976388	0.578	rs13263987	ENSG00000253741.1	CTD-2292P10.4	4.09	8.08e-05	0.0474	0.4	0.36	Urinary tract infection frequency;	chr8:142745969	chr8:142702252~142726973:-
GBM	cis	rs832540	0.669	rs832539	ENSG00000225230.1	AC008937.3	4.09	8.09e-05	0.0474	0.48	0.36	Coronary artery disease;	chr5:56903559	chr5:56900041~56910714:-
GBM	cis	rs6788497	0.643	rs11720784	ENSG00000242551.2	POU5F1P6	4.09	8.09e-05	0.0474	0.59	0.36	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128388296	chr3:128674735~128677005:-
GBM	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	4.09	8.1e-05	0.0474	0.42	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
GBM	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-4.09	8.1e-05	0.0475	-0.64	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
GBM	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	4.09	8.1e-05	0.0475	0.35	0.36	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
GBM	cis	rs2255336	0.748	rs60110638	ENSG00000245648.1	RP11-277P12.20	-4.09	8.12e-05	0.0475	-0.46	-0.36	Blood protein levels;	chr12:10444712	chr12:10363769~10398506:+
GBM	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-4.09	8.12e-05	0.0476	-0.61	-0.36	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
GBM	cis	rs7829975	0.508	rs1594437	ENSG00000233609.3	RP11-62H7.2	4.09	8.12e-05	0.0476	0.42	0.36	Mood instability;	chr8:8968365	chr8:8961200~8979025:+
GBM	cis	rs11771526	0.551	rs1008652	ENSG00000273014.1	RP11-225B17.2	4.09	8.13e-05	0.0476	0.65	0.36	Body mass index;	chr7:32214791	chr7:32758882~32759353:+
GBM	cis	rs9393777	0.623	rs9366658	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26469638	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs9358944	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26469647	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs9348719	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26469804	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs56296968	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26474343	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs3757150	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26476554	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs16891717	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26476915	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs9358946	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26478699	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs9358947	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26478772	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs7756567	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26481414	chr6:26956992~27023924:+
GBM	cis	rs9393777	0.623	rs9358948	ENSG00000224843.5	LINC00240	4.09	8.13e-05	0.0476	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26483578	chr6:26956992~27023924:+
GBM	cis	rs17772222	0.917	rs61984736	ENSG00000222990.1	RNU4-22P	4.09	8.13e-05	0.0476	0.46	0.36	Coronary artery calcification;	chr14:88626359	chr14:88513498~88513663:+
GBM	cis	rs59893503	0.649	rs2462636	ENSG00000233539.4	AC011294.3	4.09	8.14e-05	0.0476	0.74	0.36	Immature fraction of reticulocytes;	chr7:47395747	chr7:46673785~46759851:-
GBM	cis	rs6802315	0.863	rs2364921	ENSG00000272247.1	RP11-379F4.9	-4.09	8.14e-05	0.0477	-0.43	-0.36	Periodontitis (CDC/AAP);	chr3:158804674	chr3:158801257~158801935:-
GBM	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	4.09	8.14e-05	0.0477	0.26	0.36	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
GBM	cis	rs733592	0.56	rs2158515	ENSG00000258273.1	RP11-370I10.4	4.09	8.16e-05	0.0477	0.38	0.36	Plateletcrit;	chr12:48113885	chr12:48333755~48333901:-
GBM	cis	rs9393777	0.588	rs3799380	ENSG00000224843.5	LINC00240	-4.09	8.16e-05	0.0477	-0.55	-0.36	Intelligence (multi-trait analysis);	chr6:26466954	chr6:26956992~27023924:+
GBM	cis	rs9450351	0.744	rs12528808	ENSG00000203875.9	SNHG5	-4.09	8.16e-05	0.0477	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85495926	chr6:85660950~85678736:-
GBM	cis	rs9450351	0.744	rs9353319	ENSG00000203875.9	SNHG5	-4.09	8.16e-05	0.0477	-0.9	-0.36	Interferon gamma-induced protein 10 levels;	chr6:85522825	chr6:85660950~85678736:-
GBM	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	4.09	8.16e-05	0.0477	0.35	0.36	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
GBM	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-4.09	8.17e-05	0.0478	-0.37	-0.36	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
GBM	cis	rs56205728	0.582	rs1869901	ENSG00000273855.1	RP11-133K1.12	4.09	8.17e-05	0.0478	0.37	0.36	Schizophrenia;	chr15:40303426	chr15:40285468~40285909:-
GBM	cis	rs753955	0.798	rs9580740	ENSG00000205861.10	C1QTNF9B-AS1	-4.09	8.17e-05	0.0478	-0.47	-0.36	Lung cancer;	chr13:23712183	chr13:23888889~23897263:+
GBM	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	4.09	8.17e-05	0.0478	0.44	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
GBM	cis	rs17508449	0.819	rs4839331	ENSG00000232450.1	RP4-730K3.3	-4.09	8.18e-05	0.0478	-0.6	-0.36	Leprosy;	chr1:113619009	chr1:113698884~113699631:-
GBM	cis	rs17508449	0.819	rs77892281	ENSG00000232450.1	RP4-730K3.3	-4.09	8.18e-05	0.0478	-0.6	-0.36	Leprosy;	chr1:113620995	chr1:113698884~113699631:-
GBM	cis	rs7567389	0.719	rs11890243	ENSG00000236682.1	AC068282.3	4.09	8.18e-05	0.0478	0.4	0.36	Self-rated health;	chr2:127200465	chr2:127389130~127400580:+
GBM	cis	rs9532669	0.889	rs7339089	ENSG00000168852.11	TPTE2P5	4.09	8.18e-05	0.0478	0.48	0.36	Cervical cancer;	chr13:40863790	chr13:40822296~40921749:-
GBM	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-4.09	8.18e-05	0.0478	-0.36	-0.36	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
GBM	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-4.09	8.18e-05	0.0478	-0.37	-0.36	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
GBM	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-4.09	8.18e-05	0.0478	-0.37	-0.36	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
GBM	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	4.09	8.18e-05	0.0478	0.44	0.36	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
GBM	cis	rs2739330	0.791	rs4822458	ENSG00000272787.1	KB-226F1.2	4.08	8.18e-05	0.0478	0.33	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23969211~23969873:+
GBM	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	4.08	8.19e-05	0.0478	0.49	0.36	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
GBM	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	4.08	8.19e-05	0.0478	0.63	0.36	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
GBM	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	4.08	8.19e-05	0.0479	0.43	0.36	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
GBM	cis	rs1899951	0.732	rs2881479	ENSG00000274514.1	Metazoa_SRP	-4.08	8.19e-05	0.0479	-0.55	-0.36	Body mass index;	chr3:12325606	chr3:12576961~12577237:-
GBM	cis	rs1153858	1	rs1153858	ENSG00000259433.2	CTD-2651B20.4	4.08	8.19e-05	0.0479	0.42	0.36	Homoarginine levels;	chr15:45360505	chr15:45330209~45332634:-
GBM	cis	rs3768617	0.51	rs10797838	ENSG00000224468.3	RP11-181K3.4	-4.08	8.2e-05	0.0479	-0.29	-0.36	Fuchs's corneal dystrophy;	chr1:183107885	chr1:183138402~183141282:-
GBM	cis	rs17685	0.712	rs7794454	ENSG00000127957.15	PMS2P3	4.08	8.21e-05	0.048	0.43	0.36	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:75502930~75528148:-
GBM	cis	rs55661361	0.532	rs3802902	ENSG00000254941.1	RP11-677M14.5	-4.08	8.21e-05	0.048	-0.39	-0.36	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124765139	chr11:124807822~124808269:-
GBM	cis	rs1420956	0.646	rs7231167	ENSG00000264151.4	RP11-739N10.1	4.08	8.21e-05	0.048	0.47	0.36	Obesity-related traits;	chr18:27568257	chr18:27336379~27595164:-
GBM	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	4.08	8.21e-05	0.048	0.35	0.36	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
GBM	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	4.08	8.22e-05	0.048	0.52	0.36	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
GBM	cis	rs4380275	0.782	rs4468850	ENSG00000223751.1	AC116609.2	4.08	8.22e-05	0.048	0.39	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:742488~747767:+
GBM	cis	rs4380275	0.782	rs4335978	ENSG00000223751.1	AC116609.2	4.08	8.22e-05	0.048	0.39	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:742488~747767:+
GBM	cis	rs4380275	0.782	rs4854369	ENSG00000223751.1	AC116609.2	4.08	8.22e-05	0.048	0.39	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:742488~747767:+
GBM	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	4.08	8.22e-05	0.048	0.38	0.36	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
GBM	cis	rs453301	0.652	rs2043129	ENSG00000233609.3	RP11-62H7.2	4.08	8.22e-05	0.048	0.42	0.36	Joint mobility (Beighton score);	chr8:8967994	chr8:8961200~8979025:+
GBM	cis	rs1816537	0.625	rs12788026	ENSG00000214264.4	KCTD9P4	4.08	8.22e-05	0.048	0.39	0.36	Body mass index;	chr11:113129490	chr11:112180773~112183191:+
GBM	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	4.08	8.23e-05	0.048	0.49	0.36	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
GBM	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	4.08	8.23e-05	0.048	0.49	0.36	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
GBM	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-4.08	8.23e-05	0.0481	-0.39	-0.36	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
GBM	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-4.08	8.23e-05	0.0481	-0.39	-0.36	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
GBM	cis	rs2836950	0.545	rs11700449	ENSG00000238141.2	BRWD1-AS1	-4.08	8.23e-05	0.0481	-0.36	-0.36	Menarche (age at onset);	chr21:39150493	chr21:39315707~39323218:+
GBM	cis	rs875971	0.545	rs10950036	ENSG00000222364.1	RNU6-96P	-4.08	8.24e-05	0.0481	-0.41	-0.36	Aortic root size;	chr7:66353241	chr7:66395191~66395286:+
GBM	cis	rs875971	0.545	rs6460298	ENSG00000222364.1	RNU6-96P	-4.08	8.24e-05	0.0481	-0.41	-0.36	Aortic root size;	chr7:66442783	chr7:66395191~66395286:+
GBM	cis	rs9393777	0.588	rs6456727	ENSG00000224843.5	LINC00240	4.08	8.25e-05	0.0481	0.53	0.36	Intelligence (multi-trait analysis);	chr6:26470927	chr6:26956992~27023924:+
GBM	cis	rs73198271	0.722	rs11785741	ENSG00000253893.2	FAM85B	4.08	8.25e-05	0.0481	0.48	0.36	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748002	chr8:8167819~8226614:-
GBM	cis	rs10507419	1	rs10507419	ENSG00000276672.1	RP11-142E9.1	4.08	8.25e-05	0.0481	0.41	0.36	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);	chr13:34612315	chr13:33846190~33850825:+
GBM	cis	rs950169	0.881	rs150965	ENSG00000275120.1	RP11-182J1.17	4.08	8.26e-05	0.0481	0.48	0.36	Schizophrenia;	chr15:84537296	chr15:84599434~84606463:-
GBM	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-4.08	8.27e-05	0.0482	-0.46	-0.36	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
GBM	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	4.08	8.28e-05	0.0482	0.37	0.36	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
GBM	cis	rs3768617	0.51	rs729819	ENSG00000224468.3	RP11-181K3.4	-4.08	8.29e-05	0.0483	-0.31	-0.36	Fuchs's corneal dystrophy;	chr1:183139899	chr1:183138402~183141282:-
GBM	cis	rs7932813	0.6	rs7109936	ENSG00000246820.2	RP11-379P15.1	-4.08	8.29e-05	0.0483	-0.36	-0.36	Waist circumference;	chr11:7686640	chr11:8169167~8178903:+
GBM	cis	rs950169	0.922	rs11638445	ENSG00000275120.1	RP11-182J1.17	4.08	8.29e-05	0.0483	0.45	0.36	Schizophrenia;	chr15:84594463	chr15:84599434~84606463:-
GBM	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-4.08	8.29e-05	0.0483	-0.36	-0.36	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
GBM	cis	rs10911251	0.546	rs2274984	ENSG00000224468.3	RP11-181K3.4	4.08	8.29e-05	0.0483	0.29	0.36	Colorectal cancer;	chr1:183138311	chr1:183138402~183141282:-
GBM	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-4.08	8.29e-05	0.0483	-0.51	-0.36	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
GBM	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	4.08	8.3e-05	0.0483	0.41	0.36	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
GBM	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	4.08	8.3e-05	0.0483	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	4.08	8.3e-05	0.0483	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
GBM	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	4.08	8.3e-05	0.0483	0.42	0.36	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
GBM	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-4.08	8.3e-05	0.0483	-0.4	-0.36	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
GBM	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	4.08	8.3e-05	0.0483	0.42	0.36	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
GBM	cis	rs950169	0.96	rs35159785	ENSG00000275120.1	RP11-182J1.17	4.08	8.3e-05	0.0484	0.49	0.36	Schizophrenia;	chr15:84135262	chr15:84599434~84606463:-
GBM	cis	rs66486766	1	rs66486766	ENSG00000275120.1	RP11-182J1.17	4.08	8.3e-05	0.0484	0.49	0.36	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84599434~84606463:-
GBM	cis	rs832187	0.629	rs13272	ENSG00000280620.1	SCAANT1	4.08	8.31e-05	0.0484	0.47	0.36	Schizophrenia;	chr3:64000494	chr3:63911518~63911772:-
GBM	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	4.08	8.32e-05	0.0484	0.44	0.36	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
GBM	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-4.08	8.32e-05	0.0484	-0.4	-0.36	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-4.08	8.32e-05	0.0484	-0.4	-0.36	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-4.08	8.32e-05	0.0484	-0.4	-0.36	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
GBM	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-4.08	8.32e-05	0.0484	-0.4	-0.36	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
GBM	cis	rs8014671	0.567	rs6573971	ENSG00000235812.4	ADAM21P1	4.08	8.33e-05	0.0485	0.43	0.36	Prostate cancer;	chr14:70544752	chr14:70245491~70247801:-
GBM	cis	rs7216064	0.859	rs7502307	ENSG00000278219.1	AC145343.1	-4.08	8.33e-05	0.0485	-0.42	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67993845	chr17:68101538~68101639:+
GBM	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-4.08	8.34e-05	0.0485	-0.41	-0.36	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
GBM	cis	rs7312933	0.558	rs4768402	ENSG00000257225.1	RP11-328C8.4	4.08	8.34e-05	0.0485	0.4	0.36	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42361774	chr12:42459366~42466128:+
GBM	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	4.08	8.34e-05	0.0486	0.41	0.36	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	4.08	8.34e-05	0.0486	0.41	0.36	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	4.08	8.34e-05	0.0486	0.41	0.36	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
GBM	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	4.08	8.34e-05	0.0486	0.41	0.36	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
GBM	cis	rs1719271	0.908	rs1684049	ENSG00000277351.1	RP11-325L12.6	-4.08	8.35e-05	0.0486	-0.6	-0.36	Platelet count;	chr15:64904577	chr15:65049188~65049802:-
GBM	cis	rs6785206	0.614	rs13065032	ENSG00000206417.7	H1FX-AS1	-4.08	8.35e-05	0.0486	-0.6	-0.36	Lymphocyte percentage of white cells;	chr3:128791751	chr3:129315392~129326225:+
GBM	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	4.08	8.35e-05	0.0486	0.42	0.36	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
GBM	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	4.08	8.37e-05	0.0487	0.38	0.36	Height;	chr6:109332929	chr6:109382795~109383666:+
GBM	cis	rs10497721	1	rs10180253	ENSG00000227542.1	AC092614.2	4.08	8.37e-05	0.0487	0.8	0.36	Diabetes (incident);	chr2:192046661	chr2:191229165~191246172:-
GBM	cis	rs10497721	1	rs13415649	ENSG00000227542.1	AC092614.2	4.08	8.37e-05	0.0487	0.8	0.36	Diabetes (incident);	chr2:192047287	chr2:191229165~191246172:-
GBM	cis	rs10497721	1	rs4330061	ENSG00000227542.1	AC092614.2	4.08	8.37e-05	0.0487	0.8	0.36	Diabetes (incident);	chr2:192047771	chr2:191229165~191246172:-
GBM	cis	rs10497721	1	rs2884023	ENSG00000227542.1	AC092614.2	4.08	8.37e-05	0.0487	0.8	0.36	Diabetes (incident);	chr2:192050512	chr2:191229165~191246172:-
GBM	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-4.08	8.37e-05	0.0487	-0.49	-0.36	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
GBM	cis	rs2933343	0.818	rs6764681	ENSG00000261159.1	RP11-723O4.9	-4.08	8.37e-05	0.0487	-0.39	-0.36	IgG glycosylation;	chr3:128849537	chr3:128859716~128860526:-
GBM	cis	rs1153858	0.943	rs1145079	ENSG00000259433.2	CTD-2651B20.4	-4.08	8.37e-05	0.0487	-0.41	-0.36	Homoarginine levels;	chr15:45389563	chr15:45330209~45332634:-
GBM	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-4.08	8.37e-05	0.0487	-0.64	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-4.08	8.37e-05	0.0487	-0.64	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
GBM	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-4.08	8.37e-05	0.0487	-0.64	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
GBM	cis	rs9393777	0.588	rs4518487	ENSG00000224843.5	LINC00240	4.08	8.38e-05	0.0487	0.55	0.36	Intelligence (multi-trait analysis);	chr6:26467303	chr6:26956992~27023924:+
GBM	cis	rs9425766	0.962	rs1322780	ENSG00000270084.1	GAS5-AS1	-4.08	8.38e-05	0.0487	-0.4	-0.36	Life satisfaction;	chr1:173896448	chr1:173863248~173863941:+
GBM	cis	rs9425766	0.962	rs9425435	ENSG00000270084.1	GAS5-AS1	-4.08	8.38e-05	0.0487	-0.4	-0.36	Life satisfaction;	chr1:173896936	chr1:173863248~173863941:+
GBM	cis	rs683250	0.931	rs558426	ENSG00000227097.5	RPS28P7	-4.08	8.38e-05	0.0488	-0.38	-0.36	Subcortical brain region volumes;	chr11:83585477	chr11:82689559~82689768:+
GBM	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-4.08	8.39e-05	0.0488	-0.31	-0.36	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
GBM	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	4.08	8.4e-05	0.0488	0.26	0.36	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
GBM	cis	rs4642101	0.64	rs9877049	ENSG00000213943.3	KRT18P17	4.08	8.4e-05	0.0488	0.38	0.36	QRS complex (12-leadsum);	chr3:12779732	chr3:12787393~12788671:-
GBM	cis	rs3736858	0.932	rs12430940	ENSG00000261105.4	LMO7-AS1	-4.08	8.4e-05	0.0488	-0.64	-0.36	Interleukin-9 levels;	chr13:75827479	chr13:75604700~75635994:-
GBM	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-4.08	8.4e-05	0.0489	-0.3	-0.36	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
GBM	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	4.08	8.4e-05	0.0489	0.52	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
GBM	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	4.08	8.4e-05	0.0489	0.52	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
GBM	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-4.08	8.41e-05	0.0489	-0.46	-0.36	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
GBM	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	4.08	8.41e-05	0.0489	0.42	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
GBM	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	4.08	8.41e-05	0.0489	0.36	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
GBM	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-4.08	8.41e-05	0.0489	-0.48	-0.36	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
GBM	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-4.08	8.41e-05	0.0489	-0.48	-0.36	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
GBM	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.96	rs62019463	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84744856	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs62019464	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84751238	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs11637142	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84752696	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs12910012	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84755431	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs12899981	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84759142	chr15:84599434~84606463:-
GBM	cis	rs12908161	0.92	rs35758837	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84768151	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs17600551	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84776027	chr15:84599434~84606463:-
GBM	cis	rs12908161	1	rs36033486	ENSG00000275120.1	RP11-182J1.17	4.08	8.42e-05	0.0489	0.46	0.36	Schizophrenia;	chr15:84776461	chr15:84599434~84606463:-
GBM	cis	rs853679	0.607	rs34788973	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Depression;	chr6:27911422	chr6:28015568~28015777:+
GBM	cis	rs853679	0.607	rs61742093	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Depression;	chr6:27912204	chr6:28015568~28015777:+
GBM	cis	rs67340775	0.834	rs13218875	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Lung cancer in ever smokers;	chr6:27916234	chr6:28015568~28015777:+
GBM	cis	rs853679	0.607	rs67040724	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Depression;	chr6:27937731	chr6:28015568~28015777:+
GBM	cis	rs853679	0.607	rs67662114	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Depression;	chr6:27964523	chr6:28015568~28015777:+
GBM	cis	rs853679	0.607	rs13216117	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Depression;	chr6:27970706	chr6:28015568~28015777:+
GBM	cis	rs853679	0.607	rs36101351	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Depression;	chr6:27975591	chr6:28015568~28015777:+
GBM	cis	rs853679	0.607	rs28360499	ENSG00000199851.2	U3	4.08	8.42e-05	0.0489	0.93	0.36	Depression;	chr6:27977618	chr6:28015568~28015777:+
GBM	cis	rs7216064	0.817	rs12603589	ENSG00000278219.1	AC145343.1	-4.08	8.42e-05	0.0489	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829132	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.817	rs12601921	ENSG00000278219.1	AC145343.1	-4.08	8.42e-05	0.0489	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829238	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.813	rs12601919	ENSG00000278219.1	AC145343.1	-4.08	8.42e-05	0.0489	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829258	chr17:68101538~68101639:+
GBM	cis	rs7216064	0.954	rs12602556	ENSG00000278219.1	AC145343.1	-4.08	8.42e-05	0.0489	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67830745	chr17:68101538~68101639:+
GBM	cis	rs7216064	1	rs62084208	ENSG00000278219.1	AC145343.1	-4.08	8.42e-05	0.0489	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67831327	chr17:68101538~68101639:+
GBM	cis	rs7216064	1	rs62084210	ENSG00000278219.1	AC145343.1	-4.08	8.42e-05	0.0489	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67832594	chr17:68101538~68101639:+
GBM	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-4.08	8.42e-05	0.0489	-0.38	-0.36	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-4.08	8.42e-05	0.0489	-0.38	-0.36	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-4.08	8.42e-05	0.0489	-0.38	-0.36	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
GBM	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-4.08	8.42e-05	0.0489	-0.38	-0.36	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
GBM	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	4.08	8.42e-05	0.0489	0.4	0.36	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
GBM	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-4.08	8.43e-05	0.0489	-0.4	-0.36	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
GBM	cis	rs526231	0.764	rs599447	ENSG00000175749.11	EIF3KP1	4.08	8.43e-05	0.049	0.53	0.36	Primary biliary cholangitis;	chr5:103302154	chr5:103032376~103033031:+
GBM	cis	rs761746	0.577	rs2012150	ENSG00000240591.1	RP11-247I13.11	4.08	8.43e-05	0.049	0.35	0.36	Intelligence;	chr22:31820153	chr22:31454251~31464204:+
GBM	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-4.08	8.44e-05	0.049	-0.36	-0.36	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
GBM	cis	rs10246939	0.579	rs6969430	ENSG00000261797.1	RP11-744I24.3	-4.08	8.44e-05	0.049	-0.44	-0.36	Bitter taste perception;	chr7:141831340	chr7:141512698~141513183:-
GBM	cis	rs875971	0.862	rs4718319	ENSG00000236529.1	RP13-254B10.1	-4.08	8.44e-05	0.049	-0.38	-0.36	Aortic root size;	chr7:66187797	chr7:65840212~65840596:+
GBM	cis	rs875971	0.723	rs28391294	ENSG00000236529.1	RP13-254B10.1	-4.08	8.44e-05	0.049	-0.38	-0.36	Aortic root size;	chr7:66189328	chr7:65840212~65840596:+
GBM	cis	rs875971	0.83	rs6967708	ENSG00000236529.1	RP13-254B10.1	-4.08	8.44e-05	0.049	-0.38	-0.36	Aortic root size;	chr7:66192326	chr7:65840212~65840596:+
GBM	cis	rs875971	0.895	rs7782806	ENSG00000236529.1	RP13-254B10.1	-4.08	8.44e-05	0.049	-0.38	-0.36	Aortic root size;	chr7:66192910	chr7:65840212~65840596:+
GBM	cis	rs875971	0.895	rs6460278	ENSG00000236529.1	RP13-254B10.1	-4.08	8.44e-05	0.049	-0.38	-0.36	Aortic root size;	chr7:66197749	chr7:65840212~65840596:+
GBM	cis	rs875971	0.862	rs6460279	ENSG00000236529.1	RP13-254B10.1	-4.08	8.44e-05	0.049	-0.38	-0.36	Aortic root size;	chr7:66197774	chr7:65840212~65840596:+
GBM	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	4.08	8.45e-05	0.0491	0.42	0.36	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
GBM	cis	rs3736858	0.935	rs9530471	ENSG00000261105.4	LMO7-AS1	-4.08	8.45e-05	0.0491	-0.64	-0.36	Interleukin-9 levels;	chr13:75845638	chr13:75604700~75635994:-
GBM	cis	rs3742264	0.656	rs741669	ENSG00000235903.6	CPB2-AS1	4.08	8.46e-05	0.0491	0.44	0.36	Blood protein levels;	chr13:45941886	chr13:46052806~46113332:+
GBM	cis	rs10007052	0.568	rs13434447	ENSG00000248810.1	RP11-362F19.1	-4.08	8.46e-05	0.0491	-0.39	-0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr4:141089541	chr4:141319450~141332618:-
GBM	cis	rs62184315	0.536	rs62183651	ENSG00000273240.1	RP11-455J20.3	-4.08	8.46e-05	0.0491	-0.53	-0.36	Alcohol dependence (age at onset);	chr2:189647251	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs62183652	ENSG00000273240.1	RP11-455J20.3	-4.08	8.46e-05	0.0491	-0.53	-0.36	Alcohol dependence (age at onset);	chr2:189648877	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs62183653	ENSG00000273240.1	RP11-455J20.3	-4.08	8.46e-05	0.0491	-0.53	-0.36	Alcohol dependence (age at onset);	chr2:189650099	chr2:189763859~189764456:-
GBM	cis	rs62184315	0.536	rs72920421	ENSG00000273240.1	RP11-455J20.3	-4.08	8.46e-05	0.0491	-0.53	-0.36	Alcohol dependence (age at onset);	chr2:189650292	chr2:189763859~189764456:-
GBM	cis	rs9393777	0.623	rs3734544	ENSG00000224843.5	LINC00240	4.08	8.47e-05	0.0491	0.59	0.36	Intelligence (multi-trait analysis);	chr6:26468432	chr6:26956992~27023924:+
GBM	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	4.08	8.47e-05	0.0491	0.42	0.36	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
GBM	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-4.08	8.47e-05	0.0491	-0.55	-0.36	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
GBM	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-4.08	8.47e-05	0.0491	-0.55	-0.36	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
GBM	cis	rs440932	1	rs440932	ENSG00000253893.2	FAM85B	-4.08	8.47e-05	0.0492	-0.45	-0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8167819~8226614:-
GBM	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	4.08	8.47e-05	0.0492	0.64	0.36	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
GBM	cis	rs2717463	0.669	rs10778732	ENSG00000258048.1	RP11-530C5.1	4.08	8.47e-05	0.0492	0.51	0.36	Positive affect;	chr12:80369679	chr12:79690144~79778451:+
GBM	cis	rs61041384	0.661	rs78351440	ENSG00000256092.2	RP13-942N8.1	-4.08	8.48e-05	0.0492	-0.81	-0.36	Schizophrenia;	chr12:123010742	chr12:123363868~123366113:+
GBM	cis	rs17318866	0.579	rs10458080	ENSG00000217385.1	PSMC1P11	4.08	8.49e-05	0.0492	0.48	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);	chr6:3809703	chr6:4702463~4703779:+
GBM	cis	rs4713118	0.513	rs9368547	ENSG00000218016.2	ZNF192P2	-4.08	8.49e-05	0.0492	-0.5	-0.36	Parkinson's disease;	chr6:28060289	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs183244	ENSG00000218016.2	ZNF192P2	-4.08	8.49e-05	0.0492	-0.5	-0.36	Parkinson's disease;	chr6:28064060	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149950	ENSG00000218016.2	ZNF192P2	-4.08	8.49e-05	0.0492	-0.5	-0.36	Parkinson's disease;	chr6:28065261	chr6:28188050~28189432:+
GBM	cis	rs4713118	0.513	rs149951	ENSG00000218016.2	ZNF192P2	-4.08	8.49e-05	0.0492	-0.5	-0.36	Parkinson's disease;	chr6:28065309	chr6:28188050~28189432:+
GBM	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-4.08	8.49e-05	0.0492	-0.5	-0.36	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
GBM	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-4.08	8.49e-05	0.0492	-0.45	-0.36	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
GBM	cis	rs9304270	0.722	rs2116413	ENSG00000267652.1	RP11-188I24.1	4.08	8.49e-05	0.0492	0.43	0.36	Obesity-related traits;	chr18:42400639	chr18:41789162~41789395:-
GBM	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	4.08	8.49e-05	0.0493	0.36	0.36	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
GBM	cis	rs4568518	0.616	rs11766489	ENSG00000279048.1	RP11-511H23.2	4.07	8.5e-05	0.0493	0.29	0.36	Measles;	chr7:17964047	chr7:17940503~17942922:+
GBM	cis	rs4568518	0.616	rs11766586	ENSG00000279048.1	RP11-511H23.2	4.07	8.5e-05	0.0493	0.29	0.36	Measles;	chr7:17964342	chr7:17940503~17942922:+
GBM	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
GBM	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
GBM	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-4.07	8.51e-05	0.0493	-0.5	-0.36	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
GBM	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-4.07	8.51e-05	0.0493	-0.43	-0.36	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
GBM	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
GBM	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	4.07	8.51e-05	0.0493	0.49	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
GBM	cis	rs4713118	0.591	rs2056924	ENSG00000199851.2	U3	4.07	8.51e-05	0.0493	0.46	0.36	Parkinson's disease;	chr6:27722395	chr6:28015568~28015777:+
GBM	cis	rs9393777	0.545	rs56303243	ENSG00000224843.5	LINC00240	4.07	8.52e-05	0.0493	0.57	0.36	Intelligence (multi-trait analysis);	chr6:26485499	chr6:26956992~27023924:+
GBM	cis	rs8114671	0.662	rs6058146	ENSG00000269202.1	RP4-614O4.12	-4.07	8.52e-05	0.0493	-0.45	-0.36	Height;	chr20:34952726	chr20:35201747~35203288:-
GBM	cis	rs8114671	0.57	rs3761144	ENSG00000269202.1	RP4-614O4.12	-4.07	8.52e-05	0.0493	-0.45	-0.36	Height;	chr20:34956272	chr20:35201747~35203288:-
GBM	cis	rs440932	1	rs378974	ENSG00000253893.2	FAM85B	-4.07	8.52e-05	0.0493	-0.45	-0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8167819~8226614:-
GBM	cis	rs79903896	0.748	rs179544	ENSG00000258640.3	RPL21P5	-4.07	8.52e-05	0.0494	-0.77	-0.36	Night sleep phenotypes;	chr14:30761597	chr14:31111569~31112239:-
GBM	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	4.07	8.53e-05	0.0494	0.45	0.36	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
GBM	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	4.07	8.53e-05	0.0494	0.45	0.36	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
GBM	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	4.07	8.53e-05	0.0494	0.33	0.36	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
GBM	cis	rs2235649	0.833	rs9926962	ENSG00000260260.1	SNHG19	-4.07	8.54e-05	0.0494	-0.43	-0.36	Blood metabolite levels;	chr16:1801825	chr16:2154797~2155358:-
GBM	cis	rs875971	0.545	rs11770063	ENSG00000236529.1	RP13-254B10.1	4.07	8.54e-05	0.0494	0.39	0.36	Aortic root size;	chr7:66318029	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs3936065	ENSG00000236529.1	RP13-254B10.1	4.07	8.54e-05	0.0494	0.39	0.36	Aortic root size;	chr7:66325577	chr7:65840212~65840596:+
GBM	cis	rs875971	0.545	rs4718335	ENSG00000236529.1	RP13-254B10.1	4.07	8.54e-05	0.0494	0.39	0.36	Aortic root size;	chr7:66339619	chr7:65840212~65840596:+
GBM	cis	rs62355901	0.505	rs62355912	ENSG00000271828.1	CTD-2310F14.1	4.07	8.55e-05	0.0495	0.93	0.36	Breast cancer;	chr5:56788004	chr5:56927874~56929573:+
GBM	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	4.07	8.55e-05	0.0495	0.34	0.36	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
GBM	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	4.07	8.55e-05	0.0495	0.39	0.36	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
GBM	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	4.07	8.55e-05	0.0495	0.39	0.36	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
GBM	cis	rs7267979	0.586	rs6037057	ENSG00000125804.12	FAM182A	-4.07	8.55e-05	0.0495	-0.46	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:26054655~26086917:+
GBM	cis	rs7267979	0.586	rs6050429	ENSG00000125804.12	FAM182A	-4.07	8.55e-05	0.0495	-0.46	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:26054655~26086917:+
GBM	cis	rs4713118	0.866	rs2179094	ENSG00000199851.2	U3	4.07	8.55e-05	0.0495	0.48	0.36	Parkinson's disease;	chr6:27774046	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.739	rs2893931	ENSG00000199851.2	U3	4.07	8.55e-05	0.0495	0.48	0.36	Parkinson's disease;	chr6:27780231	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.824	rs2092075	ENSG00000199851.2	U3	4.07	8.55e-05	0.0495	0.48	0.36	Parkinson's disease;	chr6:27781551	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.824	rs13211701	ENSG00000199851.2	U3	4.07	8.55e-05	0.0495	0.48	0.36	Parkinson's disease;	chr6:27782300	chr6:28015568~28015777:+
GBM	cis	rs4713118	0.824	rs9468229	ENSG00000199851.2	U3	4.07	8.55e-05	0.0495	0.48	0.36	Parkinson's disease;	chr6:27782307	chr6:28015568~28015777:+
GBM	cis	rs6583331	0.667	rs9824819	ENSG00000273013.1	CTD-2002J20.1	-4.07	8.55e-05	0.0495	-0.39	-0.36	Vitiligo;	chr3:196617291	chr3:196474801~196475394:+
GBM	cis	rs7612209	0.607	rs6443513	ENSG00000225790.1	RP11-2L8.1	-4.07	8.56e-05	0.0495	-0.4	-0.36	Cognitive performance;	chr3:177896903	chr3:177934823~177937662:+
GBM	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	4.07	8.56e-05	0.0495	0.44	0.36	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
GBM	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-4.07	8.56e-05	0.0495	-0.48	-0.36	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
GBM	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	4.07	8.57e-05	0.0496	0.43	0.36	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
GBM	cis	rs1150668	0.83	rs2023493	ENSG00000218016.2	ZNF192P2	-4.07	8.57e-05	0.0496	-0.41	-0.36	Pubertal anthropometrics;	chr6:28432385	chr6:28188050~28189432:+
GBM	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-4.07	8.57e-05	0.0496	-0.35	-0.36	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
GBM	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-4.07	8.57e-05	0.0496	-0.35	-0.36	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
GBM	cis	rs12549025	0.796	rs11135744	ENSG00000243265.1	RP11-1149O23.1	4.07	8.57e-05	0.0496	0.52	0.36	Reticulocyte fraction of red cells;	chr8:23543642	chr8:23206918~23207369:+
GBM	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	4.07	8.57e-05	0.0496	0.35	0.36	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
GBM	cis	rs3213958	0.574	rs56290036	ENSG00000249274.1	PDLIM1P4	-4.07	8.58e-05	0.0496	-0.56	-0.36	Blood protein levels;	chr3:98845479	chr3:98782188~98783193:+
GBM	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-4.07	8.58e-05	0.0496	-0.34	-0.36	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
GBM	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-4.07	8.58e-05	0.0496	-0.34	-0.36	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
GBM	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	4.07	8.58e-05	0.0496	0.48	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
GBM	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	4.07	8.58e-05	0.0496	0.35	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
GBM	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	4.07	8.58e-05	0.0496	0.42	0.36	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
GBM	cis	rs9828933	0.808	rs3733125	ENSG00000280620.1	SCAANT1	4.07	8.59e-05	0.0496	0.7	0.35	Type 2 diabetes;	chr3:63995959	chr3:63911518~63911772:-
GBM	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-4.07	8.59e-05	0.0496	-0.4	-0.35	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
GBM	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-4.07	8.59e-05	0.0496	-0.4	-0.35	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
GBM	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	4.07	8.59e-05	0.0496	0.58	0.35	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
GBM	cis	rs66823261	0.741	rs7841786	ENSG00000253166.2	RP11-585F1.6	-4.07	8.6e-05	0.0497	-0.45	-0.35	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:202660~202897:-
GBM	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	4.07	8.6e-05	0.0497	0.41	0.35	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
GBM	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	4.07	8.61e-05	0.0497	0.41	0.35	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
GBM	cis	rs3768617	0.51	rs2296288	ENSG00000224468.3	RP11-181K3.4	-4.07	8.61e-05	0.0497	-0.29	-0.35	Fuchs's corneal dystrophy;	chr1:183103455	chr1:183138402~183141282:-
GBM	cis	rs3742264	0.656	rs2075427	ENSG00000235903.6	CPB2-AS1	4.07	8.62e-05	0.0498	0.44	0.35	Blood protein levels;	chr13:45941470	chr13:46052806~46113332:+
GBM	cis	rs6903823	0.508	rs1778484	ENSG00000218016.2	ZNF192P2	-4.07	8.63e-05	0.0498	-0.42	-0.35	Pulmonary function;	chr6:28273021	chr6:28188050~28189432:+
GBM	cis	rs11773103	0.881	rs11971310	ENSG00000224046.1	AC005076.5	4.07	8.63e-05	0.0498	0.56	0.35	Bipolar disorder or major depressive disorder (combined);	chr7:87136326	chr7:87151423~87152420:-
GBM	cis	rs11773103	0.881	rs11978231	ENSG00000224046.1	AC005076.5	4.07	8.63e-05	0.0498	0.56	0.35	Bipolar disorder or major depressive disorder (combined);	chr7:87136444	chr7:87151423~87152420:-
GBM	cis	rs11773103	0.881	rs73204813	ENSG00000224046.1	AC005076.5	4.07	8.63e-05	0.0498	0.56	0.35	Bipolar disorder or major depressive disorder (combined);	chr7:87137427	chr7:87151423~87152420:-
GBM	cis	rs2282300	0.739	rs7925340	ENSG00000254532.1	RP11-624D11.2	-4.07	8.64e-05	0.0498	-0.48	-0.35	Morning vs. evening chronotype;	chr11:30258861	chr11:30044058~30084343:-
GBM	cis	rs2282300	0.702	rs4379811	ENSG00000254532.1	RP11-624D11.2	-4.07	8.64e-05	0.0498	-0.48	-0.35	Morning vs. evening chronotype;	chr11:30273213	chr11:30044058~30084343:-
GBM	cis	rs2282300	0.739	rs3858428	ENSG00000254532.1	RP11-624D11.2	-4.07	8.64e-05	0.0498	-0.48	-0.35	Morning vs. evening chronotype;	chr11:30275003	chr11:30044058~30084343:-
GBM	cis	rs9425766	0.678	rs1951625	ENSG00000270084.1	GAS5-AS1	-4.07	8.64e-05	0.0499	-0.42	-0.35	Life satisfaction;	chr1:173867464	chr1:173863248~173863941:+
GBM	cis	rs9425766	0.64	rs1322774	ENSG00000270084.1	GAS5-AS1	-4.07	8.64e-05	0.0499	-0.42	-0.35	Life satisfaction;	chr1:173870102	chr1:173863248~173863941:+
GBM	cis	rs2115630	0.967	rs28595395	ENSG00000225151.9	GOLGA2P7	4.07	8.65e-05	0.0499	0.38	0.35	P wave terminal force;	chr15:84791721	chr15:84199311~84230136:-
GBM	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	4.07	8.66e-05	0.0499	0.49	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
GBM	cis	rs453301	0.686	rs11785634	ENSG00000254340.1	RP11-10A14.3	-4.07	8.66e-05	0.0499	-0.44	-0.35	Joint mobility (Beighton score);	chr8:9035087	chr8:9141424~9145435:+
GBM	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	4.07	8.66e-05	0.0499	0.49	0.35	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
GBM	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	4.07	8.66e-05	0.0499	0.49	0.35	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
GBM	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-4.07	8.66e-05	0.0499	-0.4	-0.35	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
GBM	cis	rs4820834	0.569	rs5763932	ENSG00000275258.1	AC004832.1	-4.07	8.67e-05	0.05	-0.38	-0.35	Coronary artery calcification;	chr22:30289375	chr22:30411646~30411755:+
GBM	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
GBM	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
GBM	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
GBM	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
GBM	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
GBM	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-4.07	8.67e-05	0.05	-0.4	-0.35	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
GBM	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	4.07	8.67e-05	0.05	0.45	0.35	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
GBM	cis	rs2239547	0.603	rs7644973	ENSG00000242142.1	SERBP1P3	4.07	8.67e-05	0.05	0.54	0.35	Schizophrenia;	chr3:53048921	chr3:53064283~53065091:-
GBM	cis	rs418939	0.537	rs395313	ENSG00000246316.6	RP11-492A10.1	4.07	8.67e-05	0.05	0.52	0.35	Intelligence (multi-trait analysis);	chr5:114586939	chr5:114488997~114668410:-
GBM	cis	rs853679	1	rs68141011	ENSG00000199851.2	U3	4.07	8.68e-05	0.05	0.7	0.35	Depression;	chr6:28250019	chr6:28015568~28015777:+
GBM	cis	rs418939	0.537	rs421243	ENSG00000246316.6	RP11-492A10.1	-4.07	8.68e-05	0.05	-0.51	-0.35	Intelligence (multi-trait analysis);	chr5:114578845	chr5:114488997~114668410:-
GBM	cis	rs418939	0.537	rs1863312	ENSG00000246316.6	RP11-492A10.1	4.07	8.68e-05	0.05	0.51	0.35	Intelligence (multi-trait analysis);	chr5:114530588	chr5:114488997~114668410:-
GBM	cis	rs418939	0.537	rs647362	ENSG00000246316.6	RP11-492A10.1	4.07	8.68e-05	0.05	0.51	0.35	Intelligence (multi-trait analysis);	chr5:114530629	chr5:114488997~114668410:-
GBM	cis	rs418939	0.537	rs397787	ENSG00000246316.6	RP11-492A10.1	4.07	8.68e-05	0.05	0.51	0.35	Intelligence (multi-trait analysis);	chr5:114535423	chr5:114488997~114668410:-
GBM	cis	rs418939	0.537	rs2553498	ENSG00000246316.6	RP11-492A10.1	4.07	8.68e-05	0.05	0.51	0.35	Intelligence (multi-trait analysis);	chr5:114577407	chr5:114488997~114668410:-
GBM	cis	rs418939	0.537	rs625885	ENSG00000246316.6	RP11-492A10.1	4.07	8.68e-05	0.05	0.51	0.35	Intelligence (multi-trait analysis);	chr5:114577518	chr5:114488997~114668410:-
GBM	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-19.81	7.28e-39	5.02e-28	-1.28	-0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-19.52	2.72e-38	9.39e-28	-1.27	-0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	18.04	2.55e-35	8.81e-26	1.31	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	17.66	1.56e-34	4.68e-25	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	17.66	1.56e-34	4.68e-25	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	17.66	1.56e-34	4.68e-25	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	17.58	2.21e-34	6.09e-25	1.3	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	17.58	2.21e-34	6.09e-25	1.3	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	17.31	8.22e-34	1.89e-24	1.3	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	17.31	8.22e-34	1.89e-24	1.3	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	17.31	8.22e-34	1.89e-24	1.3	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	17.2	1.39e-33	2e-24	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	16.94	4.94e-33	6.68e-24	1.27	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	16.67	1.82e-32	2.12e-23	1.28	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	16.67	1.82e-32	2.12e-23	1.28	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	16.66	1.93e-32	2.15e-23	1.23	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	16.66	1.93e-32	2.15e-23	1.23	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	16.66	1.93e-32	2.15e-23	1.23	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	16.59	2.71e-32	2.88e-23	1.27	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
GBM	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	16.46	5.09e-32	5.24e-23	0.98	0.84	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-16.36	8.43e-32	8.42e-23	-0.96	-0.84	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	16.34	9.17e-32	8.78e-23	0.96	0.84	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	16.33	9.84e-32	9.05e-23	0.98	0.84	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	16.27	1.31e-31	1e-22	0.96	0.83	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	16.27	1.31e-31	1e-22	0.96	0.83	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	16.27	1.31e-31	1e-22	0.96	0.83	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	16.27	1.31e-31	1e-22	0.96	0.83	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	16.27	1.31e-31	1e-22	0.96	0.83	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	16.25	1.42e-31	1.04e-22	0.96	0.83	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	16.24	1.5e-31	1.05e-22	1.27	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	16.24	1.5e-31	1.05e-22	1.27	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	16.24	1.5e-31	1.05e-22	1.27	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
GBM	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	16.21	1.75e-31	1.2e-22	0.98	0.83	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	16.21	1.75e-31	1.2e-22	0.98	0.83	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	16.17	2.2e-31	1.45e-22	0.96	0.83	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-15.94	6.69e-31	3.66e-22	-1.25	-0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	15.75	1.79e-30	6.52e-22	1.24	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
GBM	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-15.43	8.89e-30	2.44e-21	-0.94	-0.82	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	15.35	1.3e-29	3.46e-21	1.23	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
GBM	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	15.1	4.67e-29	1.16e-20	0.94	0.82	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
GBM	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	15.1	4.67e-29	1.16e-20	0.94	0.82	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-14.68	4.04e-28	9.1e-20	-0.91	-0.81	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	14.56	7.22e-28	1.62e-19	0.92	0.81	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	14.5	1.02e-27	2.1e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	14.43	1.43e-27	2.91e-19	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	14.43	1.43e-27	2.91e-19	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	14.43	1.43e-27	2.91e-19	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
GBM	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	14.31	2.64e-27	5.32e-19	1.09	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
GBM	trans	rs13177918	0.677	rs3857421	ENSG00000226396.1	RP5-1056L3.3	-14.24	3.92e-27	7.85e-19	-0.9	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	14.23	4.01e-27	7.99e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	14.23	4.01e-27	7.99e-19	1.26	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
GBM	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	14.12	7.24e-27	1.42e-18	1.1	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
GBM	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	14.01	1.25e-26	2.39e-18	1.25	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	14.01	1.25e-26	2.39e-18	1.25	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	14.01	1.25e-26	2.39e-18	1.25	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	14	1.36e-26	2.57e-18	1.23	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
GBM	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	13.93	1.88e-26	3.49e-18	1.1	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
GBM	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	13.84	3e-26	5.48e-18	1.12	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
GBM	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	13.78	4.11e-26	7.2e-18	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
GBM	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	13.78	4.16e-26	7.29e-18	1.23	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
GBM	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	13.78	4.31e-26	7.52e-18	0.93	0.79	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
GBM	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	13.75	4.81e-26	8.34e-18	1.22	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
GBM	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	13.75	4.81e-26	8.34e-18	1.22	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
GBM	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	13.75	4.81e-26	8.34e-18	1.22	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
GBM	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	13.69	6.85e-26	1.18e-17	1.06	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	13.63	9.18e-26	1.56e-17	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-13.59	1.12e-25	1.89e-17	-1.06	-0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	13.57	1.28e-25	2.14e-17	1.06	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
GBM	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	13.53	1.54e-25	2.59e-17	1.1	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
GBM	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	13.52	1.65e-25	2.76e-17	0.94	0.78	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.729	rs12453125	ENSG00000187870.7	RNFT1P3	-13.51	1.69e-25	2.82e-17	-0.94	-0.78	White blood cell count;	chr17:59968715	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	13.49	1.93e-25	3.2e-17	0.91	0.78	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	13.48	2.08e-25	3.42e-17	1.21	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
GBM	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	13.42	2.75e-25	4.52e-17	1.07	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	13.41	2.94e-25	4.82e-17	1.06	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
GBM	trans	rs8081395	0.509	rs1292045	ENSG00000187870.7	RNFT1P3	13.35	4.03e-25	6.51e-17	0.9	0.78	White blood cell count;	chr17:59869851	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.677	rs4841	ENSG00000226396.1	RP5-1056L3.3	13.06	1.83e-24	2.83e-16	0.88	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13183077	ENSG00000226396.1	RP5-1056L3.3	13.06	1.83e-24	2.83e-16	0.88	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs3797622	ENSG00000226396.1	RP5-1056L3.3	13.06	1.83e-24	2.83e-16	0.88	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.798	rs12516161	ENSG00000213058.3	RP4-765C7.2	13.04	2.02e-24	3.13e-16	1.18	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:178411616~178411972:+
GBM	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	12.98	2.81e-24	4.25e-16	0.93	0.77	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	12.98	2.81e-24	4.25e-16	0.93	0.77	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	12.98	2.81e-24	4.25e-16	0.93	0.77	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	12.98	2.81e-24	4.25e-16	0.93	0.77	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	12.98	2.81e-24	4.25e-16	0.93	0.77	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	12.98	2.81e-24	4.25e-16	0.93	0.77	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	12.98	2.86e-24	4.32e-16	0.93	0.77	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	12.97	2.99e-24	4.35e-16	0.93	0.77	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
GBM	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	12.91	4.03e-24	5.84e-16	1.06	0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
GBM	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	12.9	4.31e-24	6.19e-16	1.18	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
GBM	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	12.9	4.31e-24	6.19e-16	1.18	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
GBM	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	12.9	4.31e-24	6.19e-16	1.18	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.677	rs13161417	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13161156	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13181401	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs4541646	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs3900644	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs2070844	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs2073472	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.629	rs2070842	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13171800	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs2070841	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13177951	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13177970	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13164105	ENSG00000226396.1	RP5-1056L3.3	12.79	7.73e-24	1.06e-15	0.9	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:19608114~19608568:+
GBM	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	12.69	1.31e-23	1.76e-15	0.93	0.76	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	12.69	1.31e-23	1.76e-15	0.93	0.76	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	12.69	1.31e-23	1.76e-15	0.93	0.76	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
GBM	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	12.69	1.35e-23	1.81e-15	0.89	0.76	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-12.68	1.39e-23	1.86e-15	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	12.67	1.47e-23	1.96e-15	0.89	0.76	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	12.67	1.47e-23	1.96e-15	0.89	0.76	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-12.65	1.64e-23	2.17e-15	-1.01	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
GBM	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-12.64	1.69e-23	2.23e-15	-1.01	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-12.64	1.69e-23	2.23e-15	-1.01	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-12.64	1.74e-23	2.29e-15	-1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
GBM	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	12.64	1.76e-23	2.31e-15	1.02	0.76	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
GBM	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	12.63	1.84e-23	2.38e-15	0.92	0.76	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	12.63	1.84e-23	2.38e-15	0.92	0.76	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	12.63	1.84e-23	2.38e-15	0.92	0.76	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	12.63	1.84e-23	2.38e-15	0.92	0.76	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	12.63	1.84e-23	2.38e-15	0.92	0.76	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
GBM	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-12.58	2.32e-23	2.97e-15	-1.01	-0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
GBM	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-12.58	2.32e-23	2.97e-15	-1.01	-0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
GBM	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	12.57	2.45e-23	3.11e-15	1.17	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
GBM	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	12.57	2.52e-23	3.19e-15	1.07	0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
GBM	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-12.56	2.63e-23	3.33e-15	-1.01	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-12.54	2.89e-23	3.63e-15	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
GBM	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-12.54	2.92e-23	3.66e-15	-0.92	-0.76	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
GBM	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-12.53	3.01e-23	3.77e-15	-1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
GBM	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	12.53	3.11e-23	3.88e-15	0.92	0.76	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	12.53	3.17e-23	3.9e-15	0.92	0.76	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
GBM	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	12.53	3.17e-23	3.9e-15	0.92	0.76	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	12.53	3.17e-23	3.9e-15	0.92	0.76	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	12.52	3.18e-23	3.9e-15	0.92	0.76	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
GBM	trans	rs13177918	0.798	rs12516161	ENSG00000224114.1	RP11-343H5.4	12.52	3.23e-23	3.94e-15	1.15	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:206695837~206696269:-
GBM	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-12.45	4.8e-23	5.8e-15	-0.87	-0.76	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	12.44	4.87e-23	5.87e-15	1.1	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
GBM	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-12.42	5.62e-23	6.72e-15	-1.01	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
GBM	trans	rs13177918	0.677	rs13161099	ENSG00000226396.1	RP5-1056L3.3	12.41	5.78e-23	6.88e-15	0.89	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.629	rs13161261	ENSG00000226396.1	RP5-1056L3.3	12.41	5.78e-23	6.88e-15	0.89	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:19608114~19608568:+
GBM	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-12.4	6.31e-23	7.51e-15	-1.01	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	12.39	6.39e-23	7.52e-15	0.87	0.76	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
GBM	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	12.39	6.39e-23	7.52e-15	0.87	0.76	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
GBM	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	12.38	6.76e-23	7.94e-15	1	0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
GBM	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	12.33	9.06e-23	1.06e-14	0.88	0.75	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	12.33	9.06e-23	1.06e-14	0.88	0.75	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	12.32	9.58e-23	1.1e-14	0.88	0.75	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	12.32	9.58e-23	1.1e-14	0.88	0.75	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	12.32	9.58e-23	1.1e-14	0.88	0.75	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	12.32	9.58e-23	1.1e-14	0.88	0.75	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	12.32	9.58e-23	1.1e-14	0.88	0.75	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	12.32	9.58e-23	1.1e-14	0.88	0.75	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
GBM	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-12.32	9.66e-23	1.11e-14	-0.89	-0.75	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-12.3	1.07e-22	1.22e-14	-1.02	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-12.28	1.14e-22	1.3e-14	-1.02	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-12.27	1.22e-22	1.38e-14	-1.01	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-12.27	1.22e-22	1.38e-14	-1.01	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	12.27	1.25e-22	1.41e-14	0.87	0.75	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
GBM	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	12.26	1.31e-22	1.45e-14	0.92	0.75	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
GBM	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	12.24	1.43e-22	1.58e-14	0.87	0.75	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-12.24	1.46e-22	1.61e-14	-1.03	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
GBM	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	12.23	1.57e-22	1.71e-14	0.91	0.75	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	12.23	1.57e-22	1.71e-14	0.91	0.75	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
GBM	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	12.22	1.66e-22	1.8e-14	0.87	0.75	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	12.22	1.66e-22	1.8e-14	0.87	0.75	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.75	rs58256223	ENSG00000226396.1	RP5-1056L3.3	12.21	1.67e-22	1.81e-14	0.87	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:19608114~19608568:+
GBM	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	12.13	2.57e-22	2.7e-14	0.87	0.75	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	12.13	2.57e-22	2.7e-14	0.87	0.75	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	12.13	2.57e-22	2.7e-14	0.87	0.75	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.677	rs57890152	ENSG00000226396.1	RP5-1056L3.3	12.11	2.85e-22	2.97e-14	0.89	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.686	rs12654827	ENSG00000226396.1	RP5-1056L3.3	12.11	2.85e-22	2.97e-14	0.89	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.677	rs13160685	ENSG00000226396.1	RP5-1056L3.3	12.11	2.85e-22	2.97e-14	0.89	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:19608114~19608568:+
GBM	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	12.11	2.99e-22	3.08e-14	0.88	0.75	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	12.11	2.99e-22	3.08e-14	0.88	0.75	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	12.11	2.99e-22	3.08e-14	0.88	0.75	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	12.11	2.99e-22	3.08e-14	0.88	0.75	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	12.11	2.99e-22	3.08e-14	0.88	0.75	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	12.11	2.99e-22	3.08e-14	0.88	0.75	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	12.11	2.99e-22	3.08e-14	0.88	0.75	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	12.07	3.59e-22	3.66e-14	0.86	0.75	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	12.07	3.59e-22	3.66e-14	0.86	0.75	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	12.07	3.59e-22	3.66e-14	0.86	0.75	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	12.07	3.59e-22	3.66e-14	0.86	0.75	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	12.07	3.59e-22	3.66e-14	0.86	0.75	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
GBM	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-12.06	3.82e-22	3.86e-14	-0.88	-0.75	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-12.06	3.82e-22	3.86e-14	-0.88	-0.75	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-12.06	3.82e-22	3.86e-14	-0.88	-0.75	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
GBM	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-12.06	3.9e-22	3.92e-14	-1.01	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-12.06	3.9e-22	3.92e-14	-1.01	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	12.04	4.32e-22	4.32e-14	0.88	0.75	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	12.03	4.4e-22	4.38e-14	0.86	0.75	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	12.03	4.4e-22	4.38e-14	0.86	0.75	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
GBM	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-12.03	4.55e-22	4.51e-14	-0.88	-0.75	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
GBM	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	12.02	4.72e-22	4.66e-14	1.19	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
GBM	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	12.02	4.72e-22	4.66e-14	1.19	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
GBM	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	12.02	4.72e-22	4.66e-14	1.19	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
GBM	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	12.02	4.73e-22	4.66e-14	0.99	0.75	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
GBM	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	12	5.21e-22	5.11e-14	0.86	0.75	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
GBM	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	11.99	5.44e-22	5.32e-14	0.99	0.75	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
GBM	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	11.98	5.93e-22	5.71e-14	0.86	0.75	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	11.98	5.93e-22	5.71e-14	0.86	0.75	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	11.98	5.93e-22	5.71e-14	0.86	0.75	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	11.98	6e-22	5.71e-14	0.87	0.74	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
GBM	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-11.97	6.23e-22	5.89e-14	-0.85	-0.74	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-11.97	6.23e-22	5.89e-14	-0.85	-0.74	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
GBM	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-11.97	6.23e-22	5.89e-14	-0.85	-0.74	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
GBM	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	11.93	7.67e-22	7.16e-14	0.88	0.74	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	11.93	7.85e-22	7.32e-14	0.87	0.74	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
GBM	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	11.91	8.34e-22	7.73e-14	0.99	0.74	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
GBM	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	11.91	8.34e-22	7.73e-14	0.99	0.74	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
GBM	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	11.91	8.34e-22	7.73e-14	0.99	0.74	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
GBM	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-11.91	8.55e-22	7.9e-14	-1.09	-0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.75	rs59354956	ENSG00000226396.1	RP5-1056L3.3	11.9	9.22e-22	8.48e-14	0.87	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:19608114~19608568:+
GBM	trans	rs916888	0.773	rs9896243	ENSG00000263503.1	RP11-707O23.5	11.89	9.33e-22	8.56e-14	1.04	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45600869~45602340:-
GBM	trans	rs916888	0.773	rs199439	ENSG00000263503.1	RP11-707O23.5	11.89	9.41e-22	8.63e-14	1.01	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45600869~45602340:-
GBM	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	11.83	1.31e-21	1.19e-13	0.9	0.74	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
GBM	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	11.82	1.36e-21	1.22e-13	1.01	0.74	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
GBM	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	11.82	1.36e-21	1.22e-13	1.01	0.74	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
GBM	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	11.82	1.39e-21	1.25e-13	1.18	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
GBM	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	11.79	1.61e-21	1.44e-13	0.98	0.74	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
GBM	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	11.76	1.93e-21	1.72e-13	1.11	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	11.73	2.27e-21	2.02e-13	1.01	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
GBM	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	11.73	2.3e-21	2.03e-13	0.84	0.74	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	11.73	2.3e-21	2.03e-13	0.84	0.74	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	11.73	2.3e-21	2.03e-13	0.84	0.74	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	11.73	2.3e-21	2.03e-13	0.84	0.74	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	11.73	2.3e-21	2.03e-13	0.84	0.74	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	11.73	2.3e-21	2.03e-13	0.84	0.74	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs538628	ENSG00000263503.1	RP11-707O23.5	11.72	2.43e-21	2.12e-13	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45600869~45602340:-
GBM	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	11.71	2.51e-21	2.2e-13	0.84	0.74	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
GBM	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	11.69	2.82e-21	2.45e-13	0.84	0.74	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	11.69	2.82e-21	2.45e-13	0.84	0.74	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	11.69	2.85e-21	2.48e-13	0.86	0.74	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	11.65	3.53e-21	3.03e-13	1.09	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
GBM	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	11.64	3.57e-21	3.06e-13	0.84	0.74	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
GBM	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-11.63	3.82e-21	3.27e-13	-0.88	-0.74	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
GBM	trans	rs916888	0.773	rs199445	ENSG00000263503.1	RP11-707O23.5	11.62	3.99e-21	3.39e-13	1.01	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45600869~45602340:-
GBM	trans	rs916888	0.773	rs199443	ENSG00000263503.1	RP11-707O23.5	11.62	3.99e-21	3.39e-13	1.01	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45600869~45602340:-
GBM	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	11.6	4.41e-21	3.74e-13	0.84	0.73	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-11.53	6.68e-21	5.59e-13	-0.84	-0.73	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-11.52	7.02e-21	5.86e-13	-1.07	-0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
GBM	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	11.5	7.62e-21	6.32e-13	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-11.5	7.76e-21	6.42e-13	-0.84	-0.73	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs199535	ENSG00000263503.1	RP11-707O23.5	11.5	7.89e-21	6.51e-13	1.01	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45600869~45602340:-
GBM	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	11.46	9.63e-21	7.86e-13	0.84	0.73	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
GBM	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	11.43	1.1e-20	8.97e-13	0.86	0.73	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
GBM	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-11.4	1.29e-20	1.05e-12	-1.01	-0.73	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
GBM	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-11.4	1.33e-20	1.08e-12	-0.88	-0.73	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
GBM	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-11.39	1.37e-20	1.1e-12	-0.94	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
GBM	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-11.38	1.51e-20	1.22e-12	-0.87	-0.73	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	11.37	1.57e-20	1.25e-12	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	11.37	1.57e-20	1.25e-12	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	11.37	1.57e-20	1.25e-12	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	11.37	1.57e-20	1.25e-12	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	11.37	1.57e-20	1.25e-12	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	11.37	1.57e-20	1.25e-12	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	11.37	1.57e-20	1.25e-12	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
GBM	trans	rs916888	0.773	rs169201	ENSG00000263503.1	RP11-707O23.5	11.33	1.92e-20	1.52e-12	0.99	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45600869~45602340:-
GBM	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	11.32	2.09e-20	1.66e-12	0.83	0.73	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
GBM	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	11.31	2.17e-20	1.71e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	11.31	2.2e-20	1.73e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	11.31	2.2e-20	1.73e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	11.31	2.2e-20	1.73e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	11.31	2.2e-20	1.73e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
GBM	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	11.31	2.2e-20	1.73e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	11.31	2.2e-20	1.73e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	11.31	2.2e-20	1.73e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
GBM	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	11.3	2.24e-20	1.76e-12	0.94	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
GBM	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	11.29	2.42e-20	1.88e-12	0.96	0.73	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
GBM	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	11.28	2.56e-20	1.99e-12	0.84	0.72	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs199457	ENSG00000263503.1	RP11-707O23.5	11.26	2.76e-20	2.15e-12	0.98	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45600869~45602340:-
GBM	trans	rs916888	0.687	rs199456	ENSG00000263503.1	RP11-707O23.5	11.24	3.19e-20	2.47e-12	0.98	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45600869~45602340:-
GBM	trans	rs916888	0.773	rs199451	ENSG00000263503.1	RP11-707O23.5	11.24	3.19e-20	2.47e-12	0.98	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45600869~45602340:-
GBM	trans	rs916888	0.773	rs199447	ENSG00000263503.1	RP11-707O23.5	11.19	4.06e-20	3.13e-12	0.98	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	11.19	4.09e-20	3.15e-12	0.93	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs1378358	ENSG00000263503.1	RP11-707O23.5	11.16	4.71e-20	3.63e-12	0.99	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45600869~45602340:-
GBM	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	11.16	4.81e-20	3.69e-12	0.93	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
GBM	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	11.16	4.84e-20	3.71e-12	1.01	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	11.16	4.84e-20	3.71e-12	1.01	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
GBM	trans	rs916888	0.773	rs199534	ENSG00000263503.1	RP11-707O23.5	11.11	6.23e-20	4.75e-12	0.99	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45600869~45602340:-
GBM	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	11.1	6.82e-20	5.16e-12	0.81	0.72	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs199448	ENSG00000263503.1	RP11-707O23.5	11.07	7.66e-20	5.79e-12	0.97	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45600869~45602340:-
GBM	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	11.04	9.31e-20	7.01e-12	0.99	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
GBM	trans	rs916888	0.773	rs199533	ENSG00000263503.1	RP11-707O23.5	11.02	1.04e-19	7.78e-12	0.99	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45600869~45602340:-
GBM	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	11.01	1.12e-19	8.25e-12	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	11.01	1.12e-19	8.25e-12	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	11.01	1.12e-19	8.25e-12	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	11.01	1.12e-19	8.25e-12	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	11.01	1.12e-19	8.25e-12	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	11.01	1.12e-19	8.25e-12	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	11.01	1.12e-19	8.25e-12	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
GBM	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-10.96	1.41e-19	1.02e-11	-0.84	-0.71	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.798	rs12516161	ENSG00000239528.1	RPS14P8	10.89	2.08e-19	1.5e-11	1.12	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	10.83	2.82e-19	2.01e-11	0.99	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
GBM	trans	rs916888	0.779	rs199528	ENSG00000263503.1	RP11-707O23.5	10.83	2.9e-19	2.06e-11	0.98	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs199525	ENSG00000263503.1	RP11-707O23.5	10.83	2.9e-19	2.06e-11	0.98	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45600869~45602340:-
GBM	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-10.66	7.14e-19	4.94e-11	-0.84	-0.71	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
GBM	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	10.58	1.11e-18	7.6e-11	0.97	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
GBM	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	10.57	1.2e-18	8.16e-11	0.89	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	10.56	1.21e-18	8.23e-11	0.8	0.7	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	10.49	1.82e-18	1.23e-10	0.98	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	10.49	1.82e-18	1.23e-10	0.98	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
GBM	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	10.46	2.15e-18	1.42e-10	0.79	0.7	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	10.46	2.15e-18	1.42e-10	0.79	0.7	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	10.46	2.15e-18	1.42e-10	0.79	0.7	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	10.46	2.15e-18	1.42e-10	0.79	0.7	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	10.43	2.5e-18	1.64e-10	0.79	0.7	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	10.43	2.5e-18	1.64e-10	0.79	0.7	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	10.43	2.5e-18	1.64e-10	0.79	0.7	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
GBM	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-10.38	3.27e-18	2.14e-10	-0.83	-0.7	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
GBM	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	10.38	3.29e-18	2.15e-10	0.83	0.7	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
GBM	trans	rs13177918	0.798	rs12516161	ENSG00000226396.1	RP5-1056L3.3	10.37	3.52e-18	2.29e-10	0.82	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.557	rs12520101	ENSG00000226396.1	RP5-1056L3.3	10.36	3.6e-18	2.34e-10	0.76	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	10.32	4.55e-18	2.93e-10	0.95	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
GBM	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	10.3	5.08e-18	3.23e-10	0.79	0.69	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	10.28	5.67e-18	3.57e-10	0.81	0.69	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
GBM	trans	rs13177918	1	rs13161334	ENSG00000226396.1	RP5-1056L3.3	10.16	1.08e-17	6.65e-10	0.82	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:19608114~19608568:+
GBM	trans	rs13177918	1	rs35007082	ENSG00000226396.1	RP5-1056L3.3	10.16	1.08e-17	6.65e-10	0.82	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:19608114~19608568:+
GBM	trans	rs13177918	1	rs13177918	ENSG00000226396.1	RP5-1056L3.3	10.16	1.08e-17	6.65e-10	0.82	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:19608114~19608568:+
GBM	trans	rs916888	0.821	rs199506	ENSG00000263503.1	RP11-707O23.5	-10.15	1.14e-17	7e-10	-0.91	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45600869~45602340:-
GBM	trans	rs916888	0.697	rs199516	ENSG00000263503.1	RP11-707O23.5	-10.12	1.31e-17	7.98e-10	-0.9	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45600869~45602340:-
GBM	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	10.11	1.4e-17	8.52e-10	0.76	0.69	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
GBM	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	10.1	1.47e-17	8.89e-10	0.93	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
GBM	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	10.1	1.5e-17	9.06e-10	0.8	0.69	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
GBM	trans	rs916888	0.821	rs199514	ENSG00000263503.1	RP11-707O23.5	-10.09	1.54e-17	9.33e-10	-0.91	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45600869~45602340:-
GBM	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	10.06	1.81e-17	1.09e-09	0.93	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-10.05	1.91e-17	1.15e-09	-0.77	-0.68	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
GBM	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-10.05	1.91e-17	1.15e-09	-0.77	-0.68	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
GBM	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	10.04	2.04e-17	1.22e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
GBM	trans	rs916888	0.821	rs70600	ENSG00000263503.1	RP11-707O23.5	10.02	2.34e-17	1.4e-09	0.9	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45600869~45602340:-
GBM	trans	rs916888	0.738	rs199515	ENSG00000263503.1	RP11-707O23.5	-10	2.5e-17	1.49e-09	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45600869~45602340:-
GBM	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	9.99	2.75e-17	1.63e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	9.99	2.75e-17	1.63e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	9.99	2.75e-17	1.63e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	9.99	2.75e-17	1.63e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	9.99	2.75e-17	1.63e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	9.99	2.75e-17	1.63e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	9.99	2.75e-17	1.63e-09	0.98	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
GBM	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-9.97	3.01e-17	1.78e-09	-0.77	-0.68	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
GBM	trans	rs916888	0.821	rs199504	ENSG00000263503.1	RP11-707O23.5	-9.93	3.72e-17	2.19e-09	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45600869~45602340:-
GBM	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	9.93	3.74e-17	2.19e-09	0.91	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.906	rs12652032	ENSG00000226396.1	RP5-1056L3.3	9.87	5.1e-17	2.99e-09	0.81	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:19608114~19608568:+
GBM	trans	rs916888	0.821	rs199512	ENSG00000263503.1	RP11-707O23.5	-9.85	5.6e-17	3.25e-09	-0.89	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs199509	ENSG00000263503.1	RP11-707O23.5	-9.85	5.6e-17	3.25e-09	-0.89	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs199507	ENSG00000263503.1	RP11-707O23.5	-9.85	5.6e-17	3.25e-09	-0.89	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs415430	ENSG00000263503.1	RP11-707O23.5	-9.85	5.6e-17	3.25e-09	-0.89	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45600869~45602340:-
GBM	trans	rs916888	0.779	rs430685	ENSG00000263503.1	RP11-707O23.5	-9.85	5.6e-17	3.25e-09	-0.89	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs199505	ENSG00000263503.1	RP11-707O23.5	-9.85	5.6e-17	3.25e-09	-0.89	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs70602	ENSG00000263503.1	RP11-707O23.5	-9.85	5.6e-17	3.25e-09	-0.89	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45600869~45602340:-
GBM	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-9.83	6.28e-17	3.63e-09	-0.82	-0.68	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
GBM	trans	rs7312770	0.637	rs705700	ENSG00000196656.7	AC004057.1	9.82	6.91e-17	3.99e-09	0.73	0.68	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr4:113214046~113217170:-
GBM	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	9.8	7.7e-17	4.41e-09	1.04	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.626	rs3819332	ENSG00000226396.1	RP5-1056L3.3	9.79	8.15e-17	4.63e-09	0.73	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.626	rs13170300	ENSG00000226396.1	RP5-1056L3.3	9.79	8.15e-17	4.63e-09	0.73	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.626	rs13175436	ENSG00000226396.1	RP5-1056L3.3	9.79	8.15e-17	4.63e-09	0.73	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.603	rs13175992	ENSG00000226396.1	RP5-1056L3.3	9.79	8.15e-17	4.63e-09	0.73	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.626	rs67026795	ENSG00000226396.1	RP5-1056L3.3	9.79	8.15e-17	4.63e-09	0.73	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.578	rs35919198	ENSG00000226396.1	RP5-1056L3.3	9.79	8.15e-17	4.63e-09	0.73	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.603	rs10447222	ENSG00000226396.1	RP5-1056L3.3	9.79	8.15e-17	4.63e-09	0.73	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:19608114~19608568:+
GBM	trans	rs916888	0.779	rs199526	ENSG00000214425.5	LRRC37A4P	9.76	9.45e-17	5.35e-09	0.88	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	9.74	1.04e-16	5.87e-09	0.79	0.67	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	9.73	1.08e-16	6.04e-09	0.75	0.67	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	9.73	1.08e-16	6.04e-09	0.75	0.67	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	9.73	1.08e-16	6.04e-09	0.75	0.67	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	9.73	1.08e-16	6.04e-09	0.75	0.67	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	9.73	1.08e-16	6.04e-09	0.75	0.67	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	9.73	1.08e-16	6.04e-09	0.75	0.67	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	9.73	1.08e-16	6.04e-09	0.75	0.67	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
GBM	trans	rs8081395	0.627	rs180536	ENSG00000187870.7	RNFT1P3	9.72	1.14e-16	6.37e-09	0.87	0.67	White blood cell count;	chr17:59919445	chr17:20743333~20754501:-
GBM	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	9.72	1.19e-16	6.58e-09	1.1	0.67	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	9.72	1.19e-16	6.58e-09	1.1	0.67	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
GBM	trans	rs8081395	0.58	rs180515	ENSG00000187870.7	RNFT1P3	9.71	1.23e-16	6.82e-09	0.87	0.67	White blood cell count;	chr17:59946914	chr17:20743333~20754501:-
GBM	trans	rs7312770	0.637	rs705699	ENSG00000196656.7	AC004057.1	9.7	1.3e-16	7.19e-09	0.73	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr4:113214046~113217170:-
GBM	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-9.67	1.56e-16	8.51e-09	-0.84	-0.67	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
GBM	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-9.67	1.56e-16	8.51e-09	-0.84	-0.67	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
GBM	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-9.67	1.56e-16	8.51e-09	-0.84	-0.67	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
GBM	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	9.63	1.83e-16	9.86e-09	0.74	0.67	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	9.62	2.01e-16	1.08e-08	0.94	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-9.56	2.79e-16	1.49e-08	-1.01	-0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
GBM	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	9.56	2.81e-16	1.5e-08	0.82	0.67	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
GBM	trans	rs916888	0.821	rs199513	ENSG00000263503.1	RP11-707O23.5	-9.55	2.88e-16	1.53e-08	-0.86	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45600869~45602340:-
GBM	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	9.54	3.12e-16	1.66e-08	1.05	0.66	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
GBM	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-9.53	3.23e-16	1.71e-08	-0.83	-0.66	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
GBM	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-9.53	3.23e-16	1.71e-08	-0.83	-0.66	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
GBM	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	9.52	3.38e-16	1.79e-08	0.89	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
GBM	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	9.52	3.39e-16	1.79e-08	0.93	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
GBM	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	9.52	3.48e-16	1.83e-08	0.83	0.66	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
GBM	trans	rs13177918	0.559	rs10447224	ENSG00000226396.1	RP5-1056L3.3	9.49	4e-16	2.1e-08	0.72	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.559	rs10447225	ENSG00000226396.1	RP5-1056L3.3	9.49	4e-16	2.1e-08	0.72	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:19608114~19608568:+
GBM	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	9.46	4.73e-16	2.45e-08	1.07	0.66	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	9.46	4.73e-16	2.45e-08	1.07	0.66	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	9.46	4.73e-16	2.45e-08	1.07	0.66	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	9.46	4.73e-16	2.45e-08	1.07	0.66	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
GBM	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	9.43	5.41e-16	2.78e-08	0.88	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
GBM	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	9.43	5.41e-16	2.78e-08	0.88	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
GBM	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	9.38	7.04e-16	3.6e-08	1.07	0.66	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	9.38	7.28e-16	3.72e-08	1.06	0.66	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
GBM	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	9.36	8.01e-16	4.08e-08	0.7	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
GBM	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	9.34	8.96e-16	4.55e-08	0.88	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
GBM	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	9.32	1.01e-15	5.07e-08	1.06	0.66	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	9.32	1.01e-15	5.07e-08	1.06	0.66	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
GBM	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-9.31	1.05e-15	5.29e-08	-0.77	-0.66	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
GBM	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	9.29	1.14e-15	5.71e-08	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
GBM	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	9.29	1.14e-15	5.71e-08	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
GBM	trans	rs13177918	0.559	rs12109637	ENSG00000226396.1	RP5-1056L3.3	9.28	1.21e-15	6.03e-08	0.69	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	9.25	1.43e-15	7e-08	0.95	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	9.25	1.43e-15	7e-08	0.95	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	9.24	1.51e-15	7.36e-08	0.92	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
GBM	trans	rs8081395	0.603	rs1292047	ENSG00000187870.7	RNFT1P3	9.24	1.55e-15	7.54e-08	0.87	0.65	White blood cell count;	chr17:59877805	chr17:20743333~20754501:-
GBM	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	9.24	1.55e-15	7.55e-08	1.06	0.65	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
GBM	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	9.22	1.66e-15	8.06e-08	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
GBM	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	9.22	1.66e-15	8.06e-08	0.87	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
GBM	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	9.22	1.69e-15	8.17e-08	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
GBM	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	9.22	1.72e-15	8.33e-08	0.81	0.65	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
GBM	trans	rs916888	0.779	rs199526	ENSG00000263503.1	RP11-707O23.5	-9.19	1.95e-15	9.41e-08	-0.87	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45600869~45602340:-
GBM	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-9.18	2.07e-15	9.91e-08	-0.84	-0.65	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
GBM	trans	rs8081395	0.627	rs12952730	ENSG00000187870.7	RNFT1P3	9.18	2.12e-15	1.02e-07	0.85	0.65	White blood cell count;	chr17:59901475	chr17:20743333~20754501:-
GBM	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-9.1	3.3e-15	1.49e-07	-0.81	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
GBM	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-9.1	3.3e-15	1.49e-07	-0.81	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
GBM	trans	rs13177918	0.798	rs2343805	ENSG00000224114.1	RP11-343H5.4	9.09	3.48e-15	1.56e-07	0.91	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr1:206695837~206696269:-
GBM	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	9.08	3.56e-15	1.6e-07	0.72	0.65	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
GBM	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	9.07	3.89e-15	1.73e-07	1.03	0.65	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000212829.8	RPS26P3	-9.07	3.89e-15	1.73e-07	-0.73	-0.65	Cognitive function;	chr12:56084218	chr9:9090898~9091245:+
GBM	trans	rs877636	0.692	rs7971751	ENSG00000212829.8	RPS26P3	-9.07	3.89e-15	1.73e-07	-0.73	-0.65	Cognitive function;	chr12:56084874	chr9:9090898~9091245:+
GBM	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-9.05	4.13e-15	1.83e-07	-0.7	-0.65	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
GBM	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-9.05	4.25e-15	1.87e-07	-0.83	-0.64	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
GBM	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-9.04	4.46e-15	1.95e-07	-0.84	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
GBM	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	9.04	4.52e-15	1.98e-07	1.06	0.64	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
GBM	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-9.02	4.89e-15	2.12e-07	-0.84	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
GBM	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	9.02	5.01e-15	2.16e-07	1.03	0.64	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
GBM	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	9.01	5.2e-15	2.24e-07	0.8	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
GBM	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	9.01	5.2e-15	2.24e-07	0.8	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
GBM	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	8.97	6.34e-15	2.71e-07	0.87	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
GBM	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-8.96	6.88e-15	2.89e-07	-0.76	-0.64	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
GBM	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-8.96	6.88e-15	2.89e-07	-0.76	-0.64	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
GBM	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-8.96	7.03e-15	2.95e-07	-0.74	-0.64	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	8.95	7.41e-15	3.09e-07	0.76	0.64	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
GBM	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-8.94	7.53e-15	3.13e-07	-0.84	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
GBM	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-8.93	8.08e-15	3.33e-07	-0.71	-0.64	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	8.92	8.63e-15	3.53e-07	0.78	0.64	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	8.92	8.63e-15	3.53e-07	0.78	0.64	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
GBM	trans	rs7614738	1	rs7614738	ENSG00000197582.5	GPX1P1	8.91	8.93e-15	3.64e-07	0.78	0.64	Red cell distribution width;	chr3:49273698	chrX:13378735~13379340:-
GBM	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	8.9	9.23e-15	3.76e-07	0.78	0.64	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
GBM	trans	rs916888	0.61	rs199446	ENSG00000263503.1	RP11-707O23.5	-8.9	9.52e-15	3.88e-07	-0.81	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45600869~45602340:-
GBM	trans	rs916888	0.61	rs199536	ENSG00000263503.1	RP11-707O23.5	-8.9	9.52e-15	3.88e-07	-0.81	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45600869~45602340:-
GBM	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	8.9	9.61e-15	3.9e-07	0.78	0.64	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	8.9	9.61e-15	3.9e-07	0.78	0.64	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	8.9	9.61e-15	3.9e-07	0.78	0.64	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	8.89	9.79e-15	3.97e-07	0.78	0.64	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
GBM	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-8.88	1.08e-14	4.35e-07	-0.72	-0.64	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
GBM	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	8.87	1.12e-14	4.51e-07	0.84	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
GBM	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	8.87	1.13e-14	4.55e-07	0.88	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
GBM	trans	rs916888	0.61	rs199444	ENSG00000263503.1	RP11-707O23.5	8.84	1.3e-14	5.2e-07	0.81	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45600869~45602340:-
GBM	trans	rs916888	0.61	rs199442	ENSG00000263503.1	RP11-707O23.5	8.84	1.3e-14	5.2e-07	0.81	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45600869~45602340:-
GBM	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-8.84	1.33e-14	5.32e-07	-0.81	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
GBM	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	8.83	1.36e-14	5.44e-07	1.07	0.64	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
GBM	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	8.83	1.38e-14	5.53e-07	0.86	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
GBM	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-8.82	1.45e-14	5.75e-07	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
GBM	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-8.82	1.45e-14	5.75e-07	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
GBM	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-8.82	1.45e-14	5.75e-07	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
GBM	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-8.82	1.45e-14	5.75e-07	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
GBM	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-8.82	1.45e-14	5.75e-07	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
GBM	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-8.82	1.45e-14	5.75e-07	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
GBM	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-8.82	1.45e-14	5.75e-07	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
GBM	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-8.8	1.63e-14	6.41e-07	-0.75	-0.63	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
GBM	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-8.79	1.65e-14	6.45e-07	-0.83	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
GBM	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	8.78	1.79e-14	6.95e-07	0.78	0.63	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
GBM	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	8.78	1.83e-14	7.04e-07	0.86	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
GBM	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	8.78	1.83e-14	7.04e-07	0.86	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
GBM	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-8.76	2.02e-14	7.46e-07	-0.71	-0.63	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-8.75	2.05e-14	7.46e-07	-0.77	-0.63	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-8.75	2.05e-14	7.46e-07	-0.77	-0.63	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	8.75	2.05e-14	7.46e-07	0.77	0.63	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
GBM	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-8.75	2.15e-14	7.82e-07	-0.83	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
GBM	trans	rs7312770	0.612	rs773114	ENSG00000212829.8	RPS26P3	8.74	2.16e-14	7.84e-07	0.68	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:9090898~9091245:+
GBM	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	8.74	2.22e-14	8.05e-07	0.77	0.63	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
GBM	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	8.74	2.22e-14	8.05e-07	0.77	0.63	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
GBM	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	8.73	2.28e-14	8.25e-07	0.77	0.63	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
GBM	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	8.71	2.65e-14	9.56e-07	0.99	0.63	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
GBM	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	8.7	2.75e-14	9.88e-07	0.77	0.63	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
GBM	trans	rs13177918	0.798	rs2343805	ENSG00000213058.3	RP4-765C7.2	8.7	2.76e-14	9.91e-07	0.89	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr1:178411616~178411972:+
GBM	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	8.7	2.79e-14	1e-06	0.77	0.63	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
GBM	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	8.68	2.96e-14	1.06e-06	0.76	0.63	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
GBM	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-8.68	3.08e-14	1.1e-06	-0.64	-0.63	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
GBM	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	8.66	3.43e-14	1.22e-06	1.02	0.63	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
GBM	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	8.66	3.47e-14	1.23e-06	0.73	0.63	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	8.65	3.48e-14	1.23e-06	0.77	0.63	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	8.65	3.49e-14	1.23e-06	0.77	0.63	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	8.65	3.49e-14	1.23e-06	0.77	0.63	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	8.65	3.49e-14	1.23e-06	0.77	0.63	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
GBM	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	8.65	3.62e-14	1.28e-06	0.79	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
GBM	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	8.65	3.62e-14	1.28e-06	0.79	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
GBM	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-8.64	3.66e-14	1.29e-06	-0.74	-0.63	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
GBM	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-8.64	3.67e-14	1.29e-06	-0.69	-0.63	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
GBM	trans	rs916888	0.61	rs199530	ENSG00000263503.1	RP11-707O23.5	-8.64	3.69e-14	1.3e-06	-0.79	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45600869~45602340:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-8.64	3.75e-14	1.32e-06	-0.63	-0.63	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
GBM	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-8.64	3.75e-14	1.32e-06	-0.63	-0.63	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
GBM	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	8.64	3.85e-14	1.35e-06	0.76	0.63	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
GBM	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	8.63	3.97e-14	1.39e-06	0.96	0.63	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
GBM	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-8.62	4.12e-14	1.44e-06	-0.72	-0.63	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-8.62	4.12e-14	1.44e-06	-0.72	-0.63	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	8.62	4.22e-14	1.47e-06	0.72	0.63	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	8.61	4.35e-14	1.52e-06	0.73	0.63	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
GBM	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	8.6	4.61e-14	1.61e-06	0.73	0.63	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
GBM	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	8.6	4.64e-14	1.61e-06	0.75	0.63	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
GBM	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-8.6	4.67e-14	1.62e-06	-0.72	-0.63	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-8.6	4.67e-14	1.62e-06	-0.72	-0.63	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
GBM	trans	rs916888	0.647	rs199524	ENSG00000263503.1	RP11-707O23.5	-8.59	4.81e-14	1.67e-06	-0.8	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45600869~45602340:-
GBM	trans	rs916888	0.647	rs199523	ENSG00000263503.1	RP11-707O23.5	-8.59	4.81e-14	1.67e-06	-0.8	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45600869~45602340:-
GBM	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	8.59	5.01e-14	1.73e-06	0.74	0.63	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	8.59	5.01e-14	1.73e-06	0.74	0.63	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	8.59	5.01e-14	1.73e-06	0.74	0.63	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
GBM	trans	rs13177918	0.798	rs12514700	ENSG00000226396.1	RP5-1056L3.3	8.58	5.2e-14	1.8e-06	0.72	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:19608114~19608568:+
GBM	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-8.58	5.23e-14	1.81e-06	-0.71	-0.62	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
GBM	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	8.58	5.31e-14	1.83e-06	0.84	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
GBM	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	8.57	5.52e-14	1.9e-06	0.77	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
GBM	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-8.56	5.86e-14	2.01e-06	-0.74	-0.62	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-8.56	5.86e-14	2.01e-06	-0.74	-0.62	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-8.56	5.86e-14	2.01e-06	-0.74	-0.62	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-8.55	5.95e-14	2.04e-06	-0.74	-0.62	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.626	rs2748240	ENSG00000226396.1	RP5-1056L3.3	8.55	5.96e-14	2.04e-06	0.67	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:19608114~19608568:+
GBM	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	8.55	6e-14	2.05e-06	0.73	0.62	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	8.55	6e-14	2.05e-06	0.73	0.62	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
GBM	trans	rs916888	0.61	rs199454	ENSG00000263503.1	RP11-707O23.5	-8.55	6.09e-14	2.08e-06	-0.78	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45600869~45602340:-
GBM	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	8.55	6.09e-14	2.08e-06	0.73	0.62	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	8.55	6.09e-14	2.08e-06	0.73	0.62	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-8.55	6.09e-14	2.08e-06	-0.73	-0.62	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
GBM	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	8.55	6.18e-14	2.1e-06	0.7	0.62	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
GBM	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	8.53	6.61e-14	2.24e-06	1.04	0.62	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
GBM	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-8.51	7.47e-14	2.52e-06	-0.69	-0.62	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	8.51	7.48e-14	2.52e-06	0.75	0.62	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	8.51	7.5e-14	2.52e-06	0.73	0.62	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	8.51	7.5e-14	2.52e-06	0.73	0.62	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	8.51	7.6e-14	2.55e-06	0.75	0.62	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	8.51	7.6e-14	2.55e-06	0.75	0.62	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
GBM	trans	rs916888	0.61	rs199452	ENSG00000263503.1	RP11-707O23.5	8.5	7.81e-14	2.55e-06	0.77	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45600869~45602340:-
GBM	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-8.5	7.81e-14	2.55e-06	-0.73	-0.62	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-8.5	7.84e-14	2.55e-06	-0.74	-0.62	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	8.5	7.84e-14	2.55e-06	0.74	0.62	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
GBM	trans	rs916888	0.61	rs199453	ENSG00000263503.1	RP11-707O23.5	8.5	7.85e-14	2.55e-06	0.77	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45600869~45602340:-
GBM	trans	rs916888	0.647	rs199449	ENSG00000263503.1	RP11-707O23.5	8.5	7.85e-14	2.55e-06	0.77	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45600869~45602340:-
GBM	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-8.5	7.99e-14	2.6e-06	-0.9	-0.62	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
GBM	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	8.5	8.08e-14	2.63e-06	0.73	0.62	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
GBM	trans	rs7312770	0.637	rs705700	ENSG00000212829.8	RPS26P3	8.49	8.21e-14	2.67e-06	0.68	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:9090898~9091245:+
GBM	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-8.49	8.24e-14	2.68e-06	-0.73	-0.62	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-8.49	8.39e-14	2.72e-06	-0.74	-0.62	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-8.49	8.4e-14	2.73e-06	-0.69	-0.62	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
GBM	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	8.48	8.75e-14	2.84e-06	0.85	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
GBM	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-8.48	9.01e-14	2.91e-06	-0.71	-0.62	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-8.48	9.01e-14	2.91e-06	-0.71	-0.62	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	8.47	9.24e-14	2.98e-06	0.73	0.62	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	8.47	9.24e-14	2.98e-06	0.73	0.62	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-8.45	1.05e-13	3.17e-06	-0.68	-0.62	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
GBM	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	8.44	1.06e-13	3.17e-06	0.74	0.62	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
GBM	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	8.44	1.1e-13	3.26e-06	0.83	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
GBM	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.3e-06	-0.72	-0.62	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-8.43	1.12e-13	3.31e-06	-0.72	-0.62	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-8.43	1.13e-13	3.32e-06	-0.72	-0.62	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-8.43	1.13e-13	3.32e-06	-0.72	-0.62	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-8.43	1.13e-13	3.32e-06	-0.72	-0.62	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-8.43	1.13e-13	3.32e-06	-0.72	-0.62	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-8.43	1.13e-13	3.32e-06	-0.72	-0.62	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	8.43	1.15e-13	3.39e-06	0.74	0.62	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	8.43	1.15e-13	3.39e-06	0.74	0.62	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	8.42	1.18e-13	3.46e-06	0.74	0.62	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	8.42	1.22e-13	3.56e-06	0.74	0.62	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	8.42	1.22e-13	3.58e-06	0.75	0.62	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	8.41	1.28e-13	3.73e-06	0.75	0.62	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	8.4	1.31e-13	3.82e-06	0.73	0.62	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	8.4	1.35e-13	3.91e-06	0.76	0.62	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	8.39	1.44e-13	4.16e-06	0.74	0.62	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	8.39	1.44e-13	4.16e-06	0.74	0.62	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
GBM	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-8.37	1.54e-13	4.43e-06	-0.72	-0.62	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-8.37	1.55e-13	4.45e-06	-0.71	-0.62	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.798	rs13182116	ENSG00000226396.1	RP5-1056L3.3	-8.37	1.56e-13	4.47e-06	-0.7	-0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:19608114~19608568:+
GBM	trans	rs7312770	0.637	rs705699	ENSG00000212829.8	RPS26P3	8.37	1.57e-13	4.49e-06	0.67	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr9:9090898~9091245:+
GBM	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-8.36	1.62e-13	4.56e-06	-0.72	-0.62	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.603	rs2343806	ENSG00000226396.1	RP5-1056L3.3	8.36	1.62e-13	4.56e-06	0.65	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:19608114~19608568:+
GBM	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-8.36	1.69e-13	4.73e-06	-0.75	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
GBM	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-8.36	1.69e-13	4.73e-06	-0.75	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
GBM	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	8.35	1.78e-13	4.99e-06	0.72	0.61	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
GBM	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	8.34	1.85e-13	5.16e-06	0.98	0.61	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
GBM	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	8.33	1.91e-13	5.32e-06	0.73	0.61	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
GBM	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-8.33	1.92e-13	5.35e-06	-0.7	-0.61	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
GBM	trans	rs916888	0.779	rs199526	ENSG00000264070.1	DND1P1	-8.33	1.94e-13	5.4e-06	-0.81	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45585871~45586929:+
GBM	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-8.32	2e-13	5.53e-06	-0.71	-0.61	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-8.32	2e-13	5.53e-06	-0.71	-0.61	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-8.32	2e-13	5.53e-06	-0.71	-0.61	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-8.32	2e-13	5.53e-06	-0.71	-0.61	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-8.32	2e-13	5.53e-06	-0.71	-0.61	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
GBM	trans	rs916888	0.61	rs199438	ENSG00000263503.1	RP11-707O23.5	8.32	2.02e-13	5.57e-06	0.77	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45600869~45602340:-
GBM	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	8.32	2.03e-13	5.62e-06	0.91	0.61	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
GBM	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	8.32	2.06e-13	5.7e-06	0.74	0.61	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	8.3	2.29e-13	6.18e-06	0.73	0.61	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-8.3	2.29e-13	6.18e-06	-0.73	-0.61	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	8.29	2.36e-13	6.37e-06	0.71	0.61	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	8.29	2.38e-13	6.42e-06	0.76	0.61	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
GBM	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-8.29	2.39e-13	6.44e-06	-0.74	-0.61	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
GBM	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	8.29	2.44e-13	6.58e-06	0.73	0.61	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	8.28	2.51e-13	6.7e-06	0.72	0.61	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	8.28	2.51e-13	6.7e-06	0.72	0.61	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
GBM	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	8.28	2.54e-13	6.77e-06	0.75	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
GBM	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-8.28	2.59e-13	6.89e-06	-0.77	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
GBM	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-8.28	2.59e-13	6.89e-06	-0.77	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
GBM	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	8.27	2.6e-13	6.89e-06	0.73	0.61	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	8.27	2.6e-13	6.89e-06	0.73	0.61	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	8.27	2.6e-13	6.89e-06	0.73	0.61	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	8.27	2.6e-13	6.89e-06	0.73	0.61	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	8.27	2.6e-13	6.89e-06	0.73	0.61	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	8.27	2.6e-13	6.89e-06	0.73	0.61	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
GBM	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	8.27	2.65e-13	7.03e-06	0.98	0.61	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	8.27	2.65e-13	7.03e-06	0.98	0.61	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
GBM	trans	rs916888	0.61	rs199436	ENSG00000263503.1	RP11-707O23.5	-8.27	2.69e-13	7.12e-06	-0.76	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45600869~45602340:-
GBM	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	8.26	2.78e-13	7.32e-06	0.9	0.61	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
GBM	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	8.26	2.78e-13	7.32e-06	0.9	0.61	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
GBM	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-8.25	2.95e-13	7.75e-06	-0.73	-0.61	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
GBM	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-8.24	3.11e-13	8.13e-06	-0.75	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
GBM	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-8.24	3.14e-13	8.22e-06	-0.71	-0.61	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-8.23	3.23e-13	8.43e-06	-0.74	-0.61	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	8.23	3.34e-13	8.69e-06	0.7	0.61	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
GBM	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-8.21	3.55e-13	9.2e-06	-0.69	-0.61	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-8.21	3.55e-13	9.2e-06	-0.69	-0.61	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-8.21	3.55e-13	9.2e-06	-0.69	-0.61	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-8.21	3.55e-13	9.2e-06	-0.69	-0.61	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-8.21	3.55e-13	9.2e-06	-0.69	-0.61	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-8.21	3.55e-13	9.2e-06	-0.69	-0.61	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	8.21	3.57e-13	9.25e-06	0.73	0.61	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	8.21	3.58e-13	9.25e-06	0.73	0.61	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	8.21	3.58e-13	9.25e-06	0.73	0.61	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	8.21	3.58e-13	9.25e-06	0.73	0.61	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	8.21	3.7e-13	9.55e-06	0.76	0.61	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
GBM	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	8.2	3.81e-13	9.81e-06	0.6	0.61	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-8.2	3.89e-13	1e-05	-0.67	-0.61	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
GBM	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-8.2	3.89e-13	1e-05	-0.67	-0.61	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
GBM	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	8.19	4.01e-13	1.03e-05	0.74	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
GBM	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	8.18	4.19e-13	1.07e-05	0.71	0.61	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	8.18	4.19e-13	1.07e-05	0.71	0.61	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
GBM	trans	rs13253073	0.525	rs35509895	ENSG00000260318.1	COX6CP1	8.18	4.33e-13	1.1e-05	1.07	0.61	Glucose homeostasis traits;	chr8:99872093	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	8.17	4.56e-13	1.16e-05	0.98	0.61	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
GBM	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	8.15	5.11e-13	1.3e-05	0.97	0.6	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
GBM	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	8.14	5.13e-13	1.3e-05	0.81	0.6	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
GBM	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	8.14	5.21e-13	1.32e-05	0.73	0.6	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	8.13	5.58e-13	1.41e-05	0.7	0.6	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	8.11	6.13e-13	1.53e-05	0.71	0.6	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
GBM	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	8.1	6.55e-13	1.64e-05	0.8	0.6	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	8.1	6.55e-13	1.64e-05	0.8	0.6	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
GBM	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	8.1	6.55e-13	1.64e-05	0.8	0.6	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	8.1	6.55e-13	1.64e-05	0.8	0.6	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
GBM	trans	rs916888	0.602	rs199508	ENSG00000214425.5	LRRC37A4P	8.09	6.84e-13	1.71e-05	0.73	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:45506741~45550335:-
GBM	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	8.09	6.91e-13	1.72e-05	0.76	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
GBM	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	8.09	6.91e-13	1.72e-05	0.76	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
GBM	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-8.08	7.03e-13	1.75e-05	-0.71	-0.6	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
GBM	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-8.08	7.17e-13	1.78e-05	-0.73	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
GBM	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	8.07	7.74e-13	1.92e-05	1.01	0.6	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
GBM	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-8.07	7.78e-13	1.93e-05	-0.85	-0.6	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-8.07	7.78e-13	1.93e-05	-0.72	-0.6	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	8.07	7.78e-13	1.93e-05	0.72	0.6	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-8.06	7.82e-13	1.94e-05	-0.73	-0.6	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
GBM	trans	rs13177918	0.603	rs2748241	ENSG00000226396.1	RP5-1056L3.3	8.06	7.85e-13	1.94e-05	0.63	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:19608114~19608568:+
GBM	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-8.06	7.94e-13	1.97e-05	-0.66	-0.6	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
GBM	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	8.06	7.97e-13	1.97e-05	0.74	0.6	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
GBM	trans	rs916888	0.531	rs183211	ENSG00000263503.1	RP11-707O23.5	8.05	8.43e-13	2.08e-05	0.74	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45600869~45602340:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-8.04	8.76e-13	2.16e-05	-0.59	-0.6	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
GBM	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-8.03	9.16e-13	2.26e-05	-0.72	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-8.03	9.17e-13	2.26e-05	-0.69	-0.6	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
GBM	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	8.03	9.28e-13	2.28e-05	0.86	0.6	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
GBM	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	8.02	1e-12	2.45e-05	0.72	0.6	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
GBM	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	8.01	1.05e-12	2.56e-05	0.8	0.6	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
GBM	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	8	1.07e-12	2.61e-05	0.63	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-7.99	1.17e-12	2.83e-05	-0.66	-0.6	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
GBM	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-7.99	1.17e-12	2.83e-05	-0.66	-0.6	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
GBM	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	7.99	1.17e-12	2.84e-05	0.65	0.6	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
GBM	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	7.98	1.22e-12	2.95e-05	0.8	0.6	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
GBM	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	7.98	1.22e-12	2.95e-05	0.8	0.6	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
GBM	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-7.97	1.3e-12	3.13e-05	-0.76	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
GBM	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-7.97	1.3e-12	3.13e-05	-0.76	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
GBM	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	7.97	1.3e-12	3.14e-05	0.71	0.6	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
GBM	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	7.96	1.32e-12	3.19e-05	0.58	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
GBM	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	7.96	1.35e-12	3.25e-05	0.56	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
GBM	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	7.95	1.4e-12	3.37e-05	0.73	0.6	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-7.95	1.44e-12	3.46e-05	-0.88	-0.6	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	7.94	1.47e-12	3.52e-05	0.97	0.6	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-7.94	1.53e-12	3.66e-05	-0.88	-0.59	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
GBM	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	7.93	1.55e-12	3.71e-05	0.82	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
GBM	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	7.93	1.55e-12	3.71e-05	0.82	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
GBM	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	7.92	1.62e-12	3.85e-05	0.97	0.59	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
GBM	trans	rs13177918	0.798	rs2343805	ENSG00000226396.1	RP5-1056L3.3	7.92	1.68e-12	4e-05	0.65	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr1:19608114~19608568:+
GBM	trans	rs7312770	0.637	rs705699	ENSG00000225071.1	GS1-184P14.2	7.9	1.82e-12	4.32e-05	0.57	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:24429573~24429920:-
GBM	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	7.89	1.98e-12	4.7e-05	0.93	0.59	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-7.88	2.01e-12	4.77e-05	-0.71	-0.59	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	7.88	2.03e-12	4.79e-05	0.96	0.59	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	7.88	2.03e-12	4.79e-05	0.96	0.59	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	7.88	2.03e-12	4.79e-05	0.96	0.59	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	7.88	2.03e-12	4.79e-05	0.96	0.59	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	7.88	2.03e-12	4.79e-05	0.96	0.59	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	7.88	2.03e-12	4.79e-05	0.96	0.59	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-7.88	2.05e-12	4.83e-05	-0.65	-0.59	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
GBM	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-7.88	2.05e-12	4.83e-05	-0.65	-0.59	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
GBM	trans	rs3749237	0.964	rs10865959	ENSG00000197582.5	GPX1P1	7.87	2.18e-12	5.14e-05	0.8	0.59	Resting heart rate;	chr3:49853569	chrX:13378735~13379340:-
GBM	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	7.86	2.22e-12	5.22e-05	0.72	0.59	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
GBM	trans	rs13177918	0.798	rs2343805	ENSG00000239528.1	RPS14P8	7.86	2.27e-12	5.33e-05	0.86	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr5:116562562~116562930:+
GBM	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	7.85	2.36e-12	5.54e-05	0.93	0.59	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	7.85	2.39e-12	5.59e-05	0.95	0.59	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	7.85	2.39e-12	5.59e-05	0.95	0.59	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	7.85	2.39e-12	5.59e-05	0.95	0.59	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
GBM	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-7.84	2.45e-12	5.72e-05	-0.7	-0.59	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
GBM	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	7.83	2.66e-12	6.19e-05	0.8	0.59	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	7.83	2.66e-12	6.19e-05	0.8	0.59	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
GBM	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	7.83	2.66e-12	6.19e-05	0.8	0.59	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
GBM	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-7.82	2.8e-12	6.47e-05	-0.74	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
GBM	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	7.82	2.83e-12	6.53e-05	0.7	0.59	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	7.81	2.91e-12	6.7e-05	0.92	0.59	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	7.81	2.94e-12	6.76e-05	0.7	0.59	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-7.8	3.03e-12	6.97e-05	-0.65	-0.59	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
GBM	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	7.8	3.09e-12	7.11e-05	0.79	0.59	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
GBM	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-7.79	3.21e-12	7.37e-05	-0.76	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
GBM	trans	rs11098499	0.954	rs6857105	ENSG00000275858.1	RP11-291L22.8	7.79	3.21e-12	7.37e-05	0.7	0.59	Corneal astigmatism;	chr4:119301143	chr10:38450738~38451069:-
GBM	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-7.79	3.31e-12	7.59e-05	-0.76	-0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
GBM	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	7.78	3.42e-12	7.83e-05	0.72	0.59	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
GBM	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	7.78	3.46e-12	7.9e-05	0.79	0.59	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
GBM	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	7.78	3.46e-12	7.9e-05	0.79	0.59	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	7.78	3.46e-12	7.9e-05	0.79	0.59	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	7.78	3.46e-12	7.9e-05	0.79	0.59	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
GBM	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	7.78	3.46e-12	7.9e-05	0.79	0.59	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
GBM	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-7.77	3.54e-12	8.06e-05	-0.67	-0.59	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
GBM	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	7.77	3.6e-12	8.15e-05	0.95	0.59	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	7.77	3.6e-12	8.15e-05	0.95	0.59	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	7.77	3.6e-12	8.15e-05	0.95	0.59	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-7.77	3.65e-12	8.27e-05	-0.67	-0.59	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
GBM	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-7.76	3.73e-12	8.44e-05	-0.64	-0.59	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
GBM	trans	rs916888	0.602	rs199508	ENSG00000263503.1	RP11-707O23.5	-7.76	3.76e-12	8.51e-05	-0.73	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:45600869~45602340:-
GBM	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-7.75	3.95e-12	8.92e-05	-0.86	-0.59	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-7.74	4.19e-12	9.4e-05	-0.69	-0.59	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
GBM	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	7.74	4.33e-12	9.68e-05	0.7	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
GBM	trans	rs7312770	0.637	rs705700	ENSG00000234354.3	RPS26P47	7.73	4.38e-12	9.79e-05	0.67	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr13:100539901~100540248:-
GBM	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-7.72	4.62e-12	0.000103	-0.96	-0.58	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-7.72	4.62e-12	0.000103	-0.96	-0.58	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-7.72	4.62e-12	0.000103	-0.96	-0.58	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-7.72	4.62e-12	0.000103	-0.96	-0.58	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-7.72	4.62e-12	0.000103	-0.96	-0.58	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
GBM	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-7.72	4.64e-12	0.000103	-0.65	-0.58	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
GBM	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	7.72	4.65e-12	0.000104	0.62	0.58	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-7.72	4.78e-12	0.000106	-0.84	-0.58	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-7.71	4.85e-12	0.000108	-0.7	-0.58	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	7.71	4.85e-12	0.000108	0.7	0.58	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	7.71	4.85e-12	0.000108	0.7	0.58	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	7.71	4.85e-12	0.000108	0.7	0.58	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	7.71	4.85e-12	0.000108	0.7	0.58	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	7.71	4.85e-12	0.000108	0.7	0.58	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-7.71	4.85e-12	0.000108	-0.67	-0.58	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-7.7	5.17e-12	0.000114	-0.86	-0.58	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-7.7	5.21e-12	0.000115	-0.95	-0.58	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-7.7	5.21e-12	0.000115	-0.95	-0.58	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-7.7	5.21e-12	0.000115	-0.95	-0.58	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-7.7	5.21e-12	0.000115	-0.95	-0.58	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-7.7	5.21e-12	0.000115	-0.95	-0.58	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-7.7	5.21e-12	0.000115	-0.95	-0.58	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-7.7	5.21e-12	0.000115	-0.95	-0.58	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
GBM	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-7.69	5.52e-12	0.000122	-0.69	-0.58	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
GBM	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	7.68	5.75e-12	0.000126	0.67	0.58	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-7.68	5.85e-12	0.000128	-0.9	-0.58	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	7.68	5.9e-12	0.000129	0.7	0.58	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
GBM	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	7.67	5.97e-12	0.00013	0.63	0.58	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
GBM	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	7.67	5.97e-12	0.00013	0.63	0.58	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
GBM	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	7.67	5.97e-12	0.00013	0.63	0.58	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
GBM	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	7.67	5.97e-12	0.00013	0.63	0.58	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
GBM	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-7.67	5.97e-12	0.00013	-0.68	-0.58	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-7.67	5.97e-12	0.00013	-0.68	-0.58	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
GBM	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-7.67	5.97e-12	0.00013	-0.68	-0.58	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
GBM	trans	rs7312770	0.637	rs705699	ENSG00000234354.3	RPS26P47	7.67	6.16e-12	0.000134	0.66	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr13:100539901~100540248:-
GBM	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	7.66	6.27e-12	0.000136	0.63	0.58	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
GBM	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	7.66	6.33e-12	0.000138	0.91	0.58	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
GBM	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	7.66	6.4e-12	0.000139	0.79	0.58	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
GBM	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-7.66	6.51e-12	0.000141	-0.92	-0.58	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-7.65	6.71e-12	0.000145	-0.95	-0.58	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	7.64	6.94e-12	0.00015	0.55	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
GBM	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	7.64	7.13e-12	0.000154	0.7	0.58	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
GBM	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	7.64	7.15e-12	0.000155	0.67	0.58	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
GBM	trans	rs8081395	0.651	rs1292067	ENSG00000187870.7	RNFT1P3	-7.64	7.25e-12	0.000156	-0.76	-0.58	White blood cell count;	chr17:59853285	chr17:20743333~20754501:-
GBM	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	7.63	7.39e-12	0.000159	0.7	0.58	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-7.62	7.74e-12	0.000163	-0.7	-0.58	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-7.62	7.74e-12	0.000163	-0.7	-0.58	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
GBM	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
GBM	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	7.62	7.74e-12	0.000163	0.7	0.58	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-7.62	7.9e-12	0.000166	-0.66	-0.58	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
GBM	trans	rs10917477	0.655	rs34980758	ENSG00000224237.1	MINOS1P3	-7.61	8.19e-12	0.000171	-0.74	-0.58	Thyroid function;	chr1:19566291	chr3:27214816~27215018:-
GBM	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	7.61	8.21e-12	0.000171	0.67	0.58	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	7.61	8.21e-12	0.000171	0.67	0.58	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	7.61	8.21e-12	0.000171	0.67	0.58	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	7.61	8.21e-12	0.000171	0.67	0.58	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	7.61	8.21e-12	0.000171	0.67	0.58	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	7.61	8.21e-12	0.000171	0.67	0.58	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
GBM	trans	rs877636	0.859	rs3741499	ENSG00000196656.7	AC004057.1	-7.61	8.41e-12	0.000175	-0.68	-0.58	Cognitive function;	chr12:56080595	chr4:113214046~113217170:-
GBM	trans	rs916888	0.602	rs199508	ENSG00000264070.1	DND1P1	-7.6	8.63e-12	0.000179	-0.71	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:45585871~45586929:+
GBM	trans	rs7312770	0.637	rs705700	ENSG00000204652.6	RPS26P8	7.6	8.67e-12	0.00018	0.61	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:45608571~45608918:+
GBM	trans	rs3749237	0.964	rs2352975	ENSG00000197582.5	GPX1P1	7.6	8.77e-12	0.000182	0.78	0.58	Resting heart rate;	chr3:49854452	chrX:13378735~13379340:-
GBM	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	7.6	8.77e-12	0.000182	0.7	0.58	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
GBM	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	7.59	8.99e-12	0.000186	0.62	0.58	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
GBM	trans	rs877636	1	rs705696	ENSG00000196656.7	AC004057.1	7.59	9.16e-12	0.000189	0.68	0.58	Cognitive function;	chr12:56086864	chr4:113214046~113217170:-
GBM	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	7.59	9.28e-12	0.000191	0.7	0.58	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	7.59	9.28e-12	0.000191	0.7	0.58	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	7.59	9.28e-12	0.000191	0.7	0.58	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	7.59	9.28e-12	0.000191	0.7	0.58	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
GBM	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	7.58	9.39e-12	0.000193	0.96	0.58	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
GBM	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	7.58	9.52e-12	0.000196	0.8	0.58	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
GBM	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	7.58	9.57e-12	0.000197	0.84	0.58	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
GBM	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	7.57	9.96e-12	0.000204	0.84	0.58	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
GBM	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	7.57	9.96e-12	0.000204	0.84	0.58	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	7.57	9.96e-12	0.000204	0.84	0.58	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	7.57	9.96e-12	0.000204	0.84	0.58	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	7.57	9.96e-12	0.000204	0.84	0.58	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
GBM	trans	rs877636	1	rs877636	ENSG00000212829.8	RPS26P3	-7.56	1.05e-11	0.000215	-0.68	-0.58	Cognitive function;	chr12:56086799	chr9:9090898~9091245:+
GBM	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-7.56	1.07e-11	0.000217	-0.69	-0.58	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
GBM	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-7.55	1.13e-11	0.000229	-0.75	-0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
GBM	trans	rs916888	0.61	rs142167	ENSG00000263503.1	RP11-707O23.5	-7.53	1.23e-11	0.000249	-0.7	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45600869~45602340:-
GBM	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	7.53	1.24e-11	0.00025	0.69	0.57	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	7.53	1.24e-11	0.00025	0.69	0.57	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	7.53	1.24e-11	0.00025	0.69	0.57	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	7.52	1.28e-11	0.000258	0.93	0.57	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
GBM	trans	rs877636	1	rs2292239	ENSG00000196656.7	AC004057.1	7.52	1.29e-11	0.000259	0.67	0.57	Cognitive function;	chr12:56088396	chr4:113214046~113217170:-
GBM	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	7.52	1.29e-11	0.00026	0.91	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	7.52	1.29e-11	0.00026	0.91	0.57	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
GBM	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	7.52	1.32e-11	0.000266	0.8	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
GBM	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	7.52	1.32e-11	0.000266	0.8	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
GBM	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-7.52	1.33e-11	0.000268	-0.81	-0.57	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
GBM	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	7.52	1.34e-11	0.000269	0.64	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
GBM	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-7.51	1.37e-11	0.000275	-0.94	-0.57	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	7.51	1.38e-11	0.000277	0.9	0.57	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	7.51	1.38e-11	0.000277	0.9	0.57	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
GBM	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	7.51	1.38e-11	0.000277	0.9	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	7.5	1.43e-11	0.000285	0.9	0.57	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.532	rs4833624	ENSG00000275858.1	RP11-291L22.8	7.5	1.47e-11	0.000294	0.69	0.57	Corneal astigmatism;	chr4:119664342	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.532	rs12512646	ENSG00000275858.1	RP11-291L22.8	7.5	1.47e-11	0.000294	0.69	0.57	Corneal astigmatism;	chr4:119664578	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	7.5	1.48e-11	0.000295	0.91	0.57	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	7.5	1.48e-11	0.000295	0.91	0.57	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	7.5	1.48e-11	0.000295	0.91	0.57	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	7.5	1.48e-11	0.000295	0.91	0.57	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-7.5	1.48e-11	0.000295	-0.9	-0.57	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
GBM	trans	rs877636	1	rs4759229	ENSG00000196656.7	AC004057.1	-7.49	1.51e-11	0.000301	-0.67	-0.57	Cognitive function;	chr12:56080696	chr4:113214046~113217170:-
GBM	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-7.48	1.57e-11	0.000312	-0.66	-0.57	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
GBM	trans	rs877636	0.74	rs705702	ENSG00000196656.7	AC004057.1	-7.48	1.59e-11	0.000317	-0.67	-0.57	Cognitive function;	chr12:55996852	chr4:113214046~113217170:-
GBM	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-7.48	1.61e-11	0.000319	-0.7	-0.57	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-7.48	1.61e-11	0.000319	-0.7	-0.57	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
GBM	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	7.48	1.65e-11	0.000325	0.83	0.57	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	7.48	1.65e-11	0.000325	0.83	0.57	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	7.48	1.65e-11	0.000325	0.83	0.57	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
GBM	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	7.47	1.66e-11	0.000328	0.69	0.57	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	7.47	1.66e-11	0.000328	0.69	0.57	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-7.47	1.73e-11	0.00034	-0.91	-0.57	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.566	rs17051356	ENSG00000275858.1	RP11-291L22.8	7.46	1.75e-11	0.000345	0.68	0.57	Corneal astigmatism;	chr4:119664153	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	7.46	1.79e-11	0.000351	0.9	0.57	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	7.46	1.79e-11	0.000351	0.9	0.57	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	7.46	1.79e-11	0.000351	0.9	0.57	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-7.46	1.81e-11	0.000354	-0.85	-0.57	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.637	rs705699	ENSG00000204652.6	RPS26P8	7.46	1.81e-11	0.000354	0.6	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	7.45	1.85e-11	0.000362	0.93	0.57	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	7.45	1.85e-11	0.000362	0.93	0.57	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
GBM	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	7.45	1.85e-11	0.000362	0.93	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	7.45	1.85e-11	0.000362	0.93	0.57	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
GBM	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	7.45	1.85e-11	0.000362	0.93	0.57	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
GBM	trans	rs877636	0.702	rs61937249	ENSG00000196656.7	AC004057.1	7.45	1.85e-11	0.000362	0.67	0.57	Cognitive function;	chr12:55988132	chr4:113214046~113217170:-
GBM	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	7.44	1.96e-11	0.000379	0.65	0.57	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	7.44	1.96e-11	0.000379	0.65	0.57	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	7.44	1.96e-11	0.000379	0.65	0.57	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	7.44	1.96e-11	0.000379	0.65	0.57	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	7.44	1.96e-11	0.000379	0.65	0.57	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	7.44	1.96e-11	0.000379	0.65	0.57	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	7.44	1.97e-11	0.000381	0.65	0.57	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
GBM	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-7.44	1.97e-11	0.000381	-0.71	-0.57	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	7.44	1.99e-11	0.000384	0.89	0.57	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
GBM	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	7.44	1.99e-11	0.000384	0.89	0.57	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	7.44	1.99e-11	0.000384	0.89	0.57	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
GBM	trans	rs112721625	1	rs112721625	ENSG00000187870.7	RNFT1P3	7.43	2.05e-11	0.000394	0.76	0.57	Monocyte count;	chr17:59850066	chr17:20743333~20754501:-
GBM	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	7.43	2.1e-11	0.000405	0.8	0.57	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-7.43	2.1e-11	0.000405	-0.8	-0.57	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
GBM	trans	rs877636	0.74	rs772920	ENSG00000196656.7	AC004057.1	7.43	2.11e-11	0.000406	0.66	0.57	Cognitive function;	chr12:55996580	chr4:113214046~113217170:-
GBM	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	7.42	2.13e-11	0.000409	0.83	0.57	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	7.42	2.15e-11	0.000413	0.84	0.57	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
GBM	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-7.42	2.16e-11	0.000414	-0.9	-0.57	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
GBM	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-7.42	2.18e-11	0.000418	-0.65	-0.57	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
GBM	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-7.42	2.22e-11	0.000425	-0.74	-0.57	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
GBM	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	7.41	2.34e-11	0.000447	0.67	0.57	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	7.41	2.34e-11	0.000447	0.67	0.57	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	7.41	2.34e-11	0.000447	0.92	0.57	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
GBM	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	7.41	2.34e-11	0.000447	0.92	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
GBM	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	7.41	2.34e-11	0.000447	0.92	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
GBM	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-7.4	2.38e-11	0.000453	-0.64	-0.57	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
GBM	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-7.4	2.38e-11	0.000453	-0.93	-0.57	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-7.4	2.38e-11	0.000453	-0.93	-0.57	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-7.4	2.38e-11	0.000453	-0.93	-0.57	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	7.39	2.53e-11	0.000479	0.68	0.57	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
GBM	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
GBM	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-7.39	2.58e-11	0.000485	-0.69	-0.57	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	7.39	2.58e-11	0.000485	0.69	0.57	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	7.39	2.58e-11	0.000485	0.92	0.57	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	7.39	2.58e-11	0.000485	0.92	0.57	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-7.38	2.63e-11	0.000493	-0.94	-0.57	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	7.37	2.77e-11	0.00052	0.6	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
GBM	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	7.37	2.84e-11	0.000532	0.64	0.57	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	7.37	2.84e-11	0.000532	0.64	0.57	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	7.37	2.85e-11	0.000532	0.91	0.57	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	7.37	2.85e-11	0.000532	0.91	0.57	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	7.37	2.85e-11	0.000532	0.91	0.57	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	7.37	2.86e-11	0.000534	0.71	0.57	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-7.36	2.91e-11	0.000543	-0.94	-0.57	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-7.35	3.04e-11	0.000567	-0.94	-0.57	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
GBM	trans	rs877636	0.702	rs773110	ENSG00000196656.7	AC004057.1	7.35	3.12e-11	0.000579	0.66	0.57	Cognitive function;	chr12:55981353	chr4:113214046~113217170:-
GBM	trans	rs877636	0.702	rs773111	ENSG00000196656.7	AC004057.1	7.35	3.12e-11	0.000579	0.66	0.57	Cognitive function;	chr12:55981956	chr4:113214046~113217170:-
GBM	trans	rs877636	0.702	rs773112	ENSG00000196656.7	AC004057.1	7.35	3.12e-11	0.000579	0.66	0.57	Cognitive function;	chr12:55982097	chr4:113214046~113217170:-
GBM	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-7.33	3.44e-11	0.000638	-0.9	-0.56	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
GBM	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	7.33	3.52e-11	0.000651	0.9	0.56	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
GBM	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
GBM	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-7.32	3.57e-11	0.000659	-0.7	-0.56	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-7.32	3.58e-11	0.00066	-0.95	-0.56	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
GBM	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-7.32	3.66e-11	0.000673	-0.7	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
GBM	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	7.32	3.68e-11	0.000675	0.58	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
GBM	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	7.31	3.84e-11	0.000703	0.67	0.56	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-7.3	3.94e-11	0.000719	-0.9	-0.56	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-7.3	3.94e-11	0.000719	-0.9	-0.56	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	7.3	3.94e-11	0.000719	0.9	0.56	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
GBM	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	7.3	4e-11	0.000731	0.61	0.56	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	7.3	4.06e-11	0.000737	0.91	0.56	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
GBM	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	7.3	4.06e-11	0.000737	0.91	0.56	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	7.3	4.06e-11	0.000737	0.91	0.56	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
GBM	trans	rs66887589	0.592	rs62320740	ENSG00000275858.1	RP11-291L22.8	7.29	4.15e-11	0.000751	0.63	0.56	Diastolic blood pressure;	chr4:119358331	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	7.29	4.19e-11	0.000759	0.94	0.56	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	7.29	4.19e-11	0.000759	0.94	0.56	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	7.29	4.19e-11	0.000759	0.94	0.56	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	7.29	4.31e-11	0.000779	0.88	0.56	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	7.28	4.53e-11	0.000816	0.59	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
GBM	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	7.27	4.63e-11	0.00083	0.94	0.56	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	7.27	4.63e-11	0.00083	0.94	0.56	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
GBM	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	7.27	4.68e-11	0.000841	0.76	0.56	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
GBM	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	7.27	4.69e-11	0.000842	0.9	0.56	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-7.27	4.73e-11	0.000848	-0.66	-0.56	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	7.26	4.83e-11	0.000865	0.89	0.56	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.637	rs705699	ENSG00000243403.1	RP11-330L19.1	7.26	4.84e-11	0.000867	0.57	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr15:64592979~64593326:+
GBM	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	7.26	4.87e-11	0.000871	0.9	0.56	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	7.26	4.88e-11	0.000872	0.67	0.56	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
GBM	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-7.26	4.99e-11	0.000891	-0.69	-0.56	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
GBM	trans	rs877636	0.702	rs773109	ENSG00000196656.7	AC004057.1	7.26	5.02e-11	0.000895	0.65	0.56	Cognitive function;	chr12:55980911	chr4:113214046~113217170:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-7.25	5.15e-11	0.000919	-0.61	-0.56	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
GBM	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-7.25	5.15e-11	0.000919	-0.61	-0.56	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
GBM	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-7.25	5.25e-11	0.000936	-0.6	-0.56	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
GBM	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	7.24	5.33e-11	0.000945	0.57	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+
GBM	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-7.24	5.37e-11	0.000945	-0.79	-0.56	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-7.24	5.37e-11	0.000945	-0.79	-0.56	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-7.24	5.37e-11	0.000945	-0.79	-0.56	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
GBM	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	7.24	5.37e-11	0.000945	0.89	0.56	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-7.24	5.37e-11	0.000945	-0.89	-0.56	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-7.24	5.46e-11	0.00096	-0.6	-0.56	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
GBM	trans	rs877636	0.859	rs3741499	ENSG00000212829.8	RPS26P3	-7.24	5.53e-11	0.00097	-0.66	-0.56	Cognitive function;	chr12:56080595	chr9:9090898~9091245:+
GBM	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	7.24	5.54e-11	0.000972	0.9	0.56	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-7.23	5.64e-11	0.000988	-0.92	-0.56	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-7.23	5.66e-11	0.000992	-0.85	-0.56	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	7.22	5.96e-11	0.00104	0.9	0.56	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	7.22	5.96e-11	0.00104	0.9	0.56	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	7.22	5.96e-11	0.00104	0.9	0.56	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	7.22	5.96e-11	0.00104	0.9	0.56	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	7.22	5.96e-11	0.00104	0.9	0.56	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
GBM	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-7.22	6.05e-11	0.00106	-0.64	-0.56	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
GBM	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
GBM	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	7.21	6.22e-11	0.00107	0.65	0.56	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-7.19	7.01e-11	0.0012	-0.78	-0.56	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
GBM	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-7.18	7.46e-11	0.00126	-0.69	-0.56	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	7.18	7.5e-11	0.00127	0.88	0.56	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
GBM	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	7.18	7.56e-11	0.00127	0.63	0.56	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
GBM	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-7.17	7.61e-11	0.00128	-0.89	-0.56	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-7.16	8.09e-11	0.00136	-0.88	-0.56	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
GBM	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	7.16	8.12e-11	0.00136	0.59	0.56	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
GBM	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	7.16	8.23e-11	0.00138	0.68	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
GBM	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	7.16	8.23e-11	0.00138	0.68	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
GBM	trans	rs7312770	0.637	rs705699	ENSG00000212994.5	RPS26P6	7.15	8.55e-11	0.00143	0.59	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:100895771~100896118:+
GBM	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	7.15	8.72e-11	0.00145	0.91	0.55	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
GBM	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-7.15	8.8e-11	0.00145	-0.88	-0.55	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-7.15	8.8e-11	0.00145	-0.88	-0.55	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-7.14	8.95e-11	0.00148	-0.91	-0.55	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	7.14	9.15e-11	0.00151	0.93	0.55	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
GBM	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-7.13	9.47e-11	0.00155	-0.67	-0.55	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
GBM	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	7.12	9.93e-11	0.00162	0.66	0.55	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
GBM	trans	rs11650106	0.529	rs35391268	ENSG00000187870.7	RNFT1P3	-7.12	1.02e-10	0.00166	-0.69	-0.55	Lipoprotein-associated phospholipase A2 activity and mass;	chr17:59692637	chr17:20743333~20754501:-
GBM	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	7.12	1.02e-10	0.00166	0.74	0.55	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
GBM	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-7.11	1.03e-10	0.00168	-0.61	-0.55	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-7.11	1.03e-10	0.00168	-0.61	-0.55	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-7.11	1.03e-10	0.00168	-0.61	-0.55	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-7.11	1.03e-10	0.00168	-0.61	-0.55	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-7.11	1.03e-10	0.00168	-0.61	-0.55	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-7.11	1.04e-10	0.00169	-0.91	-0.55	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
GBM	trans	rs4822044	0.568	rs1883370	ENSG00000268568.1	AC007228.9	7.11	1.07e-10	0.00174	0.88	0.55	Cannabis dependence symptom count;	chr22:41747736	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	7.09	1.15e-10	0.00185	0.74	0.55	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-7.09	1.18e-10	0.00191	-0.59	-0.55	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	7.08	1.2e-10	0.00193	0.88	0.55	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	7.08	1.22e-10	0.00197	0.89	0.55	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	7.08	1.22e-10	0.00197	0.89	0.55	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-7.08	1.24e-10	0.002	-0.59	-0.55	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
GBM	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-7.07	1.26e-10	0.00202	-0.67	-0.55	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-7.07	1.29e-10	0.00207	-0.77	-0.55	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-7.07	1.32e-10	0.0021	-0.94	-0.55	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	7.06	1.32e-10	0.00211	0.67	0.55	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-7.06	1.33e-10	0.00213	-0.94	-0.55	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	7.06	1.37e-10	0.00218	0.61	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
GBM	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	7.04	1.52e-10	0.0024	0.63	0.55	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-7.03	1.54e-10	0.00242	-0.77	-0.55	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
GBM	trans	rs10028773	0.632	rs34481394	ENSG00000275858.1	RP11-291L22.8	7.03	1.55e-10	0.00244	0.68	0.55	Educational attainment;	chr4:119327219	chr10:38450738~38451069:-
GBM	trans	rs10028773	0.666	rs35231872	ENSG00000275858.1	RP11-291L22.8	7.03	1.55e-10	0.00244	0.68	0.55	Educational attainment;	chr4:119327221	chr10:38450738~38451069:-
GBM	trans	rs10028773	0.7	rs35653026	ENSG00000275858.1	RP11-291L22.8	7.03	1.55e-10	0.00244	0.68	0.55	Educational attainment;	chr4:119327223	chr10:38450738~38451069:-
GBM	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	7.03	1.59e-10	0.0025	0.6	0.55	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
GBM	trans	rs73099903	0.611	rs7306523	ENSG00000229939.1	RP11-111F16.2	7.03	1.59e-10	0.0025	0.8	0.55	Systolic blood pressure;	chr12:53000180	chrX:111618808~111619094:+
GBM	trans	rs73099903	0.611	rs7957445	ENSG00000229939.1	RP11-111F16.2	7.03	1.59e-10	0.0025	0.8	0.55	Systolic blood pressure;	chr12:53014796	chrX:111618808~111619094:+
GBM	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-7.03	1.6e-10	0.0025	-0.91	-0.55	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-7.03	1.6e-10	0.0025	-0.91	-0.55	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	7.03	1.61e-10	0.00253	0.91	0.55	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	7.02	1.62e-10	0.00254	0.93	0.55	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
GBM	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	7.02	1.65e-10	0.00258	0.59	0.55	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	7.02	1.65e-10	0.00258	0.59	0.55	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	7.02	1.65e-10	0.00258	0.59	0.55	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
GBM	trans	rs66887589	0.592	rs28580295	ENSG00000275858.1	RP11-291L22.8	7.02	1.65e-10	0.00258	0.62	0.55	Diastolic blood pressure;	chr4:119357718	chr10:38450738~38451069:-
GBM	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-7.02	1.66e-10	0.00259	-0.59	-0.55	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-7.02	1.69e-10	0.00264	-0.93	-0.55	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-7.02	1.69e-10	0.00264	-0.93	-0.55	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
GBM	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-7.01	1.7e-10	0.00265	-0.6	-0.55	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
GBM	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-7.01	1.74e-10	0.00271	-0.9	-0.55	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
GBM	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-7.01	1.76e-10	0.00273	-0.61	-0.55	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
GBM	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-7.01	1.76e-10	0.00273	-0.61	-0.55	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
GBM	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-7	1.84e-10	0.00286	-0.63	-0.55	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
GBM	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	7	1.85e-10	0.00288	0.62	0.55	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
GBM	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	6.99	1.93e-10	0.00298	0.59	0.55	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	6.99	1.93e-10	0.00298	0.59	0.55	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
GBM	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	6.99	1.95e-10	0.00301	0.57	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
GBM	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-6.98	1.97e-10	0.00304	-0.76	-0.55	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
GBM	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	6.98	1.98e-10	0.00305	0.67	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
GBM	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	6.98	2e-10	0.00308	0.59	0.55	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-6.98	2.02e-10	0.00311	-0.93	-0.55	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
GBM	trans	rs877636	1	rs877636	ENSG00000234354.3	RPS26P47	-6.98	2.04e-10	0.00313	-0.68	-0.55	Cognitive function;	chr12:56086799	chr13:100539901~100540248:-
GBM	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	6.98	2.05e-10	0.00315	0.77	0.55	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	6.98	2.05e-10	0.00315	0.77	0.55	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	6.98	2.05e-10	0.00315	0.77	0.55	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
GBM	trans	rs877636	1	rs705696	ENSG00000212829.8	RPS26P3	6.98	2.06e-10	0.00316	0.64	0.55	Cognitive function;	chr12:56086864	chr9:9090898~9091245:+
GBM	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	6.97	2.07e-10	0.00317	0.6	0.55	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
GBM	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-6.97	2.08e-10	0.00318	-0.9	-0.55	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
GBM	trans	rs877636	0.859	rs3741499	ENSG00000204652.6	RPS26P8	-6.97	2.08e-10	0.00319	-0.62	-0.55	Cognitive function;	chr12:56080595	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-6.96	2.25e-10	0.00343	-0.95	-0.54	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
GBM	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-6.95	2.3e-10	0.00351	-0.67	-0.54	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
GBM	trans	rs8067354	0.789	rs1292068	ENSG00000187870.7	RNFT1P3	6.95	2.32e-10	0.00353	0.74	0.54	Hemoglobin concentration;	chr17:59851958	chr17:20743333~20754501:-
GBM	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-6.94	2.45e-10	0.00372	-0.89	-0.54	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
GBM	trans	rs9898641	1	rs9898641	ENSG00000187870.7	RNFT1P3	6.93	2.53e-10	0.00384	0.68	0.54	Interleukin-1-beta levels;	chr17:59493672	chr17:20743333~20754501:-
GBM	trans	rs877636	1	rs2292239	ENSG00000212829.8	RPS26P3	6.93	2.61e-10	0.00396	0.63	0.54	Cognitive function;	chr12:56088396	chr9:9090898~9091245:+
GBM	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	6.93	2.65e-10	0.004	0.79	0.54	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
GBM	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	6.93	2.65e-10	0.004	0.79	0.54	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
GBM	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-6.92	2.71e-10	0.0041	-0.78	-0.54	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-6.92	2.71e-10	0.0041	-0.78	-0.54	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-6.92	2.71e-10	0.0041	-0.78	-0.54	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
GBM	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-6.92	2.74e-10	0.00413	-0.67	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
GBM	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	6.92	2.76e-10	0.00417	0.91	0.54	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-6.91	2.79e-10	0.0042	-0.78	-0.54	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
GBM	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	6.9	3e-10	0.00449	0.92	0.54	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
GBM	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	6.9	3e-10	0.00449	0.92	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	6.9	3e-10	0.00449	0.92	0.54	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
GBM	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	6.9	3e-10	0.00449	0.92	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	6.9	3.01e-10	0.0045	0.84	0.54	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
GBM	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	6.89	3.09e-10	0.00462	0.58	0.54	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	6.89	3.09e-10	0.00462	0.58	0.54	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	6.89	3.14e-10	0.00469	0.96	0.54	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	6.88	3.27e-10	0.00488	0.84	0.54	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
GBM	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	6.88	3.3e-10	0.00492	0.63	0.54	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
GBM	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	6.88	3.32e-10	0.00493	0.61	0.54	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
GBM	trans	rs877636	0.702	rs773110	ENSG00000212829.8	RPS26P3	6.88	3.36e-10	0.00499	0.63	0.54	Cognitive function;	chr12:55981353	chr9:9090898~9091245:+
GBM	trans	rs877636	0.702	rs773111	ENSG00000212829.8	RPS26P3	6.88	3.36e-10	0.00499	0.63	0.54	Cognitive function;	chr12:55981956	chr9:9090898~9091245:+
GBM	trans	rs877636	0.702	rs773112	ENSG00000212829.8	RPS26P3	6.88	3.36e-10	0.00499	0.63	0.54	Cognitive function;	chr12:55982097	chr9:9090898~9091245:+
GBM	trans	rs9428238	0.677	rs2797180	ENSG00000253572.2	RP11-107N7.1	-6.88	3.37e-10	0.005	-0.6	-0.54	Heart rate variability traits (SDNN);	chr1:115814733	chr5:77942757~77946438:-
GBM	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-6.88	3.38e-10	0.00501	-0.89	-0.54	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-6.87	3.46e-10	0.00512	-0.57	-0.54	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
GBM	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-6.87	3.46e-10	0.00512	-0.57	-0.54	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
GBM	trans	rs80033912	0.713	rs7629936	ENSG00000197582.5	GPX1P1	6.87	3.5e-10	0.00518	0.75	0.54	Intelligence (multi-trait analysis);	chr3:49799274	chrX:13378735~13379340:-
GBM	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-6.87	3.51e-10	0.0052	-0.6	-0.54	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
GBM	trans	rs7811142	1	rs7783159	ENSG00000228546.2	CTA-313A17.3	6.86	3.68e-10	0.00542	0.82	0.54	Platelet count;	chr7:100419831	chr7:102337316~102339115:+
GBM	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	6.86	3.75e-10	0.00551	0.91	0.54	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
GBM	trans	rs877636	0.702	rs773109	ENSG00000212829.8	RPS26P3	6.85	3.83e-10	0.00562	0.63	0.54	Cognitive function;	chr12:55980911	chr9:9090898~9091245:+
GBM	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-6.85	3.9e-10	0.00572	-0.89	-0.54	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
GBM	trans	rs7811142	1	rs11559117	ENSG00000228546.2	CTA-313A17.3	6.84	3.95e-10	0.00578	0.79	0.54	Platelet count;	chr7:100478991	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs2406253	ENSG00000228546.2	CTA-313A17.3	6.84	3.95e-10	0.00578	0.79	0.54	Platelet count;	chr7:100479650	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs4463351	ENSG00000228546.2	CTA-313A17.3	6.84	3.95e-10	0.00578	0.79	0.54	Platelet count;	chr7:100480603	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	6.84	3.95e-10	0.00578	0.79	0.54	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	6.84	3.95e-10	0.00578	0.79	0.54	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs11763511	ENSG00000228546.2	CTA-313A17.3	6.84	3.95e-10	0.00578	0.79	0.54	Platelet count;	chr7:100484321	chr7:102337316~102339115:+
GBM	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	6.84	3.96e-10	0.00578	0.6	0.54	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
GBM	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	6.84	4.01e-10	0.00586	0.85	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
GBM	trans	rs2708977	0.549	rs2678381	ENSG00000280122.1	RP11-87G24.2	-6.83	4.25e-10	0.00615	-0.63	-0.54	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96775529	chr17:76966285~76969530:-
GBM	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-6.83	4.25e-10	0.00616	-0.6	-0.54	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
GBM	trans	rs877636	0.74	rs705698	ENSG00000196656.7	AC004057.1	6.83	4.28e-10	0.00619	0.63	0.54	Cognitive function;	chr12:55990903	chr4:113214046~113217170:-
GBM	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	6.83	4.28e-10	0.00619	0.62	0.54	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
GBM	trans	rs877636	0.702	rs61937249	ENSG00000212829.8	RPS26P3	6.83	4.33e-10	0.00627	0.63	0.54	Cognitive function;	chr12:55988132	chr9:9090898~9091245:+
GBM	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-6.82	4.47e-10	0.00646	-0.57	-0.54	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
GBM	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-6.82	4.47e-10	0.00646	-0.89	-0.54	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
GBM	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	6.82	4.56e-10	0.00658	0.67	0.54	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
GBM	trans	rs17060993	1	rs73568453	ENSG00000259146.3	RP1-261D10.2	6.8	4.88e-10	0.00701	1.19	0.54	Musician's dystonia;	chr8:27067136	chr14:71292729~71321814:-
GBM	trans	rs17060993	1	rs6993147	ENSG00000259146.3	RP1-261D10.2	-6.8	4.88e-10	0.00701	-1.19	-0.54	Musician's dystonia;	chr8:27069249	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.764	rs7844318	ENSG00000259146.3	RP1-261D10.2	-6.8	4.88e-10	0.00701	-1.19	-0.54	Musician's dystonia;	chr8:27070203	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.867	rs10866854	ENSG00000259146.3	RP1-261D10.2	-6.8	4.88e-10	0.00701	-1.19	-0.54	Musician's dystonia;	chr8:27077035	chr14:71292729~71321814:-
GBM	trans	rs17060993	1	rs9314339	ENSG00000259146.3	RP1-261D10.2	-6.8	4.88e-10	0.00701	-1.19	-0.54	Musician's dystonia;	chr8:27081570	chr14:71292729~71321814:-
GBM	trans	rs17060993	1	rs2028908	ENSG00000259146.3	RP1-261D10.2	-6.8	4.88e-10	0.00701	-1.19	-0.54	Musician's dystonia;	chr8:27087083	chr14:71292729~71321814:-
GBM	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-6.8	5e-10	0.00716	-0.92	-0.54	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.657	rs10434028	ENSG00000275858.1	RP11-291L22.8	6.8	5.03e-10	0.00721	0.64	0.54	Corneal astigmatism;	chr4:119373309	chr10:38450738~38451069:-
GBM	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	6.79	5.07e-10	0.00725	0.82	0.54	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
GBM	trans	rs2708977	0.549	rs6706734	ENSG00000280122.1	RP11-87G24.2	-6.79	5.23e-10	0.00746	-0.63	-0.53	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96764214	chr17:76966285~76969530:-
GBM	trans	rs877636	0.74	rs772920	ENSG00000212829.8	RPS26P3	6.79	5.24e-10	0.00747	0.62	0.53	Cognitive function;	chr12:55996580	chr9:9090898~9091245:+
GBM	trans	rs877636	1	rs4759229	ENSG00000204652.6	RPS26P8	-6.79	5.24e-10	0.00747	-0.61	-0.53	Cognitive function;	chr12:56080696	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-6.79	5.26e-10	0.00749	-0.92	-0.53	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
GBM	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	6.78	5.35e-10	0.00761	0.77	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
GBM	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	6.78	5.35e-10	0.00761	0.77	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
GBM	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-6.78	5.44e-10	0.00772	-0.61	-0.53	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
GBM	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-6.78	5.44e-10	0.00772	-0.61	-0.53	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
GBM	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	6.78	5.55e-10	0.00788	0.86	0.53	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
GBM	trans	rs10028773	0.515	rs9994488	ENSG00000275858.1	RP11-291L22.8	6.78	5.56e-10	0.00789	0.64	0.53	Educational attainment;	chr4:119666626	chr10:38450738~38451069:-
GBM	trans	rs13177918	0.717	rs6874318	ENSG00000226396.1	RP5-1056L3.3	-6.77	5.66e-10	0.00803	-0.54	-0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:19608114~19608568:+
GBM	trans	rs17060993	0.557	rs116062011	ENSG00000259146.3	RP1-261D10.2	6.77	5.68e-10	0.00805	1.18	0.53	Musician's dystonia;	chr8:27061647	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.85	rs73568451	ENSG00000259146.3	RP1-261D10.2	6.77	5.68e-10	0.00805	1.18	0.53	Musician's dystonia;	chr8:27066544	chr14:71292729~71321814:-
GBM	trans	rs17060993	1	rs17060993	ENSG00000259146.3	RP1-261D10.2	-6.77	5.68e-10	0.00805	-1.18	-0.53	Musician's dystonia;	chr8:27064595	chr14:71292729~71321814:-
GBM	trans	rs7811142	0.83	rs28495773	ENSG00000228546.2	CTA-313A17.3	6.77	5.7e-10	0.00807	0.79	0.53	Platelet count;	chr7:100345960	chr7:102337316~102339115:+
GBM	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	6.77	5.81e-10	0.00821	0.86	0.53	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
GBM	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	6.77	5.81e-10	0.00821	0.86	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-6.77	5.84e-10	0.00824	-0.91	-0.53	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
GBM	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-6.77	5.87e-10	0.00827	-0.61	-0.53	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
GBM	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-6.77	5.87e-10	0.00827	-0.61	-0.53	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
GBM	trans	rs4775602	1	rs1516850	ENSG00000279647.1	CH507-254M2.5	6.76	5.91e-10	0.00833	0.79	0.53	Response to radiotherapy in prostate cancer (overall toxicity);	chr15:46552838	chr21:7385058~7388799:-
GBM	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-6.76	5.98e-10	0.00842	-0.77	-0.53	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.637	rs705699	ENSG00000223416.3	RPS26P15	6.76	6e-10	0.00845	0.55	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr1:58056133~58056480:-
GBM	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	6.76	6e-10	0.00845	0.72	0.53	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
GBM	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	6.75	6.17e-10	0.00867	0.9	0.53	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
GBM	trans	rs916888	0.779	rs199498	ENSG00000263503.1	RP11-707O23.5	6.75	6.21e-10	0.00873	0.7	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45600869~45602340:-
GBM	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	6.75	6.25e-10	0.00878	0.8	0.53	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	6.75	6.25e-10	0.00878	0.8	0.53	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
GBM	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-6.75	6.31e-10	0.00886	-0.61	-0.53	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
GBM	trans	rs877636	1	rs4759229	ENSG00000212829.8	RPS26P3	-6.75	6.35e-10	0.00891	-0.63	-0.53	Cognitive function;	chr12:56080696	chr9:9090898~9091245:+
GBM	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	6.74	6.58e-10	0.00922	0.88	0.53	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
GBM	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	6.74	6.6e-10	0.00924	0.6	0.53	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
GBM	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	6.74	6.63e-10	0.00929	0.66	0.53	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
GBM	trans	rs9646944	0.891	rs13027294	ENSG00000268027.4	AC006129.2	-6.74	6.64e-10	0.0093	-0.7	-0.53	Blood protein levels;	chr2:102243614	chr19:41545192~41555462:+
GBM	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-6.74	6.73e-10	0.00941	-0.84	-0.53	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
GBM	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	6.73	6.85e-10	0.00956	0.64	0.53	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
GBM	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	6.73	6.91e-10	0.00965	0.58	0.53	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	6.73	6.91e-10	0.00965	0.58	0.53	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-6.73	6.92e-10	0.00965	-0.77	-0.53	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
GBM	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-6.73	6.95e-10	0.0097	-0.65	-0.53	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
GBM	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-6.73	7.09e-10	0.00987	-0.88	-0.53	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-6.73	7.09e-10	0.00987	-0.88	-0.53	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
GBM	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	6.73	7.13e-10	0.00992	0.65	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
GBM	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	6.72	7.15e-10	0.00996	0.55	0.53	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
GBM	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-6.72	7.24e-10	0.0101	-0.77	-0.53	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
GBM	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-6.72	7.24e-10	0.0101	-0.61	-0.53	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
GBM	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	6.72	7.27e-10	0.0101	0.77	0.53	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
GBM	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	6.72	7.3e-10	0.0101	0.57	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
GBM	trans	rs877636	1	rs2292239	ENSG00000204652.6	RPS26P8	6.72	7.48e-10	0.0104	0.6	0.53	Cognitive function;	chr12:56088396	chr17:45608571~45608918:+
GBM	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	6.71	7.53e-10	0.0104	0.63	0.53	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	6.71	7.53e-10	0.0104	0.63	0.53	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	6.71	7.53e-10	0.0104	0.63	0.53	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
GBM	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	6.71	7.53e-10	0.0104	0.63	0.53	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
GBM	trans	rs7312770	0.637	rs705700	ENSG00000223416.3	RPS26P15	6.71	7.54e-10	0.0104	0.55	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:58056133~58056480:-
GBM	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	6.71	7.55e-10	0.0104	0.78	0.53	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-6.71	7.55e-10	0.0104	-0.78	-0.53	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
GBM	trans	rs877636	1	rs705696	ENSG00000204652.6	RPS26P8	6.71	7.63e-10	0.0105	0.6	0.53	Cognitive function;	chr12:56086864	chr17:45608571~45608918:+
GBM	trans	rs13177918	0.734	rs6579790	ENSG00000226396.1	RP5-1056L3.3	6.71	7.74e-10	0.0107	0.57	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:19608114~19608568:+
GBM	trans	rs13177918	0.734	rs6579791	ENSG00000226396.1	RP5-1056L3.3	6.71	7.74e-10	0.0107	0.57	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:19608114~19608568:+
GBM	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	6.71	7.76e-10	0.0107	0.76	0.53	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
GBM	trans	rs12712135	0.706	rs6543114	ENSG00000231971.4	RP11-557H15.3	-6.71	7.79e-10	0.0107	-0.77	-0.53	Blood protein levels;	chr2:102309534	chr6:134428240~134520585:-
GBM	trans	rs73099903	0.611	rs7485642	ENSG00000229939.1	RP11-111F16.2	6.71	7.88e-10	0.0108	0.75	0.53	Systolic blood pressure;	chr12:52997717	chrX:111618808~111619094:+
GBM	trans	rs877636	0.859	rs3741499	ENSG00000234354.3	RPS26P47	-6.7	8.08e-10	0.0111	-0.66	-0.53	Cognitive function;	chr12:56080595	chr13:100539901~100540248:-
GBM	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	6.7	8.1e-10	0.0111	0.85	0.53	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
GBM	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	6.7	8.1e-10	0.0111	0.85	0.53	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	6.7	8.1e-10	0.0111	0.85	0.53	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	6.7	8.1e-10	0.0111	0.85	0.53	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	6.7	8.1e-10	0.0111	0.85	0.53	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	6.7	8.1e-10	0.0111	0.85	0.53	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
GBM	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	6.7	8.15e-10	0.0111	0.82	0.53	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
GBM	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	6.7	8.22e-10	0.0112	0.63	0.53	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
GBM	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	6.7	8.22e-10	0.0112	0.66	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
GBM	trans	rs17060993	0.717	rs74646766	ENSG00000259146.3	RP1-261D10.2	6.69	8.44e-10	0.0115	1.14	0.53	Musician's dystonia;	chr8:27051358	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.867	rs73564851	ENSG00000259146.3	RP1-261D10.2	6.69	8.44e-10	0.0115	1.14	0.53	Musician's dystonia;	chr8:27051760	chr14:71292729~71321814:-
GBM	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	6.69	8.62e-10	0.0117	0.61	0.53	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
GBM	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	6.68	8.78e-10	0.0119	0.83	0.53	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
GBM	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	6.68	8.79e-10	0.0119	0.65	0.53	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
GBM	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	6.68	8.79e-10	0.0119	0.65	0.53	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
GBM	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	6.68	8.79e-10	0.0119	0.65	0.53	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
GBM	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	6.68	8.82e-10	0.0119	0.75	0.53	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	6.68	8.82e-10	0.0119	0.75	0.53	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	6.68	8.82e-10	0.0119	0.75	0.53	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	6.68	8.82e-10	0.0119	0.75	0.53	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
GBM	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-6.68	8.91e-10	0.0121	-0.84	-0.53	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
GBM	trans	rs17060993	0.681	rs73568431	ENSG00000259146.3	RP1-261D10.2	6.68	8.91e-10	0.0121	1.14	0.53	Musician's dystonia;	chr8:27052486	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.867	rs7834004	ENSG00000259146.3	RP1-261D10.2	6.68	8.91e-10	0.0121	1.14	0.53	Musician's dystonia;	chr8:27052633	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.867	rs17056733	ENSG00000259146.3	RP1-261D10.2	6.68	8.91e-10	0.0121	1.14	0.53	Musician's dystonia;	chr8:27055390	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.717	rs17056735	ENSG00000259146.3	RP1-261D10.2	6.68	8.91e-10	0.0121	1.14	0.53	Musician's dystonia;	chr8:27055476	chr14:71292729~71321814:-
GBM	trans	rs17060993	0.867	rs73568441	ENSG00000259146.3	RP1-261D10.2	6.68	8.91e-10	0.0121	1.14	0.53	Musician's dystonia;	chr8:27057606	chr14:71292729~71321814:-
GBM	trans	rs2963482	0.691	rs2963444	ENSG00000269608.1	CTB-167G5.3	-6.68	9e-10	0.0122	-0.69	-0.53	Nonsyndromic cleft lip with or without cleft palate;	chr5:158511862	chr19:53616802~53617254:+
GBM	trans	rs877636	0.701	rs34415530	ENSG00000196656.7	AC004057.1	6.67	9.45e-10	0.0127	0.63	0.53	Cognitive function;	chr12:56050848	chr4:113214046~113217170:-
GBM	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	6.66	9.7e-10	0.0131	0.55	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
GBM	trans	rs2963482	0.691	rs2963446	ENSG00000269608.1	CTB-167G5.3	6.66	9.82e-10	0.0132	0.7	0.53	Nonsyndromic cleft lip with or without cleft palate;	chr5:158511494	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.658	rs2963443	ENSG00000269608.1	CTB-167G5.3	6.66	9.82e-10	0.0132	0.7	0.53	Nonsyndromic cleft lip with or without cleft palate;	chr5:158512319	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.658	rs2946157	ENSG00000269608.1	CTB-167G5.3	6.66	9.82e-10	0.0132	0.7	0.53	Nonsyndromic cleft lip with or without cleft palate;	chr5:158512394	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.691	rs2964509	ENSG00000269608.1	CTB-167G5.3	6.66	9.82e-10	0.0132	0.7	0.53	Nonsyndromic cleft lip with or without cleft palate;	chr5:158512575	chr19:53616802~53617254:+
GBM	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	6.66	9.9e-10	0.0133	0.53	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
GBM	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	6.66	1.01e-09	0.0135	0.59	0.53	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
GBM	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	6.66	1.01e-09	0.0135	0.72	0.53	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
GBM	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	6.65	1.01e-09	0.0135	0.85	0.53	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	6.65	1.01e-09	0.0136	0.56	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
GBM	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	6.65	1.02e-09	0.0136	0.65	0.53	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
GBM	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	6.65	1.04e-09	0.0138	0.63	0.53	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	6.65	1.04e-09	0.0138	0.63	0.53	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	6.65	1.04e-09	0.0138	0.63	0.53	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	6.65	1.04e-09	0.0138	0.63	0.53	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	6.65	1.04e-09	0.0138	0.63	0.53	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	6.65	1.04e-09	0.0138	0.63	0.53	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	6.65	1.04e-09	0.0138	0.63	0.53	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-6.65	1.04e-09	0.0138	-0.63	-0.53	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	6.65	1.04e-09	0.0139	0.84	0.53	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
GBM	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	6.65	1.05e-09	0.014	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	6.65	1.05e-09	0.014	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	6.65	1.05e-09	0.014	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	6.65	1.05e-09	0.014	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.72	0.53	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	6.64	1.07e-09	0.0141	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
GBM	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	6.64	1.07e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	6.64	1.07e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	6.64	1.07e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	6.64	1.08e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	6.64	1.08e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	6.64	1.08e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	6.64	1.08e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	6.64	1.08e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	6.64	1.08e-09	0.0142	0.62	0.53	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
GBM	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	6.64	1.08e-09	0.0142	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	6.64	1.08e-09	0.0142	0.73	0.53	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
GBM	trans	rs7811142	1	rs11761725	ENSG00000228546.2	CTA-313A17.3	6.64	1.09e-09	0.0144	0.82	0.53	Platelet count;	chr7:100442192	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs2406255	ENSG00000228546.2	CTA-313A17.3	6.64	1.09e-09	0.0144	0.82	0.53	Platelet count;	chr7:100456067	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	6.64	1.1e-09	0.0144	0.75	0.53	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs7783550	ENSG00000228546.2	CTA-313A17.3	-6.63	1.13e-09	0.0147	-0.72	-0.53	Platelet count;	chr7:100390182	chr7:102337316~102339115:+
GBM	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-6.63	1.15e-09	0.0149	-0.76	-0.53	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
GBM	trans	rs9646944	0.836	rs10178214	ENSG00000268027.4	AC006129.2	-6.63	1.16e-09	0.0151	-0.69	-0.53	Blood protein levels;	chr2:102242461	chr19:41545192~41555462:+
GBM	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-6.62	1.17e-09	0.0152	-0.71	-0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
GBM	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	6.62	1.17e-09	0.0152	0.75	0.53	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	6.62	1.18e-09	0.0152	0.77	0.53	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	6.62	1.18e-09	0.0152	0.77	0.53	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
GBM	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-6.62	1.18e-09	0.0153	-0.6	-0.53	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
GBM	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-6.62	1.18e-09	0.0153	-0.6	-0.53	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
GBM	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-6.62	1.19e-09	0.0154	-0.58	-0.53	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
GBM	trans	rs7811142	0.83	rs118119933	ENSG00000228546.2	CTA-313A17.3	6.62	1.21e-09	0.0156	0.89	0.53	Platelet count;	chr7:100341427	chr7:102337316~102339115:+
GBM	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	6.62	1.22e-09	0.0158	0.62	0.53	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
GBM	trans	rs66887589	0.967	rs59516282	ENSG00000275858.1	RP11-291L22.8	-6.61	1.28e-09	0.0164	-0.59	-0.52	Diastolic blood pressure;	chr4:119580861	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	6.6	1.29e-09	0.0166	0.62	0.52	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	6.6	1.29e-09	0.0166	0.62	0.52	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.526	rs10026625	ENSG00000275858.1	RP11-291L22.8	6.6	1.32e-09	0.0169	0.61	0.52	Corneal astigmatism;	chr4:119358981	chr10:38450738~38451069:-
GBM	trans	rs741301	0.543	rs9969380	ENSG00000244757.1	RP11-45A16.4	-6.6	1.33e-09	0.017	-0.5	-0.52	Type 2 diabetes nephropathy;	chr7:36788086	chr9:116288618~116318689:-
GBM	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	6.59	1.39e-09	0.0177	0.66	0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
GBM	trans	rs7811142	1	rs6972167	ENSG00000228546.2	CTA-313A17.3	6.59	1.39e-09	0.0177	0.75	0.52	Platelet count;	chr7:100482390	chr7:102337316~102339115:+
GBM	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	6.59	1.39e-09	0.0177	0.86	0.52	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
GBM	trans	rs2963482	0.725	rs2419901	ENSG00000269608.1	CTB-167G5.3	6.58	1.44e-09	0.0183	0.71	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158516468	chr19:53616802~53617254:+
GBM	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	6.58	1.45e-09	0.0184	0.53	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
GBM	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	6.58	1.46e-09	0.0185	0.64	0.52	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
GBM	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	6.58	1.46e-09	0.0185	0.65	0.52	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
GBM	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-6.58	1.47e-09	0.0187	-0.7	-0.52	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
GBM	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	6.58	1.48e-09	0.0187	0.56	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
GBM	trans	rs41526344	0.688	rs6785594	ENSG00000229388.1	RP11-442N24__B.1	6.57	1.51e-09	0.0192	0.73	0.52	Body mass index (change over time) in chronic obstructive pulmonary disease;	chr3:2933166	chr1:28643228~28648581:+
GBM	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	6.57	1.53e-09	0.0193	0.72	0.52	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
GBM	trans	rs7312770	0.637	rs705699	ENSG00000234192.1	RP11-57C13.5	6.57	1.56e-09	0.0197	0.59	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr10:87642607~87642954:+
GBM	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-6.57	1.56e-09	0.0197	-0.84	-0.52	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-6.56	1.59e-09	0.02	-0.87	-0.52	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
GBM	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	6.56	1.59e-09	0.02	0.61	0.52	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
GBM	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	6.56	1.6e-09	0.0201	0.74	0.52	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
GBM	trans	rs8067354	0.872	rs1292060	ENSG00000187870.7	RNFT1P3	6.56	1.62e-09	0.0204	0.72	0.52	Hemoglobin concentration;	chr17:59836488	chr17:20743333~20754501:-
GBM	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-6.56	1.63e-09	0.0205	-0.6	-0.52	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
GBM	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	6.56	1.65e-09	0.0207	0.57	0.52	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
GBM	trans	rs73099903	0.611	rs10876400	ENSG00000229939.1	RP11-111F16.2	6.55	1.66e-09	0.0208	0.76	0.52	Systolic blood pressure;	chr12:53043071	chrX:111618808~111619094:+
GBM	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	6.55	1.66e-09	0.0208	0.64	0.52	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
GBM	trans	rs394563	0.589	rs1900300	ENSG00000235358.1	RP11-399E6.1	-6.55	1.72e-09	0.0215	-0.48	-0.52	Dupuytren's disease;	chr6:149320491	chr1:41242373~41284861:+
GBM	trans	rs394563	0.619	rs4895787	ENSG00000235358.1	RP11-399E6.1	-6.55	1.72e-09	0.0215	-0.48	-0.52	Dupuytren's disease;	chr6:149325364	chr1:41242373~41284861:+
GBM	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-6.54	1.8e-09	0.0223	-0.71	-0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
GBM	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	6.53	1.83e-09	0.0226	0.62	0.52	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-6.53	1.83e-09	0.0226	-0.62	-0.52	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
GBM	trans	rs877636	0.702	rs61937249	ENSG00000204652.6	RPS26P8	6.53	1.84e-09	0.0227	0.59	0.52	Cognitive function;	chr12:55988132	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	6.53	1.85e-09	0.0228	0.82	0.52	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	6.53	1.85e-09	0.0228	0.82	0.52	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	6.53	1.85e-09	0.0228	0.82	0.52	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.612	rs773114	ENSG00000234192.1	RP11-57C13.5	6.53	1.85e-09	0.0228	0.58	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:87642607~87642954:+
GBM	trans	rs7811142	1	rs7794485	ENSG00000228546.2	CTA-313A17.3	6.53	1.86e-09	0.0228	0.79	0.52	Platelet count;	chr7:100471313	chr7:102337316~102339115:+
GBM	trans	rs877636	0.701	rs7302200	ENSG00000196656.7	AC004057.1	6.53	1.87e-09	0.023	0.63	0.52	Cognitive function;	chr12:56055651	chr4:113214046~113217170:-
GBM	trans	rs9858542	0.903	rs17080528	ENSG00000197582.5	GPX1P1	-6.53	1.88e-09	0.023	-0.68	-0.52	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49352409	chrX:13378735~13379340:-
GBM	trans	rs877636	0.702	rs773110	ENSG00000204652.6	RPS26P8	6.53	1.88e-09	0.0231	0.58	0.52	Cognitive function;	chr12:55981353	chr17:45608571~45608918:+
GBM	trans	rs877636	0.702	rs773111	ENSG00000204652.6	RPS26P8	6.53	1.88e-09	0.0231	0.58	0.52	Cognitive function;	chr12:55981956	chr17:45608571~45608918:+
GBM	trans	rs877636	0.702	rs773112	ENSG00000204652.6	RPS26P8	6.53	1.88e-09	0.0231	0.58	0.52	Cognitive function;	chr12:55982097	chr17:45608571~45608918:+
GBM	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	6.53	1.9e-09	0.0232	0.73	0.52	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	6.53	1.9e-09	0.0232	0.73	0.52	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
GBM	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-6.52	1.91e-09	0.0232	-0.64	-0.52	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
GBM	trans	rs2963482	0.691	rs2964510	ENSG00000269608.1	CTB-167G5.3	6.52	1.91e-09	0.0232	0.69	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158513166	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.691	rs2963442	ENSG00000269608.1	CTB-167G5.3	6.52	1.91e-09	0.0232	0.69	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158513285	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.691	rs2963441	ENSG00000269608.1	CTB-167G5.3	6.52	1.91e-09	0.0232	0.69	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158513888	chr19:53616802~53617254:+
GBM	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-6.52	1.95e-09	0.0237	-0.55	-0.52	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
GBM	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	6.52	1.97e-09	0.0239	0.76	0.52	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	6.52	1.97e-09	0.0239	0.76	0.52	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
GBM	trans	rs877636	0.702	rs773109	ENSG00000204652.6	RPS26P8	6.52	1.99e-09	0.0241	0.59	0.52	Cognitive function;	chr12:55980911	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-6.52	1.99e-09	0.0241	-0.85	-0.52	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-6.52	1.99e-09	0.0241	-0.83	-0.52	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	6.52	1.99e-09	0.0241	0.83	0.52	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	6.52	1.99e-09	0.0241	0.83	0.52	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	6.52	1.99e-09	0.0241	0.83	0.52	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	6.52	1.99e-09	0.0241	0.83	0.52	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
GBM	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	6.51	2e-09	0.0242	0.6	0.52	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
GBM	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	6.51	2e-09	0.0242	0.86	0.52	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
GBM	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	6.51	2.01e-09	0.0243	0.54	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
GBM	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	6.51	2.02e-09	0.0244	0.56	0.52	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	6.51	2.02e-09	0.0244	0.56	0.52	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
GBM	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	6.51	2.05e-09	0.0247	0.54	0.52	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
GBM	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	6.51	2.08e-09	0.025	0.75	0.52	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
GBM	trans	rs2898279	0.815	rs2003423	ENSG00000253671.1	RP11-806O11.1	-6.51	2.09e-09	0.0251	-0.52	-0.52	Small cell lung carcinoma;	chr8:11445502	chr8:17808941~17820868:+
GBM	trans	rs7312770	0.637	rs705699	ENSG00000235459.5	RPS26P31	6.5	2.1e-09	0.0253	0.55	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:122681315~122681662:+
GBM	trans	rs877636	1	rs4759229	ENSG00000234354.3	RPS26P47	-6.5	2.11e-09	0.0254	-0.64	-0.52	Cognitive function;	chr12:56080696	chr13:100539901~100540248:-
GBM	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	6.5	2.16e-09	0.0259	0.6	0.52	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
GBM	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-6.5	2.17e-09	0.026	-0.8	-0.52	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
GBM	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	6.5	2.18e-09	0.0261	0.76	0.52	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	6.5	2.18e-09	0.0261	0.76	0.52	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
GBM	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	6.5	2.2e-09	0.0264	0.59	0.52	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
GBM	trans	rs877636	0.74	rs705702	ENSG00000204652.6	RPS26P8	-6.49	2.21e-09	0.0264	-0.59	-0.52	Cognitive function;	chr12:55996852	chr17:45608571~45608918:+
GBM	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-6.49	2.25e-09	0.0269	-0.72	-0.52	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
GBM	trans	rs9329221	0.619	rs591346	ENSG00000253893.2	FAM85B	6.49	2.25e-09	0.0269	0.58	0.52	Neuroticism;	chr8:9960555	chr8:8167819~8226614:-
GBM	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	6.49	2.25e-09	0.0269	0.63	0.52	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	6.49	2.25e-09	0.0269	0.63	0.52	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	6.49	2.25e-09	0.0269	0.63	0.52	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	6.49	2.25e-09	0.0269	0.63	0.52	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	6.49	2.25e-09	0.0269	0.63	0.52	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	6.49	2.25e-09	0.0269	0.63	0.52	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-6.48	2.32e-09	0.0277	-0.73	-0.52	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
GBM	trans	rs7312770	0.637	rs705700	ENSG00000234192.1	RP11-57C13.5	6.48	2.37e-09	0.028	0.59	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:87642607~87642954:+
GBM	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-6.48	2.38e-09	0.0282	-0.6	-0.52	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
GBM	trans	rs10028773	0.515	rs9994651	ENSG00000275858.1	RP11-291L22.8	6.48	2.41e-09	0.0285	0.61	0.52	Educational attainment;	chr4:119666648	chr10:38450738~38451069:-
GBM	trans	rs7811142	1	rs73161762	ENSG00000228546.2	CTA-313A17.3	6.48	2.42e-09	0.0286	0.81	0.52	Platelet count;	chr7:100417223	chr7:102337316~102339115:+
GBM	trans	rs66887589	1	rs66887589	ENSG00000275858.1	RP11-291L22.8	-6.47	2.43e-09	0.0287	-0.58	-0.52	Diastolic blood pressure;	chr4:119588124	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-6.47	2.44e-09	0.0287	-0.62	-0.52	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	6.47	2.44e-09	0.0287	0.62	0.52	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
GBM	trans	rs7811142	0.887	rs111972532	ENSG00000228546.2	CTA-313A17.3	6.47	2.5e-09	0.0294	0.77	0.52	Platelet count;	chr7:100471465	chr7:102337316~102339115:+
GBM	trans	rs2963482	0.691	rs2946158	ENSG00000269608.1	CTB-167G5.3	6.47	2.51e-09	0.0295	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158510175	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.697	rs2964504	ENSG00000269608.1	CTB-167G5.3	6.47	2.51e-09	0.0295	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158510339	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.658	rs2963448	ENSG00000269608.1	CTB-167G5.3	6.47	2.51e-09	0.0295	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158510418	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.594	rs2963447	ENSG00000269608.1	CTB-167G5.3	6.47	2.51e-09	0.0295	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158510514	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.658	rs2964505	ENSG00000269608.1	CTB-167G5.3	6.47	2.51e-09	0.0295	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158510602	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.658	rs2964506	ENSG00000269608.1	CTB-167G5.3	6.47	2.51e-09	0.0295	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158510647	chr19:53616802~53617254:+
GBM	trans	rs2963482	0.658	rs2964507	ENSG00000269608.1	CTB-167G5.3	6.47	2.51e-09	0.0295	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158510679	chr19:53616802~53617254:+
GBM	trans	rs66887589	0.72	rs11724758	ENSG00000275858.1	RP11-291L22.8	6.47	2.54e-09	0.0298	0.59	0.52	Diastolic blood pressure;	chr4:119318723	chr10:38450738~38451069:-
GBM	trans	rs66887589	0.72	rs2036858	ENSG00000275858.1	RP11-291L22.8	6.47	2.54e-09	0.0298	0.59	0.52	Diastolic blood pressure;	chr4:119328082	chr10:38450738~38451069:-
GBM	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	6.46	2.55e-09	0.0299	0.61	0.52	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
GBM	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	6.46	2.59e-09	0.0303	0.59	0.52	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
GBM	trans	rs7811142	1	rs11771419	ENSG00000228546.2	CTA-313A17.3	6.46	2.61e-09	0.0305	0.72	0.52	Platelet count;	chr7:100390780	chr7:102337316~102339115:+
GBM	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	6.46	2.62e-09	0.0305	0.62	0.52	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	6.46	2.62e-09	0.0305	0.62	0.52	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
GBM	trans	rs2877832	0.545	rs7145685	ENSG00000274356.1	RP11-216L13.21	-6.46	2.62e-09	0.0306	-0.88	-0.52	Diabetes related insulin traits;	chr14:27634699	chr9:136728953~136729855:-
GBM	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	6.46	2.65e-09	0.0309	0.77	0.52	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	6.46	2.65e-09	0.0309	0.77	0.52	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
GBM	trans	rs2963482	0.626	rs2963452	ENSG00000269608.1	CTB-167G5.3	6.46	2.65e-09	0.0309	0.68	0.52	Nonsyndromic cleft lip with or without cleft palate;	chr5:158504825	chr19:53616802~53617254:+
GBM	trans	rs13090388	1	rs13090388	ENSG00000197582.5	GPX1P1	-6.46	2.67e-09	0.031	-0.68	-0.52	Educational attainment (years of education);Intelligence (multi-trait analysis);	chr3:49353649	chrX:13378735~13379340:-
GBM	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	6.45	2.69e-09	0.0312	0.73	0.52	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-6.45	2.71e-09	0.0314	-0.83	-0.52	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
GBM	trans	rs7565329	0.62	rs6709038	ENSG00000179611.3	DGKZP1	-6.45	2.71e-09	0.0314	-1.1	-0.52	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr2:67856463	chr13:43968424~43971199:+
GBM	trans	rs877636	1	rs705696	ENSG00000234354.3	RPS26P47	6.45	2.74e-09	0.0318	0.64	0.52	Cognitive function;	chr12:56086864	chr13:100539901~100540248:-
GBM	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	6.45	2.78e-09	0.0322	0.72	0.52	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
GBM	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	6.45	2.79e-09	0.0323	0.72	0.52	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
GBM	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	6.44	2.84e-09	0.0328	0.72	0.51	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
GBM	trans	rs877636	1	rs2292239	ENSG00000234354.3	RPS26P47	6.44	2.85e-09	0.0329	0.63	0.51	Cognitive function;	chr12:56088396	chr13:100539901~100540248:-
GBM	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-6.44	2.86e-09	0.0329	-0.85	-0.51	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
GBM	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-6.44	2.86e-09	0.0329	-0.85	-0.51	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
GBM	trans	rs17060993	1	rs13265301	ENSG00000259146.3	RP1-261D10.2	-6.44	2.87e-09	0.0331	-1.13	-0.51	Musician's dystonia;	chr8:27075793	chr14:71292729~71321814:-
GBM	trans	rs7811142	1	rs2897358	ENSG00000228546.2	CTA-313A17.3	6.44	2.93e-09	0.0338	0.74	0.51	Platelet count;	chr7:100491017	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs60478351	ENSG00000228546.2	CTA-313A17.3	6.44	2.93e-09	0.0338	0.74	0.51	Platelet count;	chr7:100491394	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs7787620	ENSG00000228546.2	CTA-313A17.3	6.44	2.93e-09	0.0338	0.74	0.51	Platelet count;	chr7:100491611	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs11769700	ENSG00000228546.2	CTA-313A17.3	6.44	2.93e-09	0.0338	0.74	0.51	Platelet count;	chr7:100492426	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	6.43	2.96e-09	0.0339	0.72	0.51	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	6.43	2.96e-09	0.0339	0.72	0.51	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	6.43	2.96e-09	0.0339	0.72	0.51	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	6.43	2.96e-09	0.0339	0.72	0.51	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	6.43	2.96e-09	0.0339	0.72	0.51	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	6.43	2.96e-09	0.0339	0.72	0.51	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
GBM	trans	rs7930295	0.505	rs34303332	ENSG00000236257.1	EI24P2	6.43	2.99e-09	0.0341	0.93	0.51	Schizophrenia;	chr11:125544288	chr1:158454198~158455273:+
GBM	trans	rs6733160	0.508	rs329497	ENSG00000231804.1	RP11-317B17.3	6.43	3.04e-09	0.0347	0.66	0.51	Allergic dermatitis (nickel);	chr2:64100458	chr9:88484852~88485325:-
GBM	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-6.43	3.06e-09	0.0349	-0.7	-0.51	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
GBM	trans	rs4846217	0.92	rs12139158	ENSG00000259356.1	RP11-90E5.1	-6.43	3.07e-09	0.035	-0.71	-0.51	Platelet count;	chr1:10265552	chr15:100126106~100129743:+
GBM	trans	rs1137	1	rs205638	ENSG00000260621.1	RP11-413H22.2	6.43	3.09e-09	0.0352	0.66	0.51	Myopia (pathological);	chr2:74722940	chr16:56409320~56411683:+
GBM	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	6.42	3.16e-09	0.0359	0.69	0.51	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
GBM	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	6.42	3.16e-09	0.0359	0.69	0.51	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
GBM	trans	rs9858542	0.951	rs1800668	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358324	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs1987628	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49361826	chrX:13378735~13379340:-
GBM	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs7648841	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs6446264	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs11706370	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-6.42	3.17e-09	0.0359	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
GBM	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	6.42	3.18e-09	0.0359	0.58	0.51	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
GBM	trans	rs9329221	0.655	rs656319	ENSG00000253893.2	FAM85B	6.42	3.18e-09	0.036	0.58	0.51	Neuroticism;	chr8:9956901	chr8:8167819~8226614:-
GBM	trans	rs736801	0.808	rs2522057	ENSG00000260685.1	RP11-326L17.1	6.41	3.29e-09	0.0371	0.63	0.51	Mosquito bite size;Breast cancer;	chr5:132466255	chr15:75950464~75951144:-
GBM	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	6.41	3.31e-09	0.0373	0.58	0.51	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
GBM	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-6.41	3.36e-09	0.0378	-0.79	-0.51	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-6.41	3.38e-09	0.038	-0.85	-0.51	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
GBM	trans	rs11220082	0.666	rs12789687	ENSG00000236257.1	EI24P2	-6.41	3.4e-09	0.0382	-0.65	-0.51	Schizophrenia;	chr11:125461254	chr1:158454198~158455273:+
GBM	trans	rs11220082	0.666	rs12223186	ENSG00000236257.1	EI24P2	-6.41	3.4e-09	0.0382	-0.65	-0.51	Schizophrenia;	chr11:125461743	chr1:158454198~158455273:+
GBM	trans	rs7811142	1	rs11763414	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100419221	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs67163493	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100426215	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs60257855	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100429157	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs6975729	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100430564	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.887	rs4074838	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100435042	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs11764818	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100445432	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.945	rs6955362	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100458543	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs6975514	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100458597	chr7:102337316~102339115:+
GBM	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	6.4	3.42e-09	0.0382	0.74	0.51	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
GBM	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	6.4	3.42e-09	0.0382	0.62	0.51	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	6.4	3.42e-09	0.0382	0.62	0.51	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	6.4	3.42e-09	0.0382	0.62	0.51	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
GBM	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	6.4	3.42e-09	0.0382	0.62	0.51	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
GBM	trans	rs13253073	0.545	rs35769167	ENSG00000260318.1	COX6CP1	6.4	3.45e-09	0.0386	0.93	0.51	Glucose homeostasis traits;	chr8:99872095	chr16:11903923~11904137:-
GBM	trans	rs394563	0.559	rs13219868	ENSG00000235358.1	RP11-399E6.1	-6.4	3.46e-09	0.0386	-0.49	-0.51	Dupuytren's disease;	chr6:149365382	chr1:41242373~41284861:+
GBM	trans	rs394563	0.591	rs6570963	ENSG00000235358.1	RP11-399E6.1	-6.4	3.46e-09	0.0386	-0.49	-0.51	Dupuytren's disease;	chr6:149370219	chr1:41242373~41284861:+
GBM	trans	rs394563	0.591	rs6570964	ENSG00000235358.1	RP11-399E6.1	-6.4	3.46e-09	0.0386	-0.49	-0.51	Dupuytren's disease;	chr6:149370723	chr1:41242373~41284861:+
GBM	trans	rs7811142	1	rs11773661	ENSG00000228546.2	CTA-313A17.3	6.4	3.47e-09	0.0387	0.75	0.51	Platelet count;	chr7:100475446	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.943	rs66958101	ENSG00000228546.2	CTA-313A17.3	6.4	3.47e-09	0.0387	0.75	0.51	Platelet count;	chr7:100476397	chr7:102337316~102339115:+
GBM	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	6.4	3.47e-09	0.0387	0.55	0.51	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	6.4	3.47e-09	0.0387	0.55	0.51	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
GBM	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	6.4	3.5e-09	0.039	0.81	0.51	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	6.4	3.5e-09	0.039	0.81	0.51	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	6.4	3.5e-09	0.039	0.81	0.51	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	6.4	3.5e-09	0.039	0.81	0.51	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	6.4	3.5e-09	0.039	0.81	0.51	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
GBM	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	6.4	3.52e-09	0.0391	0.53	0.51	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
GBM	trans	rs4846217	0.92	rs17397129	ENSG00000259356.1	RP11-90E5.1	6.39	3.61e-09	0.04	0.68	0.51	Platelet count;	chr1:10285404	chr15:100126106~100129743:+
GBM	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	6.39	3.65e-09	0.0404	0.54	0.51	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
GBM	trans	rs1137	1	rs205634	ENSG00000260621.1	RP11-413H22.2	-6.39	3.67e-09	0.0406	-0.67	-0.51	Myopia (pathological);	chr2:74728226	chr16:56409320~56411683:+
GBM	trans	rs1137	1	rs205633	ENSG00000260621.1	RP11-413H22.2	-6.39	3.67e-09	0.0406	-0.67	-0.51	Myopia (pathological);	chr2:74728242	chr16:56409320~56411683:+
GBM	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-6.39	3.7e-09	0.0409	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-6.39	3.7e-09	0.0409	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
GBM	trans	rs7811142	1	rs7803454	ENSG00000228546.2	CTA-313A17.3	6.39	3.73e-09	0.0412	0.8	0.51	Platelet count;	chr7:100393925	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.943	rs11769886	ENSG00000228546.2	CTA-313A17.3	6.39	3.73e-09	0.0412	0.8	0.51	Platelet count;	chr7:100400984	chr7:102337316~102339115:+
GBM	trans	rs11220082	0.666	rs12224788	ENSG00000236257.1	EI24P2	-6.39	3.73e-09	0.0412	-0.65	-0.51	Schizophrenia;	chr11:125459165	chr1:158454198~158455273:+
GBM	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	6.39	3.74e-09	0.0413	0.55	0.51	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	6.39	3.74e-09	0.0413	0.55	0.51	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
GBM	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	6.39	3.74e-09	0.0413	0.55	0.51	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
GBM	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-6.39	3.75e-09	0.0414	-0.58	-0.51	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
GBM	trans	rs877636	0.74	rs772920	ENSG00000204652.6	RPS26P8	6.38	3.76e-09	0.0414	0.57	0.51	Cognitive function;	chr12:55996580	chr17:45608571~45608918:+
GBM	trans	rs6924995	1	rs6924995	ENSG00000260920.2	RP1-228H13.5	-6.38	3.8e-09	0.0418	-0.57	-0.51	Response to statins (LDL cholesterol change);	chr6:16161194	chr1:40464319~40466767:+
GBM	trans	rs4846217	0.764	rs997482	ENSG00000259356.1	RP11-90E5.1	-6.38	3.82e-09	0.042	-0.7	-0.51	Platelet count;	chr1:10213121	chr15:100126106~100129743:+
GBM	trans	rs4846217	0.92	rs6702280	ENSG00000259356.1	RP11-90E5.1	-6.38	3.82e-09	0.042	-0.7	-0.51	Platelet count;	chr1:10220716	chr15:100126106~100129743:+
GBM	trans	rs12137527	1	rs12137527	ENSG00000259356.1	RP11-90E5.1	-6.38	3.82e-09	0.042	-0.7	-0.51	Tonsillectomy;	chr1:10255239	chr15:100126106~100129743:+
GBM	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-6.38	3.82e-09	0.042	-0.59	-0.51	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
GBM	trans	rs17060993	0.867	rs73564844	ENSG00000259146.3	RP1-261D10.2	6.38	3.86e-09	0.0423	1.11	0.51	Musician's dystonia;	chr8:27049021	chr14:71292729~71321814:-
GBM	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	6.38	3.86e-09	0.0424	0.59	0.51	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
GBM	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-6.38	3.92e-09	0.043	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-6.38	3.92e-09	0.043	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-6.38	3.92e-09	0.043	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
GBM	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-6.38	3.92e-09	0.043	-0.67	-0.51	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
GBM	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	6.37	3.94e-09	0.043	0.82	0.51	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	6.37	3.94e-09	0.043	0.81	0.51	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	6.37	3.94e-09	0.043	0.81	0.51	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	6.37	3.94e-09	0.043	0.81	0.51	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	6.37	3.94e-09	0.043	0.81	0.51	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
GBM	trans	rs11220082	0.666	rs35203305	ENSG00000236257.1	EI24P2	-6.37	4.06e-09	0.0441	-0.66	-0.51	Schizophrenia;	chr11:125468987	chr1:158454198~158455273:+
GBM	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	6.37	4.07e-09	0.0441	0.69	0.51	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
GBM	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	6.37	4.07e-09	0.0442	0.59	0.51	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
GBM	trans	rs2963482	0.659	rs1317146	ENSG00000269608.1	CTB-167G5.3	6.37	4.1e-09	0.0444	0.68	0.51	Nonsyndromic cleft lip with or without cleft palate;	chr5:158500583	chr19:53616802~53617254:+
GBM	trans	rs66887589	0.934	rs12648182	ENSG00000275858.1	RP11-291L22.8	-6.36	4.15e-09	0.0448	-0.57	-0.51	Diastolic blood pressure;	chr4:119582736	chr10:38450738~38451069:-
GBM	trans	rs66887589	0.807	rs9799664	ENSG00000275858.1	RP11-291L22.8	6.36	4.16e-09	0.0448	0.59	0.51	Diastolic blood pressure;	chr4:119405523	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	6.36	4.17e-09	0.045	0.82	0.51	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
GBM	trans	rs11098499	0.575	rs9996586	ENSG00000275858.1	RP11-291L22.8	6.36	4.19e-09	0.0451	0.59	0.51	Corneal astigmatism;	chr4:119405787	chr10:38450738~38451069:-
GBM	trans	rs66887589	0.627	rs3872807	ENSG00000275858.1	RP11-291L22.8	6.36	4.19e-09	0.0451	0.59	0.51	Diastolic blood pressure;	chr4:119439096	chr10:38450738~38451069:-
GBM	trans	rs66887589	0.56	rs9684327	ENSG00000275858.1	RP11-291L22.8	6.36	4.19e-09	0.0451	0.59	0.51	Diastolic blood pressure;	chr4:119444286	chr10:38450738~38451069:-
GBM	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-6.36	4.29e-09	0.0462	-0.83	-0.51	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-6.36	4.31e-09	0.0463	-0.84	-0.51	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
GBM	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-6.35	4.35e-09	0.0468	-0.72	-0.51	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
GBM	trans	rs41526344	0.539	rs77035745	ENSG00000229388.1	RP11-442N24__B.1	6.35	4.36e-09	0.0469	0.73	0.51	Body mass index (change over time) in chronic obstructive pulmonary disease;	chr3:2932541	chr1:28643228~28648581:+
GBM	trans	rs6924995	0.956	rs6921316	ENSG00000260920.2	RP1-228H13.5	-6.35	4.38e-09	0.0471	-0.57	-0.51	Response to statins (LDL cholesterol change);	chr6:16157030	chr1:40464319~40466767:+
GBM	trans	rs2275606	0.719	rs76374996	ENSG00000237505.5	PKN2-AS1	-6.35	4.41e-09	0.0474	-1.18	-0.51	Leprosy;	chr6:146607128	chr1:88537513~88685204:-
GBM	trans	rs877636	0.692	rs2271194	ENSG00000234192.1	RP11-57C13.5	-6.35	4.44e-09	0.0477	-0.6	-0.51	Cognitive function;	chr12:56083910	chr10:87642607~87642954:+
GBM	trans	rs9646944	0.519	rs1041973	ENSG00000231971.4	RP11-557H15.3	6.35	4.47e-09	0.048	0.78	0.51	Blood protein levels;	chr2:102339008	chr6:134428240~134520585:-
GBM	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	6.35	4.49e-09	0.0481	0.72	0.51	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
GBM	trans	rs11220082	0.644	rs34435097	ENSG00000236257.1	EI24P2	-6.35	4.51e-09	0.0483	-0.66	-0.51	Schizophrenia;	chr11:125469075	chr1:158454198~158455273:+
GBM	trans	rs11220082	0.666	rs7103665	ENSG00000236257.1	EI24P2	-6.35	4.51e-09	0.0483	-0.66	-0.51	Schizophrenia;	chr11:125472998	chr1:158454198~158455273:+
GBM	trans	rs11220082	0.644	rs61917855	ENSG00000236257.1	EI24P2	-6.35	4.51e-09	0.0483	-0.66	-0.51	Schizophrenia;	chr11:125473652	chr1:158454198~158455273:+
GBM	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	6.35	4.55e-09	0.0486	0.58	0.51	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
GBM	trans	rs6924995	0.956	rs9367897	ENSG00000260920.2	RP1-228H13.5	-6.34	4.57e-09	0.0489	-0.56	-0.51	Response to statins (LDL cholesterol change);	chr6:16158043	chr1:40464319~40466767:+
GBM	trans	rs6924995	0.956	rs9349997	ENSG00000260920.2	RP1-228H13.5	-6.34	4.57e-09	0.0489	-0.56	-0.51	Response to statins (LDL cholesterol change);	chr6:16158632	chr1:40464319~40466767:+
GBM	trans	rs6924995	0.956	rs6918029	ENSG00000260920.2	RP1-228H13.5	-6.34	4.57e-09	0.0489	-0.56	-0.51	Response to statins (LDL cholesterol change);	chr6:16159490	chr1:40464319~40466767:+
GBM	trans	rs6924995	0.956	rs6939285	ENSG00000260920.2	RP1-228H13.5	-6.34	4.57e-09	0.0489	-0.56	-0.51	Response to statins (LDL cholesterol change);	chr6:16160515	chr1:40464319~40466767:+
GBM	trans	rs9646944	1	rs11677452	ENSG00000268027.4	AC006129.2	-6.34	4.62e-09	0.0492	-0.65	-0.51	Blood protein levels;	chr2:102248776	chr19:41545192~41555462:+
GBM	trans	rs9646944	1	rs9646944	ENSG00000268027.4	AC006129.2	-6.34	4.62e-09	0.0492	-0.65	-0.51	Blood protein levels;	chr2:102249415	chr19:41545192~41555462:+
GBM	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-6.34	4.64e-09	0.0494	-0.7	-0.51	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
GBM	trans	rs7811142	0.943	rs10241492	ENSG00000228546.2	CTA-313A17.3	6.34	4.67e-09	0.0497	0.74	0.51	Platelet count;	chr7:100397190	chr7:102337316~102339115:+
GBM	trans	rs9329221	0.621	rs522483	ENSG00000253893.2	FAM85B	6.34	4.68e-09	0.0498	0.58	0.51	Neuroticism;	chr8:9955459	chr8:8167819~8226614:-
GBM	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	6.34	4.7e-09	0.0499	0.69	0.51	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	6.34	4.7e-09	0.0499	0.69	0.51	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	6.34	4.7e-09	0.0499	0.69	0.51	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	6.34	4.7e-09	0.0499	0.69	0.51	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
GBM	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	6.34	4.7e-09	0.0499	0.69	0.51	Platelet count;	chr7:100385512	chr7:102337316~102339115:+